PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Giampieri, S; Garcia-Escudero, R; Green, J; Storey, A				Giampieri, S; Garcia-Escudero, R; Green, J; Storey, A			Human papillomavirus type 77 E6 protein selectively inhibits p53-dependent transcription of proapoptotic genes following UV-B irradiation	ONCOGENE			English	Article						p53; apoptosis; transcriptional activation; HPV; UV-B	TUMOR-SUPPRESSOR PROTEIN; NONMELANOMA SKIN-CANCER; EPIDERMODYSPLASIA-VERRUCIFORMIS; P53-INDUCED APOPTOSIS; E6 PROTEINS; P53 MUTANTS; HPV TYPES; ACTIVATION; PROMOTERS; DEFINES	DNA damage, such as that elicited by UV-B, can induce either a cell cycle arrest or apoptosis that can be signalled by the p53 protein through the activation of a number of downstream cellular target genes. In contrast to oncogenic anogenital human papillomaviruses (HPVs), which mediate proteolytic degradation of p53, the E6 protein of cutaneous HPVs, such as HPV 77, do not promote p53 degradation. We have previously shown, however, that expression of HPV 77 E6 can effectively block UV-induced apoptosis in cells that have UY-activated p53. Here, we report that expression of the E6 protein from the cutaneous HPV 77 attenuates the UY-induced transactivation of p53-regulated proapoptotic genes Fas, PUMAbeta, Apaf-1, PIG3. This inhibition of p53-activation of proapoptotic genes by HPV77 E6 is exerted selectively, as the increased expression of p53 target genes involved in cell cycle arrest or regulatory functions regulation, such as p21 and Hdm2, is unaffected. Our data suggest that HPV 77 E6 may play an important role in specifically deregulating p53-dependent transactivation of proapoptotic genes upon UV-B irradiation.	Canc Res UK, Skin Tumour Lab, London E1 2AT, England	Cancer Research UK	Storey, A (corresponding author), Canc Res UK, Skin Tumour Lab, 2 Newark St, London E1 2AT, England.	alan.storey@cancer.org.uk	Garcia-Escudero, Ramon/A-2735-2012	Garcia-Escudero, Ramon/0000-0001-5640-6542; Storey, Alan/0000-0003-2001-9772; Giampieri, Silvia/0000-0001-5484-3140; Green, Judith/0000-0001-6825-9404				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; de Villiers EM, 1999, SEMIN CANCER BIOL, V9, P413, DOI 10.1006/scbi.1999.0145; Delius H, 1998, VIROLOGY, V240, P359, DOI 10.1006/viro.1997.8943; Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002/1096-9071(200007)61:3&lt;289::AID-JMV2&gt;3.0.CO;2-Z; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Malanchi I, 2002, ONCOGENE, V21, P5665, DOI 10.1038/sj.onc.1205617; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Orth G, 2001, J VIROL, V75, P4952, DOI 10.1128/JVI.75.10.4952-4953.2001; ORTH G, 1986, CIBA F SYMP, V120, P157; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; Rapp B, 1997, J VIROL, V71, P6956, DOI 10.1128/JVI.71.9.6956-6966.1997; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Scolnick DM, 1997, CANCER RES, V57, P3693; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; STOREY A, 1995, ONCOGENE, V11, P653; Storey A, 2002, TRENDS MOL MED, V8, P417, DOI 10.1016/S1471-4914(02)02387-0; Surentheran T, 1998, J CLIN PATHOL, V51, P606, DOI 10.1136/jcp.51.8.606; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wattre P, 1996, ANN BIOL CLIN-PARIS, V54, P189; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	32	31	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5864	5870		10.1038/sj.onc.1207711	http://dx.doi.org/10.1038/sj.onc.1207711			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15077176				2022-12-25	WOS:000222629800017
J	Martin-Oliva, D; O'Valle, F; Munoz-Gamez, JA; Valenzuela, MT; Nunez, MI; Aguilar, M; de Almodovar, JMR; del Moral, RG; Oliver, FJ				Martin-Oliva, D; O'Valle, F; Munoz-Gamez, JA; Valenzuela, MT; Nunez, MI; Aguilar, M; de Almodovar, JMR; del Moral, RG; Oliver, FJ			Crosstalk between PARP-1 and NF-kappa B modulates the promotion of skin neoplasia	ONCOGENE			English	Article						skin carcinogenesis; PARP-1; NF-kappa B; inflammation	NITRIC-OXIDE SYNTHASE; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; DEFICIENT MICE; HUMAN CANCER; FACTOR-ALPHA; EXPRESSION; CELLS; CARCINOGENESIS	Poly (ADP-ribose) polymerase-1 (PARP-1)-deficient mice are protected against septic shock, type I diabetes, stroke and inflammation. It is now accepted that inflammation and related events, such as activation of NF-kappaB, are key components in the initiation and progression of epithelial cancer and in particular in the neoplastic transformation of keratinocytes and skin carcinogenesis. Here, we report that PARP-1-deficient mice display a strikingly reduced susceptibility to skin carcinogenesis. In parp-1(-/-) mice, development of papilloma-like premalignant lesions induced with DMBA and TPA, is strongly delayed and the final number of tumor-bearing mice and total tumor number were significantly reduced. In addition, epidermis of parp-1(-/-) mice did not show increased proliferation rates after treatment with carcinogen. Deregulated NF-kappaB is a hallmark for tumorigenesis together with the concomitant release of early inflammatory mediators. In the absence of PARP-1, NF-kappaB activation and induction kappaB-target genes did not take place during the promotion of tumor development. These results suggest that PARP-1 abolition impairs the promotion of skin carcinogenesis interfering with the activation of NF-kappaB and might have an important implication in targeting PARP-1 as a new antineoplastic therapeutic approach.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Hosp, Granada, Spain; Univ Granada, Dept Pathol, E-18071 Granada, Spain; Univ Granada, Dept Radiol & Phys Med, E-18071 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Granada; University of Granada	Oliver, FJ (corresponding author), CSIC, Inst Parasitol & Biomed, C Ventanilla 11, Granada 18001, Spain.	joliver@ipb.csic.es	OValle, Francisco/AAA-9151-2019; Martín-Oliva, David/L-8472-2014; Núñez, María Isabel/L-9924-2014; Oliver, Javier/S-1725-2018	Martín-Oliva, David/0000-0002-8095-5442; Núñez, María Isabel/0000-0001-8159-7969; Oliver, Javier/0000-0001-8468-1998; Ruiz De Almodovar Rivera, Jose Mariano/0000-0002-7053-1072				Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Bauerle PA, 1996, CELL, V87, P13; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; EMURCIA JM, 1997, P NATL ACAD SCI USA, V94, P73037; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Musgrave BL, 1999, EXP CELL RES, V252, P96, DOI 10.1006/excr.1999.4631; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Nozaki T, 2003, CANCER SCI, V94, P497, DOI 10.1111/j.1349-7006.2003.tb01472.x; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PANDOLFI F, 1992, CANCER, V69, P1165; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Tucker PC, 2001, FASEB J, V15, P2241, DOI 10.1096/fj.01-0133com; Velasco M, 1997, J BIOL CHEM, V272, P23025, DOI 10.1074/jbc.272.37.23025; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Weinberg WC, 1999, CANCER RES, V59, P2050; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	42	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5275	5283		10.1038/sj.onc.1207696	http://dx.doi.org/10.1038/sj.onc.1207696			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077172				2022-12-25	WOS:000222491600003
J	Pohlmann, T; Bockmann, RA; Grubmuller, H; Uchanska-Ziegler, B; Ziegler, A; Alexiev, U				Pohlmann, T; Bockmann, RA; Grubmuller, H; Uchanska-Ziegler, B; Ziegler, A; Alexiev, U			Differential peptide dynamics is linked to major histocompatibility complex polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II MHC MOLECULES; CONFORMATIONAL-CHANGES; TCR BINDING; CELL; HLA-B27; RECOGNITION; AMINO; TIME; FLEXIBILITY; SUBTYPE	Peptide presentation by major histocompatibility complex (MHC) molecules is of central importance for immune responses, which are triggered through recognition of peptide-loaded MHC molecules (pMHC) by cellular ligands such as T-cell receptors (TCR). However, a unifying link between structural features of pMHC and cellular responses has not been established. Instead, pMHC/TCR binding studies suggest conformational and/or flexibility changes of the binding partners as a possible cause of differential T-cell stimulation, but information on real-time dynamics is lacking. We therefore probed the real-time dynamics of a MHC-bound nonapeptide (m9), by combining time-resolved fluorescence depolarization and molecular dynamics simulations. Here we show that the nanosecond dynamics of this peptide presented by two human MHC class I subtypes (HLA-B*2705 and HLA-B*2709) with differential autoimmune disease association varies dramatically, despite virtually identical crystal structures. The peptide dynamics is linked to the single, buried polymorphic residue 116 in the peptide binding groove. Pronounced peptide flexibility is seen only for the non-disease-associated subtype HLA-B*2709, suggesting an entropic control of peptide recognition. Thermodynamic data obtained for two additional peptides support this hypothesis.	Free Univ Berlin, Dept Phys, D-14195 Berlin, Germany; Max Planck Inst Biophys Chem, Theoret & Computat Biophys Dept, D-37077 Gottingen, Germany; Humboldt Univ, Charite Univ Med Berlin, Inst Immungenet, D-14050 Berlin, Germany	Free University of Berlin; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Alexiev, U (corresponding author), Free Univ Berlin, Dept Phys, Arnimallee 14, D-14195 Berlin, Germany.	alexiev@physik.fu-berlin.de	Böckmann, Rainer A/G-7863-2015; Alexiev, Ulrike/L-8478-2016	Böckmann, Rainer A/0000-0002-9325-5162; 				Alexiev U, 2003, J MOL BIOL, V328, P705, DOI 10.1016/S0022-2836(03)00326-7; AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Bankovich AJ, 2003, IMMUNITY, V18, P7, DOI 10.1016/S1074-7613(02)00517-4; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; de Haan EC, 2002, BIOORGAN MED CHEM, V10, P1939, DOI 10.1016/S0968-0896(01)00434-5; Degano M, 2000, IMMUNITY, V12, P251, DOI 10.1016/S1074-7613(00)80178-8; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; Ferrara GB, 2001, BLOOD, V98, P3150, DOI 10.1182/blood.V98.10.3150; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Fiorillo MT, 1998, EUR J IMMUNOL, V28, P2508, DOI 10.1002/(SICI)1521-4141(199808)28:08<2508::AID-IMMU2508>3.0.CO;2-1; GAKAMSKY DM, 1995, IMMUNOL LETT, V44, P195, DOI 10.1016/0165-2478(94)00214-C; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hillig RC, 2004, J BIOL CHEM, V279, P652, DOI 10.1074/jbc.M307457200; Housset D, 2003, TRENDS IMMUNOL, V24, P429, DOI 10.1016/S1471-4906(03)00180-7; Hulsmeyer M, 2004, J EXP MED, V199, P271, DOI 10.1084/jem.20031690; Hulsmeyer M, 2002, J BIOL CHEM, V277, P47844, DOI 10.1074/jbc.M206392200; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kalergis AM, 2001, NAT IMMUNOL, V2, P229, DOI 10.1038/85286; Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Nojima H, 2003, CHEM PHARM BULL, V51, P923; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; Reche PA, 2003, J MOL BIOL, V331, P623, DOI 10.1016/S0022-2836(03)00750-2; Reiser JB, 2002, IMMUNITY, V16, P345, DOI 10.1016/S1074-7613(02)00288-1; Rudolph MG, 2002, ANNU REV BIOPH BIOM, V31, P121, DOI 10.1146/annurev.biophys.31.082901.134423; SCHLITTER J, 1993, CHEM PHYS LETT, V215, P617, DOI 10.1016/0009-2614(93)89366-P; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920	37	74	74	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28197	28201		10.1074/jbc.C400128200	http://dx.doi.org/10.1074/jbc.C400128200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15084610	Green Published, hybrid			2022-12-25	WOS:000222265400048
J	Ji, HL; Benos, DJ				Ji, HL; Benos, DJ			Degenerin sites mediate proton activation of delta beta gamma-epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CATION CHANNELS; SENSING ION CHANNELS; NA+ CHANNEL; XENOPUS OOCYTES; ALPHA-SUBUNIT; EXTERNAL PROTONS; FROG SKIN; ISCHEMIA; ENAC; TRANSPORT	The delta-subunit of epithelial Na+ channels (ENaC) is predominately expressed in brain, heart, and pancreas. The amiloride sensitivity, Na+ conductance, and critical domains for gating are characterized as a cross between proton-activated Na+ channels and alpha-ENaC. The hypothesis that external protons may activate human delta-ENaC was addressed by expressing deltabetagamma-hENaC in Xenopus oocytes and evaluating proton-activated current with the two-electrode voltage clamp technique. Our results showed that protons transiently evoked a Na+ current with an EC50 of pH 6 overlapped on the basal current of deltabetagamma-hENaC. Proton-activated current was not observed in uninjected oocytes. Studies on gating kinetics revealed that activation, desensitization, and recovery times of proton-activated Na+ current were 3.8 +/- 0.5 s, 253 +/- 9.5 s, and 10 +/- 3.6 s, respectively (n = 4-12). Alkali metal cation selectivity of the proton-activated current was identical to that of the basal current of deltabetagamma-hENaC. The metabolic acids, lactate, pyruvate, and formate, modified the proton-activated current, as did hypo-osmotic stress. EDTA, hypo-osmolarity, and lactate enhanced proton activation synergistically. Our results suggest that delta-hENaC subunit is essential for proton-activated current and gamma-subunit may potentially regulate the response of delta-hENaC to protons. We have concluded that deltabetagamma-hENaC is a proton-activated cation channel whose closing gate can be regulated by a proton-induced conformational change. Proton-sensitivity of deltabetagamma-hENaC may be an important mechanism for integrating external ischemic signals in inflamed and hypoxic tissues.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ji, HL (corresponding author), 1918 Univ Blvd,844 MCLM, Birmingham, AL 35294 USA.	ji@physiology.uab.edu	JI, HONGLONG/N-7822-2014	JI, HONGLONG/0000-0002-3228-7144	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK056095, R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56095, DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen NJ, 2002, J PHYSIOL-LONDON, V543, P521, DOI 10.1113/jphysiol.2002.020297; Awayda MS, 2000, AM J PHYSIOL-CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; Bertog M, 2000, AM J PHYSIOL-CELL PH, V278, pC885, DOI 10.1152/ajpcell.2000.278.5.C885; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; CHUNG RS, 1977, SURG FORUM, V28, P435; COBBE SM, 1980, J MOL CELL CARDIOL, V12, P745, DOI 10.1016/0022-2828(80)90077-2; CUTHBERT AW, 1976, MOL PHARMACOL, V12, P945; FUNDER J, 1967, ACTA PHYSIOL SCAND, V71, P65, DOI 10.1111/j.1748-1716.1967.tb03710.x; GRINSTEIN S, 1978, J MEMBRANE BIOL, V40, P261, DOI 10.1007/BF02026010; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; Ji HL, 2004, J BIOL CHEM, V279, P8428, DOI 10.1074/jbc.M312012200; Ji HL, 2003, BIOPHYS J, V84, p529A; Ji HL, 2003, FASEB J, V17, pA913; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Kellenberger S, 2003, MOL PHARMACOL, V64, P848, DOI 10.1124/mol.64.4.848; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; Ladilov Y, 2000, CARDIOVASC RES, V47, P394, DOI 10.1016/S0008-6363(00)00108-5; Langloh ALB, 2000, AM J PHYSIOL-CELL PH, V278, pC277, DOI 10.1152/ajpcell.2000.278.2.C277; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; Lazrak A, 2000, AM J PHYSIOL-LUNG C, V278, pL848, DOI 10.1152/ajplung.2000.278.4.L848; LEAF A, 1964, AM J PHYSIOL, V207, P547, DOI 10.1152/ajplegacy.1964.207.3.547; LI JHY, 1981, ADV PHYSL SCI, V3, P151; MANDEL LJ, 1978, AM J PHYSIOL, V235, pC35, DOI 10.1152/ajpcell.1978.235.1.C35; Maroto R, 2001, J BIOL CHEM, V276, P23867, DOI 10.1074/jbc.M101500200; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mori S, 2002, BRAIN RES, V957, P1, DOI 10.1016/S0006-8993(02)03574-6; PALMER LG, 1982, J MEMBRANE BIOL, V67, P91, DOI 10.1007/BF01868651; Palmer LG, 2001, J MEMBRANE BIOL, V184, P305, DOI 10.1007/s00232-001-0092-3; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; ROUSSEAU B, 1971, BIOCHIM BIOPHYS ACTA, V233, P591, DOI 10.1016/0005-2736(71)90157-X; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; USSING HH, 1949, ACTA PHYSIOL SCAND, V17, P1, DOI 10.1111/j.1748-1716.1949.tb00550.x; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WALZ W, 1993, DEV NEUROSCI-BASEL, V15, P216, DOI 10.1159/000111337; Yamamura H, 2004, J BIOL CHEM, V279, P12529, DOI 10.1074/jbc.M400274200; Zhang P, 1999, BIOPHYS J, V77, P3043, DOI 10.1016/S0006-3495(99)77135-3; Zima AV, 2003, J PHYSIOL-LONDON, V550, P765, DOI 10.1113/jphysiol.2003.040345	51	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26939	26947		10.1074/jbc.M401143200	http://dx.doi.org/10.1074/jbc.M401143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084585	hybrid			2022-12-25	WOS:000222120400019
J	Fabrick, JA; Baker, JE; Kanost, MR				Fabrick, JA; Baker, JE; Kanost, MR			Innate immunity in a pyralid moth - Functional evaluation of domains from a beta-1,3-glucan recognition protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPHENOLOXIDASE-ACTIVATING ENZYME; LIPOPOLYSACCHARIDE-BINDING PROTEIN; COMPLEMENT-LIKE PROTEIN; SILKWORM BOMBYX-MORI; PRO-PHENOL-OXIDASE; C-TYPE LECTIN; PATTERN-RECOGNITION; MANDUCA-SEXTA; PROPHENOLOXIDASE-ACTIVATION; IMMUNOGLOBULIN SUPERFAMILY	Invertebrates, like vertebrates, utilize pattern recognition proteins for detection of microbes and subsequent activation of innate immune responses. We report structural and functional properties of two domains from a beta-1,3-glucan recognition protein present in the hemolymph of a pyralid moth, Plodia interpunctella. A recombinant protein corresponding to the first 181 amino-terminal residues bound to beta-1,3-glucan, lipopolysaccharide, and lipoteichoic acid, polysaccharides found on cell surfaces of microorganisms, and also activated the prophenoloxidase-activating system, an immune response pathway in insects. The amino-terminal domain consists primarily of an alpha-helical secondary structure with a minor beta-structure. This domain was thermally stable and resisted proteolytic degradation. The 290 residue carboxyl-terminal domain, which is similar in sequence to glucanases, had less affinity for the polysaccharides, did not activate the prophenoloxidase cascade, had a more complicated CD spectrum, and was heat-labile and susceptible to proteinase digestion. The carboxyl-terminal domain bound to laminarin, a beta-1,3-glucan with beta-1,6 branches, but not to curdlan, a beta-1,3-glucan that lacks branching. These results indicate that the two domains of Plodia beta-1,3-glucan recognition protein, separated by a putative linker region, bind microbial polysaccharides with differing specificities and that the amino-terminal domain, which is unique to this class of pattern recognition receptors from invertebrates, is responsible for stimulating prophenoloxidase activation.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; ARS, USDA, Grain Mkt & Prod Res Ctr, Manhattan, KS 66502 USA	Kansas State University; United States Department of Agriculture (USDA)	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	kanost@ksu.edu		Kanost, Michael/0000-0002-6827-0061; Fabrick, Jeffrey/0000-0002-3893-9545	NIGMS NIH HHS [R37 GM041247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; Bilej M, 2001, J BIOL CHEM, V276, P45840, DOI 10.1074/jbc.M107220200; Chosa N, 1997, INSECT BIOCHEM MOLEC, V27, P61, DOI 10.1016/S0965-1748(96)00070-7; Dimopoulos G, 2003, CELL MICROBIOL, V5, P3, DOI 10.1046/j.1462-5822.2003.00252.x; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P203, DOI 10.1016/0003-9861(73)90406-2; DOHKE K, 1973, ARCH BIOCHEM BIOPHYS, V157, P210, DOI 10.1016/0003-9861(73)90407-4; DULARAY B, 1985, INSECT BIOCHEM, V15, P827, DOI 10.1016/0020-1790(85)90112-X; Fabrick JA, 2003, INSECT BIOCHEM MOLEC, V33, P579, DOI 10.1016/S0965-1748(03)00029-8; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gorman MJ, 2001, INSECT BIOCHEM MOLEC, V31, P257, DOI 10.1016/S0965-1748(00)00145-4; Imler JL, 2002, CURR TOP MICROBIOL, V270, P63; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; JOMORI T, 1991, J BIOL CHEM, V266, P13318; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kawasaki K, 1996, INSECT BIOCHEM MOLEC, V26, P355, DOI 10.1016/0965-1748(95)00101-8; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; Koizumi N, 1997, EUR J BIOCHEM, V248, P217, DOI 10.1111/j.1432-1033.1997.t01-1-00217.x; LADENDORFF NE, 1991, ARCH INSECT BIOCHEM, V18, P285, DOI 10.1002/arch.940180410; Lagueux M, 2000, P NATL ACAD SCI USA, V97, P11427, DOI 10.1073/pnas.97.21.11427; LEE IY, 2002, BIOPOLYMERS, V5, P135; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEONARD C, 1985, INSECT BIOCHEM, V15, P803, DOI 10.1016/0020-1790(85)90109-X; LEONARD C, 1985, J INSECT PHYSIOL, V31, P789, DOI 10.1016/0022-1910(85)90072-1; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; Marmaras VJ, 1996, ARCH INSECT BIOCHEM, V31, P119, DOI 10.1002/(SICI)1520-6327(1996)31:2&lt;119::AID-ARCH1&gt;3.0.CO;2-V; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; RATCLIFFE NA, 1984, SCIENCE, V226, P557, DOI 10.1126/science.226.4674.557; Rowley A.F., 1986, P381; *SAS I, 1998, SAS SYST WIND VERS 7; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; SHINOHARA Y, 1995, J BIOCHEM-TOKYO, V117, P1076; Sritunyalucksana K, 2002, DEV COMP IMMUNOL, V26, P237, DOI 10.1016/S0145-305X(01)00074-X; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; Theopold U, 1999, BIOCHEM BIOPH RES CO, V261, P923, DOI 10.1006/bbrc.1999.1121; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Tsuchiya M, 1996, FEMS IMMUNOL MED MIC, V15, P129, DOI 10.1016/0928-8244(96)00053-3; Wang Y, 2001, PROTEIN EXPRES PURIF, V23, P328, DOI 10.1006/prep.2001.1517; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; Young SH, 2000, J BIOL CHEM, V275, P11874, DOI 10.1074/jbc.275.16.11874; Yu XQ, 1999, INSECT BIOCHEM MOLEC, V29, P585, DOI 10.1016/S0965-1748(99)00036-3; Yu XQ, 2002, EUR J BIOCHEM, V269, P1827, DOI 10.1046/j.1432-1033.2002.02830.x; Yu XQ, 2002, INSECT BIOCHEM MOLEC, V32, P1287, DOI 10.1016/S0965-1748(02)00091-7; Yu XQ, 2000, J BIOL CHEM, V275, P37373, DOI 10.1074/jbc.M003021200	59	42	49	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26605	26611		10.1074/jbc.M403382200	http://dx.doi.org/10.1074/jbc.M403382200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084591	hybrid			2022-12-25	WOS:000222003000086
J	Townson, SM; Kang, KY; Lee, AV; Oesterreich, S				Townson, SM; Kang, KY; Lee, AV; Oesterreich, S			Structure-function analysis of the estrogen receptor alpha corepressor scaffold attachment factor-B1 - Identification of a potent transcriptional repression domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MATRIX PROTEIN; HNRNP-U/SAF-A; HISTONE DEACETYLASE; BINDING-PROTEIN; MULTIPLE INTERACTIONS; HET/SAF-B; SAF-B; RNA; REGIONS; MOTIF	Scaffold attachment factor-B1 (SAFB1) is a nuclear matrix protein that has been proposed to couple chromatin structure, transcription, and RNA processing. We have previously shown that SAFB1 can repress estrogen receptor (ERalpha)-mediated transactivation. Here we present a structure-function study showing that transactivation is mediated via an intrinsic and transferable C-terminal repression domain (RD). A similar C-terminal RD was found in the family member SAFB2. Removal of the RD from SAFB1 resulted in a dominant-negative SAFB1 protein that increased ligand-dependent and - independent ERalpha activity. SAFB1RD-mediated repression was partly blocked by histone deacetylase inhibitors; however, no histone deacetylase inhibitors were identified in a yeast two-hybrid screen using the RD as bait. Instead, SAFB1RD was found to interact with TAFII68, a member of the basal transcription machinery. We propose a model in which SAFB1 represses ERalpha activity via indirect association with histone deacetylation and interaction with the basal transcription machinery.	Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Oesterreich, S (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Plaza,BCM 600, Houston, TX 77030 USA.	steffio@breastcenter.tmc.edu		Lee, Adrian/0000-0001-9917-514X	NATIONAL CANCER INSTITUTE [R01CA097213, K01CA077674] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097213, K01 CA77674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bode J, 2000, CRIT REV EUKAR GENE, V10, P73; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Bode J, 1996, CRIT REV EUKAR GENE, V6, P115, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.20; Boulikas T, 1995, INT REV CYTOL, V162A, P279; Carty SM, 2002, MOL CELL PROTEOMICS, V1, P598, DOI 10.1074/mcp.M200029-MCP200; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dobrzycka KM, 2003, ENDOCR-RELAT CANCER, V10, P517, DOI 10.1677/erc.0.0100517; Eggert H, 2001, J STEROID BIOCHEM, V78, P59, DOI 10.1016/S0960-0760(01)00074-7; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Frisch M, 2002, GENOME RES, V12, P349, DOI 10.1101/gr.206602.ArticlepublishedonlinebeforeprintinJanuary2002; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hong W, 2002, MOL CANCER RES, V1, P48; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Hu YC, 2002, J BIOL CHEM, V277, P33571, DOI 10.1074/jbc.M203531200; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Jepsen K, 2002, J CELL SCI, V115, P689; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Li J, 2003, MOL CELL BIOL, V23, P7437, DOI 10.1128/MCB.23.21.7437-7447.2003; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Martens JHA, 2002, MOL CELL BIOL, V22, P2598, DOI 10.1128/MCB.22.8.2598-2606.2002; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Oesterreich S, 2001, BRIT J CANCER, V84, P493, DOI 10.1054/bjoc.2000.1606; OESTERREICH S, 2000, EJC SUPPL, V4, P43; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Scott RE, 2003, J CELL BIOCHEM, V90, P6, DOI 10.1002/jcb.10618; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Tai HH, 2003, BIOCHEM BIOPH RES CO, V308, P170, DOI 10.1016/S0006-291X(03)01354-8; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Townson SM, 2000, CLIN CANCER RES, V6, P3788; Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10; Trifillis P, 1999, RNA, V5, P1071, DOI 10.1017/S1355838299981803; Weighardt F, 1999, J CELL SCI, V112, P1465; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	55	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26074	26081		10.1074/jbc.M313726200	http://dx.doi.org/10.1074/jbc.M313726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066997	hybrid			2022-12-25	WOS:000222003000020
J	Al-Fageeh, M; Li, QJ; Dashwood, WM; Myzak, MC; Dashwood, RH				Al-Fageeh, M; Li, QJ; Dashwood, WM; Myzak, MC; Dashwood, RH			Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32	ONCOGENE			English	Article						beta-catenin; TCF/LEF; APC; Wnt signaling; colorectal cancer; CTNNB1; human beta-catenin gene; Ctnnb1; rat beta-catenin gene	WNT SIGNALING PATHWAY; RAT COLON TUMORS; MUTATIONAL ANALYSIS; ADHESION SYSTEM; LIVER-TUMORS; GENE CTNNB1; CELL-LINES; CANCER; CADHERIN; DEGRADATION	beta-Catenin, a member of the Wnt signaling pathway, is downregulated by glycogen synthase kinase-3beta (GSK-3beta)-dependent phosphorylation of Ser/Thr residues in the N-terminus of the protein, followed by ubiquitination and proteosomal degradation. In human and rodent cancers, mutations that substitute one of the critical Ser/Thr residues in the GSK-3beta region of beta-catenin stabilize the protein and activate beta-catenin/TCF/LEF target genes. This study examined three oncogenic beta-catenin mutants from rat colon tumors containing substitutions adjacent to amino-acid residue Ser33, a key target for phosphorylation by GSK-3beta. Compared with wild-type beta-catenin (WT), the beta-catenin mutants D32G, D32N, and D32Y strongly activated TCF-4-dependent transcription in HEK293 cells, and there was accumulation of beta-catenin in the cell lysates. Immunoblotting with phosphospecific antibodies indicated that there was little if any effect on the phosphorylation of Ser37, Thr41 or Ser45; however, the phosphorylation of Ser33 appeared to be affected in the beta-catenin mutants. Specifically, antiphospho-beta-catenin 33/37/41 antibody identified high, intermediate and low expression levels of phosphorylated beta-catenin in cells transfected with D32G, D32N and D32Y, respectively. Experiments with the proteosome inhibitor N-acetyl-Leu-Leu-norleucinal ( ALLN) revealed ubiquitinated bands on all three mutant beta-catenins, as well as on WT beta-catenin. The relative order of ubiquitination was WT>D32G>D32N>D32Y, in parallel with findings from the phosphorylation studies. These results are discussed in the context of previous studies, which indicated that amino-acid residue D32 lies within the ubiquitination recognition motif of beta-catenin.	Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst Sci & Med, 571 Weniger Hall, Corvallis, OR 97331 USA.	rod.dashwood@oregonstate.edu	Dashwood, Roderick H/E-9090-2011; Dashwood, Roderick/AAF-2025-2020	Li, Qingjie/0000-0003-1405-7000	NCI NIH HHS [R01 CA065525-07, CA65525, R01 CA080176-05, R01 CA065525-09, R01 CA080176-02, R01 CA065525-08, R01 CA080176-04, R01 CA065525-06A1, P01 CA090890-01A29001, R01 CA065525, P01 CA090890-05, R29 CA065525, CA80176, P01 CA090890-05S1, CA90890, R01 CA080176, P01 CA090890-01A20003, P01 CA090890, R01 CA080176-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065525, P01CA090890, R29CA065525, R01CA080176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Blum CA, 2003, MOL CARCINOGEN, V36, P195, DOI 10.1002/mc.10112; Blum CA, 2001, CARCINOGENESIS, V22, P315, DOI 10.1093/carcin/22.2.315; Clements WM, 2002, CANCER RES, V62, P3503; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Dashwood RH, 1998, CANCER RES, V58, P1127; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Hagen T, 2002, BIOCHEM BIOPH RES CO, V294, P324, DOI 10.1016/S0006-291X(02)00485-0; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Li QJ, 2002, GENE, V283, P255, DOI 10.1016/S0378-1119(01)00839-3; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Polakis P, 2000, GENE DEV, V14, P1837; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Suzui M, 1999, MOL CARCINOGEN, V24, P232, DOI 10.1002/(SICI)1098-2744(199903)24:3<232::AID-MC10>3.0.CO;2-M; Takahashi M, 1998, CANCER RES, V58, P42; Van Gassen G, 2000, MOL MED, V6, P570, DOI 10.1007/BF03401795; Wang ZH, 2003, CANCER RES, V63, P5234	32	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2004	23	28					4839	4846		10.1038/sj.onc.1207634	http://dx.doi.org/10.1038/sj.onc.1207634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064718	Green Accepted			2022-12-25	WOS:000222104200004
J	Abu-Arish, A; Frenkiel-Krispin, D; Fricke, T; Tzfira, T; Citovsky, V; Wolf, SG; Elbaum, M				Abu-Arish, A; Frenkiel-Krispin, D; Fricke, T; Tzfira, T; Citovsky, V; Wolf, SG; Elbaum, M			Three-dimensional reconstruction of Agrobacterium VirE2 protein with single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMEFACIENS-MEDIATED TRANSFORMATION; MOLECULAR-WEIGHT DNA; T-DNA; PLANT-CELLS; VIRD2 PROTEIN; ELECTRON-MICROSCOPY; BINDING-PROTEIN; NUCLEAR IMPORT; HELICAL FILAMENTS; CROWN GALL	Agrobacterium tumefaciens infects plant cells by a unique mechanism involving an interkingdom genetic transfer. A single-stranded DNA substrate is transported across the two cell walls along with the bacterial virulence proteins VirD2 and VirE2. A single VirD2 molecule covalently binds to the 5'-end of the single-stranded DNA, while the VirE2 protein binds stoichiometrically along the length of the DNA, without sequence specificity. An earlier transmission/scanning transmission electron microscopy study indicated a solenoidal ("telephone coil") organization of the VirE2-DNA complex. Here we report a three-dimensional reconstruction of this complex using electron microscopy and single-particle image-processing methods. We find a hollow helical structure of 15.7-nm outer diameter, with a helical rise of 51.5 nm and 4.25 VirE2 proteins/turn. The inner face of the protein units contains a continuous wall and an inward protruding shelf. These structures appear to accommodate the DNA binding. Such a quaternary arrangement naturally sequesters the DNA from cytoplasmic nucleases and suggests a mechanism for its nuclear import by decoration with host cell factors. Coexisting with the helices, we also found VirE2 tetrameric ring structures. A two-dimensional average of the latter confirms the major features of the three-dimensional reconstruction.	Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Electron Microscopy Unit, IL-76100 Rehovot, Israel; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Weizmann Institute of Science; Weizmann Institute of Science; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Elbaum, M (corresponding author), Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel.	michael.elbaum@weizmann.ac.il	WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063; Citovsky, Vitaly/0000-0003-2024-6844				Bako L, 2003, P NATL ACAD SCI USA, V100, P10108, DOI 10.1073/pnas.1733208100; Ballas N, 1997, P NATL ACAD SCI USA, V94, P10723, DOI 10.1073/pnas.94.20.10723; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; Citovsky V, 1997, J MOL BIOL, V271, P718, DOI 10.1006/jmbi.1997.1230; CITOVSKY V, 1989, P NATL ACAD SCI USA, V86, P1193, DOI 10.1073/pnas.86.4.1193; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; de Groot MJA, 1998, NAT BIOTECHNOL, V16, P839, DOI 10.1038/nbt0998-839; DECLEENE M, 1976, BOT REV, V42, P389, DOI 10.1007/BF02860827; Duckely M, 2003, FEMS MICROBIOL LETT, V223, P1, DOI 10.1016/S0378-1097(03)00246-5; Dumas F, 2001, P NATL ACAD SCI USA, V98, P485, DOI 10.1073/pnas.011477898; DURRENBERGER F, 1989, P NATL ACAD SCI USA, V86, P9154, DOI 10.1073/pnas.86.23.9154; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Escobar MA, 2003, TRENDS PLANT SCI, V8, P380, DOI 10.1016/S1360-1385(03)00162-6; FELDHERR CM, 1990, ELECTRON MICROSC REV, V3, P73, DOI 10.1016/0892-0354(90)90014-J; FINCH JT, 1972, J MOL BIOL, V66, P291, DOI 10.1016/0022-2836(72)90480-9; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Frary A, 2001, TRANSGENIC RES, V10, P121, DOI 10.1023/A:1008924726270; GAUDIN V, 1994, PLANT PHYSIOL BIOCH, V32, P11; Gelvin SB, 2000, ANNU REV PLANT PHYS, V51, P223, DOI 10.1146/annurev.arplant.51.1.223; Gelvin SB, 2003, MICROBIOL MOL BIOL R, V67, P16, DOI 10.1128/MMBR.67.1.16-37.2003; Gelvin SB, 1998, J BACTERIOL, V180, P4300, DOI 10.1128/JB.180.16.4300-4302.1998; Gelvin SB, 2003, TRENDS BIOTECHNOL, V21, P95, DOI 10.1016/S0167-7799(03)00005-2; Gouka RJ, 1999, NAT BIOTECHNOL, V17, P598, DOI 10.1038/9915; Hamilton CM, 1997, GENE, V200, P107, DOI 10.1016/S0378-1119(97)00388-0; Heymann JB, 2001, J STRUCT BIOL, V133, P156, DOI 10.1006/jsbi.2001.4339; Ishida Y, 1996, NAT BIOTECHNOL, V14, P745, DOI 10.1038/nbt0696-745; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Mysore KS, 1998, MOL PLANT MICROBE IN, V11, P668, DOI 10.1094/MPMI.1998.11.7.668; Owen CH, 1996, J STRUCT BIOL, V116, P167, DOI 10.1006/jsbi.1996.0027; Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01-06-0308; PERALTA EG, 1985, P NATL ACAD SCI USA, V82, P5112, DOI 10.1073/pnas.82.15.5112; Piers KL, 1996, P NATL ACAD SCI USA, V93, P1613, DOI 10.1073/pnas.93.4.1613; Relic B, 1998, P NATL ACAD SCI USA, V95, P9105, DOI 10.1073/pnas.95.16.9105; SCHEIFFELE P, 1995, J BIOL CHEM, V270, P1269, DOI 10.1074/jbc.270.3.1269; SEN P, 1989, J BACTERIOL, V171, P2573, DOI 10.1128/jb.171.5.2573-2580.1989; Sheng JS, 1996, PLANT CELL, V8, P1699, DOI 10.1105/tpc.8.10.1699; Tzfira T, 2001, EMBO J, V20, P3596, DOI 10.1093/emboj/20.13.3596; Tzfira T, 2002, TRENDS CELL BIOL, V12, P121, DOI 10.1016/S0962-8924(01)02229-2; Tzfira T, 2000, MOL PLANT PATHOL, V1, P201, DOI 10.1046/j.1364-3703.2000.00026.x; Valentine L, 2003, PLANT PHYSIOL, V133, P948, DOI 10.1104/pp.103.032243; Vergunst AC, 2000, SCIENCE, V290, P979, DOI 10.1126/science.290.5493.979; WANG K, 1987, SCIENCE, V235, P587, DOI 10.1126/science.235.4788.587; Ward DV, 2001, P NATL ACAD SCI USA, V98, P385, DOI 10.1073/pnas.98.2.385; Yang SX, 2001, J MOL BIOL, V314, P1077, DOI 10.1006/jmbi.2000.5213; YOUNG C, 1988, J BACTERIOL, V170, P3367, DOI 10.1128/jb.170.8.3367-3374.1988; Ziemienowicz A, 2001, PLANT CELL, V13, P369, DOI 10.1105/tpc.13.2.369; Zupan J, 2000, PLANT J, V23, P11, DOI 10.1046/j.1365-313x.2000.00808.x; Zupan JR, 1996, P NATL ACAD SCI USA, V93, P2392, DOI 10.1073/pnas.93.6.2392; Zupan JR, 1998, CURR OPIN MICROBIOL, V1, P649, DOI 10.1016/S1369-5274(98)80110-0	51	54	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25359	25363		10.1074/jbc.M401804200	http://dx.doi.org/10.1074/jbc.M401804200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15054095	hybrid			2022-12-25	WOS:000221827900058
J	Satoh, Y; Matsumura, I; Tanaka, H; Ezoe, S; Sugahara, H; Mizuki, M; Shibayama, H; Ishiko, E; Ishiko, J; Nakajima, K; Kanakura, Y				Satoh, Y; Matsumura, I; Tanaka, H; Ezoe, S; Sugahara, H; Mizuki, M; Shibayama, H; Ishiko, E; Ishiko, J; Nakajima, K; Kanakura, Y			Roles for c-Myc in self-renewal of hematopoietic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; IN-VITRO; TELOMERASE ACTIVITY; CYCLIN E/CDK2; DNA-BINDING; TRANSCRIPTION; EXPRESSION; TARGET; EXPANSION; PROTEIN	Notch and HOXB4 have been reported to expand hematopoietic stem cells (HSCs) in vitro. However, their critical effector molecules remain undetermined. We found that the expression of c-myc, cyclin D2, cyclin D3, cyclin E, and E2F1 was induced or enhanced during Notch1- or HOXB4-induced self-renewal of murine HSCs. Since c-Myc can act as a primary regulator of G(1)/S transition, we examined whether c-Myc alone can induce self-renewal of HSCs. In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-) Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days. c-Myc activated by 4-hydroxytamoxifen augmented telomerase activities and increased the number of CFU-Mix about 2-fold in colony assays. Also, in reconstitution assays, HSCs expanded by c-Myc could reconstitute hematopoiesis for more than 6 months. As for the mechanism of c-myc induction by Notch1, we found that activated forms of Notch1 (NotchIC) and its downstream effector recombination signal-binding protein-J kappa (RBP-VP16) can activate the c-myc promoter through the element between -195 bp and -161 bp by inducing the DNA-binding complex. Together, these results suggest that c-Myc can support self-renewal of HSCs as a downstream mediator of Notch and HOXB4.	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Osaka City Univ, Grad Sch Med, Dept Immunol, Osaka 5458585, Japan	Osaka University; Osaka Metropolitan University	Matsumura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	matumura@bldon.med.osaka-u.ac.jp		ISHIKO, JUN/0000-0003-3518-5108				Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng T, 2001, BLOOD, V98, P3643, DOI 10.1182/blood.V98.13.3643; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dao MA, 2002, BLOOD, V99, P499, DOI 10.1182/blood.V99.2.499; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; Ezoe S, 2002, BLOOD, V100, P3512, DOI 10.1182/blood-2002-04-1177; Fortunel NO, 2000, BLOOD, V96, P2022; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; HIYAMA K, 1995, J IMMUNOL, V155, P3711; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakauchi H, 2001, ANN NY ACAD SCI, V938, P18; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OGAWA S, 1995, BLOOD, V86, P1548, DOI 10.1182/blood.V86.4.1548.bloodjournal8641548; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; RAGIONE FD, 1997, BIOCHEM BIOPH RES CO, V231, P73; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; Szilvassy SJ, 2001, EXP HEMATOL, V29, P1494, DOI 10.1016/S0301-472X(01)00751-2; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Yokota T, 1998, BLOOD, V91, P3263, DOI 10.1182/blood.V91.9.3263.3263_3263_3272	54	112	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24986	24993		10.1074/jbc.M400407200	http://dx.doi.org/10.1074/jbc.M400407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15067010	hybrid			2022-12-25	WOS:000221827900012
J	Koski, MK; Haapalainen, AM; Hiltunen, JK; Glumoff, T				Koski, MK; Haapalainen, AM; Hiltunen, JK; Glumoff, T			A two-domain structure of one subunit explains unique features of eukaryotic hydratase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENOYL-COA HYDRATASE; PEROXISOMAL MULTIFUNCTIONAL ENZYME; BIFUNCTIONAL PROTEIN-DEFICIENCY; SITE-DIRECTED MUTAGENESIS; RAT-LIVER; AEROMONAS-CAVIAE; MOLECULAR-CLONING; DIFFRACTION DATA; FATTY-ACIDS; BIOSYNTHESIS	2-Enoyl-CoA hydratase 2, a part from multifunctional enzyme type 2, hydrates trans-2-enoyl-CoA to 3-hydroxyacyl-CoA in the (3R)-hydroxy-dependent route of peroxisomal beta-oxidation of fatty acids. Unliganded and (3R)-hydroxydecanoyl coenzyme A-complexed crystal structures of 2-enoyl-CoA hydratase 2 from Candida tropicalis multifunctional enzyme type 2 were solved to 1.95- and 2.35-Angstrom resolution, respectively. 2-Enoyl-CoA hydratase 2 is a dimeric, alpha+beta protein with a novel quaternary structure. The overall structure of the two-domain subunit of eukaryotic 2-enoyl-CoA hydratase 2 resembles the homodimeric, hot dog fold structures of prokaryotic (R)-specific 2-enoyl-CoA hydratase and beta-hydroxydecanoyl thiol ester dehydrase. Importantly, though, the eukaryotic hydratase 2 has a complete hot dog fold only in its C-domain, whereas the N-domain lacks a long central alpha-helix, thus creating space for bulkier substrates in the binding pocket and explaining the observed difference in substrate preference between eukaryotic and prokaryotic enzymes. Although the N- and C-domains have an identity of < 10% at the amino acid level, they share a 50% identity at the nucleotide level and fold similarly. We suggest that a subunit of 2-enoyl-CoA hydratase 2 has evolved via a gene duplication with the concomitant loss of one catalytic site. The hydrogen bonding network of the active site of 2-enoyl-CoA hydratase 2 resembles the active site geometry of mitochondrial (S)-specific 2-enoyl-CoA hydratase 1, although in a mirror image fashion. This arrangement allows the reaction to occur by similar mechanism, supported by mutagenesis and mechanistic studies, although via reciprocal stereochemistry.	Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	Glumoff, T (corresponding author), Univ Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	tuomo.glumoff@oulu.fi		Hiltunen, Kalervo/0000-0002-3073-9602				Bahnson BJ, 2002, BIOCHEMISTRY-US, V41, P2621, DOI 10.1021/bi015844p; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 2001, J APPL CRYSTALLOGR, V34, P97, DOI 10.1107/S0021889800017362; DieuaideNoubhani M, 1996, EUR J BIOCHEM, V240, P660, DOI 10.1111/j.1432-1033.1996.0660h.x; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; Engel CK, 1998, J MOL BIOL, V275, P847, DOI 10.1006/jmbi.1997.1491; Fukui T, 1997, J BACTERIOL, V179, P4821, DOI 10.1128/jb.179.15.4821-4830.1997; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; Hisano T, 2003, J BIOL CHEM, V278, P617, DOI 10.1074/jbc.M205484200; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kiema TR, 1999, BIOCHEMISTRY-US, V38, P2991, DOI 10.1021/bi981646v; Koski MK, 2003, ACTA CRYSTALLOGR D, V59, P1302, DOI 10.1107/S090744490300982X; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Madison LL, 1999, MICROBIOL MOL BIOL R, V63, P21, DOI 10.1128/MMBR.63.1.21-53.1999; MOHRIG JR, 1995, SCIENCE, V269, P527; Moller G, 2001, MOL CELL ENDOCRINOL, V171, P61, DOI 10.1016/S0303-7207(00)00388-9; MOTHES G, 1995, CAN J MICROBIOL, V41, P68, DOI 10.1139/m95-170; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Qin YM, 2000, J BIOL CHEM, V275, P4965, DOI 10.1074/jbc.275.7.4965; Qin YM, 1997, BIOCHEM J, V321, P21, DOI 10.1042/bj3210021; Qin YM, 1997, BIOCHEM J, V328, P377, DOI 10.1042/bj3280377; Reiser SE, 2000, APPL MICROBIOL BIOT, V53, P209, DOI 10.1007/s002530050010; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsuge T, 2000, FEMS MICROBIOL LETT, V184, P193, DOI 10.1111/j.1574-6968.2000.tb09013.x; Tsuge T, 2003, APPL ENVIRON MICROB, V69, P4830, DOI 10.1128/AEM.69.8.4830-4836.2003; van Grunsven EG, 1999, HUM MOL GENET, V8, P1509, DOI 10.1093/hmg/8.8.1509; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	37	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24666	24672		10.1074/jbc.M400293200	http://dx.doi.org/10.1074/jbc.M400293200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051722	hybrid			2022-12-25	WOS:000221702500097
J	Schmelter, T; Trigatti, BL; Gerber, GE; Mangroo, D				Schmelter, T; Trigatti, BL; Gerber, GE; Mangroo, D			Biochemical demonstration of the involvement of fatty acyl-CoA synthetase in fatty acid translocation across the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ESCHERICHIA-COLI FADD; SACCHAROMYCES-CEREVISIAE; TRANSPORT PROTEIN; 3T3-L1 ADIPOCYTES; TRANSMEMBRANE MOVEMENT; BINDING PROTEIN; SIGNATURE MOTIF; FLIP-FLOP; LONG	Fatty acyl-CoA synthetase, the first enzyme of the beta-oxidation pathway, has been proposed to be involved in long chain fatty acid translocation across the plasma membrane of prokaryotic and eukaryotic cells. To test this proposal, we used an in vitro system consisting of Escherichia coli inner ( plasma) membrane vesicles containing differing amounts of trapped fatty acyl-CoA synthetase and its substrates CoA and ATP. This system allowed us to investigate the involvement of fatty acyl-CoA synthetase independently of other proteins that are involved in fatty acid translocation across the outer membrane and in downstream steps in beta-oxidation, because these proteins are not retained in the inner membrane vesicles. Fatty acid uptake in vesicles containing fatty acyl-CoA synthetase was dependent on the amount of exogenous ATP and CoASH trapped by freeze-thawing. The uptake of fatty acid in the presence of nonlimiting amounts of ATP and CoASH was dependent on the amount of endogenous fatty acyl-CoA synthetase either retained within vesicles during isolation or trapped within vesicles after isolation by freeze-thawing. Moreover, the fatty acid taken up by the vesicles was converted to fatty acyl-CoA. These data are consistent with the proposal that fatty acyl-CoA synthetase facilitates long chain fatty acid permeation of the inner membrane by a vectorial thioesterification mechanism.	Univ Guelph, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Guelph; McMaster University	Mangroo, D (corresponding author), Univ Guelph, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada.	dmangroo@uoguelph.ca		Trigatti, Bernardo (Dino) L./0000-0002-4556-119X				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; AZIZAN A, 1994, J BACTERIOL, V176, P6653, DOI 10.1128/JB.176.21.6653-6662.1994; Azizan A, 1999, ARCH BIOCHEM BIOPHYS, V365, P299, DOI 10.1006/abbi.1999.1171; BLACK PN, 1987, J BIOL CHEM, V262, P1412; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Caviglia JM, 2004, J BIOL CHEM, V279, P11163, DOI 10.1074/jbc.M311392200; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Gargiulo CE, 1999, J LIPID RES, V40, P881; GINSBURGH CL, 1984, J BIOL CHEM, V259, P8437; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Hamilton JA, 2003, CURR OPIN LIPIDOL, V14, P263, DOI 10.1097/00041433-200306000-00006; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1972, BIOCHIM BIOPHYS ACTA, V265, P367, DOI 10.1016/0304-4157(72)90014-7; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KAMEDA K, 1987, BIOCHEM INT, V14, P227; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KONINGS WN, 1973, P NATL ACAD SCI USA, V70, P3376, DOI 10.1073/pnas.70.12.3376; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; KUMAR GB, 1993, J BIOL CHEM, V268, P15469; MALAMY MH, 1964, BIOCHEMISTRY-US, V3, P1889, DOI 10.1021/bi00900a017; MALOY SR, 1981, J BIOL CHEM, V256, P3735; MANGROO D, 1995, BIOCHEM CELL BIOL, V73, P223, DOI 10.1139/o95-027; MANGROO D, 1992, J BIOL CHEM, V267, P17095; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; MANGROO D, 1991, FASEB J, V5, P6602; MANGROO D, 1991, CAN FED BIOL SOC P, V34, P85; NUNN WD, 1979, J BIOL CHEM, V254, P9130; NUNN WD, 1986, J BIOL CHEM, V261, P167; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; OSUMI T, 1979, BIOCHIM BIOPHYS ACTA, V574, P258; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; OVERATH P, 1967, BIOCHEM BIOPH RES CO, V29, P28, DOI 10.1016/0006-291X(67)90535-9; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; SAMUEL D, 1970, European Journal of Biochemistry, V12, P576, DOI 10.1111/j.1432-1033.1970.tb00889.x; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SPECTOR AA, 1969, J LIPID RES, V10, P56; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Trigatti BL, 1996, BIOCHEM J, V313, P487, DOI 10.1042/bj3130487; Uberti MA, 2003, BBA-PROTEINS PROTEOM, V1645, P193, DOI 10.1016/S1570-9639(02)00540-X; Weimar JD, 2002, J BIOL CHEM, V277, P29369, DOI 10.1074/jbc.M107022200; ZHOU SL, 1992, J BIOL CHEM, V267, P14456; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	52	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24163	24170		10.1074/jbc.M313632200	http://dx.doi.org/10.1074/jbc.M313632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15067008	hybrid			2022-12-25	WOS:000221702500039
J	Ren, Y; Chan, HM; Li, Z; Lin, CL; Nicholls, J; Chen, CF; Lee, PY; Lui, V; Bacher, M; Tam, PKH				Ren, Y; Chan, HM; Li, Z; Lin, CL; Nicholls, J; Chen, CF; Lee, PY; Lui, V; Bacher, M; Tam, PKH			Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma	ONCOGENE			English	Article						MIF; N-myc; neuroblastoma; MAPK; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; HUMAN-MELANOMA CELLS; ANGIOGENIC FACTORS; HEPATOCELLULAR-CARCINOMA; TUMOR-GROWTH; FACTOR MIF; RECEPTORS; CANCER; STAGE; ADENOCARCINOMA	Macrophage migration inhibitory factor (MIF) has been linked to fundamental processes such as control of cell proliferation, cell survival, angiogenesis, and tumor progression. The expression of MIF has been reported in several tumors. However, the precise role of MIF in tumor cells remains unclear. In the present study, we investigated the expression pattern and the function of MIF in neuroblastoma. Our results showed that intracellular MIF was upregulated in neuroblastoma tumor tissues and cell lines. MIF protein expression significantly correlated with the grade of tumor differentiation. In addition, we found that MIF induced a significant dose-dependent increase of vascular endothelial growth factor and interleukin-8 secretion. We also observed that an increased MIF expression level correlated with N-Myc protein ( the N-myc oncogene product) expression in neuroblastoma tissues. MIF increased the expression of N-myc mRNA and N-Myc protein and induced N-Myc translocation from the cytoplasm to nucleus in neuroblastoma cell lines. MIF-induced N-Myc expression was found to be dependent on ERK signaling pathways. The inhibition of ERK activation reduced MIF-mediated N-Myc expression. These results suggest that MIF may contribute to the progression of neuroblastoma by ( a) inducing N-Myc expression and ( b) upregulating the expression of angiogenic factors.	Univ Hong Kong, Med Ctr, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Med Ctr, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Med Ctr, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; Univ Marburg, Inst Immunol, D-35032 Marburg, Germany	University of Hong Kong; University of Hong Kong; University of Hong Kong; Philipps University Marburg	Ren, Y (corresponding author), Univ Hong Kong, Med Ctr, Dept Surg, Room L09-56,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	yren@hkucc.hku.hk; paultam@hkucc.hku.hk	Lee, Pui Yue/C-4332-2009; Nicholls, John Malcolm/C-4375-2009; /C-4359-2009; /C-4405-2009	Nicholls, John Malcolm/0000-0001-7217-7444; /0000-0002-1758-8854; /0000-0001-6231-3035				Akbar SMF, 2001, CANCER LETT, V171, P125, DOI 10.1016/S0304-3835(01)00606-1; BERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Bin Q, 2002, TUMOR BIOL, V23, P123, DOI 10.1159/000064028; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BROWN LF, 1993, CANCER RES, V53, P4727; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chambery D, 1999, CANCER RES, V59, P2898; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Ferrer FA, 2000, J UROLOGY, V164, P1016, DOI 10.1016/S0022-5347(05)67240-0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Mattern J, 1996, BRIT J CANCER, V73, P931, DOI 10.1038/bjc.1996.166; Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Misawa A, 2000, CANCER RES, V60, P64; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Rossler J, 1999, INT J CANCER, V81, P113; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; SINGH RK, 1994, CANCER RES, V54, P3242; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Wada RK, 1997, CANCER LETT, V121, P181, DOI 10.1016/S0304-3835(97)00351-0; Yang YB, 2000, J CLIN ENDOCR METAB, V85, P4721, DOI 10.1210/jc.85.12.4721	48	78	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4146	4154		10.1038/sj.onc.1207490	http://dx.doi.org/10.1038/sj.onc.1207490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064733				2022-12-25	WOS:000221520200013
J	Nandakumar, J; Ho, CK; Lima, CD; Shuman, S				Nandakumar, J; Ho, CK; Lima, CD; Shuman, S			RNA substrate specificity and structure-guided mutational analysis of bacteriophage T4 RNA ligase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(+)-DEPENDENT DNA-LIGASE; CRYSTAL-STRUCTURE; CAPPING ENZYME; FUNCTIONAL DOMAINS; MITOCHONDRIAL RNA; EDITING LIGASES; COMPLEX; GENE; PURIFICATION; MECHANISM	Here we report that bacteriophage T4 RNA ligase 2 (Rnl2) is an efficient catalyst of RNA ligation at a 3'-OH/ 5'-PO4 nick in a double-stranded RNA or an RNA . DNA hybrid. The critical role of the template strand in approximating the reactive 3'-OH and 5'-PO4 termini is underscored by the drastic reductions in the RNA-sealing activity of Rnl2 when the duplex substrates contain gaps or flaps instead of nicks. RNA nick joining requires ATP and a divalent cation cofactor ( either Mg or Mn). Neither dATP, GTP, CTP, nor UTP can substitute for ATP. We identify by alanine scanning seven functionally important amino acids (Tyr-5, Arg-33, Lys-54, Gln-106, Asp-135, Arg-155, and Ser-170) within the N-terminal nucleotidyltransferase domain of Rnl2 and impute specific roles for these residues based on the crystal structure of the AMP-bound enzyme. Mutational analysis of 14 conserved residues in the C-terminal domain of Rnl2 identifies 3 amino acids ( Arg-266, Asp-292, and Glu-296) as essential for ligase activity. Our findings consolidate the evolutionary connections between bacteriophage Rnl2 and the RNA-editing ligases of kinetoplastid protozoa.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Sloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Ho, KIong/GPP-6051-2022	Nandakumar, Jayakrishnan/0000-0001-9146-2785; Lima, Christopher/0000-0002-9163-6092	NIGMS NIH HHS [GM63611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BAYMILLER J, 1994, GENE, V142, P129, DOI 10.1016/0378-1119(94)90367-0; Blanc V, 1999, J BIOL CHEM, V274, P24289, DOI 10.1074/jbc.274.34.24289; Blondal T, 2003, NUCLEIC ACIDS RES, V31, P7247, DOI 10.1093/nar/gkg914; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Doherty AJ, 1999, NUCLEIC ACIDS RES, V27, P3253, DOI 10.1093/nar/27.16.3253; Doherty AJ, 1999, J MOL BIOL, V285, P63, DOI 10.1006/jmbi.1998.2301; Durantel D, 1998, J GEN VIROL, V79, P629, DOI 10.1099/0022-1317-79-3-629; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 1997, J VIROL, V71, P1931, DOI 10.1128/JVI.71.3.1931-1937.1997; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Lim JH, 2001, ARCH BIOCHEM BIOPHYS, V388, P253, DOI 10.1006/abbi.2001.2291; MARTINS A, 2004, IN PRESS J BIOL CHEM; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Palazzo SS, 2003, MOL BIOCHEM PARASIT, V127, P161, DOI 10.1016/S0166-6851(02)00333-X; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Sawaya R, 2003, J BIOL CHEM, V278, P43928, DOI 10.1074/jbc.M307839200; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Shuman S, 1995, BIOCHEMISTRY-US, V34, P16138, DOI 10.1021/bi00049a029; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P3536, DOI 10.1093/nar/26.15.3536; SRISKANDA V, 2002, J BIOL CHEM, V277, P9685; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Yin SM, 2004, VIROLOGY, V319, P141, DOI 10.1016/j.virol.2003.10.037; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200	38	67	77	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31337	31347		10.1074/jbc.M402394200	http://dx.doi.org/10.1074/jbc.M402394200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15084599	hybrid			2022-12-25	WOS:000222726800054
J	Johns, TG; Adamas, TE; Cochran, JR; Hall, NE; Hoyne, PA; Olsen, MJ; Kim, YS; Rothacker, J; Nice, EC; Walker, F; Ritter, G; Jungbluth, AJ; Old, LJ; Ward, CW; Burgess, AW; Wittrup, KD; Scott, AM				Johns, TG; Adamas, TE; Cochran, JR; Hall, NE; Hoyne, PA; Olsen, MJ; Kim, YS; Rothacker, J; Nice, EC; Walker, F; Ritter, G; Jungbluth, AJ; Old, LJ; Ward, CW; Burgess, AW; Wittrup, KD; Scott, AM			Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SURFACE DISPLAY; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; EGF; MUTANT; TARGET; DOMAIN; GENE; LUNG; AMPLIFICATION	The epidermal growth factor receptor (EGFR) is over-expressed in many epithelial cancers, an observation often correlated with poor clinical outcome. Overexpression of the EGFR is commonly caused by EGFR gene amplification and is sometimes associated with expression of a variant EGFR (de2-7 EGFR or EGFRvIII) bearing an internal deletion in its extracellular domain. Monoclonal antibody (mAb) 806 is a novel EGFR antibody with significant antitumor activity that recognizes both the de2-7 EGFR and a subset of the wild type (wt) EGFR when overexpressed but does not bind the wt EGFR expressed in normal tissues. Despite only binding to a low proportion of the wt EGFR expressed in A431 tumor cells (similar to10%), mAb 806 displays robust antitumor activity against A431 xenografts grown in nude mice. To elucidate the mechanism leading to its unique specificity and mode of antitumor activity, we have determined the EGFR binding epitope of mAb 806. Analysis of mAb 806 binding to EGFR fragments expressed either on the surface of yeast or in an immunoblot format identified a disulfide-bonded loop (amino acids 287-302) that contains the mAb 806 epitope. Indeed, mAb 806 binds with apparent high affinity (similar to30 nM) to a synthetic EGFR peptide corresponding to these amino acids. Analysis of EGFR structures indicates that the epitope is fully exposed only in the transitional form of the receptor that occurs because EGFR changes from the inactive tethered conformation to a ligand-bound active form. It would seem that mAb 806 binds this small proportion of transient receptors, preventing their activation, which in turn generates a strong antitumor effect. Finally, our observations suggest that the generation of antibodies to transitional forms of growth factor receptors may represent a novel way of reducing normal tissue targeting yet retaining antitumor activity.	Austin Hosp, Oncogen Signalling Lab, Ludwig Inst Canc Res, Tumor Targeting Program, Heidelberg, Vic 3084, Australia; CSIRO Hlth Sci & Nutr, Parkville, Vic 3052, Australia; MIT, Cambridge, MA 02139 USA; Royal Melbourne Hosp, Epithelial Biochem Lab, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York, NY 10021 USA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center	Johns, TG (corresponding author), Austin Hosp, Oncogen Signalling Lab, Ludwig Inst Canc Res, Tumor Targeting Program, Level 6,Harold Stokes Bldg,Studley Rd, Heidelberg, Vic 3084, Australia.	terry.johns@ludwig.edu.au	Nice, Edouard C/B-1026-2011; Adams, Timothy E/I-6231-2012; Johns, Terrance/C-2441-2008	Adams, Timothy E/0000-0003-3436-0066; Johns, Terrance/0000-0002-8874-4543; Kim, Yong-Sung/0000-0003-2673-1509; Scott, Andrew/0000-0002-6656-295X; Olsen, Mark/0000-0003-2871-1923; Rothacker, Julie/0000-0001-7560-4982; Hall, Nathan/0000-0001-8942-0498	NATIONAL CANCER INSTITUTE [R01CA096504] Funding Source: NIH RePORTER; NCI NIH HHS [CA96504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Busam KJ, 2001, BRIT J DERMATOL, V144, P1169, DOI 10.1046/j.1365-2133.2001.04226.x; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cochran JR, 2004, J IMMUNOL METHODS, V287, P147, DOI 10.1016/j.jim.2004.01.024; de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Frederick L, 2000, CANCER RES, V60, P1383; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Herberman RB, 2002, SEMIN ONCOL, V29, P27, DOI 10.1053/sonc.2002.33079; Herbst RS, 2001, EXPERT OPIN BIOL TH, V1, P719, DOI 10.1517/14712598.1.4.719; Herbst RS, 2002, CANCER-AM CANCER SOC, V94, P1593, DOI 10.1002/cncr.10372; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499; Leahy DJ, 2000, PROTEIN EXPRES PURIF, V20, P500, DOI 10.1006/prep.2000.1331; Luwor RB, 2001, CANCER RES, V61, P5355; Lynch DH, 2002, SEMIN ONCOL, V29, P47, DOI 10.1053/sonc.2002.31522; MALDEN LT, 1988, CANCER RES, V48, P2711; MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; Mishima K, 2001, CANCER RES, V61, P5349; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Stragliotto G, 1996, EUR J CANCER, V32A, P636, DOI 10.1016/0959-8049(95)00592-7; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tang CK, 2000, CANCER RES, V60, P3081; Wakeling AE, 2002, CURR OPIN PHARMACOL, V2, P382, DOI 10.1016/S1471-4892(02)00183-2; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wikstrand CJ, 1998, J NEUROVIROL, V4, P148, DOI 10.3109/13550289809114515; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zhen YJ, 2003, BIOCHEMISTRY-US, V42, P5478, DOI 10.1021/bi027101p	44	115	216	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30375	30384		10.1074/jbc.M401218200	http://dx.doi.org/10.1074/jbc.M401218200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15075331	hybrid			2022-12-25	WOS:000222531900063
J	Feng, LB; Guedes, S; Wang, TW				Feng, LB; Guedes, S; Wang, TW			Atrophin-1-interacting protein 4/human itch is a ubiquitin E3 ligase for human enhancer of filamentation 1 in transforming growth factor-beta signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ANAPHASE-PROMOTING COMPLEX; FAMILY-MEMBER HEF1; DOCKING PROTEIN; WW DOMAIN; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; CAS-L; DEGRADATION; INTEGRIN	Atrophin-1-interacting protein 4 (AIP4) is the human homolog of the mouse Itch protein (hItch), an E3 ligase for Notch and JunB. Human enhancer of filamentation 1 (HEF1) has been implicated in signaling pathways such as those mediated by integrin, T cell receptor, and B cell receptor and functions as a multidomain docking protein. Recent studies suggest that HEF1 is also involved in the transforming growth factor-beta (TGF-beta) signaling pathways, by interacting with Smad3, a key signal transducer downstream of the TGF-beta type I receptor. The interaction of Smad3 with HEF1 induces HEF1 proteasomal degradation, which was further enhanced by TGF-beta stimulation. The detailed molecular mechanisms of HEF1 degradation regulated by Smad3 were poorly understood. Here we report our studies that demonstrate the function of AIP4 as an ubiquitin E3 ligase for HEF1. AIP4 forms a complex with both Smad3 and HEF1 through its WW domains in a TGF-beta-independent manner and regulates HEF1 ubiquitination and degradation, which can be enhanced by TGF-beta stimulation. These findings reveal a new mechanism for Smad3-regulated proteasomal degradation events and also broaden the network of cross-talk between the TGF-beta signaling pathway and those involving HEF1 and AIP4.	Virginia Mason, Benaroya Res Inst, Seattle, WA 98101 USA	Benaroya Research Institute; Virginia Mason Medical Center	Wang, TW (corresponding author), Virginia Mason, Benaroya Res Inst, 1201 9th Ave, Seattle, WA 98101 USA.	wangt@vmresearch.org						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Fashena SJ, 2002, J CELL SCI, V115, P99; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Kamiguchi K, 1999, J IMMUNOL, V163, P563; Kanda H, 1997, EUR J IMMUNOL, V27, P2113, DOI 10.1002/eji.1830270840; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Law SF, 1998, MOL CELL BIOL, V18, P3540, DOI 10.1128/MCB.18.6.3540; Law SF, 1999, EXP CELL RES, V252, P224, DOI 10.1006/excr.1999.4609; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Margolis RL, 1996, MOL BRAIN RES, V36, P219, DOI 10.1016/0169-328X(95)00241-J; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Stroschein SL, 2001, GENE DEV, V15, P2822; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093; Zheng MZ, 2002, J BIOL CHEM, V277, P39599, DOI 10.1074/jbc.M202263200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	36	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29681	29690		10.1074/jbc.M403221200	http://dx.doi.org/10.1074/jbc.M403221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15051726	hybrid			2022-12-25	WOS:000222445300104
J	Dasgupta, A; Ramsey, KL; Smith, JS; Auble, DT				Dasgupta, A; Ramsey, KL; Smith, JS; Auble, DT			Sir antagonist 1 (San1) is a ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATING-TYPE LOCI; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; TRANSCRIPTIONAL STATES; CHROMATIN-STRUCTURE; SILENCING PROTEINS; SHUTTLE VECTORS; GENE-EXPRESSION; HISTONE H2B; YEAST	Mutations in Sir Antagonist 1 (SAN1) suppress defects in SIR4 and SPT16 in Saccharomyces cerevisiae. San1 contains a RING domain, suggesting that it functions by targeting mutant sir4 and spt16 proteins for degradation by a ubiquitin-mediated pathway. Consistent with this idea, mutant sir4 and spt16 proteins are unstable in SAN1 cells but are stabilized in san1Delta cells. We demonstrate that San1 possesses ubiquitin-protein isopeptide ligase activity in vitro, and the ubiquitin-protein isopeptide ligase activity of San1 is required for its function in vivo. Wild-type Sir4 has a half-life of about 21 min, and san1Delta increased Sir4 half-life to >90 min. In contrast, san1Delta did not affect the stability of wild-type Spt16, Sir3, Sir2, or the Spt16-associated proteins Pob3 and Nhp6. Loss of SAN1 also did not affect the stability of Ste6-166, a highly unstable protein in yeast. These results support the idea that San1 controls the turnover of a specific class of unstable nuclear proteins. Sir4 nucleates the assembly of silent chromatin at telomeres and the silent mating-type loci (HM) in S. cerevisiae. Sir4 can also affect silencing in the rDNA indirectly by sequestering limiting Sir2. Increasing the stability of wild-type Sir4 by deleting SAN1 had only subtle effects on silencing, suggesting that silent chromatin in yeast is robustly buffered against changes in Sir4 stability. Consistent with the idea that San1 participates as an accessory factor to regulate silent chromatin, including the silent mating-type loci, microarray analysis defined a small but statistically significant role for San1 in transcription of several mating pheromone-responsive genes.	Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Auble, DT (corresponding author), Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave,Rm 6213, Charlottesville, VA 22908 USA.	dta4n@virginia.edu			NCI NIH HHS [P30-CA44579] Funding Source: Medline; NIGMS NIH HHS [GM55763, GM61692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA044579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055763, R01GM061692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2002, CELL, V111, P281, DOI 10.1016/S0092-8674(02)01081-4; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Aravind L, 1998, CURR BIOL, V8, pR111, DOI 10.1016/S0960-9822(98)70982-0; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Evans DRH, 1998, GENETICS, V150, P1393; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Freiberg G, 2000, CURR GENET, V37, P221, DOI 10.1007/s002940050523; Georgel PT, 2001, P NATL ACAD SCI USA, V98, P8584, DOI 10.1073/pnas.151258798; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Guarente L, 2000, GENE DEV, V14, P1021; HABER JE, 1979, GENETICS, V93, P13; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kahana A, 1999, MOL CELL BIOL, V19, P6608; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KLAR AJS, 1979, GENETICS, V93, P37; Laroche T, 2000, J STRUCT BIOL, V129, P159, DOI 10.1006/jsbi.2000.4240; Lau A, 2002, GENE DEV, V16, P2935, DOI 10.1101/gad.764102; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Parsons XH, 2003, P NATL ACAD SCI USA, V100, P1609, DOI 10.1073/pnas.0434064100; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; RINE J, 1979, GENETICS, V93, P877; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SCHNELL R, 1989, GENETICS, V122, P29; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MS, 1998, GENETICS, V150, P613; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1998, GENETICS, V149, P1205; Stone EM, 1996, J CELL BIOL, V135, P571, DOI 10.1083/jcb.135.3.571; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; SUSSEL L, 1993, MOL CELL BIOL, V13, P3919, DOI 10.1128/MCB.13.7.3919; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; XU QL, 1995, MOL CELL BIOL, V15, P6025; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553; Zhang ZM, 1997, MOL CELL BIOL, V17, P5461, DOI 10.1128/MCB.17.9.5461; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	68	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26830	26838		10.1074/jbc.M400894200	http://dx.doi.org/10.1074/jbc.M400894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078868	hybrid			2022-12-25	WOS:000222120400006
J	Murphy, KJ; Merry, CLR; Lyon, M; Thompson, JE; Roberts, IS; Gallagher, JT				Murphy, KJ; Merry, CLR; Lyon, M; Thompson, JE; Roberts, IS; Gallagher, JT			A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ESCHERICHIA-COLI; FLAVOBACTERIUM-HEPARINUM; SOLVOLYTIC DESULFATION; SUBSTRATE-SPECIFICITY; BINDING; POLYSACCHARIDE; PROTEOGLYCANS; DIVERSITY; SEQUENCE	Elucidation of the molecular structure of heparan sulfate (HS) is the key to understanding its functional versatility as a co-receptor for growth factors and morphogens. We have identified and exploited the novel substrate specificity of the coliphage K5 lyase in studies of the domain organization of HS. We show that K5 lyase cleaves HS principally within non-sulfated sequences of four or more N-acetylated disaccharides. Uniquely, sections comprising alternating N-acetylated and N-sulfated units are resistant to the enzyme, as are the highly sulfated S domains. Spacing of the K5 lyase cleavage sites ( similar to 7 - 8 kDa) is similar to that of the S domains. On the basis of these findings, we propose a refined model of the structure of HS in which N-acetylated sequences of four to five disaccharide units (GlcNAc-GlcUA)(4 -5) are positioned centrally between the S domains. The latter are embedded within N-acetylated and N-sulfated sequences, forming extended regions of hypervariable sulfation distributed at regular intervals along the polymer chain. K5 lyase provides a means of excision of these composite sulfated regions for structural and functional analyses.	Canc Res UK, Manchester M20 4BX, Lancs, England; Univ Manchester, Dept Med Oncol, Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Cancer Research UK; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Manchester	Merry, CLR (corresponding author), Canc Res UK, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	cmerry@picr.man.ac.uk		Lyon, Malcolm/0000-0001-9575-6879; merry, catherine/0000-0002-3490-2809				Blackhall FH, 2003, BIOCHEM J, V375, P131, DOI 10.1042/BJ20030730; Clarke BR, 2000, J BACTERIOL, V182, P3761, DOI 10.1128/JB.182.13.3761-3766.2000; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; Gallagher JT, 2000, PROTEOGLYCANS STRUCT, P27; GUPTA DS, 1982, FEMS MICROBIOL LETT, V16, P13; Hanfling P, 1996, J BACTERIOL, V178, P4747; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Legoux R, 1996, J BACTERIOL, V178, P7260, DOI 10.1128/jb.178.24.7260-7264.1996; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAGASAWA K, 1974, CARBOHYD RES, V36, P265, DOI 10.1016/S0008-6215(00)83047-5; Ono K, 1999, GLYCOBIOLOGY, V9, P705, DOI 10.1093/glycob/9.7.705; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Robinson CJ, 2001, J CELL SCI, V114, P853; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1	41	111	114	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27239	27245		10.1074/jbc.M401774200	http://dx.doi.org/10.1074/jbc.M401774200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15047699	hybrid			2022-12-25	WOS:000222120400052
J	Pai, HV; Kommaddi, RP; Chinta, SJ; Mori, T; Boyd, MR; Ravindranath, V				Pai, HV; Kommaddi, RP; Chinta, SJ; Mori, T; Boyd, MR; Ravindranath, V			A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; XENOBIOTIC METABOLISM; CONSTITUTIVE EXPRESSION; MULTIPLE FORMS; MONOOXYGENASE; SYSTEM; IDENTIFICATION; INDUCIBILITY; LOCALIZATION; ACTIVATION	A frameshift mutation 138delT generates an open reading frame in the pseudogene, cytochrome P4502D7 (CYP2D7), and an alternate spliced functional transcript of CYP2D7 containing partial inclusion of intron 6 was identified in human brain but not in liver or kidney from the same individual. mRNA and protein of the brain variant CYP2D7 were detected in 6 of 12 human autopsy brains. Genotyping revealed the presence of the frameshift mutation 138delT only in those human subjects who expressed the brain variant CYP2D7. Genomic DNA analysis in normal volunteers revealed the presence of functional CYP2D7 in 4 of 8 individuals. In liver, the major organ involved in drug metabolism, a minor metabolic pathway mediated by CYP2D6 metabolizes codeine (pro-drug) to morphine ( active drug), whereas norcodeine is the major metabolite. In contrast, when expressed in Neuro2a cells, brain variant CYP2D7 metabolized codeine to morphine with greater efficiency compared with the corresponding activity in cells expressing CYP2D6. Morphine binds to mu-opioid receptors in certain regions of the central nervous system, such as periaqueductal gray, and produces pain relief. The brain variant CYP2D7 and mu-opioid receptor colocalize in neurons of the periaqueductal gray area in human brain, indicating that metabolism of codeine to morphine could occur at the site of opioid action. Histiospecific isoforms of P450 generated by alternate splicing, which mediate selective metabolism of pro- drugs within tissues, particularly the brain, to generate active drugs may play an important role in drug action and provide newer insights into the genetics of metabolism.	Natl Brain Res Inst, Manesar 122050, Haryana, India; NCI, Mol Targets Dev Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA; Univ S Alabama, Canc Res Inst, Mobile, AL 36688 USA	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of South Alabama	Ravindranath, V (corresponding author), Natl Brain Res Inst, Manesar 122050, Haryana, India.	vijir@nbrc.ac.in			NIMH NIH HHS [MH55494] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANANDATHEERTHAVARADA HK, 1990, BRAIN RES, V536, P339, DOI 10.1016/0006-8993(90)90047-F; ANANDATHEERTHAVARADA HK, 1992, BIOCHEM J, V288, P483, DOI 10.1042/bj2880483; BHAGWAT SV, 1995, ARCH BIOCHEM BIOPHYS, V320, P73, DOI 10.1006/abbi.1995.1344; Bhagwat SV, 1996, BIOCHEM PHARMACOL, V51, P1469, DOI 10.1016/0006-2952(96)00088-3; BHAMRE S, 1992, BIOCHEM PHARMACOL, V44, P1223, DOI 10.1016/0006-2952(92)90390-5; BOYD MR, 1980, CRC CR REV TOXICOL, V7, P103, DOI 10.3109/10408448009037487; Brosen K, 1993, Psychopharmacol Ser, V10, P199; Caraco Y, 1996, DRUG METAB DISPOS, V24, P761; CHEN ZR, 1990, LIFE SCI, V46, P1067; Chinta SJ, 2002, MOL BRAIN RES, V103, P49, DOI 10.1016/S0169-328X(02)00177-8; Christie MJ, 2000, CLIN EXP PHARMACOL P, V27, P520, DOI 10.1046/j.1440-1681.2000.03291.x; DEMONTELLANO O, 1986, CYTOCHROME P 459 STR; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; GRAM TE, 1986, ANNU REV PHARMACOL, V26, P259; Hedlund E, 2001, CURR DRUG METAB, V2, P245, DOI 10.2174/1389200013338513; HODGSON AV, 1993, MOL CELL BIOCHEM, V120, P171, DOI 10.1007/BF00926090; Kalow W., 1992, PHARMACOGENETICS DRU; Kim I, 2002, CLIN CHEM, V48, P1486; KIMURA S, 1989, AM J HUM GENET, V45, P889; KODAIRA H, 1989, P NATL ACAD SCI USA, V86, P716, DOI 10.1073/pnas.86.2.716; KOMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P721, DOI 10.1006/bbrc.1993.2309; Lattard V, 2003, MOL PHARMACOL, V63, P253, DOI 10.1124/mol.63.1.253; Lovlie R, 2001, PHARMACOGENETICS, V11, P45, DOI 10.1097/00008571-200102000-00006; McFadyen MCE, 1998, BIOCHEM PHARMACOL, V55, P825, DOI 10.1016/S0006-2952(97)00516-9; MCLEMORE TL, 1990, J NATL CANCER I, V82, P1420, DOI 10.1093/jnci/82.17.1420; Pai H. V., 2002, Pharmacogenomics Journal, V2, P243, DOI 10.1038/sj.tpj.6500115; RAVINDRANATH V, 1995, DRUG METAB REV, V27, P419, DOI 10.3109/03602539508998330; RAVINDRANATH V, 1989, BRAIN RES, V496, P331, DOI 10.1016/0006-8993(89)91083-4; SINDRUP SH, 1993, PAIN, V53, P335, DOI 10.1016/0304-3959(93)90229-I; Sindrup SH, 1995, PHARMACOGENETICS, V5, P335, DOI 10.1097/00008571-199512000-00001; TYNDALE RF, 1991, BRIT J CLIN PHARMACO, V31, P655, DOI 10.1111/j.1365-2125.1991.tb05588.x; Upadhya SC, 2000, ARCH BIOCHEM BIOPHYS, V373, P23, DOI 10.1006/abbi.1999.1477; Voirol P, 2000, BRAIN RES, V855, P235, DOI 10.1016/S0006-8993(99)02354-9; Wang HM, 1997, ARCH BIOCHEM BIOPHYS, V344, P365, DOI 10.1006/abbi.1997.0230; WARNER M, 1993, J STEROID BIOCHEM, V47, P191, DOI 10.1016/0960-0760(93)90074-7; WARNER M, 1994, P NATL ACAD SCI USA, V91, P1019, DOI 10.1073/pnas.91.3.1019; Wilcox RA, 2000, ANAESTH INTENS CARE, V28, P611, DOI 10.1177/0310057X0002800602; Williams DG, 2002, BRIT J ANAESTH, V89, P839, DOI 10.1093/bja/aef284; Zanger UM, 2004, N-S ARCH PHARMACOL, V369, P23, DOI 10.1007/s00210-003-0832-2	40	59	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27383	27389		10.1074/jbc.M402337200	http://dx.doi.org/10.1074/jbc.M402337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15051713	hybrid			2022-12-25	WOS:000222120400069
J	Selvamurugan, N; Kwok, S; Partridge, NC				Selvamurugan, N; Kwok, S; Partridge, NC			Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta-stimulated collagenase-3 expression in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOARTHRITIC CHONDROCYTES; TGF-BETA; C-JUN; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST-DIFFERENTIATION; COOPERATIVE INTERACTION; ACTIVATOR PROTEIN-1; CBFA1 CONTRIBUTES; PROMOTER	We have previously shown that transforming growth factor (TGF)-beta1, a crucial molecule in metastatic bone cancer, stimulates collagenase-3 expression in the human breast cancer cell line, MDA-MB231. To understand the molecular mechanisms responsible for TGF-beta1 response on collagenase-3 promoter activity, a functional analysis of the promoter region of the collagenase-3 gene was carried out, and we identified the distal runt domain (RD) and proximal RD/activator protein-1 (AP-1) sites as necessary for full TGF-beta1-stimulated collagenase-3 promoter activity. Gel shift, real time reverse transcriptase-PCR, and Western blot analyses showed increased levels of c-Jun, JunB, and Cbfa1/Runx2 upon TGF-beta1 treatment in MDA-MB231 cells. Co-immunoprecipitation in vitro studies identified no physical interaction between JunB and Cbfa1/Runx2, whereas Smad3 interacted with both. Chromatin immunoprecipitation experiments confirmed interaction of Smad3 with JunB and Cbfa1/Runx2. Under basal conditions, Cbfa1/Runx2 bound to both the proximal RD/AP-1 and distal RD sites. In response to TGF-beta1, Cbfa1/Runx2 was seen only at the distal RD site, whereas JunB occupied the proximal RD/ AP-1 site. An assemblage of Smad3, JunB, and Cbfa1/ Runx2 at the distal RD site of the collagenase-3 promoter occurred in response to TGF-beta1 in MDA-MB231 cells. Co-transfection of Smad3, JunB, and Cbfa1/ Runx2 constructs along with a constitutively active TGF-beta type I receptor construct identified functional interaction of these proteins and transcriptional activation of the collagenase-3 gene by TGF-beta1. Taken together, our results suggest that TGF-beta1 stimulated JunB and Cbfa1/ Runx2 to bind to their respective DNA consensus sites and that Smad3 is likely to stabilize their interaction to confer functional TGF-beta1-stimulation of collagenase-3 expression in MDA-MB231 cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Selvamurugan, N (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	selvamn2@umdnj.edu	Selvamurugan, Nagarajan/P-7894-2016	Selvamurugan, Nagarajan/0000-0003-3713-1920; Partridge, Nicola/0000-0002-5406-4814	NIDDK NIH HHS [R01 DK047420, DK47420] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047420, R56DK047420] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Attisano L, 2001, MOL CELL ENDOCRINOL, V180, P3, DOI 10.1016/S0303-7207(01)00524-X; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Barnes GL, 2003, CANCER RES, V63, P2631; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Benderdour M, 2002, J RHEUMATOL, V29, P1262; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DALONZO RC, 2002, PRINCIPLES BONE BIOL, P251; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Ito Y, 2001, J BONE MINER METAB, V19, P188, DOI 10.1007/s007740170041; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mauviel A, 1996, J BIOL CHEM, V271, P24824, DOI 10.1074/jbc.271.40.24824; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROBERTS AB, 1990, PHILOS T R SOC B, V327, P145, DOI 10.1098/rstb.1990.0050; Selvamurugan N, 2000, J CELL BIOCHEM, V79, P182, DOI 10.1002/1097-4644(20001101)79:2<182::AID-JCB20>3.0.CO;2-0; Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; SELVAMURUGAN N, 2000, MOL CELL BIOL RES CO, V4, P218; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; STEIN GS, 1998, FRONT BIOSCI, V3, pD848; Tardif G, 2001, J RHEUMATOL, V28, P1631; Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	62	96	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27764	27773		10.1074/jbc.M312870200	http://dx.doi.org/10.1074/jbc.M312870200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084595	hybrid			2022-12-25	WOS:000222120400111
J	De Ioannes, P; Moltedo, B; Oliva, H; Pacheco, R; Faunes, F; De Ioannes, AE; Becker, MI				De Ioannes, P; Moltedo, B; Oliva, H; Pacheco, R; Faunes, F; De Ioannes, AE; Becker, MI			Hemocyanin of the molluscan Concholepas concholepas exhibits an unusual heterodecameric array of subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEYHOLE LIMPET HEMOCYANIN; OCTOPUS-DOFLEINI HEMOCYANIN; HALIOTIS-TUBERCULATA; MONOCLONAL-ANTIBODIES; FUNCTIONAL UNITS; OLIGOMERIC STABILITY; QUATERNARY STRUCTURE; ANGSTROM RESOLUTION; POLYACRYLAMIDE-GELS; ORGANIZATION	We describe here the structure of the hemocyanin from the Chilean gastropod Concholepas concholepas (CCH), emphasizing some attributes that make it interesting among molluscan hemocyanins. CCH exhibits a predominant didecameric structure as revealed by electron microscopy and a size of 8 MDa by gel filtration, and, in contrast with other mollusc hemocyanins, its stabilization does not require additional Ca2+ and/or Mg2+ in the medium. Polyacrylamide gel electrophoresis studies, analyses by a MonoQ FPLC column, and Western blots with specific monoclonal antibodies showed that CCH is made by two subunits noncovalently linked, named CCH-A and CCH-B, with molecular masses of 405 and 350 kDa, respectively. Interestingly, one of the subunits undergoes changes within the macromolecule; we demonstrated that CCH-A has an autocleavage site that under reducing conditions is cleaved to yield two polypeptides, CCH-A1 ( 300 kDa) and CCH-A2 ( 108 kDa), whereas CCH-B remains unchanged. The CCH-A nick occurs at 4 C, increases at 37 C, and is not inhibited by the addition of protease inhibitors and/or divalent cations. Since the CCH structure is a heterodimer, we investigated whether subunits would be either intermingled, forming heterodecamers, or assembled as two homogeneous decamers. Light scattering and electron microscope studies of the in vitro reassociation of purified CCH subunits demonstrated that the sole addition of Mg2+ is needed for its reassembly into the native decameric molecule; no homodecamer reorganization was found with either CCH-A or CCH-B subunits alone. Our evidence showed that C. concholepas hemocyanin is an unusual example of heterodecameric organization.	BIOSONDA Corp, Dept Res & Dev, Santiago 7750269, Chile		Becker, MI (corresponding author), BIOSONDA Corp, Dept Res & Dev, Ave Alcalde Eduardo Castillo Velasco 2902, Santiago 7750269, Chile.	mib@biosonda.cl	Becker, María/R-8252-2019	Pacheco, Rodrigo/0000-0001-8057-9806				Becker MI, 1998, HYBRIDOMA, V17, P373, DOI 10.1089/hyb.1998.17.373; BECKER MI, 2001, SCAN J IMMUNOL S1, V54, P107; Behrens JW, 2002, J EXP BIOL, V205, P253; BONAFE CFS, 1994, BIOCHEMISTRY-US, V33, P2651, DOI 10.1021/bi00175a038; BONAVENTURA C, 1981, ARCH BIOCHEM BIOPHYS, V211, P589, DOI 10.1016/0003-9861(81)90493-8; BROUWER M, 1978, BIOCHEMISTRY-US, V17, P2810, DOI 10.1021/bi00607a017; Coligan J.E., 1994, CURRENT PROTOCOLS IM, V2; Cordova JL, 2001, J SHELLFISH RES, V20, P55; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Destoumieux-Garzon D, 2001, J BIOL CHEM, V276, P47070, DOI 10.1074/jbc.M103817200; Ding K, 2002, J BIOL CHEM, V277, P33353, DOI 10.1074/jbc.M203383200; Dolashka-Angelova P, 2003, BBA-PROTEINS PROTEOM, V1646, P77, DOI 10.1016/S1570-9639(02)00549-6; FERNANDEZMORAN H, 1966, J MOL BIOL, V16, P191, DOI 10.1016/S0022-2836(66)80272-3; GARRIDO J, 1981, DEV COMP IMMUNOL, V5, P691, DOI 10.1016/S0145-305X(81)80044-4; Gebauer W, 1999, J STRUCT BIOL, V128, P280, DOI 10.1006/jsbi.1999.4198; Gebauer W, 2002, J STRUCT BIOL, V139, P153, DOI 10.1016/S1047-8477(02)00591-9; GEBAUER W, 1994, ZOOL-ANAL COMPLEX SY, V98, P51; Gebauer W, 1999, ARCH BIOCHEM BIOPHYS, V372, P128, DOI 10.1006/abbi.1999.1478; Harris JR, 2000, MICRON, V31, P613, DOI 10.1016/S0968-4328(99)00145-6; Harris JR, 1999, MICRON, V30, P597, DOI 10.1016/S0968-4328(99)00036-0; HARRIS JR, 1993, J STRUCT BIOL, V111, P96, DOI 10.1006/jsbi.1993.1040; HERSCOWITZ HB, 1972, IMMUNOLOGY, V22, P51; HERSKOVITS TT, 1986, BIOCHEMISTRY-US, V25, P3612, DOI 10.1021/bi00360a020; Idakieva K, 2002, MICRON, V33, P7, DOI 10.1016/S0968-4328(00)00099-8; Jurincic-Winkler CD, 2000, EUR UROL, V37, P45, DOI 10.1159/000052392; Keller H, 1999, EUR J BIOCHEM, V264, P27, DOI 10.1046/j.1432-1327.1999.00564.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamy J, 1998, J MOL BIOL, V284, P1051, DOI 10.1006/jmbi.1998.2235; LAMY J, 1987, BIOCHEMISTRY-US, V26, P3509, DOI 10.1021/bi00386a039; Lieb B, 1999, EUR J BIOCHEM, V265, P134, DOI 10.1046/j.1432-1327.1999.00694.x; Lieb B, 2001, P NATL ACAD SCI USA, V98, P4546, DOI 10.1073/pnas.071049998; Manosalva H, 2004, HYBRIDOMA HYBRIDOM, V23, P45, DOI 10.1089/153685904322772024; MARKL J, 1991, NATURWISSENSCHAFTEN, V78, P512, DOI 10.1007/BF01131401; Markl J, 2001, J CANCER RES CLIN, V127, pR3, DOI 10.1007/BF01470992; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meissner U, 2000, J MOL BIOL, V298, P21, DOI 10.1006/jmbi.2000.3631; MELLEMA JE, 1972, NATURE, V239, P146, DOI 10.1038/239146a0; MILLER KI, 1990, P NATL ACAD SCI USA, V87, P1496, DOI 10.1073/pnas.87.4.1496; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Mura CV, 2002, J IMMUNOL METHODS, V260, P263, DOI 10.1016/S0022-1759(01)00546-4; Musselli C, 2001, J CANCER RES CLIN, V127, pR20, DOI 10.1007/BF01470995; Oliva H, 2002, HYBRIDOMA HYBRIDOM, V21, P365, DOI 10.1089/153685902761022715; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; SALVATO B, 1979, BIOCHEMISTRY-US, V18, P2731, DOI 10.1021/bi00580a007; Sohngen SM, 1997, EUR J BIOCHEM, V248, P602, DOI 10.1111/j.1432-1033.1997.00602.x; Swerdlow RD, 1996, COMP BIOCHEM PHYS B, V113, P537, DOI 10.1016/0305-0491(95)02091-8; TAKANARI H, 1990, BIOL CELL, V70, P83, DOI 10.1016/0248-4900(90)90363-8; Tan IP, 1996, BIOL REPROD, V54, P1300, DOI 10.1095/biolreprod54.6.1300; TERWILLIGER NB, 1988, COMP BIOCHEM PHYS B, V89, P189, DOI 10.1016/0305-0491(88)90282-9; Torres M, 1999, J AGR FOOD CHEM, V47, P4231, DOI 10.1021/jf981336j; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Holde KE, 2001, J BIOL CHEM, V276, P15563, DOI 10.1074/jbc.R100010200; van Holde KE, 2000, BIOPHYS CHEM, V86, P165, DOI 10.1016/S0301-4622(00)00154-X; VANHOLDE KE, 1991, J MOL BIOL, V217, P307, DOI 10.1016/0022-2836(91)90545-H; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WALKER JM, 1996, PROTEIN PROTOCOLS HD, P127	56	41	45	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26134	26142		10.1074/jbc.M400903200	http://dx.doi.org/10.1074/jbc.M400903200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075320	hybrid			2022-12-25	WOS:000222003000027
J	Furlow, JD; Yang, HY; Hsu, M; Lim, W; Ermio, DJ; Chiellini, G; Scanlan, TS				Furlow, JD; Yang, HY; Hsu, M; Lim, W; Ermio, DJ; Chiellini, G; Scanlan, TS			Induction of larval tissue resorption in Xenopus laevis tadpoles by the thyroid hormone receptor agonist GC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PROGRAM; AMPHIBIAN METAMORPHOSIS; CELL-PROLIFERATION; TAIL RESORPTION; RESPONSE GENES; BETA GENE; IN-VIVO; MICE; ALPHA; ISOFORMS	A major challenge in understanding nuclear hormone receptor function is to determine how the same ligand can cause very different tissue-specific responses. Tissue specificity may result from the presence of more than one receptor subtype arising from multiple receptor genes or alternative splicing. Recently, high affinity analogs of nuclear receptor ligands have been synthesized that show subtype selectivity. These analogs can greatly facilitate the study of receptor subtype-specific functions in organisms where mutational analysis is problematic or where it is desirable for receptors to be expressed in their normal physiological contexts. We describe here the effects of the synthetic thyroid hormone analog GC-1 on the metamorphosis of the frog Xenopus laevis. The most potent natural thyroid hormone, 3,5,3'-triidothyronine or T3, shows similar binding affinity and transactivation dose-response curves for both thyroid hormone receptor isotypes, designated TRalpha and TRbeta. GC-1, however, binds to and activates TRbeta at least an order of magnitude better than it does TRbeta. GC-1 efficiently induces death and resorption of premetamorphic tadpole tissues such as the gills and the tail, two tissues that strongly induce thyroid hormone receptor beta during metamorphosis. GC-1 has less effect on the growth of adult tissues such as the hindlimbs, which express high TRalpha levels. The effectiveness of GC-1 in inducing tail resorption and tail gene expression correlates with increasing TRbeta levels. These results illustrate the utility of subtype selective ligands as probes of nuclear receptor function in vivo.	Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California Davis; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Furlow, JD (corresponding author), Univ Calif Davis, Sect Neurobiol Physiol & Behav, 1 Shields Ave, Davis, CA 95616 USA.	jdfurlow@ucdavis.edu			NIDDK NIH HHS [R01 DK055511] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANKER DE, 1991, MOL CELL BIOL, V11, P5079, DOI 10.1128/MCB.11.10.5079; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; Berry DL, 1998, DEV BIOL, V203, P12, DOI 10.1006/dbio.1998.8974; Berry DL, 1998, DEV BIOL, V203, P24, DOI 10.1006/dbio.1998.8975; Blumberg B, 1996, P NATL ACAD SCI USA, V93, P4873, DOI 10.1073/pnas.93.10.4873; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; BROWN DD, 1995, RECENT PROG HORM RES, V50, P309; BUCKBINDER L, 1992, J BIOL CHEM, V267, P25786; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; Denver RJ, 1997, J BIOL CHEM, V272, P8179, DOI 10.1074/jbc.272.13.8179; Dodd M.H.I., 1976, P467; ELICEIRI BP, 1994, J BIOL CHEM, V269, P24459; Fairclough L, 1997, DEV GROWTH DIFFER, V39, P273; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; Furlow JD, 1999, MOL ENDOCRINOL, V13, P2076, DOI 10.1210/me.13.12.2076; Furlow JD, 1997, DEV BIOL, V182, P284, DOI 10.1006/dbio.1996.8478; Furlow JD, 2002, ENDOCRINOLOGY, V143, P3295, DOI 10.1210/en.2002-220126; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; Johansson C, 1999, AM J PHYSIOL-HEART C, V276, pH2006, DOI 10.1152/ajpheart.1999.276.6.H2006; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; Lim W, 2002, J BIOL CHEM, V277, P35664, DOI 10.1074/jbc.M205608200; MACHUCA I, 1995, MOL ENDOCRINOL, V9, P96, DOI 10.1210/me.9.1.96; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NISHIKAWA A, 1994, DEV BIOL, V165, P86, DOI 10.1006/dbio.1994.1236; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Safi R, 1997, J MOL EVOL, V44, P595, DOI 10.1007/PL00006182; Shi YB, 1998, INT J DEV BIOL, V42, P107; SHI YB, 1993, J BIOL CHEM, V268, P20312; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; Tata J R, 1998, Cell Res, V8, P259; TATA JR, 1991, DEV BIOL, V146, P72, DOI 10.1016/0012-1606(91)90447-B; Tong W, 1999, MOL CELL BIOL, V19, P2251; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wagner RL, 2001, MOL ENDOCRINOL, V15, P398, DOI 10.1210/me.15.3.398; WANG Z, 1993, J BIOL CHEM, V268, P16270; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; Yoh Sunnie M, 2002, Methods Mol Biol, V202, P129; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	44	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26555	26562		10.1074/jbc.M402847200	http://dx.doi.org/10.1074/jbc.M402847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15056670	hybrid			2022-12-25	WOS:000222003000080
J	Lively, TN; Nguyen, TN; Galasinski, SK; Goodrich, JA				Lively, TN; Nguyen, TN; Galasinski, SK; Goodrich, JA			The basic leucine zipper domain of c-Jun functions in transcriptional activation through interaction with the N terminus of human TATA-binding protein-associated factor-1 (human TAF(II)250)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DNA-BINDING; BOX-BINDING; TFIID COMPLEX; MINOR-GROOVE; PROMOTER SELECTIVITY; V-JUN; FOS; DROSOPHILA; VITRO	We previously reported that c-Jun binds directly to the N-terminal 163 amino acids of Homo sapiens TATA-binding protein-associated factor-1 (hsTAF1), causing a derepression of transcription factor IID (TFIID)-driven transcription (Lively, T. N., Ferguson, H. A., Galasinski, S. K., Seto, A. G., and Goodrich, J. A. (2001) J. Biol. Chem. 276, 25582-25588). This region of hsTAF1 binds TATA-binding protein to repress TFIID DNA binding and transcription. Here we show that the basic leucine zipper domain of c-Jun, which allows for DNA binding and homodimerization, is necessary and sufficient for interaction with hsTAF1. Interestingly, the isolated basic leucine zipper domain of c-Jun was able to derepress TFIID-directed basal transcription in vitro. Moreover, when the N-terminal region of hsTAF1 was added to in vitro transcription reactions and overexpressed in cells, it blocked c-Jun activation. c-Fos, another basic leucine zipper protein, did not interact with hsTAF1, but c-Fos/c-Jun heterodimers did bind the N terminus of hsTAF1. Our studies show that, in addition to dimerization and DNA binding, the well characterized basic leucine zipper domain of c-Jun functions in transcriptional activation by binding to the N terminus of hsTAF1 to derepress transcription.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Goodrich, JA (corresponding author), Univ Colorado, Dept Chem & Biochem, 215 UCB, Boulder, CO 80309 USA.	james.goodrich@colorado.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055235, T32GM008759, T32GM007135] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008759, T32 GM08759, T32 GM142607, GM-55235, T32 GM07135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bartusel T, 2003, ONCOGENE, V22, P2932, DOI 10.1038/sj.onc.1206494; Bertolino E, 2002, MOL CELL, V10, P397, DOI 10.1016/S1097-2765(02)00597-X; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Ferguson HA, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.20.e98; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Kim LJ, 2001, MOL CELL BIOL, V21, P3503, DOI 10.1128/MCB.21.10.3503-3513.2001; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Lively TN, 2001, J BIOL CHEM, V276, P25582, DOI 10.1074/jbc.M100278200; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Rojo-Niersbach E, 1999, J BIOL CHEM, V274, P33778, DOI 10.1074/jbc.274.47.33778; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	51	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26257	26265		10.1074/jbc.M400892200	http://dx.doi.org/10.1074/jbc.M400892200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087451	hybrid			2022-12-25	WOS:000222003000043
J	Castaldo, P; Stefanoni, P; Miceli, F; Coppola, G; del Giudice, EM; Bellini, G; Pascotto, A; Trudell, JR; Harrison, NL; Annunziato, L; Taglialatela, M				Castaldo, P; Stefanoni, P; Miceli, F; Coppola, G; del Giudice, EM; Bellini, G; Pascotto, A; Trudell, JR; Harrison, NL; Annunziato, L; Taglialatela, M			A novel hyperekplexia-causing mutation in the pre-transmembrane segment 1 of the human glycine receptor alpha(1) subunit reduces membrane expression and impairs gating by agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-SUBUNIT; HEREDITARY HYPEREKPLEXIA; FRAMESHIFT MUTATION; MISSENSE MUTATION; ALPHA-1 SUBUNIT; STARTLE DISEASE; XENOPUS-OOCYTES; GENE GLRA1; DOMAIN; MOUSE	In this study, we have compared the functional consequences of three mutations (R218Q, V260M, and Q266H) in the alpha(1) subunit of the glycine receptor (GlyRA1) causing hyperekplexia, an inherited neurological channelopathy. In HEK-293 cells, the agonist EC50s for glycine-activated Cl- currents were increased from 26 muM in wtGlyRA1, to 5747, 135, and 129 muM in R218Q, V260M, and Q266H GlyRA1 channels, respectively. Cl- currents elicited by beta-alanine and taurine, which behave as agonists at wtGlyRA1, were decreased in V260M and Q266H mutant receptors and virtually abolished in GlyRA1 R218Q receptors. Gly-gated Cl- currents were similarly antagonized by low concentrations of strychnine in both wild-type (wt) and R218Q GlyRA1 channels, suggesting that the Arg-218 residue plays a crucial role in GlyRA1 channel gating, with only minor effects on the agonist/antagonist binding site, a hypothesis supported by our molecular model of the GlyRA1 subunit. The R218Q mutation, but not the V260M or the Q266H mutation, caused a marked decrease of receptor subunit expression both in total cell lysates and in isolated plasma membrane proteins. This decreased expression does not seem to explain the reduced agonist sensitivity of GlyRA1 R218Q channels since no difference in the apparent sensitivity to glycine or taurine was observed when wtGlyRA1 receptors were expressed at levels comparable with those of R218Q mutant receptors. In conclusion, multiple mechanisms may explain the dramatic decrease in GlyR function caused by the R218Q mutation, possibly providing the molecular basis for its association with a more severe clinical phenotype.	Univ Naples Federico II, Sch Med, Dept Neurosci, Div Pharmacol, I-80131 Naples, Italy; Univ Naples 2, Dept Child Neuropsychiat, I-80138 Naples, Italy; Univ Naples 2, Dept Pediat, I-80138 Naples, Italy; Stanford Univ, Beckman Program Mol & Genet Med, Dept Anesthesia, Stanford, CA 94305 USA; Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	University of Naples Federico II; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Stanford University; Cornell University; Cornell University	Taglialatela, M (corresponding author), Univ Naples Federico II, Sch Med, Dept Neurosci, Div Pharmacol, Via Pansini 5, I-80131 Naples, Italy.	mtaglial@unina.it	Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/ABH-4262-2020; del Giudice, Emanuele Muraglia/AAC-2824-2019; Taglialatela, Maurizio/A-2062-2019; Miceli, Francesco/H-3767-2013	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; Miceli, Francesco/0000-0002-5393-1402; Coppola, Giangennaro/0000-0002-9574-0081; ANNUNZIATO, LUCIO/0000-0002-8534-8270	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013378] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA013378] Funding Source: Medline; NIGMS NIH HHS [R01 GM63034, R01 GM45129] Funding Source: Medline; Telethon [GGP030209] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon)		Auerbach A, 1998, J GEN PHYSIOL, V112, P181, DOI 10.1085/jgp.112.2.181; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Bertaccini E, 2001, INT REV NEUROBIOL, V48, P141, DOI 10.1016/S0074-7742(01)48015-9; Breitinger HG, 2002, CHEMBIOCHEM, V3, P1043, DOI 10.1002/1439-7633(20021104)3:11<1042::AID-CBIC1042>3.0.CO;2-7; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brune W, 1996, AM J HUM GENET, V58, P989; BUCKWALTER MS, 1994, HUM MOL GENET, V3, P2025, DOI 10.1093/hmg/3.11.2025; Buttner C, 2001, J BIOL CHEM, V276, P42978, DOI 10.1074/jbc.M102121200; Castaldo P, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0003.2002; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Coppola G, 2003, NEUROLOGY, V61, P131, DOI 10.1212/01.WNL.0000069465.53698.BD; del Giudice EM, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e71; del Giudice EM, 2001, EUR J HUM GENET, V9, P873, DOI 10.1038/sj.ejhg.5200729; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Hu XQ, 2003, J BIOL CHEM, V278, P46583, DOI 10.1074/jbc.M308974200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kling C, 1997, NEUROSCIENCE, V78, P411, DOI 10.1016/S0306-4522(96)00567-2; Kumamoto E, 1997, PROG NEUROBIOL, V52, P197, DOI 10.1016/S0301-0082(97)00016-6; LANGOSCH D, 1993, FEBS LETT, V336, P540, DOI 10.1016/0014-5793(93)80872-R; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Manganas LN, 2001, J BIOL CHEM, V276, P49427, DOI 10.1074/jbc.M109325200; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Milani N, 1996, AM J HUM GENET, V58, P420; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moorhouse AJ, 1999, MOL PHARMACOL, V55, P386, DOI 10.1124/mol.55.2.386; RYAN SG, 1992, ANN NEUROL, V31, P663, DOI 10.1002/ana.410310615; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; Saint Jan DD, 2001, J PHYSIOL-LONDON, V535, P741; Saul B, 1999, J NEUROSCI, V19, P869; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; Schmieden V, 1999, MOL PHARMACOL, V56, P464, DOI 10.1124/mol.56.3.464; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; TALEB O, 1994, EMBO J, V13, P1318, DOI 10.1002/j.1460-2075.1994.tb06384.x; Trudell JR, 2002, BBA-BIOMEMBRANES, V1565, P91, DOI 10.1016/S0005-2736(02)00512-6; Trudell JR, 2002, BRIT J ANAESTH, V89, P32, DOI 10.1093/bja/aef157; Wen H, 2002, J NEUROSCI, V22, P7991, DOI 10.1523/jneurosci.22-18-07991.2002; Zhou L, 2002, BRAIN DEV-JPN, V24, P669, DOI 10.1016/S0387-7604(02)00095-5	43	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25598	25604		10.1074/jbc.M311021200	http://dx.doi.org/10.1074/jbc.M311021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066993	hybrid			2022-12-25	WOS:000221827900087
J	Foster, MW; Stamler, JS				Foster, MW; Stamler, JS			New insights into protein S-nitrosylation - Mitochondria as a model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAT-LIVER MITOCHONDRIA; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; IN-VIVO; SARCOSINE DEHYDROGENASE; NITROSATIVE STRESS; OUTER-MEMBRANE; SERUM-ALBUMIN; MECHANISM	The biological effects of nitric oxide ( NO) are in significant part mediated through S-nitrosylation of cysteine thiol. Work on model thiol substrates has raised the idea that molecular oxygen (O-2) is required for S-nitrosylation by NO; however, the relevance of this mechanism at the low physiological pO(2) of tissues is unclear. Here we have used a proteomic approach to study S-nitrosylation reactions in situ. We identify endogenously S-nitrosylated proteins in subcellular organelles, including dihydrolipoamide dehydrogenase and catalase, and show that these, as well as hydroxymethylglutaryl-CoA synthase and sarcosine dehydrogenase (SarDH), are S-nitrosylated by NO under strictly anaerobic conditions. S-Nitrosylation of SarDH by NO is best rationalized by a novel mechanism involving the covalently bound flavin of the enzyme. We also identify a set of mitochondrial proteins that can be S-nitrosylated through multiple reaction channels, including anaerobic/oxidative, NO/O-2, and GSNO-mediated transnitrosation. Finally, we demonstrate that steady state levels of S-nitrosylation are higher in mitochondrial extracts than the intact organelles, suggesting the importance of denitrosylation reactions. Collectively, our results provide new insight into the determinants of S-nitrosothiol levels in subcellular compartments.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Rm 321 MSRB,Box 2612, Durham, NC 27710 USA.	STAML001@mc.duke.edu		Stamler, Jonathan/0000-0002-6866-1572				BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Brunelli L, 2001, FREE RADICAL BIO MED, V30, P709, DOI 10.1016/S0891-5849(00)00512-8; Chan NL, 2004, BIOCHEMISTRY-US, V43, P118, DOI 10.1021/bi030172j; COOK RJ, 1984, J BIOL CHEM, V259, P2475; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Datta B, 2004, CIRCULATION, V109, P1339, DOI 10.1161/01.CIR.0000124450.07016.1D; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; DULING BR, 1970, CIRC RES, V27, P669, DOI 10.1161/01.RES.27.5.669; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Eschenbrenner M, 1999, GENOMICS, V59, P300, DOI 10.1006/geno.1999.5886; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Gnaiger E, 1998, BBA-BIOENERGETICS, V1365, P249, DOI 10.1016/S0005-2728(98)00076-0; GORCZYNSKI RJ, 1978, AM J PHYSIOL, V235, pH505, DOI 10.1152/ajpheart.1978.235.5.H505; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Greenawalt J W, 1979, Methods Enzymol, V55, P88; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Houk KN, 2003, J AM CHEM SOC, V125, P6972, DOI 10.1021/ja029655l; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Jourd'heuil D, 2003, J BIOL CHEM, V278, P15720, DOI 10.1074/jbc.M300203200; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; OEI J, 1985, BIOCHIM BIOPHYS ACTA, V840, P1, DOI 10.1016/0304-4165(85)90154-0; PATEL MS, 1995, METHOD ENZYMOL, V252, P186; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; RADI R, 1991, J BIOL CHEM, V266, P22028; Richmond KN, 1999, AM J PHYSIOL-HEART C, V277, pH1831, DOI 10.1152/ajpheart.1999.277.5.H1831; Rizzo MA, 2003, J CELL BIOL, V161, P243, DOI 10.1083/jcb.200301063; Romeo AA, 2003, J AM CHEM SOC, V125, P14370, DOI 10.1021/ja0289752; Romeo AA, 2001, J AM CHEM SOC, V123, P1782, DOI 10.1021/ja005612y; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 2004, CIRC RES, V94, P414, DOI 10.1161/01.RES.0000122071.55721.BC; Stamler JS, 2002, CURR OPIN CHEM BIOL, V6, P779, DOI 10.1016/S1367-5931(02)00383-6; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Steffen M, 2001, BIOCHEM J, V356, P395, DOI 10.1042/0264-6021:3560395; Tao LM, 2003, BIOCHEMISTRY-US, V42, P3326, DOI 10.1021/bi0269963; VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131, DOI 10.1152/ajpcell.1991.260.6.C1131; WHALEN WJ, 1967, CIRC RES, V21, P251, DOI 10.1161/01.RES.21.3.251; Wiegant FAC, 1999, FEBS LETT, V455, P179, DOI 10.1016/S0014-5793(99)00806-6; Williams JG, 2003, P NATL ACAD SCI USA, V100, P6376, DOI 10.1073/pnas.1037299100; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	68	145	152	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25891	25897		10.1074/jbc.M313853200	http://dx.doi.org/10.1074/jbc.M313853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069080	hybrid			2022-12-25	WOS:000221827900121
J	Green, KA; Naylor, MJ; Lowe, ET; Wang, PB; Marshman, E; Streuli, CH				Green, KA; Naylor, MJ; Lowe, ET; Wang, PB; Marshman, E; Streuli, CH			Caspase-mediated cleavage of insulin receptor substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND INVOLUTION; GROWTH-FACTOR-I; PLECKSTRIN HOMOLOGY DOMAIN; PROGRAMMED CELL-DEATH; EPITHELIAL-CELLS; PROTEIN-KINASE; APOPTOTIC FUNCTION; SURVIVAL SIGNALS; BH3 DOMAIN; 1ST STAGE	Apoptosis is an important mechanism for maintaining tissue homeostasis. The efficient induction and execution of apoptosis are essential for cell clearance in specific developmental situations. Insulin-like growth factor (IGF)-I is a survival factor for epithelial cells in the mammary gland, and its withdrawal or inhibition leads to apoptosis. In this paper we describe a novel mechanism that may lead to suppression of an IGF-I-mediated signaling pathway through cleavage of insulin receptor substrate (IRS). During the process of forced weaning, when mammary epithelial cells rapidly enter apoptosis in vivo, IRS-1 and IRS-2 disappear. We have used cultured mammary epithelial cells to demonstrate that IRS removal can be mediated through the action of caspase 10. Caspase 10 activation and IRS-1 cleavage are regulated by a MKK1-signaling pathway but not by a phosphatidylinositol- 3 kinase pathway nor by the extracellular proapoptotic ligands FasL, tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL), or transforming growth factor-beta3. In addition we show that the loss of IRS-1 after MKK1 inhibition prevents IGF-mediated phosphorylation of FKHRL1.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Streuli, CH (corresponding author), Univ Manchester, Sch Biol Sci, Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	cstreuli@man.ac.uk						ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; Badock V, 2001, CELL DEATH DIFFER, V8, P308, DOI 10.1038/sj.cdd.4400812; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen F, 2003, J BIOL CHEM, V278, P6848, DOI 10.1074/jbc.M212021200; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEL PL, 1997, SCIENCE, V278, P687; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Giampietri C, 2003, CELL DEATH DIFFER, V10, P175, DOI 10.1038/sj.cdd.4401137; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; GREEN KA, 2004, IN PRESS CELL MOL LI; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hadsell DL, 2001, ENDOCRINOLOGY, V142, P1479, DOI 10.1210/en.142.4.1479; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KITTRELL FS, 1992, CANCER RES, V52, P1924; Kook S, 2000, MOL BIOL CELL, V11, P929, DOI 10.1091/mbc.11.3.929; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kritikou EA, 2003, DEVELOPMENT, V130, P3459, DOI 10.1242/dev.00578; Lacher MD, 2003, CELL DEATH DIFFER, V10, P528, DOI 10.1038/sj.cdd.4401197; Lee AV, 2003, CLIN CANCER RES, V9, p516S; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Leroith Derek, 1995, Progress in Growth Factor Research, V6, P433, DOI 10.1016/0955-2235(96)00009-9; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Lund LR, 1996, DEVELOPMENT, V122, P181; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Marti A, 1997, EUR J CELL BIOL, V73, P158; Marti A, 2000, ADV EXP MED BIOL, V480, P195; Marti A, 2001, MECH DEVELOP, V104, P89, DOI 10.1016/S0925-4773(01)00381-1; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nakajima K, 2000, J BIOL CHEM, V275, P10484, DOI 10.1074/jbc.275.14.10484; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Prince JM, 2002, DEV DYNAM, V223, P497, DOI 10.1002/dvdy.10070; Pullan S, 1996, J CELL SCI, V109, P631; Pullan Shirley E., 1996, P97; Runswick SK, 2001, NAT CELL BIOL, V3, P823, DOI 10.1038/ncb0901-823; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schere-Levy C, 2003, EXP CELL RES, V282, P35, DOI 10.1006/excr.2002.5666; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Sohn BH, 2001, BIOCHEM J, V360, P31, DOI 10.1042/0264-6021:3600031; Song J, 2000, J CLIN INVEST, V106, P1209, DOI 10.1172/JCI10411; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Tseng YH, 2002, J BIOL CHEM, V277, P31601, DOI 10.1074/jbc.M202932200; Vainshtein I, 2001, J BIOL CHEM, V276, P8073, DOI 10.1074/jbc.M008436200; Velthuis JHL, 2002, J BIOL CHEM, V277, P24631, DOI 10.1074/jbc.M111572200; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zhang XH, 2000, BREAST CANCER RES, V2, P170, DOI 10.1186/bcr50; Zhao L, 2002, MOL ENDOCRINOL, V16, P2902, DOI 10.1210/me.2001-0330; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	68	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25149	25156		10.1074/jbc.M402395200	http://dx.doi.org/10.1074/jbc.M402395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069074	hybrid			2022-12-25	WOS:000221827900030
J	Smith, SA; Tabita, FR				Smith, SA; Tabita, FR			Glycine 176 affects catalytic properties and stability of the Synechococcus sp strain PCC6301 ribulose-1,5-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE; ACTIVATION; CARBAMATE; MECHANISM; RUBISCO; CO2	A previously described system for biological selection of randomly mutagenized ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) employing the phototrophic bacterium Rhodobacter capsulatus (Smith, S. A., and Tabita, F. R. (2003) J. Mol. Biol. 331, 557-569) was used to select a catalytically altered form of a cyanobacterial (Synechococcus sp. strain PCC6301) enzyme. This mutant Rubisco, in which conserved glycine 176 was replaced with an aspartate residue, was not able to support CO2-dependent growth of the host strain. Site-directed mutant proteins were also constructed, e. g. asparagine and alanine residues replaced the native glycine with the result that these mutant proteins either greatly reduced the ability of R. capsulatus to support growth or had little effect, respectively. Growth phenotypes were consistent with the Rubisco activity levels associated with these proteins, and this was also borne out with purified recombinant proteins. Despite being catalytically challenged, the G176D and G176N mutant proteins were found to exhibit a more favorable interaction with CO2 than the wild type protein but exhibited a reduced affinity for the substrate ribulose 1,5-bisphosphate. The G176A enzyme differed little from the wild type protein in these properties. None of the mutants had CO2/O-2 specificities that differed markedly from the wild type. Further studies taken from the known structure of the Synechococcus Rubisco indicated that substitutions at Gly-176 affected associations between large subunits. Supporting experimental data included an unusual protein concentration-dependent effect on in vitro activity, differences in thermal stability relative to the wild type protein, and aberrant migration on nondenaturing polyacrylamide gels. From these results, it is apparent that residues not directly located within the active site but near large subunit interfaces can affect key kinetic properties of Rubisco. These results suggest that further bioselection protocols (using these proteins as starting material) might yield novel mutant forms of Rubisco that relate to key functional properties.	Ohio State Univ, Dept Microbiol & Plant Mol Biol, Biotechnol Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol & Plant Mol Biol, Biotechnol Program, 484 W 12th Ave, Columbus, OH 43210 USA.	tabita.1@osu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Cheng ZQ, 1998, PROTEIN ENG, V11, P457, DOI 10.1093/protein/11.6.457; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Horken KM, 1999, ARCH BIOCHEM BIOPHYS, V361, P183, DOI 10.1006/abbi.1998.0979; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LORIMER GH, 1980, BIOCHEMISTRY-US, V19, P5321, DOI 10.1021/bi00564a027; Maniatis T., 1982, MOL CLONING LAB MANU; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MIZIORKO HM, 1979, J BIOL CHEM, V254, P270; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; ORMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449, DOI 10.1016/0003-9861(61)90073-X; Paoli GC, 1998, J BACTERIOL, V180, P4258, DOI 10.1128/JB.180.16.4258-4269.1998; Smith SA, 2003, J MOL BIOL, V331, P557, DOI 10.1016/S0022-2836(03)00786-1; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; WEAVER KE, 1983, J BACTERIOL, V156, P507, DOI 10.1128/JB.156.2.507-515.1983; WHITMAN W, 1976, BIOCHEM BIOPH RES CO, V71, P1034, DOI 10.1016/0006-291X(76)90758-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	22	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25632	25637		10.1074/jbc.M401360200	http://dx.doi.org/10.1074/jbc.M401360200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15067012	hybrid			2022-12-25	WOS:000221827900091
J	Pinakoulaki, E; Ohta, T; Soulimane, T; Kitagawa, T; Varotsis, C				Pinakoulaki, E; Ohta, T; Soulimane, T; Kitagawa, T; Varotsis, C			Simultaneous resonance Raman detection of the heme a(3)-Fe-CO and Cu-B-CO species in CO-bound ba(3)-cytochrome c oxidase from Thermus thermophilus - Evidence for a charge transfer Cu-B-CO transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNIQUE ACTIVE-SITE; BINUCLEAR CENTER; INFRARED-SPECTROSCOPY; DOCKING SITE; FTIR; TEMPERATURE; COMPLEX; BINDING; A(3)	Understanding of the chemical nature of the dioxygen and nitric oxide moiety of ba(3)-cytochrome c oxidase from Thermus thermophilus is crucial for elucidation of its physiological function. In the present work, direct resonance Raman (RR) observation of the Fe-C-O stretching and bending modes and the C-O stretching mode of the Cu-B-CO complex unambiguously establishes the vibrational characteristics of the heme-copper moiety in ba(3)-oxidase. We assigned the bands at 507 and 568 cm(-1) to the Fe-CO stretching and Fe-C-O bending modes, respectively. The frequencies of these modes in conjunction with the C-O mode at 1973 cm(-1) showed, despite the extreme values of the Fe-CO and C-O stretching vibrations, the presence of the alpha-conformation in the catalytic center of the enzyme. These data, distinctly different from those observed for the caa(3)-oxidase, are discussed in terms of the proposed coupling of the alpha- and beta-conformations that occur in the binuclear center of heme-copper oxidases with enzymatic activity. The Cu-B-CO complex was identified by its nu(CO) at 2053 cm(-1) and was strongly enhanced with 413.1 nm excitation indicating the presence of a metal-to-ligand charge transfer transition state near 410 nm. These findings provide, for the first time, RR vibrational information on the EPR silent Cu-B(I) that is located at the O-2 delivery channel and has been proposed to play a crucial role in both the catalytic and proton pumping mechanisms of heme-copper oxidases.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Okazaki Natl Res Inst, Ctr Integrat Biosci, Aichi 4448585, Japan; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	University of Crete; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece.	varotsis@edu.uoc.gr		Pinakoulaki, Eftychia/0000-0003-3320-6112; Varotsis, Constantinos/0000-0003-2771-8891				ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; Das TK, 2001, BIOPHYS J, V80, P2039, DOI 10.1016/S0006-3495(01)76177-2; Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; Hirota S, 1999, BIOCHEMISTRY-US, V38, P14256, DOI 10.1021/bi991129s; HIROTA S, 1994, J PHYS CHEM-US, V98, P6652, DOI 10.1021/j100077a035; HOSLER JP, 1994, J AM CHEM SOC, V116, P5515, DOI 10.1021/ja00091a084; Koutsoupakis C, 2004, BIOPHYS J, V86, P2438, DOI 10.1016/S0006-3495(04)74300-3; Koutsoupakis C, 2003, J AM CHEM SOC, V125, P14728, DOI 10.1021/ja036107e; Koutsoupakis C, 2003, J BIOL CHEM, V278, P36806, DOI 10.1074/jbc.M307117200; Koutsoupakis K, 2003, J BIOL CHEM, V278, P14893, DOI 10.1074/jbc.M210293200; Koutsoupakis K, 2002, J BIOL CHEM, V277, P32860, DOI 10.1074/jbc.M204943200; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P9446, DOI 10.1021/bi960392f; Pinakoulaki E, 2002, J BIOL CHEM, V277, P32867, DOI 10.1074/jbc.M205568200; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Stavrakis S, 2002, J AM CHEM SOC, V124, P3814, DOI 10.1021/ja0169825; Varotsis C, 1998, J PHYS CHEM B, V102, P7670, DOI 10.1021/jp9824095; WANG JL, 1993, J AM CHEM SOC, V115, P3390, DOI 10.1021/ja00061a072; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WANG JL, 1995, J AM CHEM SOC, V117, P9363, DOI 10.1021/ja00141a033	21	33	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22791	22794		10.1074/jbc.C400124200	http://dx.doi.org/10.1074/jbc.C400124200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15066990	Green Published, hybrid			2022-12-25	WOS:000221570900002
J	Mayhew, CN; Perkin, LM; Zhang, XP; Sage, J; Jacks, T; Knudsen, ES				Mayhew, CN; Perkin, LM; Zhang, XP; Sage, J; Jacks, T; Knudsen, ES			Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents	ONCOGENE			English	Article						cell cycle checkpoints; chemotherapeutics; immortalization; thymidylate synthase; retinoblastoma tumor suppressor	RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; LARGE T-ANTIGEN; DNA-DAMAGE; FUNCTIONAL INACTIVATION; THYMIDYLATE SYNTHETASE; GENE-EXPRESSION; G(1) ARREST; P53; PROTEIN	The retinoblastoma (RB) tumor suppressor has been proposed to function as a key mediator of cell cycle checkpoints induced by chemotherapeutic agents. However, these prior studies have relied on embryonic fibroblasts harboring chronic loss of RB, a condition under which compensation of RB functions is known to occur. Here we utilized primary adult. broblasts derived from mice harboring loxP sites flanking exon 3 of the Rb gene to delineate the action of RB in the chemotherapeutic response. In this system we find that targeted disruption of Rb leads to little overt change in cell cycle distribution. However, these cells exhibited deregulation of RB/E2F target genes and became aneuploid following culture in the absence of RB. When challenged with both DNA damaging and antimetabolite chemotherapeutics, RB was required for primary adult cells to undergo DNA damage checkpoint responses and loss of RB resulted in enhanced aneuploidy following challenge. In contrast, following spontaneous immortalization and the loss of functional p53 signaling, the antimetabolite 5-fluorouracil (5-FU) failed to induce arrest despite the presence of RB. In these immortal cultures RB/E2F targets were deregulated in a complex, gene-specific manner and RB was required for the checkpoint response to camptothecin (CPT). Mechanistic analyses of the checkpoint responses in primary cells indicated that loss of RB leads to increased p53 signaling and decreased viability following both CPT and 5-FU treatment. However, the mechanism through which these agents act to facilitate cell cycle inhibition through RB were distinct. These studies underscore the critical role of RB in DNA-damage checkpoint signaling and demonstrate that RB mediates chemotherapeutic-induced cell cycle inhibition in adult. broblasts by distinct mechanisms.	Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	University System of Ohio; University of Cincinnati; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu	Mayhew, Christopher N/AGB-4929-2022		NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 59268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EL DW, 1993, CELL, V75, P817; Flatt PM, 2000, DRUG METAB REV, V32, P283, DOI 10.1081/DMR-100102335; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lentini L, 2002, NEOPLASIA, V4, P380, DOI 10.1038/sj.neo.7900256; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Markey MP, 2002, CANCER RES, V62, P6587; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RITTLING SR, 1992, ONCOGENE, V7, P935; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; SOMMER H, 1974, BIOCHEM BIOPH RES CO, V57, P689, DOI 10.1016/0006-291X(74)90601-9; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3	77	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4107	4120		10.1038/sj.onc.1207503	http://dx.doi.org/10.1038/sj.onc.1207503			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064736				2022-12-25	WOS:000221520200009
J	Preto, A; Singhrao, SK; Haughton, MF; Kipling, D; Wynford-Thomas, D; Jones, CJ				Preto, A; Singhrao, SK; Haughton, MF; Kipling, D; Wynford-Thomas, D; Jones, CJ			Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy	ONCOGENE			English	Article						p53; telomerase; cancer; senescence; therapy	THYROID EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; LIFE-SPAN; HUMAN FIBROBLASTS; MUTATIONS; SENESCENCE; INHIBITION; EXPRESSION; MECHANISMS; LINES	Telomerase activity in tumours is often associated with p53 mutation. Many antitelomerase therapies take advantage of the inability of cells expressing mutant p53 to undergo replicative senescence, since this allows telomere erosion to continue until 'crisis', hence providing the desired cytotoxic effect. However, some tumour types, including breast, melanomas and thyroid, retain wild-type p53 function and the effectiveness of antitelomerase therapies in such tumour cells have not been adequately addressed. To explore this, we made use of two thyroid cancer cell lines K1 and K2, which retain wt p53. Telomere erosion induced by the expression of a dominant-negative (DN) hTERT resulted in delayed onset of growth arrest in K1 and K2 cells, reminiscent of replicative senescence, with low levels of BrdU labelling and apoptosis, associated with high p21(WAF1) and senescence-associated beta galactosidase expression. In contrast, abrogation of p53 function by the expression of HPV16 E6 in K1 and K2 cells either at the same time as DNhTERT or just prior to the onset of senescence allowed cells to continue growing until 'crisis'. Likewise, microinjection of a p53 neutralizing antibody into 'senescent' K1 DNhTERT cells permitted re-entry into the cell cycle. We conclude that thyroid tumour cells with wild-type p53 retain an intact p53-mediated growth arrest response to telomere erosion. This raises the intriguing question of why, therefore, p53 mutation is not selected for in such cancers, and also calls into question the therapeutic value of telomerase inhibitors in such cases.	Univ Wales Coll Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales; Univ Porto, IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal	Cardiff University; Universidade do Porto	Jones, CJ (corresponding author), Univ Wales Coll Med, Dept Pathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	Jonescj@cf.ac.uk	Preto, Ana/H-8112-2012	Preto, Ana/0000-0002-7302-0630; Jones, Christopher/0000-0002-5447-8187				Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bond JA, 1996, INT J CANCER, V67, P563, DOI 10.1002/(SICI)1097-0215(19960807)67:4<563::AID-IJC16>3.0.CO;2-8; BOND JA, 1995, CANCER RES, V55, P2404; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Brousset P, 1997, J CLIN ENDOCR METAB, V82, P4214, DOI 10.1210/jc.82.12.4214; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davis T, 2003, J CELL SCI, V116, P1349, DOI 10.1242/jcs.00331; Delhommeau FO, 2002, ONCOGENE, V21, P8262, DOI 10.1038/sj.onc.1206054; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FLORENES VA, 1994, BRIT J CANCER, V69, P253, DOI 10.1038/bjc.1994.48; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Goldman MA, 2003, DRUG DISCOV TODAY, V8, P294, DOI 10.1016/S1359-6446(03)02625-4; Granger MP, 2002, CRIT REV ONCOL HEMAT, V41, P29, DOI 10.1016/S1040-8428(01)00188-3; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Jones CJ, 1996, MOL CELL ENDOCRINOL, V116, P115, DOI 10.1016/0303-7207(95)03697-0; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Saretzki G, 2003, CANCER LETT, V194, P209, DOI 10.1016/S0304-3835(02)00708-5; SHAY JW, 1993, ONCOGENE, V8, P1407; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WYLLIE FS, 1995, ONCOGENE, V10, P49; Wyllie FS, 1999, BRIT J CANCER, V79, P1111, DOI 10.1038/sj.bjc.6690177; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458	30	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4136	4145		10.1038/sj.onc.1207564	http://dx.doi.org/10.1038/sj.onc.1207564			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064743				2022-12-25	WOS:000221520200012
J	Wang, JW; Gamsby, JJ; Highfill, SL; Mora, LB; Bloom, GC; Yeatman, TJ; Pan, TC; Ramne, AL; Chodosh, LA; Cress, WD; Chen, JD; Kerr, WG				Wang, JW; Gamsby, JJ; Highfill, SL; Mora, LB; Bloom, GC; Yeatman, TJ; Pan, TC; Ramne, AL; Chodosh, LA; Cress, WD; Chen, JD; Kerr, WG			Deregulated expression of LRBA facilitates cancer cell growth	ONCOGENE			English	Article						LRBA; gene expression profiling; RNA interference; p53; E2F	CHEDIAK-HIGASHI-SYNDROME; KINASE ANCHOR PROTEIN; MAMMALIAN-CELLS; IDENTIFICATION; GENE; P53; CLASSIFICATION; INVOLVEMENT; PATHWAYS; RECEPTOR	LRBA expression is induced by mitogens in lymphoid and myeloid cells. The Drosophila LRBA orthologue rugose/ DAKAP550 is involved in Notch, Ras and EGFR pathways. These findings suggest that LRBA could play a role in cell types that have increased proliferative and survival capacity. Here, we show by microarray and real-time PCR analyses that LRBA is overexpressed in several different cancers relative to their normal tissue controls. We also show that LRBA promoter activity and endogenous LRBA mRNA levels are reduced by p53 and increased by E2F1, indicating that mutations in the tumor suppressors p53 and Rb could contribute to the deregulation of LRBA. Furthermore, inhibition of LRBA expression by RNA interference, or inhibition of its function by a dominant-negative mutant, leads to significant growth inhibition of cancer cells, demonstrating that deregulated expression of LRBA contributes to the altered growth properties of a cancer cell. Finally, we show that the phosphorylation of EGFR is affected by the dominant-negative mutant, suggesting LRBA plays a role in the mammalian EGFR pathway. These findings demonstrate that LRBA facilitates cancer cell growth and thus LRBA may represent a novel molecular target for cancer therapy.	Immunol Programs, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Comprehens Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem, Tampa, FL 33612 USA; Mol Oncol Programs, Tampa, FL 33612 USA; Gastrointestinal Programs, Tampa, FL 33612 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Kerr, WG (corresponding author), 12902 Magnolia Dr,SRB-2, Tampa, FL 33612 USA.	kerrw@moffitt.usf.edu	Gamsby, Joshua J/H-9606-2014; Wang, Jia-Wang/I-4966-2012; Kerr, William G/B-8616-2015	Kerr, William G/0000-0002-4720-7135	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027405] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL72523] Funding Source: Medline; NIDDK NIH HHS [R01 DK54767] Funding Source: Medline; NINDS NIH HHS [P01 NS27405] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Bloom G, 2004, AM J PATHOL, V164, P9, DOI 10.1016/S0002-9440(10)63090-8; Dyomin VG, 2002, GENOMICS, V80, P158, DOI 10.1006/geno.2002.6822; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; Harborth J, 2001, J CELL SCI, V114, P4557; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jogl G, 2002, EMBO J, V21, P4785, DOI 10.1093/emboj/cdf502; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kerr WG, 1996, P NATL ACAD SCI USA, V93, P3947, DOI 10.1073/pnas.93.9.3947; Kwak E, 1999, MOL BIOL CELL, V10, P4429, DOI 10.1091/mbc.10.12.4429; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; MORRIS C, 2002, BREAST CANC RES TREA, V75; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Shamloula HK, 2002, GENETICS, V161, P693; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Spritz RA, 1998, J CLIN IMMUNOL, V18, P97, DOI 10.1023/A:1023247215374; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang JW, 2001, J IMMUNOL, V166, P4586, DOI 10.4049/jimmunol.166.7.4586; Wang XL, 2000, J NEUROSCI, V20, P8551; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8	29	55	60	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4089	4097		10.1038/sj.onc.1207567	http://dx.doi.org/10.1038/sj.onc.1207567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064745				2022-12-25	WOS:000221520200007
J	Yatabe, Y; Mitsudomi, T; Takahashi, T				Yatabe, Y; Mitsudomi, T; Takahashi, T			Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation	ONCOGENE			English	Article						maspin; non-small-cell lung cancers; intratumor heterogeneity; promoter DNA methylation; cellular properties	THYROID TRANSCRIPTION FACTOR; MAMMARY EPITHELIAL-CELLS; MESSENGER-RNA EXPRESSION; SUPPRESSOR GENE MASPIN; HUMAN BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; ADENOCARCINOMAS; CARCINOMAS; P53; PATTERNS	Maspin has been demonstrated to be a suppressor of invasion and cell motility in vitro, whereas in vivo analyses have reported that increased expression of maspin is associated with malignant behavior. The present study examined maspin expression in normal lung and non-small-cell lung cancers. Only proximal airway cells in the normal lung expressed maspin, and the expression was associated with decreased methylation. This association was also observed in non-small-cell lung cancers, but the expression was quite different among histologic subtypes; 20 of 21 squamous cell carcinomas showed intense, uniform expression, whereas the expression status varied among adenocarcinomas. Of the 119 adenocarcinomas, 60 were negative, 23 positive and 36 showed a heterogeneous expression pattern. The expression was inversely correlated with markers of peripheral airway cells. Taken together, the results suggest that maspin may be expressed in association with the proximal airway cell type. It is of note that the heterogeneous expression pattern of maspin is quite distinctive, showing geographic positivity in the individual tumors. Separate analysis of methylation status in positive and negative portions of individual tumors provided an instance of intratumor diversity associated with promoter DNA methylation.	Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Yatabe, Y (corresponding author), Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan.	yyatabe@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bieche I, 2003, BRIT J CANCER, V88, P863, DOI 10.1038/sj.bjc.6600812; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Goldstein NS, 2001, AM J CLIN PATHOL, V116, P319, DOI 10.1309/550P-QLJX-D84W-F6DN; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Hida T, 1998, CANCER RES, V58, P3761; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KAWAI J, 1993, NUCLEIC ACIDS RES, V21, P5604, DOI 10.1093/nar/21.24.5604; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lau SK, 2002, MODERN PATHOL, V15, P538, DOI 10.1038/modpathol.3880560; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maass N, 2001, CLIN CANCER RES, V7, P812; Marchetti A, 1996, J PATHOL, V179, P254, DOI 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J; Markl IDC, 2001, CANCER RES, V61, P5875; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Nass SJ, 2000, CANCER RES, V60, P4346; Nishio M, 1997, CLIN CANCER RES, V3, P1051; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yatabe Y, 1998, CANCER RES, V58, P1042; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	43	48	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	2004	23	23					4041	4049		10.1038/sj.onc.1207557	http://dx.doi.org/10.1038/sj.onc.1207557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048080				2022-12-25	WOS:000221520200001
J	Yatabe, N; Kyo, S; Maida, Y; Nishi, H; Nakamura, M; Kanaya, T; Tanaka, M; Isaka, K; Ogawa, S; Inoue, M				Yatabe, N; Kyo, S; Maida, Y; Nishi, H; Nakamura, M; Kanaya, T; Tanaka, M; Isaka, K; Ogawa, S; Inoue, M			HIF-1-mediated activation of telomerase in cervical cancer cells	ONCOGENE			English	Article						hypoxia; telomerase; HIF-1; hTERT; cervical cancer	HYPOXIA-INDUCIBLE FACTOR-1; FACTOR 1-ALPHA; C-MYC; UNFAVORABLE PROGNOSIS; TUMOR ANGIOGENESIS; GENE-EXPRESSION; O-2 TENSION; FACTOR-I; TRANSCRIPTION; OVEREXPRESSION	Hypoxia-inducible factor 1 (HIF-1) is a key regulator of O-2 homeostasis, which regulates the expression of several genes linked to angiogenesis and energy metabolism. Tumor hypoxia has been shown to be associated with poor prognosis in a variety of tumors, and HIF-1 induced by hypoxia plays pivotal roles in tumor progression. The presence of putative HIF-1-binding sites on the promoter of human telomerase reverse transcriptase gene ( hTERT) prompted us to examine the involvement of HIF-1 in the regulation of hTERT and telomerase in tumor hypoxia. The telomeric repeat amplification protocol (TRAP) assay revealed that hypoxia activated telomerase in cervical cancer ME180 cells, with peak induction at 24-48 h of hypoxia. Notably, hTERT mRNA expression was upregulated at 6-12 h of hypoxia, concordant with the elevation of HIF-1 protein levels at 6 h. hTERT protein levels were subsequently upregulated at 24 h and later. Luciferase assays using reporter plasmids containing hTERT core promoter revealed that hTERT transcription was significantly activated in hypoxia and by HIF-1 overexpression, and that the two putative binding sites within the core promoter are responsible for this activation. Chromatin immunoprecipitation assay identfied the specific binding of HIF-1 to these sites (competing with c-Myc), which was enhanced in hypoxia. The present findings suggest that hypoxia activates telomerase via transcriptional activation of hTERT, and that HIF-1 plays a critical role as a transcription factor. They also suggest the existence of novel mechanisms of telomerase activation in cancers, and have implications for the molecular basis of hypoxia-induced tumor progression and HIF-1-based cancer gene therapy.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Tokyo Med Univ, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1600023, Japan; Kanazawa Univ, Sch Med, Dept Neuroanat, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Tokyo Medical University; Kanazawa University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp						Akakura N, 2001, CANCER RES, V61, P6548; Birner P, 2000, CANCER RES, V60, P4693; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mazure NM, 2002, CANCER RES, V62, P1158; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Ravi R, 2000, GENE DEV, V14, P34; RUSSO CA, 1995, CANCER RES, V55, P1122; Schindl M, 2002, CLIN CANCER RES, V8, P1831; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sivridis E, 2002, CANCER-AM CANCER SOC, V95, P1055, DOI 10.1002/cncr.10774; Takakura M, 1999, CANCER RES, V59, P551; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yasumoto S, 1996, ONCOGENE, V13, P433	30	99	108	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3708	3715		10.1038/sj.onc.1207460	http://dx.doi.org/10.1038/sj.onc.1207460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15048086	Green Submitted			2022-12-25	WOS:000221101700023
J	Nandan, MO; Yoon, HS; Zhao, WD; Ouko, LA; Chanchevalap, S; Yang, VW				Nandan, MO; Yoon, HS; Zhao, WD; Ouko, LA; Chanchevalap, S; Yang, VW			Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras	ONCOGENE			English	Article						IKLF; transformation; mitogen-activated protein kinase; Egr1; cyclin D1; proliferation; small interfering RNA; anchorage-independent growth	SMOOTH-MUSCLE-CELLS; BTEB2 TRANSCRIPTION FACTOR; PROTEIN-KINASE ACTIVATION; CYCLIN D1; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; PLASMA-MEMBRANE; RAF-1 PROTEIN; NIH 3T3-CELLS	Previous studies indicate that Kruppel-like factor 5 (KLF5), also known as intestinal-enriched Kruppel-like factor (IKLF), is a positive regulator of cell proliferation and gives rise to a transformed phenotype when overexpressed. Here we demonstrate that levels of KLF5 transcript and protein are significantly elevated in oncogenic H-Ras-transformed NIH3T3 cells. These cells display an accelerated rate of proliferation in both serum-containing and serum-deprived media and form anchorage-independent colonies in soft agar assays. H-Ras-transformed cells also contain elevated mitogen-activated protein kinase (MAPK) activity. When treated with inhibitors of MEK ( MAPK kinase), H-Ras-transformed cells lose their growth advantage and no longer form colonies. Significantly, levels of KLF5 transcript and protein are substantially reduced in H-Ras-transformed cells treated with MEK inhibitors. Moreover, inhibition of KLF5 expression in H-Ras-transformed cells with KLF5-specific small interfering RNA ( siRNA) leads to a decreased rate of proliferation and a significant reduction in colony formation. H-Ras-transformed cells also contain elevated levels of Egr1 that are diminished by MEK inhibitors. Inhibition of Egr1 by siRNA results in a reduced level of KLF5, indicating that Egr1 mediates the inductive action of MAPK on KLF5. Lastly, KLF5 activates expression of cyclin D1. These findings indicate that the increased expression of KLF5 in H-Ras-transformed cells is secondary to increased MAPK activity from H-Ras overexpression and that the elevated level of KLF5 is in part responsible for the proproliferative and transforming activities of oncogenic H-Ras.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu		Mandayam, Nandan/0000-0002-4061-9348	NCI NIH HHS [CA84197, R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230, DK64399, DK52230, R24 DK064399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FILMUS J, 1994, ONCOGENE, V9, P3627; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; KUO ML, 1993, CANCER LETT, V74, P197, DOI 10.1016/0304-3835(93)90243-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Ogata T, 2000, J THORAC CARDIOV SUR, V119, P983, DOI 10.1016/S0022-5223(00)70093-6; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Simmen RCM, 2002, FRONT BIOSCI-LANDMRK, V7, pD1556, DOI 10.2741/simmen; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Winston JT, 1996, ONCOGENE, V12, P127; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	62	119	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3404	3413		10.1038/sj.onc.1207397	http://dx.doi.org/10.1038/sj.onc.1207397			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077182	Green Accepted			2022-12-25	WOS:000220975000015
J	Sarrio, D; Perez-Mies, B; Hardisson, D; Moreno-Bueno, G; Suarez, A; Cano, A; Martinez-Perez, J; Gamallo, C; Palacios, J				Sarrio, D; Perez-Mies, B; Hardisson, D; Moreno-Bueno, G; Suarez, A; Cano, A; Martinez-Perez, J; Gamallo, C; Palacios, J			Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions	ONCOGENE			English	Article						lobular breast cancer; p120ctn; E-cadherin; catenins	TYROSINE PHOSPHORYLATION; MESENCHYMAL TRANSITIONS; CATENIN EXPRESSION; BETA-CATENIN; IN-SITU; ADHESION; P120(CTN); PROTEIN; CANCER; SRC	Accumulating evidences indicate that p120 catenin, a member of the E-cadherin (E-CD)/catenin adhesion complex, plays a role in tumor invasion. To establish the expression pattern of p120 in breast cancer, we analysed 326 breast tissue biopsies by tissue microarray. Most of the lobular tumors (88%) showed exclusive cytoplasmic localization, and 6% of them also had p120 nuclear staining. Cytoplasmic p120 strongly associated with complete loss of E-CD and beta-catenin not only in lobular carcinoma and its metastases but also in atypical lobular hyperplasias. In the latter, loss of heterozygosity of E-CD gene was also observed. Complete loss of E-CD and cytoplasmic and nuclear p120 staining was also observed in primary lobular cancer cell cultures generated by us. In ductal tumors, by contrast, reduction of p120 and E-CD in membrane was very common (57 and 53%, respectively), whereas cytoplasmic p120 staining was rarely seen. This simultaneous reduction of membranous E-CD and p120 was not associated with increased Src kinase activity. To demonstrate that cytoplasmic p120 localization was a consequence of the absence of E-CD, the endogenous E-CD was re-expressed in MDA-231 cells by 5-Aza-2'-deoxycytidine (5Aza) treatment. After treatment, p120 shifted from the cytoplasm to the membrane, where it colocalized with endogenous E-CD. Additionally, suppressing E-CD expression in Madin-Darby canine kidney cells by stable transfection of the transcriptional repressors Snail, E47 or Slug, provokes p120 cytoplasmic localization and p120 isoform switching. In conclusion, abnormal cytoplasmic and nuclear localization of p120, which are mediated by the absence of E-CD, characteristically occur in the early stages of lobular breast cancer and are maintained during tumor progression to metastasis. Consequently, p120 may be an important mediator of the oncogenic effects derived from E-CD inactivation, including enhanced motility and invasion, in lobular breast cancer.	CNIO, Programa Patol Mol, Madrid, Spain; Hosp La Paz, Dept Pathol, Madrid, Spain; UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; La Princesa Hosp, Dept Pathol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital de La Princesa	Palacios, J (corresponding author), CNIO, Programa Patol Mol, C Melchor Fernandez Almagro 3, Madrid, Spain.	jpalacios@cnio.es	Hardisson, David/AAN-3833-2020; SARRIO, DAVID/Y-8903-2019; Palacios, Jose/AAV-3765-2020; Moreno-Bueno, Gema/K-9354-2016; Hardisson, David/E-2832-2010; Martin-Perez, Jorge/A-3522-2008; Hardisson, David/A-6259-2011	Moreno-Bueno, Gema/0000-0002-5030-6687; Hardisson, David/0000-0002-2183-3699; Martin-Perez, Jorge/0000-0002-2292-0057; Sarrio, David/0000-0003-4886-8290; Perez Mies, Belen/0000-0001-5764-5182				Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Dillon DA, 1998, AM J PATHOL, V152, P75; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; GAMALLO C, 1993, AM J PATHOL, V142, P987; GRAFF JR, 1995, CANCER RES, V55, P5195; Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jawhari AU, 1999, J PATHOL, V189, P180, DOI 10.1002/(SICI)1096-9896(199910)189:2<180::AID-PATH414>3.0.CO;2-2; Jiang WG, 2000, SURG ONCOL, V9, P151, DOI 10.1016/S0960-7404(01)00010-X; KEISERBILCK A, 1998, GENOMICS, V50, P129; KOHY N, 2002, INT J CANCER, V104, P44; Lishman SC, 1999, HISTOPATHOLOGY, V35, P195; Lu YJ, 1998, CANCER RES, V58, P4721; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Mayerle J, 2003, GASTROENTEROLOGY, V124, P949, DOI 10.1053/gast.2003.50142; Mo YY, 1996, CANCER RES, V56, P2633; Montonen O, 2001, J HISTOCHEM CYTOCHEM, V49, P1487, DOI 10.1177/002215540104901202; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakopoulou L, 2002, HISTOPATHOLOGY, V40, P536, DOI 10.1046/j.1365-2559.2002.01392.x; Ozawa M, 2001, J CELL SCI, V114, P503; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tomita K, 2000, CANCER RES, V60, P3650; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Vara JAF, 2000, BIOCHEM J, V345, P17, DOI 10.1042/0264-6021:3450017	44	143	157	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3272	3283		10.1038/sj.onc.1207439	http://dx.doi.org/10.1038/sj.onc.1207439			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077190				2022-12-25	WOS:000220975000002
J	Cariou, B; Capitaine, N; Le Marcis, V; Vega, N; Bereziat, V; Kergoat, M; Laville, M; Girard, J; Vidal, H; Burnol, AF				Cariou, B; Capitaine, N; Le Marcis, V; Vega, N; Bereziat, V; Kergoat, M; Laville, M; Girard, J; Vidal, H; Burnol, AF			Increased adipose tissue expression of Grb14 in several models of insulin resistance	FASEB JOURNAL			English	Article						thiazolidinediones; zeta interacting protein; Goto-Kakizaki rats; insulin signaling	ACTIVATED RECEPTOR-GAMMA; HUMAN SKELETAL-MUSCLE; KINASE-C-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; DIFFERENTIAL REGULATION; HUMAN ADIPOCYTES; ADAPTER GRB14; PROTEINS; THIAZOLIDINEDIONES	Grb14 is an effector of insulin signaling, which directly inhibits insulin receptor catalytic activity in vitro. Here, we investigated whether the expression of Grb14 and its binding partner ZIP (PKC zeta interacting protein) is regulated during insulin resistance in type 2 diabetic rodents and humans. Grb14 expression was increased in adipose tissue of both ob/ob mice and Goto-Kakizaki ( GK) rats, whereas there was no difference in liver. An increase was also observed in subcutaneous adipose tissue of type 2 diabetic subjects when compared with controls. ZIP expression was increased in adipose tissue of ob/ob mice and type 2 diabetic patients, but it did not vary in GK rats. Hormonal regulation of Grb14 and ZIP expression was then investigated in 3T3-F442A adipocytes. In this model, insulin stimulated Grb14 expression, while TNF-alpha increased ZIP expression. Moreover, the insulin-sensitizing drugs thiazolidinediones (TZDs) decreased Grb14 expression in 3T3-F442A adipocytes. Finally, we investigated the dynamic regulation of Grb14 expression in ob/ob mice in several conditions improving their insulin sensitivity. Prolonged fasting and treatment with metformin significantly decreased Grb14 expression in peri-epidydimal adipose tissue, while there was only a trend to a diminution after TZD treatment. Taken together, these results suggest that the regulation of Grb14 expression in adipose tissue may play a physiological role in insulin sensitivity.	Univ Paris 05, CNRS, UMR 8104, INSERM,U567,Inst Cochin,Dept Endocrinol, F-75674 Paris, France; Fac Med R Laennec, Ctr Rech & Nutr Humaine Lyon, Lyon, France; Hop Edouard Herriot, Serv Endocrinol Diabetol & Nutr, Lyon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Lyon	Burnol, AF (corresponding author), Univ Paris 05, CNRS, UMR 8104, INSERM,U567,Inst Cochin,Dept Endocrinol, F-75674 Paris, France.	burnol@cochin.inserm.fr	Vidal, Hubert/M-6674-2017; Díaz, Nicanor Vega/R-4903-2019; Burnol, Anne-Francoise/P-2181-2017	Vidal, Hubert/0000-0002-9467-0317; Cariou, Bertrand/0000-0002-1580-8040; BEREZIAT, Veronique/0000-0002-9795-549X				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Cariou B, 2002, MOL CELL BIOL, V22, P6959, DOI 10.1128/MCB.22.20.6959-6970.2002; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COONEY GJ, 2004, IN PRESS EMBO J; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hemming R, 2001, BIOCHEM CELL BIOL, V79, P21, DOI 10.1139/bcb-79-1-21; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Jiang GQ, 2002, DIABETES, V51, P2412, DOI 10.2337/diabetes.51.8.2412; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; Motoshima H, 2002, J CLIN ENDOCR METAB, V87, P5662, DOI 10.1210/JC.2002-020635; ORourke CM, 1997, METABOLISM, V46, P192, DOI 10.1016/S0026-0495(97)90301-2; OSTMAN J, 1979, METABOLISM, V28, P1198, DOI 10.1016/0026-0495(79)90131-8; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Rieusset J, 2001, DIABETOLOGIA, V44, P544, DOI 10.1007/s001250051660; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SHAFRIR E, 1992, DIABETES METAB REV, V8, P179, DOI 10.1002/dmr.5610080302; Smith U, 2002, INT J OBESITY, V26, P897, DOI 10.1038/sj.ijo.0802028; Smith U, 2001, FASEB J, V15, P215, DOI 10.1096/fj.00-0020com; Wick KR, 2003, J BIOL CHEM, V278, P8460, DOI 10.1074/jbc.M208518200; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	36	50	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					965	+		10.1096/fj.03-0824fje	http://dx.doi.org/10.1096/fj.03-0824fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059968				2022-12-25	WOS:000221108800019
J	Methot, N; Vaillancourt, JP; Huang, JQ; Colucci, J; Han, YX; Menard, S; Zamboni, R; Toulmond, S; Nicholson, DW; Roy, S				Methot, N; Vaillancourt, JP; Huang, JQ; Colucci, J; Han, YX; Menard, S; Zamboni, R; Toulmond, S; Nicholson, DW; Roy, S			A caspase active site probe reveals high fractional inhibition needed to block DNA fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; IN-VIVO; MYOCARDIAL-ISCHEMIA; IMPROVES SURVIVAL; INDUCED APOPTOSIS; GRANZYME-B; ACTIVATION; SEPSIS; LYMPHOCYTE; PATHWAYS	Apoptotic markers consist of either caspase substrate cleavage products or phenotypic changes that manifest themselves as a consequence of caspase-mediated substrate cleavage. We have shown recently that pharmacological inhibitors of caspase activity prevent the appearance of two such apoptotic manifestations, alphaII-spectrin cleavage and DNA fragmentation, but that blockade of the latter required a significantly higher concentration of inhibitor. We investigated this phenomenon through the use of a novel radiolabeled caspase inhibitor, [I-125] M808, which acts as a caspase active site probe. [I-125] M808 bound to active caspases irreversibly and with high sensitivity in apoptotic cell extracts, in tissue extracts from several commonly used animal models of cellular injury, and in living cells. Moreover, [I-125] M808 detected active caspases in septic mice when injected intravenously. Using this caspase probe, an active site occupancy assay was developed and used to measure the fractional inhibition required to block apoptosis- induced DNA fragmentation. In thymocytes, occupancy of up to 40% of caspase active sites had no effect on DNA fragmentation, whereas inhibition of half of the DNA cleaving activity required between 65 and 75% of active site occupancy. These results suggest that a high and persistent fractional inhibition will be required for successful caspase inhibition-based therapies.	Merck Frosst Ctr Therapeut Res, Merck Res Labs, Dept Biochem & Mol Biol, Montreal, PQ H9H 3L1, Canada	Merck & Company	Methot, N (corresponding author), Merck Frosst Ctr Therapeut Res, Merck Res Labs, Dept Biochem & Mol Biol, 16711 Trans Canada Highway, Montreal, PQ H9H 3L1, Canada.	nathalie_methot@merck.com						Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Adrie C, 2001, AM J RESP CRIT CARE, V164, P389, DOI 10.1164/ajrccm.164.3.2009088; Ayala A, 1996, BLOOD, V87, P4261, DOI 10.1182/blood.V87.10.4261.bloodjournal87104261; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Chapman JG, 2002, EUR J PHARMACOL, V456, P59, DOI 10.1016/S0014-2999(02)02484-6; Chen JL, 2002, J NEUROL SCI, V199, P17, DOI 10.1016/S0022-510X(02)00075-8; Coopersmith CM, 2002, CRIT CARE MED, V30, P195, DOI 10.1097/00003246-200201000-00028; Cursio R, 2000, Transpl Int, V13 Suppl 1, pS568, DOI 10.1111/j.1432-2277.2000.tb02108.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Gibson RE, 2000, CURR PHARM DESIGN, V6, P973, DOI 10.2174/1381612003399987; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoglen NC, 2001, J PHARMACOL EXP THER, V297, P811; Holly TA, 1999, J MOL CELL CARDIOL, V31, P1709, DOI 10.1006/jmcc.1999.1006; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; McIlroy D, 2000, GENE DEV, V14, P549; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Methot N, 2004, J EXP MED, V199, P199, DOI 10.1084/jem.20031791; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; REVESZ L, 1994, TETRAHEDRON LETT, V35, P9693, DOI 10.1016/0040-4039(94)88361-0; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Schroeder S, 2001, LANGENBECK ARCH SURG, V386, P42; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Waarde A, 2000, CURR PHARM DESIGN, V6, P1593, DOI 10.2174/1381612003398951; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WANG SD, 1994, J IMMUNOL, V152, P5014; Wiessner C, 2000, CELL MOL BIOL, V46, P53	44	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27905	27914		10.1074/jbc.M400247200	http://dx.doi.org/10.1074/jbc.M400247200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15067000	hybrid			2022-12-25	WOS:000222265400012
J	Levasseur, DN; Ryan, TM; Reilly, MP; McCune, SL; Asakura, T; Townes, TM				Levasseur, DN; Ryan, TM; Reilly, MP; McCune, SL; Asakura, T; Townes, TM			A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEATION-CONTROLLED AGGREGATION; CELL-DISEASE; DEOXYHEMOGLOBIN-S; TRANSGENIC MICE; MOUSE MODEL; CHEMICAL DIFFERENCE; CRYSTAL-STRUCTURE; BETA-THALASSEMIA; STEM-CELLS; GLOBIN	A new recombinant, human anti-sickling beta-globin polypeptide designated beta(AS3) (beta(Gly16) --> Asp/betaGlu(22) --> Ala/betaThr(87) --> Gln) was designed to increase affinity for alpha-globin. The amino acid substitutions at beta22 and beta87 are located at axial and lateral contacts of the sickle hemoglobin (HbS) polymers and strongly inhibit deoxy-HbS polymerization. The beta16 substitution confers the recombinant beta-globin subunit (beta(AS3)) with a competitive advantage over beta(S) for interaction with the alpha-globin polypeptide. Transgenic mouse lines that synthesize high levels of HbAS3 (alpha(2)beta(2)(AS3)) were established, and recombinant HbAS3 was purified from hemolysates and then characterized. HbAS3 binds oxygen cooperatively and has an oxygen affinity that is comparable with fetal hemoglobin. Delay time experiments demonstrate that HbAS3 is a potent inhibitor of HbS polymerization. Subunit competition studies confirm that beta(AS3) has a distinct advantage over beta(S) for dimerization with alpha-globin. When equal amounts of beta(S)- and beta(AS3)-globin monomers compete for limiting alpha-globin chains up to 82% of the tetramers formed is HbAS3. Knock-out transgenic mice that express exclusively human HbAS3 were produced. When these mice were bred with knock-out transgenic sickle mice the beta(AS3) polypeptides corrected all hematological parameters and organ pathology associated with the disease. Expression of beta(AS3)-globin should effectively lower the concentration of HbS in erythrocytes of patients with sickle cell disease, especially in the 30% percent of these individuals who coinherit alpha-thalassemia. Therefore, constructs expressing the beta(AS3)-globin gene may be suitable for future clinical trials for sickle cell disease.	Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Townes, TM (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, 502 Kaul Genet Bldg,720 20th St S, Birmingham, AL 35294 USA.	ttownes@uab.edu		Ryan, Thomas/0000-0002-8982-0253	NATIONAL CANCER INSTITUTE [T32CA009467] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057619, R01HL035559, P60HL038632] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09467] Funding Source: Medline; NHLBI NIH HHS [HL35559, HL 43508, HL38632, HL57619] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1987, J CHROMATOGR-BIOMED, V419, P303, DOI 10.1016/0378-4347(87)80291-8; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1980, J BIOL CHEM, V255, P7595; ALTAY C, 1977, AM J HEMATOL, V3, P1; ASAKURA T, 1986, OXYGEN TRANSPORT RED; BAGLIONI C, 1963, BIOCHIM BIOPHYS ACTA, V78, P637, DOI 10.1016/0006-3002(63)91029-1; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BEHRINGER RR, 1989, SCIENCE, V245, P971, DOI 10.1126/science.2772649; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BRITTENHAM G, 1979, AM J HEMATOL, V6, P107, DOI 10.1002/ajh.2830060203; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; BUNN HF, 1987, BLOOD, V69, P1; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; CY IP, 1986, ANAL BIOCHEM, V156, P348, DOI 10.1016/0003-2697(86)90264-2; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; HIGGS DR, 1989, BLOOD, V73, P1081; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; KUTLAR A, 1990, HUM GENET, V85, P106; Levasseur DN, 2003, BLOOD, V102, P4312, DOI 10.1182/blood-2003-04-1251; LEWIS MK, 1990, NUCLEIC ACIDS RES, V18, P3439, DOI 10.1093/nar/18.12.3439; MCCUNE SL, 1994, P NATL ACAD SCI USA, V91, P9852, DOI 10.1073/pnas.91.21.9852; MCDONALD MJ, 1987, J BIOL CHEM, V262, P5951; MRABET NT, 1986, J BIOL CHEM, V261, P5222; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; SAMBROOK J, 1989, MOL CLONING LAB MANU, P390; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHROEDER WA, 1985, HEMOGLOBIN, V9, P461, DOI 10.3109/03630268508997024; TURCI SM, 1985, J CHROMATOGR, V343, P168, DOI 10.1016/S0378-4347(00)84581-8; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WOOD WG, 1980, BRIT J HAEMATOL, V45, P431, DOI 10.1111/j.1365-2141.1980.tb07163.x	40	50	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27518	27524		10.1074/jbc.M402578200	http://dx.doi.org/10.1074/jbc.M402578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084588	hybrid			2022-12-25	WOS:000222120400084
J	Imamura, Y; Katahira, T; Kitamura, D				Imamura, Y; Katahira, T; Kitamura, D			Identification and characterization of a novel BASH N terminus-associated protein, BNAS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; CELL LINKER PROTEIN; RECEPTOR-MEDIATED ACTIVATION; BRUTONS TYROSINE KINASE; JUN NH2-TERMINAL KINASE; ANTIGEN RECEPTOR; MAP KINASE; B-LYMPHOCYTES; DEVELOPMENTAL PROGRESSION; ALLELIC EXCLUSION	A B cell-specific adaptor protein, BASH ( also known as BLNK or SLP-65), is crucial for B cell receptor (BCR) signaling. BASH binds to various signaling intermediates, such as Btk, PLCgamma2, Vav, and Grb2, through its well defined motifs. Although functional significance of such interactions has been documented, BASH-mediated signal transduction mechanism is not fully understood. Using the yeast two-hybrid system, we have identified a novel protein that binds to a conserved N-terminal domain of BASH, which we named BNAS2 (BASH N terminus associated protein 2). From its deduced amino acid sequence, BNAS2 is presumed to contain four transmembrane domains, which are included in a central MARVEL domain, and to localize to endoplasmic reticulum. BNAS2 was co-precipitated with BASH as well as Btk and ERK2 from a lysate of mouse B cell line. In the transfected cells, the exogenous BNAS2 was localized in a mesh-like structure in the cytoplasm resembling that of endoplasmic reticulum ( ER) and nuclear membrane. BASH was co-localized with BNAS2 in a manner dependent on its N-terminal domain. RT-PCR analysis indicated that BNAS2 mRNA is expressed ubiquitously except for plasma cells. In chicken B cell line DT40, overexpression of BNAS2 resulted in an enhancement of BCR ligation-mediated transcriptional activation of Elk1, but not of NF-kappaB, in a manner dependent on the dose of BNAS2. Thus BNAS2 may serve as a scaffold for signaling proteins such as BASH, Btk, and ERK at the ER and nuclear membrane and may facilitate ERK activation by signaling from cell-surface receptors.	Tokyo Univ Sci, Res Inst Biol Sci, Noda, Chiba 2780022, Japan; Matsumoto Dent Univ, Dept Pharmacol, Shiojiri, Nagano 3990781, Japan	Tokyo University of Science; Matsumoto Dental University	Kitamura, D (corresponding author), Tokyo Univ Sci, Res Inst Biol Sci, 2669 Yamazaki, Noda, Chiba 2780022, Japan.	kitamura@rs.noda.tus.ac.jp						AMIOT M, 1990, J IMMUNOL, V145, P4322; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Breitwieser GE, 1997, AM J PHYSIOL-CELL PH, V272, pC957, DOI 10.1152/ajpcell.1997.272.3.C957; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chiu CW, 2002, EMBO J, V21, P6461, DOI 10.1093/emboj/cdf658; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Goitsuka R, 2000, INT IMMUNOL, V12, P573, DOI 10.1093/intimm/12.4.573; Goitsuka R, 1998, J IMMUNOL, V161, P5804; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Katsuta H, 1998, J IMMUNOL, V160, P1547; Kersseboom R, 2003, J EXP MED, V198, P91, DOI 10.1084/jem.20030615; KITANI S, 1991, J BIOL CHEM, V266, P1903; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEVY S, 1991, J BIOL CHEM, V266, P14597; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Nagaoka H, 2000, J EXP MED, V192, P171, DOI 10.1084/jem.192.2.171; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; SCHWARTZALBIEZ R, 1988, J IMMUNOL, V140, P905; Shaw AC, 1999, P NATL ACAD SCI USA, V96, P2239, DOI 10.1073/pnas.96.5.2239; Shaw AC, 1999, J EXP MED, V189, P123, DOI 10.1084/jem.189.1.123; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Tsuji S, 2001, J EXP MED, V194, P529, DOI 10.1084/jem.194.4.529; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; YAGI T, 1993, ONCOGENE, V8, P3343; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	60	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26425	26432		10.1074/jbc.M403685200	http://dx.doi.org/10.1074/jbc.M403685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087455	hybrid			2022-12-25	WOS:000222003000064
J	Petropoulos, AD; Xaplanteri, MA; Dinos, GP; Wilson, DN; Kalpaxis, DL				Petropoulos, AD; Xaplanteri, MA; Dinos, GP; Wilson, DN; Kalpaxis, DL			Polyamines affect diversely the antibiotic potency - Insight gained from kinetic studies of the blasticidin S and spiramycin interactions with functional ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; ESCHERICHIA-COLI RIBOSOMES; TRANSFER-RNA; PHOTOAFFINITY POLYAMINES; PROTEIN-SYNTHESIS; STRUCTURAL BASIS; BOND FORMATION; PEPTIDYLTRANSFERASE; SPERMINE; BINDING	The effects of spermine on peptidyltransferase inhibition by an aminohexosylcytosine nucleoside, blasticidin S, and by a macrolide, spiramycin, were investigated in a model system derived from Escherichia coli, in which a peptide bond is formed between puromycin and AcPhe-tRNA bound at the P-site of poly(U)-programmed ribosomes. Kinetics revealed that blasticidin S, after a transient phase of interference with the A-site, is slowly accommodated near to the P-site so that peptide bond is still formed but with a lower catalytic rate constant. At high concentrations of blasticidin S (> 10 x K-i), a second drug molecule binds to a weaker binding site on ribosomes, and this may account for the onset of a subsequent mixed-noncompetitive inhibition phase. Spermine enhances the blasticidin S inhibitory effect by facilitating the drug accommodation to both sites. On the other hand, spiramycin (A) was found competing with puromycin for the A-site of AcPhe-tRNA.poly(U).70 S ribosomal complex (C) via a two-step mechanism, according to which the fast formation of the encounter complex CA is followed by a slow isomerization to a tighter complex, termed C*A. In contrast to that observed with blasticidin S, spermine reduced spiramycin potency by decreasing the formation and stability of complex C*A. Polyamine effects on drug binding were more pronounced when a mixture of spermine and spermidine was used, instead of spermine alone. Our kinetic results correlate well with cross-linking and crystallographic data and suggest that polyamines bound at the vicinity of the antibiotic binding pockets modulate diversely the interaction of these drugs with ribosomes.	Univ Patras, Sch Med, Biochem Lab, GR-26500 Patras, Greece; Max Planck Inst Mol Genet, AG Ribosomen, D-14195 Berlin, Germany	University of Patras; Max Planck Society	Kalpaxis, DL (corresponding author), Univ Patras, Sch Med, Biochem Lab, GR-26500 Patras, Greece.	dimkal@med.upatras.gr	Kalpaxis, Dimitrios L./A-5195-2008; Dinos, George/AAR-8444-2020; Wilson, Daniel/AAE-8504-2019	Dinos, George/0000-0003-3914-7408; Wilson, Daniel/0000-0003-3816-3828				Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Amarantos I, 2002, NUCLEIC ACIDS RES, V30, P2832, DOI 10.1093/nar/gkf404; Amarantos I, 2001, BIOCHEMISTRY-US, V40, P7641, DOI 10.1021/bi010010s; Amarantos I, 2000, NUCLEIC ACIDS RES, V28, P3733, DOI 10.1093/nar/28.19.3733; BALLESTA JPG, 1990, RIBOSOME, P502; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; Champney W. S., 2001, Current Drug Targets - Infectious Disorders, V1, P19, DOI 10.2174/1568005013343281; CLARK E, 1991, BIOCHEMISTRY-US, V30, P4009, DOI 10.1021/bi00230a028; COHEN SS, 1998, GUIDE POLYAMINES, P495; Depardieu F, 2001, ANTIMICROB AGENTS CH, V45, P319, DOI 10.1128/AAC.45.1.319-323.2001; DINOS G, 1993, BIOCHEMISTRY-US, V32, P10638, DOI 10.1021/bi00091a014; DRAINAS D, 1994, BBA-PROTEIN STRUCT M, V1208, P55, DOI 10.1016/0167-4838(94)90159-7; ERION MD, 1987, BIOCHEMISTRY-US, V26, P3417, DOI 10.1021/bi00386a025; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hansen JL, 2003, J MOL BIOL, V330, P1061, DOI 10.1016/S0022-2836(03)00668-5; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; KALPAXIS DL, 1986, EUR J BIOCHEM, V154, P267, DOI 10.1111/j.1432-1033.1986.tb09392.x; KALPAXIS DL, 1993, ARCH BIOCHEM BIOPHYS, V300, P629, DOI 10.1006/abbi.1993.1087; Kirillov SV, 1999, RNA, V5, P1003, DOI 10.1017/S1355838299990568; MENNINGER JR, 1982, ANTIMICROB AGENTS CH, V21, P811, DOI 10.1128/AAC.21.5.811; MITCHELL P, 1993, NUCLEIC ACIDS RES, V21, P887, DOI 10.1093/nar/21.4.887; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; PESTKA S, 1974, ANTIMICROB AGENTS CH, V5, P255, DOI 10.1128/AAC.5.3.255; Pestka S, 1974, Methods Enzymol, V30, P261; PESTKA S, 1972, J BIOL CHEM, V247, P4669; Polacek N, 1998, RNA, V4, P1282, DOI 10.1017/S1355838298980347; Poulsen SM, 2000, J MOL BIOL, V304, P471, DOI 10.1006/jmbi.2000.4229; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; SEGEL IH, 1993, ENZYME KINETICS, P39; Spahn CMT, 1996, J MOL MED, V74, P423, DOI 10.1007/s001090050044; SYNETOS D, 1987, BIOCHIM BIOPHYS ACTA, V923, P275, DOI 10.1016/0304-4165(87)90014-6; TERAOKA H, 1973, EUR J BIOCHEM, V33, P578, DOI 10.1111/j.1432-1033.1973.tb02718.x; THEOCHARIS DA, 1986, EUR J BIOCHEM, V159, P479, DOI 10.1111/j.1432-1033.1986.tb09911.x; Triman KL, 1999, ADV GENET, V41, P157, DOI 10.1016/S0065-2660(08)60153-4; Vester B, 2001, ANTIMICROB AGENTS CH, V45, P1, DOI 10.1128/AAC.45.1.1-12.2001; VOGEL Z, 1971, J MOL BIOL, V60, P339, DOI 10.1016/0022-2836(71)90298-1; Xaplanteri MA, 2003, NUCLEIC ACIDS RES, V31, P5074, DOI 10.1093/nar/gkg686	41	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26518	26525		10.1074/jbc.M313634200	http://dx.doi.org/10.1074/jbc.M313634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075341	hybrid			2022-12-25	WOS:000222003000075
J	Xiao, YC; Tang, JZ; Yang, YJ; Wang, MC; Hu, WJ; Xie, JY; Zeng, XZ; Liang, SP				Xiao, YC; Tang, JZ; Yang, YJ; Wang, MC; Hu, WJ; Xie, JY; Zeng, XZ; Liang, SP			Jingzhaotoxin-III, a novel spider toxin inhibiting activation of voltage-gated sodium channel in rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTHUS-MARTENSI KARSCH; 3-DIMENSIONAL STRUCTURE; PEPTIDE TOXINS; NA+ CHANNELS; VENOM; NEUROTOXINS; EVOLUTION; INACTIVATION; CONTRACTION; CLONING	We have isolated a cardiotoxin, denoted jingzhaotoxin-III (JZTX-III), from the venom of the Chinese spider Chilobrachys jingzhao. The toxin contains 36 residues stabilized by three intracellular disulfide bridges (I-IV, II-V, and III-VI), assigned by a chemical strategy of partial reduction and sequence analysis. Cloned and sequenced using 3'-rapid amplification of cDNA ends and 5'-rapid amplification of cDNA ends, the full-length cDNA encoded a 63-residue precursor of JZTX-III. Different from other spider peptides, it contains an uncommon endoproteolytic site (-X-Ser-) anterior to mature protein and the intervening regions of 5 residues, which is the smallest in spider toxin cDNAs identified to date. Under whole cell recording, JZTX-III showed no effects on voltage-gated sodium channels (VGSCs) or calcium channels in dorsal root ganglion neurons, whereas it significantly inhibited tetrodotoxin-resistant VGSCs with an IC50 value of 0.38 muM in rat cardiac myocytes. Different from scorpion beta-toxins, it caused a 10-mV depolarizing shift in the channel activation threshold. The binding site for JZTX-III on VGSCs is further suggested to be site 4 with a simple competitive assay, which at 10 muM eliminated the slowing currents induced by Buthus martensi Karsch I (BMK-I, scorpion alpha-like toxin) completely. JZTX-III shows higher selectivity for VGSC isoforms than other spider toxins affecting VGSCs, and the toxin hopefully represents an important ligand for discriminating cardiac VGSC subtype.	Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China	Hunan Normal University	Liang, SP (corresponding author), Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China.	liangsp@hunnu.edu.cn	Xiao, Yucheng/H-3600-2012					Alami M, 2003, BIOCHEM J, V375, P551, DOI 10.1042/BJ20030688; Cao CM, 2002, PFLUG ARCH EUR J PHY, V443, P635, DOI 10.1007/s00424-001-0743-3; Cardoso FC, 2003, TOXICON, V41, P755, DOI 10.1016/S0041-0101(03)00011-4; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; Corzo G, 2003, FEBS LETT, V547, P43, DOI 10.1016/S0014-5793(03)00666-5; Cummins TR, 2001, J NEUROSCI, V21, P5952, DOI 10.1523/JNEUROSCI.21-16-05952.2001; Diao JB, 2003, TOXICON, V42, P715, DOI 10.1016/j.toxicon.2003.08.007; Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4; Goldin AL, 2002, J EXP BIOL, V205, P575; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Herzog RI, 2003, J NEUROSCI, V23, P8261; Huys I, 2003, EUR J NEUROSCI, V17, P1786, DOI 10.1046/j.1460-9568.2003.02613.x; Ji YH, 1996, TOXICON, V34, P987, DOI 10.1016/0041-0101(96)00065-7; Li DL, 2003, FEBS LETT, V555, P616, DOI 10.1016/S0014-5793(03)01303-6; Lopreato GF, 2001, P NATL ACAD SCI USA, V98, P7588, DOI 10.1073/pnas.131171798; Maier SKG, 2002, P NATL ACAD SCI USA, V99, P4073, DOI 10.1073/pnas.261705699; Middleton RE, 2002, BIOCHEMISTRY-US, V41, P14734, DOI 10.1021/bi026546a; Nicholson GM, 1998, PFLUG ARCH EUR J PHY, V436, P117, DOI 10.1007/s004240050612; Ogata N, 2002, JPN J PHARMACOL, V88, P365, DOI 10.1254/jjp.88.365; Omecinsky DO, 1996, BIOCHEMISTRY-US, V35, P2836, DOI 10.1021/bi952605r; Peng K, 2002, J BIOL CHEM, V277, P47564, DOI 10.1074/jbc.M204063200; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Shu Q, 2002, PROTEIN SCI, V11, P245, DOI 10.1110/ps.30502; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Sun YM, 2003, J BIOL CHEM, V278, P24125, DOI 10.1074/jbc.M211931200; Wang CZ, 2003, TOXICON, V42, P613, DOI 10.1016/j.toxicon.2003.08.005; Xiao XC, 2003, EUR J PHARMACOL, V477, P1, DOI 10.1016/S0014-2999(03)02190-3; ZHU MS, 2001, J BAODING TEACHERS C, V14, P1; Zhu SY, 2003, FASEB J, V17, P1765, DOI 10.1096/fj.02-1044fje	30	55	60	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26220	26226		10.1074/jbc.M401387200	http://dx.doi.org/10.1074/jbc.M401387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084603	hybrid			2022-12-25	WOS:000222003000038
J	Cui, XY; Hu, QD; Tekaya, M; Shimoda, Y; Ang, BT; Nie, DY; Sun, L; Hu, WP; Karsak, M; Duka, T; Takeda, Y; Ou, LY; Dawe, GS; Yu, FG; Ahmed, S; Jin, LH; Schachner, M; Watanabe, K; Arsenijevic, Y; Xiao, ZC				Cui, XY; Hu, QD; Tekaya, M; Shimoda, Y; Ang, BT; Nie, DY; Sun, L; Hu, WP; Karsak, M; Duka, T; Takeda, Y; Ou, LY; Dawe, GS; Yu, FG; Ahmed, S; Jin, LH; Schachner, M; Watanabe, K; Arsenijevic, Y; Xiao, ZC			NB-3/Notch1 pathway via Deltex1 promotes neural progenitor cell differentiation into oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION MOLECULE NB-3; CONTACTIN/F3 SUBGROUP; MULTIPLE-SCLEROSIS; NOTCH RECEPTOR; STEM-CELLS; RAT-BRAIN; NEUROGENESIS; F3/CONTACTIN; GLIOGENESIS; MATURATION	Neurons and glia in the vertebrate central nervous system arise in temporally distinct, albeit overlapping, phases. Neurons are generated first followed by astrocytes and oligodendrocytes from common progenitor cells. Increasing evidence indicates that axon-derived signals spatiotemporally modulate oligodendrocyte maturation and myelin formation. Our previous observations demonstrate that F3/contactin is a functional ligand of Notch during oligodendrocyte maturation, revealing the existence of another group of Notch ligands. Here, we establish that NB-3, a member of the F3/contactin family, acts as a novel Notch ligand to participate in oligodendrocyte generation. NB-3 triggers nuclear translocation of the Notch intracellular domain and promotes oligodendrogliogenesis from progenitor cells and differentiation of oligodendrocyte precursor cells via Deltex1. In primary oligodendrocytes, NB-3 increases myelin-associated glycoprotein transcripts. Thus, the NB-3/Notch signaling pathway may prove to be a molecular handle to treat demyelinating diseases.	Singapore Gen Hosp, Dept Clin Res, Neurobiol Lab, Singapore 169608, Singapore; Singapore Gen Hosp, Grp Stem Cell Res, Singapore 169608, Singapore; Harbin Med Coll, Dept Histol & Embryol, Harbin 150086, Peoples R China; Natl Univ Singapore, Dept Anat, Singapore 117597, Singapore; Eye Hosp Jules Gonin, Unit Oculogenet, CH-1004 Lausanne, Switzerland; Nagaoka Univ Technol, Dept Bioengn, Nagaoka, Niigata 9402188, Japan; Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 169608, Singapore; Univ Hamburg, Zentrum Mol Neurobiol, D-20251 Hamburg, Germany; Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Clin Pharm & Pharmacol, Kagoshima 8908544, Japan; Natl Univ Singapore, Dept Pharmacol, Singapore 119260, Singapore; Inst Mol & Cell Biol, Singapore 117609, Singapore	Singapore General Hospital; Singapore General Hospital; Harbin Medical University; National University of Singapore; Nagaoka University of Technology; Singapore General Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Kagoshima University; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Xiao, ZC (corresponding author), Singapore Gen Hosp, Dept Clin Res, Neurobiol Lab, Block A,7 Hosp Dr, Singapore 169608, Singapore.	gcrxzc@sgh.com.sg	xiao, zhicheng/A-1529-2011; Messier, Claude/A-2322-2008; Nie, Duyu A./AAR-6211-2020	Messier, Claude/0000-0002-4791-1763; Nie, Duyu A./0000-0002-4280-6956; Arsenijevic, Yvan/0000-0001-6960-1291; Dawe, Gavin/0000-0001-6119-701X; Karsak, Meliha/0000-0001-6612-6317				*ABI, 1997, US B ABI, V2; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Arsenijevic Y, 2001, J NEUROSCI, V21, P7194, DOI 10.1523/JNEUROSCI.21-18-07194.2001; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Berglund EO, 1999, NEURON, V24, P739, DOI 10.1016/S0896-6273(00)81126-5; BOGLER O, 1997, CURRENT PROTOCOLS NE; COLELLO RJ, 1998, CURRENT PROTOCOLS NE; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Genoud S, 2002, J CELL BIOL, V158, P709, DOI 10.1083/jcb.200202002; HARLOW E, 1998, ANTIBODIES LAB MANUA, P53; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Itoh K, 2002, BRAIN RES PROTOC, V10, P23; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Jack C, 2001, MOL BRAIN RES, V87, P166, DOI 10.1016/S0169-328X(01)00010-9; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Lee S, 2000, GENE, V245, P253, DOI 10.1016/S0378-1119(00)00031-7; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Morrison SJ, 2001, CURR OPIN CELL BIOL, V13, P666, DOI 10.1016/S0955-0674(00)00269-6; Ogawa J, 1996, NEUROSCI LETT, V218, P173, DOI 10.1016/S0304-3940(96)13156-6; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; RichterLandsberg C, 1996, J NEUROSCI RES, V45, P161, DOI 10.1002/(SICI)1097-4547(19960715)45:2<161::AID-JNR8>3.0.CO;2-8; Rogister B, 1999, MOL CELL NEUROSCI, V14, P287, DOI 10.1006/mcne.1999.0790; Sauvageot CM, 2002, CURR OPIN NEUROBIOL, V12, P244, DOI 10.1016/S0959-4388(02)00322-7; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimazaki K, 1998, NEUROSCI LETT, V245, P117, DOI 10.1016/S0304-3940(98)00179-7; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Takeda Y, 2003, J NEUROBIOL, V56, P252, DOI 10.1002/neu.10222; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	34	102	113	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25858	25865		10.1074/jbc.M313505200	http://dx.doi.org/10.1074/jbc.M313505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082708	hybrid			2022-12-25	WOS:000221827900117
J	Ito, T; Tsukumo, S; Suzuki, N; Motohashi, H; Yamamoto, M; Fujii-Kuriyama, Y; Mimura, J; Lin, TM; Peterson, RE; Tohyama, C; Nohara, K				Ito, T; Tsukumo, S; Suzuki, N; Motohashi, H; Yamamoto, M; Fujii-Kuriyama, Y; Mimura, J; Lin, TM; Peterson, RE; Tohyama, C; Nohara, K			A constitutively active arylhydrocarbon receptor induces growth inhibition of Jurkat T cells through changes in the expression of genes related to apoptosis and cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; RETINOBLASTOMA PROTEIN; CYTOKINE PRODUCTION; AH RECEPTOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; CYTOCHROME P4501A1; DEFICIENT MICE; TRANSCRIPTION; SUPPRESSION; ACTIVATION	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is known to suppress T cell-dependent immune reactions through the activation of the arylhydrocarbon receptor (AhR). Our previous findings suggest that TCDD inhibits the activation and subsequent expansion of T cells following antigen stimulation in mice, leading to a decreased level of T cell-derived cytokines involved in antibody production. In the present study, we investigated the effects of activated AhR on T cells by transiently expressing a constitutively active AhR (CA-AhR) mutant in AhR-null Jurkat T cells. In agreement with our previous findings, CA-AhR markedly inhibited the growth of Jurkat T cells. The inhibited cell growth was found to be concomitant with both an increase in the annexin V-positive apoptotic cells and the accumulation of cells in the G(1) phase. The growth inhibition was also shown to be mediated by both xenobiotic response element (XRE)-dependent and -independent mechanisms, because an A78D mutant of the CA-AhR, which lacks the ability of XRE-dependent transcription, partially inhibited the growth of Jurkat T cells. Furthermore, we demonstrated that CA-AhR induces expression changes in genes related to apoptosis and cell cycle arrest. These expression changes were shown to be solely mediated in an XRE-dependent manner, because the A78D mutant of the CA-AhR did not induce them. To summarize, these results suggest that AhR activation causes apoptosis and cell cycle arrest, especially through expression changes in genes related to apoptosis and cell cycle arrest by the XRE-dependent mechanism, leading to the inhibition of T cell growth.	Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki 3058506, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA	National Institute for Environmental Studies - Japan; University of Tsukuba; University of Wisconsin System; University of Wisconsin Madison	Nohara, K (corresponding author), Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki 3058506, Japan.	keikon@nies.go.jp	Suzuki, Norio/AAZ-9458-2021; Suzuki, Norio/F-3456-2010; Motohashi, Hozumi/AAZ-2628-2020; Tohyama, Chiharu/AAI-5598-2020; Mimura, Junsei/E-7893-2013	Suzuki, Norio/0000-0001-6100-3350; Tohyama, Chiharu/0000-0003-1061-6872; 				Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Birnbaum LS, 2000, FOOD ADDIT CONTAM A, V17, P275, DOI 10.1080/026520300283351; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; Dearstyne EA, 2002, TOXICOLOGY, V170, P139, DOI 10.1016/S0300-483X(01)00542-X; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; Doi H, 2003, CHEMOSPHERE, V52, P655, DOI 10.1016/S0045-6535(03)00112-7; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Fujimaki H, 2002, TOXICOL SCI, V66, P117, DOI 10.1093/toxsci/66.1.117; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; HOLSAPPLE MP, 1991, TOXICOLOGY, V69, P219, DOI 10.1016/0300-483X(91)90184-3; Hossain A, 1998, J BIOL CHEM, V273, P19853, DOI 10.1074/jbc.273.31.19853; Ito T, 2002, TOXICOL SCI, V70, P46, DOI 10.1093/toxsci/70.1.46; Kerkvliet NI, 2002, TOXICOL APPL PHARM, V185, P146, DOI 10.1006/taap.2002.9537; Kerkvliet NI, 1996, J IMMUNOL, V157, P2310; Kerkvliet NI, 2002, INT IMMUNOPHARMACOL, V2, P277, DOI 10.1016/S1567-5769(01)00179-5; Kohle C, 2002, ARCH BIOCHEM BIOPHYS, V402, P172, DOI 10.1016/S0003-9861(02)00076-0; Laiosa MD, 2003, J IMMUNOL, V171, P4582, DOI 10.4049/jimmunol.171.9.4582; Lawrence BP, 1996, TOXICOL APPL PHARM, V138, P275, DOI 10.1006/taap.1996.0126; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Levine SL, 2000, MOL PHARMACOL, V58, P1517, DOI 10.1124/mol.58.6.1517; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; Nohara K, 2002, TOXICOLOGY, V172, P49, DOI 10.1016/S0300-483X(01)00582-0; Park JH, 2003, TOXICOL LETT, V145, P55, DOI 10.1016/S0378-4274(03)00259-5; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Staples JE, 1998, J IMMUNOL, V160, P3844; Tanaka J, 1999, BIOCHEM BIOPH RES CO, V264, P938, DOI 10.1006/bbrc.1999.1617; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; TOHYAMA C, 2002, ENV SCI, V9, P37; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vorderstrasse BA, 2001, TOXICOL APPL PHARM, V171, P157, DOI 10.1006/taap.2000.9122; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711; Zeytun A, 2002, TOXICOLOGY, V178, P241, DOI 10.1016/S0300-483X(02)00230-5	45	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25204	25210		10.1074/jbc.M402143200	http://dx.doi.org/10.1074/jbc.M402143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069065	hybrid			2022-12-25	WOS:000221827900037
J	Schotte, P; Denecker, G; Van den Broeke, A; Vandenabeele, P; Cornelis, GR; Beyaert, R				Schotte, P; Denecker, G; Van den Broeke, A; Vandenabeele, P; Cornelis, GR; Beyaert, R			Targeting Rac1 by the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSFECTED CELL-LINES; RHO GTPASES; ACTIN POLYMERIZATION; TYROSINE-PHOSPHATASE; VIRULENCE FACTORS; FOCAL ADHESIONS; GENE-EXPRESSION; III SECRETION; HOST-CELLS	Yersinia bacteria can take control of the host cell by injecting so-called Yop effector proteins into the cytosol of the cells to which they adhere. Using Yersinia enterocolitica strains that are deficient for one or more Yops, we could show that YopE and, to a lesser extent, YopT interfere with the caspase-1-mediated maturation of prointerleukin-1beta in macrophages. In addition, overexpression of YopE and YopT was shown to prevent the autoproteolytic activation of caspase-1 in a way that is dependent on their inhibitory effect on Rho GTPases. Expression of constitutive-active or dominant-negative Rho GTPase mutants or treatment with Rho GTPase inhibitors confirmed the role of Rho GTPases and, in particular, Rac1 in the autoactivation of caspase-1. Rac1-induced caspase-1 activation was mediated by its effect on LIM kinase-1, which is targeting the actin cytoskeleton. Rac-1 and LIM kinase-1 dominant-negative mutants were shown to inhibit caspase-1 activation induced by overexpression of Asc, which is a caspase-1-activating adaptor protein. Moreover, Rac1 as well as YopE and YopT significantly modulated caspase-1 oligomerization. These results highlight a previously unknown function of Rho GTPases in the activation of caspase-1 and give new insight on the role of YopE in immune-escape mechanisms of Yersinia.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium; State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signalling & Cell Death, B-9052 Ghent, Belgium; Univ Basel, Bioctr, Div Mol Microbiol, CH-4056 Basel, Switzerland	Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; University of Basel	Beyaert, R (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Belgium.	rudi@dmbr.ugent.be	Beyaert, Rudi/B-2589-2009; Denecker, Geertrui/E-8134-2010; Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009	Vandenabeele, Peter/0000-0002-6669-8822; Denecker, Geertrui/0000-0002-2515-2911; Beyaert, Rudi/0000-0002-5704-582X				Aepfelbacher M, 2003, J BIOL CHEM, V278, P33217, DOI 10.1074/jbc.M303349200; Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Black DS, 2000, CELL MICROBIOL, V2, P401, DOI 10.1046/j.1462-5822.2000.00061.x; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BLISKA JB, 1995, INFECT IMMUN, V63, P681, DOI 10.1128/IAI.63.2.681-685.1995; Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; Boquet P, 2003, TRENDS CELL BIOL, V13, P238, DOI 10.1016/S0962-8924(03)00037-0; Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cotteret S, 2002, GENOME BIOL, V3; Denecker G, 2001, J BIOL CHEM, V276, P19706, DOI 10.1074/jbc.M101573200; Desmedt M, 1998, J IMMUNOL, V160, P5300; Dukuzumuremyi JM, 2000, J BIOL CHEM, V275, P35281, DOI 10.1074/jbc.M003009200; Fitzgerald KA, 2000, MICROBES INFECT, V2, P933, DOI 10.1016/S1286-4579(00)00396-8; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Goto M, 1999, CYTOKINE, V11, P16, DOI 10.1006/cyto.1998.0390; Grosdent N, 2002, INFECT IMMUN, V70, P4165, DOI 10.1128/IAI.70.8.4165-4176.2002; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Iriarte M, 1998, MOL MICROBIOL, V29, P915, DOI 10.1046/j.1365-2958.1998.00992.x; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEUNG KY, 1990, INFECT IMMUN, V58, P3262, DOI 10.1128/IAI.58.10.3262-3271.1990; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 2001, BIOCHEM BIOPH RES CO, V280, P652, DOI 10.1006/bbrc.2000.4190; McDonald C, 2003, J BIOL CHEM, V278, P18514, DOI 10.1074/jbc.M301226200; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Oral HB, 1999, ANAL BIOCHEM, V267, P196, DOI 10.1006/abio.1998.2984; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Ruckdeschel K, 1996, INFECT IMMUN, V64, P724, DOI 10.1128/IAI.64.3.724-733.1996; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sauvonnet N, 2002, MOL MICROBIOL, V45, P805, DOI 10.1046/j.1365-2958.2002.03053.x; Sauvonnet N, 2002, J BIOL CHEM, V277, P25133, DOI 10.1074/jbc.M203239200; Schafer H, 1997, J IMMUNOL METHODS, V204, P89, DOI 10.1016/S0022-1759(97)00040-9; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANDENABEELE P, 1990, J IMMUNOL METHODS, V135, P25, DOI 10.1016/0022-1759(90)90252-Q; Vasudevan A, 1999, J MED CHEM, V42, P1333, DOI 10.1021/jm9900873; Viboud GI, 2001, EMBO J, V20, P5373, DOI 10.1093/emboj/20.19.5373; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wilkins TD, 1996, TRENDS MICROBIOL, V4, P49, DOI 10.1016/0966-842X(96)81508-3; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	55	112	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25134	25142		10.1074/jbc.M401245200	http://dx.doi.org/10.1074/jbc.M401245200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060067	hybrid			2022-12-25	WOS:000221827900028
J	Hansen, JL; Theilade, J; Haunso, S; Sheikh, SP				Hansen, JL; Theilade, J; Haunso, S; Sheikh, SP			Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits G alpha(q) protein signaling but not ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; V2 VASOPRESSIN RECEPTORS; COUPLED RECEPTOR; FUNCTIONAL RECONSTITUTION; CRYSTAL-STRUCTURE; TRANSFER BRET; DIMERIZATION; INTERNALIZATION; RHODOPSIN; MEMBRANES	The 7-transmembrane or G protein-coupled receptors relay signals from hormones and sensory stimuli to multiple signaling systems at the intracellular face of the plasma membrane including heterotrimeric G proteins, ERK1/2, and arrestins. It is an emerging concept that 7-transmembrane receptors form oligomers; however, it is not well understood which roles oligomerization plays in receptor activation of different signaling systems. To begin to address this question, we used the angiotensin II type 1 (AT(1)) receptor, a key regulator of blood pressure and fluid homeostasis that in specific context has been described to activate ERKs without activating G proteins. By using bioluminescence resonance energy transfer, we demonstrate that AT(1) receptors exist as oligomers in transfected COS-7 cells. AT(1) oligomerization was both constitutive and receptor-specific as neither agonist, antagonist, nor co-expression with three other receptors affected the bioluminescence resonance energy transfer 2 signal. Furthermore, the oligomerization occurs early in biosynthesis before surface expression, because we could control AT(1) receptor export from the endoplasmic reticulum or Golgi by using regulated secretion/aggregation technology (RPDTM). Co-expression studies of wild type AT(1) and AT(1) receptor mutants, defective in either ligand binding or G protein and ERK activation, yielded an interesting result. The mutant receptors specifically exerted a dominant negative effect on Galpha(q) activation, whereas ERK activation was preserved. These data suggest that distinctly active conformations of AT(1) oligomers can couple to each of these signaling systems and imply that oligomerization plays an active role in supporting these distinctly active conformations of AT(1) receptors.	Univ Copenhagen, Mol Cardiol Lab, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Ctr Heart, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Copenhagen Heart Arrythmia Res Ctr, Copenhagen Univ Hosp Sect 9312, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Fac Hlth, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen	Sheikh, SP (corresponding author), Univ Copenhagen, Mol Cardiol Lab, 20 Juliane Mariesvej, DK-2100 Copenhagen, Denmark.	sheikh@molheart.dk		Theilade, Juliane/0000-0003-0612-8884				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Barki-Harrington L, 2003, CIRCULATION, V108, P1611, DOI 10.1161/01.CIR.0000092166.30360.78; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; CARSON MC, 1987, MOL ENDOCRINOL, V1, P147, DOI 10.1210/mend-1-2-147; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Floyd DH, 2003, J BIOL CHEM, V278, P35354, DOI 10.1074/jbc.M305607200; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Hansen JL, 2000, CIRC RES, V87, P753, DOI 10.1161/01.RES.87.9.753; Hansen JL, 2004, MOL PHARMACOL, V65, P770, DOI 10.1124/mol.65.3.770; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Jensen AA, 2002, EUR J BIOCHEM, V269, P5076, DOI 10.1046/j.1432-1033.2002.03218.x; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Le Gouill C, 1999, J BIOL CHEM, V274, P12548, DOI 10.1074/jbc.274.18.12548; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Novi F, 2004, J BIOL CHEM, V279, P7476, DOI 10.1074/jbc.M306818200; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Olivares-Reyes JA, 2001, J BIOL CHEM, V276, P37761; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; PAGLIN S, 1982, P NATL ACAD SCI-BIOL, V79, P3739, DOI 10.1073/pnas.79.12.3739; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; ROGERS TB, 1984, J BIOL CHEM, V259, P8106; RONDEAU JJ, 1990, BIOCHEM J, V268, P443, DOI 10.1042/bj2680443; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; SIEMENS IR, 1991, J NEUROCHEM, V57, P690, DOI 10.1111/j.1471-4159.1991.tb03801.x; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Theilade J, 2002, FEBS LETT, V518, P195, DOI 10.1016/S0014-5793(02)02701-1; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	55	66	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24108	24115		10.1074/jbc.M400092200	http://dx.doi.org/10.1074/jbc.M400092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15056658	hybrid			2022-12-25	WOS:000221702500033
J	Hinkle, CL; Sunnarborg, SW; Loiselle, D; Parker, CE; Stevenson, M; Russell, WE; Lee, DC				Hinkle, CL; Sunnarborg, SW; Loiselle, D; Parker, CE; Stevenson, M; Russell, WE; Lee, DC			Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family - The juxtamembrane stalk determines cleavage efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CELL-SURFACE; EGF RECEPTOR; TRANSFORMING GROWTH; TGF-ALPHA; MICE LACKING; HB-EGF; EPITHELIAL-CELLS; METALLOPROTEASE-DISINTEGRIN; ECTODOMAIN CLEAVAGE	Epidermal growth factor (EGF) family ligands are derived by proteolytic cleavage of the ectodomains of integral membrane precursors. Previously, we established that tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) is a physiologic transforming growth factor-alpha (TGF-alpha) sheddase, and we also demonstrated enhanced shedding of amphiregulin (AR) and heparin-binding (HB)-EGF upon restoration of TACE activity in TACE-deficient EC-2 fibroblasts. Here we extended these results by showing that purified soluble TACE cleaved single sites in the juxtamembrane stalks of mouse pro-HB-EGF and pro-AR ectodomains in vitro. For pro-HB-EGF, this site matched the C terminus of the purified human growth factor, and we speculate that the AR cleavage site is also physiologically relevant. In contrast, ADAM9 and -10, both implicated in HB-EGF shedding, failed to cleave the ectodomain or cleaved at a nonphysiologic site, respectively. Cotransfection of TACE in EC-2 cells enhanced phorbol myristate acetate-induced but not constitutive shedding of epiregulin and had no effect on betacellulin (BTC) processing. Additionally, soluble TACE did not cleave the juxtamembrane stalks of either pro-BTC or pro-epiregulin ectodomains in vitro. Substitution of the shorter pro-BTC juxtamembrane stalk or truncation of the pro-TGF-alpha stalk to match the pro-BTC length reduced TGF-alpha shedding from transfected cells to background levels, whereas substitution of the pro-BTC P2-P2' sequence reduced TGF-alpha shedding less dramatically. Conversely, substitution of the pro-TGF-alpha stalk or lengthening of the pro-BTC stalk, especially when combined with substitution of the pro-TGF-alpha P2-P2' sequence, markedly increased BTC shedding. These results indicate that efficient TACE cleavage is determined by a combination of stalk length and scissile bond sequence.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Univ N Carolina Proteom & Mass Spectrometry Facil, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Vanderbilt University; Vanderbilt University	Lee, DC (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	dclee@med.unc.edu	Russell, William/A-7307-2009		NATIONAL CANCER INSTITUTE [T32CA071341, R01CA085410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053804, R56DK053804] Funding Source: NIH RePORTER; NCI NIH HHS [CA71341, CA85410] Funding Source: Medline; NIDDK NIH HHS [DK53804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Baba I, 2000, CANCER RES, V60, P6886; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Chubb AJ, 2002, BIOCHEM BIOPH RES CO, V297, P1225, DOI 10.1016/S0006-291X(02)02324-0; Conte F, 2002, BIOCHEM BIOPH RES CO, V290, P851, DOI 10.1006/bbrc.2001.6261; Deng P, 1998, BIOCHEMISTRY-US, V37, P17898, DOI 10.1021/bi9817313; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Hinkle CL, 2003, BIOCHEMISTRY-US, V42, P2127, DOI 10.1021/bi026709v; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kurisaki T, 2003, MOL CELL BIOL, V23, P55, DOI 10.1128/MCB.23.1.55-61.2003; Le Gall SM, 2003, J BIOL CHEM, V278, P45255, DOI 10.1074/jbc.M307745200; LEE DC, 2003, CYTOKINE HDB, P959; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mori S, 2003, J BIOL CHEM, V278, P46029, DOI 10.1074/jbc.M306393200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakagawa T, 1996, J BIOL CHEM, V271, P30858, DOI 10.1074/jbc.271.48.30858; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; Nemzek JA, 2001, J IMMUNOL METHODS, V255, P149, DOI 10.1016/S0022-1759(01)00419-7; ONO M, 1994, J BIOL CHEM, V269, P31315; Pan BC, 2002, MOL HUM REPROD, V8, P734, DOI 10.1093/molehr/8.8.734; PAPAC DI, 1994, PROTEIN SCI, V3, P1485, DOI 10.1002/pro.5560030914; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Raska CS, 2003, J AM SOC MASS SPECTR, V14, P1076, DOI 10.1016/S1044-0305(03)00405-7; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Saxon ML, 1999, J BIOL CHEM, V274, P28356, DOI 10.1074/jbc.274.40.28356; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Singh AB, 2004, J CELL SCI, V117, P1365, DOI 10.1242/jcs.01037; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tada H, 1999, J CELL BIOCHEM, V72, P423, DOI 10.1002/(SICI)1097-4644(19990301)72:3<423::AID-JCB11>3.3.CO;2-G; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; Takemura T, 2002, KIDNEY INT, V61, P1968, DOI 10.1046/j.1523-1755.2002.00358.x; Takemura T, 2001, J AM SOC NEPHROL, V12, P964, DOI 10.1681/ASN.V125964; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; Wiesen JF, 1999, DEVELOPMENT, V126, P335; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200; Zhou HM, 2004, MOL CELL BIOL, V24, P96, DOI 10.1128/MCB.24.1.96-104.2004	80	119	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24179	24188		10.1074/jbc.M312141200	http://dx.doi.org/10.1074/jbc.M312141200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15066986	hybrid			2022-12-25	WOS:000221702500041
J	Kerr, NCH; Holmes, FE; Wynick, D				Kerr, NCH; Holmes, FE; Wynick, D			Novel Isoforms of the sodium channels Na(v)1.8 and Na(v)1.5 are produced by a conserved mechanism in mouse and rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEBRILE SEIZURES PLUS; MESSENGER-RNA; NA+ CHANNEL; GENOMIC ORGANIZATION; MOLECULAR-CLONING; GENERALIZED EPILEPSY; CODING SEQUENCE; EXPRESSION; SCN5A; GENE	The voltage-gated sodium channel Na(v)1.8 is only expressed in subsets of neurons in dorsal root ganglia (DRG) and trigeminal and nodose ganglia. We have isolated mouse partial length Na(v)1.8 cDNA clones spanning the exon 17 sequence, which have 17 nucleotide substitutions and 12 predicted amino acid differences from the published sequence. The absence of a mutually exclusive alternative exon 17 was confirmed by sequencing 4.1 kilobases of genomic DNA spanning exons 16-18 of Scn10a. A novel cDNA isoform was identified, designated Na(v)1.8c, which results from alternative 3'-splice site selection at a CAG/CAG motif to exclude the codon for glutamine 1031 within the interdomain cytoplasmic loop IDII/III. The ratio of Na(v)1.8c (CAG-skipped) to Na(v)1.8 (CAG-inclusive) mRNA in mouse is similar to2:1 in adult DRG, trigeminal ganglion, and neonatal DRG. A Na(v)1.8c isoform also occurs in rat DRG, but is less common. Of the two other tetrodotoxin-resistant channels, no analogous alternative splicing of mouse Na(v)1.9 was detected, whereas rare alternative splicing of Na(v)1.5 at a CAG/CAG motif resulted in the introduction of a CAG trinucleotide. This isoform, designated Na(v)1.5c, is conserved in rat and encodes an additional glutamine residue that disrupts a putative CK2 phosphorylation site. In summary, novel isoforms of Na(v)1.8 and Na(v)1.5 are each generated by alternative splicing at CAG/CAG motifs, which result in the absence or presence of predicted glutamine residues within the interdomain cytoplasmic loop IDII/III. Mutations of sodium channels within this cytoplasmic loop have previously been demonstrated to alter electrophysiological properties and cause cardiac arrhythmias and epilepsy.	LINE, Bristol BS1 3NY, Avon, England; NeuroTargets Ltd, Surrey Technol Ctr, Surrey GU2 7YG, England	University of Bristol	Wynick, D (corresponding author), LINE, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England.	d.wynick@bristol.ac.uk			Medical Research Council [G0300028(65120), G0300028] Funding Source: Medline; MRC [G0300028] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ackerman MJ, 2001, JAMA-J AM MED ASSOC, V286, P2264, DOI 10.1001/jama.286.18.2264; Akopian AN, 1999, NAT NEUROSCI, V2, P541, DOI 10.1038/9195; Akopian AN, 1999, FEBS LETT, V445, P177, DOI 10.1016/S0014-5793(99)00126-X; Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Baker CVH, 2001, DEV BIOL, V232, P1, DOI 10.1006/dbio.2001.0156; Bennett ES, 2001, J PHYSIOL-LONDON, V535, P371, DOI 10.1111/j.1469-7793.2001.t01-1-00371.x; Blum R, 2002, NATURE, V419, P687, DOI 10.1038/nature01085; Chen J, 1997, GENE, V202, P7, DOI 10.1016/S0378-1119(97)00433-2; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; Culbertson MR, 2003, CURR OPIN GENET DEV, V13, P207, DOI 10.1016/S0959-437X(03)00014-5; Dib-Hajj SD, 1999, GENOMICS, V59, P309, DOI 10.1006/geno.1999.5890; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; Donahue LM, 2000, BRAIN RES, V887, P335, DOI 10.1016/S0006-8993(00)03033-X; Escayg A, 2001, AM J HUM GENET, V68, P866, DOI 10.1086/319524; Garg R, 2002, GENE, V291, P123, DOI 10.1016/S0378-1119(02)00589-9; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; HAMANN M, 1994, J PHYSIOL-LONDON, V475, P305, DOI 10.1113/jphysiol.1994.sp020071; HARTMANN HA, 1994, CIRC RES, V75, P114, DOI 10.1161/01.RES.75.1.114; Hartmann HA, 1999, NAT NEUROSCI, V2, P593, DOI 10.1038/10147; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; Kerr NCH, 2000, NEUROREPORT, V11, P3909, DOI 10.1097/00001756-200011270-00060; Khasar SG, 1998, NEUROSCI LETT, V256, P17, DOI 10.1016/S0304-3940(98)00738-1; Korsgaard MPG, 2001, PFLUG ARCH EUR J PHY, V443, P18, DOI 10.1007/s004240100625; Kuzmenkin A, 2003, PFLUG ARCH EUR J PHY, V447, P71, DOI 10.1007/s00424-003-1137-5; Lai J, 2002, PAIN, V95, P143, DOI 10.1016/S0304-3959(01)00391-8; Laird JMA, 2002, J NEUROSCI, V22, P8352; Laverdiere M, 2000, NUCLEIC ACIDS RES, V28, P1489, DOI 10.1093/nar/28.6.1489; Lemaillet G, 2003, J BIOL CHEM, V278, P27333, DOI 10.1074/jbc.M303327200; Lin WW, 1998, GROWTH HORM IGF RES, V8, P225, DOI 10.1016/S1096-6374(98)80115-9; Lossin C, 2002, NEURON, V34, P877, DOI 10.1016/S0896-6273(02)00714-6; Lu KM, 2002, J LIPID RES, V43, P565; LUPA MT, 1995, J PHYSIOL-LONDON, V483, P109, DOI 10.1113/jphysiol.1995.sp020571; Makielski JC, 2003, CIRC RES, V93, P821, DOI 10.1161/01.RES.0000096652.14509.96; Malhotra JD, 2001, CIRCULATION, V103, P1303; Malik-Hall M, 2003, MOL BRAIN RES, V110, P298, DOI 10.1016/S0169-328X(02)00661-7; MAURER RA, 1981, J BIOL CHEM, V256, P524; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Ogata K, 2000, BIOCHEM BIOPH RES CO, V267, P271, DOI 10.1006/bbrc.1999.1858; Ou Y, 2002, NEUROGASTROENT MOTIL, V14, P477, DOI 10.1046/j.1365-2982.2002.00348.x; Papadatos GA, 2002, P NATL ACAD SCI USA, V99, P6210, DOI 10.1073/pnas.082121299; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Plant KE, 1996, NUCLEIC ACIDS RES, V24, P3514, DOI 10.1093/nar/24.18.3514; Plummer NW, 1998, GENOMICS, V54, P287, DOI 10.1006/geno.1998.5550; Plummer NW, 1999, GENOMICS, V57, P323, DOI 10.1006/geno.1998.5735; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Pollard AJ, 2002, J BIOL CHEM, V277, P15241, DOI 10.1074/jbc.M109046200; Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640; Rabert DK, 1998, PAIN, V78, P107, DOI 10.1016/S0304-3959(98)00120-1; Renganathan M, 2002, MOL BRAIN RES, V106, P70, DOI 10.1016/S0169-328X(02)00411-4; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; Roza C, 2003, J PHYSIOL-LONDON, V550, P921, DOI 10.1113/jphysiol.2003.046110; Sangameswaran L, 1996, J BIOL CHEM, V271, P5953, DOI 10.1074/jbc.271.11.5953; Schoenfeld JR, 1998, J MOL CELL CARDIOL, V30, P2269, DOI 10.1006/jmcc.1998.0787; Schwartz PJ, 2000, NEW ENGL J MED, V343, P262, DOI 10.1056/NEJM200007273430405; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; Souslova VA, 1997, GENOMICS, V41, P201, DOI 10.1006/geno.1997.4669; Spampanato J, 2003, NEUROSCIENCE, V116, P37, DOI 10.1016/S0306-4522(02)00698-X; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; Stordeur P, 2002, J IMMUNOL METHODS, V259, P55, DOI 10.1016/S0022-1759(01)00489-6; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Tate S, 1998, NAT NEUROSCI, V1, P653, DOI 10.1038/3652; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; Ye B, 2003, PHYSIOL GENOMICS, V12, P187, DOI 10.1152/physiolgenomics.00117.2002; Yoshimura N, 2001, J NEUROSCI, V21, P8690, DOI 10.1523/JNEUROSCI.21-21-08690.2001; Zhang H, 2000, BBA-BIOMEMBRANES, V1467, P406, DOI 10.1016/S0005-2736(00)00238-8; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919; ZHOU JH, 1994, J BIOL CHEM, V269, P18563; Zimmer T, 2002, AM J PHYSIOL-HEART C, V282, pH1007, DOI 10.1152/ajpheart.00644.2001	73	44	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24826	24833		10.1074/jbc.M401281200	http://dx.doi.org/10.1074/jbc.M401281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047701	Green Accepted, hybrid			2022-12-25	WOS:000221702500113
J	Duxbury, MS; Ito, H; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Ashley, SW; Whang, EE			CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GPI-ANCHORED PROTEINS; FAMILY KINASES; CANCER-CELLS; LIPID RAFTS; IN-VIVO; V-SRC; UROKINASE RECEPTOR; EPITHELIAL-CELLS	Despite lacking transmembrane or intracellular domains, glycosylphosphatidylinositol-anchored proteins can modulate intracellular signaling events, in many cases through aggregation within membrane "lipid raft" microdomains. CEACAM6 is a glycosylphosphatidylinositol-linked cell surface protein of importance in the anchorage-independent survival and metastasis of pancreatic adenocarcinoma cells. We examined the effects of antibody-mediated cross-linking of CEACAM6 on intracellular signaling events and anchorage-independent survival of the CEACAM6-overexpressing pancreatic ductal adenocarcinoma cell line, BxPC3. CEACAM6 cross-linking increased c-Src activation and induced tyrosine phosphorylation of p125(FAK) focal adhesion kinase. Focal adhesion kinase phosphorylation was dependent on c-Src kinase activation, for which caveolin-1 was required. CEACAM6 cross-linking induced a significant increase in cellular resistance to anoikis. These observations represent the first characterization of the mechanism through which this important cell surface oncoprotein influences intracellular signaling events and hence malignant cellular behavior.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V311, P786, DOI 10.1016/j.bbrc.2003.10.060; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; DUXBURY MS, 2004, IN PRESS SURGERY; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Farivar RS, 2003, J SURG RES, V115, P219, DOI 10.1016/S0022-4804(03)00246-4; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gardner-Thorpe J, 2002, BIOCHEM BIOPH RES CO, V293, P391, DOI 10.1016/S0006-291X(02)00237-1; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harris TJC, 2002, BIOESSAYS, V24, P996, DOI 10.1002/bies.10172; Hisano C, 2003, CELL BIOL INT, V27, P415, DOI 10.1016/S1065-6995(03)00032-5; Ito H, 2003, SURGERY, V134, P221, DOI 10.1067/msy.2003.224; Jantscheff P, 2003, J CLIN ONCOL, V21, P3638, DOI 10.1200/JCO.2003.55.135; Kasahara K, 1999, BIOPHYS CHEM, V82, P121, DOI 10.1016/S0301-4622(99)00111-8; Kasahara K, 2002, NEUROCHEM RES, V27, P823, DOI 10.1023/A:1020265225916; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; KODERA Y, 1993, BRIT J CANCER, V68, P130, DOI 10.1038/bjc.1993.300; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Li SW, 1996, J BIOL CHEM, V271, P3863; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MAYNE KM, 1993, BRIT J HAEMATOL, V83, P30, DOI 10.1111/j.1365-2141.1993.tb04627.x; McCaw SE, 2003, MOL MICROBIOL, V49, P623, DOI 10.1046/j.1365-2958.2003.03591.x; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; Nair KS, 2001, CELL IMMUNOL, V208, P96, DOI 10.1006/cimm.2001.1772; OKADA M, 1991, J BIOL CHEM, V266, P24249; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmitter T, 2004, J EXP MED, V199, P35, DOI 10.1084/jem.20030204; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tooze JA, 1995, EXP HEMATOL, V23, P1484; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zhu ZY, 2001, CANCER RES, V61, P1707	64	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23176	23182		10.1074/jbc.M402051200	http://dx.doi.org/10.1074/jbc.M402051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047698	hybrid			2022-12-25	WOS:000221570900048
J	Mishra, SK; Yang, ZB; Mazumdar, A; Talukder, AH; Larose, L; Kumar, R				Mishra, SK; Yang, ZB; Mazumdar, A; Talukder, AH; Larose, L; Kumar, R			Metastatic tumor antigen 1 short form (MTA1s) associates with casein kinase I-gamma 2, an estrogen-responsive kinase	ONCOGENE			English	Article						metastasis-associated protein-1 short form; casein kinase I-gamma 2; estrogen response element	PROTEIN-KINASE; BETA-CATENIN; RECEPTOR-ALPHA; I EPSILON; PHOSPHORYLATION; EXPRESSION; COMPLEX; CLONING; FAMILY; NURD	Recent studies have shown that metastasis-associated protein-1 short form (MTA1s) - metastatic tumor antigen 1 short form sequesters estrogen receptor-alpha (ER-alpha) in the cytoplasm of breast cancer cells. Using a yeast two-hybrid screening to clone MTA1s-interacting proteins, we identified casein kinase I-gamma 2 (CKI-gamma2, a ubiquitously expressed cytoplasmic kinase) as an MTA1s-binding protein. We show that MTA1s interacts with CKI-gamma2 both in vitro and in vivo and colocalizes in the cytoplasm. In addition, we found that CKI-gamma2 can phosphorylate MTA1s, but not ER, in an antiestrogen-dependent manner and that estrogen stimulates CKI-gamma2 activity that could be effectively blocked by a specific inhibitor of CKI. CKI-gamma2 could further potentiate the ER corepressive function of MTA1s. Kinase dead CK1-gamma2 could not repress estrogen-induced ER transactivation functions. Results from mutagenesis studies suggest that substitution of the serine residue at 321 to alanine, which is a possible CKI-gamma2 phopshorylation site in MTA1s, results in a significant reduction in the ability of MTA1s to repress ER transactivation. These findings identified MTA1s as a target of CKI-gamma2, and provided new evidence to suggest that CKI-gamma2 phosphorylates and modulates the functions of MTA1s, and that these extranuclear effects of estrogen might have important implications in regulating the functions of MTA1s in human mammary epithelial and cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B2, Canada	University of Texas System; UTMD Anderson Cancer Center; McGill University	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org		Mishra, Sandip/0000-0002-0776-6581	NCI NIH HHS [CA90970, CA098823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098823, R01CA090970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Dubois T, 2001, J BIOL CHEM, V276, P18757, DOI 10.1074/jbc.M010005200; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Kitabayashi AN, 1997, GENOMICS, V46, P133, DOI 10.1006/geno.1997.4991; Kleene R, 1999, J CELL SCI, V112, P2539; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Kreegipuu A, 1998, FEBS LETT, V430, P45, DOI 10.1016/S0014-5793(98)00503-1; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Kumar R, 2003, CELL, V113, P142, DOI 10.1016/S0092-8674(03)00274-5; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; SIMKOWSKI KW, 1980, J BIOL CHEM, V255, P6456; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tzeng DZ, 1996, BIOCHEM BIOPH RES CO, V223, P554, DOI 10.1006/bbrc.1996.0933; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	34	28	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4422	4429		10.1038/sj.onc.1207569	http://dx.doi.org/10.1038/sj.onc.1207569			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077195				2022-12-25	WOS:000221661300008
J	Milenkovic, D; Kozjak, V; Wiedemann, N; Lohaus, C; Meyer, HE; Guiard, B; Pfanner, N; Meisinger, C				Milenkovic, D; Kozjak, V; Wiedemann, N; Lohaus, C; Meyer, HE; Guiard, B; Pfanner, N; Meisinger, C			Sam35 of the mitochondrial protein sorting and assembly machinery is a peripheral outer membrane protein essential for cell viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT CHANNEL; TOM COMPLEX; INTERMEMBRANE SPACE; BIOGENESIS; BETA; PREPROTEINS; RECEPTORS; METAXIN; PORE; TRANSLOCASE	The mitochondrial outer membrane contains two integral proteins essential for cell viability, Tom40 of the translocase of the outer membrane ( TOM complex) and Sam50 of the sorting and assembly machinery ( SAM complex). Here we report the identification of Sam35, the first peripheral mitochondrial outer membrane protein that is essential for cell viability. Sam35 ( encoded by the Saccharomyces cerevisiae ORF YHR083w) is a novel subunit of the SAM complex and is crucial for the assembly pathway of outer membrane beta- barrel proteins, such as the precursors of Tom40 and porin. Sam35 is not required for the import of inner membrane or matrix targeted proteins. The presence of two essential proteins in the SAM complex, Sam35 and Sam50, indicates that it plays a central role in mitochondrial biogenesis.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Ruhr Univ Bochum, Med Proteom Ctr, D-44780 Bochum, Germany; Univ Paris 06, Ctr Genet Mol, Lab Propre CNRS, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Freiburg; Ruhr University Bochum; UDICE-French Research Universities; Sorbonne Universite	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	Nikolaus.Pfanner@biochemie.uni-freiburg.de	Kozjak-Pavlovic, Vera/E-1494-2013; Pfanner, Nikolaus/AAV-7878-2021; Meisinger, Chris/J-1110-2014	Kozjak-Pavlovic, Vera/0000-0001-9658-7018; Meisinger, Chris/0000-0002-8326-3548; Wiedemann, Nils/0000-0001-8305-6728				Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Armstrong LC, 1999, J CELL BIOCHEM, V74, P11, DOI 10.1002/(SICI)1097-4644(19990701)74:1<11::AID-JCB2>3.0.CO;2-V; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Johnson AE, 2004, NAT STRUCT MOL BIOL, V11, P113, DOI 10.1038/nsmb0204-113; KEIL P, 1993, J BIOL CHEM, V268, P19177; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Matouschek A, 2001, NAT STRUCT BIOL, V8, P284, DOI 10.1038/86140; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Mihara K, 2003, NATURE, V424, P505, DOI 10.1038/424505a; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Niedenthal R, 1999, YEAST, V15, P1775, DOI 10.1002/(SICI)1097-0061(199912)15:16<1775::AID-YEA496>3.3.CO;2-L; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Ryan MT, 2004, CURR BIOL, V14, pR207, DOI 10.1016/j.cub.2004.02.024; Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Wang XF, 2001, EMBO REP, V2, P628, DOI 10.1093/embo-reports/kve135; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200	37	112	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22781	22785		10.1074/jbc.C400120200	http://dx.doi.org/10.1074/jbc.C400120200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15067005	hybrid			2022-12-25	WOS:000221417100130
J	Hecker, TP; Ding, Q; Rege, TA; Hanks, SK; Gladson, CL				Hecker, TP; Ding, Q; Rege, TA; Hanks, SK; Gladson, CL			Overexpression of FAK promotes Ras activity through the formation of a FAK/p120RasGAP complex in malignant astrocytoma cells	ONCOGENE			English	Article						focal adhesion kinase (FAK); Ras; RasGAP; astrocytoma; glioma; glioblastoma; proliferation	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; SRC TRANSFORMATION; P21 GTPASE; V-SRC; ACTIVATION; GAP; PATHWAY; DOMAIN; PROLIFERATION	Focal adhesion kinase (FAK) signaling may be mediated through the modulation of Ras activity. We have shown previously that grade III malignant astrocytoma biopsy samples exhibit elevated levels of FAK, and that overexpression of FAK in U-251MG malignant astrocytoma cells promotes the phosphorylation of Shc, a potential upstream mediator of Ras activity. Here, we report that overexpression of FAK promotes Ras activity in U-251MG malignant astrocytoma cells cultured in aggregate suspension or as monolayers adherent to vitronectin. The overexpression of FAK also promoted the association of FAK with p120RasGAP, which is a negative regulator of Ras activity, in the U-251MG cells cultured in aggregate suspension, with this association being abrogated upon plating of the cells onto vitronectin. An association of FAK with p120RasGAP also was observed in malignant astrocytoma biopsy samples, but not in normal brain samples. As overexpression of FAK in U-251MG cells in aggregate suspension culture reduced the amount of p120RasGAP complexed with active Ras, we hypothesize that the association of FAK with p120 RasGAP may facilitate Ras activity. The overexpression of a mutated FAK in which the Y397 had been mutated to F did not result in the formation of the FAK/p120RasGAP complex and did not promote Ras activity, indicating that the Y397 residue of FAK plays a role in the formation of this complex and in the activation of Ras. Moreover, the overexpression of mutated FAK (397F) was found to inhibit anchorage-independent growth. These data provide the basis for a previously undescribed mechanism in which the elevated expression of FAK can promote Ras activity through its competitive recruitment of p120RasGAP, thereby diminishing the association of p120RasGAP with active Ras.	Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Med Scientist Training Program, Birmingham, AL 35294 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Vanderbilt University	Gladson, CL (corresponding author), Univ Alabama, Dept Pathol, Div Neuropathol, LHRB 567, 701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu			NATIONAL CANCER INSTITUTE [R01CA097100, R01CA059958] Funding Source: NIH RePORTER; NCI NIH HHS [CA97100, CA59958] Funding Source: Medline; NIGMS NIH HHS [GM49882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Ding H, 2001, CANCER RES, V61, P3826; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; Hecker TP, 2002, CANCER RES, V62, P2699; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; LIEUBEAUTEILLET R, 1995, CANCER RES, V58, P4957; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; Mohan PM, 1999, CANCER RES, V59, P3369; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Serpente N, 1996, MOL CELL NEUROSCI, V7, P391, DOI 10.1006/mcne.1996.0028; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Wang DY, 2000, J CELL SCI, V113, P4221; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	34	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3962	3971		10.1038/sj.onc.1207541	http://dx.doi.org/10.1038/sj.onc.1207541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15077193				2022-12-25	WOS:000221382000008
J	Tanaka, T; Akatsuka, S; Ozeki, M; Shirase, T; Hiai, H; Toyokuni, S				Tanaka, T; Akatsuka, S; Ozeki, M; Shirase, T; Hiai, H; Toyokuni, S			Redox regulation of annexin 2 and its implications for oxidative stress-induced renal carcinogenesis and metastasis	ONCOGENE			English	Article						annexin 2; iron; redox regulation; carcinogenesis; metastasis; renal cell carcinoma	TUMOR-SUPPRESSOR GENE; ROUS-SARCOMA-VIRUS; FERRIC NITRILOTRIACETATE; CELL CARCINOMA; WISTAR RATS; INSULIN-RECEPTOR; KINASE SUBSTRATE; RESPONSE GENES; ALLELIC LOSS; II TETRAMER	Ferric nitrilotriacetate (Fe-NTA) induces oxidative renal damage leading to a high incidence of renal cell carcinoma (RCC) in rats. Differential display analysis of such RCCs revealed elevated expression of annexin 2 (Anx2), a substrate for kinases and a receptor for tissue-type plasminogen activator and plasminogen. We conducted this study to clarify the significance of Anx2 in Fenton reaction-based carcinogenesis. Messenger RNA and protein levels of Anx2 were increased time-dependently in the rat kidney after Fe-NTA administration as well as in LLC-PK1 cells after exposure to H2O2. The latter was inhibited by pretreatment with N-acetylcysteine, pyrrolidine dithiocarbamate or catalase. Immunohistochemistry revealed negligible staining in the normal renal proximal tubules, but strong staining in regenerating proximal tubules, karyomegalic cells and RCCs. Metastasizing RCCs showed higher Anx2 protein levels. Anx2 was phosphorylated at serine and tyrosine residues in these cells and coimmunoprecipitated with phosphorylated actin. Overexpression of Anx2 induced a higher cell proliferation rate in LLC-PK1 cells. In contrast, a decrease in proliferation leading to apoptosis was observed after Anx2 antisense treatment to cell lines established from Fe-NTA-induced RCCs. These results suggest that Anx2 is regulated by redox status, and that persistent operation of this adaptive mechanism plays a role in the proliferation and metastasis of oxidative stress-induced cancer.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.	toyokuni@path1.med.kyoto-u.ac.jp	Akatsuka, Shinya/C-9806-2010; Toyokuni, Shinya/C-1358-2010; Toyokuni, Shinya/ABE-7714-2021	Akatsuka, Shinya/0000-0002-9944-8803; Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				Aarli A, 1997, APMIS, V105, P699, DOI 10.1111/j.1699-0463.1997.tb05073.x; AMES BN, 1991, OXIDATIVE DAMAGE & REPAIR, P181; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; Chetcuti A, 2001, CANCER RES, V61, P6331; CHIANG YP, 1993, CANCER RES, V53, P6017; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; EBINA Y, 1986, J NATL CANCER I, V76, P107; Emoto K, 2001, ANTICANCER RES, V21, P1339; ERIKSON E, 1981, J BIOL CHEM, V256, P1381; Forman HJ, 2002, MOL CELL BIOCHEM, V234, P49, DOI 10.1023/A:1015913229650; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; Hajjar KA, 1998, J INVEST MED, V46, P364; Hajjar KA, 1997, ANN NY ACAD SCI, V811, P337, DOI 10.1111/j.1749-6632.1997.tb52013.x; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HAMAZAKI S, 1988, TOXICOL APPL PHARM, V92, P500, DOI 10.1016/0041-008X(88)90190-1; HAMAZAKI S, 1985, TOXICOL APPL PHARM, V77, P267, DOI 10.1016/0041-008X(85)90326-6; Hiroyasu M, 2002, AM J PATHOL, V160, P419, DOI 10.1016/S0002-9440(10)64860-2; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; JONES PG, 1992, J BIOL CHEM, V267, P13993; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; KUMBLE KD, 1992, CANCER RES, V52, P163; KUMBLE KD, 1992, J CELL SCI, V101, P35; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; LI JL, 1987, CANCER RES, V47, P1867; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu L, 1996, AM J PHYSIOL-LUNG C, V270, pL668, DOI 10.1152/ajplung.1996.270.4.L668; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; Nakanishi H, 1996, JPN J CANCER RES, V87, P1218, DOI 10.1111/j.1349-7006.1996.tb03136.x; Nishiyama Y, 1995, JPN J CANCER RES, V86, P1150, DOI 10.1111/j.1349-7006.1995.tb03308.x; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OZAKI T, 1993, ONCOGENE, V8, P1707; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; Ramasamy S, 1998, J LIPID RES, V39, P268; REEVES SA, 1992, CANCER RES, V52, P6871; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tanaka T, 2000, AM J PATHOL, V156, P2149, DOI 10.1016/S0002-9440(10)65085-7; Tanaka T, 1997, LAB INVEST, V77, P145; Tanaka T, 1999, ONCOGENE, V18, P3793, DOI 10.1038/sj.onc.1202707; TOYOKUNI S, 1990, CANCER RES, V50, P5574; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; TOYOKUNI S, 1994, INT J CANCER, V57, P123, DOI 10.1002/ijc.2910570122; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Toyokuni S, 2003, PATHOL INT, V53, P259, DOI 10.1046/j.1320-5463.2003.01465.x; Toyokuni S, 1997, LAB INVEST, V76, P365; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; Toyokuni S, 1997, FREE RADICAL BIO MED, V22, P1019, DOI 10.1016/S0891-5849(96)00489-3; TOYOKUNI S, 1995, INT J CANCER, V62, P309, DOI 10.1002/ijc.2910620313; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Zhang DX, 1997, CANCER RES, V57, P2410; Zhao WQ, 2003, J BIOL CHEM, V278, P4205, DOI 10.1074/jbc.M210545200; Zhou S, 2003, MUTAGENESIS, V18, P287, DOI 10.1093/mutage/18.3.287	64	78	91	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3980	3989		10.1038/sj.onc.1207555	http://dx.doi.org/10.1038/sj.onc.1207555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048081				2022-12-25	WOS:000221382000010
J	Cronauer, MV; Schulz, WA; Burchardt, T; Ackermann, R; Burchardt, M				Cronauer, MV; Schulz, WA; Burchardt, T; Ackermann, R; Burchardt, M			Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines	ONCOGENE			English	Article						androgen receptor; p53; prostate cancer; pifithrin; MDM2; probasin promoter	WILD-TYPE P53; CARCINOMA-CELLS; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID-RECEPTOR; MUTATIONS; PROTEIN; GROWTH; EXPRESSION; ADENOVIRUS; APOPTOSIS	Current therapy for advanced prostate cancer is mainly based on androgen deprivation, although most patients relapse to androgen-insensitive disease. Several mechanisms contributing to androgen-independent growth including alterations in the structure or expression of the androgen receptor (AR) and its cofactors have been identified. Recent evidence suggests that p53 is involved in androgen signaling. The analysis of the effect of p53 on androgen signaling was performed in 22Rv1 and LNCaP prostate cancer cells that express both p53 and AR. The overexpression of p53 diminished the androgenic response in both cell lines in a reporter gene assay. Conversely, the inhibition of p53 by three different p53 inhibitors, Pifithrin-1alpha (PFT-1alpha), an inhibitor of p53-dependent transactivation; MDM2, a regulator of p53 expression; and a dominant-negative N-terminally truncated p53 gene also reduced transactivation of androgen-dependent reporter genes. The inactivation of p53 by PFT-1alpha decreased AR-protein expression in both 22Rv1 and LNCaP cells. Our findings confirm that the overexpression of wild-type p53 decreases androgen function, whereas p53 expression at physiological levels stabilizes AR signaling. Thus, our findings suggest that there is a balance of AR and p53 expression during the androgen-dependent growth of prostate cancer, which is obliterated during further progression of the disease.	Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Burchardt, M (corresponding author), Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany.	mb706@hotmail.com	Schulz, Wolfgang A./A-6523-2008; Cronauer, Marcus/AAG-7457-2021; Schulz, Wolfgang/N-3402-2019	Schulz, Wolfgang/0000-0002-2196-463X				Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; APRIKIAN AG, 1994, J UROLOGY, V151, P1276, DOI 10.1016/S0022-5347(17)35231-X; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Burchardt M, 2001, PROSTATE, V48, P225, DOI 10.1002/pros.1101; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen TS, 2000, CANCER RES, V60, P2132; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Coursen JD, 1997, MOL CARCINOGEN, V19, P191; Cronauer MV, 2000, BRIT J CANCER, V82, P39; Cronauer MV, 1997, IN VITRO CELL DEV-AN, V33, P742; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0; Eastham JA, 1995, CLIN CANCER RES, V1, P1111; Eastham JA, 2000, J UROLOGY, V164, P814, DOI 10.1016/S0022-5347(05)67320-X; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Freedland SJ, 2003, PROSTATE, V55, P299, DOI 10.1002/pros.10226; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gurova KV, 2002, ONCOGENE, V21, P153, DOI 10.1038/sj.onc.1205001; HASSE A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P16, DOI 10.1016/0167-4781(92)90092-E; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hobisch A, 1998, CANCER RES, V58, P4640; ISAACS WB, 1991, CANCER RES, V51, P4716; Jacobberger JW, 1999, CYTOMETRY, V38, P201, DOI 10.1002/(SICI)1097-0320(19991015)38:5<201::AID-CYTO2>3.0.CO;2-F; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Lee YG, 2001, IN VIVO, V15, P157; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; Makri D, 1998, INT J ONCOL, V12, P621; MARTH C, 1990, CANCER RES, V50, P7037; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Osman I, 1999, CLIN CANCER RES, V5, P2082; Patel BJ, 2000, J UROLOGY, V164, P1420, DOI 10.1016/S0022-5347(05)67210-2; Peehl DM, 1994, ATLAS HUMAN TUMOR CE, P387; Pocard M, 1996, ONCOGENE, V12, P875; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; RUNNEBAUM IB, 1994, FEBS LETT, V353, P29, DOI 10.1016/0014-5793(94)00953-8; Schumacher G, 2001, INT J CANCER, V91, P159, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1026>3.3.CO;2-E; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shi XB, 2002, PROSTATE, V51, P59, DOI 10.1002/pros.10072; Sinisl AA, 2002, IN VITRO CELL DEV-AN, V38, P165; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; Steinhoff C, 2002, INT J ONCOL, V21, P1033; Tepper CG, 2002, CANCER RES, V62, P6606; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9	57	77	78	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3541	3549		10.1038/sj.onc.1207346	http://dx.doi.org/10.1038/sj.onc.1207346			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077179				2022-12-25	WOS:000221101700005
J	Lin, KM; Hollander, JM; Kao, VY; Lin, B; Macpherson, L; Dillmann, WH				Lin, KM; Hollander, JM; Kao, VY; Lin, B; Macpherson, L; Dillmann, WH			Myocyte protection by 10 kD heat shock protein (Hsp10) involves the mobile loop and attenuation of the Ras GTP-ase pathway	FASEB JOURNAL			English	Article						ischemia reperfusion injury; temperature-sensitive mutant; chaperonin; electron transport chain	HYDROGEN EXCHANGE INHIBITION; MYOCARDIAL PROTECTION; SIGNALING PATHWAYS; HSP60; EXPRESSION; ISCHEMIA; INJURY; CELLS; CARDIOMYOCYTES; HYPERTROPHY	Heat shock proteins (hsp), hsp60 and hsp10, are involved in the folding of imported mitochondrial proteins and the refolding of denatured proteins after stress. We examined whether hsp10 can reduce myocyte death by its mitochondrial function or by interacting with cytoplasmic signaling pathways. Overexpression of hsp10 by adenoviral infection decreased myocyte death induced by hydrogen peroxide, sodium cyanide, and simulated ischemia and reoxygenation (SI/RO). We generated an adenoviral vector coding for a temperature-sensitive mutant hsp10 protein (P34H), incapable of cooperatively refolding denatured malate dehydrogenase with hsp60. Overexpression of the hsp10 mutant potentiated SI/RO-induced myocyte death. Analysis of electron transport chain function revealed increased Complex I capacity with hsp10 overexpression, whereas hsp10( P34H) overexpression decreased Complex II capacity. Hsp10 overexpression preserved both Complex I and II function after SI/RO. Examination of the Ras GTP-ase signaling pathway indicated that inhibition of Ras was required for protection by hsp10. Constitutive activation of Ras abolished the effects afforded by hsp10 and hsp10(P34H). Hsp10 overexpression inactivated Raf, ERK, and p90Ribosomal kinase (p90RSK) before and after SI/RO. Our results suggest that complex mechanisms are involved in the protection by hsp10 against SI/RO-induced myocyte death. This mechanism may involve the hsp10 mobile loop and attenuation of the Ras GTP-ase signaling pathway.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Natl Hlth Res Inst, Div Med Engn Res, Taipei, Taiwan	University of California System; University of California San Diego; National Health Research Institutes - Taiwan	Dillmann, WH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	wdillmann@ucsd.edu	Lin, Kurt Ming-Chao/E-3975-2010	Lin, Kurt/0000-0003-1371-5569; Macpherson, Lindsey/0000-0002-1089-3733	NHLBI NIH HHS [HL49434] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049434, R01HL049434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anversa P, 2000, J HEART LUNG TRANSPL, V19, pS1, DOI 10.1016/S1053-2498(99)00111-4; Avkiran M, 2002, J AM COLL CARDIOL, V39, P747, DOI 10.1016/S0735-1097(02)01693-5; Bishopric Nanette H., 2001, Current Opinion in Pharmacology, V1, P141, DOI 10.1016/S1471-4892(01)00032-7; Buerke M, 1999, AM J CARDIOL, V83, p19G; Carmicle S, 2002, J BIOL CHEM, V277, P155, DOI 10.1074/jbc.M107624200; Cicconi S, 2003, J CELL PHYSIOL, V195, P27, DOI 10.1002/jcp.10219; Dillmann W H, 1999, Infect Dis Obstet Gynecol, V7, P55, DOI 10.1002/(SICI)1098-0997(1999)7:1/2<55::AID-IDOG11>3.0.CO;2-M; Dubaquie Y, 1997, P NATL ACAD SCI USA, V94, P9011, DOI 10.1073/pnas.94.17.9011; Dubaquie Y, 1998, EMBO J, V17, P5868, DOI 10.1093/emboj/17.20.5868; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FLAMENG W, 1995, CURR OPIN CARDIOL, V10, P577, DOI 10.1097/00001573-199511000-00005; GUPTA RS, 1995, MOL MICROBIOL, V15, P1, DOI 10.1111/j.1365-2958.1995.tb02216.x; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Hurtado C, 2001, BASIC RES CARDIOL, V96, P312, DOI 10.1007/s003950170038; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jin G, 2000, J SURG RES, V94, P124, DOI 10.1006/jsre.2000.6014; Karmazyn M, 1999, CIRC RES, V85, P777, DOI 10.1161/01.RES.85.9.777; Landry S J, 1999, Pac Symp Biocomput, P520; Landry SJ, 1997, BIOCHEMISTRY-US, V36, P10975, DOI 10.1021/bi971141p; Lau S, 1997, CIRCULATION, V96, P2287; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Mentzer RM, 2003, ANN THORAC SURG, V75, pS700, DOI 10.1016/S0003-4975(02)04700-8; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Richardson A, 2001, J BIOL CHEM, V276, P4981, DOI 10.1074/jbc.M008628200; SINGH B, 1990, BIOCHEM BIOPH RES CO, V169, P391, DOI 10.1016/0006-291X(90)90344-M; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; Wang QD, 2002, CARDIOVASC RES, V55, P25, DOI 10.1016/S0008-6363(02)00261-4; Yifrach O, 2000, P NATL ACAD SCI USA, V97, P1521, DOI 10.1073/pnas.040449997	33	29	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1004	+		10.1096/fj.03-0348fje	http://dx.doi.org/10.1096/fj.03-0348fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059967				2022-12-25	WOS:000221108800018
J	Neels, JG; Thinnes, T; Loskutoff, DJ				Neels, JG; Thinnes, T; Loskutoff, DJ			Angiogenesis in an in vivo model of adipose tissue development	FASEB JOURNAL			English	Article						obesity; neovascularization; adipocytes; endothelial cells; progenitor cells	NECROSIS-FACTOR-ALPHA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ENDOTHELIAL-CELLS; INSULIN-RESISTANCE; PROGENITOR CELLS; FAT PADS; EXPRESSION; OBESITY; ADIPOCYTE; GROWTH	Obesity is associated with an increased risk for cardiovascular disease and cancer. Angiogenesis is a critical component of these pathological processes, and expanding adipose tissue represents one of the few sites of active angiogenesis in the adult. Despite the potential importance of angiogenesis in obesity, little is known about underlying mechanisms. This problem is magnified by the absence of useful quantitative model systems. In this report, we examine the angiogenic process using the 3T3-F442A model of adipose tissue development. In this model, 3T3-F442A preadipocytes are implanted subcutaneously into athymic Balb/c nude mice. We show that these cells develop into highly vascularized fat pads over the next 14-21 days, and that these fat pads are morphologically similar to normal subcutaneous adipose tissue. Histological studies demonstrate that a new microvasculature is evident as early as 5 days after cell implantation, and real-time quantitative RT-PCR analyses show that the expression of endothelial cell markers and adipogenesis markers increase in parallel during fat pad development. Finally, these preliminary studies suggest that the neovasculature originates by sprouting from larger, host-derived blood vessels that run parallel to peripheral nerves and that endothelial progenitor cells play little, if any, role in this process.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd,VB-3, La Jolla, CA 92037 USA.	loskutof@scripps.edu	Neels, Jaap G/F-5534-2010	Neels, Jaap G/0000-0002-5900-8395	NHLBI NIH HHS [HL59549] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoki S, 2003, CELL STRUCT FUNCT, V28, P55; Asano A, 1997, BIOCHEM J, V328, P179, DOI 10.1042/bj3280179; BILLINGS E, 1989, PLAST RECONSTR SURG, V83, P368, DOI 10.1097/00006534-198902000-00033; Bouloumie A, 2002, ANN ENDOCRINOL-PARIS, V63, P91; BURNSTOCK G, 1994, BRIT J PLAST SURG, V47, P527, DOI 10.1016/0007-1226(94)90136-8; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P219, DOI 10.1097/00006534-199102000-00001; Fitzpatrick TE, 1998, EXP CELL RES, V245, P155, DOI 10.1006/excr.1998.4240; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; HAUSMAN GJ, 1991, MICROVASC RES, V41, P111, DOI 10.1016/0026-2862(91)90012-Z; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hutley LJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1037, DOI 10.1152/ajpendo.2001.281.5.E1037; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kawaguchi N, 1999, CYTOTECHNOLOGY, V31, P215, DOI 10.1023/A:1008198731341; Kral JG, 1999, PLAST RECONSTR SURG, V104, P1732, DOI 10.1097/00006534-199911000-00018; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Mandrup S, 1997, P NATL ACAD SCI USA, V94, P4300, DOI 10.1073/pnas.94.9.4300; Masuda H, 2003, CARDIOVASC RES, V58, P390, DOI 10.1016/S0008-6363(02)00785-X; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Patrick CW, 1999, TISSUE ENG, V5, P139, DOI 10.1089/ten.1999.5.139; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Ryan TJ, 1995, CLIN DERMATOL, V13, P493, DOI 10.1016/0738-081X(95)00092-T; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; SCANNELL G, 1993, J SURG RES, V54, P281, DOI 10.1006/jsre.1993.1044; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Straczkowski M, 2002, J CLIN ENDOCR METAB, V87, P4602, DOI 10.1210/jc.2002-020135; Toriyama K, 2002, TISSUE ENG, V8, P157, DOI 10.1089/107632702753503144; VARZANEH FE, 1994, METABOLISM, V43, P906, DOI 10.1016/0026-0495(94)90275-5; Voswinckel R, 2003, CIRC RES, V93, P372, DOI 10.1161/01.RES.0000087643.60150.C2; Zangani D, 1999, DIFFERENTIATION, V64, P91, DOI 10.1046/j.1432-0436.1999.6420091.x	42	142	149	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					983	+		10.1096/fj.03-1101fje	http://dx.doi.org/10.1096/fj.03-1101fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084517				2022-12-25	WOS:000221108800006
J	van den Biggelaar, AHJ; de Craen, AJM; Gussekloo, J; Huizinga, TWJ; Heijmans, BT; Frolich, M; Kirkwood, TBL; Westendorp, RGJ				van den Biggelaar, AHJ; de Craen, AJM; Gussekloo, J; Huizinga, TWJ; Heijmans, BT; Frolich, M; Kirkwood, TBL; Westendorp, RGJ			Inflammation underlying cardiovascular mortality is a late consequence of evolutionary programming	FASEB JOURNAL			English	Article						ageing; pleiotropy; pro-inflammatory; anti-inflammatory	DENSITY-LIPOPROTEIN CHOLESTEROL; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; DISEASE; INTERLEUKIN-10; LONGEVITY; REPRODUCTION; POLYMORPHISM; IMMUNITY; BURDEN	With the increase in life expectancy, death from cardiovascular disease has risen greatly. There is increasing evidence that inflammation plays an important role in cardiovascular disease. We postulate that the development of cardiovascular disease in old age is a late consequence of evolutionary programming for a pro-inflammatory response to resist infections in early age. In 311 women, aged 85 yr old, the production of the pro- and anti-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-10 was determined in lipopolysaccharide-stimulated whole blood samples and studied prospectively in association with cardiovascular mortality. High TNF-alpha was a risk factor for death from cardiovascular disease (relative risk [RR] = 1.56; 95% confidence interval [CI]: 1-2.40), whereas high IL-10 was protective (RR = 0.58; 95% CI: 0.40-0.85). A genetic variant of the IL-10 gene promoter, which is associated with lower IL-10 production, was found to predispose to a 2.8-fold higher cardiovascular mortality risk ( 95% CI: 1.17-6.60). Reproductive success, which was studied as a measure of evolutionary programming because it trades off with early survival by pro- inflammatory resistance genes, was negatively associated with an increasing production of TNF-alpha (RR = 0.77; 95% CI: 0.68-0.88), while a positive association with IL-10 was found (RR = 1.22; 95% CI: 1.05-1.41). We suggest that cardiovascular mortality is a late consequence of evolutionary programming for a pro-inflammatory response.	Leiden Univ, Med Ctr, Dept Gen Internal Med, Sect Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Reumatol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Epidemiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Chem, NL-2300 RC Leiden, Netherlands; Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Newcastle University - UK	van den Biggelaar, AHJ (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, Sect Gerontol & Geriatr, C2-R,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	Biggelaar@lumc.nl	Gussekloo, Jacobijn/ABE-3879-2021	Gussekloo, Jacobijn/0000-0001-7186-8278	Biotechnology and Biological Sciences Research Council [BEP17042] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		[Anonymous], 1992, INT STAT CLASS DIS R, V1-3; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Bonow RO, 2002, CIRCULATION, V106, P1602, DOI 10.1161/01.CIR.0000035036.22612.2B; Bootsma-van der Wiel A, 2002, J CLIN EPIDEMIOL, V55, P1119, DOI 10.1016/S0895-4356(02)00505-X; DAY INM, 1994, ANAL BIOCHEM, V222, P389, DOI 10.1006/abio.1994.1507; Doblhammer G, 2003, P ROY SOC B-BIOL SCI, V270, P1541, DOI 10.1098/rspb.2003.2400; Haukim N, 2002, GENES IMMUN, V3, P313, DOI 10.1038/sj.gene.6363881; Hill JA, 1995, HUM REPROD, V10, P114, DOI 10.1093/humrep/10.suppl_2.114; Kirkwood TBL, 2002, NATURE, V419, P794, DOI 10.1038/419794a; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lowe PR, 2003, CRIT CARE MED, V31, P34, DOI 10.1097/00003246-200301000-00005; Makhseed M, 2003, AM J REPROD IMMUNOL, V49, P308, DOI 10.1034/j.1600-0897.2003.00038.x; Makhseed M, 2000, HUM REPROD, V15, P2011, DOI 10.1093/humrep/15.9.2011; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; Perkins DJ, 2000, J INFECT DIS, V182, P988, DOI 10.1086/315762; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Rose MR, 2002, EVOLUTION, V56, P1982; Santos AR, 2002, J INFECT DIS, V186, P1687, DOI 10.1086/345366; Sgro CM, 2000, EVOLUTION, V54, P2152, DOI 10.1111/j.0014-3820.2000.tb01257.x; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Tong S, 2004, LANCET, V363, P129, DOI 10.1016/S0140-6736(03)15265-8; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; van den Biggelaar AHJ, 2002, J INFECT DIS, V186, P1474, DOI 10.1086/344352; van der Linden MW, 1998, J IMMUNOL METHODS, V218, P63, DOI 10.1016/S0022-1759(98)00108-2; van Exel E, 2002, STROKE, V33, P1135, DOI 10.1161/01.STR.0000014206.05597.9E; van Exel E, 2002, DIABETES, V51, P1088, DOI 10.2337/diabetes.51.4.1088; Westendorp RGJ, 1998, NATURE, V396, P743, DOI 10.1038/25519; Westendorp RGJ, 2001, NAT MED, V7, P873, DOI 10.1038/90868; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6; Weverling-Rijnsburger AWE, 2003, ARCH INTERN MED, V163, P1549, DOI 10.1001/archinte.163.13.1549; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Yarnell J, 2003, INT J EPIDEMIOL, V32, P71, DOI 10.1093/ije/dyg038	37	40	41	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1022	+		10.1096/fj.03-1162fje	http://dx.doi.org/10.1096/fj.03-1162fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084512				2022-12-25	WOS:000221108800001
J	Zijlstra, A; Aimes, RT; Zhu, D; Regazzoni, K; Kupriyanova, T; Seandel, M; Deryugina, EI; Quigley, JP				Zijlstra, A; Aimes, RT; Zhu, D; Regazzoni, K; Kupriyanova, T; Seandel, M; Deryugina, EI; Quigley, JP			Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; GROWTH-FACTOR; I COLLAGEN; MOLECULAR-CLONING; TISSUE INHIBITOR; ACTIVATION; EXPRESSION; SURFACE; MMP-13; PLASMINOGEN	We have demonstrated previously that new blood vessel formation induced by angiogenic growth factors in onplants placed on the chorioallantoic membrane (CAM) of the chick embryos is critically dependent on the cleavage of fibrillar collagen by a previously unidentified interstitial collagenase. In the present study we have used a quantitative CAM angiogenesis system to search for and functionally characterize host avian collagenases responsible for the collagen remodeling associated with angiogenesis. Among the matrix metalloproteinases ( MMPs) identified in the CAM onplant tissue, the chicken MMP-13 (chMMP-13) was the only enzyme whose induction and expression coincided with the onset of angiogenesis and blood vessel formation. The chMMP-13 cDNA has been cloned and recombinantly expressed. The chMMP-13 protein has been purified, characterized in vitro, and examined in situ in the CAM. MMP-13-positive cells appear in the CAM shortly after angiogenic stimulation and then accumulate in the collagen onplant tissue. Morphologically, the chMMP-13-containing cells appear as hematopoietic cells of monocyte/macrophage lineage. In vitro, the chMMP-13 proenzyme is rapidly and efficiently activated through the urokinase plasminogen activator/plasminogen/plasmin cascade into a collagenase capable of cleaving native but not the (r/r) mutant collagenase-resistant collagen. Surprisingly, nanogram levels of purified chMMP-13 elicit an angiogenic response in the CAM onplants comparable with that induced by the angiogenic growth factors. The chMMP-13-mediated response was efficiently blocked by select protease inhibitors indicating that plasmin-activated chMMP-13 can function as an angiogenic factor in vivo. Altogether, the results of this study extend the physiological role of MMP-13, previously associated with cartilage/bone resorption, to the collagen remodeling involved in the angiogenic cascade.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Quigley, JP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jquigley@scripps.edu	zijlstra, andries/G-4564-2013	zijlstra, andries/0000-0001-8460-8803	NATIONAL CANCER INSTITUTE [R01CA055852] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER; NCI NIH HHS [CA55852] Funding Source: Medline; NHLBI NIH HHS [HL31950] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Aimes RT, 1998, J CELL PHYSIOL, V174, P342, DOI 10.1002/(SICI)1097-4652(199803)174:3<342::AID-JCP8>3.3.CO;2-K; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; D'Angelo M, 2000, J CELL BIOCHEM, V77, P678, DOI 10.1002/(SICI)1097-4644(20000615)77:4<678::AID-JCB15>3.3.CO;2-G; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; Deryugina EI, 2002, CANCER RES, V62, P580; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hahn-Dantona EA, 2000, J BIOL CHEM, V275, P40827, DOI 10.1074/jbc.M006234200; Hangai M, 2002, AM J PATHOL, V161, P1429, DOI 10.1016/S0002-9440(10)64418-5; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Jeffrey JJ, 1998, BIOL EXTRAC, P15; Knauper V, 2002, FEBS LETT, V532, P127, DOI 10.1016/S0014-5793(02)03654-2; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Leeman MF, 2002, CRIT REV BIOCHEM MOL, V37, P149, DOI 10.1080/10409230290771483; Lei HQ, 1999, BIOL REPROD, V60, P183, DOI 10.1095/biolreprod60.1.183; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Netzel-Arnett S, 2002, J BIOL CHEM, V277, P45154, DOI 10.1074/jbc.M206354200; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; QUIGLEY JP, 1974, J BIOL CHEM, V249, P4306; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; Somerville RPT, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-216; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yu Q, 2000, GENE DEV, V14, P163	39	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27633	27645		10.1074/jbc.M313617200	http://dx.doi.org/10.1074/jbc.M313617200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15066996	hybrid			2022-12-25	WOS:000222120400098
J	Fernandez, P; Carretero, J; Medina, PP; Jimenez, AI; Rodriguez-Perales, S; Paz, MF; Cigudosa, JC; Esteller, M; Lombardia, L; Morente, M; Sanchez-Verde, L; Sotelo, T; Sanchez-Cespedes, M				Fernandez, P; Carretero, J; Medina, PP; Jimenez, AI; Rodriguez-Perales, S; Paz, MF; Cigudosa, JC; Esteller, M; Lombardia, L; Morente, M; Sanchez-Verde, L; Sotelo, T; Sanchez-Cespedes, M			Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations	ONCOGENE			English	Article						LKB1/STK11; Peutz-Jeghers syndrome; lung adenocarcinomas; cDNA microarrays	PEUTZ-JEGHERS-SYNDROME; SERINE/THREONINE PROTEIN-KINASE; SERINE-THREONINE KINASE; TUMOR-SUPPRESSOR; SOMATIC MUTATIONS; GROWTH ARREST; KNOCKOUT MICE; IN-VIVO; CANCER; LKB1/STK11	LKB1, a tumor-suppressor gene that codifies for a serine/threonine kinase, is mutated in the germ-line of patients affected with the Peutz-Jeghers syndrome (PJS), which have an increased incidence of several cancers including gastrointestinal, pancreatic and lung carcinomas. Regarding tumors arising in non-PJS patients, we recently observed that at least one-third of lung adenocarcinomas (LADs) harbor somatic LKB1 gene mutations, supporting a role for LKB1 in the origin of some sporadic tumors. To characterize the pattern of LKB1 mutations in LADs further, we first screened for LKB1 gene alterations ( gene mutations, promoter hypermethylation and homozygous deletions) in 19 LADs and, in agreement with our previous data, five of them (26%) were shown to harbor mutations, all of which gave rise to a truncated protein. Recent reports demonstrate that LKB1 is able to suppress cell growth, but little is known about the specific mechanism by which it functions. To further our understanding of LKB1 function, we analysed global expression in lung primary tumors using cDNA microarrays to identify LKB1-specific variations in gene expression. In all, 34 transcripts, 24 of which corresponded to known genes, differed significantly between tumors with and without LKB1 gene alterations. Among the most remarkable findings was deregulation of transcripts involved in signal transduction (e.g. FRAP1/mTOR, ARAF1 and ROCK2), cytoskeleton (e.g. MPP1), transcription factors (e.g. MEIS2, ATF5), metabolism of AMP (AMPD3 and APRT) and ubiquitinization (e.g. USP16 and UBE2L3). Real-time quantitative RT-PCR on 15 tumors confirmed the upregulation of the homeobox MEIS2 and of the AMP-metabolism AMPD3 transcripts in LKB1-mutant tumors. In addition, immunohistochemistry in 10 of the lung tumors showed the absence of phosphorylated FRAP1/mTOR protein in LKB1-mutant tumors, indicating that LKB1 mutations do not lead to FRAP1/mTOR protein kinase activation. In conclusion, our results reveal that several important factors contribute to LKB1-mediated carcinogenesis in LADs, confirming previous observations and identifying new putative pathways that should help to elucidate the biological role of LKB1.	Spanish Natl Canc Ctr, Lymphomas & Lung Canc Lab, Madrid, Spain; Spanish Natl Canc Ctr, Cytogenet Unit, Madrid, Spain; Spanish Natl Canc Ctr, Canc Epigenet Lab, Madrid, Spain; Spanish Natl Canc Ctr, Tumor Bank, Madrid, Spain; Spanish Natl Canc Ctr, Immunohistochem Unit, Madrid, Spain; Spanish Natl Canc Ctr, Histol Unit, Madrid, Spain; Hosp Univ 12 Octubre, Dept Pathol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario 12 de Octubre	Sanchez-Cespedes, M (corresponding author), Spanish Natl Canc Ctr, Lymphomas & Lung Canc Lab, Madrid, Spain.	msanchez@cnio.es	Rodriguez-Perales, Sandra/T-7667-2017; Vico, Pedro Pablo Medina/D-1688-2013; Carretero, Julian/N-5214-2014; Esteller, Manel/L-5956-2014; Cigudosa, Juan C/E-4105-2016; Sanchez-Cespedes, Montse/H-8485-2012	Rodriguez-Perales, Sandra/0000-0001-7221-3636; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Carretero, Julian/0000-0001-7269-8506; Esteller, Manel/0000-0003-4490-6093; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Fernandez, Paloma/0000-0001-5941-8442; Morente, Manuel M/0000-0001-6004-330X				Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; CARRETERO J, 2004, ONCOGENE        0315; Choe G, 2003, CANCER RES, V63, P2742; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Geerts D, 2003, CANCER LETT, V197, P87, DOI 10.1016/S0304-3835(03)00087-9; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; HANSSEN AMN, 1995, J MED GENET, V32, P117, DOI 10.1136/jmg.32.2.117; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; Nezu J, 1999, BIOCHEM BIOPH RES CO, V261, P750, DOI 10.1006/bbrc.1999.1047; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Schimanski CC, 1999, CANCER RES, V59, P5169; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tracey L, 2002, AM J PATHOL, V161, P1825, DOI 10.1016/S0002-9440(10)64459-8; Watts JL, 2000, DEVELOPMENT, V127, P1467; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zhang X, 2002, GENE DEV, V16, P2097, DOI 10.1101/gad.1007602	39	55	63	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5084	5091		10.1038/sj.onc.1207665	http://dx.doi.org/10.1038/sj.onc.1207665			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077168				2022-12-25	WOS:000222237300015
J	Li, D; Stuehr, DJ; Yeh, SR; Rousseau, DL				Li, D; Stuehr, DJ; Yeh, SR; Rousseau, DL			Heme distortion modulated by ligand-protein interactions in inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; HIGH-LEVEL EXPRESSION; STOPPED-FLOW ANALYSIS; ELECTRON-TRANSFER; OXYGENASE DOMAIN; L-ARGININE; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; NO SYNTHASE; NONPLANAR PORPHYRINS	The catalytic center of nitric-oxide synthase ( NOS) consists of a thiolate-coordinated heme macrocycle, a tetrahydrobiopterin (H4B) cofactor, and an L-arginine (L-Arg)/N-hydroxyarginine substrate binding site. To determine how the interplay between the cofactor, the substrates, and the protein matrix housing the heme regulates the enzymatic activity of NOS, the CO-, NO-, and CN--bound adducts of the oxygenase domain of the inducible isoform of NOS (iNOS(oxy)) were examined with resonance Raman spectroscopy. The Raman data of the CO- bound ferrous protein demonstrated that the presence of L-Arg causes the Fe-C-O moiety to adopt a bent structure because of an H-bonding interaction whereas H4B binding exerts no effect. Similar behavior was found in the CN--bound ferric protein and in the nitric oxide (NO)-bound ferrous protein. In contrast, in the NO- bound ferric complexes, the addition of L-Arg alone does not affect the structural properties of the Fe-N-O moiety, but H4B binding forces it to adopt a bent structure, which is further enhanced by the subsequent addition of L-Arg. The differential interactions between the various heme ligands and the protein matrix in response to L-Arg and/or H4B binding is coupled to heme distortions, as reflected by the development of a variety of out-of-plane heme modes in the low frequency Raman spectra. The extent and symmetry of heme deformation modulated by ligand, substrate, and cofactor binding may provide important control over the catalytic and autoinhibitory properties of the enzyme.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	rousseau@aecom.yu.edu		Yeh, Syun-Ru/0000-0002-9858-386X	NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL65465] Funding Source: Medline; NIGMS NIH HHS [GM54806, GM07288, GM51491, GM08572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Abu-Soud HM, 1999, BIOCHEMISTRY-US, V38, P12446, DOI 10.1021/bi990698x; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; BARKIGIA KM, 1993, J AM CHEM SOC, V115, P3627, DOI 10.1021/ja00062a029; BARKIGIA KM, 1988, J AM CHEM SOC, V110, P7566, DOI 10.1021/ja00230a063; BARKIGIA KM, 1990, J AM CHEM SOC, V112, P8851, DOI 10.1021/ja00180a029; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; Blackwood ME, 1998, BIOCHEMISTRY-US, V37, P779, DOI 10.1021/bi972616f; Chen YS, 2002, BIOCHEMISTRY-US, V41, P4618, DOI 10.1021/bi011877t; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Couture M, 2001, J BIOL CHEM, V276, P38280; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Deng TJ, 2001, J AM CHEM SOC, V123, P269, DOI 10.1021/ja001517d; Fan BC, 1997, BIOCHEMISTRY-US, V36, P12660, DOI 10.1021/bi9715369; Fedorov R, 2003, ARCH BIOCHEM BIOPHYS, V409, P25, DOI 10.1016/S0003-9861(02)00555-6; Fukuzumi S, 1999, ANGEW CHEM INT EDIT, V38, P964, DOI 10.1002/(SICI)1521-3773(19990401)38:7<964::AID-ANIE964>3.0.CO;2-O; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; HU SZ, 1993, J BIOL CHEM, V268, P6189; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; Hurshman AR, 2002, BIOCHEMISTRY-US, V41, P3439, DOI 10.1021/bi012002h; JORDAN T, 1995, PROTEIN SCI, V4, P716; Jung C, 2000, BIOCHEMISTRY-US, V39, P10163, DOI 10.1021/bi0003792; KORTH HG, 1994, J BIOL CHEM, V269, P17776; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARLETTA MA, 1993, ADV EXP MED BIOL, V338, P281; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Mayer B, 1998, N-S ARCH PHARMACOL, V358, P127, DOI 10.1007/PL00005233; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; RENNER MW, 1994, J AM CHEM SOC, V116, P8582, DOI 10.1021/ja00098a019; Roberts SA, 2001, BIOCHEMISTRY-US, V40, P11327, DOI 10.1021/bi0109257; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Sato H, 1998, FEBS LETT, V430, P377, DOI 10.1016/S0014-5793(98)00699-1; Scheele JS, 1997, J BIOL CHEM, V272, P12523, DOI 10.1074/jbc.272.19.12523; Schelvis JPM, 2002, BIOCHEMISTRY-US, V41, P5695, DOI 10.1021/bi0118456; Shelnutt J.A., 2000, PORPHYRIN HDB, V7, P168; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Tierney DL, 2000, J AM CHEM SOC, V122, P5405, DOI 10.1021/ja993685f; TSUBAKI M, 1990, BIOCHEMISTRY-US, V29, P8805, DOI 10.1021/bi00489a043; VALENZUELA JG, 1995, J EXP BIOL, V198, P1519; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Werner ER, 2003, EXP BIOL MED, V228, P1291, DOI 10.1177/153537020322801108; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; XIE QW, 1994, J BIOL CHEM, V269, P28500; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	70	63	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26489	26499		10.1074/jbc.M400968200	http://dx.doi.org/10.1074/jbc.M400968200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066989	hybrid			2022-12-25	WOS:000222003000072
J	Mic, FA; Sirbu, IO; Duester, G				Mic, FA; Sirbu, IO; Duester, G			Retinoic acid synthesis controlled by Raldh2 is required early for limb bud initiation and then later as a proximodistal signal during apical ectodermal ridge formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZING ACTIVITY; VITAMIN-A; EMBRYONIC-DEVELOPMENT; LETHAL DEFECT; CHICK; MOUSE; EXPRESSION; OUTGROWTH; PATTERN; DHAND	We present evidence for the existence of two phases of retinoic acid ( RA) signaling required for vertebrate limb development. Limb RA synthesis is under the control of retinaldehyde dehydrogenase-2 (Raldh2) expressed in the lateral plate mesoderm, which generates a proximodistal RA signal during limb outgrowth. We report that Raldh2(-/-) embryos lack trunk mesodermal RA activity and fail to initiate forelimb development. This is associated with deficient expression of important limb determinants Tbx5, Meis2, and dHand needed to establish forelimb bud initiation, proximal identity, and the zone of polarizing activity (ZPA), respectively. Limb expression of these genes can be rescued by maternal RA treatment limited to embryonic day 8 (E8) during limb field establishment, but the mutant forelimbs obtained at E10 display a significant growth defect associated with a smaller apical ectodermal ridge (AER), referred to here as an apical ectodermal mound (AEM). In these RA-deficient forelimbs, a ZPA expressing Shh forms, but it is located distally adjacent to the Fgf8 expression domain in the AEM rather than posteriorly as is normal. AER formation in Raldh2(-/-) forelimbs is rescued by continuous RA treatment through E10, which restores RA to distal ectoderm fated to become the AER. Our findings indicate the existence of an early phase of RA signaling acting upstream of Tbx5, Meis2, and dHand, followed by a late phase of RA signaling needed to expand AER structure fully along the distal ectoderm. During ZPA formation, RA acts early to activate expression of dHand, but it is not required later for Shh activation.	Burnham Inst, Oncodev Biol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, Oncodev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	duester@burnham.org	Sirbu, Ioan Ovidiu/F-1841-2010; Sirbu, Ioan Ovidiu/AAP-1290-2021	Sirbu, Ioan Ovidiu/0000-0003-1618-9656; Sirbu, Ioan Ovidiu/0000-0003-1618-9656	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062848] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62848, R01 GM062848-02, R01 GM062848] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn DG, 2002, NATURE, V417, P754, DOI 10.1038/nature00814; Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903; Begemann G, 2001, DEVELOPMENT, V128, P3081; Charite J, 2000, DEVELOPMENT, V127, P2461; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; Dupe V, 2003, P NATL ACAD SCI USA, V100, P14036, DOI 10.1073/pnas.2336223100; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Grandel H, 2002, DEVELOPMENT, V129, P2851; Helms JA, 1996, DEVELOPMENT, V122, P1385; Lewandoski M, 2000, NAT GENET, V26, P460, DOI 10.1038/82609; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; MADEN M, 1982, NATURE, V295, P672, DOI 10.1038/295672a0; Mercader N, 2000, DEVELOPMENT, V127, P3961; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; Mic FA, 2002, DEVELOPMENT, V129, P2271; Mic FA, 2003, DEV BIOL, V264, P191, DOI 10.1016/S0012-1606(03)00403-2; Mic FA, 2003, P NATL ACAD SCI USA, V100, P7135, DOI 10.1073/pnas.1231422100; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; Moon AM, 2000, DEVELOPMENT, V127, P989; Ng JK, 2002, DEVELOPMENT, V129, P5161; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 2002, DEVELOPMENT, V129, P3563; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; Power SC, 1999, DEV DYNAM, V216, P469, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<469::AID-DVDY15>3.0.CO;2-3; Qin P, 2002, TERATOLOGY, V66, P224, DOI 10.1002/tera.10082; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SCOTT WJ, 1994, DEV BIOL, V165, P397, DOI 10.1006/dbio.1994.1262; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Stratford T, 1999, MECH DEVELOP, V81, P115, DOI 10.1016/S0925-4773(98)00231-7; Stratford T, 1996, CURR BIOL, V6, P1124, DOI 10.1016/S0960-9822(02)70679-9; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Sun X, 2000, NAT GENET, V25, P83, DOI 10.1038/75644; Swindell EC, 1999, DEV BIOL, V216, P282, DOI 10.1006/dbio.1999.9487; TAMURA K, 1990, DEV BIOL, V140, P20, DOI 10.1016/0012-1606(90)90049-O; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1989, DEVELOPMENT, V106, P691; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620; Welscher PT, 2002, GENE DEV, V16, P421, DOI 10.1101/gad.219202; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	47	76	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26698	26706		10.1074/jbc.M401920200	http://dx.doi.org/10.1074/jbc.M401920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069081	hybrid			2022-12-25	WOS:000222003000096
J	Nho, CW; O'Dwyer, PJ				Nho, CW; O'Dwyer, PJ			NF-kappa B activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOMYCIN-C TREATMENT; DT-DIAPHORASE; KINASE-ALPHA; TRANSCRIPTION FACTORS; DIFFERENTIAL REGULATION; BRASSICA VEGETABLES; CANCER PREVENTION; INDUCTION; BETA; TNF	Chemoprevention by the dithiolethione analogue oltipraz (4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione) may occur through several mechanisms, among them stimulation of detoxication activity. The phase II detoxication enzyme, NAD(P) H: quinone oxidoreductase 1 (NQO1; EC 1.6.99.2) also known as quinone reductase (QR) is well established to undergo transcriptional activation following oltipraz treatment of colon cancer cells in culture. Promoter analysis of the QR gene in oltipraztreated cells reveals the involvement of both the AP-1 and NF-kappaB elements in the response. The emerging role of NF-kappaB in cell survival prompted a fuller analysis of effects of oltipraz on this pathway. Oltipraz treatment of both HCT116 and HT29 cells results in the induction of proteins involved in both pathways of NF-kappaB activation, including p65, IkappaB kinase alpha (IKKalpha), IkappaB kinase beta (IKKbeta), and NF-kappaB-inducing kinase (NIK). IkappaBalpha total protein levels were unchanged, but phosphorylation of the inhibitor was also induced in both lines. Electrophoretic mobility shift assay ( EMSA) analysis confirmed induction of protein binding to a consensus NF-kappaB element, and transcriptional activation was further confirmed using a reporter construct. Transcriptional activation of QR was decreased in a dose-dependent manner by dominant-negative NF-kappaB in both cell lines. The molecular mechanism that triggers IKK activation in response to oltipraz was also examined using inhibitory constructs of NIK and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 3 (MEKK3). We found that both MEKK3 and NIK exert effects on IKKalpha/beta activation, but through different pathways. Furthermore, the receptor-interacting protein ( RIP) was found to interact strongly with MEKK3 during oltipraz-induced NF-kappaB signaling, implying a role for tumor necrosis factor receptor signaling in the action of oltipraz. These results implicate a novel signaling pathway for the action of oltipraz in QR gene regulation.	Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	O'Dwyer, PJ (corresponding author), Univ Penn, Sch Med, Div Hematol Oncol, 51 N 39th St,MAB-103, Philadelphia, PA 19104 USA.	peter.odwyer@uphs.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA078272] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78272] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BENSON AB, 1993, J CELL BIOCHEM, P278; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Clapper ML, 1998, PHARMACOL THERAPEUT, V78, P17, DOI 10.1016/S0163-7258(97)00164-2; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Elewaut D, 1999, J IMMUNOL, V163, P1457; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Jobin C, 1997, J IMMUNOL, V158, P226; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kensler TW, 1998, CANCER EPIDEM BIOMAR, V7, P127; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LI Y, 1993, J BIOL CHEM, V268, P21454; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ODwyer PJ, 1997, CANCER RES, V57, P1050; ODwyer PJ, 1997, CLIN CANCER RES, V3, P783; Patten EJ, 1999, BIOCHEM BIOPH RES CO, V257, P149, DOI 10.1006/bbrc.1999.0422; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sharma RA, 2001, EUR J CANCER, V37, P12, DOI 10.1016/S0959-8049(00)00326-9; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sporn MB, 2002, NAT REV CANCER, V2, P537, DOI 10.1038/nrc844; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Szarka CE, 2001, CANCER DETECT PREV, V25, P352; van Poppel G, 1999, ADV EXP MED BIOL, V472, P159; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yao KS, 1996, CANCER RES, V56, P1731; YAO KS, 1995, BIOCHEM PHARMACOL, V49, P275, DOI 10.1016/0006-2952(94)00544-V; Yao KS, 2003, BIOCHEM PHARMACOL, V66, P15, DOI 10.1016/S0006-2952(03)00163-1; Yao KS, 1997, MOL PHARMACOL, V51, P422; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	50	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26019	26027		10.1074/jbc.M309022200	http://dx.doi.org/10.1074/jbc.M309022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15047705	hybrid			2022-12-25	WOS:000222003000013
J	Suda, T; Kamiyama, S; Suzuki, M; Kikuchi, N; Nakayama, K; Narimatsu, H; Jigami, Y; Aoki, T; Nishihara, S				Suda, T; Kamiyama, S; Suzuki, M; Kikuchi, N; Nakayama, K; Narimatsu, H; Jigami, Y; Aoki, T; Nishihara, S			Molecular cloning and characterization of a human multisubstrate specific nucleotide-sugar transporter homologous to Drosophila fringe connection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; HEPARAN-SULFATE; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; GLYCOSYLATION; GLYCOSYLTRANSFERASE; ACETYLGALACTOSAMINE; LOCALIZATION; COMPLEX	Nucleotide-sugar transporters are crucial components in the synthesis of glycoconjugates. We identified a novel human nucleotide-sugar transporter gene, hfrc1, which is homologous to Drosophila melanogaster fringe connection, Caenorhabditis elegans sqv-7, and human UGTrel7. HFRC1 was localized within the Golgi apparatus following its transient expression in HCT116 cells. In human tissues, hfrc1 and UGTrel7 exhibited similar tissue distributions, although hfrc1 transcripts showed a 10 times greater abundance than those of UGTrel7. The heterologous expression of HFRC1 in the yeast revealed the multisubstrate specific transport activity of HFRC1 (for UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-glucose (UDP-Glc), and GDP-mannose (GDP-Man), with apparent Km values of 8.0, 2.1, and 0.14 muM, respectively). In the mammalian cells, HFRC1 transported UDP-GlcNAc and UDP-Glc, but not GDP-Man. Overexpression of the hfrc1 gene in HCT116 cells modulated the cell surface heparan sulfate expression status. These results suggest that HFRC1 takes part in the synthesis of heparan sulfate by regulating the level of UDP-GlcNAc, a donor substrate for the heparan sulfate synthases.	Soka Univ, Fac Engn, Dept Bioinformat, Cell Biol Lab, Tokyo 1928577, Japan; Tokyo Med Univ, Dept Surg, Shinjuku Ku, Tokyo 1600023, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058586, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Soka University; Tokyo Medical University; Seikagaku Corporation; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Nishihara, S (corresponding author), Soka Univ, Fac Engn, Dept Bioinformat, Cell Biol Lab, 1-236 Tangi Cho, Tokyo 1928577, Japan.	shoko@t.soka.ac.jp	Narimatsu, Hisashi/M-4757-2018	Narimatsu, Hisashi/0000-0002-8402-133X; Nishihara, Shoko/0000-0002-1668-2603				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Kasahara M, 1996, P NATL ACAD SCI USA, V93, P9096, DOI 10.1073/pnas.93.17.9096; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Nakayama K, 2003, GLYCOBIOLOGY, V13, P673, DOI 10.1093/glycob/cwg099; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Prydz K, 2000, J CELL SCI, V113, P193; Ramakrishnan B, 2001, J BIOL CHEM, V276, P37665, DOI 10.1074/jbc.M102458200; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; UEMURA M, 1992, CANCER RES, V52, P6153; VERBERT A, 1987, BIOCHIMIE, V69, P91, DOI 10.1016/0300-9084(87)90240-9	36	50	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26469	26474		10.1074/jbc.M311353200	http://dx.doi.org/10.1074/jbc.M311353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082721	hybrid			2022-12-25	WOS:000222003000069
J	Vruchte, DT; Lloyd-Evans, E; Veldman, RJ; Neville, DCA; Dwek, RA; Platt, FM; van Blitterswijk, WJ; Sillence, DJ				Vruchte, DT; Lloyd-Evans, E; Veldman, RJ; Neville, DCA; Dwek, RA; Platt, FM; van Blitterswijk, WJ; Sillence, DJ			Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID-STORAGE DISEASES; MUCOLIPIDOSIS TYPE-IV; ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; LIPID RAFTS; RETROGRADE TRANSPORT; CELL-SURFACE; ANNEXIN-II; LYSOSOMAL CHOLESTEROL; POLARIZED EPITHELIA	Glycosphingolipids are endocytosed and targeted to the Golgi apparatus but are mistargeted to lysosomes in sphingolipid storage disorders. Substrate reduction therapy utilizes imino sugars to inhibit glucosylceramide synthase and potentially abrogate the effects of storage. Niemann-Pick type C (NPC) disease is a disorder of intracellular transport where glycosphingolipids (GSLs) and cholesterol accumulate in endosomal compartments. The mechanisms of altered intracellular trafficking are not known but may involve the mistargeting and disrupted function of proteins associated with GSL membrane microdomains. Membrane microdomains were isolated by Triton X-100 and sucrose density gradient ultracentrifugation. High pressure liquid chromatography and mass spectrometric analysis of NPC1(-/-) mouse brain revealed large increases in GSL. Sphingosine was also found to be a component of membrane microdomains, and in NPC liver and spleen, large increases in cholesterol and sphingosine were found. GSL and cholesterol levels were increased in mutant NPC1-null Chinese hamster ovary cells as well as U18666A and progesterone induced NPC cell culture models. However, inhibition of GSL synthesis in NPC cells with N-butyldeoxygalactonojirimycin led to marked decreases in GSL but only small decreases in cholesterol levels. Both annexin 2 and 6, membrane-associated proteins that are important in endocytic trafficking, show distorted distributions in NPC cells. Altered BODIPY lactosylceramide targeting, decreased endocytic uptake of a fluid phase marker, and mistargeting of annexin 2 (phenotypes associated with NPC) are reversed by inhibition of GSL synthesis. It is suggested that accumulating GSL is part of a mislocalized membrane microdomain and is responsible for the deficit in endocytic trafficking found in NPC disease.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	University of Oxford; Netherlands Cancer Institute	Sillence, DJ (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	dan@glycob.ox.ac.uk	Sillence, Dan J/J-9513-2019; Platt, Frances/G-1004-2010	Sillence, Dan J/0000-0003-4747-5655; Neville, David/0000-0003-2385-8993; Platt, Frances/0000-0001-7614-0403				Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blom TS, 2001, BIOCHEMISTRY-US, V40, P14635, DOI 10.1021/bi0156714; BREIMER ME, 1975, LIPIDS, V10, P17, DOI 10.1007/BF02532188; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Corvera S, 2000, J BIOL CHEM, V275, P31414, DOI 10.1074/jbc.M001708200; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Diakonova M, 1997, J CELL SCI, V110, P1199; DIAMOND JM, 1994, NATURE, V368, P291, DOI 10.1038/368291a0; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; FRANEY RJ, 1968, CLIN CHIM ACTA, V21, P255, DOI 10.1016/0009-8981(68)90135-6; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; George T, 2001, CELL MOL BIOL, V47, P1179; Gillard BK, 1998, GLYCOBIOLOGY, V8, P885, DOI 10.1093/glycob/8.9.885; GOLDIN E, 1992, BIOCHIM BIOPHYS ACTA, V1127, P303, DOI 10.1016/0005-2760(92)90236-O; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Gu F, 2000, J BIOL CHEM, V275, P8154, DOI 10.1074/jbc.275.11.8154; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Hornick CA, 1997, AM J PHYSIOL-CELL PH, V273, pC1075, DOI 10.1152/ajpcell.1997.273.3.C1075; Hunnam V, 2001, J AM SOC MASS SPECTR, V12, P1220, DOI 10.1016/S1044-0305(01)00309-9; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Khine AA, 1998, J CELL PHYSIOL, V176, P281, DOI 10.1002/(SICI)1097-4652(199808)176:2<281::AID-JCP6>3.0.CO;2-K; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Lloyd-Evans E, 2003, BIOCHEM J, V375, P561, DOI 10.1042/BJ20030613; Lusa S, 2001, J CELL SCI, V114, P1893; Malathi K, 2004, J CELL BIOL, V164, P547, DOI 10.1083/jcb.200310046; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Merrill AH, 2000, METHOD ENZYMOL, V312, P3; MILLERPODRAZA H, 1992, BIOCHIM BIOPHYS ACTA, V1124, P45, DOI 10.1016/0005-2760(92)90124-E; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; NEVILLE DCA, 2004, IN PRESS ANAL BIOCH; Nix M, 2000, CELL DEATH DIFFER, V7, P413, DOI 10.1038/sj.cdd.4400666; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Pelled D, 2003, J BIOL CHEM, V278, P29496, DOI 10.1074/jbc.M302964200; Pentchev P G, 1980, Birth Defects Orig Artic Ser, V16, P225; PENTCHEV PG, 1984, J BIOL CHEM, V259, P5784; PENTCHEV PG, 1980, BIOCHIM BIOPHYS ACTA, V619, P669, DOI 10.1016/0005-2760(80)90116-2; Pons M, 2001, EXP CELL RES, V269, P13, DOI 10.1006/excr.2001.5268; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; RODRIGUEZLAFRASSE C, 1994, BBA-MOL BASIS DIS, V1226, P138, DOI 10.1016/0925-4439(94)90021-3; ROFF CF, 1991, DEV NEUROSCI-BASEL, V13, P315, DOI 10.1159/000112179; Romiti E, 2001, FEBS LETT, V506, P163, DOI 10.1016/S0014-5793(01)02878-2; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sillence DJ, 2003, TRENDS CELL BIOL, V13, P195, DOI 10.1016/S0962-8924(03)00033-3; Sillence DJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-24; Sillence DJ, 2000, J LIPID RES, V41, P1252; Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232-JLR200; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; STEINHART WL, 1984, INTERVIROLOGY, V21, P70, DOI 10.1159/000149504; Sugimoto Y, 2001, P NATL ACAD SCI USA, V98, P12391, DOI 10.1073/pnas.221181998; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; Tsai B, 2003, EMBO J, V22, P4346, DOI 10.1093/emboj/cdg439; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANCE DE, 1967, J LIPID RES, V8, P621; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VANIER MT, 1983, BIOCHIM BIOPHYS ACTA, V750, P178, DOI 10.1016/0005-2760(83)90218-7; Vanier MT, 1999, NEUROCHEM RES, V24, P481, DOI 10.1023/A:1022575511354; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; WAKI H, 1994, ANAL BIOCHEM, V222, P156, DOI 10.1006/abio.1994.1467; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898	92	138	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26167	26175		10.1074/jbc.M311591200	http://dx.doi.org/10.1074/jbc.M311591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078881	hybrid			2022-12-25	WOS:000222003000031
J	Aiello, R; Messina, A; Schiffler, B; Benz, R; Tasco, G; Casadio, R; De Pinto, V				Aiello, R; Messina, A; Schiffler, B; Benz, R; Tasco, G; Casadio, R; De Pinto, V			Functional characterization of a second porin isoform in Drosophila melanogaster - DmPorin2 forms voltage-independent cation-selective pores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; MITOCHONDRIAL OUTER-MEMBRANE; PERMEABILITY TRANSITION PORE; MATRIX PROTEIN PORIN; VDAC ION CHANNEL; ESCHERICHIA-COLI; CYTOCHROME-C; CELL-DEATH; FAMILY; YEAST	Mitochondrial porins or voltage-dependent anion-selective channels are channel-forming proteins mainly found in the mitochondrial outer membrane. Genome sequencing of the fruit fly Drosophila melanogaster revealed the presence of three additional porin-like genes. No functional information was available for the different gene products. In this work we have studied the function of the gene product closest to the known Porin gene (CG17137 coding for DmPorin2). Its coding sequence was expressed in Escherichia coli. The recombinant DmPorin2 protein is able to form channels similar to those formed by DmPorin1 reconstituted in artificial membranes. Furthermore, DmPorin2 is clearly voltage-independent and cation-selective, whereas its counterpart isoform 1 is voltage-dependent and anion-selective. Sequence comparison of the two porin isoforms indicates the exchange of four lysines in DmPorin1 for four glutamic acids in DmPorin2. We have mutated two of them (Glu-66 and Glu-163) to lysines to investigate their role in the functional features of the pore. The mutants E163K and E66K/E163K are endowed with an almost full inversion of the ion selectivity. Both single mutations partially restore the voltage dependence of the pore. We found that an additional effect with the double mutant E66K/E163K was the restoration of voltage dependence. Protein structure predictions highlight a 16 beta-strand pattern, typical for porins. In a three-dimensional model of DmPorin2, Glu-66 and Glu-163 are close to the rim of the channel, on two opposite sides. DmPorin2 is expressed in all the fly tissues and in all the developmental stages tested. Our main conclusions are as follows. 1) The CG17137 gene may express a porin with a functional role in D. melanogaster. 2) We have identified two amino acids of major relevance for the voltage dependence of the porin pore.	Univ Catania, Dept Chem Sci, I-95125 Catania, Italy; Univ Wurzburg, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany; Univ Bologna, Dept Biol, Biocomp Unit, I-40126 Bologna, Italy	University of Catania; University of Wurzburg; University of Bologna	De Pinto, V (corresponding author), Univ Catania, Dept Chem Sci, Viale A Doria 6, I-95125 Catania, Italy.	vdpbiofa@unict.it	Messina, Angela/ABC-9518-2020; De Pinto, Vito/AAC-2634-2019; Casadio, Rita/K-4814-2015; Casadio, Rita/K-3747-2017	Casadio, Rita/0000-0002-7462-7039; Benz, Roland/0000-0002-9510-9265; De Pinto, Vito/0000-0001-5513-2906; MESSINA, Angela Anna/0000-0002-5745-9846				BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P313; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Blachly-Dyson E, 2001, IUBMB LIFE, V52, P113; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Casadio R, 2002, FEBS LETT, V520, P1, DOI 10.1016/S0014-5793(02)02758-8; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; De Pinto Vito, 2003, Ital J Biochem, V52, P17; DEPINTO V, 1989, BIOCHIM BIOPHYS ACTA, V987, P1, DOI 10.1016/0005-2736(89)90447-1; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; Eswar N, 2003, NUCLEIC ACIDS RES, V31, P3375, DOI 10.1093/nar/gkg543; FIEK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429, DOI 10.1016/0005-2736(82)90354-6; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; Jacoboni I, 2001, PROTEIN SCI, V10, P779, DOI 10.1110/ps.37201; Komarov AG, 2004, BIOPHYS J, V86, P152, DOI 10.1016/S0006-3495(04)74093-X; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; Martelli P.L., 2002, BIOINFORMATICS, V18, pS46; Messina A, 1996, FEBS LETT, V384, P9, DOI 10.1016/0014-5793(96)00268-2; Oliva M, 1998, FEBS LETT, V430, P327, DOI 10.1016/S0014-5793(98)00693-0; Oliva M, 2002, MOL GENET GENOMICS, V267, P746, DOI 10.1007/s010438-002-0714-1; Popp B, 1996, J BIOL CHEM, V271, P13593, DOI 10.1074/jbc.271.23.13593; POPP B, 1995, BIOCHEMISTRY-US, V34, P3352, DOI 10.1021/bi00010a026; RAUCH G, 1994, BIOCHEM BIOPH RES CO, V200, P908, DOI 10.1006/bbrc.1994.1536; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; Schulz GE, 2000, CURR OPIN STRUC BIOL, V10, P443, DOI 10.1016/S0959-440X(00)00120-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; SZABO I, 1993, FEBS LETT, V330, P206, DOI 10.1016/0014-5793(93)80274-X; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540; Xu X, 2001, J MEMBRANE BIOL, V180, P73, DOI 10.1007/s002320010060; ZIZI M, 1995, J MEMBRANE BIOL, V144, P121	47	20	23	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25364	25373		10.1074/jbc.M310572200	http://dx.doi.org/10.1074/jbc.M310572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15054101	hybrid			2022-12-25	WOS:000221827900059
J	Miyazaki, M; Dobrzyn, A; Man, WC; Chu, KK; Sampath, H; Kim, HJ; Ntambi, JN				Miyazaki, M; Dobrzyn, A; Man, WC; Chu, KK; Sampath, H; Kim, HJ; Ntambi, JN			Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; TRANSGENIC MICE; PROTEIN-1 EXPRESSION; 3T3-L1 PREADIPOCYTES; INSULIN-RESISTANCE; NUCLEAR SREBP-1C; OLEOYL-COA; US ADULTS; CHOLESTEROL; LIVERS	Stearoyl-CoA desaturase (SCD) synthesizes oleate necessary for the biosynthesis of triglycerides and other lipids. Mice with a targeted disruption of the SCD1 gene are deficient in tissue oleate and have reduced expression of the sterol regulatory element-binding protein ( SREBP) and its target genes. The SREBP-1c isoform is a known mediator of insulin action on hepatic gene expression, but its transcriptional effects due to glucose or fructose are still unclear. We found that fructose compared with glucose is a stronger inducer of SREBP-1c and lipogenic gene expression, causing a dramatic increase in hepatic triglyceride levels. However, when fed to the SCD1-/- mice, fructose failed to induce SREBP-1 or lipogenic genes and the triglyceride levels were not increased. Instead fructose feeding caused a decrease in hepatic glycogen and plasma glucose levels. The induction of SREBP-1 and lipogenic gene expression as well as the levels of liver triglycerides, glycogen, and plasma glucose was partially restored when the fructose diet was supplemented with very high levels of oleate (20% by weight) but not with palmitate, stearate, or linoleate. Fructose in a long term feeding induced the expression of SCD1 and that of other lipogenic genes in the liver of SREBP-1c-/- mice, and a further increase in expression of these genes occurred when the fructose diet was supplemented with oleate. Our observations demonstrated that oleate produced by SCD is necessary for fructose-mediated induction of lipogenic gene expression through SREBP-1c-dependent and -independent mechanisms and suggested that SCD1 gene expression is important in lipid and carbohydrate homeostasis.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ntambi, JN (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ntambi@biochem.wisc.edu	Dobrzyn, Agnieszka/R-4073-2016	Dobrzyn, Agnieszka/0000-0002-6331-9460	NIDDK NIH HHS [R01 DK162388] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN RC, 1966, J BIOL CHEM, V241, P5467; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Beiraghi S, 2003, GENE, V309, P11, DOI 10.1016/S0378-1119(03)00461-x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101; Elliott SS, 2002, AM J CLIN NUTR, V76, P911, DOI 10.1093/ajcn/76.5.911; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Garbay B, 1998, J NEUROCHEM, V71, P1719; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Hardy S, 2000, CANCER RES, V60, P6353; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; HARDY S, 2003, J BIOL CHEM, V12, P278; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lee Y, 2002, IMMUNOLOGY, V107, P435, DOI 10.1046/j.1365-2567.2002.01532.x; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Medina JM, 2002, J PHYSIOL-PARIS, V96, P265, DOI 10.1016/S0928-4257(02)00015-3; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Miyazaki M, 2003, J BIOL CHEM, V278, P33904, DOI 10.1074/jbc.M304724200; Miyazaki M, 2001, J BIOL CHEM, V276, P39455, DOI 10.1074/jbc.M106442200; Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; Ntambi JM, 2001, J MOL NEUROSCI, V16, P273, DOI 10.1385/JMN:16:2-3:273; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Roche E, 1999, DIABETES, V48, P2007, DOI 10.2337/diabetes.48.10.2007; ROEHRIG KL, 1974, ANAL BIOCHEM, V58, P414, DOI 10.1016/0003-2697(74)90210-3; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimizu S, 2003, J BIOL CHEM, V278, P43095, DOI 10.1074/jbc.M306880200; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; WATERS KM, 1994, J BIOL CHEM, V269, P27773; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255; Zheng Y, 2001, GENOMICS, V71, P182, DOI 10.1006/geno.2000.6429	65	223	239	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25164	25171		10.1074/jbc.M402781200	http://dx.doi.org/10.1074/jbc.M402781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066988	hybrid			2022-12-25	WOS:000221827900032
J	Salazar, G; Love, R; Styers, ML; Werner, E; Peden, A; Rodriguez, S; Gearing, M; Wainer, BH; Faundez, V				Salazar, G; Love, R; Styers, ML; Werner, E; Peden, A; Rodriguez, S; Gearing, M; Wainer, BH; Faundez, V			AP-3-dependent mechanisms control the targeting of a chloride channel (ClC-3) in neuronal and non-neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE BIOGENESIS; IN-VITRO; TRANSFERRIN RECEPTOR; PLASMA-MEMBRANE; PC12 CELLS; ZINC; PROTEIN; TRANSPORTER; ENDOSOMES; GLUTAMATE	Adaptor protein (AP)-2 and AP-3-dependent mechanisms control the sorting of membrane proteins into synaptic vesicles. Mouse models deficient in AP-3, mocha, develop a neurological phenotype of which the central feature is an alteration of the luminal synaptic vesicle composition. This is caused by a severe reduction of vesicular levels of the zinc transporter 3 (ZnT3). It is presently unknown whether this mocha defect is restricted to ZnT3 or encompasses other synaptic vesicle proteins capable of modifying synaptic vesicle contents, such as transporters or channels. In this study, we identified a chloride channel, ClC-3, whose level in synaptic vesicles and hippocampal mossy fiber terminals was reduced in the context of the mocha AP-3 deficiency. In PC-12 cells, ClC-3 was present in transferrin receptor-positive endosomes, where it was targeted to synaptic-like microvesicles (SLMV) by a mechanism sensitive to brefeldin A, a signature of the AP-3-dependent route of SLMV biogenesis. ClC-3 was packed in SLMV along with the AP-3-targeted synaptic vesicle protein ZnT3. Co-segregation of ClC-3 and ZnT3 to common intracellular compartments was functionally significant as revealed by increased vesicular zinc transport with increased ClC3 expression. Our work has identified a synaptic vesicle protein in which trafficking to synaptic vesicles is regulated by AP-3. In addition, our findings indicate that ClC-3 and ZnT3 reside in a common vesicle population where they functionally interact to determine vesicle luminal composition.	Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Genentech Inc, San Francisco, CA 94080 USA	Emory University; Emory University; Emory University; Roche Holding; Genentech	Faundez, V (corresponding author), Whitehead Biomed Res Bldg,615 Michael St,Rm 446, Atlanta, GA 30322 USA.	faundez@cellbio.emory.edu		Love, Rachal/0000-0002-7038-8747; Werner, Erica/0000-0002-8183-1601; Peden, Andrew/0000-0003-0144-7712; Faundez, Victor/0000-0002-2114-5271	NINDS NIH HHS [R01-NS42599-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042599] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Blagoveshchenskaya AD, 1999, MOL BIOL CELL, V10, P3979, DOI 10.1091/mbc.10.11.3979; Blumstein J, 2001, J NEUROSCI, V21, P8034, DOI 10.1523/JNEUROSCI.21-20-08034.2001; Boehm M, 2002, GENE, V286, P175, DOI 10.1016/S0378-1119(02)00422-5; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Clift-O'Grady L, 1998, METHODS, V16, P150, DOI 10.1006/meth.1998.0662; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cole TB, 2000, EPILEPSY RES, V39, P153, DOI 10.1016/S0920-1211(99)00121-7; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; Faundez VV, 2000, MOL BIOL CELL, V11, P2591, DOI 10.1091/mbc.11.8.2591; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; Huang EP, 1997, P NATL ACAD SCI USA, V94, P13386, DOI 10.1073/pnas.94.25.13386; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kantheti P, 2003, MAMM GENOME, V14, P157, DOI 10.1007/s00335-002-2238-8; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; Lim C, 1997, J COMP NEUROL, V385, P325, DOI 10.1002/(SICI)1096-9861(19970901)385:3<325::AID-CNE1>3.0.CO;2-5; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Murakawa R, 2001, J COMP NEUROL, V429, P113, DOI 10.1002/1096-9861(20000101)429:1<113::AID-CNE9>3.0.CO;2-D; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Reimer RJ, 2001, CURR OPIN CELL BIOL, V13, P417, DOI 10.1016/S0955-0674(00)00230-1; Salazar G, 2004, MOL BIOL CELL, V15, P575, DOI 10.1091/mbc.E03-06-0401; Salem N, 1998, NAT NEUROSCI, V1, P551, DOI 10.1038/2787; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Seong E, 2004, TRENDS GENET, V20, P59, DOI 10.1016/j.tig.2003.12.006; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Shimada K, 2000, AM J PHYSIOL-GASTR L, V279, pG268, DOI 10.1152/ajpgi.2000.279.2.G268; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Ueno S, 2002, J CELL BIOL, V158, P215, DOI 10.1083/jcb.200204066; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; Wei ML, 1998, J CELL BIOL, V140, P565, DOI 10.1083/jcb.140.3.565; Yang W, 2000, J CELL SCI, V113, P4077; ZALEWSKI PD, 1994, J HISTOCHEM CYTOCHEM, V42, P877, DOI 10.1177/42.7.8014471; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	52	95	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25430	25439		10.1074/jbc.M402331200	http://dx.doi.org/10.1074/jbc.M402331200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073168	hybrid			2022-12-25	WOS:000221827900066
J	Singh, SV; Herman-Antosiewicz, A; Singh, AV; Lew, KL; Srivastava, SK; Kamath, R; Brown, KD; Zhang, L; Baskaran, R				Singh, SV; Herman-Antosiewicz, A; Singh, AV; Lew, KL; Srivastava, SK; Kamath, R; Brown, KD; Zhang, L; Baskaran, R			Sulforaphane-induced G(2)/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; DNA-DAMAGE; HELICOBACTER-PYLORI; UP-REGULATION; GLUTATHIONE; APOPTOSIS; ISOTHIOCYANATES; VEGETABLES; CHK1; ATR	Previously, we showed that sulforaphane (SFN), a naturally occurring cancer chemopreventive agent, effectively inhibits proliferation of PC-3 human prostate cancer cells by causing caspase-9- and caspase-8-mediated apoptosis. Here, we demonstrate that SFN treatment causes an irreversible arrest in the G(2)/M phase of the cell cycle. Cell cycle arrest induced by SFN was associated with a significant decrease in protein levels of cyclin B1, cell division cycle (Cdc) 25B, and Cdc25C, leading to accumulation of Tyr-15-phosphorylated (inactive) cyclin-dependent kinase 1. The SFN-induced decline in Cdc25C protein level was blocked in the presence of proteasome inhibitor lactacystin, but lactacystin did not confer protection against cell cycle arrest. Interestingly, SFN treatment also resulted in a rapid and sustained phosphorylation of Cdc25C at Ser-216, leading to its translocation from the nucleus to the cytoplasm because of increased binding with 14-3-3beta. Increased Ser-216 phosphorylation of Cdc25C upon treatment with SFN was the result of activation of checkpoint kinase 2 (Chk2), which was associated with Ser-1981 phosphorylation of ataxia telangiectasia-mutated, generation of reactive oxygen species, and Ser-139 phosphorylation of histone H2A.X, a sensitive marker for the presence of DNA double-strand breaks. Transient transfection of PC-3 cells with Chk2-specific small interfering RNA duplexes significantly attenuated SFN-induced G(2)/M arrest. HCT116 human colon cancer-derived Chk2(-/-) cells were significantly more resistant to G(2)/M arrest by SFN compared with the wild type HCT116 cells. These findings indicate that Chk2-mediated phosphorylation of Cdc25C plays a major role in irreversible G(2)/M arrest by SFN. Activation of Chk2 in response to DNA damage is well documented, but the present study is the first published report to link Chk2 activation to cell cycle arrest by an isothiocyanate.	Univ Pittsburgh, Sch Med, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Singh, SV (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Hillman Canc Ctr, Res Pavil Suite 2-32A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@msx.upmc.edu	Zhang, Lin/A-7389-2009	Zhang, Lin/0000-0003-0018-3903; Herman-Antosiewicz, Anna/0000-0003-0526-2168	NATIONAL CANCER INSTITUTE [R01CA101753] Funding Source: NIH RePORTER; NCI NIH HHS [CA60945, CA101753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barcelo S, 1996, CARCINOGENESIS, V17, P277, DOI 10.1093/carcin/17.2.277; Bonnesen C, 2001, CANCER RES, V61, P6120; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V403, P65, DOI 10.1016/S0027-5107(98)00050-5; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chiao JW, 2002, INT J ONCOL, V20, P631; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Fimognari C, 2002, CARCINOGENESIS, V23, P581, DOI 10.1093/carcin/23.4.581; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gamet-Payrastre L, 2000, CANCER RES, V60, P1426; Gao XQ, 2001, P NATL ACAD SCI USA, V98, P15221, DOI 10.1073/pnas.261572998; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Haristoy X, 2003, ANTIMICROB AGENTS CH, V47, P3982, DOI 10.1128/AAC.47.12.3982-3984.2003; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342; Kohlmeier L, 1997, FASEB J, V11, P2141; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Liu QH, 2000, GENE DEV, V14, P1448; Maheo K, 1997, CANCER RES, V57, P3649; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Morgan DO, 1992, CURR OPIN GENET DEV, V2, P33, DOI 10.1016/S0959-437X(05)80318-1; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shishu, 2003, PLANTA MED, V69, P184, DOI 10.1055/s-2003-37713; Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733; Wu LY, 2001, J HYPERTENS, V19, P1819, DOI 10.1097/00004872-200110000-00016; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Ye LX, 2001, CARCINOGENESIS, V22, P1987, DOI 10.1093/carcin/22.12.1987; Zhang SMM, 2000, CANCER EPIDEM BIOMAR, V9, P477; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147; ZHANG YS, 1994, CANCER RES, V54, pS1976; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	52	308	313	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25813	25822		10.1074/jbc.M313538200	http://dx.doi.org/10.1074/jbc.M313538200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073169	hybrid			2022-12-25	WOS:000221827900112
J	Stauffer, ME; Chazin, WJ				Stauffer, ME; Chazin, WJ			Physical interaction between replication protein A and Rad51 promotes exchange on single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC COMPLEX-FORMATION; NUCLEOTIDE EXCISION-REPAIR; 70 KDA SUBUNIT; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; RPA; DOMAIN; XPA; DYNAMICS	Replication protein A (RPA) is displaced from single-stranded DNA (ssDNA) by Rad51 during the initiation of homologous recombination. Interactions between these proteins have been reported, but the functional significance of the direct RPA-Rad51 interaction has yet to be elucidated. We have identified and characterized the interaction between DNA-binding domain A of RPA (RPA70A) and the N-terminal domain of Rad51 (Rad51N). NMR chemical shift mapping showed that Rad51N binds to the ssDNA-binding site of RPA70A, suggesting a competitive mechanism for the displacement of RPA from ssDNA by Rad51. A structure of the RPA70A-Rad51N complex was generated by experimentally guided modeling and then used to design mutations that disrupt the binding interface. Functional ATP hydrolysis assays were performed for wild-type Rad51 and a mutant defective in binding RPA. Rates of RPA displacement for the mutant were significantly below those of wild-type Rad51, suggesting that a direct RPA-Rad51 interaction is involved in displacing RPA in the initiation stage of genetic recombination.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Phys, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Chazin, WJ (corresponding author), Vanderbilt Univ, Dept Biochem, 5140 MRB III, Nashville, TN 37232 USA.	walter.chazin@vanderbilt.edu			NCI NIH HHS [T32 CA009582, P30 CA68485, T32 CA09582] Funding Source: Medline; NIEHS NIH HHS [P50 ES00267] Funding Source: Medline; NIGMS NIH HHS [F32 GM068352, R01 GM65484, R01 GM065484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM068352, R01GM065484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Arunkumar AI, 2003, J BIOL CHEM, V278, P41077, DOI 10.1074/jbc.M305871200; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bhattacharya S, 2004, J BIOMOL NMR, V28, P195, DOI 10.1023/B:JNMR.0000013818.02364.3a; Bhattacharya S, 2002, PROTEIN SCI, V11, P2316, DOI 10.1110/ps.0209202; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Daughdrill GW, 2003, NUCLEIC ACIDS RES, V31, P4176, DOI 10.1093/nar/gkg451; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Hermanson-Miller IL, 2002, BIOCHEMISTRY-US, V41, P2402, DOI 10.1021/bi0112863; Jackson D, 2002, J MOL BIOL, V321, P133, DOI 10.1016/S0022-2836(02)00541-7; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Kowalczykowski SC, 2000, NAT STRUCT BIOL, V7, P1087, DOI 10.1038/81923; Krejci L, 2001, MOL CELL BIOL, V21, P966, DOI 10.1128/MCB.21.3.966-976.2001; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; Lee JH, 2003, NUCLEIC ACIDS RES, V31, P4747, DOI 10.1093/nar/gkg683; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Patrick SM, 2002, J BIOL CHEM, V277, P16096, DOI 10.1074/jbc.M200816200; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	38	82	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25638	25645		10.1074/jbc.M400029200	http://dx.doi.org/10.1074/jbc.M400029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15056657	hybrid			2022-12-25	WOS:000221827900092
J	Zou, W; Borrelli, S; Gilbert, M; Liu, TM; Pon, RA; Jennings, HJ				Zou, W; Borrelli, S; Gilbert, M; Liu, TM; Pon, RA; Jennings, HJ			Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-GD3 MONOCLONAL-ANTIBODY; IMMUNOLOGICAL ADJUVANT QS-21; METASTATIC MELANOMA; MALIGNANT-MELANOMA; CONJUGATE VACCINE; TUMOR-GROWTH; SIALIC-ACID; PHASE-I; NEISSERIA-MENINGITIDIS; CARBOHYDRATE ANTIGENS	N-Propionyl, N-butyryl (N-Bu), and N-benzoyl mannosamine, as precursors of sialic acid biosynthesis, were incubated with human melanoma SK-MEL-28 cells and resulted in the replacement of N-acetyl groups on the cell surface sialic acid residues, including those associated with GD3. Meanwhile, vaccines containing GD3 and modified GD3 tetrasaccharide-keyhole limpet hemocyanin conjugates were synthesized, and BALB/c mice were immunized with them together with monophosphoryl lipid A adjuvant. The GD3Bu-keyhole limpet hemocyanin conjugate raised the highest IgG titers without any cross-reactivity to unmodified GD3. Expression of GD3Bu epitopes on the surface of SK-MEL-28 cells was confirmed in vitro and in vivo by the binding of a polyclonal antiserum and monoclonal antibody (mAb) 2A, both of which specifically recognize GD3Bu, and by mass spectroscopic analysis of glycolipids extracted from cells. Following expression of GD3Bu on the surface of SK-MEL-28 cells, the cells could be lysed by mAb 2A and GD3Bu antiserum in the presence of complement. Although less effective in the control of existing large size tumors (similar to10 mm inner diameter) on BALB/c nu/nu mice, mAb 2A in combination with ManNBu effectively protected mice from SK-MEL-28 tumor grafting. This approach may provide a method to augment the immunogenicity of sialylated human antigens and to avoid generating an autoimmune response to them at same time.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Jennings, HJ (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	Harry.Jennings@nrc.ca		Gilbert, Michel/0000-0002-0204-4408				Charter NW, 2002, J BIOL CHEM, V277, P9255, DOI 10.1074/jbc.M111619200; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; De Meo C, 2001, J ORG CHEM, V66, P5490; DIPPOLD WG, 1980, P NATL ACAD SCI USA, V79, P317; DOHI T, 1988, CANCER RES, V48, P5680; GIBERT M, 2000, J BIOL CHEM, V275, P3896; Hakomori S, 1996, CANCER RES, V56, P5309; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAKOMORI S, 1983, HDB LIPID RES, V3, P1; HELLING F, 1994, CANCER RES, V54, P197; HELLING F, 1995, CANCER RES, V55, P2783; HONSIK CJ, 1986, P NATL ACAD SCI USA, V83, P7893, DOI 10.1073/pnas.83.20.7893; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; ISHIDA H, 1993, CARBOHYD RES, V246, P75, DOI 10.1016/0008-6215(93)84025-2; Jennings HJ, 1997, INT J INFECT DIS, V1, P158; JUE R, 1978, BIOCHEMISTRY-US, V17, P5399, DOI 10.1021/bi00618a013; Kanazawa J, 2000, CANCER IMMUNOL IMMUN, V49, P253, DOI 10.1007/s002620000101; Kennett R H, 1978, Curr Top Microbiol Immunol, V81, P77; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; Kirkwood JM, 2000, CANCER, V88, P2693, DOI 10.1002/1097-0142(20000615)88:12<2693::AID-CNCR7>3.3.CO;2-V; Kirkwood JM, 2001, J CLIN ONCOL, V19, P2370, DOI 10.1200/JCO.2001.19.9.2370; KITAMURA K, 1995, P NATL ACAD SCI USA, V92, P2805, DOI 10.1073/pnas.92.7.2805; Kondo T, 1996, J CARBOHYD CHEM, V15, P857, DOI 10.1080/07328309608005696; Lee FT, 2001, CANCER RES, V61, P4474; Liu TM, 2000, J BIOL CHEM, V275, P32832, DOI 10.1074/jbc.C000573200; Livingston P, 1997, CANCER IMMUNOL IMMUN, V43, P324, DOI 10.1007/s002620050340; Livingston P, 1998, SEMIN ONCOL, V25, P636; Livingston P, 2001, CLIN CANCER RES, V7, P1837; LIVINGSTON PO, 1995, IMMUNOL REV, V145, P147, DOI 10.1111/j.1600-065X.1995.tb00080.x; Livingston PO, 2000, J CLIN IMMUNOL, V20, P85, DOI 10.1023/A:1006697728855; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Marquina G, 1996, CANCER RES, V56, P5165; MINASIAN LM, 1995, CANCER, V75, P2251, DOI 10.1002/1097-0142(19950501)75:9<2251::AID-CNCR2820750910>3.0.CO;2-F; Nasi ML, 1997, MELANOMA RES, V7, pS155; NUDELMAN E, 1982, J BIOL CHEM, V257, P2752; NUNOMURA S, 1988, TETRAHEDRON LETT, V29, P5681, DOI 10.1016/S0040-4039(00)80845-X; Plested JS, 1999, INFECT IMMUN, V67, P5417, DOI 10.1128/IAI.67.10.5417-5426.1999; Pon RA, 1997, J EXP MED, V185, P1929, DOI 10.1084/jem.185.11.1929; Ragupathi G, 1996, CANCER IMMUNOL IMMUN, V43, P152, DOI 10.1007/s002620050316; Ragupathi G, 1998, GLYCOCONJUGATE J, V15, P217, DOI 10.1023/A:1006936826730; Ragupathi G, 2000, INT J CANCER, V85, P659, DOI 10.1002/(SICI)1097-0215(20000301)85:5&lt;659::AID-IJC11&gt;3.0.CO;2-5; Ravindranath MH, 1998, INT J CANCER, V75, P117, DOI 10.1002/(SICI)1097-0215(19980105)75:1<117::AID-IJC18>3.0.CO;2-D; REN SL, 1992, J BIOL CHEM, V267, P12632; RITTER G, 1990, IMMUNOBIOLOGY, V182, P32, DOI 10.1016/S0171-2985(11)80581-4; RITTER G, 1991, INT J CANCER, V48, P379, DOI 10.1002/ijc.2910480312; Scott AM, 2001, J CLIN ONCOL, V19, P3976, DOI 10.1200/JCO.2001.19.19.3976; Soiffer RJ, 1997, CLIN CANCER RES, V3, P17; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAI T, 1985, INT J CANCER, V35, P607, DOI 10.1002/ijc.2910350507; TAI T, 1988, ARCH BIOCHEM BIOPHYS, V260, P51, DOI 10.1016/0003-9861(88)90423-7; TSUCHIDA T, 1987, J NATL CANCER I, V78, P55, DOI 10.1093/jnci/78.1.55; YAMAKAWA T, 1986, CHEM PHYS LIPIDS, V42, P75, DOI 10.1016/0009-3084(86)90044-7; Zeng GC, 2000, CANCER RES, V60, P6670; Zeng GC, 2000, INT J CANCER, V88, P53, DOI 10.1002/1097-0215(20001001)88:1<53::AID-IJC8>3.0.CO;2-7; Zhang H, 1998, CANCER RES, V58, P2844; Zhang SL, 1997, INT J CANCER, V73, P42, DOI 10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1; Zou W, 1996, J CARBOHYD CHEM, V15, P279, DOI 10.1080/07328309608005653	60	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25390	25399		10.1074/jbc.M402787200	http://dx.doi.org/10.1074/jbc.M402787200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15047693	hybrid			2022-12-25	WOS:000221827900062
J	Aphasizheva, I; Aphasizhev, R; Simpson, L				Aphasizheva, I; Aphasizhev, R; Simpson, L			RNA-editing terminal uridylyl transferase 1 - Identification of functional domains by mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCA-ADDING ENZYME; YEAST POLY(A) POLYMERASE; SMALL NUCLEAR-RNA; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; LIGASE ACTIVITIES; COMPLEX; LEISHMANIA; URIDYLYLTRANSFERASE; MITOCHONDRIA; PROTEINS	The catalytic, RNA-binding and oligomerization domains of the RNA-editing terminal uridylyl transferase 1 (RET1) from Leishmania tarentolae mitochondria were characterized by mutational analysis. Significant N- and C-terminal portions of the protein were found to be dispensable for UTP polymerization in vitro. Changes of conserved amino acids in the active site demonstrated a general similarity of sugar-phosphate moiety recognition of the incoming ribonucleotide triphosphate by RET1 and eukaryotic poly(A) polymerases. Overlapping RNA-binding and oligomerization regions were mapped to the C-terminal region, which is conserved only among trypanosomatid RET1 enzymes. In the absence of an RNA primer, RET1 can use UTP itself to initiate nucleotide transfer and produce poly( U) molecules of several hundred nucleotides. An N-terminal zinc finger motif is essential for enzyme activity; deletion of this motif or chelation of zinc inhibits activity.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Simpson, L (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 6780 MRL, Los Angeles, CA 90095 USA.	simpson@kdna.ucla.edu		Afasizheva, Inna/0000-0003-2695-2950; Afasizhev, Ruslan/0000-0002-4595-6618	NIAID NIH HHS [AI09102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009102, R01AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS NC, 1986, P NATL ACAD SCI USA, V83, P221, DOI 10.1073/pnas.83.2.221; Aphasizhev R, 2003, RNA, V9, P62, DOI 10.1261/rna.2134303; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Aphasizhev R, 2002, CELL, V108, P637, DOI 10.1016/S0092-8674(02)00647-5; APHASIZHEV R, 2003, P NATL ACAD SCI US; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; Bard J, 2000, SCIENCE, V289, P1346, DOI 10.1126/science.289.5483.1346; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Ernst NL, 2003, MOL CELL, V11, P1525, DOI 10.1016/S1097-2765(03)00185-0; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; Martin G, 1999, PROTEIN SCI, V8, P2380; Martin G, 1998, RNA, V4, P226; Martin G, 2000, EMBO J, V19, P4193, DOI 10.1093/emboj/19.16.4193; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; Sillero MAG, 2002, EUR J BIOCHEM, V269, P5323, DOI 10.1046/j.1432-1033.2002.03253.x; Simpson L, 2004, RNA, V10, P159, DOI 10.1261/rna.5170704; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Trippe R, 2003, EUR J BIOCHEM, V270, P971, DOI 10.1046/j.1432-1033.2003.03466.x; Trippe R, 1998, NUCLEIC ACIDS RES, V26, P3119, DOI 10.1093/nar/26.13.3119; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3275, DOI 10.1093/nar/15.8.3275; Worthey EA, 2003, NUCLEIC ACIDS RES, V31, P6392, DOI 10.1093/nar/gkg870; Yue DX, 1996, RNA, V2, P895; ZABEL P, 1981, NUCLEIC ACIDS RES, V9, P2433, DOI 10.1093/nar/9.11.2433	28	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24123	24130		10.1074/jbc.M401234200	http://dx.doi.org/10.1074/jbc.M401234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15060068	hybrid			2022-12-25	WOS:000221702500035
J	Shegogue, D; Trojanowska, M				Shegogue, D; Trojanowska, M			Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEPATIC STELLATE CELLS; CAP-DEPENDENT INITIATION; ISOLATED RAT HEPATOCYTES; HUMAN LUNG FIBROBLASTS; PROTEIN-KINASE B; MESSENGER-RNA; GENE-EXPRESSION; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; TRANSLATION INITIATION	The mammalian target of rapamycin ( mTOR) is a multifunctional protein involved in the regulation of cell growth, proliferation, and differentiation. The goal of this study was to determine the role of mTOR in type I collagen regulation. The pharmacological inhibitor of phosphatidylinositol (PI) 3-kinase, LY294002, significantly inhibited collagen type I protein and mRNA levels. The effects of LY294002 were more pronounced on the collagen alpha1( I) chain, which was inhibited at the transcriptional and mRNA stability levels versus collagen \alpha2( I) chain, which was inhibited through a decrease in mRNA stability. In contrast, addition of the PI 3-kinase inhibitor, wortmannin, did not alter type I collagen steady-state mRNA levels. This observation and further experiments using an inactive LY294002 analogue suggested that collagen mRNA levels are inhibited independent of PI 3-kinase. Additional experiments have established that mTOR positively regulates collagen type I synthesis in human fibroblasts. These conclusions are based on results demonstrating that inhibition of mTOR activity using a specific inhibitor, rapamycin, reduced collagen mRNA levels. Furthermore, decreasing mTOR expression by about 50% by using small interfering RNA resulted in a significant decrease of collagen mRNA (75% COL1A1 decrease and 28% COL1A2 decrease) and protein levels. Thus, mTOR plays an essential role in regulating basal expression of collagen type I gene in dermal fibroblasts. Together, our data suggest that the classical PI 3-kinase pathway, which places mTOR downstream of PI 3-kinase, is not involved in mTOR-dependent regulation of type I collagen synthesis in dermal fibroblasts. Because collagen overproduction is a main feature of fibrosis, identification of mTOR as a critical mediator of its regulation may provide a suitable target for drug or gene therapy.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA	Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Ste 912,POB 250637, Charleston, SC 29425 USA.	trojanme@musc.edu		Trojanowska, Maria/0000-0001-9550-7178	NHLBI NIH HHS [HL07260-25] Funding Source: Medline; NIAMS NIH HHS [AR42334, AR44883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044883, R01AR042334, R56AR044883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banholzer R, 1997, MOL CELL BIOL, V17, P3254, DOI 10.1128/MCB.17.6.3254; BAUM BJ, 1980, J BIOL CHEM, V255, P2843; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chen AP, 1999, J BIOL CHEM, V274, P158, DOI 10.1074/jbc.274.1.158; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; DEWET W, 1987, J BIOL CHEM, V262, P16032; Dumont F J, 1996, Life Sci, V58, P373; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; ECKES B, 1993, FEBS LETT, V318, P129, DOI 10.1016/0014-5793(93)80006-G; Eckes B, 1996, BIOCHEM J, V315, P549, DOI 10.1042/bj3150549; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FERTIN C, 1991, CELL MOL BIOL, V37, P823; Fisher GJ, 2000, J CLIN INVEST, V106, P663, DOI 10.1172/JCI9362; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; HAMALAINEN L, 1985, J BIOL CHEM, V260, P720; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Ichiki Y, 1997, J RHEUMATOL, V24, P90; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ivarsson M, 1998, MATRIX BIOL, V16, P409, DOI 10.1016/S0945-053X(98)90014-2; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Jimenez SA, 2001, J CLIN INVEST, V108, P1395, DOI 10.1172/JCI200112347; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Krupsky M, 1997, J BIOL CHEM, V272, P13864, DOI 10.1074/jbc.272.21.13864; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Levy MT, 2000, J HEPATOL, V32, P218, DOI 10.1016/S0168-8278(00)80066-5; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MYERS JC, 1983, J BIOL CHEM, V258, P128; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; ONEILL L, 1991, CARDIOSCIENCE, V2, P1; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Pedersen S, 1997, EUR J BIOCHEM, V247, P449, DOI 10.1111/j.1432-1033.1997.00449.x; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Poon M, 2002, LANCET, V359, P619, DOI 10.1016/S0140-6736(02)07751-6; Ricupero DA, 2001, AM J PHYSIOL-CELL PH, V281, pC99, DOI 10.1152/ajpcell.2001.281.1.C99; Rishikof DC, 1998, BIOCHEM J, V331, P417, DOI 10.1042/bj3310417; Rolfe FG, 1997, J IMMUNOL METHODS, V202, P143, DOI 10.1016/S0022-1759(96)00245-1; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Salh B, 1998, J IMMUNOL, V161, P6947; Salles FJ, 1999, METH MOL B, V118, P441; Sato M, 2002, J INVEST DERMATOL, V118, P704, DOI 10.1046/j.1523-1747.2002.01719.x; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Sousa JE, 2001, CIRCULATION, V104, P2007, DOI 10.1161/hc4201.098056; STEELE JG, 1992, J BIOMED MATER RES, V26, P861, DOI 10.1002/jbm.820260704; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YAMAKAGE A, 1992, J EXP MED, V175, P1227, DOI 10.1084/jem.175.5.1227; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Zhu JL, 1999, GASTROENTEROLOGY, V117, P1198, DOI 10.1016/S0016-5085(99)70406-3	75	99	105	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23166	23175		10.1074/jbc.M401238200	http://dx.doi.org/10.1074/jbc.M401238200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047702	hybrid			2022-12-25	WOS:000221570900047
J	Hensen, EF; Jordanova, ES; van Minderhout, IJHM; Hogendoorn, PCW; Taschner, PEM; van der Mey, AGL; Devilee, P; Cornelisse, CJ				Hensen, EF; Jordanova, ES; van Minderhout, IJHM; Hogendoorn, PCW; Taschner, PEM; van der Mey, AGL; Devilee, P; Cornelisse, CJ			Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families	ONCOGENE			English	Article						paraganglioma; phaeochromocytoma; imprinting; SDHD; inheritance; monosomy 11	COMPARATIVE GENOMIC HYBRIDIZATION; BECKWITH-WIEDEMANN SYNDROME; NONCHROMAFFIN PARAGANGLIOMAS; HEREDITARY PARAGANGLIOMA; NECK PARAGANGLIOMAS; GLOMUS TUMORS; GENE; DNA; HEAD; HETEROZYGOSITY	Germline mutations in succinate dehydrogenase subunits B, C and D (SDHB, SDHC and SDHD), genes encoding subunits of mitochondrial complex II, cause hereditary paragangliomas and phaeochromocytomas. In SDHB (1p36)- and SDHC (1q21)-linked families, disease inheritance is autosomal dominant. In SDHD (11q23)linked families, the disease phenotype is expressed only upon paternal transmission of the mutation, consistent with maternal imprinting. However, SDHD shows biallelic expression in brain, kidney and lymphoid tissues (Baysal et al., 2000). Moreover, consistent loss of the wild-type (wt) maternal allele in SDHD-linked tumours suggests expression of the maternal SDHD allele in normal paraganglia. Here we demonstrate exclusive loss of the entire maternal chromosome 11 in SDHD-linked paragangliomas and phaeochromocytomas, suggesting that combined loss of the wt SDHD allele and maternal 11p region is essential for tumorigenesis. We hypothesize that this is driven by selective loss of one or more imprinted genes in the 11p15 region. In paternally, but not in maternally derived SDHD mutation carriers, this can be achieved by a single event, that is, non-disjunctional loss of the maternal chromosome 11. Thus, the exclusive paternal transmission of the disease can be explained by a somatic genetic mechanism targeting both the SDHD gene on 11q23 and a paternally imprinted gene on 11p15.5, rather than imprinting of SDHD.	Leiden Univ, Med Ctr, Dept Pathol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Otolaryngol & Head & Neck Surg, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Cornelisse, CJ (corresponding author), Leiden Univ, Med Ctr, Dept Pathol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	c.j.cornelisse@lumc.nl	Hogendoorn, Pancras/O-6494-2019; Taschner, Peter/J-8853-2014; Hogendoorn, Pancras C.W./H-5859-2015; DEVILEE, PETER/ABR-2140-2022	Hogendoorn, Pancras/0000-0002-1513-8104; Taschner, Peter/0000-0001-9621-465X; Hogendoorn, Pancras C.W./0000-0002-1513-8104; Jordanova, Ekaterina/0000-0003-3890-7102; Jordanova, Ekaterina S./0000-0002-8121-1322				ABELN ECA, 1994, BRIT J CANCER, V70, P255, DOI 10.1038/bjc.1994.289; Astrom K, 2003, HUM GENET, V113, P228, DOI 10.1007/s00439-003-0969-6; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1997, AM J HUM GENET, V60, P121; BEERMAN H, 1990, INT J CANCER, V45, P34, DOI 10.1002/ijc.2910450108; Biggs PJ, 2003, ONCOGENE, V22, P3288, DOI 10.1038/sj.onc.1206384; Burns JL, 2001, DEVELOPMENT, V128, P3819; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; Dannenberg H, 2001, AM J PATHOL, V158, P1937, DOI 10.1016/S0002-9440(10)64662-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dekker PBD, 2003, HUM PATHOL, V34, P690, DOI 10.1016/S0046-8177(03)00237-5; Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7; DEVILEE P, 1994, GENE CHROMOSOME CANC, V11, P71, DOI 10.1002/gcc.2870110202; Edstrom E, 2000, AM J PATHOL, V156, P651, DOI 10.1016/S0002-9440(10)64769-4; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Fournet JC, 2001, AM J PATHOL, V158, P2177, DOI 10.1016/S0002-9440(10)64689-5; Gicquel C, 1997, J CLIN ENDOCR METAB, V82, P2559, DOI 10.1210/jc.82.8.2559; Haralambieva E, 2002, J PATHOL, V198, P163, DOI 10.1002/path.1197; Jordanova ES, 2002, GENE CHROMOSOME CANC, V35, P38, DOI 10.1002/gcc.10093; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Lui WO, 2002, ONCOGENE, V21, P1117, DOI 10.1038/sj.onc.1205149; MARIMAN ECM, 1993, HUM GENET, V91, P357, DOI 10.1007/BF00217356; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; van Schothorst EM, 1998, AM J HUM GENET, V63, P468, DOI 10.1086/301951; van Schothorst EM, 1998, HUM PATHOL, V29, P1045, DOI 10.1016/S0046-8177(98)90411-7; VANDERMEY AGL, 1991, BRIT J CANCER, V63, P298, DOI 10.1038/bjc.1991.69; VANDERMEY AGL, 1989, LANCET, V2, P1291; WAYE JS, 1987, CHROMOSOMA, V95, P182, DOI 10.1007/BF00330349; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; Weksberg R, 1996, MED PEDIATR ONCOL, V27, P462, DOI 10.1002/(SICI)1096-911X(199611)27:5<462::AID-MPO13>3.0.CO;2-C	36	106	113	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4076	4083		10.1038/sj.onc.1207591	http://dx.doi.org/10.1038/sj.onc.1207591			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064708				2022-12-25	WOS:000221520200005
J	Schwindling, SL; Noll, A; Montenarh, M; Gotz, C				Schwindling, SL; Noll, A; Montenarh, M; Gotz, C			Mutation of a CK2 phosphorylation site in cdc25C impairs importin alpha/beta binding and results in cytoplasmic retention	ONCOGENE			English	Article						protein kinase CK2; phosphorylation; importin alpha/beta; nuclear import; cdc25C	CASEIN KINASE-II; NUCLEAR-LOCALIZATION SEQUENCE; CYCLIN-DEPENDENT KINASES; PORE-TARGETING COMPLEX; 14-3-3 PROTEIN-BINDING; POLO-LIKE KINASE; CELL-CYCLE; T-ANTIGEN; BETA-SUBUNIT; MITOTIC PHOSPHORYLATION	cdc25C is a phosphatase, which activates the mitosis-promoting factor cyclin B1/cdc2 by dephosphorylation, and thus triggers G(2)/M transition. The activity of cdc25C itself is controlled by phosphorylation of certain amino-acid residues, which among other things determines the subcellular localization of the enzyme. Here, we describe a new phosphorylation site at threonine 236 of cdc25C, which is phosphorylated by protein kinase CK2. This phosphorylation site is located near the nuclear localization signal ( amino acids 239 - 245). We demonstrate that cdc25C interacts with importin beta and the importin alpha/beta heterodimer but not with importin a. We further found that a cdc25C phosphorylation mutant where threonine 236 was replaced by aspartic acid as well as cdc25C phosphorylated by CK2 binds importin b or the importin alpha/beta heterodimer less efficiently than wild type or the corresponding alanine mutant. Furthermore, the cdc25C(T236D) shows a retarded uptake into the nucleus in a cell import assay. Inhibition of protein kinase CK2 enzyme activity in vivo resulted in an enhanced nuclear localization of cdc25C. Thus, phosphorylation of cdc25C at threonine 236 is an important signal for the retention of cdc25C in the cytoplasm.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Gotz, C (corresponding author), Univ Saarland, Gebaude 44, D-66421 Homburg, Germany.	bccgoe@uniklinik-saarland.de	Montenarh, Mathias/AAB-6689-2020					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; Bureik M, 1997, BIOL CHEM, V378, P1361, DOI 10.1515/bchm.1997.378.11.1361; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Dotan I, 2001, BIOCHEM BIOPH RES CO, V288, P603, DOI 10.1006/bbrc.2001.5804; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Faust M, 2002, CELL MOL LIFE SCI, V59, P2155, DOI 10.1007/s000180200022; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510; Forwood JK, 1999, BIOCHEM BIOPH RES CO, V257, P731, DOI 10.1006/bbrc.1999.0370; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, J CELL SCI, P75; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kasahara H, 1999, MOL CELL BIOL, V19, P526; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Li Y, 2002, BIOCHEM BIOPH RES CO, V298, P439, DOI 10.1016/S0006-291X(02)02470-1; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LITCHFIELD DW, 1995, BBA-MOL CELL RES, V1269, P69, DOI 10.1016/0167-4889(95)00100-7; LORENZ A, 1992, INT J ONCOL, V1, P571; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; Miller ME, 2001, J CELL SCI, V114, P1811; Montenarh M, 2003, ADV CLIN EXP MED, V12, P15; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PIWNICAWORMS H, 1991, COLD SH Q B, V56, P567; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Schneider E, 2002, ONCOGENE, V21, P5031, DOI 10.1038/sj.onc.1205690; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	71	23	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4155	4165		10.1038/sj.onc.1207566	http://dx.doi.org/10.1038/sj.onc.1207566			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064744				2022-12-25	WOS:000221520200014
J	Hoon, DSB; Spugnardi, M; Kuo, C; Huang, SK; Morton, DL; Taback, B				Hoon, DSB; Spugnardi, M; Kuo, C; Huang, SK; Morton, DL; Taback, B			Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients	ONCOGENE			English	Article						MGMT; RAR-beta 2; RASSF1A; methylation; melanoma	ABERRANT PROMOTER METHYLATION; CPG ISLAND HYPERMETHYLATION; POLYMERASE-CHAIN-REACTION; DNA METHYLATION; PROGNOSTIC-SIGNIFICANCE; MULTIPLE GENES; CANCER; RASSF1A; EXPRESSION; MARKERS	Aberrant methylation of CpG islands in promoter regions of tumor suppressor genes (TSG) has been demonstrated in epithelial origin tumors. However, the methylation pro. ling of tumor-related gene promoter regions in cutaneous melanoma tumors has not been reported. Seven known or candidate TSGs that are frequently hypermethylated in carcinomas were assessed by methylation-specific polymerase chain reaction (MSP) in 15 melanoma cell lines and 130 cutaneous melanoma tumors. Four TSGs were frequently hypermethylated in 86 metastatic tumor specimens: retinoic acid receptor-beta2 (RAR-beta2) (70%), RAS association domain family protein 1A (RASSF1A) (57%), and O-6-methylguanine DNA methylatransferase (MGMT) (34%), and death-associated protein kinase (DAPK) (19%). Hypermethylation of MGMT, RASSF1A, and DAPK was significantly lower in primary melanomas (n = 20) compared to metastatic melanomas. However, hypermethylation of RAR-beta2 was 70% in both primary and metastatic melanomas. Cell lines had hypermethylation profiles similar to those of metastatic melanomas. The analysis of these four markers of metastatic tumors demonstrated that 97% had greater than or equal to1 gene(s) and 59% had greater than or equal to2 genes hypermethylated. The methylation of genes was verified by bisulfite sequencing. The mRNA transcripts could be re-expressed in melanoma cell lines having hypermethylated genes following treatment with 5'-aza 2'-deoxycytidine (5Aza-dC). Analysis of melanoma patients' plasma (preoperative blood; n = 31) demonstrated circulating hypermethylated MGMT, RAR-beta2, and RASSF1A DNA for at least one of the markers in 29% of the patients. Our findings indicate that the incidence of TSG hypermethylation increases during tumor progression. Methylation of TSG may play a significant role in cutaneous melanoma progression.	St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; St Johns Hlth Ctr, John Wayne Canc Inst, Div Surg Oncol, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683	NATIONAL CANCER INSTITUTE [R21CA100314, P01CA029605] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA 13917, R21 CA100314, P0 CA 29605, P01 CA029605, P01 CA029605-270006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bostick PJ, 1999, J CLIN ONCOL, V17, P3238, DOI 10.1200/JCO.1999.17.10.3238; Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0; Christmann M, 2001, INT J CANCER, V92, P123, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.3.CO;2-M; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600; Eads CA, 1999, CANCER RES, V59, P2302; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2001, CANCER RES, V61, P3225; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fujiwara Y, 1999, CANCER RES, V59, P1567; Goessl C, 2000, CANCER RES, V60, P5941; Harden SV, 2003, CLIN CANCER RES, V9, P1370; Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747; Johnson PJ, 2002, CLIN CHEM, V48, P1186; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Lo KW, 2001, CANCER RES, V61, P3877; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maruyama R, 2001, CANCER RES, V61, P8659; Paz MF, 2003, CANCER RES, V63, P1114; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rosas SLB, 2001, CANCER RES, V61, P939; Shi HD, 2003, CANCER RES, V63, P2164; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Sirchia SM, 2002, CANCER RES, V62, P2455; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Spugnardi M, 2003, CANCER RES, V63, P1639; Taback B, 2001, CANCER RES, V61, P5723; Takeuchi H, 2003, CANCER RES, V63, P441; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Ueki T, 2000, CANCER RES, V60, P1835; Usadel H, 2002, CANCER RES, V62, P371; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	40	181	201	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4014	4022		10.1038/sj.onc.1207505	http://dx.doi.org/10.1038/sj.onc.1207505			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15064737	Green Accepted			2022-12-25	WOS:000221382000014
J	Vega, MI; Huerta-Yepaz, S; Garban, H; Jazirehi, A; Emmanouilides, C; Bonavida, B				Vega, MI; Huerta-Yepaz, S; Garban, H; Jazirehi, A; Emmanouilides, C; Bonavida, B			Rituximab inhibits p38 MAPK activity in 2F7 BNHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance	ONCOGENE			English	Article						Rituximab; non-Hodgkin's lymphoma; p38 MAPK; NF-kappa B; chemosensitization	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; NON-HODGKINS-LYMPHOMA; HUMAN INTERLEUKIN-10 PROMOTER; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; CELL-LINE; TNF-ALPHA; IN-VIVO; INDUCTION	We have recently reported that Rituximab (anti-CD20) sensitizes drug-resistant 2F7 and 10C9 B Non-Hodgkin's lymphoma (NHL) cell lines to the apoptotic effects of various chemotherapeutic drugs by downregulation of IL-10 and Bcl-2 expression. The mechanism by which Rituximab induces downregulation of IL-10 was examined. We hypothesized that Rituximab may inhibit p38 MAPK activity that regulates IL-10 expression via Sp1. Treatment of 2F7 cells with Rituximab or the p38 inhibitor SB203580 inhibited the constitutive p38 MAPK activity and resulted in the inhibition of Sp1, IL-10, STAT3, and Bcl-2. Inhibition of the Src-family PTKs, Lyn, and Src-family PTKs upstream signaling molecules of the p38MAPK pathway, by PP2, a specific Src-family kinase inhibitor, resulted in the inhibition of p38MAPK and IL-10 expression. In addition to p38 MAPK, Rituximab also inhibited NF-kappaB activity. Inhibition of the Src PTKs, MAPK, and NF-kappaB activities by Rituximab or by specific chemical inhibitors sensitized the cells to CDDP-mediated apoptosis. The above signaling-mediated effects by Rituximab were observed with similar kinetics beginning at 1 h following treatment. Thus, altogether, these results demonstrate that signaling by Rituximab results in the inhibition of the p38MAPK pathway, which in turn inhibits the transcription of IL-10 via Sp1. Inhibition of the IL-10 autocrine/paracrine loop results in the inhibition of STAT3 activity and, consequently, inhibition of Bcl-2 expression and sensitization to drugs-apoptosis. Further, Rituximab-mediated signaling identifies several new intracellular targets in NHL that may be of potential therapeutic interest for the development of new drugs in the treatment of drug-refractory NHL tumor cells.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Bonavida, B (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Vega, Mario I/0000-0002-3932-2483; Garban, Hermes/0000-0001-7754-5357	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alas S, 2001, CLIN CANCER RES, V7, P709; ALAS S, 2001, CAN RES, V6, P1; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Coiffier B, 2003, BLOOD REV, V17, P25, DOI 10.1016/S0268-960X(02)00059-0; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eskdale J, 1997, IMMUNOGENETICS, V46, P120, DOI 10.1007/s002510050250; Foey AD, 1998, J IMMUNOL, V160, P920; Foran JM, 2002, BEST PRACT RES CL HA, V15, P449, DOI 10.1053/beha.2002.0222; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Gan XH, 1999, CELL IMMUNOL, V193, P125, DOI 10.1006/cimm.1999.1457; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hu XT, 2001, CANCER RES, V61, P6290; Huhn D, 2001, BLOOD, V98, P1326, DOI 10.1182/blood.V98.5.1326; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; KUBE D, 1995, CYTOKINE, V7, P1, DOI 10.1006/cyto.1995.1001; LEVINE AM, 1992, BLOOD, V80, P8; LIDA M, 1999, LEUKEMIA, V13, P585; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Miki H, 1999, ANTICANCER RES, V19, P5283; Mori N, 1997, EUR J HAEMATOL, V59, P162; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Polyak MJ, 1998, J IMMUNOL, V161, P3242; REFF ME, 1994, BLOOD, V83, P435; Riley LK, 2000, SEMIN ONCOL, V27, P17, DOI 10.1053/sonc.2000.20424; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Semac I, 2003, CANCER RES, V63, P534; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; Thieblemont C, 2002, INT J HEMATOL, V76, P394, DOI 10.1007/BF02982804; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vockerodt M, 2001, VIROLOGY, V280, P183, DOI 10.1006/viro.2000.0768; Voorzanger N, 1996, CANCER RES, V56, P5499; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200	47	112	122	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3530	3540		10.1038/sj.onc.1207336	http://dx.doi.org/10.1038/sj.onc.1207336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077178				2022-12-25	WOS:000221101700004
J	Giannini, G; Rinaldi, C; Ristori, E; Ambrosini, MI; Cerignoli, F; Viel, A; Bidoli, E; Berni, S; D'Amati, G; Scambia, G; Frati, L; Screpanti, I; Gulino, A				Giannini, G; Rinaldi, C; Ristori, E; Ambrosini, MI; Cerignoli, F; Viel, A; Bidoli, E; Berni, S; D'Amati, G; Scambia, G; Frati, L; Screpanti, I; Gulino, A			Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability	ONCOGENE			English	Article						MRE11; MMR defect; colorectal cancer; NBS1; DNA double strand breaks repair	STRAND BREAK REPAIR; DEFICIENT COLORECTAL CANCERS; MISMATCH REPAIR; TARGET GENES; DNA-REPAIR; MONONUCLEOTIDE REPEATS; FRAMESHIFT MUTATIONS; COLON-CANCER; PROTEIN; INACTIVATION	Frequent mutations of coding nucleotide repeats are thought to contribute significantly to carcinogenesis associated with microsatellite instability (MSI). We have shown that shortening of the poly(T) 11 within the polypyrimidine stretch/accessory splicing signal of human MRE11 leads to the reduced expression and functional impairment of the MRE11/NBS1/RAD50 complex. This mutation was selectively found in mismatch repair (MMR) defective cell lines and potentially identifies MRE11 as a novel target for MSI. Here, we examined 70 microsatellite unstable primary human cancers and we report that MRE11 mutations occur in 83.7 and 50% of the colorectal and endometrial cancers, respectively. In the colorectal cancer series, mutated MRE11 is more frequently associated with advanced age at diagnosis and A/B stages. Biallelic mutations were present in 38.8% of the cases and more frequently associated with lower (G1/G2) grade tumors. Impaired MRE11 expression was prevalent in primary colorectal tumors with larger and biallelic shortening of the poly(T)11. Immunohistochemistry confirmed the impaired MRE11 expression and revealed NBS1-defective expression in MRE11 mutated cancers. Together with the observation that perturbation of the MRE11/NBS1/RAD50 complex predisposes to cancer, our work highlights MRE11 as a new common target in the MMR deficient tumorigenesis and suggests its role in colorectal carcinogenesis.	Univ Roma La Sapienza, Policlin Umberto I, Dept Expt Med & Pathol, I-00161 Rome, Italy; Neuromed Inst, Pozzilli, Italy; Univ Aquila, Dept Expt Med, Laquila L7100, Italy; Ctr Riferimento Oncol, IRCCS, Div Expt Oncol 1, I-33081 Aviano, Italy; Ctr Riferimento Oncol, IRCCS, Dept Preclin & Epidemiol Res, I-33081 Aviano, Italy; Univ Sacred Heart, Dept Gynecol, I-00168 Rome, Italy; Cenci Bolognetti Fdn, Inst Pasteur, I-00161 Rome, Italy	Sapienza University Rome; University Hospital Sapienza Rome; IRCCS Neuromed; University of L'Aquila; IRCCS Aviano (CRO); IRCCS Aviano (CRO); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Fondazione Cenci Bolognetti	Giannini, G (corresponding author), Univ Roma La Sapienza, Policlin Umberto I, Dept Expt Med & Pathol, Viale Regina Elena 324, I-00161 Rome, Italy.	giuseppe.giannini@uniroma1.it	Bidoli, Ettore/AAC-1762-2020; Viel, Alessandra/J-7116-2018; Frati, Luigi/ABI-7437-2020; Giannini, Giuseppe/B-5672-2013; d'Amati, Giulia/F-1251-2011	Bidoli, Ettore/0000-0001-8273-9084; Viel, Alessandra/0000-0003-2804-0840; Giannini, Giuseppe/0000-0003-0299-4056; d'Amati, Giulia/0000-0002-6959-691X				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bender CF, 2002, GENE DEV, V16, P2237, DOI 10.1101/gad.1007902; Boland CR, 1998, CANCER RES, V58, P5248; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Casorelli I, 2003, DNA REPAIR, V2, P547, DOI 10.1016/S1568-7864(03)00020-X; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Duval A, 2002, ONCOGENE, V21, P8062, DOI 10.1038/sj.onc.1206013; Duval A, 2002, CANCER RES, V62, P2447; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; Fukuda T, 2001, CANCER RES, V61, P23; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kim NG, 2001, CANCER RES, V61, P36; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matsuoka S, 2001, CANCER RES, V61, P5362; Mori Y, 2002, CANCER RES, V62, P3641; Park J, 2002, CANCER RES, V62, P1284; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; Perucho M, 2003, ONCOGENE, V22, P2223, DOI 10.1038/sj.onc.1206580; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tessitore A, 2003, GENE CHROMOSOME CANC, V36, P198, DOI 10.1002/gcc.10145; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Varon R, 2001, CANCER RES, V61, P3570; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Zhang L, 2001, CANCER RES, V61, P3801	36	93	97	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2004	23	15					2640	2647		10.1038/sj.onc.1207409	http://dx.doi.org/10.1038/sj.onc.1207409			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048091	Green Published			2022-12-25	WOS:000220714900005
J	Simard, AR; Rivest, S				Simard, AR; Rivest, S			Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia	FASEB JOURNAL			English	Article						chimeric mice; GFP mice; gliogenesis; inflammation; innate immunity; antigen-presenting cells; macrophages; CD11c	INNATE IMMUNE-RESPONSE; ADULT-MOUSE BRAIN; MICE; ENCEPHALOMYELITIS; PLAY	Pluripotent stem cells can differentiate into a variety of cell types during tissue development and regeneration. However, it is still unclear whether bone marrow-derived stem cells can migrate across the blood-brain barrier in many regions of the central nervous system (CNS) and if these cells can readily differentiate into functional parenchymal microglia. We thus studied the differentiation fate of bone marrow stem cells upon immigration into the CNS. To this end, we systemically transplanted stem cells that express green fluorescent protein (GFP) into lethally irradiated mice and found that these cells immigrated into the brain parenchyma of many regions of the CNS. Nearly all of the infiltrating cells had a highly ramified morphology and colocalized with the microglial marker iba1. Moreover, these cells expressed high levels of the protein CD11c, indicating that microglia of bone marrow origin may be potent antigen presenting cells. These data suggest that microglia of blood origin could activate cells of the adaptive immune system and cause harm to the CNS. Therefore, these results may have great clinical relevance for both immune-derived neuronal disorders and cancer patients undergoing allogeneic hematopoietic stem-cell transplantation.	CHUL Res Ctr, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Anat & Physiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Rivest, S (corresponding author), CHUL Res Ctr, Mol Endocrinol Lab, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	Serge.Rivest@crchul.ulaval.ca	Simard, Alain/E-1493-2013	Simard, Alain/0000-0002-3499-6235; Rivest, Serge/0000-0002-6082-770X				Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Nadeau S, 2003, J NEUROSCI, V23, P5536, DOI 10.1523/jneurosci.23-13-05536.2003; Soulet D, 2003, J CELL BIOL, V162, P257, DOI 10.1083/jcb.200301097; Tran EH, 1998, J IMMUNOL, V161, P3767; Vallieres L, 2003, J NEUROSCI, V23, P5197; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442	14	279	293	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					998	+		10.1096/fj.04-1517fje	http://dx.doi.org/10.1096/fj.04-1517fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084516				2022-12-25	WOS:000221108800005
J	Watanabe, N; Araki, W; Chui, DH; Makifuchi, T; Ihara, Y; Tabira, T				Watanabe, N; Araki, W; Chui, DH; Makifuchi, T; Ihara, Y; Tabira, T			Glypican-1 as an A beta binding HSPG in the human brain: Its localization in DIG domains and possible roles in the pathogenesis of Alzheimer's disease	FASEB JOURNAL			English	Article						beta-amyloid protein; SH-SY5Y cells; heparan sulfate proteoglycans	HEPARAN-SULFATE PROTEOGLYCAN; GPI-ANCHORED PROTEINS; INSOLUBLE MEMBRANE COMPARTMENT; AMYLOID-BETA; CELL-SURFACE; A-BETA-42 ACCUMULATION; SENILE PLAQUES; LIPID RAFTS; PEPTIDE; INHIBITION	Previous studies have suggested that heparan sulfate proteoglycans (HSPGs) play a role in deposition of beta-amyloid protein (Abeta) in the Alzheimer's disease (AD) brain. In the present study, we demonstrated that glypican-1 can bind fibrillar Abeta, and the binding is mainly mediated by heparan sulfate (HS) chains. Further analysis revealed that glypican-1 is the major HSPG localized in detergent-insoluble glycosphingolipid-enriched (DIG) domains where all machineries for Abeta production exist and Abeta is accumulated as monomeric and oligomeric forms. Immunohistochemical studies demonstrated that glypican-1 is localized in primitive plaques as well as classic plaques. Moreover, overexpression of glypican-1 and amyloid precursor protein in SH-SY5Y cells resulted in reduced cell viability and made cells more susceptible to thapsigargin-induced stress and Abeta toxicity. The results raise the possibility that glypican-1 interacts with oligomerized or polymerized Abeta in such a specific compartment as DIG, resulting not only in amyloid deposition in senile plaques of AD brain, but also in accelerating neuronal cell death in response to stress and Abeta.	Natl Inst Longev Sci, Aichi 4748522, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; Natl Saigata Hosp, Dept Clin Res, Niigata 9493193, Japan; Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan	National Center for Neurology & Psychiatry - Japan; RIKEN; University of Tokyo	Watanabe, N (corresponding author), Natl Inst Longev Sci, 36-3 Gengo, Aichi 4748522, Japan.	watanabn@nils.go.jp	Araki, Wataru/G-7913-2014	Araki, Wataru/0000-0001-8467-6937				ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Bame KJ, 1997, J BIOL CHEM, V272, P17005, DOI 10.1074/jbc.272.27.17005; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1993, BRAIN RES, V627, P199, DOI 10.1016/0006-8993(93)90321-D; BUEE L, 1993, BRAIN RES, V601, P154, DOI 10.1016/0006-8993(93)91706-X; Castillo GM, 1997, J NEUROCHEM, V69, P2452; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; Chui DH, 2001, J ALZHEIMERS DIS, V3, P231; Chui DH, 1998, J NEUROSCI RES, V53, P99; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Donahue JE, 1999, P NATL ACAD SCI USA, V96, P6468, DOI 10.1073/pnas.96.11.6468; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FILMUS J, 2000, PROTEOGLYCANS, P161; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Ginsberg SD, 1999, J NEUROPATH EXP NEUR, V58, P815, DOI 10.1097/00005072-199908000-00004; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GONZALEZ AD, 1998, J CELL BIOL, V141, P1407; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guo Q, 1997, J NEUROSCI, V17, P4212; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; KOIKE F, 1988, J NEUROL SCI, V85, P9, DOI 10.1016/0022-510X(88)90031-7; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LITWACK ED, 1994, J NEUROSCI, V14, P3713; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; OGURI K, 1995, GLYCOCONJUGATE J, V12, P520; Oshima N, 2001, AM J PATHOL, V158, P2209, DOI 10.1016/S0002-9440(10)64693-7; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SNOW AD, 1994, AM J PATHOL, V144, P337; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Tabira T, 2002, FRONT BIOSCI-LANDMRK, V7, pA44, DOI 10.2741/tabira; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; van Horssen J, 2001, ACTA NEUROPATHOL, V102, P604; VANGOOL D, 1993, DEMENTIA, V4, P308, DOI 10.1159/000107338; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Verbeek MM, 1999, AM J PATHOL, V155, P2115, DOI 10.1016/S0002-9440(10)65529-0; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yanagisawa K, 1998, NEUROBIOL AGING, V19, pS65, DOI 10.1016/S0197-4580(98)00032-3; YANAGISAWA LP, 1998, FEBS LETT, V19, pS65; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	59	52	58	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1013	+		10.1096/fj.03-1040fje	http://dx.doi.org/10.1096/fj.03-1040fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084524				2022-12-25	WOS:000221108800013
J	Markey, M; Siddiqui, H; Knudsen, ES				Markey, M; Siddiqui, H; Knudsen, ES			Geminin is targeted for repression by the retinoblastoma tumor suppressor pathway through intragenic E2F sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; PROTEIN; INHIBITION; GENE; PHOSPHORYLATION; EXPRESSION; ACTIVATION; MITOSIS; XENOPUS; ARREST	The geminin protein is a critical regulator of DNA replication. It functions to control replication fidelity by blocking the assembly of prereplication complexes in the S and G(2) phases of the cell cycle. Geminin protein levels, which are low in G(0)/G(1) and increase at the G(1)/S transition, are controlled through coordinate transcriptional and proteolytic regulation. Here we show that geminin is regulated transcriptionally by the retinoblastoma tumor suppressor (RB)/E2F pathway. Initially, we observed that the activation of RB led to the repression of geminin transcription. Conversely, Rb-null mouse embryonic fibroblasts have enhanced the expression of geminin relative to wild type mouse embryonic fibroblasts. Similarly, an acute loss of Rb in mouse adult fibroblasts deregulated geminin RNA and protein levels. To delineate the responsible regulatory motifs, luciferase reporter constructs containing fragments of the geminin promoter were generated. An analysis of the critical regulatory cis-acting elements in the geminin promoter indicated that intragenic E2F sites downstream of the first exon were responsible for RB-mediated repression of geminin. The direct analysis of the endogenous geminin promoter revealed that these intragenic E2F sites are occupied by E2F proteins, and the mutation of these sites eliminates responsiveness to RB. Together, these data link the expression of geminin to the RB/E2F pathway and represent the first promoter analysis of this important regulator of DNA replication.	Univ Cincinnati, Vontz Ctr Mol Studies, Dept Cell Biol, Cincinnati, OH 45267 USA	University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Vontz Ctr Mol Studies, Dept Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu		Markey, Michael/0000-0002-8593-2290				Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Broceno C, 2002, P NATL ACAD SCI USA, V99, P14200, DOI 10.1073/pnas.212519499; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Dimitrova DS, 2002, J CELL SCI, V115, P51; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jegga AG, 2002, GENOME RES, V12, P1408, DOI 10.1101/gr.255002; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Khan SH, 1998, CANCER RES, V58, P396; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kobayashi T, 2002, J CELL SCI, V115, P3159; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Kulartz M, 2003, BIOCHEM BIOPH RES CO, V305, P412, DOI 10.1016/S0006-291X(03)00773-3; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Markey MP, 2002, CANCER RES, V62, P6587; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sun WH, 2002, EMBO J, V21, P1437, DOI 10.1093/emboj/21.6.1437; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	32	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29255	29262		10.1074/jbc.M313482200	http://dx.doi.org/10.1074/jbc.M313482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15084580	hybrid			2022-12-25	WOS:000222445300054
J	Konig, S; Hinard, V; Arnaudeau, S; Holzer, N; Potter, G; Bader, CR; Bernheim, L				Konig, S; Hinard, V; Arnaudeau, S; Holzer, N; Potter, G; Bader, CR; Bernheim, L			Membrane hyperpolarization triggers myogenin and myocyte enhancer factor-2 expression during human myoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; SKELETAL-MUSCLE DIFFERENTIATION; FUSION-COMPETENT MYOBLASTS; CREATINE-KINASE ENHANCER; REGULATORY ELEMENTS; POTASSIUM CHANNELS; KIR2.1 CHANNELS; SATELLITE CELLS; K+ CURRENT; GENE	It is widely thought that myogenin is one of the earliest detectable markers of skeletal muscle differentiation. Here we show that, during human myoblast differentiation, an inward rectifier K+ channel (Kir2.1) and its associated hyperpolarization trigger expression and activity of the myogenic transcription factors, myogenin and myocyte enhancer factor-2 (MEF2). Furthermore, Kir2.1 current precedes and is required for the developmental increase in expression/activity of myogenin and MEF2. Drugs or antisense reducing Kir2.1 current diminished or suppressed fusion as well as expression/ activity of myogenin and MEF2. In contrast, LY294002, an inhibitor of phosphatidylinositol 3-kinase ( a pathway controlling initiation of the myogenic program) that inhibited both myogenin/MEF2 expression and fusion, did not affect Kir2.1 current. This non-blockade by LY294002 indicates that Kir2.1 acts upstream of myogenin and MEF2. We propose that Kir2.1 channel activation is a required key early event that initiates myogenesis by turning on myogenin and MEF2 transcription factors via a hyperpolarization-activated Ca2+-dependent pathway.	Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Hop Cantonal Univ Geneva, Dept Neurosci Clin & Dermatol, Div Rech Clin Neuromusculaire, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Konig, S (corresponding author), Ctr Med Univ Geneva, Dept Physiol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Stephane.Konig@medecine.unige.ch		Koenig, Stephane/0000-0002-0801-279X				ADAMS DJ, 1980, J GEN PHYSIOL, V75, P493, DOI 10.1085/jgp.75.5.493; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BAROFFIO A, 1993, MUSCLE NERVE, V16, P498, DOI 10.1002/mus.880160511; Baroffio A, 1996, DIFFERENTIATION, V60, P47, DOI 10.1046/j.1432-0436.1996.6010047.x; Bijlenga P, 1998, J PHYSIOL-LONDON, V512, P317, DOI 10.1111/j.1469-7793.1998.317be.x; Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; DallAsta V, 1997, EXP CELL RES, V231, P260, DOI 10.1006/excr.1996.3469; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; Espinos E, 2001, NEUROMUSCULAR DISORD, V11, P341, DOI 10.1016/S0960-8966(00)00204-2; Fischer-Lougheed J, 2001, J CELL BIOL, V153, P677, DOI 10.1083/jcb.153.4.677; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Friday BB, 2003, DIFFERENTIATION, V71, P217, DOI 10.1046/j.1432-0436.2003.710303.x; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Hamann M, 1995, J PHYSIOL-LONDON, V489, P791, DOI 10.1113/jphysiol.1995.sp021092; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Liu JH, 1999, BRIT J PHARMACOL, V126, P245, DOI 10.1038/sj.bjp.0702321; Liu JH, 1998, J PHYSIOL-LONDON, V510, P467, DOI 10.1111/j.1469-7793.1998.467bk.x; Liu JH, 2003, DEVELOPMENT, V130, P3437, DOI 10.1242/dev.00562; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Pardo LA, 1998, J CELL BIOL, V143, P767, DOI 10.1083/jcb.143.3.767; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016	34	63	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28187	28196		10.1074/jbc.M313932200	http://dx.doi.org/10.1074/jbc.M313932200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15084602	hybrid			2022-12-25	WOS:000222265400047
J	Lairson, LL; Chiu, CPC; Ly, HD; He, SM; Wakarchuk, WW; Strynadka, NCJ; Withers, SG				Lairson, LL; Chiu, CPC; Ly, HD; He, SM; Wakarchuk, WW; Strynadka, NCJ; Withers, SG			Intermediate trapping on a mutant retaining alpha-galactosyltransferase identifies an unexpected aspartate residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEISSERIA-MENINGITIDIS; CRYSTAL-STRUCTURE; CYCLODEXTRIN GLYCOSYLTRANSFERASE; BIOSYNTHESIS; COMPLEX; ENZYME; ROLES; ALPHA-1,3-GALACTOSYLTRANSFERASE; CLASSIFICATION; GLYCOSYLATION	Lipopolysaccharyl-alpha-1,4-galactosyltransferase C (LgtC), a glycosyltransferase family 8 alpha-1,4-galactosyltransferase from Neisseria meningitidis, catalyzes the transfer of galactose from UDP galactose to terminal lactose-containing acceptor sugars with net retention of anomeric configuration. To investigate the potential role of discrete nucleophilic catalysis suggested by the double displacement mechanism generally proposed for retaining glycosyltransferases, the side chain amide of Gln-189, which is suitably positioned to act as the catalytic nucleophile of LgtC, was substituted with the more nucleophilic carboxylate-containing side chain of glutamate in the hope of accumulating a glycosyl-enzyme intermediate. The resulting mutant was subjected to kinetic, mass spectrometric, and x-ray crystallographic analysis. Although the K-m for UDP-galactose is not significantly altered, the k(cat) was reduced to 3% that of the wild type enzyme. Electrospray mass spectrometric analysis revealed that a steady state population of the Q189E variant contains a covalently bound galactosyl moiety. Liquid chromatographic/mass spectrometric analysis of fragmented proteolytic digests identified the site of labeling not as Glu-189 but, surprisingly, as the sequentially adjacent Asp-190. However, the side chain carboxylate of Asp-190 is located 8.9 Angstrom away from the donor substrate in the available crystal structure. Kinetic analysis of a D190N mutant at this position revealed a k(cat) value 3000-fold lower than that of the wild type enzyme. A 2.6-crystal structure of the Q189E mutant with bound uridine 5'-diphospho-2-deoxy-2-fluoro-alpha-D-galactopyranose revealed no significant perturbation of the mode of donor sugar binding nor of active site configuration. This is the first trapping of an intermediate in the active site of a retaining glycosyltransferase and, although not conclusive, implicates Asp-190 as an alternative candidate catalytic nucleophile, thereby rekindling a longstanding mechanistic debate.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of British Columbia; University of British Columbia; National Research Council Canada	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca	Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Lairson, Luke/0000-0001-6701-996X				Boix E, 2001, J BIOL CHEM, V276, P48608, DOI 10.1074/jbc.M108828200; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Fukuda M, 1996, CANCER RES, V56, P2237; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gibbons BJ, 2002, J MOL BIOL, V319, P463, DOI 10.1016/S0022-2836(02)00305-4; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; GOSSELIN S, 1994, ANAL BIOCHEM, V220, P92, DOI 10.1006/abio.1994.1303; Jack DL, 1998, J IMMUNOL, V160, P1346; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; KOBATA A, 1993, ACCOUNTS CHEM RES, V26, P319, DOI 10.1021/ar00030a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEATHERBARROW RJ, 1990, GRAFIT VERSION 4 0; Ljungh A, 1996, FEMS IMMUNOL MED MIC, V16, P117, DOI 10.1016/S0928-8244(96)00073-9; Ly HD, 2002, BIOCHEMISTRY-US, V41, P6572, DOI 10.1021/bi025160x; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mark BL, 2002, CAN J CHEM, V80, P1064, DOI 10.1139/V02-130; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchell EP, 1996, BIOCHEMISTRY-US, V35, P7341, DOI 10.1021/bi960072w; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Mosi R, 1997, BIOCHEMISTRY-US, V36, P9927, DOI 10.1021/bi970618u; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; Watts AG, 2003, J AM CHEM SOC, V125, P7532, DOI 10.1021/ja0344967; Withers S.G., 1997, COMPREHENSIVE BIOL C, P119; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zhang YN, 2003, BIOCHEMISTRY-US, V42, P13512, DOI 10.1021/bi035430r	38	80	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28339	28344		10.1074/jbc.M400451200	http://dx.doi.org/10.1074/jbc.M400451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15075344	hybrid			2022-12-25	WOS:000222265400066
J	Milutinovic, S; Brown, SE; Zhuang, QL; Szyf, M				Milutinovic, S; Brown, SE; Zhuang, QL; Szyf, M			DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN MECP2; CPG METHYLATION; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; GROWTH-REGULATION; DOWN-REGULATION; HUMAN CANCERS; METHYLTRANSFERASE; PROMOTER; HYPOMETHYLATION	DNA methyltransferase 1 (DNMT1) catalyzes the postreplication methylation of DNA and is responsible for maintaining the DNA methylation pattern during cell division. A long list of data supports a role for DNMT1 in cellular transformation and inhibitors of DNMT1 were shown to have antitumorigenic effects. It was long believed that DNMT1 promoted tumorigenesis by maintaining the hypermethylated and silenced state of tumor suppressor genes. We have previously shown that DNMT1 knock down by either antisense oligonucleotides directed at DNMT1 or expressed antisense activates a number of genes involved in stress response and cell cycle arrest by a DNA methylation-independent mechanism. In this report we demonstrate that antisense knock down of DNMT1 in human lung carcinoma A549 and embryonal kidney HEK293 cells induces gene expression by a mechanism that does not involve either of the known epigenomic mechanisms, DNA methylation, histone acetylation, or histone methylation. The mechanism of activation of the cell cycle inhibitor p21 and apoptosis inducer BIK by DNMT1 inhibition is independent of the mechanism of activation of the same genes by histone deacetylase inhibition. We determine whether DNMT1 knock down activates one of the nodal transcription activation pathways in the cell and demonstrate that DNMT1 activates Sp1 response elements. This activation of Sp1 response does not involve an increase in either Sp1 or Sp3 protein levels in the cell or the occupancy of the Sp1 elements with these proteins. The methylation-independent regulation of Sp1 elements by DNMT1 unravels a novel function for DNMT1 in gene regulation. DNA methylation was believed to be a mechanism for suppression of CG-rich Sp1-bearing promoters. Our data suggest a fundamentally different and surprising role for DNMT1 regulation of CG-rich genes by a mechanism independent of DNA methylation and histone acetylation. The implications of our data on the biological roles of DNMT1 and the therapeutic potential of DNMT1 inhibitors as anticancer agents are discussed.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Chen T, 2002, ARCH BIOCHEM BIOPHYS, V408, P171, DOI 10.1016/S0003-9861(02)00564-7; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Gupta A, 2003, CANCER RES, V63, P664; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HERMAN JG, 1995, CANCER RES, V55, P4525; INAMDAR NM, 1991, PLANT MOL BIOL, V17, P111, DOI 10.1007/BF00036811; JONES PA, 1983, RECENT RES CANCER, V84, P202; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pagliuca A, 2000, J CELL BIOCHEM, V76, P360, DOI 10.1002/(SICI)1097-4644(20000301)76:3<360::AID-JCB3>3.0.CO;2-1; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 2003, AGEING RES REV, V2, P299, DOI 10.1016/S1568-1637(03)00012-6; Szyf M, 2002, METHODS, V27, P184, DOI 10.1016/S1046-2023(02)00073-7; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; Szyf M, 2000, ANN NY ACAD SCI, V910, P156; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wu J C, 1985, Prog Clin Biol Res, V198, P119; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	54	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27915	27927		10.1074/jbc.M312823200	http://dx.doi.org/10.1074/jbc.M312823200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15087453	hybrid			2022-12-25	WOS:000222265400013
J	Schuh, K; Cartwright, EJ; Jankevics, E; Bundschu, K; Liebermann, J; Williams, JC; Armesilla, AL; Emerson, M; Oceandy, D; Knobeloch, KP; Neyses, L				Schuh, K; Cartwright, EJ; Jankevics, E; Bundschu, K; Liebermann, J; Williams, JC; Armesilla, AL; Emerson, M; Oceandy, D; Knobeloch, KP; Neyses, L			Plasma membrane Ca2+ ATPase 4 is required for sperm motility and male fertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; MOUSE SPERM; ACROSOME REACTION; CA2+-ATPASE; CHANNELS; ENTRY; MICE; EXPRESSION; ISOFORMS; MUTATION	Calcium and Ca2+-dependent signals play a crucial role in sperm motility and mammalian fertilization, but the molecules and mechanisms underlying these Ca2+-dependent pathways are incompletely understood. Here we show that homozygous male mice with a targeted gene deletion of isoform 4 of the plasma membrane calcium/ calmodulin-dependent calcium ATPase (PMCA), which is highly enriched in the sperm tail, are infertile due to severely impaired sperm motility. Furthermore, the PMCA inhibitor 5-(and-6)-carboxyeosin diacetate succinimidyl ester reduced sperm motility in wild-type animals, thus mimicking the effects of PMCA4 deficiency on sperm motility and supporting the hypothesis of a pivotal role of the PMCA4 on the regulation of sperm function and intracellular Ca2+ levels.	Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Latvia, Biochem Res & Study Ctr, LV-1067 Riga, Latvia; Univ Wurzburg, Dept Obstet & Gynecol, D-97080 Wurzburg, Germany; FMP, D-12207 Berlin, Germany; Univ Manchester, Div Cardiol, Manchester M13 9PT, Lancs, England	University of Wurzburg; University of Latvia; University of Wurzburg; University of Manchester	Schuh, K (corresponding author), Univ Wurzburg, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	schuh_k@klinik.uni-wuerzburg.de; ludwig.neyses@man.ac.uk	Neyses, Ludwig/AGY-7446-2022; Oceandy, Delvac/G-9911-2015	Oceandy, Delvac/0000-0002-6242-6491; Armesilla, Angel/0000-0003-3546-5580; Cartwright, Elizabeth/0000-0002-6836-7795	Medical Research Council [G0200020] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; BRANDT P, 1992, J BIOL CHEM, V267, P4376; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Choi HS, 1999, J PHYSIOL-LONDON, V515, P109, DOI 10.1111/j.1469-7793.1999.109ad.x; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Feng HL, 2003, ARCH ANDROLOGY, V49, P19, DOI 10.1080/01485010290031556-1; Fukami K, 2003, J CELL BIOL, V161, P79, DOI 10.1083/jcb.200210057; GATTO C, 1995, BIOCHEMISTRY-US, V34, P965, DOI 10.1021/bi00003a031; GATTO C, 1993, AM J PHYSIOL, V264, pC1577, DOI 10.1152/ajpcell.1993.264.6.C1577; Goellner GM, 2003, ANN NY ACAD SCI, V986, P461, DOI 10.1111/j.1749-6632.2003.tb07230.x; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; Matzuk MM, 2002, NAT CELL BIOL, V4, pS41; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Publicover SJ, 1999, HUM REPROD, V14, P873, DOI 10.1093/humrep/14.4.873; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; Schuh K, 2003, J BIOL CHEM, V278, P9778, DOI 10.1074/jbc.M212507200; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Street VA, 1998, NAT GENET, V19, P390, DOI 10.1038/1284; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Takahashi K, 1999, BIOCHEM BIOPH RES CO, V261, P773, DOI 10.1006/bbrc.1999.1102; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wennemuth G, 2003, J GEN PHYSIOL, V122, P115, DOI 10.1085/jgp.200308839; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; Wood CD, 2003, J CELL BIOL, V161, P89, DOI 10.1083/jcb.200212053; Zacharias DA, 1999, BBA-GEN SUBJECTS, V1428, P397, DOI 10.1016/S0304-4165(99)00058-6	38	188	198	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28220	28226		10.1074/jbc.M312599200	http://dx.doi.org/10.1074/jbc.M312599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15078889	hybrid, Green Published			2022-12-25	WOS:000222265400051
J	Tomita, T; Noguchi, K; Mimuro, H; Ukaji, F; Ito, K; Sugawara-Tomita, N; Hashimoto, Y				Tomita, T; Noguchi, K; Mimuro, H; Ukaji, F; Ito, K; Sugawara-Tomita, N; Hashimoto, Y			Pleurotolysin, a novel sphingomyelin-specific two-component cytolysin from the edible mushroom Pleurotus ostreatus, assembles into a transmembrane pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; FLAMMULINA-VELUTIPES; ALPHA-TOXIN; PROTEIN; CHOLESTEROL; MEMBRANES; OLIGOMERIZATION; FLAMMUTOXIN; QUANTITIES; HEMOLYSINS	Self-assembling, pore-forming cytolysins are illustrative molecules for the study of the assembly and membrane insertion of transmembrane pores. Here we purified pleurotolysin, a novel sphingomyelin-specific two-component cytolysin from the basidiocarps of Pleurotus ostreatus and studied the pore-forming properties of the cytolysin. Pleurotolysin consisted of non-associated A (17 kDa) and B (59 kDa) components, which cooperatively caused leakage of potassium ions from human erythrocytes and swelling of the cells at nanomolar concentrations, leading to colloid-osmotic hemolysis. Hemolytic assays in the presence of poly( ethylene glycol) s with different hydrodynamic diameters suggested that pleurotolysin formed membrane pores with a functional diameter of 3.8-5 nm. Pleurotolysin-induced lysis of human erythrocytes was specifically inhibited by the addition of sphingomyelin-cholesterol liposomes to the extracellular space. Pleurotolysin A specifically bound to sphingomyelin-cholesterol liposomes and caused leakage of the internal carboxyfluorescein in concert with pleurotolysin B. Experiments including solubilization of pleurotolysin-treated erythrocytes with 2% (w/v) SDS at 25degreesC and SDS-polyacrylamide gel electrophoresis/Western immunoblotting showed that pleurotolysin A and B bound to human erythrocytes in this sequence and assembled into an SDS-stable, 700-kDa complex. Ring-shaped structures with outer and inner diameters of 14 and 7 nm, respectively, were isolated from the solubilized erythrocyte membranes by a sucrose gradient centrifugation. Pleurotolysin A and B formed an SDS-stable, ring-shaped complex of the same dimensions on sphingomyelin-cholesterol liposomes as well.	Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Aoba Ku, Sendai, Miyagi 9818555, Japan; Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Sakura Ku, Saitama 3888570, Japan	Tohoku University; Saitama University	Tomita, T (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Aoba Ku, Sendai, Miyagi 9818555, Japan.	tomita@biochem.tohoku.ac.jp						Berne S, 2002, BBA-GEN SUBJECTS, V1570, P153, DOI 10.1016/S0304-4165(02)00190-3; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BERNHEIMER AW, 1979, BIOCHIM BIOPHYS ACTA, V585, P451, DOI 10.1016/0304-4165(79)90090-4; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Espinar MTF, 1997, CURR GENET, V32, P420, DOI 10.1007/s002940050297; FAULSTICH H, 1983, BIOCHEMISTRY-US, V22, P4574, DOI 10.1021/bi00288a035; FREEDMAN JC, 1979, J GEN PHYSIOL, V74, P157, DOI 10.1085/jgp.74.2.157; GERLACH E, 1963, BIOCHEM Z, V337, P477; KUSUMI A, 1986, BIOCHIM BIOPHYS ACTA, V854, P307, DOI 10.1016/0005-2736(86)90124-0; LIN JY, 1974, NATURE, V252, P235, DOI 10.1038/252235a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Menestrina G, 2003, FEBS LETT, V552, P54, DOI 10.1016/S0014-5793(03)00850-0; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; OLDFIELD E, 1978, BIOCHEMISTRY-US, V17, P2727, DOI 10.1021/bi00607a006; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; RALSTON E, 1981, BIOCHIM BIOPHYS ACTA, V649, P133, DOI 10.1016/0005-2736(81)90019-5; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; ROUSER G, 1968, BIOLOGICAL MEMBRANES, P5; SABIROV RZ, 1993, GEN PHYSIOL BIOPHYS, V12, P95; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Sepcic K, 2003, EUR J BIOCHEM, V270, P1199, DOI 10.1046/j.1432-1033.2003.03480.x; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Sugawara-Tomita N, 2002, J BACTERIOL, V184, P4747, DOI 10.1128/JB.184.17.4747-4756.2002; Tadjibaeva G, 2000, BBA-BIOMEMBRANES, V1467, P431, DOI 10.1016/S0005-2736(00)00240-6; Tomita T, 1998, BIOCHEM J, V333, P129, DOI 10.1042/bj3330129; Tomita T, 1997, BIOSCI BIOTECH BIOCH, V61, P565, DOI 10.1271/bbb.61.565; TOMITA T, 1992, J BIOL CHEM, V267, P13391; WADSTROM T, 1971, BIOCHIM BIOPHYS ACTA, V242, P308, DOI 10.1016/0005-2744(71)90110-0; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4; WILMSEN HU, 1985, EUR BIOPHYS J BIOPHY, V12, P199; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375	33	92	96	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26975	26982		10.1074/jbc.M402676200	http://dx.doi.org/10.1074/jbc.M402676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084605	hybrid			2022-12-25	WOS:000222120400023
J	Enomoto, Y; Enomoto, K; Kitamura, T; Kanda, T				Enomoto, Y; Enomoto, K; Kitamura, T; Kanda, T			Keratinocyte-specific POU transcription factor hSkn-1a represses the growth of cervical cancer cell lines	ONCOGENE			English	Article						hSkn-1a; cervical cancer; keratinocyte differentiation; POU-transcription factor	DIFFERENTIATION; EXPRESSION; GENE; PROMOTER; ELEGANS; DOMAIN; OCT-1	The POU transcription factor human Skn-1a (hSkn-1a) specifically promotes the proliferation of keratinocytes and enhances their differentiation. We examined the effects of hSkn-1a on cervical cancer cell lines of epithelial origin, in which the differentiation program is interrupted. From HeLa/Tet-On, a clone that can be induced to make hSkn-1a by doxycycline (HeLa/hSkn-1a) was prepared and characterized. Shortly after the induction, the cells expressed cytokeratin 10 (K10), a major marker protein in differentiating keratinocytes. While maintained for several days in the presence of doxycycline, the HeLa/hSkn-1a cells showed a slightly prolonged time of population doubling, the occasional appearance of. at cells with lowered DNA synthesis, and a low level of apoptotic DNA fragmentation. In SiHa and HeLa S3 cultures, K10 mRNA and apoptotic DNA fragmentation were detected at 48 h after infection with an adenoviral vector capable of expressing hSkn-1a. A colony inhibition assay showed that the growth of HeLa S3, SiHa, CaSki, and C-33A cells was repressed, as seen from the decreased number and average size of the drug-resistant colonies at 2 or 3 weeks after transfection with a plasmid that can express hSkn-1a and neomycin resistance gene. These results suggest that the expression of hSkn-1a represses the growth of the cervical cancer cells through the partial resumption of the differentiation pathway followed by slow suppression of cell replication and apoptosis.	Natl Inst Infect Dis, Div Mol Genet, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Fac Med, Dept Urol, Bunkyo Ku, Tokyo 1138655, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo	Kanda, T (corresponding author), Natl Inst Infect Dis, Div Mol Genet, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	kanda@nih.go.jp	Kitamura, Toshio/AAA-2071-2021					Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Enomoto K, 2003, BIOCHEM BIOPH RES CO, V303, P580, DOI 10.1016/S0006-291X(03)00395-4; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fusenig N E, 1995, Recent Results Cancer Res, V139, P1; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; Hietala KA, 1997, J PATHOL, V183, P305; Hildesheim J, 2001, J CELL SCI, V114, P1913; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Kukimoto I, 2001, J VIROL, V75, P9302, DOI 10.1128/JVI.75.19.9302-9311.2001; WATANABE S, 1993, JPN J CANCER RES, V84, P1043, DOI 10.1111/j.1349-7006.1993.tb02799.x; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727	15	11	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5014	5022		10.1038/sj.onc.1207653	http://dx.doi.org/10.1038/sj.onc.1207653			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077167				2022-12-25	WOS:000222237300007
J	Horke, S; Reumann, K; Schweizer, M; Will, H; Heise, T				Horke, S; Reumann, K; Schweizer, M; Will, H; Heise, T			Nuclear trafficking of La protein depends on a newly identified nucleolar localization signal and the ability to bind RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SS-B AUTOANTIGEN; LUPUS ANTIGEN-LA; RECOGNITION MOTIF; SMALL RIBONUCLEOPROTEINS; RIBOSOMAL-RNA; NASCENT RNA; VIRUS-RNA; DOMAINS; TRANSLATION; PRECURSOR	Here we provide evidence for an interaction-dependent subnuclear trafficking of the human La (hLa) protein, known as transient interaction partner of a variety of RNAs. Among these, precursor transcripts of certain RNAs are located in the nucleoplasm or nucleolus. Here we examined which functional domains of hLa are involved in its nuclear trafficking. By using green fluorescent-hLa fusion proteins, we discovered a nucleolar localization signal and demonstrated its functionality in a heterologous context. In addition, we revealed that the RRM2 motif of hLa is essential both for its RNA binding competence in vitro and in vivo and its exit from the nucleolus. Our data imply that hLa traffics between different subnuclear compartments, which depend decisively on a functional nucleolar localization signal as well as on RNA binding. Directed trafficking of hLa is fully consistent with its function in the maturation of precursor RNAs located in different subnuclear compartments.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Krankenhaus Hamburg Eppendorf, Zentrum Mol Neurobiol, Abt Elektronenmikroskopie, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Heise, T (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52,Postfach 201652, D-20251 Hamburg, Germany.	heise@hpi.uni-hamburg.de		Horke, Sven/0000-0003-1309-3923				Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; ALSPAUGH MA, 1976, ARTHRITIS RHEUM-US, V19, P216, DOI 10.1002/art.1780190214; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Annilo T, 1998, BIOCHEM BIOPH RES CO, V249, P759, DOI 10.1006/bbrc.1998.9187; ARNOLD GJ, 1986, GENE, V44, P287, DOI 10.1016/0378-1119(86)90193-9; Ayukawa K, 2000, J BIOL CHEM, V275, P34465, DOI 10.1074/jbc.M003673200; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Broekhuis CHD, 2000, BIOCHEMISTRY-US, V39, P3023, DOI 10.1021/bi992308c; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAN EKL, 1987, MOL CELL BIOL, V7, P2588, DOI 10.1128/MCB.7.7.2588; CHAN EKL, 1989, NUCLEIC ACIDS RES, V17, P2233, DOI 10.1093/nar/17.6.2233; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; DENG JS, 1981, J CELL BIOL, V91, P654, DOI 10.1083/jcb.91.3.654; Dundr M, 2002, MOL CELL, V9, P5, DOI 10.1016/S1097-2765(02)00433-1; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Eilbracht J, 2001, P NATL ACAD SCI USA, V98, P3849, DOI 10.1073/pnas.071042298; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Gerbi SA, 2002, MOL BIOL CELL, V13, P3123, DOI 10.1091/mbc.01-12-0596; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; Heise T, 1999, J VIROL, V73, P474, DOI 10.1128/JVI.73.1.474-481.1999; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Horke S, 2002, J BIOL CHEM, V277, P34949, DOI 10.1074/jbc.M201911200; Houtsmuller AB, 2001, HISTOCHEM CELL BIOL, V115, P13, DOI 10.1007/s004180000234; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Intine RV, 2002, MOL CELL, V9, P1113, DOI 10.1016/S1097-2765(02)00533-6; Intine RVA, 2000, MOL CELL, V6, P339, DOI 10.1016/S1097-2765(00)00034-4; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; Kruhlak MJ, 2000, J CELL BIOL, V150, P41, DOI 10.1083/jcb.150.1.41; Kufel J, 2000, MOL CELL BIOL, V20, P5415, DOI 10.1128/MCB.20.15.5415-5424.2000; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Long KS, 2001, RNA, V7, P1589; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Meissner M, 2000, J CELL BIOCHEM, V76, P559, DOI 10.1002/(SICI)1097-4644(20000315)76:4<559::AID-JCB4>3.0.CO;2-U; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; Pellar GJ, 2003, CHROMOSOMA, V111, P461, DOI 10.1007/s00412-003-0231-y; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Raats JMH, 2003, EUR J CELL BIOL, V82, P131, DOI 10.1078/0171-9335-00304; RINKE J, 1985, NUCLEIC ACIDS RES, V13, P2617, DOI 10.1093/nar/13.7.2617; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rutjes SA, 1999, CELL DEATH DIFFER, V6, P976, DOI 10.1038/sj.cdd.4400571; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; Swedlow JR, 2001, GENOME BIOL, V2; Tan DSW, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-17; TOPFER F, 1993, J IMMUNOL, V150, P3091; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Ueki N, 1998, BIOCHEM BIOPH RES CO, V252, P97, DOI 10.1006/bbrc.1998.9606; Verheggen C, 2002, EMBO J, V21, P2736, DOI 10.1093/emboj/21.11.2736; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; Zirwes RF, 2000, MOL BIOL CELL, V11, P1153, DOI 10.1091/mbc.11.4.1153	79	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26563	26570		10.1074/jbc.M401017200	http://dx.doi.org/10.1074/jbc.M401017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15060081	hybrid			2022-12-25	WOS:000222003000081
J	Ouko, L; Ziegler, TR; Gu, LH; Eisenberg, LM; Yang, VW				Ouko, L; Ziegler, TR; Gu, LH; Eisenberg, LM; Yang, VW			Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CONVERGENT EXTENSION MOVEMENTS; COLORECTAL-CANCER; BETA-CATENIN; WNT/BETA-CATENIN; E-CADHERIN; FRIZZLED HOMOLOGS; MOLECULAR-CLONING; EXPRESSION; MUTATIONS	Wnts are morphogens with well recognized functions during embryogenesis. Aberrant Wnt signaling has been demonstrated to be important in colorectal carcinogenesis. However, the role of Wnt in regulating normal intestinal epithelial cell proliferation is not well established. Here we determine that Wnt11 is expressed throughout the mouse intestinal tract including the epithelial cells. Conditioned media from Wnt11-secreting cells stimulated proliferation and migration of IEC6 intestinal epithelial cells. Co-culture of Wnt11-secreting cells with IEC6 cells resulted in morphological transformation of the latter as evidenced by the formation of foci, a condition also accomplished by stable transfection of IEC6 with a Wnt11-expressing construct. Treatment of IEC6 cells with Wnt11 conditioned media failed to induce nuclear translocation of beta-catenin but led to increased activities of protein kinase C and Ca2+/calmodulin-dependent protein kinase II. Inhibition of protein kinase C resulted in a decreased ability of Wnt11 to induce foci formation in IEC6 cells. Finally, E-cadherin was redistributed in Wnt11-treated IEC6 cells, resulting in diminished E-cadherin-mediated cell-cell contact. We conclude that Wnt11 stimulates proliferation, migration, cytoskeletal rearrangement, and contact-independent growth of IEC6 cells by a beta-catenin-independent mechanism. These findings may help understand the molecular mechanisms that regulate proliferation and migration of intestinal epithelial cells.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Med, Div Endocrinol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA	Emory University; Emory University; Emory University; Medical University of South Carolina	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu			NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055850, R01DK052230, R24DK064399] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker N, 2000, BIOESSAYS, V22, P961; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BJERKNES M, 1981, AM J ANAT, V160, P105, DOI 10.1002/aja.1001600109; Bond J, 2003, DEV DYNAM, V227, P536, DOI 10.1002/dvdy.10333; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Buyse M, 2003, AM J PATHOL, V163, P1969, DOI 10.1016/S0002-9440(10)63555-9; Buyse M, 2002, J BIOL CHEM, V277, P28182, DOI 10.1074/jbc.M203281200; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Christiansen JH, 1996, ONCOGENE, V12, P2705; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dimitriadis A, 2001, CANCER LETT, V166, P185, DOI 10.1016/S0304-3835(01)00428-1; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Eisenberg CA, 1999, DEV DYNAM, V216, P45, DOI 10.1002/(SICI)1097-0177(199909)216:1<45::AID-DVDY7>3.0.CO;2-L; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Jonsson M, 1998, BRIT J CANCER, V78, P430, DOI 10.1038/bjc.1998.511; Kirikoshi H, 2001, INT J MOL MED, V8, P651; Kispert A, 1996, DEVELOPMENT, V122, P3627; Kitaeva MN, 1997, CANCER RES, V57, P4478; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuhl M, 2002, SEMIN CELL DEV BIOL, V13, P243, DOI 10.1016/S1084-9521(02)00050-2; Kuhl M, 2001, MECH DEVELOP, V106, P61, DOI 10.1016/S0925-4773(01)00416-6; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lickert H, 2001, MECH DEVELOP, V105, P181, DOI 10.1016/S0925-4773(01)00390-2; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520; Marlow F, 2002, CURR BIOL, V12, P876, DOI 10.1016/S0960-9822(02)00864-3; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; McBride HJ, 2003, DEV BIOL, V256, P18, DOI 10.1016/S0012-1606(02)00118-5; Merlin D, 2001, J BIOL CHEM, V276, P39282, DOI 10.1074/jbc.M105077200; Millar JBA, 2002, GENOME BIOL, V3; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Miyaki M, 1999, CANCER RES, V59, P4506; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Perry I, 1999, J CLIN PATHOL-MOL PA, V52, P166, DOI 10.1136/mp.52.4.166; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Polakis P, 2000, GENE DEV, V14, P1837; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; QUARONI A, 1978, P NATL ACAD SCI USA, V75, P5548, DOI 10.1073/pnas.75.11.5548; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; Tada M, 2000, DEVELOPMENT, V127, P2227; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Theodosiou NA, 2003, DEV BIOL, V259, P258, DOI 10.1016/S0012-1606(03)00185-4; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wang HY, 2003, SCIENCE, V300, P1529, DOI 10.1126/science.1085259; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu LF, 2000, GENE DEV, V14, P585; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yoshida R, 2001, INT J ONCOL, V18, P513; Zschiesche W, 1997, ANTICANCER RES, V17, P561	91	80	86	2	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26707	26715		10.1074/jbc.M402877200	http://dx.doi.org/10.1074/jbc.M402877200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084607	Green Accepted, hybrid			2022-12-25	WOS:000222003000097
J	Padilla, S; Jonassen, T; Jimenez-Hidalgo, MA; Fernandez-Ayala, DJM; Lopez-Lluch, G; Marbois, B; Navas, P; Clarke, CF; Santos-Ocana, C				Padilla, S; Jonassen, T; Jimenez-Hidalgo, MA; Fernandez-Ayala, DJM; Lopez-Lluch, G; Marbois, B; Navas, P; Clarke, CF; Santos-Ocana, C			Demethoxy-Q, an intermediate of coenzyme Q biosynthesis, fails to support respiration in Saccharomyces cerevisiae and lacks antioxidant activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS CLK-1; MEMBRANE ELECTRON-TRANSPORT; CYTOCHROME BC(1) COMPLEX; IRON-SULFUR PROTEIN; TIMING GENE CLK-1; UBIQUINONE BIOSYNTHESIS; ESCHERICHIA-COLI; POTENTIAL IMPLICATIONS; PLASMA-MEMBRANE; LONGEVITY GENE	Caenorhabditis elegans clk-1 mutants cannot produce coenzyme Q(9) and instead accumulate demethoxy-Q(9) (DMQ(9)). DMQ(9) has been proposed to be responsible for the extended lifespan of clk-1 mutants, theoretically through its enhanced antioxidant properties and its decreased function in respiratory chain electron transport. In the present study, we assess the functional roles of DMQ(6) in the yeast Saccharomyces cerevisiae. Three mutations designed to mirror the clk-1 mutations of C. elegans were introduced into COQ7, the yeast homologue of clk-1: E233K, predicted to disrupt the di-iron carboxylate site considered essential for hydroxylase activity; L237Stop, a deletion of 36 amino acid residues from the carboxyl terminus; and P175Stop, a deletion of the carboxyl-terminal half of Coq7p. Growth on glycerol, quinone content, respiratory function, and response to oxidative stress were analyzed in each of the coq7 mutant strains. Yeast strains lacking Q(6) and producing solely DMQ(6) were respiratory deficient and unable to support either NADH-cytochrome c reductase or succinate-cytochrome c reductase activities. DMQ(6) failed to protect cells against oxidative stress generated by H2O2 or linolenic acid. Thus, in the yeast model system, DMQ does not support respiratory activity and fails to act as an effective antioxidant. These results suggest that the life span extension observed in the C. elegans clk-1 mutants cannot be attributed to the presence of DMQ per se.	Univ Pablo de Olavide, Ctr Andaluz Biol Desarrollo, Seville 41013, Spain; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); University of California System; University of California Los Angeles	Santos-Ocana, C (corresponding author), Univ Pablo de Olavide, Ctr Andaluz Biol Desarrollo, Carretera Utrera Km 1, Seville 41013, Spain.	csantos@dex.upo.es	NAVAS, PLACIDO/R-5943-2019; Lopez-Lluch, Guillermo/N-4742-2014; Ocaña, Carlos Santos/E-8115-2011	NAVAS, PLACIDO/0000-0002-4115-7966; Lopez-Lluch, Guillermo/0000-0001-9830-8502; Ocaña, Carlos Santos/0000-0002-2379-796X; Fernandez-Ayala, Daniel Jose Moreno/0000-0001-8176-1431	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG019777, R01AG019777] Funding Source: NIH RePORTER; NIA NIH HHS [AG19777] Funding Source: Medline; NIGMS NIH HHS [GM45952] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi A, 2003, FEBS LETT, V543, P174, DOI 10.1016/S0014-5793(03)00419-8; Asencio C, 2003, FASEB J, V17, P1135, DOI 10.1096/fj.02-1022fje; BAA SW, 2004, J BIOL CHEM, V279, P10052; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Berthold DA, 2002, J BIOL CHEM, V277, P43608, DOI 10.1074/jbc.M206724200; Boumans H, 1998, BIOCHEM J, V331, P877, DOI 10.1042/bj3310877; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; Brandt U, 1996, BBA-BIOENERGETICS, V1275, P41, DOI 10.1016/0005-2728(96)00048-5; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; Burgess J, 2003, J BIOL CHEM, V278, P49555, DOI 10.1074/jbc.M308507200; Davidson JF, 2001, MOL CELL BIOL, V21, P8483, DOI 10.1128/MCB.21.24.8483-8489.2001; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; FRERMAN FE, 1988, BIOCHEM SOC T, V16, P416, DOI 10.1042/bst0160416; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; Higuchi R., 1990, PCR PROTOCOLS GUIDE; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Holt SJ, 2003, MECH AGEING DEV, V124, P779, DOI 10.1016/S0047-6374(03)00132-5; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Jonassen T, 2000, J BIOL CHEM, V275, P12381, DOI 10.1074/jbc.275.17.12381; Jonassen T, 2003, J BIOL CHEM, V278, P51735, DOI 10.1074/jbc.M308760200; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kwon O, 2000, FEMS MICROBIOL LETT, V186, P157, DOI 10.1016/S0378-1097(00)00134-8; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Miyadera H, 2002, FEBS LETT, V512, P33, DOI 10.1016/S0014-5793(02)02282-2; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Murakami S, 1996, GENETICS, V143, P1207; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Nakai D, 2001, BIOCHEM BIOPH RES CO, V289, P463, DOI 10.1006/bbrc.2001.5977; Namy O, 2001, EMBO REP, V2, P787, DOI 10.1093/embo-reports/kve176; Namy O, 2002, MOL MICROBIOL, V43, P641, DOI 10.1046/j.1365-2958.2002.02770.x; Obungu VH, 1998, J BIOL CHEM, V273, P11917, DOI 10.1074/jbc.273.19.11917; Ong WC, 1997, YEAST, V13, P1357, DOI 10.1002/(SICI)1097-0061(199711)13:14<1357::AID-YEA180>3.0.CO;2-3; POON WW, 1997, MOL ASPECTS MED, V18, P121; Prelich G, 1999, TRENDS GENET, V15, P261, DOI 10.1016/S0168-9525(99)01749-7; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; Rose MD., 1990, METHODS YEAST GENETI; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Shibata Y, 2003, SCIENCE, V302, P1779, DOI 10.1126/science.1087167; SIKORSKI RS, 1989, GENETICS, V122, P19; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1981, J BIOENERG BIOMEMBR, V13, P1, DOI 10.1007/BF00744743; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Vajo Z, 1999, MAMM GENOME, V10, P1000, DOI 10.1007/s003359901147; van Hellemond JJ, 2003, PHILOS T ROY SOC B, V358, P205, DOI 10.1098/rstb.2002.1182; Velazquez I, 2001, ARCH BIOCHEM BIOPHYS, V389, P7, DOI 10.1006/abbi.2001.2293; VILLALBA JM, 1995, P NATL ACAD SCI USA, V92, P4887, DOI 10.1073/pnas.92.11.4887; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WONG A, 1995, GENETICS, V139, P1247; YOUNG IG, 1973, J BACTERIOL, V114, P42, DOI 10.1128/JB.114.1.42-52.1973; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4; ZWECK A, 1989, EUR J BIOCHEM, V183, P199, DOI 10.1111/j.1432-1033.1989.tb14913.x	70	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25995	26004		10.1074/jbc.M400001200	http://dx.doi.org/10.1074/jbc.M400001200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078893	hybrid, Green Published			2022-12-25	WOS:000222003000010
J	Thorey, IS; Hinz, B; Hoeflich, A; Kaesler, S; Bugnon, P; Elmlinger, M; Wanke, R; Wolf, E; Werner, S				Thorey, IS; Hinz, B; Hoeflich, A; Kaesler, S; Bugnon, P; Elmlinger, M; Wanke, R; Wolf, E; Werner, S			Transgenic mice reveal novel activities of growth hormone in wound repair, angiogenesis, and myofibroblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH MUSCLE ACTIN; FACTOR-BINDING PROTEIN-2; SKIN INCISIONAL WOUNDS; FACTOR-I; IGF-I; TRANSFORMING GROWTH-FACTOR-BETA-1; CULTURED FIBROBLASTS; COLLAGEN LATTICES; MESSENGER-RNA; TISSUE	An increasing number of patients are being treated with growth hormone (GH) for the enhancement of body growth but also as an anti-aging strategy. However, the side effects of GH have been poorly defined. In this study we determined the effect of GH on wound repair and its mechanisms of action at the wound site. For this purpose, we performed wound healing studies in transgenic mice overexpressing GH. Full thickness incisional and excisional wounds of transgenic animals developed extensive, highly vascularized granulation tissue. However, wound bursting strength was not increased. Wound closure was strongly delayed as a result of enhanced granulation tissue formation and impaired wound contraction. The latter effect is most likely due to a significantly reduced number of myofibroblasts at the wound site. By using in vitro studies with stressed collagen lattices, we identified GH as an inhibitor of transforming growth factor beta-induced myofibroblast differentiation, resulting in a reduction in fibroblast contractile activity. These results revealed novel roles of GH in angiogenesis and myofibroblast differentiation, which are most likely not mediated via insulin-like growth factors at the wound site. Furthermore, our data suggested that systemic GH treatment is detrimental for wound healing in healthy individuals.	ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; Univ Munich, Gene Ctr, Inst Mol Anim Breeding, D-81377 Munich, Germany; Swiss Fed Inst Technol, Lab Cell Biophys, CH-1015 Lausanne, Switzerland; Univ Tubingen, Childrens Hosp, D-72076 Tubingen, Germany; Univ Munich, Inst Vet Pathol, D-80539 Munich, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Munich; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Munich	Werner, S (corresponding author), ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland.	Sabine.Werner@cell.biol.ethz.ch		Wanke, Rudiger/0000-0002-0153-224X; Wolf, Eckhard/0000-0002-0430-9510; Werner, Sabine/0000-0001-7397-8710; Hinz, Boris/0000-0002-0526-393X; Hoeflich, Andreas/0000-0003-2018-2836				Ashcroft GS, 2002, J CLIN INVEST, V110, P615, DOI 10.1172/JCI200215704; Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; BANG P, 1994, J ENDOCRINOL, V143, pC1; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Bitar MS, 1997, HORM METAB RES, V29, P383, DOI 10.1055/s-2007-979060; BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; Clemmons David R., 1999, V17, P273; Cummings DE, 2003, ANNU REV MED, V54, P513, DOI 10.1146/annurev.med.54.101601.152147; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dunaiski V, 2002, GROWTH HORM IGF RES, V12, P381, DOI 10.1016/S1096-6374(02)00080-1; EHRLICH HP, 1990, TISSUE CELL, V22, P407, DOI 10.1016/0040-8166(90)90070-P; Eming SA, 1996, J INVEST DERMATOL, V107, P113, DOI 10.1111/1523-1747.ep12298351; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Ghofrani A, 1999, PLAST RECONSTR SURG, V104, P470, DOI 10.1097/00006534-199908000-00020; GIANNINI S, 1994, J CLIN ENDOCR METAB, V79, P1824, DOI 10.1210/jc.79.6.1824; GOULD J, 1995, LIFE SCI, V56, P587, DOI 10.1016/0024-3205(94)00491-A; GREEN H, 1985, DIFFERENTIATION, V29, P195, DOI 10.1111/j.1432-0436.1985.tb00316.x; Grose R, 2002, EMBO REP, V3, P575, DOI 10.1093/embo-reports/kvf119; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hoeflich A, 2001, ENDOCRINOLOGY, V142, P1889, DOI 10.1210/en.142.5.1889; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Jeschke MG, 1999, GENE THER, V6, P1015, DOI 10.1038/sj.gt.3300923; JYUNG RW, 1994, SURGERY, V115, P233; Kanekar S, 2000, CELL ADHES COMMUN, V7, P513, DOI 10.3109/15419060009040308; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; Kuroda K, 2001, J DERMATOL SCI, V26, P156, DOI 10.1016/S0923-1811(00)00155-9; Lal SO, 2000, GROWTH HORM IGF RES, V10, P39, DOI 10.1016/S1096-6374(00)80008-8; LEE YR, 1996, ENDOCRINOLOGY, V137, P5378; LYNCH SE, 1989, J CLIN INVEST, V84, P640, DOI 10.1172/JCI114210; Martin JL, 1999, CONT ENDOCRINOL, V17, P227; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; RASMUSSEN LH, 1995, EUR J SURG, V161, P157; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Seyer-Hansen M, 1999, GROWTH HORM IGF RES, V9, P254, DOI 10.1054/ghir.1999.0116; SEYERHANSEN M, 1993, EUR SURG RES, V25, P162, DOI 10.1159/000129273; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STEENFOS HH, 1992, J ENDOCRINOL, V132, P293, DOI 10.1677/joe.0.1320293; Struman I, 1999, P NATL ACAD SCI USA, V96, P1246, DOI 10.1073/pnas.96.4.1246; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wanke R, 1999, J INVEST DERMATOL, V113, P967, DOI 10.1046/j.1523-1747.1999.00807.x; WELSH KM, 1991, J DERMATOL SURG ONC, V17, P942, DOI 10.1111/j.1524-4725.1991.tb01694.x; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WOLF E, 1994, ENDOCRINOLOGY, V135, P1877, DOI 10.1210/en.135.5.1877; WOLF E, 1996, WELFARE TRANSGENIC A, P26; ZAIZEN Y, 1995, EUR J PEDIATR SURG, V5, P226, DOI 10.1055/s-2008-1066211	48	40	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26674	26684		10.1074/jbc.M311467200	http://dx.doi.org/10.1074/jbc.M311467200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15070902	hybrid			2022-12-25	WOS:000222003000094
J	Zhou, WL; Zhao, Q; Sutton, R; Cumming, H; Wang, X; Cerruti, L; Hall, M; Wu, RQ; Cunningham, JM; Jane, SM				Zhou, WL; Zhao, Q; Sutton, R; Cumming, H; Wang, X; Cerruti, L; Hall, M; Wu, RQ; Cunningham, JM; Jane, SM			The role of p22 NF-E4 in human globin gene switching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GAMMA-GLOBIN; LOCUS-CONTROL REGION; HIGH-LEVEL EXPRESSION; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; HUMAN FETAL; CHROMATIN-STRUCTURE; BETA-THALASSEMIA; IN-VIVO; TRANSCRIPTION	The human stage selector protein, a complex containing the ubiquitous transcription factor CP2 and the erythroid-specific factor p22 NF-E4, facilitates the interaction of the gamma-globin genes with the locus control region in fetal erythroid cells. Enforced expression of p22 NF-E4 in K562 cells and human cord blood progenitors increases fetal globin gene expression, and in progenitors, reduces beta-globin expression. To examine the role of NF-E4 in an in vivo model of hemoglobin switching, we enforced the expression of p22 NF-E4 in transgenic mice carrying the human beta-globin locus yeast artificial chromosome. Although murine erythropoiesis and globin gene expression is unaffected in these mice, the expression profile of the human globin genes is altered. All three transgenic lines displayed an increased gamma:beta-globin ratio in E12.5-14.5 fetal liver, resulting in a delay in the fetal/adult switch. At E12.5, this is primarily due to a reduction of beta-gene expression, whereas at E14.5, the increased gamma:beta ratio is due to enhanced gamma-gene expression. Despite this, the switch in globin subtype is fully completed in the adult bone marrow. These findings indicate that p22 NF-E4 is capable of influencing human globin gene expression in vivo but is incapable of overriding the intrinsic mechanisms governing gamma-gene silencing in this context.	Royal Melbourne Hosp, Rotary Bone Marrow Res Lab, Parkville, Vic 3050, Australia; St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38101 USA	Royal Melbourne Hospital; St Jude Children's Research Hospital	Jane, SM (corresponding author), Rotary Bone Marrow Res Lab, Royal Melbourne Hosp PO,Grattan St, Parkville, Vic 3050, Australia.	jane@wehi.edu.au	Zhao, Quan/E-9147-2011; Jane, Stephen/D-6659-2011	Zhao, Quan/0000-0002-8533-1938; Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749, R01HL069232] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [R01 HL69232-01, P01 HL53749-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DIGNAM JD, METHODS ENZYMOL, V182, P194; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; METCALF D, 1984, HEAMTOPOIETIC COLONY; MORLEY BJ, 1991, BLOOD, V78, P1355; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; Ristaldi MS, 2001, EMBO J, V20, P5242, DOI 10.1093/emboj/20.18.5242; Sambrook J., 2002, MOL CLONING LAB MANU; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Schubeler D, 2000, GENE DEV, V14, P940; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; STARCK J, 1994, BLOOD, V84, P1656; TARAMELLI R, 1986, NUCLEIC ACIDS RES, V14, P7017, DOI 10.1093/nar/14.17.7017; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Zhou WL, 2000, MOL CELL BIOL, V20, P7662, DOI 10.1128/MCB.20.20.7662-7672.2000	40	35	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26227	26232		10.1074/jbc.M402191200	http://dx.doi.org/10.1074/jbc.M402191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084587	hybrid			2022-12-25	WOS:000222003000039
J	Kanda, N; Seno, H; Konda, Y; Marusawa, H; Kanai, M; Nakajima, T; Kawashima, T; Nanakin, A; Sawabu, T; Uenoyama, Y; Sekikawa, A; Kawada, M; Suzuki, K; Kayahara, T; Fukui, H; Sawada, M; Chiba, T				Kanda, N; Seno, H; Konda, Y; Marusawa, H; Kanai, M; Nakajima, T; Kawashima, T; Nanakin, A; Sawabu, T; Uenoyama, Y; Sekikawa, A; Kawada, M; Suzuki, K; Kayahara, T; Fukui, H; Sawada, M; Chiba, T			STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells	ONCOGENE			English	Article						STAT3; survivin; cancer; stomach	SIGNALING INDUCES APOPTOSIS; EPIDERMAL-GROWTH-FACTOR; TRANSCRIPTION FACTOR; MESSENGER-RNA; HUMAN OVARIAN; DNA-BINDING; INHIBITION; GENE; INTERLEUKIN-6; RESISTANCE	Signal transduction and activator of transcription 3(STAT3) signaling is constitutively activated in various tumors, and is involved in cell survival and proliferation during oncogenesis. There are few reports, however, on the role of STAT3 signaling in gastric cancer. The aim of the present study was to clarify the role of STAT3 signaling in apoptosis and cellular proliferation in gastric cancer. Here we reported that STAT3 was constitutively activated in various human gastric cancer cells and its inhibition by ectopic dominant-negative STAT3 or Janus kinase inhibitor, tyrphostin AG490, induced apoptosis. Furthermore, STAT3 inhibition markedly decreased survivin expression, and forced expression of survivin rescued AGS cells from apoptosis induced by STAT3 inhibition. Although some reports demonstrated that the PI3K/Akt pathway regulates survivin expression, inhibition of the PI3K/Akt pathway did not affect survivin expression in AGS and MKN1 cells. Finally, activated form of STAT3, Tyr-705 phospho-stat3, was found in the nucleus of cancer cells in 11 of 40 (27.5%) human gastric cancer specimens. These findings suggest that constitutively activated STAT3 signaling supports gastric cancer cell survival in association with survivin expression.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Seno, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Shogoin Kawara Cho 54, Kyoto 6068507, Japan.	seno@kuhp.kyoto-u.ac.jp	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648; Seno, Hiroshi/0000-0002-8509-8128; Marusawa, Hiroyuki/0000-0002-4286-2712				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bisping G, 2003, BLOOD, V101, P2775, DOI 10.1182/blood-2002-09-2907; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Buettner R, 2002, CLIN CANCER RES, V8, P945; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fukuda S, 2001, BLOOD, V98, P2091, DOI 10.1182/blood.V98.7.2091; Gianani R, 2001, HUM PATHOL, V32, P119, DOI 10.1053/hupa.2001.21897; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ikeguchi M, 2002, BRIT J CANCER, V87, P883, DOI 10.1038/sj.bjc.6600546; Izuishi K, 2000, CANCER RES, V60, P6201; Kanai M, 2003, ONCOGENE, V22, P548, DOI 10.1038/sj.onc.1206109; Kawasaki H, 1998, CANCER RES, V58, P5071; Konno R, 2000, MOL HUM REPROD, V6, P529, DOI 10.1093/molehr/6.6.529; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Mora LB, 2002, CANCER RES, V62, P6659; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Werner M, 2001, J CANCER RES CLIN, V127, P207, DOI 10.1007/s004320000195; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3; Zhang T, 2001, CANCER RES, V61, P8664; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	42	259	307	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4921	4929		10.1038/sj.onc.1207606	http://dx.doi.org/10.1038/sj.onc.1207606			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077160	Green Submitted			2022-12-25	WOS:000222104200013
J	Champagne, C; Landry, MC; Gingras, MC; Lavoie, JN				Champagne, C; Landry, MC; Gingras, MC; Lavoie, JN			Activation of adenovirus type 2 early region 4 ORF4 cytoplasmic death function by direct binding to Src kinase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; MIDDLE-T-ANTIGEN; FOCAL ADHESION KINASE; E4ORF4 PROTEIN; TYROSINE KINASE; V-SRC; C-SRC; TRANSFORMED-CELLS; P53-INDEPENDENT APOPTOSIS; SACCHAROMYCES-CEREVISIAE	Adenovirus type 2 (Ad2) early region 4 ORF4 (E4orf4) triggers a major death pathway that requires its accumulation in cellular membranes and its tyrosine phosphorylation. This program is regulated by Src family kinases and triggers a potent ZVAD ( benzyloxycarbonyl-VAD)- and Bcl2-resistant cell death response in human-transformed cells. How E4orf4 deregulates Src-dependent signaling is unknown. Here we provide strong evidence that a physical interaction requiring the kinase domain of Src and the arginine-rich motif of E4orf4 is involved. The Src binding domain of E4orf4 overlaps with, but is distinct from that of the Balpha subunit of protein phosphatase 2A (PP2A-Balpha) and some E4orf4 complexes contain both PP2A and Src. Functional assays using mutant E4orf4 revealed that deregulation of Src signaling, activation of the Jun kinase pathway, and cell blebbing were all critically dependent on Src binding. In contrast, PP2A-Balpha binding per se was not required to engage the Src-dependent death pathway but was more critical for triggering a distinct death activity. Both E4orf4 death activities were manifested within a given cell population, were typified by distinct morphological features, and contributed to overall cell killing, although to different extents in various cell types. We conclude that E4orf4 binding to the Src kinase domain leads to deregulation of Src signaling and plays a crucial role in induction of the cytoplasmic death pathway. Nonetheless, both Src and PP2A enzymes are critical targets of E4orf4 that likely cooperate to trigger E4orf4-induced tumor cell killing and whose relative contributions may vary in function of the cellular background.	Univ Laval, Hotel Dieu Quebec, CHUQ, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Lavoie, JN (corresponding author), Univ Laval, Hotel Dieu Quebec, CHUQ, Ctr Rech Cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	josee.lavoie@crhdq.ulaval.ca		Lavoie, Josee N/0000-0001-6912-1132				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Choidas A, 1998, EUR J CELL BIOL, V77, P81, DOI 10.1016/S0171-9335(98)80075-7; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; DAMUNI Z, 1994, FEBS LETT, V352, P311, DOI 10.1016/0014-5793(94)00981-3; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gingras MC, 2002, MOL CELL BIOL, V22, P41, DOI 10.1128/MCB.22.1.41-56.2002; Glover HR, 1999, ONCOGENE, V18, P4364, DOI 10.1038/sj.onc.1202816; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUPTA R, 1994, BIOCHEM BIOPH RES CO, V205, P1043, DOI 10.1006/bbrc.1994.2771; Hauck CR, 2002, J BIOL CHEM, V277, P12487, DOI 10.1074/jbc.C100760200; Hauck CR, 2001, J BIOL CHEM, V276, P17653, DOI 10.1074/jbc.M009329200; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Lee S, 1999, MOL CELL BIOL, V19, P1486; Liu W, 2003, CELL DEATH DIFFER, V10, P772, DOI 10.1038/sj.cdd.4401238; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; MULLER U, 1992, J VIROL, V66, P5867; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tauber B, 2001, GENE, V278, P1, DOI 10.1016/S0378-1119(01)00722-3; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Violette SM, 2001, BONE, V28, P54, DOI 10.1016/S8756-3282(00)00427-0; Xiong WC, 1998, J CELL SCI, V111, P1981; Yokoyama N, 2001, FEBS LETT, V505, P460, DOI 10.1016/S0014-5793(01)02874-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25905	25915		10.1074/jbc.M400933200	http://dx.doi.org/10.1074/jbc.M400933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070897	hybrid			2022-12-25	WOS:000221827900123
J	Cummins, SF; Nichols, AE; Amare, A; Hummon, AB; Sweedler, JV; Nagle, GT				Cummins, SF; Nichols, AE; Amare, A; Hummon, AB; Sweedler, JV; Nagle, GT			Characterization of aplysia enticin and temptin, two novel water-borne protein pheromones that act in concert with attractin to stimulate mate attraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; CILIATE EUPLOTES-RAIKOVI; PEPTIDE PHEROMONE; ATRIAL GLAND; MOLECULAR-CLONING; MATING PHEROMONE; COPULATORY-BEHAVIOR; BIOLOGICAL-ACTIVITY; SEX-PHEROMONE; PEDAL PEPTIDE	Mate attraction in Aplysia involves a long-distance water-borne signal (attractin) that is released during egg laying. Other pheromones are predicted to be released during egg laying that act in concert with albumen gland attractin to stimulate attraction, but their identities are unknown. To identify other candidate water-borne pheromones, we employed differential library screening of an albumen gland cDNA library, Northern blot analysis, purification, characterization, cloning, and expression of albumen gland proteins, matrix-assisted laser desorption ionization mass spectrometry, pheromone secretion assays, behavioral bioassays, immunolocalization studies, and comparative genomics. Four genes, Alb-23, Alb-24, Alb-69, and Alb-172, were highly expressed in Aplysia californica albumen glands and encoded novel proteins. The products of the Alb-24 ("enticin") and Alb-172 ("temptin") precursors were soluble and highly abundant in albumen gland extracts, whereas Alb-23 and Alb-69 were membrane-associated proteins. A comparative analysis showed that the predicted Aplysia brasiliana enticin and temptin proteins were 90 and 91% identical, respectively, to their A. californica homologs. T-maze attraction bioassay studies have previously demonstrated that egg cordons alone are attractive to Aplysia but that attractin alone is not. In the present study, however, the combination of attractin, enticin, and temptin was found to be significantly attractive to potential mates and doubled the number of animals attracted to this stimulus compared with control animals. The combined data strongly suggest that enticin and temptin are novel candidate water-borne protein pheromones that act in concert with attractin to attract Aplysia to form and maintain egg-laying and mating aggregations.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst, Urbana, IL 61801 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Nagle, GT (corresponding author), 2 138 Med Res Bldg, Galveston, TX 77555 USA.	gtnagle@utmb.edu	Sweedler, Jonathan V/A-9405-2009; Cummins, Scott/I-6420-2016	Sweedler, Jonathan V/0000-0003-3107-9922; Cummins, Scott/0000-0002-1454-2076	NINDS NIH HHS [NS31609, R01 NS031609] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031609, R29NS031609] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akalal DBG, 2003, PEPTIDES, V24, P1117, DOI 10.1016/j.peptides.2003.06.001; Akalal DBG, 2003, MOL BRAIN RES, V117, P228, DOI 10.1016/S0169-328X(03)00287-0; ASPEY WP, 1976, BEHAV BIOL, V17, P301, DOI 10.1016/S0091-6773(76)90662-3; AUDESIRK TE, 1979, BIOL BULL, V157, P407, DOI 10.2307/1541026; AUDESIRK TE, 1977, BEHAV BIOL, V20, P235, DOI 10.1016/S0091-6773(77)90799-4; BEGNOCHE VL, 1996, J NEUROPHYSIOL, V75, P2162; BLANKENSHIP JE, 1983, FED PROC, V42, P96; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGGESHALL RE, 1972, TISSUE CELL, V4, P105, DOI 10.1016/S0040-8166(72)80011-9; Cummins SF, 2004, PEPTIDES, V25, P185, DOI 10.1016/j.peptides.2003.12.018; DESGROSEILLERS L, 1994, BBA-GENE STRUCT EXPR, V1217, P322, DOI 10.1016/0167-4781(94)90293-3; Fan XM, 1997, MOL BRAIN RES, V48, P167, DOI 10.1016/S0169-328X(97)00154-X; Garimella R, 2003, BIOCHEMISTRY-US, V42, P9970, DOI 10.1021/bi0274322; Hummon AB, 2003, J PROTEOME RES, V2, P650, DOI 10.1021/pr034046d; JAHANPARWAR B, 1976, PHYSIOLOGY, V19, P240; Kikuyama S, 2002, COMP BIOCHEM PHYS B, V132, P69, DOI 10.1016/S1096-4959(01)00534-6; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; Kodama T, 2003, YEAST, V20, P109, DOI 10.1002/yea.939; KUPFERMA.I, 1974, BEHAV BIOL, V12, P317, DOI 10.1016/S0091-6773(74)91503-X; Li WM, 2002, SCIENCE, V296, P138, DOI 10.1126/science.1067797; LLOYD PE, 1989, J NEUROSCI, V9, P312; LUPORINI P, 1995, J EUKARYOT MICROBIOL, V42, P208, DOI 10.1111/j.1550-7408.1995.tb01567.x; MONSMA SA, 1988, GENE DEV, V2, P1063, DOI 10.1101/gad.2.9.1063; NAGLE GT, 1986, J BIOL CHEM, V261, P7853; NAGLE GT, 1990, J BIOL CHEM, V265, P22329; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; Novotny MV, 2003, BIOCHEM SOC T, V31, P117, DOI 10.1042/BST0310117; Painter SD, 1998, BIOL BULL-US, V194, P120, DOI 10.2307/1543042; PAINTER SD, 1985, J MORPHOL, V186, P167, DOI 10.1002/jmor.1051860204; Painter SD, 2003, BIOL BULL-US, V205, P16, DOI 10.2307/1543441; PAINTER SD, 1989, BEHAV NEURAL BIOL, V51, P222, DOI 10.1016/S0163-1047(89)90857-1; PAINTER SD, 1991, BIOL BULL, V181, P81, DOI 10.2307/1542491; PAINTER SD, 2004, IN PRESS P NATL ACAD; PEARSON WL, 1989, J NEUROSCI, V9, P318; PLIMMER JR, 1982, ANNU REV PHARMACOL, V22, P297, DOI 10.1146/annurev.pa.22.040182.001501; RAFFIONI S, 1988, J BIOL CHEM, V263, P18152; RAFFIONI S, 1989, BIOCHEMISTRY-US, V28, P5250, DOI 10.1021/bi00438a049; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P2071, DOI 10.1073/pnas.89.6.2071; Ram JL, 1999, FASEB J, V13, P945, DOI 10.1096/fasebj.13.8.945; ROELOFS WL, 1995, P NATL ACAD SCI USA, V92, P44, DOI 10.1073/pnas.92.1.44; Roelofs WL, 2002, P NATL ACAD SCI USA, V99, P13621, DOI 10.1073/pnas.152445399; Rollmann SM, 1999, SCIENCE, V285, P1907, DOI 10.1126/science.285.5435.1907; ROTHMAN BS, 1986, J BIOL CHEM, V261, P1616; Saudan P, 2002, EUR J BIOCHEM, V269, P989, DOI 10.1046/j.0014-2956.2001.02733.x; Savic I, 2001, NEURON, V31, P661, DOI 10.1016/S0896-6273(01)00390-7; Schein CH, 2001, BIOPHYS J, V81, P463, DOI 10.1016/S0006-3495(01)75714-1; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; SUSSWEIN AJ, 1983, BEHAV NEURAL BIOL, V39, P203, DOI 10.1016/S0163-1047(83)90859-2; SUSSWEIN AJ, 1984, BEHAV NEURAL BIOL, V41, P203; Takamatsu N, 1995, FEBS LETT, V377, P373, DOI 10.1016/0014-5793(95)01375-X; Wabnitz PA, 1999, NATURE, V401, P444, DOI 10.1038/46724; Zeeck E, 1998, CHEMOECOLOGY, V8, P33, DOI 10.1007/PL00001801	53	60	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25614	25622		10.1074/jbc.M313585200	http://dx.doi.org/10.1074/jbc.M313585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15054104	Green Published, hybrid			2022-12-25	WOS:000221827900089
J	Fierro, AF; Wurth, GA; Zweifach, A				Fierro, AF; Wurth, GA; Zweifach, A			Cross-talk with Ca2+ influx does not underlie the role of extracellular signal-regulated kinases in cytotoxic T lymphocyte lytic granule exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NATURAL-KILLER-CELLS; MICROTUBULE-ORGANIZING CENTER; CAPACITATIVE CALCIUM-ENTRY; INDUCED ERK ACTIVATION; EFFECTOR FUNCTIONS; GOLGI-APPARATUS; HUMAN PLATELETS; PATHWAY; BINDING	One important mechanism cytotoxic T lymphocytes use to kill target cells is exocytosis of lytic granules that contain cytotoxic agents such as perforin and granzyme. Ca2+ influx and activation of protein kinase C have been known for many years to be key signals for granule exocytosis. Recent work has suggested that activation of extracellular signal-regulated kinases (ERK), members of the mitogen-activated protein kinase ( MAP kinase) family, may be a third required signal. We surmised that the involvement of ERK in lytic granule exocytosis could be mediated through cross-talk with Ca2+ influx, rather than constituting an independent signal. We tested this idea using TALL-104 human leukemic CTLs as a model system and discovered the following. 1) ERK inhibition caused a modest decrease in the amplitude of increases in intracellular Ca2+ concentration, but this effect cannot account for the profound inhibition of granule exocytosis. 2) Ca2+ influx can activate ERK in TALL-104 cells, but this effect does not contribute to ERK activation stimulated by solid phase anti-CD3 monoclonal antibodies. We conclude that cross-talk between ERK signaling and Ca2+ does not mediate the role of ERK in CTL lytic granule exocytosis.	Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Zweifach, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, 4200 E 9th Ave, Denver, CO 80262 USA.	adam.zweifach@UCHSC.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054839] Funding Source: NIH RePORTER; NIAID NIH HHS [AI054839] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atherfold PA, 1999, MOL IMMUNOL, V36, P543, DOI 10.1016/S0161-5890(99)00076-0; Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Berg NN, 1998, J IMMUNOL, V161, P2919; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BERKE G, 1994, ANNU REV IMMUNOL, V12, P736; CESANO A, 1992, IN VITRO CELL DEV-AN, V28A, P648; Djeu JY, 2002, CLIN CANCER RES, V8, P636; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUTZ JP, 1993, J IMMUNOL, V150, P2591; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Elzi DJ, 2001, AM J PHYSIOL-CELL PH, V281, pC350; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FORTIER AH, 1989, CELL IMMUNOL, V124, P64, DOI 10.1016/0008-8749(89)90112-3; Franklin RA, 2000, MOL IMMUNOL, V37, P675, DOI 10.1016/S0161-5890(00)00087-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAAGEN IA, 1992, CLIN EXP IMMUNOL, V90, P368; HAVERSTICK DM, 1991, J IMMUNOL, V146, P3306; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; JUSZCZAK RJ, 1989, J BIOL CHEM, V264, P810; KUPFER A, 1983, P NATL ACAD SCI-BIOL, V80, P7224, DOI 10.1073/pnas.80.23.7224; KUPFER A, 1984, J IMMUNOL, V133, P2762; LANCKI DW, 1987, J IMMUNOL, V138, P3646; LANGLET C, 1992, J IMMUNOL METHODS, V151, P107, DOI 10.1016/0022-1759(92)90108-6; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; LICHTENFELS R, 1994, J IMMUNOL METHODS, V172, P227, DOI 10.1016/0022-1759(94)90110-4; Lilic M, 1999, EUR J IMMUNOL, V29, P3971, DOI 10.1002/(SICI)1521-4141(199912)29:12<3971::AID-IMMU3971>3.0.CO;2-5; Lyubchenko TA, 2003, J PHYSIOL-LONDON, V547, P835, DOI 10.1113/jphysiol.2002.033522; Lyubchenko TA, 2001, IMMUNITY, V15, P847, DOI 10.1016/S1074-7613(01)00233-3; Milella M, 1997, J IMMUNOL, V158, P3148; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NISHIMURA T, 1987, J IMMUNOL, V139, P2888; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Puente LG, 2000, J IMMUNOL, V165, P6865, DOI 10.4049/jimmunol.165.12.6865; Rosado JA, 2001, J BIOL CHEM, V276, P15659, DOI 10.1074/jbc.M009218200; Rosado JA, 2002, TRENDS CARDIOVAS MED, V12, P229, DOI 10.1016/S1050-1738(02)00161-5; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; SITKOVSKY MV, 1988, IMMUNOL REV, V103, P127, DOI 10.1111/j.1600-065X.1988.tb00754.x; TAKAYAMA H, 1987, J IMMUNOL METHODS, V104, P183, DOI 10.1016/0022-1759(87)90502-3; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Trotta R, 1998, J IMMUNOL, V161, P6648; Vezina J, 2001, J IMMUNOL METHODS, V252, P163, DOI 10.1016/S0022-1759(01)00333-7; Zamoyska R, 2003, IMMUNOL REV, V191, P107, DOI 10.1034/j.1600-065X.2003.00015.x; Zweifach A, 2000, J CELL BIOL, V148, P603, DOI 10.1083/jcb.148.3.603	49	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25646	25652		10.1074/jbc.M400296200	http://dx.doi.org/10.1074/jbc.M400296200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060074	hybrid			2022-12-25	WOS:000221827900093
J	Filippova, M; Parkhurst, L; Duerkesen-Hughes, PJ				Filippova, M; Parkhurst, L; Duerkesen-Hughes, PJ			The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; NECROSIS-FACTOR RECEPTOR; HUMAN KERATINOCYTES; MEDIATED APOPTOSIS; HPV E6; E6-ENHANCED SUSCEPTIBILITY; CASPASE-8 ACTIVATION; ADENOVIRUS E4-ORF1; SIGNALING PATHWAY	High risk strains of human papillomavirus (HPV), such as HPV 16, cause human cervical carcinoma. The E6 protein of HPV 16 mediates the rapid degradation of the tumor suppressor p53, although this is not the only function of E6 and cannot completely explain its transforming potential. Previous work in our laboratory has demonstrated that E6 can protect cells from tumor necrosis factor-induced apoptosis by binding to the C-terminal end of tumor necrosis factor R1, thus blocking apoptotic signal transduction. In this study, E6 was shown to also protect cells from apoptosis induced via the Fas pathway. Furthermore, use of an inducible E6 expression system demonstrated that this protection is dose-dependent, with higher levels of E6 leading to greater protection. Although E6 suppresses activation of both caspase 3 and caspase 8, it does not affect apoptotic signaling through the mitochondrial pathway. Mammalian two-hybrid and in vitro pull-down assays were then used to demonstrate that E6 binds directly to the death effector domain of Fas-associated death domain (FADD), with deletion and site-directed mutants enabling the localization of the E6-binding site to the N-terminal end of the FADD death effector domain. E6 is produced in two forms as follows: a full-length version of similar to16 kDa and a smaller version of about half that size corresponding to the N-terminal half of the full-length protein. Pull-down and functional assays demonstrated that the full-length version, but not the small version of E6, was able to bind to FADD and to protect cells from Fas-induced apoptosis. In addition, binding to E6 leads to degradation of FADD, with the loss of cellular FADD proportional to the amount of E6 expressed. These results support a model in which E6-mediated degradation of FADD prevents transmission of apoptotic signals via the Fas pathway.	Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Dept Biochem & Microbiol, Loma Linda, CA 92354 USA	Loma Linda University	Duerkesen-Hughes, PJ (corresponding author), Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Dept Biochem & Microbiol, 11085 Campus St,121 Mortensen Hall, Loma Linda, CA 92354 USA.	pdhughes@som.llu.edu	Duerksen-Hughes, Penelope/A-3488-2008	Duerksen-Hughes, Penelope/0000-0002-0998-2157	NCI NIH HHS [1R01 CA095461-01A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095461] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar-Lemarroy A, 2002, ONCOGENE, V21, P165, DOI 10.1038/sj.onc.1204979; Aguilar-Lemarroy A, 2001, INT J CANCER, V93, P823, DOI 10.1002/ijc.1405; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; Be XB, 2001, BIOCHEMISTRY-US, V40, P1293, DOI 10.1021/bi0019592; Benedict CA, 2003, CYTOKINE GROWTH F R, V14, P349, DOI 10.1016/S1359-6101(03)00030-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; Degenhardt YY, 2001, J VIROL, V75, P11791, DOI 10.1128/JVI.75.23.11791-11802.2001; Du MJ, 2002, BIOCHEM BIOPH RES CO, V296, P962, DOI 10.1016/S0006-291X(02)02041-7; Duerksen-Hughes PJ, 1999, VIROLOGY, V264, P55, DOI 10.1006/viro.1999.9977; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; Filippova M, 2002, J BIOL CHEM, V277, P21730, DOI 10.1074/jbc.M200113200; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; Fogel S, 1998, VIROLOGY, V244, P97, DOI 10.1006/viro.1998.9086; Gao QS, 1999, MOL CELL BIOL, V19, P733; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hay S, 2002, J GEN VIROL, V83, P1547, DOI 10.1099/0022-1317-83-7-1547; HOWLEY PM, 1992, PRINCESS TAKAMATSU S, V22, P239; Hu SM, 1997, J BIOL CHEM, V272, P9621; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Inoue T, 1998, MOL CARCINOGEN, V21, P215; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kabsch K, 2002, ONCOGENE, V21, P947, DOI 10.1038/sj.onc.1205147; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kim PKM, 2003, BIOCHEM BIOPH RES CO, V302, P290, DOI 10.1016/S0006-291X(03)00186-4; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kobayashi T, 2001, Nihon Jibiinkoka Gakkai Kaiho, V104, P139; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Langelier Y, 2002, J GEN VIROL, V83, P2779, DOI 10.1099/0022-1317-83-11-2779; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Liu Y, 1999, J BIOL CHEM, V274, P24819, DOI 10.1074/jbc.274.35.24819; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MCNICOL P, 1995, J CLIN MICROBIOL, V33, P1169, DOI 10.1128/JCM.33.5.1169-1173.1995; Mishima K, 2003, INT J CANCER, V105, P593, DOI 10.1002/ijc.11133; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Shally M, 1996, VIRUS RES, V42, P81, DOI 10.1016/0168-1702(96)01301-9; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; Shisler JL, 2001, VIROLOGY, V282, P14, DOI 10.1006/viro.2001.0834; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Spitkovsky D, 1996, ONCOGENE, V13, P1027; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivenugopal KS, 2002, ONCOGENE, V21, P5940, DOI 10.1038/sj.onc.1205762; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tourneur L, 2003, ONCOGENE, V22, P2795, DOI 10.1038/sj.onc.1206399; TROSSMESILATY S, 1998, P NATL ACAD SCI USA, V95, P8058; Tsukumo S, 1999, GENES CELLS, V4, P541, DOI 10.1046/j.1365-2443.1999.00280.x; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Vikhanskaya F, 2002, INT J CANCER, V97, P732, DOI 10.1002/ijc.10114; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Yang J, 1998, CARCINOGENESIS, V19, P1117, DOI 10.1093/carcin/19.6.1117; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	90	123	127	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25729	25744		10.1074/jbc.M401172200	http://dx.doi.org/10.1074/jbc.M401172200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073179	hybrid			2022-12-25	WOS:000221827900103
J	Jones, JC; Phatnani, HP; Haystead, TA; MacDonald, JA; Alam, SM; Greenleaf, AL				Jones, JC; Phatnani, HP; Haystead, TA; MacDonald, JA; Alam, SM; Greenleaf, AL			C-terminal repeat domain kinase I phosphorylates Ser2 and Ser5 of RNA polymerase IIC-terminal domain repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE; PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; CTDK-I; TRANSCRIPTIONAL ELONGATION; DIHYDROFOLATE-REDUCTASE; PROCESSING FACTORS; DISTINCT ROLES; CAPPING ENZYME; HEAT-SHOCK	The C-terminal repeat domain (CTD) of the largest subunit of RNA polymerase II is composed of tandem heptad repeats with consensus sequence Tyr1-Ser2-ro3-Thr4-Ser5-Pro6-Ser7. In yeast, this heptad sequence is repeated about 26 times, and it becomes hyperphosphorylated during transcription predominantly at serines 2 and 5. A network of kinases and phosphatases combine to determine the CTD phosphorylation pattern. We sought to determine the positional specificity of phosphorylation by yeast CTD kinase-I (CTDK-I), an enzyme implicated in various nuclear processes including elongation and pre-mRNA3'-end formation. Toward this end, we characterized monoclonal antibodies commonly employed to study CTD phosphorylation patterns and found that the H5 monoclonal antibody reacts with CTD species phosphorylated at Ser2 and/or Ser5. We therefore used antibody-independent methods to study CTDK-I, and we found that CTDK-I phosphorylates Ser5 of the CTD if the CTD substrate is either unphosphorylated or prephosphorylated at Ser2. When Ser5 is already phosphorylated, CTDK-I phosphorylates Ser2 of the CTD. We also observed that CTDK-I efficiently generates doubly phosphorylated CTD repeats; CTD substrates that already contain Ser2-PO4 or Ser5-PO4 are more readily phosphorylated by CTDK-I than unphosphorylated CTD substrates.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Human Vaccine Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Greenleaf, AL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	arno@biochem.duke.edu	Alam, S. Munir/AAC-6711-2019	MacDonald, Justin/0000-0002-9238-8473	NIGMS NIH HHS [R01 GM040505-14, GM40505, R01 GM040505] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040505] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Bienkiewicz EA, 2000, J MOL BIOL, V297, P119, DOI 10.1006/jmbi.2000.3545; Boehm AK, 2003, MOL CELL BIOL, V23, P7628, DOI 10.1128/MCB.23.21.7628-7637.2003; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; KANG ME, 1993, J BIOL CHEM, V268, P25033; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Lee JM, 1997, J BIOL CHEM, V272, P10990; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Lindstrom DL, 2001, GENETICS, V159, P487; Liu J, 2000, MOL BIOL EVOL, V17, P1061, DOI 10.1093/oxfordjournals.molbev.a026387; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Morris DP, 1997, METHODS, V12, P264, DOI 10.1006/meth.1997.0478; Morris DP, 2000, J BIOL CHEM, V275, P39935, DOI 10.1074/jbc.M004118200; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Ostapenko D, 2003, EUKARYOT CELL, V2, P274, DOI 10.1128/EC.2.2.274-283.2003; Patturajan M, 1999, J BIOL CHEM, V274, P27823, DOI 10.1074/jbc.274.39.27823; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Skaar DA, 2002, MOL CELL, V10, P1429, DOI 10.1016/S1097-2765(02)00731-1; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WEST ML, 1995, GENETICS, V140, P1223; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Yuryev A, 1996, GENETICS, V143, P661; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	47	109	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24957	24964		10.1074/jbc.M402218200	http://dx.doi.org/10.1074/jbc.M402218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15047695	Green Accepted, hybrid			2022-12-25	WOS:000221827900009
J	Morenilla-Palao, C; Planells-Cases, R; Garcia-Sanz, N; Ferrer-Montiel, A				Morenilla-Palao, C; Planells-Cases, R; Garcia-Sanz, N; Ferrer-Montiel, A			Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN RECEPTOR; SYNAPTOTAGMIN-IX; VR1; ACTIVATION; PHOSPHORYLATION; DESENSITIZATION; SENSITIZATION; DETERMINANT; NOCICEPTION; RELEASE	The vanilloid receptor-1 (TRPV1) plays a key role in the perception of peripheral thermal and inflammatory pain. TRPV1 expression and channel activity are notably up-regulated by proalgesic agents. The transduction pathways involved in TRPV1 sensitization are still elusive. We have used a yeast two-hybrid screen to identify proteins that associate with the N terminus of TRPV1. We report that two vesicular proteins, Snapin and synaptotagmin IX (Syt IX), strongly interact in vitro and in vivo with the TRPV1 N-terminal domain. In primary dorsal root ganglion neurons, TRPV1 co-distributes in vesicles with Syt IX and the vesicular protein synaptobrevin. Neither Snapin nor Syt IX affected channel function, but they notably inhibited protein kinase C (PKC)-induced potentiation of TRPV1 channel activity with a potency that rivaled the blockade evoked by botulinum neurotoxin A, a potent blocker of neuronal exocytosis. Noteworthily, we found that PKC activation induced a rapid delivery of functional TRPV1 channels to the plasma membrane. Botulinum neurotoxin A blocked the TRPV1 membrane translocation induced by PKC that was activated with a phorbol ester or the metabotropic glutamate receptor mGluR5. Therefore, our results indicate that PKC signaling promotes at least in part the SNARE-dependent exocytosis of TRPV1 to the cell surface. Taken together, these findings imply that activity-dependent delivery of channels to the neuronal surface may contribute to the buildup and maintenance of thermal inflammatory hyperalgesia in peripheral nociceptor terminals.	Univ Miguel Hernandez, Inst Biol Mol & Celular, Elche, Alicante, Spain	Universidad Miguel Hernandez de Elche	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Ave Ferrocarril S-N, Elche, Alicante, Spain.	aferrer@umh.es	Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Morenilla-Palao, Cruz/0000-0002-8159-1206				Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Amaya F, 2003, BRAIN RES, V963, P190, DOI 10.1016/S0006-8993(02)03972-0; Bhave G, 2003, P NATL ACAD SCI USA, V100, P12480, DOI 10.1073/pnas.2032100100; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Blanes-Mira C, 2001, BIOCHEMISTRY-US, V40, P2234, DOI 10.1021/bi001919y; Bonnington JK, 2003, J PHYSIOL-LONDON, V551, P433, DOI 10.1113/jphysiol.2003.039990; Cabedo H, 2002, J BIOL CHEM, V277, P19905, DOI 10.1074/jbc.M201587200; Caprini M, 2003, EMBO J, V22, P3004, DOI 10.1093/emboj/cdg294; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Crandall M, 2002, PAIN, V98, P109, DOI 10.1016/S0304-3959(02)00034-9; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Eaton BA, 2000, J NEUROSCI, V20, P7334; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Garcia-Martinez C, 2002, P NATL ACAD SCI USA, V99, P2374, DOI 10.1073/pnas.022285899; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Haberman Y, 2003, J CELL SCI, V116, P4307, DOI 10.1242/jcs.00719; Hu HJ, 2002, J NEUROSCI, V22, P7444; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Nakahara K, 1997, J NEUROCHEM, V69, P1467; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Numazaki M, 2003, P NATL ACAD SCI USA, V100, P8002, DOI 10.1073/pnas.1337252100; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Yang Y, 2002, P NATL ACAD SCI USA, V99, P17060, DOI 10.1073/pnas.242624699; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu HL, 2002, P NATL ACAD SCI USA, V99, P17055, DOI 10.1073/pnas.232588899	42	311	332	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25665	25672		10.1074/jbc.M311515200	http://dx.doi.org/10.1074/jbc.M311515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066994	hybrid			2022-12-25	WOS:000221827900095
J	Puig-Kroger, A; Serrano-Gomez, D; Caparros, E; Dominguez-Soto, A; Relloso, M; Colmenares, M; Martinez-Munoz, L; Longo, N; Sanchez-Sanchez, N; Rincon, M; Rivas, L; Sanchez-Mateos, P; Fernandez-Ruiz, E; Corbi, AL				Puig-Kroger, A; Serrano-Gomez, D; Caparros, E; Dominguez-Soto, A; Relloso, M; Colmenares, M; Martinez-Munoz, L; Longo, N; Sanchez-Sanchez, N; Rincon, M; Rivas, L; Sanchez-Mateos, P; Fernandez-Ruiz, E; Corbi, AL			Regulated expression of the pathogen receptor dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin in THP-1 human leukemic cells, monocytes, and macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; DC-SIGN CD209; TGF-BETA; DIFFERENTIATION; ANTIGEN; IL-4; INTERLEUKIN-4; MATURATION; IDENTIFICATION; PROGENITORS	Dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) is a type II C-type lectin that functions as an adhesion receptor and mediates binding and internalization of pathogens such as virus (human immunodeficiency virus, hepatitis C), bacteria (Mycobacterium), fungi, and parasites. DC-SIGN expression in vivo is primarily restricted to interstitial dendritic cells (DC) and certain tissue macrophages. We now report that leukemic THP-1 cells, widely used as a model for monocyte-macrophage differentiation, express very low basal levels of DC-SIGN and that DC-SIGN expression in THP-1 cells is regulated during differentiation. Differentiation-inducing agents (phorbol ester, bryostatin) conveyed THP-1 cells with the ability to up-regulate DC-SIGN mRNA levels and cell surface expression in response to interleukin-4 (IL-4) or IL-13. DC-SIGN up-regulation required a functional JAK-STAT signaling pathway, was inhibited in the presence of lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-alpha), and conferred THP-1 cells with increased pathogen recognition and T cell stimulatory capabilities. The up-regulation of DC-SIGN on THP-1 cells resembles its inducible expression on monocytes and macrophages, where DC-SIGN expression is also induced by IL-4/IL-13 and negatively regulated by TNF-alpha, LPS, and vitamin D-3. These results point to THP-1 cells as a useful cellular system to characterize the pathogen-binding capabilities of DC-SIGN and to dissect the molecular mechanisms that control its regulated and tissue-specific expression in myeloid dendritic cells, and the results suggest that DC-SIGN constitutes a marker for both DC and alternatively activated macrophages.	CSIC, Ctr Invest Biol, Madrid 28040, Spain; Hosp Univ Gregorio Maranon, Unidad Inmunooncol, Madrid 28006, Spain; Univ Vermont, Dept Med & Immunobiol, Burlington, VT 05405 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); General University Gregorio Maranon Hospital; University of Vermont	Corbi, AL (corresponding author), CSIC, Ctr Invest Biol, Ramiro Maetzu 9, Madrid 28040, Spain.	acorbi@cib.csic.es	Sanchez-Mateos, Paloma/E-8931-2013; Colmenares, Maria Isabel/H-2848-2017; Serrano-Gómez, Diego/W-2857-2018; Relloso, Miguel/K-2238-2014; DOMINGUEZ-SOTO, ANGELES/K-5937-2014; Corbi, Angel/B-7194-2011; Corbí, Angel L./ABC-8146-2020; Martínez-Muñoz, Laura/C-2719-2017; Fernández-Ruiz, Elena/A-7971-2019; Rivas, Luis/O-8657-2017; Puig, Amaya/B-6164-2015; Caparrós, Esther/AHD-3233-2022	Colmenares, Maria Isabel/0000-0003-4114-277X; Serrano-Gómez, Diego/0000-0003-4965-8869; Relloso, Miguel/0000-0002-9181-2244; Corbi, Angel/0000-0003-1980-5733; Corbí, Angel L./0000-0003-1980-5733; Martínez-Muñoz, Laura/0000-0003-3098-279X; Fernández-Ruiz, Elena/0000-0001-5380-1686; Rivas, Luis/0000-0002-2958-3233; Puig, Amaya/0000-0003-2943-9757; Caparrós, Esther/0000-0002-9681-0408; Dominguez Soto, Angeles/0000-0003-1299-5992				Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; BOMBARA C, 1992, J CELL PHYSIOL, V153, P30, DOI 10.1002/jcp.1041530106; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Cambi A, 2003, EUR J IMMUNOL, V33, P532, DOI 10.1002/immu.200310029; Chehimi J, 2003, J LEUKOCYTE BIOL, V74, P757, DOI 10.1189/jlb.0503231; Chen Z, 2003, J IMMUNOL, V171, P3627, DOI 10.4049/jimmunol.171.7.3627; Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200; Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HART PH, 1995, J LEUKOCYTE BIOL, V57, P909, DOI 10.1002/jlb.57.6.909; Hulette BC, 2001, ARCH DERMATOL RES, V293, P147, DOI 10.1007/s004030000201; Kodelja V, 1998, J IMMUNOL, V160, P1411; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; LAUENER RP, 1990, EUR J IMMUNOL, V20, P2375, DOI 10.1002/eji.1830201103; LENT PL, 2003, ARTHRITIS RHEUM, V48, P360; Li Y, 1997, LEUKEMIA RES, V21, P391, DOI 10.1016/S0145-2126(96)00078-1; Mummidi S, 2001, J BIOL CHEM, V276, P33196, DOI 10.1074/jbc.M009807200; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Puig-Kroger A, 2000, J IMMUNOL, V165, P4338, DOI 10.4049/jimmunol.165.8.4338; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Rougier N, 1998, EUR J CELL BIOL, V75, P287, DOI 10.1016/S0171-9335(98)80124-6; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; St Louis DC, 1999, J IMMUNOL, V162, P3237; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VEY E, 1992, J IMMUNOL, V149, P2040; WONG HL, 1992, J IMMUNOL, V148, P2118; Zhu JF, 2000, J EXP MED, V192, P1125, DOI 10.1084/jem.192.8.1125	41	82	89	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25680	25688		10.1074/jbc.M311516200	http://dx.doi.org/10.1074/jbc.M311516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070901	hybrid, Green Published			2022-12-25	WOS:000221827900097
J	Wearsch, PA; Jakob, CA; Vallin, A; Dwek, RA; Rudd, PM; Cresswell, P				Wearsch, PA; Jakob, CA; Vallin, A; Dwek, RA; Rudd, PM; Cresswell, P			Major histocompatibility complex class I molecules expressed with monoglucosylated N-linked glycans bind calreticulin independently of their assembly status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; HLA CLASS-I; QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; HEAVY-CHAINS; GLYCOPROTEIN GLUCOSYLTRANSFERASE; ANTIGEN PRESENTATION; PEPTIDE COMPLEXES; P-DOMAIN	The assembly of major histocompatibility complex (MHC) class I molecules with peptides in the endoplasmic reticulum (ER) is a critical step in the presentation of viral antigens to CD8+ T cells. This process is subject to quality control restrictions that prevent free class I heavy chains (HCs) and peptide-free HC-beta(2)-microglobulin (beta(2)m) dimers from exiting the ER. The lectin-like chaperone calreticulin associates with HC-beta(2)m heterodimers prior to peptide binding, but its precise role in regulating the subsequent events of peptide association and ER to Golgi transport remains undefined. In vitro analysis of the assembly process has been limited by the specificity of calreticulin for monoglucosylated N-linked glycans, which are transient biosynthetic intermediates. To address this problem, we developed a novel expression system using Saccharomyces cerevisiae glycosylation mutants to produce class I HC bearing N-linked oligosaccharides with the specific structure Glc(1)Man(9)GlcNAc(2). The monoglucosylated glycan proved to be both necessary and sufficient for in vitro binding of calreticulin to MHC class I molecules. Calreticulin bound as efficiently to peptide-loaded MHC class I complexes as it did to folding intermediates created in vitro, namely free class I HC and empty HC-beta(2)m heterodimers. Thus, calreticulin is unable to discriminate between native and non-native MHC class I conformations and therefore unlikely to play a role in the recognition and release of peptide-loaded complexes from the ER. Furthermore, the recombinant expression system developed in this study can be used to produce a broad range of calreticulin substrates to elucidate its general mechanism of activity in vitro.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; ETH, Inst Microbiol, CH-8092 Zurich, Switzerland; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	Howard Hughes Medical Institute; Yale University; ETH Zurich; University of Oxford	Cresswell, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 300 Cedar St,POB 208011, New Haven, CT 06520 USA.	peter.cresswell@yale.edu	Wearsch, Pamela/K-8505-2014	Wearsch, Pamela/0000-0002-9569-3852; vallin, Antonio/0000-0003-2729-6916				ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Cresswell P, 2000, TRAFFIC, V1, P301, DOI 10.1034/j.1600-0854.2000.010402.x; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; Guthrie G.R.F.C., 1991, GUIDE YEAST GENETICS; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Jakob CA, 1998, GLYCOBIOLOGY, V8, P155, DOI 10.1093/glycob/8.2.155; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; Mancino L, 2002, P NATL ACAD SCI USA, V99, P5931, DOI 10.1073/pnas.092031799; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Peterson JR, 1999, J CELL SCI, V112, P2775; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	51	37	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25112	25121		10.1074/jbc.M401721200	http://dx.doi.org/10.1074/jbc.M401721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15056662	hybrid			2022-12-25	WOS:000221827900026
J	Weber, J; Muharemagic, A; Wilke-Mounts, S; Senior, AE				Weber, J; Muharemagic, A; Wilke-Mounts, S; Senior, AE			Analysis of sequence determinants of F1Fo-ATP synthase in the N-terminal region of alpha subunit for binding of delta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ATP SYNTHASE; ESCHERICHIA-COLI; F1F0-ATP SYNTHASE; QUANTITATIVE-DETERMINATION; F0F1-ATP SYNTHASE; CATALYTIC SITES; CROSS-LINKING; B-SUBUNIT; F-1-ATPASE; F-1	The stator in F1Fo-ATP synthase resists strain generated by rotor torque. In Escherichia coli, the b(2)delta subunit complex comprises the stator, bound to subunit a in F-o and to the alpha(3)beta(3) hexagon of F-1. Previous work has shown that N-terminal residues of alpha subunit are involved in binding delta. A synthetic peptide consisting of the first 22 residues of alpha(alphaN1-22) binds specifically to isolated wildtype delta subunit with 1: 1 stoichiometry and high affinity, accounting for a major portion of the binding energy between delta and F-1. Residues alpha6-18 are predicted by secondary structure algorithms and helical wheels to be alpha-helical and amphipathic, and a potential helix capping box occurs at residues alpha3-8. We introduced truncations, deletions, and mutations into alphaN1-22 and examined their effects on binding to the delta subunit. The deletions and mutations were introduced also into the N-terminal region of the uncA (alpha subunit) gene to determine effects on cell growth in vivo and membrane ATP synthase activity in vitro. Effects seen in the peptides were well correlated with those seen in the uncA gene. The results show that, with the possible exception of residues close to the initial Met, all of the alphaN1-22 sequence is required for binding of delta to alpha. Within this sequence, an amphipathic helix seems important. Hydrophobic residues on the predicted nonpolar surface are important for delta binding, namely alphaIle-8, alphaLeu-11, alphaIle-12, alphaIle-16, and alphaPhe-19. Several or all of these residues probably make direct interaction with helices 1 and 5 of delta. The potential capping box sequence per se appeared less important. Impairment of alpha/delta binding brings about functional impairment due to reduced level of assembly of ATP synthase in cells.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Diez M, 2004, BIOCHEMISTRY-US, V43, P1054, DOI 10.1021/bi0357098; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Kersten MV, 2000, BIOCHEMISTRY-US, V39, P3856, DOI 10.1021/bi992699v; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Nishizaka T, 2004, NAT STRUCT MOL BIOL, V11, P142, DOI 10.1038/nsmb721; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; Weber J, 2004, J BIOL CHEM, V279, P11253, DOI 10.1074/jbc.M312576200; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; WILKENS S, 1997, NAT STRUCT BIOL, V4, P197	28	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25673	25679		10.1074/jbc.M402738200	http://dx.doi.org/10.1074/jbc.M402738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069069	hybrid			2022-12-25	WOS:000221827900096
J	Kast-Woelbern, HR; Dana, SL; Cesario, RM; Sun, L; de Grandpre, LY; Brooks, ME; Osburn, DL; Reifel-Miller, A; Klausing, K; Leibowitz, MD				Kast-Woelbern, HR; Dana, SL; Cesario, RM; Sun, L; de Grandpre, LY; Brooks, ME; Osburn, DL; Reifel-Miller, A; Klausing, K; Leibowitz, MD			Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PROFILE; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; CHOLESTEROL HOMEOSTASIS; INSULIN ACTION; IDENTIFICATION; TRANSCRIPTION; ADD1/SREBP1; RETENTION; AGONISTS	Insulin-induced gene 1 (INSIG-1) is a key regulator in the processing of the sterol regulatory element-binding proteins (SREBPs). We demonstrated that Insig-1 is regulated by peroxisome proliferator-activated receptor gamma (PPARgamma) providing a link between insulin sensitization/glucose homeostasis and lipid homeostasis. Insig-1 was identified as a PPARgamma target gene using microarray analysis of mRNA from the white adipose tissue of diabetic (db/db) animals treated with PPARgamma agonists. Insig1 was induced in subcutaneous (9-fold) and epididymal (4-fold) fat pads from db/db mice treated for 8 days with the PPARgamma agonist rosiglitazone (30 mg/kg/day). This in vivo response was confirmed in differentiated C3H10T1/2 adipocytes treated with rosiglitazone. To elucidate the molecular mechanisms regulating INSIG-1 expression, we cloned and characterized the human INSIG-1 promoter. Co-expression of PPARgamma and RXRalpha transactivated the INSIG-1 promoter in the presence of PPARgamma agonists. This induction was attenuated when a dominant negative PPARgamma construct was transfected into cells. Furthermore, a PPARgamma antagonist repressed the transactivation of the INSIG-1 promoter-reporter construct. Truncations of the promoter resulted in the identification of a PPAR response element that mediated the regulation of the promoter. We demonstrated with recombinant proteins that the PPARgamma/RXRalpha heterodimer binds directly to this PPAR response element. In addition to regulation by PPARgamma/RXRalpha, we demonstrated that the INSIG-1 promoter is regulated by transcriptionally active SREBP. The sterol response element was identified 380 base pairs upstream of the transcriptional start site. These findings suggest that the regulation of Insig-1 by PPARgamma agonists could in turn regulate SREBP processing and thus couple insulin sensitizers with the regulation of lipid homeostasis.	Ligand Pharmaceut Inc, Dept Mol & Cell Biol, San Diego, CA 92121 USA; Ligand Pharmaceut Inc, Dept Pharmacol, San Diego, CA 92121 USA; Ligand Pharmaceut Inc, Dept Mol Oncol, San Diego, CA 92121 USA; Eli Lilly & Co, Lilly Res Labs, Div Endocrine Res, Indianapolis, IN 46285 USA	Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Eli Lilly	Kast-Woelbern, HR (corresponding author), Ligand Pharmaceut Inc, Dept Mol & Cell Biol, 10275 Sci Ctr Dr, San Diego, CA 92121 USA.	hwoelbern@ligand.com						Albrektsen T, 2002, DIABETES, V51, P1042, DOI 10.2337/diabetes.51.4.1042; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Bortoff KD, 1997, ENDOCRINE, V7, P199, DOI 10.1007/BF02778142; Croston GE, 1997, ENDOCRINOLOGY, V138, P3779, DOI 10.1210/en.138.9.3779; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; Flier JS, 1999, P NATL ACAD SCI USA, V96, P14191, DOI 10.1073/pnas.96.25.14191; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; Gurnell M, 2003, J CLIN ENDOCR METAB, V88, P2412, DOI 10.1210/jc.2003-030435; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Janowski BA, 2002, P NATL ACAD SCI USA, V99, P12675, DOI 10.1073/pnas.202471599; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Larsen TM, 2003, INT J OBESITY, V27, P147, DOI 10.1038/sj.ijo.802223; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Li JP, 2003, P NATL ACAD SCI USA, V100, P9476, DOI 10.1073/pnas.1133426100; Li JP, 2002, AM J PHYSIOL-ENDOC M, V282, pE1334, DOI 10.1152/ajpendo.00516.2001; Nesto RW, 2004, DIABETES CARE, V27, P256, DOI 10.2337/diacare.27.1.256; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Peng Y, 1997, GENOMICS, V43, P278, DOI 10.1006/geno.1997.4821; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	30	84	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23908	23915		10.1074/jbc.M403145200	http://dx.doi.org/10.1074/jbc.M403145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15073165	hybrid			2022-12-25	WOS:000221702500011
J	Tenhunen, O; Sarman, B; Kerkela, R; Szokodi, I; Papp, L; Toth, M; Ruskoaho, H				Tenhunen, O; Sarman, B; Kerkela, R; Szokodi, I; Papp, L; Toth, M; Ruskoaho, H			Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE GENE; LEFT-VENTRICULAR HYPERTROPHY; TRANSCRIPTION FACTOR GATA4; CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; IN-VIVO; VENTRAL MORPHOGENESIS; SIGNALING PATHWAYS; GROWTH-RESPONSES; AT(1) RECEPTOR	The zinc finger transcription factor GATA-4 has been implicated as a critical regulator of inducible cardiac gene expression and as a potential mediator of the hypertrophic program. However, the precise intracellular mechanisms that regulate the DNA-binding activity of GATA-4 are not fully understood. The aim of the present study was to examine the role of mitogen-activated protein kinases (p38 kinase, extracellular signal-regulated protein kinase, and c-Jun N-terminal protein kinase) in the left ventricular wall stress-induced activation of GATA-4 DNA binding in adult heart. Isolated perfused rat hearts were subjected to increased left ventricular wall stress by inflating a balloon in the ventricle. Gel mobility shift assays were used to analyze the transacting factors that interact with the GATA motifs of the B-type natriuretic peptide promoter. The left ventricular wall stress rapidly activated GATA-4 DNA binding and significantly increased the levels of phosphorylated p38 kinase, extracellular signal-regulated protein kinase, and c-Jun N-terminal protein kinase. The wall stress-induced increase in the DNA-binding activity of GATA-4 was abolished both in the presence of the p38 inhibitor SB239063 and MEK1/2 inhibitor U0126. In contrast, the inhibition of c-Jun N-terminal protein kinase by CEP11004 had no effect on the baseline or stretch-induced GATA-4 DNA binding. Moreover, GATA-4 DNA binding was up-regulated by mechanical stretch in the isolated rat atria via p38 and extracellular signal-regulated protein kinase. In conclusion, the present study demonstrates that both p38 and extracellular signal-regulated protein kinase are required for the stretch-induced GATA-4 binding in intact heart.	Univ Oulu, Bioctr Oulu, Dept Pharmacol & Toxicol, FIN-90014 Oulu, Finland; Hungarian Acad Sci, Mol Genet Res Grp, H-1083 Budapest, Hungary; Semmelweis Univ, Dept Med 1, H-1083 Budapest, Hungary; Univ Pecs, Fac Med, Inst Heart, H-7624 Pecs, Hungary	University of Oulu; Hungarian Academy of Sciences; Semmelweis University; University of Pecs	Ruskoaho, H (corresponding author), Univ Oulu, Bioctr Oulu, Dept Pharmacol & Toxicol, POB 5000, FIN-90014 Oulu, Finland.	heikki.ruskoaho@oulu.fi	Szokodi, Istvan/X-3704-2019	Szokodi, Istvan/0000-0002-2162-6155				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Behr TM, 2001, CIRCULATION, V104, P1292, DOI 10.1161/hc3601.094275; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cornelius T, 1997, HYPERTENSION, V30, P1348, DOI 10.1161/01.HYP.30.6.1348; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hautala N, 2002, PFLUG ARCH EUR J PHY, V443, P362, DOI 10.1007/s004240100699; Hautala N, 2001, CIRCULATION, V103, P730; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; KELLEY C, 1993, DEVELOPMENT, V118, P817; Kerkela R, 2002, J BIOL CHEM, V277, P13752, DOI 10.1074/jbc.M105736200; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2002, J MOL CELL CARDIOL, V34, P611, DOI 10.1006/jmcc.2002.2011; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Lorell BH, 2000, CIRCULATION, V102, P470; Magga J, 1997, CIRCULATION, V96, P3053, DOI 10.1161/01.CIR.96.9.3053; Marttila M, 2001, ENDOCRINOLOGY, V142, P4693, DOI 10.1210/en.142.11.4693; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Pikkarainen S, 2003, J BIOL CHEM, V278, P23807, DOI 10.1074/jbc.M302719200; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Samarel AM, 2001, J MOL CELL CARDIOL, V33, P1637, DOI 10.1006/jmcc.2001.1427; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; Schunkert H, 1995, J CLIN INVEST, V96, P2768, DOI 10.1172/JCI118346; Stromer H, 1997, AM J PHYSIOL-HEART C, V272, pH501, DOI 10.1152/ajpheart.1997.272.1.H501; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Suo M, 2002, HYPERTENSION, V39, P803, DOI 10.1161/hy0302.105214; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Tavi P, 1998, CIRC RES, V83, P1165, DOI 10.1161/01.RES.83.11.1165; Thienelt CD, 1997, CIRCULATION, V95, P2677, DOI 10.1161/01.CIR.95.12.2677; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Yamamoto K, 2001, CIRCULATION, V103, P1459, DOI 10.1161/01.CIR.103.10.1459; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200	49	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24852	24860		10.1074/jbc.M314317200	http://dx.doi.org/10.1074/jbc.M314317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051723	hybrid			2022-12-25	WOS:000221702500116
J	Zapata, DA; Schamel, WWA; Torres, PS; Alarcon, B; Rossi, NE; Navarro, MN; Toribio, ML; Regueiro, JR				Zapata, DA; Schamel, WWA; Torres, PS; Alarcon, B; Rossi, NE; Navarro, MN; Toribio, ML; Regueiro, JR			Biochemical differences in the alpha beta T cell receptor center dot CD3 surface complex between CD8(+) and CD4(+) human mature T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAMER BINDING; CD3 COMPLEX; TCR; RECEPTOR; EXPRESSION; GLYCOSYLATION; ASSOCIATION; DEFICIENCY; MATURATION; MOLECULES	We have reported the existence of biochemical and conformational differences in the alphabeta T cell receptor (TCR) complex between CD4(+) and CD8(+) CD3gamma-deficient (gamma(-)) mature T cells. In the present study, we have furthered our understanding and extended the observations to primary T lymphocytes from normal (gamma(+)) individuals. Surface TCR.CD3 components from CD4(+) alphabeta T cells, other than CD3gamma, were detectable and similar in size to CD4(+) gamma(+) controls. Their native TCR.CD3 complex was also similar to CD4(+) gamma(+) controls, except for an alphabeta(deltaepsilon)(2)zeta(2) instead of an alphabetagammaepsilondeltaepsilonzeta(2) stoichiometry. In contrast, the surface TCRalpha, TCRbeta, and CD3delta chains of CD8(+) gamma(-) T cells did not possess their usual sizes. Using confocal immunofluorescence, TCRalpha was hardly detectable in CD8(+) gamma(-) T cells. Blue native gels (BN-PAGE) demonstrated the existence of a heterogeneous population of TCR.CD3 in these cells. Using primary peripheral blood T lymphocytes from normal (gamma(+)) donors, we performed a broad epitopic scan. In contrast to all other TCR.CD3-specific monoclonal antibodies, RW2-8C8 stained CD8(+) better than it did CD4(+) T cells, and the difference was dependent on glycosylation of the TCR.CD3 complex but independent of T cell activation or differentiation. RW2-8C8 staining of CD8(+) T cells was shown to be more dependent on lipid raft integrity than that of CD4(+) T cells. Finally, immunoprecipitation studies on purified primary CD4(+) and CD8(+) T cells revealed the existence of TCR glycosylation differences between the two. Collectively, these results are consistent with the existence of conformational or topological lineage-specific differences in the TCR.CD3 from CD4(+) and CD8(+) wild type T cells. The differences may be relevant for cis interactions during antigen recognition and signal transduction.	Univ Complutense Madrid, Fac Med, E-28040 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Regueiro, JR (corresponding author), Univ Complutense Madrid, Fac Med, E-28040 Madrid, Spain.	regueiro@med.ucm.es	Regueiro, José R./B-5499-2014; Alarcon, Balbino/N-9648-2016; Rossi, Nineth/ABE-4009-2021; Toribio, Maria L/C-2039-2017	Regueiro, José R./0000-0001-8442-7762; Alarcon, Balbino/0000-0001-7820-1070; Toribio, Maria L/0000-0002-8637-0373; Navarro, Maria N./0000-0003-3977-812X				Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Carrasco YR, 2001, J EXP MED, V193, P1045, DOI 10.1084/jem.193.9.1045; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Daniels MA, 2002, NAT IMMUNOL, V3, P903, DOI 10.1038/ni1002-903; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; Drake DR, 2001, J IMMUNOL, V166, P7009, DOI 10.4049/jimmunol.166.12.7009; FINKEL TH, 1987, NATURE, V330, P179, DOI 10.1038/330179a0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Haks MC, 1998, EMBO J, V17, P1871, DOI 10.1093/emboj/17.7.1871; Hartel S, 1998, ANAL BIOCHEM, V258, P277, DOI 10.1006/abio.1998.2594; Hayes SM, 2002, IMMUNITY, V16, P827, DOI 10.1016/S1074-7613(02)00320-5; Hayes SM, 2002, J EXP MED, V196, P1355, DOI 10.1084/jem.20021196; Lim LCL, 1998, CLIN DIAGN LAB IMMUN, V5, P392, DOI 10.1128/CDLI.5.3.392-398.1998; MACKALL CL, 1993, BLOOD, V82, P2585; Malissen B, 1999, ADV IMMUNOL, V72, P103, DOI 10.1016/S0065-2776(08)60018-8; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Pacheco-Castro A, 1998, J IMMUNOL, V161, P3152; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schamel WWA, 2000, IMMUNITY, V13, P5, DOI 10.1016/S1074-7613(00)00003-0; SPITS H, 1985, J IMMUNOL, V135, P1922; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; THIBAULT G, 1995, J IMMUNOL, V154, P3814; TIMON M, 1993, EUR J IMMUNOL, V23, P1440, DOI 10.1002/eji.1830230706; Torres PS, 2003, J IMMUNOL, V170, P5947, DOI 10.4049/jimmunol.170.12.5947; Uhlin M, 2003, SCAND J IMMUNOL, V57, P99, DOI 10.1046/j.1365-3083.2003.01188.x; VANDEGRIEND RJ, 1988, J IMMUNOL, V140, P1107; YOKOYAMA WM, 1991, CURRENT PROTOCOLS IM; Zapata DA, 1999, J BIOL CHEM, V274, P35119, DOI 10.1074/jbc.274.49.35119	35	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24485	24492		10.1074/jbc.M311455200	http://dx.doi.org/10.1074/jbc.M311455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15060077	hybrid			2022-12-25	WOS:000221702500076
J	Drivdahl, R; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Plymate, SR				Drivdahl, R; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Plymate, SR			Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9	ONCOGENE			English	Article						SOX9; prostate; androgens; IGF; cancer	PROTEIN-RELATED PROTEIN-1; MANGANESE SUPEROXIDE-DISMUTASE; ANDROGEN RECEPTOR; CANCER CELLS; EPITHELIAL-CELLS; BINDING; EXPRESSION; GENES; SEX; KINASE	Overexpression of mac25 in the prostate cancer cell line M12 effects a dramatic reversal of the transformed phenotype. cDNA array analysis of RNA from cells overproducing the mac25 protein (M12/mac25) indicated upregulation of the sex determining transcription factor SOX9. In this study, we have confirmed increased expression of SOX9 in M12/mac25 cells and have further investigated the physiological effects of increased SOX9 production. Greatly increased levels of SOX9 RNA and mature protein were demonstrated in cells transfected with a SOX9 cDNA (M12/SOX9), and gel mobility shift assays confirmed binding of nuclear protein from these cells to an oligonucleotide containing the SOX9 consensus binding sequence. M12/SOX9 cells assumed the spindle-shaped morphology characteristic of M12/mac25 cells, suggesting that SOX9 mediates some effects of mac25. Elevated expression of SOX9 resulted in a decreased rate of cellular proliferation, cell cycle arrest in G0/G1, and increased sensitivity to apoptosis. Tumor development in athymic nude mice was inhibited by 80%. Finally, prostate-specific antigen and the androgen receptor, two genes whose expression is characteristic of differentiated cells, were both upregulated in M12/SOX9 cells. These data indicate that SOX9 contributes to growth regulation by mac25 via inhibition of cell growth and promotion of differentiation.	Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98105 USA; Univ Washington, Sch Med, Mol & Cell Biol Program, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98107 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Plymate, SR (corresponding author), Univ Washington, Harborview Med Ctr, Box 359755,325 9th Ave, Seattle, WA 98104 USA.	splymate@u.washington.edu			NCI NIH HHS [R01-CA56283, P01-CA85859] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA085859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Bowles J, 2001, GENOME BIOL, V2; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarkson MJ, 2002, TRENDS ENDOCRIN MET, V13, P106, DOI 10.1016/S1043-2760(01)00541-0; Damon SE, 1998, ENDOCRINOLOGY, V139, P3456, DOI 10.1210/en.139.8.3456; Drivdahl RH, 2001, ENDOCRINOLOGY, V142, P1990, DOI 10.1210/en.142.5.1990; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURNEY RM, 1989, FOCUS, V10, P5; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.3.CO;2-E; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Hwa V, 1998, J CLIN ENDOCR METAB, V83, P4355, DOI 10.1210/jc.83.12.4355; Kanai Y, 1999, HUM MOL GENET, V8, P691, DOI 10.1093/hmg/8.4.691; Kato MV, 1996, ONCOGENE, V12, P1361; Kent J, 1996, DEVELOPMENT, V122, P2813; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; KOMATSU K, 2001, BIOCHEM BIOPH RES CO, V276, P109; Koopman P, 2001, J EXP ZOOL, V290, P463, DOI 10.1002/jez.1089; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Marshall OJ, 2000, MOL GENET METAB, V71, P455, DOI 10.1006/mgme.2000.3081; Millikan LE, 1999, CLIN DERMATOL, V17, P353, DOI 10.1016/S0738-081X(99)00018-8; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Olney PN, 1999, AM J MED GENET, V84, P20, DOI 10.1002/(SICI)1096-8628(19990507)84:1<20::AID-AJMG5>3.3.CO;2-E; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; PEEHL DM, 1986, IN VITRO CELL DEV B, V22, P82; Plymate SR, 2003, ONCOGENE, V22, P1024, DOI 10.1038/sj.onc.1206210; Preiss S, 2001, J BIOL CHEM, V276, P27864, DOI 10.1074/jbc.M101278200; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729; Spokony RF, 2002, DEVELOPMENT, V129, P421; Sprenger CC, 1999, CANCER RES, V59, P2370; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tran CP, 2002, MOL CANCER RES, V1, P113; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	55	50	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4584	4593		10.1038/sj.onc.1207603	http://dx.doi.org/10.1038/sj.onc.1207603			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077158				2022-12-25	WOS:000221799000008
J	Yamagata, K; Daitoku, H; Shimamoto, Y; Matsuzaki, H; Hirota, K; Ishida, J; Fukamizu, A				Yamagata, K; Daitoku, H; Shimamoto, Y; Matsuzaki, H; Hirota, K; Ishida, J; Fukamizu, A			Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; INSULIN-RESPONSE SEQUENCES; FACTOR-BINDING PROTEIN-1; PHOSPHOENOLPYRUVATE CARBOXYKINASE; FACTOR FKHR; HEPATIC GLUCONEOGENESIS; PROMOTER ACTIVITY; FEEDBACK-REGULATION; COACTIVATOR PGC-1; FACTOR 4-ALPHA	Bile acid homeostasis is tightly controlled by the feedback mechanism in which an atypical orphan nuclear receptor (NR) small heterodimer partner (SHP) inactivates several NRs such as liver receptor homologue-1 and hepatocyte nuclear factor 4. Although NRs have been implicated in the transcriptional regulation of gluconeogenic genes, the effect of bile acids on gluconeogenic gene expression remained unknown. Here, we report that bile acids inhibit the expression of gluconeogenic genes, including glucose-6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase, and fructose 1,6-bis phosphatase in an SHP-dependent fashion. Cholic acid diet decreased the mRNA levels of these gluconeogenic enzymes, whereas those of SHP were increased. Reporter assays demonstrated that the promoter activity of phosphoenolpyruvate carboxykinase and fructose 1,6-bis phosphatase via hepatocyte nuclear factor 4, or that of G6Pase via the forkhead transcription factor Foxo1, was down-regulated by treatment with chenodeoxicholic acid and with transfected SHP. Remarkably, Foxo1 interacted with SHP in vivo and in vitro, which led to the repression of Foxo1-mediated G6Pase transcription by competition with a coactivator cAMP response element-binding protein-binding protein. These findings reveal a novel mechanism by which bile acids regulate gluconeogenic gene expression via an SHP-dependent regulatory pathway.	Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan	University of Tsukuba	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Ten Noudai 1-1-1, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Matsuzaki, Hitomi/0000-0002-8890-5933; YAMAGATA, Kazuyuki/0000-0002-5804-6090				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Ayala JE, 1999, DIABETES, V48, P1885, DOI 10.2337/diabetes.48.9.1885; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borgius LJ, 2002, J BIOL CHEM, V277, P49761, DOI 10.1074/jbc.M205641200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Chen WL, 2003, GENE, V313, P71, DOI 10.1016/S0378-1119(03)00631-0; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Fukuoka M, 2003, INT J MOL MED, V12, P503; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hatta M, 2002, INT J MOL MED, V9, P147; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552; OBrien RM, 1995, BBA-GENE STRUCT EXPR, V1264, P284, DOI 10.1016/0167-4781(95)00194-8; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Perrot V, 2003, J BIOL CHEM, V278, P26111, DOI 10.1074/jbc.M212750200; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shimamoto Y, 2004, J BIOL CHEM, V279, P7770, DOI 10.1074/jbc.M310577200; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200	45	226	244	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23158	23165		10.1074/jbc.M314322200	http://dx.doi.org/10.1074/jbc.M314322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047713	hybrid			2022-12-25	WOS:000221570900046
J	Delva, L; Gallais, I; Guillouf, C; Denis, N; Orvain, C; Moreau-Gachelin, F				Delva, L; Gallais, I; Guillouf, C; Denis, N; Orvain, C; Moreau-Gachelin, F			Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells	ONCOGENE			English	Article						Spi-1/PU.1; TLS; erythroleukemia; transcription factor; splicing interference	RNA-BINDING PROTEIN; HUMAN MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR PU.1; POLYMERASE-II; CHROMOSOMAL TRANSLOCATION; DNA-BINDING; PUTATIVE ONCOGENE; ACTIVATION DOMAIN; TERMINAL DOMAIN; IN-VIVO	The hematopoietic transcription factor Spi-1/PU.1 is an oncoprotein participating to the malignant transformation of proerythroblasts in the Friend erythroleukemia or in the erythroleukemic process developed in spi-1 transgenic mice. Overexpression of Spi-1 in proerythroblasts blocks their differentiation. We have shown that Spi-1 promotes the use of the proximal 5'-splice site during the E1A pre-mRNA splicing and interferes with the effect of TLS (Translocated in LipoSarcoma) in this splicing assay. TLS was identified from chromosomal translocations in human liposarcoma and acute myeloid leukemia. Here, we determine the function of Spi-1 domains in splicing and in the interference with TLS. In transient transfection assays in erythroid cells, we show that the DNA binding domain cooperates with the transactivation domain or the PEST region of Spi-1 to modify the function of TLS in splicing. Interestingly, the 27 C-terminal amino acids, which determine the DNA binding activity of Spi-1, are necessary for the splicing function of Spi-1 as well as for its ability to interfere with TLS. Finally, we demonstrate that in leukemic proerythroblasts overexpressing Spi-1, TLS has lost its splicing effect. Thus, we hypothesize that oncogenic pathways in proerythroblasts may involve the ability of Spi-1 to alter splicing.	Inst Curie, INSERM, U528, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	framoreau@curie.fr		DELVA, Laurent/0000-0002-1086-3964				Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CALVIO C, 1995, RNA, V1, P724; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; FU XD, 1995, RNA, V1, P663; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Lerga A, 2001, J BIOL CHEM, V276, P6807, DOI 10.1074/jbc.M008304200; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; OHNO T, 1994, ONCOGENE, V9, P3087; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Perkel JM, 1998, J IMMUNOL, V160, P241; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Wu SP, 1997, EMBO J, V16, P4421, DOI 10.1093/emboj/16.14.4421; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	55	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4389	4399		10.1038/sj.onc.1207578	http://dx.doi.org/10.1038/sj.onc.1207578			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064749				2022-12-25	WOS:000221661300005
J	Pang, R; Yuen, J; Yuen, MF; Lai, CL; Lee, TKW; Man, K; Poon, RTP; Fan, ST; Wong, CM; Ng, IOL; Kwong, YL; Tse, E				Pang, R; Yuen, J; Yuen, MF; Lai, CL; Lee, TKW; Man, K; Poon, RTP; Fan, ST; Wong, CM; Ng, IOL; Kwong, YL; Tse, E			PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma	ONCOGENE			English	Article						PIN1; peptidyl-prolyl-isomerase; beta-catenin; hepatocellular carcinoma	CYCLIN D1 OVEREXPRESSION; TARGET; AMPLIFICATION; ACTIVATION; EXPRESSION; FREQUENT; PATHWAY; CANCER; MOUSE	The peptidyl-proplyl-isomerase, PIN1, upregulates beta-catenin by inhibiting its interaction with APC. beta-catenin accumulation occurs in about 70% of hepatocellular carcinoma (HCC), of which only 20% are due to beta-catenin mutations. The role of PIN1 in beta-catenin upregulation in HCC was investigated. PIN1 was shown to be overexpressed in more than 50% of HCC. All cases with PIN1 overexpression also showed beta-catenin accumulation, with 68% of cases showing concomitant beta-catenin and cyclin D1 accumulation. PIN1 was shown to contribute to beta-catenin and cyclin D1 overexpression directly by in vitro cell-line transfection experiments. Finally, we showed that PIN1 overexpression and beta-catenin gene mutations appeared to be mutually exclusive events, leading to beta-catenin accumulation in HCC. These results showed that PIN1 overexpression leading to beta-catenin accumulation might be a critical event in hepatocarcinogenesis, and that PIN1 is a potential target for therapeutic intervention in HCC.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Haematol Oncol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Gastroenterol & Hepatol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Kwong, YL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Haematol Oncol, Hong Kong, Hong Kong, Peoples R China.	ylkwong@hku.hk; ewctse@hku.hk.or	Fan, Sheung Tat/C-4138-2009; Tse, Eric/ABB-4021-2020; WONG, Chun-Ming/A-6739-2009	Tse, Eric/0000-0002-8351-4722; WONG, Chun-Ming/0000-0002-2497-7858; Lai, Ching-Lung/0000-0002-5927-2436; Ng, Irene Oi-lin/0000-0001-7532-2029; Lee, Kin Wah/0000-0003-0682-322X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Brown JJ, 2000, HEPATOLOGY, V31, P173, DOI 10.1002/hep.510310126; Chen TC, 1998, CANCER LETT, V134, P23, DOI 10.1016/S0304-3835(98)00238-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Deane NG, 2001, CANCER RES, V61, P5389; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Ihara A, 1996, HEPATOLOGY, V23, P1441, DOI 10.1053/jhep.1996.v23.pm0008675162; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Manickan E, 2001, J BIOL CHEM, V276, P13989, DOI 10.1074/jbc.M009770200; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NISHIDA N, 1994, CANCER RES, V54, P3107; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	25	92	102	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4182	4186		10.1038/sj.onc.1207493	http://dx.doi.org/10.1038/sj.onc.1207493			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064734				2022-12-25	WOS:000221520200018
J	Zhang, M; Altuwaijri, S; Yeh, S				Zhang, M; Altuwaijri, S; Yeh, S			RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness	ONCOGENE			English	Article						alpha-vitamin E succinate; prostate cancer tumor invasion; matrix metalloproteinases	VITAMIN-E SUCCINATE; TUMOR-CELLS; EXPRESSION; INVASION; GROWTH; METALLOPROTEINASES; PROLIFERATION; METASTASES; SECRETION; RECEPTOR	RRR-alpha-tocopheryl succinate (alpha-vitamin E succinate, VES), one of the vitamin E derivatives, can effectively inhibit the proliferation of human prostate cancer cells. However, little is known about its effect on prostate cancer cell invasive ability. Tumor metastasis is a complex process and the extracellular matrix (ECM) is the first barrier that tumor cells encounter. Therefore, we tested the effect of VES on the invasion of different prostate tumor cells, PC-3, DU-145, and LNCaP, through Matrigel, a reconstituted ECM, using an in vitro cell invasion assay. The invasion of PC-3 and DU-145 cells through Matrigel was inhibited by 20 muM VES after treating for 24 h. The condition did not alter cell survival, cell cycle, cell adhesion or cell motility. We further investigated whether the ability of VES to inhibit prostate cancer cell invasiveness was associated with its ability to inhibit the activity of matrix metalloproteinases (MMPs), the key enzymes in the proteolysis of basement membrane during invasion. PC-3 and DU-145 cells that were treated with VES showed a significant reduction in the levels of MMP-9 in the culture medium. In contrast, LNCaP cells, which did not secrete MMP-9, were poorly invasive in Matrigel and were hardly affected by treatment with VES. This is the first report suggesting that VES inhibits human prostate cancer cell invasiveness and the reduction of secreted MMP-9 activity could be one of the contributory factors, which points to the potential use of VES in the prevention and therapy of prostate cancer invasion.	Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA; Peking Univ, Inst Urol, Beijing 100871, Peoples R China	University of Rochester; University of Rochester; Peking University	Yeh, S (corresponding author), Univ Rochester, Dept Urol, Rochester, NY 14642 USA.	shuyuan_yeh@urmc.rochester.edu			NIDDK NIH HHS [DK60912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINI A, 1987, CANCER RES, V47, P3239; Barnett KT, 2002, J SURG RES, V106, P292, DOI 10.1006/jsre.2002.6466; CHEESEMAN KH, 1995, FREE RADICAL BIO MED, V19, P591, DOI 10.1016/0891-5849(95)00083-A; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Denmeade SR, 1997, BRIT J UROL, V79, P2, DOI 10.1111/j.1464-410X.1997.tb00794.x; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hu YC, 2002, J BIOL CHEM, V277, P33571, DOI 10.1074/jbc.M203531200; IWAMOTO Y, 1992, ADV EXP MED BIOL, V324, P141; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107; Kampa M, 2000, NUTR CANCER, V37, P223, DOI 10.1207/S15327914NC372_16; Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X; LOKESHWAR BL, 1993, CANCER RES, V53, P4493; Nagakawa O, 1998, CANCER LETT, V133, P27, DOI 10.1016/S0304-3835(98)00186-4; Ni J, 2003, BIOCHEM BIOPH RES CO, V300, P357, DOI 10.1016/S0006-291X(02)02851-6; Prasad KN, 2003, J AM COLL NUTR, V22, P108, DOI 10.1080/07315724.2003.10719283; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; SOKOL RJ, 1993, GASTROENTEROLOGY, V104, P1727, DOI 10.1016/0016-5085(93)90652-S; Stearns ME, 1996, INVAS METAST, V16, P116; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TERRANOVA VP, 1986, JNCI-J NATL CANCER I, V77, P311; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Weber T, 2002, CLIN CANCER RES, V8, P863; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P7408, DOI 10.1073/pnas.102014399; Zi XL, 2000, CANCER RES, V60, P5617	26	64	67	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3080	3088		10.1038/sj.onc.1207435	http://dx.doi.org/10.1038/sj.onc.1207435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048090				2022-12-25	WOS:000220845200012
J	Mosser, DD; Morimoto, RI				Mosser, DD; Morimoto, RI			Molecular chaperones and the stress of oncogenesis	ONCOGENE			English	Review						heat-shock proteins; molecular chaperones; apoptosis; hsp90; hsp70; hsp27	N-TERMINAL KINASE; HUMAN HSP70 PROMOTER; SHOCK-PROTEIN HSP70; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; C-DEPENDENT ACTIVATION; HEAT-SHOCK; CYTOCHROME-C; CELL-DEATH; NEGATIVE REGULATOR; JNK PHOSPHORYLATION	Protein-damaging stresses induce the expression of 'heat-shock proteins', which have essential roles in protecting cells from the potentially lethal effects of stress and proteotoxicity. These stress-protective heat-shock proteins are often overexpressed in cells of various cancers and have been suggested to be contributing factors in tumorigenesis. An underlying basis of oncogenesis is the acquisition and accumulation of mutations that provide the transformed cell with the combined characteristics of deregulated cell proliferation and suppressed cell death. Heat-shock proteins with dual roles as regulators of protein conformation and stress sensors may therefore have intriguing and central roles in both cell proliferation and apoptosis. It has been established that heat-shock proteins exhibit specificity to particular classes of polypeptide substrates and client proteins in vivo, and that chaperones can stabilize mutations that affect the folded conformation. Likewise, overexpression of chaperones has also been shown to protect cells against apoptotic cell death. The involvement of chaperones, therefore, in such diverse roles might suggest novel anticancer therapeutic approaches targeting heat-shock protein function for a broad spectrum of tumor types.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	University of Guelph; Northwestern University	Mosser, DD (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	rmosser@uoguelph.ca; r-morimoto@northwestern.edu	Mosser, Dick D/A-7391-2008	Mosser, Richard/0000-0002-9183-2288	NIGMS NIH HHS [R37 GM038109] Funding Source: Medline; PHS HHS [38109] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; CHENG LL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P26, DOI 10.1016/0167-4781(92)90048-5; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FERRIS DK, 1988, P NATL ACAD SCI USA, V85, P3850, DOI 10.1073/pnas.85.11.3850; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 2002, J APPL PHYSIOL, V92, P1743, DOI 10.1152/japplphysiol.01101.2001; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GaleaLauri J, 1996, J IMMUNOL, V157, P4109; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Guay J, 1997, J CELL SCI, V110, P357; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; Helmbrecht K, 2000, CELL PROLIFERAT, V33, P341, DOI 10.1046/j.1365-2184.2000.00189.x; Hettinga JVE, 1996, INT J CANCER, V67, P800; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; HOHFELD J, 1995, CELL, V83, P589; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jolly C, 1997, HUM GENET, V101, P81, DOI 10.1007/s004390050591; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Krilleke D, 2003, INT J CANCER, V107, P520, DOI 10.1002/ijc.11331; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lepock JR, 2003, INT J HYPERTHER, V19, P252, DOI 10.1080/0265673031000065042; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Ma N, 2001, INT J RADIAT ONCOL, V50, P1041, DOI 10.1016/S0360-3016(01)01596-6; Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nishitai G, 2004, J BIOL CHEM, V279, P1621, DOI 10.1074/jbc.M310335200; Nollen EAA, 2002, J CELL SCI, V115, P2809; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 2001, CELL STRESS CHAPERON, V6, P49, DOI 10.1379/1466-1268(2001)006<0049:HPMOTC>2.0.CO;2; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; STEGE GJJ, 1994, EXP CELL RES, V214, P279, DOI 10.1006/excr.1994.1259; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Tran SEF, 2003, CELL DEATH DIFFER, V10, P1137, DOI 10.1038/sj.cdd.4401278; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Volloch V, 1998, CELL STRESS CHAPERON, V3, P265, DOI 10.1054/csac.1998.0120; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; VOLM M, 1995, CANCER LETT, V95, P195, DOI 10.1016/0304-3835(95)03893-2; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Woessmann W, 1999, J CELL BIOCHEM, V74, P648, DOI 10.1002/(SICI)1097-4644(19990915)74:4<648::AID-JCB14>3.0.CO;2-6; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	125	410	434	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2907	2918		10.1038/sj.onc.1207529	http://dx.doi.org/10.1038/sj.onc.1207529			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077153				2022-12-25	WOS:000220799600017
J	Menez, J; Chansac, BL; Dorothee, G; Vergnon, I; Jalil, A; Carlier, MF; Chouaib, S; Mami-Chouaib, F				Menez, J; Chansac, BL; Dorothee, G; Vergnon, I; Jalil, A; Carlier, MF; Chouaib, S; Mami-Chouaib, F			Mutant alpha-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinoma	ONCOGENE			English	Article						alpha-actinin-4; tumor suppressor gene; cytoskeleton; cell migration; lung carcinoma	HUMAN NEUROBLASTOMA-CELLS; ALPHA-ACTININ; T-LYMPHOCYTES; POINT MUTATION; TUMOR; EXPRESSION; ADHESION; PROTEIN; FIBRONECTIN; INVASION	The precise role of alpha-actinin-4 encoding gene (ACTN4) is not very well understood. It has been reported to elicit tumor suppressor activity and to regulate cellular motility. To further assess the function of human ACTN4, we studied a lung carcinoma cell line expressing a mutated alpha-actinin-4, which is recognized as a tumor antigen by autologous CD8(+) cytotoxic T lymphocytes (CTL). Confocal immunofluorescence microscopy indicated that, while wild-type (WT) alpha-actinin-4 stains into actin cytoskeleton and cell surface ruffles, the mutated protein is only dispersed in the cytoplasm of the lung carcinoma cells. This loss of association with the cell surface did not appear to correlate with a decrease in in vitro alpha-actinin-4 crosslinking to filamentous (F)-actin. Interestingly, experiments using cell lines stably expressing ACTN4 demonstrated that as opposed to WT gene, mutant ACTN4 was unable to inhibit tumor cell growth in vitro and in vivo. Moreover, the expression of mutant alpha-actinin-4 resulted in the loss of tumor cell capacity to migrate. The identification of an inactivating mutation in ACTN4 emphasizes its role as a tumor suppressor gene and underlines the involvement of cytoskeleton alteration in tumor development and metastasis.	Inst Gustave Roussy, INSERM, U487,Inst Federat Rech 54, Lab Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mami-Chouaib, F (corresponding author), Inst Gustave Roussy, INSERM, U487,Inst Federat Rech 54, Lab Cytokines & Immunol Tumeurs Humaines, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	cfathia@igr.fr	Chouaib, Salem/F-7939-2016; Mami-Chouaib, Fathia/E-5267-2016; DOROTHEE, Guillaume/O-9760-2016	DOROTHEE, Guillaume/0000-0001-5763-3632; JALIL, Abdelali/0000-0003-2710-8735				Akamatsu H, 1996, CANCER RES, V56, P4541; Araki N, 2000, J CELL SCI, V113, P3329; Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; Beck-Engeser GB, 2001, J EXP MED, V194, P285, DOI 10.1084/jem.194.3.285; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BENZEEV A, 1994, ADV EXP MED BIOL, V358, P147; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; BURRIDGE K, 1990, CELL DIFFER DEV, V32, P337, DOI 10.1016/0922-3371(90)90048-2; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Dorothee G, 2002, J IMMUNOL, V169, P809, DOI 10.4049/jimmunol.169.2.809; Echchakir H, 2001, CANCER RES, V61, P4078; Echchakir H, 2002, P NATL ACAD SCI USA, V99, P9358, DOI 10.1073/pnas.142308199; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1994, J CELL SCI, V107, P1773; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gonzalez AM, 2001, J CELL SCI, V114, P4197; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Jiang W G, 1995, Eur J Surg Oncol, V21, P307, DOI 10.1016/S0748-7983(95)91690-3; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nikolopoulos SN, 2000, ONCOGENE, V19, P380, DOI 10.1038/sj.onc.1203310; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Spengler BA, 1997, ONCOL RES, V9, P467; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; Wang HY, 2002, J EXP MED, V195, P1397, DOI 10.1084/jem.20020141; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	46	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2630	2639		10.1038/sj.onc.1207347	http://dx.doi.org/10.1038/sj.onc.1207347			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048094				2022-12-25	WOS:000220714900004
J	Ma, DWL; Seo, JM; Davidson, LA; Callaway, ES; Fan, YY; Lupton, JR; Chapkin, RS				Ma, DWL; Seo, JM; Davidson, LA; Callaway, ES; Fan, YY; Lupton, JR; Chapkin, RS			n-3 PUFA Alter caveolae lipid composition and resident protein localization in mouse colon	FASEB JOURNAL			English	Article						caveolin-1; cholesterol; endothelial constitutive nitric oxide synthase; fatty acids; Ras Proteins	POLYUNSATURATED FATTY-ACIDS; ELECTRON MICROSCOPY; H-RAS; EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; SIGNAL-TRANSDUCTION; MEMBRANE RAFTS; FISH-OIL; CHOLESTEROL; CELLS	Caveolae, by virtue of their unique lipid environment, serve as signaling platforms that regulate cellular events. Perturbations in caveolae lipid composition have been shown in vitro to displace proteins from lipid microdomains, thereby altering their functionality and subsequent downstream signaling. Because membrane remodeling may not be accurately represented by using pharmacological treatments and in vitro models, we investigated the in vivo ability of dietary n-3 polyunsaturated fatty acids (PUFA) to alter caveolae lipid environment and the compartmentalization of resident proteins in mouse colonic mucosa. n-3 PUFA were examined for their chemoprotective, membrane lipid-modifying properties. Colonic caveolae in mice fed n-6 or n-3 PUFA enriched diets were characteristically enriched in cholesterol, sphingomyelin, and caveolin-1. n-3 PUFA feeding, compared with n-6 PUFA, significantly altered colonic caveolae microenvironment by increasing phospholipid n-3 fatty acyl content and reducing both cholesterol (by 46%) and caveolin-1 (by 53%), without altering total cellular levels. Concomitantly, localization of caveolae-resident signaling proteins H-Ras and eNOS in colonic caveolae was decreased by n-3 PUFA, by 45 and 56%, respectively. The distribution of noncaveolae proteins K-Ras and clathrin was unaffected. Moreover, EGF-stimulated H-Ras, but not K-Ras activation was significantly suppressed following n-3 PUFA feeding, in parallel with the selective alterations in their microlocalization. These findings reveal a novel modality by which n-3 PUFA remodel membrane microdomains in vivo and thereby alter caveolae protein localization and functionality.	Texas A&M Univ, Fac Nutr, Mol & Cell Biol sect, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Chapkin, RS (corresponding author), Texas A&M Univ, Fac Nutr, Mol & Cell Biol sect, 442 Kleberg Ctr,TAMU 2471, College Stn, TX 77843 USA.	r-chapkin@tamu.edu		Chapkin, Robert/0000-0002-6515-3898; Ma, David/0000-0002-1165-5972	NATIONAL CANCER INSTITUTE [R01CA082907, R01CA059034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA059034, CA-59034, CA-82907] Funding Source: Medline; NIEHS NIH HHS [P30-ES-09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brzustowicz MR, 2002, BIOCHEMISTRY-US, V41, P12509, DOI 10.1021/bi0262808; CHAPKIN RS, 1990, LIPIDS, V25, P827, DOI 10.1007/BF02535905; Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066, DOI 10.1152/ajpcell.2001.280.5.C1066; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Davidson LA, 1999, CARCINOGENESIS, V20, P785, DOI 10.1093/carcin/20.5.785; Field FJ, 1998, J LIPID RES, V39, P1938; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRITSCHE KL, 1988, J NUTR, V118, P425, DOI 10.1093/jn/118.4.425; Hailstones D, 1998, J LIPID RES, V39, P369; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hashimoto M, 1999, LIPIDS, V34, P1297, DOI 10.1007/s11745-999-0481-6; Hong MY, 2002, CARCINOGENESIS, V23, P1919, DOI 10.1093/carcin/23.11.1919; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; KALT MR, 1971, J ULTRA MOL STRUCT R, V36, P633, DOI 10.1016/S0022-5320(71)90020-7; Kim K, 1997, INT J CANCER, V71, P767, DOI 10.1002/(SICI)1097-0215(19970529)71:5<767::AID-IJC13>3.0.CO;2-5; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Mitchell DC, 1998, BIOPHYS J, V75, P896, DOI 10.1016/S0006-3495(98)77578-2; MOLLENHAUER HH, 1964, STAIN TECHNOL, V39, P111; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Schroeder F, 2001, EXP BIOL MED, V226, P873, DOI 10.1177/153537020122601002; Shaikh SR, 2002, BIOCHEMISTRY-US, V41, P10593, DOI 10.1021/bi025712b; Silvius JR, 2002, J MEMBRANE BIOL, V190, P83, DOI 10.1007/s00232-002-1026-4; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Thai TP, 2001, HUM MOL GENET, V10, P127, DOI 10.1093/hmg/10.2.127; White MA, 2001, NAT CELL BIOL, V3, pE172, DOI 10.1038/35087098; Zhu Y, 2000, ARTERIOSCL THROM VAS, V20, P2465, DOI 10.1161/01.ATV.20.11.2465	48	153	159	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1040	+		10.1096/fj.03-1430fje	http://dx.doi.org/10.1096/fj.03-1430fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084525				2022-12-25	WOS:000221108800014
J	Hallier, M; Ivanova, N; Rametti, A; Pavlov, M; Ehrenberg, MN; Felden, B				Hallier, M; Ivanova, N; Rametti, A; Pavlov, M; Ehrenberg, MN; Felden, B			Pre-binding of small protein B to a stalled ribosome triggers trans-translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; 10SA RNA; TAGGING SYSTEM; TMRNA; SMPB; DEGRADATION; COMPETITION; RESCUE; SITE	To rescue stalled ribosomes, eubacteria employ a molecule, transfer messenger RNA ( tmRNA), which functions both as a tRNA and as an mRNA. With the help of small protein B ( SmpB), tmRNA restarts protein synthesis and adds by the trans-translation mechanism a peptide tag to the stalled protein to target it for destruction by cellular proteases. Here, the cellular location and expression of endogenous SmpB were monitored in vivo. We report that SmpB is associated with 70S ribosomes and not in the soluble fraction, independently of the presence of tmRNA. In vitro, SmpB that is pre-bound to a stalled ribosome can trigger initiation of trans-translation. Our results demonstrate the existence of a novel pathway for the entry of tmRNA to the ribosome and for the trans-transfer of a nascent peptide chain from peptidyl-tRNA to charged tmRNA.	Univ Rennes 1, Unite Propre Rech & Enseignement Super Jeune Equi, F-35043 Rennes, France; Uppsala Univ, BMC, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	Universite de Rennes; Uppsala University	Felden, B (corresponding author), Univ Rennes 1, Unite Propre Rech & Enseignement Super Jeune Equi, 2 Ave Pr Leon Bernard, F-35043 Rennes, France.	bfelden@univ-rennes1.fr	felden, brice/L-4825-2015; Hallier, Marc/L-2031-2015					Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Bordeau V, 2002, BIOCHIMIE, V84, P723, DOI 10.1016/S0300-9084(02)01442-6; Collier J, 2002, MOL MICROBIOL, V45, P745, DOI 10.1046/j.1365-2958.2002.03045.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Felden B, 1999, BBA-GENE STRUCT EXPR, V1446, P145, DOI 10.1016/S0167-4781(99)00085-8; Gillet R, 2001, MOL MICROBIOL, V42, P879, DOI 10.1046/j.1365-2958.2001.02701.x; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gutmann S, 2003, NATURE, V424, P699, DOI 10.1038/nature01831; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Ivanova N, 2004, J MOL BIOL, V338, P33, DOI 10.1016/j.jmb.2004.02.043; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; JELENC PC, 1980, ANAL BIOCHEM, V105, P369, DOI 10.1016/0003-2697(80)90472-8; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Komine Y, 1996, J BIOCHEM-TOKYO, V119, P463; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Lee S, 2001, RNA, V7, P999, DOI 10.1017/S1355838201010342; LEE SY, 1978, J BACTERIOL, V133, P1015, DOI 10.1128/JB.133.2.1015-1023.1978; Masse E, 2003, GENE DEV, V17, P2374, DOI 10.1101/gad.1127103; MEEK JL, 1980, P NATL ACAD SCI-BIOL, V77, P1632, DOI 10.1073/pnas.77.3.1632; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; RUDINGERTHIRION J, 1999, RNA, V5, P1; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Withey JH, 2002, CURR OPIN MICROBIOL, V5, P154, DOI 10.1016/S1369-5274(02)00299-0; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612	33	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25978	25985		10.1074/jbc.M314086200	http://dx.doi.org/10.1074/jbc.M314086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069072	hybrid			2022-12-25	WOS:000222003000008
J	Herbst, R; Marciano-Cabral, F; Leippe, M				Herbst, R; Marciano-Cabral, F; Leippe, M			Antimicrobial and pore-forming peptides of free-living and potentially highly pathogenic Naegleria fowleri are released from the same precursor molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID ACTIVATOR PROTEINS; ENTAMOEBA-HISTOLYTICA; PROTEOLYSIS; PROSAPOSIN; ANTIBACTERIAL; AMOEBAPORES; MECHANISM; INSECT; CELLS	The pore-forming polypeptides of Naegleria fowleri, naegleriapores A and B, are processed from separate multipeptide precursor structures. According to their transcripts, each precursor molecule appears to contain additional naegleriapore-like polypeptides, all of which share a structural motif of six invariant cysteine residues within their amino acid sequence. To identify the putative pronaegleriapore-derived peptides at the protein level, amoebic extracts were screened for small cysteine-rich polypeptides by fluorescently labeling their cysteine residues. Three novel naegleriapore isoforms derived from the precursor molecule of naegleriapore B were identified. Two of the isoforms were purified to homogeneity and tested for their biological activity. The pore-forming activity of the novel peptides was remarkably lower than that of the originally isolated naegleriapores, but both peptides killed bacteria by permeabilizing their cytoplasmic membranes. Collectively, these results indicate that naegleriapore isoforms with antibacterial and pore-forming activity are proteolytically released from the same precursor protein, presumably to generate a phylogenetically ancient complementary antimicrobial arsenal.	Univ Kiel, Inst Zool, D-24098 Kiel, Germany; Ruhr Univ Bochum, Dept Special Zool, D-44780 Bochum, Germany; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol & Immunol, Richmond, VA 23298 USA	University of Kiel; Ruhr University Bochum; Virginia Commonwealth University	Leippe, M (corresponding author), Univ Kiel, Inst Zool, Olshausenstr 40, D-24098 Kiel, Germany.	mleippe@zoologie.uni-kiel.de	Leippe, Matthias/AAP-1677-2020	Herbst, Rosa/0000-0002-2379-7433				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; FULFORD DE, 1986, J PROTOZOOL, V33, P498, DOI 10.1111/j.1550-7408.1986.tb05649.x; Herbst R, 2002, J BIOL CHEM, V277, P22353, DOI 10.1074/jbc.M201475200; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; Hiraiwa M, 1997, ARCH BIOCHEM BIOPHYS, V341, P17, DOI 10.1006/abbi.1997.9958; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; Leonova T, 1996, J BIOL CHEM, V271, P17312, DOI 10.1074/jbc.271.29.17312; MA P, 1990, REV INFECT DIS, V12, P490; MARCIANOCABRAL F, 1988, MICROBIOL REV, V52, P114, DOI 10.1128/MMBR.52.1.114-133.1988; Nickel R, 1999, EUR J BIOCHEM, V265, P1002, DOI 10.1046/j.1432-1327.1999.00807.x; OKEEFE DO, 1994, ANAL BIOCHEM, V222, P86, DOI 10.1006/abio.1994.1458; Pena SV, 1997, J IMMUNOL, V158, P2680; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TERRY AS, 1988, J BIOL CHEM, V263, P5745; YOUNG JDE, 1989, J BIOL CHEM, V264, P1077; Zaltash S, 1998, FEBS LETT, V423, P1, DOI 10.1016/S0014-5793(97)01582-2; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	21	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25955	25958		10.1074/jbc.M401965200	http://dx.doi.org/10.1074/jbc.M401965200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075336	hybrid			2022-12-25	WOS:000222003000005
J	Hwang, SG; Ryu, JH; Kim, IC; Jho, EH; Jung, HC; Kim, K; Kim, SJ; Chun, JS				Hwang, SG; Ryu, JH; Kim, IC; Jho, EH; Jung, HC; Kim, K; Kim, SJ; Chun, JS			Wnt-7a causes loss of differentiated phenotype and inhibits apoptosis of articular chondrocytes via different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-INDUCED APOPTOSIS; PROTEIN-KINASE-C; CHICK LIMB BUD; BETA-CATENIN; N-CADHERIN; EXPRESSION; CHONDROGENESIS; GROWTH; DEDIFFERENTIATION; OSTEOARTHRITIS	Although regulation of chondrogenesis and cartilage development by Wnt signaling is well established, the function of Wnt in the maintenance and destruction of cartilage remains largely unknown. Here we investigated the involvement and regulatory mechanisms of Wnt signaling in cartilage destruction. We found that interleukin-1beta, the primary pro-inflammatory cytokine involved in cartilage destruction, induces expression of Wnt-5a and - 7a in primary culture articular chondrocytes. The level of beta-catenin was also increased in chondrocytes of arthritic cartilage, suggesting the association of Wnt/beta-catenin signaling with arthritic cartilage destruction. In addition, our results show that Wnt-7a induces dedifferentiation and inhibits NO-induced apoptosis of primary culture articular chondrocytes. Wnt-7a induces dedifferentiation of articular chondrocytes by stimulating transcriptional activity of beta-catenin, whereas NO-induced apoptosis is inhibited via the activation of cell survival signaling, such as phosphatidylinositol 3-kinase and Akt, which block apoptotic signaling cascade. Our results collectively suggest that Wnt-7a is associated with cartilage destruction by regulating the maintenance of differentiation status and the apoptosis of articular chondrocytes via different mechanisms.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Kongju Natl Univ, Dept Biol Sci, Chungnam 314701, South Korea	Gwangju Institute of Science & Technology (GIST); University of Seoul; Chonnam National University; Kongju National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	jschun@kjist.ac.kr		Jho, Eek-hoon/0000-0003-2414-6234				Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926-001-0069-3; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bergwitz C, 2001, BBA-MOL CELL RES, V1538, P129, DOI 10.1016/S0167-4889(00)00123-3; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Ghosh P, 2002, BIOGERONTOLOGY, V3, P85, DOI 10.1023/A:1015219716583; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; James IE, 2000, OSTEOARTHR CARTILAGE, V8, P452, DOI 10.1053/joca.1999.0321; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Kitagaki J, 2003, OSTEOARTHR CARTILAGE, V11, P36, DOI 10.1053/joca.2002.0863; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lisovsky M, 2002, CURR BIOL, V12, P53, DOI 10.1016/S0960-9822(01)00628-5; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lyu J, 2003, J BIOL CHEM, V278, P13487, DOI 10.1074/jbc.M300591200; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Oh CD, 2003, J BIOL CHEM, V278, P36563, DOI 10.1074/jbc.M304857200; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Piepenburg O, 2000, MOL CELL, V6, P203, DOI 10.1016/S1097-2765(00)00022-8; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Tufan AC, 2002, EXP CELL RES, V273, P197, DOI 10.1006/excr.2001.5448; Tufan AC, 2001, FASEB J, V15, P1436, DOI 10.1096/fj.00-0784fje; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yang X, 2000, DEVELOPMENT, V127, P3695; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	41	98	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26597	26604		10.1074/jbc.M401401200	http://dx.doi.org/10.1074/jbc.M401401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082716	hybrid			2022-12-25	WOS:000222003000085
J	Klaavuniemi, T; Kelloniemi, A; Ylanne, J				Klaavuniemi, T; Kelloniemi, A; Ylanne, J			The ZASP-like motif in actinin-associated LIM protein is required for interaction with the alpha-actinin rod and for targeting to the muscle Z-line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN; PDZ-DOMAIN; CYTOSKELETAL PROTEINS; SKELETAL-MUSCLE; KINASE-C; Z-BAND; RIL; FILAMENTS; BINDING; CYPHER	The Z-line is a specialized structure connecting adjacent sarcomeres in muscle cells. alpha-Actinin cross-links actin filaments in the Z-line. Several PDZ-LIM domain proteins localize to the Z-line and interact with alpha-actinin. Actinin-associated LIM protein (ALP), C-terminal LIM domain protein (CLP36), and Z band alternatively spliced PDZ-containing protein ( ZASP) have a conserved region named the ZASP-like motif (ZM) between PDZ and LIM domains. To study the interactions and function of ALP we used purified recombinant proteins in surface plasmon resonance measurements. We show that ALP and alpha-actinin 2 have two interaction sites. The ZM motif was required for the interaction of ALP internal region with the alpha-actinin rod and for targeting of ALP to the Z-line. The PDZ domain of ALP bound to the C terminus of alpha-actinin. This is the first indication that the ZM motif would have a direct role in a protein-protein interaction. These results suggest that the two interaction sites of ALP would stabilize certain conformations of alpha-actinin 2 that would strengthen the Z-line integrity.	Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Ylanne, J (corresponding author), Univ Oulu, Dept Biochem, Linnanmaa H4, FIN-90570 Oulu, Finland.	jari.ylanne@oulu.fi		Ylanne, Jari/0000-0003-4627-021X				Atkinson RA, 2001, NAT STRUCT BIOL, V8, P853, DOI 10.1038/nsb1001-853; Bashirova AA, 1998, GENE, V210, P239, DOI 10.1016/S0378-1119(98)00080-8; Bauer K, 2000, BLOOD, V96, P4236; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; GLUKHOVA MA, 1990, J BIOL CHEM, V265, P13042; Guy PM, 1999, MOL BIOL CELL, V10, P1973, DOI 10.1091/mbc.10.6.1973; Harris BZ, 2001, J CELL SCI, V114, P3219; Henderson JR, 2003, CELL MOTIL CYTOSKEL, V54, P254, DOI 10.1002/cm.10102; Huang CQ, 2003, J BIOL CHEM, V278, P7360, DOI 10.1074/jbc.M211875200; KIESS M, 1995, ONCOGENE, V10, P61; Kotaka M, 2000, J CELL BIOCHEM, V78, P558, DOI 10.1002/1097-4644(20000915)78:4<558::AID-JCB5>3.0.CO;2-I; Kotaka M, 1999, J CELL BIOCHEM, V72, P279, DOI 10.1002/(SICI)1097-4644(19990201)72:2<279::AID-JCB12>3.0.CO;2-7; Kotaka M, 2001, J CELL BIOCHEM, V83, P463, DOI 10.1002/jcb.1244; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Luther PK, 2002, J MOL BIOL, V315, P9, DOI 10.1006/jmbi.2001.5217; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; Nakagawa N, 2000, BIOCHEM BIOPH RES CO, V272, P505, DOI 10.1006/bbrc.2000.2787; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Pomies P, 1999, J BIOL CHEM, V274, P29242, DOI 10.1074/jbc.274.41.29242; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Taylor KA, 2000, J CELL BIOL, V149, P635, DOI 10.1083/jcb.149.3.635; VALENTINRANC C, 1991, J BIOL CHEM, V266, P7668; Vallenius T, 2004, EXP CELL RES, V293, P117, DOI 10.1016/j.yexcr.2003.09.004; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; Vatta M, 2003, J AM COLL CARDIOL, V42, P2014, DOI 10.1016/j.jacc.2003.10.021; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0; Young P, 2000, EMBO J, V19, P6331, DOI 10.1093/emboj/19.23.6331; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092	39	61	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26402	26410		10.1074/jbc.M401871200	http://dx.doi.org/10.1074/jbc.M401871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084604	hybrid			2022-12-25	WOS:000222003000061
J	Zhu, H; Yin, SM; Shuman, S				Zhu, H; Yin, SM; Shuman, S			Characterization of polynucleotide kinase/phosphatase enzymes from mycobacteriophages omega and Cjw1 and vibriophage KVP40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-RANGE VIBRIOPHAGE; TRANSFER-RNA LIGASE; DEOXYRIBONUCLEIC-ACID; RAT-LIVER; ENZYMATIC BREAKAGE; RIBONUCLEIC-ACID; ESCHERICHIA-COLI; T4 BACTERIOPHAGE; CALF THYMUS; DNA KINASE	Coliphage T4 Pnkp is a bifunctional polynucleotide 5'-kinase/3'-phosphatase that catalyzes the end-healing steps of a RNA repair pathway. Here we show that mycobacteriophages Omega and Cjw1 and vibriophage KVP40 also encode bifunctional Pnkp enzymes consisting of a proximal 5'-kinase module with an essential P-loop motif, GXGK(S/T), and a distal 3'-phosphatase module with an essential acyl-phosphatase motif, DX-DGT. Biochemical characterization of the viral Pnkp proteins reveals several shared features, including an alkaline pH optimum for the kinase component, an intrinsic RNA kinase activity, and a homotetrameric or homodimeric quaternary structure, that distinguish them from the monomeric DNA-specific phosphatase/kinase enzymes found in mammals and fission yeast. Whereas the phage 5'-kinases differ from each other in their preferences for phosphorylation of 5' overhangs, blunt ends, or recessed ends, none of them displays the preference for recessed ends reported for mammalian DNA kinase. We hypothesize that Pnkp provides phages that have it with a means to evade an RNA-damaging antiviral host response. Genetic complementation of the essential end-healing steps of yeast tRNA splicing by the Omega and Cjw1 Pnkp enzymes establishes their capacity to perform RNA repair reactions in vivo. A supportive correlation is that Omega and Cjw1, which are distinguished from other mycobacteriophages by their possession of a Pnkp enzyme, are also unique among the mycobacteriophages in their specification of putative RNA ligases.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BECKER A, 1967, P NATL ACAD SCI USA, V58, P1996, DOI 10.1073/pnas.58.5.1996; BECKER A, 1967, J BIOL CHEM, V242, P936; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; DEPEW RE, 1974, J VIROL, V13, P888, DOI 10.1128/JVI.13.4.888-897.1974; Eastberg JH, 2004, NUCLEIC ACIDS RES, V32, P653, DOI 10.1093/nar/gkh212; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; HARVEY CL, 1971, J BIOL CHEM, V246, P4523; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; JARVEST RL, 1981, BIOCHEM J, V199, P273, DOI 10.1042/bj1990273; Jilani A, 1999, J CELL BIOCHEM, V73, P188, DOI 10.1002/(SICI)1097-4644(19990501)73:2<188::AID-JCB5>3.3.CO;2-8; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; KarimiBusheri F, 1997, J CELL BIOCHEM, V64, P258, DOI 10.1002/(SICI)1097-4644(199702)64:2<258::AID-JCB9>3.0.CO;2-W; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVIN CJ, 1976, J BIOL CHEM, V251, P1767; LILLEHAUG JR, 1976, BIOCHEMISTRY-US, V15, P1858, DOI 10.1021/bi00654a011; LILLEHAUG JR, 1977, EUR J BIOCHEM, V73, P499, DOI 10.1111/j.1432-1033.1977.tb11343.x; Mani RS, 2001, BIOCHEMISTRY-US, V40, P12967, DOI 10.1021/bi011383w; Martins A, 2004, J BIOL CHEM, V279, P18220, DOI 10.1074/jbc.M313386200; MATSUZAKI S, 1992, MICROBIOL IMMUNOL, V36, P93, DOI 10.1111/j.1348-0421.1992.tb01645.x; Meijer M, 2002, J BIOL CHEM, V277, P4050, DOI 10.1074/jbc.M109383200; MIDGLEY CA, 1985, EMBO J, V4, P2695, DOI 10.1002/j.1460-2075.1985.tb03989.x; Miller ES, 2003, J BACTERIOL, V185, P5220, DOI 10.1128/JB.185.17.5220-5233.2003; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2933; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2923; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; PANET A, 1973, BIOCHEMISTRY-US, V12, P5045, DOI 10.1021/bi00749a003; Pedulla ML, 2003, CELL, V113, P171, DOI 10.1016/S0092-8674(03)00233-2; PENNER M, 1995, J MOL BIOL, V249, P857, DOI 10.1006/jmbi.1995.0343; PHEIFFER BH, 1982, BIOCHEM BIOPH RES CO, V109, P1297, DOI 10.1016/0006-291X(82)91918-0; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sawaya R, 2003, J BIOL CHEM, V278, P43928, DOI 10.1074/jbc.M307839200; Schwer B, 2004, P NATL ACAD SCI USA, V101, P2788, DOI 10.1073/pnas.0305859101; SHUMAN S, 1979, J BIOL CHEM, V254, P396; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; TAMURA S, 1981, EUR J BIOCHEM, V115, P449; TERAOKA H, 1975, EUR J BIOCHEM, V58, P297, DOI 10.1111/j.1432-1033.1975.tb02376.x; VANDESAN.JH, 1973, BIOCHEMISTRY-US, V12, P5050, DOI 10.1021/bi00749a004; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; WEISS B, 1967, P NATL ACAD SCI USA, V57, P1021, DOI 10.1073/pnas.57.4.1021; WEISS B, 1968, J BIOL CHEM, V243, P4556; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Yin SM, 2004, VIROLOGY, V319, P141, DOI 10.1016/j.virol.2003.10.037; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200	59	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26358	26369		10.1074/jbc.M403200200	http://dx.doi.org/10.1074/jbc.M403200200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15056675	hybrid			2022-12-25	WOS:000222003000056
J	Ghibaudo, D; Cohen, L; Penin, F; Martin, A				Ghibaudo, D; Cohen, L; Penin, F; Martin, A			Characterization of GB virus B polyprotein processing reveals the existence of a novel 13-kDa protein with partial homology to hepatitis C virus p7 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CHANNEL; NONSTRUCTURAL PROTEIN-3; SIGNAL PEPTIDE; E2-NS2 REGION; IDENTIFICATION; AGENT; RNA; GLYCOPROTEINS; POLYPEPTIDE; EXPRESSION	Although responsible for a major health problem worldwide, hepatitis C virus is difficult to study because of the absence of fully permissive cell cultures or experimental animal models other than the chimpanzee. GB virus B (GBV-B), a closely related hepatotropic virus that infects small New World primates and replicates efficiently in primary hepatocyte cultures, is an attractive surrogate model system. However, little is known about processing of the GBV-B polyprotein. Because an understanding of these events is critical to further development of model GBV-B systems, we characterized signal peptidase processing of the polyprotein segment containing the putative structural proteins. We identified the exact N termini of the mature GBV-B envelope proteins, E1 and E2, and the first nonstructural protein, NS2, by direct amino acid sequencing. Interestingly, these studies document the existence of a previously unrecognized 13-kDa protein (p13) located between E2 and NS2 within the polyprotein. We compared the sequence of the p13 protein to that of hepatitis C virus p7, a small membrane-spanning protein with a similar location in the polyprotein and recently identified ion channel activity. The C-terminal half of p13 shows clear homology with p7, suggesting a common function, but the substantially larger size of p13, with 4 rather than 2 predicted transmembrane segments, indicates a different structural organization and/or additional functions. The identification of p13 in the GBV-B polyprotein provides strong support for the hypothesis that ion channel-forming proteins are essential for the life cycle of flaviviruses, possibly playing a role in virion morphogenesis and/or virus entry into cells.	Inst Pasteur, CNRS, URA 1966, Unite Genet Mol Virus Resp, F-75724 Paris 15, France; Inst Chim Biol Prot, CNRS, UMR 5086, IFR Biosci 128, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Martin, A (corresponding author), Inst Pasteur, CNRS, URA 1966, Unite Genet Mol Virus Resp, 25 Rue Dr Roux, F-75724 Paris 15, France.	annettem@pasteur.fr	PENIN, Francois/A-7315-2008; Martin, Annette/A-2425-2016	Martin, Annette/0000-0002-3054-3925				Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Beard MR, 2001, J VIROL, V75, P1414, DOI 10.1128/JVI.75.3.1414-1426.2001; Blanchard E, 2002, J VIROL, V76, P4073, DOI 10.1128/JVI.76.8.4073-4079.2002; Bukh J, 2001, J MED VIROL, V65, P694, DOI 10.1002/jmv.2092; Butkiewicz N, 2000, J VIROL, V74, P4291, DOI 10.1128/JVI.74.9.4291-4301.2000; Carrere-Kremer S, 2002, J VIROL, V76, P3720, DOI 10.1128/JVI.76.8.3720-3730.2002; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629; Cohen L, 2002, J VIROL, V76, P7495, DOI 10.1128/JVI.76.15.7495-7505.2002; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; Elbers K, 1996, J VIROL, V70, P4131, DOI 10.1128/JVI.70.6.4131-4135.1996; FournillierJacob A, 1996, J GEN VIROL, V77, P1055, DOI 10.1099/0022-1317-77-5-1055; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; Gonzalez ME, 2003, FEBS LETT, V552, P28, DOI 10.1016/S0014-5793(03)00780-4; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harada T, 2000, J VIROL, V74, P9498, DOI 10.1128/JVI.74.20.9498-9506.2000; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HOLSINGER LJ, 1995, J VIROL, V69, P1219, DOI 10.1128/JVI.69.2.1219-1225.1995; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; HUANG XQ, 1990, COMPUT APPL BIOSCI, V6, P373; KARAYIANNIS P, 1989, HEPATOLOGY, V9, P186, DOI 10.1002/hep.1840090204; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lanford RE, 2003, VIROLOGY, V311, P72, DOI 10.1016/S0042-6822(03)00193-4; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; LINDENBACH BD, 2001, FIELDS VIROLOGY, V1, P991; Martin A, 2003, P NATL ACAD SCI USA, V100, P9962, DOI 10.1073/pnas.1731505100; MARTIN A, 1995, VIROLOGY, V213, P213, DOI 10.1006/viro.1995.1561; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ohba K, 1996, FEBS LETT, V378, P232, DOI 10.1016/0014-5793(95)01441-1; Pallaoro M, 2001, J VIROL, V75, P9939, DOI 10.1128/JVI.75.20.9939-9946.2001; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Pietschmann Thomas, 2003, Clin Liver Dis, V7, P23, DOI 10.1016/S1089-3261(02)00071-5; PilotMatias TJ, 1996, J MED VIROL, V48, P329, DOI 10.1002/(SICI)1096-9071(199604)48:4&lt;329::AID-JMV6&gt;3.0.CO;2-9; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Premkumar A, 2004, FEBS LETT, V557, P99, DOI 10.1016/S0014-5793(03)01453-4; Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479; ROST B, 1995, PROTEIN SCI, V4, P521; Sakai A, 2003, P NATL ACAD SCI USA, V100, P11646, DOI 10.1073/pnas.1834545100; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sbardellati A, 2000, J GEN VIROL, V81, P2183, DOI 10.1099/0022-1317-81-9-2183; Scarselli E, 1997, J VIROL, V71, P4985, DOI 10.1128/JVI.71.7.4985-4989.1997; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; von Heijne G, 1998, NATURE, V396, P111, DOI 10.1038/24036; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhong WD, 1999, VIROLOGY, V261, P216, DOI 10.1006/viro.1999.9871	58	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24965	24975		10.1074/jbc.M401148200	http://dx.doi.org/10.1074/jbc.M401148200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060070	hybrid			2022-12-25	WOS:000221827900010
J	Loh, E; Hong, WJ				Loh, E; Hong, WJ			The binary interacting network of the conserved oligomeric Golgi tethering complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCYST; YEAST; HOMOLOG	Several recent studies have revealed the existence of a conserved oligomeric Golgi ( COG) complex consisting of several novel proteins as well as known Golgi proteins that were identified by independent approaches. The mammalian COG complex contains eight subunits: COG1/LdlBp, COG2/LdlCp, COG3/Sec34, COG4/Cod1, COG5/GTC-90/Cod4, COG6/Cod2, COG7, and COG8/Dor1. COG1, COG2, and COG7 seem structurally unique to mammalian cells, whereas the other five subunits are structurally conserved in yeast, which also contains three other unique proteins (COG1/Sec36p/Cod3p, COG2/Sec35p, and COG7/Cod5p). We report here the network of intermolecular interactions of the COG complex, revealed by in vitro translation and co-immunoprecipitation approaches. Our results suggest that COG4 serves as a core component of the complex by interacting directly with COG1, COG2, COG5, and COG7. COG3 is incorporated by its direct interaction with COG1 and COG2, whereas COG6 and COG8 do not interact with any individual subunit. Incorporation of COG6 into the complex depends on the concerted interaction of both COG5 and COG7, whereas optimal incorporation of COG8 depends on the concerted interaction of COG5, COG6, and COG7. Because COG4 (together with COG1, COG2, and COG3) is among the four essential genes of the COG complex in yeast, this molecular network highlights the structural basis for a crucial role of COG4 in the assembly/function of the complex. A model for the assembly of the COG complex is presented.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbhwj@imcb.a-star.edu.sg	HONG, Wanjin/E-9927-2010					Barr F, 2000, ESSAYS BIOCHEM, V36, P37, DOI 10.1042/bse0360037; Conibear E, 2003, MOL BIOL CELL, V14, P1610, DOI 10.1091/mbc.E02-10-0654; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; Farkas RM, 2003, MOL BIOL CELL, V14, P190, DOI 10.1091/mbc.E02-06-0343; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Loh E, 2002, J BIOL CHEM, V277, P21955, DOI 10.1074/jbc.M202326200; Panic B, 2003, CURR BIOL, V13, P405, DOI 10.1016/S0960-9822(03)00091-5; Peterson MR, 2001, TRAFFIC, V2, P476, DOI 10.1034/j.1600-0854.2001.20705.x; Pfeffer S, 2001, MOL CELL, V8, P729, DOI 10.1016/S1097-2765(01)00371-9; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; Prigent M, 2003, J CELL BIOL, V163, P1111, DOI 10.1083/jcb.200305029; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; SCHELLER RH, 1995, NEURON, V14, P893; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Siniossoglou S, 2002, J BIOL CHEM, V277, P48318, DOI 10.1074/jbc.M209428200; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	29	48	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24640	24648		10.1074/jbc.M400662200	http://dx.doi.org/10.1074/jbc.M400662200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047703	hybrid			2022-12-25	WOS:000221702500094
J	Revankar, CM; Vines, CM; Cimino, DF; Prossnitz, ER				Revankar, CM; Vines, CM; Cimino, DF; Prossnitz, ER			Arrestins block G protein-coupled receptor-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-FORMYL PEPTIDE; BETA-ARRESTINS; AGONIST AFFINITY; DOWN-REGULATION; CELL-DEATH; DESENSITIZATION; PHOSPHORYLATION; ACTIVATION; INTERNALIZATION; BETA-ARRESTIN-2	G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptors (GPCRs) activate numerous cellular signals through the combined actions of G proteins, GPCR kinases, and arrestins. Although arrestins have traditionally been thought of as mediating GPCR desensitization, they have now been shown to play important roles in the internalization, trafficking, and signaling of many GPCRs. We demonstrate that in cells devoid of arrestins, the stimulation of numerous GPCRs including the N-formyl peptide receptor (FPR) initiates rapid cell rounding, annexin V positivity, and caspase activation followed by cell death. The apoptotic response is initiated by G protein signaling and involves activation of phosphoinositide 3-kinase, mitogen-activated protein kinases, and c-Src resulting in cytochrome c release from mitochondria and ultimately caspase 9 and caspase 3 activation. Reconstitution with either arrestin-2 or arrestin-3 is completely sufficient to prevent FPR-mediated apoptosis. Surprisingly, a non-desensitizing and non-internalizing mutant of the FPR is unable to initiate apoptosis, indicating that receptor phosphorylation and internalization, but not solely chronic activation due to a lack of desensitization, are critical determinants for the induction of apoptosis by the FPR. We further demonstrate that this response is not unique to the FPR with numerous additional GPCRs, including the V2 vasopressin, angiotensin II (type 1A), and CXCR2 receptors, capable of initiating apoptosis upon stimulation, whereas GPCRs such as the beta(2)-adrenergic receptor and CXCR4 are not capable of initiating apoptotic signaling. These data demonstrate for the first time that arrestins play a critical and completely unexpected role in the suppression GPCR-mediated apoptosis, which we show is a common consequence of GPCR-mediated cellular activation in the absence of arrestins.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Prossnitz, ER (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.	eprossnitz@salud.unm.edu	Sawant, Kirti V/H-3778-2013; Prossnitz, Eric R./B-4543-2008		NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014668, P20RR011830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007538, R01AI036357, R01AI043932, R29AI036357] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA88339] Funding Source: Medline; NCRR NIH HHS [P20 RR11830, 1 S10 RR14668] Funding Source: Medline; NIAID NIH HHS [T32 AI007538, AI43932, AI36357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Dalle S, 2002, MOL CELL BIOL, V22, P6272, DOI 10.1128/MCB.22.17.6272-6285.2002; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Inagami T, 1999, J AM SOC NEPHROL, V10, pS2; Key TA, 2003, J BIOL CHEM, V278, P4041, DOI 10.1074/jbc.M204687200; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; MILLER WE, 2001, SCI STKE; Ono SJ, 2003, J ALLERGY CLIN IMMUN, V111, P1185, DOI 10.1067/mai.2003.1594; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Philchenkov AA, 2003, BIOCHEMISTRY-MOSCOW+, V68, P365, DOI 10.1023/A:1023635510363; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Potter RM, 2002, J BIOL CHEM, V277, P8970, DOI 10.1074/jbc.M111086200; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Ranganathan R, 2003, SCIENCE, V299, P1677, DOI 10.1126/science.1082509; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200	43	103	106	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24578	24584		10.1074/jbc.M402121200	http://dx.doi.org/10.1074/jbc.M402121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051714	hybrid			2022-12-25	WOS:000221702500087
J	Scholzen, TE; Steinhoff, M; Sindrilaru, A; Schwarz, A; Bunnett, NW; Luger, TA; Armstrong, CA; Ansel, JC				Scholzen, TE; Steinhoff, M; Sindrilaru, A; Schwarz, A; Bunnett, NW; Luger, TA; Armstrong, CA; Ansel, JC			Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage	FASEB JOURNAL			English	Article						neurogenic inflammation; tachykinins; tachykinin receptors; substance P; sensory neurons	GENE-RELATED PEPTIDE; TACHYKININ NK1 RECEPTOR; SUBSTANCE-P RECEPTORS; GUINEA-PIG ILEUM; DENDRITIC CELLS; HUMAN-MONOCYTES; NEUTRAL ENDOPEPTIDASE; HUMAN-SKIN; NEUTROPHIL ACCUMULATION; CIRCULAR MUSCLE	Sensory neuropeptides such as neurokinin A (NKA) or particularly substance P (SP) by neurokinin receptor (NK-R) activation modulate skin and immune cells functions during neurogenic inflammation. In this study, we examined the relative importance of SP/NK-1Rs or NKA/NK-2Rs in a murine model for allergic contact dermatitis (ACD) and tested if the functional absence of NK-Rs will impair inflammatory response in vivo. Mice lacking NK-1Rs (C57BL/6J-NK-1R(-/-)) displayed a significantly reduced ACD inflammatory ear swelling response to dinitrofluorobenzene (DNFB) with histological less edema and 50% fewer infiltrating leukocytes compared with the ACD response in wild-type (+/+) animals. In NK-1R(+/+) mice, transient NK-1R inhibition impaired ACD sensitization. In vitro haptenized bone marrow-derived dendritic cells from NK-1R(+/+) mice matured in the presence of an NK-1R antagonist displayed a reduced capability to induce T cell proliferation in vitro and ACD after adoptive transfer into naive wild-type mice in vivo. By contrast, NK-2R inhibition significantly enhanced the ACD response in NK-1R null or in wild-type mice, whereas epicutaneous application of NK-2R agonists diminished the ACD inflammation. Thus, NK-1R and SP are required for antigen sensitization and a full inflammatory response to cutaneous allergens and NKA and the NK-2R mediate a contrasting anti-inflammatory role in ACD. Thus, SP, NKA, NK-1R, and NK-2R have important but differential roles in the regulation of cutaneous inflammatory responses.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany; Univ Munster, Dept Dermatol, Inst Expt Dermatol, D-48149 Munster, Germany; Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA	University of Munster; University of Munster; Northwestern University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scholzen, TE (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Von Esmarch Str 58, D-48149 Munster, Germany.	thoscho@uni-muenster.de	Sindrilaru, Anca/G-1203-2014; Steinhoff, Martin/F-6312-2013	Steinhoff, Martin/0000-0002-7090-2187; Bunnett, Nigel W./0000-0003-3367-0644	NIAID NIH HHS [AI41493] Funding Source: Medline; NIAMS NIH HHS [R03AR44969] Funding Source: Medline; NICHD NIH HHS [HD33024] Funding Source: Medline; NIDDK NIH HHS [DK48207, DK39957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039957, R37DK039957] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahluwalia AA, 1998, BRIT J PHARMACOL, V124, P1013, DOI 10.1038/sj.bjp.0701978; ANSEL JC, 1993, J IMMUNOL, V150, P4478; Ansel JC, 1996, J INVEST DERMATOL, V106, P198, DOI 10.1111/1523-1747.ep12330326; ASAHINA A, 1995, J IMMUNOL, V154, P3056; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BRAIN SD, 1986, J INVEST DERMATOL, V87, P533, DOI 10.1111/1523-1747.ep12455620; Brunelleschi S, 1996, NEUROPEPTIDES, V30, P456, DOI 10.1016/S0143-4179(96)90010-4; Brunelleschi S, 2000, NEUROPEPTIDES, V34, P45, DOI 10.1054/npep.1999.0786; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Castagliuolo I, 2002, BRIT J PHARMACOL, V136, P271, DOI 10.1038/sj.bjp.0704697; De Giorgio R, 1998, J NEUROIMMUNOL, V82, P175, DOI 10.1016/S0165-5728(97)00201-4; EK L, 1990, J INVEST DERMATOL, V94, P761; FONG TM, 1996, NEUROGENIC INFLAMMAT, P3; GILLARDON F, 1995, EUR J PHARM-ENVIRON, V293, P395, DOI 10.1016/S0014-2999(95)80098-0; GOEBELER M, 1994, ARCH DERMATOL RES, V286, P341, DOI 10.1007/BF00402226; Grabbe S, 1996, J IMMUNOL, V156, P473; Gunzer M, 2001, J IMMUNOL METHODS, V258, P55, DOI 10.1016/S0022-1759(01)00466-5; GUTWALD J, 1991, J INVEST DERMATOL, V96, P695, DOI 10.1111/1523-1747.ep12470630; Ho WZ, 1997, J IMMUNOL, V159, P5654; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; Holzer P, 1991, PHARMACOL REV, V43, P144; Ichinose M, 1996, PEPTIDES, V17, P1405, DOI 10.1016/S0196-9781(96)00198-2; Inoue A, 1999, J NEUROCHEM, V73, P2206; JEANJEAN AP, 1995, NEUROSCIENCE, V68, P151, DOI 10.1016/0306-4522(95)00106-S; Joos GF, 2000, ALLERGY, V55, P321, DOI 10.1034/j.1398-9995.2000.00112.x; Labeur MS, 1999, J IMMUNOL, V162, P168; Lai JP, 1998, J NEUROIMMUNOL, V86, P80, DOI 10.1016/S0165-5728(98)00025-3; Lambrecht BN, 1999, EUR J IMMUNOL, V29, P3815, DOI 10.1002/(SICI)1521-4141(199912)29:12<3815::AID-IMMU3815>3.0.CO;2-#; LEPRE M, 1994, EUR J PHARMACOL, V258, P23, DOI 10.1016/0014-2999(94)90053-1; Lieb K, 1996, J NEUROIMMUNOL, V67, P77; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; MAGGI CA, 1994, BRIT J PHARMACOL, V112, P150, DOI 10.1111/j.1476-5381.1994.tb13045.x; MAGGI CA, 1994, BRIT J PHARMACOL, V112, P161, DOI 10.1111/j.1476-5381.1994.tb13046.x; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; Marriott I, 2001, J NEUROIMMUNOL, V114, P131, DOI 10.1016/S0165-5728(00)00466-5; Marriott I, 2000, J NEUROIMMUNOL, V102, P163, DOI 10.1016/S0165-5728(99)00182-4; MCELROY AB, 1992, J MED CHEM, V35, P2582, DOI 10.1021/jm00092a008; MCGREGOR PE, 1994, J PHARMACOL TOXICOL, V32, P73, DOI 10.1016/1056-8719(94)90056-6; Niizeki H, 1997, J IMMUNOL, V159, P5183; OKAMOTO A, 1994, BIOCHEM J, V299, P683, DOI 10.1042/bj2990683; PAYAN DG, 1984, J IMMUNOL, V132, P1601; PERRETTI M, 1993, IMMUNOLOGY, V80, P73; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; Quinlan KL, 1998, AM J PHYSIOL-CELL PH, V275, pC1580, DOI 10.1152/ajpcell.1998.275.6.C1580; Rameshwar P, 1997, ACTA HAEMATOL-BASEL, V98, P59; RAMESHWAR P, 1993, J IMMUNOL, V151, P2484; REGOLI D, 1996, NEUROGENIC INFLAMMAT, P91; Reilly DM, 1997, BRIT J DERMATOL, V137, P163, DOI 10.1046/j.1365-2133.1997.18001893.x; Ricciardolo FLM, 2000, BRIT J PHARMACOL, V129, P915, DOI 10.1038/sj.bjp.0703135; Saban R, 2000, AM J PATHOL, V156, P775, DOI 10.1016/S0002-9440(10)64944-9; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; Scholzen T, 1998, EXP DERMATOL, V7, P81, DOI 10.1111/j.1600-0625.1998.tb00307.x; Scholzen TE, 2003, J IMMUNOL, V170, P3866, DOI 10.4049/jimmunol.170.7.3866; Scholzen TE, 2002, J INVEST DERMATOL, V119, P308; Scholzen TE, 2001, J IMMUNOL, V166, P1285, DOI 10.4049/jimmunol.166.2.1285; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Song IS, 2000, EXP DERMATOL, V9, P42, DOI 10.1034/j.1600-0625.2000.009001042.x; Staniek V, 1999, PATHOBIOLOGY, V67, P51, DOI 10.1159/000028051; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Sunderkotter C, 2001, EXP DERMATOL, V10, P391, DOI 10.1034/j.1600-0625.2001.100602.x; SUNG CP, 1992, PEPTIDES, V13, P429, DOI 10.1016/0196-9781(92)90071-A; van der Kleij HPM, 2003, J IMMUNOL, V171, P2074, DOI 10.4049/jimmunol.171.4.2074; Zachariae H, 1970, Allerg Asthma (Leipz), V16, P9; ZENG XP, 1994, J PHARMACOL EXP THER, V270, P1295	64	39	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1007	+		10.1096/fj.03-0658fje	http://dx.doi.org/10.1096/fj.03-0658fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084523				2022-12-25	WOS:000221108800012
J	Song, L; Tuan, RS				Song, L; Tuan, RS			Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow	FASEB JOURNAL			English	Article						plasticity; osteogenesis; adipogenesis; chondrogenesis	PROGENITOR CELLS; DNA METHYLATION; TRABECULAR BONE; DIFFERENTIATION; HETEROGENEITY; PLURIPOTENCY; REGENERATION; EXPRESSION; PHENOTYPE; FUSION	Transdifferentiation is a process whereby one cell type committed to and progressing along a specific developmental lineage switches into another cell type of a different lineage through genetic reprogramming. Even though this process has been well studied and established in amphibian systems, it is unclear if mammalian cells possess the same potential. Recent in vivo transplantation studies showed that adult mesenchymal stem cells (MSCs) were able to differentiate into mesoderm-derived cell types as well as cells with neuroectodermal and endodermal characteristics, suggesting that transdifferentiation occurs in mammalian systems. However, there are concerns over these findings because of the possibility of progenitor cell contamination and cell fusion. In this study, we have developed an in vitro differentiation strategy to assess if human MSCs that have differentiated into a given mesenchyme cell lineage can transdifferentiate into other cell types in response to inductive extracellular cues. Our results showed that fully differentiated cells from hMSCs were capable of dedifferentiation and transdifferentiation into cells of another developmental lineage at single cell levels.	NIAMSD, Cartilage & Orthopaed Branch, NIH, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Tuan, RS (corresponding author), NIAMSD, Cartilage & Orthopaed Branch, NIH, US Dept HHS, 50 South Dr,Room 1503, Bethesda, MD 20892 USA.	tuanr@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041131, ZIAAR041131] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097-4644(20010401)81:1<23::AID-JCB1021>3.0.CO;2-H; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301-472X(00)00160-0; BERESFORD JN, 1992, J CELL SCI, V102, P341; Caterson E, 2002, MOL BIOTECHNOL, V20, P245, DOI 10.1385/MB:20:3:245; Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464; Eisenberg Leonard M., 2003, Birth Defects Research, V69, P209, DOI 10.1002/bdrc.10017; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Li LH, 1999, EXP CELL RES, V253, P541, DOI 10.1006/excr.1999.4666; Ma HL, 2003, J BIOMED MATER RES A, V64A, P273, DOI 10.1002/jbm.a.10370; MORRISON J, 1989, ANN CLIN PSYCHIATRY, V1, P25; Muraglia A, 2000, J CELL SCI, V113, P1161; Noth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736-0266(02)00018-9; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; Nye HLD, 2003, DEV DYNAM, V226, P280, DOI 10.1002/dvdy.10236; Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006-291X(02)00661-7; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; OWEN ME, 1987, J CELL SCI, V87, P731; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tsonis PA, 2000, DEV BIOL, V221, P273, DOI 10.1006/dbio.2000.9667; Tuli R, 2003, MOL BIOTECHNOL, V23, P37, DOI 10.1385/MB:23:1:37; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Wang ML, 2002, J ORTHOP RES, V20, P1175, DOI 10.1016/S0736-0266(02)00076-1; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	31	291	310	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					980	+		10.1096/fj.03-1100fje	http://dx.doi.org/10.1096/fj.03-1100fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084518				2022-12-25	WOS:000221108800007
J	Subramanian, VS; Marchant, JS; Boulware, MJ; Said, HM				Subramanian, VS; Marchant, JS; Boulware, MJ; Said, HM			A C-terminal region dictates the apical plasma membrane targeting of the human sodium-dependent vitamin C transporter-1 in polarized epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; ACID TRANSPORTER; INTRACELLULAR TRAFFICKING; SORTING SIGNALS; BETA-TURNS; CELLS; PROTEINS; FAMILY; PREDICTION; EXPRESSION	The human sodium-dependent vitamin C transporter (hSVCT1) mediates sodium-dependent cellular uptake of the essential micronutrient L-ascorbic acid ( vitamin C). However, the molecular determinants that control the cell surface expression, subcellular distribution, and dynamics of hSVCT1 remain undefined. To identify molecular determinants involved in hSVCT1 targeting in polarized epithelia, we used live cell imaging approaches to resolve the targeting and trafficking dynamics of hSVCT1 truncation mutants in renal and intestinal cells. Confocal imaging demonstrated that hSVCT1 was expressed at the apical cell surface and video rate measurements revealed hSVCT1 also resided in a heterogeneous population of intracellular organelles with discrete dynamic properties. By progressive truncation of the cytoplasmic C-terminal tail of hSVCT1, we delimited an essential role for an embedded ten amino acid sequence PICPVFKGFS ( amino acids 563 - 572) in defining the physiological targeting of hSVCT1. Intriguingly, this sequence bears significant homology to recently identified apical targeting motifs in two other sodium-dependent transporters, and we suggest this conservation is reflected topologically through the adoption of a beta-turn confirmation in the cytoplasmic C-tail of each transporter. Our results provide the first direct resolution of functional hSVCT1 expression at the apical cell surface of polarized epithelia and define an apical targeting signal of relevance to transporters of diverse substrate specificity.	Dept Vet Affairs Med Ctr, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities	Said, HM (corresponding author), Dept Vet Affairs Med Ctr, 151, Long Beach, CA 90822 USA.	hmsaid@uci.edu	Marchant, Jonathan/Q-5484-2019; MARCHANT, Jonathan/B-8051-2009	Marchant, Jonathan/0000-0001-6592-0877; MARCHANT, Jonathan/0000-0001-6592-0877	NCI NIH HHS [P30-CA77598] Funding Source: Medline; NIDDK NIH HHS [DK-58057, DK-56061, DK-63750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA077598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK063750, R37DK056061, R01DK058057, R01DK056061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boulware MJ, 2003, BIOCHEM J, V376, P43, DOI 10.1042/BJ20031220; Bronfman FC, 2003, J NEUROSCI, V23, P3209; Callamaras N, 1999, CELL CALCIUM, V26, P271, DOI 10.1054/ceca.1999.0085; Carr AC, 1999, AM J CLIN NUTR, V69, P1086; Cheng CL, 2002, J NEUROSCI, V22, P10643; Chou KC, 1997, J PEPT RES, V49, P120; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Duclos S, 2003, J CELL SCI, V116, P907, DOI 10.1242/jcs.00259; Dunbar LA, 1998, ACTA PHYSIOL SCAND, V163, P289; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; Kaur H, 2003, PROTEIN SCI, V12, P627, DOI 10.1110/ps.0228903; Liang WJ, 2001, MOL MEMBR BIOL, V18, P87, DOI 10.1080/09687680120706; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; Maulen NP, 2003, J BIOL CHEM, V278, P9035, DOI 10.1074/jbc.M205119200; Mellian I, 1995, COLD SPRING HARB SYM, V60, P745, DOI 10.1101/SQB.1995.060.01.080; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Packer L., 1997, VITAMIN C HLTH DIS; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Rajan DP, 1999, BIOCHEM BIOPH RES CO, V262, P762, DOI 10.1006/bbrc.1999.1272; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Said HM, 2004, AM J PHYSIOL-GASTR L, V286, pG491, DOI 10.1152/ajpgi.00361.2003; Sakai T, 1998, BIOCHEM BIOPH RES CO, V242, P151, DOI 10.1006/bbrc.1997.7577; Subramanian VS, 2003, J BIOL CHEM, V278, P3976, DOI 10.1074/jbc.M210717200; Sun AQ, 2003, J BIOL CHEM, V278, P4000, DOI 10.1074/jbc.M207163200; Takanaga H, 2004, PFLUG ARCH EUR J PHY, V447, P677, DOI 10.1007/s00424-003-1104-1; Trinczek B, 1999, J CELL SCI, V112, P2355; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Wang HP, 1999, BBA-BIOMEMBRANES, V1461, P1, DOI 10.1016/S0005-2736(99)00182-0; Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0	33	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27719	27728		10.1074/jbc.M400876200	http://dx.doi.org/10.1074/jbc.M400876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084584	hybrid			2022-12-25	WOS:000222120400106
J	Oh, J; Takahashi, R; Adachi, E; Kondo, S; Kuratomi, S; Noma, A; Alexander, DB; Motoda, H; Okada, A; Seiki, M; Itoh, T; Itohara, S; Takahashi, C; Noda, M				Oh, J; Takahashi, R; Adachi, E; Kondo, S; Kuratomi, S; Noma, A; Alexander, DB; Motoda, H; Okada, A; Seiki, M; Itoh, T; Itohara, S; Takahashi, C; Noda, M			Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice	ONCOGENE			English	Article						MMP-2; MT1-MMP; angiogenesis; myogenesis	CENTRAL CORE DISEASE; ARTERIAL ENLARGEMENT; EXTRACELLULAR-MATRIX; CONGENITAL MYOPATHIES; IV COLLAGENASE; KEY REGULATOR; GELATINASE-A; ANGIOGENESIS; EXPRESSION; ACTIVATION	The matrix metalloproteinase (MMP) family (similar to25 members in mammals) has been implicated in extracellular matrix remodeling associated with embryonic development, cancer formation and progression, and various other physiological and pathological events. Inactivating mutations in individual matrix metalloproteinase genes in mice described so far, however, are nonlethal at least up to the first few weeks after birth, suggesting functional redundancy among MMP family members. Here, we report that mice lacking two MMPs, MMP-2 (nonmembrane type) and MT1-MMP ( membrane type), die immediately after birth with respiratory failure, abnormal blood vessels, and immature muscle fibers reminiscent of central core disease. In the absence of MMP-2 and MT1-MMP, myoblast fusion in vitro is also significantly retarded. These findings suggest functional overlap in mice between the two MMPs with distinct molecular natures.	Kyoto Univ, Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Kitasato Univ, Grad Sch Med Sci, Dept Physiol & Biophys, Kanagawa 2288555, Japan; Kyoto Univ, Grad Sch Med, Dept Phys & Biophys, Sakyo Ku, Kyoto 6068501, Japan; Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Tokyo 1088639, Japan; Shionogi & Co Ltd, Discovery Res Labs, Fukushima Ku, Osaka 5530002, Japan; RIKEN, Brain Sci Inst, Lab Behav Genet, Wako, Saitama 3510198, Japan	Kyoto University; Kyoto University; Kitasato University; Kyoto University; University of Tokyo; Shionogi & Company Limited; RIKEN	Noda, M (corresponding author), Kyoto Univ, Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp	Itohara, Shigeyoshi/I-8769-2012; Seiki, Motoharu/K-9443-2015	Itohara, Shigeyoshi/0000-0002-2410-9989; Oh, Junseo/0000-0002-0754-4946				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; de Kleijn DPV, 2001, FEBS LETT, V501, P37, DOI 10.1016/S0014-5793(01)02622-9; Deryugina EI, 2002, CANCER RES, V62, P580; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FAHIME EE, 2000, EXP CELL RES, V258, P279; FANANAPAZIR L, 1993, P NATL ACAD SCI USA, V90, P3993, DOI 10.1073/pnas.90.9.3993; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FELIPE MI, 1983, HISTOCHEM PATHOL, P319; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540, DOI 10.1152/ajpheart.2000.279.4.H1540; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Karwowski JK, 1999, J SURG RES, V87, P122, DOI 10.1006/jsre.1999.5707; Lattanzi G, 2000, BIOCHEM BIOPH RES CO, V277, P639, DOI 10.1006/bbrc.2000.3735; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; PODLESKI TR, 1979, EXP CELL RES, V122, P317, DOI 10.1016/0014-4827(79)90308-2; REPONEN P, 1992, J BIOL CHEM, V267, P7856; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Sho E, 2002, EXP MOL PATHOL, V73, P142, DOI 10.1006/exmp.2002.2457; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Tronc F, 2000, ARTERIOSCL THROM VAS, V20, pE120, DOI 10.1161/01.ATV.20.12.e120; Tubridy N, 2001, CURR OPIN NEUROL, V14, P575, DOI 10.1097/00019052-200110000-00005; VANDERVEN PFM, 1995, J NEUROL SCI, V129, P199, DOI 10.1016/0022-510X(94)00282-S; VITA G, 1994, J NEUROL SCI, V124, P71, DOI 10.1016/0022-510X(94)90013-2; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	36	103	105	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5041	5048		10.1038/sj.onc.1207688	http://dx.doi.org/10.1038/sj.onc.1207688			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064723				2022-12-25	WOS:000222237300010
J	Zhang, YX; Hamburger, AW				Zhang, YX; Hamburger, AW			Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; CELL-CYCLE PROGRESSION; BREAST-CANCER CELLS; TUMOR-CELLS; ANDROGEN RECEPTOR; CARCINOMA-CELLS; EXPRESSION; ACTIVATION; DNA; GROWTH	The ErbB3/4 ligand heregulin (HRG) profoundly affects cell growth and differentiation, but its mechanism of action is poorly understood. Ebp1, a protein isolated by its binding to ErbB3, inhibits cell growth and represses transcription of E2F-regulated cell cycle genes. Since Ebp1 shares 38% identity with a Schizosaccharomyces pombe DNA-binding protein, we postulated that Ebp1 could bind E2F consensus elements in an HRG-inducible manner, leading to transcriptional repression. We show here that GST-Ebp1 bound to the DNA sequence bound by the S. pombe protein. Whereas GST-Ebp1 alone failed to bind E2F1 promoter elements, Ebp1 contained in nuclear lysates associated with E2F1 consensus sequences in the E2F1 promoter. Endogenous Ebp1 was recruited to the E2F1 promoter in vivo as demonstrated by chromatin immunoprecipitation assays. Ebp1 bound E2F consensus oligonucleotides in association with E2F1, retinoblastoma protein, and HDAC2. HRG regulated the association of Ebp1 with E2F promoter sequences and enhanced the ability of Ebp1 to repress transcription. Our findings suggest that Ebp1, by linking HRG activation of membrane receptors to E2F gene activity, may be a downstream modulator of the effects of HRG on cell cycle progression.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Hamburger, AW (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, BRB 9-047,655 W Baltimore St, Baltimore, MD 21201 USA.	ahamburg@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA076047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76047] Funding Source: Medline; PHS HHS [R21 088882-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Alroy I, 1999, MOL CELL BIOL, V19, P1961; BACUS SS, 1993, CANCER RES, V53, P5251; Bacus SS, 1996, ONCOGENE, V12, P2535; Barnes CJ, 2002, CANCER RES, V62, P1251; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cress WD, 1996, MOL CELL BIOL, V16, P2119; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; DEGREGORI J, 1995, MOL CELL BIOL, V15, P5846; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Farhana L, 2002, CANCER RES, V62, P3842; HARA E, 1993, ONCOGENE, V8, P1023; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lessor TJ, 2001, MOL CELL ENDOCRINOL, V175, P185, DOI 10.1016/S0303-7207(01)00387-2; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Lewis GD, 1996, CANCER RES, V56, P1457; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Nakagawa Y, 1997, ACTA MED OKAYAMA, V51, P195; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1992, SCIENCE, V258, P424; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Talukder AH, 2000, CANCER RES, V60, P276; Wang QB, 2001, ANAL BIOCHEM, V289, P217, DOI 10.1006/abio.2000.4960; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Xia XM, 2001, BIOCHEM BIOPH RES CO, V289, P240, DOI 10.1006/bbrc.2001.5942; Xia XM, 2001, J CELL PHYSIOL, V187, P209, DOI 10.1002/jcp.1075; YAMADA H, 1994, YEAST, V10, P883, DOI 10.1002/yea.320100704; Yoo JY, 2000, BRIT J CANCER, V82, P683; Zhang YX, 2003, NUCLEIC ACIDS RES, V31, P2168, DOI 10.1093/nar/gkg318; Zhang YX, 2002, ONCOGENE, V21, P5609, DOI 10.1038/sj.onc.1205638	40	42	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26126	26133		10.1074/jbc.M314305200	http://dx.doi.org/10.1074/jbc.M314305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073182	hybrid			2022-12-25	WOS:000222003000026
J	Jones, CE; Green, EM; Stephens, JA; Mueser, TC; Nossal, NG				Jones, CE; Green, EM; Stephens, JA; Mueser, TC; Nossal, NG			Mutations of bacteriophage T4 59 helicase loader defective in binding fork DNA and in interactions with T4 32 single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR BRANCH MIGRATION; 4-WAY JUNCTION DNA; ASSEMBLY PROTEIN; GENE-59 PROTEIN; ARCHITECTURAL PROTEINS; REPLICATION PROTEINS; LOADING PROTEIN; RECOMBINATION; PURIFICATION; COMPLEX	Bacteriophage T4 gene 59 protein greatly stimulates the loading of the T4 gene 41 helicase in vitro and is required for recombination and recombination-dependent DNA replication in vivo. 59 protein binds preferentially to forked DNA and interacts directly with the T4 41 helicase and gene 32 single-stranded DNA-binding protein. The helicase loader is an almost completely alpha-helical, two-domain protein, whose N-terminal domain has strong structural similarity to the DNA-binding domains of high mobility group proteins. We have previously speculated that this high mobility group-like region may bind the duplex ahead of the fork, with the C-terminal domain providing separate binding sites for the fork arms and at least part of the docking area for the helicase and 32 protein. Here, we characterize several mutants of 59 protein in an initial effort to test this model. We find that the I87A mutation, at the position where the fork arms would separate in the model, is defective in binding fork DNA. As a consequence, it is defective in stimulating both unwinding by the helicase and replication by the T4 system. 59 protein with a deletion of the two C-terminal residues, Lys(216) and Tyr(217), binds fork DNA normally. In contrast to the wild type, the deletion protein fails to promote binding of 32 protein on short fork DNA. However, it binds 32 protein in the absence of DNA. The deletion is also somewhat defective in stimulating unwinding of fork DNA by the helicase and replication by the T4 system. We suggest that the absence of the two terminal residues may alter the configuration of the lagging strand fork arm on the surface of the C-terminal domain, so that it is a poorer docking site for the helicase and 32 protein.	NIDDK, NIH, Dept Mol & Cell Biol, Bethesda, MD 20892 USA; Univ Toledo, Dept Chem, Toledo, OH 43606 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Toledo	Nossal, NG (corresponding author), NIDDK, NIH, Dept Mol & Cell Biol, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.	ngn@helix.nih.gov	Green, Erin/J-6098-2019; Jones, Charles/GVS-9497-2022	Green, Erin/0000-0003-3923-6726	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRY J, 1994, J BIOL CHEM, V269, P33049; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105; CHA TA, 1989, J BIOL CHEM, V264, P12220; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; Jones CE, 2001, P NATL ACAD SCI USA, V98, P8312, DOI 10.1073/pnas.121009398; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Klein HL, 2002, MOL CELL, V9, P471, DOI 10.1016/S1097-2765(02)00493-8; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Mosig G, 1995, METHOD ENZYMOL, V262, P587; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; Nossal NG, 2001, MOL CELL, V7, P31, DOI 10.1016/S1097-2765(01)00152-6; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; YONESAKI T, 1994, J BIOL CHEM, V269, P1284; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	38	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25721	25728		10.1074/jbc.M402128200	http://dx.doi.org/10.1074/jbc.M402128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084598	hybrid			2022-12-25	WOS:000221827900102
J	Chae, HD; Yun, J; Bang, YJ; Shin, DY				Chae, HD; Yun, J; Bang, YJ; Shin, DY			Cdk2-dependent phosphorylation of the NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell cycle G1/S and G2/M transitions	ONCOGENE			English	Article						NF-Y; cell cycle; cdc2; cdk2; G1/G2	CCAAT-BINDING PROTEIN; MACROPHAGE DIFFERENTIATION; G(2) ARREST; KINASE; DNA; SENESCENCE; INHIBITION; COMPLEX; P53; ACTIVATION	We previously reported that cdk2 phosphorylates two serine residues near the DNA-binding domain of the YA subunit of NF-Y transcription factor and this phosphorylation is essential for DNA binding of NF-Y. In this study, we examined the effects of a phosphorylation-deficient mutant form of YA, YA-aa, in which the two serine residues are replaced with alanine, on the cell cycle and expression of the NF-Y target genes. Transient transfection assays show that YA-aa inhibits transcription from the NF-Y target promoters, such as cdc2, cyclin A, and cdc25C. Moreover, this inhibitory function of YA-aa can be suppressed by the expression of wild-type YA, implying that YA-aa inhibits transcription of those NF-Y target genes by inactivating wild-type YA. Since NF-Y target genes include the cell cycle-regulatory genes that ensure orderly progression of the cell cycle, we examined the effects of YA-aa in cell cycle progression. We constructed a recombinant adenovirus encoding YA-aa and found that YA-aa expression leads to repression of cell cycle-regulatory genes, such as cyclin A, RNR R2, DNA polymerase a, cdc2, cyclin B, and cdc25C. Consistently, YA-aa expression results in the inactivation of both cdc2 and cdk2. Furthermore, cell cycle analysis reveals that YA-aa induces cell cycle arrest at both G1 and G2/M. These results suggest that cdk2-dependent phosphorylation of NF-Y is essential for the expression of the cell cycle-regulatory genes and therefore for cell cycle progression at both G1/S and G2/M.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea	Dankook University; Seoul National University (SNU)	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol & Immunol, Cheonan 330714, South Korea.	dreamer@dku.edu	Chae, Hee-Don/D-2620-2011; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Currie RA, 1998, J BIOL CHEM, V273, P18220, DOI 10.1074/jbc.273.29.18220; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; LI XY, 1992, J BIOL CHEM, V267, P8984; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PANG JH, 1993, J BIOL CHEM, V268, P2909; Park J S, 2001, Cancer Res Treat, V33, P236, DOI 10.4143/crt.2001.33.3.236; Park M, 2000, CANCER RES, V60, P542; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Sinha S, 1996, MOL CELL BIOL, V16, P328; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	28	54	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4084	4088		10.1038/sj.onc.1207482	http://dx.doi.org/10.1038/sj.onc.1207482			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064732				2022-12-25	WOS:000221520200006
J	Furuta, S; Hidaka, E; Ogata, A; Yokota, S; Kamata, T				Furuta, S; Hidaka, E; Ogata, A; Yokota, S; Kamata, T			Ras is involved in the negative control of autophagy through the class IPI3-kinase	ONCOGENE			English	Article						autophagy; PI3-kinase; Ras	PHOSPHOINOSITIDE 3-OH KINASE; PROTEIN-DEGRADATION; HT-29 CELLS; MACROAUTOPHAGY; GROWTH; TRANSFORMATION; PROTEOLYSIS; HEPATOCYTES; INHIBITION; MECHANISMS	Ras proteins exert a pivotal regulatory function in signal transduction involved in cell proliferation and their activation mutation leads to malignant cell transformation. However, the role of Ras proteins in autophagy, an intracellular protein degradation process in cell growth control is unknown. In the present study, we demonstrate that the degradation of long-lived proteins in NIH3T3 cells in response to nutrient starvation was significantly suppressed by oncogenic RasVal12 transformation in a rapamycin ( mTOR inhibitor)-sensitive manner. Morphologic observations also show the decrease in the formation of autophagic vacuoles upon the Ras transformation. Furthermore, epidermal growth factor or serum downregulated the protein degradation induced by serum starvation and the dominant-negative RasAsn17 mutant counteracted this suppressive effect, indicating that Ras mediates the growth factor downregulation of autophagy. The suppression of protein degradation by the activated RasVal12 was mediated by the class I phosphatidyl inositol 3-kinase (PI3-kinase), but not either or Raf Ral GDS. Consistent with this, RasVal12 and class I PI3-kinase inhibited the rate of autophagic sequestration of LDH. These data suggest that Ras plays a critical role as a negative regulator for nutrient deprivation-induced autophagy through the class I PI3-kinase signaling pathway.	Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Lab Med, Nagano 3908621, Japan; Yamanashi Univ, Sch Med, Biol Lab, Tamaho, Yamanashi 4093898, Japan	Shinshu University; Shinshu University; University of Yamanashi	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Asahi 3-1-1, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp						Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; BALLARD FJ, 1980, J CELL PHYSIOL, V105, P335, DOI 10.1002/jcp.1041050216; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Franch HA, 2001, J BIOL CHEM, V276, P19126, DOI 10.1074/jbc.M101777200; Furuta S, 2002, ONCOGENE, V21, P7060, DOI 10.1038/sj.onc.1205790; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; KAMATA T, 1988, P NATL ACAD SCI USA, V85, P5799, DOI 10.1073/pnas.85.16.5799; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; OGIERDENIS E, 2003, BIOCHIM BIOPHYS ACTA, V1366, P177; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SLUIJTERS DA, 2000, BIOCHEM J, V351, P545; YOKOTA S, 1993, EUR J CELL BIOL, V62, P372	24	119	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3898	3904		10.1038/sj.onc.1207539	http://dx.doi.org/10.1038/sj.onc.1207539			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15064741				2022-12-25	WOS:000221382000002
J	Alphonse, G; Bionda, C; Aloy, MT; Ardail, D; Rousson, R; Rodriguez-Lafrasse, C				Alphonse, G; Bionda, C; Aloy, MT; Ardail, D; Rousson, R; Rodriguez-Lafrasse, C			Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels	ONCOGENE			English	Article						SQ20B cells; SCC61 cells; gamma-irradiation; apoptosis; inhibitors of sphingolipid metabolism	RADIATION-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; NIEMANN-PICK DISEASE; CANCER-CELLS; GLUCOSYLCERAMIDE SYNTHASE; IONIZING-RADIATION; LEUKEMIA-CELLS; DNA-DAMAGE; TUMOR-CELL; SPHINGOMYELINASE	Recent strategies to sensitize radioresistant tumours are based on combining gamma-irradiation with inducers of apoptosis. We report that the combination of three inhibitors of sphingolipid metabolism, DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol. HCl(DL-PDMP) +imipramine+/-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-MAPP), with 10-Gy irradiation triggers both mitotic and apoptotic killing in radioresistant SQ20B squamous carcinoma cells. In these cells, apoptosis is defective due to a lack of ceramide generation upstream, which cannot be explained by sphingomyelinase (neutral and acidic) deficiency or rapid derivation to the sphingolipid pathway. We present evidence of a functional transduction death pathway when ceramide generation is restored, which involves the mitochondrial-mediated pathway coupled to alterations in redox status and to executive caspases activation. The poly-drug treatment restored apoptosis to levels similar to those observed in radiosensitive SCC61 squamous carcinoma cells. Simultaneous exposure to gamma-irradiation and poly-drug treatment acted synergistically in SQ20B cells to produce a marked increase in both mitochondrial dysfunction and caspase cleavage, which led to a 7.8-fold increase in apoptosis within 48 h, relative to irradiated cells. Moreover, the results suggest that the ceramide released by irradiation or poly-drug treatment converges upon common cellular targets. Modulation of endogenous ceramide levels by inhibitors of sphingolipid metabolism may represent a new cellular target for the sensitization of radioresistant tumours to gamma-ray therapy.	Lyon Sud Med Sch, Dept Biochem, INSERM, U189, F-69921 Oullins, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Rodriguez-Lafrasse, C (corresponding author), Lyon Sud Med Sch, Dept Biochem, INSERM, U189, BP12, F-69921 Oullins, France.	rodriguez@lyon-sud.univ-lyon1.fr	Alphonse, Gersende/G-7721-2018; Rodriguez-Lafrasse, Claire/G-7741-2018					Alphonse G, 2002, INT J RADIAT BIOL, V78, P821, DOI 10.1080/09553000210153943; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Chmura SJ, 1997, CANCER RES, V57, P4340; Chmura SJ, 1997, CANCER RES, V57, P1270; Choi MS, 2003, GENE, V315, P113, DOI 10.1016/S0378-1119(03)00721-2; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Decaudin D, 1998, INT J ONCOL, V12, P141; di Bartolomeo S, 2001, BIOCHEM BIOPH RES CO, V288, P269, DOI 10.1006/bbrc.2001.5748; El-Assaad W, 2003, BIOCHEM J, V376, P725, DOI 10.1042/BJ20030888; Fiske CH, 1925, J BIOL CHEM, V66, P375; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gewirtz DA, 2000, BREAST CANCER RES TR, V62, P223, DOI 10.1023/A:1006414422919; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grazide S, 2002, FASEB J, V16, P1685, DOI 10.1096/fj.01-0794fje; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; Itoh M, 2003, CLIN CANCER RES, V9, P415; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Jafrezou JP, 2001, FASEB J, V15, P123, DOI 10.1096/fj.00-0305com; Kimura K, 2003, CELL DEATH DIFFER, V10, P240, DOI 10.1038/sj.cdd.4401145; Kokunai T, 2001, J NEURO-ONCOL, V51, P111, DOI 10.1023/A:1010645205169; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lavrentiadou SN, 2001, AM J RESP CELL MOL, V25, P676, DOI 10.1165/ajrcmb.25.6.4321; Lee JU, 1999, EUR J CANCER, V35, P1374, DOI 10.1016/S0959-8049(99)00134-3; Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2; Lin JY, 2001, ANTICANCER RES, V21, P831; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Lozano J, 2001, J BIOL CHEM, V276, P442, DOI 10.1074/jbc.M006353200; Lucci A, 1998, ANTICANCER RES, V18, P475; MATSUO N, 1992, BIOCHIM BIOPHYS ACTA, V1116, P97, DOI 10.1016/0304-4165(92)90105-4; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Michael JM, 1997, CANCER RES, V57, P3600; NEUSCHWANDERTETRI BA, 1989, ANAL BIOCHEM, V179, P236, DOI 10.1016/0003-2697(89)90121-8; Pena LA, 2000, CANCER RES, V60, P321; Perry DK, 1999, BIOCHEM SOC T, V27, P399, DOI 10.1042/bst0270399; Petit PX, 1997, MOL CELL BIOCHEM, V174, P185, DOI 10.1023/A:1006848205880; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Ramstedt B, 2002, FEBS LETT, V531, P33, DOI 10.1016/S0014-5793(02)03406-3; Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087; Rodriguez-Lafrasse C, 2002, INT J CANCER, V101, P589, DOI 10.1002/ijc.10652; Rodriguez-Lafrasse C, 2001, BIOCHEM J, V357, P407, DOI 10.1042/0264-6021:3570407; RODRIGUEZLAFRASSE C, 1994, BBA-MOL BASIS DIS, V1226, P138, DOI 10.1016/0925-4439(94)90021-3; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sautin Y, 2000, THYROID, V10, P733, DOI 10.1089/thy.2000.10.733; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Selzner M, 2001, CANCER RES, V61, P1233; Shi YQ, 2001, RADIAT ENVIRON BIOPH, V40, P301, DOI 10.1007/s00411-001-0124-5; Shinoura N, 2001, INT J CANCER, V93, P252, DOI 10.1002/ijc.1327; Sietsma H, 2000, CLIN CANCER RES, V6, P942; Solary E, 2001, THERAPIE, V56, P511; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sugiki H, 2000, BRIT J DERMATOL, V143, P1154, DOI 10.1046/j.1365-2133.2000.03882.x; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VANIER MT, 1980, CLIN CHIM ACTA, V106, P257, DOI 10.1016/0009-8981(80)90309-5; Veldman RJ, 2003, FASEB J, V17, P1144, DOI 10.1096/fj.02-1053fje; Yokogawa K, 2002, METHOD FIND EXP CLIN, V24, P81, DOI 10.1358/mf.2002.24.2.677131	70	55	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2703	2715		10.1038/sj.onc.1207357	http://dx.doi.org/10.1038/sj.onc.1207357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048093				2022-12-25	WOS:000220714900012
J	Ziel, KA; Campbell, CC; Wilson, GL; Gillespie, MN				Ziel, KA; Campbell, CC; Wilson, GL; Gillespie, MN			Ref-1/Ape is critical for formation of the hypoxia-inducible transcriptional complex on the hypoxic response element of the rat pulmonary artery endothelial cell VEGF gene	FASEB JOURNAL			English	Article						vascular endothelial growth factor; PAEC; HIF-1	SMOOTH-MUSCLE-CELLS; FACTOR-I; HUMAN AP-ENDONUCLEASE-1; BINDING-PROTEIN; DNA-DAMAGE; MITOCHONDRIAL; REPRESSION; MECHANISM; CALCIUM; 1-ALPHA	The co-transcription factor and DNA repair enzyme, Redox effector factor1/apurinic/apyrimidinic endonuclease (Ref-1/Ape), facilitates DNA binding and transcriptional activity of a number of transactivating factors, including those governing hypoxia-induced gene expression HIF-1. It is not known, however, whether Ref-1/Ape is a component of the hypoxic transcriptional complex. Electrophoretic mobility shift assays failed to detect direct DNA binding of Ref-1/Ape to either the HIF-1 or AP1 DNA recognition sequences present in the hypoxic response element of the VEGF gene. However, immunodepletion of Ref-1/Ape from nuclear extract prevented DNA binding of ATF/CREB and HIF-1 to the HIF-1 DNA recognition sequence. DNA affinity-precipitation analyses showed that Ref-1/Ape was part of the multiprotein transcriptional complex forming on a 64-mer sequence encompassing a minimal hypoxic response element. Immunodepletion of Ref-1/Ape prevented probe association with HIF-1, p300, ATF, and CREB. Co-immunoprecipitation experiments indicated that Ref-1/Ape present in nuclear extract interacted with HIF-1 and p300 but not ATF/CREB. However, when Ref-1/Ape was immunoprecipitated from the oligonucleotide probe, both HIF-1 and p300 remained probe-associated while ATF/CREB co-immunoprecipitated. These findings suggest that Ref-1/Ape is a critical component of the hypoxia-inducible transcriptional complex forming on the VEGF gene's hypoxic response element and that the presence of Ref-1/Ape in the complex is required for the apparent high affinity association between HIF-1 and its DNA recognition sequence.	Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama	Gillespie, MN (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, MSB 3344, Mobile, AL 36688 USA.	mgillesp@jaguar1.usouthal.edu						Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Babal P, 2002, AM J PHYSIOL-LUNG C, V282, pL840, DOI 10.1152/ajplung.00347.2001; Bhakat KK, 2003, METHOD ENZYMOL, V371, P292; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Englander EW, 1999, J NEUROSCI RES, V58, P262, DOI 10.1002/(SICI)1097-4547(19991015)58:2<262::AID-JNR6>3.0.CO;2-W; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fuchs S, 2003, J HYPERTENS, V21, P327, DOI 10.1097/00004872-200302000-00024; Grishko V, 2001, FASEB J, V15, P1267, DOI 10.1096/fj.00-0755fje; He TR, 2003, AM J PHYSIOL-HEART C, V285, pH804, DOI 10.1152/ajpheart.01080.2002; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Moller P, 2001, FASEB J, V15, P1181, DOI 10.1096/fj.00-0703com; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; WANG GL, 1993, J BIOL CHEM, V268, P21513; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	22	59	64	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					986	+		10.1096/fj.03-1160fje	http://dx.doi.org/10.1096/fj.03-1160fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084519				2022-12-25	WOS:000221108800008
J	Kim, KY; Kim, BC; Xu, ZL; Kim, SJ				Kim, KY; Kim, BC; Xu, ZL; Kim, SJ			Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; MOLECULAR-CLONING; BINDING MOTIF; CROSS-TALK; IN-VIVO; IDENTIFICATION; PHOSPHORYLATION; PATHWAYS; FAMILY	Although transforming growth factor beta1 (TGF-beta1) acts via the Smad signaling pathway to initiate de novo gene transcription, the TGF-beta1-induced MAPK kinase activation that is involved in the regulation of apoptosis is less well understood. Even though the p38 MAP kinase and c-Jun NH2-terminal kinases (JNKs) are involved in TGF-beta1- induced cell death in hepatoma cells, the upstream mediators of these kinases remain to be defined. We show here that the members of the mixed lineage kinase (MLK) family ( including MLK1, MLK2, MLK3, and dual leucine zipper-bearing kinase (DLK)) are expressed in FaO rat hepatoma cells and are likely to act between p38 and TGF-beta receptor kinase in death signaling. TGF-beta1 treatment leads to an increase in MLK3 activity. Overexpression of MLK3 enhances TGF-beta1-induced apoptotic death in FaO cells and Hep3B human hepatoma cells, whereas expression of the dominant-negative forms of MLK3 suppresses cell death induced by TGF-beta1. The dominant-negative forms of MLK1 and -2 also suppress TGF-beta1-induced cell death. In MLK3-overexpressing cells, ERK, JNKs, and p38 MAP kinases were further activated in response to TGF-beta1 compared with the control cells. In contrast, overexpression of the dominant-negative MLK3 resulted in suppression of TGF-beta1-induced MAP kinase activation and TGF-beta1-induced caspase-3 activation. We also show that only the inhibition of the p38 pathway suppressed TGF-beta1-induced apoptosis. These observations support a role for MLKs in the TGF-beta1-induced cell death mechanism.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Kangweon Natl Univ, Coll Nat Sci, Chunchon 200701, South Korea; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kangwon National University; Columbia University; Columbia University	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.	kims@mail.nih.gov		Xu, Zhiheng/0000-0002-4809-2851	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Hartkamp J, 1999, CANCER RES, V59, P2195; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hsing AY, 1996, CANCER RES, V56, P5146; ING YL, 1994, ONCOGENE, V9, P1745; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Stadheim TA, 1998, BIOCHEM BIOPH RES CO, V245, P266, DOI 10.1006/bbrc.1998.8410; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yue J, 2004, J CELL PHYSIOL, V199, P284, DOI 10.1002/jcp.10469; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	38	78	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29478	29484		10.1074/jbc.M313947200	http://dx.doi.org/10.1074/jbc.M313947200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15069087	hybrid			2022-12-25	WOS:000222445300080
J	Rabizadeh, S; Xavier, RJ; Ishiguro, K; Bernabeortiz, J; Lopez-Ilasaca, M; Khokhlatchev, A; Mollahan, P; Pfeifer, GP; Avruch, J; Seed, B				Rabizadeh, S; Xavier, RJ; Ishiguro, K; Bernabeortiz, J; Lopez-Ilasaca, M; Khokhlatchev, A; Mollahan, P; Pfeifer, GP; Avruch, J; Seed, B			The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIGENETIC INACTIVATION; PROMOTES APOPTOSIS; FAMILY PROTEIN; CYCLE EXIT; RAS; KINASE; GENE; DROSOPHILA; PROLIFERATION; ACTIVATION	The connector enhancer of KSR (CNK) is a multidomain scaffold protein discovered in Drosophila, where it is necessary for Ras activation of the Raf kinase. Recent studies have shown that CNK1 also interacts with RalA and Rho and participates in some aspects of signaling by these GTPases. Herein we demonstrate a novel aspect of CNK1 function, i.e. reexpression of CNK1 suppresses tumor cell growth and promotes apoptosis. As shown previously for apoptosis induced by Ki-Ras(G12V), CNK1-induced apoptosis is suppressed by a dominant inhibitor of the mammalian sterile 20 kinases 1 and (MST1/MST2). Immunoprecipitates of MST1 endogenous to LoVo colon cancer cells contain endogenous CNK1; however, no association of these two polypeptides can be detected in a yeast two-hybrid assay. CNK1 does, however, bind directly to the RASSF1A and RASSF1C polypeptides, constitutive binding partners of the MST1/2 kinases. Deletion of the MST1 carboxyl-terminal segment that mediates its binding to RASSF1A/C eliminates the association of MST1 with CNK1. Coexpression of CNK1 with the tumor suppressive isoform, RASSF1A, greatly augments CNK1-induced apoptosis, whereas the nonsuppressive RASSF1C isoform is without effect on CNK1-induced apoptosis. Overexpression of CNK1-(1-282), a fragment that binds RASSF1A but is not proapoptotic, blocks the apoptosis induced by CNK1 and by Ki-Ras( G12V). Thus, in addition to its positive role in the proliferative outputs of active Ras, the CNK1 scaffold protein, through its binding of a RASSF1A.MST complex, also participates in the proapoptotic signaling initiated by active Ras.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02215 USA; Buck Inst Age Res, Discovery Translat Unit, Novato, CA 94945 USA; Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; City Hope Natl Med Ctr, Dept Biol, Duarte, CA 91010 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Buck Institute for Research on Aging; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; City of Hope	Seed, B (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, 50 Blossom St, Boston, MA 02114 USA.	seed@molbio.mgh.harvard.edu		Ishiguro, Kazuhiro/0000-0003-1776-2805; Bernabe-Ortiz, Julio Cesar/0000-0003-0313-1033				Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200; Aoyama Y, 2004, ONCOGENE, V23, P3426, DOI 10.1038/sj.onc.1207486; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Douziech M, 2003, EMBO J, V22, P5068, DOI 10.1093/emboj/cdg506; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; van Drogen F, 2002, CURR BIOL, V12, pR53, DOI 10.1016/S0960-9822(01)00672-8; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; VOS MD, 2003, J BIOL CHEM, V278, P21943; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	43	78	83	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29247	29254		10.1074/jbc.M401699200	http://dx.doi.org/10.1074/jbc.M401699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15075335	hybrid, Green Published			2022-12-25	WOS:000222445300053
J	Ludes-Meyers, JH; Kil, H; Bednarek, AK; Drake, J; Bedford, MT; Aldaz, CM				Ludes-Meyers, JH; Kil, H; Bednarek, AK; Drake, J; Bedford, MT; Aldaz, CM			WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins	ONCOGENE			English	Article						tumor suppressors; WW domain; protein-protein interaction	DOMAIN-CONTAINING OXIDOREDUCTASE; FRA16D; COMMON; GENES; MOTIF	WWOX, the gene that maps to common chromosomal fragile site FRA16D, is frequently affected by aberrations in multiple types of cancers. WWOX encodes a 46 kDa protein that contains two WW domains and a short-chain oxidoreductase (SDR) domain. We recently demonstrated that ectopic expression of WWOX inhibits xenograft tumor growth of tumorigenic breast cancer cells. Little is known of the biochemical function(s) of WWOX. The SDR domain is predicted to be involved in sex-steroid metabolism and the WW domains are likely involved in protein-protein interactions. In this report, we identify the specific proline-rich ligand for WWOX as PPXY and show that the amino-terminal WW domain is responsible for this interaction. Using the WWOX WW domains as a probe, we screened high-density protein arrays and identified five candidate-binding partners. The binding to one of these candidates, small membrane protein of the lysosome/late endosome (SIMPLE), was further analysed, and we observed that a specific PPSY motif in the SIMPLE amino-acid sequence was required to interact with the amino-terminal WW domain of WWOX. In addition, immunofluorescence staining demonstrated that endogenous WWOX and SIMPLE co-localize to perinuclear compartments of MCF-7 human breast cancer cells. These studies demonstrate that WWOX contains a Group I WW domain that binds known cellular proteins containing the specific ligand PPXY. Identification and characterization of WWOX interacting proteins will lead to an understanding of the biological functions of WWOX in normal and tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Med Univ Lodz, IPh&B Dept Med Biochem, PL-92215 Lodz, Poland	University of Texas System; UTMD Anderson Cancer Center; Medical University Lodz	Aldaz, CM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.	maldaz@odin.mdacc.tmc.edu	Aldaz, C. Marcelo/E-7868-2011; Bedford, Mark T/E-7856-2011; Bednarek, Andrzej K./S-9664-2016	Aldaz, C. Marcelo/0000-0002-2453-2939; Bednarek, Andrzej K./0000-0002-4570-4154	NATIONAL CANCER INSTITUTE [R01CA102444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102444, R01 CA102444-06A1, R01 CA102444-03, R01 CA102444-01, R01 CA102444-02, R01 CA102444-05, R01 CA102444-07, R01 CA102444-04, R01 CA 102 444] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Moriwaki Y, 2001, J BIOL CHEM, V276, P23065, DOI 10.1074/jbc.M011660200; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Sambrook J, 2001, MOL CLONING LAB MANU; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Winfield SL, 1997, GENOME RES, V7, P1020, DOI 10.1101/gr.7.10.1020	21	96	102	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5049	5055		10.1038/sj.onc.1207680	http://dx.doi.org/10.1038/sj.onc.1207680			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064722	Green Accepted			2022-12-25	WOS:000222237300011
J	Zanier, R; Briot, D; du Villard, JAD; Sarasin, A; Rosselli, F				Zanier, R; Briot, D; du Villard, JAD; Sarasin, A; Rosselli, F			Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation	ONCOGENE			English	Article						Fanconi anemia; leukemia; gene expression; microarray; DNA repair	NECROSIS-FACTOR-ALPHA; CELL MYELOPROLIFERATIVE DISORDER; HEMATOPOIETIC STEM-CELLS; MYELOID-LEUKEMIA CELLS; GROWTH-FACTOR; PROTEIN; COMPLEMENTATION; TRANSCRIPTION; INTERACTS; RECEPTOR	Loss of Fanconi anemia ( FA) proteins activity by recessive inherited mutations in one of the FA genes leads to a disease characterized by bone marrow failure, myeloid leukemia and DNA damage hypersensitivity. The aim of this work was to improve our understanding of the FA syndrome de. ning the transcription profile of the FA complementation group C (FANCC)-deficient cells in comparison to their ectopically corrected counterpart using oligonucleotide microarrays. In this way, 49 RNAs have been isolated, which showed a consistent differential pattern of expression among FANCC mutated and corrected cells. The observed specific changes in gene expression suggest that FANCC regulates specifically myeloid differentiation and unmasks a previously unsuspected anti-inflammatory role for the FA proteins. In spite of the DNA damage hypersensitivity of the syndrome, no gene coding for a protein directly involved in DNA repair/damage response was found to be deregulated in our analysis. This observation suggests that FANCC does not directly control genes involved in DNA repair at the transcriptional level, but does not exclude a regulation at the translational or post-translational level, or by protein/protein interactions. The potential role of the differentially expressed genes in FA phenotype as well as a functional- and cellular-based clustering of the identified genes are presented and discussed.	Inst Gustave Roussy, CNRS, UPR 2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rosselli, F (corresponding author), Inst Gustave Roussy, CNRS, UPR 2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	rosselli@igr.fr	Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745				Ahmad SI, 2002, BIOESSAYS, V24, P439, DOI 10.1002/bies.10082; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Curtis DJ, 2000, EXP HEMATOL, V28, P1250, DOI 10.1016/S0301-472X(00)00537-3; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Dolis D, 1997, BIOPHYS CHEM, V68, P221, DOI 10.1016/S0301-4622(97)00048-3; Folias A, 2002, HUM MOL GENET, V11, P2591, DOI 10.1093/hmg/11.21.2591; Grompe M, 2001, HUM MOL GENET, V10, P2253, DOI 10.1093/hmg/10.20.2253; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Hashimoto S, 1999, BLOOD, V94, P845, DOI 10.1182/blood.V94.3.845.415k09_845_852; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; Jobin C, 1999, J IMMUNOL, V163, P3474; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li YL, 1997, J CLIN INVEST, V100, P2873, DOI 10.1172/JCI119836; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MACDONALD D, 1995, LEUKEMIA, V9, P1628; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Mills JC, 2001, NAT CELL BIOL, V3, pE175, DOI 10.1038/35087108; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Pang QS, 2001, BLOOD, V97, P1644, DOI 10.1182/blood.V97.6.1644; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; Reber M, 2001, MECH DEVELOP, V100, P75, DOI 10.1016/S0925-4773(00)00493-7; ROSSELLI F, 1994, BLOOD, V83, P1216; Rousset S, 2002, PHOTOCHEM PHOTOBIOL, V75, P159, DOI 10.1562/0031-8655(2002)075<0159:MAIFAF>2.0.CO;2; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; SCHULTZ JC, 1993, AM J HEMATOL, V42, P196, DOI 10.1002/ajh.2830420211; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Sullivan DM, 1996, INVEST OPHTH VIS SCI, V37, P766; Sun ZX, 2001, GENE DEV, V15, P3217, DOI 10.1101/gad946701; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; Walker L, 2001, STEM CELLS, V19, P543, DOI 10.1634/stemcells.19-6-543; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; Ward PA, 2002, MOL CELL BIOCHEM, V234, P225, DOI 10.1023/A:1015944709177; Xie Y, 2000, BRIT J HAEMATOL, V111, P1057, DOI 10.1111/j.1365-2141.2000.02450.x; Zhang F, 1999, CARCINOGENESIS, V20, P445, DOI 10.1093/carcin/20.3.445	49	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5004	5013		10.1038/sj.onc.1207677	http://dx.doi.org/10.1038/sj.onc.1207677			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077170				2022-12-25	WOS:000222237300006
J	Johnson, MD; Yu, LR; Conrads, TP; Kinoshita, Y; Uo, T; Matthews, JD; Lee, SW; Smith, RD; Veenstra, TD; Morrison, RS				Johnson, MD; Yu, LR; Conrads, TP; Kinoshita, Y; Uo, T; Matthews, JD; Lee, SW; Smith, RD; Veenstra, TD; Morrison, RS			Proteome analysis of DNA damage-induced neuronal death using high throughput mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE MEDIATOR PROTEIN-2; ACTIN DEPOLYMERIZING FACTOR; ALZHEIMERS-DISEASE; CELL-DEATH; PARKINSONS-DISEASE; OXIDATIVE STRESS; NEUROFIBRILLARY TANGLES; TRANSCRIPTIONAL TARGET; LIQUID-CHROMATOGRAPHY; HIPPOCAMPAL-NEURONS	Isotope-coded affinity tag reagents and high throughput mass spectrometry were used to quantitate changes in the expression of 150 proteins in mouse wild-type (p53(+/+)) cortical neurons undergoing DNA damage-induced death. Immunological techniques confirmed several of the changes in protein expression, but microarray analysis indicated that many of these changes were not accompanied by altered mRNA expression. Proteome analysis revealed perturbations in mitochondrial function, free radical production, and neuritogenesis that were not observed in p53-deficient neurons. Changes in Tau, cofilin, and other proteins recapitulated abnormalities observed in neurodegenerative states in vivo. Additionally, DNA damage caused a p53-dependent decrease in expression of members of the protein kinase A (PKA) signaling pathway. PKA inhibition promoted death in the absence of DNA damage, revealing a novel mechanism by which endogenous down-regulation of PKA signaling may contribute to p53-dependent neuronal death. These data demonstrate the power of high throughput mass spectrometry for quantitative analysis of the neuronal proteome.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; NCI, Biomed Proteom Program, SAIC Frederick, Frederick, MD 21702 USA; Pacific NW Natl Lab, Environm & Mol Sci Lab, Richland, WA 99352 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol Surg, Boston, MA 02115 USA	University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Morrison, RS (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Box 356470,1959 NE Pacific St, Seattle, WA 98195 USA.	yael@u.washington.edu	Lee, Sang-Won/H-6760-2013; Smith, Richard D/J-3664-2012	Lee, Sang-Won/0000-0002-5042-0084; Smith, Richard D/0000-0002-2381-2349; Yu, Li-Rong/0000-0001-6084-991X	NINDS NIH HHS [K08 NS43482-01, NS41714, NS35533, NS39617] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035533, K08NS043482, F32NS041714, R01NS039617] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Atlante A, 2001, FEBS LETT, V497, P1, DOI 10.1016/S0014-5793(01)02437-1; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Ethell IM, 1999, J CELL BIOL, V144, P575, DOI 10.1083/jcb.144.3.575; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanson MG, 1998, J NEUROSCI, V18, P7361; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jensen PK, 1999, ANAL CHEM, V71, P2076, DOI 10.1021/ac990196p; Johnson MD, 2002, J BIOL CHEM, V277, P23000, DOI 10.1074/jbc.M201907200; Johnson MD, 1999, J NEUROSCI, V19, P2996; Kim SH, 2001, J NEURAL TRANSM-SUPP, P223; Kurihara LJ, 2001, HUM MOL GENET, V10, P1963, DOI 10.1093/hmg/10.18.1963; Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Li LJ, 2001, ANAL CHEM, V73, P3312, DOI 10.1021/ac010192w; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MACIVER SK, 1995, NEUROREPORT, V6, P1985, DOI 10.1097/00001756-199510010-00008; Maselli AG, 2002, J CELL SCI, V115, P1939; Meberg PJ, 2000, J NEUROSCI, V20, P2459; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Sah R, 1999, J NEUROSCI, V19, P9209; Saito A, 2003, J NEUROSCI, V23, P1710; Satoh J, 2001, J NEUROL SCI, V189, P113, DOI 10.1016/S0022-510X(01)00555-X; Schonberger SJ, 2001, PROTEOMICS, V1, P1519, DOI 10.1002/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L; Shen YF, 2001, ANAL CHEM, V73, P1766, DOI 10.1021/ac0011336; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761	48	22	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26685	26697		10.1074/jbc.M401274200	http://dx.doi.org/10.1074/jbc.M401274200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15060066	hybrid, Green Published			2022-12-25	WOS:000222003000095
J	Liao, GX; Zhang, MY; Harhaj, EW; Sun, SC				Liao, GX; Zhang, MY; Harhaj, EW; Sun, SC			Regulation of the NF-kappa B-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; UBIQUITIN LIGASE; ACTIVATION; LYMPHOTOXIN; CD40; PATHWAYS; MDM2; IKK; TNF; NF-KAPPA-B2	The NF-kappaB family of transcription factors plays a pivotal role in regulation of diverse biological processes, including immune responses, cell growth, and apoptosis. Activation of NF-kappaB is mediated by both canonical and noncanonical signaling pathways. Although the canonical pathway has been extensively studied, the mechanism mediating the noncanonical pathway is still poorly understood. Recent studies have identified the NF-kappaB-inducing kinase (NIK) as a key component of the noncanonical pathway of NF-kappaB activation; however, how the signaling function of NIK is regulated remains unknown. We report here that one important mechanism of NIK regulation is through its dynamic interaction with the tumor necrosis factor receptor-associated factor 3 (TRAF3). TRAF3 physically associates with NIK via a specific sequence motif located in the N-terminal region of NIK; this molecular interaction appears to target NIK for degradation by the proteasome. Interestingly, induction of noncanonical NF-kappaB signaling by extracellular signals involves degradation of TRAF3 and the concomitant enhancement of NIK expression. These results suggest that induction of noncanonical NF-kappaB signaling may involve the rescue of NIK from TRAF3-mediated negative regulation.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER; NCI NIH HHS [CA94922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HAMANO T, 1982, J IMMUNOL, V129, P1403; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Haxhinasto SA, 2002, J IMMUNOL, V169, P1145, DOI 10.4049/jimmunol.169.3.1145; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Iciek LA, 1997, J IMMUNOL, V158, P4769; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kuai J, 2003, J BIOL CHEM, V278, P14363, DOI 10.1074/jbc.M208672200; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lin SC, 1996, MOL CELL BIOL, V16, P4591; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; Xu LG, 2002, J IMMUNOL, V169, P6883, DOI 10.4049/jimmunol.169.12.6883; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	48	359	376	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26243	26250		10.1074/jbc.M403286200	http://dx.doi.org/10.1074/jbc.M403286200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084608	hybrid			2022-12-25	WOS:000222003000041
J	Murdaca, J; Treins, C; Monthouel-Kartmann, MN; Pontier-Bres, R; Kumar, S; Van Obberghen, E; Giorgetti-Peraldi, S				Murdaca, J; Treins, C; Monthouel-Kartmann, MN; Pontier-Bres, R; Kumar, S; Van Obberghen, E; Giorgetti-Peraldi, S			Grb10 prevents Nedd4-mediated vascular endothelial growth factor receptor-2 degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN GRB10; FACTOR-I; TYROSINE KINASE; SIGNALING PATHWAY; DOWN-REGULATION; CDNA CLONING; UBIQUITIN; INSULIN; EXPRESSION; ENDOCYTOSIS	One of the cellular mechanisms used to prevent continuous and enhanced activation in response to growth factors is the internalization and degradation of their receptors. Little is known about the molecular mechanisms involved in vascular endothelial growth factor receptor-2 (VEGF-R2) degradation. In a previous work, we have shown that the adaptor protein Grb10 is a positive regulator of the VEGF signaling pathway. Indeed, VEGF stimulates Grb10 expression, and Grb10 overexpression induces an increase in the amount and the tyrosine phosphorylation of VEGF-R2. In the present manuscript, we demonstrate that Grb10 stimulates VEGF-R2 expression by inhibiting the Nedd4-mediated VEGF-R2 degradation. First, we show that proteasome inhibition by MG132 induces an increase in VEGF-R2 amount, and that VEGF-R2 is ubiquitinated in response to VEGF. Expression of Nedd4, a HECT domain-containing ubiquitin ligase, induces the disappearance of VEGF-R2 in cells, suggesting that Nedd4 is involved in VEGF-R2 degradation. To determine whether Nedd4 directly ubiquitinates VEGF-R2, we expressed a ubiquitin ligase-deficient mutant Nedd4C854S. In the presence of Nedd4C854S, VEGF-R2 is expressed and ubiquitinated. These results suggest that VEGF-R2 is ubiquitinated but that Nedd4 is not involved in this process. Finally, we show that Grb10 constitutively associates with Nedd4. Co-expression of Nedd4 and Grb10 restores the expression of VEGF-R2, suggesting that Grb10 inhibits the Nedd4-mediated degradation of VEGF-R2. In this study, we show that Grb10 acts as a positive regulator in VEGF-R2 signaling and protects VEGF-R2 from degradation by interacting with Nedd4, a component of the endocytic machinery.	Fac Med, INSERM, U145, Inst Federatif Rech 50, F-06107 Nice 2, France; Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institute Medical & Veterinary Science Australia	Giorgetti-Peraldi, S (corresponding author), Fac Med, INSERM, U145, Inst Federatif Rech 50, F-06107 Nice 2, France.	peraldis@unice.fr	Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814; Giorgetti-Peraldi, Sophie/0000-0002-2751-2618; PONTIER-BRES, Rodolphe/0000-0002-4139-5913				Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; Clague MJ, 2001, J CELL SCI, V114, P3075; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Deng YP, 2003, J BIOL CHEM, V278, P39311, DOI 10.1074/jbc.M304599200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Duval M, 2003, J BIOL CHEM, V278, P20091, DOI 10.1074/jbc.M301410200; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; Giorgetti-Peraldi S, 2001, ONCOGENE, V20, P3959, DOI 10.1038/sj.onc.1204520; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; OOI J, 1995, ONCOGENE, V10, P1621; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; van Kerkhof P, 2001, MOL BIOL CELL, V12, P2556, DOI 10.1091/mbc.12.8.2556; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wang J, 1999, MOL CELL BIOL, V19, P6217; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wick KR, 2003, J BIOL CHEM, V278, P8460, DOI 10.1074/jbc.M208518200	48	104	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26754	26761		10.1074/jbc.M311802200	http://dx.doi.org/10.1074/jbc.M311802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15060076	hybrid			2022-12-25	WOS:000222003000102
J	Edavettal, SC; Lee, KA; Negishi, M; Linhardt, RJ; Liu, J; Pedersen, LC				Edavettal, SC; Lee, KA; Negishi, M; Linhardt, RJ; Liu, J; Pedersen, LC			Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; N-DEACETYLASE/N-SULFOTRANSFERASE; HERPES-SIMPLEX-VIRUS; ANTITHROMBIN-III; ESTROGEN SULFOTRANSFERASE; HUMAN CDNAS; BINDING; BIOSYNTHESIS; EXPRESSION; CRYSTALLOGRAPHY	Heparan sulfate interacts with antithrombin, a protease inhibitor, to regulate blood coagulation. Heparan sulfate 3-O-sulfotransferase isoform 1 performs the crucial last step modification in the biosynthesis of anticoagulant heparan sulfate. This enzyme transfers the sulfuryl group (SO3) from 3'-phosphoadenosine 5'-phosphosulfate to the 3-OH position of a glucosamine residue to form the 3-O-sulfo glucosamine, a structural motif critical for binding of heparan sulfate to antithrombin. In this study, we report the crystal structure of 3-O-sulfotransferase isoform 1 at 2.5-Angstrom resolution in a binary complex with 3'-phosphoadenosine 5'-phosphate. This structure reveals residues critical for 3'-phosphoadenosine 5'-phosphosulfate binding and suggests residues required for the binding of heparan sulfate. In addition, site-directed mutagenesis analyses suggest that residues Arg-67, Lys-68, Arg-72, Glu-90, His-92, Asp-95, Lys-123, and Arg-276 are essential for enzymatic activity. Among these essential amino acid residues, we find that residues Arg-67, Arg-72, His-92, and Asp-95 are conserved in heparan sulfate 3-O-sulfotransferases but not in heparan N-deacetylase/N-sulfotransferase, suggesting a role for these residues in conferring substrate specificity. Results from this study provide information essential for understanding the biosynthesis of anticoagulant heparan sulfate and the general mechanism of action of heparan sulfate sulfotransferases.	Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Rensselaer Polytech Inst, Dept Chem & Biol Chem, Troy, NY 12180 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Rensselaer Polytechnic Institute	Liu, J (corresponding author), Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Rm 309,Beard Hall, Chapel Hill, NC 27599 USA.	jian_liu@unc.edu	Pedersen, Lars/C-6173-2019; Negishi, Masahiko/F-7805-2019	Pedersen, Lars/0000-0002-4488-4077; Negishi, Masahiko/0000-0002-2076-8928	NIAID NIH HHS [AI50050] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005, Z01ES080040, ZIAES080040] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BOYER C, 1986, THROMB HAEMOSTASIS, V56, P18; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen JH, 2003, GLYCOBIOLOGY, V13, P785, DOI 10.1093/glycob/cwg101; Dewerchin M, 2003, CIRC RES, V93, P1120, DOI 10.1161/01.RES.0000103634.69868.4F; Duncan MB, 2004, BBA-GEN SUBJECTS, V1671, P34, DOI 10.1016/j.bbagen.2003.12.010; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gorokhov A, 2000, BIOPHYS J, V79, P2909, DOI 10.1016/S0006-3495(00)76528-3; Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P13117, DOI 10.1021/bi020507h; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 2003, BIOCHEM SOC T, V31, P331, DOI 10.1042/BST0310331; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuberan B, 2003, NAT BIOTECHNOL, V21, P1343, DOI 10.1038/nbt885; Lee KA, 2003, J BIOL CHEM, V278, P44593, DOI 10.1074/jbc.M308312200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu Jian, 2002, P475; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Myette JR, 2002, BIOCHEM BIOPH RES CO, V290, P1206, DOI 10.1006/bbrc.2001.6268; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188; Weitz JI, 2003, J CLIN INVEST, V111, P952, DOI 10.1172/JCI200318234; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200	39	60	64	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25789	25797		10.1074/jbc.M401089200	http://dx.doi.org/10.1074/jbc.M401089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060080	Green Published, hybrid			2022-12-25	WOS:000221827900109
J	Stephan, F; Kobor, MS; Philippi, A; Greenblatt, J; Tschochner, H				Stephan, F; Kobor, MS; Philippi, A; Greenblatt, J; Tschochner, H			Dephosphorylation of RNA polymerase I by Fcp1p is required for efficient rRNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; UPSTREAM ACTIVATION FACTOR; TRANSCRIPTION FACTOR UBF; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; RDNA TRANSCRIPTION; DEPENDENT REGULATION; TIF-IA; PREINITIATION COMPLEX; GENE-TRANSCRIPTION	Differently phosphorylated forms of RNA polymerase (Pol) II are required to guide the enzyme through the transcription cycle. Here, we show that a phosphorylation/dephosphorylation cycle is also important for RNA polymerase I-dependent synthesis of rRNA precursors. A key component of the Pol II transcription system is Fcp1p, a phosphatase that dephosphorylates the C-terminal domain of the largest Pol II subunit. Fcp1p stimulates transcription elongation and is required for Pol II recycling after transcription termination. We found that Fcp1p is also part of the RNA Pol I transcription apparatus. Fcp1p is required for efficient rDNA transcription in vivo, and also, recombinant Fcp1p stimulates rRNA synthesis both in promoter-dependent and in nonspecific transcription assays in vitro. We demonstrate that Fcp1 activity is not involved in the formation of the initiation-active form of Pol I (the Pol I-Rrn3p complex) and propose that dephosphorylation of Pol I by Fcp1p facilitates chain elongation during rRNA synthesis.	Univ Regensburg, Inst Biochem Mikrobiol & Genet, D-94034 Regensburg, Germany; Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	University of Regensburg; Ruprecht Karls University Heidelberg; University of California System; University of California Berkeley; University of Toronto; University of Toronto	Tschochner, H (corresponding author), Univ Regensburg, Inst Biochem Mikrobiol & Genet, Univ Str 1, D-94034 Regensburg, Germany.	herbert.tschochner@vkl.uni-regensburg.de		Kobor, Michael/0000-0003-4140-1743				Aprikian P, 2001, MOL CELL BIOL, V21, P4847, DOI 10.1128/MCB.21.15.4847-4855.2001; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; Bradsher J, 2002, MOL CELL, V10, P819, DOI 10.1016/S1097-2765(02)00678-0; BREANT B, 1983, EUR J BIOCHEM, V130, P247; BUHLER JM, 1980, J BIOL CHEM, V255, P9949; BUHLER JM, 1976, FEBS LETT, V71, P37, DOI 10.1016/0014-5793(76)80893-9; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Fath S, 2000, J CELL BIOL, V149, P575, DOI 10.1083/jcb.149.3.575; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Hirschler-Laszkiewicz I, 2003, J BIOL CHEM, V278, P18953, DOI 10.1074/jbc.M301093200; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HUET J, 1982, EMBO J, V1, P1193, DOI 10.1002/j.1460-2075.1982.tb00012.x; Iben S, 2002, CELL, V109, P297, DOI 10.1016/S0092-8674(02)00729-8; Keener J, 1998, J BIOL CHEM, V273, P33795, DOI 10.1074/jbc.273.50.33795; Keener J, 1997, P NATL ACAD SCI USA, V94, P13458, DOI 10.1073/pnas.94.25.13458; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kuhn A, 1998, J MOL BIOL, V284, P1, DOI 10.1006/jmbi.1998.2164; Lalo D, 1996, J BIOL CHEM, V271, P21062, DOI 10.1074/jbc.271.35.21062; Lin CW, 1996, MOL CELL BIOL, V16, P6436; Mandal SS, 2002, MOL CELL BIOL, V22, P7543, DOI 10.1128/MCB.22.21.7543-7552.2002; Milkereit P, 1997, BIOL CHEM, V378, P1433, DOI 10.1515/bchm.1997.378.12.1433; Milkereit P, 1998, EMBO J, V17, P3692, DOI 10.1093/emboj/17.13.3692; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; MUSTERS W, 1989, NUCLEIC ACIDS RES, V17, P9661, DOI 10.1093/nar/17.23.9661; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Siddiqi IN, 2001, EMBO J, V20, P4512, DOI 10.1093/emboj/20.16.4512; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; Steffan JS, 1998, MOL CELL BIOL, V18, P3752, DOI 10.1128/MCB.18.7.3752; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; Yuan XJ, 2002, EMBO REP, V3, P1082, DOI 10.1093/embo-reports/kvf212; Zhai WG, 1999, MOL CELL BIOL, V19, P2791; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4	55	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25251	25259		10.1074/jbc.M401867200	http://dx.doi.org/10.1074/jbc.M401867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073185	hybrid			2022-12-25	WOS:000221827900043
J	del Arco, A; Satrustegui, J				del Arco, A; Satrustegui, J			Identification of a novel human subfamily of mitochondrial carriers with calcium-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; NUCLEOTIDE POOL SIZE; ATP-MG/PI CARRIER; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-CHARACTERIZATION; PERMEABILITY TRANSITION; GLUTAMATE TRANSPORTER; TISSUE DISTRIBUTION; MOLECULAR-CLONING; SOLUTE CARRIER	Aralar1 and citrin were identified as calcium binding aspartate/glutamate carriers (AGC) in mitochondria. The presence of calcium binding motifs facing the extramitochondrial space allows the regulation of the transport activity of these carriers by cytosolic calcium and provides a new mechanism to transduce calcium signals in mitochondria without the requirement of calcium entry in the organelle. We now report the complete characterization of a second subfamily of human calcium binding mitochondrial carriers named SCaMC ( short calcium-binding mitochondrial carriers). We have identified three SCaMC genes in the human genome. All code for highly conserved proteins (about 70-80% identity), of about 500 amino acids with a characteristic mitochondrial carrier domain at the C terminus, and an N-terminal extension harboring four EF-hand binding motifs with high similarity to calmodulin. All SCaMC proteins were found to be located exclusively in mitochondria, and their N-terminal extensions were dispensable for the correct mitochondrial targeting of the polypeptides. SCaMC-1 is the human orthologue of the rabbit Efinal protein, which was reported to be located in peroxisomes, and SCaMC-2 is the human orthologue of the rat MCSC protein, described as up-regulated by dexamethasone in AR42J cells. One of the SCaMC genes, SCaMC-2, has four variants generated by alternative splicing, resulting in proteins with a common C terminus but with variations in their N-terminal halves, including the loss of one to three EF-hand motifs. These results make SCaMC one of most complex subfamilies of mitochondrial carriers and suggest that the large number of isoforms and splice variants may confer different calcium sensitivity to the transport activity of these carriers.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Dept Mol Biol, E-28049 Madrid, Spain; Univ Castilla La Mancha, Fac Ciencias Medio Ambiente, Ctr Reg Invest Biomed, Area Bioquim, Toledo 45071, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Universidad de Castilla-La Mancha	del Arco, A (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Dept Mol Biol, E-28049 Madrid, Spain.	adelarco@cbm.uam.es	Satrustegui, Jorgina/R-6732-2019; del Arco, Araceli/R-5653-2019	Satrustegui Gil Delgado, Jorgina/0000-0003-3377-2667; del Arco, Araceli/0000-0002-6839-542X				APRILLE JR, 1981, ARCH BIOCHEM BIOPHYS, V212, P689, DOI 10.1016/0003-9861(81)90413-6; APRILLE JR, 1988, FASEB J, V2, P2547, DOI 10.1096/fasebj.2.10.3290024; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Camacho JA, 2003, MOL GENET METAB, V79, P257, DOI 10.1016/S1096-7192(03)00105-7; Cattini PA, 1998, MOL CELL BIOCHEM, V189, P33, DOI 10.1023/A:1006852312188; Cavero S, 2003, MOL MICROBIOL, V50, P1257, DOI 10.1046/j.1365-2958.2003.03742.x; Csordas G, 2003, J BIOL CHEM, V278, P42273, DOI 10.1074/jbc.M305248200; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 2002, EUR J BIOCHEM, V269, P3313, DOI 10.1046/j.1432-1033.2002.03018.x; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Dyall SD, 2000, MOL CELL BIOL, V20, P2488, DOI 10.1128/MCB.20.7.2488-2497.2000; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; Fountoulakis M, 2003, ELECTROPHORESIS, V24, P260, DOI 10.1002/elps.200390022; GOLDSTEIN FG, 1982, ARCH BIOCHEM BIOPHYS, V213, P7, DOI 10.1016/0003-9861(82)90433-7; Haeseleer F, 2000, J BIOL CHEM, V275, P1247, DOI 10.1074/jbc.275.2.1247; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; HAGEN T, 1993, ARCH BIOCHEM BIOPHYS, V303, P195, DOI 10.1006/abbi.1993.1273; Hagen T, 2003, AM J PHYSIOL-GASTR L, V285, pG274, DOI 10.1152/ajpgi.00052.2003; Iijima M, 2001, ADV ENZYME REGUL, V41, P325, DOI 10.1016/S0065-2571(00)00022-4; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; JOYAL JL, 1992, J BIOL CHEM, V267, P19198; Kobayashi K, 1999, NAT GENET, V22, P159, DOI 10.1038/9667; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lasorsa FM, 2003, J BIOL CHEM, V278, P38686, DOI 10.1074/jbc.M304988200; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Mashima H, 2003, J BIOL CHEM, V278, P9520, DOI 10.1074/jbc.M208398200; Millar AH, 2003, PLANT PHYSIOL, V131, P443, DOI 10.1104/pp.009985; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; NOSEK MT, 1990, J BIOL CHEM, V265, P8444; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Prohl C, 2001, MOL CELL BIOL, V21, P1089, DOI 10.1128/MCB.21.4.1089-1097.2001; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SolerMira A, 1996, YEAST, V12, P485, DOI 10.1002/(SICI)1097-0061(199604)12:5<485::AID-YEA928>3.0.CO;2-U; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; van Roermund CWT, 2001, MOL CELL BIOL, V21, P4321, DOI 10.1128/MCB.21.13.4321-4329.2001; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Visser WF, 2002, BIOCHEM BIOPH RES CO, V299, P494, DOI 10.1016/S0006-291X(02)02663-3; Voncken F, 2002, MOL MICROBIOL, V44, P1441, DOI 10.1046/j.1365-2958.2002.02959.x; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WALKER JE, 1993, J BIOENERG BIOMEMBR, V4, P35; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; Wistow G, 2002, MOL VIS, V8, P196; Yang XL, 2002, MOL GENET METAB, V75, P369, DOI 10.1016/S1096-7192(02)00008-2; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; Zhang XP, 2002, TRENDS PLANT SCI, V7, P14, DOI 10.1016/S1360-1385(01)02180-X; Zuniga S, 1999, YEAST, V15, P945, DOI 10.1002/(SICI)1097-0061(199907)15:10B<945::AID-YEA394>3.0.CO;2-6	55	93	99	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24701	24713		10.1074/jbc.M401417200	http://dx.doi.org/10.1074/jbc.M401417200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15054102	hybrid			2022-12-25	WOS:000221702500101
J	Samaha, FF; Rubenstein, RC; Yan, WS; Ramkumar, M; Levy, DI; Ahn, YJ; Sheng, SH; Kleyman, TR				Samaha, FF; Rubenstein, RC; Yan, WS; Ramkumar, M; Levy, DI; Ahn, YJ; Sheng, SH; Kleyman, TR			Functional polymorphism in the carboxyl terminus of the alpha-subunit of the human epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; SENSITIVE NA+ CHANNEL; LIDDLE-SYNDROME; BETA-SUBUNIT; MEMBRANE TOPOLOGY; GAMMA-SUBUNIT; ESSENTIAL-HYPERTENSION; BLACK-PEOPLE; MUTATIONS; AMILORIDE	A common human epithelial sodium channel ( ENaC) polymorphism, alphaT663A, is present in the cytoplasmic C terminus of the alpha-subunit, although it is unclear whether this polymorphism segregates with blood pressure. We examined whether this polymorphism was associated with differences in functional Na+ channel expression. Whole cell amiloride-sensitive currents in Xenopus oocytes expressing wild type channels (alphaT663betagamma) were significantly similar to1.3-2.0-fold higher than currents measured in oocytes expressing channels with an Ala, Gly or Leu, or Lys at position alpha663. In contrast, differences in functional human ENaC expression were not observed with oocytes expressing channels having Thr (wild type), Ser, or Asp at this position. The surface expression of channels, measured using an epitope-tagged beta-subunit, was significantly reduced in oocytes expressing alphaT663Abetagamma when compared with oocytes expressing alphaT663betagamma. The corresponding polymorphism was generated in the mouse alpha-subunit (malphaA692T) and was not associated with differences in functional alphabetagamma-mouse ENaC expression. The polymorphism is present in a region that is not well conserved between human and mouse. We generated a mouse/human chimera by replacement of the distal C terminus of the mouse alpha-subunit with the distal C terminus of the human alpha-subunit. Co-expression of this m(1-678)/h(650-669)T663A chimera with mouse betagamma led to a significant reduction in whole cell Na+ currents and surface expression when compared with m(1-678)/h( 650-669) T663-mbetagamma. Our results suggest that h alphaT663A is a functional polymorphism that affects human ENaC surface expression.	Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rubenstein, RC (corresponding author), Childrens Hosp Philadelphia, Div Pulm Med, 34th St & Civ Ctr Blvd,Abramson 410C, Philadelphia, PA 19104 USA.	rrubenst@mail.med.upenn.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702; Rubenstein, Ronald/0000-0002-3138-4006; Levy, Daniel/0000-0003-0603-0297	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354, R37DK051391, R01DK058046, R01DK051391] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58046, DK54354, DK51391] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Ambrosius WT, 1999, HYPERTENSION, V34, P631, DOI 10.1161/01.HYP.34.4.631; AMBROSIUS WT, 2003, HYPERTENSION, V41, pE1; Baker EH, 2002, HYPERTENSION, V40, P13, DOI 10.1161/01.HYP.0000022570.02119.75; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; Bruns JB, 2003, AM J PHYSIOL-RENAL, V285, pF600, DOI 10.1152/ajprenal.00095.2003; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Corvol P, 1999, HYPERTENSION, V33, P1324, DOI 10.1161/01.HYP.33.6.1324; Cui Y, 1997, P NATL ACAD SCI USA, V94, P9962, DOI 10.1073/pnas.94.18.9962; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; Hummler E, 2003, CURR HYPERTENS REP, V5, P11, DOI 10.1007/s11906-003-0005-1; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Persu A, 1998, HYPERTENSION, V32, P129, DOI 10.1161/01.HYP.32.1.129; RENARD S, 1994, J BIOL CHEM, V269, P12981; Saxena A, 2002, J CLIN ENDOCR METAB, V87, P3344, DOI 10.1210/jcem.87.7.8674; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Sugiyama T, 2001, HYPERTENS RES, V24, P515, DOI 10.1291/hypres.24.515; Warnock DG, 2001, AM J MED SCI, V322, P302, DOI 10.1097/00000441-200112000-00002; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200; ZAR JH, 1984, BIOSTAT ANAL, P241; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	37	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23900	23907		10.1074/jbc.M401941200	http://dx.doi.org/10.1074/jbc.M401941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069064	hybrid			2022-12-25	WOS:000221702500010
J	Schmidt-Hansen, B; Klingelhofer, J; Grum-Schwensen, B; Christensen, A; Andresen, S; Kruse, C; Hansen, T; Ambartsumian, N; Lukanidin, E; Grigorian, M				Schmidt-Hansen, B; Klingelhofer, J; Grum-Schwensen, B; Christensen, A; Andresen, S; Kruse, C; Hansen, T; Ambartsumian, N; Lukanidin, E; Grigorian, M			Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; SQUAMOUS-CELL CARCINOMAS; MATRIX METALLOPROTEINASES; HUMAN COLLAGENASE-3; PROGNOSTIC MARKERS; OSTEOSARCOMA CELLS; EXPRESSION; DIFFERENTIATION; TARGET; CANCER	Causal implication of S100A4 in inducing metastases was convincingly shown previously. However, the mechanisms that associate S100A4 with tumor progression are not well understood. S100A4 protein, as a typical member of the S100 family, exhibits dual, intracellular and extracellular, functions. This work is focused on the extracellular function of S100A4, in particular its involvement in tumor-stroma interplay in VMR (mouse adenocarcinoma cell line) tumor cells, which exhibit stroma-dependent metastatic phenotype. We demonstrated the reciprocal influence of tumor and stroma cells where tumor cells stimulate S100A4 secretion from fibroblasts in culture. In turn, extracellular S100A4 modifies the cytoskeleton and focal adhesions and triggers several other events in tumor cells. We found stabilization of the tumor suppressor protein p53 and modulation of its function. In particular, extracellular S100A4 down-regulates the pro-apoptotic bax and the angiogenesis inhibitor thrombospondin-1 genes. For the first time, we demonstrate here that the S100A4 protein added to the extracellular space strongly stimulates proteolytic activity of VMR cells. This activity most probably is associated with matrix metalloproteinases and, in particular, with matrix metalloproteinase-13. Finally, the application of the recombinant S100A4 protein confers stroma-independent metastatic phenotype on VMR tumor cells. In conclusion, our results indicate that metastasis-inducing S100A4 protein plays a pivotal role in the tumor-stroma environment. S100A4 released either by tumor or stroma cells triggers pro-metastatic cascades in tumor cells.	Danish Canc Soc, Dept Mol Cell Biol, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Grigorian, M (corresponding author), Danish Canc Soc, Dept Mol Cell Biol, Inst Canc Biol, Strand Blvd 49, DK-2100 Copenhagen, Denmark.	mg@cancer.d	Hansen, Thomas/GWZ-2858-2022; Hansen, Thomas Folkmann/O-5965-2014; Klingelhöfer, Jörg/C-1676-2013	Hansen, Thomas Folkmann/0000-0001-6703-7762; Grum-Schwensen, Birgitte/0000-0001-6677-1869				Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; ANDELA VB, 2003, CLIN ORTHOP RE S OCT, pS75, DOI DOI 10.1097/01.BLO.0000093048.96273.AA; Andersen K, 1998, ANTICANCER RES, V18, P3299; Belot N, 2002, BBA-PROTEINS PROTEOM, V1600, P74, DOI 10.1016/S1570-9639(02)00447-8; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bjornland K, 1999, CANCER RES, V59, P4702; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; DeClerck YA, 2000, EUR J CANCER, V36, P1258, DOI 10.1016/S0959-8049(00)00094-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Duarte WR, 1999, BIOCHEM BIOPH RES CO, V255, P416, DOI 10.1006/bbrc.1999.0214; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FERNANDEZRESA P, 1995, ANAL BIOCHEM, V224, P434, DOI 10.1006/abio.1995.1063; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FORD HL, 1995, ONCOGENE, V10, P1597; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Fulle S, 1999, NEUROSCIENCE, V89, P991, DOI 10.1016/S0306-4522(98)00386-8; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, AM J PATHOL, V151, P499; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Kubista H, 1999, NEUROSCIENCE, V90, P493, DOI 10.1016/S0306-4522(98)00422-9; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Maelandsmo GM, 1996, CANCER RES, V56, P5490; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Rudland PS, 2000, CANCER RES, V60, P1595; SENIN VM, 1984, VESTN AKAD MED NAUK+, P85; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Xie B, 1998, J BIOL CHEM, V273, P11583, DOI 10.1074/jbc.273.19.11583; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234	47	125	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24498	24504		10.1074/jbc.M400441200	http://dx.doi.org/10.1074/jbc.M400441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047714	hybrid			2022-12-25	WOS:000221702500078
J	Smirnova, M; Van Komen, S; Sung, P; Hannah, LK				Smirnova, M; Van Komen, S; Sung, P; Hannah, LK			Effects of tumor-associated mutations on Rad54 functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; RECOMBINATION FACTORS RAD51; HOMOLOGY-DIRECTED REPAIR; DNA JOINT FORMATION; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENT; CHROMOSOMAL BREAKS; REPLICATION FORKS; YEAST RAD51; IONIZING-RADIATION	Yeast RAD54 gene, a member of the RAD52 epistasis group, plays an important role in homologous recombination and DNA double strand break repair. Rad54 belongs to the Snf2/Swi2 protein family, and it possesses a robust DNA-dependent ATPase activity, uses free energy from ATP hydrolysis to supercoil DNA, and cooperates with the Rad51 recombinase in DNA joint formation. There are two RAD54-homologous genes in human cells, hRAD54 and RAD54B. Mutations in these human genes have been found in tumors. These tumor-associated mutations map to conserved regions of the hRad54 and hRad54B proteins. Here we introduced the equivalent mutations into the Saccharomyces cerevisiae RAD54 gene in an effort to examine the functional consequences of these gene changes. One mutant, rad54 G484R, showed sensitivity to DNA-damaging agents and reduced homologous recombination rates, indicating a loss of function. Even though the purified rad54 G484R mutant protein retained the ability to bind DNA and interact with Rad51, it was nearly devoid of ATPase activity and was similarly defective in DNA supercoiling and D-loop formation. Two other mutants, rad54 N616S and rad54 D442Y, were not sensitive to genotoxic agents and behaved like the wild type allele in homologous recombination assays. Consistent with the mild phenotype associated with the rad54 N616S allele, its encoded protein was similar to wild type Rad54 protein in biochemical attributes. Because dysfunctional homologous recombination gives rise to genome instability, our results are consistent with the premise that tumor-associated mutations in hRad54 and Rad54B could contribute to the tumor phenotype or enhance the genome instability seen in tumor cells.	NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Inst, New York, NY 10016 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	New York University; New York University; Yale University	Sung, P (corresponding author), NYU, Sch Med, Dept Biochem, MSB 367,550 1st Ave, New York, NY 10016 USA.	Patrick.Sung@yale.edu		Klein, Hannah/0000-0003-4228-8535	NIGMS NIH HHS [GM57814, GM53738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1988, GENETICS, V119, P779; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Klein HL, 1997, GENETICS, V147, P1533; Klein HL, 2001, GENETICS, V159, P1501; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Miyagawa K, 2002, EMBO J, V21, P175, DOI 10.1093/emboj/21.1.175; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; PALLADINO F, 1992, GENETICS, V132, P23; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sherman F., 1986, METHODS YEAST GENETI; Shinohara M, 1997, GENETICS, V147, P1545; Shor E, 2002, GENETICS, V162, P647; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tanaka K, 2000, J BIOL CHEM, V275, P26316, DOI 10.1074/jbc.M910306199; Tanaka K, 2002, NUCLEIC ACIDS RES, V30, P1346, DOI 10.1093/nar/30.6.1346; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Wolner B, 2003, MOL CELL, V12, P221, DOI 10.1016/S1097-2765(03)00242-9; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu VPCC, 2000, GENE DEV, V14, P1400	61	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24081	24088		10.1074/jbc.M402719200	http://dx.doi.org/10.1074/jbc.M402719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15056673	hybrid, Green Submitted			2022-12-25	WOS:000221702500030
J	Vares, G; Ory, K; Lectard, B; Levalois, C; Altmeyer-Morel, S; Chevillard, S; Lebeau, J				Vares, G; Ory, K; Lectard, B; Levalois, C; Altmeyer-Morel, S; Chevillard, S; Lebeau, J			Progesterone prevents radiation-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						progesterone; apoptosis; breast; cancer	P53 TUMOR-SUPPRESSOR; MAMMARY-GLAND; HORMONAL-REGULATION; GROWTH-INHIBITION; EPITHELIAL-CELLS; MENSTRUAL-CYCLE; CROSS-TALK; DNA-DAMAGE; BCL-2; RECEPTOR	Sex steroid hormones play an essential role in the control of homeostasis in the mammary gland. Although the involvement of progesterone in cellular proliferation and differentiation is well established, its exact role in the control of cell death still remains unclear. As dysregulation of the apoptotic process plays an important role in the pathogenesis of breast cancer, we investigated the regulation of apoptosis by progesterone in various breast cancer cell lines. Our results show that progesterone treatment protects against radiation-induced apoptosis. This prevention appears to be mediated by the progesterone receptor and is unrelated to p53 status. There is also no correlation with the intrinsic hormonal effect on cell proliferation, as the presence of cells in a particular phase of the cell cycle. Surprisingly, progesterone partly allows bypassing of the irradiation-induced growth arrest in G(2)/M in PgR + cells, leading to an increase in cell proliferation after irradiation. One consequence of this effect is a higher rate of chromosome damage in these proliferating progesterone-treated cells compared to what is observed in untreated irradiated cells. We propose that progesterone, by inhibiting apoptosis and promoting the proliferation of cells with DNA damage, potentially facilitates the emergence of genetic mutations that may play a role in malignant transformation.	CEA, DSV, DRR, LCE, F-92265 Fontenay Aux Roses, France	CEA	Lebeau, J (corresponding author), CEA, DSV, DRR, LCE, 60-68 Ave GenLeclerc,BP6, F-92265 Fontenay Aux Roses, France.	lebeau@dsvidf.cea.fr	Vares, Guillaume/S-6530-2019; Vares, Guillaume/A-9257-2011	Vares, Guillaume/0000-0002-6191-9032; Vares, Guillaume/0000-0002-6191-9032; Chevillard, Sylvie/0000-0001-5889-4041				Alkhalaf M, 2002, EUR J CANCER PREV, V11, P481, DOI 10.1097/00008469-200210000-00011; BARDON S, 1987, CANCER RES, V47, P1441; Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420; Biri A, 2002, MUTAT RES-GEN TOX EN, V521, P113, DOI 10.1016/S1383-5718(02)00217-6; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FERGUSON DJP, 1981, BRIT J CANCER, V44, P177, DOI 10.1038/bjc.1981.168; Flototto T, 2001, HORM METAB RES, V33, P451, DOI 10.1055/s-2001-16936; Formby B, 1998, ANN CLIN LAB SCI, V28, P360; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; JUENGEL JL, 1993, ENDOCRINOLOGY, V132, P249, DOI 10.1210/en.132.1.249; Kandouz M, 1999, J STEROID BIOCHEM, V69, P463, DOI 10.1016/S0960-0760(99)00069-2; Kao GD, 2001, ONCOGENE, V20, P3486, DOI 10.1038/sj.onc.1204445; Kester HA, 2003, EXP CELL RES, V284, P264, DOI 10.1016/S0014-4827(02)00017-4; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; KirschVolders M, 1997, MUTAT RES-GEN TOX EN, V392, P19, DOI 10.1016/S0165-1218(97)00042-6; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Lanari C, 2002, BREAST CANCER RES, V4, P240, DOI 10.1186/bcr539; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lebeau J, 2002, ANTICANCER RES, V22, P2161; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin VCL, 2003, AM J PATHOL, V162, P1781, DOI 10.1016/S0002-9440(10)64313-1; LUCIANO AM, 1994, BIOL REPROD, V51, P646, DOI 10.1095/biolreprod51.4.646; LUKIC B, 1987, MUTAT RES, V191, P121, DOI 10.1016/0165-7992(87)90140-0; Lydon JP, 1999, CANCER RES, V59, P4276; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Murdoch WJ, 2002, MOL CELL ENDOCRINOL, V186, P61, DOI 10.1016/S0303-7207(01)00675-X; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; Ory K, 2001, BREAST CANCER RES TR, V68, P187, DOI 10.1023/A:1012288510743; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; ROTELLO RJ, 1992, AM J PATHOL, V140, P449; SABOURIN JC, 1994, INT J CANCER, V59, P1, DOI 10.1002/ijc.2910590102; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Thordarson G, 2001, CARCINOGENESIS, V22, P1027, DOI 10.1093/carcin/22.7.1027	45	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4603	4613		10.1038/sj.onc.1207601	http://dx.doi.org/10.1038/sj.onc.1207601			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064714				2022-12-25	WOS:000221799000010
J	Smith, WA; Schurter, BT; Wong-Staal, F; David, M				Smith, WA; Schurter, BT; Wong-Staal, F; David, M			Arginine methylation of RNA helicase A determines its subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE TRANSPORT ELEMENT; PROTEIN; SEQUENCES; BINDING; TRANSCRIPTION; CONTAINS; PEPTIDES; SIGNALS; TYPE-1; EXPORT	RNA helicase A (RHA) undergoes nuclear translocation via a classical import mechanism utilizing karyopherin beta. The nuclear transport domain (NTD) of RHA is known to be necessary and sufficient for its bi-directional nuclear trafficking. We report here that arginine methylation is a novel requirement for NTD-mediated nuclear import. Nuclear translocation of glutathione S-transferase (GST)-NTD fusion proteins is abrogated by arginine-methylation inhibitors. However, in vitro arginine-methylation of GST-NTD prior to injection allows the fusion protein to localize to the nucleus in the presence of methylation inhibitors. Removal of the arginine-rich C-terminal region negates the effects of the methylation inhibitors on NTD import, suggesting that methylation of the NTD C terminus the relieves the cytoplasmic retention of RHA. The NTD physically interacts with PRMT1, the major protein arginine methyltransferase. These findings provide evidence for a novel arginine methylation-dependent regulatory pathway controlling the nuclear import of RHA.	Univ Calif San Diego, Dept Biol, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	David, M (corresponding author), Univ Calif San Diego, Dept Biol, Div Biol Sci, Bonner Hall 3138,9500 Gilman Dr, La Jolla, CA 92093 USA.	midavid@ucsd.edu			NCI NIH HHS [R01CA80105] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Fineberg K, 2003, BIOCHEMISTRY-US, V42, P2625, DOI 10.1021/bi0206199; Fujii R, 2001, J BIOL CHEM, V276, P5445, DOI 10.1074/jbc.M006892200; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; LEE CG, 1993, J BIOL CHEM, V268, P16822; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Zhang SS, 2002, J BIOL CHEM, V277, P843, DOI 10.1074/jbc.M109393200; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; Zhu W, 2002, J BIOL CHEM, V277, P35787, DOI 10.1074/jbc.C200346200	25	100	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22795	22798		10.1074/jbc.C300512200	http://dx.doi.org/10.1074/jbc.C300512200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15084609	hybrid			2022-12-25	WOS:000221570900003
J	Knockaert, M; Blondel, M; Bach, S; Leost, M; Elbi, C; Hager, GL; Nagy, SR; Han, D; Denison, M; Ffrench, M; Ryan, XZP; Magiatis, P; Polychronopoulos, P; Greengard, P; Skaltsounis, L; Meijer, L				Knockaert, M; Blondel, M; Bach, S; Leost, M; Elbi, C; Hager, GL; Nagy, SR; Han, D; Denison, M; Ffrench, M; Ryan, XZP; Magiatis, P; Polychronopoulos, P; Greengard, P; Skaltsounis, L; Meijer, L			Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins	ONCOGENE			English	Article						aryl hydrocarbon receptor; indirubin; cyclin-dependent kinase; glycogen synthase kinase; GSK-3 beta; kinase inhibitor; cancer	AH RECEPTOR; CELL-CYCLE; ARYLHYDROCARBON RECEPTOR; CRYSTAL-STRUCTURE; DIOXIN RECEPTOR; MESSENGER-RNAS; TYRIAN PURPLE; MICE LACKING; EXPRESSION; PROTEIN	Indirubin, a bis-indole obtained from various natural sources, is responsible for the reported antileukemia activity of a Chinese Medicinal recipe, Danggui Longhui Wan. However, its molecular mechanism of action is still not well understood. In addition to inhibition of cyclin-dependent kinases and glycogen synthase kinase-3, indirubins have been reported to activate the aryl hydrocarbon receptor (AhR), a cotranscriptional factor. Here, we confirm the interaction of AhR and indirubin using a series of indirubin derivatives and show that their binding modes to AhR and to protein kinases are unrelated. As reported for other AhR ligands, binding of indirubins to AhR leads to its nuclear translocation. Furthermore, the apparent survival of AhR-/- and +/+ cells, as measured by the MTT assay, is equally sensitive to the kinase-inhibiting indirubins. Thus, the cytotoxic effects of indirubins are AhR-independent and more likely to be linked to protein kinase inhibition. In contrast, a dramatic cytostatic effect, as measured by actual cell counts and associated with a sharp G1 phase arrest, is induced by 1-methyl-indirubins, a subfamily of AhR-active but kinase-inactive indirubins. As shown for TCDD (dioxin), this effect appears to be mediated through the AhR-dependent expression of p27(KIP1). Altogether these results suggest that AhR activation, rather than kinase inhibition, is responsible for the cytostatic effects of some indirubins. In contrast, kinase inhibition, rather than AhR activation, represents the main mechanism underlying the cytotoxic properties of this class of promising antitumor molecules.	CNRS, Cell Cycle Grp, F-29682 Roscoff, France; Biol Stn, F-29682 Roscoff, France; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA; Univ Lyon 1, Lab Cytol Analyt & Cytogenet Mol, F-69373 Lyon 08, France; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, GR-15771 Athens, Greece	Centre National de la Recherche Scientifique (CNRS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Davis; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Rockefeller University; National & Kapodistrian University of Athens	Meijer, L (corresponding author), CNRS, Cell Cycle Grp, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr	Magiatis, Prokopios/A-2008-2008; skaltsounis, alexios leandros/AAE-9617-2019; BACH, Stéphane/ABD-5865-2020; Blondel, Marc/AAJ-9049-2020	Blondel, Marc/0000-0003-4897-2995; Magiatis, Prokopios/0000-0002-0399-5344; , laurent/0000-0003-3511-4916	NATIONAL CANCER INSTITUTE [Z01BC005450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699] Funding Source: NIH RePORTER; NIEHS NIH HHS [5P42ES04699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; [Anonymous], 1992, CHIN DRUGS PLANT ORI; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Balfour-Paul Jenny, 1998, INDIGO; Bergander L, 2003, DRUG METAB DISPOS, V31, P233, DOI 10.1124/dmd.31.2.233; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Bradshaw TD, 2002, CURR PHARM DESIGN, V8, P2475, DOI 10.2174/1381612023392784; Chotani G, 2000, BBA-PROTEIN STRUCT M, V1543, P434, DOI 10.1016/S0167-4838(00)00234-X; Cooksey CJ, 2001, MOLECULES, V6, P736, DOI 10.3390/60900736; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; DEALLER SF, 1988, J CLIN MICROBIOL, V26, P2152, DOI 10.1128/JCM.26.10.2152-2156.1988; Denison MS, 1998, TARG ORG T, P3; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FFRENCH M, 1985, CYTOMETRY, V6, P47, DOI 10.1002/cyto.990060109; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; Guthrie C, 1991, GUIDE YEAST GENETICS; Hahn ME, 2002, CHEM-BIOL INTERACT, V141, P131, DOI 10.1016/S0009-2797(02)00070-4; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hayashibara T, 2003, BIOCHEM BIOPH RES CO, V300, P128, DOI 10.1016/S0006-291X(02)02793-6; Heath-Pagliuso S, 1998, BIOCHEMISTRY-US, V37, P11508, DOI 10.1021/bi980087p; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Jacobs MN, 2003, J STEROID BIOCHEM, V84, P117, DOI 10.1016/S0960-0760(03)00021-9; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Joiakim A, 2003, DRUG METAB DISPOS, V31, P1279, DOI 10.1124/dmd.31.11.1279; Kawanishi M, 2003, MUTAT RES-GEN TOX EN, V540, P99, DOI 10.1016/S1383-5718(03)00174-8; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kolluri SK, 2001, CANCER RES, V61, P8534; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kuchenhoff A, 1999, FERTIL STERIL, V71, P354, DOI 10.1016/S0015-0282(98)00437-3; Kuramoto N, 2003, J NEUROCHEM, V85, P264, DOI 10.1046/j.1471-4159.2003.01679.x; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MacNeil IA, 2001, J MOL MICROB BIOTECH, V3, P301; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Maugard T, 2001, PHYTOCHEMISTRY, V58, P897, DOI 10.1016/S0031-9422(01)00335-1; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Miller CA, 1997, J BIOL CHEM, V272, P32824, DOI 10.1074/jbc.272.52.32824; Miller CA, 1999, TOXICOL APPL PHARM, V160, P297, DOI 10.1006/taap.1999.8769; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagy SR, 2002, TOXICOL SCI, V65, P200, DOI 10.1093/toxsci/65.2.200; Nagy SR, 2002, BIOCHEMISTRY-US, V41, P861, DOI 10.1021/bi011373v; PETERS JM, 1995, TOXICOL APPL PHARM, V134, P214, DOI 10.1006/taap.1995.1186; Petersen SL, 2000, J COMP NEUROL, V427, P428, DOI 10.1002/1096-9861(20001120)427:3<428::AID-CNE9>3.0.CO;2-P; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Primot A, 2000, PROTEIN EXPRES PURIF, V20, P394, DOI 10.1006/prep.2000.1321; Procopio M, 2002, EUR J BIOCHEM, V269, P13, DOI 10.1046/j.0014-2956.2002.02619.x; RANNUG U, 1992, MUTAT RES, V282, P219, DOI 10.1016/0165-7992(92)90099-4; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Safe S, 2002, INT J ONCOL, V20, P1123; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Santini RP, 2001, J PHARMACOL EXP THER, V299, P718; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Song JS, 2002, P NATL ACAD SCI USA, V99, P14694, DOI 10.1073/pnas.232562899; Spink BC, 2003, BIOCHEM PHARMACOL, V66, P2313, DOI 10.1016/j.bcp.2003.08.019; Wei YD, 2000, ARCH BIOCHEM BIOPHYS, V383, P99, DOI 10.1006/abbi.2000.2037; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Yoon BI, 2002, TOXICOL SCI, V70, P150, DOI 10.1093/toxsci/70.1.150	72	87	94	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4400	4412		10.1038/sj.onc.1207535	http://dx.doi.org/10.1038/sj.onc.1207535			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077192				2022-12-25	WOS:000221661300006
J	Little, KC; Chartrand, P				Little, KC; Chartrand, P			Genomic DNA is captured and amplified during double-strand break (DSB) repair in human cells	ONCOGENE			English	Article						DNA repair; human genome; double-strand break (DSB); amplification; SV40	ATAXIA-TELANGIECTASIA; INTEGRATION SITE; MAMMALIAN CHROMOSOME; BROKEN CHROMOSOMES; SIMIAN-VIRUS-40; SV40; SEQUENCES; IDENTIFICATION; AMPLIFICATION; EXPRESSION	Genomic stability is maintained by the surveillance and repair of DNA damage. Here, we describe a mechanism whereby repair of extrachromosomal DNA double-strand breaks (DSBs) in human cells can be accompanied by capture of genomic DNA fragments. The availability of the human genome sequence enabled us to characterize these inserts in cells from a normal individual and from a patient with ataxia telangiectasia ( AT), deficient for the damage response kinase ATM and prone to genomic instability. We find AT cells exhibit insertions of human chromosomal DNA fragments in excess of 17 kb during DSB repair, whereas we detected no such genomic inserts in normal cells. However, the presence of simian virus 40 (SV40), used to transform these cell lines, resulted in capture of genomic DNA associated with sites of viral integration in both cell types. The genomic instability at sites of SV40 integration was exported to other sites of DNA damage, and acquisition of the viral origin of replication resulted in gene amplification through autonomous replication of the plasmid harbouring the repaired extrachromosomal DSB. Should this same phenomenon apply to the repair of chromsomal DSBs, genome rearrangements made possible via this DSB insertional repair pose risks to genomic integrity, and may contribute to tumorigenic progression.	Hop Notre Dame de Bon Secours, Ctr Rech CHUM, Montreal, PQ H2L 4M1, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal	Chartrand, P (corresponding author), Hop Notre Dame de Bon Secours, Ctr Rech CHUM, 1560 Rue Sherbrooke Est,Room Y4622, Montreal, PQ H2L 4M1, Canada.	pierre.chartrand@umontreal.ca						Allen C, 2003, DNA REPAIR, V2, P1147, DOI 10.1016/S1568-7864(03)00139-3; BENNER SE, 1991, ANTI-CANCER DRUG, V2, P11, DOI 10.1097/00001813-199102000-00002; Carbone M, 2003, INT J CANCER, V106, P140, DOI 10.1002/ijc.11189; Corbin S, 2002, CANCER RES, V62, P3477; COX R, 1986, MOL BIOL MED, V3, P229; CROCE CM, 1977, P NATL ACAD SCI USA, V74, P315, DOI 10.1073/pnas.74.1.315; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Garcea RL, 2003, J VIROL, V77, P5039, DOI 10.1128/JVI.77.9.5039-5045.2003; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; Gorbunova V, 1997, NUCLEIC ACIDS RES, V25, P4650, DOI 10.1093/nar/25.22.4650; HARA H, 1987, EXP CELL RES, V168, P531, DOI 10.1016/0014-4827(87)90025-5; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Huang KC, 1999, VIROLOGY, V262, P457, DOI 10.1006/viro.1999.9952; HWANG SP, 1980, VIROLOGY, V105, P196, DOI 10.1016/0042-6822(80)90167-1; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KUCHERLAPATI R, 1978, P NATL ACAD SCI USA, V75, P4460, DOI 10.1073/pnas.75.9.4460; Lednicky JA, 1997, J GEN VIROL, V78, P1697, DOI 10.1099/0022-1317-78-7-1697; Li YL, 2001, ENVIRON MOL MUTAGEN, V37, P128, DOI 10.1002/em.1020; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lin YF, 2001, NUCLEIC ACIDS RES, V29, P3975, DOI 10.1093/nar/29.19.3975; Lin YF, 2001, GENETICS, V158, P1665; Lobrich M, 2000, GENE CHROMOSOME CANC, V27, P59; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; MAULBECKER C, 1992, J VIROL, V66, P2195, DOI 10.1128/JVI.66.4.2195-2207.1992; Mendoza SM, 1998, ONCOGENE, V17, P2457, DOI 10.1038/sj.onc.1202179; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; MURNANE JP, 1985, EXP CELL RES, V158, P119, DOI 10.1016/0014-4827(85)90437-9; Popescu NC, 2003, CANCER LETT, V192, P1, DOI 10.1016/S0304-3835(02)00596-7; POWELL S, 1993, MUTAT RES, V294, P9, DOI 10.1016/0921-8777(93)90053-J; RABIN M, 1984, J VIROL, V49, P445, DOI 10.1128/JVI.49.2.445-451.1984; Ricchetti M, 1999, NATURE, V402, P96, DOI 10.1038/47076; ROSCHEISEN C, 1994, SOMAT CELL MOLEC GEN, V20, P493, DOI 10.1007/BF02255840; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; RUNGER TM, 1992, MUTAT RES, V293, P47, DOI 10.1016/0921-8777(92)90007-P; Salomon S, 1998, EMBO J, V17, P6086, DOI 10.1093/emboj/17.20.6086; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Shera KA, 2001, J VIROL, V75, P12339, DOI 10.1128/JVI.75.24.12339-12346.2001; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Stewart AR, 1998, J NEUROVIROL, V4, P182; Tachibana A, 2002, BIOCHEM BIOPH RES CO, V297, P275, DOI 10.1016/S0006-291X(02)02191-5; TATSUMIMIYAJIMA J, 1993, MUTAT RES, V294, P317, DOI 10.1016/0921-8777(93)90014-8; Testa JR, 1998, CANCER RES, V58, P4505; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S0002-9343(03)00087-1; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Wurtele H, 2003, GENE THER, V10, P1791, DOI 10.1038/sj.gt.3302074; YANO O, 1991, CELL STRUCT FUNCT, V16, P63, DOI 10.1247/csf.16.63; Yu X, 1999, MOL CELL, V4, P873, DOI 10.1016/S1097-2765(00)80397-4; Zhou Y, 2003, CANCER RES, V63, P5781	54	12	12	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4166	4172		10.1038/sj.onc.1207570	http://dx.doi.org/10.1038/sj.onc.1207570			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048077				2022-12-25	WOS:000221520200015
J	Sullivan, A; Syed, N; Gasco, M; Bergamaschi, D; Trigiante, G; Attard, M; Hiller, L; Farrell, PJ; Smith, P; Lu, X; Crook, T				Sullivan, A; Syed, N; Gasco, M; Bergamaschi, D; Trigiante, G; Attard, M; Hiller, L; Farrell, PJ; Smith, P; Lu, X; Crook, T			Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo	ONCOGENE			English	Article						carcinoma; p53; SNP; apoptosis; clinical outcome	COLORECTAL-CANCER CELLS; P53-DEPENDENT APOPTOSIS; PUMA; VARIANTS; MEDIATOR; AGENTS; NOXA	A single-nucleotide polymorphism (SNP) in exon 4 results in expression of either arginine (72R) or proline (72P) at codon 72 of p53. We demonstrate that the in vitro response of cells exposed to anticancer agents is strongly influenced by this SNP in wild-type p53. In inducible systems and in cells expressing the endogenous protein, expression of 72P wild-type p53 results in a predominant G1 arrest, with only a minor apoptosis, at drug concentrations causing extensive apoptosis in cells expressing the 72R wild-type variant. The superior apoptosis-inducing activity of the 72R form correlates with more efficient induction of specific apoptosis-associated genes, and is maximal in the presence of serine 46 (S46). In vivo, the outcome of chemo-radiotherapy of squamous carcinomas is more favourable in cancers retaining a wild-type 72R allele, such cases having higher response rates and longer survival than those with wild-type 72P. Together, these results reveal that this SNP is an important determinant of response to anticancer agents in cells expressing wild-type p53. Analysis of complete p53 genotype (mutation and SNP) merits detailed investigation as a simple means for prediction of treatment response and survival in clinical oncology.	St Marys Hosp, Imperial Coll Fac Med, Ludwig Inst Canc Res, London W1, England; S Croce & Carle Hosp, Dept Med Oncol, I-12100 Cuneo, Italy; Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England	Imperial College London; Ludwig Institute for Cancer Research; Cancer Research UK; University of Birmingham	Crook, T (corresponding author), St Marys Hosp, Imperial Coll Fac Med, Ludwig Inst Canc Res, Norfolk Pl, London W1, England.	t.crook@ic.ac.uk		Farrell, Paul/0000-0002-6754-9351; Bergamaschi, Daniele/0000-0002-3955-1091; Lu, Xin/0000-0002-6587-1152				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; SJALANDER A, 1995, HUM HERED, V45, P144, DOI 10.1159/000154275; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	26	215	235	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3328	3337		10.1038/sj.onc.1207428	http://dx.doi.org/10.1038/sj.onc.1207428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077186				2022-12-25	WOS:000220975000007
J	Clayton, A; Turkes, A; Dewitt, S; Steadman, R; Mason, MD; Hallett, MB				Clayton, A; Turkes, A; Dewitt, S; Steadman, R; Mason, MD; Hallett, MB			Adhesion and signaling by B cell-derived exosomes: the role of integrins	FASEB JOURNAL			English	Article						calcium signaling; inflammation; ICAM-1; fibroblasts	ACTIVATION; MATURATION; MICROVESICLES; LYMPHOCYTES; LIGATION; PROTEINS; VESICLES; RELEASE	Exosomes are nanometer-sized vesicles secreted by various cells, with potentially diverse roles in physiology. Although emphasis has been placed on their involvement in immune modulation, their potential for more wide-ranging biological effects has not been appreciated. A common exosome feature is the expression of adhesion molecules, which include the integrin family. We have for the first time addressed the possible function of B cell-derived exosome-integrins by examining adhesive interactions of exosomes ( immobilized onto beads) with extracellular matrix (ECM) components and cytokine-treated fibroblasts. Integrin (beta1 and beta2) expression was demonstrated by Western blotting and flow cytometry. Binding studies ( with blocking antibodies) demonstrated their function in adhesion to collagen-I, fibronectin, and tumor necrosis factor (TNF)-alpha-activated fibroblasts. Exosome adhesion to TNF-alpha-activated fibroblasts also triggered integrin-dependent changes in cytosolic calcium, measured by single cell imaging. Thus, B cell-derived exosomes express functional integrins, which are capable of mediating anchorage to ECM and cell-surface adhesion molecules, and may be a novel mode of delivering adhesion signals at distances beyond that of direct cell-cell contact during inflammation.	Cardiff Univ, Velindre Hosp, Dept Med, Sect Clin Oncol, Cardiff CF14 2TL, S Glam, Wales; Cardiff Univ, Dept Surg, Neutrophil Signaling Grp, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Velindre Hospital; Cardiff University; Cardiff University	Clayton, A (corresponding author), Cardiff Univ, Velindre Hosp, Dept Med, Sect Clin Oncol, Whitchurch, Cardiff CF14 2TL, S Glam, Wales.	aled.clayton@velindre-tr.wales.nhs.uk	Steadman, Robert/O-1614-2016; Mason, Malcolm D/H-6979-2013; Hallett, Maurice/I-6866-2012	Steadman, Robert/0000-0002-1303-2496; Hallett, Maurice/0000-0001-8197-834X; Dewitt, Sharon/0000-0001-8169-8241				Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Blaber R, 2003, J AM SOC NEPHROL, V14, P116, DOI 10.1097/01.ASN.0000040595.35207.62; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Clayton A, 1998, J CELL SCI, V111, P443; Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5; Clayton A, 2003, EUR J IMMUNOL, V33, P522, DOI 10.1002/immu.200310028; Denzer K, 2000, J IMMUNOL, V165, P1259, DOI 10.4049/jimmunol.165.3.1259; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; DOYLE A, 1994, CELL TISSUE CULTURE, V2; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; HALLETT MB, 1990, CELL CALCIUM, V11, P655, DOI 10.1016/0143-4160(90)90020-U; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HURLEY EA, 1991, J VIROL, V65, P3958, DOI 10.1128/JVI.65.7.3958-3963.1991; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; Karlsson M, 2001, EUR J IMMUNOL, V31, P2892, DOI 10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I; Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7; LANGE TS, 1994, EXP CELL RES, V214, P381, DOI 10.1006/excr.1994.1271; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Leitinger B, 2002, J CELL SCI, V115, P963; Nimako M, 1997, CANCER RES, V57, P4855; Rabesandratana H, 1998, BLOOD, V91, P2573, DOI 10.1182/blood.V91.7.2573.2573_2573_2580; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	32	232	251	1	37	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					977	+		10.1096/fj.03-1094fje	http://dx.doi.org/10.1096/fj.03-1094fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059973				2022-12-25	WOS:000221108800024
J	Choi, YG; Kim, JI; Jeon, YC; Park, SJ; Choi, EK; Rubenstein, R; Kascsak, RJ; Carp, RI; Kim, YS				Choi, YG; Kim, JI; Jeon, YC; Park, SJ; Choi, EK; Rubenstein, R; Kascsak, RJ; Carp, RI; Kim, YS			Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION END-PRODUCTS; MAILLARD REACTION; ALZHEIMER-DISEASE; OXIDATIVE STRESS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; KNOCKOUT MICE; GLYCOSYLATION; N-EPSILON-(CARBOXYMETHYL)LYSINE; GLYCOXIDATION	Transmissible spongiform encephalopathies (TSEs) are transmissible neurodegenerative diseases characterized by the accumulation of an abnormally folded prion protein, termed PrPSc, and the development of pathological features of astrogliosis, vacuolation, neuronal cell loss, and in some cases amyloid plaques. Although considerable structural characterization of prion protein has been reported, neither the method of conversion of cellular prion protein, PrPC, into the pathogenic isoform nor the post-translational modification processes involved is known. We report that in animal and human TSEs, one or more lysines at residues 23, 24, and 27 of PrPSc are covalently modified with advanced glycosylation end products (AGEs), which may be carboxymethyllysine (CML), one of the structural varieties of AGEs. The arginine residue at position 37 may also be modified with AGE, but not the arginine residue at position 25. This result suggests that nonenzymatic glycation is one of the post-translational modifications of PrPSc. Furthermore, immunostaining studies indicate that, at least in clinically affected hamsters, astrocytes are the first site of this glycation process.	Hallym Univ, Ilsong Inst Life Sci, Coll Med, Anyang 431060, Kyeonggi Do, South Korea; Hallym Univ, Dept Microbiol, Coll Med, Anyang 431060, Kyeonggi Do, South Korea; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA	Hallym University; Hallym University; Institute for Basic Research in Developmental Disabilities	Kim, YS (corresponding author), Hallym Univ, Ilsong Inst Life Sci, Coll Med, 1605-4 Kwanyangdong, Anyang 431060, Kyeonggi Do, South Korea.	yskim@hallym.ac.kr						Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; BRONWLEE M, 1988, NEW ENGL J MED, V318, P1315; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; Castellani R, 1996, BRAIN RES, V737, P195, DOI 10.1016/0006-8993(96)00729-9; DIEDRICH JF, 1991, P NATL ACAD SCI USA, V88, P375, DOI 10.1073/pnas.88.2.375; Dukic-Stefanovic S, 2002, J IMMUNOL METHODS, V266, P45, DOI 10.1016/S0022-1759(02)00097-2; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kascsak RJ, 1997, IMMUNOL INVEST, V26, P259, DOI 10.3109/08820139709048931; Khalifah RG, 1996, BIOCHEMISTRY-US, V35, P4645, DOI 10.1021/bi9525942; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mironova R, 2003, J BIOL CHEM, V278, P51068, DOI 10.1074/jbc.M307470200; Mironova R, 2001, MOL MICROBIOL, V39, P1061, DOI 10.1046/j.1365-2958.2001.02304.x; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; Miyata T, 1997, KIDNEY INT, V51, P1170, DOI 10.1038/ki.1997.160; Miyata T, 1996, P NATL ACAD SCI USA, V93, P2353, DOI 10.1073/pnas.93.6.2353; Montrasio F, 2001, P NATL ACAD SCI USA, V98, P4034, DOI 10.1073/pnas.051609398; Nerlich AG, 1999, ATHEROSCLEROSIS, V144, P41, DOI 10.1016/S0021-9150(99)00038-6; Pan T, 2001, J BIOL CHEM, V276, P37284, DOI 10.1074/jbc.M107358200; Raeber AJ, 1998, BRAIN PATHOL, V8, P715, DOI 10.1111/j.1750-3639.1998.tb00197.x; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Shaked GM, 2001, J BIOL CHEM, V276, P31479, DOI 10.1074/jbc.C100278200; Shibayama P, 1999, DIABETES, V48, P1842, DOI 10.2337/diabetes.48.9.1842; SMITH MA, 1994, ANN NY ACAD SCI, V738, P447; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787	35	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30402	30409		10.1074/jbc.M400854200	http://dx.doi.org/10.1074/jbc.M400854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15084583	hybrid			2022-12-25	WOS:000222531900066
J	Chen, F; Arseven, OK; Cryns, VL				Chen, F; Arseven, OK; Cryns, VL			Proteolysis of the mismatch repair protein MLH1 by caspase-3 promotes DNA damage-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; CYTOCHROME-C RELEASE; MEDIATED CLEAVAGE; POLY(ADP-RIBOSE) POLYMERASE; IONIZING-RADIATION; CELL-DEATH; ACTIVATION; MUTATION; HMLH1; IDENTIFICATION	Caspases are critical proapoptotic proteases that execute cell death signals by selectively cleaving proteins at Asp residues to alter their function. Caspases trigger apoptotic chromatin degradation by activating caspase-activated DNase and by inactivating a number of enzymes that sense or repair DNA damage. We have identified the mismatch repair protein MLH1 as a novel caspase-3 substrate by screening small pools of a human prostate adenocarcinoma cDNA library for cDNAs encoding caspase substrates. In this report, we demonstrate that human MLH1 is specifically cleaved by caspase-3 at Asp(418) in vitro. Furthermore, MLH1 is rapidly proteolyzed by caspase-3 in cancer cells induced to undergo apoptosis by treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the topoisomerase II inhibitor etoposide, which damages DNA. Importantly, proteolysis of MLH1 by caspase-3 triggers its partial redistribution from the nucleus to the cytoplasm and generates a proapoptotic carboxyl-terminal product. In addition, we demonstrate that a caspase-3 cleavage-resistant D418E MLH1 mutant inhibits etoposide-induced apoptosis but has little effect on TRAIL-induced apoptosis. These results indicate that the proteolysis of MLH1 by caspase-3 plays a functionally important and previously unrecognized role in the execution of DNA damage-induced apoptosis.	Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Cell Death Regulat Lab, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Cryns, VL (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Cell Death Regulat Lab, Tarry 15-755,303 E Chicago Ave, Chicago, IL 60611 USA.	v-cryns@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA097198] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA097198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1997, CLIN CANCER RES, V3, P1763; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Bischof O, 2001, J BIOL CHEM, V276, P12068, DOI 10.1074/jbc.M006462200; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brieger A, 2002, GUT, V51, P677, DOI 10.1136/gut.51.5.677; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chen F, 2002, J BIOL CHEM, V277, P16775, DOI 10.1074/jbc.M201322200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Davis TW, 1998, CANCER RES, V58, P767; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gong JG, 1999, NATURE, V399, P806; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Heinen CD, 2002, CANCER BIOL THER, V1, P477, DOI 10.4161/cbt.1.5.160; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 2000, NATURE, V407, P687, DOI 10.1038/35037701; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lin XJ, 2001, CANCER RES, V61, P1508; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Partlin MM, 2003, ONCOGENE, V22, P819, DOI DOI 10.1038/SJ.0NC.1206252; Pati D, 2002, MOL CELL BIOL, V22, P8267, DOI 10.1128/MCB.22.23.8267-8277.2002; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wang Y, 2000, GENE DEV, V14, P927; Yan T, 2001, CANCER RES, V61, P8290; Zhan QM, 2002, ONCOGENE, V21, P5335, DOI 10.1038/sj.onc.1205665; Zhang H, 1999, CANCER RES, V59, P3021; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	67	27	29	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27542	27548		10.1074/jbc.M400971200	http://dx.doi.org/10.1074/jbc.M400971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087450	hybrid			2022-12-25	WOS:000222120400087
J	Kageyama, A; Oka, M; Okada, T; Nakamura, S; Ueyama, T; Saito, N; Hearing, VJ; Ichihashi, M; Nishigori, C				Kageyama, A; Oka, M; Okada, T; Nakamura, S; Ueyama, T; Saito, N; Hearing, VJ; Ichihashi, M; Nishigori, C			Down-regulation of melanogenesis by phospholipase D2 through ubiquitin proteasome-mediated degradation of tyrosinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; MESSENGER-RNA LEVELS; GTP-BINDING PROTEIN; B16 MELANOMA-CELLS; MAMMALIAN-CELLS; D ACTIVATION; D1; PIGMENTATION; MELANOCYTES	The involvement of phospholipase D (PLD) in the regulation of melanogenesis was examined. Treatment of B16 mouse melanoma cells with 12-O-tetradecanoylphorbol-13- acetate (TPA) resulted in the activation of PLD and a decrease in melanin content. 1-Butanol, but not 2-butanol, completely blocked the TPA-induced inhibition of melanogenesis, suggesting the involvement of PLD in this event. Reverse transcription-PCR and immunoblot analyses revealed the existence of both PLD isozymes, PLD1 and PLD2, in B16 cells. When PLD1 or PLD2 was introduced into those cells by an adenoviral gene-transfer technique, both PLD1 and PLD2 were activated by TPA. When PLD1 and PLD2 were overexpressed, PLD2 potently caused a decrease in melanin content, whereas the effect of PLD1 expression on melanin content was minimal. Over-expression of PLD2 itself did not affect protein kinase C activity, as assessed by the intracellular distribution and levels of expression of each isoform expressed in B16 cells. The effects of TPA on the down-regulation of basal or alpha-melanocyte-stimulating hormone-enhanced melanogenesis were almost completely blocked by expressing a lipase activity-negative mutant, LN-PLD2, but not by LN-PLD1. Further, the PLD2-induced decrease in melanin content was accompanied by a decrease in the amount and activity of tyrosinase, a key enzyme in melanogenesis, whereas the mRNA level of tyrosinase was unchanged by the over-expression of PLD2. Moreover, treatment with proteasome inhibitors completely blocked the PLD2-induced down-regulation of melanogenesis. Taken together, the present results indicate that the TPA-induced down-regulation of melanogenesis is mediated by PLD2 but not by PLD1 through the ubiquitin proteasome-mediated degradation of tyrosinase. This suggests that PLD2 may play an important role in regulating pigmentation in vivo.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Dermatol, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Clin Mol Med, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Biochem, Kobe, Hyogo 6500017, Japan; Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Kobe, Hyogo 6578501, Japan; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Kobe University; Kobe University; Kobe University; Kobe University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Oka, M (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Dermatol, Kobe, Hyogo 6500017, Japan.	oka@med.kobe-u.ac.jp			DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDO H, 1995, J CELL PHYSIOL, V163, P608, DOI 10.1002/jcp.1041630322; Ando H, 2004, J BIOL CHEM, V279, P15427, DOI 10.1074/jbc.M313701200; Bertolotto C, 1998, ONCOGENE, V16, P1665, DOI 10.1038/sj.onc.1201685; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Freyberg Z, 2002, MOL BIOL CELL, V13, P3930, DOI 10.1091/mbc.02-04-0059; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; FULLER BB, 1990, MOL CELL ENDOCRINOL, V72, P81, DOI 10.1016/0303-7207(90)90097-R; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KUZUMAKI T, 1993, EXP CELL RES, V207, P33, DOI 10.1006/excr.1993.1159; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Mahalingam H, 1996, J CELL PHYSIOL, V168, P549, DOI 10.1002/(SICI)1097-4652(199609)168:3<549::AID-JCP7>3.0.CO;2-P; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Meier KE, 1999, BBA-MOL CELL BIOL L, V1439, P199, DOI 10.1016/S1388-1981(99)00095-5; Mosher DB, 1987, DERMATOLOGY GENERAL, P794; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Nakamura S, 1998, P NATL ACAD SCI USA, V95, P12249, DOI 10.1073/pnas.95.21.12249; Nakamura S, 1995, P NATL ACAD SCI USA, V92, P12319, DOI 10.1073/pnas.92.26.12319; Ohguchi K, 2004, J BIOL CHEM, V279, P3408, DOI 10.1074/jbc.M308054200; Oka M, 2002, BIOCHEM BIOPH RES CO, V294, P1109, DOI 10.1016/S0006-291X(02)00614-9; Oka M, 2000, J INVEST DERMATOL, V115, P699, DOI 10.1046/j.1523-1747.2000.00095.x; OKA M, 1993, J INVEST DERMATOL, V100, pS204, DOI 10.1111/1523-1747.ep12465200; POMERANTZ SH, 1969, SCIENCE, V164, P838, DOI 10.1126/science.164.3881.838; QUEVEDO WC, 1987, BIOL MELANOCYTES DER, P224; Sarkar S, 2001, BIOCHEM J, V359, P599, DOI 10.1042/0264-6021:3590599; Siddiqi AR, 2000, BBA-MOL CELL RES, V1497, P103, DOI 10.1016/S0167-4889(00)00049-5; Singer WD, 1996, J BIOL CHEM, V271, P4504; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; WAKELAM MJO, 1995, SIGNAL TRANSDUCTION, P271; Xie Z, 2002, BBA-MOL CELL BIOL L, V1580, P9, DOI 10.1016/S1388-1981(01)00168-8; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121	49	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27774	27780		10.1074/jbc.M401786200	http://dx.doi.org/10.1074/jbc.M401786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15067002	hybrid			2022-12-25	WOS:000222120400112
J	Leikina, E; Mittal, A; Cho, MS; Melikov, K; Kozlov, MM; Chernomordik, LV				Leikina, E; Mittal, A; Cho, MS; Melikov, K; Kozlov, MM; Chernomordik, LV			Influenza hemagglutinins outside of the contact zone are necessary for fusion pore expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED MEMBRANE-FUSION; VIRUS HEMAGGLUTININ; BIOLOGICAL-MEMBRANES; LATERAL MOBILITY; HEMIFUSION; CELL; FISSION; PATHWAY; PH; CONFORMATION	Current models for membrane fusion in diverse biological processes are focused on the local action of fusion proteins present in the contact zone where the proteins anchored in one membrane might interact directly with the other membrane. Are the fusion proteins outside of the contact zone just bystanders? Here we assess the role of these "outsider" proteins in influenza virus hemagglutinin-mediated fusion between red blood cells and either hemagglutinin-expressing cells or viral particles. To selectively inhibit or enhance the actions of hemagglutinin outsiders, the antibodies that bind to hemagglutinin and proteases that cleave it were conjugated to polystyrene microspheres too large to enter the contact zone. We also involved hemagglutinin outsiders into interactions with additional red blood cells. We find the hemagglutinin outsiders to be necessary and sufficient for fusion. Interfering with the activity of the hemagglutinin outsiders inhibited fusion. Selective conversion of hemagglutinin outsiders alone into fusion-competent conformation was sufficient to achieve fusion. The discovered functional role of fusion proteins located outside of the contact zone suggests a tempting analogy to mechanisms by which proteins mediate membrane fission from outside of the fission site.	NICHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tel Aviv University; Sackler Faculty of Medicine	Chernomordik, LV (corresponding author), NICHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, NIH, Bldg 10,Rm 10D04,10 Ctr Dr, Bethesda, MD 20892 USA.	lchern@helix.nih.gov	Mittal, Aditya/E-3087-2010; Melikov, Kamran/A-6604-2009	Mittal, Aditya/0000-0002-4030-0951; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001501] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001501] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Burger KNJ, 2000, TRAFFIC, V1, P605, DOI 10.1034/j.1600-0854.2000.010804.x; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Corda D, 2002, CELL MOL LIFE SCI, V59, P1819, DOI 10.1007/PL00012508; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; DOXSEY SJ, 1985, J CELL BIOL, V101, P19, DOI 10.1083/jcb.101.1.19; Edwards MJ, 2001, J VIROL, V75, P10208, DOI 10.1128/JVI.75.21.10208-10218.2001; Frolov VA, 2000, TRAFFIC, V1, P622, DOI 10.1034/j.1600-0854.2000.010806.x; GUTMAN O, 1993, BIOCHEMISTRY-US, V32, P101, DOI 10.1021/bi00052a014; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Jacobson KA, 1997, BBA-BIOMEMBRANES, V1330, P138, DOI 10.1016/S0005-2736(97)00128-4; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kozlov MM, 2002, TRAFFIC, V3, P256, DOI 10.1034/j.1600-0854.2002.030403.x; Leikina E, 2000, MOL BIOL CELL, V11, P2359, DOI 10.1091/mbc.11.7.2359; Leikina E, 2001, BIOCHEMISTRY-US, V40, P8378, DOI 10.1021/bi010466+; Leikina E, 2000, BIOPHYS J, V79, P1415, DOI 10.1016/S0006-3495(00)76393-4; Markovic I, 2001, J CELL BIOL, V155, P833, DOI 10.1083/jcb.200103005; MATLIN KS, 1981, J CELL BIOL, V91, P601, DOI 10.1083/jcb.91.3.601; Melikyan GB, 1997, VIROLOGY, V235, P118, DOI 10.1006/viro.1997.8686; MELIKYAN GB, 1995, J CELL BIOL, V131, P679, DOI 10.1083/jcb.131.3.679; Melikyan GB, 1997, J CELL BIOL, V136, P995, DOI 10.1083/jcb.136.5.995; Mittal A, 2001, BIOPHYS J, V81, P1521, DOI 10.1016/S0006-3495(01)75806-7; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; TAYLOR HP, 1987, VIROLOGY, V159, P288, DOI 10.1016/0042-6822(87)90466-1; Tong SG, 1996, BIOCHEMISTRY-US, V35, P4956, DOI 10.1021/bi9526903; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; WHALLEY T, 1994, BIOCHEM J, V302, P391, DOI 10.1042/bj3020391; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; White JM, 1995, COLD SPRING HARB SYM, V60, P581, DOI 10.1101/SQB.1995.060.01.062; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053	33	45	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26526	26532		10.1074/jbc.M401883200	http://dx.doi.org/10.1074/jbc.M401883200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078874	hybrid			2022-12-25	WOS:000222003000076
J	Ajroud, K; Sugimori, T; Goldmann, WH; Fathallah, DM; Xiong, JP; Arnaout, MA				Ajroud, K; Sugimori, T; Goldmann, WH; Fathallah, DM; Xiong, JP; Arnaout, MA			Binding affinity of metal ions to the CD11b A-domain is regulated by integrin activation and ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATION REGULATION; I-DOMAIN; CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT; STRUCTURAL BASIS; CR3 CD11B/CD18; CA2+; ADHESION; COLLAGEN; SITE	The divalent cations Mg2+ and Ca2+ regulate the interaction of integrins with their cognate ligands, with Mg2+ uniformly facilitating and Ca2+ generally inhibiting such interactions in vitro. Because both cations are present in mM concentrations in vivo, the physiologic relevance of the in vitro observations is unclear. We measured the affinity of both cations to the inactive and active states of the ligand- and cation-binding A-domain (CD11bA) from integrin CD11b/CD18 in the absence and presence of the single-chain 107 antibody (scFv107), an activation-insensitive ligand- mimetic antibody. Using titration calorimetry, we found that Mg2+ and Ca2+ display equivalent (mM) affinities to inactive CD11bA. Activation induced a similar to10-fold increase in the binding affinity of Mg2+ to CD11bA with no change in that of Ca2+ (106 muM +/- 16 and 2.1 mM +/- 0.19, respectively, n = 4). This increase is largely driven by favorable enthalpy. scFv107 induced a 50-80-fold increase in the binding affinity of Ca2+ (but not Mg2+ or Mn2+) to either form of CD11bA. Thus the affinity of metal ions to integrins is itself regulated by the activation state of these receptors and by certain ligands. These findings, which we expect will be applicable in vivo, elucidate a new level of regulation of the integrin-metal-ligand ternary complex and help explain some of the discrepant effects of Ca2+ on integrin-ligand interactions.	Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Inst Pasteur, Immunol Lab, Mol Biotechnol Grp, Tunis 1002, Tunisia	Harvard University; Massachusetts General Hospital; Harvard University; Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, 149 13th St, Charlestown, MA 02129 USA.	arnaout@receptor.mgh.harvard.edu	Goldmann, Wolfgang H/H-5572-2013					Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; Brady GP, 1997, CURR OPIN STRUC BIOL, V7, P215, DOI 10.1016/S0959-440X(97)80028-0; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Chen LL, 2001, J BIOL CHEM, V276, P36520, DOI 10.1074/jbc.M106216200; Doolittle RF, 1998, CURR OPIN STRUC BIOL, V8, P792, DOI 10.1016/S0959-440X(98)80100-0; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Griggs DW, 1998, J BIOL CHEM, V273, P22113, DOI 10.1074/jbc.273.34.22113; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; Habermann SM, 1996, PROTEIN SCI, V5, P1229, DOI 10.1002/pro.5560050702; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; KARLSSON R, 1993, J IMMUNOL METHODS, V166, P75, DOI 10.1016/0022-1759(93)90330-A; Karpusas M, 2003, J MOL BIOL, V327, P1031, DOI 10.1016/S0022-2836(03)00203-1; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Li R, 1999, METH MOL B, V129, P105; Li R, 2002, J IMMUNOL, V168, P1219, DOI 10.4049/jimmunol.168.3.1219; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; Pepinsky RB, 2002, BIOCHEMISTRY-US, V41, P7125, DOI 10.1021/bi020024d; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; SMITH JW, 1994, J BIOL CHEM, V269, P960; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; Vorup-Jensen T, 2003, P NATL ACAD SCI USA, V100, P1873, DOI 10.1073/pnas.0237387100; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	41	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25483	25488		10.1074/jbc.M402901200	http://dx.doi.org/10.1074/jbc.M402901200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070893	hybrid			2022-12-25	WOS:000221827900072
J	Al-Khalili, L; Kotova, O; Tsuchida, H; Ehren, I; Feraille, E; Krook, A; Chibalin, AV				Al-Khalili, L; Kotova, O; Tsuchida, H; Ehren, I; Feraille, E; Krook, A; Chibalin, AV			ERK1/2 mediates insulin stimulation of Na,K-ATPase by phosphorylation of the alpha-subunit in human skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EXERCISE-INDUCED TRANSLOCATION; K+ PUMP SUBUNITS; PLASMA-MEMBRANE; NA+/K+-ATPASE; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; WIDE PREDICTION; XENOPUS OOCYTES; NA+,K+-ATPASE	Insulin stimulates Na+,K+-ATPase activity and induces translocation of Na+,K+-ATPase molecules to the plasma membrane in skeletal muscle. We determined the molecular mechanism by which insulin regulates Na+,K+-ATPase in differentiated primary human skeletal muscle cells (HSMCs). Insulin action on Na+,K+-ATPase was dependent on ERK1/2 in HSMCs. Sequence analysis of Na+,K+-ATPase alpha-subunits revealed several potential ERK phosphorylation sites. Insulin increased ouabain-sensitive Rb-86(+) uptake and [H-3]ouabain binding in intact cells. Insulin also increased phosphorylation and plasma membrane content of the Na+,K+-ATPase alpha(1)- and alpha(2)-subunits. Insulin-stimulated Na+,K+-ATPase activation, phosphorylation, and translocation of alpha-subunits to the plasma membrane were abolished by 20 muM PD98059, which is an inhibitor of MEK1/2, an upstream kinase of ERK1/2. Furthermore, inhibitors of phosphatidylinositol 3-kinase (100 nM wortmannin) and protein kinase C (10 muM GF109203X) had similar effects. Notably, insulin-stimulated ERK1/2 phosphorylation was abolished by wortmannin and GF109203X in HSMCs. Insulin also stimulated phosphorylation of alpha(1)- and alpha(2)-subunits on Thr-Pro amino acid motifs, which form specific ERK substrates. Furthermore, recombinant ERK1 and -2 kinases were able to phosphorylate alpha-subunit of purified human Na+,K+-ATPase in vitro. In conclusion, insulin stimulates Na+,K+-ATPase activity and translocation to plasma membrane in HSMCs via phosphorylation of the alpha-subunits by ERK1/2 mitogen-activated protein kinase.	Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Surg Sci, Urol Sect, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; Hop Cantonal Univ Geneva, Div Nephrol, CH-1211 Geneva, Switzerland	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Geneva	Chibalin, AV (corresponding author), Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, Eulers Vag 4,4 Tr, SE-17177 Stockholm, Sweden.	Alexander.Chibalin@kirurgi.ki.se	Krook, Anna/K-1192-2015	Krook, Anna/0000-0002-0891-0258; Feraille, Eric/0000-0003-1656-8365; Chibalin, Alexander/0000-0002-6339-6271; Ehren, Ingrid/0000-0001-7995-1252				Al-Khalili L, 2004, ACTA PHYSIOL SCAND, V180, P395, DOI 10.1111/j.1365-201X.2004.01259.x; Al-Khalili L, 2003, FEBS LETT, V536, P198, DOI 10.1016/S0014-5793(03)00047-4; ALKHALILI L, 2004, IN PRESS AM J PHYSL; Aydemir-Koksoy A, 2001, AM J PHYSIOL-HEART C, V280, pH1869, DOI 10.1152/ajpheart.2001.280.4.H1869; Beguin P, 1996, BIOCHEMISTRY-US, V35, P14098, DOI 10.1021/bi960516o; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 2001, ENDOCRINOLOGY, V142, P3474, DOI 10.1210/en.142.8.3474; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; Clausen T, 1996, ACTA PHYSIOL SCAND, V156, P227, DOI 10.1046/j.1365-201X.1996.209000.x; Dombrowski L, 1996, AM J PHYSIOL-ENDOC M, V270, pE667, DOI 10.1152/ajpendo.1996.270.4.E667; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Feraille E, 1999, MOL BIOL CELL, V10, P2847, DOI 10.1091/mbc.10.9.2847; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Fotis H, 1999, EUR J BIOCHEM, V260, P904, DOI 10.1046/j.1432-1327.1999.00237.x; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gonin S, 2001, MOL BIOL CELL, V12, P255, DOI 10.1091/mbc.12.2.255; Gronborg M, 2002, MOL CELL PROTEOMICS, V1, P517, DOI 10.1074/mcp.M200010-MCP200; He SW, 2001, AM J PHYSIOL-REG I, V281, pR917, DOI 10.1152/ajpregu.2001.281.3.R917; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; HUNDAL HS, 1993, FEBS LETT, V328, P253, DOI 10.1016/0014-5793(93)80938-Q; Isenovic ER, 2004, ENDOCRINOLOGY, V145, P1151, DOI 10.1210/en.2003-0100; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; Juel C, 2001, PFLUG ARCH EUR J PHY, V443, P212, DOI 10.1007/s004240100674; Juel C, 2000, AM J PHYSIOL-REG I, V278, pR1107, DOI 10.1152/ajpregu.2000.278.4.R1107; Khundmiri SJ, 2004, J BIOL CHEM, V279, P17418, DOI 10.1074/jbc.M311715200; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu HZ, 2000, BIOCHEM BIOPH RES CO, V274, P845, DOI 10.1006/bbrc.2000.3208; Lucking K, 1996, AM J PHYSIOL-RENAL, V271, pF253, DOI 10.1152/ajprenal.1996.271.2.F253; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McDonough AA, 2002, AM J PHYSIOL-RENAL, V282, pF967, DOI 10.1152/ajprenal.00360.2001; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; SWEADNER KJ, 1992, J BIOL CHEM, V267, P769; Sweeney G, 1998, DIABETOLOGIA, V41, P1199, DOI 10.1007/s001250051052; Sweeney G, 1998, MOL CELL BIOCHEM, V182, P121, DOI 10.1023/A:1006805510749; Sweeney G, 2001, AM J PHYSIOL-CELL PH, V281, pC1797, DOI 10.1152/ajpcell.2001.281.6.C1797; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Upadhyay D, 2003, FEBS LETT, V545, P173, DOI 10.1016/S0014-5793(03)00527-1; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; Widegren U, 2001, ACTA PHYSIOL SCAND, V172, P227, DOI 10.1046/j.1365-201x.2001.00855.x; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe Michael B, 2004, Methods Mol Biol, V250, P237; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	55	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25211	25218		10.1074/jbc.M402152200	http://dx.doi.org/10.1074/jbc.M402152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069082	hybrid			2022-12-25	WOS:000221827900038
J	Carro, S; Bergo, A; Mengoni, M; Bachi, A; Badaracco, G; Kilstrup-Nielsen, C; Landsberger, N				Carro, S; Bergo, A; Mengoni, M; Bachi, A; Badaracco, G; Kilstrup-Nielsen, C; Landsberger, N			A novel protein, Xenopus p20, influences the stability of MeCP2 through direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG BINDING DOMAIN; TRANSCRIPTIONAL REPRESSOR MECP2; RETT-SYNDROME MUTATIONS; WHEY ACIDIC PROTEIN; DNA METHYLATION; MAMMALIAN DEVELOPMENT; HISTONE DEACETYLASE; CHROMOSOMAL PROTEIN; NEURONAL GENES; CHROMATIN	MeCP2 is the founder member of a family of methyl-CpG-binding proteins able to repress transcription from methylated DNA. To date, MeCP2 action seems to involve the delivery on modified DNA of histone deacetylase activity, followed by histone methylating activity. It has been recently demonstrated that MECP2 mutations cause Rett syndrome, a childhood neurological disorder that represents one of the most common causes of mental retardation in females. Here we show that a novel Xenopus laevis protein of 20 kDa, p20, is able to interact in vivo and in vitro with MeCP2. The p20 sequence revealed that it belongs to the family of the WAP (whey acidic protein) proteins, often functioning as a protease inhibitor. Therefore, we asked whether the p20 can influence the MeCP2 half-life. We demonstrate that, indeed, the xp20 not only can significantly increase the stability of an exogenously expressed MeCP2 in Xenopus oocytes but also can stabilize the human endogenous MeCP2. The capability of the mammalian methyl-CpG-binding protein to interact with p20 is confirmed by co-immunoprecipitation experiments performed over-expressing the WAP protein. Glutathione S-transferase pull-down assays reveal that the MeCP2 residues localized between the methyl-binding domain and the transcriptional repression domain is the primary interaction surface. Our data suggest that regulation of MeCP2 metabolism might be of relevant importance; in accordance with this, previous results have shown that some Rett syndrome mutations are characterized by a decrease in MeCP2 stability.	Univ Insubria, Dipartimento Biol Strutturale & Funz, I-21052 Busto Arsizio, Italy; San Raffaele Sci Inst, Dipartimento Ric Biol & Technol, I-20132 Milan, Italy	University of Insubria; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Landsberger, N (corresponding author), Univ Insubria, Dipartimento Biol Strutturale & Funz, Via Alberto Giussano 12, I-21052 Busto Arsizio, Italy.	landsben@uninsubria.it	bachi, angela/B-3527-2015; Kilstrup-Nielsen, Charlotte/A-6348-2014; Stella, Maria Stella/GVS-1585-2022	bachi, angela/0000-0003-4842-6556; Landsberger, Nicoletta/0000-0003-0820-3155; Carro, Maria Stella/0000-0002-8570-7691; Kilstrup-Nielsen, Charlotte/0000-0003-4977-4077	Telethon [GP0072Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; Clauss A, 2002, BIOCHEM J, V368, P233, DOI 10.1042/BJ20020869; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; HAGBERG B, 1985, ACTA PAEDIATR SCAND, V74, P405, DOI 10.1111/j.1651-2227.1985.tb10993.x; HENNINGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P3733, DOI 10.1093/nar/10.12.3733; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jost J, 1993, STEROID HORMONE DEPE, P425; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ranganathan S, 1999, J MOL GRAPH MODEL, V17, P106, DOI 10.1016/S1093-3263(99)00023-6; Shahbazian MD, 2002, AM J HUM GENET, V71, P1259, DOI 10.1086/345360; Uttenweiler-Joseph S, 2001, PROTEOMICS, V1, P668, DOI 10.1002/1615-9861(200104)1:5<668::AID-PROT668>3.3.CO;2-J; Vacca M, 2001, J MOL MED, V78, P648, DOI 10.1007/s001090000155; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Wan MM, 1999, AM J HUM GENET, V65, P1520, DOI 10.1086/302690; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172	35	15	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25623	25631		10.1074/jbc.M402571200	http://dx.doi.org/10.1074/jbc.M402571200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15056664	hybrid			2022-12-25	WOS:000221827900090
J	Chen, CM; Gong, YS; Zhang, M; Chen, JJ				Chen, CM; Gong, YS; Zhang, M; Chen, JJ			Reciprocal cross-talk between Nod2 and TAK1 signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; KINASE KINASE KINASE; CROHNS-DISEASE; IMMUNE-RESPONSES; ACTIVATION; RECEPTOR; GENE; PROTEIN	Mutations in the leucine-rich repeat (LRR) domain of Nod2 have been implicated in the pathogenesis of Crohn's disease, yet the function of Nod2 and regulation of the Nod2 pathway remain unclear. In this study, we determined that mitogen-activated protein kinase kinase transforming growth factor (TGF)-beta-activated kinase 1 (TAK1) interacts with Nod2 and is required for Nod2-mediated NF-kappaB activation. The dominant negative form of TAK1 abolished muramyl dipeptide-induced NF-kappaB activation in Nod2-expressing cells. Nod2, acting in a reciprocal manner, inhibited TAK1-induced NF-kappaB activation in RICK-deficient embryonic fibroblasts. Nod2 appears to interact with TAK1 through its LRR region to exert its inhibitory effect on TAK1-induced NF-kappaB activation. Further, wild-type LRR more effectively suppressed NF-kappaB activation induced by TAK1 than LRR with a 3020insC mutation. Considered together, these findings demonstrate a critical role for TAK1 in Nod2-mediated innate immune responses and reveal a novel function for Nod2 in the regulation of the TAK1 signaling pathway.	Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Chen, JJ (corresponding author), Univ Michigan, Dept Internal Med, Div Gastroenterol, 1150 W Med Ctr Dr,4500 MSRB I, Ann Arbor, MI 48109 USA.	jjjchen@umich.edu			NATIONAL CANCER INSTITUTE [K08CA087943] Funding Source: NIH RePORTER; NCI NIH HHS [CA87943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beutler B, 2001, IMMUNITY, V15, P5, DOI 10.1016/S1074-7613(01)00176-5; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Elson CO, 2002, NEW ENGL J MED, V346, P614, DOI 10.1056/NEJM200202213460812; FERGUSON A, 1994, BRIT MED J, V309, P355, DOI 10.1136/bmj.309.6951.355; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Judge Thomas, 2002, Gastroenterology, V122, P826, DOI 10.1016/S0016-5085(02)80138-X; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; McGovern DPB, 2001, GUT, V49, P752, DOI 10.1136/gut.49.6.752; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Neurath MF, 1998, ANN NY ACAD SCI, V859, P149, DOI 10.1111/j.1749-6632.1998.tb11119.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Shanahan F, 2001, GASTROENTEROLOGY, V120, P622, DOI 10.1053/gast.2001.22122; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wald D, 2001, EUR J IMMUNOL, V31, P3747, DOI 10.1002/1521-4141(200112)31:12<3747::AID-IMMU3747>3.0.CO;2-E; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	33	67	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25876	25882		10.1074/jbc.M400682200	http://dx.doi.org/10.1074/jbc.M400682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075345	hybrid			2022-12-25	WOS:000221827900119
J	Gomez-Pinto, I; Cubero, E; Kalko, SG; Monaco, V; van der Marel, G; van Boom, JH; Orozco, M; Gonzalez, C				Gomez-Pinto, I; Cubero, E; Kalko, SG; Monaco, V; van der Marel, G; van Boom, JH; Orozco, M; Gonzalez, C			Effect of bulky lesions on DNA - Solution structure of a DNA duplex containing a cholesterol adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CODON 61 SEQUENCE; MOLECULAR-DYNAMICS SIMULATIONS; REFINED SOLUTION STRUCTURE; NMR SOLUTION STRUCTURE; DG MISMATCH OPPOSITE; ESCHERICHIA-COLI; SOLUTION CONFORMATION; MODIFIED DEOXYGUANOSINE; BASE DISPLACEMENT	The three-dimensional solution structure of two DNA decamers of sequence d(CCACXGGAAC)-(GTTCCGGTGG) with a modified nucleotide containing a cholesterol derivative (X) in its C1'(chol)alpha or C1'(chol)beta diastereoisomer form has been determined by using NMR and restrained molecular dynamics. This DNA derivative is recognized with high efficiency by the UvrB protein, which is part of the bacterial nucleotide excision repair, and the alpha anomer is repaired more efficiently than the beta one. The structures of the two decamers have been determined from accurate distance constraints obtained from a complete relaxation matrix analysis of the NOE intensities and torsion angle constraints derived from J-coupling constants. The structures have been refined with molecular dynamics methods, including explicit solvent and applying the particle mesh Ewald method to properly evaluate the long range electrostatic interactions. These calculations converge to well defined structures whose conformation is intermediate between the A- and B-DNA families as judged by the root mean square deviation but with sugar puckerings and groove shapes corresponding to a distorted B-conformation. Both duplex adducts exhibit intercalation of the cholesterol group from the major groove of the helix and displacement of the guanine base opposite the modified nucleotide. Based on these structures and molecular dynamics calculations, we propose a tentative model for the recognition of damaged DNA substrates by the UvrB protein.	Univ Barcelona, Dept Bioquim, E-08028 Barcelona, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Leiden Univ, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Inst Recerca Biomed, Barcelona 08028, Spain	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Leiden University; Leiden University - Excl LUMC; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Gonzalez, C (corresponding author), Univ Barcelona, Dept Bioquim, C Marti & Franques 1-11, E-08028 Barcelona, Spain.	cgonzalez@iqfr.csic.es	Gonzalez, Carlos/A-4734-2013; Gómez-Pinto, Irene/J-7063-2012	Gonzalez, Carlos/0000-0001-8796-1282; Gómez-Pinto, Irene/0000-0001-8221-6830; Kalko, Susana/0000-0002-6701-0233; Orozco Lopez, Modesto/0000-0002-8608-3278				ALEMAN C, 1991, J COMPUT CHEM, V12, P664, DOI 10.1002/jcc.540120603; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Bleczinski CF, 1999, J AM CHEM SOC, V121, P10889, DOI 10.1021/ja9920415; BORGIAS BA, 1990, J MAGN RESON, V87, P475, DOI 10.1016/0022-2364(90)90305-S; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Brown K, 2001, P NATL ACAD SCI USA, V98, P8507, DOI 10.1073/pnas.151251898; Buschta-Hedayat N, 1999, P NATL ACAD SCI USA, V96, P6090, DOI 10.1073/pnas.96.11.6090; Buterin T, 2000, CANCER RES, V60, P1849; CASE DA, 1997, AMBER VERSION 5; Coppel Y, 1997, BIOCHEMISTRY-US, V36, P4817, DOI 10.1021/bi962677y; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; COSMAN M, 1994, BIOCHEMISTRY-US, V33, P11507, DOI 10.1021/bi00204a013; Cosman M, 1996, BIOCHEMISTRY-US, V35, P9850, DOI 10.1021/bi9605346; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P4145, DOI 10.1021/bi00067a001; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P12488, DOI 10.1021/bi00097a029; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P1295, DOI 10.1021/bi00004a024; COSMAN M, 1994, BIOCHEMISTRY-US, V33, P11518, DOI 10.1021/bi00204a014; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; FENG BB, 1995, BIOCHEMISTRY-US, V34, P14021, DOI 10.1021/bi00043a008; Feng BB, 1996, BIOCHEMISTRY-US, V35, P7316, DOI 10.1021/bi952526f; GAMPER HB, 1993, NUCLEIC ACIDS RES, V21, P145, DOI 10.1093/nar/21.1.145; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; Gelpi JL, 2001, PROTEINS, V45, P428, DOI 10.1002/prot.1159; Giri I, 2002, BIOCHEMISTRY-US, V41, P5462, DOI 10.1021/bi012116t; Gomez-Pinto I, 2003, CHEMBIOCHEM, V4, P40, DOI 10.1002/cbic.200390012; GOOSEN N, 1998, NUCL ACID M, V12, P103; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JOHNSTON DS, 1995, BIOCHEMISTRY-US, V34, P14037, DOI 10.1021/bi00043a009; Jorgensen LB, 2000, J BIOMOL STRUCT DYN, V18, P45, DOI 10.1080/07391102.2000.10506646; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Jourdan M, 1999, BIOCHEMISTRY-US, V38, P3985, DOI 10.1021/bi982743r; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRIEG AM, 1993, P NATL ACAD SCI USA, V90, P1048, DOI 10.1073/pnas.90.3.1048; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lavery R., 1990, CURVES VERSION 5 1; Li ZJ, 1999, BIOCHEMISTRY-US, V38, P16045, DOI 10.1021/bi9903650; Li ZJ, 1999, BIOCHEMISTRY-US, V38, P14820, DOI 10.1021/bi991607z; Li ZJ, 1999, BIOCHEMISTRY-US, V38, P2969, DOI 10.1021/bi982072x; Li ZJ, 2001, BIOCHEMISTRY-US, V40, P6743, DOI 10.1021/bi002785r; Lin CH, 2001, J MOL BIOL, V306, P1059, DOI 10.1006/jmbi.2001.4425; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; Monaco V, 1999, NUCLEOS NUCLEOT NUCL, V18, P1339, DOI 10.1080/07328319908044710; Moolenaar GF, 2000, J BIOL CHEM, V275, P8044, DOI 10.1074/jbc.275.11.8044; Moolenaar GF, 2000, J BIOL CHEM, V275, P8038, DOI 10.1074/jbc.275.11.8038; Moolenaar GF, 1998, NUCLEIC ACIDS RES, V26, P462, DOI 10.1093/nar/26.2.462; Moolenaar GF, 2002, P NATL ACAD SCI USA, V99, P1467, DOI 10.1073/pnas.032584099; Moolenaar GF, 2001, EMBO J, V20, P6140, DOI 10.1093/emboj/20.21.6140; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Muhr P, 1996, MAGN RESON CHEM, V34, P137, DOI 10.1002/(SICI)1097-458X(199602)34:2<137::AID-OMR841>3.3.CO;2-H; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; ORREN DK, 1992, J BIOL CHEM, V267, P780; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Schwartz JL, 1997, BIOCHEMISTRY-US, V36, P11069, DOI 10.1021/bi971306u; Shields GC, 1997, J AM CHEM SOC, V119, P7463, DOI 10.1021/ja970601z; Shimotakahara S, 2000, J MOL BIOL, V302, P377; SKLENAR V, 1986, FEBS LETT, V208, P94, DOI 10.1016/0014-5793(86)81539-3; Soliva R, 2001, NUCLEIC ACIDS RES, V29, P2973, DOI 10.1093/nar/29.14.2973; SPIELMANN HP, 1995, BIOCHEMISTRY-US, V34, P12937, DOI 10.1021/bi00040a004; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; Volk DE, 2003, BIOCHEMISTRY-US, V42, P1410, DOI 10.1021/bi026745u; YEH HJC, 1995, BIOCHEMISTRY-US, V34, P13570, DOI 10.1021/bi00041a037; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P6212, DOI 10.1021/bi9524732; ZHOU JH, 1994, CANCER RES, V54, P5783	83	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24552	24560		10.1074/jbc.M311751200	http://dx.doi.org/10.1074/jbc.M311751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047709	hybrid			2022-12-25	WOS:000221702500084
J	Felicetti, F; Bottero, L; Felli, N; Mattia, G; Labbaye, C; Alvino, E; Peschle, C; Colombo, MP; Care, A				Felicetti, F; Bottero, L; Felli, N; Mattia, G; Labbaye, C; Alvino, E; Peschle, C; Colombo, MP; Care, A			Role of PLZF in melanoma progression	ONCOGENE			English	Article						PLZF; homeobox gene; cDNA expression array; melanoma; tumor progression	ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER GENE; GROWTH-FACTOR; TRANSCRIPTION FACTOR; INTEGRIN EXPRESSION; CELL-GROWTH; PROTEIN; HOXB7; ALPHA; ALPHA(V)BETA(3)	The promyelocytic leukemia zinc finger (PLZF) protein has been described as a transcriptional repressor of homeobox (HOX)-containing genes during embryogenesis. As we previously demonstrated a functional link between overexpression of HOXB7 and melanoma progression.. we investigated the lack of PLZF as the possible cause of HOXB7 constitutive activation in these neoplastic cells. Accordingly, we found PLZF expression in melanocytes, but not in melanoma cells, a pattern inversely related to that of HOXB7. PLZF retroviral gene transduction was then performed in a panel of melanoma cell lines, and tumorigenicity was compared with that of empty vector-transduced control cell lines. Evaluation of in vitro migration, invasion and adhesion indicated that PLZF gene transduction induced a less malignant phenotype, as confirmed through in vitro studies performed in athymic nude mice. This reduced tumorigenicity was not coupled with HOXB7 repression. In order to find more about the molecular targets of PLZF, the gene expression profiles of PLZF- and empty vector-transduced A375 melanoma cells were analysed by Atlas Cancer macro-array. Among several genes modulated by PLZF enforced expression, of particular interest were integrin alphavbeta3, osteonectin/SPARC and matrix metalloprotease-9 that were downmodulated, and the tyrosinase-related protein-1 that was upregulated in all the analysed samples. This profile confirms the reduced tumorigenic phenotype with reversion to a more differentiated, melanocyte like, pattern, thus suggesting a suppressor role for PLZF in solid tumors. Moreover, these results indicate that PLZF and HOXB7 are functionally independent and that their coupled deregulation may account for most of the alterations described in melanomas.	Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00100 Rome, Italy; Ist Nazl Tumori, Dept Expt Oncol, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan	Care, A (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	a.care@iss.it	felli, nadia/G-2088-2012; CARE', Alessandra/H-5090-2016; Alvino, Ester/J-8148-2012; Mattia, Gianfranco/K-5194-2016; Colombo, Mario P./V-7166-2017; Felicetti, Federica/N-7077-2017; Labbaye, Catherine/J-9930-2016	felli, nadia/0000-0001-6763-3361; CARE', Alessandra/0000-0003-4106-3342; Alvino, Ester/0000-0001-9467-7634; Mattia, Gianfranco/0000-0001-7047-6360; Colombo, Mario P./0000-0003-0042-7955; Felicetti, Federica/0000-0003-4628-0696; Labbaye, Catherine/0000-0003-1255-4396				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; ALBINI A, 1987, CANCER RES, V47, P3239; Alvino E, 2002, J INVEST DERMATOL, V118, P79, DOI 10.1046/j.0022-202x.2001.01611.x; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BOUKERCHE H, 1995, BRIT J CANCER, V72, P108, DOI 10.1038/bjc.1995.285; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 2001, CANCER RES, V61, P6532; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Dubrulle J, 2002, CURR OPIN GENET DEV, V12, P519, DOI 10.1016/S0959-437X(02)00335-0; Fang D, 2002, NUCLEIC ACIDS RES, V30, P3096, DOI 10.1093/nar/gkf424; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hofmann UB, 2000, J INVEST DERMATOL, V115, P625, DOI 10.1046/j.1523-1747.2000.00114.x; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Lacal PM, 2000, J INVEST DERMATOL, V115, P1000, DOI 10.1046/j.1523-1747.2000.00199.x; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Meccia E, 2003, BBA-GENE STRUCT EXPR, V1626, P1, DOI 10.1016/S0167-4781(03)00018-6; Niu J, 2002, INT J CANCER, V99, P529, DOI 10.1002/ijc.10397; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OHASHI K, 1994, ONCOGENE, V9, P699; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; Pati D, 2002, MOL CELL BIOL, V22, P8267, DOI 10.1128/MCB.22.23.8267-8277.2002; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Satyamoorthy K, 2002, CANCER BIOL THER, V1, P14, DOI 10.4161/cbt.1.1.32; Seftor REB, 1998, AM J PATHOL, V153, P1347, DOI 10.1016/S0002-9440(10)65719-7; Sturm RA, 2002, CANCER RES, V62, P226; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; vandenOord JJ, 1997, AM J PATHOL, V151, P665; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	40	56	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4567	4576		10.1038/sj.onc.1207597	http://dx.doi.org/10.1038/sj.onc.1207597			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077196				2022-12-25	WOS:000221799000006
J	Riesterer, O; Zingg, D; Hummerjohann, J; Bodis, S; Pruschy, M				Riesterer, O; Zingg, D; Hummerjohann, J; Bodis, S; Pruschy, M			Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells	ONCOGENE			English	Article						PKB/Akt; VEGF receptor; rapamycin; PTK787/ZK222584; protein degradation	AKT/PROTEIN KINASE-B; SIGNAL-TRANSDUCTION PATHWAY; TUMOR RADIATION RESPONSE; PROSTATE-CANCER CELLS; GROWTH-FACTOR; IONIZING-RADIATION; PANCREATIC-CANCER; COLON-CANCER; ANGIOGENESIS; EXPRESSION	An intact VEGF receptor/PI3K/PKB/Akt signaling cascade protects endothelial cells from apoptotic stress-stimuli and mediates the formation of new blood vessels in pathological conditions such as cancer. Therefore, downregulation of this signaling cascade is of clinical interest for antiangiogenic cancer therapy. In this report, we demonstrate that VEGF controls the protein stability of the serine-threonine kinase PKB/Akt via inhibition of PKB/Akt protein degradation. VEGF deprivation or blockage of the VEGF signal transduction cascade with the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 resulted in a specific decrease of the PKB/Akt protein level and subsequent cellular restimulation with VEGF rescued its stability. Real-time quantitative RTPCR analysis demonstrated that VEGF does not regulate PKB/Akt gene expression. On the other hand, broad range inhibitors of caspases and the proteasome complex prevented VEGF-dependent downregulation of the PKB/Akt protein level indicating that PKB/Akt protein stability is regulated by VEGF-controlled proteolysis. Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability. These results demonstrate a novel regulatory mechanism of the activated VEGF receptor/mTOR-signal transduction pathway to control the protein stability of PKB/Akt and survival threshold in endothelial cells.	Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Pruschy, M (corresponding author), Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland.	martin.pruschy@usz.ch		Bodis, Stephan/0000-0003-1078-8711; Riesterer, Oliver/0000-0002-9508-0546; Pruschy, Martin/0000-0002-3124-9015				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1993, CANCER RES, V53, P4727; Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO;2-O; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan J, 2002, CANCER CELL, V1, P257, DOI 10.1016/S1535-6108(02)00042-9; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Eshleman JS, 2002, CANCER RES, V62, P7291; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Geng L, 2001, CANCER RES, V61, P2413; Geoerger B, 2001, CANCER RES, V61, P1527; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gorski DH, 1999, CANCER RES, V59, P3374; Griffin RJ, 2002, CANCER RES, V62, P1702; Grunwald V, 2002, CANCER RES, V62, P6141; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Gupta VK, 2002, CANCER J, V8, P47, DOI 10.1097/00130404-200201000-00009; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hess C, 2001, BRIT J CANCER, V85, P2010, DOI 10.1054/bjoc.2001.2166; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Ikeda N, 1999, BRIT J CANCER, V79, P1553, DOI 10.1038/sj.bjc.6690248; Itakura J, 2000, INT J CANCER, V85, P27; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kozin SV, 2001, CANCER RES, V61, P39; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Lee CG, 2000, CANCER RES, V60, P5565; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Madhusudan S, 2002, CURR OPIN PHARMACOL, V2, P403, DOI 10.1016/S1471-4892(02)00184-4; Manley PW, 2002, EXPERT OPIN INV DRUG, V11, P1715, DOI 10.1517/13543784.11.12.1715; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Matter A, 2001, DRUG DISCOV TODAY, V6, P1005, DOI 10.1016/S1359-6446(01)01939-0; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Shaheen RM, 1999, CANCER RES, V59, P5412; Shi YJ, 2002, CANCER RES, V62, P5027; Solit DB, 2003, CANCER RES, V63, P2139; Sun L, 2000, DRUG DISCOV TODAY, V5, P344, DOI 10.1016/S1359-6446(00)01534-8; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Tenzer A, 2001, CANCER RES, V61, P8203; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Weidner Noel, 1996, P167; Wood JM, 2000, CANCER RES, V60, P2178; Xu J, 2002, J BIOL CHEM, V277, P35561, DOI 10.1074/jbc.M203805200; Yao Y, 2001, ACTA NEUROCHIR, V143, P159, DOI 10.1007/s007010170122; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zhong H, 2000, CANCER RES, V60, P1541	68	65	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2004	23	26					4624	4635		10.1038/sj.onc.1207596	http://dx.doi.org/10.1038/sj.onc.1207596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064712				2022-12-25	WOS:000221799000012
J	Yan, WS; Samaha, FF; Ramkumar, M; Kleyman, TR; Rubenstein, RC				Yan, WS; Samaha, FF; Ramkumar, M; Kleyman, TR; Rubenstein, RC			Cystic fibrosis transmembrane conductance regulator differentially regulates human and mouse epithelial sodium channels in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL INTERACTIONS; CHLORIDE CHANNELS; DELTA-F508 CFTR; NA+ CHANNEL; CELL LINE; GENISTEIN; ENAC; ACTIVATION; 4-PHENYLBUTYRATE; MECHANISM	The cystic fibrosis transmembrane conductance regulator ( CFTR), in addition to its well defined Cl- channel properties, regulates other ion channels. CFTR inhibits murine or rat epithelial Na+ channel (mENaC or rENaC) currents in many epithelial and non-epithelial cells, whereas murine or rat ENaC increases CFTR functional expression. These regulatory interactions are reproduced in Xenopus oocytes where both the open probability and surface expression of wild type CFTR Cl- channels are increased when CFTR is co-expressed with alphabetagamma mENaC, and conversely the activity of mENaC is inhibited after wild type CFTR activation. Using the Xenopus oocyte expression system, differences in functional regulatory interactions were observed when CFTR was co-expressed with either alphabetagamma mENaC or alphabetagamma human ENaC (hENaC). Co-expression of CFTR and alphabetagamma mENaC or hENaC resulted in an similar to 3-fold increase in CFTR Cl- current compared with oocytes expressing CFTR alone. Oocytes co-injected with both CFTR and mENaC or hENaC expressed an amiloride-sensitive whole cell current that was decreased compared with that observed with the injection of mENaC or hENaC alone before CFTR activation with forskolin/3-isobutyl-1- methylxanthine. CFTR activation resulted in a further 50% decrease in mENaC-mediated currents, an similar to 20% decrease in alpha-T663-hENaC-mediated currents, and essentially no change in alpha-A663-hENaC-mediated currents. Changes in ENaC functional expression correlated with ENaC surface expression by oocyte surface biotinylation experiments. Assessment of regulatory interactions between CFTR and chimeric mouse/human ENaCs suggest that the 20 C-terminal amino acid residues of alpha ENaC confer species specificity regarding ENaC inhibition by activated CFTR.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Kleyman, TR (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu	Ramkumar, Mohan/ABG-6906-2021	Rubenstein, Ronald/0000-0002-3138-4006	NIDDK NIH HHS [DK54354, DK58046, DK56305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058046, R01DK054354, R01DK056305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Nakkash L, 2001, J PHARMACOL EXP THER, V296, P464; Ambrosius WT, 1999, HYPERTENSION, V34, P631, DOI 10.1161/01.HYP.34.4.631; Andersson C, 2000, EUR RESPIR J, V15, P937, DOI 10.1034/j.1399-3003.2000.15e21.x; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Briel M, 1998, J PHYSIOL-LONDON, V508, P825, DOI 10.1111/j.1469-7793.1998.825bp.x; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Hopf A, 1999, J BIOL CHEM, V274, P13894, DOI 10.1074/jbc.274.20.13894; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; HWANG TC, 1997, AM J PHYSIOL, V273, P988; Illek B, 1999, AM J PHYSIOL-CELL PH, V277, pC833, DOI 10.1152/ajpcell.1999.277.4.C833; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Ji HL, 2000, J BIOL CHEM, V275, P27947; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Konstas AA, 2002, J BIOL CHEM, V277, P25377, DOI 10.1074/jbc.M201925200; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Ling BN, 1997, J BIOL CHEM, V272, P594; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Nagel G, 2001, EMBO REP, V2, P249, DOI 10.1093/embo-reports/kve045; NAGEL G, 2001, PEDIATR PULM, V22, P209; Pratt JH, 2003, HYPERTENSION, V41, pE1; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Suaud L, 2002, J BIOL CHEM, V277, P50341, DOI 10.1074/jbc.M209641200; Suaud L, 2002, J BIOL CHEM, V277, P8928, DOI 10.1074/jbc.M111482200; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; YARDEN JS, 2001, PEDIATR PULM, V22, P219	34	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23183	23192		10.1074/jbc.M402373200	http://dx.doi.org/10.1074/jbc.M402373200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047694	hybrid			2022-12-25	WOS:000221570900049
J	Schreiber, K; Cannon, RE; Karrison, T; Beck-Engeser, G; Huo, DZ; Tennant, RW; Jensen, H; Kast, WM; Krausz, T; Meredith, SC; Chen, LP; Schreiber, H				Schreiber, K; Cannon, RE; Karrison, T; Beck-Engeser, G; Huo, DZ; Tennant, RW; Jensen, H; Kast, WM; Krausz, T; Meredith, SC; Chen, LP; Schreiber, H			Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors	ONCOGENE			English	Article						HPV 16; human papilloma virus 16; E6/E7; vHa ras; transgenic mice; synergy; primary tumors	HUMAN-PAPILLOMAVIRUS TYPE-16; T-LYMPHOCYTE EPITOPE; TRANSGENIC MICE; HA-RAS; CERVICAL-CANCER; K-RAS; HIGH PREVALENCE; UTERINE CERVIX; HIGH-RISK; INTRAEPITHELIAL NEOPLASIA	E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the development of certain types of cancers. However, these oncogenes are insufficient to transform normal cells into an immortalized or malignant state. Mutant Ha-ras cooperates with E6/E7 of HPV subtype 16 in transformation of cells in vitro and may contribute to some HPV-associated cancers in humans. This study investigates whether HPV16 E6/E7 and v-Ha-ras synergize in vivo. FVB/n mice transgenic for v-Ha-ras gene (R+) were crossed with transgenic C57BL/6 mice that harbor E6/E7 of HPV16 (E+). Beginning at about 3 months of age, the bitransgenic E+R+(C57BL/6 x FVB/n) F1 mice developed mouth, eye and ear tumors. By 6 months, the prevalence of these types of mouth, eye and ear tumors was 100, 71 and 79% respectively in the E+R+ mice. Most tumors grew progressively until the mice had to be killed. The median times for the appearance of the first mouth, eye and ear tumor were 3.6, 4.3 and 4.2 months, respectively. For the two singly transgenic groups of mice, the prevalence of mouth, eye and ear tumors was 0, 0 and 6% (E-R+) and 0, 0 and 0% (E+R-), respectively, and the median time to first tumor was greater than 12 months for singly transgenic mice (E-R+, E+R-). Thus, a remarkable synergy occurred between the v-Ha-ras and HPV16 E6/E7 oncogenes in the development of primary tumors in mice.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; NIEHS, Lab Environm Carcinogenesis & Mutagenesis, Res Triangle Pk, NC 27709 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Mayo Clin, Dept Immunol, Rochester, MN 55905 USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Chicago; University of Southern California; Mayo Clinic	Schreiber, H (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 3008, Chicago, IL 60637 USA.	hszz@midway.uchicago.edu		Jensen, Heather/0000-0002-1712-9682; Kast, W Martin/0000-0003-2321-3159	NATIONAL CANCER INSTITUTE [R01CA022677, P01CA097296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021175, Z01ES100610] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA22677, P01-CA97296, R01-CA37516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonio LV, 2003, J CLIN VIROL, V27, P263, DOI 10.1016/S1386-6532(02)00181-6; Alonio LV, 2000, MEDICINA-BUENOS AIRE, V60, P895; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BERGMANN K, 1994, INT J CANCER, V59, P463, DOI 10.1002/ijc.2910590405; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.2307/2334776; Campo MS, 1998, TRENDS MICROBIOL, V6, P424, DOI 10.1016/S0966-842X(98)01385-7; Coussens LM, 1996, AM J PATHOL, V149, P1899; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; Daniel D, 2003, J EXP MED, V197, P1017, DOI 10.1084/jem.20021047; Dokianakis DN, 1999, ONCOL REP, V6, P1327; DRINKWATER NR, 1991, PROG EXP TUMOR RES, V33, P1; Eiben GL, 2002, CANCER RES, V62, P5792; FELTKAMP MCW, 1995, EUR J IMMUNOL, V25, P2638, DOI 10.1002/eji.1830250935; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; Gillison, 2000, Br J Surg, V87, P362, DOI 10.1046/j.1365-2168.2000.01383-3.x; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; Golijow CD, 1999, GYNECOL ONCOL, V75, P108, DOI 10.1006/gyno.1999.5528; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; *IARC, 1995, IARC MON EV CARC RIS, V64, P245; *IARC, 1995, IARC MON EV CARC RIS, V64, P65; Janicek MF, 2001, CA-CANCER J CLIN, V51, P92, DOI 10.3322/canjclin.51.2.92; Jin YT, 1997, AM J PATHOL, V150, P1327; Kantz DC, 1999, BIOTECHNIQUES, V27, P278, DOI 10.2144/99272bm13; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klug SJ, 2001, CANCER EPIDEM BIOMAR, V10, P1009; Klussmann JP, 2001, CANCER-AM CANCER SOC, V92, P2875, DOI 10.1002/1097-0142(20011201)92:11&lt;2875::AID-CNCR10130&gt;3.0.CO;2-7; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee JH, 1996, GYNECOL ONCOL, V62, P49, DOI 10.1006/gyno.1996.0188; Lin XH, 1996, J CELL BIOCHEM, V63, P463, DOI 10.1002/(SICI)1097-4644(19961215)63:4<463::AID-JCB8>3.0.CO;2-R; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Melero I, 1997, J VIROL, V71, P3998, DOI 10.1128/JVI.71.5.3998-4004.1997; Mouron SA, 2000, MUTAT RES-GEN TOX EN, V469, P127, DOI 10.1016/S1383-5718(00)00066-8; Pedroza-Saavedra A, 2000, ARCH VIROL, V145, P603, DOI 10.1007/s007050050050; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Prokopakis P, 2002, ONCOL REP, V9, P129; RESSING ME, 1995, J IMMUNOL, V154, P5934; Riley RR, 2003, CANCER RES, V63, P4862; Ringstrom E, 2002, CLIN CANCER RES, V8, P3187; RIOU G, 1988, ONCOGENE, V3, P329; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schlecht NF, 2003, JNCI-J NATL CANCER I, V95, P1336, DOI 10.1093/jnci/djg037; Scott IU, 2002, OPHTHALMOLOGY, V109, P542, DOI 10.1016/S0161-6420(01)00991-5; Siegel CT, 2000, J EXP MED, V191, P1945, DOI 10.1084/jem.191.11.1945; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Stenzel A, 2001, PATHOL RES PRACT, V197, P597, DOI 10.1016/S0344-0338(04)70133-8; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Tsai ST, 1997, INT J CANCER, V71, P208; WILLIS G, 1993, GYNECOL ONCOL, V49, P359, DOI 10.1006/gyno.1993.1140; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	58	24	26	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3972	3979		10.1038/sj.onc.1207507	http://dx.doi.org/10.1038/sj.onc.1207507			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15077191				2022-12-25	WOS:000221382000009
J	Warming, S; Suzuki, T; Yamaguchi, TP; Jenkins, NA; Copeland, NG				Warming, S; Suzuki, T; Yamaguchi, TP; Jenkins, NA; Copeland, NG			Early B-cell factor-associated zinc-finger gene is a frequent target of retroviral integration in murine B-cell lymphomas	ONCOGENE			English	Article						EBFAZ; EVI3; B-cell lymphoma	ACUTE LYMPHOBLASTIC-LEUKEMIA; PRE-B; PROTEIN; MOUSE; IDENTIFICATION; EXPRESSION; LAMBDA-5; STRAINS; CLONING; LOCUS	The early B-cell factor (EBF)-associated zinc-finger protein (EBFAZ) binds to and negatively regulates EBF, a basic helix-loop-helix transcription factor required for B-cell lineage commitment and development of the olfactory epithelium. It also binds to SMA- and MAD-related protein 1 (SMAD1) and SMAD4 in response to bone morphogenic protein 2 (BMP2) signaling. It is highly related to ecotropic viral integration site 3 (EVI3), a protein that, like EBFAZ, contains 30 Kruppel-like zinc finger repeats. In previous studies, we showed that Evi3 is a frequent target of retroviral integration in AKXD27 B-cell lymphomas. Here, we show that EBFAZ is also a frequent target. Integrations at Ebfaz and Evi3 are mutually exclusive, suggesting that they function in the same tumor pathway. Lymphomas with integrations at Ebfaz or Evi3 express the pre-B-cell-specific marker immunoglobulin lambda chain 5, and contain immunoglobulin heavy-chain rearrangements, suggesting that they are blocked at an early B-cell stage. Unlike Evi3, which is expressed at low levels in normal B cells, or Ebfaz, which is not expressed in B cells, both genes are highly expressed following viral integration. Collectively, our results suggest that ectopic expression of Ebfaz can substitute for the upregulated expression of Evi3 in B-cell disease and highlight the importance of this gene family in hematopoietic cancer.	NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Canc & Dev Lab, Ctr Canc Res, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Copeland, NG (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, W 7th St & Ft Detrick, Frederick, MD 21702 USA.	copeland@ncifcrf.gov	Warming, Soren/ABD-5729-2021	Warming, Soren/0000-0002-5721-0741	NATIONAL CANCER INSTITUTE [ZIABC010345, Z01BC010345] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Heerema NA, 1999, LEUKEMIA, V13, P679, DOI 10.1038/sj.leu.2401413; Hiai H, 2003, CANCER SCI, V94, P847, DOI 10.1111/j.1349-7006.2003.tb01365.x; HILDEN JM, 1995, BLOOD, V86, P3876, DOI 10.1182/blood.V86.10.3876.bloodjournal86103876; JUSTICE MJ, 1994, J VIROL, V68, P1293, DOI 10.1128/JVI.68.3.1293-1300.1994; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Seong C, 1998, BRIT J HAEMATOL, V101, P189, DOI 10.1046/j.1365-2141.1998.00657.x; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Smadja NV, 2001, BLOOD, V98, P2229, DOI 10.1182/blood.V98.7.2229; SUZUKI T, 2002, NAT GENET, V19, P19; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652	19	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2727	2731		10.1038/sj.onc.1207452	http://dx.doi.org/10.1038/sj.onc.1207452			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048087				2022-12-25	WOS:000220714900014
J	Fukuchi, J; Hiipakka, RA; Kokontis, JM; Nishimura, K; Igarashi, K; Liao, S				Fukuchi, J; Hiipakka, RA; Kokontis, JM; Nishimura, K; Igarashi, K; Liao, S			TATA-binding protein-associated factor 7 regulates polyamine transport activity and polyamine analog-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER; C-JUN; ESCHERICHIA-COLI; EXPRESSION; CELLS; GENE; ACTIVATION; GROWTH; MUTANTS; BIS(GUANYLHYDRAZONE)	Identification of the polyamine transporter gene will be useful for modulating polyamine accumulation in cells and should be a good target for controlling cell proliferation. Polyamine transport activity in mammalian cells is critical for accumulation of the polyamine analog methylglyoxal bis(guanylhydrazone) (MGBG) that induces apoptosis, although a gene responsible for transport activity has not been identified. Using a retroviral gene trap screen, we generated MGBG-resistant Chinese hamster ovary (CHO) cells to identify genes involved in polyamine transport activity. One gene identified by the method encodes TATA-binding protein-associated factor 7 (TAF7), which functions not only as one of the TAFs, but also a coactivator for c-Jun. TAF7-deficient cells had decreased capacity for polyamine uptake (20% of CHO cells), decreased AP-1 activation, as well as resistance to MGBG-induced apoptosis. Stable expression of TAF7 in TAF7-deficient cells restored transport activity (55% of CHO cells), AP-1 gene transactivation (100% of CHO cells), and sensitivity to MGBG-induced apoptosis. Overexpression of TAF7 in CHO cells did not increase transport activity, suggesting that TAF7 may be involved in the maintenance of basal activity. c-Jun NH2-terminal kinase inhibitors blocked MGBG-induced apoptosis without alteration of polyamine transport. Decreased TAF7 expression, by RNA interference, in androgen-independent human prostate cancer LN-CaP104-R1 cells resulted in lower polyamine transport activity (25% of control) and resistance to MGBG-induced growth arrest. Taken together, these results reveal a physiological function of TAF7 as a basal regulator for mammalian polyamine transport activity and MGBG-induced apoptosis.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan	University of Chicago; University of Chicago; Chiba University	Liao, S (corresponding author), Univ Chicago, Ben May Inst Canc Res, MC6027,5841 S Maryland Ave, Chicago, IL 60637 USA.	sliao@huggins.bsd.uchicago.edu		Igarashi, Kazuei/0000-0003-3751-3187; Nishimura, Kazuhiro/0000-0002-6209-5522	NCCIH NIH HHS [AT00850] Funding Source: Medline; NCI NIH HHS [CA58073] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058073] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000850] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ADAIR GM, 1985, MOL CELL BIOL, V5, P109, DOI 10.1128/MCB.5.1.109; ADAIR GM, 1984, SOMAT CELL MOLEC GEN, V10, P283, DOI 10.1007/BF01535250; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Bhattacharya S, 2003, AM J PHYSIOL-GASTR L, V285, pG980, DOI 10.1152/ajpgi.00206.2003; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BYERS TL, 1989, BIOCHEM J, V263, P745, DOI 10.1042/bj2630745; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; Chen Y, 2003, ONCOGENE, V22, P4964, DOI 10.1038/sj.onc.1206725; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Cullis PM, 1999, CHEM BIOL, V6, P717, DOI 10.1016/S1074-5521(00)80019-8; Davidson K, 1998, ANTI-CANCER DRUG, V9, P635, DOI 10.1097/00001813-199808000-00009; Fiermonte G, 2003, J BIOL CHEM, V278, P32778, DOI 10.1074/jbc.M302317200; Gegonne A, 2001, P NATL ACAD SCI USA, V98, P12432, DOI 10.1073/pnas.211444798; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; HEATON MA, 1988, J CELL PHYSIOL, V136, P133, DOI 10.1002/jcp.1041360117; HESTON WDW, 1991, CANCER SURV, V11, P217; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAKINUMA Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P171, DOI 10.1016/0003-9861(87)90483-8; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KOKONTIS J, 1994, CANCER RES, V54, P1566; Kuroiwa A, 2001, CHROMOSOME RES, V9, P641, DOI 10.1023/A:1012952223509; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; MANDEL JL, 1978, J CELL PHYSIOL, V97, P335, DOI 10.1002/jcp.1040970308; MATSUI I, 1980, BIOCHIM BIOPHYS ACTA, V633, P87, DOI 10.1016/0304-4165(80)90040-9; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Munz C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Paasinen-Sohns A, 2000, J CELL BIOL, V151, P801, DOI 10.1083/jcb.151.4.801; Patel AR, 1997, AM J PHYSIOL-CELL PH, V273, pC1020, DOI 10.1152/ajpcell.1997.273.3.C1020; PEGG AE, 1988, CANCER RES, V48, P759; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; RAGO R, 1990, ANAL BIOCHEM, V191, P31; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEPPANEN P, 1980, FEBS LETT, V111, P99, DOI 10.1016/0014-5793(80)80770-8; Shao D, 1996, J CELL PHYSIOL, V166, P43; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; WILLIAMSASHMAN HG, 1972, BIOCHEM BIOPH RES CO, V46, P288, DOI 10.1016/0006-291X(72)90661-4; WILLIAMSASHMAN HG, 1979, PERSPECT BIOL MED, V22, P421; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301	53	17	18	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29921	29929		10.1074/jbc.M401078200	http://dx.doi.org/10.1074/jbc.M401078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15078871	hybrid			2022-12-25	WOS:000222531900008
J	Nagayama, S; Iiizumi, M; Katagiri, T; Toguchida, J; Nakamura, Y				Nagayama, S; Iiizumi, M; Katagiri, T; Toguchida, J; Nakamura, Y			Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas	ONCOGENE			English	Article						synovial sarcomas; PDZ domain; upregulation; small interfering RNA	SOFT-TISSUE SARCOMAS; PROTEIN; CHEMOTHERAPY; DOXORUBICIN; IFOSFAMIDE; ASSOCIATION; COMPLEXES; SSX; SYT	In an earlier study designed to investigate molecular mechanisms of carcinogenesis in synovial sarcomas (SSs), we applied a cDNA microarray to detect human genes with significantly increased expression in SS cells. Among the genes selected in this way, we identified a novel transcript, subsequently designated PDZK4 (PDZ domain-containing 4), that was specifically upregulated in all of the 13 SS cases we examined. On Northern blots of normal human tissues, the PDZK4 transcript was expressed only in fetal brain. Immmunocytochemical staining of transfected COS7 cells showed that the PDZK4 gene product localized mainly under the plasma membrane. Treatment of human SS cells with small interfering RNA (siRNA) inhibited the expression of PDZK4 and resulted in the suppression of tumor-cell growth. Induction of exogenous PDZK4 expression promoted growth of T98G and COS7 cells in which no endogenous expression of PDZK4 was observed. Taken together, these findings strongly suggest that inappropriate expression of PDZK4 might play an important role in the proliferation of SS cells and that the gene might be a suitable molecular target for designing of novel drugs to treat SS patients.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genet Unit, Tokyo 1088639, Japan; Kyoto Univ, Dept Surg & Surg Basic Sci, Grad Sch Med, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068507, Japan	University of Tokyo; Kyoto University; Kyoto University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genet Unit, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp						ANTMAN K, 1993, J CLIN ONCOL, V11, P1276, DOI 10.1200/JCO.1993.11.7.1276; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Edmonson JH, 2002, CANCER, V94, P786, DOI 10.1002/cncr.10259; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV-100102557; Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nagayama S, 2002, CANCER RES, V62, P5859; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; *SARC MET COLL, 1998, LANCET, V350, P1647; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van de Rijn M, 1999, AM J CLIN PATHOL, V112, P43; WEISS SW, 2001, ENZINGER WEISSS SOFT; Wunder JS, 1998, J BONE JOINT SURG AM, V80A, P1020, DOI 10.2106/00004623-199807000-00011; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200	25	22	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5551	5557		10.1038/sj.onc.1207710	http://dx.doi.org/10.1038/sj.onc.1207710			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15077175				2022-12-25	WOS:000222588400015
J	Choudhury, GG				Choudhury, GG			A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase C epsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1 alpha transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT1 SERINE PHOSPHORYLATION; IFN-GAMMA; PKC-EPSILON; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; TARGETED DISRUPTION; ACTIVE STAT1; BMP-2 GENE; ALPHA; REQUIRES	Interferon-gamma (IFN-gamma) exerts an pleiotropic effect in mesangial cells in inflammatory glomerular diseases. The biologic effect of IFN-gamma is mediated by STAT1alpha. The precise mechanism by which IFN-gamma stimulates the transcriptional activity of STAT1alpha is poorly understood. I investigated the role of protein kinase C (PKC) epsilon in regulating the transcriptional activation of STAT1alpha in mesangial cells. IFN-gamma increased PKCepsilon activity in a time-dependent manner with a concomitant increase in STAT1alpha transcriptional activity. Expression of constitutively active PKCepsilon mimicked the effect of IFN-gamma on STAT1alpha-dependent transcription. Expression of dominant negative PKCepsilon inhibited IFN-gamma-induced STAT1alpha-dependent transcription. Ly294002, a pharmacological inhibitor of phosphatidylinositol ( PI) 3-kinase, blocked IFN-gamma-induced PKCepsilon activity and resulted in inhibition of STAT1alpha transcriptional activity but had no effect on STAT1alpha tyrosine phosphorylation and STAT1alpha-DNA complex formation. A PKC inhibitor, H7, also had no effect on STAT1alpha tyrosine phosphorylation and DNA binding. However, Ly294002 and H7 blocked IFN-gamma-induced serine phosphorylation of STAT1alpha. These data indicate that PI 3 kinase-dependent PKCepsilon regulates STAT1alpha transcriptional activity in the absence of any effect on its DNA binding capability. In addition to activating PKCepsilon, IFN-gamma increased MAPK activity, resulting in transcriptional activation of Elk-1, a nuclear target of MAPK. Ly294002 or a dominant negative PI 3-kinase significantly blocked IFN-gamma-induced MAPK activity. On the other hand, ectopic expression of constitutively active PKCepsilon significantly increased MAPK activity. IFN-gamma-stimulated MAPK phosphorylated STAT1alpha in vitro. Inhibition of MAPK activity blocked IFN-gamma-induced serine phosphorylation of STAT1alpha; but its tyrosine phosphorylation and DNA binding were partially inhibited. Finally, expression of dominant negative MAPK significantly inhibited IFN-gamma-induced STAT1alpha-dependent transcription. These data provide the first evidence that IFN-gamma stimulates PKCepsilon in a PI 3-kinase-sensitive manner to activate MAPK, which regulates STAT1alpha transcriptional activity.	Univ Texas, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Choudhury, GG (corresponding author), Univ Texas, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA.	choudhuryg@uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055815, P50DK061597] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK061597, R01 DK55815] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; BALKWILL FR, 1977, INT J CANCER, V20, P500, DOI 10.1002/ijc.2910200405; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; BISWAS P, 1995, FEBS LETT, V373, P146, DOI 10.1016/0014-5793(95)01025-A; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Carvalho-Pinto CE, 2002, J IMMUNOL, V169, P1058, DOI 10.4049/jimmunol.169.2.1058; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; CELADA A, 1986, J IMMUNOL, V137, P2373; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Chatterjee-Kishore M, 2000, J BIOL CHEM, V275, P20406, DOI 10.1074/jbc.M001861200; CHOUDHURY GG, 1993, AM J PHYSIOL, V265, pF634, DOI 10.1152/ajprenal.1993.265.5.F634; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Choudhury GG, 2003, CELL SIGNAL, V15, P161, DOI 10.1016/S0898-6568(02)00057-8; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Choudhury GG, 1996, KIDNEY INT, V49, P19, DOI 10.1038/ki.1996.3; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Choudhury GG, 2000, BIOCHEM BIOPH RES CO, V273, P1069, DOI 10.1006/bbrc.2000.3081; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Ghosh-Choudhury NG, 2003, J BIOL CHEM, V278, P21998, DOI 10.1074/jbc.M302277200; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GRANDALIANO G, 1994, J LAB CLIN MED, V123, P282; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; HUWILER A, 1993, EXP NEPHROL, V1, P19; Ikezumi Y, 2003, J AM SOC NEPHROL, V14, P888, DOI 10.1097/01.ASN.0000056604.13964.62; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; JOHNSON RJ, 1995, KIDNEY INT, V47, P62, DOI 10.1038/ki.1995.7; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kitching AR, 1999, J AM SOC NEPHROL, V10, P752; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li RCX, 2000, AM J PHYSIOL-HEART C, V279, pH1679, DOI 10.1152/ajpheart.2000.279.4.H1679; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; MATTILA P, 1993, SCAND J IMMUNOL, V38, P197, DOI 10.1111/j.1365-3083.1993.tb01713.x; MATTILA P, 1992, BIOCHEM BIOPH RES CO, V189, P1732, DOI 10.1016/0006-291X(92)90278-S; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MENE P, 1989, PHYSIOL REV, V69, P1372; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Nakashima O, 2000, KIDNEY INT, V57, P2249, DOI 10.1046/j.1523-1755.2000.00085.x; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; PONZONI M, 1993, FEBS LETT, V322, P120, DOI 10.1016/0014-5793(93)81550-J; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; Ring GH, 1999, J IMMUNOL, V163, P2243; SCHENA FP, 1992, J AM SOC NEPHROL, V2, pS167; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schwarting A, 1998, J IMMUNOL, V161, P494; Senthil D, 2002, AM J PHYSIOL-RENAL, V283, pF1226, DOI 10.1152/ajprenal.00109.2002; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Valente AJ, 1998, J IMMUNOL, V161, P3719; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Whiteside CI, 2002, AM J PHYSIOL-RENAL, V282, pF975, DOI 10.1152/ajprenal.00014.2002; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	78	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27399	27409		10.1074/jbc.M403530200	http://dx.doi.org/10.1074/jbc.M403530200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15082710	hybrid			2022-12-25	WOS:000222120400071
J	Ondr, JK; Pham, CTN				Ondr, JK; Pham, CTN			Characterization of murine cathepsin W and its role in cell-mediated cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL CYSTEINE PROTEASES; DIPEPTIDYL PEPTIDASE-I; ENDOPLASMIC-RETICULUM; T-LYMPHOCYTES; GRANZYME-A; CHROMOSOMAL LOCALIZATION; ESTABLISHED TUMORS; TARGET-CELLS; EXPRESSION; APOPTOSIS	Cathepsin W is a member of the papain-like family of cysteine proteases. In this report, we have isolated the cDNA for murine CtsW (mCtsW) from a splenocyte library. The deduced 371-amino-acid sequence shares 68% identity with human CtsW and includes the conserved catalytic triad cysteine, histidine, and asparagine found in all members of this family. In addition to the full-length form of mCtsW, we have isolated an alternatively spliced form of the mRNA that lacks a complete catalytic triad. An S1 nuclease protection assay and a Western blot analysis showed that mCtsW is mainly restricted to the CD8(+) T cell and natural killer cell compartments. In addition, we confirmed that, like its human homologue, mCtsW is localized mainly to the endoplasmic reticulum and its expression is up-regulated upon activation. We also characterized the mCtsW locus using bacterial artificial chromosome clones. The gene consists of 10 coding exons and 9 introns spanning 3.2 kb. To elucidate the physiologic role of this protease, we generated mice deficient in mCtsW. Our data establish that mCtsW is not required for cytotoxic lymphocyte-induced target cell death in vitro. In addition, mCtsW deficiency does not alter the susceptibility of cytotoxic lymphocytes to suicide or fratricide after degranulation. Thus, mCtsW does not have a unique role in target cell apoptosis or cytotoxic cell survival in vitro.	Washington Univ, Sch Med, Div Rheumatol, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Pham, CTN (corresponding author), Washington Univ, Sch Med, Div Rheumatol, Dept Internal Med, 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.	cpham@im.wustl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI049261, R01AI049261, T32AI007163] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07163, R01 AI049261, AI49261] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balaji KN, 2002, J EXP MED, V196, P493, DOI 10.1084/jem.20011836; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Brinkworth RI, 2000, INT J BIOCHEM CELL B, V32, P373, DOI 10.1016/S1357-2725(99)00129-6; Brown J, 1998, LEUKEMIA, V12, P1771, DOI 10.1038/sj.leu.2401164; Buhling F, 2002, BIOL CHEM, V383, P1285, DOI 10.1515/BC.2002.144; Buhling F, 2000, ADV EXP MED BIOL, V477, P241; Cygler M, 1997, BIOCHIMIE, V79, P645, DOI 10.1016/S0300-9084(97)83497-9; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; Maclvor DM, 1999, BLOOD, V93, P963, DOI 10.1182/blood.V93.3.963.403k18_963_973; Matsui K, 2003, INT IMMUNOL, V15, P797, DOI 10.1093/intimm/dxg078; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; Mullbacher A, 1996, P NATL ACAD SCI USA, V93, P5783, DOI 10.1073/pnas.93.12.5783; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Pham CTN, 1997, J BIOL CHEM, V272, P10695, DOI 10.1074/jbc.272.16.10695; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; Shresta S, 1997, J BIOL CHEM, V272, P20236, DOI 10.1074/jbc.272.32.20236; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; Simon MM, 1997, J EXP MED, V186, P1781, DOI 10.1084/jem.186.10.1781; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wex T, 2003, FEBS LETT, V552, P115, DOI 10.1016/S0014-5793(03)00895-0; Wex T, 1998, BIOCHEM BIOPH RES CO, V248, P255, DOI 10.1006/bbrc.1998.8954; Wex T, 1999, BIOCHEM BIOPH RES CO, V259, P401, DOI 10.1006/bbrc.1999.0700; Wex T, 2001, J IMMUNOL, V167, P2172, DOI 10.4049/jimmunol.167.4.2172; Wex T, 2000, ADV EXP MED BIOL, V477, P271	38	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27525	27533		10.1074/jbc.M400304200	http://dx.doi.org/10.1074/jbc.M400304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15087452	hybrid			2022-12-25	WOS:000222120400085
J	Zou, YL; Ewton, DZ; Deng, XB; Mercer, SE; Friedman, E				Zou, YL; Ewton, DZ; Deng, XB; Mercer, SE; Friedman, E			Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE; MIRK PROTEIN-KINASE; DEPENDENT KINASE; BINDING PROTEIN; D1; CELLS; DIFFERENTIATION; INHIBITOR; PREVENTS; DEGRADATION	The phosphorylation of cyclin D1 at threonine 286 by glycogen synthase kinase 3beta (GSK3beta) has been shown to be required for the ubiquitination and nuclear export of cyclin D1 and its subsequent degradation in the proteasome. The mutation of the nearby residue, threonine 288, to nonphosphorylatable alanine has also been shown to reduce the ubiquitination of cyclin D1, suggesting that phosphorylation at threonine 288 may also lead to degradation of cyclin D1. We now demonstrate that the G(0)/G(1)-active arginine-directed protein kinase Mirk/dyrk1B binds to cyclin D1 and phosphorylates cyclin D1 at threonine 288 in vivo and that the cyclin D1-T288A construct is more stable than wild-type cyclin D1. Transient overexpression of Mirk in nontransformed Mv1Lu lung epithelial cells blocked cells in G(0)/ G(1). Depletion of endogenous Mirk by RNA interference increased cyclin D1 protein levels but not mRNA levels, indicating that Mirk destabilizes cyclin D1 protein. Destabilization was confirmed by induction of a stable Mirk transfectant of Mv1Lu cells, which blocked cell migration (Zou, Y., Lim, S., Lee, K., Deng, X., and Friedman, E. ( 2003) J. Biol. Chem. 278, 49573 - 49581), and caused a decrease in the half-life of endogenous cyclin D1, concomitant with an increase in Mirk expression. In vitro cyclin D1 was phosphorylated in an additive fashion by Mirk and GSK3beta. Mirk-phosphorylated cyclin D1 mutated at the GSK3beta phosphorylation site and was capable of phosphorylating cyclin D1 in the presence of the GSK3beta inhibitor LiCl. Mirk may function together with GSK3beta to assist cell arrest in G(0)/G(1) by destabilizing cyclin D1.	Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.	friedmae@upstate.edu			NCI NIH HHS [R01 CA67405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BORJA PF, 2001, EMBO J, V20, P5737; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ewton DZ, 2003, INT J CANCER, V103, P21, DOI 10.1002/ijc.10743; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; LEE H, 1993, J BIOL CHEM, V268, P8181; Lee K, 2000, CANCER RES, V60, P3631; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Lu FM, 2003, CANCER RES, V63, P7056; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Pellettieri J, 2003, DEV CELL, V5, P451, DOI 10.1016/S1534-5807(03)00231-4; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Skurat AV, 2004, J BIOL CHEM, V279, P2490, DOI 10.1074/jbc.M301769200; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zou YL, 2003, J BIOL CHEM, V278, P49573, DOI 10.1074/jbc.M307556200	28	91	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27790	27798		10.1074/jbc.M403042200	http://dx.doi.org/10.1074/jbc.M403042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075324	hybrid			2022-12-25	WOS:000222120400114
J	Hatakeyama, M; Yumoto, N; Yu, X; Shirouzu, M; Yokoyama, S; Konagaya, A				Hatakeyama, M; Yumoto, N; Yu, X; Shirouzu, M; Yokoyama, S; Konagaya, A			Transformation potency of ErbB heterodimer signaling is determined by B-Raf kinase	ONCOGENE			English	Article						ErbB; B-Raf; transformation; PP2A; PKA	EPIDERMAL-GROWTH-FACTOR; PROTEIN PHOSPHATASE 2A; PLECKSTRIN HOMOLOGY DOMAIN; MAP KINASE; ACTIVATION; PHOSPHORYLATION; DEPHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION; TRANSDUCTION	Cellular transformation occurs only in cells that express both ErbB1 and ErbB4 receptors, but not in cells expressing only one or the other of these receptors. However, when both receptors are coexpressed and ligand-stimulated, they interact with virtually the same adaptor/effector proteins as when expressed singly. To reveal the underlying regulatory mechanism of the kinase/phosphatase network in ErbB homo- and heterodimer receptor signaling, extracellular signal-regulated kinase (ERK) and Akt activities were evaluated in the presence of several enzyme inhibitors in ligand-induced cells expressing ErbB1 (E1), ErbB4 (E4), and ErbB1/ErbB4 (E1/4) receptor. The PP2A inhibitor okadaic acid showed receptor-specific inhibitory profiles for ERK and Akt activities. Moreover, B-Raf isolated only from E1/4 cells could induce in vitro phosphorylation for MEK; this B-Raf kinase activity was abolished by pretreatment of the cells with okadaic acid. Our study further showed that the E1/4 cell-specific B-Raf activity was stimulated by PLCgamma and subsequent Rap1 activation. The present study suggests that B-Raf kinase, which was specifically activated in the cells coexpressing ErbB1 and ErbB4 receptors, elevates total ERK activity within the cell and, therefore, can induce cellular transformation.	RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, Kanagawa 2300045, Japan; RIKEN Genom Sci Ctr, Prot Res Grp, Tsurumi Ku, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; SPring8, RIKEN Harima Inst, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; SPring8, RIKEN Harima Inst, Structurome Grp, Sayo, Hyogo 6795148, Japan	RIKEN; RIKEN; University of Tokyo; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Hatakeyama, M (corresponding author), RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Kanagawa 2300045, Japan.	marikoh@gsc.riken.jp	Okada, Mariko/N-6933-2015; Yokoyama, Shigeyuki/N-6911-2015; Konagaya, Akihiko/F-9302-2014; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Brose MS, 2002, CANCER RES, V62, P6997; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Hatakeyama M, 2003, BIOCHEM J, V373, P451, DOI 10.1042/BJ20021824; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim JH, 2002, EUR J BIOCHEM, V269, P2323, DOI 10.1046/j.1432-1033.2002.02877.x; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Oehrl W, 2003, J BIOL CHEM, V278, P17819, DOI 10.1074/jbc.M209951200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	45	9	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5023	5031		10.1038/sj.onc.1207664	http://dx.doi.org/10.1038/sj.onc.1207664			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064721				2022-12-25	WOS:000222237300008
J	Hashigasako, A; Machide, M; Nakamura, T; Matsumoto, K; Nakamura, T				Hashigasako, A; Machide, M; Nakamura, T; Matsumoto, K; Nakamura, T			Bi-directional regulation of Ser-985 phosphorylation of c-Met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; JUXTAMEMBRANE DOMAIN; MOLECULAR-CLONING; IDENTIFICATION; CANCER; KERATINOCYTES; MUTATION; PATHWAY; STRESS; HGF/SF	Previous studies indicated that treatment of cells with 12-O-tetradecanoylphorbol-13-acetate induced phosphorylation of Ser-985 at the juxtamembrane of c-Met, the receptor tyrosine kinase for hepatocyte growth factor (HGF), and this was associated with decreased tyrosine phosphorylation of c-Met. However, the regulatory mechanisms and the biological significance of the Ser-985 phosphorylation in c-Met remain unknown. When A549 human lung cancer cells were exposed to oxidative stress with H2O2, H2O2 treatment induced phosphorylation of Ser-985, but this was abrogated by an inhibitor for protein kinase C (PKC). Likewise, treatment of cells with NaF (an inhibitor of protein phosphatases) allowed for phosphorylation of Ser-985, and a protein phosphatase responsible for dephosphorylation of Ser-985 was identified to be protein phosphatase 2A (PP2A). The effects of PKC inhibitors revealed that PKCdelta and -epsilon were responsible for the Ser-985 phosphorylation of c-Met, and pull-down analysis indicated that associations of PKCdelta and -epsilon with c-Met may be involved in the regulation of Ser-985 phosphorylation of c-Met. Instead, PP2A was constitutively associated with c-Met, whereas its activity to dephosphorylate Ser-985 of c-Met was decreased when cells were exposed to H2O2. Addition of HGF to A549 cells in culture induced c-Met tyrosine phosphorylation, the result being mitogenic response and cell scattering. In contrast, in the presence of H2O2 stress, HGF-dependent tyrosine phosphorylation of c-Met was largely suppressed with a reciprocal relationship to Ser-985 phosphorylation, and this event was associated with abrogation of cellular responsiveness to HGF. These results indicate that Ser-985 phosphorylation of c-Met is bi-directionally regulated through PKC and PP2A, and the Ser-985 phosphorylation status may provide a unique mechanism that confers cellular responsiveness/unresponsivenss to HGF, depending on extracellular conditions.	Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, Suita, Osaka 5650871, Japan; Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448787, Japan	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Nakamura, T (corresponding author), Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, 2-2-B7 Yamada Oka, Suita, Osaka 5650871, Japan.	nakamura@onbich.med.osaka-u.ac.jp	Matsumoto, Kunio/D-8441-2015	Matsumoto, Kunio/0000-0002-6532-4482				Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COCHET C, 1984, J BIOL CHEM, V259, P2553; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; Funakoshi H, 2003, CLIN CHIM ACTA, V327, P1, DOI 10.1016/S0009-8981(02)00302-9; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Ivaska J, 2003, BIOCHEM SOC T, V31, P90, DOI 10.1042/bst0310090; Kitajima Y, 1999, J INVEST DERM SYMP P, V4, P137, DOI 10.1038/sj.jidsp.5640197; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KUPPUSWAMY D, 1991, CELL SIGNAL, V3, P107, DOI 10.1016/0898-6568(91)90017-O; LEE CC, 1994, J BIOL CHEM, V269, P19457; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Ma PC, 2003, CANCER RES, V63, P6272; Matsumoto K, 2003, CANCER SCI, V94, P321, DOI 10.1111/j.1349-7006.2003.tb01440.x; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Meier M, 2000, VASC MED, V5, P173, DOI 10.1177/1358836X0000500307; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAKEHARA T, 1992, J BIOCHEM-TOKYO, V112, P330, DOI 10.1093/oxfordjournals.jbchem.a123900; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	33	79	80	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26445	26452		10.1074/jbc.M314254200	http://dx.doi.org/10.1074/jbc.M314254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075332	hybrid			2022-12-25	WOS:000222003000066
J	Murphy, JM; Ford, SC; Olsen, JE; Gustin, SE; Jeffrey, PD; Ollis, DL; Young, IG				Murphy, JM; Ford, SC; Olsen, JE; Gustin, SE; Jeffrey, PD; Ollis, DL; Young, IG			Interleukin-3 binding to the murine beta(IL-3) and human beta c receptors involves functional epitopes formed by domains 1 and 4 of different protein chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HIGH-AFFINITY BINDING; HUMAN GM-CSF; COMPLETE EXTRACELLULAR DOMAIN; HUMAN GROWTH-HORMONE; IL-5 RECEPTORS; ALPHA-CHAIN; CYTOKINE RECEPTORS; EXPRESSION CLONING; CRYSTAL-STRUCTURE	Interleukin-3 (IL-3) is a cytokine produced by activated T-cells and mast cells that is active on a broad range of hematopoietic cells and in the nervous system and appears to be important in several chronic inflammatory diseases. In this study, alanine substitutions were used to investigate the role of residues of the human beta-common (hbetac) receptor and the murine IL-3-specific (beta(IL-3)) receptor in IL-3 binding. We show that the domain 1 residues, Tyr(15) and Phe(79), of the hbetac receptor are important for high affinity IL-3 binding and receptor activation as shown previously for the related cytokines, interleukin-5 and granulocyte-macrophage colony-stimulating factor, which also signal through this receptor subunit. From the x-ray structure of hbetac, it is clear that the domain 1 residues cooperate with domain 4 residues to form a novel ligand-binding interface involving the two protein chains of the intertwined homodimer receptor. We demonstrate by ultracentrifugation that the beta(IL-3) receptor is also a homodimer. Its high sequence homology with hbetac suggests that their structures are homologous, and we identified an analogous binding interface in betaIL-3 for direct IL-3 binding to the high affinity binding site in hbetac. Tyr(21) (A-B loop), Phe(85), and Asn(87) (E-F loop) of domain 1; Ile(320) of the interdomain loop; and Tyr(348) (B'-C' loop) and Tyr(401) (F'-G' loop) of domain 4 were shown to have critical individual roles and Arg(84) and Tyr(317) major secondary roles in direct murine IL-3 binding to the beta(IL-3) receptor. Most surprising, none of the key residues for direct IL-3 binding were critical for high affinity binding in the presence of the murine IL-3 alpha receptor, indicating a fundamentally different mechanism of high affinity binding to that used by hbetac.	Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research; Australian National University	Young, IG (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia.	Ian.Young@anu.edu.au	Murphy, James/B-4863-2017; Ollis, David/I-5967-2014	Murphy, James/0000-0003-0195-3949; 				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; Chiang CS, 1996, J CLIN INVEST, V97, P1512, DOI 10.1172/JCI118574; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; DeLano WL, 2002, PYMOL USERS MANUAL; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Gustin SE, 2001, EUR J BIOCHEM, V268, P2905, DOI 10.1046/j.1432-1327.2001.02178.x; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; HAIG DM, 1988, IMMUNOLOGY, V65, P205; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOBAYASHI M, 1989, BLOOD, V73, P1836; LOCK P, 1994, P NATL ACAD SCI USA, V91, P252, DOI 10.1073/pnas.91.1.252; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; Middleton SA, 1999, J BIOL CHEM, V274, P14163, DOI 10.1074/jbc.274.20.14163; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; Morris C F, 1990, Immunol Ser, V49, P177; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy JM, 2003, J BIOL CHEM, V278, P10572, DOI 10.1074/jbc.M211664200; Nicola NA, 1996, BLOOD, V87, P2665, DOI 10.1182/blood.V87.7.2665.bloodjournal8772665; Rossjohn J, 2000, BLOOD, V95, P2491; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WANG HM, 1992, J BIOL CHEM, V267, P979; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; YONEHARA S, 1990, INT IMMUNOL, V2, P143, DOI 10.1093/intimm/2.2.143; Zhang JL, 2002, J MOL BIOL, V315, P399, DOI 10.1006/jmbi.2001.5243	39	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26500	26508		10.1074/jbc.M402705200	http://dx.doi.org/10.1074/jbc.M402705200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15060062	hybrid			2022-12-25	WOS:000222003000073
J	Deng, QD; Huang, S				Deng, QD; Huang, S			PRDM5 is silenced in human cancers and has growth suppressive activities	ONCOGENE			English	Article						PRDM5 (PRDM5); PR/SET domain; tumor suppressors; 4q25-q26; PRDM2	HUMAN HEPATOCELLULAR-CARCINOMA; ZINC-FINGER PROTEIN; PR-DOMAIN FAMILY; CPG ISLANDS; SET DOMAIN; HISTONE METHYLTRANSFERASES; GENE-EXPRESSION; CHROMOSOMES 4Q; RIZ1; FREQUENT	Several genes that contain the PR (PRDI-BF1 and RIZ) domain have been linked with human cancers. We describe here a new PR-domain-containing gene designated as PRDM5 (PFM2). A PRDM5 cDNA was isolated based on its homology to the PR domain of RIZ1 (PRDM2). The gene encodes an open reading frame of 630 amino acids and contains a PR domain in the NH-terminal region followed by 16 zinc finger motifs. Radiation hybrid analysis mapped PRDM5 to human chromosome 4q26, a region thought to harbor tumor suppressor genes for breast, ovarian, liver, lung, colon, and other cancers. The gene has a CpG island promoter and is silenced in human breast, ovarian, and liver cancers. A recombinant adenovirus expressing PRDM5 caused G2/M arrest and apoptosis upon infection of tumor cells. These results suggest that inactivation of PRDM5 may play a role in carcinogenesis.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Huang, S (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@burnham.org			NATIONAL CANCER INSTITUTE [R01CA076146] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arribas R, 1999, LAB INVEST, V79, P111; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Du Y, 2001, CANCER RES, V61, P8094; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.3.CO;2-B; Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; He LS, 1998, CANCER RES, V58, P4238; HEON E, 1995, HUM MOL GENET, V4, P1435, DOI 10.1093/hmg/4.8.1435; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kim KC, 2003, CANCER BIOL THER, V2, P491, DOI 10.4161/cbt.2.5.629; Kim KC, 2003, CANCER RES, V63, P7619; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; MITRA AB, 1994, CANCER RES, V54, P4481; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.0.CO;2-U; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schwendel A, 1998, BRIT J CANCER, V78, P806, DOI 10.1038/bjc.1998.583; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Tirkkonen M, 1997, CANCER RES, V57, P1222; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Wang XL, 1999, ONCOGENE, V18, P823, DOI 10.1038/sj.onc.1202318; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360; Yang XH, 1999, GENOMICS, V61, P319, DOI 10.1006/geno.1999.5967	44	78	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4903	4910		10.1038/sj.onc.1207615	http://dx.doi.org/10.1038/sj.onc.1207615			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077163				2022-12-25	WOS:000222104200011
J	Li, L; Hooi, D; Chhabra, SR; Pritchard, D; Shaw, PE				Li, L; Hooi, D; Chhabra, SR; Pritchard, D; Shaw, PE			Bacterial N-acylhomoserine lactone-induced apoptosis in breast carcinoma cells correlated with down-modulation of STAT3	ONCOGENE			English	Article						apoptosis; autocrine signal; Janus kinases; cell cycle	PSEUDOMONAS-AERUGINOSA; CONSTITUTIVE ACTIVATION; SIGNALING PATHWAY; CANCER CELLS; C-MYC; SURVIVAL; GROWTH; KINASE; SRC; DIFFERENTIATION	Cell growth is promoted by mitogens and survival factors, which activate intracellular signalling pathways to control cell cycle progression and cellular integrity. Proliferation signals are transmitted through Ras and Rho family small G-proteins coupled to mitogen-activated protein kinase ( MAPK) cascades, while survival signals are propagated by lipid-dependent kinases such as phosphatidylinositide 3-kinases (PI3Ks) and protein kinase B (Akt/PKB). Recently, signal transducer and activator of transcription ( STAT) proteins were identified as positive regulators of proliferation in a variety of cell types. Persistent activation of these pathways is associated with tumour cell growth, whereas their inhibition can halt proliferation and precipitate apoptotic cell death. The human pathogen Pseudomonas aeruginosa uses quorum-sensing signal molecules (QSSMs) to regulate virulence gene expression. QSSMs also suppress host immune responses although the mechanism of suppression is unknown. Here, we demonstrate that the QSSM N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) from P. aeruginosa blocks proliferation and induces apoptosis in human BC cell lines. Analyses of signalling events reveal that OdDHL has little or no effect on MAPK cascades, partially inhibits the Akt/PKB pathway and ablates STAT3 activity. Pharmacological inhibition of each pathway independently indicates that STAT3 activity is critical for BC cell proliferation and survival, while a constitutively active STAT3 confers resistance to OdDHL. These results support the notion of OdDHL as a bioactive molecule in eukaryotic systems and a paradigm for a novel class of antiproliferative compounds.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Univ Nottingham, Sch Pharm, Immune Modulat Res Grp, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.	peter.shaw@nottingham.ac.uk		SHAW, Peter/0000-0002-2598-4283				Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gooch JL, 1999, CANCER LETT, V144, P31, DOI 10.1016/S0304-3835(99)00208-6; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Pesci EC, 1997, J BACTERIOL, V179, P3127, DOI 10.1128/jb.179.10.3127-3132.1997; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Seidel HM, 2000, ONCOGENE, V19, P2645, DOI 10.1038/sj.onc.1203550; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Smith RS, 2002, J BACTERIOL, V184, P1132, DOI 10.1128/jb.184.4.1132-1139.2002; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Telford G, 1998, INFECT IMMUN, V66, P36, DOI 10.1128/IAI.66.1.36-42.1998; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200	39	107	111	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4894	4902		10.1038/sj.onc.1207612	http://dx.doi.org/10.1038/sj.onc.1207612			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064716				2022-12-25	WOS:000222104200010
J	Magdinier, F; Yusufzai, TM; Felsenfeld, G				Magdinier, F; Yusufzai, TM; Felsenfeld, G			Both CTCF-dependent and -independent insulators are found between the mouse T cell receptor alpha and Dad1 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; ENHANCER-BLOCKING ACTIVITY; MATRIX-ATTACHMENT REGIONS; BETA-GLOBIN DOMAIN; ALPHA/DELTA LOCUS; BINDING-PROTEIN; TRANSGENE EXPRESSION; NUCLEAR-MATRIX; TCR-ALPHA; CHROMATIN	The T cell rearrangement of the T cell receptor (TCR) genes TCRalpha and delta is specifically regulated by a complex interplay between enhancer elements and chromatin structure. The alpha enhancer is active in T cells and drives TCRalpha recombination in collaboration with a locus control region-like element located downstream of the Calpha gene on mouse chromosome 14. Twelve kb further downstream lies another gene, Dad1, with a program of expression different from that of TCRalpha. The similar to6-kb locus control region element lying between them contains multiple regulatory sites with a variety of roles in regulating the two genes. Previous evidence has indicated that among these there are widely distributed regions with enhancer blocking (insulating) activity. We have shown in this report that one of these sites, not previously examined, strongly binds the insulator protein CCTC-binding factor (CTCF) in vitro and in vivo and can function in an enhancer blocking assay. However, other regions within the 6-kb element that also can block enhancers clearly do not harbor CTCF sites and thus must reflect the presence of a previously undetected and distinct vertebrate insulator activity.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Felsenfeld, G (corresponding author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	gary.felsenfeld@nih.gov	Magdinier, Frederique/I-4735-2016	Magdinier, Frederique/0000-0002-0159-9559	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK034001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Byrd K, 2003, J CELL BIOL, V162, P565, DOI 10.1083/jcb.200305013; Chao W, 2002, SCIENCE, V295, P345, DOI 10.1126/science.1065982; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DIAZ P, 1994, IMMUNITY, V1, P207, DOI 10.1016/1074-7613(94)90099-X; Dunn KL, 2003, EXP CELL RES, V288, P218, DOI 10.1016/S0014-4827(03)00185-X; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 2001, NAT GENET, V28, P335, DOI 10.1038/ng570; Forrester WC, 1999, GENE DEV, V13, P3003, DOI 10.1101/gad.13.22.3003; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Glusman G, 2001, IMMUNITY, V15, P337, DOI 10.1016/S1074-7613(01)00200-X; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hong NA, 1999, J IMMUNOL, V163, P1888; Hong NA, 1997, MOL CELL BIOL, V17, P2151, DOI 10.1128/MCB.17.4.2151; KALOS M, 1995, MOL CELL BIOL, V15, P198, DOI 10.1128/MCB.15.1.198; Krangel MS, 2000, IMMUNOL RES, V22, P127, DOI 10.1385/IR:22:2-3:127; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Makishima T, 1997, GENES CELLS, V2, P129, DOI 10.1046/j.1365-2443.1997.1070303.x; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Ortiz BD, 1999, MOL CELL BIOL, V19, P1901; Ortiz BD, 2001, J IMMUNOL, V167, P3836, DOI 10.4049/jimmunol.167.7.3836; PhiVan L, 1996, BIOCHEMISTRY-US, V35, P10735, DOI 10.1021/bi9603783; Robinett CC, 1997, MOL CELL BIOL, V17, P2866, DOI 10.1128/MCB.17.5.2866; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Santoso B, 2000, J BIOL CHEM, V275, P1952, DOI 10.1074/jbc.275.3.1952; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; Sleckman BP, 1997, IMMUNITY, V7, P505, DOI 10.1016/S1074-7613(00)80372-6; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; SUGIMOTO A, 1995, EMBO J, V14, P4434, DOI 10.1002/j.1460-2075.1995.tb00122.x; Villemure JF, 2001, J MOL BIOL, V312, P963, DOI 10.1006/jmbi.2001.5015; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172; Zhong XP, 1999, J IMMUNOL, V163, P295	51	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25381	25389		10.1074/jbc.M403121200	http://dx.doi.org/10.1074/jbc.M403121200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082712	hybrid			2022-12-25	WOS:000221827900061
J	Wollenberg, MS; Simon, SM				Wollenberg, MS; Simon, SM			Signal sequence cleavage of peptidyl-tRNA prior to release from the ribosome and translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; ER MEMBRANE; GTP; MITOCHONDRIA; PEROXISOMES; PROTEOLYSIS; PRECURSOR; PUROMYCIN	Many secretory polypeptides undergo cleavage of their signal sequence. In this study, we observed and quantitated the presence of a tRNA-bound, ribosome-associated polypeptide subpopulation present in vitro. This subpopulation was accessible to signal peptidase on ribosome-associated polypeptides longer than 114 amino acids. This demonstrates that it is possible for a peptidyl-tRNA species, in the midst of translation, to be processed by the endoplasmic reticulum signal peptidase implying that the peptidase is closely associated with the mammalian translocon.	Rockefeller Univ, Lab Cellular Biophys, New York, NY 10021 USA	Rockefeller University	Simon, SM (corresponding author), Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave,Box 304, New York, NY 10021 USA.	simon@rockefeller.edu		Simon, Sanford/0000-0002-8615-4224				BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Bruce BD, 2000, TRENDS CELL BIOL, V10, P440, DOI 10.1016/S0962-8924(00)01833-X; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; DOBBERSTEIN B, 1977, P NATL ACAD SCI USA, V74, P1082, DOI 10.1073/pnas.74.3.1082; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kanner EM, 2003, J BIOL CHEM, V278, P7920, DOI 10.1074/jbc.M207462200; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NATHANS D, 1964, P NATL ACAD SCI USA, V51, P585, DOI 10.1073/pnas.51.4.585; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; Promega Corp, 2000, CAN PANCR MICR MEMBR; PUGSLEY AP, 1990, ANNU REV GENET, V24, P67; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TALMADGE K, 1980, P NATL ACAD SCI-BIOL, V77, P3988, DOI 10.1073/pnas.77.7.3988; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679	37	3	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24919	24922		10.1074/jbc.C400018200	http://dx.doi.org/10.1074/jbc.C400018200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082722	hybrid			2022-12-25	WOS:000221827900004
J	Marszalek, JR; Kitidis, C; Dararutana, A; Lodish, HF				Marszalek, JR; Kitidis, C; Dararutana, A; Lodish, HF			Acyl-CoA synthetase 2 overexpression enhances fatty acid internalization and neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; PC12 CELLS; RAT-LIVER; MEMBRANE; PROTEIN; EXPRESSION; CLONING; RETINA; BRAIN; TRANSPORT	During neurodevelopment neurons increase phospholipid synthesis to generate additional plasma membrane that makes up the growing neurites. Compared with most cell types, neurons contain a high percentage of the polyunsaturated fatty acids (PUFAs) arachidonic acid ( AA) and docosahexaenoic acid (DHA). By utilizing PC12 cell lines as a model neuronal cell line, we examined the internalization rate of AA, DHA, and non-essential oleic acid (OA), as well as their effects on neurite outgrowth. When wild type cells were differentiated, the rate of AA and DHA internalization increased 50% more than the rate of OA internalization. When media were supplemented with AA or DHA, the average neurite length was increased by similar to40%, but supplementation with the same amount of OA had no effect. We also increased the levels of acyl-CoA synthetase-1 (ACS1) and ACS2 proteins to determine whether they contribute to PUFA internalization or neurite outgrowth. Overexpression of ACS1 increased the rate of OA internalization by 55%, and AA and DHA uptake was increased by 25%, but there was no significant change in neurite outgrowth. In ACS2-overexpressing cells, in contrast, the rate of OA internalization increased by 90%, AA by 115%, and DHA by 70%. The average aggregate neurite length in ACS2-overexpressing cells was increased by similar to40% when the media were supplemented with PUFAs, but there was no change with OA supplementation. Taken together, these results support the hypotheses that ACSs are rate-limiting for fatty acid internalization and that ACS2 enhances neurite outgrowth by promoting PUFA internalization.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066105] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL66105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen GW, 2000, MOL BRAIN RES, V76, P315, DOI 10.1016/S0169-328X(00)00014-0; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Bazan NG, 2003, J LIPID RES, V44, P2221, DOI 10.1194/jlr.R300013-JLR200; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; BLACK PN, 1988, J BACTERIOL, V170, P2850, DOI 10.1128/jb.170.6.2850-2854.1988; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; DEHAUT F, 1993, NEUROSCI LETT, V161, P133, DOI 10.1016/0304-3940(93)90277-R; Ding L, 1998, FEBS LETT, V429, P109, DOI 10.1016/S0014-5793(98)00490-6; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Gargiulo CE, 1999, J LIPID RES, V40, P881; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; Ikemoto A, 1999, ARCH BIOCHEM BIOPHYS, V364, P67, DOI 10.1006/abbi.1999.1110; INNIS SM, 1991, PROG LIPID RES, V30, P39, DOI 10.1016/0163-7827(91)90006-Q; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Kim HY, 2001, J MOL NEUROSCI, V16, P223, DOI 10.1385/JMN:16:2-3:223; Lauritzen L, 2001, PROG LIPID RES, V40, P1, DOI 10.1016/S0163-7827(00)00017-5; Lewin TM, 2002, ARCH BIOCHEM BIOPHYS, V404, P263, DOI 10.1016/S0003-9861(02)00247-3; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Li JX, 1998, BRAIN RES, V803, P44, DOI 10.1016/S0006-8993(98)00595-2; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; OKUDA S, 1994, NEUROSCIENCE, V63, P691, DOI 10.1016/0306-4522(94)90515-0; Pownall HJ, 2003, ACTA PHYSIOL SCAND, V178, P357, DOI 10.1046/j.1365-201X.2003.01154.x; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903; Smallheiser NR, 1996, BRAIN RES, V721, P39, DOI 10.1016/0006-8993(96)00134-5; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J NEUROCHEM, V62, P1231; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	36	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23882	23891		10.1074/jbc.M313460200	http://dx.doi.org/10.1074/jbc.M313460200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051725	hybrid			2022-12-25	WOS:000221702500008
J	Nicholls, CD; Shields, MA; Lee, PWK; Robbins, SM; Beattie, TL				Nicholls, CD; Shields, MA; Lee, PWK; Robbins, SM; Beattie, TL			UV-dependent alternative splicing uncouples p53 activity and PIG3 gene function through rapid proteolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TUMOR-SUPPRESSOR PROTEIN; NAD(P)H-QUINONE OXIDOREDUCTASE-1; HUMAN CANCER; SR PROTEINS; DNA-DAMAGE; APOPTOSIS; KINASE; PROMOTER; STRESS	The p53-inducible gene 3 (PIG3) is a transcriptional target of the tumor suppressor protein p53 and is thought to play a role in apoptosis. In this report, we identify a novel alternatively spliced product from the PIG3 gene that we call PIG3AS ( PIG3 alternative splice). PIG3AS results from alternative pre-mRNA splicing that skips exon 4 of the five exons included in the PIG3 transcript. The resulting protein product shares its first 206 amino acids with PIG3 but has a unique 42-amino acid C terminus. In unstressed cells and after most DNA damage conditions that induce transcription from the PIG3 gene, production of the PIG3 transcript dominates. However, in response to UV light, pre-mRNA splicing shifts dramatically in favor of PIG3AS. Unlike the PIG3 protein, the PIG3AS protein is rapidly degraded with a short half-life and is stabilized by proteasome inhibition. Our results illustrate the first example of an endogenous, UV-inducible, alternative splicing event and that control of the splicing machinery is involved in the cellular DNA damage response. They also suggest that rapid proteolytic degradation represents a cellular mechanism for uncoupling p53 activity from PIG3 gene activation that is independent of promoter selectivity.	Univ Calgary, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Beattie, TL (corresponding author), Heritage Med Res Bldg, Calgary, AB T2N 4N1, Canada.	tbeattie@ucalgary.ca						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Anwar A, 2002, J BIOL CHEM, V277, P14060, DOI 10.1074/jbc.M111576200; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Caballero OL, 2001, DIS MARKERS, V17, P67, DOI 10.1155/2001/184856; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Contente A, 2003, CANCER RES, V63, P1756; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Holmila R, 2003, Hum Mutat, V21, P101, DOI 10.1002/humu.9104; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KRAWCZAK M, 1992, HUM GENET, V90, P41; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Traver RD, 1997, BRIT J CANCER, V75, P69, DOI 10.1038/bjc.1997.11; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Varley JM, 2001, ONCOGENE, V20, P2647, DOI 10.1038/sj.onc.1204369; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang ZN, 2003, CANCER RES, V63, P655; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492	48	24	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24171	24178		10.1074/jbc.M401049200	http://dx.doi.org/10.1074/jbc.M401049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15067011	hybrid			2022-12-25	WOS:000221702500040
J	Janne, PA; Li, C; Zhao, XJ; Girard, L; Chen, TH; Minna, J; Christiani, DC; Johnson, BE; Meyerson, M				Janne, PA; Li, C; Zhao, XJ; Girard, L; Chen, TH; Minna, J; Christiani, DC; Johnson, BE; Meyerson, M			High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines	ONCOGENE			English	Article						lung neoplasm; non-small cell; small-cell carcinoma; loss of heterozygosity; single-nucleotide polymorphism	GENOME-WIDE DETECTION; GENE-EXPRESSION; TUMOR PROGRESSION; BLADDER-CANCER; ADENOCARCINOMA; CARCINOMAS; CLASSIFICATION; PATTERNS; SURVIVAL; DNA	Chromosomal loss of heterozygosity (LOH) is a common mechanism for the inactivation of tumor suppressor genes in human epithelial cancers. Hybridization to single-nucleotide polymorphism (SNP) arrays is an efficient method to detect genome-wide cancer LOH. Here, we survey LOH patterns in a panel of 33 human lung cancer cell lines using SNP array hybridization containing 1500 SNPs. We compared the LOH patterns generated by SNP array hybridization to those previously obtained by 399 microsatellite markers and find a high degree of concordance between the two methods. A novel informatics platform, dChipSNP, was used to perform hierarchical tumor clustering based on genome-wide LOH patterns. We demonstrate that this method can separate non-small-cell and small-cell lung cancer samples based on their shared LOH. Furthermore, we analysed seven human lung cancer cell lines using a novel 10000 SNP array and demonstrate that this is an efficient and reliable method of high-density allelotyping. Using this array, we identified small regions of LOH that were not detected by lower density SNP arrays or by standard microsatellite marker panels.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm & Crit Care Unit, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital	Meyerson, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Mayer 446,44 Binney St, Boston, MA 02115 USA.	matthew_meyerson@dfci.harvard.edu	Meyerson, Matthew L/E-7123-2012; Wang, Weili/D-1546-2011		NATIONAL CANCER INSTITUTE [K12CA087723, R01CA092824, P50CA070907, P30CA006516] Funding Source: NIH RePORTER; NCI NIH HHS [1K12CA87723-01, 2P30 CA06516-39, P50CA70907, R01CA92824] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Dumur CI, 2003, GENOMICS, V81, P260, DOI 10.1016/S0888-7543(03)00020-X; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; FONG KM, 1995, CANCER RES, V55, P220; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Girard L, 2000, CANCER RES, V60, P4894; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hoque MO, 2003, CANCER RES, V63, P2216; JANNE PA, 2002, P AM ASS CAN RES, V43, pA3147; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lieberfarb ME, 2003, CANCER RES, V63, P4781; LIN M, 2003, IN PRESS BIOINFORMAT; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Mitsudomi T, 1996, CLIN CANCER RES, V2, P1185; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Primdahl H, 2002, J NATL CANCER I, V94, P216; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; Tseng JE, 1999, CANCER RES, V59, P4798; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; WANG ZC, 2003, IN PRESS CANC RES; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	30	79	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2716	2726		10.1038/sj.onc.1207329	http://dx.doi.org/10.1038/sj.onc.1207329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048096				2022-12-25	WOS:000220714900013
J	Berthou, S; Aebersold, DM; Schmidt, LS; Stroka, D; Heigl, C; Streit, B; Stalder, D; Gruber, G; Liang, CX; Howlett, AR; Candinas, D; Greiner, RH; Lipson, KE; Zimmer, Y				Berthou, S; Aebersold, DM; Schmidt, LS; Stroka, D; Heigl, C; Streit, B; Stalder, D; Gruber, G; Liang, CX; Howlett, AR; Candinas, D; Greiner, RH; Lipson, KE; Zimmer, Y			The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants	ONCOGENE			English	Article						Met receptor; activating mutation; receptor tyrosine kinase inhibitor	GROWTH-FACTOR RECEPTOR; GASTROINTESTINAL STROMAL TUMORS; PAPILLARY RENAL-CARCINOMAS; CHRONIC MYELOID-LEUKEMIA; FACTOR SCATTER FACTOR; TYROSINE KINASE; SOMATIC MUTATIONS; C-MET; CYTOGENETIC RESPONSES; IMATINIB MESYLATE	Point mutations constitute a major mode of oncogenic activation of the Met receptor tyrosine kinase. Met is aberrantly activated in many types of human malignancies and its deregulated activity is correlated with aggressive tumor traits such as abnormal proliferation and survival, leading to tumor growth, local invasion and metastasis. Here we report that the Met kinase inhibitor SU11274 differentially affects the kinase activity and subsequent signaling of various mutant forms of Met. Two Met variants tested, M1268T and H1112Y, were potently inhibited by 2 muM SU11274, while two other variants, L1213V and Y1248H, remained resistant under similar experimental conditions. Inhibition of the kinase altered cell proliferation, morphology and motility, while cells containing resistant mutants appeared unaffected by the compound. The basis for the sensitivity or resistance to SU11274 is discussed in terms of the position of the mutations predicted from a homology model.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland; SAIC Frederick Inc, Basic Res Program, NCI Frederick, Ft Detrick, MD 21702 USA; Univ Bern, Inselspital, Dept Visceral Surg, CH-3010 Bern, Switzerland; SUGEN Inc, San Francisco, CA 94080 USA	University of Bern; University of Bern; University Hospital of Bern; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Bern; University Hospital of Bern; Pfizer	Zimmer, Y (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35-D-809, CH-3010 Bern, Switzerland.	yitzhak.zimmer@dkf5.unibe.ch	Stroka, Deborah M/F-1806-2013; Aebersold, Daniel Matthias/C-2946-2013	Aebersold, Daniel Matthias/0000-0002-9493-3834; Stroka, Deborah/0000-0002-3517-3871; Lipson, Kenneth/0000-0001-8847-6051	PHS HHS [N01-C0-12400] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aebersold DM, 2003, ONCOGENE, V22, P8519, DOI 10.1038/sj.onc.1206968; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; de Silva MV, 2003, PATHOL ONCOL RES, V9, P13, DOI 10.1007/BF03033708; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Haddad R, 2001, ANTICANCER RES, V21, P4243; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Longati P, 2001, CURR DRUG TARGETS, V2, P41, DOI 10.2174/1389450013348920; Lorenzato A, 2002, CANCER RES, V62, P7025; Ma PC, 2003, CANCER RES, V63, P6272; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Miller M, 2001, PROTEINS, V44, P32, DOI 10.1002/prot.1069; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Park WS, 1999, CANCER RES, V59, P307; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sattler M, 2003, CANCER RES, V63, P5462; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; To CTT, 1998, ONCOL REP, V5, P1013; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Wang XY, 2003, MOL CANCER THER, V2, P1085	33	153	167	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5387	5393		10.1038/sj.onc.1207691	http://dx.doi.org/10.1038/sj.onc.1207691			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064724				2022-12-25	WOS:000222491600014
J	Creagh, EM; Murphy, BM; Duriez, PJ; Duckett, CS; Martin, SJ				Creagh, EM; Murphy, BM; Duriez, PJ; Duckett, CS; Martin, SJ			Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED INHIBITOR; PROGRAMMED CELL-DEATH; BACULOVIRUS INHIBITOR; DEGRADATION; IAP; XIAP; ACTIVATION; REAPER; DIAP1; GRIM	Inhibitor of apoptosis proteins (IAPs) can block apoptosis through binding to active caspases and antagonizing their function. IAP function can be neutralized by Smac/Diablo, an IAP-binding protein that is released from mitochondria during apoptosis. In addition to their ability to interact with caspases, certain IAPs also display ubiquitin-protein isopeptide ligase activity because of the presence of a RING domain. However, it is not known whether the ubiquitin-protein isopeptide ligase activities of human IAPs contribute to their apoptosis inhibitory activity or whether this IAP property can be modulated through association with Smac/Diablo. Here we demonstrate that the ubiquitin ligase activities of XIAP, and to a lesser extent c-IAP-1 and c-IAP2, are potently repressed through binding to Smac/Diablo. We also show that mutation of the XIAP RING domain rendered this IAP a less effective inhibitor of apoptosis, suggesting that the ubiquitin ligase activity of XIAP contributes to its anti-apoptotic function. These data suggest that Smac/Diablo potentiates apoptosis by simultaneously antagonizing caspase-IAP interactions and repressing IAP ubiquitin ligase activities.	Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Trinity College Dublin; University of Michigan System; University of Michigan	Martin, SJ (corresponding author), Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland.	martinsj@tcd.ie	Murphy, Brona/D-4873-2012; Murphy, Brona/P-2544-2019; Creagh, Emma/AAX-1064-2021	Murphy, Brona/0000-0002-6740-8858; Murphy, Brona/0000-0002-6740-8858; Creagh, Emma/0000-0001-7631-4370; Martin, Seamus/0000-0002-8539-3143; Duckett, Colin/0000-0001-9413-2263				Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 2002, CELL, V9, P1031; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rodriguez A, 2002, EMBO J, V21, P2189, DOI 10.1093/emboj/21.9.2189; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Shin H, 2003, BIOCHEM J, V373, P965, DOI 10.1042/BJ20030583; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	45	55	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26906	26914		10.1074/jbc.M313859200	http://dx.doi.org/10.1074/jbc.M313859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078891	hybrid, Green Published			2022-12-25	WOS:000222120400015
J	Hardy, MP; O'Neill, LAJ				Hardy, MP; O'Neill, LAJ			The murine Irak2 gene encodes four alternatively spliced isoforms, two of which are inhibitory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECEPTOR-ASSOCIATED KINASE; DNA-BINDING; INTERLEUKIN-1 RECEPTOR; EXPRESSION; ACTIVATION; FAMILY; MEMBER; MYD88; IDENTIFICATION	The interleukin-1 receptor-associated kinases (IRAKs) are important downstream signaling components of Toll-like receptors (TLRs). To date, four mammalian IRAKs have been found, namely IRAK-1, IRAK-2, IRAK-4, and IRAK-M. Herein, we show a detailed analysis of the genomic region encompassing the murine Irak2 gene and the molecular cloning of four isoforms of Irak2 ( designated Irak2a, Irak2b, Irak2c, and Irak2d) generated by alternative splicing at the 5'-end of the gene. This alternative splicing has direct effects on the expression of the N-terminal death domain and/or interdomain. No evidence of similar alternative splicing was found for the human IRAK2 gene. When overexpressed, Irak2a and Irak2b potentiated NF-kappaB activation by lipopolysaccharide. Importantly, Irak2c and Irak2d were inhibitory. The promoter for Irak2c differed from that of the other Irak2 isoforms in that it contained putative NF-kappaB binding sites. Lipopolysaccharide induced the expression of Irak2c, indicating a possible negative feedback effect on the signaling pathway. Alternative splicing of the Irak2 gene in mice will therefore generate agonistic or antagonistic Irak2 isoforms, which is likely to have consequences for the regulation of TLR signaling. These observations identify another distinguishing feature between mice and humans in the TLR system that is likely to be due to differences in the selective pressure imposed by pathogens on each species during evolution.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Biotechnol, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	O'Neill, LAJ (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Coll Green, Dublin 2, Ireland.	laoneill@tcd.ie		O'Neill, Luke/0000-0002-4333-2748				Bray N, 2003, GENOME RES, V13, P97, DOI 10.1101/gr.789803; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; DUNNE A, 2003, SCI STKE; GRILLI M, 1993, INT REV CYTOL, V143, P1; Hardy MP, 2002, BIOCHEM J, V365, P355, DOI 10.1042/BJ20020105; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Janssens S, 2003, FEBS LETT, V548, P103, DOI 10.1016/S0014-5793(03)00747-6; Janssens S, 2002, CURR BIOL, V12, P467, DOI 10.1016/S0960-9822(02)00712-1; Jensen LE, 2001, J BIOL CHEM, V276, P29037, DOI 10.1074/jbc.M103815200; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rosati O, 2002, BIOCHEM BIOPH RES CO, V297, P52, DOI 10.1016/S0006-291X(02)02130-7; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	27	85	96	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27699	27708		10.1074/jbc.M403068200	http://dx.doi.org/10.1074/jbc.M403068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15082713	Green Published, hybrid			2022-12-25	WOS:000222120400104
J	Patenaude, A; Ven Murthy, MR; Mirault, ME				Patenaude, A; Ven Murthy, MR; Mirault, ME			Mitochondrial thioredoxin system - Effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCATOR; RAT-LIVER MITOCHONDRIA; DEPENDENT PEROXIDE REDUCTASE; 2 SEPARATE SITES; HYDROGEN-PEROXIDE; HYDROPEROXIDE METABOLISM; MAMMALIAN PEROXIREDOXIN; MEMBRANE-PERMEABILITY; PYRIDINE-NUCLEOTIDES	Thioredoxin-2 (Trx2) is a mitochondrial protein-disulfide oxidoreductase essential for control of cell survival during mammalian embryonic development. This suggests that mitochondrial thioredoxin reductase-2 (TrxR2), responsible for reducing oxidized Trx2, may also be a key player in the regulation of mitochondria-dependent apoptosis. With this in mind, we investigated the effects of overexpression of TrxR2, Trx2, or both on mammalian cell responses to various apoptotic inducers. Stable transfectants of mouse Neuro2A cells were generated that overexpressed TrxR2 or an EGFP-TrxR2 fusion protein. EGFP-TrxR2 was enzymatically active and was localized in mitochondria. TrxR2 protein level and TrxR activity could be increased up to 6-fold in mitochondria. TrxR2 and EGFP-TrxR2 transfectants showed reduced growth rates as compared with control cells. This growth alteration was not due to cytotoxic effects nor related to changes in basal mitochondrial transmembrane potential (DeltaPsi(m)), reactive oxygen species production, or to other mitochondrial antioxidant components such as Trx2, peroxyredoxin-3, MnSOD, GPx1, and glutathione whose levels were not affected by increased TrxR2 activity. In response to various apoptotic inducers, the extent of DeltaPsi(m) dissipation, reactive oxygen species induction, caspase activation, and loss of viability were remarkably similar in TrxR2 and control transfectants. Excess TrxR2 did not prevent trichostatin A-mediated neuronal differentiation of Neuro2A cells nor did it protect them against beta-amyloid neurotoxicity. Neither massive glutathione depletion nor co-transfection of Trx2 and TrxR2 in Neuro2A ( mouse), COS-7 ( monkey), or HeLa ( human) cells revealed any differential cellular resistance to prooxidant or non-oxidant apoptotic stimuli. Our results suggest that neither Trx2 nor TrxR2 gain of function modified the redox regulation of mitochondria-dependent apoptosis in these mammalian cells.	Univ Laval, Dept Med, Fac Med, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Med Biol, Fac Med, Quebec City, PQ G1V 4G2, Canada; CHUL CHUQ, Med Res Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Mirault, ME (corresponding author), Univ Laval, Dept Med, Entre Hosp, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	memirault@crchul.ulaval.ca			NINDS NIH HHS [R01NS37718] Funding Source: Medline; PHS HHS [NMRI98001] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037718] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BELLOMO G, 1984, EUR J BIOCHEM, V140, P1, DOI 10.1111/j.1432-1033.1984.tb08058.x; Bilodeau JF, 2002, FREE RADICAL BIO MED, V33, P1279, DOI 10.1016/S0891-5849(02)01013-4; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Boveris A, 1977, Adv Exp Med Biol, V78, P67; Bravard A, 1999, FREE RADICAL BIO MED, V26, P1027, DOI 10.1016/S0891-5849(98)00299-8; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Byrne AM, 1999, HEPATOLOGY, V29, P1523, DOI 10.1002/hep.510290521; Calderon FH, 1999, J NEUROSCI RES, V56, P620; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Erlejman AG, 2002, NEUROCHEM RES, V27, P1499, DOI 10.1023/A:1021600522299; Franco AA, 1999, FREE RADICAL BIO MED, V27, P1122, DOI 10.1016/S0891-5849(99)00166-5; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Inokoshi J, 1999, BIOCHEM BIOPH RES CO, V256, P372, DOI 10.1006/bbrc.1999.0316; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kawai H, 2000, GENE, V242, P321, DOI 10.1016/S0378-1119(99)00498-9; Kim MR, 2003, BIOCHEM BIOPH RES CO, V304, P119, DOI 10.1016/S0006-291X(03)00547-3; KOSOWER EM, 1972, BIOCHIM BIOPHYS ACTA, V264, P39, DOI 10.1016/0304-4165(72)90114-6; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Macho A, 1997, J IMMUNOL, V158, P4612; MANIATIS T, 1989, MOL CLONING LAB MANU, V3, P33; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Miranda-Vizuete A, 1999, BBA-GENE STRUCT EXPR, V1447, P113, DOI 10.1016/S0167-4781(99)00129-3; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; MOORE GA, 1986, XENOBIOTICA, V16, P873, DOI 10.3109/00498258609038969; MUSSER DA, 1994, PHOTOCHEM PHOTOBIOL, V59, P621; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nonn L, 2003, MOL CANCER RES, V1, P682; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Plaisant F, 2003, FREE RADICAL BIO MED, V34, P862, DOI 10.1016/S0891-5849(02)01440-5; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; Rigobello MP, 2002, BRIT J PHARMACOL, V136, P1162, DOI 10.1038/sj.bjp.0704823; SAXENA K, 1995, ARCH BIOCHEM BIOPHYS, V317, P79, DOI 10.1006/abbi.1995.1138; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; STOYANOVSKY D, 1993, FREE RADICAL RES COM, V19, P371, DOI 10.3109/10715769309056527; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VANMAANEN JMS, 1988, FREE RADICAL RES COM, V4, P371, DOI 10.3109/10715768809066905; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Watabe S, 1999, EUR J BIOCHEM, V264, P74, DOI 10.1046/j.1432-1327.1999.00578.x; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; Wudarczyk J, 1996, ARCH BIOCHEM BIOPHYS, V327, P215, DOI 10.1006/abbi.1996.0112; YAMAMOTO T, 1989, GENE, V80, P337; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2002, METHOD ENZYMOL, V347, P236; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	84	92	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27302	27314		10.1074/jbc.M402496200	http://dx.doi.org/10.1074/jbc.M402496200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15082714	hybrid			2022-12-25	WOS:000222120400060
J	Morgan, MR; Thomas, GJ; Russell, A; Hart, IR; Marshall, JF				Morgan, MR; Thomas, GJ; Russell, A; Hart, IR; Marshall, JF			The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE B SECRETION; ALPHA(V)BETA(3) INTEGRIN; ALPHA-V-BETA-6 INTEGRIN; TERMINAL DIFFERENTIATION; IN-VIVO; EXPRESSION; CARCINOMA; ANGIOGENESIS; ACTIVATION; RECEPTORS	Integrins promote cellular invasion through a combination of activities, including adhesion to an extracellular matrix ligand, which result in the generation of intracellular signals that lead to changes in cell behavior. Until now, there have been no data that identify a particular region of the cytoplasmic tail of integrin subunits as being responsible specifically for promoting the invasive activity of tumor cells. In this report, we show that amino acids with the sequence EKQKVDLSTDC, which are the C-terminal residues of the integrin beta6 subunit, promote alphavbeta6-dependent invasion in a matrix metalloproteinase (MMP)-9-dependent fashion. This same peptide sequence, when expressed at the cytoplasmic end of the beta3 integrin subunit, was able to enhance alphavbeta3-mediated invasive and enzymatic activity of tumor cells in an MMP-2-dependent fashion. Our results show that these 11 amino acids, when expressed at the C terminus of the beta subunit, are responsible for regulating the activity of invasion-promoting degradative enzymes, whereas the specific MMP involved in this cellular behavior is dependent on the context of the remainder of the beta integrin subunit.	John Vane Sci Ctr, Barts & London Sch Med & Dent, Canc Res UK Clin Ctr, Tumour Biol Lab, London EC1M 6BQ, England; UCL Eastman Dent Inst, London WC1X 8LD, England; Stanford Univ, Med Ctr, Dept Dermatol, Stanford, CA 94305 USA	Cancer Research UK; University of London; Queen Mary University London; University of London; University College London; Stanford University	Marshall, JF (corresponding author), John Vane Sci Ctr, Barts & London Sch Med & Dent, Canc Res UK Clin Ctr, Tumour Biol Lab, Charterhouse Sq, London EC1M 6BQ, England.	john.marshall@cancer.org.uk		Russell, Alan/0000-0001-7545-5008; Morgan, Mark/0000-0001-7728-9883; Marshall, John/0000-0002-0494-2295				Agrez M, 1999, INT J CANCER, V81, P90, DOI 10.1002/(SICI)1097-0215(19990331)81:1<90::AID-IJC16>3.0.CO;2-K; Agrez MV, 1996, BRIT J CANCER, V73, P887, DOI 10.1038/bjc.1996.158; Ahmed N, 2002, J HISTOCHEM CYTOCHEM, V50, P1371, DOI 10.1177/002215540205001010; Ahmed N, 2002, CARCINOGENESIS, V23, P237, DOI 10.1093/carcin/23.2.237; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; BREUSS JM, 1995, J CELL SCI, V108, P2241; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cass DL, 1998, J PEDIATR SURG, V33, P312, DOI 10.1016/S0022-3468(98)90453-5; Chatterjee N, 2001, J Environ Pathol Toxicol Oncol, V20, P211; Chattopadhyay N, 2001, J EXP CLIN CANC RES, V20, P269; ChristofidouSolomidou M, 1997, AM J PATHOL, V151, P975; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; Davidson B, 2002, MOL CELL ENDOCRINOL, V187, P39, DOI 10.1016/S0303-7207(01)00709-2; Di Nezza LA, 2002, CANCER, V94, P1466, DOI 10.1002/cncr.10355; Eliceiri BP, 2000, CANCER J, V6, pS245; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Furukawa A, 1998, UROLOGY, V51, P849, DOI 10.1016/S0090-4295(98)00010-7; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Jones J, 1996, ONCOGENE, V12, P119; Kerr JS, 2001, DRUG NEWS PERSPECT, V14, P143; Kumar CC, 2003, CURR DRUG TARGETS, V4, P123, DOI 10.2174/1389450033346830; LEONE D, 2003, P AM ASSOC CANC RES, V44, P4069; Li XW, 2001, J CELL SCI, V114, P2665; Liabakk NB, 1996, CANCER RES, V56, P190; Liapis H, 1997, HUM PATHOL, V28, P443, DOI 10.1016/S0046-8177(97)90033-2; Niu J, 2002, INT J CANCER, V99, P529, DOI 10.1002/ijc.10397; Niu J, 1998, BIOCHEM BIOPH RES CO, V249, P287, DOI 10.1006/bbrc.1998.9128; Park DW, 2001, GYNECOL ONCOL, V82, P442, DOI 10.1006/gyno.2001.6294; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Ria T, 2002, HAEMATOLOGICA, V87, P836; Scatena MT, 2002, TRENDS CARDIOVAS MED, V12, P83, DOI 10.1016/S1050-1738(01)00151-7; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; SMYTHE WR, 1995, CANCER METAST REV, V14, P229, DOI 10.1007/BF00690294; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Thomas GJ, 2001, J INVEST DERMATOL, V116, P898, DOI 10.1046/j.1523-1747.2001.01352.x; Vacca A, 2001, EXP HEMATOL, V29, P993, DOI 10.1016/S0301-472X(01)00674-9; Varner Judith A., 1996, P69; Xue H, 2001, BIOCHEM BIOPH RES CO, V288, P610, DOI 10.1006/bbrc.2001.5813; Yang XQ, 2001, J SURG RES, V98, P33, DOI 10.1006/jsre.2001.6150; Zhang HY, 2002, INVEST OPHTH VIS SCI, V43, P955	54	43	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26533	26539		10.1074/jbc.M401736200	http://dx.doi.org/10.1074/jbc.M401736200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15067014	hybrid			2022-12-25	WOS:000222003000077
J	Nguyen, N; Zhang, XH; Olashaw, N; Seto, E				Nguyen, N; Zhang, XH; Olashaw, N; Seto, E			Molecular cloning and functional characterization of the transcription factor YY2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YIN-YANG 1; LIPOPROTEIN RECEPTOR GENE; ELEMENT-BINDING PROTEIN; ZINC-FINGER PROTEIN; C-FOS PROMOTER; ADENOVIRUS E1A; REGULATORY ELEMENTS; MAMMALIAN-CELLS; XENOPUS OOCYTES; LEUCINE ZIPPER	YY1 is a ubiquitous zinc finger transcription factor that binds to and regulates promoters and enhancers of many cellular and viral genes. Here we report the isolation of a human cDNA encoding a DNA sequence-specific binding protein with significant homology to the transcription factor YY1. A sequence analysis of this novel protein, YY2, revealed an overall 65% identity in the DNA sequence and a 56% identity in protein sequence compared with human YY1. The most pronounced similarity between YY1 and YY2 exists within the zinc finger regions of the two proteins, and consistent with this observation, YY2 can bind to and regulate some promoters known to be controlled by YY1. Similar to YY1, YY2 contains both transcriptional activation and repression functions. The finding of a protein with structure and function similar to YY1 provides a new opportunity to explore additional mechanisms by which YY1-responsive genes can be regulated and suggests that gene regulation by YY1 is far more complicated than previously assumed.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Seto, E (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	setoe@moffitt.usf.edu			NIGMS NIH HHS [GM64850] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064850] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atchison L, 2003, EMBO J, V22, P1347, DOI 10.1093/emboj/cdg124; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Bergad PL, 2000, J BIOL CHEM, V275, P8114, DOI 10.1074/jbc.275.11.8114; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Ficzycz A, 2002, J BIOL CHEM, V277, P8382, DOI 10.1074/jbc.M110304200; Ficzycz A, 2001, J BIOL CHEM, V276, P22819, DOI 10.1074/jbc.M011188200; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hasegawa A, 2001, J IMMUNOL, V166, P1125, DOI 10.4049/jimmunol.166.2.1125; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; Last TJ, 1999, J CELL BIOCHEM, V72, P507, DOI 10.1002/(SICI)1097-4644(19990315)72:4<507::AID-JCB6>3.0.CO;2-5; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1994, ONCOGENE, V9, P1047; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; Moriuchi M, 1999, J IMMUNOL, V162, P5986; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Roy B, 1996, ONCOGENE, V13, P2359; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Sucharov CC, 2003, J BIOL CHEM, V278, P31233, DOI 10.1074/jbc.M301917200; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; *WA U GEN SEQ CTR, 1998, GENOME RES, V8, P1097; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Ye JP, 1996, MOL CELL BIOL, V16, P157; Ye JP, 1996, MOL CELL BIOL, V16, P4744; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995	64	49	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25927	25934		10.1074/jbc.M402525200	http://dx.doi.org/10.1074/jbc.M402525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15087442	hybrid			2022-12-25	WOS:000221827900125
J	Sanaa, N; Hmama, Z; Reiner, NE				Sanaa, N; Hmama, Z; Reiner, NE			Dual receptors and distinct pathways mediate interleukin-1 receptor-associated kinase degradation in response to lipopolysaccharide - Involvement of CD14/TLR4, CR3, and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PERMEABILITY-INCREASING PROTEIN; ENDOTOXIN-TOLERANT CELLS; TOLL SIGNALING PATHWAY; LPS-BINDING-PROTEIN; HUMAN-MONOCYTES; BACTERIAL LIPOPOLYSACCHARIDE; ENDOTHELIAL-CELLS; BORRELIA-BURGDORFERI; TYROSINE KINASE	Lipopolysaccharide (LPS) signaling leading to nuclear factor-kappaB activation in mononuclear phagocytes involves interleukin-1 receptor-associated kinase ( IRAK), which is rapidly activated after exposure to agonist. Although it is known that IRAK also undergoes rapid inactivation/degradation in response to LPS, providing negative feedback leading to LPS tolerance, mechanisms governing IRAK degradation are not fully understood. In the present study, examination of LPS signaling showed that IRAK degradation was bimodal and involved dual receptors and distinct pathways. Rapid degradation of IRAK, occurring within 30 min of exposure to agonist, was shown to signal through CD14/TLR4 and was regulated by phosphatidylinositol 3-kinase. A second delayed wave of IRAK degradation occurred 2 h after exposure to LPS and was mediated by CR3 independently of phosphatidylinositol 3-kinase. Thus, multiple independent mechanisms have evolved to regulate IRAK degradation, likely reflecting the importance of limiting cellular responses to LPS. Recognition of a CR3-dependent, CD14/TLR4-independent pathway leading to IRAK degradation has implications for understanding modulation of LPS responses by cells with important immunoregulatory function such as dendritic cells that are CD14(-).	Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Med, Dept Microbiol & Immunol, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Sci, Vancouver, BC V5Z 3J5, Canada; Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 3J5, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Reiner, NE (corresponding author), Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Rm 452D,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.	ethan@interchange.ubc.ca						Ammon C, 2000, IMMUNOLOGY, V100, P364, DOI 10.1046/j.1365-2567.2000.00056.x; Baltathakis L, 2001, J CELL BIOCHEM, V83, P281, DOI 10.1002/jcb.1231; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; CAMUSSI G, 1995, J IMMUNOL, V155, P316; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Flaherty SF, 1997, J SURG RES, V73, P85, DOI 10.1006/jsre.1997.5195; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; HAZIOT A, 1988, J IMMUNOL, V141, P547; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hu J, 2002, J IMMUNOL, V168, P3910, DOI 10.4049/jimmunol.168.8.3910; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; JIN HK, 1995, J CLIN INVEST, V95, P1947, DOI 10.1172/JCI117877; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; KOHN FR, 1993, J INFECT DIS, V168, P1307, DOI 10.1093/infdis/168.5.1307; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li XW, 2003, INFECT IMMUN, V71, P4414, DOI 10.1128/IAI.71.8.4414-4420.2003; LIU MK, 1994, J IMMUNOL, V153, P2642; Mayeux PR, 1997, J TOXICOL ENV HEALTH, V51, P415, DOI 10.1080/00984109708984034; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Means TK, 1999, J IMMUNOL, V163, P6748; Medvedev AE, 1998, J IMMUNOL, V160, P4535; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Perera PY, 1997, J IMMUNOL, V158, P4422; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, TRENDS GENET, V15, P291, DOI 10.1016/S0168-9525(99)01782-5; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Ropert C, 2003, J IMMUNOL, V171, P1456, DOI 10.4049/jimmunol.171.3.1456; Salh B, 1998, J IMMUNOL, V161, P6947; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Sellati TJ, 1998, J IMMUNOL, V160, P5455; SHAPIRA L, 1994, J IMMUNOL, V153, P1818; Shi C, 2001, CIRC RES, V89, P859, DOI 10.1161/hh2201.099166; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; TODD RF, 1981, J IMMUNOL, V126, P1435; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Wooten RM, 1998, J IMMUNOL, V160, P5485; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	60	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25189	25195		10.1074/jbc.M312431200	http://dx.doi.org/10.1074/jbc.M312431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069085	hybrid			2022-12-25	WOS:000221827900035
J	Shie, JL; Wu, GF; Wu, JP; Liu, FF; Laham, RJ; Oettgen, P; Li, J				Shie, JL; Wu, GF; Wu, JP; Liu, FF; Laham, RJ; Oettgen, P; Li, J			RTEF-1, a novel transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HEAVY-CHAIN GENE; CAT BINDING-FACTOR; ENHANCER FACTOR-I; SMOOTH-MUSCLE-CELLS; TROPONIN-T-GENE; CARDIAC MYOCYTES; FACTOR-BETA; FACTOR EXPRESSION; SKELETAL-MUSCLE	Vascular endothelial growth factor (VEGF) is an angiogenic growth factor known to be up-regulated in ischemic heart and hypoxic endothelial cells. However, the transcriptional regulation of VEGF in hypoxia-induced angiogenesis is not fully understood. Transcriptional enhancer factor-1 (TEF-1) is a transcriptional factor family that can regulate many genes expressed in cardiac and skeletal muscle cells by binding to myocyte-specific chloramphenicol acetyltransferase heptamer elements in the promoters of these genes. In this study, we demonstrated that related TEF-1 (RTEF-1), a member of the TEF-1 family, is up-regulated in hypoxic endothelial cells. Overexpression of RTEF-1 increases VEGF promoter activity and VEGF expression. Sequential deletion and site-directed mutation analyses of the VEGF promoter demonstrated that a GC-rich region containing four Sp1 response elements, located between -114 and -50, was essential for RTEF-1 function. This region is beyond the hypoxia-inducible factor-1alpha binding site and does not consist of M-CAT-related elements. By electrophoretic mobility shift assay, RTEF-1 was found to interact with the first Sp1 residue (-97 to -87) of the four consecutive Sp1 elements. Binding activity of RTEF-1 to VEGF promoter is also confirmed by chromatin immunoprecipitation. In addition, induction of VEGF promoter activity by RTEF-1 results in an increase of angiogenic processes including endothelial cells proliferation and vascular structure formation. These results indicate that RTEF-1 acts as a transcriptional stimulator of VEGF by regulating VEGF promoter activity through binding to Sp1 site. In addition, RTEF-1-induced VEGF promoter activity was enhanced in a hypoxic condition, indicating that RTEF-1 may play an important role in the regulation of VEGF under hypoxia.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Li, J (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiol, 330 Brookline Ave, Boston, MA 02215 USA.	jli@caregroup.harvard.edu	Oettgen, Peter/AAF-5026-2021	Wu, Guifu/0000-0002-2823-6643	NHLBI NIH HHS [R01 HL082837, HL07374-22] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082837, T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Benckert C, 2003, CANCER RES, V63, P1083; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brenneisen P, 2003, BIOCHEM J, V369, P341, DOI 10.1042/BJ20021032; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FLINK IL, 1992, J BIOL CHEM, V267, P9917; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Li J, 2002, J CELL SCI, V115, P1951; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Li J, 1997, J CLIN INVEST, V100, P18, DOI 10.1172/JCI119510; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Oettgen P, 2001, CIRC RES, V89, P380, DOI 10.1161/hh1701.095958; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Sen CK, 2002, AM J PHYSIOL-HEART C, V282, pH1821, DOI 10.1152/ajpheart.01015.2001; Sharma H S, 1992, EXS, V61, P255; SHARMA HS, 1992, J CARDIOVASC PHARM, V20, pS23, DOI 10.1097/00005344-199206201-00006; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; Tsoporis JN, 2003, AM J PHYSIOL-HEART C, V284, pH193, DOI 10.1152/ajpheart.00161.2002; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001	59	39	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25010	25016		10.1074/jbc.M403103200	http://dx.doi.org/10.1074/jbc.M403103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073166	hybrid			2022-12-25	WOS:000221827900015
J	Espert, L; Rey, C; Gonzalez, L; Degols, G; Chelbi-Alix, MK; Mechti, N; Gongora, C				Espert, L; Rey, C; Gonzalez, L; Degols, G; Chelbi-Alix, MK; Mechti, N; Gongora, C			The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappa B and IRF1 activation	ONCOGENE			English	Article						ISG20; dsRNA; NF-kappa B; IRF1; transcription; interferon	DOUBLE-STRANDED-RNA; REGULATORY FACTOR-I; PROTEIN-KINASE-R; GENE-EXPRESSION; NUCLEAR-MATRIX; VIRUS; APOPTOSIS; INDUCTION; PATHWAY; STRESS	Many interferon (IFN)-stimulated genes are also induced by double-stranded RNA (dsRNA), a component closely associated with the IFN system in the context of virus-host interactions. Recently, we demonstrated that the IFN-induced 3' --> 5' exonuclease ISG20 possesses antiviral activities against RNA viruses. Here we show that ISG20 induction by synthetic dsRNA (pIpC) is stronger and faster than its induction by IFN. Two families of transcription factors are implicated in the transcriptional activation of ISG20 by dsRNA. Initially, the NF-kappaB factors p50 and p65 bind and activate the kappaB element of the Isg20 promoter. This is followed by IRFI binding to the ISRE. As pIpC often induces protein movements in the cells, we questioned whether it could influence ISG20 localization. Interestingly and contrary to IFN, dsRNA induces a nuclear matrix enrichment of the ISG20 protein. dsRNA induction of ISG20 via NF-kappaB and its antiviral activity led us to suggest that ISG20 could participate in the cellular response to virus infection.	CNRS, UMR 5160, EFS, F-34094 Montpellier 5, France; Inst Andre Lwoff, CNRS, UPR 9045, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Gongora, C (corresponding author), CNRS, UMR 5160, EFS, 240 Ave Emile Jeanbrau, F-34094 Montpellier 5, France.	celine.gongora@ibph.pharma.univ.montp1.fr	Espert, Lucile/ABF-5614-2021	GONGORA, Celine/0000-0001-9034-4031				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Behr M, 2001, J INTERF CYTOK RES, V21, P981, DOI 10.1089/107999001753289596; Blair LA, 2002, J BIOL CHEM, V277, P359, DOI 10.1074/jbc.M109819200; Deppert W, 2000, CRIT REV EUKAR GENE, V10, P45; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Espert L, 2003, J BIOL CHEM, V278, P16151, DOI 10.1074/jbc.M209628200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Hummer BT, 2001, J VIROL, V75, P7774, DOI 10.1128/JVI.75.16.7774-7777.2001; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kehoe KE, 2001, J IMMUNOL, V167, P2496, DOI 10.4049/jimmunol.167.5.2496; Mori K, 2001, MOL CELL ENDOCRINOL, V184, P77, DOI 10.1016/S0303-7207(01)00641-4; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; Okorokov AL, 2002, ONCOGENE, V21, P356, DOI 10.1038/sj.onc.1205112; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Roti JLR, 1997, CRIT REV EUKAR GENE, V7, P343, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.30; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; TEN RM, 1993, CR ACAD SCI III-VIE, V316, P496; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	31	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4636	4640		10.1038/sj.onc.1207586	http://dx.doi.org/10.1038/sj.onc.1207586			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064705				2022-12-25	WOS:000221799000013
J	Castedo, M; Perfettini, JL; Roumier, T; Yakushijin, K; Horne, D; Medema, R; Kroemer, G				Castedo, M; Perfettini, JL; Roumier, T; Yakushijin, K; Horne, D; Medema, R; Kroemer, G			The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe	ONCOGENE			English	Article						aneuploidy; cancer; caspases; Chk-2; programmed cell death	DNA-DAMAGE CHECKPOINT; GLYCOPROTEIN COMPLEX; APOPTOSIS; ACTIVATION; P53; PHOSPHORYLATION; LOCALIZATION; CHECKING; CDC25C; DEATH	Fusion between nonsynchronized cells leads to the formation of heterokarya which transiently activate Cyclin-dependent kinase 1 (Cdk1)/cyclin B1 and enter the prophase of the cell cycle, where they arrest due to a loss of Cdk1/cyclin B1 activity, activate p53, disorganize centrosomes, and undergo apoptosis. Here, we show that the down regulation of Cdk1/cyclin B is secondary to the activation of the DNA structure checkpoint kinase Chk2. Thus, syncytia generated by the fusion of asynchronous HeLa cells contain elevated levels of active Chk2 but not Chk1. Chk2 bearing the activating phosphorylation on threonine-68 accumulates in BRCA1 nuclear bodies when the cells arrest at the G2/M boundary. Inhibition of Chk2 by transfection of a dominant-negative Chk2 mutant or a chemical inhibitor, debromohymenialdesine, stabilizes centrosomes, maintains high cyclin B1 levels, and allows for a prolonged activation of Cdk1. Under these conditions, multinuclear HeLa syncytia do not arrest at the G2/M boundary and rather enter mitotis and subsequently die during the metaphase of the cell cycle. This mitotic catastrophe is associated with the activation of the proapoptotic caspase-3. Inhibition of caspases allows the cells to go beyond the metaphase arrest, indicating that apoptosis is responsible for cell death by mitotic catastrophe. In another, completely different model of mitotic catastrophe, namely 14.3.3sigma-deficient HCT116 colon carcinoma cells treated with doxorubicin, Chk2 activation was also found to be deficient as compared to 14.3.3sigma-sufficient controls. Inhibition of Chk2 again facilitated the induction of mitotic catastrophe in HCT116 wild-type cells. In conclusion, a conflict in cell cycle progression or DNA damage can lead to mitotic catastrophe, provided that the checkpoint kinase Chk2 is inhibited. Inhibition of Chk2 thus can sensitize proliferating cells to chemotherapy-induced apoptosis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA; Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Oregon State University; Netherlands Cancer Institute	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Medema, Rene H/E-2981-2013; KROEMER, Guido/B-4263-2013; PERFETTINI, Jean-Luc/N-4699-2017; Medema, Rene H/G-5415-2011; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Medema, Rene/0000-0002-6754-0381				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirose Y, 2001, CANCER RES, V61, P5843; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lock RB, 1996, CANCER RES, V56, P4006; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mackey MA, 1996, CANCER RES, V56, P1770; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PERFETTINI JL, 2004, IN PRESS J EXP MED; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roumier T, 2003, BIOCHEM PHARMACOL, V66, P1321, DOI 10.1016/S0006-2952(03)00480-5; Senderowicz AM, 2003, CANCER CHEMOTH PHARM, V52, pS61, DOI 10.1007/s00280-003-0624-x; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Shieh SY, 2000, GENE DEV, V14, P289; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Sosa ACB, 2000, J ORG CHEM, V65, P610, DOI 10.1021/jo991277o; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Xu JH, 2003, FEBS LETT, V545, P209, DOI 10.1016/S0014-5793(03)00536-2; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yu Q, 2002, CANCER RES, V62, P5743	46	136	144	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4353	4361		10.1038/sj.onc.1207573	http://dx.doi.org/10.1038/sj.onc.1207573			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15048074				2022-12-25	WOS:000221661300001
J	Castedo, M; Perfettini, JL; Roumier, T; Valent, A; Raslova, H; Yakushijin, K; Horne, D; Feunteun, J; Lenoir, G; Medema, R; Vainchenker, W; Kroemer, G				Castedo, M; Perfettini, JL; Roumier, T; Valent, A; Raslova, H; Yakushijin, K; Horne, D; Feunteun, J; Lenoir, G; Medema, R; Vainchenker, W; Kroemer, G			Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy	ONCOGENE			English	Article						aneuploidy; cancer; caspases; Chk-2; programmed cell death	CYTOCHROME-C RELEASE; GLYCOPROTEIN COMPLEX; CHECKPOINT KINASE-2; TUMOR-CELLS; MITOCHONDRIA; CASPASE-2; P53; INSTABILITY; CANCER; ACTIVATION	A conflict in cell cycle progression or DNA damage can lead to mitotic catastrophe when the DNA structure checkpoints are inactivated, for instance when the checkpoint kinase Chk2 is inhibited. Here we show that in such conditions, cells die during the metaphase of the cell cycle, as a result of caspase activation and subsequent mitochondrial damage. Molecular ordering of these phenomena reveals that mitotic catastrophe occurs in a p53-independent manner and involves a primary activation of caspase-2, upstream of cytochrome c release, followed by caspase-3 activation and chromatin condensation. Suppression of caspase-2 by RNA interference or pseudosubstrate inhibitors as well as blockade of the mitochondrial membrane permeabilization prevent the mitotic catastrophe and allow cells to further proceed the cell cycle beyond the metaphase, leading to asymmetric cell division. Heterokarya generated by the fusion of nonsynchronized cells can be driven to divide into three or more daughter cells when Chk2 and caspases are simultaneously inhibited. Such multipolar divisions, resulting from suppressed mitotic catastrophe, lead to the asymmetric distribution of cytoplasm (anisocytosis), DNA (anisokaryosis) and chromosomes (aneuploidy). Similarly, in a model of DNA damage-induced mitotic catastrophe, suppression of apoptosis leads to the generation of aneuploid cells. Our findings delineate a molecular pathway through which DNA damage, failure to arrest the cell cycle and inhibition of apoptosis can favor the occurrence of cytogenetic abnormalities that are likely to participate in oncogenesis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Lab Gen Cellulaire Canc, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA; Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Oregon State University; Netherlands Cancer Institute	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Feunteun, Jean/AAZ-1267-2020; PERFETTINI, Jean-Luc/N-4699-2017; Raslova, Hana/N-3562-2018; Medema, Rene H/E-2981-2013; KROEMER, Guido/B-4263-2013; Medema, Rene H/G-5415-2011; Kroemer, Guido/AAY-9859-2020	PERFETTINI, Jean-Luc/0000-0002-2427-2604; Raslova, Hana/0000-0001-8846-5299; KROEMER, Guido/0000-0002-9334-4405; Feunteun, Jean/0000-0003-1212-9189; Medema, Rene/0000-0002-6754-0381; Vainchenker, William/0000-0003-4705-202X				Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Choma D, 2001, BRIT J CANCER, V85, P14, DOI 10.1054/bjoc.2001.1892; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DeWitt N, 2002, NATURE, V416, P354, DOI 10.1038/416354a; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Ferri KF, 2000, EXP CELL RES, V261, P119, DOI 10.1006/excr.2000.5062; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lock RB, 1996, CANCER RES, V56, P4006; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; Raslova H, 2003, BLOOD, V101, P541, DOI 10.1182/blood-2002-05-1553; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; Ruth AC, 2000, CANCER RES, V60, P2576; Shih IM, 2001, CANCER RES, V61, P818; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Sosa ACB, 2000, J ORG CHEM, V65, P610, DOI 10.1021/jo991277o; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tort F, 2002, BLOOD, V100, P4602, DOI 10.1182/blood-2002-04-1078; Valent A, 2001, AM J PATHOL, V158, P1579, DOI 10.1016/S0002-9440(10)64112-0; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XD, 2001, GENE DEV, V15, P2922; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	54	252	263	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4362	4370		10.1038/sj.onc.1207572	http://dx.doi.org/10.1038/sj.onc.1207572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15048075				2022-12-25	WOS:000221661300002
J	Brignone, C; Bradley, KE; Kisselev, AF; Grossman, SR				Brignone, C; Bradley, KE; Kisselev, AF; Grossman, SR			A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway	ONCOGENE			English	Article						p53; hHR23; Rad23; MDM2; proteasome; ubiquitin	DNA-REPAIR; UBA DOMAINS; PROTEASOME; PROTEIN; RAD23; BINDING; PROMOTES; SUBUNIT; STABILITY; INTERACT	Abrogation of ubiquitin/proteasome-dependent turnover of p53 is critical for its activation. UbL-UBA proteins, including human homolog of Rad23 (hHR23) proteins, may regulate proteasomal degradation of substrates such as p53, due to their ability to interact with both ubiquitinated substrates and the proteasome. siRNA-mediated depletion of hHR23A or hHR23B in human cell lines accelerated p53 degradation. In contrast, overexpression of hHR23 proteins led to the accumulation of ubiquitinated p53, and purified hHR23 proteins also blocked p53 proteasome degradation in vitro. An hHR23-MDM2 complex was identified, suggesting that MDM2 and hHR23 cooperate in the regulation of p53 proteasome degradation. Consistent with this hypothesis, an MDM2 mutant that demonstrated increased binding in vivo to hHR23A was able to ubiquitinate, but not degrade p53. Moreover, the defective phenotype of this MDM2 mutant was rescued by siRNA knockdown of hHR23A. Our data indicate that MDM2 acts at a step in the p53 degradation pathway after ubiquitination, to counteract hHR23 inhibition of p53 turnover. Moreover, our data suggest the possibility that ubiquitin ligase/UbL-UBA protein complexes, as exemplified by the MDM2/hHR23 complex, may serve a general role in regulating substrate degradation by the proteasome.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Grossman, SR (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA.	steven.grossman@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA107532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147, R01GM051923] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA107532, R01 CA107532-01] Funding Source: Medline; NIGMS NIH HHS [GM46147-10, GM51923-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Lambertson D, 1999, GENETICS, V153, P69; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEI X, 2003, J BIOL CHEM; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Zhu QZ, 2001, CANCER RES, V61, P64; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	25	57	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4121	4129		10.1038/sj.onc.1207540	http://dx.doi.org/10.1038/sj.onc.1207540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064742				2022-12-25	WOS:000221520200010
J	Strand, S; Vollmer, P; van den Abeelen, L; Gottfried, D; Alla, V; Heid, H; Kuball, J; Theobald, M; Galle, PR; Strand, D				Strand, S; Vollmer, P; van den Abeelen, L; Gottfried, D; Alla, V; Heid, H; Kuball, J; Theobald, M; Galle, PR; Strand, D			Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells	ONCOGENE			English	Article						CD95; MMP-7; apoptosis; immune evasion	FAS LIGAND; SOLUBLE FAS; IN-VIVO; SERUM; ESCAPE; KILL	The ability of tumour cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumour elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumour cells. We propose a new strategy by which tumour cells can resist CD95-induced apoptosis. We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance because it is produced by the tumour cells themselves at early stages of tumour development. Microsequencing of the positions in CD95 cleaved by MMP-7 revealed two sites in the N-terminal extracellular domain of CD95, important for preligand assembly of CD95. MMP-7 cleavage of CD95 results in reduced CD95 surface expression and decreased CD95-mediated apoptosis sensitivity of tumour cells. Treatment of MMP-7-positive HT-29 tumour cells with MMP-7-antisense oligonucleotides led to an increase in CD95-mediated apoptosis sensitivity. Finally, specific cytotoxic T-cell killing was reduced in the presence of MMP-7. Thus, MMP-7 expression in tumour cells may contribute to an apoptosis-resistant phenotype, which ultimately promotes immune escape. This activity may account for the well-established role of MMP-7 in early tumour development.	Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany; German Canc Res Ctr, Dept Cell Biol, D-69120 Heidelberg, Germany; Johannes Gutenberg Univ Mainz, Dept Hematol & Oncol, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ); Johannes Gutenberg University of Mainz	Strand, D (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Obere Zahlbacherstr 63, D-55101 Mainz, Germany.	sstrand@mail.uni-mainz.de	Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992				Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lustgarten J, 1997, HUM IMMUNOL, V52, P109, DOI 10.1016/S0198-8859(96)00292-3; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mitsiades N, 2001, CANCER RES, V61, P577; Mizutani Y, 2001, CANCER, V92, P287, DOI 10.1002/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nonomura N, 2000, UROLOGY, V55, P151, DOI 10.1016/S0090-4295(99)00379-9; Osorio LM, 2001, EUR J HAEMATOL, V66, P342, DOI 10.1034/j.1600-0609.2001.066005342.x; Pikul S, 1998, J MED CHEM, V41, P3568, DOI 10.1021/jm980253r; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; Seki N, 2002, J IMMUNOL, V168, P3484, DOI 10.4049/jimmunol.168.7.3484; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Theobald M, 1995, P NATL ACAD SCI USA, V92, P11993, DOI 10.1073/pnas.92.26.11993; Ugurel S, 2001, CLIN CANCER RES, V7, P1282; Vargo-Gogola T, 2002, CANCER RES, V62, P5559; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Woessner J.F., 2000, PROTEIN PROFILE SER	30	95	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3732	3736		10.1038/sj.onc.1207387	http://dx.doi.org/10.1038/sj.onc.1207387			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077180				2022-12-25	WOS:000221101700027
J	Karakashian, AA; Giltiay, NV; Smith, GM; Nikolova-Karakashian, MN				Karakashian, AA; Giltiay, NV; Smith, GM; Nikolova-Karakashian, MN			Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation	FASEB JOURNAL			English	Article						ceramide; PP2A; plasma membrane; IRAK	RECEPTOR-ASSOCIATED KINASE; TUMOR-NECROSIS-FACTOR; CYTOCHROME-P450 2C11 CYP2C11; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; SUBCELLULAR-LOCALIZATION; ACID SPHINGOMYELINASE; CELL-DIFFERENTIATION; FREE SPHINGOSINE	Neutral sphingomyelinase (NSMase) has been proposed to mediate interleukin (IL)-1beta signaling in liver. In this paper, we used adenovirus-mediated gene transfer to inducibly express FLAG-tagged mouse NSMase-2 in primary rat hepatocytes in order to further elucidate the molecular nature of the NSMase involved. Initial studies confirmed that the EST clone used in these experiments encoded a Mg2+-dependent NSMase. The in vitro activity of the heterologously expressed enzyme was inhibited in the presence of 0.5% Triton or 50 mM EDTA. In addition, the expression of this NSMase-2 clone in primary hepatocytes led to increased cellular levels of ceramide, indicating that the enzyme is active in situ. Immunofluorescence studies in Hep G2 cells infected with NSMase-2 expressing adenoviruses showed that the FLAG-tagged NSMase-2 was localized to the plasma membrane. Cell viability remained unchanged 72 h following infection and induction. The effect of NSMase-2 expression on IL-1beta-induced activation of c-Jun N-terminal kinase (JNK) was tested. Expression of NSMase-2 increased JNK phosphorylation between 1.5- and 2-fold over the basal level. Furthermore, NSMase-2 was found to strongly increase the ability of IL-1beta to phosphorylate JNK. This potentiation was mediated by a phosphatase from the PP2A family, possibly by modulating the phosphorylation pattern of IL-1beta receptor-associated kinase (IRAK). In conclusion, the data presented suggest that NSMase-2 could be involved in IL-1beta-induced JNK activation in hepatocytes.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky	Nikolova-Karakashian, MN (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, MS 508,800 Rose St, Lexington, KY 40536 USA.	mnikolo@uky.edu	Giltiay, Natalia V./H-8655-2019; Giltiay, Natalia/AAH-2130-2019	Giltiay, Natalia/0000-0001-7284-514X	NIA NIH HHS [R03 AG19435, R01 AG019223-01A2, R01 AG019223] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG019435, R01AG019223] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hayashi Y, 1997, J BIOL CHEM, V272, P18082, DOI 10.1074/jbc.272.29.18082; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hernandez OM, 2000, CIRC RES, V86, P198, DOI 10.1161/01.RES.86.2.198; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; HOSTETLER KY, 1979, J LIPID RES, V20, P456; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; LEVADE T, 1991, J BIOL CHEM, V266, P13519; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; Tomiuk S, 2000, J BIOL CHEM, V275, P5710, DOI 10.1074/jbc.275.8.5710; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Zumbansen M, 2002, MOL CELL BIOL, V22, P3633, DOI 10.1128/MCB.22.11.3633-3638.2002	42	68	72	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					968	+		10.1096/fj.03-0875fje	http://dx.doi.org/10.1096/fj.03-0875fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059969				2022-12-25	WOS:000221108800020
J	Li, J; Zhu, M; Manning-Bog, AB; Di Monte, DA; Fink, AL				Li, J; Zhu, M; Manning-Bog, AB; Di Monte, DA; Fink, AL			Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease	FASEB JOURNAL			English	Article						alpha-synuclein; A beta peptide; catecholamines; oxidation	ALPHA-SYNUCLEIN AGGREGATION; IN-VITRO; QUINONE FORMATION; OXYGEN RADICALS; PROTEIN DAMAGE; BETA-SYNUCLEIN; A-BETA; INHIBITION; NEUROTOXICITY; PROTOFIBRILS	Protein deposition diseases involve the aggregation of normally soluble proteins, leading to both fibrillar and amorphous deposits. The aggregation of alpha-synuclein is associated with Parkinson's disease, and the aggregation of the Abeta peptide is associated with Alzheimer's disease. Here we show that L-dopa, dopamine, and other catecholamines dissolve fibrils of alpha-synuclein and Abeta peptide generated in vitro. The catecholamines also inhibited the fibrillation of these proteins. In addition, intraneuronal alpha-synuclein deposits formed in a mouse model were dissolved by incubation of tissue slices with L-dopa. These catecholamines are susceptible to oxidative breakdown, and we show that oxidation products are more effective than the parent compounds in inhibition. The ability to dissolve fibrils provides a new approach for studying mechanisms and consequences (e.g., the relationship between fibril formation and neurodegeneration) of protein aggregation. It is also likely to help in the development of strategies for the prevention and treatment of protein deposition diseases.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Parkinsons Inst, Sunnyvale, CA USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu		Di Monte, Donato/0000-0002-8296-836X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039985] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES10806] Funding Source: Medline; NINDS NIH HHS [R01 NS39985] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; Baba M, 1998, AM J PATHOL, V152, P879; BIRKMAYER W, 1985, J NEURAL TRANSM, V64, P113, DOI 10.1007/BF01245973; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cullen KM, 1996, NEURODEGENERATION, V5, P177, DOI 10.1006/neur.1996.0025; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FREDRIKSSON A, 1994, PHARMACOL TOXICOL, V75, P36, DOI 10.1111/j.1600-0773.1994.tb00321.x; Goedert M, 2001, CLIN CHEM LAB MED, V39, P308, DOI 10.1515/CCLM.2001.047; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; LANGE KW, 1994, J NEURAL TRANSM-SUPP, P183; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Lemos-Amado F, 2001, RAPID COMMUN MASS SP, V15, P2466, DOI 10.1002/rcm.498; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Muralikrishnan D, 1998, FASEB J, V12, P905, DOI 10.1096/fasebj.12.10.905; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Rajagopalan S, 2001, MECH AGEING DEV, V122, P1499, DOI 10.1016/S0047-6374(01)00283-4; Remiao F, 2003, BIOMED CHROMATOGR, V17, P6, DOI 10.1002/bmc.203; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; SCHMIDT ML, 1995, AM J PATHOL, V147, P503; Sebastiao MP, 2000, BIOCHEM J, V351, P273, DOI 10.1042/0264-6021:3510273; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Spencer JPE, 1996, FREE RADICAL RES, V24, P95, DOI 10.3109/10715769609088005; Stenstad T, 1996, J RHEUMATOL, V23, P93; Tatsuno Y, 1990, Nihon Hoigaku Zasshi, V44, P174; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3	46	196	205	1	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					962	+		10.1096/fj.03-0770fje	http://dx.doi.org/10.1096/fj.03-0770fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059976				2022-12-25	WOS:000221108800027
J	Ahvazi, B; Boeshans, KM; Steinert, PM				Ahvazi, B; Boeshans, KM; Steinert, PM			Crystal structure of transglutaminase 3 in complex with GMP - Structural basis for nucleotide specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; TISSUE TRANSGLUTAMINASE; PROTRANSGLUTAMINASE-E; CALCIUM-IONS; BINDING; PROTEIN; ACTIVATION; EXPRESSION; TRANSFECTION; TRICHOHYALIN	Epidermal-type Transglutaminase 3(TGase3) is a Ca2+-dependent enzyme involved in the cross-linking of structural proteins required in the assembly of the cell envelope. We have recently shown that calcium-activated TGase 3, like TGase 2, can bind, hydrolyze, and is inhibited by GTP despite lacking structural homology with other GTP-binding proteins. Here we report the crystal structure determined at 2.0 Angstrom resolution of TGase 3 in complex with GMP to elucidate the structural features required for nucleotide recognition. Binding affinities for various nucleotides were found by fluorescence displacement to be as follows: guanosine 5'-3-O-( thio) triphosphate (GTPgammaS) (0.4 muM), GTP (0.6 muM), GDP (1.0 muM), GMP (0.4 muM), and ATP (28.0 muM). Furthermore, we found that GMP binds as a reversible, noncompetitive inhibitor of TGase 3 transamidation activity, similar to GTPgammaS and GDP. A genetic algorithm similarity program ( GASP) approach ( virtual ligand screening) identified three compounds from the Lead Quest(TM) data base (Tripos Inc.) based on superimposition of GTPgammaS, GDP, and GMP guanine nucleotides from our crystal structures to generate the minimum align flexible fragment. These three were nucleotide analogs without a phosphate group containing the minimal binding motif for TGase 3 that includes a nucleoside recognition groove. Binding affinities were measured as follows: TP349915 (K-d = 4.1 muM), TP395289 (K-d = 38.5 muM), TP394305 (K-d = 1.0 mM). Remarkably, these compounds do not inhibit but instead activate TGase 3 transamidation by about 10-fold. These results suggest that the nucleotide binding pocket in TGase 3 may be exploited to either enhance or inhibit the enzymatic activity as required for different therapeutic approaches.	NIAMS, Xray Crystallog Facil, Off Sci & Technol, NIH, Bethesda, MD 20892 USA; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Ahvazi, B (corresponding author), NIAMS, Xray Crystallog Facil, Off Sci & Technol, NIH, 50 S Dr,Bldg 1345, Bethesda, MD 20892 USA.	ahvazib@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041087, Z01AR041142] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Ahvazi B, 2004, J BIOL CHEM, V279, P7180, DOI 10.1074/jbc.M312310200; Ahvazi B, 2003, EXP MOL MED, V35, P228, DOI 10.1038/emm.2003.31; Ahvazi B, 2003, J BIOL CHEM, V278, P23834, DOI 10.1074/jbc.M301162200; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; AHVAZI B, 2004, J STRUCT BIOL; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; Candi E, 1998, J BIOL CHEM, V273, P13693, DOI 10.1074/jbc.273.22.13693; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1966, BIOCHIM BIOPHYS ACTA, V122, P244, DOI 10.1016/0926-6593(66)90066-X; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; JOHNSON TS, 1994, ONCOGENE, V9, P2935; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HC, 2001, J STRUCT BIOL, V135, P73, DOI 10.1006/jsbi.2001.4384; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 1996, J BIOL CHEM, V271, P4561; LEE SC, 1993, J BIOL CHEM, V268, P12164; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Melino G, 1998, Results Probl Cell Differ, V24, P175; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Niki I, 1996, J BIOCHEM, V120, P685; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; *TRIP ASS INC, SYBYL VERS 6 9; WANG ZX, 1995, FEBS LETT, V360, P111, DOI 10.1016/0014-5793(95)00062-E	46	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26716	26725		10.1074/jbc.M403481200	http://dx.doi.org/10.1074/jbc.M403481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084592	hybrid			2022-12-25	WOS:000222003000098
J	Bartrand, AJ; Iyasu, D; Brush, GS				Bartrand, AJ; Iyasu, D; Brush, GS			DNA stimulates Mec1-mediated phosphorylation of replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; SACCHAROMYCES-CEREVISIAE; CHECKPOINT GENES; MEC1-DEPENDENT PHOSPHORYLATION; MEIOTIC RECOMBINATION; RPA PHOSPHORYLATION; IONIZING-RADIATION; BINDING PROTEIN; BUDDING YEAST; CELL-GROWTH	The cellular single-stranded DNA (ssDNA)-binding protein replication protein A (RPA) becomes phosphorylated periodically during the normal cell cycle and also in response to DNA damage. In Saccharomyces cerevisiae, RPA phosphorylation requires the checkpoint protein Mec1, a protein kinase homologous in structure and function to human ATR. We confirm here that immunocomplexes containing a tagged version of Mec1 catalyze phosphorylation of purified RPA, likely reflecting an RPA kinase activity intrinsic to Mec1. A significant stimulation of this activity is observed upon the addition of covalently closed ssDNA derived from the bacteriophage M13. This stimulation is not observed with mutant RPA deficient for DNA binding, indicating that DNA-bound RPA is a preferred substrate. Stimulation is also observed upon the addition of linear ssDNA homopolymers or hydrolyzed M13 ssDNA. In contrast to circular ssDNA, these DNA cofactors stimulate both wild type and mutant RPA phosphorylation. This finding suggests that linear ssDNA can also stimulate Mec1-mediated RPA phosphorylation by activating Mec1 or an associated protein. Although the Mec1-interacting protein Ddc2 is required for RPA phosphorylation in vivo, it is required for neither basal nor ssDNA-stimulated RPA phosphorylation in vitro. Therefore, activation of Mec1-mediated RPA phosphorylation by either circular or linear ssDNA does not operate through Ddc2. Our results provide insight into the mechanisms that function in vivo to specifically induce RPA phosphorylation upon initiation of DNA replication, repair, or recombination.	Wayne State Univ, Program Mol Biol & Human Genet, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Brush, GS (corresponding author), Wayne State Univ, Program Mol Biol & Human Genet, Karmanos Canc Inst, Detroit, MI 48201 USA.	brushg@karmanos.org			NIGMS NIH HHS [GM61860] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061860] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1998, METHODS YEAST GENETI, P145; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bastin-Shanower SA, 2001, J BIOL CHEM, V276, P36446, DOI 10.1074/jbc.M104386200; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Binz SK, 2003, J BIOL CHEM, V278, P35584, DOI 10.1074/jbc.M305388200; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; Brush GS, 2001, NUCLEIC ACIDS RES, V29, P4808, DOI 10.1093/nar/29.23.4808; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Clifford DM, 2004, J BIOL CHEM, V279, P6163, DOI 10.1074/jbc.M306943200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; Grushcow JM, 1999, GENETICS, V153, P607; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Kim HS, 2003, DNA REPAIR, V2, P1321, DOI 10.1016/j.dnarep.2003.07.004; KORNBERG A, 1992, DNA REPLICATION, P275; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Mallory JC, 2003, DNA REPAIR, V2, P1041, DOI 10.1016/S1568-7864(03)00115-0; Melo JA, 2001, GENE DEV, V15, P2809; Morgan SE, 1997, CANCER RES, V57, P3386; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Paciotti V, 2000, GENE DEV, V14, P2046; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Siede W, 1996, J BACTERIOL, V178, P5841, DOI 10.1128/jb.178.19.5841-5843.1996; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	57	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26762	26767		10.1074/jbc.M312353200	http://dx.doi.org/10.1074/jbc.M312353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078888	hybrid			2022-12-25	WOS:000222003000103
J	Abadie, A; Besancon, F; Wietzerbin, J				Abadie, A; Besancon, F; Wietzerbin, J			Type I interferon and TNF alpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells	ONCOGENE			English	Article						Ewing's sarcoma; TRAIL; apoptosis; IFN alpha; IFN gamma; TNF alpha	NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVITY; LIGAND TRAIL; SARCOMA FAMILY; TRANSCRIPTIONAL ACTIVATION; TUMORICIDAL ACTIVITY; RETINOIC ACID; APO2 LIGAND; IFN-GAMMA; T-CELLS	Ewing's sarcoma is the second most common human bone tumor in childhood. Here, we investigated the sensitivity of the Ewing tumor cell line, SK-N-MC, to the apoptotic effect of type I (IFNalpha) and type II (IFNgamma) interferons and TNFalpha. We demonstrate that although IFNalpha and TNFalpha alone are unable to induce cell death, they act in synergy with IFNgamma to induce SK-N-MC cell apoptosis. The synergistic induction of apoptosis correlated with the synergistic induction of TNFalpha-related apoptosis-inducing ligand ( TRAIL) mRNA and TRAIL protein synthesis as well as of TRAIL secretion. Preparations of inducer-free supernatants from SK-N-MC cells stimulated with combinations of cytokines were shown to be cytotoxic for untreated SK-N-MC cells. This cytotoxicity was partially inhibited by addition of TRAILR2/Fc fusion protein, indicating that the secreted TRAIL mediates, at least in part, the apoptotic effect displayed by the supernatants of stimulated SK-N-MC cells. We have shown that the presence of IFNgamma is required to allow the sustained expression of IRF1 in SK-N-MC cells stimulated by addition of IFNalpha or TNFalpha suggesting that IRF1 plays a role in the synergistic induction of apoptosis by combinations of cytokines. Furthermore, we have shown that inhibition of NF-kappaB activation contributes to the IFNgamma-mediated sensitization to the apoptotic effect of TNFalpha. To our knowledge, this is the first report showing that interferon/cytokine combinations are able to induce TRAIL gene expression and TRAIL protein synthesis and secretion in Ewing sarcoma-derived cells. We believe that the observations reported here might contribute to the development of alternative new approaches to the treatment of Ewing tumors resistant to conventional therapy.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Wietzerbin, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	jeanne.wietzerbin@curie.fr						Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; AURIAS A, 1983, NEW ENGL J MED, V309, P496; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Borden, 1998, Oncologist, V3, P198; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Horowitz Marc E., 1997, P831; Javelaud D, 2002, INT J CANCER, V98, P193, DOI 10.1002/ijc.10192; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kretz-Remy C, 2001, J BIOL CHEM, V276, P43723, DOI 10.1074/jbc.M010821200; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; Langaas V, 2001, ANTICANCER RES, V21, P3733; LAWRENCE D, 2001, NATURE, V7, P382; Lejeune FJ, 2002, J CLIN INVEST, V110, P433, DOI 10.1172/JCI200216493; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; Linder RE, 1997, REPROD TOXICOL, V11, P681, DOI 10.1016/S0890-6238(97)00031-2; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; LIU SQ, 1995, NAT MED, V1, P267, DOI 10.1038/nm0395-267; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mitsiades N, 2001, CANCER RES, V61, P2704; MUNOZ E, 1994, J VIROL, V68, P8035; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Oshima K, 2001, CYTOKINE, V14, P193, DOI 10.1006/cyto.2001.0873; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rodriguez-Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sanceau J, 2002, ONCOGENE, V21, P7700, DOI 10.1038/sj.onc.1205881; Shankar AG, 2003, MED PEDIATR ONCOL, V40, P141, DOI 10.1002/mpo.10248; Shin EC, 2001, INT J CANCER, V93, P262, DOI 10.1002/ijc.1310; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Van Valen F, 2000, INT J CANCER, V88, P252, DOI 10.1002/1097-0215(20001015)88:2<252::AID-IJC17>3.0.CO;2-U; VANVALEN F, 1993, J CANCER RES CLIN, V119, P615, DOI 10.1007/BF01372725; Wadler, 1997, Oncologist, V2, P254; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang CH, 1996, J IMMUNOL, V157, P3980; [No title captured]	62	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4911	4920		10.1038/sj.onc.1207614	http://dx.doi.org/10.1038/sj.onc.1207614			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077162				2022-12-25	WOS:000222104200012
J	Hodzic, DM; Yeater, DB; Bengtsson, L; Otto, H; Stahl, PD				Hodzic, DM; Yeater, DB; Bengtsson, L; Otto, H; Stahl, PD			Sun2 is a novel mammalian inner nuclear membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; LAMIN-B-RECEPTOR; CAENORHABDITIS-ELEGANS; LEM DOMAIN; CELL-LESS; IN-VITRO; ENVELOPE; EMERIN; BINDING; MIGRATION	Sun protein (Sun1 and Sun2) cDNAs were previously cloned based on the homology of their C-terminal regions (SUN (Sad1 and UNC) domain) with the Caenorhabditis elegans protein UNC-84 whose mutation disrupts nuclear migration/positioning. In this study, we raised an anti-Sun2 serum and identified Sun2 in mammalian cells. In HeLa cells, Sun2 displays a nuclear rim-like pattern typical for a nuclear envelope protein. The Sun2 antibody signal co-localizes with nuclear pore and INM markers signals. The rim-like pattern was also observed with the recombinant full-length Sun2 protein fused to either EGFP or V5 epitopes. In addition, we found that a recombinant truncated form of Sun2, extending from amino acids 26 to 339, is sufficient to specify the nuclear envelope localization. Biochemical analyses show that Sun2 is an 85-kDa protein that is partially insoluble in detergent with high salt concentration and in chaotropic agents. Furthermore, Sun2 is enriched in purified HeLa cell nuclei. Electron microscopy analysis shows that Sun2 localizes in the nuclear envelope with a sub-population present in small clusters. Additionally, we show that the SUN domain of Sun2 is localized to the periplasmic space between the inner and the outer nuclear membranes. From our data, we conclude that Sun2 is a new mammalian inner nuclear membrane protein. Because the SUN domain is conserved from fission yeast to mammals, we suggest that Sun2 belongs to a new class of nuclear envelope proteins with potential relevance to nuclear membrane function in the context of the involvement of its components in an increasing spectrum of human diseases.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Free Univ Berlin, Inst Chem Biochem, D-141195 Berlin, Germany	Washington University (WUSTL); Johns Hopkins University; Free University of Berlin	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid, St Louis, MO 63110 USA.	pstahl@cellbiology.wustl.edu	Stahl, Philip/D-6315-2012	Bengtsson, Luiza/0000-0001-6048-3743	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI200015, AI35884] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apel ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/jbc.M004775200; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bray JD, 2002, GENOMICS, V79, P799, DOI 10.1006/geno.2002.6779; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Ellis JA, 1998, J CELL SCI, V111, P781; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1999, J CELL SCI, V112, P2485; Georgatos SD, 2001, EMBO J, V20, P2989, DOI 10.1093/emboj/20.12.2989; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Haraguchi T, 2000, J CELL SCI, V113, P779; Holaska JM, 2003, J BIOL CHEM, V278, P6969, DOI 10.1074/jbc.M208811200; Holmer L, 2001, CELL MOL LIFE SCI, V58, P1741, DOI 10.1007/PL00000813; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lee KK, 2002, MOL BIOL CELL, V13, P892, DOI 10.1091/mbc.01-06-0294; Lee KK, 2001, J CELL SCI, V114, P4567; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu J, 2003, P NATL ACAD SCI USA, V100, P4598, DOI 10.1073/pnas.0730821100; Malone CJ, 1999, DEVELOPMENT, V126, P3171; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Morris GE, 1999, HUM MOL GENET, V8, P1847, DOI 10.1093/hmg/8.10.1847; Mounkes L, 2003, CURR OPIN GENET DEV, V13, P223, DOI 10.1016/S0959-437X(03)00058-3; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Nili E, 2001, J CELL SCI, V114, P3297; Ostlund C, 2003, MUSCLE NERVE, V27, P393, DOI 10.1002/mus.10302; Raff JW, 1999, CURR BIOL, V9, pR708, DOI 10.1016/S0960-9822(99)80446-1; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; Starr DA, 2003, J CELL SCI, V116, P211, DOI 10.1242/jcs.00248; Starr DA, 2002, SCIENCE, V298, P406, DOI 10.1126/science.1075119; Starr DA, 2001, DEVELOPMENT, V128, P5039; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sun GF, 2002, BBA-MOL BASIS DIS, V1588, P241, DOI 10.1016/S0925-4439(02)00171-0; Vlcek S, 2001, CELL MOL LIFE SCI, V58, P1758, DOI 10.1007/PL00000815; Wilkinson FL, 2003, EUR J BIOCHEM, V270, P2459, DOI 10.1046/j.1432-1033.2003.03617.x; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; Worman HJ, 2000, J MEMBRANE BIOL, V177, P1, DOI 10.1007/s002320001096; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Zhang QP, 2002, GENOMICS, V80, P473, DOI 10.1006/geno.2002.6859; Zhang QP, 2001, J CELL SCI, V114, P4485; Zheng RL, 2000, P NATL ACAD SCI USA, V97, P8997, DOI 10.1073/pnas.150240197	51	159	165	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25805	25812		10.1074/jbc.M313157200	http://dx.doi.org/10.1074/jbc.M313157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082709	hybrid			2022-12-25	WOS:000221827900111
J	Mohler, PJ; Hoffman, JA; Davis, JQ; Abdi, KM; Kim, CR; Jones, SK; Davis, LH; Roberts, KF; Bennett, V				Mohler, PJ; Hoffman, JA; Davis, JQ; Abdi, KM; Kim, CR; Jones, SK; Davis, LH; Roberts, KF; Bennett, V			Isoform specificity among ankyrins - An amphipathic alpha-helix in the divergent regulatory domain of ankyrin-B interacts with the molecular co-chaperone Hdj1/Hsp40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; INOSITOL 1,4,5-TRISPHOSPHATE; NEONATAL CARDIOMYOCYTES; SARCOPLASMIC-RETICULUM; INITIAL SEGMENTS; SKELETAL-MUSCLE; PROTEIN; SPECTRIN; MEMBRANE; BINDING	Ankyrins-R, -B, and -G are a family of membrane-associated adaptors required for localization of structurally diverse proteins to specialized membrane domains, including axon initial segments, cardiomyocyte T-tubules, and epithelial cell lateral membranes. Ankyrins are often co-expressed in the same cells and, although structurally similar, have non-overlapping functions. We previously determined that the regulatory domain of ankyrin-B defines specificity between ankyrins B and G in cardiomyocytes. Here, we identify key residues on the surface of an amphipathic alpha-helix unique to the regulatory domain of ankyrin-B that are essential for the function of ankyrin-B in cardiomyocytes. Using circular dichroism, we determined that a peptide representing the predicted helix folds as a helix in solution. Alanine-scanning mutagenesis revealed that residues 1773, 1777, 1780, 1784, and 1788 located in a patch on one surface the helix are critical for ankyrin-B function in cardiomyocytes. In a parallel set of experiments we determined that the molecular co-chaperone human DnaJ homologue 1 (Hdj1)/Hsp40 interacts with the ankyrin-B regulatory domain. Moreover, interaction of Hdj1/Hsp40 with the regulatory domain was mapped by random mutagenesis to same surface of the alpha-helix that is required for ankyrin-B function. These results provide new insight into the molecular basis for specificity between ankyrin-based pathways by defining a key alpha-helix structure in the divergent regulatory domain of ankyrin-B as well as interaction of the helix with Hdj1/Hsp40, the first downstream target for ankyrin-B-specific function.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Bennett, V (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	pmohler@cellbio.duke.edu; v.bennett@cellbio.duke.edu						Abdul KM, 2002, CELL STRESS CHAPERON, V7, P156, DOI 10.1379/1466-1268(2002)007<0156:CAFAOA>2.0.CO;2; Bagnato P, 2003, J CELL BIOL, V160, P245, DOI 10.1083/jcb.200208109; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; Farinha CM, 2002, BIOCHEM J, V366, P797, DOI 10.1042/BJ20011717; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kizhatil K, 2004, J BIOL CHEM, V279, P16706, DOI 10.1074/jbc.M314296200; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; Kordeli E, 1998, J CELL SCI, V111, P2197; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; LAMBERT S, 1993, J NEUROSCI, V13, P3725; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J CELL SCI, V115, P1565; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; Ohtsuka K, 2000, INT J HYPERTHER, V16, P231, DOI 10.1080/026567300285259; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	34	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25798	25804		10.1074/jbc.M401296200	http://dx.doi.org/10.1074/jbc.M401296200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075330	hybrid			2022-12-25	WOS:000221827900110
J	Parathath, S; Sahoo, D; Darlington, YF; Peng, YN; Collins, HL; Rothblat, GH; Williams, DL; Connelly, MA				Parathath, S; Sahoo, D; Darlington, YF; Peng, YN; Collins, HL; Rothblat, GH; Williams, DL; Connelly, MA			Glycine 420 near the C-terminal transmembrane domain of SR-BI is critical for proper delivery and metabolism of high density lipoprotein cholesteryl ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CLASS-B; SCAVENGER RECEPTOR; SELECTIVE UPTAKE; EXTRALYSOSOMAL HYDROLYSIS; MEDIATED ENDOCYTOSIS; IN-VIVO; A-I; CELLS; EXPRESSION; HDL	Scavenger receptor BI, SR-BI, is a physiologically relevant receptor for high density lipoprotein (HDL) that mediates the uptake of cholesteryl esters and delivers them to a metabolically active membrane pool where they are subsequently hydrolyzed. A previously characterized SR-BI mutant, A-VI, with an epitope tag inserted into the extracellular domain near the C-terminal transmembrane segment, revealed a separation-of-function between SR-BI-mediated HDL cholesteryl ester uptake and cholesterol efflux to HDL, on one hand, and cholesterol release to small unilamellar phospholipid vesicle acceptors and an increased cholesterol oxidase-sensitive pool of membrane free cholesterol on the other. To further elucidate amino acid residues responsible for this separation-of-function phenotype, we engineered alanine substitutions and point mutations in and around the site of epitope tag insertion, and tested these for various cholesterol transport functions. We found that changing amino acid 420 from glycine to histidine had a profound effect on SR-BI function. Despite the ability to mediate selective HDL cholesteryl ester uptake, the G420H receptor had a greatly reduced ability to: 1) enlarge the cholesterol oxidase-sensitive pool of membrane free cholesterol, 2) mediate cholesterol efflux to HDL, even at low concentrations of HDL acceptor where binding-dependent cholesterol efflux predominates, and 3) accumulate cholesterol mass within the cell. Most importantly, the G420H mutant was unable to deliver the HDL cholesteryl ester to a metabolically active membrane compartment for efficient hydrolysis. These observations have important implications regarding SR-BI function as related to its structure near the C-terminal transmembrane domain.	SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Childrens Hosp Philadelphia, Dept Pediat, Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Connelly, MA (corresponding author), SUNY Stony Brook, Univ Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	connelly@pharm.sunysb.edu	Parathath, Saj/ABE-2183-2021; Eckhardt, Erik/G-1567-2010	Parathath, Sajesh/0000-0003-3431-297X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063768, R01HL058012, P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58012, HL22633, HL63768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arkin IT, 2002, BBA-BIOMEMBRANES, V1565, P347, DOI 10.1016/S0005-2736(02)00580-1; Azhar S, 1998, J CLIN ENDOCR METAB, V83, P983, DOI 10.1210/jc.83.3.983; Azhar S, 2002, MOL CELL ENDOCRINOL, V195, P1, DOI 10.1016/S0303-7207(02)00222-8; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; Briand O, 2003, BBA-MOL CELL BIOL L, V1631, P42, DOI 10.1016/S1388-1981(02)00354-2; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALVO D, 1993, J BIOL CHEM, V268, P18929; Connelly MA, 2003, TRENDS ENDOCRIN MET, V14, P467, DOI 10.1016/j.tem.2003.10.002; Connelly MA, 2003, J BIOL CHEM, V278, P25773, DOI 10.1074/jbc.M302820200; Connelly MA, 2003, J LIPID RES, V44, P331, DOI 10.1194/jlr.M200186-JLR200; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; DELAMATRE JG, 1993, J CELL PHYSIOL, V157, P164, DOI 10.1002/jcp.1041570121; Francone OL, 1997, J LIPID RES, V38, P813; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Liu Y, 2002, GENOME BIOL, V3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Rajapaksha WRAKJS, 1997, MOL CELL ENDOCRINOL, V134, P59, DOI 10.1016/S0303-7207(97)00173-1; Reaven E, 2004, J LIPID RES, V45, P513, DOI 10.1194/jlr.M300370-JLR200; REAVEN E, 1989, J LIPID RES, V30, P1551; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Ritsch A, 2004, J LIPID RES, V45, P214, DOI 10.1194/jlr.M300353-JLR200; Rothblat GH, 1999, J LIPID RES, V40, P781; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SHIMADA A, 1994, BBA-LIPID LIPID MET, V1215, P126, DOI 10.1016/0005-2760(94)90101-5; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Thuahnai ST, 2003, J LIPID RES, V44, P1132, DOI 10.1194/jlr.M200429-JLR200; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200	51	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24976	24985		10.1074/jbc.M402435200	http://dx.doi.org/10.1074/jbc.M402435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060063	hybrid			2022-12-25	WOS:000221827900011
J	Vulin, AI; Stanley, FM				Vulin, AI; Stanley, FM			Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; PROLACTIN GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; PROTEIN-KINASE; REACTIVE OXYGEN; C-JUN; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE	Oxidative stress is one of the characteristics of diabetes and is thought to be responsible for many of the pathophysiological changes caused by the disease. We previously identified an insulin response element in the promoter of plasminogen activator inhibitor 1 (PAI-1) that was activated by an unidentified member of the forkhead/winged helix (Fox) family of transcription factors. This element mediated a 5-7-fold increase in PAI-1 transcription because of insulin. Here we report that oxidative stress also caused a 3-fold increase in PAI-1 transcription and that the effect was additive with that of insulin. Antioxidants prevent this response. Mutational analysis of the PAI-1 promoter revealed that oxidative stress acted at an AP-1 site at -60/52 of the promoter. Gel mobility shift analysis demonstrated that binding to an AP-1 oligonucleotide was increased 4-fold by oxidative stress. Jun levels were increased by oxidants as assessed by reverse transcriptase-PCR. Western blotting demonstrated that a rapid and prolonged nuclear accumulation of phospho-c-Jun followed oxidant stimulation. The nuclear c-Jun phosphorylation was not observed in cells treated with reduced glutathione. Finally, JNK/SAPK activity was found to increase in response to oxidants, and inhibition of JNK/SAP blocked TBHQ-increased PAI-1-luciferase expression. Thus, oxidative stress stimulated AP-1 and activated the PAI-1 promoter.	NYU, Med Ctr, Sch Med, Dept Pharmacol,TH 450, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Stanley, FM (corresponding author), NYU, Med Ctr, Sch Med, Dept Pharmacol,TH 450, 550 1st Ave, New York, NY 10016 USA.	Stanlf01@med.nyu.edu		Stanley, Frederick/0000-0002-3684-2168				Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Ahn JD, 2001, DIABETOLOGIA, V44, P713, DOI 10.1007/s001250051680; Arts J, 1999, ARTERIOSCL THROM VAS, V19, P39, DOI 10.1161/01.ATV.19.1.39; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; Bonfigli AR, 2001, DIABETES NUTR METAB, V14, P71; Brown NJ, 2000, J CLIN ENDOCR METAB, V85, P336, DOI 10.1210/jc.85.1.336; Carmassi F, 1999, AM J MED, V107, P344, DOI 10.1016/S0002-9343(99)00240-5; Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002-9440(10)63015-5; Chen YQ, 1998, J BIOL CHEM, V273, P8225, DOI 10.1074/jbc.273.14.8225; COCKELL KA, 1995, THROMB RES, V77, P119, DOI 10.1016/0049-3848(95)91618-U; Cummings BS, 2002, AM J PHYSIOL-RENAL, V283, pF492, DOI 10.1152/ajprenal.00022.2002; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dichtl W, 1999, ARTERIOSCL THROM VAS, V19, P3025, DOI 10.1161/01.ATV.19.12.3025; Dong WM, 1998, J INTERF CYTOK RES, V18, P629, DOI 10.1089/jir.1998.18.629; Eddy AA, 2002, AM J PHYSIOL-RENAL, V283, pF209, DOI 10.1152/ajprenal.00032.2002; Gallicchio M, 1996, J IMMUNOL, V157, P2610; GOMEZ DA, 1996, J BIOL CHEM, V271, P26335; Greene EL, 2000, HYPERTENSION, V35, P942, DOI 10.1161/01.HYP.35.4.942; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Ishikawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P496, DOI 10.1006/bbrc.1997.7665; JACOB KK, 1994, J BIOL CHEM, V269, P25515; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Kontny E, 2000, J LEUKOCYTE BIOL, V67, P249, DOI 10.1002/jlb.67.2.249; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Madesh M, 1998, BBA-LIPID LIPID MET, V1389, P206, DOI 10.1016/S0005-2760(97)00155-0; Marutsuka K, 1998, CORONARY ARTERY DIS, V9, P177, DOI 10.1097/00019501-199809040-00002; McHowat J, 2001, Cardiovasc Toxicol, V1, P309, DOI 10.1385/CT:1:4:309; Mitsutake N, 2001, ONCOGENE, V20, P989, DOI 10.1038/sj.onc.1204179; NORDT TK, 1994, CIRCULATION, V89, P321, DOI 10.1161/01.CIR.89.1.321; NORDT TK, 1995, CIRCULATION, V91, P764, DOI 10.1161/01.CIR.91.3.764; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; Park SM, 1999, J IMMUNOL, V163, P631; PENG M, 1995, CELL MOL BIOL RES, V41, P189; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Remick DG, 1996, J LEUKOCYTE BIOL, V59, P471, DOI 10.1002/jlb.59.4.471; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 2000, MOL MED, V6, P680, DOI 10.1007/BF03402048; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; Schacke W, 2002, INVEST OPHTH VIS SCI, V43, P2799; SHARROCKS AD, 1992, NUCLEIC ACIDS RES, V20, P1147, DOI 10.1093/nar/20.5.1147; Siconolfi LB, 2001, J NEUROSCI, V21, P4336, DOI 10.1523/JNEUROSCI.21-12-04336.2001; Soriano FG, 2001, J MOL MED, V79, P437, DOI 10.1007/s001090100236; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; Suzuki M, 2002, LIFE SCI, V72, P59, DOI 10.1016/S0024-3205(02)02182-3; Thavasu P, 1999, CANCER RES, V59, P3980; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Vulin AI, 2002, J BIOL CHEM, V277, P20169, DOI 10.1074/jbc.M112073200; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WOLFF SP, 1993, BRIT MED BULL, V49, P642, DOI 10.1093/oxfordjournals.bmb.a072637; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Zhao M, 2001, FEBS LETT, V509, P399, DOI 10.1016/S0014-5793(01)03184-2; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	63	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25172	25178		10.1074/jbc.M403184200	http://dx.doi.org/10.1074/jbc.M403184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069077	hybrid			2022-12-25	WOS:000221827900033
J	Wang, YL; Malabarba, MG; Nagy, ZS; Kirken, RA				Wang, YL; Malabarba, MG; Nagy, ZS; Kirken, RA			Interleukin 4 regulates phosphorylation of serine 756 in the transactivation domain of Stat6 - Roles for multiple phosphorylation sites and Stat6 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR; SIGNAL-TRANSDUCTION; MAXIMAL ACTIVATION; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; IL-4; KINASE	Lymphokines interleukin-4 (IL4) and IL13 exert overlapping biological activities via the shared use of the IL4 receptor alpha-chain and signal transducer and activator of transcription 6 (Stat6). Stat6 is critical for T-helper 2 cell differentiation, B-cell Ig class switch, and allergic diseases; thus, understanding its regulation is of central importance. Phosphorylation is crucial for Stat activity. Whereas Stat6 is phosphorylated on Tyr(641), less is known about serine or threonine. We demonstrate in primary human T-cells (>95% CD3+) that IL4 and for the first time IL13 induce Stat6 serine but not threonine phosphorylation that closely paralleled early IL4 receptor alpha-chain activation (10 min). Stat6 uniquely fails to share a positionally conserved Stat serine phosphorylation sequence; however, known phosphoacceptor sites are proline-flanked. Alanine substitutions of these conserved residues revealed that the transactivation domain, which localized Ser(756) but not Ser(827) or Ser(176), is the IL4-regulated site based on phosphoamino acid analysis. Tyr(641) was dispensable for IL4-mediated serine phosphorylation, suggesting that dimerization is not preconditional. Only Stat6 Y641F variant showed a significant effect on IL4-inducible Cepsilon DNA-binding and reporter gene expression. Lastly, recent work has shown that protein phosphatase 2A negatively regulates Stat6 (Woetmann, A., Brockdorff, J., Lovato, P., Nielsen, M., Leick, V., Rieneck, K., Svejgaard, A., Geisler, C., and Odum, N. (2003) J. Biol. Chem. 278, 2787-2791). We propose this target residue(s) is distinct from Ser(756) and may be proximal to Tyr(641) at Thr(645), a residue conserved only among Stat6 members. The phosphomimic variants T645E or T645D ablated Stat6 activation, whereas polar uncharged substitutions (Gln or Asn) and additional mutants (Ala, Val, or Phe) showed no effect. These findings suggest that Stat6 has mechanisms of regulation distinct from other Stats.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	University of Texas System; IRCCS European Institute of Oncology (IEO)	Kirken, RA (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Med Sci Bldg,Rm 4-218, Houston, TX 77030 USA.	robert.a.kirken@uth.tmc.edu	Malabarba, Maria Grazia/L-4805-2015	Malabarba, Maria Grazia/0000-0002-9457-2047	NIAID NIH HHS [AI053566] Funding Source: Medline; NIDDK NIH HHS [DK38016-12] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038016] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Behbod F, 2001, J IMMUNOL, V166, P3724, DOI 10.4049/jimmunol.166.6.3724; Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Carter LL, 1996, CURR OPIN IMMUNOL, V8, P336, DOI 10.1016/S0952-7915(96)80122-1; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DEUTSCH HHJ, 1995, J IMMUNOL, V154, P3696; Dickensheets HL, 1999, P NATL ACAD SCI USA, V96, P10800, DOI 10.1073/pnas.96.19.10800; Dimberg A, 2003, BLOOD, V102, P254, DOI 10.1182/blood-2002-10-3149; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Gamero AM, 2000, J BIOL CHEM, V275, P16574, DOI 10.1074/jbc.M910149199; Goenka S, 2003, J BIOL CHEM, V278, P50362, DOI 10.1074/jbc.M305854200; Hanson EM, 2003, J BIOL CHEM, V278, P3903, DOI 10.1074/jbc.M211747200; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARADA N, 1992, J BIOL CHEM, V267, P22752; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Kirken RA, 1999, J LEUKOCYTE BIOL, V65, P891, DOI 10.1002/jlb.65.6.891; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Lu BF, 1997, J IMMUNOL, V159, P1255; Malabarba MG, 1996, BIOCHEM J, V319, P865, DOI 10.1042/bj3190865; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Nelson G, 2003, J CELL SCI, V116, P2495, DOI 10.1242/jcs.00461; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Pesu M, 2000, BLOOD, V95, P494, DOI 10.1182/blood.V95.2.494; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Skinnider BF, 2001, BLOOD, V97, P250, DOI 10.1182/blood.V97.1.250; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Uddin S, 2000, J BIOL CHEM, V275, P27634; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Woetmann A, 2003, J BIOL CHEM, V278, P2787, DOI 10.1074/jbc.M210196200; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yamashita H, 2001, MOL CELL ENDOCRINOL, V183, P151, DOI 10.1016/S0303-7207(01)00546-9; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	59	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25196	25203		10.1074/jbc.M313668200	http://dx.doi.org/10.1074/jbc.M313668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069079	hybrid			2022-12-25	WOS:000221827900036
J	Natarajan, P; Forte, TM; Chu, B; Phillips, MC; Oram, JF; Bielicki, JK				Natarajan, P; Forte, TM; Chu, B; Phillips, MC; Oram, JF; Bielicki, JK			Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; TANGIER-DISEASE; LIPID EFFLUX; APOA-I; HELICAL PEPTIDES; ANTIOXIDANT ACTIVITY; SYNTHETIC PEPTIDES; PEST SEQUENCE; ABCA1	Synthetic peptides were used in this study to identify a structural element of apolipoprotein (apo) A-I that stimulates cellular cholesterol efflux and stabilizes the ATP binding cassette transporter A1 (ABCA1). Peptides (22-mers) based on helices 1 (amino acids 44-65) and 10 (amino acids 220-241) of apoA-I had high lipid binding affinity but failed to mediate ABCA1-dependent cholesterol efflux, and they lacked the ability to stabilize ABCA1. The addition of helix 9 (amino acids 209-219) to either helix 1 (creates a 1/9 chimera) or 10 (9/10 peptide) endowed cholesterol efflux capability and ABCA1 stabilization activity similar to full-length apoA-I. Adding helix 9 to helix 1 or 10 had only a small effect on lipid binding affinity compared with the 22-mer peptides, indicating that helix length and/or determinants on the polar surface of the amphipathic alpha-helices is important for cholesterol efflux. Cholesterol efflux was specific for the structure created by the 1/9 and 9/10 helical combinations, as 33-mers composed of helices 1 and 3 (1/3), 2/9, and 4/9 failed to mediate cholesterol efflux in an ABCA1-dependent manner. Transposing helices 9 and 10 (10/9 peptide) did not change the class Y structure, hydrophobicity, or amphiphilicity of the helical combination, but the topography of negatively charged amino acids on the polar surface was altered, and the 10/9 peptide neither mediated ABCA1-dependent cholesterol efflux nor stabilized ABCA1 protein. These results suggest that a specific structural element possessing a linear array of acidic residues spanning two apoA-I amphipathic alpha-helices is required to mediate cholesterol efflux and stabilize ABCA1.	Univ Calif Berkeley, Lawrence Berkeley Lab, Donner Lab, Berkeley, CA 94720 USA; Univ Penn, Sch Med, Childrens Hosp Philadelphia, Lipid Res Grp, Philadelphia, PA 19104 USA; Univ Washington, Sch Med, Dept Med Endocrinol & Nutr, Seattle, WA 98195 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Washington; University of Washington Seattle	Bielicki, JK (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Donner Lab, MS1-224,1 Cyclotron Rd, Berkeley, CA 94720 USA.	Jkbielicki@lbl.gov	Natarajan, Pradeep/H-9764-2019	Natarajan, Pradeep/0000-0001-8402-7435; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, R01HL055493, R01HL059483, R01HL055362, P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645, HL059483, HL55362, HL22633, HL55493] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; Arakawa R, 2004, J BIOL CHEM, V279, P6217, DOI 10.1074/jbc.C300553200; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Bielicki JK, 1999, J LIPID RES, V40, P85; BIELICKI JK, 1992, J LIPID RES, V33, P1699; Bielicki JK, 2002, BIOCHEMISTRY-US, V41, P2089, DOI 10.1021/bi011716p; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chroni A, 2004, BIOCHEMISTRY-US, V43, P2126, DOI 10.1021/bi035813p; Chroni A, 2003, J BIOL CHEM, V278, P6719, DOI 10.1074/jbc.M205232200; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P593; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; FORTE TM, 1993, J LIPID RES, V34, P317; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARA H, 1991, J BIOL CHEM, V266, P3080; Jia Z, 2002, BIOCHEM BIOPH RES CO, V297, P206, DOI 10.1016/S0006-291X(02)02143-5; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MCLEAN LR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P289, DOI 10.1016/0005-2760(93)90231-W; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; Oram JF, 2003, J BIOL CHEM, V278, P52379, DOI 10.1074/jbc.M310695200; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; RIFKIND BM, 1990, AM J CARDIOL, V66, P3; ROTHBLAT GH, 1991, CURR OPIN LIPIDOL, V2, P288; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SEGREST JP, 1992, J LIPID RES, V33, P141; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; STEIN O, 1973, BIOCHIM BIOPHYS ACTA, V326, P232, DOI 10.1016/0005-2760(73)90249-X; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; VENKATACHALAPATHI YV, 1993, PROTEINS, V15, P349, DOI 10.1002/prot.340150403; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808	46	57	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24044	24052		10.1074/jbc.M400561200	http://dx.doi.org/10.1074/jbc.M400561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051721	hybrid			2022-12-25	WOS:000221702500026
J	Delaval, B; Ferrand, A; Conte, N; Larroque, C; Hernandez-Verdun, D; Prigent, C; Birnbaum, D				Delaval, B; Ferrand, A; Conte, N; Larroque, C; Hernandez-Verdun, D; Prigent, C; Birnbaum, D			Aurora B TACC1 protein complex in cytokinesis	ONCOGENE			English	Article						Aurora kinase; cell division; cytokinesis; microtubule; midbody; TACC protein; Taxin; RNAi	COILED-COIL; CHROMOSOME SEGREGATION; CENTROSOMAL PROTEIN; BREAST-CANCER; CELL-CYCLE; A KINASE; SPINDLE; MITOSIS; REGULATORS; FAMILY	Taxins are a family of centrosomal proteins important for the regulation of mitosis and microtubule dynamics. Cytokinesis, the last step of M phase, is essential for chromosomal integrity and cell division. It is highly regulated and involves a reorganization of microtubules and actin filaments. We show here that TACC1 localizes diffusely to the midzone spindle in anaphase and strongly to the midbody during cytokinesis, indicating a possible involvement of this protein in the exit of M phase. TACC1 also relocalizes to the nucleolus in interphase. We demonstrate that TACC1 and the mitotic kinase Aurora B belong to the same complex during cytokinesis. We further show that Aurora B knocked down by RNA-mediated interference prevents the formation of the midbody-and consequently affects TACC1 localization at this site-and leads to abnormal cell division and multinucleated cells.	Inst J Paoli I Calmettes, INSERM, U119, Dept Mol Oncol, F-13009 Marseille, France; CRLC Val Aurelle Paul Lamarque, INSERM, E229, Montpellier, France; Univ Rennes 1, Fac Med, CNRS,UMR Genet & Dev 6061, Grp Cycle Cellulaire, Rennes, France; Inst Jacques Monod, CNRS, F-75251 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, U119, Dept Mol Oncol, 27 Bd Lei Roure,IFR57, F-13009 Marseille, France.	birnbaurn@marseille.inserm.fr		Conte, Nathalie/0000-0002-1010-3121; Birnbaum, Daniel/0000-0001-7920-9883				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Cremet JY, 2003, MOL CELL BIOCHEM, V243, P123, DOI 10.1023/A:1021608012253; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Keryer G, 2003, MOL BIOL CELL, V14, P2436, DOI 10.1091/mbc.E02-09-0614; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; MARASCO WA, 1994, ARCH VIROL, V139, P133, DOI 10.1007/BF01309460; Maxwell CA, 2003, MOL BIOL CELL, V14, P2262, DOI 10.1091/mbc.e02-07-0377; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; ROUSSEL P, 1993, J CELL SCI, V104, P327; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Steadman BT, 2002, J BIOL CHEM, V277, P30165, DOI 10.1074/jbc.M201914200; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Tien AC, 2004, MOL CELL PROTEOMICS, V3, P93, DOI 10.1074/mcp.M300072-MCP200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	44	42	46	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4516	4522		10.1038/sj.onc.1207593	http://dx.doi.org/10.1038/sj.onc.1207593			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064709				2022-12-25	WOS:000221799000002
J	Crow, A; Acheson, RM; Le Brun, NE; Oubrie, A				Crow, A; Acheson, RM; Le Brun, NE; Oubrie, A			Structural basis of redox-coupled protein substrate selection by the cytochrome c biosynthesis protein ResA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME CHAPERONE CCME; DISULFIDE BOND ISOMERASE; ESCHERICHIA-COLI K-12; CRYSTAL-STRUCTURE; BACILLUS-SUBTILIS; BC(1) COMPLEX; FUMARATE REDUCTASE; NITRITE REDUCTASE; FORMATION INVIVO; THIOREDOXIN	Post-translational maturation of cytochromes c involves the covalent attachment of heme to the Cys-Xxx-Xxx-Cys-His motif of the apo-cytochrome. For this process, the two cysteines of the motif must be in the reduced state. In bacteria, this is achieved by dedicated, membrane-bound thiol-disulfide oxidoreductases with a high reducing power, which are essential components of cytochrome c maturation systems and are also linked to cellular disulfide-bond formation machineries. Here we report high-resolution structures of oxidized and reduced states of a soluble, functional domain of one such oxidoreductase, ResA, from Bacillus subtilis. The structures elucidate the structural basis of the protein's high reducing power and reveal the largest redox-coupled conformational changes observed to date in any thioredoxin-like protein. These redox-coupled changes alter the protein surface and illustrate how the redox state of ResA predetermines to which substrate it binds. Furthermore, a polar cavity, present only in the reduced state, may confer specificity to recognize apo-cytochrome c. The described features of ResA are likely to be general for bacterial cytochrome c maturation systems.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Div Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of East Anglia	Oubrie, A (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	a.oubrie@uea.ac.uk	Crow, Allister/F-2147-2018	Crow, Allister/0000-0001-6856-5962; Oubrie, Arthur/0000-0001-6765-9246; Le Brun, Nick/0000-0001-9780-4061				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bamford V, 1999, NAT STRUCT BIOL, V6, P1104; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Beckett CS, 2000, MOL MICROBIOL, V38, P465, DOI 10.1046/j.1365-2958.2000.02174.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Capitani G, 2001, J MOL BIOL, V311, P1037, DOI 10.1006/jmbi.2001.4913; Cook GM, 2000, MICROBIOL-SGM, V146, P527, DOI 10.1099/00221287-146-2-527; CROOKE H, 1995, MOL MICROBIOL, V15, P1139, DOI 10.1111/j.1365-2958.1995.tb02287.x; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Erlendsson LS, 2003, J BIOL CHEM, V278, P17852, DOI 10.1074/jbc.M300103200; Erlendsson LS, 2002, J BACTERIOL, V184, P1423, DOI 10.1128/JB.184.5.1423-1429.2002; Fabianek RA, 1999, ARCH MICROBIOL, V171, P92, DOI 10.1007/s002030050683; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Goulding CW, 2004, J BIOL CHEM, V279, P3516, DOI 10.1074/jbc.M311833200; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; Hennecke J, 1997, J BIOL CHEM, V272, P189; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; Le Brun NE, 2000, MOL MICROBIOL, V36, P638, DOI 10.1046/j.1365-2958.2000.01883.x; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; METHERINGHAM R, 1995, ARCH MICROBIOL, V164, P301, DOI 10.1007/BF02529965; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oubrie A, 2002, J BIOL CHEM, V277, P3727, DOI 10.1074/jbc.M109403200; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PETTIGREW GW, 1987, CYTOCHROMES C BIOL A; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Reid E, 1998, FEMS MICROBIOL LETT, V166, P369, DOI 10.1016/S0378-1097(98)00357-7; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Sambongi Y, 1996, FEBS LETT, V398, P265, DOI 10.1016/S0014-5793(96)01256-2; Sambrook J., 2002, MOL CLONING LAB MANU; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Schiott T, 1997, J BACTERIOL, V179, P1962, DOI 10.1128/jb.179.6.1962-1973.1997; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; SCOTT RA, 1996, CYTOCHROME C MULTIDI; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P45, DOI 10.1107/S0907444902018048; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Wilmanns M, 1995, P NATL ACAD SCI USA, V92, P11955, DOI 10.1073/pnas.92.26.11955; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	72	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23654	23660		10.1074/jbc.M402823200	http://dx.doi.org/10.1074/jbc.M402823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047692	hybrid			2022-12-25	WOS:000221570900107
J	Chen, XL; Lin, K; Ricciardi, RP				Chen, XL; Lin, K; Ricciardi, RP			Human Kaposi's sarcoma herpesvirus processivity factor-8 functions as a dimer in DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE PROCESSIVITY; CRYSTAL-STRUCTURE; BINDING PROTEIN; SEQUENCES; SUBUNIT; IDENTIFICATION; PHOSPHORYLATES; ASSOCIATION; COMPLEXES	In the absence of other proteins, the DNA polymerase (Pol-8) of Kaposi's sarcoma herpesvirus incorporates only several nucleotides from a primer template. However, association with the Kaposi's sarcoma herpesvirus processivity factor (PF-8) enables Pol-8 to incorporate thousands of nucleotides. Unlike the well described sliding clamp processivity factors, eukaryotic proliferating cell nuclear antigen and Escherichia coli beta-subunit, PF-8 and other herpesvirus processivity factors do not require a clamp loader or ATP to bind to template DNA. To begin to understand the mechanism used by PF-8 to achieve processivity, we have now purified PF-8 and demonstrated that it is a dimer both in solution and on the DNA. Mutational analysis of the PF-8 protein (396R) indicates that residues between 277 and 304 as well as the N-terminal 21 amino acids are required for dimerization. The results further correlate PF-8 dimerization with binding to Pol-8 and stabilizing Pol-8 on primer template. Notably, although removal of only 26 residues from the C terminus of PF-8 does not affect its ability to form dimers on DNA or to bind Pol-8, only short DNA chains (<100 nucleotides) are synthesized. This indicates that full-length PF-8 is necessary to enable Pol-8 to incorporate thousands of nucleotides. Interestingly, cross-linking of the processivity factor UL44 of cytomegalovirus reveals that it is a dimer in solution also.	Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ricciardi, RP (corresponding author), Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA.	ricciardi@biochem.dental.upenn.edu			NCI NIH HHS [CA 80602] Funding Source: Medline; NIAID NIH HHS [P30 AI 45008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI045008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Advani SJ, 2001, J VIROL, V75, P10326, DOI 10.1128/JVI.75.21.10326-10333.2001; AGULNICK AD, 1993, J GEN VIROL, V74, P1003, DOI 10.1099/0022-1317-74-6-1003; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chan SR, 2000, J VIROL, V74, P10920, DOI 10.1128/JVI.74.23.10920-10929.2000; Chaudhuri M, 2002, J VIROL, V76, P10270, DOI 10.1128/JVI.76.20.10270-10281.2002; CHOW CS, 1995, J VIROL, V69, P6965, DOI 10.1128/JVI.69.11.6965-6971.1995; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; ERTL PF, 1992, J VIROL, V66, P4126, DOI 10.1128/JVI.66.7.4126-4133.1992; GALLO ML, 1988, J VIROL, V62, P2874, DOI 10.1128/JVI.62.8.2874-2883.1988; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; HUBER HE, 1987, J BIOL CHEM, V262, P16224; KIEHL A, 1991, VIROLOGY, V184, P330, DOI 10.1016/0042-6822(91)90849-7; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; Lin K, 1998, J VIROL, V72, P6228, DOI 10.1128/JVI.72.7.6228-6232.1998; Lin K, 1998, VIROLOGY, V250, P210, DOI 10.1006/viro.1998.9348; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Marschall M, 2003, VIROLOGY, V311, P60, DOI 10.1016/S0042-6822(03)00147-8; Matsumiya S, 2001, PROTEIN SCI, V10, P17, DOI 10.1110/ps.36401; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Randell JC, 2001, MOL CELL, V8, P911, DOI 10.1016/S1097-2765(01)00355-0; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RICCIARDI RP, 2004, IN PRESS METHODS MOL; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; TSURUMI T, 1993, J VIROL, V67, P7648, DOI 10.1128/JVI.67.12.7648-7653.1993; WEILAND KL, 1994, VIRUS RES, V34, P191, DOI 10.1016/0168-1702(94)90124-4; Wu FY, 2001, J VIROL, V75, P1487, DOI 10.1128/JVI.75.3.1487-1506.2001; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	36	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28375	28386		10.1074/jbc.M400032200	http://dx.doi.org/10.1074/jbc.M400032200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15075322	hybrid			2022-12-25	WOS:000222265400070
J	Conley, BA; Koleva, R; Smith, JD; Kacer, D; Zhang, DW; Bernabeu, C; Vary, CPH				Conley, BA; Koleva, R; Smith, JD; Kacer, D; Zhang, DW; Bernabeu, C; Vary, CPH			Endoglin controls cell migration and composition of focal adhesions - Function of the cytosolic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; HUMAN-ENDOTHELIAL-CELLS; BETA-BINDING-PROTEIN; RGD-CONTAINING GLYCOPROTEIN; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; RECEPTOR SYSTEM; EXPRESSION; ZYXIN; PHOSPHORYLATION	Mutations in the human endoglin gene result in hereditary hemorrhagic telangiectasia type 1, a vascular disorder characterized by multisystemic vascular dysplasia, arteriovenous malformations, and focal dilatation of postcapillary venules. Previous studies have implicated endoglin in the inhibition of cell migration in vivo and in vitro. In the course of studies to address the relationship of the conserved cytosolic domain to endoglin function, we identified zyxin, a LIM domain protein that is concentrated at focal adhesions, as an interactor with endoglin in human umbilical vein vascular endothelial cells. This interaction is localized within the 47-amino acid carboxyl-terminal cytosolic domain of endoglin, and maps within zyxin residues 326 - 572. The endoglin-zyxin interaction was found to be largely mediated by the third LIM domain of zyxin, and is specific for endoglin because the homologous cytosolic domain of the transforming growth factor-beta type III receptor, betaglycan, fails to interact with zyxin. Expression of endoglin is associated with reduction of zyxin, as well as its interacting proteins p130(cas) and CrkII, from a focal adhesion protein fraction, and this reduction is correlated with inhibition of cell migration. We also show that endoglin-dependent: (i) inhibition of cell migration, (ii) reduction of focal adhesion-associated p130(cas)/CrkII protein levels, (iii) tyrosine phosphorylation of p130(cas), and (iv) focal adhesion-associated endoglin levels are mediated by the cytosolic domain of endoglin. These results suggest a novel mechanism of endoglin function involving its interaction with LIM domain-containing proteins, and associated adapter proteins, affecting sites of focal adhesion.	Maine Med Ctr, Ctr Mol Med, Res Inst, Scarborough, ME 04074 USA; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Maine Medical Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Vary, CPH (corresponding author), Maine Med Ctr, Ctr Mol Med, Res Inst, Scarborough, ME 04074 USA.	varyc@mmc.org	Bernabeu, Carmelo/L-3226-2014; Bernabeu, Carmelo/P-4662-2019	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162	PHS HHS [P20 15555] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; BRAVERMAN IM, 1990, J INVEST DERMATOL, V95, P422, DOI 10.1111/1523-1747.ep12555569; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chung YD, 2001, NEURON, V29, P415, DOI 10.1016/S0896-6273(01)00215-X; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; GOUGOS A, 1992, INT IMMUNOL, V4, P83, DOI 10.1093/intimm/4.1.83; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Haitjema T, 1996, ARCH INTERN MED, V156, P714, DOI 10.1001/archinte.156.7.714; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hoffman LM, 2003, MOL CELL BIOL, V23, P70, DOI 10.1128/MCB.23.1.70-79.2003; Jacobson BS, 2000, AM J PATHOL, V156, P737, DOI 10.1016/S0002-9440(10)64939-5; Jazwinska A, 2003, NAT CELL BIOL, V5, P895, DOI 10.1038/ncb1049; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Leccia MT, 1999, J INVEST DERMATOL, V113, P651, DOI 10.1046/j.1523-1747.1999.00726.x; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pece N, 1997, J CLIN INVEST, V100, P2568, DOI 10.1172/JCI119800; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Prout M, 1997, GENETICS, V146, P275; Riedy MC, 1999, EXP CELL RES, V251, P194, DOI 10.1006/excr.1999.4573; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Smith JD, 1999, CIRC RES, V84, P1212, DOI 10.1161/01.RES.84.10.1212; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; TURNER CE, 1989, J BIOL CHEM, V264, P11938; WOOD CK, 1994, J CELL SCI, V107, P709; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200	48	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27440	27449		10.1074/jbc.M312561200	http://dx.doi.org/10.1074/jbc.M312561200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084601	Green Published, hybrid			2022-12-25	WOS:000222120400075
J	Gregan, B; Jurgensen, J; Papsdorf, G; Furkert, J; Schaefer, M; Beyermann, M; Rosenthal, W; Oksche, A				Gregan, B; Jurgensen, J; Papsdorf, G; Furkert, J; Schaefer, M; Beyermann, M; Rosenthal, W; Oksche, A			Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT PHARMACOLOGICAL-PROPERTIES; ASTROGLIAL GAP-JUNCTIONS; ETB-RECEPTOR; G-PROTEIN; TRAFFICKING; ACTIVATION; ROLES; IDENTIFICATION; SUBTYPE; CLONING	Endothelin-1 (ET-1) is a potent vasoactive peptide that acts on endothelin A (ETA) and endothelin B (ETB) receptors. Although both receptor subtypes are co-expressed in numerous cells, little is known about their ability to form heterodimers. Here we show that both receptors were co-immunoprecipitated with an ETB-specific antibody using extracts from HEK293 cells stably co-expressing a fusion protein consisting of a myc-tagged ETA receptor and CFP (ET(A)myc.CFP) and a fusion protein consisting of an ETB receptor and YFP (ETB . YFP). Co-immunoprecipitation was also observed with extracts from HEK293 cells transiently co-expressing FLAG-tagged ETB and myc-tagged ETA receptors, thereby excluding that heterodimerization is mediated by the CFP/YFP moieties. Heterodimerization was further confirmed in fluorescence resonance energy transfer ( FRET) analysis of HEK293 cells transiently co-expressing ET(A)myc.CFP and ETB.YFP receptors. FRET efficiencies were between 12 and 18% in untreated and antagonist- or ET-1-treated cells, indicating constitutive heterodimerization. Prolonged stimulation (30 min) with the ETB receptor-selective agonist BQ3020 decreased FRET efficiency by 50%. This decrease was not observed when internalization was inhibited by co-expression of dominant-negative K44A.dynamin I or incubation with 450 mM sucrose. Enzyme-linked immunosorbent assay and laser scanning microscopy of cell clones stably co-expressing ET(A)myc.CFP/ET(B)flag.YFP receptors revealed a slower sequestration of the ET(B)flag.YFP receptors upon stimulation with ET-1 than with BQ3020. No difference in ET-1 or BQ3020-mediated sequestration was observed with cell clones expressing ET(B)flag.YFP receptors alone. The data suggest that ETA and ETB receptors form constitutive heterodimers, which show a slower sequestration upon stimulation with ET-1 than with BQ3020. Heterodimer dissociation along the endocytic pathway only occurs upon ETB-selective stimulation.	Charite Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Oksche, A (corresponding author), Charite Univ Med Berlin, Inst Pharmakol, Campus Benjamin Franklin,Thielallee 67-73, D-14195 Berlin, Germany.	alexander.oksche@medizin.fu-berlin.de	Oksche, Alexander/M-6678-2019	Oksche, Alexander/0000-0003-4592-1770				Angelova K, 1997, ENDOCRINE, V7, P287, DOI 10.1007/BF02801321; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Blomstrand F, 1999, AM J PHYSIOL-CELL PH, V277, pC616, DOI 10.1152/ajpcell.1999.277.4.C616; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cheng ZJ, 2003, J BIOL CHEM, V278, P52972, DOI 10.1074/jbc.M310090200; Cramer H, 2001, EUR J BIOCHEM, V268, P5449, DOI 10.1046/j.0014-2956.2001.02486.x; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P2334; Dupuis J, 1996, J APPL PHYSIOL, V81, P1510, DOI 10.1152/jappl.1996.81.4.1510; EGUCHI S, 1993, J CARDIOVASC PHARM, V22, pS161, DOI 10.1097/00005344-199322008-00043; Ehrenreich H, 1999, AM J PHYSIOL-CELL PH, V277, pC614, DOI 10.1152/ajpcell.1999.277.4.C614; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Grantcharova E, 2002, J BIOL CHEM, V277, P43933, DOI 10.1074/jbc.M208407200; Harada N, 2002, CELL MOL NEUROBIOL, V22, P207, DOI 10.1023/A:1019822107048; Hasselblatt M, 1998, BRAIN RES, V785, P253, DOI 10.1016/S0006-8993(97)01368-1; Iwasa S, 1999, ATHEROSCLEROSIS, V146, P93, DOI 10.1016/S0021-9150(99)00134-3; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KITSUKAWA Y, 1994, AM J PHYSIOL, V266, pG713, DOI 10.1152/ajpgi.1994.266.4.G713; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liu B, 2003, J BIOL CHEM, V278, P2384, DOI 10.1074/jbc.M208683200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Oksche A, 2000, J CARDIOVASC PHARM, V36, pS44; Pagano A, 2001, J NEUROSCI, V21, P1189; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sasaki Y, 1998, EUR J NEUROSCI, V10, P2984, DOI 10.1111/j.1460-9568.1998.00305.x; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; SEO B, 1994, CIRCULATION, V89, P1203, DOI 10.1161/01.CIR.89.3.1203; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	40	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27679	27687		10.1074/jbc.M403601200	http://dx.doi.org/10.1074/jbc.M403601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075338	hybrid			2022-12-25	WOS:000222120400102
J	Huang, YC; Chen, JY; Hung, WC				Huang, YC; Chen, JY; Hung, WC			Vitamin D-3 receptor/Sp1 complex is required for the induction of p27(Kip1) expression by vitamin D-3	ONCOGENE			English	Article						vitamin D-3; p27(Kip1); Sp1; small interference RNA; NF-Y	TRANSCRIPTIONAL ACTIVATION; PROMOTER ACTIVITY; GENE-EXPRESSION; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; GROWTH-INHIBITION; CANCER CELLS; NF-Y; SP1; DIFFERENTIATION; 17-BETA-ESTRADIOL	1alpha, 25-dihydroxyvitamin D-3 (vitamin D-3) has been shown to upregulate p27(Kip1) expression via Sp1 and NF-Y binding sites in the p27(Kip1) promoter. However, whether vitamin D-3 receptor (VDR) involves in this process is unclear. In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D-3-stimulated p27(Kip1) promoter activity. On the contrary, suppression of Sp1 expression by small interference RNA reduced the stimulation of p27(Kip1) promoter activity by vitamin D-3 in LNCaP cells. DNA affinity precipitation assay and chromatin immunoprecipitation assay showed that VDR bound to the p27(Kip1) promoter in vitro and in vivo. In addition, we also demonstrated that VDR interacted with Sp1 in vitro and in cells. Collectively, our results suggest that VDR is involved in the induction of p27(Kip1) by vitamin D-3 and may interact with Sp1 to modulate the expression of target genes that lack VDR response element (VDRE) in their promoters.	Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan.	hung1228@ms10.hinet.net						Boyan BD, 2002, STEROIDS, V67, P421, DOI 10.1016/S0039-128X(01)00178-7; Buitrago C, 2000, J CELL BIOCHEM, V79, P274, DOI 10.1002/1097-4644(20001101)79:2<274::AID-JCB100>3.0.CO;2-R; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; GARETH IO, 1998, J BIOL CHEM, V273, P10696; Ge YB, 2002, BBA-GENE STRUCT EXPR, V1579, P73, DOI 10.1016/S0167-4781(02)00509-2; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Guyton KZ, 2001, ANNU REV PHARMACOL, V41, P421, DOI 10.1146/annurev.pharmtox.41.1.421; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Harper JW, 1997, CANCER SURV, V29, P91; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hewetson A, 2003, J BIOL CHEM, V278, P40177, DOI 10.1074/jbc.M303921200; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Johnson CS, 2002, CANCER METAST REV, V21, P147, DOI 10.1023/A:1020836226594; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Kumagai T, 2003, J NATL CANCER I, V95, P896, DOI 10.1093/jnci/95.12.896; Liu LT, 2003, CANCER RES, V63, P3069; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu W, 2002, AM J PATHOL, V160, P511, DOI 10.1016/S0002-9440(10)64870-5; Lok CN, 2002, BIOCHEM J, V368, P741, DOI 10.1042/BJ20020791; Martinez ME, 1996, JNCI-J NATL CANCER I, V88, P1375, DOI 10.1093/jnci/88.19.1375; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Narvaez CJ, 2001, STEROIDS, V66, P301, DOI 10.1016/S0039-128X(00)00202-6; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Schwartz Z, 2003, STEROIDS, V68, P423, DOI 10.1016/S0039-128X(03)00044-8; SHABAHANG M, 1994, CANCER RES, V54, P4057; SHABAHANG M, 1993, CANCER RES, V53, P3712; SHIGEAKI K, 2000, J BIOCH, V127, P717; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; Valor LM, 2002, J BIOL CHEM, V277, P8866, DOI 10.1074/jbc.M110454200; Vidal M, 2002, MOL CELL BIOL, V22, P2777, DOI 10.1128/MCB.22.8.2777-2787.2002; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; ZHANG DE, 1994, J IMMUNOL, V153, P3276; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	45	64	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4856	4861		10.1038/sj.onc.1207621	http://dx.doi.org/10.1038/sj.onc.1207621			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064717				2022-12-25	WOS:000222104200006
J	Alonso, MBD; Zoidl, G; Taveggia, C; Bosse, F; Zoidl, C; Rahman, M; Parmantier, E; Dean, CH; Harris, BS; Wrabetz, L; Muller, HW; Jessen, KR; Mirsky, R				Alonso, MBD; Zoidl, G; Taveggia, C; Bosse, F; Zoidl, C; Rahman, M; Parmantier, E; Dean, CH; Harris, BS; Wrabetz, L; Muller, HW; Jessen, KR; Mirsky, R			Identification and characterization of ZFP-57, a novel zinc finger transcription factor in the mammalian peripheral nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWANN-CELL DEVELOPMENT; GROWTH-FACTOR; FACTOR SOX10; REPRESSION DOMAIN; NUCLEAR RECEPTORS; GENE-EXPRESSION; PROTEINS; KRUPPEL; DIFFERENTIATION; MYELINATION	To isolate new zinc finger genes expressed at early stages of peripheral nerve development, we have used PCR to amplify conserved zinc finger sequences. RNA from rat embryonic day 12 and 13 sciatic nerves, a stage when nerves contain Schwann cell precursors, was used to identify several genes not previously described in Schwann cells. One of them, zinc finger protein (ZFP)-57, proved to be the homologue of a mouse gene found in F9 teratocarcinoma cells. Its mRNA expression profile within embryonic and adult normal and transected peripheral nerves, and its distribution in the rest of the nervous system is described. High levels of expression are seen in embryonic nerves and spinal cord. These drop rapidly during the first few weeks after birth, a pattern mirrored in other parts of the nervous system. ZFP-57 localizes to the nucleus of Schwann and other cells. The sequence contains an N-terminal Kruppel-associated box ( KRAB) domain and ZFP-57 constructs containing green fluorescent protein reveal that the protein colocalizes with heterochromatin protein 1alpha to centromeric heterochromatin in a characteristic speckled pattern in NIH3T3 cells. The KRAB domain is required for this localization, because constructs lacking it target the protein to the nucleus but not to the centromeric heterochromatin. When fused to a heterologous DNA binding domain, the KRAB domain of ZFP-57 represses transcription, and full-length ZFP-57 represses Schwann cell transcription from myelin basic protein and P-0 promoters in co-transfection assays. Zfp-57 mRNA is up-regulated in Schwann cells in response to leukemia inhibitory factor and fibroblast growth factor 2.	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, D-44780 Bochum, Germany; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy; Univ Dusseldorf, Dept Neurol, Mol Neurobiol Lab, D-40225 Dusseldorf, Germany; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	University of London; University College London; Ruhr University Bochum; Vita-Salute San Raffaele University; Heinrich Heine University Dusseldorf; Medical University of South Carolina	Mirsky, R (corresponding author), UCL, Dept Anat & Dev Biol, Gower St, London WC1E 6BT, England.	r.mirsky@ucl.ac.uk	Taveggia, Carla/AAN-4784-2020; Alonso, M. Beatriz Durán/L-5858-2017	Alonso, M. Beatriz Durán/0000-0001-7784-0591; Bosse, Frank/0000-0002-8825-2071				Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; Blanchard AD, 1996, J NEUROSCI RES, V46, P630, DOI 10.1002/(SICI)1097-4547(19961201)46:5<630::AID-JNR11>3.0.CO;2-0; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; BROCKES JP, 1980, J BIOL CHEM, V255, P8374; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CONSTANTINOUDELTAS CD, 1992, GENOMICS, V12, P581, DOI 10.1016/0888-7543(92)90451-W; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Dong ZP, 1999, J NEUROSCI RES, V56, P334, DOI 10.1002/(SICI)1097-4547(19990515)56:4<334::AID-JNR2>3.0.CO;2-#; Dovat S, 1998, BBA-GENE STRUCT EXPR, V1442, P380, DOI 10.1016/S0167-4781(98)00167-5; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GAVRILOVIC J, 1995, EUR J NEUROSCI, V7, P77, DOI 10.1111/j.1460-9568.1995.tb01022.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERDEGEN T, 1993, NEUROSCIENCE, V57, P41, DOI 10.1016/0306-4522(93)90110-2; Jaegle M, 2003, GENE DEV, V17, P1380, DOI 10.1101/gad.258203; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; JESSEN KR, 1994, NEURON, V12, P509, DOI 10.1016/0896-6273(94)90209-7; Jessen KR, 2002, J ANAT, V200, P367, DOI 10.1046/j.1469-7580.2002.00046.x; Jessen KR, 1999, TRENDS NEUROSCI, V22, P402, DOI 10.1016/S0166-2236(98)01391-5; Kendall G, 1996, EUR J BIOCHEM, V236, P360, DOI 10.1111/j.1432-1033.1996.00360.x; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Kury P, 2002, J NEUROSCI, V22, P7586; Labatut-Cazabat I, 1999, NEUROREPORT, V10, P3037, DOI 10.1097/00001756-199909290-00030; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mark C, 1999, DNA CELL BIOL, V18, P381, DOI 10.1089/104454999315277; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; Mercier G, 2001, MOL BRAIN RES, V97, P137, DOI 10.1016/S0169-328X(01)00311-4; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; Mirsky R, 1999, BRAIN PATHOL, V9, P293; MIRSKY R, 2001, GLIAL CELL DEV BASIC, P1; MULLER HW, 1986, J CELL BIOL, V102, P393, DOI 10.1083/jcb.102.2.393; Nagarajan R, 2002, P NATL ACAD SCI USA, V99, P8998, DOI 10.1073/pnas.132080999; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; OKAZAKI S, 1994, J BIOL CHEM, V269, P6900; OWENS GC, 1991, DEVELOPMENT, V112, P639; Parkinson DB, 2002, MOL CELL NEUROSCI, V20, P154, DOI 10.1006/mcne.2002.1109; Parkinson DB, 2004, J CELL BIOL, V164, P385, DOI 10.1083/jcb.200307132; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; PELLEGRINO GR, 1991, P NATL ACAD SCI USA, V88, P671, DOI 10.1073/pnas.88.2.671; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; PORTER S, 1986, J NEUROSCI, V6, P3070; Ramsauer M, 2002, FASEB J, V16, P1274, DOI 10.1096/fj.01-0814fje; Remboutsika E, 1999, J CELL SCI, V112, P1671; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Slutsky SG, 2003, J BIOL CHEM, V278, P8960, DOI 10.1074/jbc.M210569200; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Stewart HJS, 1997, J NEUROBIOL, V33, P914, DOI 10.1002/(SICI)1097-4695(199712)33:7<914::AID-NEU4>3.0.CO;2-B; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; Tofaris GK, 2002, J NEUROSCI, V22, P6696; Topilko P, 1997, J NEUROSCI RES, V50, P702, DOI 10.1002/(SICI)1097-4547(19971201)50:5<702::AID-JNR7>3.0.CO;2-L; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; TOPILKO P, 2001, GLIAL CELL DEV, P223; VONSTRANDMANN EP, 1995, PROTEIN ENG, V8, P733; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Wrabetz L, 1998, J NEUROBIOL, V34, P10, DOI 10.1002/(SICI)1097-4695(199801)34:1<10::AID-NEU2>3.0.CO;2-F; Zoidl G, 2002, J NEUROSCI RES, V69, P448, DOI 10.1002/jnr.10284; ZOIDL G, 1995, EMBO J, V14, P1122, DOI 10.1002/j.1460-2075.1995.tb07095.x	71	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25653	25664		10.1074/jbc.M400415200	http://dx.doi.org/10.1074/jbc.M400415200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070898	hybrid			2022-12-25	WOS:000221827900094
J	Andrin, C; Hendzel, MJ				Andrin, C; Hendzel, MJ			F-actin-dependent insolubility of chromatin-modifying components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEAR-MATRIX; HISTONE DEACETYLASE; SWI/SNF COMPLEX; N-COR; PROTEIN COMPLEXES; MESSENGER-RNA; L5178Y CELLS; IN-VIVO; ASSOCIATION	Many complexes involved in chromatin modification are difficult to isolate and commonly found associated with nuclear matrix preparations. In this study, we examine the elution properties of chromatin-modifying components under different extraction conditions. We find that most, but not all, histone acetyltransferases and histone deacetylases predominantly partition with the nuclear pellet during intermediate salt extraction. In attempts to identify a biological basis for the observed insolubility, we demonstrate that depolymerizing cellular actin, but not cellular tubulin, mobilizes a significant proportion of the insoluble pool into the intermediate salt-soluble nuclear extract. The disruption of cellular F-actin releases a specific subset of high molecular weight, active, nuclear histone deacetylase complexes that are not found under normal conditions. This study demonstrates that actin polymerization, a physiologically relevant process, is responsible for the observed insolubility of these components during nuclear extract preparation and establishes a simple strategy for isolating subsets of chromatin-modifying complexes that are otherwise depleted or absent under the same extraction conditions.	Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Hendzel, MJ (corresponding author), Rm 3332,11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	michaelh@cancerboard.ab.ca	Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Boyer LA, 2000, BIOESSAYS, V22, P666, DOI 10.1002/1521-1878(200007)22:7<666::AID-BIES9>3.0.CO;2-Y; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; De La Espina SMD, 2003, CELL BIOL INT, V27, P233, DOI 10.1016/S1065-6995(02)00340-2; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Grzanka A, 2004, ONCOL REP, V11, P765; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Hendzel MJ, 2001, J STEROID BIOCHEM, V76, P9, DOI 10.1016/S0960-0760(00)00153-9; Herrmann H, 2003, CELL MOL LIFE SCI, V60, P1607, DOI 10.1007/s00018-003-3004-0; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ito T, 2003, CURR TOP MICROBIOL, V274, P1; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Krauss SW, 2003, P NATL ACAD SCI USA, V100, P10752, DOI 10.1073/pnas.1934680100; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; NAKAYASU H, 1983, EXP CELL RES, V143, P55, DOI 10.1016/0014-4827(83)90108-8; NAKAYASU H, 1985, EXP CELL RES, V160, P319, DOI 10.1016/0014-4827(85)90179-X; NAKAYASU H, 1986, EXP CELL RES, V163, P327, DOI 10.1016/0014-4827(86)90064-9; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Oma Y, 2003, BIOCHEM BIOPH RES CO, V301, P521, DOI 10.1016/S0006-291X(02)03073-5; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Percipalle P, 2003, P NATL ACAD SCI USA, V100, P6475, DOI 10.1073/pnas.1131933100; Percipalle P, 2002, NUCLEIC ACIDS RES, V30, P1725, DOI 10.1093/nar/30.8.1725; Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Rando OJ, 2002, P NATL ACAD SCI USA, V99, P2824, DOI 10.1073/pnas.032662899; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Subramanian T, 2003, FEBS LETT, V540, P255, DOI 10.1016/S0014-5793(03)00275-8; Sun JM, 2003, METHODS, V31, P12, DOI 10.1016/S1046-2023(03)00083-5; Szerlong H, 2003, EMBO J, V22, P3175, DOI 10.1093/emboj/cdg296; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Walss-Bass C, 2002, CELL TISSUE RES, V308, P215, DOI 10.1007/s00441-002-0539-6; Wang W, 2003, CURR TOP MICROBIOL, V274, P143; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Widlak P, 2002, J BIOL CHEM, V277, P21683, DOI 10.1074/jbc.M201027200; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	56	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25017	25023		10.1074/jbc.M401805200	http://dx.doi.org/10.1074/jbc.M401805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082715	hybrid			2022-12-25	WOS:000221827900016
J	Shirai, C; Takai, T; Nariai, M; Horigome, C; Mizuta, K				Shirai, C; Takai, T; Nariai, M; Horigome, C; Mizuta, K			Ebp2p, the yeast homolog of Epstein-Barr virus nuclear antigen 1-binding protein 2, interacts with factors of both the 60 S and the 40 S ribosomal subunit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PRE-RIBOSOMES; SECRETORY DEFECT; RNA SYNTHESIS; BIOGENESIS; IDENTIFICATION; NUCLEOLUS; CYTOPLASM; PARTICLE; SYSTEM	Ebp2p, the yeast homolog of human Epstein-Barr virus nuclear antigen 1-binding protein 2, is essential for biogenesis of the 60 S ribosomal subunit. Two-hybrid screening exhibited that, in addition to factors necessary for assembly of the 60 S subunit, Ebp2p interacts with Rps16p, ribosomal protein S16, and the 40 S ribosomal subunit assembly factor, Utp11p, as well as Yil019w, the function of which was previously uncharacterized. Depletion of Yil019w resulted in reduction in levels of both of 18 S rRNA and 40 S ribosomal subunit without affecting levels of 25 S rRNA and 60 S ribosomal subunits. 35 S pre-rRNA and aberrant 23 S RNA accumulated, indicating that pre-rRNA processing at sites A(0)-A(2) is inhibited when Yil019w is depleted. Each combination from Yil019w, Utp11p, and Rps16p showed two-hybrid interaction.	Hiroshima Univ, Grad Sch Biosphere Sci, Dept Bioresource Sci & Technol, Higashihiroshima, Japan	Hiroshima University	Mizuta, K (corresponding author), Hiroshima Univ, Grad Sch Biosphere Sci, Dept Bioresource Sci & Technol, Kagamiyama 1-4-4, Higashihiroshima, Japan.	kmizuta@hiroshima-u.ac.jp	Horigome, Chihiro/AAH-5989-2021					Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Daugeron MC, 2001, RNA, V7, P1317, DOI 10.1017/S1355838201010640; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; Kaser A, 2001, BIOL CHEM, V382, P1637, DOI 10.1515/BC.2001.199; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Miyoshi K, 2002, J BIOL CHEM, V277, P18334, DOI 10.1074/jbc.M201667200; Miyoshi K, 2001, NUCLEIC ACIDS RES, V29, P3297, DOI 10.1093/nar/29.16.3297; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Morita D, 2002, J BIOL CHEM, V277, P28780, DOI 10.1074/jbc.M203399200; MOUGEY EB, 1993, GENE DEV, V7, P1609, DOI 10.1101/gad.7.8.1609; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; SIKORSKI RS, 1989, GENETICS, V122, P19; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Tsujii R, 2000, GENES CELLS, V5, P543, DOI 10.1046/j.1365-2443.2000.00346.x; Tsuno A, 2000, MOL CELL BIOL, V20, P2066, DOI 10.1128/MCB.20.6.2066-2074.2000; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; Wehner KA, 2002, MOL CELL, V9, P329, DOI 10.1016/S1097-2765(02)00438-0; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; Wu K, 2001, NUCLEIC ACIDS RES, V29, P2938, DOI 10.1093/nar/29.14.2938	34	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25353	25358		10.1074/jbc.M403338200	http://dx.doi.org/10.1074/jbc.M403338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078877	hybrid			2022-12-25	WOS:000221827900057
J	Valeva, A; Walev, I; Weis, S; Boukhallouk, F; Wassenaar, TM; Endres, K; Fahrenholz, F; Bhakdi, S; Zitzer, A				Valeva, A; Walev, I; Weis, S; Boukhallouk, F; Wassenaar, TM; Endres, K; Fahrenholz, F; Bhakdi, S; Zitzer, A			A cellular metalloproteinase activates Vibrio cholerae pro-cytolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING TOXIN; STAPHYLOCOCCAL ALPHA-HEMOLYSIN; HEPTAMERIC TRANSMEMBRANE PORE; STRUCTURAL GENE HLYA; EL-TOR CYTOLYSIN; NUCLEOTIDE-SEQUENCE; PROTECTIVE ANTIGEN; IN-VITRO; FURIN; AEROLYSIN	Many strains of Vibrio cholerae produce a cytolysin (VCC) that forms oligomeric transmembrane pores in animal cells. The molecule is secreted as a procytolysin (pro-VCC) of 79 kDa that must be cleaved at the N terminus to generate the active 65-kDa toxin. Processing can occur in solution, and previous studies have described the action of mature VCC thus generated. However, little is known about the properties of pro-VCC itself. In this study, it is shown that pro-VCC exist as a monomer in solution and binds as a monomer to eukaryotic cells. Bound pro-VCC can then be activated either by exogenous, extracellular, or by endogenous, cell-bound proteases. In both cases, cleavage generates the 65-kDa VCC that oligomerizes to form transmembrane pores. A wide variety of exogenous proteinases can mediate activation. In contrast, the activating cellular protease is selectively inhibited by the hydroxamate inhibitor TAPI, and thus probable candidates are members of the ADAM-metalloproteinase family. Furin, MMP-2, MMP-9, and serine proteinases were excluded. Cells over-expressing ADAM-17, also known as tumor necrosis factor alpha converting enzyme, displayed increased activation of VCC, and knockout cells lacking ADAM-17 had a markedly decreased capacity to cleave the protoxin. The possibility is raised that pro-VCC is targeted to membrane sites that selectively contain or are accessible to cellular ADAM-metalloproteinases. Although many microbial toxins are activated by furin, this is the first evidence for processing by a cellular metalloproteinase. We identified ADAM-17 as a potent activator of pro-VCC.	Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Mol Microbiol & Genom Consultants, D-55576 Zotzenheim, Germany; Johannes Gutenberg Univ Mainz, Inst Biochem, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Valeva, A (corresponding author), Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, Augustuspl, D-55101 Mainz, Germany.	avaleva@uni-mainz.de	Endres, Kristina/K-4960-2015	Wassenaar, Trudy/0000-0002-7024-1139				Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; ALM RA, 1988, MOL MICROBIOL, V2, P481; Barry R, 2001, J BIOL CHEM, V276, P551, DOI 10.1074/jbc.M008097200; Fivaz M, 1999, J BIOL CHEM, V274, P37705, DOI 10.1074/jbc.274.53.37705; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; GARRED O, 1995, J BIOL CHEM, V270, P10817; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Gordon VM, 1997, INFECT IMMUN, V65, P4130, DOI 10.1128/IAI.65.10.4130-4134.1997; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; Harris JR, 2002, J STRUCT BIOL, V139, P122; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; ICHINOSE Y, 1987, INFECT IMMUN, V55, P1090, DOI 10.1128/IAI.55.5.1090-1093.1987; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KRASILNIKOV OV, 1992, BIOCHIM BIOPHYS ACTA, V1111, P7, DOI 10.1016/0005-2736(92)90268-Q; Miles G, 2001, BIOCHEMISTRY-US, V40, P8514, DOI 10.1021/bi010454o; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moschioni M, 2002, CELL MICROBIOL, V4, P397, DOI 10.1046/j.1462-5822.2002.00199.x; Nagamune K, 1996, INFECT IMMUN, V64, P4655, DOI 10.1128/IAI.64.11.4655-4658.1996; Nagamune K, 1997, J BIOL CHEM, V272, P1338, DOI 10.1074/jbc.272.2.1338; Ninin E, 2000, EUR J CLIN MICROBIOL, V19, P489, DOI 10.1007/s100960000296; Olson R, 2003, PROTEIN SCI, V12, P379, DOI 10.1110/ps.0231703; Pichel M, 2003, J CLIN MICROBIOL, V41, P124, DOI 10.1128/JCM.41.1.124-134.2003; RADER AE, 1988, INFECT IMMUN, V56, P1414, DOI 10.1128/IAI.56.6.1414-1419.1988; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SAFRIN S, 1988, REV INFECT DIS, V10, P1012; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAMAMOTO K, 1986, INFECT IMMUN, V51, P927, DOI 10.1128/IAI.51.3.927-931.1986; YAMAMOTO K, 1990, INFECT IMMUN, V58, P4106, DOI 10.1128/IAI.58.12.4106-4116.1990; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375; ZITZER A, 1995, MED MICROBIOL IMMUN, V184, P37, DOI 10.1007/BF00216788; Zitzer A, 1997, EUR J BIOCHEM, V247, P209, DOI 10.1111/j.1432-1033.1997.00209.x; ZITZER AO, 1993, ZBL BAKT-INT J MED M, V279, P494, DOI 10.1016/S0934-8840(11)80421-4	41	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25143	25148		10.1074/jbc.M313913200	http://dx.doi.org/10.1074/jbc.M313913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066987	hybrid			2022-12-25	WOS:000221827900029
J	Taylor, MD; Zhang, XY; Liu, L; Hui, CC; Mainprize, TG; Scherer, SW; Wainwright, B; Hogg, D; Rutka, JT				Taylor, MD; Zhang, XY; Liu, L; Hui, CC; Mainprize, TG; Scherer, SW; Wainwright, B; Hogg, D; Rutka, JT			Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling	ONCOGENE			English	Article						medulloblastoma; suppressor of fused; SUFU; brain tumor; WNT signaling; cerebellum	ADENOMATOUS POLYPOSIS-COLI; RUBINSTEIN-TAYBI SYNDROME; CENTRAL-NERVOUS-SYSTEM; BETA-CATENIN; CUBITUS INTERRUPTUS; GENE-EXPRESSION; SONIC HEDGEHOG; SPORADIC MEDULLOBLASTOMAS; PATHWAY COMPONENTS; NEGATIVE REGULATOR	Germline mutations of APC in patients with Turcot syndrome (colon cancer and medulloblastoma), was well as somatic mutations of APC, beta-catenin, and Axin in sporadic medulloblastomas (MBs) have shown the importance of WNT signaling in the pathogenesis of MB. A subset of children with MB have germline mutations of SUFU, a known inhibitor of Hedgehog signal transduction. A recent report suggested that murine Sufu can bind beta-catenin, export it from the nucleus, and thereby repress beta-catenin/T-cell factor (Tcf)-mediated transcription. We show that an MB-derived mutant of SUFU has lost the ability to decrease nuclear levels of beta-catenin, and cannot inhibit beta-catenin/Tcf-mediated transcription as compared to wild type SUFU. Our results suggest that loss of function of SUFU results in overactivity of both the Sonic Hedgehog, and the WNT signaling pathways, leading to excessive proliferation and failure to differentiate resulting in MB.	Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Div Med & Mol Genet, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Queensland, Ritchie Res Labs, St Lucia, Qld 4072, Australia	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Queensland	Rutka, JT (corresponding author), Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumour Res Ctr, Suite 1504,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.rutka@sickkids.ca	Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999; Wainwright, Brandon/0000-0003-0406-2092; Taylor, Michael/0000-0001-7009-3466				Baeza N, 2003, ONCOGENE, V22, P632, DOI 10.1038/sj.onc.1206156; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; Dahmen RP, 2001, CANCER RES, V61, P7039; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; EVANS G, 1993, MED PEDIATR ONCOL, V21, P433, DOI 10.1002/mpo.2950210608; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Iwao K, 1998, CANCER RES, V58, P1021; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7; Kitas G, 2001, CLIN MED, V1, P18, DOI 10.7861/clinmedicine.1-1-18; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee CS, 2000, DEVELOPMENT, V127, P109; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Mainprize T G, 2000, Clin Neurosurg, V47, P259; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Meng XW, 2001, J BIOL CHEM, V276, P40113, DOI 10.1074/jbc.M105317200; Methot N, 2000, DEVELOPMENT, V127, P4001; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Nakagawa H, 1999, JPN J CANCER RES, V90, P982, DOI 10.1111/j.1349-7006.1999.tb00845.x; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Skousen GJ, 1996, AM J MED GENET, V66, P367, DOI 10.1002/(SICI)1096-8628(19961218)66:3<367::AID-AJMG27>3.3.CO;2-8; Steigerwald K, 2001, J MED GENET, V38, P257, DOI 10.1136/jmg.38.4.257; Stone DM, 1999, J CELL SCI, V112, P4437; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Taylor MD, 2001, PEDIATR NEUROSURG, V35, P235, DOI 10.1159/000050428; Taylor MD, 1999, J NEUROSURG, V90, P946, DOI 10.3171/jns.1999.90.5.0946; Taylor MD, 2000, NEUROSURGERY, V47, P888, DOI 10.1097/00006123-200010000-00020; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Vortmeyer AO, 1999, CANCER, V85, P2662, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2662::AID-CNCR24>3.0.CO;2-0; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wechsler-Reya RJ, 2003, RECENT PROG HORM RES, V58, P227, DOI 10.1210/rp.58.1.227; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yokota N, 2002, INT J CANCER, V101, P198, DOI 10.1002/ijc.10559; YONG WH, 1995, NEW ENGL J MED, V333, P524; Zurawel RH, 1998, CANCER RES, V58, P896	53	59	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4577	4583		10.1038/sj.onc.1207605	http://dx.doi.org/10.1038/sj.onc.1207605			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077159				2022-12-25	WOS:000221799000007
J	Yin, F; Bruemmer, D; Blaschke, F; Hsueh, WA; Law, RE; Van Herle, AJ				Yin, F; Bruemmer, D; Blaschke, F; Hsueh, WA; Law, RE; Van Herle, AJ			Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells	ONCOGENE			English	Article						troglitazone; breast cancer cell; GADD45; JNK; p38; ERK1/2	ACTIVATED RECEPTOR-GAMMA; PROTEIN-KINASE ACTIVATION; PPAR-GAMMA; POSTTRANSCRIPTIONAL REGULATION; LIGAND TROGLITAZONE; GROWTH-INHIBITION; CYCLE ARREST; COLON-CANCER; IN-VITRO; STRESS	We previously reported that the PPARgamma agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells. To understand the mechanisms of antiproliferative and pro-apoptotic effects of TRO, we screened a limited DNA array containing 23 genes involved in regulating either the cell cycle and/or apoptosis. Four of the 23 genes screened exhibited regulation by TRO, with growth arrest and DNA damage-inducible gene 45 (GADD45) being the most strongly upregulated. TRO induced GADD45 mRNA expression in a time- and dose-dependent manner. Depletion of GADD45 by siRNA abrogated TRO-induced apoptosis in MCF-7 cells demonstrating the physiological relevance of GADD45 upregulation. Signaling pathways mediating TRO-induced GADD45 were also investigated. Several mitogen-activated protein kinase (MAPK) pathways were involved in the induction of GADD45 by TRO. Inhibition of the c-jun N-terminal kinase MAPK pathway by SP600125 partially abolished TRO-induced GADD45 mRNA, and protein expression and apoptosis. In contrast, inhibition of the p38 MAPK pathway by SB203580, or through overexpression of a dominant-negative mutant of p38 MAPK, augmented GADD45 mRNA induction and GADD45 promoter activation as well as cell apoptosis by TRO. Blockade of the extracellular signal-regulated kinase MAPK pathway by PD98059 also enhanced TRO's effects on GADD45 and apoptosis. Two other PPARgamma agonists pioglitazone and rosiglitazone did not induce GADD45 expression. Our finding of GADD45 induction by TRO may provide a new insight concerning the mechanisms for TRO's antiproliferative and pro-apoptotic effects in breast cancer cells.	Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, F (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, 900 Vet Ave,24-130 Warren Hall, Los Angeles, CA 90024 USA.	fyin@mednet.ucla.edu						Asou H, 1999, INT J ONCOL, V15, P1027; Bae MA, 2003, MOL PHARMACOL, V63, P401, DOI 10.1124/mol.63.2.401; Begum NM, 2002, INT J ONCOL, V20, P599; Bruemmer D, 2003, CIRC RES, V93, pE38, DOI 10.1161/01.RES.0000088344.15288.E6; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chang TH, 2000, CANCER RES, V60, P1129; Chen C, 1998, AM J HEALTH-SYST PH, V55, P905, DOI 10.1093/ajhp/55.9.905; Chen F, 2001, ONCOGENE, V20, P3585, DOI 10.1038/sj.onc.1204442; CHEN IT, 1995, ONCOGENE, V11, P1931; Chitturi S, 2002, SEMIN LIVER DIS, V22, P169, DOI 10.1055/s-2002-30102; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; Hisatake J, 2000, CANCER RES, V60, P5494; Huin C, 2002, BIOL CELL, V94, P15, DOI 10.1016/S0248-4900(01)01178-9; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kostrubsky VE, 2000, DRUG METAB DISPOS, V28, P1192; Kubota T, 1998, CANCER RES, V58, P3344; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Mossner R, 2002, J INVEST DERMATOL, V119, P576, DOI 10.1046/j.1523-1747.2002.01861.x; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Otto C, 2002, PHARMACOGENOMICS, V3, P99, DOI 10.1517/14622416.3.1.99; Palakurthi SS, 2001, CANCER RES, V61, P6213; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rumi MAK, 2001, BRIT J CANCER, V84, P1640, DOI 10.1054/bjoc.2001.1821; Sakaue M, 1999, MOL PHARMACOL, V55, P668; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Sugimura A, 1999, BIOCHEM BIOPH RES CO, V261, P833, DOI 10.1006/bbrc.1999.1049; Takahashi S, 2001, CANCER RES, V61, P1187; Takashima T, 2001, INT J ONCOL, V19, P465; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906	47	74	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4614	4623		10.1038/sj.onc.1207598	http://dx.doi.org/10.1038/sj.onc.1207598			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064713				2022-12-25	WOS:000221799000011
J	Kohout, TA; Nicholas, SL; Perry, SJ; Reinhart, G; Junger, S; Struthers, RS				Kohout, TA; Nicholas, SL; Perry, SJ; Reinhart, G; Junger, S; Struthers, RS			Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HIGH-AFFINITY BINDING; FUNCTIONAL LIGAND; KINASE CASCADES; MAPK ACTIVATION; ENDOCYTOSIS; DETERMINANTS; TRANSDUCTION; CHEMOTAXIS; MIP-3-BETA	Many members of the chemokine receptor family of G protein-coupled receptors utilize multiple endogenous ligands. However, differences between the signaling properties of multiple chemokines through a single receptor have yet to be well characterized. In this study we investigated the early signaling events of CCR7 initiated by its two endogenous ligands, CCL19 and CCL21. Both CCL19 and CCL21 induce G protein activation and calcium mobilization with equal potency. However, only activation by CCL19, not CCL21, promotes robust desensitization of endogenous CCR7 in the human T cell lymphoma cell line H9. Desensitization occurs through the induction of receptor phosphorylation and beta-arrestin recruitment ( shown in HEK293 cells expressing CCR7-FLAG). The sites of CCL19-induced phosphorylation were mapped by mutating to alanines the serines and threonines found within kinase phosphorylation consensus sequences in the carboxyl terminus of CCR7. A cluster of sites, including Thr-373- 376 and Ser-378 is important for CCL19-mediated phosphorylation of the receptor, whereas residues serine 356, 357, 364, and 365 are important for basal receptor phosphorylation by protein kinase C. Activation of CCR7 by both ligands leads to signaling to the ERK1/2 mitogen-activated protein kinase pathway. However, CCL19 promotes 4-fold more ERK1/2 phosphorylation than does CCL21. The mechanism by which CCL19 activates ERK1/2 was determined to be beta-arrestin-dependent, because it is reduced both by depletion of beta-arrestin-2 with small interfering RNA and by elimination of the phosphorylation sites in the tail of the receptor. Taken together, these findings demonstrate that CCL19 and CCL21 place CCR7 in functionally distinct conformations that are independent of their G protein-coupling potency: one that allows the efficient desensitization of the receptor and activation of ERK1/2, and another that is impaired in these functions.	Neurocrine Biosci Inc, Dept Exploratory Discovery, San Diego, CA 92121 USA; Neurocrine Biosci Inc, Dept Mol Biol, San Diego, CA 92121 USA	Neurocrine Biosciences; Neurocrine Biosciences	Kohout, TA (corresponding author), Neurocrine Biosci Inc, Dept Exploratory Discovery, 10555 Sci Ctr Dr, San Diego, CA 92121 USA.	tkohout@neurocrine.com						Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; D'Ambrosio D, 2002, J IMMUNOL, V169, P2303, DOI 10.4049/jimmunol.169.5.2303; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Gantz I, 2003, AM J PHYSIOL-ENDOC M, V284, pE468, DOI 10.1152/ajpendo.00434.2002; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Ott TR, 2004, BIOCHEMISTRY-US, V43, P3670, DOI 10.1021/bi035895h; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Scandella E, 2004, BLOOD, V103, P1595, DOI 10.1182/blood-2003-05-1643; Sullivan SK, 1999, BIOCHEM BIOPH RES CO, V263, P685, DOI 10.1006/bbrc.1999.1442; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118	34	251	263	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23214	23222		10.1074/jbc.M402125200	http://dx.doi.org/10.1074/jbc.M402125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15054093	hybrid			2022-12-25	WOS:000221570900053
J	Yoshida, Y; Izumi, H; Torigoe, T; Ishiguchi, H; Yoshida, T; Itoh, H; Kohno, K				Yoshida, Y; Izumi, H; Torigoe, T; Ishiguchi, H; Yoshida, T; Itoh, H; Kohno, K			Binding of RNA to p53 regulates its oligomerization and DNA-binding activity	ONCOGENE			English	Article						p53; RNA; DNA binding; oligomerization; RNase	TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; IN-VIVO; PHOSPHORYLATION; DOMAIN; SITE; ACTIVATION; GROWTH; POLYPEPTIDE; COMPLEXES	The C-terminus of p53 is responsible for maintaining the latent, non-DNA-binding form of p53. However, the mechanism by which the C-terminus regulates DNA binding is not yet fully understood. We show here that p53 interacts with RNA via its C-terminal domain and that disruption of this interaction, by RNase A treatment, truncation or phosphorylation of the C-terminus, restores DNA-binding activity. Furthermore, the oligomerization of p53 is significantly enhanced by disrupting the interaction between p53 and RNA. These findings suggest that binding of RNA to p53 is involved in the mechanism of p53 latency.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 1, Yahatanishi Ku, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp		Yoshida, Yoichiro/0000-0001-6583-7352				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FISCELLA M, 1994, ONCOGENE, V9, P3249; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; FUCHS B, 1995, ONCOGENE, V10, P789; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; Torigoe T, 2003, NUCLEIC ACIDS RES, V31, P4523, DOI 10.1093/nar/gkg487; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Yoshida Y, 2003, CANCER RES, V63, P3729; Yoshida Y, 2002, BIOCHEM BIOPH RES CO, V295, P945, DOI 10.1016/S0006-291X(02)00757-X	43	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4371	4379		10.1038/sj.onc.1207583	http://dx.doi.org/10.1038/sj.onc.1207583			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064727				2022-12-25	WOS:000221661300003
J	Ren, Y; Roy, S; Ding, Y; Iqbal, J; Broome, JD				Ren, Y; Roy, S; Ding, Y; Iqbal, J; Broome, JD			Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein	ONCOGENE			English	Article						methyl binding protein; asparagine synthetase; leukemia	SENSING RESPONSE PATHWAY; DNA METHYLATION; GENE; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; REPRESSION; MEDIATOR; FAMILY; SITE	We have examined the methylation profiles of the asparagine synthetase (ASY) promoter in a number of human leukemic cell lines in relation to their asparagine (ASN) requirements in vitro. Cells in which the promoter is highly methylated are auxotrophs and express ASY at very low levels. Electromobility shift assays ( EMSA) of nuclear extracts with oligomers from the promoting region show, in addition to recognized transcription factor binding, a novel methyl binding protein specific for a 12 base consensus sequence, which includes a single methylated CpG. This sequence overlaps that of the amino-acid response unit of the ASY promoter, which is activated byATF4 and C/EBP. Competition by the methyl binding protein could account for the observed failure of the methylated promoter to bind these transcription factors and consequently, although other mechanisms can also be operative, for the specific repression of the gene. The ASY methyl binding protein (ASMB) is present in leukemic lymphoid and myeloid cells irrespective of their methylation status, and in normal lymphocytes after phytohemagglutinin stimulation. It has been purified by affinity chromatography and has a molecular size of 40 kDa in 10% SDS-polyacrylamide gels.	N Shore Univ Hosp, Dept Pathol, Manhasset, NY 11030 USA; NYU, Sch Med, Dept Pathol, New York, NY 10017 USA	Northwell Health; North Shore University Hospital; New York University	Broome, JD (corresponding author), N Shore Univ Hosp, Dept Pathol, Manhasset, NY 11030 USA.	jbroome@nshs.edu						ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BROOME JD, 1963, J EXP MED, V118, P99, DOI 10.1084/jem.118.1.99; BROOME JD, 1968, J EXP MED, V127, P1055, DOI 10.1084/jem.127.6.1055; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; Ehrlich M., 1993, Experientia Supplementum (Basel), V64, P145; Feng Q, 2001, GENE DEV, V15, P827; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jost J P, 1993, EXS, V64, P425; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KHAN R, 1988, J BIOL CHEM, V263, P14374; Matheson EC, 2003, CARCINOGENESIS, V24, P31, DOI 10.1093/carcin/24.1.31; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Peng H, 2001, BRIT J CANCER, V85, P930, DOI 10.1054/bjoc.2001.2000; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076	35	21	22	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3953	3961		10.1038/sj.onc.1207498	http://dx.doi.org/10.1038/sj.onc.1207498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048083				2022-12-25	WOS:000221382000007
J	Dai, Q; Liu, JH; Chen, J; Durrant, D; McIntyre, TM; Lee, RM				Dai, Q; Liu, JH; Chen, J; Durrant, D; McIntyre, TM; Lee, RM			Mitochondrial ceramide increases in UV-irradiated HeLa cells and is mainly derived from hydrolysis of sphingomyelin	ONCOGENE			English	Article						apoptosis; mitochondria; sphingomyelin; ceramide; D609; myriocin; fumonicin B	KINASE-C-DELTA; NOVO SPHINGOLIPID BIOSYNTHESIS; NF-KAPPA-B; CYTOCHROME-C; SERINE PALMITOYLTRANSFERASE; INDUCED APOPTOSIS; CASPASE ACTIVATION; ENDONUCLEASE-G; DISTINCT POOL; P53 PROTEIN	Sphingolipids are important signaling molecules in many biologic processes, but little is known about their organelle-specific roles. Using HeLa cells, we investigated the effects of UV and etoposide-induced apoptosis on the contents of sphingomyelin (SM) and ceramide in subcellular compartments. UV irradiation of HeLa cells increased the levels of SM in all subcellular fractions, but the change was most dramatic in mitochondria. Using diacylglycerol kinase assays to quantify ceramide, we found that the levels of ceramide in mitochondria increased as early as 2 h after UV irradiation and remained elevated at 6 h. The increase in mitochondrial SM and ceramide was inhibited by D609, an inhibitor of sphingomyelinase and SM synthase. The inhibition of sphingolipid production correlated with protection of the mitochondrial transmembrane potential and prevention of cytochrome c release following UV irradiation. In contrast, myriocin, an inhibitor of the de novo ceramide synthesis pathway, only partially suppressed the production of ceramides in mitochondria and cannot suppress UV-induced apoptosis. Fumonicin B1, an inhibitor of ceramide synthase, can only prevent mitochondrial ceramide synthesis and UV-induced apoptosis in a small degree. These results indicate that mitochondrial ceramide production in UV-irradiated HeLa cells is not mediated by the de novo synthesis pathway, but mainly through SM hydrolysis.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Sect Oncol, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Lee, RM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope,Suite 5244, Salt Lake City, UT 84112 USA.	ray.lee@hci.utah.edu			NCI NIH HHS [K08CA795093] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Bejaoui K, 2002, J CLIN INVEST, V110, P1301, DOI 10.1172/JCI200216450; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Deng J, 2002, ONCOGENE, V21, P44, DOI 10.1038/sj.onc.1204900; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; FINE JB, 1982, J LIPID RES, V23, P660; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Ito Y, 2001, CELL DEATH DIFFER, V8, P794, DOI 10.1038/sj.cdd.4400886; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Linn SC, 2001, BIOCHEM SOC T, V29, P831, DOI 10.1042/0300-5127:0290831; Liu JH, 2003, CANCER RES, V63, P1153; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Perry DK, 2000, ANN NY ACAD SCI, V905, P91; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Richter C, 1999, BIOCHEM SOC SYMP, V66, P27, DOI 10.1042/bss0660027; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schmelz EM, 2000, J NUTR, V130, P522, DOI 10.1093/jn/130.3.522; Schmelz EM, 2001, CANCER RES, V61, P6723; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Zhang P, 1997, J BIOL CHEM, V272, P9609	61	69	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3650	3658		10.1038/sj.onc.1207430	http://dx.doi.org/10.1038/sj.onc.1207430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077187				2022-12-25	WOS:000221101700017
J	Plug-DeMaggio, AW; Sundsvold, T; Wurscher, MA; Koop, JI; Klingelhutz, AJ; McDougall, JK				Plug-DeMaggio, AW; Sundsvold, T; Wurscher, MA; Koop, JI; Klingelhutz, AJ; McDougall, JK			Telomere erosion and chromosomal instability in cells expressing the HPV oncogene 16E6	ONCOGENE			English	Article						human papillomavirus; telomere erosion; HPV 16E6; chromosomal instability; tumorigenesis; anaphase bridges	HUMAN-PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; E6 ONCOPROTEIN; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; RECURRENT PATTERN; E7 ONCOPROTEIN; GENE-PRODUCT; HTERT GENE; INACTIVATION	Progression to advanced-stage cervical carcinomas is characterized by a recurrent pattern of chromosomal rearrangements. Structural chromosome rearrangements are generated through the fusion of broken chromosome ends. These chromosome breaks may be induced by mutagenic agents such as ionizing radiation, or chromosome ends may be exposed through extensive telomere shortening. The human papilloma virus oncogene 16E6 induces telomerase activity in human keratinocytes, a model system for cervical tumor formation. The present study explores the relationship between 16E6 expression, telomerase activity, and chromosomal instability. We show that the frequency of anaphase bridges is dependent on the level of telomerase activity in 16E6/E7-expressing clones, and is the result of telomere shortening. High frequencies of anaphase bridges, associated with low telomerase activity, correlate with increased chromosome instability. Anaphase bridge formation is also associated with the presence of micronuclei, which are shown to contain unstable chromosomes frequently involved in rearrangements. As anaphase bridges are observed in both high and low telomerase 16E6/E7 clones, but not in hTERT-expressing control clones, expression of 16E6 in these immortalized clones is not sufficient to stabilize shortened telomeres completely. We suggest a model in which HPV-induced tumorigenesis may be dependent on persistent bridge - breakage - fusion cycles that allow for continued genomic rearrangements.	Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Plug-DeMaggio, AW (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Biol Program, 1100 Fairview Ave N, Seattle, WA 98109 USA.	ademaggi@fhcrc.org	Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, CANCER RES, V62, P7075; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; FORD JH, 1988, AM J HUM GENET, V43, P733; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; McClintock B, 1941, GENETICS, V26, P234; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MUNGER K, 1989, J VIROL, V63, P4417; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Plug-Demaggio AW, 2002, ONCOGENE, V21, P7507, DOI 10.1038/sj.onc.1205903; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	37	52	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3561	3571		10.1038/sj.onc.1207388	http://dx.doi.org/10.1038/sj.onc.1207388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077181				2022-12-25	WOS:000221101700007
J	Ge, YW; Maloney, B; Sambamurti, K; Lahiri, DK				Ge, YW; Maloney, B; Sambamurti, K; Lahiri, DK			Functional characterization of the 5 ' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression	FASEB JOURNAL			English	Article						aging; beta-protein; dementia; transcription; secretase	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; DISEASE; BRAIN; MICE; APP; CYTOKINES; CLONING	Pathological characteristics of Alzheimer's disease (AD) include amyloid-beta (Abeta) plaques. Abeta is derived from the Abeta peptide precursor protein (APP) by gamma- and beta-secretases, the latter known as beta-site APP-cleaving enzyme 1 (BACE1, or herein BACE). We have also described potentially important regions in the promoter of BACE, which may regulate its activity ( 1). Herein, we have functionally dissected the regulatory regions within the BACE promoter into areas containing positive and negative regulatory elements. The 4.1 kb promoter region (- 3765/+ 364, + 1 being the transcription start site [TSS]) includes positive regulatory element in the - 2975 to - 2062 region flanked on either side by negative regulatory elements at - 3764/-2975 and - 2062/-1056. This is separated from the minimal promoter and 5' UTR by a neutral region of roughly 700 base pairs (bp). A 91 bp fragment (224/314) is the shortest region with a significant reporter gene activity and constitutes the minimal promoter element for BACE. Neuronal preference of the promoter was apparent in the 141 bp fragment (224/364) that contained the 91 bp fragment. Gel shift results also suggest the strongest signal of DNA-protein interaction with the 91 bp fragment in neuronal nuclear extracts. This interaction was strongly blocked by an activator protein (AP) 2 binding oligomer. Super gel shift assays suggest that both the AP2-binding oligomer and the 91 bp fragment interfered with each other's binding capacity. An AP2 sequence is predicted to occur within the 91 bp fragment. We also found stimulating protein (SP) 1-binding sites in this region of the promoter. Thus, functional and gel shift analysis indicate that the 91 bp fragment containing the AP2 and SP1 binding sites constitutes the core promoter region of BACE. Changes in the activity of this region could play an important role in regulating BACE activity in neurons.	Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Med Univ S Carolina, Charleston, SC 29425 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Medical University of South Carolina	Lahiri, DK (corresponding author), 791 N Union Dr, Indianapolis, IN 46206 USA.	dlahiri@iupui.edu	Lahiri, Debomoy/AAZ-3322-2020; Sambamurti, Kumar/A-1620-2012; Maloney, Bryan J/C-4924-2011	Sambamurti, Kumar/0000-0001-9507-9214; Maloney, Bryan J/0000-0003-2364-9649	NIA NIH HHS [AG18379, AG18884] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018379, R01AG018884] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bigl M, 2000, NEUROSCI LETT, V292, P107, DOI 10.1016/S0304-3940(00)01452-X; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Ge YW, 2002, ANN NY ACAD SCI, V973, P463, DOI 10.1111/j.1749-6632.2002.tb04684.x; Ghosh C, 2000, MOL BIOL REP, V27, P113, DOI 10.1023/A:1007173906990; Ghosh C, 1999, J MOL NEUROSCI, V13, P77, DOI 10.1385/JMN:13:1-2:77; Hartlage-Rubsamen M, 2003, GLIA, V41, P169, DOI 10.1002/glia.10178; Hook VYH, 2003, J NEUROSCI RES, V74, P393, DOI 10.1002/jnr.10784; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Lange-Dohna C, 2003, J NEUROSCI RES, V73, P73, DOI 10.1002/jnr.10639; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rossner S, 2001, J NEUROSCI RES, V64, P437; SAMBAMURTI K, 2004, FASEB J         0401, DOI DOI 10.1096/FJ.03-1738FJE; SCHUG J, TESS TRANSCRIPTION E; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1998, GENE, V217, P165, DOI 10.1016/S0378-1119(98)00340-0; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vattemi G, 2003, EXP NEUROL, V179, P150, DOI 10.1016/S0014-4886(02)00025-0; Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	30	53	54	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1037	+		10.1096/fj.03-1379fje	http://dx.doi.org/10.1096/fj.03-1379fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059977				2022-12-25	WOS:000221108800028
J	Karbat, I; Cohen, L; Gilles, N; Gordon, D; Gurevitz, M				Karbat, I; Cohen, L; Gilles, N; Gordon, D; Gurevitz, M			Conversion of a scorpion toxin agonist into an antagonist highlights an acidic residue involved in voltage sensor trapping during activation of neuronal Na+ channels	FASEB JOURNAL			English	Article						scorpion beta-toxin; sodium channel; voltage sensor; competitive antagonist	INSECT SODIUM-CHANNELS; DEPENDENT K+ CHANNEL; DOMAIN-II; DIVERSIFICATION; NEUROTOXINS	Gating modifiers constitute a large group of polypeptide toxins that interact with the voltage-sensing module of ion channels. Among them, scorpion beta-toxins induce a negative shift in the voltage dependence of sodium channel activation. To explain their effect, a "voltage sensor trapping" model has been proposed in which the voltage sensor of domain-II (DIIS4) is trapped in an outward, activated position by a prebound beta-toxin upon membrane depolarization. Whereas toxin effect on channel activation was enhanced upon neutralization of the two outermost arginines in DIIS4, toxin residues involved in sensor trapping have not been identified. Using the scorpion excitatory beta-toxin, Bj-xtrIT, we found two conserved acidic residues, Glu15 and Glu30, mandatory for toxin action. Whereas mutagenesis of Glu30 affected both toxicity and binding affinity, substitutions E15A/F abolished activity but had minor effects on binding. Complete uncoupling of activity from binding was obtained with mutant E15R, acting as an efficient antagonist of Bj-xtrIT. On the basis of the voltage sensor trapping model and our results, we propose that Glu15 interacts with the emerging gating charges of DIIS4 upon membrane depolarization. Conserved acidic residues found in a variety of gating modifiers from scorpions and spiders may interact similarly with the voltage sensor.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Ramat Aviv, Tel Aviv, Israel; CEA Saclay, Dept Ingn Etud Prot, F-91191 Gif Sur Yvette, France	Tel Aviv University; CEA; UDICE-French Research Universities; Universite Paris Saclay	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Ramat Aviv, Tel Aviv, Israel.	dgordon@post.tau.ac.il						Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gilles N, 2003, FEBS LETT, V540, P81, DOI 10.1016/S0014-5793(03)00226-6; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Gordon Dalia, 1997, Invertebrate Neuroscience, V3, P103, DOI 10.1007/BF02480365; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; Hille B., 1992, IONIC CHANNELS EXCIT; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Lee D, 2000, J INSECT PHYSIOL, V46, P499, DOI 10.1016/S0022-1910(99)00136-5; Mitrovic N, 1998, J GEN PHYSIOL, V111, P451, DOI 10.1085/jgp.111.3.451; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Rash LD, 2002, TOXICON, V40, P225, DOI 10.1016/S0041-0101(01)00199-4; REED L. J., 1938, AMER JOUR HYG, V27, P493; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; SCHILD HO, 1957, PHARMACOL REV, V9, P242; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Xiong YM, 1999, TOXICON, V37, P1165, DOI 10.1016/S0041-0101(98)00253-0	24	41	43	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					683	689		10.1096/fj.03-0733com	http://dx.doi.org/10.1096/fj.03-0733com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054090				2022-12-25	WOS:000221108800038
J	Hirche, TO; Crouch, EC; Espinola, M; Brokelman, TJ; Mecham, RP; DeSilva, N; Cooley, J; Remold-O'Donnell, E; Belaaouaj, A				Hirche, TO; Crouch, EC; Espinola, M; Brokelman, TJ; Mecham, RP; DeSilva, N; Cooley, J; Remold-O'Donnell, E; Belaaouaj, A			Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ENHANCES PHAGOCYTOSIS; LEUKOCYTE ELASTASE; HOST-DEFENSE; SP-A; LUNG; BINDING; PROTEASES; DEGRADATION; CALCIUM	Surfactant protein D (SP-D) plays important roles in innate immunity including the defense against bacteria, fungi, and respiratory viruses. Because SP-D specifically interacts with neutrophils that infiltrate the lung in response to acute inflammation and infection, we examined the hypothesis that the neutrophil-derived serine proteinases (NSPs): neutrophil elastase, proteinase-3, and cathepsin G degrade SP-D. All three human NSPs specifically cleaved recombinant rat and natural human SP-D dodecamers in a time- and dose-dependent manner, which was reciprocally dependent on calcium concentration. The NSPs generated similar, relatively stable, disulfide cross-linked immunoreactive fragments of similar to35 kDa ( reduced), and sequencing of a major catheptic fragment definitively localized the major sites of cleavage to a highly conserved subregion of the carbohydrate recognition domain. Cleavage markedly reduced the ability of SP-D to promote bacterial aggregation and to bind to yeast mannan in vitro. Incubation of SP-D with isolated murine neutrophils led to the generation of similar fragments, and cleavage was inhibited with synthetic and natural serine proteinase inhibitors. In addition, neutrophils genetically deficient in neutrophil elastase and/or cathepsin G were impaired in their ability to degrade SP-D. Using a mouse model of acute bacterial pneumonia, we observed the accumulation of SP-D at sites of neutrophil infiltration coinciding with the appearance of similar to35-kDa SP-D fragments in bronchoalveolar lavage fluids. Together, our data suggest that neutrophil-derived serine proteinases cleave SP-D at sites of inflammation with potential deleterious effects on its biological functions.	Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Harvard Univ, Sch Med, Ctr Blood Res, Inst Biomed Res, Boston, MA 02115 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Belaaouaj, A (corresponding author), Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA.	azzaq@im.wustl.edu	Bentaher, Abderrazzaq/M-4424-2017; A, Bentaher/F-6531-2018	A, Bentaher/0000-0001-6001-5456	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066548, P01HL029594, R01HL066415, R01HL044015] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66415, HL-66548, HL-29594, R01 HL066548, HL-44015] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj A, 2002, MICROBES INFECT, V4, P1259, DOI 10.1016/S1286-4579(02)01654-4; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Belaaouaj AA, 2000, J BIOL CHEM, V275, P27123; BIRRER P, 1995, RESPIRATION, V62, P25; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; Bufler P, 2003, AM J RESP CELL MOL, V28, P249, DOI 10.1165/rcmb.4896; CAI GZ, 1999, AM J PHYSIOL, V276, P131; Carlstedt F, 2001, CRIT CARE CLIN, V17, P139, DOI 10.1016/S0749-0704(05)70156-1; Cheng IW, 2003, CRIT CARE MED, V31, P20, DOI 10.1097/00003246-200301000-00003; Cooley J, 2001, BIOCHEMISTRY-US, V40, P15762, DOI 10.1021/bi0113925; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1993, AM J PATHOL, V142, P241; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DeSilva NS, 2003, AM J RESP CELL MOL, V29, P757, DOI 10.1165/rcmb.2003-0186OC; DONG Q, 1998, AM J PHYSIOL, V274, P97; Ganz T, 1999, P ASSOC AM PHYSICIAN, V111, P390, DOI 10.1111/paa.1999.111.5.390; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; Griese M, 2003, BBA-MOL BASIS DIS, V1638, P157, DOI 10.1016/S0925-4439(03)00063-2; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hartshorn KL, 2002, BIOCHEM J, V366, P87, DOI 10.1042/BJ20011868; Hartshorn KL, 2002, INFECT IMMUN, V70, P6129, DOI 10.1128/IAI.70.11.6129-6139.2002; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; HASLETT C, 1985, AM J PATHOL, V119, P101; Herbein JF, 2000, AM J PHYSIOL-LUNG C, V278, pL830, DOI 10.1152/ajplung.2000.278.4.L830; Herbein JF, 2001, AM J PHYSIOL-LUNG C, V281, pL268, DOI 10.1152/ajplung.2001.281.1.L268; Hirche TO, 2004, AM J RESP CELL MOL, V30, P576, DOI 10.1165/rcmb.2003-0253OC; Honda Y, 1996, CHEST, V109, P1006, DOI 10.1378/chest.109.4.1006; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; Kawabata K, 2002, EUR J PHARMACOL, V451, P1, DOI 10.1016/S0014-2999(02)02182-9; Kishore U, 2001, Results Probl Cell Differ, V33, P225; Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040; Leth-Larsen R, 2003, CLIN IMMUNOL, V108, P29, DOI 10.1016/S1521-6616(03)00042-1; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; Liau DF, 1996, BBA-LIPID LIPID MET, V1302, P117, DOI 10.1016/0005-2760(96)00042-2; Lopez-boado YS, 2004, J IMMUNOL, V172, P509, DOI 10.4049/jimmunol.172.1.509; MacIvor DM, 1999, BLOOD, V94, P4282, DOI 10.1182/blood.V94.12.4282.424k45_4282_4293; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Mariencheck WI, 2003, AM J RESP CELL MOL, V28, P528, DOI 10.1165/rcmb.2002-0141OC; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; Moraes TJ, 2003, CRIT CARE MED, V31, pS189, DOI 10.1097/01.CCM.0000057842.90746.1E; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; Owen CA, 1997, AM J PHYSIOL-LUNG C, V272, pL385, DOI 10.1152/ajplung.1997.272.3.L385; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PISON U, 1989, BIOCHIM BIOPHYS ACTA, V992, P251, DOI 10.1016/0304-4165(89)90082-2; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; RAO NV, 1993, AM J RESP CELL MOL, V8, P612, DOI 10.1165/ajrcmb/8.6.612; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Rubio F, 2004, THORAX, V59, P318, DOI 10.1136/thx.2003.014902; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Schochett P, 1999, EXP LUNG RES, V25, P595; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; TAMURA Y, 1992, MICROB PATHOGENESIS, V12, P237, DOI 10.1016/0882-4010(92)90058-V; Taneva S, 1997, BIOCHEMISTRY-US, V36, P8173, DOI 10.1021/bi963040h; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Zivin JR, 2001, AM J KIDNEY DIS, V37, P689, DOI 10.1016/S0272-6386(01)80116-5	69	80	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27688	27698		10.1074/jbc.M402936200	http://dx.doi.org/10.1074/jbc.M402936200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078883	hybrid			2022-12-25	WOS:000222120400103
J	Li, RH; Gorelik, R; Nanda, V; Law, PB; Lear, JD; DeGrado, WF; Bennett, JS				Li, RH; Gorelik, R; Nanda, V; Law, PB; Lear, JD; DeGrado, WF; Bennett, JS			Dimerization of the transmembrane domain of integrin alpha(IIb) subunit in cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT ACTIVATION; GXXXG MOTIF; SIGNAL-TRANSDUCTION; BIOLOGICAL MEMBRANE; CYTOPLASMIC DOMAINS; HELIX ASSOCIATION; ALPHA-HELICES; INTEGRIN; PROPENSITY; PROTEINS	Homo- and hetero-oligomeric interactions between the transmembrane (TM) helices of integrin alpha and beta subunits may play an important role in integrin activation and clustering. As a first step to understanding these interactions, we used the TOXCAT assay to measure oligomerization of the wild-type alpha(IIb) TM helix and single-site TM domain mutants. TOXCAT measures the oligomerization of a chimeric protein containing a TM helix in the Escherichia coli inner membrane via the transcriptional activation of the gene for chloramphenicol acetyltransferase. We found the amount of chloramphenicol acetyltransferase induced by the wild-type alpha(IIb) TM helix was approximately half that induced by the strongly dimerizing TM helix of glycophorin A, confirming that the alpha(IIb) TM domain oligomerizes in biological membranes. Mutating each of the alpha(IIb) TM domain residues to either Ala, Leu, Ile, or Val revealed that a GXXXG motif mediates oligomerization. Further, we found that the residue preceding each glycine contributed to the oligomerization interface, as did the residue at position i + 4 after the second Gly of GXXXG. Thus, the sequence XXVGXXGGXXXLXX is critical for oligomerization of alpha(IIb) TM helix. These data were used to generate an atomic model of the alpha(IIb) homodimer, revealing a family of structures with right-handed crossing angles of 40degrees to 60degrees, consistent with a 4.0-residue periodicity, and with an interface rotated by 50degrees relative to glycophorin A. Thus, although the alpha(IIb) TM helix makes use of the GXXXG framework, neighboring residues have evolved to engineer its dimerization interface, enabling it to subserve specific and specialized functions.	Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 1009, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Bennett, JS (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 1009, 422 Curie Blvd, Philadelphia, PA 19104 USA.	bennetts@mail.med.upenn.edu	Li, Renhao/B-1257-2012	Li, Renhao/0000-0002-5806-5080; Nanda, Vikas/0000-0003-2786-8347	NCI NIH HHS [K01 CA096706] Funding Source: Medline; NHLBI NIH HHS [HL54500, HL40387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA096706] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500, P01HL040387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pilpel Y, 1999, J MOL BIOL, V294, P921, DOI 10.1006/jmbi.1999.3257; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schneider D, 2004, J BIOL CHEM, V279, P9840, DOI 10.1074/jbc.M312749200; Schneider D, 2003, J BIOL CHEM, V278, P3105, DOI 10.1074/jbc.M206287200; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6	26	131	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26666	26673		10.1074/jbc.M314168200	http://dx.doi.org/10.1074/jbc.M314168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15067009	hybrid			2022-12-25	WOS:000222003000093
J	Lowe, J; Vieyra, A; Catty, P; Guillain, F; Mintz, E; Cuille, M				Lowe, J; Vieyra, A; Catty, P; Guillain, F; Mintz, E; Cuille, M			A mutational study in the transmembrane domain of Ccc2p, the yeast Cu(I)-ATPase, shows different roles for each Cys-Pro-Cys cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; WILSONS-DISEASE PROTEIN; COPB COPPER ATPASE; TOXIC MILK MOUSE; SARCOPLASMIC-RETICULUM; ENTEROCOCCUS-HIRAE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; BIOCHEMICAL-CHARACTERIZATION	Ccc2p is homologous to the human Menkes and Wilson copper ATPases and is herein studied as a model for human copper transport. Most studies to date have sought to understand how mutations in the human Menkes or Wilson genes impair copper homeostasis and induce disease. Here we analyze whether eight conserved amino acids of the transmembrane domain are important for copper transport. Wild-type Ccc2p and variants were expressed in a ccc2-Delta yeast strain to check whether they were able to restore copper transport by complementation. Wild-type Ccc2p and variants were also expressed in Sf9 cells using baculovirus to study their enzymatic properties on membrane preparations. The latter system allowed us to measure a copper-activated ATPase activity of about 20 nmol/mg/min for the wildtype Ccc2p at 37degreesC. None of the variants was as efficient as the wild type in restoring copper homeostasis. The mutation of each cysteine of the (CPC585)-C-583 motif into a serine resulted in nonfunctional proteins that could not restore copper homeostasis in yeast and had no ATPase activity. Phosphorylation by ATP was still possible with the C583S variant, although it was not possible with the C585S variant, suggesting that the cysteines of the CPC motif have a different role in copper transport. Cys(583) would be necessary for copper dissociation and/or enzyme dephosphorylation and Cys(585) would be necessary for ATP phosphorylation, suggesting a role in copper binding.	Univ Grenoble 1, Lab Biophys Mol & Cellulaire, UMR CEA CNRS 5090, CEA,DRDC,BMC, F-38054 Grenoble 9, France; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Fisicoquim Biol Aida Hasson Voloch, BR-21941902 Rio De Janeiro, Brazil	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universidade Federal do Rio de Janeiro	Cuille, M (corresponding author), Univ Grenoble 1, Lab Biophys Mol & Cellulaire, UMR CEA CNRS 5090, CEA,DRDC,BMC, 17 Rue Martyrs, F-38054 Grenoble 9, France.	cuillel@cea.fr	Lowe, Jennifer/F-1148-2013	Lowe, Jennifer/0000-0001-7378-4561				Abe K, 2003, BIOCHEMISTRY-US, V42, P15132, DOI 10.1021/bi035686x; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Bissig KD, 2001, BIOCHEM J, V357, P217, DOI 10.1042/0264-6021:3570217; Bissig KD, 2001, FEBS LETT, V507, P367, DOI 10.1016/S0014-5793(01)03009-5; Caruso-Neves C, 2000, BBA-BIOMEMBRANES, V1468, P107, DOI 10.1016/S0005-2736(00)00248-0; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; FIGUS A, 1995, AM J HUM GENET, V57, P1318; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Ge ZM, 1996, FEMS MICROBIOL LETT, V145, P181, DOI 10.1016/S0378-1097(96)00405-3; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; Haas R, 1999, Hum Mutat, V14, P88, DOI 10.1002/(SICI)1098-1004(1999)14:1<88::AID-HUMU15>3.0.CO;2-H; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, GASTROENTEROLOGY, V124, P335, DOI 10.1053/gast.2003.50066; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; Lemos AD, 2002, Z NATURFORSCH C, V57, P500; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Mills RF, 2003, PLANT J, V35, P164, DOI 10.1046/j.1365-313X.2003.01790.x; Miras R, 2001, PROTEIN EXPRES PURIF, V22, P299, DOI 10.1006/prep.2001.1436; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; Muller-Ehmsen J, 2001, AM J PHYSIOL-CELL PH, V281, pC1355, DOI 10.1152/ajpcell.2001.281.4.C1355; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Takeda K, 1999, J MEMBRANE BIOL, V170, P13, DOI 10.1007/s002329900533; Theophilos MB, 1996, HUM MOL GENET, V5, P1619, DOI 10.1093/hmg/5.10.1619; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tumer Z, 1999, ADV EXP MED BIOL, V448, P83; Voskoboinik I, 2001, BIOCHEM BIOPH RES CO, V281, P966, DOI 10.1006/bbrc.2001.4445; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; WEBER K, 1969, J BIOL CHEM, V244, P4406; Wunderli-Ye H, 2001, BIOCHEM BIOPH RES CO, V280, P713, DOI 10.1006/bbrc.2000.4176; WylerDuda P, 1996, FEBS LETT, V399, P143, DOI 10.1016/S0014-5793(96)01306-3; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	54	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25986	25994		10.1074/jbc.M308736200	http://dx.doi.org/10.1074/jbc.M308736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078884	hybrid			2022-12-25	WOS:000222003000009
J	Oury, C; Sticker, E; Cornelissen, H; De Vos, R; Vermylen, J; Hoylaerts, MF				Oury, C; Sticker, E; Cornelissen, H; De Vos, R; Vermylen, J; Hoylaerts, MF			ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR BINDING; P2X(1) ION-CHANNEL; PROTEIN-KINASE; SHAPE CHANGE; GP-IB; INTEGRIN ALPHA(IIB)BETA(3); ADENOSINE-DIPHOSPHATE; ENDOTHELIAL-CELLS; GRANULE SECRETION; RHO-KINASE	Shear stress triggers von Willebrand factor (VWF) binding to platelet glycoprotein Ibalpha and subsequent integrin alpha(IIb)beta(3)-dependent platelet aggregation. Concomitantly, nucleotides are released from platelet-dense granules, and ADP is known to contribute to shear-induced platelet aggregation (SIPA). We found that the impaired SIPA of platelets from a Hermansky-Pudlak patient lacking dense granules was restored by exogenous L-beta,gamma-methylene ATP, a stable P2X(1) agonist, as well as by ADP, confirming that in addition to ADP (via P2Y(1) and P2Y(12)), ATP (via P2X(1)) also contributes to SIPA. Likewise, SIPA of apyrase-treated platelets was restored upon P2X(1) activation with L-beta,gamma-methylene ATP, which promoted granule centralization within platelets and stimulated P-selectin expression, which is a marker of alpha-granule release. In addition, during SIPA, platelet degranulation required both extracellular Ca2+ and VWF-glycoprotein Ibalpha interactions without involving alpha(IIb)beta(3). Neither platelet release nor SIPA was affected by protein kinase C inactivation, even though protein kinase C blockade inhibits platelet responses to collagen and thrombin in stirring conditions. In contrast, inhibiting myosin light chain (MLC) kinase with ML-7 reduced platelet release and SIPA by 30%. Accordingly, the potentiating effect of P2X(1) stimulation on the aggregation of apyrase-reated platelets coincided with intensified phosphorylation of MLC and was abrogated by ML-7. SIPA-nduced MLC phosphorylation occurred exclusively through released nucleotides and selective antagonism of P2X(1) with MRS2159-reduced SIPA, ATP release, and potently inhibited MLC phosphorylation. We conclude that the P2X(1) ion channel induces MLC-mediated cytoskeletal rearrangements, thus contributing to SIPA and degranulation during VWF-triggered platelet activation.	Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Univ Louvain, Lab Morphol & Mol Pathol, B-3000 Louvain, Belgium		Hoylaerts, MF (corresponding author), Univ Louvain, Ctr Mol & Vasc Biol, Herestr 49, B-3000 Louvain, Belgium.	marc.hoylaerts@med.kuleuven.ac.be		Hoylaerts, Marc/0000-0002-6474-3933; Oury, Cecile/0000-0002-7561-0132				Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; CHOW TW, 1992, BLOOD, V80, P113; Christodoulides N, 2001, THROMB RES, V102, P133, DOI 10.1016/S0049-3848(01)00243-2; Feng SJ, 2003, BLOOD, V102, P2122, DOI 10.1182/blood-2002-12-3805; Flaumenhaft R, 2003, ARTERIOSCL THROM VAS, V23, P1152, DOI 10.1161/01.ATV.0000075965.88456.48; Goto S, 1999, CIRCULATION, V99, P608, DOI 10.1161/01.CIR.99.5.608; Goto S, 2002, CIRCULATION, V105, P2531, DOI 10.1161/01.CIR.0000016703.93845.AF; Hechler B, 2003, J EXP MED, V198, P661, DOI 10.1084/jem.20030144; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; Ikeda Y, 1997, ANN NY ACAD SCI, V811, P325, DOI 10.1111/j.1749-6632.1997.tb52012.x; Kageyama S, 1997, BRIT J PHARMACOL, V122, P165, DOI 10.1038/sj.bjp.0701354; Kasirer-Friede A, 2004, BLOOD, V103, P3403, DOI 10.1182/blood-2003-10-3664; KONSTANTOPOULOS K, 1995, THROMB HAEMOSTASIS, V74, P1329; KROLL MH, 1993, J BIOL CHEM, V268, P3520; Kroll MH, 1996, BLOOD, V88, P1525; Kunapuli SP, 2003, CURR OPIN PHARMACOL, V3, P175, DOI 10.1016/S1471-4892(03)00007-9; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; MOAKE JL, 1988, BLOOD, V71, P1366; MORITZ MW, 1983, J LAB CLIN MED, V101, P537; Murugappan S, 2004, J BIOL CHEM, V279, P2360, DOI 10.1074/jbc.M306960200; Nakai K., 1997, Life Sciences, V60, P181; ODA A, 1995, THROMB HAEMOSTASIS, V74, P736; Oury C, 2003, BLOOD, V101, P3969, DOI 10.1182/blood-2002-10-3215; Oury C, 2002, BLOOD, V100, P2499, DOI 10.1182/blood-2002-03-0812; Oury C, 2001, THROMB HAEMOSTASIS, V86, P1264; PAINTER RG, 1984, EXP CELL RES, V155, P198, DOI 10.1016/0014-4827(84)90781-X; Pasquet JM, 2002, THROMB HAEMOSTASIS, V88, P115; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; Resendiz JC, 2003, MOL PHARMACOL, V63, P639, DOI 10.1124/mol.63.3.639; Rolf MG, 2001, THROMB HAEMOSTASIS, V85, P303, DOI 10.1055/s-0037-1615684; Ruggeri ZM, 2003, CURR OPIN HEMATOL, V10, P142, DOI 10.1097/00062752-200303000-00008; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Toth-Zsamboki E, 2003, J BIOL CHEM, V278, P46661, DOI 10.1074/jbc.M308452200; Turner NA, 2001, BLOOD, V98, P3340, DOI 10.1182/blood.V98.12.3340; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087	44	38	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26266	26273		10.1074/jbc.M402032200	http://dx.doi.org/10.1074/jbc.M402032200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087444	hybrid, Green Published			2022-12-25	WOS:000222003000044
J	Sall, A; Caserta, S; Jolicoeur, P; Franqueville, L; de Turenne-Tessier, M; Ooka, T				Sall, A; Caserta, S; Jolicoeur, P; Franqueville, L; de Turenne-Tessier, M; Ooka, T			Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein	ONCOGENE			English	Article						Epstein-Barr virus; BARF1 gene; growth factor	EPITHELIAL-CELLS; TRANSCRIPTIONAL EXPRESSION; NASOPHARYNGEAL CARCINOMA; MALIGNANT-TRANSFORMATION; GENE; EBV; ESTABLISHMENT; LYMPHOMA; GROWTH; LINE	We previously reported that BARF1 gene has either an immortalizing effect, when expressed in primary primate epithelial cells, or a malignant transforming activity, when expressed in established and nontumoral rodent fibroblast or human B-cell lines. As predicted from sequence analysis, we found that BARF1 coded protein can be secreted from different cell lines, among them BARF1-transfected Balb/c3T3 rodent fibroblasts. Thus, as an initial step to clarify BARF1 oncogenic functions, we investigated whether the secreted form of BARF1 protein can activate the cell cycle as a growth factor. Since efficient BARF1 expression could be obtained from 293-tTA cells infected with a tetracycline-regulatable recombinant adenovirus, secreted BARF1 product could be purified from the culture medium of such cells by ammonium sulfate precipitation, ion exchange chromotography and sucrose gradient sedimentation. We describe in this paper that addition of a purified product of secreted BARF1 protein to serum-free culture medium of Balb/c3T3 rodent fibroblasts, human Louckes B-cell line and primary monkey kidney epithelial cells resulted in a cell cycle activation that was inhibited by affinity-purified anti-BARF1 antibody. Our demonstration of a specific stimulation of cell cycle in vitro by BARF1 secreted product suggests that this EBV-encoded BARF1 protein could act as a growth factor in vivo.	Univ Lyon 1, Fac Med RTH Laennec, CNRS,UMR 5537, Mol Virol Lab, F-69372 Lyon 08, France; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; National Research Council Canada	Ooka, T (corresponding author), Univ Lyon 1, Fac Med RTH Laennec, CNRS,UMR 5537, Mol Virol Lab, F-69372 Lyon 08, France.	ooka@laennec.univ-lyon1.fr	Caserta, Sergio/E-4602-2012	Caserta, Sergio/0000-0002-4400-0059				Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; Danve C, 2001, VIROLOGY, V288, P223, DOI 10.1006/viro.2001.1072; Decaussin G, 2000, CANCER RES, V60, P5584; DETURENNETESSIE.M, UNPUB; Gao YN, 2002, ONCOGENE, V21, P825, DOI 10.1038/sj.onc.1205130; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; Massie B, 1998, CYTOTECHNOLOGY, V28, P53, DOI 10.1023/A:1008013211222; Nishikawa J, 1999, J VIROL, V73, P1286, DOI 10.1128/JVI.73.2.1286-1292.1999; OOKA T, 2001, EBV REP, V8, P177; RICKINSON AB, 2002, FIELDS VIROLOGY, P257; SbihLammali F, 1996, J MED VIROL, V49, P7, DOI 10.1002/(SICI)1096-9071(199605)49:1&lt;7::AID-JMV2&gt;3.0.CO;2-A; Sheng W, 2003, J VIROL, V77, P3859, DOI 10.1128/JVI.77.6.3859-3865.2003; Sheng W, 2001, ONCOGENE, V20, P1176, DOI 10.1038/sj.onc.1204217; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; Xue SA, 2002, INT J CANCER, V99, P635, DOI 10.1002/ijc.10372; ZHANG CX, 1992, VIRUS RES, V26, P153, DOI 10.1016/0168-1702(92)90154-2; zur Hausen A, 2000, CANCER RES, V60, P2745	23	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4938	4944		10.1038/sj.onc.1207607	http://dx.doi.org/10.1038/sj.onc.1207607			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064715				2022-12-25	WOS:000222104200015
J	Liu, JQ; Zelko, IN; Folz, RJ				Liu, JQ; Zelko, IN; Folz, RJ			Reoxygenation-induced constriction in murine coronary arteries - The role of endothelial NADPH oxidase (gp91(phox)) and intracellular superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL ISCHEMIA/REPERFUSION INJURY; FREE-RADICAL GENERATION; REPERFUSION INJURY; NAD(P)H OXIDASE; NITRIC-OXIDE; DISMUTASE; HYPOXIA; CELLS; OVEREXPRESSION; MICE	Previous work suggests that superoxide mediates hypoxia/reoxygenation (H/R)-induced constriction of isolated mouse coronary arteries ( CA). To determine the source of superoxide overproduction during H/R we studied CA obtained from transgenic (Tg) mice overexpressing human CuZn-superoxide dismutase ( SOD) and mice lacking gp91(phox) using an in vitro vascular ring bioassay. We found that under normoxic conditions CA isolated from wild type (wt) mice, CuZn-SOD Tg mice and gp91(phox) knock-out mice had similar contractile responses to U46619 and hypoxia and similar dilation responses to acetylcholine. In wt CA, 30 min of hypoxia (1% O-2) followed by reoxygenation (16% O-2) resulted in further coronary vasoconstriction (internal diameter from 105 +/- 11 to 84.5 +/- 17.9 mum), whereas this response was completely blocked in both CuZn-SOD Tg and gp91(phox) knock-out CA (104.3 +/- 10.5 to 120.7 +/- 14 mum and 143.3 +/- 15.3 to 172.7 +/- 12.5 mum, respectively, p < 0.01). Furthermore, we show that H/R enhances the generation of superoxide radicals in wt CA (25.8 +/- 0.7 relative light units per second (RLU/s)), whereas CuZn-SOD Tg CA (12.2 +/- 0.8 RLU/s, p < 0.01) and gp91(phox) CA (12.5 +/- 0.9 RLU/s, p < 0.01) show reduced levels. These results demonstrate that H/R-induced vasoconstriction is mediated by intracellular superoxide overproduction via endothelial NADPH oxidase gp91(phox). Therefore, increasing endogenous levels of CuZn-SOD in CA may provide a novel cardioprotective strategy for maintaining coronary perfusion under conditions of H/R.	Duke Univ, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Liu, JQ (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care, Box 2620,Rm 341 MSRB, Durham, NC 27710 USA.	john.liu@duke.edu	Zelko, Igor N/L-2673-2013	Zelko, Igor N/0000-0003-3976-3884	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064894] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-64894] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barbe C., 2001, Archives of Physiology and Biochemistry, V109, P24, DOI 10.1076/apab.109.1.24.4277; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BJORKMAN JA, 1991, BASIC RES CARDIOL, V86, P236, DOI 10.1007/BF02190603; BOLLI R, 1991, CARDIOVASC DRUG THER, V5, P249, DOI 10.1007/BF00054747; Brandes RP, 1997, J PHYSIOL-LONDON, V500, P331, DOI 10.1113/jphysiol.1997.sp022024; BROWN IP, 1993, AM J PHYSIOL, V264, pH821, DOI 10.1152/ajpheart.1993.264.3.H821; Chen EP, 1998, J THORAC CARDIOV SUR, V115, P450, DOI 10.1016/S0022-5223(98)70289-2; Chen EP, 1996, CIRCULATION, V94, P412; Chen ZY, 2000, FREE RADICAL BIO MED, V29, P589, DOI 10.1016/S0891-5849(00)00363-4; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; DIGNAN RJ, 1995, J THORAC CARDIOV SUR, V109, P892, DOI 10.1016/S0022-5223(95)70313-6; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Ghio AJ, 2003, AM J RESP CELL MOL, V29, P653, DOI 10.1165/rcmb.2003-0070OC; GRASER T, 1992, J CARDIOVASC PHARM, V20, pS117; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hoffmeyer MR, 2000, CIRC RES, V87, P812, DOI 10.1161/01.RES.87.9.812; JIANG C, 1994, BRIT J PHARMACOL, V111, P711, DOI 10.1111/j.1476-5381.1994.tb14795.x; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KWAN YW, 1989, BRIT J PHARMACOL, V96, P857, DOI 10.1111/j.1476-5381.1989.tb11895.x; Lee YH, 1998, YONSEI MED J, V39, P252, DOI 10.3349/ymj.1998.39.3.252; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; LIN Q, 1999, J APPL PHYSIOL, V87, P1392; Liu Q, 1997, BRIT J PHARMACOL, V120, P728, DOI 10.1038/sj.bjp.0700939; Lopes LR, 1999, J BIOL CHEM, V274, P15533, DOI 10.1074/jbc.274.22.15533; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MELLEMKJAER S, 1994, EUR J PHARM-ENVIRON, V270, P307, DOI 10.1016/0926-6917(94)90006-X; MohazzabH KM, 1996, AM J PHYSIOL-HEART C, V270, pH1044, DOI 10.1152/ajpheart.1996.270.3.H1044; Nozik-Grayck E, 2003, AM J PHYSIOL-HEART C, V285, pH2327, DOI 10.1152/ajpheart.00507.2003; OTANI H, 1986, J SURG RES, V41, P126, DOI 10.1016/0022-4804(86)90017-X; PEARSON PJ, 1990, CIRC RES, V67, P385, DOI 10.1161/01.RES.67.2.385; Pearson PJ, 1996, CLIN EXP PHARMACOL P, V23, P634, DOI 10.1111/j.1440-1681.1996.tb01749.x; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; RUBANYI GM, 1985, J PHYSIOL-LONDON, V364, P45, DOI 10.1113/jphysiol.1985.sp015728; SELLKE FW, 1992, J THORAC CARDIOV SUR, V104, P357; Souza HP, 2002, AM J PHYSIOL-HEART C, V282, pH466, DOI 10.1152/ajpheart.00482.2001; Terada LS, 1996, AM J PHYSIOL-HEART C, V270, pH945, DOI 10.1152/ajpheart.1996.270.3.H945; TODA N, 1992, AM J PHYSIOL, V262, pH678, DOI 10.1152/ajpheart.1992.262.3.H678; VANHAECKE J, 1991, J AM COLL CARDIOL, V18, P224, DOI 10.1016/S0735-1097(10)80243-8; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Wang PH, 1998, P NATL ACAD SCI USA, V95, P4556, DOI 10.1073/pnas.95.8.4556; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	45	136	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24493	24497		10.1074/jbc.M402920200	http://dx.doi.org/10.1074/jbc.M402920200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15070892	hybrid			2022-12-25	WOS:000221702500077
J	Song, J; Lu, YC; Yokoyama, K; Rossi, J; Chiu, R				Song, J; Lu, YC; Yokoyama, K; Rossi, J; Chiu, R			Cyclophilin a is required for retinoic acid-induced neuronal differentiation in p19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; INTERNAL STANDARDS; HOUSEKEEPING GENES; EXPRESSION; LOCALIZATION; PROTEIN; BRAIN	Stable transfectants with expression of small interfering RNA for targeting cyclophilin A (CypA) in p19 cells lose their potential for retinoic acid (RA)-induced neuronal differentiation but not Me2SO-induced mesodermal differentiation. This difference suggests that CypA is specifically required for the RA-induced neuronal pathway. In addition to the loss of RA-induced RA receptor beta expression and retinoic acid response element (RARE)-binding activity, a dramatic reduction in RA-induced RARE-mediated luciferase activity in the CypA knockdown cell line suggests that CypA affects RARE-mediated regulation of gene expression. Silent mutation of target sequences confirms the specificity of RNA interference in p19 embryonal carcinoma cells. Collectively, our data reveal that a novel function of CypA is required in the processing of RA-induced neuronal differentiation in p19 embryonal carcinoma cells.	Univ Calif Los Angeles, Dent Res Inst, Sch Dent, Los Angeles, CA 90095 USA; RIKEN, Bioresource Ctr, Tsukuba, Ibaraki 305, Japan; City Hope Natl Med Ctr, Div Mol Biol, Beckman Res Inst, Duarte, CA 91010 USA; Univ Calif Los Angeles, Dept Surg Oncol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; RIKEN; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Chiu, R (corresponding author), Univ Calif Los Angeles, Dent Res Inst, Sch Dent, Los Angeles, CA 90095 USA.	rchiu@dent.ucla.edu			NCI NIH HHS [CA66746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; Ansari H, 2002, MOL CELL BIOL, V22, P6993, DOI 10.1128/MCB.22.20.6993-7003.2002; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Chiu R, 2003, CELL MOL NEUROBIOL, V23, P929, DOI 10.1023/B:CEMN.0000005321.11544.cc; Colgan J, 2000, GENOMICS, V68, P167, DOI 10.1006/geno.2000.6295; EASTER SS, 1993, J NEUROSCI, V13, P285; Gill RM, 1998, EXP CELL RES, V244, P157, DOI 10.1006/excr.1998.4197; Goldner FM, 1996, J COMP NEUROL, V372, P283; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Liour SS, 2000, J NEUROSCI RES, V62, P363, DOI 10.1002/1097-4547(20001101)62:3<363::AID-JNR6>3.0.CO;2-E; Lipskaia L, 1998, J CELL PHYSIOL, V176, P50, DOI 10.1002/(SICI)1097-4652(199807)176:1<50::AID-JCP6>3.0.CO;2-7; Nahreini P, 2001, CELL MOL NEUROBIOL, V21, P65, DOI 10.1023/A:1007173329237; Paterno GD, 1997, MOL BRAIN RES, V49, P247, DOI 10.1016/S0169-328X(97)00157-5; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Song J, 2001, J BIOL CHEM, V276, P19897, DOI 10.1074/jbc.M010658200; Steele BK, 2002, ANAL BIOCHEM, V307, P341, DOI 10.1016/S0003-2697(02)00045-3; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815	19	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24414	24419		10.1074/jbc.M311406200	http://dx.doi.org/10.1074/jbc.M311406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047706	hybrid			2022-12-25	WOS:000221702500067
J	Thyrell, L; Hjortsberg, L; Arulampalam, V; Panaretakis, T; Uhles, S; Dagnell, M; Zhivotovsky, B; Leibiger, I; Grander, D; Pokrovskaja, K				Thyrell, L; Hjortsberg, L; Arulampalam, V; Panaretakis, T; Uhles, S; Dagnell, M; Zhivotovsky, B; Leibiger, I; Grander, D; Pokrovskaja, K			Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; CONFERS RESISTANCE; PROTEIN-KINASE; STAT-PATHWAY; IRS-PATHWAY; ACTIVATION; INDUCTION	Interferon (IFN) alpha induces a caspase-dependent apoptosis that is associated with activation of the proapoptotic Bak and Bax, loss of mitochondrial membrane potential, and release of cytochrome c. In addition to the onset of the classical Jak-STAT pathway, IFNalpha also induced phosphoinositide 3-kinase (PI3K) activity. Pharmacological inhibition of PI3K activity by Ly294002 disrupted IFN-induced apoptosis upstream of mitochondria. Inhibition of mTOR by rapamycin or by overexpression of a kinase dead mutant of mTOR, efficiently blocked IFNalpha-induced apoptosis. A PI3K and mTOR-dependent phosphorylation of p70S6 kinase and 4E-BP1 repressor was induced by IFNalpha treatment of cells and was strongly inhibited by Ly294002 or rapamycin. The activation of Jak-STAT signaling upon IFNalpha stimulation was not affected by abrogating PI3K/mTOR pathway. Neither was the expression of several IFNalpha target genes affected, nor the ability of IFNalpha to protect against virus-induced cell death affected by inhibition of the PI3K/mTOR pathway. These data demonstrate that an intact PI3K/mTOR pathway is necessary for the ability of IFNalpha to induce apoptosis, whereas activation of the Jak-STAT pathway alone appears to be insufficient for this specific IFNalpha-induced effect.	Karolinska Hosp & Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden; Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Grander, D (corresponding author), Karolinska Hosp & Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, Res Lab Radiumhemmet, R8 03, S-17176 Stockholm, Sweden.	dan.grander@cck.ki.se	Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; Dagnell, Markus/0000-0002-5925-6794; Uhles, Sabine/0000-0002-2836-8726; Pokrovskaja Tamm, Katja/0000-0001-6359-1256; Panaretakis, Theocharis/0000-0001-5754-6950				Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEMAYER EM, 1988, INTERFERONS OTHER RE; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Lindner Daniel J, 2002, Curr Oncol Rep, V4, P510, DOI 10.1007/s11912-002-0065-4; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; MANABE A, 1993, LEUKEMIA, V7, P1990; Minami R, 2000, EXP HEMATOL, V28, P244, DOI 10.1016/S0301-472X(99)00156-3; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Otsuki T, 1998, BRIT J HAEMATOL, V103, P518, DOI 10.1046/j.1365-2141.1998.01000.x; Panaretakis T, 2003, ONCOGENE, V22, P4543, DOI 10.1038/sj.onc.1206503; Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Prejean C, 2001, J IMMUNOL, V167, P4553, DOI 10.4049/jimmunol.167.8.4553; Rani MRS, 2002, J BIOL CHEM, V277, P38456, DOI 10.1074/jbc.M203204200; RHIM JS, 1989, ANTICANCER RES, V9, P1345; Ronni T, 1998, J INTERF CYTOK RES, V18, P773, DOI 10.1089/jir.1998.18.773; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 2000, BIOCHEM BIOPH RES CO, V270, P158, DOI 10.1006/bbrc.2000.2402; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	45	94	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24152	24162		10.1074/jbc.M312219200	http://dx.doi.org/10.1074/jbc.M312219200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15056668	hybrid			2022-12-25	WOS:000221702500038
J	Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Gespach, C; Attoub, S				Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Gespach, C; Attoub, S			Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes	ONCOGENE			English	Article						beta-catenin; E-cadherin tumor suppressor gene; EGF-R; PI3-kinase; Rho GTPases; Wnt pathway	EPIDERMAL-GROWTH-FACTOR; ANCHORAGE-INDEPENDENT GROWTH; HUMAN COLON-CANCER; BETA-CATENIN; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; CONSTITUTIVE ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; FOCAL ADHESIONS	STAT3 is frequently overexpressed and constitutively activated by tyrosine phosphorylation during malignant transformation. Despite the clear importance of STAT3 in cell proliferation and survival in diverse human cancers, its possible contribution to tumor cell adhesion, motility and invasion remains hypothetical. We therefore compared the transforming properties of STAT3wt, its constitutively activated dimeric form STAT3C, and the dominant negative mutant STAT3-Y705F in human colorectal HCT8/S11 cancer cells. Both STAT3wt and STAT3C exert a permissive action to the proinvasive activity of the scatter factor HGF in HCT8/S11 cells. In contrast, the monomeric and cytoplasmic mutant Y705F induces a constitutive invasive phenotype through Wnt/Rho-independent and EGFR/PI3-kinase-dependent pathways. Accordingly, Y705F decreases cell-cell homotypic adhesions, and increases cell motility and scattering, as well as lamellipodia-type cellular extensions. STAT3-Y705F-transfected HCT8/S11 cells display an increased tyrosine phosphorylation of the cell-cell adhesion regulator beta-catenin and its dissociation from the invasion suppressor E-cadherin at cell-cell contacts. Our data imply that both invasion promoter and repressor genes are controlled by the canonical STAT3 transcription pathways. Disruption of this cascade by Y705F reveals the proinvasive potential of altered forms of STAT3 as a persistent signaling adaptor in cytokine/transforming growth factor receptor scaffolds and oncogenic pathways.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Attoub, S (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	attoub@st-antoine.inserm.fr	de wever, olivier/J-3094-2013; Attoub, Samir/N-6852-2018	de wever, olivier/0000-0002-5453-760X; 				Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Boterberg T, 2000, CELL ADHES COMMUN, V7, P299, DOI 10.3109/15419060009015001; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BRACKE ME, 2000, COLLAGEN INVASION AS, V58, P81; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Goiot H, 2001, GASTROENTEROLOGY, V121, P1417, DOI 10.1053/gast.2001.29581; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hiscox S, 1999, J CELL SCI, V112, P3081; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ilan N, 1999, J CELL SCI, V112, P3005; Irby RB, 2002, CANCER RES, V62, P2669; Kim K, 2001, CELL BIOL INT, V25, P421, DOI 10.1006/cbir.2000.0650; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Laird AD, 2003, MOL CANCER THER, V2, P461; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; OSUGI T, 2001, J BIOL CHEM, V14, P14; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sartor CI, 1997, CANCER RES, V57, P978; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; Uttamsingh S, 2003, J BIOL CHEM, V278, P18798, DOI 10.1074/jbc.M211522200; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Xie H, 1998, J CELL SCI, V111, P615; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	75	35	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3317	3327		10.1038/sj.onc.1207437	http://dx.doi.org/10.1038/sj.onc.1207437			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077188				2022-12-25	WOS:000220975000006
J	Guicciardi, ME; Leist, M; Gores, GJ				Guicciardi, ME; Leist, M; Gores, GJ			Lysosomes in cell death	ONCOGENE			English	Review						cathepsins; Spi2A; TNF alpha	MEDIATED HEPATOCYTE APOPTOSIS; HIPPOCAMPAL NEURONAL DEATH; CATHEPSIN-B CONTRIBUTES; PH-INDUCED INACTIVATION; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; CYSTEINE PROTEASES; MEMBRANE PERMEABILIZATION; INCREASED EXPRESSION; TNF-ALPHA	For many years apoptosis research has focused on caspases and their putative role as sole executioners of programmed cell death. Accumulating information now suggests that lysosomal cathepsins are also pivotally involved in this process, especially in pathological conditions. In particular, the role of lysosomes and lysosomal enzymes in initiation and execution of the apoptotic program has become clear in several models, to the point that the existence of a 'lysosomal pathway of apoptosis' is now generally accepted. This pathway of apoptosis can be activated by death receptors, lipid mediators, and photo-damage. Lysosomal proteases can be released from the lysosomes into the cytosol, where they contribute to the apoptotic cascade upstream of mitochondria. This review focuses on the players and the molecular mechanisms involved in the lysosomal pathway of apoptosis as well as on the importance of this pathway in development and pathology.	Mayo Clin, Coll Med, Rochester, MN 55905 USA; H Lundbeck & Co AS, DK-2500 Valby, Denmark	Mayo Clinic; Lundbeck Corporation	Gores, GJ (corresponding author), Mayo Med Sch Clin & Fdn, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu	Leist, Marcel/D-2133-2010	Leist, Marcel/0000-0002-3778-8693	NIDDK NIH HHS [DK63947] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063947] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; BANAYSCHWARTZ M, 1987, NEUROCHEM RES, V12, P361, DOI 10.1007/BF00993246; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; CAMPO E, 1994, AM J PATHOL, V145, P301; Canbay A, 2003, J CLIN INVEST, V112, P152, DOI 10.1172/JCI200317740; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CASTIGLIONI T, 1994, HUM PATHOL, V25, P857, DOI 10.1016/0046-8177(94)90003-5; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; Cuervo AM, 2000, EXP GERONTOL, V35, P119, DOI 10.1016/S0531-5565(00)00075-9; Dare E, 2001, FREE RADICAL BIO MED, V30, P1347, DOI 10.1016/S0891-5849(01)00526-3; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; Demoz M, 1999, J CELL BIOCHEM, V73, P370, DOI 10.1002/(SICI)1097-4644(19990601)73:3<370::AID-JCB8>3.0.CO;2-N; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, NAT CELL BIOL, V2, pE63, DOI 10.1038/35008692; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foghsgaard L, 2002, J BIOL CHEM, V277, P39499, DOI 10.1074/jbc.M206669200; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Hishita T, 2001, CANCER RES, V61, P2878; Houseweart MK, 2003, CELL DEATH DIFFER, V10, P1329, DOI 10.1038/sj.cdd.4401309; Houseweart MK, 2003, J NEUROBIOL, V56, P315, DOI 10.1002/neu.10253; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; Ishisaka R, 1999, CELL STRUCT FUNCT, V24, P465, DOI 10.1247/csf.24.465; Ishisaka R, 2001, J BIOCHEM-TOKYO, V129, P35, DOI 10.1093/oxfordjournals.jbchem.a002833; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jaattela M, 2002, ANN MED, V34, P480, DOI 10.1080/078538902321012423; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Jones B, 1998, AM J PHYSIOL-GASTR L, V275, pG723, DOI 10.1152/ajpgi.1998.275.4.G723; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Katunuma N, 2003, BIOL CHEM, V384, P883, DOI 10.1515/BC.2003.099; Katunuma N, 2001, ADV ENZYME REGUL, V41, P237, DOI 10.1016/S0065-2571(00)00018-2; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Levicar N, 2003, ACTA NEUROCHIR, V145, P825, DOI 10.1007/s00701-003-0097-z; Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2; Li W, 2003, BIOCHEM J, V371, P429, DOI 10.1042/BJ20021520; Lieuallen K, 2001, HUM MOL GENET, V10, P1867, DOI 10.1093/hmg/10.18.1867; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Madge LA, 2003, J BIOL CHEM, V278, P21295, DOI 10.1074/jbc.M212837200; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MATUS A, 1987, BIOCHEMISTRY-US, V26, P8083, DOI 10.1021/bi00399a010; Mayer A, 1997, CANCER INVEST, V15, P106, DOI 10.3109/07357909709115762; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakanishi H, 1997, J NEUROCHEM, V68, P739; Nishimura Y, 1998, Pathol Oncol Res, V4, P283; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003; Persson HL, 2003, FREE RADICAL BIO MED, V34, P1295, DOI 10.1016/S0891-5849(03)00106-0; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; REMPEL SA, 1994, CANCER RES, V54, P6027; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Roberts Lewis R., 1999, Cell Biochemistry and Biophysics, V30, P71, DOI 10.1007/BF02737885; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Shuja S, 1996, INT J CANCER, V66, P420, DOI 10.1002/(SICI)1097-0215(19960516)66:4<420::AID-IJC2>3.0.CO;2-Y; SINHA AA, 1995, PROSTATE, V26, P171, DOI 10.1002/pros.2990260402; SMOLEN JE, 1986, BIOCHIM BIOPHYS ACTA, V886, P1, DOI 10.1016/0167-4889(86)90205-3; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; SUKOH N, 1994, CANCER, V74, P46, DOI 10.1002/1097-0142(19940701)74:1<46::AID-CNCR2820740109>3.0.CO;2-G; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Tsuchiya K, 1999, EXP NEUROL, V155, P187, DOI 10.1006/exnr.1998.6988; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; TURK B, 1995, BIOL CHEM H-S, V376, P225, DOI 10.1515/bchm3.1995.376.4.225; Turk B, 1997, BIOL CHEM, V378, P141; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang JH, 1997, AM J PHYSIOL-CELL PH, V272, pC1543, DOI 10.1152/ajpcell.1997.272.5.C1543; WATANABE M, 1989, BIOCHEM MED METAB B, V42, P21, DOI 10.1016/0885-4505(89)90037-6; Welss T, 2003, BIOCHEMISTRY-US, V42, P7381, DOI 10.1021/bi027307q; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Xing RY, 1998, CANCER RES, V58, P904; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; ZDOLSEK J, 1993, FREE RADICAL RES COM, V18, P71, DOI 10.3109/10715769309147344; Zhao M, 2000, FEBS LETT, V485, P104, DOI 10.1016/S0014-5793(00)02195-5; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhao M, 2001, FEBS LETT, V509, P399, DOI 10.1016/S0014-5793(01)03184-2; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x	108	576	597	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2881	2890		10.1038/sj.onc.1207512	http://dx.doi.org/10.1038/sj.onc.1207512			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077151	Green Submitted			2022-12-25	WOS:000220799600015
J	Corry, DB; Kiss, A; Song, LZ; Song, L; Xu, J; Lee, SH; Werb, Z; Kheradmand, F				Corry, DB; Kiss, A; Song, LZ; Song, L; Xu, J; Lee, SH; Werb, Z; Kheradmand, F			Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines	FASEB JOURNAL			English	Article						chemotaxis; cytokines; gelatinase B; matrix metalloproteinase-9	BRONCHIAL EPITHELIAL-CELLS; MATRIX METALLOPROTEINASES; AIRWAY HYPERREACTIVITY; ADAPTIVE IMMUNITY; GELATINASE B; MURINE MODEL; IN-VIVO; ASTHMA; MICE; EOSINOPHILS	The mechanisms that initiate allergic lung inflammation are relevant to expression of diseases such as asthma, but the factors underlying resolution of inflammation are equally important. Previously, we demonstrated the importance of matrix metalloproteinase 2 (MMP2) for airway egression of lung eosinophils, a critical anti-inflammatory mechanism without which mice are rendered highly susceptible to lethal asphyxiation. Here we show that leukocyte MMP9 is the dominant airway MMP controlling inflammatory cell egression. The allergic lung phenotype of MMP9(-/-) mice was similar to WT and was not altered by concomitant deletion of the MMP2 gene ( double knockout; dko). However, inflammatory cells accumulated aberrantly in the lungs of allergen-challenged MMP9(-/-) and dko mice and fewer eosinophils and neutrophils were present in bronchoalveolar lavage. These aberrant cellular trafficking patterns were explained by disruption of transepithelial chemokine gradients, in MMP2(-/-) mice affecting only eotaxin (CCL11), but in MMP9(-/-) and dko mice involving eotaxin, MARC (CCL7), and TARC (CCL17). Thus, by establishing multiple transepithelial chemokine gradients, MMP9 is broadly implicated in the resolution of allergic inflammation, an essential protective mechanism that overlaps with a more limited role played by MMP2.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Pulm & Crit Care Med Sect, Houston, TX 77030 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Francisco	Kheradmand, F (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza Suite 520B, Houston, TX 77030 USA.	farrahk@bcm.tmc.edu	Lee, Seung-Hyo/B-9922-2015	Lee, Seung-Hyo/0000-0003-0010-4072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072419, K02HL072062, R01HL069585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL069585, K02 HL 72062, HL 69585, HL 72419, K02 HL072062, R01 HL072419] Funding Source: Medline; NIAID NIH HHS [AI 53194, P01 AI053194, P01 AI053194-050004] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Betsuyaku T, 1999, AM J RESP CELL MOL, V20, P1303, DOI 10.1165/ajrcmb.20.6.3558; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Cataldo D, 2000, INT ARCH ALLERGY IMM, V123, P259, DOI 10.1159/000024452; Cataldo DD, 2002, AM J PATHOL, V161, P491, DOI 10.1016/S0002-9440(10)64205-8; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1999, CURR OPIN IMMUNOL, V11, P610, DOI 10.1016/S0952-7915(99)00025-4; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; DUBOIS GR, 1994, ANN NY ACAD SCI, V725, P268, DOI 10.1111/j.1749-6632.1994.tb39809.x; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; Foster PS, 2001, IMMUNOL REV, V179, P173, DOI 10.1034/j.1600-065X.2001.790117.x; Geske FJ, 2002, INT J HEMATOL, V76, P16, DOI 10.1007/BF02982714; GLEICH GJ, 1993, AGENT ACTION SUPPL, V43, P223; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hozumi A, 2001, AM J PHYSIOL-LUNG C, V281, pL1444, DOI 10.1152/ajplung.2001.281.6.L1444; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kheradmand F, 2002, J CELL SCI, V115, P839; KORENAGA M, 1994, INT J PARASITOL, V24, P951, DOI 10.1016/0020-7519(94)90159-7; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Lee KS, 2003, J ALLERGY CLIN IMMUN, V111, P1278, DOI 10.1067/mai.2003.1501; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Luster AD, 2002, CURR OPIN IMMUNOL, V14, P129, DOI 10.1016/S0952-7915(01)00308-9; Luster AD, 2001, GASTROENTEROLOGY, V120, P291, DOI 10.1053/gast.2001.21403; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; McGuire JK, 2003, AM J PATHOL, V162, P1831, DOI 10.1016/S0002-9440(10)64318-0; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SMITH H, 1992, CLIN EXP ALLERGY, V22, P187, DOI 10.1111/j.1365-2222.1992.tb03072.x; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sweet David G, 2002, Paediatr Respir Rev, V3, P140, DOI 10.1016/S1526-0550(02)00010-0; Vermaelen KY, 2003, J IMMUNOL, V171, P1016, DOI 10.4049/jimmunol.171.2.1016; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang M, 1999, P NATL ACAD SCI USA, V96, P6885, DOI 10.1073/pnas.96.12.6885; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yao PM, 1998, AM J RESP CELL MOL, V18, P813, DOI 10.1165/ajrcmb.18.6.2984	56	160	166	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					995	+		10.1096/fj.03-1412fje	http://dx.doi.org/10.1096/fj.03-1412fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059974	Green Accepted			2022-12-25	WOS:000221108800025
J	D'Alessandris, C; Andreozzi, F; Federici, M; Cardellini, M; Brunetti, A; Ranalli, M; Del Guerra, S; Lauro, D; Del Prato, S; Marchetti, P; Lauro, R; Sesti, G				D'Alessandris, C; Andreozzi, F; Federici, M; Cardellini, M; Brunetti, A; Ranalli, M; Del Guerra, S; Lauro, D; Del Prato, S; Marchetti, P; Lauro, R; Sesti, G			Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells	FASEB JOURNAL			English	Article						glucose toxicity; hexosamine pathway; diabetes mellitus	HEXOSAMINE PATHWAY; INDUCE APOPTOSIS; SECRETION; RECEPTOR; GLUCOSE; POLYMORPHISM; SURVIVAL; ISLETS; RAT; DYSFUNCTION	Because adverse effects of glucose were attributed to its increased routing through the hexosamine pathway (HBP), we inquired whether HBP activation affects pancreatic beta-cell survival. Exposure of human islets to high glucose resulted in increased apoptosis of beta-cells upon serum deprivation that was reversed by azaserine. Also, glucosamine, a direct precursor of the downstream product of the HBP, increased human beta-cells apoptosis upon serum deprivation, which was reversed by benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside (BADGP), an inhibitor of protein O-glycosylation. These results were reproduced in RIN rat beta-cells. Glucosamine treatment resulted in inhibition of tyrosine-phosphorylation of the insulin receptor (IR), IRS-1, and IRS-2, which was associated with increased O-glycosylation. These changes caused impaired activation of the PI 3-kinase/Akt survival signaling that resulted in reduced GSK-3 and FOXO1a inactivation. BADGP reversed the glucosamine-induced reduction in insulin-stimulated phosphorylation of IR, IRS-1, IRS-2, Akt, GSK-3, and FOXO1a. Impaired FOXO1a inactivation sustained expression of the pro-apoptotic protein Bim, without affecting Bad, Bcl-XL, or Bcl-2 expression. These results indicate that hyperglycemia may increase susceptibility to apoptosis of human and rat beta-cell through activation of the HBP. Increased routing of glucose through this metabolic pathway results in impaired activation of the IR/IRSs/PI3-kinase/ Akt survival pathway by induction of O-glycosylation of signaling molecules.	Univ Magna Graecia di Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, Biochem Lab, IDI,IRCCS, Rome, Italy; Univ Pisa, Dept Endocrinol & Metab, Metab Unit, Pisa, Italy	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Pisa	Sesti, G (corresponding author), Univ Magna Graecia di Catanzaro, Dipartimento Med Sperimentale & Clin, Via Tommaso Campanella 115, I-88100 Catanzaro, Italy.	sesti@unicz.it	Sesti, Giorgio/B-1509-2012; Cardellini, Marina/AAC-1096-2019; Lauro, Davide/K-4683-2018; Marchetti, Piero/J-7439-2013; Federici, Massimo/G-9940-2012; Brunetti, Antonio/K-7756-2016; Del Prato, Stefano/K-3405-2016; Del+Prato, Stefano/AAC-9197-2021; Andreozzi, Francesco/J-4073-2018	Marchetti, Piero/0000-0003-4907-0635; Federici, Massimo/0000-0003-4989-5194; Del Prato, Stefano/0000-0002-5388-0270; Sesti, Giorgio/0000-0002-1618-7688; Lauro, Davide/0000-0002-8597-4415; Brunetti, Antonio/0000-0003-1533-8779; Andreozzi, Francesco/0000-0001-9375-1513	Telethon [E.1309] Funding Source: Medline	Telethon(Fondazione Telethon)		Aikawa R, 2000, CIRCULATION, V102, P2873; Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Borboni P, 1999, ENDOCRINOLOGY, V140, P5530, DOI 10.1210/en.140.12.5530; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; Federici M, 2001, FASEB J, V15, P22; Federici M, 1999, DIABETES, V48, P2277, DOI 10.2337/diabetes.48.12.2277; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; GIACCARI A, 1995, DIABETOLOGIA, V38, P518, DOI 10.1007/BF00400719; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUPTA R, IDENTIFYING INTRACEL; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; Hennige AM, 2002, BIOCHEM BIOPH RES CO, V290, P85, DOI 10.1006/bbrc.2001.6144; Hribal ML, 2003, FASEB J, V17, P1340, DOI 10.1096/fj.02-0685fje; James LR, 2002, DIABETES, V51, P1146, DOI 10.2337/diabetes.51.4.1146; KAHN CR, 1995, NATURE, V373, P384; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Konrad RJ, 2002, INT J MOL MED, V10, P535; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Sesti G, 2002, ANN MED, V34, P444, DOI 10.1080/078538902321012397; Sesti G, 2003, DIABETES, V52, P1280, DOI 10.2337/diabetes.52.5.1280; Shankar RR, 1998, METABOLISM, V47, P573, DOI 10.1016/S0026-0495(98)90242-6; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	47	71	73	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					959	+		10.1096/fj.03-0725fje	http://dx.doi.org/10.1096/fj.03-0725fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059979				2022-12-25	WOS:000221108800030
J	Grounds, MD; Torrisi, J				Grounds, MD; Torrisi, J			Anti-TNF alpha (Remicade (R)) therapy protects dystrophic skeletal muscle from necrosis	FASEB JOURNAL			English	Article						mdx mice; dystropathology; DMD	JUVENILE IDIOPATHIC ARTHRITIS; DUCHENNE MUSCULAR-DYSTROPHY; MDX MICE; RHEUMATOID-ARTHRITIS; MEMBRANE REPAIR; MYOGENIC CELLS; CROHNS-DISEASE; ANIMAL-MODELS; EXPRESSION; INFLIXIMAB	Necrosis of skeletal muscle fibers in the lethal childhood myopathy Duchenne muscular dystrophy (DMD) results from defects in the cell membrane-associated protein, dystrophin. This study tests the novel hypothesis that the initial sarcolemmal breakdown resulting from dystrophin deficiency is exacerbated by inflammatory cells and that cytokines, specifically tumor necrosis factor- (TNF), contribute to muscle necrosis. To block in vivo TNF bioactivity, young dystrophic mdx mice (a model for DMD) were injected weekly from 7 days of age with the anti-TNF antibody Remicade(R) before the onset of muscle necrosis and dystropathology that normally occurs at 21 days postnatally. The extent of inflammation, muscle necrosis, and myotube formation was measured by histological analysis from 18 to 28 days and muscle damage was also visualized by penetration of Evans blue dye into myofibers. Data from Remicade(R)-treated and control mdx mice were compared with mdx/TNF(-/-) mice that lack TNF. Pharmacological blockade of TNF activity with Remicade(R) clearly delayed and greatly reduced the breakdown of dystrophic muscle, in marked contrast to the situation in mdx and mdx/TNF(-/-) mice. Remicade(R) had no adverse effect on new muscle formation. Remicade(R) is a highly specific anti-inflammatory intervention, and clinical application to muscular dystrophies is suggested by this marked protective effect against skeletal muscle breakdown.	Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009 USA	University of Western Australia		mgrounds@anhb.uwa.edu		Grounds, Miranda/0000-0002-4530-9402				AREND WP, 2002, J RHEUMATOL S, V65, P16; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; BEILHARZ MW, 1992, MOL CELL NEUROSCI, V3, P326, DOI 10.1016/1044-7431(92)90029-2; Billiau AD, 2002, J RHEUMATOL, V29, P1111; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Cheung EV, 2003, INFLAMM RES, V52, P170, DOI 10.1007/s000110300068; Collins RA, 2001, J HISTOCHEM CYTOCHEM, V49, P989, DOI 10.1177/002215540104900807; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Cozzi F, 2001, ACTA NEUROPATHOL, V101, P469; Doherty KR, 2003, TRENDS MOL MED, V9, P327, DOI 10.1016/S1471-4914(03)00136-9; Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Engvall E, 2003, FASEB J, V17, P1579, DOI 10.1096/fj.02-1215rev; Gabay C, 2002, EXPERT OPIN BIOL TH, V2, P135, DOI 10.1517/14712598.2.2.135; GOSSELIN LE, 2003, IN PRESS MUSCLE NERV; Hamer PW, 2002, J ANAT, V200, P69, DOI 10.1046/j.0021-8782.2001.00008.x; Hodge-Dufour J, 1998, P NATL ACAD SCI USA, V95, P13806, DOI 10.1073/pnas.95.23.13806; Hoffman EP, 2002, RHEUM DIS CLIN N AM, V28, P743, DOI 10.1016/S0889-857X(02)00031-5; Hyams JS, 2000, J PEDIATR-US, V137, P192, DOI 10.1067/mpd.2000.107161; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Kuru S, 2003, ACTA NEUROPATHOL, V105, P217, DOI 10.1007/s00401-002-0632-4; Lahdenne P, 2003, ANN RHEUM DIS, V62, P245, DOI 10.1136/ard.62.3.245; LEFAUCHEUR JP, 1995, ANAT REC, V242, P70, DOI 10.1002/ar.1092420109; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC370, DOI 10.1152/ajpcell.00453.2002; Lundberg I E, 2000, Curr Rheumatol Rep, V2, P216, DOI 10.1007/s11926-000-0082-y; MCGEACHIE JK, 1993, J NEUROL SCI, V119, P169, DOI 10.1016/0022-510X(93)90130-Q; McGeachie JK, 1999, J ANAT, V194, P287, DOI 10.1046/j.1469-7580.1999.19420287.x; MCLOUGHLIN TJ, 2003, IN PRESS CELL TISSUE; MITCHELL CA, 1992, CELL TISSUE RES, V269, P159, DOI 10.1007/BF00384736; Moghadaszadeh B, 2003, HUM MOL GENET, V12, P2467, DOI 10.1093/hmg/ddg264; Muntoni F, 2002, NEUROMUSCULAR DISORD, V12, pS162, DOI 10.1016/S0960-8966(02)00101-3; Nguyen HH, 2002, P NATL ACAD SCI USA, V99, P5616, DOI 10.1073/pnas.082613599; Nguyen HX, 2003, J PHYSIOL-LONDON, V550, P347, DOI 10.1113/jphysiol.2003.040907; Nguyen HX, 2003, J PHYSIOL-LONDON, V547, P125, DOI 10.1113/jphysiol.2002.031450; Pizza FX, 2001, AM J PHYSIOL-CELL PH, V281, pC335, DOI 10.1152/ajpcell.2001.281.1.C335; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Schatzberg SJ, 1999, NEUROMUSCULAR DISORD, V9, P289, DOI 10.1016/S0960-8966(99)00011-5; Serrano MS, 2001, ANN PHARMACOTHER, V35, P823; Skuk D, 2003, J MUSCLE RES CELL M, V24, P285; Spencer MJ, 2000, NEUROMUSCULAR DISORD, V10, P612, DOI 10.1016/S0960-8966(00)00160-7; Spencer MJ, 2002, HUM MOL GENET, V11, P2645, DOI 10.1093/hmg/11.21.2645; Spencer MJ, 2001, NEUROMUSCULAR DISORD, V11, P556, DOI 10.1016/S0960-8966(01)00198-5; Straub V, 2000, MAGNET RESON MED, V44, P655, DOI 10.1002/1522-2594(200010)44:4<655::AID-MRM22>3.0.CO;2-T; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Tews DS, 1998, CLIN IMMUNOL IMMUNOP, V87, P240, DOI 10.1006/clin.1998.4527; Torrente Y, 2003, CELL TRANSPLANT, V12, P91, DOI 10.3727/000000003783985115; Tseng BS, 2002, J APPL PHYSIOL, V93, P537, DOI 10.1152/japplphysiol.00202.2002; van Deventer SJH, 1999, ALIMENT PHARM THER, V13, P3, DOI 10.1046/j.1365-2036.1999.00024.x; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Warren GL, 2002, FASEB J, V16, P1630, DOI 10.1096/fj.02-0187fje; Wells Dominic J, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S146239940200515X; Wong BLY, 2002, J CHILD NEUROL, V17, P183, DOI 10.1177/088307380201700306; Xing J, 2002, NEUROBIOL DIS, V10, P234, DOI 10.1006/nbdi.2002.0504	56	189	196	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					676	682		10.1096/fj.03-1024com	http://dx.doi.org/10.1096/fj.03-1024com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054089				2022-12-25	WOS:000221108800037
J	Ohtsuka, T; Jensen, MR; Kim, HG; Kim, KT; Lee, SW				Ohtsuka, T; Jensen, MR; Kim, HG; Kim, KT; Lee, SW			The negative role of cyclin G in ATM-dependent p53 activation	ONCOGENE			English	Article						p53; cyclin G; ATM; cell cycle; DNA damage	DNA-DAMAGE; G2/M ARREST; PHOSPHORYLATION; GROWTH; CELLS; MODULATION; P53-MDM2; PROTEIN; TARGET; MDM2	Cyclin G is one of the earliest p53 target genes to be identified, but its function in the p53 pathway has been elusive. Although the precise mechanisms of cyclin G in this novel network have not been explored, recent studies have demonstrated that cyclin G is a key regulator of the p53-Mdm2 network. Here we present evidence that cyclin G-mediated p53 regulation is dependent upon the status of ataxia-telangiectasia mutated (ATM) protein, which activates p53 in response to DNA damage. Abrogation of cyclin G enhances p53 accumulation and phosphorylation of p53 at the Ser-15 residue, resulting in cell cycle arrest. Ectopically expressed cyclin G significantly reduces the steady-state levels of p53 as well as that of phosphorylated p53 at Ser-15 after DNA damage in normal human dermal fibroblasts containing normal ATM. However, cyclin G does not cause similar reductions in p53 levels in ATM-mutated cells. We also show that translocation of cyclin G to the nucleus requires functional ATM. Thus, our findings identify a new role of cyclin G in ATM-dependent p53 regulation and in cell cycle regulation during DNA damage.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; FIRC Inst Mol Oncol, Milan, Italy	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; IFOM - FIRC Institute of Molecular Oncology	Lee, SW (corresponding author), Harvard Inst Med, 4 Blackfan Circle,Room 921, Boston, MA 02115 USA.	slee2@caregroup.harvard.edu			NCI NIH HHS [CA78356, CA85681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078356, R01CA085681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen XB, 2002, DEV CELL, V2, P518, DOI 10.1016/S1534-5807(02)00182-X; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Jensen MR, 2003, HEPATOLOGY, V37, P862, DOI 10.1053/jhep.2003.50137; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao L, 2003, MOL CANCER RES, V1, P195	20	43	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5405	5408		10.1038/sj.onc.1207693	http://dx.doi.org/10.1038/sj.onc.1207693			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077171				2022-12-25	WOS:000222491600016
J	Li, FW; Templeton, TJ; Popov, V; Comer, JE; Tsuboi, T; Torii, M; Vinetz, JM				Li, FW; Templeton, TJ; Popov, V; Comer, JE; Tsuboi, T; Torii, M; Vinetz, JM			Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSQUITO MIDGUT STAGES; SPOROGONIC DEVELOPMENT; A-DOMAIN; FALCIPARUM; GALLINACEUM; ANTIBODIES; CTRP; IDENTIFICATION; CHITINASES; INFECTION	The mosquito midgut ookinete stage of the malaria parasite, Plasmodium, possesses microneme secretory organelles that mediate locomotion and midgut wall egress to establish sporogonic stages and subsequent transmission. The purpose of this study was 2-fold: 1) to determine whether there exists a single micronemal population with respect to soluble and membrane-associated secreted proteins; and 2) to evaluate the ookinete micronemal proteins chitinase (PgCHT1), circumsporozoite and TRAP-related protein (CTRP), and von Willebrand factor A domain-related protein ( WARP) as immunological targets eliciting sera-blocking malaria parasite infectivity to mosquitoes. Indirect immunofluorescence localization studies in Plasmodium gallinaceum using specific antisera showed that all three proteins are distributed intracellularly with a similar granular cytoplasmic appearance and with focal concentration of PgCHT1 and PgCTRP, but not PgWARP, at the ookinete apical end. Immunogold double-labeling electron microscopy, using antisera against the membrane-associated protein CTRP and the soluble WARP, showed that these two proteins co-localized to the same micronemal population. Within the microneme CTRP was associated peripherally at the microneme membrane, whereas PgCHT1 and WARP were diffuse within the micronemal lumen. Sera produced against Plasmodium falciparum WARP significantly reduced the infectivity of P. gallinaceum to Aedes aegypti and P. falciparum to Anopheles mosquitoes. Antisera against PgCTRP and PgCHT1 also significantly reduced the infectivity of P. gallinaceum for A. aegypti. These results support the concept that ookinete micronemal proteins may constitute a general class of malaria transmission-blocking vaccine candidates.	Univ Calif San Diego, Dept Med, Div Infect Dis, La Jolla, CA 92093 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA; Ehime Univ, Sch Med, Dept Mol Parasitol, Shigenobu, Ehime 7910295, Japan	University of California System; University of California San Diego; Cornell University; University of Texas System; University of Texas Medical Branch Galveston; Ehime University	Vinetz, JM (corresponding author), Univ Calif San Diego, Dept Med, Div Infect Dis, Rm 2052,9500 Gilman Dr 0640, La Jolla, CA 92093 USA.	jvinetz@ucsd.edu	Tsuboi, Takafumi/AAK-6145-2021	Tsuboi, Takafumi/0000-0002-7415-1325; Vinetz, Joseph/0000-0001-8344-2004	NIAID NIH HHS [K02AI50049, R01AI45999] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI050049, R01AI045999] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham EG, 2004, J BIOL CHEM, V279, P5573, DOI 10.1074/jbc.M307582200; BERNER R, 1983, J ULTRA MOL STRUCT R, V83, P195, DOI 10.1016/S0022-5320(83)90077-1; Carter R, 2001, VACCINE, V19, P2309, DOI 10.1016/S0264-410X(00)00521-1; CARTER R, 1984, MOL BIOCHEM PARASIT, V13, P235, DOI 10.1016/0166-6851(84)90116-6; Dessens JT, 1999, EMBO J, V18, P6221, DOI 10.1093/emboj/18.22.6221; Gozar MMG, 1998, INFECT IMMUN, V66, P59, DOI 10.1128/IAI.66.1.59-64.1998; Hisaeda H, 2000, INFECT IMMUN, V68, P6618, DOI 10.1128/IAI.68.12.6618-6623.2000; Kaslow DC, 1997, INT J PARASITOL, V27, P183, DOI 10.1016/S0020-7519(96)00148-8; KAUSHAL DC, 1984, MOL BIOCHEM PARASIT, V11, P145, DOI 10.1016/0166-6851(84)90061-6; KAUSHAL DC, 1983, J IMMUNOL, V131, P2557; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; Langer RC, 2000, INFECT IMMUN, V68, P6461, DOI 10.1128/IAI.68.11.6461-6465.2000; Langer RC, 2002, INFECT IMMUN, V70, P1581, DOI 10.1128/IAI.70.3.1581-1590.2002; Langer RC, 2002, INFECT IMMUN, V70, P102, DOI 10.1128/IAI.70.1.102-106.2002; Limviroj W, 2002, J PARASITOL, V88, P664, DOI 10.1645/0022-3395(2002)088[0664:IEMOOP]2.0.CO;2; McCormick CJ, 1999, MOL BIOCHEM PARASIT, V100, P111, DOI 10.1016/S0166-6851(99)00052-3; MUNDERLOH UG, 1987, J PARASITOL, V73, P919, DOI 10.2307/3282511; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; ROSENBERG R, 1982, J PARASITOL, V68, P653, DOI 10.2307/3280924; Stowers A, 2001, EXPERT OPIN BIOL TH, V1, P619, DOI 10.1517/14712598.1.4.619; Stowers AW, 2000, INFECT IMMUN, V68, P5530, DOI 10.1128/IAI.68.10.5530-5538.2000; Templeton TJ, 2000, MOL MICROBIOL, V36, P1, DOI 10.1046/j.1365-2958.2000.01821.x; Trottein F, 1995, MOL BIOCHEM PARASIT, V74, P129, DOI 10.1016/0166-6851(95)02489-1; VAUGHAN JA, 1991, J PARASITOL, V77, P758, DOI 10.2307/3282712; VAUGHAN JA, 1994, AM J TROP MED HYG, V51, P233, DOI 10.4269/ajtmh.1994.51.233; VAUGHAN JA, 1994, J PARASITOL, V80, P674, DOI 10.2307/3283245; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Vinetz JM, 2000, J BIOL CHEM, V275, P10331, DOI 10.1074/jbc.275.14.10331; Yuda M, 1999, J EXP MED, V189, P1947, DOI 10.1084/jem.189.12.1947; Yuda M, 2001, MOL BIOCHEM PARASIT, V116, P65, DOI 10.1016/S0166-6851(01)00304-8	31	59	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26635	26644		10.1074/jbc.M401385200	http://dx.doi.org/10.1074/jbc.M401385200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069061	hybrid			2022-12-25	WOS:000222003000090
J	Kim, M; Yang, HL; Kim, SK; Reche, PA; Tirabassi, RS; Hussey, RE; Chishti, Y; Rheinwald, JG; Morehead, TJ; Zech, T; Damon, IK; Welsh, RM; Reinherz, EL				Kim, M; Yang, HL; Kim, SK; Reche, PA; Tirabassi, RS; Hussey, RE; Chishti, Y; Rheinwald, JG; Morehead, TJ; Zech, T; Damon, IK; Welsh, RM; Reinherz, EL			Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS ANTIVIRAL IMMUNITY; ERBB SIGNALING NETWORK; GENOME DNA-SEQUENCES; VACCINIA VIRUS; FACTOR-ALPHA; CRYSTAL-STRUCTURE; FACTOR RECEPTOR; CELLS; EPIREGULIN; SPECIFICITY	Variola, the causative agent of smallpox, is a highly infectious double-stranded DNA virus of the orthopox genus that replicates within the cytoplasm of infected cells. For unknown reasons prominent skin manifestations, including "pox," mark the course of this systemic human disease. Here we characterized smallpox growth factor (SPGF), a protein containing an epidermal growth factor (EGF)-like domain that is conserved among orthopox viral genomes, and investigated its possible mechanistic link. We show that after recombinant expression, refolding, and purification, the EGF domain of SPGF binds exclusively to the broadly expressed cellular receptor, erb-B1 (EGF receptor), with subnanomolar affinity, stimulating the growth of primary human keratinocytes and fibroblasts. High affinity monoclonal antibodies specific for SPGF reveal in vivo immunoprotection in a murine vaccinia pneumonia model by a mechanism distinct from viral neutralization. These findings suggest that blockade of pathogenic factor actions, in general, may be advantageous to the infected host.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Lab Immunobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Ctr Dis Control & Prevent, Poxvirus Sect, Atlanta, GA 30333 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Centers for Disease Control & Prevention - USA	Reinherz, EL (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Lab Immunobiol, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu	Reche, Pedro A/B-1881-2013	Reche, Pedro A/0000-0003-3966-5838; Zech, Tobias/0000-0001-8394-088X	NIAID NIH HHS [AI19807, AI50900] Funding Source: Medline; NIAMS NIH HHS [P30 AR042689, AR35506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019807, R37AI019807, R01AI050900, R56AI019807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035506, P30AR042689] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APELLA E, 1988, FEBS LETT, V231, P1; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1988, J VIROL, V62, P866, DOI 10.1128/JVI.62.3.866-874.1988; BULLER RML, 1988, VIROLOGY, V164, P182, DOI 10.1016/0042-6822(88)90635-6; Chen HD, 2001, NAT IMMUNOL, V2, P1067, DOI 10.1038/ni727; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Fenner Frank, 1988, SMALLPOX ITS ERADICA; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096; KEMPE CH, 1960, PEDIATRICS, V26, P176; Kim M, 2001, J BIOL CHEM, V276, P42667, DOI 10.1074/jbc.M104166200; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; Locker JK, 2000, MOL BIOL CELL, V11, P2497, DOI 10.1091/mbc.11.7.2497; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NANNEY LB, 1990, J INVEST DERMATOL, V94, P742, DOI 10.1111/1523-1747.ep12874601; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; OHMURA E, 1990, CANCER RES, V50, P4915; OPGENORTH A, 1993, VIROLOGY, V192, P701, DOI 10.1006/viro.1993.1092; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; RUBY J, 1991, LYMPHOKINE CYTOK RES, V10, P353; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schluns KS, 1997, J IMMUNOL, V158, P2704; Schon M, 1996, J INVEST DERMATOL, V107, P428, DOI 10.1111/1523-1747.ep12363411; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; Shchelkunov SN, 2000, VIROLOGY, V266, P361, DOI 10.1006/viro.1999.0086; SHCHELKUNOV SN, 1995, VIRUS RES, V36, P107, DOI 10.1016/0168-1702(94)00113-Q; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SONNHAMMER ELL, 1998, 6 INT C INT SYST MOL, P175; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; Tanaka T, 2001, J MOL CELL CARDIOL, V33, P1627, DOI 10.1006/jmcc.2001.1428; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; TUBO RA, 1987, ONCOGENE RES, V1, P407; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoo JY, 2003, P NATL ACAD SCI USA, V100, P1157, DOI 10.1073/pnas.0336385100	53	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25838	25848		10.1074/jbc.M400343200	http://dx.doi.org/10.1074/jbc.M400343200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070899	Green Accepted, hybrid			2022-12-25	WOS:000221827900115
J	Nur-E-Kamal, A; Gross, SR; Pan, Z; Balklava, Z; Ma, JJ; Liu, LF				Nur-E-Kamal, A; Gross, SR; Pan, Z; Balklava, Z; Ma, JJ; Liu, LF			Nuclear translocation of cytochrome c during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN CONDENSATION; CELL-DEATH; CASPASE 9; DNA; PATHWAYS; NUCLEOSOMES; ACTIVATION; RECEPTORS; BRAIN; MICE	Release of cytochrome c from mitochondria is a major event during apoptosis. Released cytochrome c has been shown to activate caspase-dependent apoptotic signals. In this report, we provide evidence for a novel role of cytochrome c in caspase-independent nuclear apoptosis. We showed that cytochrome c, released from mitochondria upon apoptosis induction, gradually accumulates in the nucleus as evidenced by both immunofluorescence and subcellular fractionation. Parallel to nuclear accumulation of cytochrome c, acetylated histone H2A, but not unmodified H2A, was released from the nucleus to the cytoplasm. Addition of purified cytochrome c to isolated nuclei recapitulated the preferential release of acetylated, but not deacetylated, histone H2A. Cytochrome c was also found to induce chromatin condensation. These results suggest that the nuclear accumulation of cytochrome c may be directly involved in the remodeling of chromatin. Our results provide evidence of a novel role for cytochrome c in inducing nuclear apoptosis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Nur-E-Kamal, A (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	nurekasa@umdnj.edu	Balklava, Zita/AAU-6146-2021	Balklava, Zita/0000-0001-9039-9710; gross, stephane/0000-0002-0867-8866; Liu, Leroy/0000-0001-9396-763X; Pan, Zui/0000-0003-4105-901X	NATIONAL CANCER INSTITUTE [R01CA039662, R01CA095739] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662, CA95739] Funding Source: Medline; NHLBI NIH HHS [HL69000] Funding Source: Medline; NIA NIH HHS [AG15556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Baxter BK, 1998, J BIOL CHEM, V273, P17517, DOI 10.1074/jbc.273.28.17517; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; D'Mello SR, 2000, J NEUROSCI RES, V59, P24, DOI 10.1002/(SICI)1097-4547(20000101)59:1<24::AID-JNR4>3.3.CO;2-#; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Meiners S, 2001, J NEUROSCI, V21, P7215, DOI 10.1523/JNEUROSCI.21-18-07215.2001; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Sanchez-Gomez MV, 2003, J NEUROSCI, V23, P9519; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	25	97	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24911	24914		10.1074/jbc.C400051200	http://dx.doi.org/10.1074/jbc.C400051200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073175	Green Accepted, hybrid			2022-12-25	WOS:000221827900002
J	Nishiura, M; Kon, T; Shiroguchi, K; Ohkura, R; Shima, T; Toyoshima, YY; Sutoh, K				Nishiura, M; Kon, T; Shiroguchi, K; Ohkura, R; Shima, T; Toyoshima, YY; Sutoh, K			A single-headed recombinant fragment of Dictyostelium cytoplasmic dynein can drive the robust sliding of microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; ACTIVATED ATPASE; DISCOIDEUM; PROTEINS; DOMAINS	A cytoplasmic dynein is a microtubule-based motor protein involved in diverse cellular functions, such as organelle transport and chromosome segregation. The dynein has two ring-shaped heads that contain six repeats of the AAA domain responsible for ATP hydrolysis. It has been proposed that the ATPase-dependent swing of a stalk and a stem emerging from each of the heads generates the power stroke (Burgess, S. A. (2003) Nature 421, 715-718). To understand the molecular mechanism of the dynein power stroke, it is essential to establish an easy and reproducible method to express and purify the recombinant dynein with full motor activities. Here we report the expression and purification of the C-terminal 380-kDa fragment of the Dictyostelium cytoplasmic dynein heavy-chain fused with an affinity tag and green fluorescent protein. The purified single-headed recombinant protein drove the robust minus-end-directed sliding of microtubules at a velocity of 1.2 mum/s. This recombinant protein had a high basal ATPase activity (similar to4 s(-1)), which was further activated by > 15-fold on the addition of 40 muM microtubules. These results show that the 380-kDa recombinant fragment retains all the structures required for motor functions, i.e. the ATPase activity highly stimulated by microtubules and the robust motility.	Univ Tokyo, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB)	Sutoh, K (corresponding author), Univ Tokyo, Dept Life Sci, Meguro Ku, Komaba 3-8-1, Tokyo 1538902, Japan.	sutoh@bio.c.u-tokyo.ac.jp	Kon, Takahide/AAG-6975-2021	Kon, Takahide/0000-0002-1231-7609				Blaauw M, 2000, GENE, V252, P71, DOI 10.1016/S0378-1119(00)00227-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Iyadurai SJ, 1999, CURR BIOL, V9, P771, DOI 10.1016/S0960-9822(99)80340-6; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SM, 2000, J CELL SCI, V113, P2521; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; Koonce MP, 2000, MOL BIOL CELL, V11, P523, DOI 10.1091/mbc.11.2.523; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; Mocz G, 2001, STRUCTURE, V9, P93, DOI 10.1016/S0969-2126(00)00557-8; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; SCHLATTERER C, 1992, EUR J CELL BIOL, V58, P172; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P1575, DOI 10.1021/bi00005a013; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P409; Sullivan KF, 1999, METHOD CELL BIOL, V58, P183; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; Vallee RB, 1998, TRENDS CELL BIOL, V8, P490, DOI 10.1016/S0962-8924(98)01379-8; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8	29	72	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					22799	22802		10.1074/jbc.M313362200	http://dx.doi.org/10.1074/jbc.M313362200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15051717	hybrid			2022-12-25	WOS:000221570900004
J	Manenti, G; Galbiati, F; Gianni-Barrera, R; Pettinicchio, A; Acevedo, A; Dragani, TA				Manenti, G; Galbiati, F; Gianni-Barrera, R; Pettinicchio, A; Acevedo, A; Dragani, TA			Haplotype sharing suggests that a genomic segment containing six genes accounts for the pulmonary adenoma susceptibility 1 (Pas1) locus activity in mice	ONCOGENE			English	Article						genetic susceptibility; inbred strains; lung tumors; Kras2	QUANTITATIVE TRAIT LOCUS; LUNG-TUMOR SUSCEPTIBILITY; BUTYLATED HYDROXYTOLUENE; CANCER; MOUSE; PROTEIN; RISK; CARCINOGENESIS; TUMORIGENESIS; POLYMORPHISM	The pulmonary adenoma susceptibility 1 (Pas1) locus affects inherited predisposition and resistance to chemically induced lung tumorigenesis in mice. The A/J and C57BL/6J mouse strains carry the susceptibility and resistance allele, respectively. We identified and geno-typed 65 polymorphisms in the Pas1 locus region in 29 mouse inbred strains, and delimited the Pas1 locus to a minimal region of 468 kb containing six genes. That region defined a core Pas1 haplotype with 42 tightly linked markers, including intragenic polymorphisms in five genes (Bcat1, Lrmp, Las1, Ghiso, and Kras2) and amino-acid changes in three genes ( Lrmp, Las1, Lmna-rs1). In (A/J x C57BL/6J) F1 mouse lung tumors, the Lmna-rs1 gene was completely downregulated, whereas allele-specific downregulation of the C57BL/6J-derived allele was observed at the Las1 gene, suggesting the potential role of these genes in tumor suppression. These results indicate a complex multigenic nature of the Pas1 locus, and point to a functional role for both intronic and exonic polymorphisms of the Pas1 haplotype in lung tumor susceptibility.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ La Laguna, Fac Med, Tenerife, Spain	Fondazione IRCCS Istituto Nazionale Tumori Milan; Universidad de la Laguna	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Arozena, Abraham Acevedo/L-6584-2018; Gianni-Barrera, Roberto/ACU-4280-2022; Manenti, Giacomo/J-3339-2017	Dragani, Tommaso A./0000-0001-5915-4598; Arozena, Abraham Acevedo/0000-0001-6127-7116; Gianni-Barrera, Roberto/0000-0001-6303-4513; Manenti, Giacomo/0000-0002-4887-4482				AKAMATSU Y, 1975, J NATL CANCER I, V55, P893, DOI 10.1093/jnci/55.4.893; Askling J, 1999, AM J RESP CRIT CARE, V160, P1668, DOI 10.1164/ajrccm.160.5.9904045; Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; BEHRENS TW, 1994, J IMMUNOL, V153, P682; Brownson RC, 2000, CANCER CAUSE CONTROL, V11, P853, DOI 10.1023/A:1008999202040; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Darvasi A, 2002, TRENDS GENET, V18, P489, DOI 10.1016/S0168-9525(02)02767-1; De Luca M, 2003, NAT GENET, V34, P429, DOI 10.1038/ng1218; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 2003, CANCER RES, V63, P3011; Eden A, 1999, FEBS LETT, V457, P255, DOI 10.1016/S0014-5793(99)01054-6; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kawakami K, 2001, CLIN CANCER RES, V7, P4096; Liang TB, 2003, P NATL ACAD SCI USA, V100, P4690, DOI 10.1073/pnas.0737182100; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; MALKINSON AM, 1984, J NATL CANCER I, V73, P925; Manenti G, 1999, GENOME RES, V9, P639; Manenti G, 2002, INT J CANCER, V99, P555, DOI 10.1002/ijc.10386; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; TRAININ N, 1967, INT J CANCER, V2, P326, DOI 10.1002/ijc.2910020407; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wang M, 2003, CANCER RES, V63, P3317; Webb KE, 2003, EXP HEMATOL, V31, P488, DOI 10.1016/S0301-472X(03)00065-1; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	35	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4495	4504		10.1038/sj.onc.1207584	http://dx.doi.org/10.1038/sj.onc.1207584			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064703				2022-12-25	WOS:000221661300015
J	Johansson, E; Olsson, O; Nystrom, T				Johansson, E; Olsson, O; Nystrom, T			Progression and specificity of protein oxidation in the life cycle of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUBISCO; STRESS; DAMAGE; SENESCENCE; EXPRESSION; INDUCTION; MECHANISM; SPAN	Protein carbonylation is an irreversible oxidative process leading to a loss of function of the modified proteins, and in a variety of model systems, including worms, flies, and mammals, carbonyl levels gradually increase with age. In contrast, we report here that in Arabidopsis thaliana an initial increase in protein oxidation during the first 20 days of the life cycle of the plant is followed by a drastic reduction in protein carbonyls prior to bolting and flower development. Protein carbonylation prior to the transition to flowering targets specific proteins such as Hsp70, ATP synthases, the large subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco), and proteins involved in light harvesting/energy transfer and the C2 oxidative photosynthetic carbon cycle. The precipitous fall in protein carbonyl levels is due to the specific reduction in the levels of oxidized proteins rather than an overall loss of chlorophyll and Rubisco associated with the senescence syndrome. The results are discussed in light of contemporary theories of aging in animals.	Univ Gothenburg, Dept Cell & Mol Biol, S-40530 Gothenburg, Sweden	University of Gothenburg	Nystrom, T (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol, Box 462, S-40530 Gothenburg, Sweden.	Nystrom@gmm.gu.se		Olsson, Olof/0000-0003-3962-9183				Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bleecker AB, 1997, PLANT CELL, V9, P1169, DOI 10.1105/tpc.9.7.1169; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Clark SE, 1997, PLANT CELL, V9, P1067, DOI 10.1105/tpc.9.7.1067; Das N, 2001, BIOCHEM J, V360, P209, DOI 10.1042/0264-6021:3600209; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; HENSEL LL, 1993, PLANT CELL, V5, P553, DOI 10.1105/tpc.5.5.553; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; Jing HC, 2002, PLANT J, V32, P51, DOI 10.1046/j.1365-313X.2002.01400.x; Kerstetter RA, 1997, PLANT CELL, V9, P1001, DOI 10.1105/tpc.9.7.1001; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; Nakamura A, 1996, J BIOCHEM, V119, P768; Neuwald AF, 1999, GENOME RES, V9, P27; Nood?n L.D., 1988, SENESCENCE AGING PLA, P329, DOI DOI 10.1016/B978-0-12-520920-5.50007-9.; NOODEN LD, 1993, AUST J PLANT PHYSIOL, V20, P639, DOI 10.1071/PP9930639; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pantke U, 1999, FREE RADICAL BIO MED, V27, P1080, DOI 10.1016/S0891-5849(99)00144-6; PORTIS AR, 1995, J EXP BOT, V46, P1285, DOI 10.1093/jxb/46.special_issue.1285; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; SALVUCCI ME, 1987, PLANT PHYSIOL, V84, P930, DOI 10.1104/pp.84.3.930; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; Somerville C.R., 1982, METHODS CHLOROPLAST, P129; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Sun JT, 1999, MOL CELL BIOL, V19, P216; Sung DY, 2001, PLANT PHYSIOL, V126, P789, DOI 10.1104/pp.126.2.789; Taylor NL, 2002, J BIOL CHEM, V277, P42663, DOI 10.1074/jbc.M204761200; Thomas H, 2002, MECH AGEING DEV, V123, P747, DOI 10.1016/S0047-6374(01)00420-1; Thomson W. W., 1987, Plant senescence: its biochemistry and physiology. Proceedings of the Tenth Annual Symposium in Plant Physiology, 8-10 January, 1987, University of California, Riverside, California, USA., P20; WERNEKE JM, 1989, PLANT CELL, V1, P815, DOI 10.1105/tpc.1.8.815; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wilson JB, 1997, PHYSIOL PLANTARUM, V99, P511, DOI 10.1034/j.1399-3054.1997.990321.x; Yamamoto Y, 1998, BIOCHEMISTRY-US, V37, P1565, DOI 10.1021/bi9707640; Zhang N, 1999, P NATL ACAD SCI USA, V96, P9438, DOI 10.1073/pnas.96.16.9438	38	188	196	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22204	22208		10.1074/jbc.M402652200	http://dx.doi.org/10.1074/jbc.M402652200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15070894	hybrid			2022-12-25	WOS:000221417100066
J	Hui, LJ; Zhang, X; Wu, X; Lin, ZX; Wang, QK; Li, YX; Hu, GX				Hui, LJ; Zhang, X; Wu, X; Lin, ZX; Wang, QK; Li, YX; Hu, GX			Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment	ONCOGENE			English	Article						alternative splicing prediction; database; cancer; EST alignment	EXPRESSED SEQUENCE TAGS; COMPUTATIONAL ANALYSIS; GENE-EXPRESSION; DATABASE; PROTEIN; EXON	Several databases have been published to predict alternative splicing of mRNAs by analysing the exon linkage relationship by alignment of expressed sequence tags (ESTs) to the genome sequence; however, little effort has been made to investigate the relationship between cancers and alternative splicing. We developed a program, Alternative Splicing Assembler (ASA), to look for splicing variants of human gene transcripts by genome-wide ESTs alignment. Using ASA, we constructed the biosino alternative splicing database (BASD), which predicted splicing variants for reference sequences from the reference sequence database (RefSeq) and presented them in both graph and text formats. EST clusters that differ from the reference sequences in at least one splicing site were counted as splicing variants. Of 4322 genes screened, 3490 (81%) were observed with at least one alternative splicing variants. To discover the variants associated with cancers, tissue sources of EST sequences were extracted from the UniLib database and ESTs from the same tissue type were counted. These were regarded as the indicators for gene expression level. Using Fisher's exact test, alternative splicing variants, of which EST counts were significantly different between cancer tissues and their counterpart normal tissues, were identified. It was predicted that 2149 variants, or 383 variants after Bonferroni correction, of 26 812 variants were likely tumor-associated. By reverse transcription-PCR, 11 of 13 novel alternative splicing variants and eight of nine variants' tissue specificity were confirmed in hepatocelluar carcinoma and in lung cancer. The possible involvement of alternative splicing in cancer is discussed.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Shanghai Jiao Tong Univ, Inst Microelect, Shanghai 200030, Peoples R China; Zhongshan Hosp, Liver Canc Inst, Guangzhou, Peoples R China; Shanghai Jiao Tong Univ, Sch Life Sci, Shanghai 200030, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Bioinformat Ctr, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Li, YX (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Room 400,Cell Bldg,Yueyang Rd 320, Shanghai 200031, Peoples R China.	yxli@sibs.ac.cn; xbshu@sunm.shcnc.ac.cn	Wu, Xin/B-2244-2010					Ars E, 2000, NUCLEIC ACIDS RES, V28, P1307, DOI 10.1093/nar/28.6.1307; Baranova AV, 2001, FEBS LETT, V508, P143, DOI 10.1016/S0014-5793(01)03028-9; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; Coward E, 2002, TRENDS GENET, V18, P53, DOI 10.1016/S0168-9525(01)02525-2; Dralyuk I, 2000, NUCLEIC ACIDS RES, V28, P296, DOI 10.1093/nar/28.1.296; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; Hogenesch JB, 2001, CELL, V106, P413, DOI 10.1016/S0092-8674(01)00467-6; Huang RM, 2003, CANCER RES, V63, P3775; Huang YH, 2002, NUCLEIC ACIDS RES, V30, P186, DOI 10.1093/nar/30.1.186; Ji HK, 2001, NUCLEIC ACIDS RES, V29, P260, DOI 10.1093/nar/29.1.260; Kan ZY, 2002, GENOME RES, V12, P1837, DOI 10.1101/gr.764102; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; Kaufmann D, 2002, CANCER RES, V62, P1503; Kawamoto S, 2000, GENOME RES, V10, P1817, DOI 10.1101/gr.151500; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Matsui A, 2000, CANCER LETT, V150, P23, DOI 10.1016/S0304-3835(99)00368-7; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Scheurle D, 2000, CANCER RES, V60, P4037; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Stamm S, 2000, DNA CELL BIOL, V19, P739, DOI 10.1089/104454900750058107; Thompson TE, 2002, CANCER RES, V62, P3251; Valve EM, 2001, LAB INVEST, V81, P815, DOI 10.1038/labinvest.3780291; van der Spuy J, 2002, HUM MOL GENET, V11, P823, DOI 10.1093/hmg/11.7.823; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang ZN, 2003, CANCER RES, V63, P655; Wolfsberg TG, 1997, NUCLEIC ACIDS RES, V25, P1626, DOI 10.1093/nar/25.8.1626; Xie HQ, 2002, GENOMICS, V80, P326, DOI 10.1006/geno.2002.6841; Xu L, 2001, CANCER RES, V61, P3176; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492	39	62	64	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3013	3023		10.1038/sj.onc.1207362	http://dx.doi.org/10.1038/sj.onc.1207362			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048092				2022-12-25	WOS:000220845200005
J	Wang, XH; Su, Y; Deb, K; Raposo, M; Morrow, JD; Reese, J; Paria, BC				Wang, XH; Su, Y; Deb, K; Raposo, M; Morrow, JD; Reese, J; Paria, BC			Prostaglandin E-2 is a product of induced prostaglandin-endoperoxide synthase 2 and microsomal-type prostaglandin E synthase at the implantation site of the hamster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MOUSE UTERUS; DELAYED IMPLANTATION; EMBRYO IMPLANTATION; E-2 SYNTHASE; PREGNANCY; INDOMETHACIN; PROGESTERONE; ESTROGEN; CYCLOOXYGENASE	Certain uterine prostaglandins (PGs) are elevated at implantation sites and are needed to trigger the events of blastocyst implantation that include blastocyst-uterine attachment and stromal decidualization with vascular permeability changes. Several decades of investigations showed that treatment with PG synthesis inhibitors, prior to or during the time of implantation, resulted in either complete inhibition or a delay in implantation or reduction in the number of implantation sites with diminished decidual tissue. Consistent with these findings, we observed that whereas a selective PG endoperoxide synthase (Ptgs) 1 inhibitor SC-560 failed to inhibit implantation, a selective Ptgs2 inhibitor SC-236 showed significantly reduced number and size of implantation sites in progesterone-treated ovariectomized pregnant hamsters. It is known that Ptgs2 expression and Ptgs2-derived prostacyclin (PGI(2)) synthesis at implantation sites are needed for implantation in the mouse (a rodent that needs ovarian estrogen for implantation). However, it is unknown which Ptgs and PG synthases produce which PGs at implantation sites of the hamster (a rodent that does not need ovarian estrogen for implantation). Here we demonstrate that as blastocyst implantation proceeds, a reduction in Ptgs1 expression from uterine luminal epithelial cells and a gradual induction in Ptgs2 expression exclusively in luminal epithelial and adjacent decidual cells occurred at implantation sites of hamsters. Results also reveal that PGE(2), but not PGI(2), is the major PG at implantation sites where Ptgs2 and microsomal type PGE synthases but not PGI synthases are co-expressed. This elevated uterine PGE(2) at implantation sites may serve to initiate or amplify physiological signals required for specific aspects of the implantation process in hamsters.	Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med & Pharmacol, Nashville, TN 37232 USA; Univ Kansas, Med Ctr, Kansas City, KS 66160 USA	Vanderbilt University; Vanderbilt University; University of Kansas; University of Kansas Medical Center	Paria, BC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, 1161 21st Ave S, Nashville, TN 37232 USA.	bc.paria@vanderbilt.edu		Reese, Jeff/0000-0001-8751-6146	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD044741] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD042636, R03HD040193, R01HD037394, R01HD042636, K08HD040221] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77839] Funding Source: Medline; NCRR NIH HHS [RR 00095] Funding Source: Medline; NICHD NIH HHS [HD 40193, HD 37394, HD 40221, HD 42636, HD 44741] Funding Source: Medline; NIDDK NIH HHS [DK 48831] Funding Source: Medline; NIGMS NIH HHS [GM 15431] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajuebor MN, 2000, AM J PHYSIOL-GASTR L, V279, pG238; BEHRMAN HR, 1979, ANNU REV PHYSIOL, V41, P685, DOI 10.1146/annurev.ph.41.030179.003345; BIGGERS JD, 1978, BIOL REPROD, V19, P519, DOI 10.1095/biolreprod19.3.519; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; CHIDA S, 1986, PROSTAGLANDINS, V3, P337; DAS SK, 1994, DEVELOPMENT, V120, P1071; DEY SK, 1980, PROSTAGLANDINS, V19, P449, DOI 10.1016/0090-6980(80)90078-7; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DEZIEGLER D, 1995, HUM REPROD, V10, P4, DOI 10.1093/humrep/10.1.4; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; FEINBERG BB, 1993, J REPROD IMMUNOL, V23, P109, DOI 10.1016/0165-0378(93)90001-X; Forsberg L, 2000, FEBS LETT, V471, P78, DOI 10.1016/S0014-5793(00)01367-3; GEORGE FW, 1978, SCIENCE, V199, P200, DOI 10.1126/science.579477; GHOSH D, 1994, HUM REPROD, V9, P629, DOI 10.1093/oxfordjournals.humrep.a138561; GIANNINA T, 1971, CONTRACEPTION, V3, P347, DOI 10.1016/0010-7824(71)90073-4; Harper M. J. K., 1969, Biology of Reproduction, V1, P253, DOI 10.1095/biolreprod1.3.253; HARPER MJK, 1983, BIOL REPROD, V28, P350, DOI 10.1095/biolreprod28.2.350; HOFFMAN LH, 1978, PROSTAGLANDINS, V15, P823, DOI 10.1016/0090-6980(78)90148-X; HOFFMAN LH, 1978, BIOL REPROD, V18, P148, DOI 10.1095/biolreprod18.1.148; HOVERSLAND RC, 1982, J REPROD FERTIL, V66, P259, DOI 10.1530/jrf.0.0660259; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; JONES MA, 1984, ENDOCRINOLOGY, V115, P817, DOI 10.1210/endo-115-2-817; KENNEDY TG, 1977, BIOL REPROD, V16, P286, DOI 10.1095/biolreprod16.3.286; KENNEDY TG, 1979, BIOL REPROD, V20, P560, DOI 10.1095/biolreprod20.3.560; KHURANA NK, 1987, J REPROD FERTIL, V79, P275, DOI 10.1530/jrf.0.0790275; KWUN JK, 1974, AUST J BIOL SCI, V27, P275, DOI 10.1071/BI9740275; LALA PK, 1989, AM J REPROD IMMUNOL, V20, P147, DOI 10.1111/j.1600-0897.1989.tb00987.x; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LAU IF, 1973, PROSTAGLANDINS, V4, P795, DOI 10.1016/0090-6980(73)90115-9; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Liu GZ, 2003, J BIOL CHEM, V278, P14956, DOI 10.1074/jbc.M212229200; Loftin CD, 2002, J CLIN INVEST, V110, P549, DOI 10.1172/JCI200214924; Marions L, 1999, MOL HUM REPROD, V5, P961, DOI 10.1093/molehr/5.10.961; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; MEYER RK, 1969, P 2 INT C PRIM, V2, P30; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Ni H, 2002, BIOL REPROD, V67, P351, DOI 10.1095/biolreprod67.1.351; ORSINI MW, 1962, P SOC EXP BIOL MED, V110, P713; Paria BC, 1999, DEV BIOL, V208, P488, DOI 10.1006/dbio.1999.9206; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PERRY JS, 1973, NATURE, V245, P45, DOI 10.1038/245045a0; PHILLIPS CA, 1981, J REPROD FERTIL, V62, P73, DOI 10.1530/jrf.0.0620073; PRASAD MRN, 1960, P SOC EXP BIOL MED, V104, P48; PSYCHOYOS A, 1973, HDB PHYSL, P187; Reese J, 1999, MOL CELL ENDOCRINOL, V150, P23, DOI 10.1016/S0303-7207(99)00033-7; Reese J, 2001, ENDOCRINOLOGY, V142, P3198, DOI 10.1210/en.142.7.3198; Ricchi P, 2003, J CLIN GASTROENTEROL, V37, P281, DOI 10.1097/00004836-200310000-00004; SAKSENA SK, 1976, ACTA ENDOCRINOL-COP, V81, P801, DOI 10.1530/acta.0.0810801; SANANES N, 1981, J ENDOCRINOL, V89, P25, DOI 10.1677/joe.0.0890025; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Song H, 2002, DEVELOPMENT, V129, P2879; Sookvanichsilp N, 2002, CONTRACEPTION, V65, P373, DOI 10.1016/S0010-7824(01)00322-5; Takeeda M, 2003, J PHARMACOL EXP THER, V307, P713, DOI 10.1124/jpet.103.054973; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; TERRANOVA PF, 1982, PROSTAGLANDINS, V24, P165, DOI 10.1016/0090-6980(82)90142-3; Uotila PJ, 2002, ANN MED, V34, P428, DOI 10.1080/078538902321012379; Vane JR, 1998, INFLAMM RES, V47, pS78; Wang XH, 2004, J CELL SCI, V117, P53, DOI 10.1242/jcs.00826; Wang XH, 2002, DEVELOPMENT, V129, P4125; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593; ZEGERSHOCHSCHILD F, 1995, J ASSIST REPROD GEN, V12, P224, DOI 10.1007/BF02211803	65	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30579	30587		10.1074/jbc.M400573200	http://dx.doi.org/10.1074/jbc.M400573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15078866	hybrid			2022-12-25	WOS:000222531900088
J	Hong, EM; Shin, J; Kim, HI; Lee, ST; Lee, W				Hong, EM; Shin, J; Kim, HI; Lee, ST; Lee, W			Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SHIFT RELAXATION MECHANISMS; SH2 DOMAIN; CROSS-CORRELATION; NMR-SPECTROSCOPY; PHOSPHOINOSITIDE 3-KINASE; IMPROVED SENSITIVITY; COUPLING-CONSTANTS; DISTINCT FAMILY; N-15 NMR	Human protein-tyrosine kinase-6 (PTK6, also known as breast tumor kinase (Brk)) is a member of the nonreceptor protein-tyrosine kinase family and is expressed in two-thirds of all breast tumors. To understand the structural basis of PTK6 function, we have determined the solution structure and backbone dynamics of the PTK6-Src homology 2 (SH2) domain using multidimensional NMR spectroscopy. The solution structure clearly indicates that the SH2 domain of human PTK6 contains a consensus alpha/beta-fold and a Tyr( P) peptide binding surface, which are common to other SH2 domains. However, two of the alpha-helices (alphaA and alphaB) are located on opposite faces of the central beta-sheet. In addition, the topological arrangement of a central four-stranded antiparallel beta-sheet (strands betaA, betaB, betaC, and betaD) differs from that of other Src family members. Backbone dynamics and Tyr( P) peptide titration experiments revealed that the putative ligand binding sites of the PTK6-SH2 domain undergo distinctive internal motions when compared with other regions of the protein. Surface plasmon resonance analysis showed that the Tyr( P) peptide had a dissociation constant of about 60 muM, which is substantially weaker binding than previously reported for Src family members. The solution structure together with data from the ligand binding mode of PTK6-SH2 provides insight into the molecular basis of the autoinhibitory role of PTK6.	Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea; Yonsei Univ, Coll Sci, Prot Network Res Ctr, Seoul 120749, South Korea	Yonsei University; Yonsei University	Lee, W (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, 134 Shinchon Dong, Seoul 120749, South Korea.	wlee@spin.yonsei.ac.kr	LEE, WEON TAE/AAQ-9088-2021	Lee, Seung-Taek/0000-0001-7300-9784; Lee, Weontae/0000-0003-2347-1262				Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOYD J, 1990, CHEM PHYS LETT, V175, P477, DOI 10.1016/0009-2614(90)85567-V; Cavangh J., 1996, PROTEIN NMR SPECTROS; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2188, DOI 10.1021/bi00431a033; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Goddard T. D. and Kneller D. G ., 2002, SPARKY; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1993, J MAGN RESON SER B, V102, P103, DOI 10.1006/jmrb.1993.1069; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HOEDEMAEKER FJ, 1991, J MOL BIOL, V1, P763; Hong EM, 2001, J BIOMOL NMR, V19, P291, DOI 10.1023/A:1011221125013; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Ladbury JE, 1996, BIOCHEMISTRY-US, V35, P11062, DOI 10.1021/bi960543e; Lee HY, 1998, MOL CELLS, V8, P401; LEE ST, 1993, ONCOGENE, V8, P3403; LEE W, 1994, EUR J BIOCHEM, V218, P89; Llor X, 1999, CLIN CANCER RES, V5, P1767; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; PALMER AG, 1992, MOL PHYS, V75, P699, DOI 10.1080/00268979200100511; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Serfas MS, 2003, ONCOL RES, V13, P409; Siegal G, 1998, J MOL BIOL, V276, P461, DOI 10.1006/jmbi.1997.1562; STONEHOUSE J, 1995, J BIOMOL NMR, V5, P226, DOI 10.1007/BF00211750; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Weber T, 2000, BIOCHEMISTRY-US, V39, P15860, DOI 10.1021/bi001474d; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2	54	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29700	29708		10.1074/jbc.M313185200	http://dx.doi.org/10.1074/jbc.M313185200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15056653	hybrid			2022-12-25	WOS:000222445300106
J	Ergun, S; Buschmann, C; Heukeshoven, J; Dammann, K; Schnieders, F; Lauke, H; Chalajour, F; Kilic, N; Stratling, WH; Schumann, GG				Ergun, S; Buschmann, C; Heukeshoven, J; Dammann, K; Schnieders, F; Lauke, H; Chalajour, F; Kilic, N; Stratling, WH; Schumann, GG			Cell type-specific expression of LINE-1 open reading frames 1 and 2 in fetal and adult human tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-FREQUENCY RETROTRANSPOSITION; HUMAN L1 RETROTRANSPOSITION; REVERSE TRANSCRIPTION; TRANSPOSABLE ELEMENT; IN-VITRO; PROTEIN; TRANSLATION; SEQUENCES; ENDONUCLEASE; INVOLVEMENT	The LINE-1 (L1) family of non-long terminal repeat retrotransposons is a major force shaping mammalian genomes, and its members can alter the genome in many ways. Mutational analyses have shown that coexpression of functional proteins encoded by the two L1-specific open reading frames, ORF1 and ORF2, is an essential prerequisite for the propagation of L1 elements in the genome. However, all efforts to identify ORF2-encoded proteins have failed so far. Here, applying a novel antibody we report the presence of proteins encoded by ORF2 in a subset of cellular components of human male gonads. Immunohistochemical analyses revealed coexpression of ORF1 and ORF2 in prespermatogonia of fetal testis, in germ cells of adult testis, and in distinct somatic cell types, such as Leydig, Sertoli, and vascular endothelial cells. Coexpression of both proteins in male germ cells is necessary for the observed genomic expansion of the number of L1 elements. Peptide mass fingerprinting analysis of a similar to 130-kDa polypeptide isolated from cultured human dermal microvascular endothelial cells led to the identification of ORF2-encoded peptides. An isolated similar to 45-kDa polypeptide was shown to derive from nonfunctional copies of ORF2 coding regions. The presence of both ORF1- and ORF2-encoded proteins in vascular endothelial cells and its apparent association with certain stages of differentiation and maturation of blood vessels may have functional relevance for vasculogenesis and/or angiogenesis.	Paul Ehrlich Inst, Sect Retroelements Pr2, D-63225 Langen, Germany; Univ Hamburg, Hosp Eppendorf, Inst Anat, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Inst Biochem & Mol Biol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Klin & Poliklin Inneren Med, D-20246 Hamburg, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20206 Hamburg, Germany	Paul Ehrlich Institute; University of Hamburg; University of Hamburg; University of Hamburg; Heinrich Pette Institute; University of Hamburg	Schumann, GG (corresponding author), Paul Ehrlich Inst, Sect Retroelements Pr2, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	schgr@pei.de						AKITA EM, 1993, J IMMUNOL METHODS, V160, P207, DOI 10.1016/0022-1759(93)90179-B; Asch HL, 1996, ONCOL RES, V8, P239; BECKER KG, 1993, HUM MOL GENET, V2, P1697, DOI 10.1093/hmg/2.10.1697; Boissinot S, 2001, MOL BIOL EVOL, V18, P926, DOI 10.1093/oxfordjournals.molbev.a003893; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; BRATTHAUER GL, 1994, CANCER, V73, P2333, DOI 10.1002/1097-0142(19940501)73:9<2333::AID-CNCR2820730915>3.0.CO;2-4; BRATTHAUER GL, 1992, ONCOGENE, V7, P507; BRATTHAUER GL, 1993, CANCER, V71, P2383, DOI 10.1002/1097-0142(19930401)71:7<2383::AID-CNCR2820710733>3.0.CO;2-P; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Brouha B, 2002, AM J HUM GENET, V71, P327, DOI 10.1086/341722; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; Ergun S, 1997, ADV EXP MED BIOL, V424, P163; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; Frendo JL, 2003, MOL CELL BIOL, V23, P3566, DOI 10.1128/MCB.23.10.3566-3574.2003; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Harris JR, 1998, BIOESSAYS, V20, P307, DOI 10.1002/(SICI)1521-1878(199804)20:4<307::AID-BIES7>3.3.CO;2-6; HOHJOH H, 1990, NUCLEIC ACIDS RES, V18, P4099, DOI 10.1093/nar/18.14.4099; Holstein AF, 1997, RECENT ADVANCES IN MICROSCOPY OF CELLS TISSUES AND ORGANS, P569; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; ILVES H, 1992, MOL CELL BIOL, V12, P4242, DOI 10.1128/MCB.12.9.4242; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kazazian HH, 2000, SCIENCE, V289, P1152, DOI 10.1126/science.289.5482.1152; Kilic N, 2001, Methods Mol Med, V58, P125, DOI 10.1385/1-59259-137-X:125; Kimberland ML, 1999, HUM MOL GENET, V8, P1557, DOI 10.1093/hmg/8.8.1557; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEIBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990, DOI 10.1073/pnas.87.18.6990; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; MCMILLAN JP, 1993, P NATL ACAD SCI USA, V90, P11533, DOI 10.1073/pnas.90.24.11533; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Rose MD., 1990, METHODS YEAST GENETI; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SILVA R, 1989, MOL CELL BIOL, V9, P3563, DOI 10.1128/MCB.9.8.3563; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Tchenio T, 2000, NUCLEIC ACIDS RES, V28, P411, DOI 10.1093/nar/28.2.411; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; WARTENBERG H, 1990, HUMANEMBRYOLOGIE, P745; Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493	51	132	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27753	27763		10.1074/jbc.M312985200	http://dx.doi.org/10.1074/jbc.M312985200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15056671	hybrid			2022-12-25	WOS:000222120400110
J	Huerta-Yepez, S; Vega, M; Jazirehi, A; Garban, H; Hongo, F; Cheng, GH; Bonavida, B				Huerta-Yepez, S; Vega, M; Jazirehi, A; Garban, H; Hongo, F; Cheng, GH; Bonavida, B			Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-(xL) expression	ONCOGENE			English	Article						NF-kappa B; prostate cancer; nitric oxide; TRAIL; apoptosis	CANCER-CELLS; UP-REGULATION; DNA-BINDING; BCL-X; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; PROTEIN-KINASE; ACTINOMYCIN-D; MITOCHONDRIA; OVEREXPRESSION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to be selective in the induction of apoptosis in cancer cells with minimal toxicity to normal tissues and this prompted its potential therapeutic application in cancer. However, not all cancers are sensitive to TRAIL-mediated apoptosis and, therefore, TRAIL-resistant cancer cells must be sensitized first to become sensitive to TRAIL. Treatment of prostate cancer (CaP) cell lines (DU145, PC-3, CL-1, and LNCaP) with nitric oxide donors (e.g. (Z)-1-[2-(2-aminoethyl)-N-(2-ammonio-ethyl)amino]diazen-1-ium-1, 2- diolate ( DETANONOate)) sensitized CaP cells to TRAIL-induced apoptosis and synergy was achieved. The mechanism by which DETANONOate mediated the sensitization was examined. DETANONOate inhibited the constitutive NF-kappaB activity as assessed by EMSA. Also, p50 was S-nitrosylated by DETANONOate resulting in inhibition of NF-kappaB. Inhibition of NF-kappaB activity by the chemical inhibitor Bay 11-7085, like DETANONOate, sensitized CaP to TRAIL apoptosis. In addition, DETANONOate downregulated the expression of Bcl-2 related gene (Bcl-(xL)) which is under the transcriptional regulation of NF-kappaB. The regulation of NF-kappaB and Bcl-(xL) by DETANONOate was corroborated by the use of Bcl-(xL) and Bcl-kappaB reporter systems. DETANONOate inhibited luciferase activity in the wild type and had no effect on the mutant cells. Inhibition of NF-kappaB resulted in downregulation of Bcl-(xL) expression and sensitized CaP to TRAIL-induced apoptosis. The role of Bcl-(xL) in the regulation of TRAIL apoptosis was corroborated by inhibiting Bcl-(xL) function by the chemical inhibitor 2-methoxyantimycin A(3) and this resulted in sensitization of the cells to TRAIL apoptosis. Signaling by DETANONOate and TRAIL for apoptosis was examined. DETANONOate altered the mitochondria by inducing membrane depolarization and releasing modest amounts of cytochrome c and Smac/DIABLO in the absence of downstream activation of caspases 9 and 3. However, the combination of DETANONOate and TRAIL resulted in activation of the mitochondrial pathway and activation of caspases 9 and 3, and induction of apoptosis. These findings demonstrate that DETANONOate-mediated sensitization of CaP to TRAIL-induced apoptosis is via inhibition of constitutive NF-kappaB activity and Bcl-(xL) expression.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Hosp Infectol, CMN La Raza, IMSS, Unidad Invest Med Inmunol & Infectol, Mexico City, DF, Mexico; Univ Calif Los Angeles, David Geffen Sch Med, Johnsson Comprehens Cacn Ctr, Dept Mol Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Instituto Mexicano del Seguro Social; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Vega, Mario I/0000-0002-3932-2483; Garban, Hermes/0000-0001-7754-5357	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; NCI NIH HHS [P50 CA92131-01A1] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA092131] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altuwaijri S, 2003, CANCER RES, V63, P7106; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200; Chinenov Y, 1998, J BIOL CHEM, V273, P6203, DOI 10.1074/jbc.273.11.6203; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; de Jong S, 2001, CANCER METAST REV, V20, P51, DOI 10.1023/A:1013112624971; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; Di Nardo A, 2000, BRIT J DERMATOL, V143, P491, DOI 10.1111/j.1365-2133.2000.03700.x; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Garban HJ, 2001, J BIOL CHEM, V276, P8918, DOI 10.1074/jbc.M008471200; Gasparian AV, 2002, J CELL SCI, V115, P141; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huerta-Yepez S, 2003, 94 ANN M AM ASS CANC, V44, P918; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Jun CD, 1999, J IMMUNOL, V162, P3395; Katsuyama K, 1998, ARTERIOSCL THROM VAS, V18, P1796, DOI 10.1161/01.ATV.18.11.1796; Lebedeva IV, 2000, MOL BIOL+, V34, P875, DOI 10.1023/A:1026679826610; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Li XY, 2001, CANCER RES, V61, P1699; LINDMARK R, 1983, J IMMUNOL METHODS, V62, P1, DOI 10.1016/0022-1759(83)90104-7; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Ng CP, 2002, MOL CANCER THER, V1, P1051; Ng CP, 2002, ADV CANCER RES, V85, P145, DOI 10.1016/S0065-230X(02)85005-9; Nyormoi O, 2003, CELL DEATH DIFFER, V10, P558, DOI 10.1038/sj.cdd.4401209; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Park SY, 2002, BIOCHEM BIOPH RES CO, V291, P233, DOI 10.1006/bbrc.2002.6452; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rokhlin OW, 2002, PROSTATE, V52, P1, DOI 10.1002/pros.10074; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1992, FEBS LETT, V307, P102, DOI 10.1016/0014-5793(92)80910-9; Secchiero P, 2001, BLOOD, V98, P2220, DOI 10.1182/blood.V98.7.2220; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Tillman DM, 2003, CANCER RES, V63, P5118; Tso CL, 2000, CANCER J, V6, P220; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; VEGA M, 2004, IN PRESS ONCOGENE; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Zisman A, 2001, J IMMUNOTHER, V24, P459, DOI 10.1097/00002371-200111000-00003	64	127	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4993	5003		10.1038/sj.onc.1207655	http://dx.doi.org/10.1038/sj.onc.1207655			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15048072				2022-12-25	WOS:000222237300005
J	Stokka, AJ; Carvalho, RN; Barroso, JF; Flatmark, T				Stokka, AJ; Carvalho, RN; Barroso, JF; Flatmark, T			Probing the role of crystallographically defined/predicted hinge-bending regions in the substrate-induced global conformational transition and catalytic activation of human phenylalanine hydroxylase by single-site mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; TERMINAL AUTOREGULATORY SEQUENCE; RESOLUTION CRYSTAL-STRUCTURES; LABILE ASPARAGINE RESIDUES; AMINO-ACID HYDROXYLASES; ESCHERICHIA-COLI; REGULATORY PROPERTIES; STRUCTURAL BASIS; MUTANT FORMS; ACTIVE-SITE	Phenylalanine hydroxylase (PAH) is generally considered to undergo a large and reversible conformational transition upon L-Phe binding, which is closely linked to the substrate-induced catalytic activation of this hysteretic enzyme. Recently, several crystallographically solvent-exposed hinge-bending regions including residues 31 - 34, 111 - 117, 218 - 226, and 425 - 429 have been defined/ predicted to be involved in the intra-protomer propagation of the substrate-triggered molecular motions generated at the active site. On this basis, single-site mutagenesis of key residues in these regions of the human PAH tetramer was performed in the present study, and their functional impact was measured by steady-state kinetics and the global conformational transition as assessed by surface plasmon resonance and intrinsic tryptophan fluorescence spectroscopy. A strong correlation (r(2) = 0.93 - 0.96) was observed between the L-Phe-induced global conformational transition and V-max values for wild-type human PAH and the mutant forms K113P, N223D, N426D, and N32D, in contrast to the substitution T427P, which resulted in a tetrameric form with no kinetic cooperativity. Furthermore, the flexible intra-domain linker region ( residues 31 - 34) seems to be involved in a more local conformational change, and the biochemical/biophysical properties of the G33A/G33V mutant forms support a key function of this residue in the positioning of the autoregulatory sequence ( residues 1 - 30) and thus in the regulation of the solvent and substrate access to the active site. The mutant forms revealed a variably reduced global conformational stability compared with wild-type human PAH, as measured by thermal denaturation and limited proteolysis.	Univ Bergen, Dept Biomed, Sect Biochem & Mol Biol, N-5009 Bergen, Norway	University of Bergen	Flatmark, T (corresponding author), Univ Bergen, Dept Biomed, Sect Biochem & Mol Biol, Jonas Lies Vei 91, N-5009 Bergen, Norway.	torgeir.flatmark@biomed.uib.no						Andersen OA, 2003, J MOL BIOL, V333, P747, DOI 10.1016/j.jmb.2003.09.004; Andersen OA, 2002, J MOL BIOL, V320, P1095, DOI 10.1016/S0022-2836(02)00560-0; Andersen OA, 2001, J MOL BIOL, V314, P279, DOI 10.1006/jmbi.2001.5061; Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; Bjorgo E, 2001, EUR J BIOCHEM, V268, P997, DOI 10.1046/j.1432-1327.2001.01958.x; Carvalho RN, 2003, J BIOL CHEM, V278, P15142, DOI 10.1074/jbc.M212180200; Eiken HG, 1996, HUM MUTAT, V7, P228, DOI 10.1002/(SICI)1098-1004(1996)7:3<228::AID-HUMU7>3.0.CO;2-6; Erlandsen H, 2000, BIOCHEMISTRY-US, V39, P2208, DOI 10.1021/bi992531+; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; Flatmark T, 2001, ANAL BIOCHEM, V294, P95, DOI 10.1006/abio.2001.5163; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; Horne J, 2002, PROTEIN SCI, V11, P2041, DOI 10.1110/ps.4560102; Jennings IG, 2001, FEBS LETT, V488, P196, DOI 10.1016/S0014-5793(00)02426-1; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kappock TJ, 1995, J BIOL CHEM, V270, P30532, DOI 10.1074/jbc.270.51.30532; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; Kemsley JN, 2003, J AM CHEM SOC, V125, P5677, DOI 10.1021/ja029106f; KNAPPSKOG PM, 1995, BIOCHEMISTRY-US, V34, P11790, DOI 10.1021/bi00037a017; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MARTINEZ A, 1990, EUR J BIOCHEM, V193, P211, DOI 10.1111/j.1432-1033.1990.tb19325.x; MARTINEZ A, 1993, EUR J BIOCHEM, V211, P259, DOI 10.1111/j.1432-1033.1993.tb19894.x; Miranda FF, 2002, J BIOL CHEM, V277, P40937, DOI 10.1074/jbc.M112197200; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Scriver CR, 2003, HUM MUTAT, V21, P333, DOI 10.1002/humu.10200; SHIMAN R, 1979, J BIOL CHEM, V254, P1300; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; Solstad T, 2000, EUR J BIOCHEM, V267, P6302, DOI 10.1046/j.1432-1327.2000.01715.x; Solstad T, 2003, EUR J BIOCHEM, V270, P929, DOI 10.1046/j.1432-1033.2003.03455.x; Solstad T, 2003, EUR J BIOCHEM, V270, P981, DOI 10.1046/j.1432-1033.2003.03471.x; Stokka AJ, 2003, BIOCHEM J, V369, P509, DOI 10.1042/BJ20021009; Teigen K, 2003, J BIOMOL STRUCT DYN, V20, P733, DOI 10.1080/07391102.2003.10506889; Thorolfsson M, 2003, BIOCHEMISTRY-US, V42, P3419, DOI 10.1021/bi034021s; Thorolfsson M, 2002, BIOCHEMISTRY-US, V41, P7573, DOI 10.1021/bi0160720; Wang GA, 2001, P NATL ACAD SCI USA, V98, P1537, DOI 10.1073/pnas.031561698	37	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26571	26580		10.1074/jbc.M400879200	http://dx.doi.org/10.1074/jbc.M400879200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15060071	hybrid			2022-12-25	WOS:000222003000082
J	Galliera, E; Jala, VR; Trent, JO; Bonecchi, R; Signorelli, P; Lefkowitz, RJ; Mantovani, A; Locati, M; Haribabu, B				Galliera, E; Jala, VR; Trent, JO; Bonecchi, R; Signorelli, P; Lefkowitz, RJ; Mantovani, A; Locati, M; Haribabu, B			beta-arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; DUFFY ANTIGEN; PROTEIN; ENDOCYTOSIS; AGONIST; DESENSITIZATION; PHOSPHORYLATION; US28; TRANSDUCTION; RECOGNITION	Seven transmembrane receptors mediate diverse physiological responses including hormone action, olfaction, neurotransmission, and chemotaxis. Human D6 is a non-signaling seven-transmembrane receptor expressed on lymphatic endothelium interacting with most inflammatory CC-chemokines resulting in their rapid internalization. Here, we demonstrate that this scavenging activity is mediated by continuous internalization and constant surface expression of the receptor, a process involving the clathrin-coated pit-dependent pathway. D6 constitutively associates with the cytoplasmic adaptor beta-arrestin, and this interaction is essential for D6 internalization. An acidic region, but not the putative phosphorylation sites in the cytoplasmic tail of D6, is critical for receptor interaction with beta-arrestin and subsequent internalization. Neither the native D6 nor mutants uncoupled from beta-arrestin activate any G-protein-mediated signaling pathways. Therefore, D6 may be considered a decoy receptor structurally adapted to perform chemokine scavenging.	Univ Louisville Hlth Sci, James Fraham Brown Canc Ctr, Louisville, KY 40202 USA; Univ Louisville Hlth Sci, Dept Microbiol & Immunol, Louisville, KY 40202 USA; Univ Louisville Hlth Sci, Dept Med, Louisville, KY 40202 USA; Univ Milan, Inst Gen Pathol, Ctr Eccellenza Innovaz Diagnost & Terapeut, I-20133 Milan, Italy; Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of Louisville; University of Louisville; University of Louisville; University of Milan; Duke University; Howard Hughes Medical Institute; Duke University	Haribabu, B (corresponding author), Univ Louisville Hlth Sci, James Fraham Brown Canc Ctr, Delia Baxter Bldg 119 B,580 Preston St, Louisville, KY 40202 USA.	H0bodd01@gwise.louisville.edu	Bonecchi, Raffaella/ABI-2390-2020; Locati, Massimo/ABF-6807-2021; Locati, Massimo/H-8404-2015; Jala, Venkatakrishna R/K-7255-2018; Mantovani, Alberto/HCI-7449-2022; Bonecchi, Raffaella/A-3140-2009; Lefkowitz, Robert/AAW-2649-2021; Bodduluri, Haribabu/A-2584-2010	Locati, Massimo/0000-0003-3077-590X; Jala, Venkatakrishna R/0000-0002-4206-7305; Mantovani, Alberto/0000-0001-5578-236X; Bodduluri, Haribabu/0000-0002-8261-3294; trent, John/0000-0002-7346-4231; Bonecchi, Raffaella/0000-0003-3346-5333; signorelli, paola/0000-0003-2368-2393	FIC NIH HHS [TW-01198] Funding Source: Medline; NIAID NIH HHS [AI-43184, AI-52381] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043184, R01AI052381] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Akalin E, 2003, TRANSPLANTATION, V75, P1496, DOI 10.1097/01.TP.0000061228.38243.26; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; Bonecchi R, 2004, J IMMUNOL, V172, P4972, DOI 10.4049/jimmunol.172.8.4972; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Dawson TC, 2000, BLOOD, V96, P1681, DOI 10.1182/blood.V96.5.1681.h8001681a_1681_1684; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fra AM, 2003, J IMMUNOL, V170, P2279, DOI 10.4049/jimmunol.170.5.2279; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lee JS, 2003, J IMMUNOL, V170, P5244, DOI 10.4049/jimmunol.170.10.5244; Luttrell LM, 2002, J CELL SCI, V115, P455; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Miller WE, 2003, J BIOL CHEM, V278, P21663, DOI 10.1074/jbc.M303219200; Mokros T, 2002, J BIOL CHEM, V277, P45122, DOI 10.1074/jbc.M208214200; Murphy PM, 2000, PHARMACOL REV, V52, P145; NEOTE K, 1994, BLOOD, V84, P44; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Nibbs RJB, 2001, AM J PATHOL, V158, P867, DOI 10.1016/S0002-9440(10)64035-7; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; RENT JO, 2003, J BIOL CHEM, V278, P47136; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VISHNIVETSKIY SA, 2003, J BIOL CHEM; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	42	131	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25590	25597		10.1074/jbc.M400363200	http://dx.doi.org/10.1074/jbc.M400363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084596	hybrid			2022-12-25	WOS:000221827900086
J	Bertrand-Philippe, M; Ruddell, RG; Arthur, MJP; Thomas, J; Mungalsingh, N; Mann, DA				Bertrand-Philippe, M; Ruddell, RG; Arthur, MJP; Thomas, J; Mungalsingh, N; Mann, DA			Regulation of tissue inhibitor of metalloproteinase 1 gene transcription by RUNX1 and RUNX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; MATRIX METALLOPROTEINASES; LIVER FIBROSIS; DNA-BINDING; REPRESSION; PROMOTER; APOPTOSIS; EXPRESSION; UPSTREAM; TARGETS	Tissue inhibitor of metalloproteinase 1 (TIMP1) is a contributory factor to fibrosis of a variety of organs including the liver. UTE-1 is a regulatory DNA motif essential for TIMP1 promoter activity in a variety of cell types including hepatic stellate cells (HSC), the key pro-fibrogenic cells of the liver. In this study we identify RUNX1 and RUNX2 as UTE-1-binding proteins that are induced at the post-transcriptional level during activation of HSC. RUNX1 is expressed in at least two major isoforms, RUNX1B and RUNX1A. Overexpression of full-length RUNX1B isoform in HSC repressed TIMP1 promoter activity, whereas the truncated RUNX1A isoform and RUNX2 functioned as stimulators. To gain further understanding of the way in which RUNX1 isoforms differentially regulate TIMP1 transcription, we investigated the relationship between the UTE-1 site and its adjacent upstream serum-response element (SRE) in the promoter. The UTE-1 and SRE sites cooperate in a synergistic fashion to stimulate transcription of a heterologous minimal active promoter providing that they are in close proximity. The key regulatory sequence within the SRE is an AP-1 site that in HSC directs high level transcription via its interaction with JunD. RUNX1A was shown to interact directly with JunD, and by contrast RUNX1B failed to interact with JunD. Co-expression studies showed that RUNX1B can repress JunD-stimulated TIMP1 promoter activity. From these observations we propose that JunD and RUNX factors assemble at the adjacent SRE and UTE-1 sites in the TIMP1 promoter and form functional interactions that stimulate transcription. However, RUNX1B is unable to interact with JunD, and as such its occupancy at the UTE-1 site disrupts the optimal assembly of transcriptional activators required for directing high level TIMP1 promoter function.	Univ Southampton, Sch Med, Southampton Gen Hosp, Div Infect Inflammat & Repair,Liver Grp, Southampton SO16 6YD, Hants, England	University of Southampton	Mann, DA (corresponding author), Univ Southampton, Sch Med, Southampton Gen Hosp, Div Infect Inflammat & Repair,Liver Grp, Level D,S Acad Block, Southampton SO16 6YD, Hants, England.	dam2@soton.ac.uk		Mann, Derek/0000-0003-0950-243X				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Arthur MJP, 1999, ALCOHOL CLIN EXP RES, V23, P940, DOI 10.1111/j.1530-0277.1999.tb04208.x; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Batchelor WB, 1998, PROG CARDIOVASC DIS, V41, P35, DOI 10.1016/S0033-0620(98)80021-2; Bever CT, 1999, NEUROLOGY, V53, P1380, DOI 10.1212/WNL.53.7.1380; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gaca MDA, 2003, MATRIX BIOL, V22, P229, DOI 10.1016/S0945-053X(03)00017-9; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Javed A, 2000, J CELL SCI, V113, P2221; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li GY, 1999, CANCER RES, V59, P6267; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Lin HL, 2002, KIDNEY INT, V62, P60, DOI 10.1046/j.1523-1755.2002.00403.x; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; Ohbayashi H, 2002, CURR PROTEIN PEPT SC, V3, P409, DOI 10.2174/1389203023380549; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097-4644(20010301)80:3<424::AID-JCB160>3.0.CO;2-6; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Taimr P, 2003, HEPATOLOGY, V37, P87, DOI 10.1053/jhep.2003.50002; Trim JE, 2000, J BIOL CHEM, V275, P6657, DOI 10.1074/jbc.275.9.6657; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Yoshiji H, 2000, HEPATOLOGY, V32, P1248, DOI 10.1053/jhep.2000.20521	36	37	39	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24530	24539		10.1074/jbc.M311804200	http://dx.doi.org/10.1074/jbc.M311804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051730	hybrid			2022-12-25	WOS:000221702500082
J	Franzke, CW; Tasanen, K; Borradori, L; Huotari, V; Bruckner-Tuderman, L				Franzke, CW; Tasanen, K; Borradori, L; Huotari, V; Bruckner-Tuderman, L			Shedding of collagen XVII/BP180 structural motifs influence cleavage from cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA CONVERTING-ENZYME; HYPOHIDROTIC ECTODERMAL DYSPLASIA; AMYLOID PRECURSOR PROTEIN; TRIPLE-HELIX; INTRACELLULAR MATURATION; TRANSMEMBRANE PROTEIN; MEMBRANE-PROTEIN; XIII COLLAGEN; L-SELECTIN; DOMAIN	Collagen XVII/BP180, an epithelial adhesion molecule, belongs to the group of collagenous transmembrane proteins, which are characterized by ectodomain shedding. We recently showed that ADAMs can cleave collagen XVII, but also that furin participates in this process (Franzke, C. W., Tasanen, K., Schacke, H., Zhou, Z., Tryggvason, K., Mauch, C., Zigrino, P., Sunnarborg, S., Lee, D. C., Fahrenholz, F., and Bruckner-Tuderman, L. (2002) EMBO J. 21, 5026-5035). To define the cleavage region in the juxtamembranous NC16A linker domain and assess its structure and requirements for shedding, we constructed deletion mutants of the NC16A domain, expressed them in COS-7 cells, and analyzed their structural integrity and shedding behavior. A mutant lacking the furin consensus sequence was shed in a normal manner, demonstrating that furin does not cleave collagen XVII but rather activates ADAMs (a disintegrin and metalloproteinase). Large deletions of the NC16A domain prevented shedding, and analysis of defined smaller deletions pointed to the stretch of amino acid residues 528-547 as important for sheddase recognition and cleavage. Secondary protein structure predictions showed that deletion of this stretch resulted in an NC16A domain with a positive net charge and an amphipathic alpha-helix, which can cause conformational changes in the collagen XVII homotrimer. Assessment of triple-helix folding of the mutants revealed a lower thermal stability of all non-shed variants than of wild-type collagen XVII or the shed mutants. In contrast, deletion of the putative nucleation site for triple-helix folding of collagenous transmembrane proteins did not affect folding of collagen XVII. The data indicate that the conformation of the NC16A domain and steric availability of the cleavage site influence shedding and is important for folding of collagen XVII.	Univ Freiburg, Dept Dermatol, D-79106 Freiburg, Germany; Univ Oulu, Dept Dermatol, SF-90220 Oulu, Finland; Univ Oulu, Dept Clin Chem, SF-90220 Oulu, Finland; Univ Hosp Geneva, Dept Dermatol, CH-1211 Geneva 14, Switzerland	University of Freiburg; University of Oulu; University of Oulu; University of Geneva	Bruckner-Tuderman, L (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79106 Freiburg, Germany.	bruckner_tuderman@haut.ukl.uni-freiburg.de		Tasanen, Kaisa/0000-0001-8056-5949				Althoff K, 2001, BIOCHEM J, V353, P663, DOI 10.1042/0264-6021:3530663; Areida SK, 2001, J BIOL CHEM, V276, P1594, DOI 10.1074/jbc.M008709200; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; BRUCKNER P, 1981, EUR J BIOCHEM, V118, P607, DOI 10.1111/j.1432-1033.1981.tb05562.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Elomaa O, 2001, HUM MOL GENET, V10, P953, DOI 10.1093/hmg/10.9.953; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ESKELINEN S, 1992, J CELL PHYSIOL, V150, P122, DOI 10.1002/jcp.1041500117; Frank S, 2003, J BIOL CHEM, V278, P7747, DOI 10.1074/jbc.C200698200; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2003, MATRIX BIOL, V22, P299, DOI 10.1016/S0945-053X(03)00051-9; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hirako Y, 2003, J BIOCHEM, V133, P197, DOI 10.1093/jb/mvg024; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Peiretti F, 2003, EXP CELL RES, V285, P278, DOI 10.1016/S0014-4827(03)00052-1; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schumann H, 1997, AM J HUM GENET, V60, P1344, DOI 10.1086/515463; Schumann H, 2000, AM J PATHOL, V156, P685, DOI 10.1016/S0002-9440(10)64772-4; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200; Zillikens D, 1999, J INVEST DERMATOL, V113, P947, DOI 10.1046/j.1523-1747.1999.00808.x; Zone JJ, 1998, J INVEST DERMATOL, V110, P207, DOI 10.1046/j.1523-1747.1998.00129.x	43	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24521	24529		10.1074/jbc.M308835200	http://dx.doi.org/10.1074/jbc.M308835200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047704	hybrid			2022-12-25	WOS:000221702500081
J	Maye, P; Zheng, J; Li, L; Wu, DQ				Maye, P; Zheng, J; Li, L; Wu, DQ			Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERGENT EXTENSION MOVEMENTS; WNT/BETA-CATENIN; BETA-CATENIN; FRIZZLED HOMOLOGS; WINGLESS SIGNAL; XENOPUS EMBRYOS; CELL FATE; DROSOPHILA; PROTEINS; FAMILY	The effect of a noncanonical Wnt, Wnt11, on canonical Wnt signaling stimulated by Wnt1 and activated forms of LRP5 (low density lipoprotein receptor-related protein-5), Dishevelled1 (Dvl1), and beta-catenin was examined in NIH3T3 cells and P19 embryonic carcinoma cells. Wnt11 repressed Wnt1-mediated activation of LEF-1 reporter activity in both cell lines. However, Wnt11 was unable to inhibit canonical signaling activated by LRP5, Dvl1, or beta-catenin in NIH3T3 cells, although it could in P19 cells. In addition, Wnt11-mediated inhibition of canonical signaling in NIH3T3 cells is ligand-specific; Wnt11 could effectively repress canonical signaling activated by Wnt1, Wnt3, or Wnt3a but not by Wnt7a or Wnt7b. Co-culture experiments with NIH3T3 cells showed that the co-expression of Wnt11 with Wnt1 was not an essential requirement for the inhibition, suggesting receptor competition as a possible mechanism. Moreover, in both cell types, elevation of intracellular Ca2+ levels, which can result from Wnt11 treatment, led to the inhibition of canonical signaling. This result suggests that Wnt11 might not be able to signal in NIH3T3. Furthermore, P19 cells were found to express both endogenous canonical Wnts and Wnt11. Knockdown of Wnt11 expression using siRNA resulted in increased LEF-1 reporter activity, thus indicating that Wnt11-mediated suppression of canonical signaling exists in vivo.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China	University of Connecticut; St Jude Children's Research Hospital; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Wu, DQ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, MC3301,263 Farmington Ave, Farmington, CT 06030 USA.	dwu@neuron.uchc.edu		Maye, Peter/0000-0003-0098-4399; Zheng, Jie/0000-0001-6524-6800	NCI NIH HHS [CA85420] Funding Source: Medline; NIGMS NIH HHS [GM54167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bell E, 2003, DEVELOPMENT, V130, P1381, DOI 10.1242/dev.00344; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Gieseler K, 1999, MECH DEVELOP, V85, P123, DOI 10.1016/S0925-4773(99)00097-0; Gieseler K, 1995, CR ACAD SCI III-VIE, V318, P1101; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuhl M, 2001, MECH DEVELOP, V106, P61, DOI 10.1016/S0925-4773(01)00416-6; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PRIEVE MG, 2003, BMC DEV BIOL; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rauch GJ, 1997, COLD SPRING HARB SYM, V62, P227, DOI 10.1101/SQB.1997.062.01.028; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Strapps WR, 2001, DEVELOPMENT, V128, P4829; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200	48	109	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24659	24665		10.1074/jbc.M311724200	http://dx.doi.org/10.1074/jbc.M311724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15067007	hybrid			2022-12-25	WOS:000221702500096
J	Xia, FZ; Gao, XD; Kwan, E; Lam, PPL; Chan, LL; Sy, KY; Sheu, L; Wheeler, MB; Gaisano, HY; Tsushima, RG				Xia, FZ; Gao, XD; Kwan, E; Lam, PPL; Chan, LL; Sy, KY; Sheu, L; Wheeler, MB; Gaisano, HY; Tsushima, RG			Disruption of pancreatic beta-cell lipid rafts modifies K(v)2.1 channel gating and insulin exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT K+ CHANNELS; CA2+ CHANNELS; POTASSIUM CHANNELS; DOWN-REGULATION; MESSENGER-RNAS; PC12 CELLS; B-CELLS; SECRETION; EXPRESSION; ISLETS	In pancreatic beta-cells, the predominant voltage-gated Ca2+ channel (Ca(V)1.2) and K+ channel (K(V)2.1) are directly coupled to SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein ( SNAP) receptor) proteins. These SNARE proteins modulate channel expression and gating and closely associate these channels with the insulin secretory vesicles. We show that K(V)2.1 and Ca(V)1.2, but not K(V)1.4, SUR1, or Kir6.2, target to specialized cholesterol-rich lipid raft domains on beta-cell plasma membranes. Similarly, the SNARE proteins syntaxin 1A, SNAP-25, and VAMP-2, but not Munc-13-1 or n-Sec1, are associated with lipid rafts. Disruption of the lipid rafts by depleting membrane cholesterol with methyl-beta-cyclodextrin shunts K(V)2.1, Ca(V)1.2, and SNARE proteins out of lipid rafts. Furthermore, methyl-beta-cyclodextrin inhibits K(V)2.1 but not Ca(V)1.2 channel activity and enhances single-cell exocytic events and insulin secretion. Membrane compartmentalization of ion channels and SNARE proteins in lipid rafts may be critical for the temporal and spatial coordination of insulin release, forming what has been described as the excitosome complex.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Tsushima, RG (corresponding author), Univ Toronto, Dept Med, 1 Kings Coll Circle,Rm 7308, Toronto, ON M5S 1A8, Canada.	r.tsushima@utoronto.ca		Wheeler, Michael B./0000-0002-7480-7267				Barg S, 2001, BIOPHYS J, V81, P3308, DOI 10.1016/S0006-3495(01)75964-4; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Geng XH, 2003, DIABETES, V52, P767, DOI 10.2337/diabetes.52.3.767; IWASHIMA Y, 1993, DIABETES, V42, P948, DOI 10.2337/diabetes.42.7.948; Iwashima Y, 2001, BIOCHEM BIOPH RES CO, V280, P923, DOI 10.1006/bbrc.2000.4122; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; MALAISSELAGAE F, 1984, BIOCHEM BIOPH RES CO, V123, P1062, DOI 10.1016/S0006-291X(84)80241-7; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MORGAN NG, 1985, BIOCHEM J, V231, P629, DOI 10.1042/bj2310629; Namkung Y, 2001, J CLIN INVEST, V108, P1015, DOI 10.1172/JCI13310; Olofsson CS, 2002, PFLUG ARCH EUR J PHY, V444, P43, DOI 10.1007/s00424-002-0781-5; ORCI L, 1981, PHILOS T ROY SOC B, V296, P47, DOI 10.1098/rstb.1981.0170; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Roe MW, 1996, AM J PHYSIOL-ENDOC M, V270, pE133, DOI 10.1152/ajpendo.1996.270.1.E133; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Yan LZ, 2004, DIABETES, V53, P597, DOI 10.2337/diabetes.53.3.597	39	146	149	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24685	24691		10.1074/jbc.M314314200	http://dx.doi.org/10.1074/jbc.M314314200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15073181	hybrid			2022-12-25	WOS:000221702500099
J	Zhu, M; Han, SB; Zhou, FM; Carter, SA; Fink, AL				Zhu, M; Han, SB; Zhou, FM; Carter, SA; Fink, AL			Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN AMYLOIDOSIS; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PRION PROTEIN; FIBRILS; NEUROTOXICITY; AGGREGATION; PEPTIDE; MODEL	Amyloidoses and related protein deposition diseases involve the transformation of normally soluble proteins into insoluble deposits, usually fibrillar in nature. Although it was originally assumed that the fibrils were the toxic species, this assumption has recently been called into question. Accumulating evidence in several systems suggests that oligomeric intermediates on the aggregation pathway may be toxic. In the present study we used in situ atomic force microscopy to monitor aggregation in aqueous solution in real time. The sample used was an amyloidogenic immunoglobulin light chain, involved in AL or light chain amyloidosis. The nature of the observed oligomeric intermediates was dependent on the conditions of incubation, especially pH and ionic strength. Several different aggregation intermediates with a variety of morphologies, including annular or torus-shaped species, were observed. The data indicate that protein aggregation can be very complex, involving a variety of different oligomeric intermediates whose population will be determined by the kinetic and thermodynamic competition between them.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Phys, Santa Cruz, CA 95064 USA; Calif State Univ Los Angeles, Dept Chem, Los Angeles, CA 90032 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; California State University System; California State University Los Angeles	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu	Han, Shubo/ABA-4350-2021	Han, Shubo/0000-0002-0216-5111	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM063530] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK055675] Funding Source: Medline; NIGMS NIH HHS [GM63530-10] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellotti V, 2000, J STRUCT BIOL, V130, P280, DOI 10.1006/jsbi.2000.4248; Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; BUXBAUM JN, 1990, ANN INTERN MED, V112, P455, DOI 10.7326/0003-4819-76-3-112-6-455; Carrotta R, 2001, PROTEIN SCI, V10, P1312, DOI 10.1110/ps.42501; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Gallo G, 1996, AM J PATHOL, V148, P1397; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; Kagan BL, 2002, PEPTIDES, V23, P1311, DOI 10.1016/S0196-9781(02)00067-0; Khurana R, 2003, AMYLOID, V10, P97, DOI 10.3109/13506120309041731; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kim YS, 2001, BRAIN RES, V908, P93, DOI 10.1016/S0006-8993(01)02575-6; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lin MX, 1997, J BIOL CHEM, V272, P44; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stevens F J, 1995, Methods Mol Biol, V51, P51; STEVENS FJ, 1995, BIOCHEMISTRY-US, V34, P10697, DOI 10.1021/bi00034a001; STEVENS PW, 1995, PROTEIN SCI, V4, P421; Stolz M, 2000, J STRUCT BIOL, V131, P171, DOI 10.1006/jsbi.2000.4301; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Vanik DL, 2002, J BIOL CHEM, V277, P49065, DOI 10.1074/jbc.M207511200; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Walsh DT, 2002, NEUROBIOL DIS, V10, P20, DOI 10.1006/nbdi.2002.0485; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	37	76	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24452	24459		10.1074/jbc.M400004200	http://dx.doi.org/10.1074/jbc.M400004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15056656	hybrid			2022-12-25	WOS:000221702500072
J	Song, QJ; Young, KB; Chu, GX; Gulick, J; Gerst, M; Grupp, IL; Robbins, J; Kranias, EG				Song, QJ; Young, KB; Chu, GX; Gulick, J; Gerst, M; Grupp, IL; Robbins, J; Kranias, EG			Overexpression of phospholamban in slow-twitch skeletal muscle is associated with depressed contractile function and muscle remodeling	FASEB JOURNAL			English	Article						transgenesis; Ca2+-cycling protein; fiber type	HEAVY-CHAIN GENE; CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; PROTEIN-KINASE; IN-VIVO; DILATED CARDIOMYOPATHY; FKBP12 BINDING; FIBER-TYPE; PHOSPHORYLATION	The relative amount of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) and its crucial inhibitor phospholamban (PLN) are closely regulated and play a pivotal role in maintaining muscle function. The functional importance of PLN has been intensively investigated in cardiac muscle. However, little is known about the role of PLN in the slow-twitch skeletal muscle, which expresses a significantly lower level of PLN but a similar level of SERCA2a compared with cardiac muscle. Thus, to define the physiological significance of PLN in slow-twitch skeletal muscle, we generated transgenic mice with PLN-specific overexpression in soleus, which is largely composed of slow-muscle fibers. The PLN protein levels and the PLN/SERCA2a ratio in transgenic soleus were comparable with those in cardiac muscle. Assessment of isometric-twitch contractions indicated that PLN overexpression was associated with depressed rates of contraction and relaxation, which were not linked to reduced SERCA2a abundance, although the levels of other key Ca2+-handling proteins, including ryanodine receptor, FKBP12, and L-type Ca2+ channel, were significantly decreased. However, isoproterenol stimulation reversed the inhibitory effects of PLN on the transgenic soleus twitch kinetics. Furthermore, the PLN-overexpressing soleus had smaller muscle size, mass, and cross-sectional area compared with wild-types. Interestingly, the percentage of slow fibers was increased in PLN-overexpressing soleus. Taken together, these findings indicate that increased PLN expression in slow-twitch skeletal muscle is associated with impaired contractile function and muscle remodeling.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert B Sabin Way,POB 670575, Cincinnati, OH 45267 USA.	Litsa.Kranias@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064018, R01HL026057, R37HL026057] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26057, HL64018] Funding Source: Medline; PHS HHS [P4012358] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Avila G, 2003, J BIOL CHEM, V278, P22600, DOI 10.1074/jbc.M205866200; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; Brittsan AG, 2000, J BIOL CHEM, V275, P12129, DOI 10.1074/jbc.275.16.12129; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; CARL SL, 1995, MUSCLE NERVE, V18, P1232, DOI 10.1002/mus.880181104; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CHIN ER, 1996, PHYSIOLOGIST, V39, pA75; Dash R, 2001, CIRCULATION, V103, P889, DOI 10.1161/01.CIR.103.6.889; Dulhunty AF, 2002, PROG BIOPHYS MOL BIO, V79, P45, DOI 10.1016/S0079-6107(02)00013-5; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HARRER JM, 1995, BIOTECHNIQUES, V18, P995; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KARCZEWSKI P, 1987, BIOMED BIOCHIM ACTA, V46, P433; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; Knotts S, 1996, DEV DYNAM, V206, P182, DOI 10.1002/(SICI)1097-0177(199606)206:2<182::AID-AJA7>3.0.CO;2-E; KRANIAS EG, 1985, BIOCHEM J, V226, P113, DOI 10.1042/bj2260113; Kubis HP, 2003, AM J PHYSIOL-CELL PH, V285, pC56, DOI 10.1152/ajpcell.00377.2002; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lamb GD, 2000, CLIN EXP PHARMACOL P, V27, P216, DOI 10.1046/j.1440-1681.2000.03224.x; Liu YW, 1997, AM J PHYSIOL-CELL PH, V273, pC1915, DOI 10.1152/ajpcell.1997.273.6.C1915; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; MENDEZ J, 1960, METABOLISM, V9, P184; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Movsesian Matthew A., 1992, Second Messengers and Phosphoproteins, V14, P151; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; RINDT H, 1993, J BIOL CHEM, V268, P5332; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; ROTMAN EI, 1995, J BIOL CHEM, V270, P16371, DOI 10.1074/jbc.270.27.16371; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Slack JP, 1997, AM J PHYSIOL-CELL PH, V273, pC1, DOI 10.1152/ajpcell.1997.273.1.C1; SRETER FA, 1987, AM J PHYSIOL, V253, pC296, DOI 10.1152/ajpcell.1987.253.2.C296; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; Ward CW, 2003, FASEB J, V17, P1517, DOI 10.1096/fj.02-1083fje; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615	46	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					974	+		10.1096/fj.03-1058fje	http://dx.doi.org/10.1096/fj.03-1058fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059971				2022-12-25	WOS:000221108800022
J	Dhar, SK; Lynn, BC; Daosukho, C; St Clair, DK				Dhar, SK; Lynn, BC; Daosukho, C; St Clair, DK			Identification of nucleophosmin as an NF-kappa B co-activator for the induction of the human SOD2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-SUPEROXIDE-DISMUTASE; TUMOR-NECROSIS-FACTOR; ISCHEMIC BRAIN-INJURY; TRANSCRIPTION FACTOR; MALIGNANT PHENOTYPE; TRANSGENIC MICE; FACTOR-ALPHA; DNA-BINDING; MNSOD GENE; CELLS	Manganese superoxide dismutase (MnSOD) is an antioxidant enzyme essential for the survival of life. We have reported that NF-kappaB is essential but not sufficient for the synergistic induction of MnSOD by phorbol 12-myristate 13-acetate and cytokines. To further identify transcription factors and co-activators that participate in the induction of MnSOD, we used NF-kappaB affinity chromatography to isolate potential NF-kappaB interacting proteins. Proteins eluted from the NF-kappaB affinity column were subjected to proteomic analysis and verified by Western analysis. Nucleophosmin (NPM), a nucleolar phosphoprotein, is the most abundant single protein identified. Co-immunoprecipitation studies suggest a physical interaction between NPM and NF-kappaB proteins. To verify the role of NPM on MnSOD gene transcription, cells were transfected with constructs expressing NPM in sense or antisense orientation as well as interference RNA. The results indicate that an increase NPM expression leads to increased MnSOD gene transcription in a dose-dependent manner. Consistent with this, expression of small interfering RNA for NPM leads to inhibition of MnSOD gene transcription but does not have any effect on the expression of interleukin-8, suggesting that the effect of NPM is selective. These results identify NPM as a partner of the NF-kappaB transcription complex in the induction of MnSOD by phorbol 12-myristate 13-acetate and cytokines.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Dept Chem, Mass Spectrometry Facil, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.	DSTCL00@pop.uky.edu		Lynn, Bert/0000-0001-8426-3024	NCI NIH HHS [R01 CA049797, CA 49797, R01 CA049797-13, CA 59835] Funding Source: Medline; NHLBI NIH HHS [HL 03544] Funding Source: Medline; NIA NIH HHS [AG 05119, P01 AG005119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA059835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG005119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; CARRIER F, 1994, P NATL ACAD SCI USA, V91, P1554, DOI 10.1073/pnas.91.4.1554; Chan EC, 2002, J CLIN ENDOCR METAB, V87, P2435, DOI 10.1210/jc.87.6.2435; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DELMAESTRO R, 1989, MECH AGEING DEV, V48, P15, DOI 10.1016/0047-6374(89)90022-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; EASTGATE J, 1993, BLOOD, V81, P639; FUJII J, 1991, J BIOL CHEM, V266, P23142; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Keller JN, 1998, J NEUROSCI, V18, P687; Kiningham KK, 1997, CANCER RES, V57, P5265; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; MANGANARO F, 1995, FREE RADICAL BIO MED, V19, P823, DOI 10.1016/0891-5849(95)02008-X; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Porntadavity S, 2001, DNA CELL BIOL, V20, P473, DOI 10.1089/104454901316976109; SAFFORD SE, 1994, CANCER RES, V54, P4261; Shevchenko A, 1996, BIOCHEM SOC T, V24, P893, DOI 10.1042/bst0240893; St Clair DK, 2002, METHOD ENZYMOL, V349, P306, DOI 10.1016/S0076-6879(02)49345-7; SUZUKI K, 1993, AM J PHYSIOL, V265, pH1173, DOI 10.1152/ajpheart.1993.265.4.H1173; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; URANO M, 1995, CANCER RES, V55, P2490; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; ZABEL U, 1991, J BIOL CHEM, V266, P252; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852; Zhu CH, 2001, ANTIOXID REDOX SIGN, V3, P387, DOI 10.1089/15230860152409031; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200	52	91	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28209	28219		10.1074/jbc.M403553200	http://dx.doi.org/10.1074/jbc.M403553200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15087454	hybrid, Green Accepted			2022-12-25	WOS:000222265400050
J	Alisio, A; Mueckler, M				Alisio, A; Mueckler, M			Relative proximity and orientation of helices 4 and 8 of the GLUT1 glucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; SUGAR PERMEATION PATHWAY; EXOFACIAL LIGAND-BINDING; ESCHERICHIA-COLI; XENOPUS-OOCYTES; LACTOSE PERMEASE; ACCESSIBILITY; MECHANISM; PROTEINS; MEMBRANE	A structure has been proposed for glucose transporter-1 ( GLUT1) based upon homology modeling that is consistent with the results of numerous mutagenesis studies (Mueckler, M., and Makepeace, C. (2004) J. Biol. Chem. 279, 10494-10499). To further test and refine this model, the relative orientation and proximity of transmembrane helices 4 and 8 were analyzed by chemical crosslinking of di-cysteine mutants created in a reporter GLUT1 construct. All six native cysteine residues of GLUT1 were changed to either glycine or serine residues by site-directed mutagenesis, resulting in a functional Glut1 construct with Cys mutated to Gly/Ser (Cless). The GLUT1 reporter molecule was engineered from C-less GLUT1 by creating a unique cleavage site for factor Xa protease within the central cytoplasmic loop and by eliminating the site of N-linked glycosylation. Fourteen functional di-cysteine mutants were then created from the C-less reporter construct, each mutant containing a single cysteine residue in helix 4 and one cysteine residue in helix 8. These mutants were expressed in Xenopus oocytes, and the sensitivity of each mutant to intramolecular crosslinking by two homo-bifunctional, thiol-specific crosslinking reagents, bismale-imidehexane and 1,4-phenylenedimaleimide, was ascertained by protease cleavage followed by immunoblot analysis. Four pairs of cysteine residues, Cys(148)/Cys(328), Cys(145)/Cys(328), Cys(148)/Cys(325), and Cys(145)/Cys(325), were observed to be in close enough proximity to be susceptible to crosslinking by one or both reagents. All five of the cysteine residues susceptible to crosslinking are predicted to lie on the same face of helix 4 or 8 and to reside close to the cytoplasmic face of the membrane. These data indicate that the cytoplasmic ends of helices 4 and 8 lie within 6-16 Angstromof one another and that the two helices twist or tilt such that they are further than 16 Angstrom apart toward the center and the exoplasmic side of the membrane. An updated model for the clustering of the transmembrane helices of GLUT1 is presented based on these data.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; APPLEMAN JR, 1985, J BIOL CHEM, V260, P4575; APPLEMAN JR, 1989, BIOCHEMISTRY-US, V28, P8221, DOI 10.1021/bi00446a038; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; KELLER K, 1989, J BIOL CHEM, V264, P18884; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; Mueckler M, 2004, J BIOL CHEM, V279, P10494, DOI 10.1074/jbc.M310786200; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUECKLER MM, 1989, RED BLOOD CELL MEMBR, V11, P31; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403	29	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26540	26545		10.1074/jbc.M402303200	http://dx.doi.org/10.1074/jbc.M402303200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073187	hybrid			2022-12-25	WOS:000222003000078
J	Nishihara, H; Hwang, M; Kizaka-Kondoh, S; Eckmann, L; Insel, PA				Nishihara, H; Hwang, M; Kizaka-Kondoh, S; Eckmann, L; Insel, PA			Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PHOSPHORYLATION; GENE; CREB; PATHWAYS; ACTIVATION; BAD; TRANSCRIPTION; EXPRESSION; SURVIVAL	We recently reported that cAMP suppresses apoptosis in colon cancer cells and induces cellular inhibitor of apoptosis protein-2 (c-IAP2) via a cAMP-responsive element (CRE), suggesting a mechanism for chemoprevention of colon cancer by non-steroidal anti-inflammatory drugs. In this study, we used T84 human colon cancer cells to define the pathway by which increases in cAMP induce c-IAP2 expression. Treatment with several different cAMP agonists stimulated phosphorylation of CRE-binding protein (CREB) and activated expression of c-IAP2 in a CREB-dependent manner. Studies with pharmacological inhibitors revealed that cAMP-dependent phosphorylation of CREB required activation of ERK1/2 and p38 MAPK but was largely independent of protein kinase A. Immunoblots and transcriptional reporter assays using specific inhibitors, as well as expression of constitutively active forms of MEK1 and MKK3, showed that c-IAP2 induction by cAMP is regulated predominantly through ERK1/2 and p38 MAPK and suggested involvement of p90 ribosomal protein S6 kinase and mitogen and stress response kinase-1 as well. Consistent with those results, we found that cAMP-dependent suppression of apoptosis was blocked by treatment with inhibitors of ERK1/2 and p38 MAPK. We conclude that cAMP can induce c-IAP2 expression in colon cancer cells through CREB phosphorylation and CRE-dependent transcription in a manner that involves activation of ERK1/2 and p38 MAPK. These results emphasize that activation of kinases other than protein kinase A can mediate the actions of agents that increase cAMP, particularly in the regulation of CREB-dependent events.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Kyoto University	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pinsel@ucsd.edu	Kondoh, Shinae/C-6937-2015; Kondoh, Shinae/AAF-8745-2020	Kondoh, Shinae/0000-0003-3085-5782; Kondoh, Shinae/0000-0003-3085-5782				BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Baumann CA, 1997, MECH AGEING DEV, V94, P85, DOI 10.1016/S0047-6374(96)01860-X; Belley A, 1999, GASTROENTEROLOGY, V117, P1352, DOI 10.1016/S0016-5085(99)70285-4; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Boucher MJ, 2001, BIOCHEM BIOPH RES CO, V285, P207, DOI 10.1006/bbrc.2001.5147; Chan TA, 2002, LANCET ONCOL, V3, P166, DOI 10.1016/S1470-2045(02)00680-0; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Cho YS, 2002, P NATL ACAD SCI USA, V99, P15626, DOI 10.1073/pnas.242617799; Cho YS, 2002, CLIN CANCER RES, V8, P607; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Garcia-Bermejo L, 1998, J CELL SCI, V111, P637; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Leahy KM, 2002, CANCER RES, V62, P625; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Tortora G, 2002, CLIN CANCER RES, V8, P303; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	57	90	96	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26176	26183		10.1074/jbc.M313346200	http://dx.doi.org/10.1074/jbc.M313346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078890	hybrid			2022-12-25	WOS:000222003000032
J	Zhu, XS; Zamudio, FZ; Olbinski, BA; Possani, LD; Valdivia, CH				Zhu, XS; Zamudio, FZ; Olbinski, BA; Possani, LD; Valdivia, CH			Activation of skeletal ryanodine receptors by two novel scorpion toxins from Buthotus judaicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; MUSCLE DIHYDROPYRIDINE RECEPTOR; CA2+ RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; CA2+-RELEASE CHANNEL; PANDINUS-IMPERATOR; POTASSIUM CHANNEL; PEPTIDE; VENOM	Buthotus judaicus toxin 1 (BjTx-1) and toxin 2 (BjTx-2), two novel peptide activators of ryanodine receptors (RyR), were purified from the venom of the scorpion B. judaicus. Their amino acid sequences differ only in 1 residue out of 28 ( residue 16 corresponds to Lys in BjTx-1 and Ile in BjTx-2). Despite a slight difference in EC50, both toxins increased binding of [H-3] ryanodine to skeletal sarcoplasmic reticulum at micromolar concentrations but had no effect on cardiac or liver microsomes. Their activating effect was Ca2+-dependent and was synergized by caffeine. B. judaicus toxins also increased binding of [ 3H] ryanodine to the purified RyR1, suggesting that a direct protein-protein interaction mediates the effect of the peptides. BjTx-1 and BjTx-2 induced Ca2+ release from Ca2+-loaded sarcoplasmic reticulum vesicles in a dose-dependent manner and induced the appearance of long lived subconductance states in skeletal RyRs reconstituted into lipid bilayers. Three-dimensional structural modeling reveals that a cluster of positively charged residues (Lys(11) to Lys(16)) is a prominent structural motif of both toxins. A similar structural motif is believed to be important for activation of RyRs by imperatoxin A (IpTx(a)), another RyR-activating peptide (Gurrola, G. B., Arevalo, C., Sreekumar, R., Lokuta, A. J., Walker, J. W., and Valdivia, H. H. (1999) J. Biol. Chem. 274, 7879 - 7886). Thus, it is likely that B. judaicus toxins and imperatoxin A bind to RyRs by means of electrostatic interactions that lead to massive conformational changes in the channel protein. The different affinity and structural diversity of this family of scorpion peptides makes them excellent peptide probes to identify RyR domains that trigger the channel to open.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; Natl Autonomous Univ Mexico, Inst Biotechnol, Dept Mol Med & Bioproc, Cuernavaca 62271, Morelos, Mexico	University of Wisconsin System; University of Wisconsin Madison; Universidad Nacional Autonoma de Mexico	Zhu, XS (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 149 13th St,CYN-4,CVRC 4201, Charlestown, MA 02129 USA.	xzhu2@bics.bwh.harvard.edu	Possani, Lourival D/J-2397-2013		NHLBI NIH HHS [R01HL55438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055438] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becerril B, 1996, BIOCHEM J, V313, P753, DOI 10.1042/bj3130753; Blanc E, 1996, PROTEINS, V24, P359, DOI 10.1002/(SICI)1097-0134(199603)24:3&lt;359::AID-PROT9&gt;3.0.CO;2-B; Buisine E, 1997, J PEPT RES, V49, P545; CHU A, 1993, J MEMBRANE BIOL, V135, P49; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FAZAL A, 1989, FEBS LETT, V257, P260, DOI 10.1016/0014-5793(89)81548-0; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FURUKAWA KI, 1994, BRIT J PHARMACOL, V113, P233, DOI 10.1111/j.1476-5381.1994.tb16199.x; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; Koizumi S, 1999, J BIOL CHEM, V274, P33327, DOI 10.1074/jbc.274.47.33327; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lee CW, 2004, BIOCHEM J, V377, P385, DOI 10.1042/BJ20031192; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8; Morrissette J, 1996, BIOPHYS J, V71, P707, DOI 10.1016/S0006-3495(96)79270-6; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHWEITZ H, 1989, BIOCHEMISTRY-US, V28, P9708, DOI 10.1021/bi00451a025; Sutko JL, 1997, PHARMACOL REV, V49, P53; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; VALDIVIA HH, 1991, J BIOL CHEM, V266, P19135; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886; Zhu XS, 1999, FEBS LETT, V450, P221, DOI 10.1016/S0014-5793(99)00496-2	33	15	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26588	26596		10.1074/jbc.M403284200	http://dx.doi.org/10.1074/jbc.M403284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15067003	hybrid			2022-12-25	WOS:000222003000084
J	Ito, T; Williams, JD; Fraser, DJ; Phillips, AO				Ito, T; Williams, JD; Fraser, DJ; Phillips, AO			Hyaluronan regulates transforming growth factor-beta 1 receptor compartmentalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; EXPERIMENTAL GLOMERULONEPHRITIS; INDEPENDENT REGULATION; INTERSTITIAL FIBROSIS; DIABETIC-NEPHROPATHY; TUMOR-SUPPRESSOR; KIDNEY FIBROSIS	Transforming growth factor-beta1 (TGF-beta1) is a key cytokine involved in the pathogenesis of fibrosis in many organs. We previously demonstrated in renal proximal tubular cells that the engagement of the extracellular polysaccharide hyaluronan with its receptor CD44 attenuated TGF-beta1 signaling. In the current study we examined the potential mechanism by which the interaction between hyaluronan ( HA) and CD44 regulates TGF-beta receptor function. Affinity labeling of TGF-beta receptors demonstrated that in the unstimulated cells the majority of the receptor partitioned into EEA-1-associated non-lipid raft-associated membrane pools. In the presence of exogenous HA, the majority of the receptors partitioned into caveolin-1 lipid raft-associated pools. TGF-beta1 increased the association of activated/phosphorylated Smad proteins with EEA-1, consistent with activation of TGF-beta1 signaling following endosomal internalization. Following addition of HA, caveolin-1 associated with the inhibitory Smad protein Smad7, consistent with the raft pools mediating receptor turnover, which was facilitated by HA. Antagonism of TGF-beta1-dependent Smad signaling and the effect of HA on TGF-beta receptor associations were inhibited by depletion of membrane cholesterol using nystatin and augmented by inhibition of endocytosis. The effect of HA on TGF-beta receptor trafficking was inhibited by inhibition of HA-CD44 interactions, using blocking antibody to CD44 or inhibition of MAP kinase activation. In conclusion, we have proposed a model by which HA engagement of CD44 leads to MAP kinase-dependent increased trafficking of TGF-beta receptors to lipid raft-associated pools, which facilitates increased receptor turnover and attenuation of TGF-beta1-dependent alteration in proximal tubular cell function.	Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Phillips, AO (corresponding author), Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales.	PhillipsAO@cf.ac.uk		Fraser, Donald/0000-0003-0102-9342				Akagi Y, 1996, KIDNEY INT, V50, P148, DOI 10.1038/ki.1996.297; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BOHLE A, 1987, AM J NEPHROL, V7, P421, DOI 10.1159/000167514; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORDER WA, 1992, KIDNEY INT, V41, P566, DOI 10.1038/ki.1992.83; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ehrlich M, 2001, J CELL SCI, V114, P1777; Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x; Fraser D, 2002, AM J PATHOL, V161, P1039, DOI 10.1016/S0002-9440(10)64265-4; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HUMES HD, 1993, KIDNEY INT, V43, P575, DOI 10.1038/ki.1993.85; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; Isaka Y, 2000, KIDNEY INT, V58, P1885, DOI 10.1046/j.1523-1755.2000.00360.x; ITO T, 2004, IN PRESS AM J PATHOL; Janssen U, 2001, KIDNEY INT, V60, P126, DOI 10.1046/j.1523-1755.2001.00779.x; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; Jones SG, 2003, INT J BIOCHEM CELL B, V35, P1361, DOI 10.1016/S1357-2725(03)00040-2; KAGAMI S, 1993, LAB INVEST, V69, P68; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KULKARNI AB, 1993, AM J PATHOL, V143, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewington AJP, 2000, AM J PHYSIOL-REG I, V278, pR247, DOI 10.1152/ajpregu.2000.278.1.R247; MACKENSENHAEN S, 1981, CLIN NEPHROL, V15, P167; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Piek E, 1999, J CELL SCI, V112, P4557; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sibalic V, 1997, NEPHROL DIAL TRANSPL, V12, P1344, DOI 10.1093/ndt/12.7.1344; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tian YC, 2003, J AM SOC NEPHROL, V14, P631, DOI 10.1097/01.ASN.0000053418.56286.5E; WELLS A, 1993, TRANSPLANTATION, V55, P1346, DOI 10.1097/00007890-199306000-00025; WELLS AF, 1990, TRANSPLANTATION, V50, P240, DOI 10.1097/00007890-199008000-00014; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Yu L, 2003, KIDNEY INT, V64, P844, DOI 10.1046/j.1523-1755.2003.00162.x	54	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25326	25332		10.1074/jbc.M403135200	http://dx.doi.org/10.1074/jbc.M403135200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084590	hybrid			2022-12-25	WOS:000221827900053
J	Lova, P; Campus, F; Lombardi, R; Cattaneo, M; Sinigaglia, F; Balduini, C; Torti, M				Lova, P; Campus, F; Lombardi, R; Cattaneo, M; Sinigaglia, F; Balduini, C; Torti, M			Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE; INTEGRIN ALPHA(IIB)BETA(3); ADENOSINE-DIPHOSPHATE; SIGNAL-TRANSDUCTION; AGGREGATION; ADP; IDENTIFICATION; PATHWAYS; BINDING; CELLS	Thrombin activates human platelets through three different membrane receptors, the protease-activated receptors PAR-1 and PAR-4 and the glycoprotein Ib (GPIb)-IX-V complex. We investigated the contribution of these three receptors to thrombin-induced activation of the small GTPase Rap1B. We found that, similarly to thrombin, selective stimulation of either PAR-1 or PAR-4 by specific activating peptides caused accumulation of GTP-bound Rap1B in a dose-dependent manner. By contrast, in PAR-1- and PAR-4-desensitized platelets, thrombin failed to activate Rap1B. Thrombin, PAR-1-, or PAR-4-activating peptides also induced the increase of intracellular Ca2+ concentration and the release of serotonin in a dose-dependent manner. We found that activation of Rap1B by selected doses of agonists able to elicit comparable intracellular Ca2+ increase and serotonin release was differently dependent on secreted ADP. In the presence of the ADP scavengers apyrase or phosphocreatine-phosphocreatine kinase, activation of Rap1B induced by stimulation of either PAR-1 or PAR-4 was totally inhibited. By contrast, thrombin-induced activation of Rap1B was only minimally affected by neutralization of secreted ADP. Concomitant stimulation of both PAR-1 and PAR-4 in the presence of ADP scavengers still resulted in a strongly reduced activation of Rap1B. A similar effect was also observed upon blockade of the P2Y12 receptor for ADP, as well as in P2Y12 receptor-deficient human platelets, but not after blockade of the P2Y1 receptor. Activation of Rap1B induced by thrombin was not affected by preincubation of platelets with the anti-GPIbalpha monoclonal antibody AK2 in the absence of ADP scavengers or a P2Y12 antagonist but was totally abolished when secreted ADP was neutralized or after blockade of the P2Y12 receptor. Similarly, cleavage of the extracellular portion of GPIbalpha by the cobra venom mocarhagin totally prevented Rap1B activation induced by thrombin in the presence of apyrase and in P2Y12 receptor-deficient platelets. By contrast, inhibition of MAP kinases or p160ROCK, which have been shown to be activated upon thrombin binding to GPIb-IX-V, did not affect agonist-induced activation of Rap1B in the presence of ADP scavengers. These results indicate that although both PAR-1 and PAR-4 signal Rap1B activation, the ability of thrombin to activate this GTPase independently of secreted ADP involves co-stimulation of both receptors as well as binding to GPIb-IX-V.	Univ Pavia, Dept Biochem, Ctr Excellence Appl Biol, I-27100 Pavia, Italy; Univ Milan, Osped San Paolo, Dept Surg Med & Dent, Unit Hematol & Thrombosis, I-20142 Milan, Italy; Univ Milan, Osped Maggiore, Ist Ricovero & Cura Carattere Sci, A Bianchi Bonomi Hemophilia & Thrombosis Ctr, I-20122 Milan, Italy; Univ A Avogadro, Dept Med Sci, I-28100 Novara, Italy	University of Pavia; San Paolo-Polo Universitaria Hospital; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Eastern Piedmont Amedeo Avogadro	Torti, M (corresponding author), Univ Pavia, Dept Biochem, Ctr Excellence Appl Biol, Via Bassi 21, I-27100 Pavia, Italy.	mtorti@unipv.it	Cattaneo, Marco/AAT-4080-2020	Cattaneo, Marco/0000-0002-7343-4534				Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CATTANEO M, 1992, BLOOD, V80, P2787; Cattaneo M, 2003, P NATL ACAD SCI USA, V100, P1978, DOI 10.1073/pnas.0437879100; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, THROMB HAEMOSTASIS, V87, P722, DOI 10.1055/s-0037-1613071; De Candia E, 2001, J BIOL CHEM, V276, P4692, DOI 10.1074/jbc.M008160200; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; Dubois C, 2003, THROMB HAEMOSTASIS, V89, P853, DOI 10.1055/s-0037-1613473; Eto K, 2002, P NATL ACAD SCI USA, V99, P12819, DOI 10.1073/pnas.202380099; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Kunapuli SP, 1998, PLATELETS, V9, P343, DOI 10.1080/09537109876401; Larson MK, 2003, BLOOD, V101, P1409, DOI 10.1182/blood-2002-05-1533; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; Ramakrishnan V, 1999, P NATL ACAD SCI USA, V96, P13336, DOI 10.1073/pnas.96.23.13336; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Soslau G, 2001, J BIOL CHEM, V276, P21173, DOI 10.1074/jbc.M008249200; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; TORTI M, 1994, THROMB HAEMOSTASIS, V71, P533; Trumel C, 1999, BLOOD, V94, P4156, DOI 10.1182/blood.V94.12.4156.424k29_4156_4165; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; YAMAMOTO N, 1991, BLOOD, V77, P1740	44	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25299	25306		10.1074/jbc.M313199200	http://dx.doi.org/10.1074/jbc.M313199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078882	hybrid			2022-12-25	WOS:000221827900049
J	Kunapuli, P; Kasyapa, CS; Hawthorn, L; Cowell, JK				Kunapuli, P; Kasyapa, CS; Hawthorn, L; Cowell, JK			LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COLLAGENASE-1 MMP-1; INVASION; INHIBITION; CANCER; RAF; HETEROZYGOSITY; CHROMOSOME-10; FIBROBLASTS; INDUCTION	Gliomas take a number of different genetic routes in the progression to glioblastoma multiforme, a highly invasive variant that is mostly unresponsive to current therapies. Gliomas express elevated levels of matrix metalloproteinases ( MMPs), which have been implicated in the control of proliferation and invasion as well as neovascularization. Progressive loss of LGI1 expression has been associated with the development of high grade gliomas. We have shown previously that the forced re-expression of LGI1 in different glioma cells inhibits proliferation, invasiveness, and anchorage-independent growth in cells null for its expression. Here, using Affymetrix gene chip analysis, we show that reexpression of LGI1 in T98G cells results in the downregulation of several MMP genes, in particular MMP1 and MMP3. LGI1 expression also results in the inhibition of ERK1/2 phosphorylation but not p38 phosphorylation. Inhibition of the MAPK pathway using the pharmacological inhibitors PD98059, U0126, and SB203580 in T98G LGI1-null cells inhibits MMP1 and MMP3 production in an ERK1/2-dependent manner. Treatment of LGI1-expressing cells with phorbol myristate acetate prevents the inhibition of MMP1/3 and restores invasiveness and ERK1/2 phosphorylation, suggesting that LGI1 acts through the ERK/MAPK pathway. Furthermore, LGI1 expression promotes phosphorylation of AKT, which leads to phosphorylation of Raf1(Ser-259), an event shown previously to negatively regulate ERK1/2 signaling. These data suggest that LGI1 plays a major role in suppressing the production of MMP1/3 through the phosphatidylinositol 3-kinase/ERK pathway. Loss of LGI1 expression, therefore, may be an important event in the progression of gliomas that leads to a more invasive phenotype in these cells.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	John.Cowell@RoswellPark.org		Cowell, John/0000-0002-2079-5950; Hawthorn, Lesleyann/0000-0001-8179-0937	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046706] Funding Source: NIH RePORTER; NINDS NIH HHS [NSO46706-01] Funding Source: Medline; PHS HHS [C1A6056] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Besleaga R, 2003, VIRCHOWS ARCH, V443, P561, DOI 10.1007/s00428-003-0874-3; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Chintala SK, 1999, INT J DEV NEUROSCI, V17, P495, DOI 10.1016/S0736-5748(99)00010-6; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; JASTI SR, 2003, NAT REV CANCER, V3, P489; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; KARLBOM AE, 1993, HUM GENET, V92, P169; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; Kleihues P, 2000, PATHOLOGY GENETICS T; Kunapuli P, 2003, ONCOGENE, V22, P3985, DOI 10.1038/sj.onc.1206584; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Maitra A, 2003, CLIN CANCER RES, V9, P5988; Matsuzawa K, 1996, J NEURO-ONCOL, V30, P181; Mercapide J, 2003, INT J CANCER, V106, P676, DOI 10.1002/ijc.11286; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reuben PM, 2002, J BIOL CHEM, V277, P15190, DOI 10.1074/jbc.M200278200; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Simon C, 1998, CANCER RES, V58, P1135; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Uhm JH, 1997, CAN J NEUROL SCI, V24, P3, DOI 10.1017/S0317167100021028; VanMeter TE, 2001, J NEURO-ONCOL, V53, P213, DOI 10.1023/A:1012280925031; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	46	87	96	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23151	23157		10.1074/jbc.M314192200	http://dx.doi.org/10.1074/jbc.M314192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047712	hybrid			2022-12-25	WOS:000221570900045
J	Knight-Krajewski, S; Welsh, CF; Liu, YQ; Lyons, LS; Faysal, JM; Yang, ES; Burnstein, KL				Knight-Krajewski, S; Welsh, CF; Liu, YQ; Lyons, LS; Faysal, JM; Yang, ES; Burnstein, KL			Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells	ONCOGENE			English	Article						Rho GTPases; Rac1; Cdc42; cyclin-dependent kinase inhibitor; p21; cell cycle	INFLAMMATORY BREAST-CANCER; ACTIVATED PROTEIN-KINASE; GROWTH-INHIBITION; TUMOR-CELLS; DNA-REPLICATION; FAMILY GTPASES; IN-VIVO; EXPRESSION; PROLIFERATION; LNCAP	Abnormally suppressed levels of cyclin-dependent kinase inhibitors (CKIs) are associated with aggressive androgen-independent prostate cancer and contribute to uncontrolled proliferation. The androgen-independent human prostate cancer cell lines, LNCaP-104R1, ALVA31 and PC-3, express low levels of the CKI, p21(CIP1), compared to the less-malignant, androgen-dependent LNCaP cells. We investigated the mechanism underlying this suppression by examining the role of Rho GTPases, signaling proteins that play important roles in cell cycle progression, at least in part through regulation of CKIs. Inhibition of Rac1 induced p21 expression in androgen-independent lines but had no effect on the higher p21 levels characteristic of LNCaP cells. This induction of p21 was functionally significant as evidenced by inhibition of cyclin-dependent kinase 2 activity and decreased cell proliferation. Conversely, overexpression of constitutively active Rac1 suppressed the higher p21 levels seen in LNCaP cells. Thus, Rac1 activity is both necessary and sufficient for suppression of p21 in prostate cancer cells. Furthermore, Rac1 Activity was significantly higher in all three androgen-independent cell lines compared to LNCaP cells. Thus in three models of aggressive human prostate cancer, hyperactivity of Rac1 corresponds to suppressed levels of p21. These results are unique in describing a role for Rac1 in p21 regulation and may implicate the Rac1 signaling pathway as a potential therapeutic target for controlling prostate cancer cell growth following progression to androgen independence.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33136 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Burnstein, KL (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, R-189,1600 NW 10th Ave, Miami, FL 33136 USA.	kburnste@miami.edu			NCI NIH HHS [CA 87668] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA087668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltomaa S, 1999, PROSTATE, V39, P8; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Auer KL, 1998, BIOCHEM J, V336, P551, DOI 10.1042/bj3360551; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; Cheng L, 2000, CLIN CANCER RES, V6, P1896; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Fizazi K, 2002, CLIN CANCER RES, V8, P775; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Ghosh PM, 2002, CANCER RES, V62, P2630; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Guo YP, 1997, CLIN CANCER RES, V3, P2269; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KOKONTIS J, 1994, CANCER RES, V54, P1566; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; Liberto M, 2002, ONCOGENE, V21, P1590, DOI 10.1038/sj.onc.1205242; LOOP SM, 1995, PROSTATE, V26, P179, DOI 10.1002/pros.2990260403; LOOP SM, 1993, PROSTATE, V22, P93, DOI 10.1002/pros.2990220202; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Matsushima H, 1998, HUM PATHOL, V29, P778, DOI 10.1016/S0046-8177(98)90445-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Navone NM, 1998, CANCER METAST REV, V17, P361, DOI 10.1023/A:1006165017279; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; ORDONEZ NG, 2002, CLIN CANCER RES, V8, P775; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STAHLEBACKDHAL M, 1995, AM J PATHOL, V146, P1073; TILLEY WD, 1990, CANCER RES, V50, P5382; Tsihlias J, 1999, ANNU REV MED, V50, P401; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; VAN AL, 1997, GENE DEV, V11, P2295; van Bokhoven A, 2001, PROSTATE, V47, P36; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waltregny D, 2001, MOL ENDOCRINOL, V15, P765, DOI 10.1210/me.15.5.765; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	66	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5513	5522		10.1038/sj.onc.1207708	http://dx.doi.org/10.1038/sj.onc.1207708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15077174				2022-12-25	WOS:000222588400011
J	Tomida, S; Koshikawa, K; Yatabe, Y; Harano, T; Ogura, N; Mitsudomi, T; Some, M; Yanagisawa, K; Takahashi, T; Osada, H; Takahashi, T				Tomida, S; Koshikawa, K; Yatabe, Y; Harano, T; Ogura, N; Mitsudomi, T; Some, M; Yanagisawa, K; Takahashi, T; Osada, H; Takahashi, T			Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients	ONCOGENE			English	Article						lung cancer; gene expression profile; microarray; prognosis	SQUAMOUS DIFFERENTIATION MARKER; PROGNOSTIC-SIGNIFICANCE; CELL-LINES; ADENOCARCINOMA; CLASSIFICATION; TUMORS; METASTASIS; TRANSFORMATION; PROGRESSION; CARCINOMAS	Individualized outcome prediction classifiers were successfully constructed through expression pro. ling of a total of 8644 genes in 50 non-small-cell lung cancer (NSCLC) cases, which had been consecutively operated on within a defined short period of time and followed up for more than 5 years. The resultant classifier of NSCLCs yielded 82% accuracy for forecasting survival or death 5 years after surgery of a given patient. In addition, since two major histologic classes may differ in terms of outcome-related expression signatures, histologic-type-specific outcome classifiers were also constructed. The resultant highly predictive classifiers, designed specifically for nonsquamous cell carcinomas, showed a prediction accuracy of more than 90% independent of disease stage. In addition to the presence of heterogeneities in adenocarcinomas, our unsupervised hierarchical clustering analysis revealed for the first time the existence of clinicopathologically relevant subclasses of squamous cell carcinomas with marked differences in their invasive growth and prognosis. This finding clearly suggests that NSCLCs comprise distinct subclasses with considerable heterogeneities even within one histologic type. Overall, these findings should advance not only our understanding of the biology of lung cancer but also our ability to individualize postoperative therapies based on the predicted outcome.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan; Fuji Photo Film Co Ltd, Miyanodai Technol Dev Ctr, Kanagawa 2588538, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Immunol, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center; Fujifilm Corporation; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Yanagisawa, Kiyoshi/I-7263-2014	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; tomida, shuta/0000-0003-3786-936X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Craig SW, 2003, CURR BIOL, V13, pR236, DOI 10.1016/S0960-9822(03)00160-X; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HORIO Y, 1993, CANCER RES, V53, P1; Hu R, 1998, LUNG CANCER, V20, P25, DOI 10.1016/S0169-5002(97)00097-4; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MINNA JD, 1997, MOL BIOL LUNG CANC, P849; Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Robert C, 1999, CLIN CANCER RES, V5, P2094; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Vuong H, 2002, AM J PHYSIOL-LUNG C, V282, pL215, DOI 10.1152/ajplung.00125.2001; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	37	110	116	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5360	5370		10.1038/sj.onc.1207697	http://dx.doi.org/10.1038/sj.onc.1207697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064725				2022-12-25	WOS:000222491600011
J	Dubin, MJ; Stokes, PH; Sum, EYM; Williams, RS; Valova, VA; Robinson, PJ; Lindeman, GJ; Glover, JNM; Visvader, JE; Matthews, JM				Dubin, MJ; Stokes, PH; Sum, EYM; Williams, RS; Valova, VA; Robinson, PJ; Lindeman, GJ; Glover, JNM; Visvader, JE; Matthews, JM			Dimerization of CtIP, a BRCA1- and CtBP-interacting protein, is mediated by an N-terminal coiled-coil motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; LARGE T-ANTIGEN; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; BINDING-PROTEIN; GENE-PRODUCT; DNA-DAMAGE; BRCA1; DOMAIN; REPRESSION	CtIP is a transcriptional co-regulator that binds a number of proteins involved in cell cycle control and cell development, such as CtBP (C terminus-binding protein), BRCA1 (breast cancer-associated protein-1), and LMO4 (LIM-only protein-4). The only recognizable structural motifs within CtIP are two putative coiled-coil domains located near the N and C termini of the protein. We now show that the N-terminal coiled coil (residues 45-160), but not the C-terminal coiled coil, mediates homodimerization of CtIP in mammalian 293T cells. The N-terminal coiled coil did not facilitate binding to LMO4 and BRCA1 proteins in these cells. A protease-resistant domain (residues 27-168) that minimally encompasses the putative N-terminal coiled coil was identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. This region is predicted to contain two smaller coiled-coil regions. The CtIP-(45-160) dimerization domain is helical and dimeric, indicating that the domain does form a coiled coil. The two smaller domains, CtIP( 45-92) and CtIP-(93-160), also formed dimers of lower binding affinity, but with less helical content than the longer peptide. The hydrodynamic radius of CtIP-(45-160) is the same as those of CtIP-(45-92) and CtIP-(93-160), implying that CtIP-(45-160) does not form a single long coiled coil, but a more compact structure involving homodimerization of the two smaller coiled coils, which fold back as a four-helix bundle or other compact structure. These results suggest a specific model for CtIP homodimerization via its N terminus and contribute to an improved understanding of how this protein might assemble other factors required for its role as a transcriptional corepressor.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Childrens Med Res Inst, Westmead, NSW 2145, Australia; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Sydney; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Children's Medical Research Institute - Australia; University of Alberta	Matthews, JM (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Bldg G08, Sydney, NSW 2006, Australia.	j.matthews@mmb.usyd.edu.au	Matthews, Jacqueline/A-7322-2013; Robinson, Phillip J/G-4008-2011; Williams, R Scott/A-6059-2015	Robinson, Phillip J/0000-0002-7878-0313; Matthews, Jacqueline/0000-0001-8518-3472; Lindeman, Geoffrey/0000-0001-9386-2416; Dubin, Manu/0000-0003-2374-2456; Williams, R Scott/0000-0002-4610-8397				Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beckett D, 2001, J MOL BIOL, V314, P335, DOI 10.1006/jmbi.2001.5134; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Fusco C, 1998, GENOMICS, V51, P351, DOI 10.1006/geno.1998.5368; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hayes D., 1995, SEDIMENTATION INTERP; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 2002, J BIOL CHEM, V277, P23143, DOI 10.1074/jbc.M202079200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lee DL, 2001, J MOL BIOL, V306, P539, DOI 10.1006/jmbi.2000.4351; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shih HA, 2002, J CLIN ONCOL, V20, P994, DOI 10.1200/JCO.20.4.994; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Whitby FG, 2000, PROTEINS, V38, P49; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199	40	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26932	26938		10.1074/jbc.M313974200	http://dx.doi.org/10.1074/jbc.M313974200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084581	hybrid			2022-12-25	WOS:000222120400018
J	Roze, LV; Miller, MJ; Rarick, M; Mahanti, N; Linz, JE				Roze, LV; Miller, MJ; Rarick, M; Mahanti, N; Linz, JE			A novel cAMP-response element, CRE1, modulates expression of nor-1 in Aspergillus parasiticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; NIDULANS PENICILLIN-BIOSYNTHESIS; CCAAT BINDING COMPLEX; AFLATOXIN BIOSYNTHESIS; SIGNALING PATHWAY; REGULATORY GENE; SYNTHASE GENE; PROTEIN; GLUCOSE; AFLR	The level of aflatoxin accumulation in the filamentous fungus Aspergillus parasiticus is modulated by a variety of environmental cues. The presence of glucose ( a preferred carbon source) in liquid and solid glucose minimal salts (GMS) growth media strongly stimulated aflatoxin accumulation. Peptone ( a non-preferred carbon source) in peptone minimal salts (PMS) media stimulated only low levels of aflatoxin accumulation. Glucose stimulated transcription of the aflatoxin structural genes ver-1 and nor-1 to similar intermediate levels in liquid GMS, while on solid media, ver-1 transcription was stimulated to 20-fold higher levels than nor-1. PMS liquid and solid media stimulated very low or non-detectable levels of transcription of both genes. Electrophoretic mobility shift analysis using a nor-1 promoter fragment (norR) and A. parasiticus cell protein extracts revealed specific DNA-protein complexes of different mobility on GMS and PMS solid and liquid media. An imperfect cAMP-response element, CRE1, was identified in norR that mediated formation of the specific DNA-protein complexes. Mutation in CRE1 or AflR1 (AflR cis-acting site) caused up to a 3-fold decrease in cAMP-mediated stimulation of nor-1 promoter activity on GMS agar. South-Western blot analysis identified a 32-kDa protein that specifically bound to norR. p32 could be co-immunoprecipitated by anti-AflR antibody and co-purified with an AflR-maltose-binding protein fusion demonstrating a physical interaction between AflR and p32 in vitro. We hypothesize that p32 assists AflR in binding to the nor-1 promoter, thereby modulating nor-1 gene expression in response to environmental cues.	Michigan State Univ, Dept Food Sci & Human Nutr, Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol & Mol Genet, Lansing, MI 48824 USA; Michigan State Univ, Natl Food Safety & Toxicol Ctr, Lansing, MI 48824 USA; Michigan State Univ, Ctr Integrat Toxicol, Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University	Linz, JE (corresponding author), Michigan State Univ, Dept Food Sci & Human Nutr, 234B GM Trout Bldg, Lansing, MI 48824 USA.	jlinz@msu.edu	Linz, John/AAF-1682-2020	Miller, Michael/0000-0001-8579-1080	NCI NIH HHS [CA52003-12] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 2003, CURRENT PROTOCOLS MO; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BRAKHAGE AA, 1992, J BACTERIOL, V174, P3789, DOI 10.1128/JB.174.11.3789-3799.1992; Brakhage AA, 1999, FUNGAL GENET BIOL, V27, P243, DOI 10.1006/fgbi.1999.1136; Brown MP, 1999, FUNGAL GENET BIOL, V26, P81, DOI 10.1006/fgbi.1998.1114; BUCHANAN RL, 1984, APPL ENVIRON MICROB, V48, P306, DOI 10.1128/AEM.48.2.306-310.1984; BUCHANAN RL, 1987, APPL ENVIRON MICROB, V53, P1224, DOI 10.1128/AEM.53.6.1224-1231.1987; Cary J. W., 2000, Microbial foodborne diseases: mechanisms of pathogenesis and toxin synthesis., P317; Cary JW, 2000, APPL MICROBIOL BIOT, V53, P680, DOI 10.1007/s002530000319; Cary JW, 2002, BBA-GENE STRUCT EXPR, V1576, P316, DOI 10.1016/S0167-4781(02)00396-2; CHANG PK, 1995, APPL ENVIRON MICROB, V61, P2372, DOI 10.1128/AEM.61.6.2372-2377.1995; CHANG PK, 1992, CURR GENET, V21, P231, DOI 10.1007/BF00336846; Chiou CH, 2002, APPL ENVIRON MICROB, V68, P306, DOI 10.1128/AEM.68.1.306-315.2002; COTTY PJ, 1994, FEMS SYMP, P1; *COUNC AGR SCI TEC, 2003, B COUNC AGR SCI TECH, V139; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; Ehrlich KC, 1999, GENE, V230, P249, DOI 10.1016/S0378-1119(99)00075-X; Ehrlich KC, 2002, BBA-GENE STRUCT EXPR, V1576, P171, DOI 10.1016/S0167-4781(02)00282-8; Hicks JK, 1997, EMBO J, V16, P4916, DOI 10.1093/emboj/16.16.4916; JACKSON SP, 1993, GENE TRANSCRIPTION P, P201; KULMBURG P, 1993, MOL MICROBIOL, V7, P847, DOI 10.1111/j.1365-2958.1993.tb01175.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS M, 1997, TRANSCRIPTION FACTOR, P51; Lee LW, 2002, APPL ENVIRON MICROB, V68, P5718, DOI 10.1128/AEM.68.11.5718-5727.2002; Liang SH, 1997, APPL ENVIRON MICROB, V63, P1058, DOI 10.1128/AEM.63.3.1058-1065.1997; Liang SH, 1996, APPL ENVIRON MICROB, V62, P4568, DOI 10.1128/AEM.62.12.4568-4575.1996; Litzka O, 1996, EUR J BIOCHEM, V238, P675, DOI 10.1111/j.1432-1033.1996.0675w.x; Liu BH, 1998, APPL ENVIRON MICROB, V64, P3718; LUCHESE RH, 1993, J APPL BACTERIOL, V74, P5, DOI 10.1111/j.1365-2672.1993.tb02989.x; MILLER MJ, 2003, THESIS MICHIGAN STAT; Narendja FM, 1999, MOL CELL BIOL, V19, P6523; Orejas M, 1999, MOL MICROBIOL, V31, P177, DOI 10.1046/j.1365-2958.1999.01157.x; PAYNE GA, 1993, APPL ENVIRON MICROB, V59, P156, DOI 10.1128/AEM.59.1.156-162.1993; PEREZESTEBAN B, 1993, MOL MICROBIOL, V9, P881, DOI 10.1111/j.1365-2958.1993.tb01746.x; PESTKA JJ, 1988, J ASSOC OFF ANA CHEM, V71, P1075; PETERS DG, 1994, NUCLEIC ACIDS RES, V22, P5164, DOI 10.1093/nar/22.24.5164; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; ROZE L, 2004, IN PRESS MYCOPATHOLO; Roze LV, 2004, J FOOD PROTECT, V67, P438, DOI 10.4315/0362-028X-67.3.438; Ruijter GJG, 1997, FEMS MICROBIOL LETT, V151, P103, DOI 10.1016/S0378-1097(97)00161-4; SKORY CD, 1993, APPL ENVIRON MICROB, V59, P1642, DOI 10.1128/AEM.59.5.1642-1646.1993; SKORY CD, 1992, APPL ENVIRON MICROB, V58, P3527, DOI 10.1128/AEM.58.11.3527-3537.1992; Steidl S, 1999, MOL CELL BIOL, V19, P99; STRAUSS J, 1995, FEBS LETT, V376, P103, DOI 10.1016/0014-5793(95)01255-5; TICE G, 1981, J FOOD SCI, V47, P153; TRAIL F, 1995, MICROBIOL-UK, V141, P755, DOI 10.1099/13500872-141-4-755; TRAIL F, 1994, APPL ENVIRON MICROB, V60, P4078, DOI 10.1128/AEM.60.11.4078-4085.1994; TRAIL F, 1995, APPL ENVIRON MICROB, V61, P2665, DOI 10.1128/AEM.61.7.2665-2673.1995; Vautard-Mey G, 2000, CURR GENET, V37, P328, DOI 10.1007/s002940050535; WISEMAN DW, 1987, CAN J MICROBIOL, V33, P828, DOI 10.1139/m87-144; YU JJ, 1995, APPL ENVIRON MICROB, V61, P2365, DOI 10.1128/AEM.61.6.2365-2371.1995; Zhou R, 1999, APPL ENVIRON MICROB, V65, P5639	52	40	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27428	27439		10.1074/jbc.M400075200	http://dx.doi.org/10.1074/jbc.M400075200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15054098	hybrid			2022-12-25	WOS:000222120400074
J	Yuan, ZF; Agarwal-Mawal, A; Paudel, HK				Yuan, ZF; Agarwal-Mawal, A; Paudel, HK			14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser(9)-phosphorylated glycogen synthase kinase 3 beta in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; KINASE 3-BETA; FACTOR-I; SERINE PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; INSULIN; INACTIVATION; BINDING; PHOSPHATASE; ACTIVATION	In mammalian brain, tau, glycogen synthase kinase 3beta (GSK3beta), and 14-3-3, a phosphoserine-binding protein, are parts of a multiprotein tau phosphorylation complex. Within the complex, 14-3-3 simultaneously binds to tau and GSK3beta (Agarwal-Mawal, A., Qureshi, H. Y., Cafferty, P. W., Yuan, Z., Han, D., Lin, R., and Paudel, H. K. (2003) J. Biol. Chem. 278, 12722 - 12728). The molecular mechanism by which 14-3-3 connects GSK3beta to tau within the complex is not clear. In this study, we find that GSK3beta within the tau phosphorylation complex is phosphorylated on Ser(9). From extracts of rat brain and rat primary cultured neurons, Ser(9)-phosphorylated GSK3beta precipitates with glutathione-agarose beads coated with glutathione S-transferase-14-3-3. Similarly, from rat brain extract, Ser(9)-phosphorylated GSK3beta coimmunoprecipitates with tau. In vitro, 14-3-3 binds to GSK3beta only when the kinase is phosphorylated on Ser(9). In transfected HEK-293 cells, 14-3-3 binds to Ser(9)-phosphorylated GSK3beta and does not bind to GSK3beta (S9A). Tau, on the other hand, binds to both GSK3beta (WT) and GSK3beta (S9A). Moreover, 14-3-3 enhances the binding of tau with Ser9- phosphorylated GSK3beta by similar to3-fold but not with GSK3beta (S9A). Similarly, 14-3-3 stimulates phosphorylation of tau by Ser(9)- phosphorylated GSK3beta but not by GSK3beta (S9A). In transfected HEK-293 cells, Ser9 phosphorylation suppresses GSK3beta-catalyzed tau phosphorylation in the absence of 14-3-3. In the presence of 14-3-3, however, Ser(9)- phosphorylated GSK3beta remains active and phosphorylates tau. Our data indicate that within the tau phosphorylation complex, 14-3-3 connects Ser(9)- phosphorylated GSK3beta to tau and Ser9- phosphorylated GSK3beta phosphorylates tau.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Paudel, HK (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	hemant.paudel@mcgill.ca						Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; Agarwal-Mawal A, 2003, J BIOL CHEM, V278, P12722, DOI 10.1074/jbc.M211491200; Berg D, 2003, NAT REV NEUROSCI, V4, P752, DOI 10.1038/nrn1197; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Dohadwala M, 1998, METH MOL B, V93, P191; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; Hutton M, 2001, TRENDS MOL MED, V7, P467, DOI 10.1016/S1471-4914(01)02123-2; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x; Lesort M, 2000, NEUROSCIENCE, V99, P305, DOI 10.1016/S0306-4522(00)00200-1; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Mattson MP, 2001, TRENDS NEUROSCI, V24, P255, DOI 10.1016/S0166-2236(00)01838-5; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Planel E, 2001, J BIOL CHEM, V276, P34298, DOI 10.1074/jbc.M102780200; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Sun W, 2002, J BIOL CHEM, V277, P11933, DOI 10.1074/jbc.M107182200; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wagner U, 1996, J CELL SCI, V109, P1537; Wang YL, 2000, CELL GROWTH DIFFER, V11, P211; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YANG SD, 1989, J BIOL CHEM, V264, P5407; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377	47	70	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26105	26114		10.1074/jbc.M308298200	http://dx.doi.org/10.1074/jbc.M308298200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073173	hybrid			2022-12-25	WOS:000222003000024
J	Le Guezennec, X; Vriend, G; Stunnenberg, HG				Le Guezennec, X; Vriend, G; Stunnenberg, HG			Molecular determinants of the interaction of mad with the PAH2 domain of mSin3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; TRANSCRIPTIONAL REPRESSION; COREPRESSOR COMPLEX; SIN3/HISTONE DEACETYLASE; IN-VIVO; MYC-MAX; C-MYC; RECRUITMENT; PROTEIN; SIN3	The Sin3 co-repressor acts as a protein scaffold to recruit transcription factors via its four highly homologous paired amphipathic helix (PAH) domains. PAH2 has been shown to interact strongly with the Sin3 interacting domain (SID) of the tumor suppressor Mad. This PAH2/Mad complex has been studied extensively by NMR, but the molecular determinants that dictate the specificity of interaction remain to be elucidated. To uncover residues that convey the specificity of interaction between PAH2 and Mad, PAH2 residues contacted by the Mad-SID were introduced into the PAH1 domain of mSin3b and tested for gain-of-interaction in vivo in a yeast two-hybrid setting and further confirmed in a cell-free system. This approach led to the identification of PAH2-Phe-7 as a critical residue. Stabilization of the interaction between PAH1-Phe-7 and the Mad-SID was achieved by introducing Val-14 and Gln-39 into PAH1. Substitution of PAH2 residues contacted by the Mad-SID with their respective residues in PAH1 corroborated and extended the critical role of Phe-7 and the stabilizing role of Val-14 and Gln-39. We conclude that Phe-7 is the critical determinant and provides the molecular specificity for the association between Sin3 and Mad in regulating cell growth and differentiation.	Univ Nijmegen, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Stunnenberg, HG (corresponding author), Univ Nijmegen, Dept Mol Biol, NCMLS 191,POB 9101, NL-6500 HB Nijmegen, Netherlands.	h.stunnenberg@ncmls.kun.nl	Stunnenberg, Hendrik G./D-6875-2012; LE GUEZENNEC, Xavier/G-9635-2012; Vriend, Gert/D-6730-2011; Vriend, G./H-8112-2014	Stunnenberg, Hendrik G./0000-0002-0066-1576; LE GUEZENNEC, Xavier/0000-0002-1590-1325				Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brubaker K, 2000, CELL, V103, P655, DOI 10.1016/S0092-8674(00)00168-9; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Eilers AL, 1999, J BIOL CHEM, V274, P32750, DOI 10.1074/jbc.274.46.32750; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Krieger E, 2002, BIOINFORMATICS, V18, P315, DOI 10.1093/bioinformatics/18.2.315; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; LARSSON LG, 1994, ONCOGENE, V9, P1247; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Spronk CAEM, 2000, NAT STRUCT BIOL, V7, P1100; Spronk CAEM, 2001, J BIOMOL NMR, V19, P377, DOI 10.1023/A:1011262214741; Vermeulen M, 2004, MOL CELL BIOL, V24, P2364, DOI 10.1128/MCB.24.6.2364-2372.2004; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang Q, 2000, BIOCHEM J, V345, P335, DOI 10.1042/0264-6021:3450335; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yochum GS, 2001, MOL CELL BIOL, V21, P4110, DOI 10.1128/MCB.21.13.4110-4118.2001; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	42	10	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25823	25829		10.1074/jbc.M313860200	http://dx.doi.org/10.1074/jbc.M313860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15047710	hybrid, Green Published			2022-12-25	WOS:000221827900113
J	Nabetani, A; Yokoyama, O; Ishikawa, F				Nabetani, A; Yokoyama, O; Ishikawa, F			Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NUCLEAR-DYNAMICS; IMMORTAL HUMAN-CELLS; DOUBLE-STRAND BREAKS; CHECKPOINT PROTEIN; SCHIZOSACCHAROMYCES-POMBE; MRE11 COMPLEX; DAMAGE; PML; BODIES; ATR	Telomere maintenance is essential for continued cell proliferation. Although most cells accomplish this by activating telomerase, a subset of immortalized tumors and cell lines do so in a telomerase-independent manner, a process called alternative lengthening of telomeres (ALT). DNA recombination has been shown to be involved in ALT, but the precise mechanisms remain unknown. A fraction of cells in a given ALT population contain a unique nuclear structure called APB (ALT-associated promyelocytic leukemia (PML) body), which is characterized by the presence of telomeric DNA in the PML body. Here we describe that hRad9, hHus1, and hRad1, which form a DNA clamp complex that is associated with DNA damage, as well as its clamp loader, hRad17, are constitutive components of APB. Phosphorylated histone H2AX (gamma-H2AX), a molecular marker of double-strand breaks (DSBs), also colocalizes with some APBs. The results suggest that telomeric DNAs at APBs are recognized as DSBs. PML staining and fluorescence in situ hybridization analyses of mitotic ALT cells revealed that telomeric DNAs present at APBs are of both extrachromosomal and native telomere origins. Furthermore, we demonstrated that DNA synthesis occurs at APBs and is significantly inhibited by caffeine, an inhibitor of phosphatidylinositol 3-kinase-related kinases. Taken together, we suggest that telomeric DNAs at APBs are recognized and processed as DSBs, leading to telomeric DNA synthesis and thereby contributing to telomere maintenance in ALT cells.	Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Lab Cell Cycle Regulat, Kyoto 6068502, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Informat, Lab Mol & Cellular Assembly,Midori Ku, Yokohama, Kanagawa 2268501, Japan	Kyoto University; Tokyo Institute of Technology	Ishikawa, F (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Lab Cell Cycle Regulat, Kyoto 6068502, Japan.	fishikaw@lif.kyoto-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Grobelny JV, 2000, J CELL SCI, V113, P4577; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lombard DB, 2000, CANCER RES, V60, P2331; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Nabetani A, 2001, CHROMOSOMA, V110, P322, DOI 10.1007/s004120100153; Naka K, 2002, BIOCHEM BIOPH RES CO, V299, P863, DOI 10.1016/S0006-291X(02)02755-9; Nakamura TM, 2002, GENETICS, V161, P1437; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Ogino H, 1998, BIOCHEM BIOPH RES CO, V248, P223, DOI 10.1006/bbrc.1998.8875; Ohki R, 2004, NUCLEIC ACIDS RES, V32, P1627, DOI 10.1093/nar/gkh309; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Reddel RR, 2003, CANCER LETT, V194, P155, DOI 10.1016/S0304-3835(02)00702-4; Regev A, 1998, ONCOGENE, V17, P3455, DOI 10.1038/sj.onc.1202250; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sarkaria JN, 1999, CANCER RES, V59, P4375; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tokutake Y, 1998, BIOCHEM BIOPH RES CO, V247, P765, DOI 10.1006/bbrc.1998.8876; Tsurimoto T, 1998, BBA-GENE STRUCT EXPR, V1443, P23, DOI 10.1016/S0167-4781(98)00204-8; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu GK, 2003, CANCER RES, V63, P2589; Yeager TR, 1999, CANCER RES, V59, P4175; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	54	90	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25849	25857		10.1074/jbc.M312652200	http://dx.doi.org/10.1074/jbc.M312652200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075340	hybrid			2022-12-25	WOS:000221827900116
J	Zhou, DW; Noviello, C; D'Ambrosio, C; Scaloni, A; D'Adamio, L				Zhou, DW; Noviello, C; D'Ambrosio, C; Scaloni, A; D'Adamio, L			Growth factor receptor-bound protein 2 interaction with the tyrosine-phosphorylated tail of amyloid beta precursor protein is mediated by its Src homology 2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL FRAGMENTS; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; CYTOPLASMIC DOMAIN; A-BETA; INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; ENHANCED INTERACTION; REACTIVE ASTROCYTES; INDUCED APOPTOSIS	The sequential processing of the familial disease gene product amyloid beta precursor protein (AbetaPP) by beta- and gamma-secretases generates amyloid beta, which is considered to be the pathogenic factor of Alzheimer's disease, and the AID peptide (AbetaPP intracellular domain). The AID peptide acts as a positive regulator of apoptosis and modulates transcription and calcium release. To gain clues about the molecular mechanisms regulating the function of AbetaPP and AID, proteins interacting with the AID region of AbetaPP have been isolated using the yeast two-hybrid system. Recent evidence indicates that AbetaPP undergoes post-translational modification events in the AID region and that phosphorylation might regulate its affinity for interacting proteins. To test this possibility and to uncover AbetaPP-binding partners whose interaction depends on AbetaPP phosphorylation, we used a proteomic approach. Here we describe a protein, growth factor receptor-bound protein 2 (Grb2), that specifically binds AbetaPP, phosphorylated in Tyr(682). Furthermore, we show that this interaction is direct and that Grb2 binds to phospho-AbetaPP via its Src homology 2 region. Together with the evidence that Grb2 is in complex with AbetaPP in human brains and that these complexes are augmented in brains from Alzheimer's cases, our data indicate that Grb2 may mediate some biological and possibly pathological AbetaPP-AID function.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Ceinge Biotecnol Avanzate, I-80145 Naples, Italy; CNR, Inst Anim Prod Syst Mediterranean Environm, Proteom & Mass Spectrometry Lab, I-80147 Naples, Italy	Yeshiva University; Albert Einstein College of Medicine; CEINGE Biotecnologie Avanzate; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR)	D'Adamio, L (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu	D'Ambrosio, Chiara/C-2753-2012	D'Ambrosio, Chiara/0000-0003-2810-9270; Scaloni, Andrea/0000-0001-9362-8515; Zhou, Dawang/0000-0002-9053-5249; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441	NIA NIH HHS [R01 AG22024-01, R01 AG21588-01] Funding Source: Medline; Telethon [GFP02006] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG022024, R01AG021588] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aplin AE, 1997, NEUROREPORT, V8, P639, DOI 10.1097/00001756-199702100-00012; Bertrand E, 2001, MOL CELL NEUROSCI, V18, P503, DOI 10.1006/mcne.2001.1030; BLANCHARD BJ, 1994, BIOCHEM BIOPH RES CO, V200, P187, DOI 10.1006/bbrc.1994.1432; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chen YZ, 2003, J CELL BIOL, V163, P27, DOI 10.1083/jcb.200304003; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Ekinci FJ, 1999, BRAIN RES, V850, P207, DOI 10.1016/S0006-8993(99)02146-0; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Ghersi E, 2004, J ALZHEIMERS DIS, V6, P67; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; Grbovic OM, 2003, J BIOL CHEM, V278, P31261, DOI 10.1074/jbc.M304122200; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hill RJ, 2002, EXP HEMATOL, V30, P237, DOI 10.1016/S0301-472X(01)00794-9; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Kim HS, 2004, J NEUROSCI RES, V75, P117, DOI 10.1002/jnr.10845; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; Lau LF, 2003, NEUROSIGNALS, V12, P209, DOI 10.1159/000074622; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Martinu L, 2002, J BIOL CHEM, V277, P50996, DOI 10.1074/jbc.M204869200; Matsuda S, 2003, J BIOL CHEM, V278, P38601, DOI 10.1074/jbc.M304379200; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McPhie DL, 2003, J NEUROSCI, V23, P6914; Nishimura I, 2002, CELL DEATH DIFFER, V9, P199, DOI 10.1038/sj.cdd.4400931; Noviello C, 2003, J BIOL CHEM, V278, P31843, DOI 10.1074/jbc.M304133200; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; RAGHUNANDAN R, 1995, BIOCHEM BIOPH RES CO, V215, P1056, DOI 10.1006/bbrc.1995.2571; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; RODER HM, 1993, BIOCHEM BIOPH RES CO, V193, P639, DOI 10.1006/bbrc.1993.1672; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Russo C, 2002, ANN NY ACAD SCI, V973, P323, DOI 10.1111/j.1749-6632.2002.tb04660.x; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Russo C, 2001, NEUROBIOL DIS, V8, P173, DOI 10.1006/nbdi.2000.0357; Sastre M, 2003, J NEUROSCI, V23, P9796; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Scheinfeld MH, 2003, J BIOL CHEM, V278, P42058, DOI 10.1074/jbc.M304853200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Silva EFDE, 2003, NEUROCHEM RES, V28, P1553, DOI 10.1023/A:1025630627319; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; Standen CL, 2003, MOL CELL NEUROSCI, V24, P851, DOI 10.1016/j.mcn.2003.07.002; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Talamo F, 2003, PROTEOMICS, V3, P440, DOI 10.1002/pmic.200390059; Tarr PE, 2002, BIOCHEM BIOPH RES CO, V295, P324, DOI 10.1016/S0006-291X(02)00678-2; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; Wang Y, 2004, J BIOL CHEM, V279, P8038, DOI 10.1074/jbc.M311494200; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	68	48	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25374	25380		10.1074/jbc.M400488200	http://dx.doi.org/10.1074/jbc.M400488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15054097	hybrid			2022-12-25	WOS:000221827900060
J	Cheng, DH; Yadav, N; King, RW; Swanson, MS; Weinstein, EJ; Bedford, MT				Cheng, DH; Yadav, N; King, RW; Swanson, MS; Weinstein, EJ; Bedford, MT			Small molecule regulators of protein arginine methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; NERVE GROWTH-FACTOR; N-METHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; SUBSTRATE-SPECIFICITY; S-ADENOSYLMETHIONINE; HISTONE METHYLATION; RECEPTOR FUNCTION; GENE-EXPRESSION	Here we report the identification of small molecules that specifically inhibit protein arginine N-methyltransferase (PRMT) activity. PRMTs are a family of proteins that either monomethylate or dimethylate the guanidino nitrogen atoms of arginine side chains. This common post-translational modification is implicated in protein trafficking, signal transduction, and transcriptional regulation. Most methyltransferases use the methyl donor, S-adenosyl-L-methionine ( AdoMet), as a cofactor. Current methyltransferase inhibitors display limited specificity, indiscriminately targeting all enzymes that use AdoMet. In this screen we have identified a primary compound, AMI-1, that specifically inhibits arginine, but not lysine, methyltransferase activity in vitro and does not compete for the AdoMet binding site. Furthermore, AMI-1 prevents in vivo arginine methylation of cellular proteins and can modulate nuclear receptor-regulated transcription from estrogen and androgen response elements, thus operating as a brake on certain hormone actions.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Florida, Coll Med, Powell Gene Therapy Ctr, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; State University System of Florida; University of Florida	Bedford, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.	mtbedford@mdanderson.org	Bedford, Mark T/E-7856-2011	Swanson, Maurice/0000-0001-6245-5367	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062248, R56DK062248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIDDK NIH HHS [DK62248-01] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Cimato TR, 1997, J CELL BIOL, V138, P1089, DOI 10.1083/jcb.138.5.1089; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Henry MF, 1996, MOL CELL BIOL, V16, P3668; HURST JH, 1984, BIOCHEM BIOPH RES CO, V122, P499, DOI 10.1016/S0006-291X(84)80061-3; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; KUJUBU DA, 1993, J NEUROSCI RES, V36, P58, DOI 10.1002/jnr.490360107; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lin Q, 2001, J AM CHEM SOC, V123, P11608, DOI 10.1021/ja011423j; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; NAJBAUER J, 1990, J BIOL CHEM, V265, P12717; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; SEELEY PJ, 1984, J CELL BIOL, V98, P417, DOI 10.1083/jcb.98.2.417; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Skillman AG, 2002, BIOORG CHEM, V30, P443, DOI 10.1016/S0045-2068(02)00502-3; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Wen Y, 2000, CANCER RES, V60, P6841; WENZEL C, 1991, FEBS LETT, V280, P147, DOI 10.1016/0014-5793(91)80224-Q; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	56	254	261	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23892	23899		10.1074/jbc.M401853200	http://dx.doi.org/10.1074/jbc.M401853200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15056663	hybrid			2022-12-25	WOS:000221702500009
J	Dudek, SM; Jacobson, JR; Chiang, ET; Birukov, KG; Wang, PY; Zhan, X; Garcia, JGN				Dudek, SM; Jacobson, JR; Chiang, ET; Birukov, KG; Wang, PY; Zhan, X; Garcia, JGN			Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate - Roles for cortactin and myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN CORTACTIN; TYROSINE PHOSPHORYLATION; CORTICAL CYTOSKELETON; ACTIN POLYMERIZATION; ARP2/3 COMPLEX; SHAPE CHANGES; SRC; ACTIVATION; MLCK; RHO	We recently reported the critical importance of Rac GTPase-dependent cortical actin rearrangement in the augmentation of pulmonary endothelial cell (EC) barrier function by sphingosine 1-phosphate (S1P). We now describe functional roles for the actin-binding proteins cortactin and EC myosin light chain kinase (MLCK) in mediating this response. Antisense down-regulation of cortactin protein expression significantly inhibits S1P-induced barrier enhancement in cultured human pulmonary artery EC as measured by transendothelial electrical resistance (TER). Immunofluorescence studies reveal rapid, Rac-dependent translocation of cortactin to the expanded cortical actin band following S1P challenge, where colocalization with EC MLCK occurs within 5 min. Adenoviral overexpression of a Rac dominant negative mutant attenuates TER elevation by S1P. S1P also induces a rapid increase in cortactin tyrosine phosphorylation (within 30 s) critical to subsequent barrier enhancement, since EC transfected with a tyrosine-deficient mutant cortactin exhibit a blunted TER response. Direct binding of EC MLCK to the cortactin Src homology 3 domain appears essential to S1P barrier regulation, since cortactin blocking peptide inhibits both S1P-induced MLC phosphorylation and peak S1P-induced TER values. These data support novel roles for the cytoskeletal proteins cortactin and EC MLCK in mediating lung vascular barrier augmentation evoked by S1P.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Amer Red Cross, Dept Expt Pathol, Holland Lab, Rockville, MD 20855 USA	Johns Hopkins University; American Red Cross	Garcia, JGN (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1830 Monument St,Rm 527, Baltimore, MD 21205 USA.	drgarcia@jhmi.edu	Birukov, Konstantin/FJB-5755-2022; Garcia, Joe GN/E-8862-2010		NCI NIH HHS [R01 CA 91984-01] Funding Source: Medline; NHLBI NIH HHS [P01 HL 58064, R01 HL 52753-09] Funding Source: Medline; PHS HHS [R01 68071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091984] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753, P01HL058064, R01HL052753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Cheng Y, 2000, J CELL SCI, V113, P3161; Chew TL, 2002, J CELL BIOL, V156, P543, DOI 10.1083/jcb.200110161; Crostella L, 2001, ONCOGENE, V20, P3735, DOI 10.1038/sj.onc.1204474; Di Ciano C, 2002, AM J PHYSIOL-CELL PH, V283, pC850, DOI 10.1152/ajpcell.00018.2002; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2002, BIOCHEM BIOPH RES CO, V298, P511, DOI 10.1016/S0006-291X(02)02492-0; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Florian P, 2002, J PHYSIOL-LONDON, V545, P485, DOI 10.1113/jphysiol.2002.031161; Gandhi S, 1997, AM J PHYSIOL-RENAL, V272, pF214, DOI 10.1152/ajprenal.1997.272.2.F214; Garcia JGN, 2000, J APPL PHYSIOL, V89, P2333, DOI 10.1152/jappl.2000.89.6.2333; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; JACOBSON JR, IN PRESS AM J RESP C; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Katoh K, 2001, AM J PHYSIOL-CELL PH, V280, pC1669, DOI 10.1152/ajpcell.2001.280.6.C1669; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; LO SK, 1988, AM J PHYSIOL, V254, pH763, DOI 10.1152/ajpheart.1988.254.4.H763; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Parker JC, 2000, J APPL PHYSIOL, V89, P2241, DOI 10.1152/jappl.2000.89.6.2241; Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com; Schaerer-Brodbeck C, 2000, MOL BIOL CELL, V11, P1113, DOI 10.1091/mbc.11.4.1113; Schaphorst KL, 1997, AM J RESP CELL MOL, V17, P443, DOI 10.1165/ajrcmb.17.4.2502; Shi S, 2000, AM J PHYSIOL-LUNG C, V279, pL441, DOI 10.1152/ajplung.2000.279.3.L441; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vidal C, 2002, BLOOD, V100, P4462, DOI 10.1182/blood.V100.13.4462; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 1998, J CELL SCI, V111, P2433; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Zolotarevsky Y, 2002, GASTROENTEROLOGY, V123, P163, DOI 10.1053/gast.2002.34235	49	227	234	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24692	24700		10.1074/jbc.M313969200	http://dx.doi.org/10.1074/jbc.M313969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15056655	hybrid			2022-12-25	WOS:000221702500100
J	Hui, TY; Sheth, SS; Diffley, JM; Potter, DW; Lusis, AJ; Attie, AD; Davis, RA				Hui, TY; Sheth, SS; Diffley, JM; Potter, DW; Lusis, AJ; Attie, AD; Davis, RA			Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT CONGENIC STRAINS; UP-REGULATED PROTEIN-1; GENE-EXPRESSION; COMBINED HYPERLIPIDEMIA; MESSENGER-RNA; SELECTIVE DEFICIENCY; ADIPOSE-TISSUE; RAT-LIVER; DISULFIDE; GLUTATHIONE	Thioredoxin-interacting protein (Txnip) is a ubiquitous protein that binds with high affinity to thioredoxin and inhibits its ability to reduce sulfhydryl groups via NADPH oxidation. HcB-19 mice contain a nonsense mutation in Txnip that eliminates its expression. Unlike normal animals, HcB-19 mice have similar to3-fold increase in insulin levels when fasted. The C-peptide/insulin ratio is normal, suggesting that the hyperinsulinemia is due to increased insulin secretion. Fasted HcB-19 mice are hypoglycemic, hypertriglyceridemic, and have higher than normal levels of ketone bodies. Ablation of pancreatic beta-cells with streptozotocin completely blocks the fasting-induced hypoglycemia/hypertriglyceridemia, suggesting that these abnormalities are due to excess insulin secretion. This is supported by increased hepatic mRNA levels of the insulin-inducible, lipogenic transcription factor sterol-responsive element-binding protein-1c and two of its targets, acetyl-CoA carboxylase and fatty acid synthase. During a prolonged fast, the hyperinsulinemia up-regulates lipogenesis but fails to down-regulate hepatic phosphoenolpyruvate carboxykinase mRNA expression. Hepatic ratios of reduced: oxidized glutathione, established regulators of gluconeogenic/glycolytic/lipogenic enzymes, were elevated 30% in HcB-19 mice, suggesting a loss of Txnip-enhanced sulfhydryl reduction. The altered hepatic enzymatic profiles of HcB-19 mice divert phosphoenolpyruvate to glyceroneogenesis and lipogenesis rather than gluconeogenesis. Our findings implicate Txnip-modulated sulfhydryl redox as a central regulator of insulin secretion in beta-cells and regulation of many of the branch-points of gluconeogenesis/glycolysis/lipogenesis.	San Diego State Univ, Mammalian Cell & Mol Biol Lab, Dept Biol, Inst Mol Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med Microbiol & Human Genet, Los Angeles, CA 90095 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	California State University System; San Diego State University; California State University System; San Diego State University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Wisconsin System; University of Wisconsin Madison	Davis, RA (corresponding author), San Diego State Univ, Mammalian Cell & Mol Biol Lab, Dept Biol, Inst Mol Biol, Life Sci Bldg LS307,5500 Campanile Dr, San Diego, CA 92182 USA.	rdavis@sunstroke.sdsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051648] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51648] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; BRUNZELL JD, 1983, J LIPID RES, V24, P147; Castellani LW, 1998, NAT GENET, V18, P374, DOI 10.1038/ng0498-374; Cho YW, 2002, MOL CELLS, V13, P315; Chou Janice Yang, 2001, Current Molecular Medicine (Hilversum), V1, P25; CLARK MG, 1974, J BIOL CHEM, V249, P279; COTTAM GL, 1969, BIOCHEM BIOPH RES CO, V35, P895, DOI 10.1016/0006-291X(69)90708-6; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; Follmann H, 1995, BIOFACTORS, V5, P147; GAJA G, 1968, BIOCHEM J, V109, P867, DOI 10.1042/bj1090867; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HAWKINS RA, 1995, J INHERIT METAB DIS, V18, P558, DOI 10.1007/BF02436000; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hotta M, 1998, J EXP MED, V188, P1445, DOI 10.1084/jem.188.8.1445; ISAACS J, 1977, BIOCHIM BIOPHYS ACTA, V497, P192, DOI 10.1016/0304-4165(77)90152-0; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Jamdar SC, 1998, BBA-LIPID LIPID MET, V1393, P41, DOI 10.1016/S0005-2760(98)00055-1; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; MORRIS MD, 1972, J LIPID RES, V13, P383; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nishiyama A, 2001, IUBMB LIFE, V52, P29, DOI 10.1080/15216540252774739; OSTERLUND BR, 1980, ARCH BIOCHEM BIOPHYS, V205, P489, DOI 10.1016/0003-9861(80)90131-9; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; PONTREMOLI S, 1965, ARCH BIOCHEM BIOPHYS, V112, P7, DOI 10.1016/0003-9861(65)90003-2; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; REYES A, 1987, J BIOL CHEM, V262, P8451; Ron D, 2002, J CLIN INVEST, V109, P443, DOI 10.1172/JC1200215020; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Shalev A, 2002, ENDOCRINOLOGY, V143, P3695, DOI 10.1210/en.2002-220564; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Siri P, 2001, J BIOL CHEM, V276, P46064, DOI 10.1074/jbc.M108909200; SPIEGELMAN BM, 1981, CELL, V24, P503, DOI 10.1016/0092-8674(81)90341-X; STEINBERG D, 1961, J BIOL CHEM, V236, P1631; TALJEDAL IB, 1981, DIABETOLOGIA, V21, P1; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; Winiarska K, 2003, METABOLISM, V52, P739, DOI 10.1016/S0026-0495(03)00035-0; Wu CD, 2001, J CLIN INVEST, V107, P91, DOI 10.1172/JCI11103; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598	57	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24387	24393		10.1074/jbc.M401280200	http://dx.doi.org/10.1074/jbc.M401280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047687	hybrid			2022-12-25	WOS:000221702500064
J	Vanni, C; Parodi, A; Mancini, P; Visco, V; Ottaviano, C; Torrisi, MR; Eva, A				Vanni, C; Parodi, A; Mancini, P; Visco, V; Ottaviano, C; Torrisi, MR; Eva, A			Phosphorylation-independent membrane relocalization of ezrin following association with Dbl in vivo	ONCOGENE			English	Article						ERM; Dbl oncogene; PH domain	F-ACTIN BINDING; EZRIN/RADIXIN/MOESIN ERM PROTEINS; RHO-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; THREONINE 558; PROTO-DBL; DOMAIN; SITE; MOESIN; ACTIVATION	Ezrin, a widespread protein involved in cell migration, morphogenesis and cell adhesion, belongs to a large family of proteins known as ERM ( ezrin, radixin, moesin). These three closely related proteins are thought to function as linkers between plasma membrane and actin cytoskeleton and their function is regulated by the small GTP-binding protein Rho. It has been previously shown that the active form of radixin can bind in vitro to Dbl, a Rho-specific guanine nucleotide exchange factor, although an in vivo interaction has not yet been demonstrated. In this paper, we attempted to investigate whether ezrin can also associate with Dbl. We show here that Dbl protein can effectively bind both in vitro and in vivo to the N-terminal region ( amino acids 1 - 531) of a constitutively active mutant of ezrin and with the full-length molecule. We found that this binding is mediated by the Dbl pleckstrin homology domain, responsible for the proper subcellular localization of the Dbl protein. Moreover, we show that Dbl induces localization to the plasma membrane of both the active deletion mutant and the full-length ezrin proteins. Finally, we show that the relocalization of ezrin is independent of Dbl GEF activity. These results indicate that Dbl could induce translocation of ezrin to the plasma membrane through a mechanism that does not require ezrin C-terminus phosphorylation by Rho-associated kinases.	Ist Giannina Gaslini, Mol Biol Lab, I-16147 Genoa, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome	Eva, A (corresponding author), Ist Giannina Gaslini, Mol Biol Lab, Largo G Gaslini 5, I-16147 Genoa, Italy.	alessandraeva@ospedale-gaslini.ge.it	Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; mancini, patrizia/0000-0003-0556-2056				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; HART MJ, 1994, J BIOL CHEM, V269, P62; Hayashi K, 1999, J CELL SCI, V112, P1149; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; Niggli V, 2001, TRENDS BIOCHEM SCI, V26, P604, DOI 10.1016/S0968-0004(01)01927-2; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; RON D, 1991, NEW BIOL, V3, P372; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VAN AL, 1997, GENE DEV, V11, P2295; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Yonemura S, 2002, J CELL SCI, V115, P2569; ZANGRILLI D, 1995, CELL TRANSFORMATION, P347; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	34	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4098	4106		10.1038/sj.onc.1207509	http://dx.doi.org/10.1038/sj.onc.1207509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064738				2022-12-25	WOS:000221520200008
J	Bao, BY; Hu, YC; Ting, HJ; Lee, YF				Bao, BY; Hu, YC; Ting, HJ; Lee, YF			Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells	ONCOGENE			English	Article						vitamin D; androgen; androgen receptor; prostate cancer	9-CIS RETINOIC ACID; D-RECEPTOR EXPRESSION; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; GENE-EXPRESSION; CDK INHIBITOR; LINE LNCAP; D ANALOGS; P21 GENE; DIFFERENTIATION	Epidemiological data on prostate cancer incidence has suggested that vitamin D deficiency may be a risk factor for prostate cancer. The antiproliferative activity of 1alpha, 25-dihydroxyvitamin D-3 (1,25-VD) and its analogues has been demonstrated in many prostate cancer models, yet the detailed mechanisms underlying this protective effect of vitamin D remain to be determined. Here, we demonstrate that two androgen receptor (AR)-positive prostate cancer cell lines, LNCaP and CWR22R, are more sensitive to the growth inhibitory effects of 1,25-VD compared to the AR-negative prostate cancer cell lines, PC-3 and DU 145. 1,25-VD treatment inhibited cyclin-dependent kinase 2 (cdk2) activity and induced G0/G1 arrest. Interestingly, we also found that 1,25-VD treatment induced the expression of AR, and that the onset of the G0/G1 arrest in LNCaP and CWR22R cells is correlated with the onset of increasing expression of AR. This implies that the antiproliferative actions of 1,25-VD in AR-positive prostate cancer might be mediated through AR. Furthermore, a reduction in 1,25-VD-mediated growth inhibition was observed when AR signaling was blocked by antiandrogens, AR RNA interference, or targeted disruption of AR. Taken together, our data suggest that the androgen/AR signaling plays an important role in the antiproliferative effects of 1,25-VD and restoration of androgen responsiveness by 1,25-VD might be beneficial for the treatment of hormone-refractory prostate cancer patients.	Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Chem Engn, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Lee, YF (corresponding author), Univ Rochester, Dept Urol, Rochester, NY 14642 USA.	yifen_lee@urmc.rochester.edu	Bao, Bo-Ying/D-1789-2012; Hu, Yueh-Chiang/AAX-2370-2020; Bao, Bo-Ying/H-4589-2019	Bao, Bo-Ying/0000-0001-5510-6513; Bao, Bo-Ying/0000-0001-5510-6513; Hu, Yueh-Chiang/0000-0002-7992-0525; Ting, Huei-Ju/0000-0003-3709-5755				BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Chlenski A, 2001, PROSTATE, V47, P66; Chu YW, 1999, CYTOMETRY, V36, P333, DOI 10.1002/(SICI)1097-0320(19990801)36:4<333::AID-CYTO8>3.0.CO;2-F; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; Esquenet M, 1996, PROSTATE, V28, P182, DOI 10.1002/(SICI)1097-0045(199603)28:3<182::AID-PROS5>3.0.CO;2-H; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hedlund TE, 1996, J STEROID BIOCHEM, V58, P277, DOI 10.1016/0960-0760(96)00030-1; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; Hofman K, 2001, BIOCHEM BIOPH RES CO, V283, P97, DOI 10.1006/bbrc.2001.4738; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; MACDONALD PN, 1994, SEMIN NEPHROL, V14, P101; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MILLER GJ, 1992, CANCER RES, V52, P515; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Munker R, 1996, BLOOD, V88, P2201, DOI 10.1182/blood.V88.6.2201.bloodjournal8862201; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Myers RB, 1999, INT J CANCER, V82, P424, DOI 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B; PEEHL DM, 1994, CANCER RES, V54, P805; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307; SCHWARTZ GG, 1994, ANTICANCER RES, V14, P1077; SKOWRONSKI RJ, 1993, ENDOCRINOLOGY, V132, P1952, DOI 10.1210/en.132.5.1952; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhao XY, 2000, ENDOCRINOLOGY, V141, P2548, DOI 10.1210/en.141.7.2548; Zhao XY, 1997, ENDOCRINOLOGY, V138, P3290, DOI 10.1210/en.138.8.3290; Zhao XY, 1999, ENDOCRINOLOGY, V140, P1205, DOI 10.1210/en.140.3.1205; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3	44	52	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3350	3360		10.1038/sj.onc.1207461	http://dx.doi.org/10.1038/sj.onc.1207461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15048085				2022-12-25	WOS:000220975000009
J	Yokota, N; Mainprize, TG; Taylor, MD; Kohata, T; Loreto, M; Ueda, S; Dura, W; Grajkowska, W; Kuo, JS; Rutka, JT				Yokota, N; Mainprize, TG; Taylor, MD; Kohata, T; Loreto, M; Ueda, S; Dura, W; Grajkowska, W; Kuo, JS; Rutka, JT			Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization	ONCOGENE			English	Article						medulloblastoma; developmentally regulated gene; differentially expressed gene; subtractive suppression hybridization; cerebellum; external granule cell	PRIMITIVE NEUROECTODERMAL TUMORS; POLYMERASE-CHAIN-REACTION; RNA-BINDING PROTEIN; NERVOUS-SYSTEM; HOMEOBOX GENES; AXONAL GUIDANCE; MESSENGER-RNA; CELL FATE; BRAIN; RECEPTORS	To increase our understanding of the molecular pathogenesis of medulloblastoma (MB), we utilized the technique of suppression subtractive hybridization (SSH) to identify genes that are dysregulated in MB when compared to cerebellum. SSH-enriched cDNA libraries from both human and Ptch(+/-) heterozygous murine MBs were generated by subtracting common cDNAs from corresponding non-neoplastic cerebellum. For the human classic MB library, total human cerebellar RNA was used as control tissue; for the Ptch(+/-) heterozygous MB, non-neoplastic cerebellum from an unaffected Ptch(+/-) littermate was used as the control. Through differential screening of these libraries, over 100 upregulated tumor cDNA fragments were isolated, sequenced and identified with the NCBI BLAST program. From these, we selected genes involved in cellular proliferation, antiapoptosis, and cerebellar differentiation for further analysis. Upregulated genes identified in the human MB library included Unc33-like protein (ULIP), SOX4, Neuronatin (NNAT), the mammalian homologue of Drosophila BarH-like 1(BARHL1), the nuclear matix protein NRP/B (ENC1), and the homeobox OTX2 gene. Genes found to be upregulated in the murine MB library included cyclin D2 (Ccnd2), thymopoietin (Tmpo), Musashi-1 (Msh1), protein phosphatase 2A inhibitor-2 (I-2pp2a), and Unc5h4(D). Using semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), the mRNA expression levels for these genes were markedly higher in human MBs than in cerebellum. Western blot analysis was used to further confirm the overexpression of a subset of these genes at the protein level. Notch pathway overactivity was demonstrated in the TE671 MB cell line expressing high levels of MSH1 through HES1-Luciferase transfections. This study has revealed a panel of developmentally regulated genes that may be involved in the pathogenesis of MB.	Univ Toronto, Arthur Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada; Univ Toronto, Div Neurosurg, Toronto, ON, Canada; Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 43131, Japan; Univ Warsaw, Dept Pathol, Warsaw, Poland	University of Toronto; University of Toronto; Hamamatsu University School of Medicine; University of Warsaw	Rutka, JT (corresponding author), Hosp Sick Children, Div Neurosurg, Suite 1502,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.rutka@sickkids.ca	Kuo, John S/D-3561-2013	Kuo, John S/0000-0001-6809-4806; Taylor, Michael/0000-0001-7009-3466; Grajkowska, Wieslawa/0000-0001-8318-5781				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; BONCINELLI E, 1993, J NEUROBIOL, V24, P1356, DOI 10.1002/neu.480241008; Buhren J, 2000, J NEUROPATH EXP NEUR, V59, P229; Bulfone A, 2000, HUM MOL GENET, V9, P1443, DOI 10.1093/hmg/9.9.1443; Byk T, 1996, J NEUROSCI, V16, P688; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FRANTZ GD, 1994, J NEUROSCI, V14, P5725; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Ji W, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-12; Kanemura Y, 2001, DIFFERENTIATION, V68, P141, DOI 10.1046/j.1432-0436.2001.680208.x; KOZMIK Z, 1995, P NATL ACAD SCI USA, V92, P5709, DOI 10.1073/pnas.92.12.5709; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Lee CJ, 2002, J NEURO-ONCOL, V57, P201, DOI 10.1023/A:1015773818302; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LI W, 1992, GENETICS, V132, P675; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Michiels EMC, 1999, PHYSIOL GENOMICS, V1, P83, DOI 10.1152/physiolgenomics.1999.1.2.83; Okano H, 2002, J CELL SCI, V115, P1355; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ross ME, 1996, J NEUROSCI, V16, P210; Rostomily RC, 1997, CANCER RES, V57, P3526; Rubin JB, 2002, CANCER CELL, V2, P7, DOI 10.1016/S1535-6108(02)00090-9; Saito T, 1998, DEV BIOL, V199, P216, DOI 10.1006/dbio.1998.8889; Sambrook J., 1989, MOL CLONING; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Taylor MD, 2000, NEUROSURGERY, V47, P888, DOI 10.1097/00006123-200010000-00020; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Vincent S, 1996, INT J ONCOL, V8, P901; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang LH, 1996, J NEUROSCI, V16, P6197; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wetmore C, 2001, CANCER RES, V61, P513; Yokota N, 1996, CANCER RES, V56, P377; Yokota N, 2002, INT J CANCER, V101, P198, DOI 10.1002/ijc.10559; Yokota N, 2001, STROKE, V32, P168, DOI 10.1161/01.STR.32.1.168; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200	50	126	133	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	2004	23	19					3444	3453		10.1038/sj.onc.1207475	http://dx.doi.org/10.1038/sj.onc.1207475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064731				2022-12-25	WOS:000220975000019
J	De Wever, O; Nguyen, QD; Van Hoorde, L; Bracke, M; Bruyneel, E; Gespach, C; Mareel, M				De Wever, O; Nguyen, QD; Van Hoorde, L; Bracke, M; Bruyneel, E; Gespach, C; Mareel, M			Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac	FASEB JOURNAL			English	Article						fibroblast; transdifferentiation; collagen	HEPATOCYTE GROWTH-FACTOR; SMOOTH MUSCLE ACTIN; EPITHELIAL-CELLS; INVASIVE GROWTH; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; COLORECTAL-CARCINOMA; MET PROTOONCOGENE; CELLULAR INVASION	Myofibroblasts are present at the invasion front in colon cancer. In an attempt to understand their putative proinvasive activity, we have developed an in vitro model. Myofibroblasts isolated from colon cancer tissue or obtained through transdifferentiation of colon fibroblasts by transforming growth factor (TGF)-beta stimulate invasion of colon cancer cells into collagen type I and Matrigel. We identified two convergent proinvasive agents secreted by myofibroblasts: namely scatter factor/hepatocyte growth factor (SF/HGF) and the TGF-beta-upregulated extracellular matrix glycoprotein tenascin-C (TNC), each of which is necessary though not sufficient for invasion. Myofibroblast-stimulated invasion into collagen type I is characterized by a change from a round, nonmigratory morphotype with high RhoA and low Rac activity to an elongated, migratory morphotype with low RhoA and high Rac activity. RhoA inactivation is determined by the epidermal growth factor (EGF)-like repeats of TNC through EGF-receptor signaling that confers a permissive and priming signal for the proinvasive activity of SF/HGF that activates Rac via c-Met. We confirmed the validity of this mechanism by using pharmacological modulators and dominant negative or constitutive active mutants that interfere with RhoA-Rho kinase and Rac signaling. Our in vitro results point to a new putative proinvasive signal for colon cancer cells provided by myofibroblasts in the tumor stroma.	State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Ghent University; Ghent University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mareel, M (corresponding author), State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	marc.mareel@UGent.be	de wever, olivier/J-3094-2013	de wever, olivier/0000-0002-5453-760X				Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; Bracke M E, 2001, Methods Mol Med, V58, P81, DOI 10.1385/1-59259-137-X:081; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; Dueck M, 1999, INT J CANCER, V82, P477, DOI 10.1002/(SICI)1097-0215(19990812)82:4<477::AID-IJC2>3.0.CO;2-5; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fukuura T, 1998, BRIT J CANCER, V78, P454, DOI 10.1038/bjc.1998.514; HAZAN RB, 1997, CELL ADHES COMMUN, V4, P399; Herold-Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233; Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; LIU C, 1992, ONCOGENE, V7, P181; M D, 2001, Methods Mol Med, V58, P61, DOI 10.1385/1-59259-137-X:061; Matsuda A, 1999, INVEST OPHTH VIS SCI, V40, P1071; MIURA S, 1993, J SURG ONCOL, V53, P36, DOI 10.1002/jso.2930530111; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nakayama H, 1998, JPN J CLIN ONCOL, V28, P615, DOI 10.1093/jjco/28.10.615; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oliveira MJ, 2003, EMBO J, V22, P6161, DOI 10.1093/emboj/cdg586; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; Parr C, 2000, INT J CANCER, V85, P563, DOI 10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.0.CO;2-D; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Qian LW, 2003, CANCER LETT, V190, P105, DOI 10.1016/S0304-3835(02)00517-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIEDL SE, 1992, GASTROENTEROLOGY, V103, P400, DOI 10.1016/0016-5085(92)90827-L; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Van Hoorde L, 1999, CELL ADHES COMMUN, V7, P139, DOI 10.3109/15419069909034397; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376	54	299	306	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1016	+		10.1096/fj.03-1110fje	http://dx.doi.org/10.1096/fj.03-1110fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059978				2022-12-25	WOS:000221108800029
J	Passeron, T; Bahadoran, P; Bertolotto, C; Chiaverini, C; Busca, R; Valony, G; Bille, K; Ortonne, JP; Ballotti, R				Passeron, T; Bahadoran, P; Bertolotto, C; Chiaverini, C; Busca, R; Valony, G; Bille, K; Ortonne, JP; Ballotti, R			Cyclic AMP promotes a peripheral distribution of melanosomes and stimulates melanophilin/Slac2-a and actin association	FASEB JOURNAL			English	Article						melanocytes; alpha-melanocyte stimulating hormone	MELANOMA-CELL DIFFERENTIATION; MYOSIN-VA; GRISCELLI-SYNDROME; HUMAN MELANOCYTES; CRITICAL DETERMINANT; ORGANELLE TRANSPORT; MOLECULAR MOTORS; BINDING DOMAIN; LINKS RAB27A; WILD-TYPE	Melanosomes are melanin-containing organelles that belong to a recently individualized group of lysosome-related organelles. Recently, numerous reports have dissected the molecular mechanisms that control melanosome transport, but nothing was known about the possible regulation of melanosome distribution by exogenous physiological stimulus. In the present report, we demonstrate that a physiological melanocyte-differentiating agent such as alpha-melanocyte-stimulating hormone, through the stimulation of the cAMP pathway, induces a rapid centrifugal transport of melanosomes, leading to their accumulation at the dendrite tips of melanocytes. Interestingly, the small GTP binding proteins of the p21Rho family and one of their effectors, p160 Rho-associated kinase, but not PKA, play a key role in redistribution of melanosomes at the extremities of the dendrites. Further, we have investigated, at the molecular level, the effect of cAMP on the different proteins involved in the control of melanosome transport. We demonstrate that cAMP stimulates the expression of Rab27a and rapidly increases the interaction of the melanophilin/Slac2-a with actin. Thus, we propose that the stimulation of the interaction between melanophilin/Slac2-a and actin would allow the rapid accumulation of melanosomes in the actin-rich region of the dendrite extremities.	Fac Med Nice, INSERM, U597, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med Nice, INSERM, U597, Ave Valombrose, F-06107 Nice 2, France.	ballotti@unice.fr	Bertolotto-Ballotti, Corine/O-2155-2016; Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013	Bertolotto, Corine/0000-0001-6971-7753; Bahadoran, Philippe/0000-0002-2481-0556; Passeron, Thierry/0000-0002-0797-6570; BALLOTTI, Robert/0000-0002-7322-4908				Al-Haddad AH, 2001, MOL BIOL CELL, V12, P2742, DOI 10.1091/mbc.12.9.2742; Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Baron CL, 2001, J CELL SCI, V114, P999; Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Byers HR, 2000, J INVEST DERMATOL, V114, P990, DOI 10.1046/j.1523-1747.2000.00957.x; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Griffiths G M, 1995, Curr Top Microbiol Immunol, V198, P39; Gross SP, 2002, J CELL BIOL, V156, P855, DOI 10.1083/jcb.200105055; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JIMBOW K, 1975, J CELL BIOL, V65, P481, DOI 10.1083/jcb.65.2.481; JIMENEZCERVANTES C, 1994, PIGM CELL RES, V7, P291, DOI 10.1111/j.1600-0749.1994.tb00630.x; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Kuwahara K, 1999, FEBS LETT, V452, P314, DOI 10.1016/S0014-5793(99)00680-8; Lambert J, 1999, CELL MOL BIOL, V45, P905; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, J CLIN INVEST, V112, P450, DOI 10.1172/JCI200318264; Miyashita Y, 1996, J EXP ZOOL, V276, P125, DOI 10.1002/(SICI)1097-010X(19961001)276:2<125::AID-JEZ5>3.0.CO;2-Q; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Nascimento AAC, 1997, MOL BIOL CELL, V8, P1971, DOI 10.1091/mbc.8.10.1971; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Reilein AR, 1998, J CELL BIOL, V142, P803, DOI 10.1083/jcb.142.3.803; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SAMMAK PJ, 1992, J CELL BIOL, V117, P57, DOI 10.1083/jcb.117.1.57; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Shukla A, 2000, RESP MED, V94, P10, DOI 10.1053/rmed.1999.0700; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; WIKSWO MA, 1973, YALE J BIOL MED, V46, P592; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	54	39	42	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					989	+		10.1096/fj.03-1240fje	http://dx.doi.org/10.1096/fj.03-1240fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059972				2022-12-25	WOS:000221108800023
J	Broemer, M; Krappmann, D; Scheidereit, C				Broemer, M; Krappmann, D; Scheidereit, C			Requirement of Hsp90 activity for I kappa B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappa B activation	ONCOGENE			English	Article						ubiquitin; chaperones; proteasome; ribosome; Reed-Sternberg cells; tumor cell pharmacology	DEATH DOMAIN KINASE; RIP; INHIBITION; ALPHA; LYMPHOTOXIN; RECRUITMENT; RECEPTOR; EXPRESSION; ARSENITE; CELLS	The molecular chaperone Hsp90 affects the function and fate of a number of signaling molecules. We have investigated the Hsp90 requirement for constitutive and inducible activity of the IkappaB kinase (IKK) complex and of NF-kappaB. Inhibition by the Hsp90 ATPase inhibitors, geldanamycin (GA) and radicicol ( RC), revealed that Hsp90 controls IKKs at two levels, inducibility of enzymatic activity and biogenesis, which can be discriminated by short- and long-time GA incubation, respectively. Short-time inhibition of Hsp90 resulted in impaired IKK kinase activation by TNFalpha, IL-1beta or phorbolester PMA. Furthermore, GA inhibited constitutive activation of IKK and NF-kappaB in Hodgkin's lymphoma cells. Hsp90 function was also required for trans- and autophosphorylation of transfected IKKbeta. GA exposure for several hours resulted in a downmodulation of IKK complex alpha, beta and gamma subunits to various extent. Proteasome inhibition interfered with GA mediated IKK depletion and Hsp90 inhibition induced polyubiquitination of IKKalpha and beta during protein synthesis. In fact, GA blocked biogenesis of IKKalpha and IKKbeta but did not interfere with post-translational turnover. Together, these results define a dual requirement for Hsp90 as a regulator of NF-kappaB signaling by its general involvement in IKK activation and by its role in IKK homeostasis.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Free Univ Berlin, Fac Biol Chem & Pharm, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	scheidereit@mdc-berlin.de	Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234				BASSO AD, 2002, J BIOL CHEM, V9, P9; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chakravortty D, 2001, J IMMUNOL, V166, P2011, DOI 10.4049/jimmunol.166.3.2011; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Fisher DL, 2000, EMBO J, V19, P1516, DOI 10.1093/emboj/19.7.1516; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sugita T, 1999, BIOCHEM MOL BIOL INT, V47, P587; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yorgin PD, 2000, J IMMUNOL, V164, P2915, DOI 10.4049/jimmunol.164.6.2915; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	38	181	187	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5378	5386		10.1038/sj.onc.1207705	http://dx.doi.org/10.1038/sj.onc.1207705			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15077173				2022-12-25	WOS:000222491600013
J	Diaz, BG; Moldoveanu, T; Kuiper, MJ; Campbell, RL; Davies, PL				Diaz, BG; Moldoveanu, T; Kuiper, MJ; Campbell, RL; Davies, PL			Insertion sequence 1 of muscle-specific calpain, p94, acts as an internal propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; TERMINAL PRO-SEQUENCE; EXTRACELLULAR SECRETION; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; MESSENGER-RNA; LP82 CALPAIN; AQUALYSIN-I; RAT LENS; PROTEIN	The physiological role of the skeletal muscle-specific calpain 3, p94, is presently unknown, but defects in its gene cause limb girdle muscular dystrophy type 2A. This calcium-dependent cysteine protease resembles the large subunit of m-calpain but with three unique additional sequences: an N-terminal region (NS), and two insertions (IS1 and IS2). The latter two insertions have been linked to the chronic instability of the whole enzyme both in vivo and in vitro. We have shown previously that the core of p94 comprising NS, domains I and II, and IS1 is stable as a recombinant protein in the absence of Ca2+ and undergoes autolysis in its presence. Here we show that p94I-II cannot hydrolyze an exogenous substrate before autolysis but is increasingly able to do so when autolysis proceeds for several hours. This gain in activity is caused by cleavage of IS1 during autolysis because a deletion mutant lacking the NS region (p94I-II DeltaNS) shows the same activation profile. Similarly, the calpain inhibitors E-64 and leupeptin have almost no inhibitory effect on substrate hydrolysis by p94I-II soon after calcium addition but cause complete inhibition when autolysis progresses for several hours. As autolysis proceeds, there is release of the internal IS1 peptide, but the two portions of the core remain tightly associated. Modeling of p94I-II suggests that IS1 contains an amphipathic alpha-helix flanked by extended loops. The latter are the targets of autolysis and limited digestion by exogenous proteases. The presence and location of the alpha-helix in recombinant IS1 were confirmed by circular dichroism and by the introduction of a L286P helix-disrupting mutation. Within p94I-II, L286P caused premature autoproteolysis of the enzyme. IS1 is an elaboration of a loop in domain II near the active site, and it acts as an internal autoinhibitory propeptide, blocking the active site of p94 from substrates and inhibitors.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Prot Engn Network Centres Excellence, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca	Moldoveanu, Tudor/N-8173-2018	Moldoveanu, Tudor/0000-0003-0791-318X; Campbell, Robert/0000-0002-5473-5876				Azuma M, 2000, CURR EYE RES, V21, P710, DOI 10.1076/0271-3683(200009)21:3;1-R;FT710; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Branca D, 1999, EUR J BIOCHEM, V265, P839, DOI 10.1046/j.1432-1327.1999.00817.x; De Tullio R, 2003, BIOCHEM J, V375, P689, DOI 10.1042/BJ20030706; Farkas A, 2003, BIOL CHEM, V384, P945, DOI 10.1515/BC.2003.106; Federici C, 1999, ARCH BIOCHEM BIOPHYS, V363, P237, DOI 10.1006/abbi.1998.1091; Fukiage C, 2002, J BIOL CHEM, V277, P20678, DOI 10.1074/jbc.M200697200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Herasse M, 1999, MOL CELL BIOL, V19, P4047; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Jia ZC, 2001, BIOPHYS J, V80, P2590, DOI 10.1016/S0006-3495(01)76229-7; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Khan AR, 1998, PROTEIN SCI, V7, P815; Kinbara K, 1998, BIOCHEM J, V335, P589, DOI 10.1042/bj3350589; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kuroyanagi M, 2002, PLANT CELL PHYSIOL, V43, P143, DOI 10.1093/pcp/pcf035; Lazure C, 2002, CURR PHARM DESIGN, V8, P511, DOI 10.2174/1381612023395691; LEE YC, 1994, FEMS MICROBIOL LETT, V120, P69; Lee YC, 1996, ADV EXP MED BIOL, V379, P155; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; Ma H, 1998, EXP EYE RES, V67, P221, DOI 10.1006/exer.1998.0515; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Ma H, 2000, INVEST OPHTH VIS SCI, V41, P4232; Mikolajczyk J, 2003, J BIOL CHEM, V278, P10458, DOI 10.1074/jbc.M210564200; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Nakajima T, 2001, BBA-GENE STRUCT EXPR, V1519, P55, DOI 10.1016/S0167-4781(01)00212-3; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; OHNISHI Y, 1994, J BIOL CHEM, V269, P32800; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Rey MA, 2002, FEBS LETT, V532, P401, DOI 10.1016/S0014-5793(02)03722-5; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Rost B, 1997, PROTEINS, P192; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Todd B, 2003, J MOL BIOL, V328, P131, DOI 10.1016/S0022-2836(03)00274-2; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279	43	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27656	27666		10.1074/jbc.M313290200	http://dx.doi.org/10.1074/jbc.M313290200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073171	hybrid			2022-12-25	WOS:000222120400100
J	Reid, JD; Hunter, CN				Reid, JD; Hunter, CN			Magnesium-dependent ATPase activity and cooperativity of magnesium chelatase from Synechocystis sp PCC6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOPORPHYRIN IX CHELATASE; MG-CHELATASE; RHODOBACTER-SPHAEROIDES; ESCHERICHIA-COLI; H-SUBUNIT; ENZYME; GENES; HYDROLYSIS; CHLI; BCHI	The first committed step in chlorophyll biosynthesis is catalyzed by magnesium chelatase, a complex enzyme with at least three substrates, cooperative Mg2+ activation, and free energy coupling between ATP hydrolysis and metal-ion chelation. A detailed functional study of the behavior of the intact magnesium chelatase has been performed, including characterization of magnesium cooperativity and the stoichiometry of ATP consumption in relation to the magnesium porphyrin produced. It is demonstrated that, in vitro, this catalyzed reaction requires hydrolysis of similar to15 MgATP(2-) and that the chelation partial reaction is energetically unfavorable, under our assay conditions, with a DeltaGdegrees' of 25-33 kJ mol(-1). Given the likely metabolite concentrations in vivo, this results in the chelatase reaction operating far from equilibrium. We have also determined the steady-state kinetic behavior of the intact enzyme and have compared the kinetic parameters obtained with those observed for the partial reactions of individual subunits. K-DIX (where D-IX represents deuteroporphyrin IX) is estimated to be 3.20 muM, and K-MgATP(2-) is 0.45 mM. k(cat) for chelation is estimated to be 0.8 min(-1), suggesting that the ATP hydrolysis catalyzed by the isolated ChlI subunit is substantially slower in the intact chelatase. The magnesium-rich form of the chelatase is a more effective catalyst of the chelation reaction; magnesium activation of the chelatase increases V, as well as the specificity constant for the reaction of MgATP(2-) and D-IX, possibly as a result of a magnesium-triggered conformational change.	Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Hunter, CN (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	c.n.hunter@sheffield.ac.uk		Reid, James/0000-0003-4921-1047				Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Fodje MN, 2001, J MOL BIOL, V311, P111, DOI 10.1006/jmbi.2001.4834; Gibson LCD, 1999, BIOCHEM J, V337, P243, DOI 10.1042/0264-6021:3370243; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Guo RB, 1998, PLANT PHYSIOL, V116, P605, DOI 10.1104/pp.116.2.605; GURANOWSKI A, 1994, BIOCHEMISTRY-US, V33, P235, DOI 10.1021/bi00167a031; Hansson A, 2002, P NATL ACAD SCI USA, V99, P13944, DOI 10.1073/pnas.212504499; Hartman JJ, 1999, SCIENCE, V286, P782, DOI 10.1126/science.286.5440.782; Ishijima S, 2003, ARCH BIOCHEM BIOPHYS, V412, P126, DOI 10.1016/S0003-9861(03)00038-9; Jensen PE, 1999, BIOCHEM J, V339, P127, DOI 10.1042/0264-6021:3390127; Jensen PE, 1998, BIOCHEM J, V334, P335, DOI 10.1042/bj3340335; Jensen PE, 1996, J BIOL CHEM, V271, P16662, DOI 10.1074/jbc.271.28.16662; Jensen PE, 1996, MOL GEN GENET, V250, P383; Karger GA, 2001, BIOCHEMISTRY-US, V40, P9291, DOI 10.1021/bi010562a; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; LEEGOOD RC, 1985, PHOTOSYNTHETIC MECH; Meehan L, 1996, PLANT PHYSIOL, V112, P953, DOI 10.1104/pp.112.3.953; Mochizuki N, 2001, P NATL ACAD SCI USA, V98, P2053, DOI 10.1073/pnas.98.4.2053; Morrison J F, 1979, Methods Enzymol, V63, P257; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; Papenbrock J, 1997, PLANT J, V12, P981, DOI 10.1046/j.1365-313X.1997.12050981.x; PURICH DL, 1972, BIOCHEM J, V130, P63, DOI 10.1042/bj1300063; Reid JD, 2003, BIOCHEMISTRY-US, V42, P6912, DOI 10.1021/bi034082q; Reid JD, 2002, BIOCHEM SOC T, V30, P643, DOI 10.1042/bst0300643; SWEENY JR, 1968, BIOCHEMISTRY-US, V7, P561, DOI 10.1021/bi00842a008; THORNELEY RNF, 1992, PHILOS T R SOC B, V336, P73, DOI 10.1098/rstb.1992.0046; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; VIOLA RE, 1982, METHOD ENZYMOL, V87, P353; Walker CJ, 1997, BIOCHEM J, V327, P321; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Willows RD, 1998, J BIOL CHEM, V273, P34206, DOI 10.1074/jbc.273.51.34206; Willows RD, 2003, J BACTERIOL, V185, P3249, DOI 10.1128/JB.185.11.3249-3258.2003; Wong JT, 1975, KINETICS ENZYME MECH; WONG JTF, 1969, ARCH BIOCHEM BIOPHYS, V135, P50, DOI 10.1016/0003-9861(69)90515-3	40	69	75	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26893	26899		10.1074/jbc.M400958200	http://dx.doi.org/10.1074/jbc.M400958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15051720	hybrid			2022-12-25	WOS:000222120400013
J	Edel, MJ; Shvarts, A; Medema, JP; Bernards, R				Edel, MJ; Shvarts, A; Medema, JP; Bernards, R			An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression	ONCOGENE			English	Article						functional screen; tumor progression; cancer; transformation	COILED-COIL DOMAIN; C-MYC; CANCER; CELLS; EXPRESSION; ACTIVATION; IMMUNITY; PRODUCT; RAS	Over the past decades, much has been learnt about the genes that contribute to oncogenic transformation of primary cells in vitro. However, much less is known about the genes that contribute to the later stages of tumor progression, in which cells of ever increasing malignancy arise through clonal selection in vivo. To search for genes that confer a tumor progression phenotype in vivo, we have used a functional genetic approach. We used adenovirus-transformed mouse embryo fibroblasts, which are tumorigenic in immunodeficient nude mice, but not in immunocompetent mice, due to strong cytotoxic T-cell-mediated immune rejection. We infected these cells in vitro with several high-complexity retroviral cDNA expression libraries and selected rare variants that formed tumors in immunocompetent mice. Using this approach, we identify here the TRK-T3 oncogene as a tumor progression gene. TRK-T3 does not inhibit T-cell reactivity towards the tumor cells. Instead, we find that cells expressing TRK-T3 enhances in vivo growth rate, most likely by stimulating anchorage-independent proliferation in growth factor-limiting conditions. Our data indicate that cDNA expression libraries can be used to identify tumor progression genes in vivo that cannot be readily identified using in vitro cell culture systems.	Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2333 ZA Leiden, Netherlands	Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bernards, R (corresponding author), Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Edel, Michael J/L-1954-2014	Edel, Michael J/0000-0002-5619-8680; Bernards, Rene/0000-0001-8677-3423; Medema, Jan Paul/0000-0003-3045-2924				BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Coulie PG, 2003, CURR OPIN IMMUNOL, V15, P131, DOI 10.1016/S0952-7915(03)00009-8; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Roccato E, 2003, ONCOGENE, V22, P807, DOI 10.1038/sj.onc.1206189; Roccato E, 2002, BRIT J CANCER, V87, P645, DOI 10.1038/sj.bjc.6600544; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Toes REM, 1996, CANCER RES, V56, P3782; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Xu XW, 2003, J CUTAN PATHOL, V30, P318, DOI 10.1034/j.1600-0560.2003.00068.x	24	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4959	4965		10.1038/sj.onc.1207667	http://dx.doi.org/10.1038/sj.onc.1207667			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077169	Green Published			2022-12-25	WOS:000222237300001
J	Kockx, M; Rye, KA; Gaus, K; Quinn, CM; Wright, J; Sloane, T; Sviridov, D; Fu, Y; Sullivan, D; Burnett, JR; Rust, S; Assmann, G; Anantharamaiah, GM; Palgunachari, MN; Katz, SL; Phillips, MC; Dean, RT; Jessup, W; Kritharides, L				Kockx, M; Rye, KA; Gaus, K; Quinn, CM; Wright, J; Sloane, T; Sviridov, D; Fu, Y; Sullivan, D; Burnett, JR; Rust, S; Assmann, G; Anantharamaiah, GM; Palgunachari, MN; Katz, SL; Phillips, MC; Dean, RT; Jessup, W; Kritharides, L			Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER 1; TANGIER-DISEASE; ACYLTRANSFERASE ACTIVATION; CELLULAR CHOLESTEROL; LIPID INTERACTION; BINDING; APOE; ATHEROSCLEROSIS; DEGRADATION	Apolipoprotein A-I (apoA-I)-mediated cholesterol efflux involves the binding of apoA-I to the plasma membrane via its C terminus and requires cellular ATP-binding cassette transporter (ABCA1) activity. ApoA-I also stimulates secretion of apolipoprotein E ( apoE) from macrophage foam cells, although the mechanism of this process is not understood. In this study, we demonstrate that apoA-I stimulates secretion of apoE independently of both ABCA1-mediated cholesterol efflux and of lipid binding by its C terminus. Pulse-chase experiments using S-35-labeled cellular apoE demonstrate that macrophage apoE exists in both relatively mobile ( Em) and stable (E-s) pools, that apoA-I diverts apoE from degradation to secretion, and that only a small proportion of apoA-I-mobilized apoE is derived from the cell surface. The structural requirements for induction of apoE secretion and cholesterol efflux are clearly dissociated, as C-terminal deletions in recombinant apoA-I reduce cholesterol efflux but increase apoE secretion, and deletion of central helices 5 and 6 decreases apoE secretion without perturbing cholesterol efflux. Moreover, a range of 11- and 22-mer alpha-helical peptides representing amphipathic alpha-helical segments of apoA-I stimulate apoE secretion whereas only the C-terminal alpha-helix ( domains 220 - 241) stimulates cholesterol efflux. Other alpha-helix-containing apolipoproteins (apoA-II, apoA-IV, apoE2, apoE3, apoE4) also stimulate apoE secretion, implying a positive feedback autocrine loop for apoE secretion, although apoE4 is less effective. Finally, apoA-I stimulates apoE secretion normally from macrophages of two unrelated subjects with genetically confirmed Tangier Disease ( mutations C733R and c. 5220 - 5222delTCT; and mutations A1046D and c. 4629 - 4630insA), despite severely inhibited cholesterol efflux. We conclude that apoA-I stimulates secretion of apoE independently of cholesterol efflux, and that this represents a novel, ABCA-1-independent, positive feedback pathway for stimulation of potentially anti-atherogenic apoE secretion by alpha-helix-containing molecules including apoA-I and apoE.	Univ New S Wales, Ctr Vasc Res, Macrophage Biol Grp, Sydney, NSW 2052, Australia; Heart Res Inst, Sydney, NSW 2050, Australia; Baker Heart Res Inst, Melbourne, Vic 8008, Australia; Univ Sydney, Royal Prince Alfred Hosp, Dept Clin Biochem, Sydney, NSW 2050, Australia; Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6847, Australia; Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA; Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Canberra, Canberra, ACT 2601, Australia; Univ Sydney, Concord Hosp, Dept Cardiol, Sydney, NSW 2139, Australia	University of New South Wales Sydney; University of Sydney; Heart Research Institute; Baker Heart and Diabetes Institute; University of Sydney; Royal Perth Hospital; University of Western Australia; University of Munster; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Canberra; Concord Repatriation General Hospital; University of Sydney	Kritharides, L (corresponding author), Univ New S Wales, Ctr Vasc Res, Macrophage Biol Grp, 4th Floor Wallace Wurth Bldg, Sydney, NSW 2052, Australia.	l.kritharides@unsw.edu.au	Sviridov, Dmitri/E-7943-2010; Kritharides, Leonard/AAQ-2720-2020	Dean, Roger Thornton/0000-0002-8859-8902; Phillips, Michael/0000-0002-7147-8007; Gaus, Katharina/0000-0002-8009-9658; fu, ying/0000-0002-1261-3336	NHLBI NIH HHS [HL22633, HL34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; Arakawa R, 2000, J LIPID RES, V41, P1952; ASZTALOS BF, 1995, ARTERIOSCL THROM VAS, V15, P1419, DOI 10.1161/01.ATV.15.9.1419; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Bielicki JK, 1999, J LIPID RES, V40, P85; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOYUM A, 1984, METHOD ENZYMOL, V108, P88; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Burgess JW, 2002, J BIOL CHEM, V277, P31318, DOI 10.1074/jbc.M204200200; Burgess JW, 2001, J LIPID RES, V42, P1413; Burgess JW, 1998, J BIOL CHEM, V273, P5645, DOI 10.1074/jbc.273.10.5645; BURNETT JR, 1994, AM J CARDIOL, V73, P923, DOI 10.1016/0002-9149(94)90831-1; DEAN RT, 1979, EXP CELL BIOL, V47, P454; DENG JT, 1995, J LIPID RES, V36, P2129; DONG LM, 1994, J BIOL CHEM, V269, P22358; DORY L, 1991, J LIPID RES, V32, P783; DORY L, 1989, J LIPID RES, V30, P809; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; FIELDING CJ, 1995, J LIPID RES, V36, P211; Garner B, 1997, ATHEROSCLEROSIS, V128, P47, DOI 10.1016/S0021-9150(96)05979-5; Gaus K, 2001, BIOCHEMISTRY-US, V40, P9363, DOI 10.1021/bi010323n; Gelissen IC, 1999, J LIPID RES, V40, P1636; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P1977, DOI 10.1161/hq1201.100221; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1992, STRUCTURE FUNCTION A, P218; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LIANG HQ, 1994, J LIPID RES, V35, P1187; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; OBRIEN KD, 1994, AM J PATHOL, V144, P538; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; PYLE LE, 1995, J LIPID RES, V36, P2355; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; RYE KA, 1994, J BIOL CHEM, V269, P10298; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; SEGREST JP, 1992, J LIPID RES, V33, P141; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; STEINMETZ A, 1989, J CHROMATOGR-BIOMED, V487, P154, DOI 10.1016/S0378-4347(00)83018-2; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; TRINDER P., 1969, Journal of Clinical Pathology, V22, P158, DOI 10.1136/jcp.22.2.158; VENKATACHALAPATHI YV, 1993, PROTEINS, V15, P349, DOI 10.1002/prot.340150403; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983, DOI 10.1161/01.ATV.20.8.1983; Weinberg RB, 1996, METHOD ENZYMOL, V263, P282; Zha XH, 2003, J BIOL CHEM, V278, P10002, DOI 10.1074/jbc.C300024200; Zhao YW, 2000, J BIOL CHEM, V275, P4759, DOI 10.1074/jbc.275.7.4759	69	39	45	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					25966	25977		10.1074/jbc.M401177200	http://dx.doi.org/10.1074/jbc.M401177200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066991	hybrid			2022-12-25	WOS:000222003000007
J	Mo, E; Amin, H; Bianco, IH; Garthwaite, J				Mo, E; Amin, H; Bianco, IH; Garthwaite, J			Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE GUANYLYL CYCLASE; DEPENDENT PROTEIN-KINASES; CYCLIC-NUCLEOTIDES; OXIDE RECEPTOR; GUANOSINE 3',5'-MONOPHOSPHATE; CEREBELLAR CELLS; CGMP RESPONSE; INTACT-CELLS; ION CHANNELS; PHOSPHORYLATION	Rat platelets served as a model to evaluate quantitatively how guanylate cyclase (GC)-coupled nitric oxide (NO) receptors and phosphodiesterases (here phosphodiesterase-5) interact to transduce NO signals in cells. The platelets expressed mRNA only for the alpha(1) and beta(1) GC-coupled receptor subunits. In intact platelets, the potency of NO for elevating cGMP (EC(50) = 10 nM) was lower than in lysed platelets (EC(50) = 1.7 nM). The limiting activities of GC and phosphodiesterase in intact platelets were both very high, being equivalent to about 100 muM/s. With low phosphodiesterase activity (imposed by 100 muM sildenafil), the cGMP response over time was hyperbolic in shape for a range of NO concentrations or GC activities due to GC desensitization. Without a phosphodiesterase inhibitor, NO generated only brief cGMP transients, peaking after 2-5 s but amounting maximally to about 150 muM cGMP. The transients were caused partly by GC desensitization, which varied in rate (half-time up to 3 s) and extent (up to 80%) depending on the NO concentration, and partly by an enhancement of the phosphodiesterase catalytic activity with time, which was deduced to be up to 30-fold and to occur with a half-time of up to 5 s. The results were simulated by a quantitative model, which also explains the varied shapes of cGMP responses to NO found in other cells. Downstream phosphorylation in platelets was detectable within 2 s, and, with continuous exposure (1 min), this pathway could be engaged by subnanomolar NO concentrations (EC(50) = 0.5 nM).	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Garthwaite, J (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	john.garthwaite@ucl.ac.uk		Bianco, Isaac/0000-0002-3149-4862				Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; Bellamy TC, 2002, BRIT J PHARMACOL, V136, P95, DOI 10.1038/sj.bjp.0704687; Bellamy TC, 2001, J BIOL CHEM, V276, P4287, DOI 10.1074/jbc.M006677200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BIDRI M, 1995, BIOCHEM BIOPH RES CO, V210, P507, DOI 10.1006/bbrc.1995.1689; Colquhoun D, 1998, NEURON, V20, P381, DOI 10.1016/S0896-6273(00)80982-4; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Griffiths C, 2003, MOL PHARMACOL, V64, P1349, DOI 10.1124/mol.64.6.1349; GUTHMANN F, 1992, N-S ARCH PHARMACOL, V346, P537; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; Juilfs D M, 1999, Rev Physiol Biochem Pharmacol, V135, P67, DOI 10.1007/BFb0033670; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KEELY SL, 1978, BIOCHIM BIOPHYS ACTA, V543, P251, DOI 10.1016/0304-4165(78)90070-3; Kotera J, 2003, BIOCHEM J, V372, P419, DOI 10.1042/BJ20030107; Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058; MELLION BT, 1981, BLOOD, V57, P946; MONCADA S, 1991, P NATL ACAD SCI USA, V88, P2166, DOI 10.1073/pnas.88.6.2166; Moreland RB, 1999, TRENDS ENDOCRIN MET, V10, P97, DOI 10.1016/S1043-2760(98)00127-1; Mullershausen F, 2003, VASC PHARMACOL, V40, P161, DOI 10.1016/S1537-1891(03)00049-1; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Mullershausen F, 2001, J CELL BIOL, V155, P271, DOI 10.1083/jcb.200107001; NOLTE C, 1991, J BIOL CHEM, V266, P14808; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; SAITO M, 1979, BIOCHIM BIOPHYS ACTA, V586, P473, DOI 10.1016/0304-4165(79)90037-0; Schmidt P, 2003, EUR J PHARMACOL, V468, P167, DOI 10.1016/S0014-2999(03)01674-1; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; WOOD KS, 1987, J BIOL CHEM, V262, P5020; Wykes V, 2002, J NEUROCHEM, V83, P37, DOI 10.1046/j.1471-4159.2002.01106.x; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; ZHOU HL, 1991, J PHARMACOL EXP THER, V258, P972	39	54	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26149	26158		10.1074/jbc.M400916200	http://dx.doi.org/10.1074/jbc.M400916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075333	hybrid			2022-12-25	WOS:000222003000029
J	Parsons, SA; Millay, DP; Wilkins, BJ; Bueno, OF; Tsika, GL; Neilson, JR; Liberatore, CM; Yutzey, KE; Crabtree, GR; Tsika, RW; Molkentin, JD				Parsons, SA; Millay, DP; Wilkins, BJ; Bueno, OF; Tsika, GL; Neilson, JR; Liberatore, CM; Yutzey, KE; Crabtree, GR; Tsika, RW; Molkentin, JD			Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; WEIGHT-LIFTING EXERCISE; DIGITORUM LONGUS MUSCLE; HEAVY-CHAIN EXPRESSION; BETA-DEFICIENT MICE; CYCLOSPORINE-A; COMPENSATORY HYPERTROPHY; CARDIAC-HYPERTROPHY; GAMMA-IRRADIATION; PAX-3 EXPRESSION	The serine/threonine phosphatase calcineurin is an important regulator of calcium-activated intracellular responses in eukaryotic cells. In higher eukaryotes, calcium/calmodulin-mediated activation of calcineurin facilitates direct dephosphorylation and nuclear translocation of the transcription factor nuclear factor of activated T-cells ( NFAT). Recently, controversy has surrounded the role of calcineurin in mediating skeletal muscle cell hypertrophy. Here we examined the ability of calcineurin-deficient mice to undergo skeletal muscle hypertrophic growth following mechanical overload (MOV) stimulation or insulin-like growth factor-1 (IGF-1) stimulation. Two distinct models of calcineurin deficiency were employed: calcineurin Abeta gene-targeted mice, which show a approximate to50% reduction in total calcineurin, and calcineurin B1-LoxP-targeted mice crossed with a myosin light chain 1f cre knock-in allele, which show a greater than 80% loss of total calcineurin only in skeletal muscle. Calcineurin Abeta-/- and calcineurin B1-LoxP(fl/fl)-MLC-cre mice show essentially no defects in muscle growth in response to IGF-1 treatment or MOV stimulation, although calcineurin Abeta-/- mice show a basal defect in total fiber number in the plantaris and a mild secondary reduction in growth, consistent with a developmental defect in myogenesis. Both groups of gene-targeted mice show normal increases in Akt activation following MOV or IGF-1 stimulation. However, overload-mediated fiber-type switching was dramatically impaired in calcineurin B1-LoxP(fl/fl)-MLC-cre mice. NFAT-luciferase reporter transgenic mice failed to show a correlation between IGF-1- or MOV-induced hypertrophy and calcineurin-NFAT-dependent signaling in vivo. We conclude that calcineurin expression is important during myogenesis and fiber-type switching, but not for muscle growth in response to hypertrophic stimuli.	Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Missouri System; University of Missouri Columbia; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Molkentin, JD (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Tuluc, Petronel/C-2527-2011	Yutzey, Katherine/0000-0002-1444-7124; Neilson, Joel R./0000-0002-3408-608X; Molkentin, Jeffery/0000-0002-3558-6529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32 HL07382] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Adams GR, 2002, AM J PHYSIOL-CELL PH, V283, pC1182, DOI 10.1152/ajpcell.00173.2002; Bassel-Duby R, 2003, BIOCHEM BIOPH RES CO, V311, P1133, DOI 10.1016/j.bbrc.2003.09.020; Bigard X, 2000, J BIOL CHEM, V275, P19653, DOI 10.1074/jbc.M000430200; BOBER E, 1994, DEVELOPMENT, V120, P603; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bothe GWM, 2000, GENESIS, V26, P165, DOI 10.1002/(SICI)1526-968X(200002)26:2<165::AID-GENE22>3.0.CO;2-F; Brand-Saberi B, 1999, CELL TISSUE RES, V296, P199, DOI 10.1007/s004410051281; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CHIN ER, 1996, PHYSIOLOGIST, V39, pA75; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; Dunn SE, 2000, J CELL BIOL, V151, P663, DOI 10.1083/jcb.151.3.663; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Dupont-Versteegden EE, 2002, AM J PHYSIOL-CELL PH, V282, pC1387, DOI 10.1152/ajpcell.00424.2001; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Friday BB, 2003, DIFFERENTIATION, V71, P217, DOI 10.1046/j.1432-0436.2003.710303.x; Friday BB, 2001, J CELL SCI, V114, P303; GONYEA W, 1977, ACTA PHYSIOL SCAND, V99, P105, DOI 10.1111/j.1748-1716.1977.tb10358.x; GOULDING M, 1994, DEVELOPMENT, V120, P957; HENNIG R, 1985, NATURE, V314, P164, DOI 10.1038/314164a0; Higginson J, 2002, PFLUG ARCH EUR J PHY, V445, P437, DOI 10.1007/s00424-002-0939-1; HUBBARD RW, 1975, GROWTH, V39, P85; Irintchev A, 2002, CELL TISSUE RES, V308, P143, DOI 10.1007/s00441-002-0519-x; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; KRENN V, 1988, ANAT EMBRYOL, V179, P49, DOI 10.1007/BF00305099; Luo ZD, 1999, MOL PHARMACOL, V56, P886, DOI 10.1124/mol.56.5.886; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; Mitchell PO, 2002, AM J PHYSIOL-CELL PH, V282, pC984, DOI 10.1152/ajpcell.00483.2001; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Neilson JR, 2004, IMMUNITY, V20, P255, DOI 10.1016/S1074-7613(04)00052-4; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Parsons SA, 2003, MOL CELL BIOL, V23, P4331, DOI 10.1128/MCB.23.12.4331-4343.2003; Pette D, 2000, MICROSC RES TECHNIQ, V50, P500, DOI 10.1002/1097-0029(20000915)50:6<500::AID-JEMT7>3.0.CO;2-7; Phelan JN, 1997, ANAT REC, V247, P179, DOI 10.1002/(SICI)1097-0185(199702)247:2<179::AID-AR4>3.0.CO;2-T; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; ROSENBLATT JD, 1993, PFLUG ARCH EUR J PHY, V423, P255, DOI 10.1007/BF00374404; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; ROSS JJ, 1987, DEVELOPMENT, V100, P383; ROY RR, 1982, J APPL PHYSIOL, V52, P473, DOI 10.1152/jappl.1982.52.2.473; RUBINSTEIN NA, 1981, J CELL BIOL, V90, P128, DOI 10.1083/jcb.90.1.128; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sakuma K, 2003, HISTOCHEM CELL BIOL, V119, P149, DOI 10.1007/s00418-003-0499-2; SALLEO A, 1983, J SUBMICR CYTOL PATH, V15, P929; Sanchez H, 2003, MUSCLE NERVE, V28, P324, DOI 10.1002/mus.10423; SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Tamaki T, 1997, AM J PHYSIOL-CELL PH, V273, pC246, DOI 10.1152/ajpcell.1997.273.1.C246; Tanaka N, 1998, AM J PHYSIOL-HEART C, V275, pH393, DOI 10.1152/ajpheart.1998.275.2.H393; Torgan CE, 2001, MOL BIOL CELL, V12, P1499, DOI 10.1091/mbc.12.5.1499; TSIKA RW, 1987, J APPL PHYSIOL, V63, P2111, DOI 10.1152/jappl.1987.63.5.2111; TSIKA RW, 1995, AM J PHYSIOL-CELL PH, V269, pC665, DOI 10.1152/ajpcell.1995.269.3.C665; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413	69	139	151	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26192	26200		10.1074/jbc.M313800200	http://dx.doi.org/10.1074/jbc.M313800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082723	hybrid			2022-12-25	WOS:000222003000034
J	Thomashevski, A; High, AA; Drozd, M; Shabanowitz, J; Hunt, DF; Grant, PA; Kupfer, GM				Thomashevski, A; High, AA; Drozd, M; Shabanowitz, J; Hunt, DF; Grant, PA; Kupfer, GM			The Fanconi anemia core complex forms four complexes of different sizes in different subcellular compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-C PROTEIN; GROUP-D GENE; NUCLEAR-COMPLEX; HEMATOPOIETIC-CELLS; POSITIONAL CLONING; GAMMA-INTERFERON; DNA-DAMAGE; GROUP-A; COMPLEMENTATION; APOPTOSIS	Fanconi anemia (FA) is an autosomal recessive disease marked by congenital defects, bone marrow failure, and cancer susceptibility. FA cells exhibit a characteristic hypersensitivity to DNA crosslinking agents such as mitomycin C. The molecular mechanism for the disease remains elusive, but at least 6 FA proteins are known to be part of what is termed the FA core complex. We used affinity pulldown of FLAG-FANCA to pull down the FA complex from whole-cell extracts. Mass spectroscopy detected previously reported FA-binding proteins, including FANCA, FANCC, FANCG, cdc2, and GRP94, thus validating the approach. We further describe a method of purification of the FA core complex in an effort to find novel complex components and biochemical activity to define the function of the complex. By using conventional chromatographic fractionation of subcellular preparations, we report: (i) the FA core complex exists in a cytoplasmic form at 500-600 kDa; (ii) a larger, 750-kDa cytoplasmic form is seen only at mitosis; (iii) a nuclear form achieves a size of 2 megaDaltons; and (iv) a distinct 1-megaDalton FA core complex exists bound to chromatin that contains phosphorylated FANCA after undergoing DNA damage. We are continuing our analysis using mass spectroscopy in an effort to characterize novel binding proteins. These data will help define the biochemical role of the FA core complex in normal cell physiology as well as in the development of the FA disease state.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Kupfer, GM (corresponding author), Univ Virginia, Dept Chem, Box 441,Jordan Hall, Charlottesville, VA 22908 USA.	gk9e@virginia.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368				Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; ALTER BP, 1993, HEMATOLOGY INFANCY C, V1, P216; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1997, GENETIC BASIS HUMAN, P317; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Christianson TA, 2000, BLOOD, V95, P725, DOI 10.1182/blood.V95.2.725; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; DUTRILLAUX B, 1982, HUM GENET, V62, P327, DOI 10.1007/BF00304549; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; Fanconi G., 1927, JAHRB KINDERHEILK, V117, P257; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Haneline LS, 1998, BLOOD, V91, P4092; Hejna JA, 2000, AM J HUM GENET, V66, P1540, DOI 10.1086/302896; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hoshino T, 1998, BLOOD, V91, P4379, DOI 10.1182/blood.V91.11.4379.411k14_4379_4386; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; KAISER TN, 1982, CYTOMETRY, V2, P291; Kupfer G, 1999, EXP HEMATOL, V27, P587, DOI 10.1016/S0301-472X(99)00022-3; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Kupfer GM, 1996, BLOOD, V88, P1019; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; LO TF, 1996, NAT GENET, V14, P320; Marathi UK, 1996, BLOOD, V88, P2298, DOI 10.1182/blood.V88.6.2298.bloodjournal8862298; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Naf D, 1998, MOL CELL BIOL, V18, P5952; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Ridet A, 1997, CANCER RES, V57, P1722; STONESIFER KJ, 1987, ACTA CYTOL, V31, P125; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Whitney MA, 1996, BLOOD, V88, P49; Yagasaki H, 2001, BLOOD, V98, P3650, DOI 10.1182/blood.V98.13.3650; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; Youssoufian H, 1996, J CLIN INVEST, V97, P2003, DOI 10.1172/JCI118635	51	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26201	26209		10.1074/jbc.M400091200	http://dx.doi.org/10.1074/jbc.M400091200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082718	hybrid			2022-12-25	WOS:000222003000035
J	Vites, O; Rhee, JS; Schwarz, M; Rosenmund, C; Jahn, R				Vites, O; Rhee, JS; Schwarz, M; Rosenmund, C; Jahn, R			Reinvestigation of the role of snapin in neurotransmitter release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNARE COMPLEX; SYNAPTIC VESICLES; PROTEIN; BINDING; EXOCYTOSIS; SNAP-25; FUSION; MECHANISM; INTERACTS; SYNAPSES	Snapin, a 15-kDa protein, has been identified recently as a binding partner of SNAP-25. Moreover, snapin is regulated by phosphorylation and enhances synaptotagmin binding to SNAREs. Furthermore, snapin and C-terminal snapin fragments have been effective in changing the release properties of neurons and chromaffin cells. Here we have reinvestigated the role of snapin using both biochemical and electrophysiological approaches. Snapin is ubiquitously expressed at low levels with no detectable enrichment in the brain or in synaptic vesicles. Using non-equilibrium and equilibrium assays including pulldown experiments, co-immunoprecipitations, and CD and fluorescence anisotropy spectroscopy, we were unable to detect any specific interaction between snapin and SNAP-25. Similarly, overexpression of a C-terminal snapin fragment in hippocampal neurons failed to influence any of the analyzed parameters of neurotransmitter release. Initial biochemical characterization of recombinant snapin revealed that the protein is a stable dimer with a predominantly alpha-helical secondary structure. We conclude that the postulated role of snapin as a SNARE regulator in neurotransmitter release needs reconsideration, leaving the true function of this evolutionarily conserved protein to be discovered.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany; Max Planck Inst Med Res, Dept Neurobiol, D-69120 Heidelberg, Germany	Max Planck Society; Max Planck Society; Max Planck Society	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444; Jahn, Reinhard/0000-0003-1542-3498				Ashery U, 1999, P NATL ACAD SCI USA, V96, P1094, DOI 10.1073/pnas.96.3.1094; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROSE N, 1994, J BIOL CHEM, V269, P16780; Bruns D, 1997, J NEUROSCI, V17, P1898; Buxton P, 2003, BIOCHEM J, V375, P433, DOI 10.1042/BJ20030427; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Chou JH, 2000, J BIOL CHEM, V275, P9433, DOI 10.1074/jbc.275.13.9433; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hunt RA, 2003, BIOCHEM BIOPH RES CO, V303, P594, DOI 10.1016/S0006-291X(03)00400-5; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Shin OH, 2003, NEURON, V37, P99, DOI 10.1016/S0896-6273(02)01145-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sorensen JB, 2002, P NATL ACAD SCI USA, V99, P1627, DOI 10.1073/pnas.251673298; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637	33	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26251	26256		10.1074/jbc.M404079200	http://dx.doi.org/10.1074/jbc.M404079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084593	hybrid, Green Published			2022-12-25	WOS:000222003000042
J	Guerrero, C; Martin-Encabo, S; Fernandez-Medarde, A; Santos, E				Guerrero, C; Martin-Encabo, S; Fernandez-Medarde, A; Santos, E			C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of anchorage-independent growth	ONCOGENE			English	Article						C3G; Ras; focus formation; anchorage-independent growth; transformation suppression	EXCHANGE FACTOR C3G; HEMATOPOIETIC-CELL ADHESION; NUCLEOTIDE-RELEASING FACTOR; ADAPTER PROTEIN CRKL; SMALL GTPASE RAP1; R-RAS; FOCAL ADHESIONS; KINASE; PHOSPHORYLATION; RECEPTOR	We showed previously that exogenous overexpression of C3G, a guanine nucleotide releasing factor (GEF) for Rap1 and R-Ras proteins, blocks the focus-forming activity of cotransfected, activated, sis, ras and v-raf oncogenes in NIH 3T3 cells. In this report, we show that C3G also interferes with dbl and R-Ras focus-forming activity and demonstrate that the transformation suppressor ability of C3G maps to its Crk-binding region (SH3-b domain). Using full-length C3G and C3GDeltaCat mutant, lacking catalytic domain, we showed here that overexpression of cotransfected C3G or C3GDeltaCat inhibited oncogenic Hras(lys12)-mediated phosphorylation of ERK, without altering Ras and Raf-1 kinase activation. We also showed that, overexpressed C3G and C3GDeltaCat inhibited the viability of oncogenic Ras-induced colonies in soft agar, indicating that C3G interferes with the anchorage-independent growth of Ras-transformed cells in a Rap1-independent manner. Consistent with both observations, overexpression of exogenous C3G and C3GDeltaCat also caused downregulation of Ras-induced cyclin A expression. Altogether, our results indicate that C3G interferes with at least two separate aspects of oncogenic transformation-cell cycle progression and loss of contact inhibition-and that these inhibitory effects probably account for its transformation suppressor activity.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Santos, E (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Miguel de Unamuno, Salamanca 37007, Spain.	esantos@usal.es	Guerrero, Carmen/F-1776-2010; Fernández-Medarde, Alberto/B-3839-2017	Guerrero, Carmen/0000-0002-8747-6831; Fernández-Medarde, Alberto/0000-0002-1230-5501				Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; Guerrero C, 2002, AM J PHYSIOL-LUNG C, V282, pL1099, DOI 10.1152/ajplung.00178.2001; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SAEZ R, 1994, ONCOGENE, V9, P2977; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SAKODA T, 1992, ONCOGENE, V7, P1705; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SOZERI O, 1992, ONCOGENE, V7, P2259; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yokote K, 1998, ONCOGENE, V16, P1229, DOI 10.1038/sj.onc.1201641; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	48	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4885	4893		10.1038/sj.onc.1207622	http://dx.doi.org/10.1038/sj.onc.1207622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077165	Green Submitted			2022-12-25	WOS:000222104200009
J	Ifergan, I; Shafran, A; Jansen, G; Hooijberg, JH; Scheffer, GL; Assaraf, YG				Ifergan, I; Shafran, A; Jansen, G; Hooijberg, JH; Scheffer, GL; Assaraf, YG			Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression - A role for BCRP in cellular folate homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLYLPOLYGLUTAMATE SYNTHETASE-ACTIVITY; LIPOPHILIC ANTIFOLATE RESISTANCE; GAMMA-GLUTAMATE SYNTHETASE; WILD-TYPE; TRANSCRIPTION FACTORS; THYMIDYLATE SYNTHASE; MEMBRANE-TRANSPORT; MAMMALIAN-CELLS; CARRIER GENE; IN-VITRO	Breast cancer resistance protein (BCRP/ABCG2) is currently the only ABC transporter that exports mono- and polyglutamates of folates and methotrexate (MTX). Here we explored the relationship between cellular folate status and BCRP expression. Toward this end, MCF-7 breast cancer cells, with low BCRP and moderate multidrug resistance protein 1 (MRP1/ABCC1) levels, and their mitoxantrone (MR)-resistant MCF-7/MR subline, with BCRP overexpression and low MRP1 levels, were gradually deprived of folic acid from 2.3 muM to 3 nM resulting in the sublines MCF-7/LF and MCF-7/MR-LF. These cell lines expressed only residual BCRP mRNA and protein levels and retained a poor MRP2 (ABCC2) through MRP5 (ABCC5) expression. Furthermore, MCF7/MR-LF cells also displayed 5-fold decreased MRP1 levels relative to MCF-7/MR cells. In contrast, BCRP overexpression was largely retained in MCF-7/MR cells grown in MR-free medium containing 2.3 muM folic acid. Loss of BCRP expression in MCF-7/LF and MCF-7/MR-LF cells resulted in the following: ( a) a prominent decrease in the efflux of Hoechst 33342, a BCRP substrate; (b) an similar to2-fold increase in MR accumulation as revealed by flow cytometry; this was accompanied by a 2.5- and similar to84-fold increased MR sensitivity in these cell lines, respectively. Consistently, Ko143, a specific BCRP inhibitor, rendered MCF- 7 and MCF-7/MR cells 2.1- and similar to16.4-fold more sensitive to MR, respectively. Loss of BCRP expression also resulted in the following: ( c) an identical MTX sensitivity in these cell lines thereby losing the similar to28-fold MTX resistance of the MCF-7/MR cells; (d) an similar to2-fold increase in the 4- and 24-h accumulation of [H-3]folic acid. Furthermore, MCF-7/MR-LF cells displayed a significant increase in folylpoly-gamma-glutamate synthetase activity. Hence, consistent with the mono- and polyglutamate folate exporter function of BCRP, down-regulation of BCRP and increased folylpoly-gamma-glutamate synthetase activity appear to be crucial components of cellular adaptation to folate deficiency conditions. This is the first evidence for the possible role of BCRP in the maintenance of cellular folate homeostasis.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Free Univ Amsterdam, Med Ctr, Dept Rheumatol, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Pediat Oncol, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands	Technion Israel Institute of Technology; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Assaraf, YG (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	assaraf@tx.technion.ac.il		Jansen, Gerrit/0000-0001-8190-8368				ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720; Allen JD, 2002, MOL CANCER THER, V1, P417; Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; Assaraf YG, 2003, J BIOL CHEM, V278, P6680, DOI 10.1074/jbc.M209186200; Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; ASSARAF YG, 1993, J BIOL CHEM, V268, P4556; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chen ZS, 2002, CANCER RES, V62, P3144; Chen ZS, 2003, CANCER RES, V63, P4048; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Gates SB, 1996, BIOCHEM PHARMACOL, V52, P1477, DOI 10.1016/S0006-2952(96)00554-0; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; HENDERSON GB, 1981, BIOCHEM BIOPH RES CO, V99, P163, DOI 10.1016/0006-291X(81)91727-7; HENDERSON GB, 1990, CANCER RES, V50, P1709; Hooijberg JH, 2003, BIOCHEM PHARMACOL, V65, P765, DOI 10.1016/S0006-2952(02)01615-5; Hooijberg JH, 2004, BIOCHEM PHARMACOL, V67, P1541, DOI 10.1016/j.bcp.2003.12.022; Hooijberg JH, 1999, CANCER RES, V59, P2532; JACKMAN AL, 1991, CANCER RES, V51, P5579; JANSEN G, 1992, ONCOL RES, V4, P299; JANSEN G, 1989, CANCER RES, V49, P1959; Jansen G, 1999, CANC DRUG DISC DEV, P293; Jansen G, 1999, MOL PHARMACOL, V55, P761; Kanzaki A, 2001, JPN J CANCER RES, V92, P452, DOI 10.1111/j.1349-7006.2001.tb01115.x; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Maliepaard M, 2001, CANCER RES, V61, P3458; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; Mitomo H, 2003, BIOCHEM J, V373, P767, DOI 10.1042/BJ20030150; Mogi M, 2003, J BIOL CHEM, V278, P39068, DOI 10.1074/jbc.M306362200; Moran RG, 1999, SEMIN ONCOL, V26, P24; Rothem L, 2003, J BIOL CHEM, V278, P8935, DOI 10.1074/jbc.M209578200; Rothem L, 2004, J BIOL CHEM, V279, P374, DOI 10.1074/jbc.M309092200; Rothem L, 2002, BIOCHEM J, V367, P741, DOI 10.1042/BJ20020801; Shih C, 1997, CANCER RES, V57, P1116; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; Stark M, 2003, MOL PHARMACOL, V64, P220, DOI 10.1124/mol.64.2.220; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; TAYLOR CW, 1991, BRIT J CANCER, V63, P923, DOI 10.1038/bjc.1991.202; Turner FB, 1999, CANCER RES, V59, P6074; Volk EL, 2000, CANCER RES, V60, P3514; Volk EL, 2002, CANCER RES, V62, P5035; Volk EL, 2003, CANCER RES, V63, P5538; Wielinga PR, 1998, ANAL BIOCHEM, V263, P221, DOI 10.1006/abio.1998.2779; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Zeng H, 2001, CANCER RES, V61, P7225; Zeng H, 1999, CANCER RES, V59, P5964; Zhao RB, 2001, J BIOL CHEM, V276, P1114, DOI 10.1074/jbc.M007919200	49	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25527	25534		10.1074/jbc.M401725200	http://dx.doi.org/10.1074/jbc.M401725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15047700	hybrid, Green Published			2022-12-25	WOS:000221827900078
J	Ryu, JY; Song, JY; Lee, JM; Jeong, SW; Chow, WS; Choi, SB; Pogson, BJ; Park, YI				Ryu, JY; Song, JY; Lee, JM; Jeong, SW; Chow, WS; Choi, SB; Pogson, BJ; Park, YI			Glucose-induced expression of carotenoid biosynthesis genes in the dark is mediated by cytosolic pH in the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTOENE SYNTHASE; LIGHT; PHOTOSYNTHESIS; DEHYDROGENASE; FRUCTOSE; SEQUENCE	The expression of carotenoid biosynthesis genes coding for phytoene synthase (crtB), phytoene desaturase (crtP), zeta-carotene desaturase (crtQ), and beta-carotene hydroxylase (crtR) is dependent upon light in the cyanobacterium Synechocystis sp. PCC 6803 ( Synechocystis). We have demonstrated that the expression of the above four genes was also elevated in the dark-adapted Synechocystis cells upon glucose treatment as a consequence of transcriptional activation. Treatment with glucose analogs such as L-glucose, 3-O-methylglucose, 2-deoxyglucose, and mannose, or inactivation of glucose uptake and phosphorylation by deletion mutation of glucose transporter (glcP) and glucokinase (gk), respectively, did not induce up-regulation of carotenoid genes. When respiratory electron transport or coupling to oxidative phosphorylation was inhibited, glucose induction was not observed, indicating that respiratory electron transport per se is not critical for the expression of these genes. In agreement with this view, the extent of gene expression showed a saturation curve with increasing acridine yellow fluorescence yield, without having a close correlation with the ATP contents or ATP/ADP ratio. The results indicate that glucose induction of carotenoid gene expressions is mediated by an increase in cytosolic pH rather than either redox or glucose sensing.	Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Australian Natl Univ, Res Sch Biol Sci, Photobioenerget Grp, Canberra, ACT 2601, Australia; Myongji Univ, Dept Biol Sci, Yongin 449728, South Korea; Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	Chungnam National University; Australian National University; Myongji University; Australian National University	Park, YI (corresponding author), Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea.	yipark@cnu.ac.kr	Pogson, Barry J/C-9953-2009; Chow, Wah Soon/D-2010-2009; Park, Youn-Il/S-2997-2019	Pogson, Barry J/0000-0003-1869-2423; Park, Youn-Il/0000-0003-2912-2821; Song, Ji-Young/0000-0003-3964-1094				Alfonso M, 2000, PLANT PHYSIOL, V122, P505, DOI 10.1104/pp.122.2.505; Bohne F, 2002, BBA-GENE STRUCT EXPR, V1579, P26, DOI 10.1016/S0167-4781(02)00500-6; Cooley JW, 2001, J BACTERIOL, V183, P4251, DOI 10.1128/JB.183.14.4251-4258.2001; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; Felle HH., 1989, 2ND MESSENGERS PLANT, V6, P145; Fernandez-Gonzalez B, 1998, BBA-GENE STRUCT EXPR, V1443, P343, DOI 10.1016/S0167-4781(98)00239-5; FLORES E, 1986, J BACTERIOL, V166, P693, DOI 10.1128/jb.166.2.693-696.1986; Frank HA, 1996, PHOTOCHEM PHOTOBIOL, V63, P257, DOI 10.1111/j.1751-1097.1996.tb03022.x; GIRAUDAT J, 1995, CURR OPIN CELL BIOL, V7, P232, DOI 10.1016/0955-0674(95)80033-6; GOGARTEN JP, 1989, PLANTA, V178, P52, DOI 10.1007/BF00392526; Isfort RJ, 1996, EXP CELL RES, V226, P363, DOI 10.1006/excr.1996.0237; JOSET F, 1988, ARCH MICROBIOL, V149, P417, DOI 10.1007/BF00425581; Klein D, 1998, PLANTA, V205, P223, DOI 10.1007/s004250050315; Kujat SL, 2000, PLANT PHYSIOL, V124, P703, DOI 10.1104/pp.124.2.703; LARGADE D, 2000, APPL ENVIRON MICROB, V66, P64; Li H, 2000, J BACTERIOL, V182, P4268, DOI 10.1128/JB.182.15.4268-4277.2000; MCCARTY RE, 1980, METHOD ENZYMOL, V69, P719; MI HL, 1992, PLANT CELL PHYSIOL, V33, P1233; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Muhlbauer SK, 1998, J BIOL CHEM, V273, P20935, DOI 10.1074/jbc.273.33.20935; Mullineaux CW, 2001, MOL MICROBIOL, V41, P965, DOI 10.1046/j.1365-2958.2001.02569.x; MYERS J, 1980, PLANT PHYSIOL, V66, P1144, DOI 10.1104/pp.66.6.1144; Pfannschmidt T, 2003, TRENDS PLANT SCI, V8, P33, DOI 10.1016/S1360-1385(02)00005-5; PORTER RD, 1988, METHOD ENZYMOL, V167, P703; REDDY KJ, 1989, J BACTERIOL, V171, P3486, DOI 10.1128/jb.171.6.3486-3493.1989; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Ryu JY, 2003, MOL CELLS, V15, P240; Ryu JY, 2003, MOL CELLS, V16, P74; Salgado AP, 1999, MOL CELL ENDOCRINOL, V154, P79, DOI 10.1016/S0303-7207(99)00085-4; Schmetterer G, 1994, MOL BIOL CYANOBACTER, P409, DOI DOI 10.1007/0-306-48205-3_13; SCHMETTERER GR, 1990, PLANT MOL BIOL, V14, P697, DOI 10.1007/BF00016502; Schmitz O, 1999, PHOTOSYNTH RES, V62, P261, DOI 10.1023/A:1006340423948; Steinbrenner J, 2001, PLANT PHYSIOL, V125, P810, DOI 10.1104/pp.125.2.810; Teuber M, 2001, BBA-BIOENERGETICS, V1506, P31, DOI 10.1016/S0005-2728(01)00178-5; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; Welsch R, 2000, PLANTA, V211, P846, DOI 10.1007/s004250000352	37	46	52	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25320	25325		10.1074/jbc.M402541200	http://dx.doi.org/10.1074/jbc.M402541200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078876	hybrid			2022-12-25	WOS:000221827900052
J	Wang, YP; El-Zaru, MR; Surks, HK; Mendelsohn, ME				Wang, YP; El-Zaru, MR; Surks, HK; Mendelsohn, ME			Formin homology domain protein (FHOD1) is a cyclic GMP-dependent protein kinase I-binding protein and substrate in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; NITRIC-OXIDE; MYOSIN PHOSPHATASE; CA2+ DESENSITIZATION; P21-ACTIVATED KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; INHIBITION; RECEPTOR; IDENTIFICATION	Cyclic GMP-dependent protein kinase I (PKGI) mediates vascular relaxation by nitric oxide and related nitrovasodilators and inhibits vascular smooth muscle cell (VSMC) migration. To identify VSMC proteins that interact with PKGI, the N-terminal protein interaction domain of PKGIalpha was used to screen a yeast two-hybrid human aortic cDNA library. The formin homology (FH) domain-containing protein, FHOD1, was found to interact with PKGIalpha in this screen. FH domain-containing proteins bind Rho-family GTPases and regulate actin cytoskeletal dynamics, cell migration, and gene expression. Antisera to FHOD1 were raised and used to characterize FHOD1 expression and distribution in vascular cells. FHOD1 is highly expressed in human coronary artery, aortic smooth muscle cells, and in human arterial and venous endothelial cells. In glutathione S-transferase pull-down experiments, the FHOD1 C terminus (amino acids 964-1165) binds full-length PKGI. Both in vitro and intact cell studies demonstrate that the interaction between FHOD1 and PKGI is decreased 3- to 5-fold in the presence of the PKG activator, 8Br-cGMP. Immunofluorescence studies of human VSMC show that FHOD1 is cytoplasmic and is concentrated in the perinuclear region. PKGI also directly phosphorylates FHOD1, and studies with wild-type and mutant FHOD1-derived peptides identify Ser-1131 in the FHOD1 C terminus as the unique PKGI phosphorylation site in FHOD1. These studies demonstrate that FHOD1 is a PKGI-interacting protein and substrate in VSMCs and show that cyclic GMP negatively regulates the FHOD1-PKGI interaction. Based on the known functions of FHOD1, the data are consistent with a role for FHOD1 in cyclic GMP-dependent inhibition of VSMC stress fiber formation and/or migration.	Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr Hosp, Mol Cardiol Res Inst, Dept Med, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr Hosp, Div Cardiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 80, Boston, MA 02111 USA.	mmendelsohn@tufts-nemc.org			NHLBI NIH HHS [R01 HL55309] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055309] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; DUBEY RK, 1995, J CLIN INVEST, V96, P141, DOI 10.1172/JCI118014; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; Feil R, 2003, CIRC RES, V93, P907, DOI 10.1161/01.RES.0000100390.68771.CC; Foster DB, 2000, J BIOL CHEM, V275, P1959, DOI 10.1074/jbc.275.3.1959; Furchgott RF, 1996, JAMA-J AM MED ASSOC, V276, P1186, DOI 10.1001/jama.276.14.1186; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; Hofmann F, 2000, J CELL SCI, V113, P1671; IGNARRO LJ, 1996, KIDNEY INT, V49, pS2; Kawada T, 1997, EUR J PHARMACOL, V323, P75, DOI 10.1016/S0014-2999(97)00028-9; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Lincoln TM, 1996, METHOD ENZYMOL, V269, P149; LINCOLN TM, 1994, CYCLIC GMP BIOCH PHY; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Murad F, 1996, JAMA-J AM MED ASSOC, V276, P1189, DOI 10.1001/jama.276.14.1189; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sinnaeve P, 2002, CIRCULATION, V105, P2911, DOI 10.1161/01.CIR.0000018169.59205.CA; Surks HK, 2003, J BIOL CHEM, V278, P51484, DOI 10.1074/jbc.M305622200; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Wirth A, 2003, J PHYSIOL-LONDON, V549, P489, DOI 10.1113/jphysiol.2002.033167; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460	35	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24420	24426		10.1074/jbc.M313823200	http://dx.doi.org/10.1074/jbc.M313823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051728	hybrid			2022-12-25	WOS:000221702500068
J	Varga, K; Jurkuvenaite, A; Wakefield, J; Hong, JS; Guimbellot, JS; Venglarik, CJ; Niraj, A; Mazur, M; Sorscher, EJ; Collawn, JF; Bebok, Z				Varga, K; Jurkuvenaite, A; Wakefield, J; Hong, JS; Guimbellot, JS; Venglarik, CJ; Niraj, A; Mazur, M; Sorscher, EJ; Collawn, JF; Bebok, Z			Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; TRANS-LENTIVIRAL VECTOR; PROTEIN-KINASE-A; ENDOPLASMIC-RETICULUM; CL-SECRETION; SURFACE EXPRESSION; PREDICTABLE SAFETY; DELTA-F508 CFTR; APICAL MEMBRANE; AIRWAY CELLS	The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent protein kinase A-activated chloride channel that resides on the apical surface of epithelial cells. One unusual feature of this protein is that during biogenesis, similar to75% of wild type CFTR is degraded by the endoplasmic reticulum ( ER)associated degradative (ERAD) pathway. Examining the biogenesis and structural instability of the molecule has been technically challenging due to the limited amount of CFTR expressed in epithelia. Consequently, investigators have employed heterologous overexpression systems. Based on recent results that epithelial specific factors regulate both CFTR biogenesis and function, we hypothesized that CFTR biogenesis in endogenous CFTR expressing epithelial cells may be more efficient. To test this, we compared CFTR biogenesis in two epithelial cell lines endogenously expressing CFTR (Calu-3 and T84) with two heterologous expression systems (COS-7 and HeLa). Consistent with previous reports, 20 and 35% of the newly synthesized CFTR were converted to maturely glycosylated CFTR in COS-7 and HeLa cells, respectively. In contrast, CFTR maturation was virtually 100% efficient in Calu-3 and T84 cells. Furthermore, inhibition of the proteasome had no effect on CFTR biogenesis in Calu-3 cells, whereas it stabilized the immature form of CFTR in HeLa cells. Quantitative reverse transcriptase-PCR indicated that CFTR message levels are similar to4-fold lower in Calu-3 than HeLa cells, yet steady-state protein levels are comparable. Our results question the structural instability model of wild type CFTR and indicate that epithelial cells endogenously expressing CFTR efficiently process this protein to post-Golgi compartments.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Tranzyme Corp, Birmingham, AL 35209 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bebok, Z (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 760,1918 Univ Blvd, Birmingham, AL 35294 USA.	bebok@uab.edu		Collawn, James/0000-0002-2528-2759; Sorscher, Eric J./0000-0001-9341-3354; Guimbellot, Jennifer/0000-0002-0514-8536; Jurkuvenaite, Asta/0000-0002-9193-5797	NIDDK NIH HHS [DK60065] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060065] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ameen NA, 2000, HISTOCHEM CELL BIOL, V114, P219; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Bebok Z, 2001, AM J PHYSIOL-CELL PH, V280, pC135, DOI 10.1152/ajpcell.2001.280.1.C135; BEBOK Z, 1998, AM J PHYSIOL, V44, pC599; BEBOK Z, 1999, PED PULM S, V19, P218; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; Kappes John C, 2003, Methods Mol Med, V76, P449; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Krumins AM, 2004, J BIOL CHEM, V279, P2593, DOI 10.1074/jbc.M311600200; Li GM, 2003, J BIOL CHEM, V278, P19791, DOI 10.1074/jbc.M212250200; Li J, 1999, J BIOL CHEM, V274, P10790, DOI 10.1074/jbc.274.16.10790; Li J, 2000, BIOCHEM J, V349, P51, DOI 10.1042/0264-6021:3490051; Liu TI, 2001, J NEUROPHYSIOL, V85, P61, DOI 10.1152/jn.2001.85.1.61; Loffing J, 1999, AM J PHYSIOL-LUNG C, V277, pL700, DOI 10.1152/ajplung.1999.277.4.L700; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; Naren AP, 2000, NEWS PHYSIOL SCI, V15, P57; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Penque D, 2000, LAB INVEST, V80, P857, DOI 10.1038/labinvest.3780090; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Peter K, 2002, J BIOL CHEM, V277, P49952, DOI 10.1074/jbc.M209275200; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANT AJ, 1991, J EXP MED, V174, P799, DOI 10.1084/jem.174.4.799; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Silvis MR, 2003, J BIOL CHEM, V278, P11554, DOI 10.1074/jbc.M212843200; Straley KS, 1998, MOL BIOL CELL, V9, P1683, DOI 10.1091/mbc.9.7.1683; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Wu XY, 2000, MOL THER, V2, P47, DOI 10.1006/mthe.2000.0095; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	66	100	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22578	22584		10.1074/jbc.M401522200	http://dx.doi.org/10.1074/jbc.M401522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15066992	hybrid			2022-12-25	WOS:000221417100109
J	Hubalek, MM; Widschwendter, A; Erdel, M; Gschwendtner, A; Fiegl, HM; Muller, HM; Goebel, G; Mueller-Holzner, E; Marth, C; Spruck, CH; Reed, SI; Widschwendter, M				Hubalek, MM; Widschwendter, A; Erdel, M; Gschwendtner, A; Fiegl, HM; Muller, HM; Goebel, G; Mueller-Holzner, E; Marth, C; Spruck, CH; Reed, SI; Widschwendter, M			Cyclin E dysregulation and chromosomal instability in endometrial cancer	ONCOGENE			English	Article						cyclin E; dysregulation; chromosomal instability; endometrial cancer	BREAST-CANCER; CELL-LINES; PHOSPHORYLATION; CARCINOMAS; ACTIVATION; TRANSITION; INDUCTION	Deregulation of cyclin E, an activator of cyclin-dependent kinase 2 (Cdk2), has been associated with a broad spectrum of human malignancies. Yet the mechanism linking abnormal cyclin E expression to carcinogenesis is largely unknown. The gene encoding the F-box protein hCdc4, a key component of the molecular machinery that targets cyclin E for degradation, is frequently mutated in endometrial cancer, leading to deregulation of cyclin E expression. Here we show that hCDC4 gene mutation and hyperphosphorylation of cyclin E, a parameter that usually correlates with hCDC4 mutation, have a strong statistically significant association with polypoidy and aneuploidy in endometrial cancer. On the contrary, elevated expression of cyclin E by itself was not significantly correlated with polyploidy or aneuploidy when tumors of similar grade are evaluated. These data suggest that impairment of cell cycle regulated proteolysis of cyclin E may be linked to carcinogenesis by promoting genomic instability.	Univ Innsbruck Hosp, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Pathol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Biostat & Documentat, A-6020 Innsbruck, Austria; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Medical University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck; Scripps Research Institute	Widschwendter, M (corresponding author), Univ Innsbruck Hosp, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria.	martin.widschwendter@uibk.ac.at	Goebel, Georg/P-6909-2015; Hubalek, Michael/ABD-8041-2021; Fiegl, Heidi/K-4445-2017	Fiegl, Heidi/0000-0002-1236-6806; Widschwendter, Martin/0000-0002-7778-8380	NCI NIH HHS [CA78343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078343, R56CA078343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blegen H, 2003, ANAL CELL PATHOL, V25, P103, DOI 10.1155/2003/491362; BOCKING A, 1994, STATIC DNA CYTOMETRY, P107; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Erlanson M, 1998, CYTOMETRY, V32, P214, DOI 10.1002/(SICI)1097-0320(19980701)32:3<214::AID-CYTO8>3.3.CO;2-N; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; MIKUZ G, 1985, ANAL QUANT CYTOL, V7, P343; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Reed SI, 1996, BBA-REV CANCER, V1287, P151, DOI 10.1016/0304-419X(96)00006-6; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Suzuki A, 1997, HUM GENET, V100, P629, DOI 10.1007/s004390050565; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	25	53	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	2004	23	23					4187	4192		10.1038/sj.onc.1207560	http://dx.doi.org/10.1038/sj.onc.1207560			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048079				2022-12-25	WOS:000221520200019
J	Derouet, M; Thomas, L; Cross, A; Moots, RJ; Edwards, SW				Derouet, M; Thomas, L; Cross, A; Moots, RJ; Edwards, SW			Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; SODIUM-BUTYRATE; SURVIVAL-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BAD PHOSPHORYLATION; MULTIPLE-MYELOMA; CELL LEUKEMIA-1; BCL-2; EXPRESSION; FAMILY	Human neutrophils normally have a very short half-life and die by apoptosis. Cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) can delay this apoptosis via increases in the cellular levels of Mcl-1, an anti-apoptotic protein of the Bcl-2 family with a rapid turnover rate. Here we have shown that inhibition of the proteasome (a) decreases the rate of Mcl-1 turnover within neutrophils and (b) significantly delays apoptosis. This led us to determine whether GM-CSF could enhance neutrophil survival by altering the rate of Mcl-1 turnover. Addition of GM-CSF to neutrophils enhanced Mcl-1 stability and delayed apoptosis by signaling pathways requiring PI3K/Akt and p44/42 Erk/Mek, because inhibitors of these pathways completely abrogated the GM-CSF-mediated effect on both Mcl-1 stability and apoptosis delay. Conversely, induction of Mcl-1 hyperphosphorylation by the phosphatase inhibitor, okadaic acid, significantly accelerated both Mcl-1 turnover and apoptosis. Neither the calpain inhibitor, carbobenzoxy-valinyl-phenylalaninal, nor the pan caspase inhibitor, benzyloxycarbonyl-VAD-fluoromethylketone, had any effect on Mcl-1 stability under these conditions. These observations indicate that profound changes in the rate of neutrophil apoptosis following cytokine signaling occur via dynamic changes in the rate of Mcl-1 turnover via the proteasome.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Dept Med, Liverpool L69 7ZB, Merseyside, England	University of Liverpool; University of Liverpool	Edwards, SW (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg, Liverpool L69 7ZB, Merseyside, England.	S.W.Edwards@liv.ac.uk	Moots, Robert/AAM-8091-2020	Edwards, Steven/0000-0002-7074-0552				Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Akgul C, 2003, CELL MOL LIFE SCI, V60, P2402, DOI 10.1007/s00018-003-3110-z; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Basu A, 2002, INT J ONCOL, V21, P597; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEL PL, 1997, SCIENCE, V278, P687; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Edwards SW, 2003, CHEM IMMUNOL, V83, P204; EDWARDS SW, 1994, BIOCH PHYSL NEUTROP; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fossati G, 2003, J IMMUNOL, V170, P1964, DOI 10.4049/jimmunol.170.4.1964; Fukiage C, 1997, BBA-MOL BASIS DIS, V1361, P304, DOI 10.1016/S0925-4439(97)00043-4; Gasmi L, 1996, BLOOD, V87, P3442, DOI 10.1182/blood.V87.8.3442.bloodjournal8783442; Gojo I, 2002, CLIN CANCER RES, V8, P3527; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; Hirai I, 2001, BIOCHEM J, V359, P345, DOI 10.1042/0264-6021:3590345; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Johnson AL, 1999, ENDOCRINOLOGY, V140, P5465, DOI 10.1210/en.140.12.5465; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; Leuenroth SJ, 2000, J LEUKOCYTE BIOL, V68, P158; Makishima T, 2000, J BIOCHEM-TOKYO, V128, P399, DOI 10.1093/oxfordjournals.jbchem.a022767; MARTIN MC, 2001, J BIOL CHEM, V17, P17; Moulding D, 1996, BIOLOGICALS, V24, P301, DOI 10.1006/biol.1996.0041; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Moulding DA, 1999, J LEUKOCYTE BIOL, V65, P875, DOI 10.1002/jlb.65.6.875; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; MURRAY EJB, 1995, METABOLISM, V44, P141, DOI 10.1016/0026-0495(95)90254-6; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Poruchynsky MS, 2001, BIOCHEM PHARMACOL, V62, P1469, DOI 10.1016/S0006-2952(01)00804-8; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; SAVILL J, 1995, SEMIN CELL BIOL, V6, P385, DOI 10.1016/S1043-4682(05)80009-1; SAVILL J, 1992, CLIN SCI, V83, P649, DOI 10.1042/cs0830649; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Stringer RE, 1996, BRIT J HAEMATOL, V92, P169, DOI 10.1046/j.1365-2141.1996.00307.x; Suzuki K, 2001, J IMMUNOL, V166, P1185, DOI 10.4049/jimmunol.166.2.1185; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7; Whyte MKB, 1997, J LEUKOCYTE BIOL, V62, P195, DOI 10.1002/jlb.62.2.195; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yoon JH, 2002, CANCER RES, V62, P6500; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200	59	195	198	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26915	26921		10.1074/jbc.M313875200	http://dx.doi.org/10.1074/jbc.M313875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078892	hybrid			2022-12-25	WOS:000222120400016
J	Mizuno, K; Whittaker, MM; Bachinger, HP; Whittaker, JW				Mizuno, K; Whittaker, MM; Bachinger, HP; Whittaker, JW			Calorimetric studies on the tight binding metal interactions of Escherichia coli manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION POTENTIALS; POTENTIOMETRIC TITRATIONS; THERMUS-THERMOPHILUS; SCANNING CALORIMETRY; IRON; SITE; DENATURATION; RESOLUTION; PATHWAY; ENZYME	Escherichia coli apomanganese superoxide dismutase, prepared by removing the native metal ion under denaturing conditions, exhibits thermally triggered metal uptake behavior previously observed for thermophilic and hyperthermophilic superoxide dismutases but over a lower temperature range. Differential scanning calorimetry of aposuperoxide dismutase and metalated superoxide dismutase unfolding transitions has provided quantitative estimates of the metal binding affinities for manganese superoxide dismutase. The binding constant for Mn(II) (K-Mn( II) = 3.2 x 10(8) M-1) is surprisingly low in light of the essentially irreversible metal binding characteristic of this family of proteins and indicates that metal binding and release processes are dominated by kinetic, rather than thermodynamic, constraints. The kinetic stability of the metalloprotein complex can be traced to stabilization by elements of the protein that are independent of the presence or absence of the metal ion reflected in the thermally triggered metalation characteristic of these proteins. Binding constants for Mn(III), Fe( II), and Fe( III) complexes were estimated using quasireversible values for the unfolding enthalpy and DeltaC(p) for apo-Mn superoxide dismutase and the observed T-m values for unfolding the metalated species in the absence of denaturants. For manganese and iron complexes, an oxidation state-dependent binding affinity reflects the protein perturbation of the metal redox potential.	Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Res, Shriners Hosp Children, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Whittaker, JW (corresponding author), Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, OGI Sch Sci & Engn, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	jim@ebs.ogi.edu	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042680] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42680] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETTE WC, 1983, BIOCHEMISTRY-US, V22, P624, DOI 10.1021/bi00272a015; BEYER WF, 1991, J BIOL CHEM, V266, P303; BEYER WF, 1989, BIOCHEMISTRY-US, V28, P4403, DOI 10.1021/bi00436a042; Blaber SI, 1999, BIOPHYS J, V77, P470, DOI 10.1016/S0006-3495(99)76904-3; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; Brewer JM, 2001, INT J BIOL MACROMOL, V28, P213, DOI 10.1016/S0141-8130(00)00168-9; Edwards RA, 1998, J BIOL INORG CHEM, V3, P161, DOI 10.1007/s007750050217; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; KEELE BB, 1970, J BIOL CHEM, V245, P6176; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; LAWRENCE GD, 1979, BIOCHEMISTRY-US, V18, P3045, DOI 10.1021/bi00581a021; Leveque VJP, 2001, BIOCHEMISTRY-US, V40, P10586, DOI 10.1021/bi010792p; LIN LN, 1993, BIOCHEM J, V293, P517, DOI 10.1042/bj2930517; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Luk E, 2003, P NATL ACAD SCI USA, V100, P10353, DOI 10.1073/pnas.1632471100; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; Martell A.E., 1974, CRITICAL STABILITY C, V1, P204; McCord J M, 1993, New Horiz, V1, P70; OSE DE, 1979, ARCH BIOCHEM BIOPHYS, V194, P360, DOI 10.1016/0003-9861(79)90628-3; Quijano C, 2001, J BIOL CHEM, V276, P11631, DOI 10.1074/jbc.M009429200; Vance CK, 2001, BIOCHEMISTRY-US, V40, P13079, DOI 10.1021/bi0113317; Vance CK, 1998, J AM CHEM SOC, V120, P461, DOI 10.1021/ja972060j; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; Whittaker JW, 2000, MET IONS BIOL SYST, V37, P587; Whittaker MM, 1997, BIOCHEMISTRY-US, V36, P8923, DOI 10.1021/bi9704212; Whittaker MM, 1998, J BIOL CHEM, V273, P22188, DOI 10.1074/jbc.273.35.22188; Whittaker MM, 1999, J BIOL CHEM, V274, P34751, DOI 10.1074/jbc.274.49.34751; Whittaker MM, 2000, J BIOL INORG CHEM, V5, P402; YOST FJ, 1973, J BIOL CHEM, V248, P4905; Youn HD, 1996, BIOCHEM J, V318, P889, DOI 10.1042/bj3180889	33	49	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27339	27344		10.1074/jbc.M400813200	http://dx.doi.org/10.1074/jbc.M400813200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15082717	hybrid			2022-12-25	WOS:000222120400064
J	Brown, JM; Boysen, MS; Chung, S; Fabiyi, O; Morrison, RF; Mandrup, S; McIntosh, MK				Brown, JM; Boysen, MS; Chung, S; Fabiyi, O; Morrison, RF; Mandrup, S; McIntosh, MK			Conjugated linoleic acid induces human adipocyte delipidation - Autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KINASE-MEDIATED PHOSPHORYLATION; INDUCED INSULIN-RESISTANCE; ACTIVATED RECEPTOR-GAMMA; C-REACTIVE PROTEIN; HUMAN FAT-CELLS; FACTOR-ALPHA; GENE-EXPRESSION; TNF-ALPHA; INTERLEUKIN-6 IL-6	Dietary conjugated linoleic acid (CLA) reduces body fat in animals and some humans. Here we show that trans-10, cis-12 CLA, but not cis-9, trans-11 CLA, when added to cultures of stromal vascular cells containing newly differentiated human adipocytes, caused a time-dependent decrease in triglyceride content, insulin-stimulated glucose and fatty acid uptake, incorporation into lipid, and oxidation compared with controls. In parallel, gene expression of peroxisome proliferator-activated receptor-gamma and many of its downstream targets were diminished by trans-10, cis-12 CLA, whereas leptin gene expression was increased. Prior to changes in gene expression and metabolism, trans-10, cis-12 CLA caused a robust and sustained activation of mitogen-activated protein kinase kinase/extracellular signal-related kinase (MEK/ERK) signaling. Furthermore, the trans-10, cis-12 CLA-mediated activation of MEK/ERK could be attenuated by pretreatment with U0126 and pertussis toxin. In parallel, pretreatment with U0126 blocked the ability of trans-10, cis-12 CLA to alter gene expression and attenuate glucose and fatty acid uptake of the cultures. Intriguingly, the induction by CLA of MEK/ERK signaling was linked to hypersecretion of adipocytokines interleukin-6 and interleukin-8. Collectively, these data demonstrate for the first time that trans-10, cis-12 CLA decreases the triglyceride content of newly differentiated human adipocytes by inducing MEK/ERK signaling through the autocrine/paracrine actions of interleukins-6 and 8.	Univ N Carolina, Dept Nutr, Greensboro, NC 27402 USA; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	University of North Carolina; University of North Carolina Greensboro; University of Southern Denmark	McIntosh, MK (corresponding author), Univ N Carolina, Dept Nutr, 318 Stone Bldg, Greensboro, NC 27402 USA.	mkmcinto@uncg.edu	Mandrup, Susanne/B-6693-2008	Mandrup, Susanne/0000-0002-0961-5787; Chung, Soonkyu/0000-0001-6279-7017	NHLBI NIH HHS [R00 HL096166] Funding Source: Medline; NIDDK NIH HHS [R01DK-63070, R01 DK063070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL096166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Atta-ur-Rahman, 1999, CURR PHARM DESIGN, V5, P241; Belury MA, 2002, J NUTR, V132, P2995, DOI 10.1093/jn/131.10.2995; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; Brown JM, 2003, J LIPID RES, V44, P1287, DOI 10.1194/jlr.M300001-JLR200; Brown JM, 2001, J NUTR, V131, P2316, DOI 10.1093/jn/131.9.2316; Brown JM, 2003, J NUTR, V133, P3041, DOI 10.1093/jn/133.10.3041; Browning DD, 2000, AM J PHYSIOL-LUNG C, V279, pL1129, DOI 10.1152/ajplung.2000.279.6.L1129; Bruun JM, 2001, J CLIN ENDOCR METAB, V86, P1267, DOI 10.1210/jc.86.3.1267; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; COOK M, 1999, AD BIOL HORM SIGN S, pP26; Delany JP, 1999, AM J PHYSIOL-REG I, V276, pR1172, DOI 10.1152/ajpregu.1999.276.4.R1172; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Evans ME, 2002, J NUTR BIOCHEM, V13, P508, DOI 10.1016/S0955-2863(02)00211-5; Fasshauer M, 2003, BIOCHEM BIOPH RES CO, V301, P1045, DOI 10.1016/S0006-291X(03)00090-1; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; Fujishiro M, 2003, MOL ENDOCRINOL, V17, P487, DOI 10.1210/me.2002-0131; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; HA YL, 1987, CARCINOGENESIS, V8, P1881, DOI 10.1093/carcin/8.12.1881; HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kim SW, 2001, J BIOL CHEM, V276, P10199, DOI 10.1074/jbc.M010640200; Lagathu C, 2003, BIOCHEM BIOPH RES CO, V311, P372, DOI 10.1016/j.bbrc.2003.10.013; Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood-2002-08-2383; Lihn AS, 2003, AM J PHYSIOL-ENDOC M, V285, pE1072, DOI 10.1152/ajpendo.00206.2003; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MARSHALL MK, 1994, ENDOCRINOLOGY, V135, P141, DOI 10.1210/en.135.1.141; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Ostrowska E, 1999, J NUTR, V129, P2037, DOI 10.1093/jn/129.11.2037; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; Park Y, 1999, LIPIDS, V34, P243, DOI 10.1007/s11745-999-0359-7; Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x; Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8; Path G, 2001, J CLIN ENDOCR METAB, V86, P2281, DOI 10.1210/jc.86.5.2281; PETRUSCHKE T, 1993, J CLIN ENDOCR METAB, V76, P742, DOI 10.1210/jc.76.3.742; Riserus U, 2002, DIABETES CARE, V25, P1516, DOI 10.2337/diacare.25.9.1516; Riserus U, 2002, CIRCULATION, V106, P1925, DOI 10.1161/01.CIR.0000033589.15413.48; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Ryden M, 2002, J BIOL CHEM, V277, P1085, DOI 10.1074/jbc.M109498200; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Shimba S, 2001, J CELL SCI, V114, P2809; Souza SC, 2003, J CELL BIOCHEM, V89, P1077, DOI 10.1002/jcb.10565; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Tsuboyama-Kasaoka N, 2000, DIABETES, V49, P1534, DOI 10.2337/diabetes.49.9.1534; WEINER FR, 1991, J BIOL CHEM, V266, P23525; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Werle M, 2002, CARDIOVASC RES, V56, P284, DOI 10.1016/S0008-6363(02)00600-4; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135; Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhang HH, 2002, DIABETES, V51, P2929, DOI 10.2337/diabetes.51.10.2929	65	130	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26735	26747		10.1074/jbc.M401766200	http://dx.doi.org/10.1074/jbc.M401766200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15067015	Green Accepted, hybrid			2022-12-25	WOS:000222003000100
J	Karsten, V; Hegde, RS; Sinai, AP; Yang, M; Joiner, KA				Karsten, V; Hegde, RS; Sinai, AP; Yang, M; Joiner, KA			Transmembrane domain modulates sorting of membrane proteins in Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE GRANULE ANTIGEN; PARASITOPHOROUS VACUOLE MEMBRANE; ENDOPLASMIC-RETICULUM; MOLECULAR CHARACTERIZATION; SECRETORY PROTEINS; CYTOCHROME B(5); RETENTION; BIOGENESIS; SEQUENCE; DEGRADATION	Overlapping mechanisms that function simultaneously in the intracellular sorting of mammalian membrane proteins often confound delineation of individual sorting pathways. By analyzing sorting in the evolutionarily simpler organism Toxoplasma gondii, we demonstrate a role for transmembrane domain (TMD) length in modulating the signal-dependent segregation of membrane proteins to distinct intracellular organelles. The dense granule localization of the single pass transmembrane protein GRA4 could be completely rerouted to the Golgi and cell surface simply by replacement of its TMD with that from either vesicular stomatitis virus G or the low density lipoprotein (LDL) receptor. Mutational and biochemical analyses suggested that this effect was not caused by any specific sequence motif or strength of membrane association of the GRA4 TMD. Instead, a property imparted by the vesicular stomatitis virus G or LDL receptor TMDs, both of which are longer than the GRA4 TMD, appeared to be a decisive factor. Indeed, shortening the LDL receptor TMD to a length similar to that of GRA4 resulted in dense granule localization, whereas lengthening the GRA4 TMD resulted in rerouting to the Golgi. From these data, we conclude that although the TMD may not necessarily be a sole determinant in membrane protein sorting, its properties can markedly modulate the utilization of more conventional signal-mediated sorting pathways.	Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06520 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	Yale University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Joiner, KA (corresponding author), Univ Arizona, Hlth Sci Ctr, Coll Med, 1501 N Campbell Ave,Rm 2205, Tucson, AZ 85724 USA.	kjoiner@u.arizona.edu	Joiner, Keith/AAH-1059-2021	Hegde, Ramanujan/0000-0001-8338-852X; Joiner, Keith/0000-0003-3062-823X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008752, ZIAHD008752] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BERMUDES D, 1992, MOL BIOL CELL, V3, pA208; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Carey KL, 2000, MOL BIOCHEM PARASIT, V105, P25, DOI 10.1016/S0166-6851(99)00160-7; CESBRONDELAUW MF, 1989, P NATL ACAD SCI USA, V86, P7537, DOI 10.1073/pnas.86.19.7537; Dubey JP, 1998, CLIN MICROBIOL REV, V11, P267, DOI 10.1128/CMR.11.2.267; Fischer HG, 1998, MOL BIOCHEM PARASIT, V91, P251, DOI 10.1016/S0166-6851(97)00227-2; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; Hager KM, 1999, J CELL SCI, V112, P2631; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HIGH KP, 1994, J BIOL CHEM, V269, P9105; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Hoppe HC, 2000, CELL MICROBIOL, V2, P569, DOI 10.1046/j.1462-5822.2000.00081.x; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; Karsten V, 1997, METHODS, V13, P103, DOI 10.1006/meth.1997.0503; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Labruyere E, 1999, MOL BIOCHEM PARASIT, V102, P311, DOI 10.1016/S0166-6851(99)00092-4; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; Lecordier L, 1999, MOL BIOL CELL, V10, P1277, DOI 10.1091/mbc.10.4.1277; LECORDIER L, 1993, MOL BIOCHEM PARASIT, V59, P143, DOI 10.1016/0166-6851(93)90015-P; LECORDIER L, 1995, MOL BIOCHEM PARASIT, V70, P85, DOI 10.1016/0166-6851(95)00010-X; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MERCIER C, 1993, MOL BIOCHEM PARASIT, V58, P71, DOI 10.1016/0166-6851(93)90092-C; MEVELEC MN, 1992, MOL BIOCHEM PARASIT, V56, P227, DOI 10.1016/0166-6851(92)90172-G; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Ngo HM, 2003, J BIOL CHEM, V278, P5343, DOI 10.1074/jbc.M208291200; OSSORIO PN, 1994, J BIOL CHEM, V269, P15350; PARMLEY SF, 1993, MOL BIOCHEM PARASIT, V57, P161, DOI 10.1016/0166-6851(93)90253-T; Pedrazzini E, 2000, J CELL BIOL, V148, P899, DOI 10.1083/jcb.148.5.899; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Sato K, 2003, MOL BIOL CELL, V14, P3605, DOI 10.1091/mbc.E02-12-0777; Striepen B, 1998, MOL BIOCHEM PARASIT, V92, P325, DOI 10.1016/S0166-6851(98)00011-5; Striepen B, 2001, MOL BIOCHEM PARASIT, V113, P45, DOI 10.1016/S0166-6851(00)00379-0; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Zaliauskiene L, 2000, MOL BIOL CELL, V11, P2643, DOI 10.1091/mbc.11.8.2643	43	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26052	26057		10.1074/jbc.M400480200	http://dx.doi.org/10.1074/jbc.M400480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15056659	hybrid			2022-12-25	WOS:000222003000017
J	Tong, XJ; O'Kelly, J; Xie, D; Mori, A; Lemp, N; McKenna, R; Miller, CW; Koeffler, HP				Tong, XJ; O'Kelly, J; Xie, D; Mori, A; Lemp, N; McKenna, R; Miller, CW; Koeffler, HP			Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway	ONCOGENE			English	Article						Cyr61; beta-catenin; c-myc; p53; p21; p130	HUMAN-PAPILLOMAVIRUS TYPE-16; IMMEDIATE-EARLY GENE; GLYCOGEN-SYNTHASE KINASE; WILD-TYPE P53; BETA-CATENIN; C-MYC; TUMOR-SUPPRESSOR; BREAST-CANCER; P53-DEPENDENT APOPTOSIS; FUNCTIONAL INTERACTION	Cysteine-rich protein 61 (Cyr61) is a growth factor-inducible, immediate-early gene that has multifaceted activities in various cancers. In a previous study, we found that Cyr61 inhibited the growth of the H520 and H460 non-small-cell lung cancer (NSCLC) cell lines. In further studies, we now report that p53 plays a pivotal role in Cyr61-dependent cellular growth arrest. Blockin g Cyr61 with a Cyr61 antibody resulted in the downregulation of expression of p53 and p21, as well as partially reversing the growth suppression of H520-Cyr61 cells. Proliferation of NSCLC cell lines (NCI-H157, H125, H1299), having a mutant p53, were not suppressed by Cyr61. Inhibition of wild-type p53, by either human papilloma virus type 16 E6 or a dominant-negative p53, resulted in the rescue of the growth suppression mediated by Cyr61 in the H520-Cyr61 cells. The enhanced levels of p21(WAF1) and p130/RB2, in the Cyr61-expressing H520-Cyr61 cells, were also inhibited by blocking p53 showing that p21 and p130 were induced by p53 in these cells. In addition, levels of both c-myc and beta-catenin increased in Cyr61 stably transfected H520 cells. Moreover, beta-catenin was translocated into the nucleus in these cells. Inhibition of c-myc expression in the H520-Cyr61 cells with antisense c-myc resulted in their decreased levels of p53. Transfecting cells with a dominant-negative T-cell factor (TCF4), the specific inhibitor of the beta-catenin/TCF4 complex, downregulated the expression of c-myc. Taken together, the data suggest that Cyr61 suppressed the growth of NSCLC cells by triggering a signal transduction pathway through beta-catenin. In this pathway, Cyr61 activated the beta-catenin/TCF4 complex, which promoted the expression of c-myc and the latter induced expression of p53, and p53 upregulated p21(WAF1) and p130/RB2, resulting in growth arrest.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Surg, Los Angeles, CA 90048 USA; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Chinese Acad Sci, Inst Nutr Sci, Shanghai, Peoples R China	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Peking University; Chinese Academy of Sciences	O'Kelly, J (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.	okellyj@cshs.org		Xie, Dong/0000-0002-1150-8657	NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NCI NIH HHS [CA90388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; BODNER SM, 1992, ONCOGENE, V7, P743; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Clevers H, 2000, NAT CELL BIOL, V2, pE177, DOI 10.1038/35036424; Cox RT, 1998, CURR BIOL, V8, pR140, DOI 10.1016/S0960-9822(98)70081-8; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dang CV, 1999, MOL CELL BIOL, V19, P1; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARPER JW, 1993, CELL, V75, P805; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huang SL, 2001, CANCER RES, V61, P3373; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1992, NEW ENGL J MED, V326, P1350, DOI 10.1056/NEJM199205143262008; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marutani M, 1999, CANCER RES, V59, P4765; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Pilarsky CP, 1998, PROSTATE, V36, P85; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Seewaldt VL, 2001, CANCER RES, V61, P616; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shih IM, 2000, CANCER RES, V60, P1671; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stiegler P, 1999, ANAL QUANT CYTOL, V21, P363; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2000, CANCER RES, V60, P5603; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	81	77	96	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4847	4855		10.1038/sj.onc.1207628	http://dx.doi.org/10.1038/sj.onc.1207628			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077166				2022-12-25	WOS:000222104200005
J	Li, PF; Li, CR; Zhao, XH; Zhang, XH; Nicosia, SV; Bai, WL				Li, PF; Li, CR; Zhao, XH; Zhang, XH; Nicosia, SV; Bai, WL			P27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D-3 in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box Protein/Skp2 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D ANALOG; INHIBITOR P27; PROSTATE-CANCER; ANDROGEN RECEPTOR; GROWTH; D-3; APOPTOSIS; OVEREXPRESSION; ACCUMULATION; EXPRESSION	p27(Kip1) (p27) is a tumor suppressor whose stability is controlled by proteasome-mediated degradation, a process directed in part by cyclin-dependent kinase 2 (CDK2)-mediated phosphorylation of p27 at Thr(187) and its subsequent interaction with the Skp1-Cullin-F-box protein/Skp2 (Skp2) ubiquitin ligase. The present study shows that 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) arrests ovarian cancer cells in G(1) by stabilizing the p27 protein. 1,25( OH) 2D3 initiates a chain of events by decreasing the amounts of cyclin E and cyclin E-associated CDK2 activity. As a result, p27 phosphorylation at Thr187 and consequently the interaction with Skp2 are decreased. 1,25( OH) 2D3 also increases p27 stability by decreasing the abundance of Skp2. It is the combined effect of 1,25(OH)(2)D-3 on both the CDK2-dependent phosphorylation of p27, and thus its affinity for Skp2, and Skp2 expression that dramatically increases the stability of the p27 protein. Similar to its effects in ovarian cancer cells, 1,25( OH) 2D3 induces p27 accumulation in wild type mouse embryo fibroblasts and arrests wild type but not p27-null mouse embryo fibroblasts in G(1). Stable expression of Skp2 in OVCAR3 cells diminishes the G(1) arrest and decreases the growth response to 1,25( OH) 2D3. Taken together, the results of this study identify p27 as the key mediator of 1,25(OH)(2)D-3-induced growth suppression in G(1) and show that the hormone achieves this by decreasing the activity of CDK2 and reducing the abundance of Skp2, which act together to degrade p27.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Drug Discovery, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Bai, WL (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@hsc.usf.edu	Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Ahonen MH, 2000, INT J CANCER, V86, P40, DOI 10.1002/(SICI)1097-0215(20000401)86:1<40::AID-IJC6>3.0.CO;2-E; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHIDA K, 1985, CANCER RES, V45, P5426; Courjal F, 1996, INT J CANCER, V69, P247; DELUCA HF, 1990, METABOLISM, V39, P3, DOI 10.1016/0026-0495(90)90263-C; DEVASA SS, 1999, ATLAS CANC MORTALITY, P226; Diaz GD, 2000, CANCER RES, V60, P2304; DODD RC, 1983, P NATL ACAD SCI-BIOL, V80, P7538, DOI 10.1073/pnas.80.24.7538; DOKOH S, 1983, ENDOCRINOLOGY, V112, P200, DOI 10.1210/endo-112-1-200; EISMAN JA, 1989, P SOC EXP BIOL MED, V191, P221; EISMAN JA, 1987, CANCER RES, V47, P21; Feldman D, 1995, Adv Exp Med Biol, V375, P53; Guzey M, 2002, MOL CANCER THER, V1, P667; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; JAMES SY, 1994, J ENDOCRINOL, V141, P555, DOI 10.1677/joe.0.1410555; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Johnson JA, 1996, HISTOCHEM CELL BIOL, V105, P7, DOI 10.1007/BF01450873; Kim KK, 2003, PATHOL INT, V53, P291, DOI 10.1046/j.1440-1827.2003.01477.x; LEFKOWITZ ES, 1994, INT J EPIDEMIOL, V23, P1133, DOI 10.1093/ije/23.6.1133; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lin R, 2003, ENDOCRINOLOGY, V144, P749, DOI 10.1210/en.2002-0026; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu W, 2002, AM J PATHOL, V160, P511, DOI 10.1016/S0002-9440(10)64870-5; Liu W, 2002, BRAIN PATHOL, V12, P412; Masciullo V, 1999, CANCER RES, V59, P3790; Miettinen S, 2004, INT J CANCER, V108, P367, DOI 10.1002/ijc.11520; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Munker R, 1996, BLOOD, V88, P2201, DOI 10.1182/blood.V88.6.2201.bloodjournal8862201; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; SATO T, 1982, TOHOKU J EXP MED, V138, P445, DOI 10.1620/tjem.138.445; SAUNDERS DE, 1992, GYNECOL ONCOL, V44, P131, DOI 10.1016/0090-8258(92)90028-H; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2000, CANCER RES, V60, P3689; Shigemasa K, 2003, CLIN CANCER RES, V9, P1756; Shigemasa K, 2001, INT J ONCOL, V18, P953; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Sung V, 2000, MOL CELL ENDOCRINOL, V164, P133, DOI 10.1016/S0303-7207(00)00226-4; Wade WN, 2002, J BIOL CHEM, V277, P37301, DOI 10.1074/jbc.M204162200; Wang QM, 1997, CANCER RES, V57, P2851; Wang QM, 1996, CANCER RES, V56, P264; WATERHOUSE J, 1976, CANC INCIDENCE 5 CON, V2; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373	45	99	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25260	25267		10.1074/jbc.M311052200	http://dx.doi.org/10.1074/jbc.M311052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075339	hybrid			2022-12-25	WOS:000221827900044
J	Rim, JS; Xue, BZ; Gawronska-Kozak, B; Kozak, LP				Rim, JS; Xue, BZ; Gawronska-Kozak, B; Kozak, LP			Sequestration of thermogenic transcription factors in the cytoplasm during development of brown adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; DIET-INDUCED OBESITY; RETINOID-X-RECEPTOR; PPAR-GAMMA; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; NUCLEAR-LOCALIZATION; BINDING PROTEIN	Transcription factors that regulate gene expression during adipogenesis also control the expression of genes of thermogenesis in brown adipose tissue, in particular, the mitochondrial uncoupling protein gene (Ucp1). There is evidence that a plasticity exists among adipocytes in which activation of the Ucp1 gene together with mitochondrial biogenesis can increase the brown adipocyte character of white fat. To understand this process, we have characterized the changes in transcription that occur in interscapular brown adipocytes during development. We have found dramatic reductions in both DNA-binding activity to probes and immunoreactive protein for peroxisome proliferator-activated receptor, retinoid X receptor, CCAAT/enhancer binding protein, and cAMP-response element-binding protein regulatory motifs in nuclear extracts when mice reach adulthood. Exposure of adult mice to the cold, which reactivates Ucp1 expression, leads to a re-accumulation of factors in the nucleus. We propose that transcription factors are sequestered in the cytoplasm as mice age under conditions of reduced thermogenesis. Changes in isoform subtypes for peroxisome proliferator-activated receptor-gamma and cAMP-response element-binding proteins indicate an additional level of control on gene expression during thermogenesis. The increased movement of the RIIbeta protein kinase A regulatory subunit into the nucleus with age suggests a mechanism for regulating the phosphorylation of transcription factors in the nucleus in response to the thermogenic requirements of the animal. Nuclear factor-kappaB has been used as a model to demonstrate that the nuclear localization of transcription factors in brown fat are reduced during post-natal development. Furthermore, it was found by immunofluorescence that adrenergic stimulation of primary adipocyte cultures causes an increase of both the protein kinase A catalytic alpha-subunit and nuclear factor-kappaB into the nucleus.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Kozak, LP (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	kozaklp@pbrc.edu	Gawronska-Kozak, Barbara/A-2980-2017	Gawronska-Kozak, Barbara/0000-0002-2006-8534	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058152] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58152] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BUKOWIECKI L, 1982, AM J PHYSIOL, V242, pE353, DOI 10.1152/ajpendo.1982.242.6.E353; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Coulter AA, 2003, PHYSIOL GENOMICS, V14, P139, DOI 10.1152/physiolgenomics.00057.2003; COUSIN B, 1992, J CELL SCI, V103, P931; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Fredriksson JM, 2001, BBA-MOL CELL RES, V1538, P206, DOI 10.1016/S0167-4889(01)00070-2; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GRANNEMAN JG, 1990, J PHARMACOL EXP THER, V254, P508; Guardiola-Diaz HM, 1999, J BIOL CHEM, V274, P23368, DOI 10.1074/jbc.274.33.23368; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HOUSTEK J, 1988, BIOCHIM BIOPHYS ACTA, V935, P19, DOI 10.1016/0005-2728(88)90103-X; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Liu XT, 2003, J CLIN INVEST, V111, P399, DOI 10.1172/JCI200315737; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MILLER CA, 1991, CARCINOGENESIS, V12, P269, DOI 10.1093/carcin/12.2.269; NEDERGAARD J, 1986, BROWN ADIPOSE TISSUE, P153; Nicholls DG, 1986, BROWN ADIPOSE TISSUE, P1; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; REHNMARK S, 1990, J BIOL CHEM, V265, P22204; Rim JS, 2002, J BIOL CHEM, V277, P34589, DOI 10.1074/jbc.M108866200; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; SIDMAN RL, 1956, ANAT REC, V124, P581, DOI 10.1002/ar.1091240306; SIDMAN RL, 1954, ANAT RECORD, V118, P487, DOI 10.1002/ar.1091180303; Silva JE, 2001, J CLIN INVEST, V108, P35, DOI 10.1172/JCI13397; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VANCUROVA I, 1995, J CELL SCI, V108, P779; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1431, DOI 10.1210/mend-5-10-1431; Williams SC, 1997, GENE EXPRESSION, V6, P371; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yang LM, 1997, J IMMUNOL, V158, P2522; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	71	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25916	25926		10.1074/jbc.M402102200	http://dx.doi.org/10.1074/jbc.M402102200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073176	hybrid			2022-12-25	WOS:000221827900124
J	Roger, O; Lavigne, R; Mahmoud, M; Buisson, C; Onno, B; Zhang, BL; Robins, RJ				Roger, O; Lavigne, R; Mahmoud, M; Buisson, C; Onno, B; Zhang, BL; Robins, RJ			Quantitative H-2 NMR at natural abundance can distinguish the pathway used for glucose fermentation by lactic acid bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLUCOISOMERASE-CATALYZED INTERCONVERSION; MESENTEROIDES SUBSP CREMORIS; LACTATE-DEHYDROGENASE; LACTOCOCCUS-LACTIS; LEUCONOSTOC-MESENTEROIDES; LACTOBACILLUS-PLANTARUM; ISOTOPIC DISCRIMINATION; HEXOSE PHOSPHATES; CO-METABOLISM; HYDROGEN	For any given metabolic pathway, isotope redistribution coefficients (a(ij)) that characterize the specific derivation of each hydrogen atom can be defined. By using quantitative deuterium NMR, the redistribution of deuterium at natural abundance in lactic acid produced by the bacterial fermentation of glucose has been determined for each non-labile hydrogen atom of glucose or water and the hydrogen atoms of lactic acid. Distinct differences are observed in the lactic acid isolated from Lactococcus lactis and Leuconostoc mesenteroides that can be interpreted in terms of the different fermentative pathways used. Specifically, the affiliations observed between the H1, H3, and H4 positions of glucose with methyl and hydroxymethylene of lactic acid can give quantitative information on whether the glycolytic or the reductive pentose-phosphate pathway was involved in glucose catabolism.	Univ Nantes, CNRS UMR6006, Lab Anal Isotop & Electrochim Metab, Grp Fractionnement Isotop Metab, F-44322 Nantes, France; ENITIAA, Lab Microbiol Alimentaire Ind, F-44322 Nantes, France	Nantes Universite; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique	Robins, RJ (corresponding author), Univ Nantes, CNRS UMR6006, Lab Anal Isotop & Electrochim Metab, Grp Fractionnement Isotop Metab, BP 99208, F-44322 Nantes, France.	richard.robins@chimbio.univ-nantes.fr	Mahmoud, Mohamed hassanein/J-4178-2015; mahmoud, Mohamed/M-7486-2013; Lavigne, Regis/A-8523-2012	Mahmoud, Mohamed hassanein/0000-0003-2928-3828; mahmoud, Mohamed/0000-0002-6711-9204; Robins, Richard/0000-0002-5325-8983				CocaignBousquet M, 1996, ANTON LEEUW INT J G, V70, P253, DOI 10.1007/BF00395936; DAVIS L, 1972, J BIOL CHEM, V247, P5862; DEMOSS RD, 1955, METHOD ENZYMOL, V1, P328, DOI 10.1016/0076-6879(55)01047-1; DENNIS D, 1960, J BIOL CHEM, V235, P810; Hoefnagel MHN, 2002, MICROBIOL-SGM, V148, P1003, DOI 10.1099/00221287-148-4-1003; Koebmann BJ, 2002, ANTON LEEUW INT J G, V82, P237, DOI 10.1023/A:1020643918089; LAREAU RD, 1989, BIOCHEMISTRY-US, V28, P3619, DOI 10.1021/bi00434a070; LIEMANS V, 1989, BIOCHIM BIOPHYS ACTA, V998, P111, DOI 10.1016/0167-4838(89)90261-6; MALAISSE WJ, 1990, MOL CELL BIOCHEM, V93, P153; MCDONOUGH M, 1961, J BIOL CHEM, V236, P1220; Monnet C, 2000, APPL ENVIRON MICROB, V66, P5518, DOI 10.1128/AEM.66.12.5518-5520.2000; Neves AR, 2002, J BIOL CHEM, V277, P28088, DOI 10.1074/jbc.M202573200; Pionnier S, 2003, J AGR FOOD CHEM, V51, P2076, DOI 10.1021/jf0259617; Pionnier S, 2002, ANAL BIOCHEM, V307, P138, DOI 10.1016/S0003-2697(02)00005-2; Robins Richard J., 2003, Phytochemistry Reviews, V2, P87, DOI 10.1023/B:PHYT.0000004301.52646.a8; SCHMITT P, 1991, J FERMENT BIOENG, V71, P72, DOI 10.1016/0922-338X(91)90308-4; SCHMITT P, 1992, APPL MICROBIOL BIOT, V36, P679, DOI 10.1007/BF00183249; Silvestre V, 2001, ANAL CHEM, V73, P1862, DOI 10.1021/ac0013204; TAGUCHI H, 1991, J BIOL CHEM, V266, P12588; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; THOMSON JF, 1964, BIOCHIM BIOPHYS ACTA, V85, P177, DOI 10.1016/0926-6569(64)90239-1; VEDAMUTHU ER, 1994, J DAIRY SCI, V77, P2725, DOI 10.3168/jds.S0022-0302(94)77215-5; Zhang BL, 2003, BIOORG CHEM, V31, P227, DOI 10.1016/S0045-2068(03)00051-8; Zhang BL, 2002, J AGR FOOD CHEM, V50, P1574, DOI 10.1021/jf010776z; Zhang BL, 2000, BIOORG CHEM, V28, P1, DOI 10.1006/bioo.1999.1145; ZHANG HL, 1995, J BIOL CHEM, V270, P16023, DOI 10.1074/jbc.270.27.16023; [No title captured]	27	17	17	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24923	24928		10.1074/jbc.M401232200	http://dx.doi.org/10.1074/jbc.M401232200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15051719	hybrid			2022-12-25	WOS:000221827900005
J	Li, CY; Roy, K; Dandridge, K; Naren, AP				Li, CY; Roy, K; Dandridge, K; Naren, AP			Molecular assembly of cystic fibrosis transmembrane conductance regulator in plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; PROTEIN-KINASE; EPITHELIAL-CELLS; CROSS-LINKING; SYNTAXIN 1A; RECONSTITUTION; RECEPTOR; MONOMER; BINDING	Based on electrophysiological measurements, it has been argued that the active form of cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is a multimer. It has also been demonstrated that this multimerization is likely due to PDZ domain-interacting partners. Here we demonstrate that although CFTR in vitro can self-associate into multimers, which depends on PDZ-based interactions, this may not be the case in cell membrane. Using chemical cross-linking, we demonstrated that CFTR exists as a higher order complex in cell membrane. However, this higher order complex is predominantly CFTR dimers, and the PDZ-interacting partners (Na+/H+ exchanger regulatory factor-1 (NHERF1) and NHERF2) constitute similar to2% of this complex. Interestingly solubilizing membrane expressing CFTR in detergents such as Triton X-100, Nonidet P-40, deoxy-cholate, and SDS tended to destabilize the CFTR dimers and dissociate them into monomeric form. The dimerization of CFTR was tightly regulated by cAMP-dependent protein kinase-dependent phosphorylation and did not depend on the active form of the channel. In addition, the dimerization was not influenced by either the PDZ motif or its interacting partners ( NHERF1 and NHERF2). We also demonstrated that other signaling-related proteins such as Gbeta and syntaxin 1A can be in this higher order complex of CFTR as well. Our studies provide a deeper understanding of how the CFTR assembly takes place in native cell membrane.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Naren, AP (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 420 NASH,894 Union Ave, Memphis, TN 38163 USA.	anaren@utmem.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058545] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58545] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 2003, CURR OPIN CELL BIOL, V15, P423, DOI 10.1016/S0955-0674(03)00084-X; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Chen JH, 2002, J MEMBRANE BIOL, V188, P55, DOI 10.1007/s00232-001-0174-2; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Fancy DA, 2000, CURR OPIN CHEM BIOL, V4, P28, DOI 10.1016/S1367-5931(99)00047-2; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hallows KR, 2003, AM J PHYSIOL-CELL PH, V284, pC1297, DOI 10.1152/ajpcell.00227.2002; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Inoue G, 1999, P NATL ACAD SCI USA, V96, P14919, DOI 10.1073/pnas.96.26.14919; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; MIDDAUGH CR, 1983, MOL CELL BIOCHEM, V50, P115; Mohler Peter J, 2002, Methods Mol Med, V70, P383; Naren Anjaparavanda P, 2002, Methods Mol Med, V70, P175; Naren AP, 2000, J CLIN INVEST, V105, P377, DOI 10.1172/JCI8631; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Price Daniel, 2003, Methods Mol Biol, V218, P255; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; RIORDAN JR, 1989, SCIENCE, V245, P1066; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; SMITH JJ, 1994, J CLIN INVEST, V93, P1307, DOI 10.1172/JCI117087; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627; Zhu T, 1999, J BIOL CHEM, V274, P29102, DOI 10.1074/jbc.274.41.29102	37	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24673	24684		10.1074/jbc.M400688200	http://dx.doi.org/10.1074/jbc.M400688200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15060073	hybrid			2022-12-25	WOS:000221702500098
J	Mishra, S; Murphy, LJ				Mishra, S; Murphy, LJ			Tissue transglutaminase has intrinsic kinase activity - Identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; PHOSPHORYLATION; FIBRONECTIN; ACTIVATION; APOPTOSIS; DOMAIN; SITES; G(H); RHOA; GTP	Tissue transglutaminase (TG2) is a ubiquitous enzyme that cross-links glutamine residues with lysine residues, resulting in protein polymerization, cross-linking of dissimilar proteins, and incorporation of diamines and polyamines into proteins. It has not previously been known to have kinase activity. Recently, insulin-like growth factor-binding protein-3 (IGFBP-3) has been reported to be phosphorylated by breast cancer cell membranes. We purified the IGFBP-3 kinase activity from solubilized T47D breast cancer cell membranes using gel filtration, ion-exchange chromatography, and IGFBP-3 affinity chromatography. The fractions containing kinase activity were further purified by high pressure liquid chromatography and analyzed by tandem mass spectroscopy. TG2 was detected in fractions containing kinase activity. Antisera to TG2 and protein A-Sepharose were used to immunoprecipitate TG2 from membrane fractions. The immunoprecipitates retained IGFBP3 kinase, whereas immunoprecipitation deleted kinase activity in the membrane supernatant. The inhibitors of TG2, cystamine and monodansyl cadaverine, abolished the ability of the T47D cell membrane preparation to phosphorylate IGFBP-3. Both TG2 purified from guinea pig liver and recombinant human TG2 expressed in insect cells were able to phosphorylate IGFBP-3. TG2 kinase activity was inhibited in a concentration-dependent fashion by calcium, which has previously been shown to be important for the cross-linking activity of TG2. These data provide compelling evidence that TG2 has intrinsic kinase activity, a function that has not previously been ascribed to TG2. Furthermore, we provide evidence that TG2 is a major component of the IGFBP-3 kinase activity present on breast cancer cell membranes.	Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Murphy, LJ (corresponding author), Univ Manitoba, John Buhler Res Ctr, Rm 843,715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	ljmurph@cc.umanitoba.ca	Mishra, Suresh/W-1633-2019	Mishra, Suresh/0000-0002-0364-1538				Akimov SS, 2001, J CELL SCI, V114, P2989; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; GRIFFIN M, 2000, TISSUE TRANSGLUTAMIN, P223; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; HOECK WG, 1994, J CELL BIOCHEM, V56, P262, DOI 10.1002/jcb.240560220; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kang SK, 2002, BIOCHEM BIOPH RES CO, V293, P383, DOI 10.1016/S0006-291X(02)00197-3; KOCHHAR DM, 1993, PROG CLIN BIOL RES, V383, P815; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; Longobardi L, 2003, ENDOCRINOLOGY, V144, P1695, DOI 10.1210/en.2002-220959; Mishra S, 2003, ENDOCRINOLOGY, V144, P4042, DOI 10.1210/en.2003-0089; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, PROG GROWTH FACTOR R, V6, P205; Sakai K, 2001, J BIOL CHEM, V276, P8740, DOI 10.1074/jbc.M008359200; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Thomazy VA, 1999, CELL DEATH DIFFER, V6, P146, DOI 10.1038/sj.cdd.4400464; Tucholski J, 2003, J BIOL CHEM, V278, P26838, DOI 10.1074/jbc.M303683200; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Yamanaka Y, 1999, ENDOCRINOLOGY, V140, P1319, DOI 10.1210/en.140.3.1319	26	157	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23863	23868		10.1074/jbc.M311919200	http://dx.doi.org/10.1074/jbc.M311919200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069073	hybrid			2022-12-25	WOS:000221702500005
J	Sundaram, R; Lynch, MP; Rawale, SV; Sun, YP; Kazanji, M; Kaumaya, PTP				Sundaram, R; Lynch, MP; Rawale, SV; Sun, YP; Kazanji, M; Kaumaya, PTP			De novo design of peptide Immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCLONAL-ANTIBODIES; HTLV-I; ENVELOPE GLYCOPROTEINS; SYNTHETIC MODEL; CHAIN-LENGTH; EPITOPES; IDENTIFICATION; BINDING; DETERMINANTS; ECTODOMAIN	Peptide vaccines able to induce high affinity and protective neutralizing antibodies must rely in part on the design of antigenic epitopes that mimic the three-dimensional structure of the corresponding region in the native protein. We describe the design, structural characterization, immunogenicity, and neutralizing potential of antibodies elicited by conformational peptides derived from the human T-cell leukemia virus type 1 (HTLV-1) gp21 envelope glycoprotein spanning residues 347-374. We used a novel template design and a unique synthetic approach to construct two peptides (WCCR2T and CCR2T) that would each assemble into a triple helical coiled coil conformation mimicking the gp21 crystal structure. The peptide B-cell epitopes were grafted onto the epsilon side chains of three lysyl residues on a template backbone construct consisting of the sequence acetyl-XGKGKGKGCONH2 ( where X represents the tetanus toxoid promiscuous T cell epitope (TT) sequence 580-599). Leucine substitutions were introduced at the a and d positions of the CCR2T sequence to maximize helical character and stability as shown by circular dichroism and guanidinium hydrochloride studies. Serum from an HTLV-1-infected patient was able to recognize the selected epitopes by enzyme-linked immunosorbent assay ( ELISA). Mice immunized with the wild-type sequence ( WCCR2T) and the mutant sequence ( CCR2T) elicited high antibody titers that were capable of recognizing the native protein as shown by flow cytometry and whole virus ELISA. Sera and purified antibodies from immunized mice were able to reduce the formation of syncytia induced by the envelope glycoprotein of HTLV-1, suggesting that antibodies directed against the coiled coil region of gp21 are capable of disrupting cell-cell fusion. Our results indicate that these peptides represent potential candidates for use in a peptide vaccine against HTLV-1.	Ohio State Univ, Div Vaccine Res, Dept Obstet & Gynecol, Peptide & Prot Engn Lab, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Columbus, OH 43210 USA; Ohio State Univ, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA; Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Procter & Gamble Co, Miami Valley Labs, Corp Res Div, Cincinnati, OH 45253 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Procter & Gamble	Kaumaya, PTP (corresponding author), Suite 316,Tzagournis Med Res Facil,420 W 12th Ave, Columbus, OH 43210 USA.	kaumaya.1@osu.edu	Kaumaya, Pravin T. P/E-3354-2011		PHS HHS [A140302] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABA E, 1993, J IMMUNOL, V151, P1013; BABA E, 1995, J IMMUNOL, V154, P399; Barthe P, 2000, PROTEIN SCI, V9, P942, DOI 10.1110/ps.9.5.942; Blanchard S, 1999, J VIROL, V73, P9369, DOI 10.1128/JVI.73.11.9369-9376.1999; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Causton AS, 2002, J PEPT SCI, V8, P275, DOI 10.1002/psc.388; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Collins ND, 1996, J VIROL, V70, P7241, DOI 10.1128/JVI.70.10.7241-7246.1996; Cooper JA, 1997, MOL IMMUNOL, V34, P433, DOI 10.1016/S0161-5890(97)00056-4; Delamarre L, 1997, J VIROL, V71, P259, DOI 10.1128/JVI.71.1.259-266.1997; DESGRANGES C, 1994, AIDS RES HUM RETROV, V10, P163, DOI 10.1089/aid.1994.10.163; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Frangione-Beebe M, 2000, VACCINE, V19, P1068, DOI 10.1016/S0264-410X(00)00340-6; Futaki S, 1998, BIOPOLYMERS, V47, P75; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Gatot JS, 1998, J BIOL CHEM, V273, P12870, DOI 10.1074/jbc.273.21.12870; Grange MP, 1998, INT J CANCER, V75, P804, DOI 10.1002/(SICI)1097-0215(19980302)75:5&lt;804::AID-IJC22&gt;3.0.CO;2-4; HADLOCK KG, 1995, BLOOD, V86, P1392, DOI 10.1182/blood.V86.4.1392.bloodjournal8641392; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; IJICHI S, 1990, ANN RHEUM DIS, V49, P718, DOI 10.1136/ard.49.9.718; INOUE Y, 1992, INT J CANCER, V52, P877, DOI 10.1002/ijc.2910520608; ISLAM SA, 1990, PROTEINS, V8, P1, DOI 10.1002/prot.340080103; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; JONES WR, 1988, LANCET, V1, P1295; KAUMAYA PTP, 1992, J BIOL CHEM, V267, P6338; KAUMAYA PTP, 1990, BIOCHEMISTRY-US, V29, P13, DOI 10.1021/bi00453a002; KAUMAYA PTP, 1994, PEPTIDES CHEM STRUCT, P712; KAUMAYA PTP, 1994, PEPTIDES, V9, P133; Kaumaya PTP, 1996, PEPTIDES IMMUNOLOGY, P117; KAUMAYA PTP, 1993, PEPTIDES 1992, P139; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319; KOBSCONRAD S, 1993, J BIOL CHEM, V268, P25285; KUROKI M, 1992, J IMMUNOL, V149, P940; LAGRENADE L, 1990, LANCET, V336, P1345; LAIRMORE MD, 1995, J VIROL, V69, P6077, DOI 10.1128/JVI.69.10.6077-6089.1995; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LAUMAYA PTP, 1992, PEPTIDES CHEM BIOL, P883; Litowski JR, 2001, J PEPT RES, V58, P477, DOI 10.1034/j.1399-3011.2001.10972.x; Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200; Lu SM, 2002, J BIOL CHEM, V277, P23515, DOI 10.1074/jbc.M201981200; Maerz AL, 2000, J VIROL, V74, P6614, DOI 10.1128/JVI.74.14.6614-6621.2000; MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4; MORGAN OS, 1989, LANCET, V2, P1184; NAGY K, 1983, INT J CANCER, V32, P321, DOI 10.1002/ijc.2910320310; PALKER TJ, 1989, J IMMUNOL, V142, P971; PALKER TJ, 1992, J VIROL, V66, P5879, DOI 10.1128/JVI.66.10.5879-5889.1992; Pancino G, 1994, Curr Top Microbiol Immunol, V188, P77; Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rosenberg AR, 1998, J VIROL, V72, P7609, DOI 10.1128/JVI.72.9.7609-7614.1998; Rosenberg JR, 1997, J VIROL, V71, P7180, DOI 10.1128/JVI.71.10.7180-7186.1997; Sagara Y, 1996, J VIROL, V70, P1564, DOI 10.1128/JVI.70.3.1564-1569.1996; Starovasnik MA, 1997, P NATL ACAD SCI USA, V94, P10080, DOI 10.1073/pnas.94.19.10080; Suich DJ, 2000, BIOORGAN MED CHEM, V8, P2229, DOI 10.1016/S0968-0896(00)00135-8; TANAKA Y, 1991, J IMMUNOL, V147, P354; TANAKA Y, 1994, J VIROL, V68, P6323, DOI 10.1128/JVI.68.10.6323-6331.1994; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	64	52	54	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24141	24151		10.1074/jbc.M313210200	http://dx.doi.org/10.1074/jbc.M313210200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15060075	hybrid			2022-12-25	WOS:000221702500037
J	Martin, SS; Ridgeway, AG; Pinkas, J; Lu, Y; Reginato, MJ; Koh, EY; Michelman, M; Daley, GQ; Brugge, JS; Leder, P				Martin, SS; Ridgeway, AG; Pinkas, J; Lu, Y; Reginato, MJ; Koh, EY; Michelman, M; Daley, GQ; Brugge, JS; Leder, P			A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth	ONCOGENE			English	Article						apoptosis.; cytoskeleton; metastasis; breast; cancer; Bcl	CELL-CYCLE ENTRY; TRANSGENIC MICE; BREAST-CANCER; MAMMARY TUMORIGENESIS; LATRUNCULIN-A; MOUSE MODEL; APOPTOSIS; PROGRESSION; BAX; EXPRESSION	Many mouse models of breast cancer form large primary tumors that rarely metastasize. Models with aggressive metastasis express oncoproteins that simultaneously affect growth and apoptosis pathways. To define the role of apoptotic resistance and to model a challenge faced by tumor cells during metastatic dissemination, we focused on apoptosis induced by cell shape change. Inhibiting actin polymerization with Latrunculin-A causes cell rounding and death within hours in nontumorigenic human 10A-Ras mammary epithelial cells. In contrast, MDA-MB-231 metastatic breast tumor cells resist LA-induced death, and survive for days despite cell rounding. Infecting 10A-Ras cells with a MDA-MB-231 retroviral expression library, and selecting with Latrunculin-A repeatedly identified Bcl-xL as a suppressor of cytoskeleton-dependent death. Although Bcl-xL enhances the spread of metastatic breast tumor cell lines, the distinct effects of apoptotic resistance on tumor growth in the mammary gland and during metastasis have not been compared directly. We find that Bcl-xL overexpression in mouse mammary epithelial cells does not induce primary tumor formation or enhance MEK-induced tumorigenesis within the mammary gland environment. However, it strongly enhances metastatic potential. These results with Bcl-xL provide novel evidence that isolated apoptotic resistance can increase metastatic potential, but remain overlooked by assays based on breast tumor growth.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Genzyme Corp, Framingham, MA 01701 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Sanofi-Aventis; Genzyme Corporation; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.	leder@rascal.med.harvard.edu	Reginato, Mauricio/I-6155-2013	Reginato, Mauricio/0000-0002-7541-4094				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birchmeier C, 1996, ACTA ANAT, V156, P217; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Eischen CM, 2002, CANCER RES, V62, P2184; Fernandez Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fujita M, 2003, ONCOGENE, V22, P627, DOI 10.1038/sj.onc.1206173; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; MARTIN SS, 2004, IN PRESS BBA MOL CEL; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nikiforov MA, 1997, ONCOGENE, V15, P3007, DOI 10.1038/sj.onc.1201723; Olopade OI, 1997, CANCER J SCI AM, V3, P230; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pinkas J, 2002, CANCER RES, V62, P4781; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rubio N, 2001, LAB INVEST, V81, P725, DOI 10.1038/labinvest.3780281; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Shi HY, 2003, HISTOL HISTOPATHOL, V18, P201, DOI 10.14670/HH-18.201; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	31	56	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4641	4645		10.1038/sj.onc.1207595	http://dx.doi.org/10.1038/sj.onc.1207595			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064711				2022-12-25	WOS:000221799000014
J	Scian, MJ; Stagliano, KER; Deb, D; Ellis, MA; Carchman, EH; Das, A; Valerie, K; Deb, SP; Deb, S				Scian, MJ; Stagliano, KER; Deb, D; Ellis, MA; Carchman, EH; Das, A; Valerie, K; Deb, SP; Deb, S			Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	ONCOGENE			English	Article						'gain of function'; mutations; p53; transactivation; microarray	WILD-TYPE P53; CREB-BINDING-PROTEIN; ASPARAGINE SYNTHETASE GENE; HUMAN LEUKEMIA-CELLS; GAIN-OF-FUNCTION; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; HETERO-OLIGOMERIZATION; VIRAL PROMOTERS; BREAST-CANCER	We have studied the mechanism of mutant p53-mediated oncogenesis using several tumor-derived mutants. Using a colony formation assay, we found that the majority of the mutants increased the number of colonies formed compared to the vector. Expression of tumor-derived p53 mutants increases the rate of cell growth, suggesting that the p53 mutants have 'gain of function' properties. We have studied the gene expression pro. le of cells expressing tumor-derived p53-D281G to identify genes transactivated by mutant p53. We report the transactivation of two genes, asparagine synthetase and human telomerase reverse transcriptase. Quantitative real-time PCR confirms this upregulation. Transient transfection promoter assays verify that tumor-derived p53 mutants trans-activate these promoters significantly. An electrophoretic mobility shift assay shows that tumor-derived p53-mutants cannot bind to the wild-type p53 consensus sequence. The results presented here provide some evidence of a possible mechanism for mutant p53-mediated transactivation.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Deb, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem, POB 980614, Richmond, VA 23298 USA.	sdeb@hsc.vcu.edu	Das, Anindita/K-8003-2013; Valerie, Kristoffer/AAL-8299-2021	Das, Anindita/0000-0003-4422-7277; Anderson, Michelle/0000-0003-1510-2942	NATIONAL CANCER INSTITUTE [F31CA097520, R01CA070712, R01CA074172] Funding Source: NIH RePORTER; NCI NIH HHS [1 F31 CA97520, CA74172, CA70712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bensaad K, 2003, J BIOL CHEM, V278, P10546, DOI 10.1074/jbc.M208233200; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bronder JL, 2003, J BIOL CHEM, V278, P48861, DOI 10.1074/jbc.M304844200; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Davis BB, 2003, AM J PHYSIOL-CELL PH, V284, pC16, DOI 10.1152/ajpcell.00211.2002; Deb D, 2002, ONCOGENE, V21, P176, DOI 10.1038/sj/onc/1205035; Deb D, 2001, INT J ONCOL, V18, P401; Deb D, 1999, INT J ONCOL, V15, P413; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Doyle L Austin, 2002, Expert Rev Anticancer Ther, V2, P217, DOI 10.1586/14737140.2.2.217; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hassan S, 2003, J BIOL CHEM, V278, P38860, DOI 10.1074/jbc.M305040200; Herbert BS, 2001, BREAST CANCER RES, V3, P146, DOI 10.1186/bcr288; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hussain SP, 1998, TOXICOL LETT, V103, P219, DOI 10.1016/S0378-4274(98)00310-5; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KERN SE, 1991, ONCOGENE, V6, P131; Kerns RT, 2003, METHODS, V31, P274, DOI 10.1016/S1046-2023(03)00156-7; Kiyooka K, 1999, Ann Thorac Cardiovasc Surg, V5, P293; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LENG P, 1995, ONCOGENE, V10, P1275; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1995, ONCOGENE, V10, P2387; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Polanowska J, 2000, GENE CHROMOSOME CANC, V28, P126, DOI 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.0.CO;2-G; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Scheel C, 2002, VIRCHOWS ARCH, V440, P573, DOI 10.1007/s00428-002-0634-9; Scolnick DM, 1997, CANCER RES, V57, P3693; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Sigal A, 2000, CANCER RES, V60, P6788; Smith ER, 2001, J BIOL CHEM, V276, P31483, DOI 10.1074/jbc.C100351200; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Valerie E, 1999, UROLOGY, V54, P1082, DOI 10.1016/S0090-4295(99)00311-8; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Webb SJ, 2002, J DENT RES, V81, P17, DOI 10.1177/154405910208100105; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	90	82	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4430	4443		10.1038/sj.onc.1207553	http://dx.doi.org/10.1038/sj.onc.1207553			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077194				2022-12-25	WOS:000221661300009
J	Pavey, S; Johansson, P; Packer, L; Taylor, J; Stark, M; Pollock, PM; Walker, GJ; Boyle, GM; Harper, U; Cozzi, SJ; Hansen, K; Yudt, L; Schmidt, C; Hersey, P; Ellem, KAO; O'Rourke, MGE; Parsons, PG; Meltzer, P; Ringner, M; Hayward, NK				Pavey, S; Johansson, P; Packer, L; Taylor, J; Stark, M; Pollock, PM; Walker, GJ; Boyle, GM; Harper, U; Cozzi, SJ; Hansen, K; Yudt, L; Schmidt, C; Hersey, P; Ellem, KAO; O'Rourke, MGE; Parsons, PG; Meltzer, P; Ringner, M; Hayward, NK			Microarray expression profiling in melanoma reveals a BRAF mutation signature	ONCOGENE			English	Article						BRAF; melanoma; microarray; mitogenactivated protein kinase; mutation	PROTEIN-TYROSINE-PHOSPHATASE; N-RAS; DIFFERENTIAL DISPLAY; ONCOGENIC PATHWAYS; KINASE ACTIVATION; GENE; CANCER; CLASSIFICATION; PROGRESSION; ADHESION	We have used microarray gene expression pro. ling and machine learning to predict the presence of BRAF mutations in a panel of 61 melanoma cell lines. The BRAF gene was found to be mutated in 42 samples (69%) and intragenic mutations of the NRAS gene were detected in seven samples (11%). No cell line carried mutations of both genes. Using support vector machines, we have built a classifier that differentiates between melanoma cell lines based on BRAF mutation status. As few as 83 genes are able to discriminate between BRAF mutant and BRAF wild-type samples with clear separation observed using hierarchical clustering. Multidimensional scaling was used to visualize the relationship between a BRAF mutation signature and that of a generalized mitogen-activated protein kinase ( MAPK) activation ( either BRAF or NRAS mutation) in the context of the discriminating gene list. We observed that samples carrying NRAS mutations lie somewhere between those with or without BRAF mutations. These observations suggest that there are gene-specific mutation signals in addition to a common MAPK activation that result from the pleiotropic effects of either BRAF or NRAS on other signaling pathways, leading to measurably different transcriptional changes.	Queensland Inst Med Res, Herston, Qld 4006, Australia; Lund Univ, Dept Theoret Phys, Complex Syst Div, SE-22362 Lund, Sweden; Pk Ctr Mental Hlth, Queensland Ctr Schizophrenia Res, Wacol, Qld 4076, Australia; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Newcastle, Newcastle, NSW 2300, Australia; Mater Misericordiae Univ Hosp, Brisbane, Qld 4101, Australia	QIMR Berghofer Medical Research Institute; Lund University; Queensland Centre for Mental Health Research; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Newcastle; University College Dublin	Hayward, NK (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4006, Australia.	nickH@qimr.edu.au	hayward, nick/AAV-8802-2020; Stark, Mitchell/K-3874-2019; Pavey, Sandra/B-3662-2011; Parsons, Peter G/H-8163-2015; Stark, Mitchell S/E-3542-2010; Stark, Mitchell/K-6794-2019; Taylor, Jennifer M/A-1686-2010; Boyle, Glen/G-1347-2013; hayward, nicholas k/C-1367-2015; Ringnér, Markus/G-3641-2011; Johansson, Peter A/K-1053-2014; Walker, Graeme J/C-2548-2012; Schmidt, Christopher W/A-4353-2009	Pavey, Sandra/0000-0003-4519-5932; Parsons, Peter G/0000-0002-0473-3346; Stark, Mitchell S/0000-0002-4510-2161; Stark, Mitchell/0000-0002-4510-2161; Taylor, Jennifer M/0000-0003-4231-0181; Boyle, Glen/0000-0002-1385-529X; hayward, nicholas k/0000-0003-4760-1033; Ringnér, Markus/0000-0001-5469-8940; Johansson, Peter A/0000-0001-7015-5452; Walker, Graeme J/0000-0002-9392-8769; Schmidt, Christopher W/0000-0002-3955-5076; Pollock, Pamela/0000-0001-8420-1026	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bastian BC, 1997, CELL MOL LIFE SCI, V53, P554, DOI 10.1007/s000180050071; Brose MS, 2002, CANCER RES, V62, P6997; Castellano M, 1997, CANCER RES, V57, P4868; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cristianini N, 2000, INTRO SUPPORT VECTOR; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Francia G, 1996, CANCER RES, V56, P3855; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gorden A, 2003, CANCER RES, V63, P3955; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Johnson JP, 1997, INT J CANCER, V73, P769; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kimura ET, 2003, CANCER RES, V63, P1454; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; MUSTELIN T, 2002, SCI STKE, V115, pPE3; Naoki K, 2002, CANCER RES, V62, P7001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Prathapam T, 2002, NUCLEIC ACIDS RES, V30, P5261, DOI 10.1093/nar/gkf658; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schleger C, 2000, MOL CARCINOGEN, V28, P31, DOI 10.1002/(SICI)1098-2744(200005)28:1<31::AID-MC5>3.0.CO;2-F; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Shih IM, 1997, CANCER RES, V57, P3835; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; Troyanskaya OG, 2002, BIOINFORMATICS, V18, P1454, DOI 10.1093/bioinformatics/18.11.1454; vanElsas A, 1996, AM J PATHOL, V149, P883; Xie SH, 1997, CANCER RES, V57, P2295; Yuen ST, 2002, CANCER RES, V62, P6451; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	45	144	154	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4060	4067		10.1038/sj.onc.1207563	http://dx.doi.org/10.1038/sj.onc.1207563			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048078				2022-12-25	WOS:000221520200003
J	Cismasiu, VB; Denes, SA; Reilander, H; Michel, H; Szedlacsek, SE				Cismasiu, VB; Denes, SA; Reilander, H; Michel, H; Szedlacsek, SE			The MAM (meprin/A5-protein/PTPmu) domain is a homophilic binding site promoting the lateral dimerization of receptor-like protein-tyrosine phosphatase mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-MU; IN-VIVO; RPTP-MU; INTERMOLECULAR INTERACTIONS; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; CELL-SURFACE; EXPRESSION; IDENTIFICATION; ADHESION	The MAM (meprin/A5-protein/PTPmu) domain is present in numerous proteins with diverse functions. PTPmu belongs to the MAM-containing subclass of protein-tyrosine phosphatases (PTP) able to promote cell-to-cell adhesion. Here we provide experimental evidence that the MAM domain is a homophilic binding site of PTPmu. We demonstrate that the MAM domain forms oligomers in solution and binds to the PTPmu ectodomain at the cell surface. The presence of two disulfide bridges in the MAM molecule was evidenced and their integrity was found to be essential for MAM homophilic interaction. Our data also indicate that PTPmu ectodomain forms oligomers and mediates the cellular adhesion, even in the absence of MAM domain homophilic binding. Reciprocally, MAM is able to interact homophilically in the absence of ectodomain trans binding. The MAM domain therefore contains independent cis and trans interaction sites and we predict that its main role is to promote lateral dimerization of PTPmu at the cell surface. This finding contributes to the understanding of the signal transduction mechanism in MAM-containing PTPs.	Inst Biochem, Dept Enzymol, Bucharest 060031, Romania; Max Planck Inst Biophys, Dept Membrane Biol, D-60528 Frankfurt, Germany	Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; Max Planck Society	Szedlacsek, SE (corresponding author), Inst Biochem, Dept Enzymol, Spl Independentei 296, Bucharest 060031, Romania.	szedlacsek@biochim.ro	Szedlacsek, Stefan Eugen/F-1830-2010; Cismasiu, Valeriu Bogdan/F-1512-2011	Szedlacsek, Stefan Eugen/0000-0002-3416-5036; 				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Aricescu AR, 2001, BIOCHEM BIOPH RES CO, V280, P319, DOI 10.1006/bbrc.2000.4094; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Bianchi C, 1999, EXP CELL RES, V248, P329, DOI 10.1006/excr.1999.4428; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2002, J BIOL CHEM, V277, P47263, DOI 10.1074/jbc.M205810200; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; Brandenberger R, 2001, J CELL BIOL, V154, P447, DOI 10.1083/jcb.200103069; Buchner G, 2000, GENOMICS, V65, P16, DOI 10.1006/geno.2000.6146; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Fuchs M, 1998, MECH DEVELOP, V70, P91, DOI 10.1016/S0925-4773(97)00179-2; Gao Z, 1998, J BIOL CHEM, V273, P3415, DOI 10.1074/jbc.273.6.3415; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Lenhard T, 1996, GENE, V169, P187, DOI 10.1016/0378-1119(95)00831-4; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Rosdahl JA, 2003, J NEUROBIOL, V56, P199, DOI 10.1002/neu.10231; Rosdahl JA, 2002, MOL CELL NEUROSCI, V19, P292, DOI 10.1006/mcne.2001.1071; SAP J, 1994, MOL CELL BIOL, V14, P1; TAKAHASHI N, 1990, ANAL BIOCHEM, V188, P359, DOI 10.1016/0003-2697(90)90621-F; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	45	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26922	26931		10.1074/jbc.M313115200	http://dx.doi.org/10.1074/jbc.M313115200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084579	hybrid			2022-12-25	WOS:000222120400017
J	Matsushima, Y; Garesse, R; Kaguni, LS				Matsushima, Y; Garesse, R; Kaguni, LS			Drosophila mitochondrial transcription factor B2 regulates mitochondrial DNA copy number and transcription in Schneider cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE SPECIFICITY FACTOR; RNA-POLYMERASE; REPLICATION BUBBLE; FACTOR-A; SACCHAROMYCES-CEREVISIAE; GENETIC INTERFERENCE; SC-MTTFB; PROTEIN; MAINTENANCE; PROMOTER	We report the cloning and molecular analysis of Drosophila mitochondrial transcription factor B2 (d-mtTFB2), a protein that plays a role in mitochondrial transcription and mitochondrial DNA (mtDNA) replication in Drosophila. An RNA interference (RNAi) construct was designed that reduces expression of d-mtTFB2 to 5% of its normal level in Schneider cells. RNAi knock-down of d-mtTFB2 reduces the abundance of specific mitochondrial RNA transcripts 2- to 8-fold and decreases the copy number of mtDNA similar to3-fold. In a corollary manner, we find that overexpression of d-mtTFB2 increases both the abundance of mitochondrial RNA transcripts and the copy number of mtDNA. In a comparative experiment, we find that overexpression of Drosophila mitochondrial transcription factor A (d-TFAM) increases mtDNA copy number with no significant effect on mitochondrial transcripts. This argues for a direct role for mtTFB2 in mitochondrial transcription and suggests that, if TFAM serves a role in transcription, its endogenous level limits mtDNA copy number but not transcription. Furthermore, we suggest that mtTFB2 increases mtDNA copy number by increasing the frequency of initiation of DNA replication, whereas TFAM serves to stabilize and package mtDNA in mitochondrial nucleoids. Our work represents the first study to document the function of mtTFB2 in vivo, establishing a dual role in regulation of both transcription and replication, and provides a benchmark for comparative biochemical studies in various animal systems.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols,Dept Bioquim, E-28029 Madrid, Spain	Michigan State University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	lskaguni@msu.edu	Garesse, Rafael/F-3836-2012	Garesse, Rafael/0000-0002-0338-2281	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2; BERTHIER F, 1986, NUCLEIC ACIDS RES, V14, P4519, DOI 10.1093/nar/14.11.4519; Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4; Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P404, DOI 10.1016/S0968-0004(03)00165-8; Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Carrodeguas JA, 1996, GENE EXPRESSION, V6, P219; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Cliften PF, 1997, GENE DEV, V11, P2897, DOI 10.1101/gad.11.21.2897; Cliften PF, 2000, MOL CELL BIOL, V20, P7013, DOI 10.1128/MCB.20.18.7013-7023.2000; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717; GODDARD JM, 1978, P NATL ACAD SCI USA, V75, P3886, DOI 10.1073/pnas.75.8.3886; Goto A, 2001, BIOCHEM J, V354, P243, DOI 10.1042/0264-6021:3540243; Grams J, 2002, J BIOL CHEM, V277, P16952, DOI 10.1074/jbc.M200662200; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; JANG SH, 1991, J BIOL CHEM, V266, P22671; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Lam G, 2000, CURR BIOL, V10, P957, DOI 10.1016/S0960-9822(00)00631-X; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LISOWSKY T, 1989, MOL GEN GENET, V219, P125, DOI 10.1007/BF00261167; MANGUS DA, 1994, J BIOL CHEM, V269, P26568; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Matsushima Y, 2003, J BIOL CHEM, V278, P31149, DOI 10.1074/jbc.M303842200; McCulloch V, 2003, MOL CELL BIOL, V23, P5816, DOI 10.1128/MCB.23.16.5816-5824.2003; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; Roberti M, 2003, NUCLEIC ACIDS RES, V31, P1597, DOI 10.1093/nar/gkg272; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; Schubot FD, 2001, PROTEIN SCI, V10, P1980, DOI 10.1110/ps.11201; Seidel-Rogol BL, 2003, NAT GENET, V33, P23, DOI 10.1038/ng1064; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; SHADEL GS, 1995, MOL CELL BIOL, V15, P2101; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Takamatsu C, 2002, EMBO REP, V3, P451, DOI 10.1093/embo-reports/kvf099; Tavernarakis N, 2000, J NEUROGENET, V13, P257, DOI 10.3109/01677060009084497; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; XU BJ, 1992, NUCLEIC ACIDS RES, V20, P1053, DOI 10.1093/nar/20.5.1053; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9	55	61	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					26900	26905		10.1074/jbc.M401643200	http://dx.doi.org/10.1074/jbc.M401643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15060065	hybrid			2022-12-25	WOS:000222120400014
J	Rudberg, PC; Tholander, F; Andberg, M; Thunnissen, MMGM; Haeggstrom, JZ				Rudberg, PC; Tholander, F; Andberg, M; Thunnissen, MMGM; Haeggstrom, JZ			Leukotriene A(4) hydrolase - Identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A(4) HYDROLASE; B-4 RECEPTOR; BIFUNCTIONAL ENZYME; ALLOWS CONVERSION; CRYSTAL-STRUCTURE; ARGINYL RESIDUES; BINDING; MUTATION; ACID; 5-LIPOXYGENASE	Leukotriene ( LT) A(4) hydrolase is a bifunctional zinc metalloenzyme, which converts LTA(4) into the neutrophil chemoattractant LTB4 and also exhibits an anion-dependent aminopeptidase activity. In the x-ray crystal structure of LTA(4) hydrolase, Arg(563) and Lys(565) are found at the entrance of the active center. Here we report that replacement of Arg(563), but not Lys(565), leads to complete abrogation of the epoxide hydrolase activity. However, mutations of Arg(563) do not seem to affect substrate binding strength, because values of K-i for LTA(4) are almost identical for wild type and ( R563K) LTA(4) hydrolase. These results are supported by the 2.3-Angstrom crystal structure of (R563A) LTA(4) hydrolase, which does not reveal structural changes that can explain the complete loss of enzyme function. For the aminopeptidase reaction, mutations of Arg(563) reduce the catalytic activity (V-max = 0.3 - 20%), whereas mutations of Lys(565) have limited effect on catalysis (V-max = 58 - 108%). However, in (K565A)- and (K565M) LTA(4) hydrolase, i.e. mutants lacking a positive charge, values of the Michaelis constant for alanine-p-nitroanilide increase significantly (K-m = 480 - 640%). Together, our data indicate that Arg(563) plays an unexpected, critical role in the epoxide hydrolase reaction, presumably in the positioning of the carboxylate tail to ensure perfect substrate alignment along the catalytic elements of the active site. In the aminopeptidase reaction, Arg(563) and Lys(565) seem to cooperate to provide sufficient binding strength and productive alignment of the substrate. In conclusion, Arg(563) and Lys(565) possess distinct roles as carboxylate recognition sites for two chemically different substrates, each of which is turned over in separate enzymatic reactions catalyzed by LTA(4) hydrolase.	Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 2, S-17177 Stockholm, Sweden; Lund Univ, Dept Mol Biophys, Kemicentrum, S-22100 Lund, Sweden	Karolinska Institutet; Lund University	Haeggstrom, JZ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 2, S-17177 Stockholm, Sweden.	jesper.haeggstrom@mbb.ki.se	Thunnissen, Marjolein MGM/B-9366-2011	Blomster Andberg, Martina/0000-0002-8021-9947				Andberg MB, 1997, J BIOL CHEM, V272, P23057, DOI 10.1074/jbc.272.37.23057; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bailie MB, 1996, J IMMUNOL, V157, P5221; BARRET AJ, 1998, HDB PROTEOLYTIC ENZY, P994; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P992; Baset HA, 1998, J BIOL CHEM, V273, P27978, DOI 10.1074/jbc.273.43.27978; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BLOMSTER M, 1995, EUR J BIOCHEM, V231, P528, DOI 10.1111/j.1432-1033.1995.tb20728.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Byrum RS, 1999, J IMMUNOL, V163, P6810; Byrum RS, 1997, J EXP MED, V185, P1065, DOI 10.1084/jem.185.6.1065; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; FORDHUTCHINSON AW, 1981, PROSTAGLANDINS, V21, P143, DOI 10.1016/0090-6980(81)90204-5; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; Hogg JH, 1998, CHEM-EUR J, V4, P1698, DOI 10.1002/(SICI)1521-3765(19980904)4:9<1698::AID-CHEM1698>3.3.CO;2-A; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kull F, 1999, J BIOL CHEM, V274, P34683, DOI 10.1074/jbc.274.49.34683; Kull F, 2001, BIOCHEMISTRY-US, V40, P12695, DOI 10.1021/bi011348p; LEBLANC Y, 1987, PROSTAGLANDINS, V33, P617, DOI 10.1016/0090-6980(87)90029-3; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; Mancuso P, 2001, INFECT IMMUN, V69, P2011, DOI 10.1128/IAI.69.4.2011-2016.2001; MAYCOCK AL, 1982, J BIOL CHEM, V257, P3911; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; Mueller MJ, 1996, J BIOL CHEM, V271, P24345, DOI 10.1074/jbc.271.40.24345; MUELLER MJ, 1995, BIOCHEMISTRY-US, V34, P3536, DOI 10.1021/bi00011a007; OLLMANN IR, 1995, BIOORGAN MED CHEM, V3, P969, DOI 10.1016/0968-0896(95)00078-U; ORNING L, 1994, J BIOL CHEM, V269, P11269; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; Rudberg PC, 2002, P NATL ACAD SCI USA, V99, P4215, DOI 10.1073/pnas.072090099; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SODERLING E, 1983, ARCH BIOCHEM BIOPHYS, V220, P1, DOI 10.1016/0003-9861(83)90380-6; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Thunnissen MMGM, 2002, FASEB J, V16, P1648, DOI 10.1096/fj.01-1017fje; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WETTERHOLM A, 1995, J PHARMACOL EXP THER, V275, P31; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; Witt S, 2000, BIOCHEM J, V347, P553, DOI 10.1042/0264-6021:3470553; YAMAOKA KA, 1989, J IMMUNOL, V143, P1996; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200	61	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27376	27382		10.1074/jbc.M401031200	http://dx.doi.org/10.1074/jbc.M401031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078870	hybrid			2022-12-25	WOS:000222120400068
J	Brar, SS; Watson, M; Diaz, M				Brar, SS; Watson, M; Diaz, M			Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-SWITCH RECOMBINATION; DOUBLE-STRAND BREAKS; IMMUNOGLOBULIN VARIABLE GENES; B MESSENGER-RNA; SOMATIC HYPERMUTATION; POLYMERASE-ETA; ANTIBODY DIVERSIFICATION; CYTIDINE; REPAIR; MICE	Activation-induced cytosine deaminase (AID) is a cytosine deaminase that is critical to immunoglobulin hypermutation, class switch recombination, and gene conversion. In the context of hypermutating B cells, AID deaminates cytosine in the DNA of immunoglobulin genes, leading to the accumulation of mutations in the variable regions. However, when AID is expressed ectopically, it is a generalized mutator of G: C base pairs. Therefore, we asked whether AID may be partially regulated by an active system of nuclear export. We found that removal of a highly conserved nuclear export signal in the C terminus of AID causes accumulation of AID in the nucleus. However, a putative nuclear localization signal in the N terminus does not appear to be functional. Finally, we found that agents that induce DNA breaks caused retention of AID in the nucleus, suggesting that DNA breaks or the repair patches initiated as a result are a substrate for AID binding.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Diaz, M (corresponding author), NIEHS, Genet Mol Lab, NIH, 111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.	diaz@niehs.nih.gov		Diaz, Marilyn/0000-0002-3046-2746	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101603, ZIAES101603] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Barreto V, 2003, MOL CELL, V12, P501, DOI 10.1016/S1097-2765(03)00309-5; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Bross L, 2002, J EXP MED, V195, P1187, DOI 10.1084/jem.20011749; Bross L, 2000, IMMUNITY, V13, P589, DOI 10.1016/S1074-7613(00)00059-5; Bross Linda, 2003, Clin Dev Immunol, V10, P83, DOI 10.1080/10446670310001626571; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; CLARKE SH, 1985, J EXP MED, V161, P687, DOI 10.1084/jem.161.4.687; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; Diaz M, 2001, J IMMUNOL, V167, P327, DOI 10.4049/jimmunol.167.1.327; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Frey S, 1998, IMMUNITY, V9, P127, DOI 10.1016/S1074-7613(00)80594-4; Fugmann SD, 2003, NAT IMMUNOL, V4, P429, DOI 10.1038/ni0503-429; Gabelova A, 1997, NEOPLASMA, V44, P380; Hardianti MS, 2004, LEUKEMIA, V18, P826, DOI 10.1038/sj.leu.2403323; Honjo T, 2002, NAT IMMUNOL, V3, P800, DOI 10.1038/ni0902-800; HONJO T, 2000, CELL, V102, P565; Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101; Kong QZ, 2001, GENETICS, V158, P369; Larson ED, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-211; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Martin A, 2003, J EXP MED, V198, P1171, DOI 10.1084/jem.20030880; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Miller R. G., 1981, SIMULTANEOUS STAT IN, P6; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Nazarov OB, 2003, RADIAT RES, V160, P309, DOI 10.1667/RR3043; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Papavasiliou FN, 2002, J EXP MED, V195, P1193, DOI 10.1084/jem.20011858; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Phung QH, 1998, J EXP MED, V187, P1745, DOI 10.1084/jem.187.11.1745; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Rogozin IB, 2004, J IMMUNOL, V172, P3382, DOI 10.4049/jimmunol.172.6.3382; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Tomilin NV, 2001, RADIAT RES, V156, P347, DOI 10.1667/0033-7587(2001)156[0347:VOFNSO]2.0.CO;2; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; Whisnant-Hurst N, 1999, RADIAT RES, V151, P257, DOI 10.2307/3579936; Wiesendanger M, 2000, J EXP MED, V191, P579, DOI 10.1084/jem.191.3.579; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Yu KF, 2004, J BIOL CHEM, V279, P6496, DOI 10.1074/jbc.M311616200; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zan H, 2003, IMMUNITY, V18, P727, DOI 10.1016/S1074-7613(03)00151-1; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740	60	114	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26395	26401		10.1074/jbc.M403503200	http://dx.doi.org/10.1074/jbc.M403503200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087440	hybrid			2022-12-25	WOS:000222003000060
J	Broustas, CG; Gokhale, PC; Rahman, A; Dritschilo, A; Ahmad, I; Kasid, U				Broustas, CG; Gokhale, PC; Rahman, A; Dritschilo, A; Ahmad, I; Kasid, U			BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; BH3-ONLY PROTEINS; CYTOCHROME-C; CELL-DEATH; MITOCHONDRIA; DOXORUBICIN; COMPLEX; BINDING; CANCER; IDENTIFICATION	We report here the structure-functional characterization of a novel intronless gene, BRCC2, located on human chromosome 11q24.1. BRCC2 open reading frame (327 bp) codes for an similar to12-kDa protein (108 amino acids (aa)) localized predominantly in the cytosol and to a lesser extent in the mitochondria. Ectopic expression of BRCC2 cDNA also was found in both the cytosol and mitochondria. Exogenous expression of BRCC2 caused apoptotic cell death in three different cell lines as evidenced by enhanced chromatin condensation, DNA fragmentation, or an enhanced number of cells in the sub-G(1) phase. In human prostate cancer cells (PC-3), BRCC2-induced DNA fragmentation was blocked efficiently by coexpression of the anti-apoptotic molecule, Bcl-X-L. Transient transfection of BRCC2 cDNA into PC-3 cells in the presence of a broad-range caspase inhibitor, Z-VAD-fmk (100 muM, 24 h), abrogated DNA fragmentation. Consistently, BRCC2 expression correlated with the activation of caspase-3 and caspase-9. An N-terminal deletion mutant of BRCC2 (10.2 kDa, Delta1-16 aa) lacking a BH3-like domain (5 - 12 aa, LPIEGQEI) or BRCC2 containing a mutant BH3-like domain ( leucine 5 -->glutamate) failed to induce apoptosis, whereas a C-terminal deletion mutant (6.8 kDa, Delta62-108 aa) retained the apoptotic activity comparable to the full-length BRCC2. Finally, the treatment of HeLa cells with doxorubicin or hydrogen peroxide (H2O2) led to an increase in the mitochondrial ( heavy membrane) level of endogenous BRCC2 ( doxorubicin ( 100 ng/ml), 5 h, similar to2-fold; H2O2 (200 muM), 2 h, similar to2-fold). These findings demonstrate that BRCC2 functions as a proapoptotic molecule and suggest that BRCC2 induces a caspase-dependent mitochondrial pathway of cell death.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Radiat Med, Washington, DC 20057 USA; NeoPharm Inc, Lake Forest, IL 60045 USA	Georgetown University	Kasid, U (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Radiat Med, E208 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	kasidu@georgetown.edu		Broustas, Constantinos/0000-0001-7169-807X	NCI NIH HHS [CA74175, CA68322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175, R55CA068322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bottero V, 2001, CANCER RES, V61, P7785; Bouillet P, 2002, J CELL SCI, V115, P1567; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Futami Takashi, 2002, Nucleic Acids Res Suppl, P251; Gabra H, 1996, CANCER RES, V56, P950; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gentile M, 1999, BRIT J CANCER, V80, P843, DOI 10.1038/sj.bjc.6690430; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; GOKHALE PC, 2000, P AM ASSOC CANC RES, V1551, P244; GOODMAN J, 1977, BIOCHEM BIOPH RES CO, V77, P797, DOI 10.1016/S0006-291X(77)80048-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green PS, 2002, BBA-MOL BASIS DIS, V1588, P94, DOI 10.1016/S0925-4439(02)00144-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mund T, 2003, FASEB J, V17, P696, DOI 10.1096/fj.02-0657fje; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	34	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26780	26788		10.1074/jbc.M400159200	http://dx.doi.org/10.1074/jbc.M400159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069058	hybrid			2022-12-25	WOS:000222003000105
J	Eneqvist, T; Lundberg, E; Karlsson, A; Huang, SH; Santos, CRA; Power, DM; Sauer-Eriksson, AE				Eneqvist, T; Lundberg, E; Karlsson, A; Huang, SH; Santos, CRA; Power, DM; Sauer-Eriksson, AE			High resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-BINDING; 2.5 ANGSTROM RESOLUTION; ALTERNATIVE CONFORMATIONS; AMYLOIDOGENIC PROTEINS; RAT TRANSTHYRETIN; SPARUS-AURATA; EVOLUTION; COMPLEX; SERUM; IDENTIFICATION	Transthyretin (TTR) is an extracellular transport protein involved in the distribution of thyroid hormones and vitamin A. So far, TTR has only been found in vertebrates, of which piscine TTR displays the lowest sequence identity with human TTR (47%). Human and piscine TTR bind both thyroid hormones 3,5,3'-triiodo-L-thyronine (T-3) and 3,5,3', 5'-tetraiodo-L-thyronine (thyroxine, T-4). Human TTR has higher affinity for T-4 than T-3, whereas the reverse holds for piscine TTR. X-ray structures of Sparus aurata (sea bream) TTR have been determined as the apo-protein at 1.75 Angstrom resolution and bound to ligands T-3 and T-4, both at 1.9 Angstrom resolution. The apo structure is similar to human TTR with structural changes only at beta-strand D. This strand forms an extended loop conformation similar to the one in chicken TTR. The piscine TTR.T-4 complex shows the T-4-binding site to be similar but not identical to human TTR, whereas the TTR.T-3 complex shows the I3' halogen situated at the site normally occupied by the hydroxyl group of T-4. The significantly wider entrance of the hormone-binding channel in sea bream TTR, in combination with its narrower cavity, provides a structural explanation for the different binding affinities of human and piscine TTR to T-3 and T-4.	Umea Univ, Umea Ctr Mol Pathogenesis, SE-90187 Umea, Sweden; Univ Algarve, Ctr Ciencias MAR, P-8005139 Faro, Portugal	Umea University; Universidade do Algarve	Sauer-Eriksson, AE (corresponding author), Umea Univ, Umea Ctr Mol Pathogenesis, SE-90187 Umea, Sweden.	liz@ucmp.umu.se	Santos, Cecilia Reis Alves/C-9032-2016; Power, Deborah M/D-3333-2011	Santos, Cecilia Reis Alves/0000-0001-6074-7825; Power, Deborah M/0000-0003-1366-0246; Sauer-Eriksson, Elisabeth/0000-0003-0124-0199				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTALENA L, 1993, CLIN LAB MED, V13, P583, DOI 10.1016/S0272-2712(18)30427-X; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang L, 1999, EUR J BIOCHEM, V259, P534, DOI 10.1046/j.1432-1327.1999.00076.x; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; Connors LH, 2000, AMYLOID, V7, P54, DOI 10.3109/13506120009146826; Eneqvist T, 2003, EUR J BIOCHEM, V270, P518, DOI 10.1046/j.1432-1033.2003.03408.x; Eneqvist T, 2001, AMYLOID, V8, P149, DOI 10.3109/13506120109007359; Folli C, 2003, FEBS LETT, V555, P279, DOI 10.1016/S0014-5793(03)01248-1; Funkenstein B, 1999, MOL CELL ENDOCRINOL, V157, P67, DOI 10.1016/S0303-7207(99)00160-4; Ghosh M, 2000, ACTA CRYSTALLOGR D, V56, P1085, DOI 10.1107/S0907444900008568; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Hornberg A, 2000, J MOL BIOL, V302, P649, DOI 10.1006/jmbi.2000.4078; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; McPherson A, 1982, PREPARATION ANAL PRO; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naylor HM, 1999, BIOCHEMISTRY-US, V38, P2647, DOI 10.1021/bi982291i; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; Plante-Bordeneuve V, 2000, CURR OPIN NEUROL, V13, P569, DOI 10.1097/00019052-200010000-00011; Power DM, 2000, GEN COMP ENDOCR, V119, P241, DOI 10.1006/gcen.2000.7520; Prapunpoj P, 2002, AM J PHYSIOL-REG I, V283, pR885, DOI 10.1152/ajpregu.00042.2002; Santos CRA, 1999, ENDOCRINOLOGY, V140, P2430, DOI 10.1210/en.140.5.2430; Santos CRA, 2002, CLIN CHEM LAB MED, V40, P1244, DOI 10.1515/CCLM.2002.215; SANTOS CRA, 1996, ANN ENDOCRINOL, V57, P58; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; Sauer UH, 1997, J APPL CRYSTALLOGR, V30, P71, DOI 10.1107/S0021889896008047; Schreiber G, 1997, COMP BIOCHEM PHYS B, V116, P137, DOI 10.1016/S0305-0491(96)00212-X; Schreiber G, 2002, J ENDOCRINOL, V175, P61, DOI 10.1677/joe.0.1750061; Sunde M, 1996, EUR J BIOCHEM, V236, P491, DOI 10.1111/j.1432-1033.1996.00491.x; Wojtczak A, 1996, ACTA CRYSTALLOGR D, V52, P758, DOI 10.1107/S0907444996003046; Wojtczak A, 1997, ACTA BIOCHIM POL, V44, P505, DOI 10.18388/abp.1997_4400; WOJTCZAK A, 1993, J BIOL CHEM, V268, P6202; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P1061, DOI 10.1107/S0907444901007235; Wojtczak A, 2001, ACTA CRYSTALLOGR D, V57, P957, DOI 10.1107/S0907444901006047; YAMAUCHI K, 1993, ENDOCRINOLOGY, V132, P2254, DOI 10.1210/en.132.5.2254; Yamauchi K, 1999, EUR J BIOCHEM, V265, P944, DOI 10.1046/j.1432-1327.1999.00825.x	53	67	67	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26411	26416		10.1074/jbc.M313553200	http://dx.doi.org/10.1074/jbc.M313553200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15082720	hybrid, Green Published			2022-12-25	WOS:000222003000062
J	Hira, T; Elliott, AC; Thompson, DG; Case, RM; McLaughlin, JT				Hira, T; Elliott, AC; Thompson, DG; Case, RM; McLaughlin, JT			Multiple fatty acid sensing mechanisms operate in enteroendocrine cells - Novel evidence for direct mobilization of stored calcium by cytosolic fatty acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE STORES; CHOLECYSTOKININ SECRETION; SIGNALING MECHANISMS; RELEASE; STC-1; LINE; CA2+; RESPONSES; ENDOCRINE; GLUTAG	Fatty acids ( FA) with at least 12 carbon atoms increase intracellular Ca2+ ([Ca2+](i)) to stimulate cholecystokinin release from enteroendocrine cells. Using the murine enteroendocrine cell line STC-1, we investigated whether candidate intracellular pathways transduce the FA signal, or whether FA themselves act within the cell to release Ca2+ directly from the intracellular store. STC-1 cells loaded with fura-2 were briefly ( 3 min) exposed to saturated FA above and below the threshold length (C-8, C-10, and C-12). C-12, but not C-8 or C-10, induced a dose-dependent increase in [Ca2+](i), in the presence or absence of extracellular Ca2+. Various signaling inhibitors, including D-myo-inositol 1,4,5-triphosphate receptor antagonists, all failed to block FA-induced Ca2+ responses. To identify direct effects of cytosolic FA on the intracellular Ca2+ store, [Ca2+](i) was measured in STC-1 cells loaded with the lower affinity Ca2+ dye magfura-2, permeabilized by streptolysin O. In permeabilized cells, again C-12 but not C-8 or C-10, induced release of stored Ca2+. Although C-12 released Ca2+ in other permeabilized cell lines, only intact STC-1 cells responded to C-12 in the presence of extracellular Ca2+. In addition, 30 min exposure to C-12 induced a sustained elevation of [Ca2+](i) in the presence of extracellular Ca2+, but only a transient response in the absence of extracellular Ca2+. These results suggest that at least two FA sensing mechanisms operate in enteroendocrine cells: intracellularly, FA (greater than or equal to C-12) transiently induce Ca2+ release from intracellular Ca2+ stores. However, they also induce sustained Ca2+ entry from the extracellular medium to maintain an elevated [Ca2+](i).	Hope Hosp, Salford M6 8HD, Lancs, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Kita Ku, Sapporo, Hokkaido 0608589, Japan	University of Manchester; Hokkaido University	McLaughlin, JT (corresponding author), Hope Hosp, Clin Sci Bldg,Stott Lane, Salford M6 8HD, Lancs, England.	john.mclaughlin@man.ac.uk	Hira, Tohru/A-4286-2012	Hira, Tohru/0000-0002-0354-1617; Elliott, Austin/0000-0003-3569-9002; McLaughlin, John/0000-0001-6158-5135				Benson RSP, 2002, J PHYSIOL-LONDON, V538, P121, DOI 10.1113/jphysiol.2001.012969; Buchan AMJ, 1999, AM J PHYSIOL-GASTR L, V277, pG1103, DOI 10.1152/ajpgi.1999.277.6.G1103; Chang CH, 1998, AM J PHYSIOL-GASTR L, V275, pG192, DOI 10.1152/ajpgi.1998.275.2.G192; CHANG CH, 1994, BBA-MOL CELL RES, V1221, P339, DOI 10.1016/0167-4889(94)90259-3; Furness JB, 1999, AM J PHYSIOL-GASTR L, V277, pG922, DOI 10.1152/ajpgi.1999.277.5.G922; Gribble FM, 2003, DIABETES, V52, P1147, DOI 10.2337/diabetes.52.5.1147; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERTELENDY F, 1992, MOL CELL ENDOCRINOL, V83, P173, DOI 10.1016/0303-7207(92)90157-2; Hira T, 1999, BIOSCI BIOTECH BIOCH, V63, P1192, DOI 10.1271/bbb.63.1192; HOENIG M, 1986, ENDOCRINOLOGY, V119, P2502, DOI 10.1210/endo-119-6-2502; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Karlsson S, 2001, BIOCHEM BIOPH RES CO, V280, P610, DOI 10.1006/bbrc.2000.4165; Kazmi S, 2003, J PHYSIOL-LONDON, V553, P759, DOI 10.1113/jphysiol.2003.051680; McLaughlin J, 1999, GASTROENTEROLOGY, V116, P46, DOI 10.1016/S0016-5085(99)70227-1; McLaughlin JT, 1998, J PHYSIOL-LONDON, V513, P11, DOI 10.1111/j.1469-7793.1998.011by.x; Menezes A, 1996, J NEUROCHEM, V67, P2316; Nishi T, 2001, EXP BIOL MED, V226, P1031, DOI 10.1177/153537020122601110; Padfield PJ, 1996, BIOCHEM J, V314, P123, DOI 10.1042/bj3140123; PADFIELD PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG647, DOI 10.1152/ajpgi.1995.269.5.G647; Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166; PRPIC V, 1994, BIOCHEM BIOPH RES CO, V201, P1483, DOI 10.1006/bbrc.1994.1871; Raybould HE, 1999, AM J PHYSIOL-GASTR L, V277, pG751, DOI 10.1152/ajpgi.1999.277.4.G751; Reimann F, 2002, DIABETES, V51, P2757, DOI 10.2337/diabetes.51.9.2757; Sanders KM, 2001, J APPL PHYSIOL, V91, P1438, DOI 10.1152/jappl.2001.91.3.1438; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Sidhu SS, 2000, J PHYSIOL-LONDON, V528, P165, DOI 10.1111/j.1469-7793.2000.00165.x; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999	28	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26082	26089		10.1074/jbc.M400098200	http://dx.doi.org/10.1074/jbc.M400098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066999	hybrid, Green Published			2022-12-25	WOS:000222003000021
J	Birchenall-Roberts, MC; Fu, T; Bang, OS; Dambach, M; Resau, JH; Sadowski, CL; Bertolette, DC; Lee, HJ; Kim, SJ; Ruscetti, FW				Birchenall-Roberts, MC; Fu, T; Bang, OS; Dambach, M; Resau, JH; Sadowski, CL; Bertolette, DC; Lee, HJ; Kim, SJ; Ruscetti, FW			Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins - A molecular link of two tumor suppressor pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; P70 S6 KINASE; TGF-BETA; DEVELOPMENTAL EXPRESSION; TSC2 GENE; INHIBITOR; CELLS; DIFFERENTIATION; DOMAIN; ACID	Tuberin (TSC2) is a tumor suppressor gene. At the cellular level, tuberin is required as a critical regulator of cell growth, neuronal differentiation (Soucek, T., Holzl, G., Bernaschek, G., and Hengstschlager, M. (1998) Oncogene 16, 2197-2204), and tumor suppression (Crino, P. B., and Henske, E. P. (1999) Neurology 53, 1384-1390). Here we report a critical role for tuberin in late stage myeloid cell differentiation. Tuberin strongly augments transforming growth factor (TGF)-beta1 signal transduction pathways, including SMAD activation. We also demonstrate that the amino-terminal region of tuberin interacts specifically with the MH2 domain of SMAD2 and SMAD3 proteins to regulate TGF-beta1-responsive genes such as p21(CIP). Inhibition of tuberin expression by Tsc2 antisense greatly reduces the ability of TGF-beta to transcriptionally regulate p21(CIP), p27(KIP), and cyclin A leading to an abrogation of the antiproliferative effects of TGF-beta1. Also, inhibition of tuberin expression during stimulation of monocytic differentiation with vitamin D-3 and TGF-beta1 significantly impaired myeloid cell growth inhibition and differentiation. Together, the data demonstrate the presence of a novel activation process following TGF-beta1 stimulation that requires tuberin-dependent activity.	NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA; Van Andel Inst, Grand Rapids, MI 49506 USA; NCI Frederick, Expt Immunol Lab, Frederick, MD 21702 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birchenall-Roberts, MC (corresponding author), NCI, SAIC Frederick, Basic Res Program, POB B,Bldg 567-259, Frederick, MD 21702 USA.	birchena@mail.ncifcrf.gov			NATIONAL CANCER INSTITUTE [Z01BC009264, Z01BC005617] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; Chatterjee D, 1997, CELL GROWTH DIFFER, V8, P1083; Crino PB, 1999, NEUROLOGY, V53, P1384, DOI 10.1212/WNL.53.7.1384; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Djaborkhel R, 2000, EXP CELL RES, V261, P250, DOI 10.1006/excr.2000.5047; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; HENGSTSCHLAGER M, 2002, MUTAT RES, V488, P233; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; HU X, 2004, ONCOGENE, V20, P6840; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jobert S, 1997, EUR J HUM GENET, V5, P280, DOI 10.1159/000484778; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Kim KK, 1995, CELL MOL BIOL RES, V41, P515; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Miloloza A, 2002, J NEUROPATH EXP NEUR, V61, P154, DOI 10.1093/jnen/61.2.154; Murthy V, 2001, ACTA NEUROPATHOL, V101, P202; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ruscetti FW, 2001, INT J HEMATOL, V74, P18, DOI 10.1007/BF02982545; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; TUSCHIYA H, 1996, CANCER RES, V56, P429; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wienecke R, 1997, ANN NEUROL, V42, P230, DOI 10.1002/ana.410420215; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; ZAWEL L, 2002, CELL, V1, P611	41	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25605	25613		10.1074/jbc.M402790200	http://dx.doi.org/10.1074/jbc.M402790200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15066998	hybrid			2022-12-25	WOS:000221827900088
J	Donny, W; Demple, B				Donny, W; Demple, B			Modulation of the 5 '-deoxyribose-5-phosphate lyase and DNA synthesis activities of mammalian DNA polymerase beta by apurinic/apyrimidinic endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; HUMAN APURINIC ENDONUCLEASE; DEOXYRIBOSE PHOSPHATE EXCISION; NEGATIVE GENE-REGULATION; CELL NUCLEAR ANTIGEN; ABASIC SITES; IN-VITRO; EXTRACELLULAR CALCIUM; CATALYTIC MECHANISM; FLAP ENDONUCLEASE-1	The Ape1 protein initiates the repair of apurinic/apyrimidinic sites during mammalian base excision repair (BER) of DNA. Ape1 catalyzes hydrolysis of the 5'-phosphodiester bond of abasic DNA to create nicks flanked by 3'-hydroxyl and 5'-deoxyribose 5-phosphate (dRP) termini. DNA polymerase (pol) beta catalyzes both DNA synthesis at the 3'-hydroxyl terminus and excision of the 5'-dRP moiety prior to completion of BER by DNA ligase. During BER, Ape1 recruits pol beta to the incised apurinic/apyrimidinic site and stimulates 5'-dRP excision by pol beta. The activities of these two enzymes are thus coordinated during BER. To examine further the coordination of BER, we investigated the ability of Ape1 to modulate the deoxynucleotidyltransferase and 5'-dRP lyase activities of pol beta. We report here that Ape1 stimulates 5'-dRP excision by a mechanism independent of its apurinic/apyrimidinic endonuclease activity. We also demonstrate a second mechanism, independent of Ape1, in which conditions that support DNA synthesis by pol beta also enhance 5'-dRP excision. Ape1 modulates the gap-filling activity of pol beta by specifically inhibiting synthesis on an incised abasic substrate but not on single-nucleotide gapped DNA. In contrast to the wild-type Ape1 protein, a catalytically impaired mutant form of Ape1 did not affect DNA synthesis by pol beta. However, this mutant protein retained the ability to stimulate 5'-dRP excision by pol beta. Simultaneous monitoring of 5'-dRP excision and DNA synthesis by pol beta demonstrated that the 5'-dRP lyase activity lags behind the polymerase activity despite the coordination of these two steps by Ape1 during BER.The Ape1 protein initiates the repair of apurinic/apyrimidinic sites during mammalian base excision repair (BER) of DNA. Ape1 catalyzes hydrolysis of the 5'-phosphodiester bond of abasic DNA to create nicks flanked by 3'-hydroxyl and 5'-deoxyribose 5-phosphate (dRP) termini. DNA polymerase (pol) beta catalyzes both DNA synthesis at the 3'-hydroxyl terminus and excision of the 5'-dRP moiety prior to completion of BER by DNA ligase. During BER, Ape1 recruits pol beta to the incised apurinic/apyrimidinic site and stimulates 5'-dRP excision by pol beta. The activities of these two enzymes are thus coordinated during BER. To examine further the coordination of BER, we investigated the ability of Ape1 to modulate the deoxynucleotidyltransferase and 5'-dRP lyase activities of pol beta. We report here that Ape1 stimulates 5'-dRP excision by a mechanism independent of its apurinic/apyrimidinic endonuclease activity. We also demonstrate a second mechanism, independent of Ape1, in which conditions that support DNA synthesis by pol beta also enhance 5'-dRP excision. Ape1 modulates the gap-filling activity of pol beta by specifically inhibiting synthesis on an incised abasic substrate but not on single-nucleotide gapped DNA. In contrast to the wild-type Ape1 protein, a catalytically impaired mutant form of Ape1 did not affect DNA synthesis by pol beta. However, this mutant protein retained the ability to stimulate 5'-dRP excision by pol beta. Simultaneous monitoring of 5'-dRP excision and DNA synthesis by pol beta demonstrated that the 5'-dRP lyase activity lags behind the polymerase activity despite the coordination of these two steps by Ape1 during BER.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA071993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71993] Funding Source: Medline; NIEHS NIH HHS [T32ES007155] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Chou KM, 2003, J BIOL CHEM, V278, P18289, DOI 10.1074/jbc.M212143200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 2002, J BIOL CHEM, V277, P7637, DOI 10.1074/jbc.C100577200; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Krokan HE, 1997, BIOCHEM J, V325, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; Masuda Y, 1998, J BIOL CHEM, V273, P30360, DOI 10.1074/jbc.273.46.30360; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Meira LB, 2001, CANCER RES, V61, P5552; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; Mitra S, 2001, ENVIRON MOL MUTAGEN, V38, P180, DOI 10.1002/em.1070; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nakamura J, 1999, CANCER RES, V59, P2522; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Piersen CE, 2000, MUTAT RES-DNA REPAIR, V459, P43, DOI 10.1016/S0921-8777(99)00054-3; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Ranalli TA, 2002, J BIOL CHEM, V277, P41715, DOI 10.1074/jbc.M207207200; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wong D, 2003, J BIOL CHEM, V278, P36242, DOI 10.1074/jbc.M306065200; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	67	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25268	25275		10.1074/jbc.M400804200	http://dx.doi.org/10.1074/jbc.M400804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078879				2022-12-25	WOS:000221827900045
J	Jang, JH; Hwang, JH; Chung, CP; Choung, PH				Jang, JH; Hwang, JH; Chung, CP; Choung, PH			Identification and kinetics analysis of a novel heparin-binding site (KEDK) in human tenascin-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC TOOTH MESENCHYME; HUMAN FIBRONECTIN; CELL ATTACHMENT; STRUCTURAL REQUIREMENTS; SULFATE PROTEOGLYCANS; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; GROWTH-FACTOR; III MODULES; CYTOTACTIN	The interaction between tenascin-C (TN-C), a multi-subunit extracellular matrix protein, and heparin was examined using a surface plasmon resonance-based technique on a Biacore system. The aims of the present study were to examine the affinity of fibronectin type III repeats of TN-C fragments (TNIII) for heparin, to investigate the role of the TNIII4 domains in the binding of TN-C to heparin, and to delineate a sequence of amino acids within the TNIII4 domain, which mediates cooperative heparin binding. At a physiological salt concentration, and pH 7.4, TNIII3-5 binds to heparin with high affinity (K-D = 30 nM). However, a major heparin-binding site in TNIII5 produces a modest affinity binding at a KD near 4 muM, and a second site in TNIII4 enhances the binding by several orders of magnitude, although it was far too weak to produce an observable binding of TNIII4 by itself. Moreover, mutagenesis of the KEDK sequence in the TNIII4 domain resulted in the significant reduction of heparin-binding affinity. In addition, residues in the KEDK sequences are conserved in TN-C throughout mammalian evolution. Thus the structure-based sequence alignment, mutagenesis, and sequence conservation data together reveal a KEDK sequence in TNIII4 suggestive of a minor heparin-binding site. Finally, we demonstrate that TNIII4 contains binding sites for heparin sulfate proteoglycan and enhances the heparin sulfate proteoglycan-dependent human gingival fibroblast adhesion to TNIII5, thus providing the biological significance of heparin-binding site of TNIII4. These results suggest that the heparin-binding sites may traverse TNIII4-5 and thus require KEDK in TNIII4 for optimal heparin-binding.	Seoul Natl Univ, Coll Dent, IBEC, Seoul 110749, South Korea	Seoul National University (SNU)	Jang, JH (corresponding author), Seoul Natl Univ, Coll Dent, IBEC, 28 Yongon Dong, Seoul 110749, South Korea.	juhjang@snu.ac.kr						AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BORK P, 1993, PROTEIN SCI, V2, P1185, DOI 10.1002/pro.5560020714; CHIQUET M, 1994, PERSPECT DEV NEUROBI, V2, P67; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; Dorries U, 1996, J NEUROSCI RES, V43, P420; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feitsma K, 2000, J BIOL CHEM, V275, P9396, DOI 10.1074/jbc.275.13.9396; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; Grant RP, 1997, J BIOL CHEM, V272, P6159, DOI 10.1074/jbc.272.10.6159; GRUMET M, 1994, J BIOL CHEM, V269, P12142; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JOSHI P, 1993, J CELL SCI, V106, P389; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Lethias C, 2001, J BIOL CHEM, V276, P16432, DOI 10.1074/jbc.M010210200; MARTON LS, 1989, J BIOL CHEM, V264, P13145; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; THESLEFF I, 1987, DEVELOPMENT, V101, P289; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; WEBER P, 1995, J BIOL CHEM, V270, P4619, DOI 10.1074/jbc.270.9.4619; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691	34	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25562	25566		10.1074/jbc.M403170200	http://dx.doi.org/10.1074/jbc.M403170200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069070	hybrid			2022-12-25	WOS:000221827900082
J	Ma, YG; Cho, MY; Zhao, MY; Park, JW; Matsushita, M; Fujita, T; Lee, BL				Ma, YG; Cho, MY; Zhao, MY; Park, JW; Matsushita, M; Fujita, T; Lee, BL			Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of complement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-SYSTEM; L-ALANINE AMIDASE; SERINE-PROTEASE; PROPHENOLOXIDASE ACTIVATION; BACTERIAL PEPTIDOGLYCAN; STAPHYLOCOCCUS-AUREUS; SUGAR SPECIFICITY; LIPOTEICHOIC ACID; CUTTING EDGE; BOMBYX-MORI	The innate immune response in vertebrates and invertebrates requires the presence of pattern recognition receptors or proteins that recognize microbial cell components including lipopolysaccharide, bacterial peptidoglycan (PGN), and fungal 1,3-beta-D-glucan. We reported previously that PGN and 1,3-beta-D-glucan recognition proteins from insect hemolymph were able to induce the activation of the prophenoloxidase-activating system, one of the major invertebrate innate immune reactions. The goal of this study was to characterize the biochemical properties and effects of the human counterparts of these molecules. Soluble pattern recognition proteins were purified from human serum and identified as human mannose-binding lectin (MBL) and L-ficolin. The use of specific microbial cell component-coupled columns demonstrated that MBL and L-ficolin bind to PGN and 1,3-beta-D-glucan, respectively. Purified MBL and L-ficolin were associated with MBL-associated serine proteases-1 and -2 (MASPs) and small MBL-associated protein as determined by Western blot analysis. Finally, the binding of purified MBL/MASP and L-ficolin/MASP complexes to PGN and 1,3-beta-D-glucan, respectively, resulted in the activation of the lectin-complement pathway. These results indicate that human PGN and 1,3-beta-D-glucan recognition proteins function as complement-activating lectins.	Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea; Tokai Univ, Inst Glycotechnol, Hiratsuka, Kanagawa 2591292, Japan; Tokai Univ, Dept Appl Biochem, Hiratsuka, Kanagawa 2591292, Japan; Fukushima Med Univ Sch Med, Dept Biochem, Fukushima 9601295, Japan; Japan Sci & Technol Agcy, CREST, Fukushima 9601295, Japan	Pusan National University; Tokai University; Tokai University; Fukushima Medical University; Japan Science & Technology Agency (JST)	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Jangjeon Dong, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Jie, Ying/AAJ-4697-2021	Jie, Ying/0000-0003-4003-2579				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; Ashida Masaaki, 1998, P135; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KONOPSKI Z, 1994, BBA-MOL CELL RES, V1221, P61, DOI 10.1016/0167-4889(94)90216-X; Le Y, 1998, FEBS LETT, V425, P367, DOI 10.1016/S0014-5793(98)00267-1; Le Y, 1997, J IMMUNOL METHODS, V204, P43, DOI 10.1016/S0022-1759(97)00029-X; Lee MH, 2004, J BIOL CHEM, V279, P3218, DOI 10.1074/jbc.M309821200; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; Matsushita M, 2000, J IMMUNOL, V165, P2637, DOI 10.4049/jimmunol.165.5.2637; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; MULLER CD, 1994, RES IMMUNOL, V145, P267, DOI 10.1016/S0923-2494(94)80015-4; Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000; Neth O, 2002, J IMMUNOL, V169, P4430, DOI 10.4049/jimmunol.169.8.4430; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; OHTA M, 1990, J BIOL CHEM, V265, P1980; Petersen SV, 2001, J IMMUNOL METHODS, V257, P107, DOI 10.1016/S0022-1759(01)00453-7; RAO P, 1989, ANAL BIOCHEM, V181, P18, DOI 10.1016/0003-2697(89)90387-4; Rice PJ, 2002, J LEUKOCYTE BIOL, V72, P140; Rogers H.J., 1980, MICROBIAL CELL WALK, P190; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SAKURAI T, 1994, BIOL PHARM BULL, V17, P617; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SZABO T, 1995, J BIOL CHEM, V270, P2145, DOI 10.1074/jbc.270.5.2145; TERAI I, 1993, BIOCHEM MED METAB B, V50, P111, DOI 10.1006/bmmb.1993.1052; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Thornton BP, 1996, J IMMUNOL, V156, P1235; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; Williams DL, 1996, CLIN IMMUNOTHER, V5, P392, DOI 10.1007/BF03259335; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xu ZJ, 2001, J IMMUNOL, V167, P6975, DOI 10.4049/jimmunol.167.12.6975; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zhang R, 2003, J BIOL CHEM, V278, P42072, DOI 10.1074/jbc.M307475200; Zhao LJ, 2002, BLOOD, V100, P3233, DOI 10.1182/blood-2002-01-0252	52	123	128	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25307	25312		10.1074/jbc.M400701200	http://dx.doi.org/10.1074/jbc.M400701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078867	hybrid			2022-12-25	WOS:000221827900050
J	Ryu, KS; Kim, C; Kim, I; Yoo, S; Choi, BS; Park, C				Ryu, KS; Kim, C; Kim, I; Yoo, S; Choi, BS; Park, C			NMR application probes a novel and ubiquitous family of enzymes that alter monosaccharide configuration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; SUGAR-BINDING; GALACTOSE MUTAROTASE; RIBOSE TRANSPORT; L-FUCOSE; PROTEIN; IDENTIFICATION; PURIFICATION; EXPRESSION; ISOMERASE	By exploiting nuclear magnetic resonance (NMR) techniques along with novel applications of saturation difference analysis, we deciphered the functions of the previously uncharacterized products of three bacterial genes, rbsD, fucU, and yiiL, which are part of the ribose, fucose, and rhamnose operons of Escherichia coli, respectively. We show that RbsD catalyzes the pyran to furan conversion of ribose, whereas FucU and YiiL are involved in the catalysis of the anomeric conversion of their respective sugars. It was observed that the anomeric exchange of only ribofuranose, not ribopyranose, occurs spontaneously in solution rationalizing its evolutionary incorporation into the nucleic acid. The RbsD and FucU proteins share sequence homology and belong to the same protein family that is found from eubacteria to human, whereas the YiiL homologues exist in archae-bacteria and lower eukaryotes. These enzymes, including the galactose mutarotase, exhibit a certain degree of cross-specificity to structurally analogous sugars thereby encompassing all existing monosaccharides in terms of their reactivities. The ubiquitous presence of enzymes involved in the anomeric changes of monosaccharides highlights an importance of these activities in various cellular processes requiring efficient monosaccharide utilization.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Choi, BS (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, Gusong Dong 373-1, Taejon 305701, South Korea.	byongseok.choi@kaist.ac.kr; ckpark@kaist.ac.kr	Choi, Byong-Seok/C-1937-2011; Park, Chankyu/C-1936-2011					Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; Eschenmoser A, 1999, SCIENCE, V284, P2118, DOI 10.1126/science.284.5423.2118; FOKER JE, 1988, Patent No. 4719201; FOKER JE, 1986, Patent No. 4605644; HORECKER BL, 1960, J BIOL CHEM, V235, P1580; IIDA A, 1984, J BACTERIOL, V158, P674, DOI 10.1128/JB.158.2.674-682.1984; IZUMORI K, 1975, J BIOL CHEM, V250, P8085; Kim CH, 1997, J BACTERIOL, V179, P7631, DOI 10.1128/jb.179.24.7631-7637.1997; Kim MS, 2003, J BIOL CHEM, V278, P28173, DOI 10.1074/jbc.M304523200; Korndorfer IP, 2000, J MOL BIOL, V300, P917, DOI 10.1006/jmbi.2000.3896; LIVINGSTONE G, 1977, J SOLUTION CHEM, V6, P203, DOI 10.1007/BF00646739; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Noda K, 2003, CANCER RES, V63, P6282; OCONNELL TM, 1994, BIOCHEMISTRY-US, V33, P10985, DOI 10.1021/bi00202a018; Oh H, 1999, J BIOL CHEM, V274, P14006, DOI 10.1074/jbc.274.20.14006; Park Y, 1999, EMBO J, V18, P4149, DOI 10.1093/emboj/18.15.4149; Poulsen TS, 1999, J BACTERIOL, V181, P7126, DOI 10.1128/JB.181.22.7126-7130.1999; REEZE HH, 2001, GLYCOBIOLOGY, V11, pR129; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; Thoden JB, 2003, PROTEIN SCI, V12, P1051, DOI 10.1110/ps.0243203; Thoden JB, 2002, J BIOL CHEM, V277, P45458, DOI 10.1074/jbc.M208395200; Timson DJ, 2003, FEBS LETT, V543, P21, DOI 10.1016/S0014-5793(03)00364-8; WILLIS RC, 1974, J BIOL CHEM, V249, P6926; ZHU Y, 1986, J MOL EVOL, V23, P259, DOI 10.1007/BF02115582	25	29	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25544	25548		10.1074/jbc.M402016200	http://dx.doi.org/10.1074/jbc.M402016200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060078	hybrid			2022-12-25	WOS:000221827900080
J	Wang, SW; Konorev, EA; Kotamraju, S; Joseph, J; Kalivendi, S; Kalyanaraman, B				Wang, SW; Konorev, EA; Kotamraju, S; Joseph, J; Kalivendi, S; Kalyanaraman, B			Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms - Intermediacy of H2O2- and p53-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; REACTIVE OXYGEN; INDUCED CARDIOMYOPATHY; OXIDATIVE STRESS; CARDIAC MYOCYTES; CANCER-THERAPY; IN-VIVO; P53	Doxorubicin (DOX), a widely used chemotherapeutic agent, exhibits cardiotoxicity as an adverse side effect in cancer patients. DOX-mediated cardiomyopathy is linked to its ability to induce apoptosis in endothelial cells and cardiomyocytes by activation of p53 protein and reactive oxygen species. We evaluated the potential roles of H2O2 and p53 in DOX-induced apoptosis in normal bovine aortic endothelial cells and adult rat cardiomyocytes and in tumor cell lines PA-1 (human ovarian teratocarcinoma) and MCF-7 (human breast adenocarcinoma). Time course measurements indicated that activation of caspase-3 preceded the stimulation of p53 transcriptional activity in endothelial cells. In contrast, DOX caused early activation of p53 in tumor cells that was followed by caspase-3 activation and DNA fragmentation. These findings suggest that the transcriptional activation of p53 in DOX-induced apoptosis in endothelial cells may not be as crucial as it is in tumor cells. Further evidence was obtained using a p53 inhibitor, pifithrin-alpha. Pifithrin-alpha completely suppressed DOX-induced activation of p53 in both normal and tumor cell lines and prevented apoptosis in tumor cell lines but not in endothelial cells and cardiomyocytes. In contrast, detoxification of H2O2, either by redox-active metalloporphyrin or overexpression of glutathione peroxidase, decreased DOX-induced apoptosis in endothelial cells and cardiomyocytes but not in tumor cells. This newly discovered mechanistic difference in DOX-induced apoptotic cell death in normal versus tumor cells will be useful in developing drugs that selectively mitigate the toxic side effects of DOX without affecting its antitumor action.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NCI NIH HHS [R01 CA77822] Funding Source: Medline; NHLBI NIH HHS [P01 HL68769] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077822] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068769] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Anthoney DA, 1996, CANCER RES, V56, P1374; BUZDAR AU, 1985, CANCER, V55, P2761, DOI 10.1002/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gouaze V, 2001, MOL PHARMACOL, V60, P488; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Havre PA, 2002, CANCER RES, V62, P1443; Kalish H, 2001, J AM CHEM SOC, V123, P11719, DOI 10.1021/ja011545b; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; Ko JL, 1996, GENE DEV, V10, P1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2001, BIOCHEM PHARMACOL, V62, P657, DOI 10.1016/S0006-2952(01)00733-X; Konorev EA, 2000, AM J PHYSIOL-HEART C, V279, pH2424, DOI 10.1152/ajpheart.2000.279.5.H2424; Konorev EA, 2002, FREE RADICAL BIO MED, V33, P988, DOI 10.1016/S0891-5849(02)00989-9; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Kwok JC, 2002, MOL PHARMACOL, V62, P888, DOI 10.1124/mol.62.4.888; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MAGNELLI L, 1995, BIOCHEM BIOPH RES CO, V215, P641, DOI 10.1006/bbrc.1995.2512; Mallery SR, 1999, J CELL BIOCHEM, V73, P259; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Nakamura T, 2000, CIRCULATION, V102, P572; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nobori K, 2002, J MOL CELL CARDIOL, V34, P1387, DOI 10.1006/jmcc.2002.2091; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Poirson-Bichat F, 2000, CLIN CANCER RES, V6, P643; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Senturker S, 2002, ARCH BIOCHEM BIOPHYS, V397, P262, DOI 10.1006/abbi.2001.2681; Shacter E, 2000, BLOOD, V96, P307, DOI 10.1182/blood.V96.1.307.013k47_307_313; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; SINHA BK, 1989, CANCER RES, V49, P3844; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Suresh A, 2003, BRIT J HAEMATOL, V120, P457, DOI 10.1046/j.1365-2141.2003.04074.x; UBEZIO P, 1994, FREE RADICAL BIO MED, V16, P509, DOI 10.1016/0891-5849(94)90129-5; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wang SW, 2004, MOL CELL BIOCHEM, V255, P129, DOI 10.1023/B:MCBI.0000007269.74532.98; Wang SW, 2002, BIOCHEM J, V367, P729, DOI 10.1042/BJ20020752; WU HY, 1994, J BIOL CHEM, V269, P20067; YE JP, 1994, J BIOL CHEM, V269, P25728	46	461	480	3	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25535	25543		10.1074/jbc.M400944200	http://dx.doi.org/10.1074/jbc.M400944200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15054096	hybrid			2022-12-25	WOS:000221827900079
J	Wang, SN; Hirschberg, R				Wang, SN; Hirschberg, R			Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SMAD3; TRANSDUCTION; SKI; FIBROGENESIS; INHIBITION; EXPRESSION; INDUCTION; PROMOTER; RECEPTOR	Bone morphogenetic protein-7 (BMP7) is expressed in adult kidney and reduces renal fibrogenesis when given exogenously to rodents with experimental chronic nephropathies. In mesangial cells that regulate glomerular fibrosis in vivo, BMP7 inhibits transforming growth factor beta(TGF-beta)-driven fibrogenesis, primarily by preventing the TGF-beta-dependent down-regulation of matrix degradation and up-regulation of PAI-1. The signals and mechanisms of the BMP7 opposition to actions of TGF-beta are unknown. Here we show in mesangial cells that BMP7 reduces nuclear accumulation of Smad3 and blocks the transcriptional up-regulation of the TGF-beta/ Smad3 target, CAGA-lux. Smad5 knock-down impairs the ability of BMP7 to interfere with the activation of CAGA-lux and the accumulation of PAI-1 by TGF-beta indicating that Smad5 is required. Smad5 knock-down also reduces the rise in Smad6 upon BMP7. Forced expression of smad5 ( found to be the preferred BMP7-induced receptor-activated Smad signal in mesangial cells) or of smad6 mimics BMP7 in opposing the increase in transcriptional activation of PAI-1 and its secretion upon TGF-beta. This suggests a model for the BMP7-induced opposition to TGF-beta-dependent mesangial fibrogenesis requiring Smad5; the model involves the inhibitory Smad6 downstream of Smad5 as well as reduced availability of Smad3 in the nucleus. BMP7 does not require signaling through Erk1/2, p38, or JNK and does not utilize the TGF-beta transcriptional co-repressors Ski or SnoN in mesangial cells. These studies provide first insights into mechanisms through which BMP7 opposes TGF-beta-induced glomerular fibrogenesis.	Univ Calif Los Angeles, Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Hirschberg, R (corresponding author), Univ Calif Los Angeles, Harbor UCLA Res & Educ Inst, 1124 W Carson St,C-1-A, Torrance, CA 90502 USA.	rhirschberg@rei.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK063360] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bosukonda D, 2000, KIDNEY INT, V58, P1902, DOI 10.1046/j.1523-1755.2000.00362.x; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Fujimoto M, 2003, BIOCHEM BIOPH RES CO, V305, P1002, DOI 10.1016/S0006-291X(03)00885-4; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Lee MJ, 2003, J IMMUNOL, V170, P2557, DOI 10.4049/jimmunol.170.5.2557; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Morrissey P, 2002, NETW COMPUT, V13, P14; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Roberts AB, 2001, CHEST, V120, p43S, DOI 10.1378/chest.120.1_suppl.S43-a; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Simon N, 1999, AM J PHYSIOL-RENAL, V276, pF382, DOI 10.1152/ajprenal.1999.276.3.F382; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021; Wang S, 2003, KIDNEY INT, V63, P2037, DOI 10.1046/j.1523-1755.2003.00035.x; Wang SN, 2003, AM J PHYSIOL-RENAL, V284, pF1006, DOI 10.1152/ajprenal.00382.2002; Wang SN, 2001, J AM SOC NEPHROL, V12, P2392, DOI 10.1681/ASN.V12112392; Wendling J, 2003, MOL PHARMACOL, V64, P707, DOI 10.1124/mol.64.3.707; Wotton D, 2001, CURR TOP MICROBIOL, V254, P145; Xiao Z, 2003, J BIOL CHEM, V278, P34245, DOI 10.1074/jbc.M301596200; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zhao JS, 2000, MECH DEVELOP, V93, P71, DOI 10.1016/S0925-4773(00)00281-1	41	115	127	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23200	23206		10.1074/jbc.M311998200	http://dx.doi.org/10.1074/jbc.M311998200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047707	hybrid			2022-12-25	WOS:000221570900051
J	Farhan, H; Korkhov, VM; Paulitschke, V; Dorostkar, MM; Scholze, P; Kudlacek, O; Freissmuth, M; Sitte, HH				Farhan, H; Korkhov, VM; Paulitschke, V; Dorostkar, MM; Scholze, P; Kudlacek, O; Freissmuth, M; Sitte, HH			Two discontinuous segments in the carboxyl terminus are required for membrane targeting of the rat gamma-aminobutyric acid transporter-1 (GAT1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; ENDOPLASMIC-RETICULUM; GABA TRANSPORTER; SEROTONIN TRANSPORTER; EXOCYST COMPLEX; PDZ DOMAINS; PROTEIN; TRAFFICKING; ER; VESICLE	Like all members of the Na+/Cl--dependent neurotransmitter transporter family, the rat gamma-aminobutyric acid transporter-1 (GAT1) is sorted and targeted to specialized domains of the cell surface. Here we identify two discontinuous signals in the carboxyl terminus of GAT1 that cooperate to drive surface expression. This conclusion is based on the following observations. Upon deletion of the last 37 amino acids, the resulting GAT1-Delta37 remained trapped in the endoplasmic reticulum. The presence of 10 additional residues (GAT1-Delta27) sufficed to support the interaction with the coat protein complex II component Sec24D; surface expression of GAT1-Delta27 reached 50% of the wild type level. Additional extensions up to the position -3 (GAT1-Delta3) did not further enhance surface expression. Thus the last three amino acids (AYI) comprise a second distal signal. The sequence AYI is reminiscent of a type II PDZ-binding motif; accordingly substituting Glu for Ile abrogated the effect of this motif. Neither the AYI motif nor the last 10 residues rescued the protein from intracellular retention when grafted onto GAT1-Delta37 and GAT1-Delta32; the AYI motif was dispensable for targeting of GAT1 to the growth cone of differentiating PC12 cells. We therefore conclude that the two segments act in a hierarchical manner such that the proximal motif ((VMI571)-V-569) supports endoplasmic reticulum export of the protein and the distal AYI motif places GAT1 under the control of the exocyst.	Med Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria	Medical University of Vienna	Freissmuth, M (corresponding author), Med Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@meduniwien.ac.at	Farhan, Hesso/C-7997-2012; Sitte, Harald/O-7025-2019; Dorostkar, Mario/AAF-6399-2020; Sitte, Harald/N-2681-2013	Farhan, Hesso/0000-0002-0889-8463; Sitte, Harald/0000-0002-1339-7444; Dorostkar, Mario/0000-0001-8037-4907; Sitte, Harald/0000-0002-1339-7444; Kudlacek, Oliver/0000-0002-3086-8551; Scholze, Petra/0000-0003-4984-6034; Freissmuth, Michael/0000-0001-9398-1765; Korkhov, Volodymyr/0000-0002-0962-9433				Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Beckman ML, 1998, J NEUROSCI, V18, P6103; Blakely RD, 1998, BIOL PSYCHIAT, V44, P169, DOI 10.1016/S0006-3223(98)00124-3; Boehm S, 1997, J NEUROSCI, V17, P4066; Chiu CS, 2002, J NEUROSCI, V22, P10251; Gu HH, 1996, J BIOL CHEM, V271, P18100, DOI 10.1074/jbc.271.30.18100; Harris BZ, 2001, J CELL SCI, V114, P3219; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Iversen L, 2000, MOL PSYCHIATR, V5, P357, DOI 10.1038/sj.mp.4000728; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; MCHUGH EM, 2001, SOC NEUR ABSTR, V27, P242; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Quick MW, 1997, J NEUROSCI, V17, P2967; RADIAN R, 1990, J NEUROSCI, V10, P1319; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Vega IE, 2001, J NEUROSCI, V21, P3839, DOI 10.1523/JNEUROSCI.21-11-03839.2001; Wozniak M, 1998, BRAIN RES, V780, P311, DOI 10.1016/S0006-8993(97)01216-X; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1	37	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28553	28563		10.1074/jbc.M307325200	http://dx.doi.org/10.1074/jbc.M307325200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15073174	hybrid			2022-12-25	WOS:000222265400091
J	Bohuslav, J; Chen, LF; Kwon, H; Mu, YJ; Greene, WC				Bohuslav, J; Chen, LF; Kwon, H; Mu, YJ; Greene, WC			p53 induces NF-kappa B activation by an I kappa B kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; LIVER DEGENERATION; GENE-EXPRESSION; PROTEIN-KINASE; EMBRYONIC LETHALITY; INDUCED APOPTOSIS; MICE LACKING; GROWTH	Apoptosis induced by p53 has been proposed to involve activation of the transcription factor NF-kappaB. Here we describe the novel molecular mechanism through which p53 and DNA-damaging agents activate NF-kappaB. NF-kappaB induction by p53 does not occur through classical activation of the IkappaB kinases and degradation of IkappaBalpha. Rather, p53 expression stimulates the serine/threonine kinase ribosomal S6 kinase 1 (RSK1), which in turn phosphorylates the p65 subunit of NF-kappaB. The lower affinity of RSK1-phosphorylated p65 for its negative regulator, IkappaBalpha, decreases IkappaBalpha-mediated nuclear export of shuttling forms of NF-kappaB, thereby promoting the binding and action of NF-kappaB on cognate kappaB enhancers. These findings highlight a rather unusual pathway of NF-kappaB activation, which is utilized by the p53 tumor suppressor.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greene, WC (corresponding author), Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.	wgreene@gladstone.ucsf.edu			NCI NIH HHS [R01CA089001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonello D, 2002, CANCER LETT, V183, P179, DOI 10.1016/S0304-3835(01)00802-3; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doerre S, 1999, J IMMUNOL, V163, P269; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kang JL, 2000, TOXICOL APPL PHARM, V169, P59, DOI 10.1006/taap.2000.9039; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Teixeiro E, 1999, EUR J IMMUNOL, V29, P745, DOI 10.1002/(SICI)1521-4141(199903)29:03<745::AID-IMMU745>3.0.CO;2-0; Tergaonkar V, 2003, MOL CELL BIOL, V23, P8070, DOI 10.1128/MCB.23.22.8070-8083.2003; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	80	207	217	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26115	26125		10.1074/jbc.M313509200	http://dx.doi.org/10.1074/jbc.M313509200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073170	hybrid			2022-12-25	WOS:000222003000025
J	Qin, JZ; Jiang, ZF; Qian, YC; Casanova, JL; Li, XX				Qin, JZ; Jiang, ZF; Qian, YC; Casanova, JL; Li, XX			IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; BACTERIAL-INFECTIONS; DROSOPHILA TOLL; ACTIVATION; FAMILY; COMPLEX; MEMBER; MECHANISMS; PATHWAY; CASCADE	Interleukin-1 (IL-1) stimulation leads to the recruitment of interleukin-1 receptor-associated kinase ( IRAK) to the IL-1 receptor, where IRAK is phosphorylated, ubiquitinated, and eventually degraded. Kinase-inactive mutant IRAK is still phosphorylated in response to IL-1 stimulation when it is transfected into IRAK-deficient cells, suggesting that there must be an IRAK kinase in the pathway. The fact that IRAK4, another IRAK family member necessary for the IL-1 pathway, is able to phosphorylate IRAK in vitro suggests that IRAK4 might be the IRAK kinase. However, we now found that the IRAK4 kinase-inactive mutant had the same ability as the wild-type IRAK4 in restoring IL-1-mediated signaling in human IRAK4-deficient cells, including NFkappaB-dependent reporter gene expression, the activation of NFkappaB and JNK, and endogenous IL-8 gene expression. These results strongly indicate that the kinase activity of human IRAK4 is not necessary for IL-1 signaling. Furthermore, we showed that the kinase activity of IRAK4 was not necessary for IL-1-induced IRAK phosphorylation, suggesting that IRAK phosphorylation can probably be achieved either by autophosphorylation or by trans-phosphorylation through IRAK4. In support of this, only the impairment of the kinase activity of both IRAK and IRAK4 efficiently abolished the IL-1 pathway, demonstrating that the kinase activity of IRAK and IRAK4 is redundant for IL-1-mediated signaling. Moreover, consistent with the fact that IRAK4 is a necessary component of the IL-1 pathway, we found that IRAK4 was required for the efficient recruitment of IRAK to the IL-1 receptor complex.	Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA; Univ Paris 05, INSERM,U550, Unite Immunol & Hematol Pediat, Lab Genet Humaine Malad Infect Unite Mixte Rech, F-75270 Paris 06, France; Cleveland State Univ, Dept Biol, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University System of Ohio; Cleveland State University	Li, XX (corresponding author), Cleveland Clin Fdn, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	lix@ccf.org	Casanova, Jean-Laurent/I-3418-2017	Casanova, Jean-Laurent/0000-0002-7782-4169	NIGMS NIH HHS [GM 60020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; JIANG Z, 2002, J BIOL CHEM; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ONeill LAJ, 1997, BIOCHEM SOC T, V25, P295, DOI 10.1042/bst0250295; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	28	84	92	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26748	26753		10.1074/jbc.M400785200	http://dx.doi.org/10.1074/jbc.M400785200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15084582	hybrid			2022-12-25	WOS:000222003000101
J	Sayed, AA; Williams, DL				Sayed, AA; Williams, DL			Biochemical characterization of 2-Cys peroxiredoxins from Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; CYSTEINE-SULFINIC ACID; NECROSIS-FACTOR-ALPHA; THIOREDOXIN PEROXIDASE; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; ENZYMATIC CHARACTERIZATION; PLASMODIUM-FALCIPARUM; ANTIOXIDANT ENZYMES; MOLECULAR-CLONING	Peroxiredoxins are a large family of peroxidases that have important antioxidant and cell signaling functions. Genes encoding two novel 2-cysteine peroxiredoxin proteins were identified in the expressed sequence tag data base of the helminth parasite Schistosoma mansoni, a causative agent of schistosomiasis. The recombinant proteins showed peroxidase activity in vitro with a variety of hydroperoxides and used both the thioredoxin and the glutathione systems as electron donors. Steady-state kinetic analysis indicated that the new peroxiredoxins had saturable kinetics, whereas a previously identified schistosome peroxiredoxin was found to function with more typical unsaturable (ping-pong) kinetics. The catalytic efficiencies S. mansoni peroxiredoxins were similar to those for other peroxiredoxins studied (10(4)-10(5) M-1 s(-1)). Mutagenesis of S. mansoni peroxiredoxins indicated that glutathione dependence and kinetic differences were conferred by the C-terminal alpha-helix forming 22 amino acids. This is the first report of 2-cysteine peroxiredoxins efficiently utilizing reducing equivalents from both the thioredoxin and glutathione systems. Studies to determine the resistance to oxidative inactivation, important in regulating cell signaling pathways, showed that S. mansoni possess both bacterial-like resistant and mammalian-like sensitive peroxiredoxins. The susceptibility to oxidative inactivation was conferred by the C-terminal tail containing a tyrosine-phenylalanine motif. S. mansoni is the first organism shown to possess both robust and sensitive peroxiredoxins. The ability of schistosome peroxiredoxins to use alternative electron donors, and their variable resistance to overoxidation may reflect their presence in different cellular sites and emphasizes the significant differences in overall redox balance mechanisms between the parasite and its mammalian host.	Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA	Illinois State University	Williams, DL (corresponding author), Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA.	dlwilli@ilstu.edu						Alger HM, 2002, INT J PARASITOL, V32, P1285, DOI 10.1016/S0020-7519(02)00108-X; Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2; Bauer H, 2003, EUR J BIOCHEM, V270, P4272, DOI 10.1046/j.1432-1033.2003.03812.x; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P27670; DAMIAN RT, 1987, J PARASITOL, V73, P3, DOI 10.2307/3282338; DOENHOFF MJ, 1985, IMMUNOL TODAY, V6, P203, DOI 10.1016/0167-5699(85)90034-9; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Engels D, 2002, ACTA TROP, V82, P139, DOI 10.1016/S0001-706X(02)00045-1; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; Foulk BW, 2002, INT J PARASITOL, V32, P1487, DOI 10.1016/S0020-7519(02)00161-3; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Karanja DMS, 1997, AM J TROP MED HYG, V56, P515, DOI 10.4269/ajtmh.1997.56.515; Kawazu S, 2000, MOL BIOCHEM PARASIT, V109, P165, DOI 10.1016/S0166-6851(00)00243-7; KAZURA JW, 1985, J CLIN INVEST, V75, P1297, DOI 10.1172/JCI111830; Koo KH, 2002, ARCH BIOCHEM BIOPHYS, V397, P312, DOI 10.1006/abbi.2001.2700; Kwatia MA, 2000, J PARASITOL, V86, P908, DOI 10.1645/0022-3395(2000)086[0908:MAECOS]2.0.CO;2; Le Paslier MC, 2000, GENOMICS, V65, P87, DOI 10.1006/geno.2000.6147; LoVerde PT, 1998, PARASITOL TODAY, V14, P284, DOI 10.1016/S0169-4758(98)01261-7; Maiorino M, 1996, EUR J BIOCHEM, V238, P838, DOI 10.1111/j.1432-1033.1996.0838w.x; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; Mei HP, 1997, EXP PARASITOL, V86, P69, DOI 10.1006/expr.1997.4150; MKOJI GM, 1988, INT J PARASITOL, V18, P661, DOI 10.1016/0020-7519(88)90101-4; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; WILLIAMS DL, 1992, MOL BIOCHEM PARASIT, V52, P127, DOI 10.1016/0166-6851(92)90042-I; Williams DL, 2001, INFECT IMMUN, V69, P1134, DOI 10.1128/IAI.69.2.1134-1141.2001; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	48	100	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26159	26166		10.1074/jbc.M401748200	http://dx.doi.org/10.1074/jbc.M401748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075328	hybrid			2022-12-25	WOS:000222003000030
J	Karla, N; Kumar, V				Karla, N; Kumar, V			c-Fos is a mediator of the c-Myc-induced apoptotic signaling in serum-deprived hepatoma cells via the p38 mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; TRANSGENIC MICE; CYCLE ARREST; EXPRESSION; GENE; TARGET; GROWTH; DEATH; JUN; PROTOONCOGENES	The proto-oncogene c-myc encodes a transcription factor that plays a pivotal role in cell proliferation, differentiation, and apoptosis. The signaling mechanism of c-Myc-induced apoptosis was investigated on the human hepatoma Huh7 cells under growth factor-deprived conditions. The apoptotic process did not involve p53. Rather it was dependent on the expression of c-Fos. Activation of caspases 3 and 9 and down-regulation of Bcl2 were observed in the apoptotic process, indicating it to be a mitochondria-dependent event. An increase in the p38 mitogen-activated protein kinase that was mediated by a Rac1-dependent and cdc42-independent pathway eventually leading to up-regulation of c-Fos activity was also observed. Deletion analysis of the promoter region of the c-fos gene indicated that the ATF2-responsive element conferred the Myc-induced expression of c-Fos. Co-expression of the dominant-negative mutants of c-Fos, p38, and Rac1 blocked the Myc-mediated apoptosis. SB20358, a chemical inhibitor of p38 pathway, also specifically blocked the apoptotic signaling by c-Myc. Furthermore, co-expression of the hepatitis B virus X protein (HBx) along with Myc abrogated the apoptotic signals. The HBx expression was associated with an increase in the levels of phosphorylated AKT and down-regulation of c-Fos by Myc. Thus, c-Fos seems be a new mediator of c-Myc-induced apoptosis.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Kumar, V (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, POB 10504,Aruna Asaf Ali Marg, New Delhi 110067, India.	vijay@icgeb.res.in		Kumar, Vijay/0000-0001-6477-8274				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Cance WG, 2000, CLIN CANCER RES, V6, P2417; CHERNEY BW, 1994, P NATL ACAD SCI USA, V91, P12967, DOI 10.1073/pnas.91.26.12967; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIDOFF AN, 1993, ANTICANCER RES, V13, P2257; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Inada K, 1998, J IMMUNOL, V161, P3853; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; Kao CY, 1996, BIOCHEM BIOPH RES CO, V222, P64, DOI 10.1006/bbrc.1996.0698; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Kumari SR, 2000, CANCER INVEST, V18, P715, DOI 10.3109/07357900009012203; Lakhtakia R, 2003, J GASTROEN HEPATOL, V18, P80, DOI 10.1046/j.1440-1746.2003.02902.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Poon HK, 2000, INVEST OPHTH VIS SCI, V41, P2755; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sambrook J, 2001, MOL CLONING LAB MANU; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shih WL, 2003, J BIOL CHEM, V278, P31807, DOI 10.1074/jbc.M302580200; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shirasuna K, 1999, GENES CELLS, V4, P277, DOI 10.1046/j.1365-2443.1999.00258.x; Shiu YT, 2003, BIOCHEM BIOPH RES CO, V303, P548, DOI 10.1016/S0006-291X(03)00388-7; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Teng CS, 1998, CONTRACEPTION, V57, P281, DOI 10.1016/S0010-7824(98)00023-7; Teng CS, 2000, INT REV CYTOL, V197, P137, DOI 10.1016/S0074-7696(00)97004-9; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG XW, 1995, CANCER RES, V55, P6012; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	68	67	78	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25313	25319		10.1074/jbc.M400932200	http://dx.doi.org/10.1074/jbc.M400932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078869	hybrid			2022-12-25	WOS:000221827900051
J	Murphy, KA; Villano, CM; Dorn, R; White, LA				Murphy, KA; Villano, CM; Dorn, R; White, LA			Interaction between the aryl hydrocarbon receptor and retinoic acid pathways increases matrix metalloproteinase-1 expression in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; GENE-EXPRESSION; DIFFERENTIAL REGULATION; CLEFT-PALATE; ALL-TRANS; PROTEIN; DIOXIN; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; BINDING; TRANSCRIPTION	Exposure to the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) results in a variety of pathological lesions in humans via activation of the aryl hydrocarbon receptor (AhR) pathway. It has become apparent that this pathway interacts with a variety of signaling pathways that are believed to be involved in mediating TCDD/AhR biological effects. Our hypothesis is that TCDD mediates these pathological lesions by directly altering the expression of genes involved in matrix deposition and remodeling and that the retinoic acid signaling pathway is involved in modulating TCDD-induced effects. Therefore, we examined the effect of TCDD and all-trans retinoic acid (atRA) on the expression of matrix metalloproteinase-1 (MMP-1, interstitial collagenase), one of the proteolytic enzymes that degrade type I collagen, in normal human keratinocytes. The data show that TCDD exposure results in increased MMP-1 expression in keratinocytes that is further enhanced by co-treatment with all-trans retinoic acid. TCDD-induced expression of MMP-1 appears to be mediated through two AP-1 elements in the proximal promoter of the MMP-1 gene. However, retinoic acid-mediated induction of keratinocyte MMP-1 is a result of both promoter activation and increased mRNA stability. These findings are the first to demonstrate TCDD-induced expression of MMP-1 and to demonstrate interactions between the TCDD/AhR and retinoic acid pathways on MMP-1 expression.	Rutgers State Univ, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	White, LA (corresponding author), Rutgers State Univ, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA.	lawhite@aesop.rutgers.edu			NIEHS NIH HHS [K22 ES 00334-01 ZES1] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES000334] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1990, TOXICOL APPL PHARM, V106, P418, DOI 10.1016/0041-008X(90)90337-T; Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Benbow U, 1999, BRIT J CANCER, V79, P221, DOI 10.1038/sj.bjc.6690037; Benbrook DM, 1997, GYNECOL ONCOL, V66, P114, DOI 10.1006/gyno.1997.4736; BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Delescluse C, 2000, TOXICOLOGY, V153, P73, DOI 10.1016/S0300-483X(00)00305-X; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; FISHER C, 1995, CRIT REV ORAL BIOL M, V6, P284, DOI 10.1177/10454411950060040201; FitzGerald CT, 1996, ARCH BIOCHEM BIOPHYS, V333, P170, DOI 10.1006/abbi.1996.0378; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; Gradin K, 1999, J BIOL CHEM, V274, P13511, DOI 10.1074/jbc.274.19.13511; Guenther MG, 2000, GENE DEV, V14, P1048; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; Huang EY, 2000, GENE DEV, V14, P45; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Khasigov PZ, 2001, BIOCHEMISTRY-MOSCOW+, V66, P130, DOI 10.1023/A:1002879128392; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kobayashi T, 1998, DERMATOLOGY, V197, P1, DOI 10.1159/000017967; Krig SR, 2000, TOXICOL SCI, V56, P357, DOI 10.1093/toxsci/56.2.357; Lorick KL, 1998, BIOCHEM BIOPH RES CO, V243, P749, DOI 10.1006/bbrc.1998.8173; Luca M, 1997, AM J PATHOL, V151, P1105; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martinez JM, 2002, TOXICOL SCI, V69, P409, DOI 10.1093/toxsci/69.2.409; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; Mueller BM, 1996, CURR TOP MICROBIOL, V213, P65; Mukerjee D, 1998, J AIR WASTE MANAGE, V48, P157, DOI 10.1080/10473289.1998.10463655; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Roman BL, 1998, TOXICOL APPL PHARM, V150, P254, DOI 10.1006/taap.1998.8395; ROSAS VE, 1996, INT J DERMATOL, V35, P643; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; SADEK CM, 1994, J BIOL CHEM, V269, P16067; Sambrook J, 2001, MOL CLONING LAB MANU; Schoenermark MP, 1999, ANN NY ACAD SCI, V878, P466, DOI 10.1111/j.1749-6632.1999.tb07703.x; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takagi TN, 2000, TERATOGEN CARCIN MUT, V20, P73, DOI 10.1002/(SICI)1520-6866(2000)20:2<73::AID-TCM3>3.0.CO;2-M; VINCENTI MP, 1996, CRIT REV EUKARYOT GE; von Marschall Z, 1999, BRIT J CANCER, V80, P935, DOI 10.1038/sj.bjc.6690446; Wandel E, 2000, EXP DERMATOL, V9, P34, DOI 10.1034/j.1600-0625.2000.009001034.x; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; WESTON WM, 1995, BIOCHEM BIOPH RES CO, V207, P690, DOI 10.1006/bbrc.1995.1242; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9; YIN H, 1994, EXP CLIN IMMUNOGENET, V11, P128	55	67	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25284	25293		10.1074/jbc.M402168200	http://dx.doi.org/10.1074/jbc.M402168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075337	hybrid			2022-12-25	WOS:000221827900047
J	Palty, R; Ohana, E; Hershfinkel, M; Volokita, M; Elgazar, V; Beharier, O; Silverman, WF; Argaman, M; Sekler, I				Palty, R; Ohana, E; Hershfinkel, M; Volokita, M; Elgazar, V; Beharier, O; Silverman, WF; Argaman, M; Sekler, I			Lithium-calcium exchange is mediated by a distinct potassium-independent sodium-calcium exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-CA2+ EXCHANGER; NA+/CA2+ EXCHANGER; TRANSPORT; MUSCLE; CELLS; RESIDUES; EFFLUX; BRAIN; CA2+	Sodium-calcium exchangers have long been considered inert with respect to monovalent cations such as lithium, choline, and N-methyl-D-glucamine. A key question that has remained unsolved is how despite this, Li+ catalyzes calcium exchange in mammalian tissues. Here we report that a Na+/Ca2+ exchanger, NCLX cloned from human cells (known as FLJ22233), is distinct from both known forms of the exchanger, NCX and NCKX in structure and kinetics. Surprisingly, NCLX catalyzes active Li+/Ca2+ exchange, thereby explaining the exchange of these ions in mammalian tissues. The NCLX protein, detected as both 70- and 55-KDa polypeptides, is highly expressed in rat pancreas, skeletal muscle, and stomach. We demonstrate, moreover, that NCLX is a K+-independent exchanger that catalyzes Ca2+ flux at a rate comparable with NCX1 but without promoting Na+/Ba2+ exchange. The activity of NCLX is strongly inhibited by zinc, although it does not transport this cation. NCLX activity is only partially inhibited by the NCX inhibitor, KB-R7943. Our results provide a cogent explanation for a fundamental question. How can Li+ promote Ca2+ exchange whereas the known exchangers are inert to Li+ ions? Identification of this novel member of the Na+/Ca2+ superfamily, with distinct characteristics, including the ability to transport Li+, may provide an explanation for this phenomenon.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Morphol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Natl Inst Mol Biol Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University	Sekler, I (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel.	sekler@bgumail.bgu.ac.il	Hershfinkel, Michal/F-1548-2012; Ohana, Ehud/ABB-3060-2020; Beharier, Ofer/AAC-8016-2021; Palty, Raz/HCH-3978-2022; ohana, ehud/C-3077-2014	Hershfinkel, Michal/0000-0003-1652-1989; Ohana, Ehud/0000-0001-8598-4042				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BAYERDORFFER E, 1985, J MEMBRANE BIOL, V87, P107, DOI 10.1007/BF01870657; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; CAI X, 2003, J BIOL CHEM, V18, P18; Colvin RA, 1998, NEUROREPORT, V9, P3091, DOI 10.1097/00001756-199809140-00032; Condrescu M, 1997, J GEN PHYSIOL, V109, P41, DOI 10.1085/jgp.109.1.41; Conway SJ, 2002, ANN NY ACAD SCI, V976, P268; Deval E, 2002, CELL CALCIUM, V31, P37, DOI 10.1054/ceca.2001.0254; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Elias CL, 2001, AM J PHYSIOL-HEART C, V281, pH1334, DOI 10.1152/ajpheart.2001.281.3.H1334; FERAY JC, 1988, N-S ARCH PHARMACOL, V338, P332; GADSBY DC, 1991, ANN NY ACAD SCI, V639, P140, DOI 10.1111/j.1749-6632.1991.tb17297.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P71; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; Jeon D, 2003, NEURON, V38, P965, DOI 10.1016/S0896-6273(03)00334-9; KHANANSHVILI D, 1998, ADV MOL CEL A&B, V23, P311; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; Nakayama S, 2003, J PHYSIOL-LONDON, V551, P843, DOI 10.1113/jphysiol.2003.047795; NELSON MT, 1981, NATURE, V289, P314, DOI 10.1038/289314a0; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nitzan YB, 2002, DEV BRAIN RES, V137, P149, DOI 10.1016/S0165-3806(02)00437-6; OHANA E, 2003, J BIOL CHEM, V27, P27; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; QUEDNAU BD, 2003, PFLUEGERS ARCH EUR J, V7, P7; SCHNETKAMP PP, 2003, PFLUEGERS ARCH EUR J, V6, P6; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Sokolow S, 2004, J CLIN INVEST, V113, P265, DOI 10.1172/JCI200418688; Winkfein RJ, 2003, BIOCHEMISTRY-US, V42, P543, DOI 10.1021/bi026982x	29	99	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25234	25240		10.1074/jbc.M401229200	http://dx.doi.org/10.1074/jbc.M401229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060069	hybrid			2022-12-25	WOS:000221827900041
J	Sazonova, IY; Robinson, BR; Gladysheva, IP; Castellino, FJ; Reed, GL				Sazonova, IY; Robinson, BR; Gladysheva, IP; Castellino, FJ; Reed, GL			alpha domain deletion converts streptokinase into a fibrin-dependent plasminogen activator through mechanisms akin to staphylokinase and tissue plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; FACTOR-XIII; BINDING; COMPLEX; CONFORMATION; SUBSTRATE; KINETICS; PLASMA; SITE; UROKINASE	The mechanism of action of plasminogen (Pg) activators may affect their therapeutic properties in humans. Streptokinase (SK) is a robust Pg activator in physiologic fluids in the absence of fibrin. Deletion of a "catalytic switch" (SK residues 1-59), alters the conformation of the SK alpha domain and converts SKDelta59 into a fibrin-dependent Pg activator through unknown mechanisms. We show that the SK alpha domain binds avidly to the Pg kringle domains that maintain Glu-Pg in a tightly folded conformation. By virtue of deletion of SK residues 1-59, SKDelta59 loses the ability to unfold Glu-Pg during complex formation and becomes incapable of nonproteolytic active site formation. In this manner, SKDelta59 behaves more like staphylokinase than like SK; it requires plasmin to form a functional activator complex, and in this complex SKDelta59 does not protect plasmin from inhibition by alpha(2)-antiplasmin. At the same time, SKDelta59 is unlike staphylokinase or SK and is more like tissue Pg activator, because it is a poor activator of the tightly folded form of Glu-Pg in physiologic solutions. SKDelta59 can only activate Glu-Pg when it was unfolded by fibrin interactions or by Cl--deficient buffers. Taken together, these studies indicate that an intact alpha domain confers on SK the ability to nonproteolytically activate Glu-Pg, to unfold and process Glu-Pg substrate in physiologic solutions, and to alter the substrate-inhibitor interactions of plasmin in the activator complex. The loss of an intact alpha domain makes SKDelta59 activate Pg through classical "fibrin-dependent mechanisms" (akin to both staphylokinase and tissue Pg activator) that include: 1) a marked preference for a fibrin-bound or unfolded Glu-Pg substrate, 2) a requirement for plasmin in the activator complex, and 3) the creation of an activator complex with plasmin that is readily inhibited by alpha(2)-antiplasmin.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; University of Notre Dame	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 665 Huntington Ave, Boston, MA 02115 USA.	guyreed@hsph.harvard.edu	Gladysheva, Inna/AAU-9465-2020	Gladysheva, Inna/0000-0002-2501-9029	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013423, R01HL058496, R37HL013423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13423, HL58496, R01 HL058496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHMANN F, 2001, HEMOSTASIS THROMBOSI, P275; BANYAI L, 1984, J BIOL CHEM, V259, P6466; BARLOW GH, 1984, BIOCHEMISTRY-US, V23, P2384, DOI 10.1021/bi00306a010; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; BRINGMANN P, 1995, J BIOL CHEM, V270, P25596, DOI 10.1074/jbc.270.43.25596; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; CHRISTENSEN U, 1992, BIOCHEM J, V285, P419, DOI 10.1042/bj2850419; COLLEN D, 1993, EUR J BIOCHEM, V216, P307, DOI 10.1111/j.1432-1033.1993.tb18147.x; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; ConejeroLara F, 1996, PROTEIN SCI, V5, P2583, DOI 10.1002/pro.5560051221; FISCHER BE, 1992, BLOOD COAGUL FIBRIN, V3, P197; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gladysheva IP, 2002, J BIOL CHEM, V277, P26846, DOI 10.1074/jbc.M202999200; HOLVOET P, 1991, J BIOL CHEM, V266, P19717; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; LIJNEN HR, 1989, BLOOD, V73, P1864; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; Liu L, 2000, J BIOL CHEM, V275, P37686, DOI 10.1074/jbc.M003963200; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; LUKACOVA D, 1991, BIOCHEMISTRY-US, V30, P10164, DOI 10.1021/bi00106a013; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARSHALL JM, 1994, BIOCHEMISTRY-US, V33, P3599, DOI 10.1021/bi00178a017; MCCANCE SG, 1995, BIOCHEMISTRY-US, V34, P9581, DOI 10.1021/bi00029a035; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; MOTULSKY HG, 1994, GRAPHPAD; Mundada LV, 2003, J BIOL CHEM, V278, P24421, DOI 10.1074/jbc.M301825200; Parrado J, 1996, PROTEIN SCI, V5, P693; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; Reed GL, 1999, CIRCULATION, V99, P299, DOI 10.1161/01.CIR.99.2.299; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SAKAI M, 1989, BIOCHEM BIOPH RES CO, V162, P830, DOI 10.1016/0006-291X(89)92385-1; Sazonova IY, 2001, J BIOL CHEM, V276, P12609, DOI 10.1074/jbc.M009265200; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SILENCE K, 1993, BLOOD, V82, P1175, DOI 10.1182/blood.V82.4.1175.bloodjournal8241175; Stewart RJ, 1998, J BIOL CHEM, V273, P18292, DOI 10.1074/jbc.273.29.18292; Sundram V, 2003, J BIOL CHEM, V278, P30569, DOI 10.1074/jbc.M303799200; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; WIMAN B, 1986, THROMB HAEMOSTASIS, V55, P189; WOHL RC, 1980, J BIOL CHEM, V255, P2005; Wu DH, 2001, J BIOL CHEM, V276, P15025, DOI 10.1074/jbc.M005935200; Yakovlev S, 2000, BIOCHEMISTRY-US, V39, P15730, DOI 10.1021/bi001847a; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	55	18	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24994	25001		10.1074/jbc.M400253200	http://dx.doi.org/10.1074/jbc.M400253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069059	hybrid			2022-12-25	WOS:000221827900013
J	Selvapandiyan, A; Debrabant, A; Duncan, R; Muller, J; Salotra, P; Sreenivas, G; Salisbury, JL; Nakhasi, HL				Selvapandiyan, A; Debrabant, A; Duncan, R; Muller, J; Salotra, P; Sreenivas, G; Salisbury, JL; Nakhasi, HL			Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; MITOTIC SPINDLE POLES; VIRULENCE FACTOR; DONOVANI; CENTROSOMES; LIPOPHOSPHOGLYCAN; SEGREGATION; DELETION; DEATH; REPLACEMENT	Centrin is a calcium-binding cytoskeletal protein involved in the duplication of centrosomes in higher eukaryotes. To explore the role of centrin in the protozoan parasite Leishmania, we created Leishmania deficient in the centrin gene (LdCEN). Remarkably, centrin null mutants (LdCEN(-/-)) showed selective growth arrest as axenic amastigotes but not as promastigotes. Flow cytometry analysis confirmed that the mutant axenic amastigotes have a cell cycle arrest at the G(2)/M stage. The axenic amastigotes also showed failure of basal body duplication and failure of cytokinesis resulting in multinucleated "large" cells. Increased terminal deoxy uridine triphosphate nick end labeling positivity was observed in centrin mutant axenic amastigotes compared with wild type cells, suggesting the activation of a programmed cell death pathway. Growth of LdCEN(-/-) amastigotes in infected macrophages in vitro was inhibited and also resulted in large multinucleated parasites. Normal basal body duplication and cell division in the LdCEN knockout promastigote is unique and surprising. Further, this is the first report where disruption of a centrin gene displays stage-specific/celltype-specific failure in cell division in a eukaryote. The centrin null mutant defective in amastigote growth could be useful as a vaccine candidate against leishmaniasis.	US FDA, Ctr Biol Evaluat & Res, Off Blood Res & Review, Div Emerging & Transfus Transmitted Dis,Lab Bacter, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Off Vaccines Res & Review, Div Viral Prod,Lab Vector Borne Dis, Bethesda, MD 20892 USA; Safdarjang Hosp, Indian Council Med Res, Inst Pathol, New Delhi 110029, India; Mayo Clin, Coll Med, Tumor Biol Program, Rochester, MN 55905 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); Indian Council of Medical Research (ICMR); ICMR - National Institute of Pathology (IOP); Vardhman Mahavir Medical College & Safdarjung Hospital; Mayo Clinic	Nakhasi, HL (corresponding author), US FDA, Ctr Biol Evaluat & Res, Off Blood Res & Review, Div Emerging & Transfus Transmitted Dis,Lab Bacter, Bldg 29,Rm 222,8800 Rockville Pike, Bethesda, MD 20892 USA.	nakhasi@cber.fda.gov	Selvapandiyan, Angamuthu/AAY-2556-2021; Selvapandiyan, Angamuthu/AAA-8602-2021; Duncan, Robert/I-8168-2015	Duncan, Robert/0000-0001-8409-2501; Salisbury, Jeffrey/0000-0001-9257-4578; Gannavaram, Sreenivas/0000-0002-6557-8220; Selvapandiyan, Angamuthu/0000-0002-2194-1534; Salotra, Poonam/0000-0002-4057-4872				BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; Debrabant A, 2003, INT J PARASITOL, V33, P257, DOI 10.1016/S0020-7519(03)00008-0; Debrabant A, 2002, INT J PARASITOL, V32, P1423, DOI 10.1016/S0020-7519(02)00134-0; ERRABOLU R, 1994, J CELL SCI, V107, P9; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; Gavet O, 2003, MOL BIOL CELL, V14, P1818, DOI 10.1091/mbc.E02-11-0709; Goyard S, 2003, MOL BIOCHEM PARASIT, V130, P31, DOI 10.1016/S0166-6851(03)00142-7; Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; Jiang YQ, 1999, J BIOL CHEM, V274, P3781, DOI 10.1074/jbc.274.6.3781; Joshi PB, 1998, MOL MICROBIOL, V27, P519, DOI 10.1046/j.1365-2958.1998.00689.x; Joshi PB, 2002, MOL BIOCHEM PARASIT, V120, P33, DOI 10.1016/S0166-6851(01)00432-7; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; Klink VP, 2001, MOL BIOL CELL, V12, P761, DOI 10.1091/mbc.12.3.761; Koblenz B, 2003, J CELL SCI, V116, P2635, DOI 10.1242/jcs.00497; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; Paoletti A, 2003, MOL BIOL CELL, V14, P2793, DOI 10.1091/mbc.E02-10-0661; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Roberts SC, 2001, MOL BIOCHEM PARASIT, V115, P217, DOI 10.1016/S0166-6851(01)00293-6; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; Salisbury JL, 2004, CURR BIOL, V14, pR27, DOI 10.1016/j.cub.2003.12.019; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; Salisbury JL, 2003, CURR BIOL, V13, pR88, DOI 10.1016/S0960-9822(03)00033-2; Selvapandiyan A, 2001, J BIOL CHEM, V276, P43253, DOI 10.1074/jbc.M106806200; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; VALLEN EA, 1994, GENETICS, V137, P407; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6	39	89	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25703	25710		10.1074/jbc.M402794200	http://dx.doi.org/10.1074/jbc.M402794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084606	hybrid			2022-12-25	WOS:000221827900100
J	Wu, JJP; Guidotti, G				Wu, JJP; Guidotti, G			Proreceptor dimerization is required for insulin receptor post-translational processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I DISULFIDES; SUBUNITS; BONDS; CYSTEINE-524; ECTODOMAIN; MONOMERS	The insulin receptor is a transmembrane protein dimer composed of two alphabeta monomers held together by inter-alpha-chain disulfide bonds. In a previous report we described a monomeric insulin receptor obtained by replacing Cys-524, -682, -683, and -685 with serine (Wu, J. J., and Guidotti, G. (2002) J. Biol. Chem. 277, 27809-27817). The membrane-bound monomeric insulin receptors could be cross-linked to dimers in the presence of insulin, indicating that although covalent interactions had been abolished, noncovalent dimerization could still occur in the membrane. To eliminate noncovalent dimerization, we replaced all or some of Cys-524, -682, -683, and -685 with arginine or aspartic acid with the expectation that the electrostatic repulsion at these contact sites would prevent noncovalent dimerization. The results indicate that mutant insulin receptors that are able to form covalent dimers are expressed at the wild type level; mutants that can form noncovalent dimers are expressed at half the level of the wild type receptor, whereas insulin receptor mutants that cannot dimerize are expressed at less than 10% of the wild type level. To elucidate the mechanism of the decrease in expression of the mutant insulin receptors, we examined their subcellular localization and biosynthesis. The results suggest that the extent of expression of these mutant receptors is related to their ability to form covalent or noncovalent dimers at the proreceptor stage.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Guidotti, G (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	guidotti@fas.harvard.edu			NIDDK NIH HHS [DK27626] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027626] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; BILAN PJ, 1994, BIOCHEM BIOPH RES CO, V205, P1891, DOI 10.1006/bbrc.1994.2891; CHEATHAM B, 1992, J BIOL CHEM, V267, P7108; CHIACCHIA KB, 1991, BIOCHEM BIOPH RES CO, V176, P1178, DOI 10.1016/0006-291X(91)90409-Z; Coppi MV, 1997, ARCH BIOCHEM BIOPHYS, V346, P312, DOI 10.1006/abbi.1997.0332; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; FINN FM, 1990, P NATL ACAD SCI USA, V87, P419, DOI 10.1073/pnas.87.1.419; HEDO JA, 1983, J BIOL CHEM, V258, P20; KASUGA M, 1982, J BIOL CHEM, V257, P392; Lu KH, 1996, MOL BIOL CELL, V7, P679, DOI 10.1091/mbc.7.5.679; MACAULAY SL, 1994, BIOCHEM J, V303, P575, DOI 10.1042/bj3030575; MASSAGUE J, 1982, J BIOL CHEM, V257, P6729; OLSON TS, 1988, J BIOL CHEM, V263, P7342; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; Wu JJP, 2002, J BIOL CHEM, V277, P27809, DOI 10.1074/jbc.M200367200	19	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25765	25773		10.1074/jbc.M314281200	http://dx.doi.org/10.1074/jbc.M314281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075343	Green Published, hybrid			2022-12-25	WOS:000221827900106
J	Garnovskaya, MN; Mukhin, YV; Vlasova, TM; Grewal, JS; Ullian, ME; Tholanikunnel, BG; Raymond, JR				Garnovskaya, MN; Mukhin, YV; Vlasova, TM; Grewal, JS; Ullian, ME; Tholanikunnel, BG; Raymond, JR			Mitogen-induced rapid phosphorylation of serine 795 of the retinoblastoma gene product in vascular smooth muscle cells involves ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR PROTEIN; CYCLIN-DEPENDENT KINASES; ABL TYROSINE KINASE; BREAST-CANCER CELLS; ANGIOTENSIN-II; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; DIFFERENTIAL REGULATION; NUCLEAR-LOCALIZATION	We examined the relationship between mitogen-activated MEK (mitogen and extracellular signal-regulated protein kinase kinase) and phosphorylation of the gene product encoded by retinoblastoma ( hereafter referred to as Rb) in vascular smooth muscle cells. Brief treatment of the cells with 100 nM angiotensin II or 1 muM serotonin resulted in serine phosphorylation of Rb that was equal in magnitude to that induced by treating cells for 20 h with 10% fetal bovine serum (approximate to3 x basal). There was no detectable rapid phosphorylation of two close cousins of Rb, p107 and p130. Phosphorylation state-specific antisera demonstrated that the rapid phosphorylation occurred on Ser(795), but not on Ser(249), Thr(252), Thr(373), Ser(780), Ser(807), or Ser(811). Phosphorylation of Rb Ser(795) peaked at 10 min, lagging behind phosphorylation of MEK and ERK (extracellular signal-regulated protein kinase). Rb Ser(795) phosphorylation could be blocked by PD98059, a MEK inhibitor, and greatly attenuated by apigenin, an inhibitor of the Ras --> Raf --> MEK --> ERK pathway. The effect also appears to be mediated by CDK4. Immunoprecipitation/immunoblot studies revealed that serotonin and angiotensin II induced complex formation between CDK4, cyclin D1, and phosphorylated ERK. These studies show a rapid, novel, and selective phosphorylation of Rb Ser(795) by mitogens and demonstrate an unexpected rapid linkage between the actions of the Ras --> Raf --> MEK --> ERK pathway and the phosphorylation state of Rb.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Garnovskaya, MN (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA.	garnovsk@musc.edu		Garnovskaya, Maria/0000-0002-6216-038X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002694, R01DK052448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063909] Funding Source: NIH RePORTER; NIDDK NIH HHS [K01-DK02694, R01-DK52448] Funding Source: Medline; NIGMS NIH HHS [R01-GM63909] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Allen KE, 1997, J CELL SCI, V110, P2819; Boylan JF, 1999, EXP CELL RES, V248, P110, DOI 10.1006/excr.1999.4389; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; delaLuna S, 1996, J CELL SCI, V109, P2443; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Felzien LK, 1997, MOL IMMUNOL, V34, P507, DOI 10.1016/S0161-5890(97)00063-1; Florian JA, 1998, J PHARMACOL EXP THER, V284, P346; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; GOLINO P, 1994, NEW ENGL J MED, V331, P131; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KUO ML, 1994, CANCER LETT, V87, P91, DOI 10.1016/0304-3835(94)90414-6; KUO ML, 1994, BIOCHEM BIOPH RES CO, V212, P91767; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee SL, 1997, AM J PHYSIOL-CELL PH, V272, pC223, DOI 10.1152/ajpcell.1997.272.1.C223; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lepley DM, 1997, MOL CARCINOGEN, V19, P74, DOI 10.1002/(SICI)1098-2744(199707)19:2<74::AID-MC2>3.0.CO;2-L; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Magae J, 1996, J CELL SCI, V109, P1717; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Mukhin YV, 2003, J PHARMACOL EXP THER, V304, P968, DOI 10.1124/jpet.102.043943; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Taieb F, 1998, FEBS LETT, V425, P465, DOI 10.1016/S0014-5793(98)00291-9; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Ullian ME, 1997, AM J PHYSIOL-CELL PH, V273, pC1241, DOI 10.1152/ajpcell.1997.273.4.C1241; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; WILLERSON JT, 1991, J AM COLL CARDIOL, V17, pB101; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	66	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24899	24905		10.1074/jbc.M311622200	http://dx.doi.org/10.1074/jbc.M311622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069084	hybrid			2022-12-25	WOS:000221702500122
J	Graf, GA; Cohen, JC; Hobbs, HH				Graf, GA; Cohen, JC; Hobbs, HH			Missense mutations in ABCG5 and ABCG8 disrupt heterodimerization and trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; LIVER-X-RECEPTOR; BINDING CASSETTE TRANSPORTERS; BILIARY CHOLESTEROL SECRETION; CYSTIC-FIBROSIS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; DIETARY-CHOLESTEROL; STEROL ABSORPTION; IN-VIVO	Mutations in ABCG5 (G5) or ABCG8 (G8) cause sitosterolemia, an autosomal recessive disease characterized by sterol accumulation and premature atherosclerosis. G5 and G8 are ATP-binding cassette (ABC) half-transporters that must heterodimerize to move to the apical surface of cells. We examined the role of N-linked glycans in the formation of the G5/G8 heterodimer to gain insight into the determinants of folding and trafficking of these proteins. Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619). N-Linked glycosylation of G8 was required for efficient trafficking of the G5/G8 heterodimer, but mutations that abolished glycosylation of G5 did not prevent trafficking of the heterodimer. Both G5 and G8 are bound by the lectin chaperone, calnexin, suggesting that the calnexin cycle may facilitate folding of the G5/G8 heterodimer. To determine the effects of 13 disease-causing missense mutations in G5 and G8 on formation and trafficking of the G5/G8 heterodimer, mutant forms of the half-transporters were expressed in CHO-K1 cells. All 13 mutations reduced trafficking of the G5/G8 heterodimer from the endoplasmic reticulum to the Golgi complex, and most prevented the formation of stable heterodimers between G5 and G8. We conclude that the majority of the molecular defects in G5 and G8 that cause sitosterolemia impair transport of the sterol transporter to the cell surface.	Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Helen.Hobbs@UTSouthwestern.edu		Graf, Gregory/0000-0002-0130-9929	NHLBI NIH HHS [HL72304, HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R37HL072304, R01HL072304] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Ikeda S, 2000, BIOCHEM BIOPH RES CO, V273, P1063, DOI 10.1006/bbrc.2000.3071; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kamisako T, 2003, HEPATOL RES, V26, P348, DOI 10.1016/S1386-6346(03)00153-0; Kaneko E, 2003, J BIOL CHEM, V278, P36091, DOI 10.1074/jbc.M304153200; Keitel V, 2003, AM J PHYSIOL-GASTR L, V284, pG165, DOI 10.1152/ajpgi.00362.2002; Khovidhunkit W, 2003, J LIPID RES, V44, P1728, DOI 10.1194/jlr.M300100-JLR200; Kok T, 2003, GASTROENTEROLOGY, V124, P160, DOI 10.1053/gast.2003.50007; Leach MR, 2004, J BIOL CHEM, V279, P9072, DOI 10.1074/jbc.M310788200; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LUTJOHANN D, 1995, J LIPID RES, V36, P1763; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Pollner R, 1997, FEBS LETT, V405, P31, DOI 10.1016/S0014-5793(97)00152-X; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; SALEN G, 1989, J LIPID RES, V30, P1319; SALEN G, 1992, J LIPID RES, V33, P945; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Trappe R, 1999, BBA-GENE STRUCT EXPR, V1446, P341, DOI 10.1016/S0167-4781(99)00107-4; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200	42	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24881	24888		10.1074/jbc.M402634200	http://dx.doi.org/10.1074/jbc.M402634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15054092	hybrid			2022-12-25	WOS:000221702500120
J	Levina, E; Oren, M; Ben-Ze'ev, A				Levina, E; Oren, M; Ben-Ze'ev, A			Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics	ONCOGENE			English	Article						beta-catenin degradation by p53; Axin; beta-catenin-phosphorylation	TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; APC TUMOR-SUPPRESSOR; COLORECTAL-CANCER; COLON-CARCINOMA; CYCLIN D1; PROTEIN; ACTIVATION; COMPLEX; TARGET	beta-Catenin, a structural component of cell-cell adhesions, is also a potent signaling molecule in the Wnt pathway activating target genes together with Lef/Tcf transcription factors. In colorectal and many other types of cancer, beta-catenin is hyperactive owing to mutations in beta-catenin, or in components regulating beta-catenin degradation. Deregulated beta-catenin can cause the activation of p53, a key tumor suppressor mutated in most cancers. Activated p53 can feed back and downregulate beta-catenin. Here we investigated the mechanisms involved in downregulation of beta-catenin by p53. We found that the p53-mediated reduction in beta-catenin involves enhanced phosphorylation of beta-catenin on key NH2-terminal serines and requires CK1 and GSK-3beta activities, both being components of the beta-catenin degradation machinery. Mutations in these NH2-terminal beta-catenin serines blocked the ability of p53 to enhance the turnover of beta-catenin. p53 also induced a shift in the distribution of the scaffold molecule Axin to a Triton X-100-soluble fraction, and led to depletion of beta-catenin from this Triton-soluble fraction. The majority of Axin and phosphorylated beta-catenin, however, colocalized in Triton X-100-insoluble punctate aggregates near the plasma membrane, and kinetics studies indicated that in the presence of p53 the movement of Axin into and out of the Triton X-100-insoluble fraction is accelerated. These results suggest that p53 induces a faster mobilization of Axin into the degradation complex thereby enhancing beta-catenin turnover as part of a protective mechanism against the development of cancer.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		ben-ze'ev, avri/0000-0001-6113-3921				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hu G, 1999, MOL CELL BIOL, V19, P724; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	48	79	84	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4444	4453		10.1038/sj.onc.1207587	http://dx.doi.org/10.1038/sj.onc.1207587			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064706				2022-12-25	WOS:000221661300010
J	Radhakrishnan, SK; Feliciano, CS; Najmabadi, F; Haegebarth, A; Kandel, ES; Tyner, AL; Gartel, AL				Radhakrishnan, SK; Feliciano, CS; Najmabadi, F; Haegebarth, A; Kandel, ES; Tyner, AL; Gartel, AL			Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle	ONCOGENE			English	Article						p21; E2F-1; cell cycle; cdk2	TRANSCRIPTION FACTOR E2F1; DEPENDENT KINASES; P21; APOPTOSIS; PROGRESSION; BINDING; SUPPRESSION; REPRESSION; CHECKPOINT; ACTIVATION	p21 is a potent inhibitor of cyclin-dependent kinases capable of arresting cell cycle progression. p21 is primarily regulated at the transcriptional level by several transcription factors, including p53. Previously, we reported that certain members of the E2F family of transcription factors may activate p21 transcription via a p53-independent mechanism. To further elucidate the consequences of E2F-1-regulated induction of p21, we developed cell lines with a tamoxifen-dependent form of E2F-1. We confirmed direct interaction of E2F-1 with the proximal region of the p21 promoter. Interestingly, elevated E2F-1 activity was sufficient to arrest a substantial subset of cells in S phase and this effect was correlated to and dependent on the induction of p21 protein. Since E2F proteins control genes required for cell cycle progression and are activated by various oncogenic events, we believe that the p21-dependent arrest described in this report represents an additional mechanism that guards against unrestricted cell proliferation.	Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation	Gartel, AL (corresponding author), Univ Illinois, Coll Med, Dept Med, 840 S Wood ,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498; Tyner, Angela/0000-0001-7448-8625	NCI NIH HHS [CA91146-01A1] Funding Source: Medline; NIDDK NIH HHS [DK48836, R01 DK044525, R01 DK044525-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525, R01DK048836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farhana L, 2002, CANCER RES, V62, P3842; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; HARPER JW, 1993, CELL, V75, P805; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LOGAN TJ, 1995, CANCER RES, V55, P2883; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Takahashi Y, 2000, GENE DEV, V14, P804; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WALDMAN T, 1995, CANCER RES, V55, P5187; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang YX, 2000, CANCER RES, V60, P2025	28	84	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4173	4176		10.1038/sj.onc.1207571	http://dx.doi.org/10.1038/sj.onc.1207571			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048076				2022-12-25	WOS:000221520200016
J	Yang, O; Zhang, R; Wang, XW; Linke, SP; Sengupta, S; Hickson, ID; Pedrazzi, G; Perrera, C; Stagljar, I; Littman, SJ; Modrich, P; Harris, CC				Yang, O; Zhang, R; Wang, XW; Linke, SP; Sengupta, S; Hickson, ID; Pedrazzi, G; Perrera, C; Stagljar, I; Littman, SJ; Modrich, P; Harris, CC			The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase	ONCOGENE			English	Article						p53; Rad51; homologous recombination; DNA repair	SYNDROME GENE-PRODUCT; MODULATES HOMOLOGOUS RECOMBINATION; DOUBLE-STRAND BREAKS; HOLLIDAY JUNCTIONS; MAMMALIAN-CELLS; REPLICATION FORKS; SYNDROME PROTEIN; BULGED BASES; TUMOR-CELLS; S-PHASE	The human MSH2/6 complex is essential for mismatch recognition during the repair of replication errors. Although mismatch repair components have been implicated in DNA homologous recombination repair, the exact function of hMSH2/6 in this pathway is unclear. Here, we show that the recombinant hMSH2/6 protein complex stimulated the ability of the Bloom's syndrome gene product, BLM, to process Holliday junctions in vitro, an activity that could also be regulated by p53. Consistent with these observations, hMSH6 colocalized with BLM and phospho-ser15-p53 in hydroxyurea-induced RAD51 nuclear foci that may correspond to the sites of presumed stalled DNA replication forks and more likely the resultant DNA double-stranded breaks. In addition, we show that hMSH2 and hMSH6 coimmunoprecipitated with BLM, p53, and RAD51. Bot h the number of RAD51 foci and the amount of the BLM-p53-RAD51 complex are increased in hMSH2- or hMSH6-deficient cells. These data suggest that hMSH2/6 formed a complex with BLM-p53-RAD51 in response to the damaged DNA forks during double-stranded break repair.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Mol Canc Res, CH-8006 Zurich, Switzerland; Duke Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK; University of Oxford; University of Zurich; University of Zurich; Duke University; Duke University; Howard Hughes Medical Institute	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Rm 3068,37 Convent Dr, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	Hickson, Ian/AAJ-7548-2020; Wang, Xin Wei/B-6162-2009; Sengupta, Sagar/AGR-1063-2022	Wang, Xin Wei/0000-0001-9735-606X; Sengupta, Sagar/0000-0002-6365-1770	NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chen SH, 2001, P NATL ACAD SCI USA, V98, P13802, DOI 10.1073/pnas.241508098; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Franchitto A, 2003, ONCOGENE, V22, P2110, DOI 10.1038/sj.onc.1206254; Frei C, 2000, GENE DEV, V14, P81; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Linke SP, 2003, CANCER RES, V63, P2596; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Umar A, 1997, CANCER RES, V57, P3949; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang Y, 2000, GENE DEV, V14, P927; Warnick CT, 2001, J BIOL CHEM, V276, P27363, DOI 10.1074/jbc.M103088200; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	58	53	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3749	3756		10.1038/sj.onc.1207462	http://dx.doi.org/10.1038/sj.onc.1207462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15064730				2022-12-25	WOS:000221242500002
J	Jefford, CE; Feki, A; Harb, J; Krause, KH; Irminger-Finger, I				Jefford, CE; Feki, A; Harb, J; Krause, KH; Irminger-Finger, I			Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity	ONCOGENE			English	Article						BARD1; BRCA1; apoptosis; nuclear export; protein stability; RING	CANCER-PREDISPOSING MUTATIONS; MAMMARY EPITHELIAL-CELLS; BRCA1 TUMOR-SUPPRESSOR; RING DOMAIN; UBIQUITIN LIGASE; GENE-PRODUCT; DNA-DAMAGE; PROTEIN; IDENTIFICATION; BRCA1-BARD1	The tumor suppressor protein BARD1 plays a dual role in response to genotoxic stress: DNA repair as a BARD1 BRCA1 heterodimer and induction of apoptosis in a BRCA1-independent manner. We have constructed a series of BARD1 deletion mutants and analysed their cellular distribution and capacity to induce apoptosis. As opposed to previous studies suggesting an exclusively nuclear localization of BARD1, we found, both in tissues and cell cultures, nuclear and cytoplasmic localization of BARD1. Enhanced cytoplasmic localization of BARD1, as well as appearance of a 67 kDa C-terminal proteolytic cleavage product, coincided with apoptosis. BARD1 translocates to the nucleus independently of BRCA1. For recruitment to nuclear dots, however, the BRCA1-interacting RING finger domain is required but not sufficient. Protein levels of N-terminal RING finger deletion mutants were much higher than those of full-length BARD1, despite comparable mRNA levels, suggesting that the N-terminal region comprising the RING finger is important for BARD1 degradation. Sequences required for apoptosis induction were mapped between the ankyrin repeats and the BRCT domains coinciding with two known cancer-associated missense mutations. We suggest that nuclear and cytoplasmic localization of BARD1 reflect its dual function and that the increased cytoplasmic localization of BARD1 is associated with apoptosis.	Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; INSERM, U419, Inst Biol, F-44035 Nantes 03, France	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm)	Irminger-Finger, I (corresponding author), Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland.	irmgard.irminger@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011; Harb, Jean/S-9610-2017	Krause, Karl-Heinz/0000-0002-9033-6768; Harb, Jean/0000-0002-1727-8610; Feki, Anis/0000-0002-9817-9445				Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Baer R, 2001, NAT STRUCT BIOL, V8, P822, DOI 10.1038/nsb1001-822; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Gautier F, 2000, CANCER RES, V60, P6895; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 2002, INT J BIOCHEM CELL B, V34, P582, DOI 10.1016/S1357-2725(01)00161-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Morris JR, 2002, J BIOL CHEM, V277, P9382, DOI 10.1074/jbc.M109249200; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; RODRIGUEZ JA, 2003, ONCOGENE; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Soriano JV, 2000, ADV EXP MED BIOL, V480, P175; Spahn L, 2002, CANCER RES, V62, P4583; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199	40	46	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3509	3520		10.1038/sj.onc.1207427	http://dx.doi.org/10.1038/sj.onc.1207427			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077185	Bronze			2022-12-25	WOS:000221101700002
J	Bennett, JJ; Adusumilli, P; Petrowsky, H; Burt, BM; Roberts, G; Delman, KA; Zager, JS; Chou, TC; Fong, YM				Bennett, JJ; Adusumilli, P; Petrowsky, H; Burt, BM; Roberts, G; Delman, KA; Zager, JS; Chou, TC; Fong, YM			Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma(1)34.5 deleted oncolytic herpes virus (G207)	FASEB JOURNAL			English	Article						chemotherapy; gastric cancer; gene therapy; herpes simplex virus; HSV	SQUAMOUS-CELL CARCINOMA; SIMPLEX-VIRUS; INTRAPERITONEAL CHEMOTHERAPY; PREMATURE SHUTOFF; PROTEIN-SYNTHESIS; LIVER METASTASES; GROWTH ARREST; GENE-THERAPY; CANCER; REPLICATION	Oncolytic viruses used for gene therapy have been genetically modified to selectively target tumor cells while sparing normal host tissue. The multimutant virus G207 has been attenuated by inactivation of viral ribonucleotide reductase and by deletion of both viral gamma(1)34.5 genes. Deletion of gamma(1)34.5 greatly decreases the neurovirulence of this mutant virus but also reduces its antitumor efficacy. The mammalian homologue to the gamma(1)34.5 gene product is the GADD34 protein. This protein can functionally substitute for the gamma(1)34.5 gene and is also up-regulated during DNA damage. We postulated that combining use of the chemotherapy agent mitomycin C (MMC) with G207 will selectively up-regulate GADD34 in tumor that may complement the gamma(1)34.5 gene deletion and augment viral antitumor efficacy. This hypothesis was tested in human gastric cells in vitro and in vivo. Using both the isobologram method and combination-index method of Chou-Talalay, significant synergism was demonstrated between MMC and G207. As a result of such synergism, a dose-reduction for each agent can be accomplished over a wide range of drug-effect levels without sacrificing tumor cell kill. Northern blot analysis confirmed that expression of GADD34 mRNA was increased by MMC treatment. SiRNA directed at GADD34 decreased MMC-associated enhancement of viral proliferation and resulted in decreased viral synergy with MMC. These data indicate that induction of GADD34 selectively restores the virulent phenotype of the deleted gene in G207 and thus provides a cellular basis for the combined use of DNA-damaging agents and gamma(1)34.5 HSV mutants in the treatment of cancer.	Mem Sloan Kettering Canc Ctr, Dept Surg, Hepatobiliary Div, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Hepatobiliary Div, 1275 York Ave, New York, NY 10021 USA.	Fongy@mskcc.org	Chou, Ting-Chao/AAA-7881-2020; Petrowsky, Henrik/J-6377-2019; Chou, Ting-Chao/B-4111-2009	Chou, Ting-Chao/0000-0002-3340-1594; Petrowsky, Henrik/0000-0001-5744-0531; Chou, Ting-Chao/0000-0002-3340-1594	NATIONAL CANCER INSTITUTE [R01CA072632, R01CA080982] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 76416, R01 CA 72632, R01 R01CA/DK80982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Advani SJ, 1998, GENE THER, V5, P160, DOI 10.1038/sj.gt.3300546; Aghi M, 1999, CANCER RES, V59, P3861; Andreansky S, 1998, GENE THER, V5, P121, DOI 10.1038/sj.gt.3300550; Bao JJ, 1996, HUM GENE THER, V7, P355, DOI 10.1089/hum.1996.7.3-355; Bennett JJ, 2000, J MOL MED-JMM, V78, P166, DOI 10.1007/s001090000092; Carew JF, 1999, HUM GENE THER, V10, P1599, DOI 10.1089/10430349950017608; Carroll NM, 1997, J SURG RES, V69, P413, DOI 10.1006/jsre.1997.5089; Carroll NM, 1996, ANN SURG, V224, P323, DOI 10.1097/00000658-199609000-00008; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CHOU J, DOSE EFFECT ANAL MIC; CHOU J, 1991, QUANTITATION SYNERGI, P223; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; CHU DZJ, 1989, CANCER, V63, P364, DOI 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V; Chung RY, 1999, J VIROL, V73, P7556, DOI 10.1128/JVI.73.9.7556-7564.1999; Coukos G, 2000, CANCER GENE THER, V7, P275, DOI 10.1038/sj.cgt.7700130; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GUNDERSON LL, 1982, INT J RADIAT ONCOL, V8, P1, DOI 10.1016/0360-3016(82)90377-7; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; KELSEN D, 1999, SEMIN ONCOL, V23, P379; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; KOOBY DA, 1999, FASEB J, V6, P499; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Lamont JP, 2000, ANN SURG ONCOL, V7, P588, DOI 10.1007/BF02725338; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Rosen HR, 1998, J CLIN ONCOL, V16, P2733, DOI 10.1200/JCO.1998.16.8.2733; Toda M, 1998, HUM GENE THER, V9, P2177, DOI 10.1089/hum.1998.9.15-2177; Toda M, 1998, J IMMUNOL, V160, P4457; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; VERWEIJ J, 1990, Anti-Cancer Drugs, V1, P5, DOI 10.1097/00001813-199010000-00002; Walker JR, 1999, HUM GENE THER, V10, P2237, DOI 10.1089/10430349950017211; WILKE H, 1990, SEMIN ONCOL, V17, P61; WISBECK WM, 1986, RADIOTHER ONCOL, V7, P13, DOI 10.1016/S0167-8140(86)80120-7; Wong RJ, 2001, HUM GENE THER, V12, P253, DOI 10.1089/10430340150218396; YAZAKI T, 1995, CANCER RES, V55, P4752; Yoon SS, 2000, FASEB J, V14, P301, DOI 10.1096/fasebj.14.2.301; Yu WS, 1998, AM SURGEON, V64, P1104; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	45	60	65	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1001	+		10.1096/fj.02-1080fje	http://dx.doi.org/10.1096/fj.02-1080fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059970				2022-12-25	WOS:000221108800021
J	Budas, GR; Jovanovic, S; Crawford, RM; Jovanovic, A				Budas, GR; Jovanovic, S; Crawford, RM; Jovanovic, A			Hypoxia-induced preconditioning in adult stimulated cardiomyocytes is mediated by the opening and trafficking of sarcolemmal K(ATP) channels	FASEB JOURNAL			English	Article						ischemia; heart; Kir6.2; SUR2A; cardioprotection	SENSITIVE POTASSIUM CHANNELS; ACTION-POTENTIAL DURATION; CARDIAC-MUSCLE; H9C2 CELLS; MITOCHONDRIAL; ISCHEMIA; HEART; MEMBRANE; KINASE; CARDIOPROTECTION	The opening of sarcolemmal and mitochondrial ATP-sensitive K(+) (K(ATP)) channels in the heart is believed to mediate ischemic preconditioning, a phenomenon whereby brief periods of ischemia/reperfusion protect the heart against myocardial infarction. Here, we have applied digital epifluorescent microscopy, immunoprecipitation and Western blotting, perforated patch clamp electrophysiology, and immunofluorescence/laser confocal microscopy to examine the involvement of K(ATP) channels in cardioprotection afforded by preconditioning. We have shown that adult, stimulated-to-beat, guinea-pig cardiomyocytes survived in sustained hypoxia for similar to17 min. An episode of 5-min-long hypoxia/5-min-long reoxygenation before sustained hypoxia dramatically increased the duration of cellular survival. Experiments with different antagonists of K(ATP) channels, applied at different times during the experimental protocol, suggested that the opening of sarcolemmal K(ATP) channels at the beginning of sustained hypoxia mediate preconditioning. This conclusion was supported by perforated patch clamp experiments that revealed activation of sarcolemmal K(ATP) channels by preconditioning. Immunoprecipitation and Western blotting as well as immunofluorescence and laser confocal microscopy showed that the preconditioning is associated with the increase in K(ATP) channel proteins in sarcolemma. Inhibition of trafficking of K(ATP) channel subunits prevented preconditioning without affecting sensitivity of cardiomyocytes to hypoxia in the absence of preconditioning. We conclude that the preconditioning is mediated by the activation and trafficking of sarcolemmal K(ATP) channels.	Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland	University of Dundee	Jovanovic, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland.	a.jovanovic@dundee.ac.uk	Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318	Biotechnology and Biological Sciences Research Council [S18744, C15048] Funding Source: Medline; British Heart Foundation [PG/02/091/14227] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; COHEN MV, 1995, J MOL CELL CARDIOL, V27, P1527, DOI 10.1016/S0022-2828(95)90293-7; Crawford RM, 2003, J BIOL CHEM, V278, P31444, DOI 10.1074/jbc.M303051200; Crawford RM, 2002, EMBO J, V21, P3936, DOI 10.1093/emboj/cdf388; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; Das M, 2003, J PHYSIOL-LONDON, V547, P893, DOI 10.1113/jphysiol.2002.035006; Gallagher MM, 2000, CLIN CARDIOL, V23, P530, DOI 10.1002/clc.4960230712; GASSER RNA, 1990, J PHYSIOL-LONDON, V431, P713, DOI 10.1113/jphysiol.1990.sp018356; Gogelein H, 2001, N-S ARCH PHARMACOL, V364, P33, DOI 10.1007/s002100000391; GROSS GJ, 1992, CIRC RES, V70, P223, DOI 10.1161/01.RES.70.2.223; Hamada K, 1998, J MOL CELL CARDIOL, V30, P1369, DOI 10.1006/jmcc.1998.0701; Hanley PJ, 2002, J PHYSIOL-LONDON, V542, P735, DOI 10.1113/jphysiol.2002.023960; Hu KL, 2003, NEURON, V38, P417, DOI 10.1016/S0896-6273(03)00256-3; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic S, 2003, AM J RESP CELL MOL, V28, P363, DOI 10.1165/rcmb.2002-0101OC; Jovanovic S, 2001, INT J MOL MED, V7, P639; Lacza Z, 2003, J MOL CELL CARDIOL, V35, P1339, DOI 10.1016/S0022-2828(03)00249-9; Lascano EC, 2002, MOL CELL BIOCHEM, V236, P53, DOI 10.1023/A:1016198011919; Lhuillier L, 2002, J NEUROPHYSIOL, V88, P954, DOI 10.1152/jn.2002.88.2.954; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Marber MS, 2000, CIRC RES, V86, P926, DOI 10.1161/01.RES.86.9.926; Miki T, 2002, AM J PHYSIOL-ENDOC M, V283, pE1178, DOI 10.1152/ajpendo.00313.2002; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Murriel CL, 2003, ARCH BIOCHEM BIOPHYS, V420, P246, DOI 10.1016/j.abb.2003.08.038; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Ovide-Bordeaux S, 2000, J BIOL CHEM, V275, P37291, DOI 10.1074/jbc.M005772200; Ozcan C, 2002, AM J PHYSIOL-HEART C, V282, pH531, DOI 10.1152/ajpheart.00552.2001; Ranki HJ, 2002, J AM COLL CARDIOL, V40, P367, DOI 10.1016/S0735-1097(02)01947-2; Ranki HJ, 2001, J AM COLL CARDIOL, V38, P906, DOI 10.1016/S0735-1097(01)01428-0; Sato T, 2000, CIRCULATION, V101, P2418, DOI 10.1161/01.CIR.101.20.2418; Seharaseyon J, 2000, J MOL CELL CARDIOL, V32, P1923, DOI 10.1006/jmcc.2000.1226; Singh H, 2003, J MOL CELL CARDIOL, V35, P445, DOI 10.1016/S0022-2828(03)00041-5; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Suzuki M, 2003, CIRCULATION, V107, P682, DOI 10.1161/01.CIR.0000055187.67365.81; WILDE AAM, 1994, CARDIOVASC RES, V28, P16, DOI 10.1093/cvr/28.1.16; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	41	77	82	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1046	+		10.1096/fj.04-1602fje	http://dx.doi.org/10.1096/fj.04-1602fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084521	Green Accepted			2022-12-25	WOS:000221108800010
J	Wright, GL; Hanlon, P; Amin, K; Steenbergen, C; Murphy, E; Arcasoy, MO				Wright, GL; Hanlon, P; Amin, K; Steenbergen, C; Murphy, E; Arcasoy, MO			Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury	FASEB JOURNAL			English	Article						ATP; myocardium; signal transduction	PROTECTS; APOPTOSIS; NEURONS; GENE; RECOVERY; HYPOXIA	Erythropoietin (EPO), the principal hematopoietic cytokine that regulates mammalian erythropoiesis, exhibits diverse cellular effects in non-hematopoietic tissues. The physiologic functions of EPO are mediated by its specific cell-surface receptor EPOR. In this study, we demonstrate EPOR expression in adult rat cardiac myocytes and examine the direct effects of EPO on the heart to investigate whether recombinant EPO may exert an acute cardioprotective effect during ischemia-reperfusion injury. To determine whether EPO is cardioprotective, isolated rat hearts were perfused for 10 min in the Langendorff-mode with Krebs-Henseleit buffer in the absence or presence of brief recombinant EPO treatment while left-ventricular-developed pressure (LVDP) was measured continuously to assess contractile function. The hearts were then subjected to 20 min of normothermic global ischemia followed by 25 min of reperfusion. The post-ischemic recovery of LVDP in the untreated control hearts was 26 +/- 5% of their baseline LVDP, whereas hearts pretreated with EPO exhibited significantly improved post-ischemic recovery to 57 +/- 7%. We used P-31 nuclear magnetic resonance (NMR) spectroscopy to determine whether modulation of intracellular pH and/or high-energy phosphate levels during ischemia contributed to EPO-mediated cardioprotection. These experiments revealed that the rapid cardioprotective effect of EPO during ischemia-reperfusion injury was associated with preservation of ATP levels in the ischemic myocardium.	Duke Univ, Sch Med, Dept Med, Div Hematol, Durham, NC 27710 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; SRI Int, Biosci Div, Menlo Pk, CA 94025 USA; Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); SRI International; Duke University	Arcasoy, MO (corresponding author), Duke Univ, Sch Med, Dept Med, Div Hematol, DUMC Box 3912, Durham, NC 27710 USA.	arcas001@mc.duke.edu		Amin, Khalid/0000-0001-8992-8419	NHLBI NIH HHS [R01 HL039752, R01-HL-39752] Funding Source: Medline; NIDDK NIH HHS [R21-DK-65065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen J, 2003, AM J PHYSIOL-HEART C, V285, pH2657, DOI 10.1152/ajpheart.00557.2003; Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F; DANDREA AD, 1993, BLOOD, V82, P46, DOI 10.1182/blood.V82.1.46.bloodjournal82146; DANDREA AD, 1909, CELL, V68, P388; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; GANOTE CE, 1985, AM J PATHOL, V120, P129; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Haroon ZSA, 2003, AM J PATHOL, V163, P993, DOI 10.1016/S0002-9440(10)63459-1; Henry D H, 1995, Curr Opin Hematol, V2, P118; JONES SS, 1990, BLOOD, V76, P31; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Juul SE, 1998, EARLY HUM DEV, V52, P235, DOI 10.1016/S0378-3782(98)00030-9; KRANTZ SB, 1991, BLOOD, V77, P419; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; PAFFETTLUGASSY N, 2002, BLOOD, V100, P2277; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Rizzo JD, 2002, BLOOD, V100, P2303, DOI 10.1182/blood-2002-06-1767; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schneider S, 2001, AM J PHYSIOL-HEART C, V280, pH499; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; STEENBERGEN C, 1993, CIRC RES, V72, P112, DOI 10.1161/01.RES.72.1.112; Stuckmann I, 2003, DEV BIOL, V255, P334, DOI 10.1016/S0012-1606(02)00078-7; Suzuki N, 2002, BLOOD, V100, P2279, DOI 10.1182/blood-2002-01-0124; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; Wald MR, 1996, J CELL PHYSIOL, V167, P461, DOI 10.1002/(SICI)1097-4652(199606)167:3<461::AID-JCP10>3.3.CO;2-N; WINKELMANN JC, 1990, BLOOD, V76, P24; WOLFE CL, 1993, CIRCULATION, V87, P881, DOI 10.1161/01.CIR.87.3.881; Wu H, 1999, DEVELOPMENT, V126, P3597; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yu XB, 2002, DEVELOPMENT, V129, P505; Yu XB, 2001, BLOOD, V98, P475, DOI 10.1182/blood.V98.2.475	43	191	202	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1031	+		10.1096/fj.03-1289fje	http://dx.doi.org/10.1096/fj.03-1289fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059965				2022-12-25	WOS:000221108800016
J	Murakami, A; Shen, HQ; Ishida, S; Dickson, C				Murakami, A; Shen, HQ; Ishida, S; Dickson, C			SOX7 and GATA-4 are competitive activators of Fgf-3 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA STEM-CELLS; PROTO-ONCOGENE INT-2; RETINOIC ACID; MESSENGER-RNA; REGULATORY ELEMENTS; HEPARAN-SULFATE; MULTIPLE ROLES; EXPRESSION; GENE; DIFFERENTIATION	Fgf-3 is expressed in a dynamic and complex spatio-temporal pattern during mouse development. Previous studies identified GATA-4 as a transcription factor that binds the key regulatory element PS4A of the Fgf-3 promoter and stimulates transcription. Here we show that members of the SOX family of transcription factors also bind PS4A and differentially modulate transcription. At least five SOX genes, Sox2, Sox6, Sox7, Sox13, and Sox17, were expressed in F9 cells, and of these, Sox7 and Sox17 were dramatically induced in parallel with Fgf-3 following differentiation into parietal endoderm-like cells with retinoic acid and dibutyryl cAMP. Complexes could be detected on PS4A with SOX2, SOX7, and SOX17 by using nuclear extracts from differentiated F9 cells. However, only Sox7 expression markedly activated the Fgf-3 promoter in these cells. By contrast, SOX2 was a poor activator of Fgf-3 transcription, and when Sox2 was co-expressed with Gata4, it negatively modulated the strong activation mediated by GATA-4. More detailed analyses showed that SOX7 competes with GATA-4 for PS4A occupancy and to activate the Fgf-3 promoter. In situ hybridization analysis showed that Sox7 is co-expressed with Fgf-3 and Gata4 in the parietal endoderm of E7.5 mouse embryos. In culture, GATA-4-deficient embryonal stem cells were shown to express Fgf-3 upon differentiation into embryoid bodies, although at lower levels than were found in wild type embryonal stem cells. This Fgf-3 expression was virtually abolished when Sox7 expression was suppressed by RNA interference. These results show that SOX7 is a potent activator of Fgf-3 transcription.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; London Res Inst, Canc Res UK, London WC2A 3PX, England	Kyoto University; Cancer Research UK	Murakami, A (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	amurakam@virus.kyoto-u.ac.jp						ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DZIADEK MA, 1983, EMBO J, V2, P549, DOI 10.1002/j.1460-2075.1983.tb01461.x; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; Hagiwara N, 2000, P NATL ACAD SCI USA, V97, P4180, DOI 10.1073/pnas.97.8.4180; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; McKay IJ, 1996, DEV BIOL, V174, P370, DOI 10.1006/dbio.1996.0081; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1977, GENE DEV, V111, P1061; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Murakami A, 1999, J BIOL CHEM, V274, P17242, DOI 10.1074/jbc.274.24.17242; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; Murakami A, 2002, NUCLEIC ACIDS RES, V30, P1056, DOI 10.1093/nar/30.4.1056; Murakami A, 2001, NUCLEIC ACIDS RES, V29, P3347, DOI 10.1093/nar/29.16.3347; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; NISWANDER L, 1992, DEVELOPMENT, V114, P755; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Roose J, 1998, NUCLEIC ACIDS RES, V26, P469, DOI 10.1093/nar/26.2.469; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274; Taniguchi K, 1999, BBA-GENE STRUCT EXPR, V1445, P225, DOI 10.1016/S0167-4781(99)00047-0; Uchikawa M, 1999, MECH DEVELOP, V84, P103, DOI 10.1016/S0925-4773(99)00083-0; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J	50	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28564	28573		10.1074/jbc.M313814200	http://dx.doi.org/10.1074/jbc.M313814200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15082719	hybrid			2022-12-25	WOS:000222265400092
J	MacDonald, MJ; Husain, RD; Hoffmann-Benning, S; Baker, TR				MacDonald, MJ; Husain, RD; Hoffmann-Benning, S; Baker, TR			Immunochemical identification of coenzyme Q(0)-dihydrolipoamide adducts in the E2 components of the alpha-ketoglutarate and pyruvate dehydrogenase complexes partially explains the cellular toxicity of coenzyme Q(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; CA-2&-INDUCED MEMBRANE TRANSITION; PRIMARY BILIARY-CIRRHOSIS; 2 SEPARATE SITES; PANCREATIC-ISLETS; INSULIN-SECRETION; PYRIDINE-NUCLEOTIDES; LIPOIC ACID; PORE; INHIBITION	Coenzyme Q(0) (Q(0)), a strong electrophile, is toxic to insulin-producing cells. Q(0) was incubated with rat and human pancreatic islets and INS-1 insulinoma cells, and its attachment to cellular proteins was studied with Western analysis using antiserum raised against the benzoquinone ring structure of ubiquinone (anti-Q). Q(0) covalently bonded to two proteins, one of 50 kDa and another of 70 kDa. Both proteins were found to be mitochondrial in human and rat islet cells and in many rat organs. Mitochondria were incubated with Q(0), and affinity-purified anti-Q was used to immunoprecipitate the 50-kDa protein. Amino acid sequencing identified it as dihydrolipoamide succinyltransferase, the E2 component of the alpha-ketoglutarate dehydrogenase complex (KDC). Western analysis also showed that Q(0) bonds to the E2 components of the purified KDC and the pyruvate dehydrogenase complex (PDC). Dihydrolipoamide acetyltransferase, the E2 of the PDC, has a molecular mass of 70 kDa, and the 70-kDa protein was inferred to be this enzyme. Q(0) was found to bond only to proteins containing dihydrolipoate, and in preparations of mitochondria, thiol reducing agents facilitated the attachment of Q(0), but oxidizing agents prevented it, suggesting that Q(0) bonds to thiols of dihydrolipoamide. Incubation of human or pig PDC with Q(0) followed by matrix-assisted laser desorption ionization time-of-flight and liquid chromatography/electrospray ionization mass spectrometry analyses of chymotrypsin-digested peptides of PDC E2 confirmed that Q(0) bonds to the dihydrolipoamide in these proteins. In mitochondria, coenzymes Q(1) and Q(2) did not bond to the 50-kDa protein but competed with the bonding of Q(0) to this protein. The prevention by Q(1) of the bonding of Q(0) to KDC E2, as well as other characteristics of the Q(0) effect, are reminiscent of the action of Q(0) on the mitochondrial permeability transition pore described previously (Fontaine, E., Ichas, F., and Bernardi, P. ( 1998) J. Biol. Chem. 273, 25734 - 25740).	Univ Wisconsin, Childrens Diabet Ctr, Sch Med, Madison, WI 53706 USA; Michigan State Univ, Mass Spectrometry Facil, E Lansing, MI 48824 USA	University of Wisconsin System; University of Wisconsin Madison; Michigan State University	MacDonald, MJ (corresponding author), Med Sci Ctr, Rm 3459,1300 Univ Ave, Madison, WI 53706 USA.	mjmacdon@wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028348, R55DK028348] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28348] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Hisatomi M, 1997, JPN J PHARMACOL, V74, P203, DOI 10.1254/jjp.74.203; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Irwin WA, 2002, BIOCHEM BIOPH RES CO, V291, P215, DOI 10.1006/bbrc.2002.6457; JONAS JC, 1995, BRIT J PHARMACOL, V114, P872, DOI 10.1111/j.1476-5381.1995.tb13285.x; Kar S, 2002, J CELL PHYSIOL, V190, P356, DOI 10.1002/jcp.10063; Koike K, 1998, HEPATOLOGY, V27, P1467, DOI 10.1002/hep.510270602; Korotchkina LG, 2001, FREE RADICAL BIO MED, V30, P992, DOI 10.1016/S0891-5849(01)00491-9; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LIU GH, 1994, MOL PHARMACOL, V45, P189; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MACDONALD MJ, 1991, BIOSCIENCE REP, V11, P165, DOI 10.1007/BF01182485; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1991, ENDOCRINOLOGY, V129, P1370, DOI 10.1210/endo-129-3-1370; MACDONALD MJ, 1980, BIOCHIM BIOPHYS ACTA, V615, P223, DOI 10.1016/0005-2744(80)90025-X; Miwa I, 2000, ENDOCRINOLOGY, V141, P2767, DOI 10.1210/en.141.8.2767; Moteki S, 1996, HEPATOLOGY, V23, P436; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Sasaki M, 2000, J AUTOIMMUN, V15, P51, DOI 10.1006/jaut.2000.0390; SORENSON RL, 1994, ENDOCRINOLOGY, V134, P1975, DOI 10.1210/en.134.4.1975; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200	32	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27278	27285		10.1074/jbc.M314148200	http://dx.doi.org/10.1074/jbc.M314148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075342	hybrid			2022-12-25	WOS:000222120400057
J	Chen, RM; Fearnley, IM; Peak-Chew, SY; Walker, JE				Chen, RM; Fearnley, IM; Peak-Chew, SY; Walker, JE			The phosphorylation of Subunits of complex I from bovine heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; A ANCHORING PROTEIN; UBIQUINONE OXIDOREDUCTASE; PYRUVATE-DEHYDROGENASE; MASS-SPECTROMETRY; IDENTIFICATION; SITES; NADH; SEQUENCES; STRATEGY	In bovine heart mitochondria and in submitochondrial particles, membrane-associated proteins with apparent molecular masses of 18 and 10 kDa become strongly radiolabeled by [P-32] ATP in a cAMP-dependent manner. The 18-kDa phosphorylated protein is subunit ESSS from complex I and not as previously reported the 18 k subunit ( with the N-terminal sequence AQDQ). The phosphorylated residue in subunit ESSS is serine 20. In the 10 kDa band, the complex I subunit MWFE was phosphorylated on serine 55. In the presence of protein kinase A and cAMP, the same subunits of purified complex I were phosphorylated by [P-32] ATP at the same sites. Subunits ESSS and MWFE both contribute to the membrane arm of complex I. Each has a single hydrophobic region probably folded into a membrane spanning alpha-helix. It is likely that the phosphorylation site of subunit ESSS lies in the mitochondrial matrix and that the site in subunit MWFE is in the intermembrane space. Subunit ESSS has no known role, but subunit MWFE is required for assembly into complex I of seven hydrophobic subunits encoded in the mitochondrial genome. The possible effects of phosphorylation of these subunits on the activity and/or the assembly of complex I remain to be explored.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.	walker@mrc-dunn.cam.ac.uk		Walker, John/0000-0001-7929-2162				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Campbell David G, 2002, J Biomol Tech, V13, P119; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Papa S, 1996, FEBS LETT, V379, P299, DOI 10.1016/0014-5793(95)01532-9; Sardanelli AM, 1995, FEBS LETT, V377, P470, DOI 10.1016/0014-5793(95)01407-1; Sardanelli AM, 1996, FEBS LETT, V396, P276, DOI 10.1016/0014-5793(96)01112-X; Scacco S, 2000, J BIOL CHEM, V275, P17578, DOI 10.1074/jbc.M001174200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulenberg B, 2003, J BIOL CHEM, V278, P27251, DOI 10.1074/jbc.C300189200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STEINER AW, 1981, J NEUROCHEM, V37, P582; TECHNIKOVADOBROVA Z, 1993, FEBS LETT, V322, P51, DOI 10.1016/0014-5793(93)81109-D; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wang L, 2001, P NATL ACAD SCI USA, V98, P3220, DOI 10.1073/pnas.051633398; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Yadava N, 2004, J BIOL CHEM, V279, P12406, DOI 10.1074/jbc.M313588200; Yadava N, 2002, J BIOL CHEM, V277, P21221, DOI 10.1074/jbc.M202016200; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017; Zhuchenko O, 1996, GENOMICS, V37, P281, DOI 10.1006/geno.1996.0561	38	135	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26036	26045		10.1074/jbc.M402710200	http://dx.doi.org/10.1074/jbc.M402710200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15056672	hybrid			2022-12-25	WOS:000222003000015
J	Matsuo, K; Galson, DL; Zhao, C; Peng, L; Laplace, C; Wang, KZQ; Bachler, MA; Amano, H; Aburatani, H; Ishikawa, H; Wagner, EF				Matsuo, K; Galson, DL; Zhao, C; Peng, L; Laplace, C; Wang, KZQ; Bachler, MA; Amano, H; Aburatani, H; Ishikawa, H; Wagner, EF			Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; BONE; BINDING; DNA; DIFFERENTIATION; CALCINEURIN; INDUCTION; PATHWAY; TARGET	Osteoclasts are specialized macrophages that resorb bone. Mice lacking the AP-1 component c-Fos are osteopetrotic because of a lack of osteoclast differentiation and show an increased number of macrophages. The nature of the critical function of c-Fos in osteoclast differentiation is not known. Microarray analysis revealed that Nfatc1, another key regulator of osteoclastogenesis, was down-regulated in Fos(-/-) osteoclast precursors. Chromatin immunoprecipitation assay showed that c-Fos bound to the Nfatc1 and Acp5 promoters in osteoclasts. In vitro promoter analyses identified nuclear factor of activated T-cells (NFAT)/AP-1 sites in the osteoclast-specific Acp5 and Calcr promoters. Moreover, in Fos(-/-) precursors gene transfer of an active form of NFAT restored transcription of osteoclast-specific genes in the presence of receptor activator of the NF-kappaB ligand (RANKL), rescuing bone resorption. In the absence of RANKL, however, Fos(-/-) precursors were insensitive to NFAT-induced osteoclastogenesis unlike wild-type precursors. These data indicate that lack of Nfatc1 expression is the cause of the differentiation block in Fos(-/-) osteoclast precursors and that transcriptional induction of Nfatc1 is a major function of c-Fos in osteoclast differentiation.	Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 1608582, Japan; Res Inst Mol Pathol, A-1030 Vienna, Austria; Beth Israel Deaconess Med Ctr, Dept Med, Joint Inst, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Ctr Bone Biol, Pittsburgh, PA 15213 USA; Showa Univ, Sch Dent, Dept Pharmacol, Tokyo 1428555, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan	Keio University; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Showa University; University of Tokyo	Matsuo, K (corresponding author), Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 1608582, Japan.	matsuo@sc.itc.keio.ac.jp	Galson, Deborah L./E-9370-2010; Matsuo, Koichi/K-5695-2012	Galson, Deborah L./0000-0002-2045-8807; Matsuo, Koichi/0000-0002-1490-8955; Wagner, Erwin F/0000-0001-7872-0196	NIAMS NIH HHS [R01 AR045421, AR45421] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Diebold RJ, 1998, P NATL ACAD SCI USA, V95, P7915, DOI 10.1073/pnas.95.14.7915; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lean JM, 2000, BONE, V27, P29, DOI 10.1016/S8756-3282(00)00306-9; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Onishi M, 1996, EXP HEMATOL, V24, P324; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sherman MA, 1999, J IMMUNOL, V162, P2820; Stroud JC, 2003, J MOL BIOL, V334, P1009, DOI 10.1016/j.jmb.2003.09.065; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200	34	443	456	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26475	26480		10.1074/jbc.M313973200	http://dx.doi.org/10.1074/jbc.M313973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073183	hybrid			2022-12-25	WOS:000222003000070
J	Lin, SY; Raval, S; Zhang, ZY; Deverill, M; Siminovitch, KA; Branch, DR; Haimovich, B				Lin, SY; Raval, S; Zhang, ZY; Deverill, M; Siminovitch, KA; Branch, DR; Haimovich, B			The protein-tyrosine phosphatase SHP-1 regulates the phosphorylation of alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PLATELET INTEGRIN ALPHA(IIB)BETA(3); CELL ANTIGEN RECEPTOR; MOTH-EATEN MICE; CYTOSKELETAL REORGANIZATION; CRYSTAL-STRUCTURE; MIGRATING CELLS; BINDING DOMAIN; PTP1C; SRC	Platelet activation triggers integrin alpha(IIb)beta(3)-dependent signals and the induction of tyrosine phosphorylation of the cytoskeletal protein alpha-actinin. We have previously reported that alpha-actinin is phosphorylated by the focal adhesion kinase (FAK) (Izaguirre, G., Aguirre, L., Hu, Y.-P., Lee, H. Y., Schlaepfer, D. D., Aneskievich, B. J., and Haimovich, B. (2001) J. Biol. Chem. 276, 28676-28685). In this study, a phosphatase of 68 kDa that dephosphorylated alpha-actinin in vitro was isolated from platelet lysates by three sequential chromatography steps. The phosphatase was identified as SHP-1 by electrospray tandem mass spectrometry. alpha-Actinin was dephosphorylated in vitro by recombinant SHP-1 and by SHP-1 immunoprecipitated from unstimulated or thrombin-stimulated platelet lysates. SHP-1 immunoprecipitated from lysates of platelets adherent to fibrinogen, however, failed to dephosphorylate alpha-actinin. In contrast, the activity of SHP-1 against a synthetic substrate was not affected by the mode of platelet activation. The robust and sustained phosphorylation of alpha-actinin detected in platelets adherent to fibrinogen thus correlates with a decrease in the activity of SHP-1 toward it. Tyrosine phosphorylation of alpha-actinin is seen in vanadate-treated COS-7 cells that are co-transfected with alpha-actinin and wild type FAK. Triple transfection of the cells with cDNAs encoding for alpha-actinin, FAK, and wild type SHP-1 abolished the phosphorylation of alpha-actinin. The phosphorylation of FAK, however, was barely affected by the expression of wild type SHP-1. Both alpha-actinin and FAK were phosphorylated in cells co-expressing alpha-actinin, FAK, and a catalytic domain mutant (C453S) of SHP-1. These findings establish that SHP-1 can dephosphorylate alpha-actinin in vitro and in vivo and suggest that SHP-1 may regulate the tethering of receptors to the cytoskeleton and/or the extent of cross-linking of actin filaments in cells such as platelets.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA; Canc Inst New jersey, New Brunswick, NJ 08903 USA; Univ Toronto, Dept Med Immunol & Mol & Med Genet, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Canadian Blood Serv, Res & Dev, Toronto, ON MG5 2M1, Canada; Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON MG5 2M1, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Canadian Blood Services; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Haimovich, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA.	haimovic@umdnj.edu	Siminovitch, Katherine/K-1475-2013	ZHANG, ZHIYONG/0000-0001-8576-1607; zhang, zhiyong/0000-0003-4061-7374	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054104, R01HL054104] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54104] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEGGS AH, 1992, J BIOL CHEM, V267, P9281; Berg KL, 1998, ONCOGENE, V17, P2535, DOI 10.1038/sj.onc.1202203; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Greer SF, 1999, J IMMUNOL, V162, P5278; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Izaguirre G, 1999, J BIOL CHEM, V274, P37012, DOI 10.1074/jbc.274.52.37012; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; Judd BA, 2000, P NATL ACAD SCI USA, V97, P12056, DOI 10.1073/pnas.97.22.12056; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; Lyons BL, 2003, EXP HEMATOL, V31, P234, DOI 10.1016/S0301-472X(02)01031-7; Ma XZ, 2003, EXP HEMATOL, V31, P131, DOI 10.1016/S0301-472X(02)01025-1; Manes S, 1999, MOL CELL BIOL, V19, P3125; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Nieset JE, 1997, J CELL SCI, V110, P1013; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Oh ES, 1999, MOL CELL BIOL, V19, P3205; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pasquet JM, 2000, J BIOL CHEM, V275, P28526, DOI 10.1074/jbc.M001531200; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tseng Y, 2002, BIOPHYS J, V83, P3162, DOI 10.1016/S0006-3495(02)75319-8; Tseng Y, 2001, BIOPHYS J, V81, P1643, DOI 10.1016/S0006-3495(01)75818-3; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; WAITES GT, 1992, J BIOL CHEM, V267, P6263; Wang LL, 1999, J IMMUNOL, V162, P1318; WITKE W, 1993, J CELL BIOL, V121, P599, DOI 10.1083/jcb.121.3.599; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	60	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25755	25764		10.1074/jbc.M314175200	http://dx.doi.org/10.1074/jbc.M314175200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070900	hybrid			2022-12-25	WOS:000221827900105
J	D'Assoro, AB; Busby, R; Suino, K; Delva, E; Almodovar-Mercado, GJ; Johnson, H; Folk, C; Farrugia, DJ; Vasile, V; Stivala, F; Salisbury, JL				D'Assoro, AB; Busby, R; Suino, K; Delva, E; Almodovar-Mercado, GJ; Johnson, H; Folk, C; Farrugia, DJ; Vasile, V; Stivala, F; Salisbury, JL			Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint	ONCOGENE			English	Article						centrioles; cyclin; genomic instability; p53; retinoblastoma	GENOMIC INSTABILITY; S-PHASE; MUTANT P53; DNA-PLOIDY; EXPRESSION; KINASE; REPLICATION; DUPLICATION; INDUCTION; STABILITY	Centrosome amplification plays a key role in the origin of chromosomal instability during cancer development and progression. In this study, breast cancer cell lines with different p53 backgrounds were used to investigate the relationship between genotoxic stress, G(1)/S cell cycle checkpoint integrity, and the development of centrosome amplification. Introduction of DNA damage in the MCF-7 cell line by treatment with hydroxyurea (HU) or daunorubicin (DR) resulted in the arrest of both G(1)/S cell cycle progression and centriole duplication. In these cells, which carry functional p53, HU treatment also led to nuclear accumulation of p53 and p21(WAF1), retinoblastoma hypophosphorylation, and downregulation of cyclin A. MCF-7 cells carrying a recombinant dominant-negative p53 mutant (vMCF-7(DNp53)) exhibited a shortened G(1) phase of the cell cycle and retained a normal centrosome phenotype. However, these cells developed amplified centrosomes following HU treatment. The MDA-MB 231 cell line, which carries mutant p53 at both alleles, showed amplified centrosomes at the outset, and developed a hyperamplified centrosome phenotype following HU treatment. In cells carrying defective p53, the development of centrosome amplification also occurred following treatment with another DNA damaging agent, DR. Taken together, these findings demonstrate that loss of p53 function alone is not sufficient to drive centrosome amplification, but plays a critical role in this process following DNA damage through abrogation of the G(1)/S cell cycle checkpoint. Furthermore, these studies have important clinical implications because they suggest that breast cancers with compromised p53 function may develop centrosome amplification and consequent chromosomal instability following treatment with genotoxic anticancer drugs.	Mayo Clin Coll Med, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic	Salisbury, JL (corresponding author), Mayo Clin Coll Med, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.	Salisbury@mayo.edu	Farrugia, Daniel/E-4752-2015	Salisbury, Jeffrey/0000-0001-9257-4578	NATIONAL CANCER INSTITUTE [R01CA072836] Funding Source: NIH RePORTER; NCI NIH HHS [CA72836] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANBAZHAGAN R, 1991, ANN ONCOL, V2, P47, DOI 10.1093/oxfordjournals.annonc.a057824; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Duensing S, 2003, CRIT REV EUKAR GENE, V13, P9, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.20; Duensing S, 2002, CANCER RES, V62, P7075; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gartel AL, 2003, ONCOL RES, V13, P405; Goepfert TM, 2002, CANCER RES, V62, P4115; Gunther T, 1997, J CANCER RES CLIN, V123, P388, DOI 10.1007/s004320050076; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Jin SK, 2001, J CELL SCI, V114, P4139; KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Kronenwett U, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-8; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Loeb LA, 2001, CANCER RES, V61, P3230; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mgbonyebi OP, 1999, CANCER RES, V59, P1903; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Palazzo RE, 2003, CELL MOTIL CYTOSKEL, V54, P148, DOI 10.1002/cm.10103; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Pinto AE, 2003, INT J BIOL MARKER, V18, P7, DOI 10.1177/172460080301800102; Riley RR, 2003, CANCER RES, V63, P4862; RUBIN EH, 2003, CANC MED, V6, P781; Sakano K, 2001, JPN J CANCER RES, V92, P1166, DOI 10.1111/j.1349-7006.2001.tb02136.x; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351	51	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4068	4075		10.1038/sj.onc.1207568	http://dx.doi.org/10.1038/sj.onc.1207568			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064746				2022-12-25	WOS:000221520200004
J	Bonten, EJ; Wang, DN; Toy, JN; Mann, L; Mignardot, A; Yogalingam, G; d'Azzo, A				Bonten, EJ; Wang, DN; Toy, JN; Mann, L; Mignardot, A; Yogalingam, G; d'Azzo, A			Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis	FASEB JOURNAL			English	Article						lysosomal storage diseases; reticuloendothelial system; PPCA	HUMAN ALPHA-GLUCOSIDASE; PROTECTIVE PROTEIN; INSECT CELLS; MOUSE MODEL; GAUCHER-DISEASE; MURINE MODEL; BONE-MARROW; NEURAMINIDASE; EXPRESSION; MUTATIONS	Lysosomal storage diseases (LSDs) are monogenic disorders of metabolism caused by deficiency of hydrolytic enzymes. In several LSDs, cells of the reticuloendothelial (RE) system are the primary targets of the disease. Exogenous administration of recombinant enzymes overproduced in mammalian cells has proved effective for treating the systemic phenotype in nonneuropathic patients with LSDs. However, for the treatment of diseases with primary involvement of the RE system, the production of the therapeutic enzyme in insect cells could be an alternative and advantageous method because glycoproteins expressed in insect cells carry carbohydrates of the pauci-mannose or core-type. These recombinant enzymes are in principle already poised to be internalized by cells that express mannose receptors, including macrophages. Here, we demonstrate that three baculovirus-expressed enzymes, protective protein/cathepsin A (PPCA), neuraminidase (Neu1), and beta-glucosidase, were readily taken up and restored lysosomal function in enzyme-deficient mouse macrophages. The capacity of recombinant PPCA and Neu1 to clear the lysosomal storage in target cells was assessed in PPCA(-/-) mice, a model of galactosialidosis. Intravenously injected PPCA(-/-) mice efficiently internalized the corrective enzymes in resident macrophages of many organs. In addition, treated mice showed overall clearance of lysosomal storage in the most affected systemic organs, kidney, liver, and spleen. Our results suggest that ERT with baculovirus-expressed enzymes might be an effective treatment for nonneuropathic patients with galactosialidosis and possibly for others with LSDs that primarily involve the RE system.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	d'Azzo, A (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Mail Stop 331,332 N Lauderdale St, Memphis, TN 38105 USA.	alessandra.dazzo@stjude.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060950] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52025] Funding Source: Medline; NIGMS NIH HHS [GM-60950] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; Altmann F, 1997, GLYCOCONJUGATE J, V14, P643, DOI 10.1023/A:1018548812675; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; Bijvoet AGA, 1998, HUM MOL GENET, V7, P1815, DOI 10.1093/hmg/7.11.1815; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Bonten EJ, 2000, J BIOL CHEM, V275, P37657, DOI 10.1074/jbc.M007380200; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; Bonten EJ, 2000, HUM MOL GENET, V9, P2715, DOI 10.1093/hmg/9.18.2715; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; d'Azzo A., 2002, WILEY ENCY MOL MED, P2624; DIEHL AME, 1999, SCHIFFS DIS LIVER, V1, P39; Downs-Kelly E, 2000, J MOL NEUROSCI, V15, P251, DOI 10.1385/JMN:15:3:251; Dunder U, 2000, FASEB J, V14, P361, DOI 10.1096/fasebj.14.2.361; GALBRAITH D, 2002, BIOPROCESSING J, V1, P47; Galjaard H., 1980, GENETIC METABOLIC DI; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; Grabowski GA, 1998, BLOOD REV, V12, P115, DOI 10.1016/S0268-960X(98)90023-6; Jarvis DL, 1998, CURR OPIN BIOTECH, V9, P528, DOI 10.1016/S0958-1669(98)80041-4; Kakkis ED, 2001, MOL GENET METAB, V72, P199, DOI 10.1006/mgme.2000.3140; Kakkis ED, 2001, NEW ENGL J MED, V344, P182, DOI 10.1056/NEJM200101183440304; Liu YJ, 1998, P NATL ACAD SCI USA, V95, P2503, DOI 10.1073/pnas.95.5.2503; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Miranda SRP, 2000, GENE THER, V7, P1768, DOI 10.1038/sj.gt.3301300; NEUFELD EF, 1970, SCIENCE, V169, P141, DOI 10.1126/science.169.3941.141; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; ONO T, 1990, ANAL BIOCHEM, V187, P324, DOI 10.1016/0003-2697(90)90464-K; Paku S, 2001, AM J PATHOL, V158, P1313, DOI 10.1016/S0002-9440(10)64082-5; PARK CM, 1991, ACTA RADIOL, V32, P34; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; RAO MS, 1991, AM J PATHOL, V139, P1111; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; Sands MS, 2001, J BIOL CHEM, V276, P43160, DOI 10.1074/jbc.M107778200; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; SKLAR MD, 1985, J CELL PHYSIOL, V125, P403, DOI 10.1002/jcp.1041250307; Sly W S, 1978, Prog Clin Biol Res, V23, P547; Takahashi K, 1998, CELL TISSUE RES, V292, P311, DOI 10.1007/s004410051062; Van den Hout H, 2000, LANCET, V356, P397, DOI 10.1016/S0140-6736(00)02533-2; Van den Hout JMP, 2001, J INHERIT METAB DIS, V24, P266, DOI 10.1023/A:1010383421286; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; Yu WH, 2000, MOL GENET METAB, V71, P573, DOI 10.1006/mgme.2000.3095; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	45	37	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					971	+		10.1096/fj.03-0941fje	http://dx.doi.org/10.1096/fj.03-0941fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084520				2022-12-25	WOS:000221108800009
J	Osawa, M; Itoh, S; Ohta, S; Huang, QH; Berk, BC; Marmarosh, NL; Che, WY; Ding, B; Yan, C; Abe, J				Osawa, M; Itoh, S; Ohta, S; Huang, QH; Berk, BC; Marmarosh, NL; Che, WY; Ding, B; Yan, C; Abe, J			ERK1/2 associates with the c-met-binding domain of growth factor receptor-bound protein 2 (Grb2)-associated binder-1 (Gab1) - Role in ERK1/2 and early growth response factor-1 (Egr-1) nuclear accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN PROMOTER; MAP-KINASE; ENDOTHELIAL-CELLS; ACTIVE-TRANSPORT; GENE-EXPRESSION; SHEAR-STRESS; ACTIVATION; SIGNAL; TRANSCRIPTION; ELEMENT	Endothelial cell (EC) migration contributes to reendothelialization after angioplasty or rupture of atherosclerotic plaques. Extracellular signal-regulated kinase (ERK) 1/2 translocates to the nucleus and activates transcription factors such as Ets-like transcription factor-1 and early growth response factor-1 (Egr-1) during reendothelialization. Because ERK1/2 does not possess a nuclear localization signal (NLS), its mechanism of translocation and accumulation in the nucleus remains unclear. Because Gab1 has a putative NLS in its N-terminal region, and Gab1 associates with phosphorylated ERK1/2, we hypothesized that Gab1 participates in ERK1/2 and Egr-1 nuclear accumulation. Using regenerating EC as a model system, we found that endogenous growth factor receptor-bound protein 2-associated binder-1 ( Gab1) translocates into the nucleus in migrating EC. Wild-type red fluorescent protein-tagged Gab1 could be observed in both nucleus and cytoplasm, whereas the putative NLS deletion mutant (DeltaNLS-Gab1) specifically localized in the cytoplasm. In addition, reduction of Gab1 expression by antisense Gab1 oligos or overexpression of DeltaNLS-Gab1 inhibited serum-induced ERK1/2 and Egr-1 nuclear accumulation, suggesting a functional role for the NLS of Gab1 and a role for Gab1-ERK1/2 interactions in ERK1/2-Egr-1 nuclear accumulation. To investigate whether Gab1-ERK1/2 interaction is critical for ERK1/2 and Egr-1 nuclear accumulation, we created a dominant-negative Gab1 construct that consisted of the c-Met binding domain ( amino acids 442 536) of Gab1. We found that overexpression of the c-Met binding domain of Gab1 disrupted serum-induced Gab1-ERK1 interaction and inhibited ERK1 and Egr-1 nuclear accumulation. These data suggest that Gab1-ERK1/2 binding and their nuclear translocation play a crucial role in Egr-1 nuclear accumulation.	Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Cardiol Unit, Rochester, NY 14642 USA	University of Rochester	Abe, J (corresponding author), Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Cardiol Unit, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	jun-ichi_abe@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115; Yan, Chen/0000-0002-1397-6358	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066919, R01HL065262, R01HL049192, R01HL044721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66919, HL-49192, HL-44721, HL-65262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Huang QH, 2002, J BIOL CHEM, V277, P29330, DOI 10.1074/jbc.M112450200; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KIM SJ, 1989, J BIOL CHEM, V264, P402; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Osawa M, 2002, J CELL BIOL, V158, P773, DOI 10.1083/jcb.200205049; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wung BS, 1999, CIRC RES, V84, P804; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	34	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29691	29699		10.1074/jbc.M309371200	http://dx.doi.org/10.1074/jbc.M309371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15078886	hybrid			2022-12-25	WOS:000222445300105
J	Nair, VD; Yuen, T; Olanow, CW; Sealfon, SC				Nair, VD; Yuen, T; Olanow, CW; Sealfon, SC			Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; N-TERMINAL KINASE; DNA-DAMAGE; INDUCED APOPTOSIS; HYDROGEN-PEROXIDE; REACTIVE OXYGEN; PHOSPHOINOSITIDE 3-KINASE; NEURONAL DIFFERENTIATION	In a population of cells undergoing oxidative stress, an individual cell either succumbs to apoptotic cell death or maintains homeostasis and survives. Exposure of PC-12-D2R cells to 200 muM hydrogen peroxide (H2O2) induces apoptosis in about half of cells after 24 h. After 1-h exposure to 200 muM H2O2, both antiapoptotic extracellular regulated kinase (ERK) phosphorylation and pro-apoptotic Ser-15-p53 phosphorylation are observed. Microarray and real-time PCR assays of gene expression after H2O2 exposure identified several transcripts, including egr1, that are rapidly induced downstream of ERK. Single cell analysis of egr1 induction and of phospho-ERK and phospho-p53 formation revealed the presence of two distinct cellular programs. Whereas the proportion of cells activating ERK versus p53 at 1 h depended on H2O2 concentration, individual cells showed exclusively either phospho-p53 formation or activation of ERK and egr1 induction. Exposure to H2O2 for 1 h also elicited these two non-overlapping cellular responses in both dopaminergic SN4741 cells and differentiated postmitotic PC-12-D2R cells. Repressing p53 with pifithrin-alpha or small interfering RNA increased ERK phosphorylation by H2O2, indicating that p53- dependent suppression of ERK activity may contribute to the bi-stable single cell responses observed. By 24 h, the subset of cells in which ERK activity was suppressed exhibit caspase 3 activation and the nuclear condensation characteristic of apoptosis. These studies suggest that the individual cell rapidly and stochastically processes the oxidative stress stimulus, leading to an all-or-none cytoprotective or pro-apoptotic signaling response.	Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sealfon, SC (corresponding author), Mt Sinai Sch Med, Dept Neurol, Neurol Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	stuart.sealfon@mssm.edu		Nair, Venugopalan/0000-0002-8231-6230; Nair, Venugopalan/0000-0002-0299-0998; SEALFON, Stuart/0000-0001-5791-1217				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Anderson CNG, 1999, J NEUROSCI, V19, P664; *APPL BIOS, 1997, US B APPL BIOS, V2, P1; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Cregan SP, 1999, J NEUROSCI, V19, P7860; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Harris CA, 2001, J BIOL CHEM, V276, P37754; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Nair VD, 2003, BIOCHEM J, V373, P25, DOI 10.1042/BJ20030017; Nair VD, 2003, J BIOL CHEM, V278, P47053, DOI 10.1074/jbc.M303364200; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nollen EAA, 2002, J CELL SCI, V115, P2809; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Pantano C, 2003, J BIOL CHEM, V278, P44091, DOI 10.1074/jbc.M308487200; Park SA, 2001, MOL BRAIN RES, V93, P18, DOI 10.1016/S0169-328X(01)00176-0; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan CYI, 1998, J NEUROSCI, V18, P4042; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Yuen T, 2002, METHOD ENZYMOL, V345, P556	70	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27494	27501		10.1074/jbc.M312135200	http://dx.doi.org/10.1074/jbc.M312135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078887	hybrid			2022-12-25	WOS:000222120400081
J	Blanco, MG; Boan, F; Gomez-Marquez, J				Blanco, MG; Boan, F; Gomez-Marquez, J			A paradox in the in vitro end-joining assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; CELL-FREE-EXTRACTS; HUMAN MINISATELLITE; PROTHYMOSIN-ALPHA; GENOMIC INTEGRITY; HISTONE H1; DNA; REPAIR; RECOMBINATION; PATHWAYS	Much work has been focused on the pathways that restore the integrity of the genome after different kinds of lesions, especially double-strand breaks. A classical method to investigate double-strand break repair is the incubation of a DNA substrate with cell-free extracts. In these end-joining assays, the DNA is efficiently ligated by the proteins present in the extract, generating circular molecules and/or multimers. In contrast, using a similar in vitro system, we detected DNA cleavage rather than end ligation. When comparing our results with previous works, a paradox emerges: lower amounts of DNA become multimerized instead of degraded and higher amounts of DNA are degraded rather than multimerized. Here, we have demonstrated that when the DNA/ protein ratio is low enough, the DNA-binding proteins of the nuclear extract protect the DNA substrate, avoiding DNA degradation and vice versa. Therefore, the variation of the DNA/ protein ratio is enough to switch the outcome of the experiment from a DNA cleavage assay to a typical end-joining assay.	Univ Santiago de Compostela, Fac Biol, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, A Coruna, Spain	Universidade de Santiago de Compostela	Gomez-Marquez, J (corresponding author), Univ Santiago de Compostela, Fac Biol, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, A Coruna, Spain.	bnjgm@usc.es	Blanco, Miguel González/R-5754-2017; Blanco, Miguel González/J-6424-2012	Blanco, Miguel González/0000-0002-2883-7326; Blanco, Miguel González/0000-0002-2883-7326				ABMAYR SB, 1987, CURRENT PROTOCOLS MO; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Boan F, 1997, FEBS LETT, V418, P251, DOI 10.1016/S0014-5793(97)01389-6; Boan F, 2002, BIOCHEMISTRY-US, V41, P2166, DOI 10.1021/bi015780i; Boan F, 1998, J MOL BIOL, V278, P499, DOI 10.1006/jmbi.1998.1714; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; CHU G, 1997, J BIOL CHEM, V275, P26196; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Mason RM, 1996, NUCLEIC ACIDS RES, V24, P4946, DOI 10.1093/nar/24.24.4946; Nagaki S, 1998, BIOCHEM BIOPH RES CO, V246, P137, DOI 10.1006/bbrc.1998.8589; NICOLAS AL, 1994, MOL CELL BIOL, V14, P170, DOI 10.1128/MCB.14.1.170; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; Odersky A, 2002, J BIOL CHEM, V277, P11756, DOI 10.1074/jbc.M111304200; OGAWA Y, 1995, J BIOL CHEM, V270, P9272, DOI 10.1074/jbc.270.16.9272; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Pospiech H, 2001, NUCLEIC ACIDS RES, V29, P3277, DOI 10.1093/nar/29.15.3277; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Sathees CR, 1999, MUTAT RES-DNA REPAIR, V433, P1, DOI 10.1016/S0921-8777(98)00055-X; Segade F, 1999, INT J BIOCHEM CELL B, V31, P1243, DOI 10.1016/S1357-2725(99)00094-1; Singleton BK, 1999, FR MOLEC B, V22, P16; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Vega FV, 1998, J BIOL CHEM, V273, P10147, DOI 10.1074/jbc.273.17.10147; Yamanaka S, 2002, BIOCHEM BIOPH RES CO, V292, P268, DOI 10.1006/bbrc.2002.6647; Zhong Q, 2002, CANCER RES, V62, P3966	28	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26797	26801		10.1074/jbc.M402832200	http://dx.doi.org/10.1074/jbc.M402832200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087441	hybrid			2022-12-25	WOS:000222003000107
J	Kaneko, S; Ichinose, H; Fujimoto, Z; Kuno, A; Yura, K; Go, M; Mizuno, H; Kusakabe, I; Kobayashi, H				Kaneko, S; Ichinose, H; Fujimoto, Z; Kuno, A; Yura, K; Go, M; Mizuno, H; Kusakabe, I; Kobayashi, H			Structure and function of a family 10 beta-xylanase chimera of Streptomyces olivaceoviridis E-86 FXYN and Cellulomonas fimi Cex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; F/10 XYLANASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; PSEUDOMONAS-FLUORESCENS; BETA-1,4-GLYCANASE CEX; XYLOPENTAOSE-BINDING; CATALYTIC DOMAIN; SPECIFICITY; XYLOOLIGOSACCHARIDES	The catalytic domain of xylanases belonging to glycoside hydrolase family 10 ( GH10) can be divided into 22 modules (M1 to M22; Sato, Y., Niimura, Y., Yura, K., and Go, M. ( 1999) Gene (Amst.) 238, 93 - 101). Inspection of the crystal structure of a GH10 xylanase from Streptomyces olivaceoviridis E-86 (SoXyn10A) revealed that the catalytic domain of GH10 xylanases can be dissected into two parts, an N-terminal larger region and C-terminal smaller region, by the substrate binding cleft, corresponding to the module border between M14 and M15. It has been suggested that the topology of the substrate binding clefts of GH10 xylanases are not conserved (Charnock, S. J., Spurway, T. D., Xie, H., Beylot, M. H., Virden, R., Warren, R. A. J., Hazlewood, G. P., and Gilbert, H. J. ( 1998) J. Biol. Chem. 273, 32187 - 32199). To facilitate a greater understanding of the structure-function relationship of the substrate binding cleft of GH10 xylanases, a chimeric xylanase between SoXyn10A and Xyn10A from Cellulomonas fimi (CfXyn10A) was constructed, and the topology of the hybrid substrate binding cleft established. At the three-dimensional level, SoXyn10A and CfXyn10A appear to possess 5 subsites, with the amino acid residues comprising subsites -3 to +1 being well conserved, although the +2 subsites are quite different. Biochemical analyses of the chimeric enzyme along with SoXyn10A and CfXyn10A indicated that differences in the structure of subsite +2 influence bond cleavage frequencies and the catalytic efficiency of xylooligosaccharide hydrolysis. The hybrid enzyme constructed in this study displays fascinating biochemistry, with an interesting combination of properties from the parent enzymes, resulting in a low production of xylose.	Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058602, Japan; Yamagata Univ, Fac Sci, Dept Mat & Biol Chem, Yamagata 9908560, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; National Institute of Agrobiological Sciences - Japan; Yamagata University; Nagoya University; University of Tsukuba	Kaneko, S (corresponding author), Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	sakaneko@nfri.affrc.go.jp	Kuno, Atsushi/M-2151-2018; Yura, Kei/S-1030-2018	Kuno, Atsushi/0000-0002-6147-6171; Yura, Kei/0000-0003-0197-5478; Fujimoto, Zui/0000-0002-3551-6854				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEDARKAR S, 1992, J MOL BIOL, V228, P693, DOI 10.1016/0022-2836(92)90852-B; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; Fujimoto Z, 1997, J BIOCHEM-TOKYO, V121, P826; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; Fujimoto Z, 2004, J BIOL CHEM, V279, P9606, DOI 10.1074/jbc.M312293200; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HRMOVA M, 1995, J BIOL CHEM, V270, P14556, DOI 10.1074/jbc.270.24.14556; Kaneko S, 1999, FEBS LETT, V460, P61, DOI 10.1016/S0014-5793(99)01318-6; Kaneko S, 2000, BIOSCI BIOTECH BIOCH, V64, P741, DOI 10.1271/bbb.64.741; Kaneko S, 2000, PROTEIN ENG, V13, P873, DOI 10.1093/protein/13.12.873; Kuno A, 2000, FEBS LETT, V482, P231, DOI 10.1016/S0014-5793(00)02067-6; Kuno A, 1999, FEBS LETT, V450, P299, DOI 10.1016/S0014-5793(99)00498-6; Kuno A, 1998, J FERMENT BIOENG, V86, P434, DOI 10.1016/S0922-338X(98)80147-5; KUSAKABE I, 1983, AGR BIOL CHEM TOKYO, V47, P2713, DOI 10.1080/00021369.1983.10866038; KUSAKABE I, 1977, NIPPON NOGEIKAGAKU K, V51, P429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Leggio L, 2000, PROTEINS, V41, P362, DOI 10.1002/1097-0134(20001115)41:3<362::AID-PROT80>3.0.CO;2-N; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MATSUO N, 1991, AGR BIOL CHEM TOKYO, V55, P2905, DOI 10.1080/00021369.1991.10857129; Natesh R, 1999, J MOL BIOL, V288, P999, DOI 10.1006/jmbi.1999.2727; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P71; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Sato Y, 1999, GENE, V238, P93, DOI 10.1016/S0378-1119(99)00321-2; Schmidt A, 1998, PROTEIN SCI, V7, P2081, DOI 10.1002/pro.5560071004; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; Timell T. E., 1965, ADV CARBOHYD CHEM, V20, P409, DOI DOI 10.1016/S0096-5332(08)60304-5; TULL D, 1991, J BIOL CHEM, V266, P15621; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; YOSHIDA S, 1994, BIOSCI BIOTECH BIOCH, V58, P2068, DOI 10.1271/bbb.58.2068; YOSHIDA S, 1990, AGR BIOL CHEM TOKYO, V54, P449, DOI 10.1080/00021369.1990.10869948	53	27	28	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26619	26626		10.1074/jbc.M308899200	http://dx.doi.org/10.1074/jbc.M308899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078885	hybrid			2022-12-25	WOS:000222003000088
J	Smith, AP; DeRidder, BP; Guo, WJ; Seeley, EH; Regnier, FE; Goldsbrough, PB				Smith, AP; DeRidder, BP; Guo, WJ; Seeley, EH; Regnier, FE; Goldsbrough, PB			Proteomic analysis of Arabidopsis glutathione S-transferases from benoxacor- and copper-treated seedlings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC TOBACCO SEEDLINGS; SIGNATURE-PEPTIDE APPROACH; WHEAT TRITICUM-AESTIVUM; HERBICIDE SAFENERS; SALICYLIC-ACID; ETHYLENE; PROTEIN; PLANTS; GENE; DETOXIFICATION	Glutathione S-transferases (GSTs) are involved in many stress responses in plants, for example, participating in the detoxification of xenobiotics and limiting oxidative damage. Studies examining the regulation of this gene family in diverse plant species have focused primarily on RNA expression. A proteomics method was developed to identify GSTs expressed in Arabidopsis seedlings and to determine how the abundance of these proteins changed in response to copper, a promoter of oxidative stress, and benoxacor, a herbicide safener. Eight GSTs were identified in seedlings grown under control conditions, and only one, AtGSTU19, was induced by benoxacor. In contrast, four GSTs, AtGSTF2, AtGSTF6, AtGSTF7, and AtGSTU19, were significantly more abundant in copper-treated seedlings. The different responses to these treatments may reflect the potential for copper to affect many more aspects of plant growth and physiology compared with a herbicide safener. Differences between RNA and protein expression of GSTs indicate that both transcriptional and translational mechanisms are involved in regulation of GSTs under these conditions.	Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Goldsbrough, PB (corresponding author), Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA.	goldsbrough@purdue.edu	Smith, Aaron P/E-9043-2011; GUO, WOEI-JIUN/F-8487-2012	Seeley, Erin/0000-0002-8000-5754; Smith, Aaron/0000-0003-4422-6012				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; Chen WQ, 1999, PLANT J, V19, P667, DOI 10.1046/j.1365-313x.1999.00560.x; Coleman JOD, 1997, TRENDS PLANT SCI, V2, P144, DOI 10.1016/S1360-1385(97)01019-4; CONKLIN PL, 1995, PLANT PHYSIOL, V109, P203, DOI 10.1104/pp.109.1.203; Cummins I, 1999, PLANT J, V18, P285, DOI 10.1046/j.1365-313X.1999.00452.x; Cummins I, 1997, PESTIC BIOCHEM PHYS, V59, P35, DOI 10.1006/pest.1997.2308; Davies J, 1999, PESTIC SCI, V55, P1043, DOI 10.1002/(SICI)1096-9063(199911)55:11&lt;1043::AID-PS60&gt;3.0.CO;2-L; DeRidder BP, 2002, PLANT PHYSIOL, V130, P1497, DOI 10.1104/pp.010066; DEVOS CHR, 1993, PLANT PHYSIOL BIOCH, V31, P151; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dixon DP, 2000, ARCH BIOCHEM BIOPHYS, V384, P407, DOI 10.1006/abbi.2000.2125; Geng MH, 2000, J CHROMATOGR A, V870, P295, DOI 10.1016/S0021-9673(99)00951-6; Gonneau J, 1998, PHYSIOL PLANTARUM, V103, P114, DOI 10.1034/j.1399-3054.1998.1030114.x; Gronwald JW, 1998, PLANT PHYSIOL, V117, P877, DOI 10.1104/pp.117.3.877; IRZYK GP, 1993, PLANT PHYSIOL, V102, P803, DOI 10.1104/pp.102.3.803; Ji JY, 2000, J CHROMATOGR B, V745, P197, DOI 10.1016/S0378-4347(00)00192-4; Lieberherr D, 2003, PLANT CELL PHYSIOL, V44, P750, DOI 10.1093/pcp/pcg093; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Mira H, 2002, PLANTA, V214, P939, DOI 10.1007/s00425-001-0706-0; Mueller LA, 2000, PLANT PHYSIOL, V123, P1561, DOI 10.1104/pp.123.4.1561; Pascal S, 1999, PHYSIOL PLANTARUM, V106, P17, DOI 10.1034/j.1399-3054.1999.106103.x; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Regnier F, 2001, LC GC N AM, V19, P200; Roxas VP, 2000, PLANT CELL PHYSIOL, V41, P1229, DOI 10.1093/pcp/pcd051; Roxas VP, 1997, NAT BIOTECHNOL, V15, P988, DOI 10.1038/nbt1097-988; SCHELLER HV, 1987, PLANT PHYSIOL, V85, P1031, DOI 10.1104/pp.85.4.1031; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Smith AP, 2003, PLANT J, V36, P433, DOI 10.1046/j.1365-313X.2003.01890.x; Tabb DL, 2003, ANAL CHEM, V75, P1155, DOI 10.1021/ac026122m; Tonge R, 2001, PROTEOMICS, V1, P377; van Rossum AJ, 2001, PROTEOMICS, V1, P1463; Wagner U, 2002, PLANT MOL BIOL, V49, P515, DOI 10.1023/A:1015557300450; YU YB, 1980, PLANT PHYSIOL, V66, P281, DOI 10.1104/pp.66.2.281; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2; ZHOU JM, 1993, PLANT MOL BIOL, V22, P517, DOI 10.1007/BF00015980	36	81	95	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26098	26104		10.1074/jbc.M402807200	http://dx.doi.org/10.1074/jbc.M402807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069083	hybrid, Green Published			2022-12-25	WOS:000222003000023
J	Kogo, H; Aiba, T; Fujimoto, T				Kogo, H; Aiba, T; Fujimoto, T			Cell type-specific occurrence of caveolin-1 alpha and -1 beta in the lung caused by expression of distinct mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLOIDAL SILICA; ALPHA-ISOFORM; SHOW EVIDENCE; CAVEOLAE; PROTEIN; IDENTIFICATION; PHOSPHORYLATION; TRANSCRIPTION; TRAFFICKING; DYSFUNCTION	Two isoforms of caveolin-1, alpha and beta, had been thought to be generated by alternative translation initiation of an mRNA (FL mRNA), but we showed previously that a variant mRNA (5'V mRNA) encodes the beta isoform specifically (Kogo, H., and Fujimoto, T. (2000) FEBS Lett. 465, 119-123). In the present study, we demonstrated strong correlation between the expression of the caveolin-1 protein isoforms and mRNA variants in culture cells and the developing mouse lung. The alpha isoform protein and FL mRNA were expressed constantly during the lung development, whereas expression of the alpha isoform protein and 5'V mRNA was negligible in the fetal lung before 17.5 days post-coitum, and markedly increased simultaneously at 18.5 days post coitum, when the alveolar type I cells started to differentiate. Immunohistochemical analysis revealed the cell type-specific expression of the two isoforms; the alveolar type I cell expresses the beta isoform predominantly, while the endothelium harbors the alpha isoform chiefly. The mutually exclusive expression of caveolin-1 isoforms was verified by Western blotting of the selective plasma membrane preparation obtained from the endothelial and alveolar epithelial cells. The present result indicates that the two caveolin-1 isoforms are generated from distinct mRNAs in vivo and that their production is regulated independently at the transcriptional level. The result also suggests that the alpha and beta isoforms of caveolin-1 may have unique physiological functions.	Nagoya Univ, Grad Sch Med, Dept Anat & Mol Cell Biol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Kogo, H (corresponding author), Fujita Hlth Univ, Inst Comprehens Canc Sci, Div Mol Genet, Dengakugakubo 1-98, Toyoake, Aichi 4701192, Japan.	hkogo@fujita-hu.ac.jp	Fujimoto, Toyoshi/ABH-9058-2020; Kogo, Hiroshi/AAB-8467-2019	Fujimoto, Toyoshi/0000-0002-3601-7977; Kogo, Hiroshi/0000-0003-0584-7158				Aldred MA, 2003, CANCER RES, V63, P2864; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; CHANEY LK, 1983, J BIOL CHEM, V258, P62; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; FARR A, 1992, J HISTOCHEM CYTOCHEM, V40, P651, DOI 10.1177/40.5.1374092; Fernandez I, 2002, P NATL ACAD SCI USA, V99, P11193, DOI 10.1073/pnas.172196599; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Fujimoto T, 1998, J ELECTRON MICROSC, V47, P451, DOI 10.1093/oxfordjournals.jmicro.a023616; Fujimoto T, 2000, J CELL SCI, V113, P3509; Gumbleton M, 2001, ADV DRUG DELIVER REV, V49, P281, DOI 10.1016/S0169-409X(01)00142-9; HIRAGUN A, 1980, IN VITRO CELL DEV B, V16, P685; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; Kotton DN, 2001, DEVELOPMENT, V128, P5181; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Li SW, 1996, J BIOL CHEM, V271, P3863; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ramirez MI, 2002, J HISTOCHEM CYTOCHEM, V50, P33, DOI 10.1177/002215540205000104; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schnitzer JE, 2001, ADV DRUG DELIVER REV, V49, P265, DOI 10.1016/S0169-409X(01)00141-7; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; Stolz DB, 1999, AM J PATHOL, V155, P1487, DOI 10.1016/S0002-9440(10)65464-8; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5; YUSPA SH, 1980, CANCER RES, V40, P4694; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	43	45	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25574	25581		10.1074/jbc.M310807200	http://dx.doi.org/10.1074/jbc.M310807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15067006	hybrid			2022-12-25	WOS:000221827900084
J	Kumar, N; Khurana, S				Kumar, N; Khurana, S			Identification of a functional switch for actin severing by cytoskeletal proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; GELSOLIN; VILLIN; CALCIUM; DOMAIN; CELLS; ASSOCIATION; DISRUPTION; ACTIVATION; COMPLEX	Actin severing is vital for the organization of the actin cytoskeleton during cell motility. Severing of F-actin by the homologous proteins villin and gelsolin requires unphysiologically high calcium concentrations (20-200 muM). Here we demonstrate that high calcium releases an autoinhibited conformation in villin that is maintained by two low affinity calcium binding sites (aspartic acids 467 and 715) that interact with a cluster of basic residues in the S2 domain of villin. Mutation of either of these sites as well as tyrosine phosphorylation alters the conformation of villin resulting in a protein that can sever actin in nanomolar calcium. These results suggest that tyrosine phosphorylation rather than high calcium may be the mechanism by which villin and other related proteins sever actin in vivo.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Khurana, S (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave,Nash 402, Memphis, TN 38163 USA.	khurana@utmem.edu		Khurana, Seema/0000-0002-6884-810X; Kumar, Narendra/0000-0002-1193-0954	NIDDK NIH HHS [DK-65006, DK-54755] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065006, R01DK054755] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Choe H, 2002, J MOL BIOL, V324, P691, DOI 10.1016/S0022-2836(02)01131-2; Constantin B, 1998, J CELL SCI, V111, P1695; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; COOPER JA, 1988, J CELL BIOL, V106, P1229, DOI 10.1083/jcb.106.4.1229; De Corte V, 1999, PROTEIN SCI, V8, P234; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DITSCH A, 1995, EUR J BIOCHEM, V229, P512, DOI 10.1111/j.1432-1033.1995.tb20492.x; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; HESTERBERG LK, 1983, J BIOL CHEM, V258, P359; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; Kumar N, 2004, J BIOL CHEM, V279, P3096, DOI 10.1074/jbc.M308878200; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Lin KM, 2000, J BIOL CHEM, V275, P27746; Lu M, 1997, J CELL BIOL, V138, P1279, DOI 10.1083/jcb.138.6.1279; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; Panebra A, 2001, AM J PHYSIOL-CELL PH, V281, pC1046, DOI 10.1152/ajpcell.2001.281.3.C1046; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; Sklyarova T, 2002, J BIOL CHEM, V277, P39840, DOI 10.1074/jbc.M207052200; VILLEREAL ML, 1989, ANNU REV NUTR, V9, P347, DOI 10.1146/annurev.nu.09.070189.002023; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P2613, DOI 10.1021/bi00307a012; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; Yuan XL, 2003, J PROTEOME RES, V2, P476, DOI 10.1021/pr025589a; Zhai LW, 2002, BIOCHEMISTRY-US, V41, P11750, DOI 10.1021/bi0263762; Zhai LW, 2001, J BIOL CHEM, V276, P36163, DOI 10.1074/jbc.C100418200	25	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24915	24918		10.1074/jbc.C400110200	http://dx.doi.org/10.1074/jbc.C400110200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15084600	hybrid			2022-12-25	WOS:000221827900003
J	Marchesini, N; Osta, W; Bielawski, J; Luberto, C; Obeid, LM; Hannun, YA				Marchesini, N; Osta, W; Bielawski, J; Luberto, C; Obeid, LM; Hannun, YA			Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CYCLIN-DEPENDENT KINASES; E-CADHERIN; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; CONTACT INHIBITION; PHOSPHATIDIC-ACID; CERAMIDE PATHWAY; LEUKEMIC-CELLS	Recently, we reported that neutral sphingomyelinase 2 (nSMase2) functions as a bona fide neutral sphingomyelinase and that overexpression of nSMase2 in MCF7 breast cancer cells caused a decrease in cell growth (Marchesini, N., Luberto, C., and Hannun, Y. A. (2003) J. Biol. Chem. 278, 13775-13783). In this study, the role of endogenous nSMase2 in regulating growth arrest was investigated. The results show that endogenous nSMase2 mRNA was up-regulated similar to5-fold when MCF7 cells became growth-arrested at confluence, and total neutral SMase activity was increased by 119 +/- 41% with respect to control. Cell cycle analysis showed that up-regulation of endogenous nSMase2 correlated with G(0)/G(1) cell cycle arrest and an increase in total ceramide levels (2.4-fold). Analysis of ceramide species showed that confluence caused selective increases in very long chain ceramide C-24:1 (370 +/- 54%) and C-24:0 (266 +/- 81%) during arrest. The role of endogenous nSMase2 in growth regulation and ceramide metabolism was investigated using short interfering RNA (siRNA)-mediated loss-of-function analysis. Down-regulation of nSMase2 with specific siRNA increased the cell population of cells in S phase of the cell cycle by 59 +/- 14% and selectively reverted the effects of growth arrest on the increase in levels of very long chain ceramides. Mechanistically, confluence arrest also induced hypophosphorylation of the retinoblastoma protein (6-fold) and induction of p21(WAF1) (3-fold). Downregulation of nSMase2 with siRNA largely prevented the dephosphorylation of the retinoblastoma protein and the induction of p21(WAF1), providing a link between the action of nSMase2 and key regulators of cell cycle progression. Moreover, studies on nSMase2 localization in MCF7 cells showed that nSMase2 distributed throughout the cells in subconfluent, proliferating cultures. In contrast, nSMase2 became nearly exclusively located at the plasma membrane in confluent, contact-inhibited cells. Hence, we demonstrate for the first time that nSMase2 functions as a growth suppressor in MCF7 cells, linking confluence to the G(0)/G(1) cell cycle check point.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu		obeid, lina/0000-0002-0734-0847	NIA NIH HHS [AG16583] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Angst BD, 2001, J CELL SCI, V114, P625; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Becker KF, 1999, AM J PATHOL, V155, P1803, DOI 10.1016/S0002-9440(10)65497-1; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Burke JM, 1999, INVEST OPHTH VIS SCI, V40, P2963; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chalmers IJ, 2001, CANCER GENET CYTOGEN, V126, P39, DOI 10.1016/S0165-4608(00)00376-9; Chatterjee S, 1999, CHEM PHYS LIPIDS, V102, P79, DOI 10.1016/S0009-3084(99)00077-8; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Connor CE, 2001, CYTOMETRY, V43, P164, DOI 10.1002/1097-0320(20010301)43:3<164::AID-CYTO1044>3.0.CO;2-O; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; El-Assaad W, 1998, BIOCHEM J, V336, P735, DOI 10.1042/bj3360735; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Govers R, 2002, BIOCHEM J, V361, P193, DOI 10.1042/0264-6021:3610193; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HARPER JW, 1993, CELL, V75, P805; Hayashi Y, 1997, J BIOL CHEM, V272, P18082, DOI 10.1074/jbc.272.29.18082; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kim JH, 1999, TISSUE CELL, V31, P531, DOI 10.1054/tice.1999.0061; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lee JY, 1998, BIOCHEM J, V334, P457, DOI 10.1042/bj3340457; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lee JY, 2000, EXP CELL RES, V261, P303, DOI 10.1006/excr.2000.5028; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 1999, CHEM PHYS LIPIDS, V102, P167, DOI 10.1016/S0009-3084(99)00085-7; Lida A, 1997, BRIT J CANCER, V75, P264, DOI 10.1038/bjc.1997.43; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Luberto C, 2002, NEUROCHEM RES, V27, P609, DOI 10.1023/A:1020267831851; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Oh WJ, 1998, CANCER LETT, V129, P215, DOI 10.1016/S0304-3835(98)00105-0; Okazaki N, 2002, CARCINOGENESIS, V23, P1139, DOI 10.1093/carcin/23.7.1139; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Siddiqui RA, 2003, BIOCHEM J, V371, P621, DOI 10.1042/BJ20021667; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Vizirianakis IS, 2002, INT J ONCOL, V21, P135; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; West MR, 2002, CELL COMMUN ADHES, V9, P29, DOI 10.1080/15419060212185; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	69	123	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25101	25111		10.1074/jbc.M313662200	http://dx.doi.org/10.1074/jbc.M313662200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15051724	hybrid			2022-12-25	WOS:000221827900025
J	Orsini, F; Migliaccio, E; Moroni, M; Contursi, C; Raker, VA; Piccini, D; Martin-Padura, I; Pelliccia, G; Trinei, M; Bono, M; Puri, C; Tacchetti, C; Ferrini, M; Mannucci, R; Nicoletti, I; Lanfrancone, L; Giorgio, M; Pelicci, PG				Orsini, F; Migliaccio, E; Moroni, M; Contursi, C; Raker, VA; Piccini, D; Martin-Padura, I; Pelliccia, G; Trinei, M; Bono, M; Puri, C; Tacchetti, C; Ferrini, M; Mannucci, R; Nicoletti, I; Lanfrancone, L; Giorgio, M; Pelicci, PG			The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; OXIDATIVE STRESS; SIGNALING PATHWAY; CYTOCHROME-C; PERMEABILITY TRANSITION; HSP70 FAMILY; PROTEIN; DOMAIN; TRANSDUCTION; LONGEVITY	P66Shc regulates life span in mammals and is a critical component of the apoptotic response to oxidative stress. It functions as a downstream target of the tumor suppressor p53 and is indispensable for the ability of oxidative stress-activated p53 to induce apoptosis. The molecular mechanisms underlying the apoptogenic effect of p66Shc are unknown. Here we report the following three findings. (i) The apoptosome can be properly activated in vitro in the absence of p66Shc only if purified cytochrome c is supplied. (ii) Cytochrome c release after oxidative signals is impaired in the absence of p66Shc. (iii) p66Shc induces the collapse of the mitochondrial trans-membrane potential after oxidative stress. Furthermore, we showed that a fraction of cytosolic p66Shc localizes within mitochondria where it forms a complex with mitochondrial Hsp70. Treatment of cells with ultraviolet radiation induced the dissociation of this complex and the release of monomeric p66Shc. We propose that p66Shc regulates the mitochondrial pathway of apoptosis by inducing mitochondrial damage after dissociation from an inhibitory protein complex. Genetic and biochemical evidence suggests that mitochondria regulate life span through their effects on the energetic metabolism (mitochondrial theory of aging). Our data suggest that mitochondrial regulation of apoptosis might also contribute to life span determination.	Federaz Italiana Ric Canc, Inst Mol Oncol, I-20139 Milan, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; Univ Perugia, Dept Clin Expt Med, I-06122 Perugia, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Genoa; University of Perugia	Giorgio, M (corresponding author), Federaz Italiana Ric Canc, Inst Mol Oncol, Via Adamello 16, I-20139 Milan, Italy.	giorgio@ifom-firct.it; pgpelicci@ieo.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Migliaccio, Enrica/AAQ-8880-2020; mannucci, roberta/AAE-6662-2020; Giorgio, Marco/I-9425-2012; Franzeck, Fabian C/B-5055-2011	Lanfrancone, Luisa/0000-0002-4523-3815; Giorgio, Marco/0000-0002-5842-6042; TACCHETTI, CARLO/0000-0003-4602-000X				Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brown GC, 1995, BIOENERGETICS PRACTI; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Harlow E., 1988, ANTIBODIES LAB MANUA; Kaul SC, 2003, EXP CELL RES, V286, P96, DOI 10.1016/S0014-4827(03)00101-0; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Mitsumoto A, 2002, FREE RADICAL BIO MED, V32, P22, DOI 10.1016/S0891-5849(01)00755-9; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; NICOLLI A, 1996, J BIOL CHEM, V271, P185; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PON LA, 2001, METHODS CELL BIOL, V65; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Sadekova S, 1997, INT J RADIAT BIOL, V72, P653, DOI 10.1080/095530097142807; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Schiaffino MV, 1999, NAT GENET, V23, P108, DOI 10.1038/12715; Schwarzer C, 2002, INT J BIOCHEM CELL B, V34, P1059, DOI 10.1016/S1357-2725(02)00026-2; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; Wang XD, 2001, GENE DEV, V15, P2922; Yokoyama K, 2002, FEBS LETT, V516, P53, DOI 10.1016/S0014-5793(02)02470-5; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	30	227	245	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25689	25695		10.1074/jbc.M401844200	http://dx.doi.org/10.1074/jbc.M401844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15078873	hybrid			2022-12-25	WOS:000221827900098
J	Rhee, SH; Keates, AC; Moyer, MP; Pothoulakis, C				Rhee, SH; Keates, AC; Moyer, MP; Pothoulakis, C			MEK is a key modulator for TLR5-induced interleukin-8 and MIP3 alpha gene expression in non-transformed human colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-RESPONSE; NF-KAPPA-B; ELK-1 PHOSPHORYLATION; BACTERIAL FLAGELLIN; RECEPTOR; ACTIVATION; PROTEIN; TRANSCRIPTION; MECHANISM; PATHWAY	Flagellin, a specific ligand for Toll-like receptor 5 (TLR5), is a molecular pattern associated with several bacterial species. Recently, TLR signaling has been intensively studied. However, TLR5-associated signaling in non-transformed colonocytes has not been investigated. Here we studied the expression of cytokines induced by flagellin in non-transformed human colonic NCM460 cells and the signaling mechanisms mediating these responses. Cytokine expression array experiments showed that exposure of the cells to flagellin (100 ng/ml) for 12 h increased the expression of interleukin (IL)-8 and macrophage-inflammatory protein 3alpha (MIP3alpha) in a TLR5-specific manner. Flagellin also activated MAP kinases (ERK1/2, JNK, and p38) and degraded IkappaBalpha. Dominant negative MEK1 (a kinase that activates ERK1/2) blocked flagellin-stimulated IL-8 and MIP3alpha transcriptional activity, while the MEK-specific inhibitors PD98059 and U0126 reduced protein production of these cytokines. Conversely, transfection with a constitutively active MEK1 increased IL-8 and MIP3alpha transcriptional activity in a NFkappaB-independent manner. Furthermore, overexpression of the constitutively active MEK1 induced IL-8 and MIP3alpha protein production. We also demonstrated that C-terminal coiled-coil and TRAF-C domains of TRAF6, unable to mediate NFkappaB activation, are involved in MEK-mediated IL-8 and MIP3alpha expression. Thus, in non-transformed human colonocytes, MEK activation following flagellin/TLR5 engagement is a key modulator for NFkappaB-independent, IL-8 and MIP3alpha expression.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Gastrointestinal Neuropeptide C, Boston, MA 02215 USA; INCELL Corp, San Antonio, TX 79249 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pothoulakis, C (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Gastrointestinal Neuropeptide C, Dana 601,330 Brookline Ave, Boston, MA 02215 USA.	cpothoul@caregroup.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047343, R01DK060729, P01DK033506] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33506, DK 47343, DK 60729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banks C, 2003, J PATHOL, V199, P28, DOI 10.1002/path.1245; Cummings J H, 2003, Curr Issues Intest Microbiol, V4, P9; Elewaut D, 1999, J IMMUNOL, V163, P1457; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hart AL, 2003, J CLIN GASTROENTEROL, V36, P111, DOI 10.1097/00004836-200302000-00005; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Huang RC, 2002, CANCER RES, V62, P2806; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710, DOI 10.1152/ajpgi.2001.280.4.G710; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Kwon JH, 2003, J BIOL CHEM, V278, P875, DOI 10.1074/jbc.M208241200; Kwon JH, 2002, GUT, V51, P818, DOI 10.1136/gut.51.6.818; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Madrazo DR, 2003, INFECT IMMUN, V71, P5418, DOI 10.1128/IAI.71.9.5418-5421.2003; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Natarajan R, 2001, EXP CELL RES, V266, P203, DOI 10.1006/excr.2001.5218; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rhee SH, 2003, J BIOL CHEM, V278, P22506, DOI 10.1074/jbc.M208633200; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Sahi Jasminder, 1998, American Journal of Physiology, V275, pC1048; Salmenpera P, 2003, AM J PHYSIOL-CELL PH, V284, pC1133, DOI 10.1152/ajpcell.00293.2002; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Stagg AJ, 2003, GUT, V52, P1522, DOI 10.1136/gut.52.10.1522; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Xu HM, 2003, J BIOL CHEM, V278, P36334, DOI 10.1074/jbc.M305698200; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200; Zhou X, 2003, INFECT IMMUN, V71, P2120, DOI 10.1128/IAI.71.4.2120-2129.2003	43	73	75	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25179	25188		10.1074/jbc.M400967200	http://dx.doi.org/10.1074/jbc.M400967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069060	hybrid			2022-12-25	WOS:000221827900034
J	Chodniewicz, D; Alteraifi, AM; Zhelev, DV				Chodniewicz, D; Alteraifi, AM; Zhelev, DV			Experimental evidence for the limiting role of enzymatic reactions in chemoattractant-induced pseudopod extension in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTIN-FILAMENT TURNOVER; F-ACTIN; SIGNAL-TRANSDUCTION; NUCLEOTIDE EXCHANGE; CELL MOTILITY; PHOSPHATIDYLINOSITOL 3-KINASE; POLYMORPHONUCLEAR LEUKOCYTES; PHOSPHOINOSITIDE 3-KINASE; DISTINCT PATHWAYS	Chemoattractant-stimulated pseudopod growth in human neutrophils was used as a model system to study the rate-limiting mechanism of cytoskeleton rearrangement induced by activated G-protein-coupled receptors. Cells were activated with N-formyl-Met-Leu-Phe, and the temperature dependence of the rate of pseudopod extension was measured in the presence of pharmacological inhibitors with known mechanisms of action. Three groups of inhibitors were used: (i) inhibitors sequestering substrates involved in F-actin polymerization ( latrunculin A for G-actin and cytochalasin D for actin filament-free barbed ends) or sequestering secondary messengers (PIP-binding peptide for phosphoinositide lipids); (ii) competitively binding inhibitors (Akt-inhibitor for Akt/protein kinase B); and (iii) inhibitors that reduce enzyme activity (wortmannin for phosphoinositide 3-kinase and chelerythrine for protein kinase C). The experimental data are consistent with a model in which the relative involvement of a given pathway of F-actin polymerization to the measured rate of pseudopod extension is limited by a slowest (bottleneck) reaction in the cascade of reactions involved in the overall signaling pathway. The approach we developed was used to demonstrate that chemoattractant-induced pseudopod growth and mechanically stimulated cytoskeleton rearrangement are controlled by distinct pathways of F-actin polymerization.	Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA; United Arab Emirates Univ, Dept Mech Engn, Al Ain, U Arab Emirates	Duke University; United Arab Emirates University	Zhelev, DV (corresponding author), Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27708 USA.	dvzh@duke.edu			NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NHLBI NIH HHS [HL57629] Funding Source: Medline; NIGMS NIH HHS [GM08555] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008555] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alteraifi AM, 1997, J CELL SCI, V110, P1967; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cameron LA, 2001, CURR BIOL, V11, P130, DOI 10.1016/S0960-9822(01)00022-7; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Catz SD, 1998, PROSTAG OTH LIPID M, V55, P245, DOI 10.1016/S0090-6980(98)00021-5; Chodniewicz D, 2003, BLOOD, V102, P2251, DOI 10.1182/blood-2002-09-2936; Chodniewicz D, 2003, BLOOD, V101, P1181, DOI 10.1182/blood-2002-05-1435; Coffer PJ, 1998, BIOCHEM J, V335, P1; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cunningham CC, 2001, J BIOL CHEM, V276, P43390, DOI 10.1074/jbc.M105289200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Herant M, 2003, BIOPHYS J, V84, P3389, DOI 10.1016/S0006-3495(03)70062-9; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hoffmeister KM, 2001, J BIOL CHEM, V276, P24751, DOI 10.1074/jbc.M011642200; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Katanaev VL, 2001, BIOCHEMISTRY-MOSCOW+, V66, P351, DOI 10.1023/A:1010293809553; Kim MS, 2001, CANCER LETT, V171, P79, DOI 10.1016/S0304-3835(01)00505-5; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Lou LG, 1997, BIOCHEM BIOPH RES CO, V236, P626, DOI 10.1006/bbrc.1997.7027; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Maciver SK, 1998, EUR J BIOCHEM, V256, P388, DOI 10.1046/j.1432-1327.1998.2560388.x; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; Meyer EL, 2002, J BIOL CHEM, V277, P10869, DOI 10.1074/jbc.M106744200; Mogilner A, 2003, BIOPHYS J, V84, P1591, DOI 10.1016/S0006-3495(03)74969-8; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; OKADA T, 1994, J BIOL CHEM, V269, P3568; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Pierini LM, 2003, J BIOL CHEM, V278, P10831, DOI 10.1074/jbc.M212386200; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STOSSEL TP, 1992, INFLAMMATION BASIC P, P459; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Truhlar DG, 2001, P NATL ACAD SCI USA, V98, P848, DOI 10.1073/pnas.98.3.848; Upadhyaya A, 2003, CURR BIOL, V13, pR734, DOI 10.1016/j.cub.2003.08.051; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; Xu C, 2003, J CELL BIOL, V161, P779, DOI 10.1083/jcb.200301070; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; ZHELEV DV, 1995, BIOPHYS J, V68, P2004, DOI 10.1016/S0006-3495(95)80377-2; Zhelev DV, 2002, ANN BIOMED ENG, V30, P356, DOI 10.1114/1.1477446; Zhelev DV, 1996, CELL MOTIL CYTOSKEL, V35, P331; ZHELEV DV, 1994, BIOPHYS J, V67, P696, DOI 10.1016/S0006-3495(94)80529-6	69	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24460	24466		10.1074/jbc.M312764200	http://dx.doi.org/10.1074/jbc.M312764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051729	hybrid			2022-12-25	WOS:000221702500073
J	Pihlajamaa, T; Lankinen, H; Ylostalo, J; Valmu, L; Jaalinoja, J; Zaucke, F; Spitznagel, L; Gosling, S; Puustinen, A; Morgelin, M; Peranen, J; Maurer, P; Ala-Kokko, L; Kilpelainen, I				Pihlajamaa, T; Lankinen, H; Ylostalo, J; Valmu, L; Jaalinoja, J; Zaucke, F; Spitznagel, L; Gosling, S; Puustinen, A; Morgelin, M; Peranen, J; Maurer, P; Ala-Kokko, L; Kilpelainen, I			Characterization of recombinant amino-terminal NC4 domain of human collagen IX - Interaction with glycosaminoglycans and cartilage oligomeric matrix protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; EXTRACELLULAR-MATRIX; PSEUDOACHONDROPLASIA; BINDING; ASSOCIATION; EXPRESSION; MUTATIONS; ADHESION; DECORIN; SITE	The N-terminal NC4 domain of collagen IX is a globular structure projecting away from the surface of the cartilage collagen fibril. Several interactions have been suggested for this domain, reflecting its location and its characteristic high isoelectric point. In an attempt to characterize the NC4 domain in more detail, we set up a prokaryotic expression system to produce the domain. The purified 27.5-kDa product was analyzed for its glycosaminoglycan-binding potential by surface plasmon resonance and solid-state assays. The results show that the NC4 domain of collagen IX specifically binds heparin with a K-d of 0.6 muM, and the full-length recombinant collagen IX has an even stronger interaction with heparin, with an apparent K-d of 3.6 nM. The heparin-binding site of the NC4 domain was located in the extreme N terminus, containing a heparin-binding consensus sequence, whereas electron microscopy suggested the presence of at least three additional heparin-binding sites on full-length collagen IX. The NC4 domain was also shown to bind cartilage oligomeric matrix protein. This interaction and the association of cartilage oligomeric matrix protein with other regions of collagen IX were found to be heparin-competitive. Circular dichroism analyses of the NC4 domain indicated the presence of stabilizing disulfide bonds and a thermal denaturation point of about 80degreesC. The pattern of disulfide bond formation within the NC4 domain was identified by tryptic peptide mass mapping of the NC4 in native and reduced states. A similar pattern was demonstrated for the NC4 domain of full-length recombinant collagen IX.	Univ Helsinki, Inst Biotechnol, NMR Lab, FI-00014 Helsinki, Finland; Univ Helsinki, Prot Chem Lab, FI-00014 Helsinki, Finland; Univ Helsinki, Program Cellular Biotechnol, FI-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Helsinki Bioenerget Grp, FI-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Virol, Peptide & Prot Lab, FI-00014 Helsinki, Finland; Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA; Oulu Univ, Bioctr, Collagen Res Unit, FI-90014 Oulu, Finland; Oulu Univ, Bioctr, Dept Med Biochem & Mol Biol, FI-90014 Oulu, Finland; Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Lund Univ, Sect Mol Pathogenesis, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Univ Helsinki, Organ Chem Lab, Dept Chem, FI-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Tulane University; Tulane University; University of Oulu; University of Oulu; University of Cologne; Lund University; University of Helsinki	Pihlajamaa, T (corresponding author), Univ Helsinki, Inst Biotechnol, NMR Lab, POB 65, FI-00014 Helsinki, Finland.	Tero.Pihlajamaa@helsinki.fi	Zaucke, Frank/AAT-2688-2021; Zaucke, Frank/E-2077-2012; Ylostalo, Joni/AAH-9457-2019	Ylostalo, Joni/0000-0001-9746-1994; Puustinen, Anne/0000-0002-0262-9975	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045982] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45982] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akutsu N, 1999, EXP DERMATOL, V8, P17, DOI 10.1111/j.1600-0625.1999.tb00343.x; Aszodi A, 2000, CELL STRUCT FUNCT, V25, P73, DOI 10.1247/csf.25.73; Baneyx F, 1999, CURR OPIN BIOTECH, V10, P411, DOI 10.1016/S0958-1669(99)00003-8; Barre PE, 2000, OSTEOARTHR CARTILAGE, V8, P34, DOI 10.1053/joca.1999.0286; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRUCKNER P, 1983, EUR J BIOCHEM, V136, P333, DOI 10.1111/j.1432-1033.1983.tb07746.x; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Cooper MA, 2000, ANAL BIOCHEM, V277, P196, DOI 10.1006/abio.1999.4389; Couchman JR, 1999, J CELL SCI, V112, P3415; Douglas SP, 1998, MATRIX BIOL, V16, P497, DOI 10.1016/S0945-053X(98)90020-8; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Ehnis T, 1998, EXP CELL RES, V239, P477, DOI 10.1006/excr.1997.3895; Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380; Farjanel J, 2001, OSTEOARTHR CARTILAGE, V9, pS55, DOI 10.1053/joca.2001.0445; Hagg R, 1998, J CELL BIOL, V142, P285, DOI 10.1083/jcb.142.1.285; Hirsch MS, 1997, DEV DYNAM, V210, P249, DOI 10.1002/(SICI)1097-0177(199711)210:3<249::AID-AJA6>3.0.CO;2-G; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Hunziker EB, 1997, MICROSC RES TECHNIQ, V37, P271; IRWIN MH, 1985, J CELL BIOL, V101, P814, DOI 10.1083/jcb.101.3.814; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; Miles CA, 1998, J MOL BIOL, V277, P135, DOI 10.1006/jmbi.1997.1603; Munakata H, 1999, GLYCOBIOLOGY, V9, P1023, DOI 10.1093/glycob/9.10.1023; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320; Pfander D, 2001, AM J PATHOL, V159, P1777, DOI 10.1016/S0002-9440(10)63024-6; Pignataro B, 2000, BIOPHYS J, V78, P487, DOI 10.1016/S0006-3495(00)76611-2; Pihlajamaa T, 1999, J BIOL CHEM, V274, P22464, DOI 10.1074/jbc.274.32.22464; Poole CA, 1997, OSTEOARTHR CARTILAGE, V5, P191, DOI 10.1016/S1063-4584(97)80014-3; POOLE CA, 1987, J ORTHOP RES, V5, P509, DOI 10.1002/jor.1100050406; ROKOS I, 1994, MATRIX BIOL, V14, P1, DOI 10.1016/0945-053X(94)90024-8; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Rossi A, 2001, HUM MUTAT, V17, P159, DOI 10.1002/humu.1; Spitznagel L, 2004, BIOCHEM J, V377, P479, DOI 10.1042/BJ20031179; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; Vaughan-Thomas A, 2001, J BIOL CHEM, V276, P5303, DOI 10.1074/jbc.M008764200; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200	43	44	46	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24265	24273		10.1074/jbc.M402865200	http://dx.doi.org/10.1074/jbc.M402865200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047691	hybrid			2022-12-25	WOS:000221702500051
J	Tien, ES; Davis, JW; Heuvel, JPV				Tien, ES; Davis, JW; Heuvel, JPV			Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-REGULATORY GENES; FATTY-ACID OXIDATION; TRANSCRIPTION FACTOR; EXPRESSION ANALYSIS; COACTIVATOR; GAMMA; PPAR; INTERACTS; HYPOXIA; MICE	Like other nuclear receptors, the peroxisome proliferator-activated receptors (PPARs) use a wide variety of protein-protein interactions to properly regulate transcription of target genes. In an attempt to identify novel PPAR-interacting proteins, a cDNA expression library was screened with bacterially expressed PPARalpha. One of the genes identified as a PPARalpha-associated protein by interaction cloning was the CREB-binding protein/p300-interacting transactivator with ED-rich tail 2 (CITED2, also called p35srj/mrg1/msg1). This coactivator interacted directly with PPARalpha in the presence or absence of ligand predominantly via the ligand binding domain of the nuclear receptor. In transient transfection reporter assays, CITED2 acted as a dose-dependent coactivator of PPARalpha-dependent transcriptional regulation in the presence of several exogenous ligands. CITED2 also increased PPARgamma-dependent regulation of reporter genes but had no effect on PPARbeta activity. To determine whether CITED2 affects endogenous gene expression, this protein was stably overexpressed (CITED2+) or repressed by small inhibitor RNA (CITED2-) in immortalized mouse hepatocytes. Relative to the control stably transfected or CITED2- cells, CITED2+ cells had an increased rate of cell proliferation. Microarray analysis and real time PCR showed that several genes are differentially affected by PPARalpha ligands in CITED2+ versus CITED2- cells. Genes that were affected by PPARalpha ligands in a CITED2- modulatory manner include angiopoietin-like protein 4, forkhead C2, hypoxia-inducible factor-1alpha, and MAPK phosphatase 1. Interestingly these genes share common functions in that they are known to promote vascularization and angiogenesis in response to hypoxia. The results described here suggest that CITED2 is a coactivator of PPARalpha and that both proteins may participate in signaling cascades of hypoxic response and angiogenesis.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Heuvel, JPV (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, 226 Fenske Lab, University Pk, PA 16802 USA.	jpv2@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049009, R29DK049009] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49009] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auwerx J, 1999, CELL, V97, P161; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Belury MA, 1998, TOXICOL APPL PHARM, V151, P254, DOI 10.1006/taap.1998.8443; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bhattacharya S, 2003, NAT STRUCT BIOL, V10, P501, DOI 10.1038/nsb0703-501; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Gesta S, 2003, HORM METAB RES, V35, P158, DOI 10.1055/s-2003-39070; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG Q, 1994, J BIOL CHEM, V269, P8493; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Khan SA, 2003, J NUTR BIOCHEM, V14, P554, DOI 10.1016/S0955-2863(03)00098-6; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Mochizuki K, 2002, GENE, V291, P271, DOI 10.1016/S0378-1119(02)00625-X; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Panigrahy D, 2003, EXPERT OPIN INV DRUG, V12, P1925, DOI 10.1517/13543784.12.12.1925; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Roberts-Thomson SJ, 2000, IMMUNOL CELL BIOL, V78, P436, DOI 10.1046/j.1440-1711.2000.00921.x; Schlange T, 2000, MECH DEVELOP, V98, P157, DOI 10.1016/S0925-4773(00)00454-8; Sumanasekera WK, 2003, BIOCHEMISTRY-US, V42, P10726, DOI 10.1021/bi0347353; Sumanasekera WK, 2003, J BIOL CHEM, V278, P4467, DOI 10.1074/jbc.M211261200; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Tien ES, 2003, CANCER RES, V63, P5767; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Tugwood JD, 1998, ARCH TOXICOL, V72, P169, DOI 10.1007/s002040050483; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Yokota H, 2003, J BIOL CHEM, V278, P47275, DOI 10.1074/jbc.M304652200; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	38	98	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24053	24063		10.1074/jbc.M401489200	http://dx.doi.org/10.1074/jbc.M401489200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051727	hybrid			2022-12-25	WOS:000221702500027
J	Xu, HM; Liao, B; Zhang, QJ; Wang, BB; Li, H; Zhong, XM; Sheng, HZ; Zhao, YX; Zhao, YM; Ying, J				Xu, HM; Liao, B; Zhang, QJ; Wang, BB; Li, H; Zhong, XM; Sheng, HZ; Zhao, YX; Zhao, YM; Ying, J			Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; MAMMALIAN EMBRYO; SELF-RENEWAL; MOUSE EMBRYO; POU-DOMAIN; ES CELLS; PROTEINS; PROTEOLYSIS; EXPRESSION; ACTIVATION	The POU transcription factor Oct-4 is a master regulator affecting the fate of pluripotent embryonic stem cells. However, the precise mechanisms by which the activation and expression of Oct-4 are regulated still remain to be elucidated. We describe here a novel murine ubiquitin ligase, Wwp2, that specifically interacts with Oct-4 and promotes its ubiquitination both in vivo and in vitro. Remarkably, the expression of a catalytically inactive point mutant of Wwp2 abolishes Oct-4 ubiquitination. Moreover, Wwp2 promotes Oct-4 degradation in the presence of overexpressed ubiquitin. The degradation is blocked by treatment with proteasome inhibitor. Fusion of a single ubiquitin to Oct-4 inactivates its transcriptional activity in a heterologous Oct-4 driven reporter system. Furthermore, overexpression of Wwp2 in embryonic stem cells significantly reduces the Oct-4-transcriptional activities. Collectively, we demonstrate for the first time that Oct-4 can be posttranslationally modified by ubiquitination and that this modification dramatically suppresses its transcriptional activity. These results reveal that the functional status of Oct-4, in addition to its expression level, dictates its transcriptional activity, and the results open up a new avenue to understand how Oct-4 defines the fate of embryonic stem cells.	Shanghai Med Univ 2, Hlth Sci Ctr, Dept Dev Biol, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200025, Peoples R China; Shanghai Med Univ 2, Ctr Dev Biol, Shanghai 200092, Peoples R China; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ying, J (corresponding author), Shanghai Med Univ 2, Hlth Sci Ctr, Dept Dev Biol, 411 He Fei Rd, Shanghai 200025, Peoples R China.	yjin@sibs.ac.cn		li, hui/0000-0002-7409-7787; Liao, Bing/0000-0003-1279-1682; , jin ying/0000-0003-0070-2048				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehm A, 1998, APMIS, V106, P114, DOI 10.1111/j.1699-0463.1998.tb01326.x; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Guo Y, 2002, P NATL ACAD SCI USA, V99, P3663, DOI 10.1073/pnas.062041099; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Klenova E, 2002, METHODS, V26, P254, DOI 10.1016/S1046-2023(02)00029-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mayer RJ, 2000, NAT REV MOL CELL BIO, V1, P145; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Shao Y, 2003, EMBO REP, V4, P425, DOI 10.1038/sj.embor.embor813; Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Turksen K., 2002, EMBRYONIC STEM CELLS; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yeom YI, 1996, DEVELOPMENT, V122, P881; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhao YX, 2003, ANAL CHEM, V75, P3751, DOI 10.1021/ac034184m	51	115	118	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23495	23503		10.1074/jbc.M400516200	http://dx.doi.org/10.1074/jbc.M400516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047715	hybrid			2022-12-25	WOS:000221570900087
J	Siler, U; Barella, L; Spitzer V; Schnorr, J; Lein, M; Goralczyk, R; Wertz, K				Siler, U; Barella, L; Spitzer, V; Schnorr, J; Lein, M; Goralczyk, R; Wertz, K			Lycopene and Vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model	FASEB JOURNAL			English	Article						carotenoid; steroid; nutrigenomics; magnetic resonance imaging	PROLIFERATIVE INFLAMMATORY ATROPHY; GROWTH-FACTORS; INTRAEPITHELIAL NEOPLASIA; DIFFERENTIATION PATHWAYS; ANDROGEN RECEPTOR; ALPHA-TOCOPHEROL; VENTRAL PROSTATE; EPITHELIAL-CELLS; BETA-CAROTENE; BRAIN-TUMORS	Epidemiological studies have consistently associated high intakes of lycopene or vitamin E with a reduced prostate cancer risk. Both compounds were tested in the MatLyLu Dunning prostate cancer model to gain insight into the in vivo action of lycopene and vitamin E. Supplementation for 4 weeks with 200 ppm lycopene, 540 ppm vitamin E, or both led to plasma levels comparable with those in humans. Both compounds also accumulated in tumor tissue. Macroscopic evaluation of the tumors by magnetic resonance imaging showed a significant increase in necrotic area in the vitamin E and the lycopene treatment groups. Microarray analysis of tumor tissues revealed that both compounds regulated local gene expression. Vitamin E reduced androgen signaling without affecting androgen metabolism. Lycopene interfered with local testosterone activation by down-regulating 5-alpha-reductase and consequently reduced steroid target genes expression (cystatin-related protein 1 and 2, prostatic spermine binding protein, prostatic steroid binding protein C1, C2 and C3 chain, probasin). In addition, lycopene down-regulated prostatic IGF-I and IL-6 expression. Based on these findings, we suggest that lycopene and vitamin E contribute to the reduction of prostate cancer by interfering with internal autocrine or paracrine loops of sex steroid hormone and growth factor activation/synthesis and signaling in the prostate.	DSM Nutr Prod Human Nutr & Hlth, Carotenoid Sect, CH-4002 Basel, Switzerland; Humboldt Univ, Charite Univ Hosp, Dept Urol, Berlin, Germany	DSM NV; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wertz, K (corresponding author), DSM Nutr Prod Human Nutr & Hlth, Carotenoid Sect, POB 3255, CH-4002 Basel, Switzerland.	karin.wertz@dsm.com		Siler, Ulrich/0000-0002-2458-2629				ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S; *AM CANC SOC, 2003, CANC FACTS FIG 2003; Bonkhoff H, 1996, PROSTATE, V28, P98; Bostwick DG, 2000, PROSTATE, V43, P286; CARMENA MJ, 1986, CELL BIOCHEM FUNCT, V4, P19, DOI 10.1002/cbf.290040103; Chenevert TL, 1997, CLIN CANCER RES, V3, P1457; Chenevert TL, 2000, JNCI-J NATL CANCER I, V92, P2029, DOI 10.1093/jnci/92.24.2029; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Dennis LK, 2002, UROLOGY, V60, P78, DOI 10.1016/S0090-4295(02)01637-0; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dixon LB, 2001, J NUTR, V131, P1232, DOI 10.1093/jn/131.4.1232; DIXON LB, 1994, NEW ENGL J MED, V330, P1029; Eichholzer M, 1996, INT J CANCER, V66, P145, DOI 10.1002/(SICI)1097-0215(19960410)66:2&lt;145::AID-IJC1&gt;3.0.CO;2-2; FERLAY J, 2000, GLOBOCAN 2000 CANC I; Fleshner N, 1999, J UROLOGY, V161, P1651, DOI 10.1016/S0022-5347(05)68998-7; Friedman EJ, 1997, J UROLOGY, V158, P1585, DOI 10.1016/S0022-5347(01)64284-8; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Gann PH, 1999, CANCER RES, V59, P1225; Geldof AA, 1997, UROLOGY, V49, P795, DOI 10.1016/S0090-4295(96)00576-6; Giovannucci E, 2002, EXP BIOL MED, V227, P852, DOI 10.1177/153537020222701003; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Goralczyk R., 2004, PHYTOCHEM HLTH DIS, P285; Gromadzinska J, 2000, Int J Occup Med Environ Health, V13, P233; Hein DW, 2002, ENVIRON MOL MUTAGEN, V40, P161, DOI 10.1002/em.10103; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X; HSING AW, 1990, J NATL CANCER I, V82, P941, DOI 10.1093/jnci/82.11.941; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Huynh H, 2001, J ENDOCRINOL, V171, P109, DOI 10.1677/joe.0.1710109; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; ISAACS JT, 1981, INVEST UROL, V19, P20; ISRAEL K, 1995, NUTR CANCER, V24, P161, DOI 10.1080/01635589509514404; KAISER R, 1972, ELEMENTARE TESTS BEU; Kaplan PJ, 1999, CANCER RES, V59, P2203; Klein EA, 2003, UROL ONCOL-SEMIN ORI, V21, P59, DOI 10.1016/S1078-1439(02)00301-0; Kucuk O, 2002, CANCER METAST REV, V21, P111, DOI 10.1023/A:1020809806121; Labrie F, 2001, FRONT NEUROENDOCRIN, V22, P185, DOI 10.1006/frne.2001.0216; Lein M, 2002, ONCOGENE, V21, P2089, DOI 10.1038/sj.onc.1205267; Lieberman R, 2002, CANCER METAST REV, V21, P297, DOI 10.1023/A:1021267128567; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; PARNES HL, 2004, J UROLOGY, V171, pS75; Parnes Howard L., 2004, Journal of Urology, V171, pS68, DOI 10.1097/01.ju.0000107220.64675.74; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; Putzi MJ, 2000, UROLOGY, V56, P828, DOI 10.1016/S0090-4295(00)00776-7; Shimada K, 2003, CARCINOGENESIS, V24, P1067, DOI 10.1093/carcin/bgg058; Smith PC, 2001, PROSTATE, V48, P47; VANKAPPEL A, 2000, THESIS U C BERNARD L; Vogt TM, 2002, AM J EPIDEMIOL, V155, P1023, DOI 10.1093/aje/155.11.1023; Wang XY, 1999, PROG LIPID RES, V38, P309, DOI 10.1016/S0163-7827(99)00008-9; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; White MF, 1998, RECENT PROG HORM RES, V53, P119; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P7408, DOI 10.1073/pnas.102014399; Zhao M, 1996, BRIT J CANCER, V73, P61, DOI 10.1038/bjc.1996.11	57	134	138	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1019	+		10.1096/fj.03-1116fje	http://dx.doi.org/10.1096/fj.03-1116fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084515				2022-12-25	WOS:000221108800004
J	Azpiazu, I; Gautam, N				Azpiazu, I; Gautam, N			A fluorescence resonance energy transfer-based sensor indicates that receptor access to a G protein is unrestricted in a living mammalian cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; SIGNAL-TRANSDUCTION; MEMBRANE MICRODOMAINS; MUSCARINIC RECEPTOR; ACTIVATION; MECHANISMS; COMPLEXES; CAVEOLAE; DYNAMICS	Fluorescence recovery after photobleaching of muscarinic receptors and G protein subunits tagged with cyan or yellow fluorescent protein showed that receptors and G proteins were mobile and not immobilized on the cell membrane. The cyan fluorescent protein-tagged Galpha and yellow fluorescent protein-tagged Gbeta subunits were used to develop sensors that coupled selectively with the M2 and M3 muscarinic receptors. In living Chinese hamster ovary cells, imaging showed that sensors emitted a fluorescence resonance energy transfer signal that was abrogated on receptor activation. When sequentially activated with highly expressed muscarinic receptors and endogenous receptors expressed at low levels, sensor molecules were sensitive to the sequence of activation and the receptor numbers. The results distinguish between models proposing that receptor and G protein types interact freely with each other on the cell membrane or that they function as mutually exclusive multimolecular complexes by providing direct support for the former model in these cells.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gautam, N (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054, St Louis, MO 63110 USA.	gautam@morpheus.wustl.edu			NIGMS NIH HHS [GM46963, R01 GM046963] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Azpiazu I, 2002, METHOD ENZYMOL, V344, P112; Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; Carroll RC, 1998, EMBO J, V17, P3036, DOI 10.1093/emboj/17.11.3036; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; George SE, 1997, J NEUROCHEM, V69, P1278; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Hur EM, 2002, CELL SIGNAL, V14, P397, DOI 10.1016/S0898-6568(01)00258-3; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534-5807(03)00060-1; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 2002, MOL PHARMACOL, V61, P473, DOI 10.1124/mol.61.3.473; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	29	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27709	27718		10.1074/jbc.M403712200	http://dx.doi.org/10.1074/jbc.M403712200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15078878	hybrid			2022-12-25	WOS:000222120400105
J	Boyd, AE; Dunlop, CS; Wong, L; Radic, Z; Taylor, P; Johnson, DA				Boyd, AE; Dunlop, CS; Wong, L; Radic, Z; Taylor, P; Johnson, DA			Nanosecond dynamics of acetylcholinesterase near the active center gorge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ACETYLCHOLINESTERASE; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; OMEGA-LOOP; BACK-DOOR; LIGAND-BINDING; SNAKE-VENOM; FASCICULIN; SITE; COMPLEX	To delineate the role of peptide backbone flexibility and rapid molecular motion in acetylcholinesterase catalysis and inhibitor association, we investigated the decay of fluorescence anisotropy at three sites of fluorescein conjugation to cysteine-substitution mutants of the enzyme. One cysteine was placed in a loop at the peripheral site near the rim of the active center gorge (H287C); a second was in a helical region outside of the active center gorge (T249C); a third was at the tip of a small, flexible Omega loop well separated from the gorge (A262C). Mutation and fluorophore conjugation did not appreciably alter catalytic or inhibitor binding parameters of the enzyme. The results show that each site examined was associated with a high degree of segmental motion; however, the A262C and H287C sites were significantly more flexible than the T249C site. Association of the active center inhibitor, tacrine, and the peripheral site peptide inhibitor, fasciculin, had no effect on the anisotropy decay of fluorophores at positions 249 and 262. Fasciculin, but not tacrine, on the other hand, dramatically altered the decay profile of the fluorophore at the 287 position, in a manner consistent with fasciculin reducing the segmental motion of the peptide chain in this local region. The results suggest that the motions of residues near the active center gorge and across from the Cys(69) - Cys(96) Omega loop are uncoupled and that ligand binding at the active center or the peripheral site does not influence acetylcholinesterase conformational dynamics globally, but induces primarily domain localized decreases in flexibility proximal to the bound ligand.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of California System; University of California San Diego; University of California System; University of California Riverside	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM18360, GM07752] Funding Source: Medline; PHS HHS [P42-E10337] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERMAN JD, 1971, P NATL ACAD SCI USA, V68, P395, DOI 10.1073/pnas.68.2.395; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; DELAHOZ D, 1986, LIFE SCI, V39, P195, DOI 10.1016/0024-3205(86)90530-8; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Faerman C, 1996, FEBS LETT, V386, P65, DOI 10.1016/0014-5793(96)00374-2; Gangal M, 1998, BIOCHEMISTRY-US, V37, P13728, DOI 10.1021/bi980560z; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; Glusker Jenny P., 1985, CRYSTAL STRUCTURE AN; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; KRONMAN C, 1994, J BIOL CHEM, V269, P27819; Kryger G, 2000, ACTA CRYSTALLOGR D, V56, P1385, DOI 10.1107/S0907444900010659; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; Marchot P, 1996, PROTEIN SCI, V5, P672; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; Radic Z, 1997, J BIOL CHEM, V272, P23265, DOI 10.1074/jbc.272.37.23265; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Ravelli RBG, 1998, ACTA CRYSTALLOGR D, V54, P1359, DOI 10.1107/S0907444998005277; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Shen TY, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.041902; Shi JX, 2002, J BIOL CHEM, V277, P43301, DOI 10.1074/jbc.M204391200; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; Shi JX, 2003, J BIOL CHEM, V278, P30905, DOI 10.1074/jbc.M303730200; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Steiner RF, 1991, TOPICS FLUORESCENCE, V2; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Tai K, 2001, BIOPHYS J, V81, P715, DOI 10.1016/S0006-3495(01)75736-0; Tara S, 1999, BIOPOLYMERS, V50, P35, DOI 10.1002/(SICI)1097-0282(199907)50:1<35::AID-BIP4>3.0.CO;2-6; Tara S, 1999, BIOPOLYMERS, V50, P347, DOI 10.1002/(SICI)1097-0282(19991005)50:4<347::AID-BIP1>3.0.CO;2-R; TAYLOR P, 1974, MOL PHARMACOL, V10, P78; Wlodek ST, 1997, J AM CHEM SOC, V119, P9513, DOI 10.1021/ja971226d; Wlodek ST, 2000, BIOPOLYMERS, V53, P265, DOI 10.1002/(SICI)1097-0282(200003)53:3<265::AID-BIP6>3.3.CO;2-E; Yguerabide J, 1972, Methods Enzymol, V26, P498; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	38	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26612	26618		10.1074/jbc.M401482200	http://dx.doi.org/10.1074/jbc.M401482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078872	hybrid			2022-12-25	WOS:000222003000087
J	Datta, G; Epand, RF; Epand, RM; Chaddha, M; Kirksey, MA; Garber, DW; Lund-Katz, S; Phillips, MC; Hama, S; Navab, M; Fogelman, AM; Palgunachari, MN; Segrest, JP; Anantharamaiah, GM				Datta, G; Epand, RF; Epand, RM; Chaddha, M; Kirksey, MA; Garber, DW; Lund-Katz, S; Phillips, MC; Hama, S; Navab, M; Fogelman, AM; Palgunachari, MN; Segrest, JP; Anantharamaiah, GM			Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; I MIMETIC PEPTIDE; CORONARY ATHEROSCLEROSIS; PLASMA-CHOLESTEROL; WATER-INTERFACE; ALPHA-HELICES; INHIBITS 3; APOLIPOPROTEIN; MICE; ANALOGS	The apolipoprotein A-I mimetic peptide 4F (Ac-DW-FKAFYDKVAEKFKEAF-NH2), with four Phe residues on the nonpolar face of the amphipathic alpha-helix, is strongly anti-inflammatory, whereas two 3F analogs (3F(3) and 3F(14)) are not. To understand how changes in helix nonpolar face structure affect function, two additional 3F analogs, Ac-DKLKAFYDKVFEWAKEAF-NH2 (3F-1) and Ac-DKWKAVYDKFAEAFKEFL-NH2 (3F-2), were designed using the same amino acid composition as 3F(3) and 3F(14). The aromatic residues in 3F-1 and 3F-2 are near the polar-nonpolar interface and at the center of the nonpolar face of the helix, respectively. Like 4F, but in contrast to 3F(3) and 3F(14), these peptides effectively inhibited lytic peptide-induced hemolysis, oxidized phospholipid-induced monocyte chemotaxis, and scavenged lipid hydroperoxides from low density lipoprotein. High pressure liquid chromatography retention times and monolayer exclusion pressures indicated that there is no direct correlation of peptide function with lipid affinity. Fluorescence studies suggested that, although the peptides bind phospholipids similarly, the Trp residue in 4F, 3F-1, and 3F-2 is less motionally restricted than in 3F(3) and 3F(14). Based on these results and molecular modeling studies, we propose that the arrangement of aromatic residues in class A amphipathic helical molecules regulates entry of reactive oxygen species into peptide-phospholipid complexes, thereby reducing the extent of monocyte chemotaxis, an important step in atherosclerosis.	Univ Alabama, Med Ctr, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem, Birmingham, AL 35294 USA; Univ Alabama, Dept Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Atherosclerosis Res Unit, Birmingham, AL 35294 USA; McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, UCLA Cardiol, Atherosclerosis Res Unit, Los Angeles, CA 90095 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Anantharamaiah, GM (corresponding author), Univ Alabama, Med Ctr, Dept Med, 1808 7th Ave S,DREB 640, Birmingham, AL 35294 USA.	Ananth@uab.edu	, Richard/R-2316-2019	, Richard/0000-0002-9602-9558; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL34343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; Anantharamaiah GM, 2001, CURR SCI INDIA, V81, P53; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; BLACKBURN WD, 1991, J LIPID RES, V32, P1911; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Burger Danielle, 2002, Autoimmunity Reviews, V1, P111, DOI 10.1016/S1568-9972(01)00018-0; Cantor RS, 2003, BIOCHEMISTRY-US, V42, P11891, DOI 10.1021/bi034534z; Cantor RS, 1997, BIOCHEMISTRY-US, V36, P2339, DOI 10.1021/bi9627323; Chattopadhyay A, 2003, CHEM PHYS LIPIDS, V122, P3, DOI 10.1016/S0009-3084(02)00174-3; Datta G, 2001, J LIPID RES, V42, P1096; Demchenko AP, 2002, LUMINESCENCE, V17, P19, DOI 10.1002/bio.671; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; Filipe P, 2002, BIOCHEMISTRY-US, V41, P11057, DOI 10.1021/bi026133+; Garber DW, 2003, ATHEROSCLEROSIS, V168, P229, DOI 10.1016/S0021-9150(03)00101-1; Garber DW, 2001, J LIPID RES, V42, P545; GARBER DW, 1992, ARTERIOSCLER THROMB, V12, P886, DOI 10.1161/01.ATV.12.8.886; GLOMSET JA, 1968, J LIPID RES, V9, P155; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HO C, 1992, BIOPHYS J, V63, P897, DOI 10.1016/S0006-3495(92)81671-5; Holvoet P, 1997, ARTERIOSCL THROM VAS, V17, P2376, DOI 10.1161/01.ATV.17.11.2376; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; KARLE IL, 1988, P NATL ACAD SCI USA, V85, P299, DOI 10.1073/pnas.85.2.299; Mishra VK, 1998, BIOCHEMISTRY-US, V37, P10313, DOI 10.1021/bi980042o; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Moosmann B, 2000, EUR J BIOCHEM, V267, P5687, DOI 10.1046/j.1432-1327.2000.01658.x; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2000, J LIPID RES, V41, P1495; Navab M, 2003, CIRCULATION, V108, P232; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; Neuzil J, 1998, BIOCHEMISTRY-US, V37, P9203, DOI 10.1021/bi9730745; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; PLUMP A, 1994, P NATL ACAD SCI USA, V94, P899; Reddy ST, 2002, ARTERIOSCL THROM VAS, V22, P1877, DOI 10.1161/01.ATV.0000035700.82829.2A; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; Shah PK, 2001, CIRCULATION, V103, P3047, DOI 10.1161/hc2501.092494; TYTLER EM, 1993, J BIOL CHEM, V268, P22112; Van Lenten BJ, 2002, CIRCULATION, V106, P1127, DOI 10.1161/01.CIR.0000030182.35880.3E; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Yamaguchi Y, 1998, ATHEROSCLEROSIS, V139, P323, DOI 10.1016/S0021-9150(98)00091-4	43	68	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26509	26517		10.1074/jbc.M314276200	http://dx.doi.org/10.1074/jbc.M314276200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075321	hybrid			2022-12-25	WOS:000222003000074
J	Sedelies, KA; Sayers, TJ; Edwards, KM; Chen, WS; Pellicci, DG; Godfrey, DI; Trapani, JA				Sedelies, KA; Sayers, TJ; Edwards, KM; Chen, WS; Pellicci, DG; Godfrey, DI; Trapani, JA			Discordant regulation of granzyme H and granzyme B expression in human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE ESTERASE GENE; CATHEPSIN-G GENE; CYTOTOXIC LYMPHOCYTES; CELL-DEATH; CASPASE ACTIVATION; CYTOSOLIC DELIVERY; TARGET-CELLS; T-CELLS; APOPTOSIS; PERFORIN	We analyzed the expression of granzyme H in human blood leukocytes, using a novel monoclonal antibody raised against recombinant granzyme H. 33-kDa granzyme H was easily detected in unfractionated peripheral blood mononuclear cells, due to its high constitutive expression in CD3(-)CD56(+) natural killer (NK) cells, whereas granzyme B was less abundant. The NK lymphoma cell lines, YT and Lopez, also expressed high granzyme H levels. Unstimulated CD4(+) and particularly CD8(+) T cells expressed far lower levels of granzyme H than NK cells, and various agents that classically induce T cell activation, proliferation, and enhanced granzyme B expression failed to induce granzyme H expression in T cells. Also, granzyme H was not detected in NK T cells, monocytes, or neutrophils. There was a good correlation between mRNA and protein expression in cells that synthesize both granzymes B and H, suggesting that gzmH gene transcription is regulated similarly to gzmB. Overall, our data indicate that although the gzmB and gzmH genes are tightly linked, expression of the proteins is quite discordant in T and NK cells. The finding that granzyme H is frequently more abundant than granzyme B in NK cells is consistent with a role for granzyme H in complementing the pro-apoptotic function of granzyme B in human NK cells.	Peter MacCallum Canc Ctr, Canc Immunol Lab, Melbourne 8006, Australia; NCI, Basic Res Program, SAIC Frederick Inc, NIH, Frederick, MD 21702 USA; Austin & Repatriat Med Ctr, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia; Monash Univ, Sch Med, Dept Pathol & Immunol, Melbourne, Vic 3181, Australia	Peter Maccallum Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Monash University	Trapani, JA (corresponding author), Peter MacCallum Canc Ctr, Canc Immunol Lab, Locked Bag 1,ABeckett St, Melbourne 8006, Australia.	joe.trapani@petermac.org	Sayers, Thomas J/G-4859-2015; Chen, Weisan/E-7828-2012; Pellicci, Daniel/AAX-8539-2020	Chen, Weisan/0000-0002-5221-9771; Pellicci, Daniel/0000-0001-5305-2398; Trapani, Joseph/0000-0003-0983-1532; Godfrey, Dale/0000-0002-3009-5472	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010012] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APOSTOLIDIS VA, 1995, MOL IMMUNOL, V32, P909, DOI 10.1016/0161-5890(95)00042-D; BAKER E, 1994, IMMUNOGENETICS, V40, P235, DOI 10.1007/BF00167085; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Browne KA, 1999, MOL CELL BIOL, V19, P8604; DAVIS JE, 2003, J IMMUNOL METHODS; Edwards HM, 1999, J BIOL CHEM, V274, P30468, DOI 10.1074/jbc.274.43.30468; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GEISBERG M, 1990, TISSUE ANTIGENS, V35, P229, DOI 10.1111/j.1399-0039.1990.tb01788.x; HADDAD P, 1991, INT IMMUNOL, V3, P57, DOI 10.1093/intimm/3.1.57; HANSON RD, 1990, J BIOL CHEM, V265, P1524; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hirst CE, 2001, MOL HUM REPROD, V7, P1133, DOI 10.1093/molehr/7.12.1133; HOHN PA, 1989, J BIOL CHEM, V264, P13412; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; KLEIN JL, 1990, TISSUE ANTIGENS, V35, P220, DOI 10.1111/j.1399-0039.1990.tb01787.x; Kothapalli R, 2003, INT J ONCOL, V22, P33; LIU CC, 1989, J EXP MED, V170, P2105, DOI 10.1084/jem.170.6.2105; Maclvor DM, 1999, BLOOD, V93, P963, DOI 10.1182/blood.V93.3.963.403k18_963_973; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Netto MVP, 2002, TRANSPLANT P, V34, P476, DOI 10.1016/S0041-1345(02)02601-5; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Sayers TJ, 2001, J IMMUNOL, V166, P765, DOI 10.4049/jimmunol.166.2.765; Smyth MJ, 1996, J LEUKOCYTE BIOL, V60, P555, DOI 10.1002/jlb.60.5.555; SMYTH MJ, 1990, J EXP MED, V171, P1269, DOI 10.1084/jem.171.4.1269; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; Smyth MJ, 1995, BIOCHEM BIOPH RES CO, V217, P675, DOI 10.1006/bbrc.1995.2827; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Sutton VR, 1997, J IMMUNOL, V158, P5783; Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1998, INT REV CYTOL, V182, P111, DOI 10.1016/S0074-7696(08)62169-5; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911	38	63	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26581	26587		10.1074/jbc.M312481200	http://dx.doi.org/10.1074/jbc.M312481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069086	hybrid			2022-12-25	WOS:000222003000083
J	Tonini, T; Bagella, L; D'Andrilli, G; Claudio, PP; Giordano, A				Tonini, T; Bagella, L; D'Andrilli, G; Claudio, PP; Giordano, A			Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A	ONCOGENE			English	Article						polycomb; Ezh2; pRb2/p130	POLYCOMB-GROUP PROTEINS; RETINOBLASTOMA FAMILY PROTEINS; CDK2 KINASE; GROUP GENES; EXPRESSION; BMI-1; P107; PROLIFERATION; CLONING; DIFFERENTIATION	The polycomb group (PcG) proteins are known to be involved in maintaining the silenced state of several developmentally regulated genes. Enhancer of zeste homolog 2 (Ezh2), a member of this large protein family, has also been shown to be deregulated in different tumor types and its role, both as a potential primary effector and as a mediator of tumorigenesis, has become a subject of increased interest. We observed that Ezh2 binds to pRb2/p130, a member of the retinoblastoma family; as such, we were led to consider the possible ability of Ezh2 to modulate cell cycle progression. Both Ezh2 and pRb2/p130 repress gene expression by recruiting histone deacetylase (HDAC1), which decreases DNA accessibility for activating transcription factors. Additionally, we observed that Ezh2 interacts with the C-terminal region of pRb2/p130, essential for interaction with HDAC1. We show that Ezh2 is able to reverse pRb2/p130-HDAC1-mediated repression of the cyclin A promoter. This indicates a functional role of this complex in regulating cyclin A expression, known to be crucial in mediating cell cycle advancement. We also detected a significant decrease in the retention of HDAC1 activity associated with pRb2/p130 when Ezh2 was overexpressed. Finally, electromobility shift assays ( EMSA) demonstrated that overexpression of Ezh2 caused the abrogation of the pRb2/p130-HDAC1 complex on the cyclin A promoter. These data, taken together, suggest that Ezh2 competes with HDAC1 in binding to pRb2/p130, disrupting their occupancy on the cyclin A promoter. In this study, we propose a new mechanism for the functional inactivation of pRb2/p130 that ultimately contributes to cell cycle progression and malignant transformation.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA; Univ Siena, Policlin La Scotte, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Dept Sci Odontostomatol & Maxillo Facciali, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Bio Life Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010	Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X; BAGELLA, Luigi/0000-0003-2815-037X				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; Galderisi U, 2001, MOL CELL NEUROSCI, V17, P415, DOI 10.1006/mcne.2000.0949; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAYOL X, 1993, ONCOGENE, V8, P2561; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; Pupa SM, 1999, ONCOGENE, V18, P651, DOI 10.1038/sj.onc.1202363; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; Raschella G, 2001, MED PEDIATR ONCOL, V36, P104, DOI 10.1002/1096-911X(20010101)36:1<104::AID-MPO1024>3.0.CO;2-9; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Sanseverino F, 2003, CANCER BIOL THER, V2, P636; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Sellers WR, 2002, CANCER CELL, V2, P349, DOI 10.1016/S1535-6108(02)00187-3; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Stiegler P, 1998, CANCER RES, V58, P5049; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Tonini T, 2002, J CELL PHYSIOL, V192, P138, DOI 10.1002/jcp.10117; TURNER BM, 1991, J CELL SCI, V99, P13; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x	56	57	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4930	4937		10.1038/sj.onc.1207608	http://dx.doi.org/10.1038/sj.onc.1207608			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077161				2022-12-25	WOS:000222104200014
J	Giannetti, AM; Bjorkman, PJ				Giannetti, AM; Bjorkman, PJ			HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOCHROMATOSIS PROTEIN HFE; MEDIATED IRON UPTAKE; HEREDITARY HEMOCHROMATOSIS; CRYSTAL-STRUCTURE; CYTOPLASMIC DOMAIN; BINDING-SITE; HELA-CELLS; WILD-TYPE; ENDOCYTOSIS; EXPRESSION	Transferrin receptor (TfR) is a dimeric cell surface protein that binds both the serum iron transport protein transferrin (Fe-Tf) and HFE, the protein mutated in patients with the iron overload disorder hereditary hemochromatosis. HFE and Fe-Tf can bind simultaneously to TfR to form a ternary complex, but HFE binding to TfR lowers the apparent affinity of the Fe-Tf/TfR interaction. This apparent affinity reduction could result from direct competition between HFE and Fe-Tf for their overlapping binding sites on each TfR polypeptide chain, from negative cooperativity, or from a combination of both. To explore the mechanism of the affinity reduction, we constructed a heterodimeric TfR that contains mutations such that one TfR chain binds only HFE and the other binds only Fe-Tf. Binding studies using a heterodimeric form of soluble TfR demonstrate that TfR does not exhibit cooperativity in heterotropic ligand binding, suggesting that some or all of the effects of HFE on iron homeostasis result from competition with Fe-Tf for TfR binding. Experiments using transfected cell lines demonstrate a physiological role for this competition in altering HFE trafficking patterns.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Grad Opt Biochem & Mol Biophys, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Bjorkman, PJ (corresponding author), CALTECH, Div Biol, 1200 E Calif Blvd,MC 114-96, Pasadena, CA 91125 USA.	bjorkman@caltech.edu			NIDDK NIH HHS [1R01 DK60770] Funding Source: Medline; NIGMS NIH HHS [5T32-GM-7616] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007616] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; Cullen LM, 1999, ANNU REV MED, V50, P87; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; ENNS CA, 1981, J BIOL CHEM, V256, P9820; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Feeney GP, 2001, BBA-MOL CELL RES, V1538, P242, DOI 10.1016/S0167-4889(01)00075-1; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Giannetti AM, 2003, PLOS BIOL, V1, P341, DOI 10.1371/journal.pbio.0000051; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Henry J.B, 1996, CLIN DIAGNOSIS MANAG, V9th; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lebron JA, 1999, J MOL BIOL, V294, P239, DOI 10.1006/jmbi.1999.3252; Lebron JA, 1999, J MOL BIOL, V289, P1109, DOI 10.1006/jmbi.1999.2842; LEIBMAN A, 1977, BIOCHEMISTRY-US, V16, P1268, DOI 10.1021/bi00626a004; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Montosi G, 2000, BLOOD, V96, P1125, DOI 10.1182/blood.V96.3.1125.015k19_1125_1129; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Roy CN, 2000, FEBS LETT, V484, P271, DOI 10.1016/S0014-5793(00)02173-6; Salter-Cid L, 1999, P NATL ACAD SCI USA, V96, P5434, DOI 10.1073/pnas.96.10.5434; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SHIMOOKA T, 1986, J CELL PHYSIOL, V126, P341, DOI 10.1002/jcp.1041260304; SIPE DM, 1991, J BIOL CHEM, V266, P8002; Townsend A, 2002, LANCET, V359, P786, DOI 10.1016/S0140-6736(02)07885-6; Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Waheed A, 2002, P NATL ACAD SCI USA, V99, P3117, DOI 10.1073/pnas.042701499; West AP, 2001, J MOL BIOL, V313, P385, DOI 10.1006/jmbi.2001.5048	50	108	109	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25866	25875		10.1074/jbc.M401467200	http://dx.doi.org/10.1074/jbc.M401467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15056661	Green Submitted, hybrid, Green Accepted			2022-12-25	WOS:000221827900118
J	Huang, P; Steplock, D; Weinman, EJ; Hall, RA; Ding, Z; Li, JG; Wang, YL; Liu-Chen, LY				Huang, P; Steplock, D; Weinman, EJ; Hall, RA; Ding, Z; Li, JG; Wang, YL; Liu-Chen, LY			kappa opioid receptor interacts with Na+/H+-exchanger regulatory factor-1/ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na+/H+ exchange independent of G(i)/G(o) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; ISOLATED RAT-HEART; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; PDZ DOMAINS; BETA(2)-ADRENERGIC RECEPTOR; PARATHYROID-HORMONE; PERTUSSIS TOXIN; SIGNAL COMPLEX; H+ EXCHANGER	We previously showed that Na+/H+-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) co-immunoprecipitated with the human kappa opioid receptor (hKOR) and that its overexpression blocked the kappa agonist U50,488H-induced hKOR down-regulation by enhancing recycling. Here, we show that glutathione S-transferase (GST)-hKOR C-tail interacted with purified NHERF-1/EBP50, whereas GST or GST-C-tails of mu or delta opioid receptors did not. GST-hKOR C-tail, but not GST, bound HA-NHERF-1/EBP50 transfected into Chinese hamster ovary cells and endogenous NHERF-1/EBP50 in opossum kidney proximal tubule epithelial cells (OK cells). The PDZ domain I, but not II, of NHERF-1/EBP50 was involved in the interaction. Association of NHERF-1/EBP50 with hKOR C-tail enhanced oligomerization of NHERF-1/EBP50. NHERF-1/EBP50 was previously shown to regulate Na+/H+-exchanger 3 (NHE3) activities in OK cells. We found stimulation of OK cells with U50,488H significantly enhanced Na+/H+ exchange, which was blocked by naloxone but not by pertussis toxin pretreatment, indicating it is mediated by KORs but independent of G(i)/G(o) proteins. In OKH cells, a subclone of OK cells expressing a much lower level of NHERF-1/EBP50, U50,488H had no effect on Na+/H+ exchange, although it enhanced p44/42 mitogen-activated protein kinase phosphorylation via G(i)/G(o) proteins similar to that in OK cells. Stable transfection of NHERF-1/EBP50 into OKH cells restored the stimulatory effect of U50,488H upon Na+/H+ exchange. Thus, NHERF-1/EBP50 binds directly to KOR, and this association plays an important role in accelerating Na+/H+ exchange. We hypothesize that binding of the KOR to NHERF-1/EBP50 facilitates oligomerization of NHERF-1/EBP50, leading to stimulation of NHE3. This study provides the first direct evidence that a G protein-coupled receptor through association with NHERF-1/EBP-50 stimulates NHE3.	Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Dept Vet Affairs Med Ctr, Med Serv, Baltimore, MD 21201 USA; Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr, Atlanta, GA 30322 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Emory University	Liu-Chen, LY (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@astro.temple.edu		Hall, Randy/0000-0002-8318-8728	NIDA NIH HHS [P30 DA13429, DA11263, DA17302, DA04745] Funding Source: Medline; NIDDK NIH HHS [DK55881] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA013429, R29DA004745, R01DA004745, R01DA011263] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Bian JS, 2000, J MOL CELL CARDIOL, V32, P1415, DOI 10.1006/jmcc.2000.1175; Bian JS, 1998, J MOL CELL CARDIOL, V30, P2103, DOI 10.1006/jmcc.1998.0774; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; EINARSON MB, 2002, PROTEIN PROTEIN INTE, P37; FLIEGEL L, 1991, FEBS LETT, V279, P25, DOI 10.1016/0014-5793(91)80241-T; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hampson RE, 2000, J NEUROPHYSIOL, V84, P2356, DOI 10.1152/jn.2000.84.5.2356; Hatzoglou A, 1996, J CELL BIOCHEM, V63, P410; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; LAI HWL, 1995, FEBS LETT, V360, P97, DOI 10.1016/0014-5793(95)00088-Q; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lee JWM, 1998, J NEUROCHEM, V70, P2203; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; LI SX, 1993, BIOCHEM J, V295, P629, DOI 10.1042/bj2950629; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Mahon MJ, 2003, MOL ENDOCRINOL, V17, P2355, DOI 10.1210/me.2003-0043; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schwartz T.W., 2002, TXB RECEPTOR PHARM, P81; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 2001, KIDNEY INT, V60, P450, DOI 10.1046/j.1523-1755.2001.060002450.x; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; XIE GX, 1994, P NATL ACAD SCI USA, V91, P3779, DOI 10.1073/pnas.91.9.3779; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676; ZHU JM, 1995, LIFE SCI, V56, pPL201, DOI 10.1016/0024-3205(94)00507-O	53	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25002	25009		10.1074/jbc.M313366200	http://dx.doi.org/10.1074/jbc.M313366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070904	hybrid			2022-12-25	WOS:000221827900014
J	Mann, HH; Ozbek, S; Engel, J; Paulsson, M; Wagener, R				Mann, HH; Ozbek, S; Engel, J; Paulsson, M; Wagener, R			Interactions between the cartilage oligomeric matrix protein and matrilins - Implications for matrix assembly and the pathogenesis of chondrodysplasias	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; HUMAN ARTICULAR-CARTILAGE; TISSUE DISTRIBUTION; MOLECULAR-STRUCTURE; COLLAGEN-II; PSEUDOACHONDROPLASIA; MUTATION; DOMAIN; BINDING; CALCIUM	The cartilage oligomeric matrix protein (COMP) and matrilins are abundant non-collagenous proteins in the cartilage extracellular matrix. In the presence of calcium, COMP and matrilin-1 elute together in the gel filtration of cartilage extracts and can be co-immunoprecipitated. In a screen for ligands of matrilin-1, -3, and -4 using an ELISA-style binding assay, COMP was identified as a prominent binding partner for all three, indicating a conservation of the COMP interaction among matrilins. The interaction of COMP and matrilin-4 is saturable, and an apparent K-D of 1 nM was determined. However, only the full-length COMP and the full-length matrilin-4 proteins showed a strong interaction, indicating that the oligomeric structures markedly increase the affinity. Mutations in COMP or matrilin-3 cause related forms of human chondrodysplasia, and the COMP mutation D469Delta, which is found in patients with pseudoachondroplasia, has been shown to cause a reduced calcium binding. Despite this, the mutation causes only a slight decrease in matrilin-4 binding. This indicates that impaired binding of COMP to matrilins does not cause the pseudoachondroplasia phenotype but rather that matrilins may be co-retained in the rough endoplasmatic reticulum where COMP accumulates in the chondrocytes of patients.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Basel, Bioctr, Div Biophys Chem, CH-4056 Basel, Switzerland	University of Cologne; University of Cologne; University of Basel	Wagener, R (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	raimund.wagener@uni-koeln.de	Özbek, Suat/D-3701-2014	Ozbek, Suat/0000-0003-2569-3942				Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; Dinser R, 2002, J CLIN INVEST, V110, P505, DOI 10.1172/JCI200214386; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; Frank S, 2002, J BIOL CHEM, V277, P19071, DOI 10.1074/jbc.M202146200; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Pullig O, 2002, OSTEOARTHR CARTILAGE, V10, P253, DOI 10.1053/joca.2001.0508; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; Spitznagel L, 2004, BIOCHEM J, V377, P479, DOI 10.1042/BJ20031179; Stefansson SE, 2003, AM J HUM GENET, V72, P1448, DOI 10.1086/375556; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; THUR J, 2000, THESIS U COLOGNE COL; Vilim V, 2003, CLIN CHIM ACTA, V328, P59, DOI 10.1016/S0009-8981(02)00375-3; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307	28	130	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25294	25298		10.1074/jbc.M403778200	http://dx.doi.org/10.1074/jbc.M403778200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075323	hybrid			2022-12-25	WOS:000221827900048
J	Meunier-Jamin, C; Kapp, U; Leonard, GA; McSweeney, S				Meunier-Jamin, C; Kapp, U; Leonard, GA; McSweeney, S			The structure of the organic hydroperoxide resistance protein from Deinococcus radiodurans - Do conformational changes facilitate recycling of the redox disulfide?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCULOSIS ALKYLHYDROPEROXIDASE AHPD; CRYSTAL-STRUCTURE; MAMMALIAN PEROXIREDOXIN; IONIZING-RADIATION; GENOME; IDENTIFICATION; TRYPAREDOXINS; PEROXIDASE; MECHANISM; SURVIVAL	The three-dimensional structure of the organic hydroperoxide resistance protein (OHRP) from Deinococcus radiodurans as determined using single crystal x-ray diffraction techniques is reported. Comparison of the structure with that obtained for OHRP from Pseudomonas aeruginosa reveals that the polypeptide chain of OHRPs can adopt two significantly different conformations ("in" and "out") in the region of the active site disulfide moiety. It is postulated that the closed configuration is consistent with efficient catalysis of the reduction of organic hydroperoxides, whereas the open form is required for enzyme recycling. Comparison of the structures of OHRP and that of the osmotically induced protein C ( OsmC) from Mycoplasma pneumoniae shows that OHRPs and OsmCs are structurally homologous, perhaps indicating related functions for the two families of proteins.	European Synchrotron Radiat Facil, Macromol Crystallog Grp, F-38043 Grenoble, France	European Synchrotron Radiation Facility (ESRF)	McSweeney, S (corresponding author), European Synchrotron Radiat Facil, Macromol Crystallog Grp, BP 220, F-38043 Grenoble, France.	seanmcs@esrf.fr	Leonard, Gordon/D-2160-2019	Leonard, Gordon/0000-0001-5030-0122				Alphey MS, 2003, J BIOL CHEM, V278, P25919, DOI 10.1074/jbc.M301526200; Atichartpongkul S, 2001, MICROBIOL-SGM, V147, P1775, DOI 10.1099/00221287-147-7-1775; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; Berges J, 2000, NUKLEONIKA, V45, P23; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Burmeister WP, 2000, ACTA CRYSTALLOGR D, V56, P328, DOI 10.1107/S0907444999016261; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Choi In-Geol, 2003, Journal of Structural and Functional Genomics, V4, P31, DOI 10.1023/A:1024625122089; Conter A, 2001, RES MICROBIOL, V152, P17, DOI 10.1016/S0923-2508(00)01164-5; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P489, DOI 10.1016/S0968-0004(02)02191-6; Dauter Z, 2002, ACTA CRYSTALLOGR D, V58, P494, DOI 10.1107/S090744490200118X; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hofmann B, 2001, BIOL CHEM, V382, P459, DOI 10.1515/BC.2001.056; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karlin S, 2001, P NATL ACAD SCI USA, V98, P5240, DOI 10.1073/pnas.081077598; Koshkin A, 2003, J BIOL CHEM, V278, P29502, DOI 10.1074/jbc.M303747200; Lesniak J, 2003, PROTEIN SCI, V12, P2838, DOI 10.1110/ps.03375603; Lesniak J, 2002, EMBO J, V21, P6649, DOI 10.1093/emboj/cdf670; Levin-Zaidman S, 2003, SCIENCE, V299, P254, DOI 10.1126/science.1077865; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; Meunier-Jamin C, 2004, ACTA CRYSTALLOGR D, V60, P920, DOI 10.1107/S0907444904003993; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; Mongkolsuk S, 1998, J BACTERIOL, V180, P2636, DOI 10.1128/JB.180.10.2636-2643.1998; Montemartini M, 1999, EUR J BIOCHEM, V264, P516, DOI 10.1046/j.1432-1327.1999.00656.x; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Nunn CM, 2002, J BIOL CHEM, V277, P20033, DOI 10.1074/jbc.M200864200; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Renato J, 2003, J BIOL CHEM, V278, P11570, DOI 10.1074/jbc.M300252200; SCHRODERLEIROS HK, 2001, ACTA CRYSTALLOGR D, V57, P488; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Sheldrick GM, 1986, SHELXS 86 PROGRAM CR; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Weik M, 2002, J SYNCHROTRON RADIAT, V9, P342, DOI 10.1107/S0909049502014589; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	47	30	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25830	25837		10.1074/jbc.M312983200	http://dx.doi.org/10.1074/jbc.M312983200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15054099	hybrid			2022-12-25	WOS:000221827900114
J	Wajih, N; Sane, DC; Hutson, SM; Wallin, R				Wajih, N; Sane, DC; Hutson, SM; Wallin, R			The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system - Characterization of the system in normal and warfarin-resistant rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; 2,3-EPOXIDE REDUCTASE; SECRETORY PATHWAY; CALCIUM-BINDING; MOLECULAR-BASIS; EF-HAND; CALCIFICATION; LIVER; REQUIREMENT; METABOLISM	The vitamin K-dependent gamma-carboxylation system is responsible for post-translational modification of vitamin K-dependent proteins, converting them to Gla-containing proteins. The system consists of integral membrane proteins located in the endoplasmic reticulum membrane and includes the gamma-carboxylase and the warfarin-sensitive enzyme vitamin K-1 2,3-epoxide reductase (VKOR), which provides gamma-carboxylase with reduced vitamin K-1 cofactor. In this work, an in vitro gamma-carboxylation system was designed and used to understand how VKOR and gamma-carboxylase work together as a system and to identify factors that can regulate the activity of the system. Results are presented that demonstrate that the endoplasmic reticulum chaperone protein calumenin is associated with gamma-carboxylase and inhibits its activity. Silencing of the calumenin gene with siRNA resulted in a 5-fold increase in gamma-carboxylase activity. The results provide the first identification of a protein that can regulate the activity of the gamma-carboxylation system. The propeptides of vitamin K-dependent proteins stimulate gamma-carboxylase activity. Here we show that the factor X and prothrombin propeptides do not increase reduced vitamin K-1 cofactor production by VKOR in the system where VKOR is the rate-limiting step for gamma-carboxylation (Wallin, R., Sane, D. C., and Hutson, S. M. (2002) Thromb. Res. 108, 221-226). These findings put calumenin in a central position concerning regulation of gamma-carboxylation of vitamin K-dependent proteins. Reduced vitamin K-1 cofactor transfer between VKOR and gamma-carboxylase is shown to be significantly impaired in the in vitro gamma-carboxylation system prepared from warfarin-resistant rats. Furthermore, the sequence of the 18-kDa subunit 1 of the VKOR enzyme complex ( Rost, S., Fregin, A., Ivaskeviclus, V., Conzelmann, E., Hortnagel, K., Pelz, H-J., Lappegard K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., Muller, C. R., Storm, T. M., and Oldennburg, J. (2004) Nature 427, 537-541) was found to be identical in the two rat strains. This finding supports the notion that different forms of genetic warfarin resistance exist.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Wallin, R (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rwallin@wfubmc.edu			NHLBI NIH HHS [HL 069331, HL 60082] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069331, R01HL060082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cain D, 1998, THROMB HAEMOSTASIS, V80, P128, DOI 10.1055/s-0037-1615151; CAIN D, 1998, J BIOL CHEM, V273, P4982; Demer LL, 2003, ARTERIOSCL THROM VAS, V23, P1739, DOI 10.1161/01.ATV.0000093547.63630.0F; Funakoshi H, 2002, J NEUROSCI RES, V68, P150, DOI 10.1002/jnr.10211; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1990, BLOOD, V75, P1753; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HERMODSON MA, 1969, AM J PHYSIOL, V217, P1316, DOI 10.1152/ajplegacy.1969.217.5.1316; Honore B, 2000, FEBS LETT, V466, P11, DOI 10.1016/S0014-5793(99)01780-9; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Markussen MDK, 2003, PEST MANAG SCI, V59, P913, DOI 10.1002/ps.703; MISENHEIMER TM, 1990, BIOCHEM PHARMACOL, V40, P2079, DOI 10.1016/0006-2952(90)90238-G; Mousallem M, 2001, THROMB HAEMOSTASIS, V86, P1334, DOI 10.1055/s-0037-1616072; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SADOWSKI JA, 1976, J BIOL CHEM, V251, P2770; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Suttie J. W., 1978, Handbook of lipid research. Volume 2. The fat-soluble vitamins, P211; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; Sweatt A, 2003, J THROMB HAEMOST, V1, P178, DOI 10.1046/j.1538-7836.2003.00023.x; THJISSEN HH, 1989, BIOCHEM PHARMACOL, V38, P1115; Tie J, 2000, BLOOD, V96, P973, DOI 10.1182/blood.V96.3.973.015k55_973_978; Tishler M, 1940, J AM CHEM SOC, V62, P2866, DOI 10.1021/ja01867a066; Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343; VERMEER C, 1986, HAEMOSTASIS, V16, P239; VERMEER C, 1988, BIOCHEM PHARMACOL, V37, P2872; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Vorum H, 1998, BBA-PROTEIN STRUCT M, V1386, P121, DOI 10.1016/S0167-4838(98)00089-2; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; Wallin R, 2002, THROMB RES, V108, P221, DOI 10.1016/S0049-3848(03)00060-4; WALLIN R, 1990, BIOCHEM J, V272, P473, DOI 10.1042/bj2720473; Wallin R, 1997, METHOD ENZYMOL, V282, P395; Wallin R, 2001, FASEB J, V15, P2542, DOI 10.1096/fj.01-0337fje; Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs; WALLIN R, 1987, BIOCHEM J, V241, P389, DOI 10.1042/bj2410389; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	42	108	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25276	25283		10.1074/jbc.M401645200	http://dx.doi.org/10.1074/jbc.M401645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075329	Green Submitted, hybrid			2022-12-25	WOS:000221827900046
J	Matamoros, T; Franco, S; Vazquez-Alvarez, BM; Mas, A; Martinez, MA; Menendez-Arias, L				Matamoros, T; Franco, S; Vazquez-Alvarez, BM; Mas, A; Martinez, MA; Menendez-Arias, L			Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain - Effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DRUG-RESISTANCE; DEOXYNUCLEOSIDE TRIPHOSPHATE; ANTIRETROVIRAL THERAPY; ZIDOVUDINE RESISTANCE; CROSS-RESISTANCE; AZT RESISTANCE; RT INHIBITORS; AMINO-ACIDS; UNBLOCKING	Human immunodeficiency virus type 1 isolates having dipeptide insertions in the fingers subdomain of the reverse transcriptase (RT) show high level resistance to 3'-azido-3'-deoxythymidine (AZT) and other nucleoside analogues. Insertions are usually associated with thymidine analogue resistance mutations, such as T215Y. The resistance phenotype correlates with increased ATP-dependent phosphorolytic activity, which facilitates removal of thymidine analogues from inhibitor-terminated primers. In this report, we show that substituting Thr, Ser, or Asn for Tyr-215 in a multidrug-resistant RT, bearing a Ser-Ser insertion between codons 69 and 70, leads to AZT and stavudine resensitization through the loss of the ATP-mediated removal activity. The mutation D67N, which is rarely found in insertion-containing strains, had no effect on excision and a minor influence on resistance. Substituting Tyr-215 had a larger effect than deleting the dipeptide insertion. The presence of both the insertion and mutation T215Y in the wild-type BH10 RT conferred significant ATP-mediated removal activity and moderate resistance to AZT. However, resistance levels and unblocking activities were lower than those observed with the multidrug-resistant enzyme. Removal reactions can be inhibited by the next complementary dNTP. Both Tyr-215 and the dipeptide insertion affect RT-DNA.DNA-dNTP ternary complex formation, an effect that was not detected in the presence of foscarnet. Based on crystal structures of binary and ternary complexes of HIV-1 RT, we propose that Tyr-215 exerts its action by facilitating a proper orientation of the pyrophosphate donor molecule, whereas the effects on dNTP binding are indirect and could be related to significant conformational changes occurring during polymerization.	Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Hosp Badalona Germans Trias & Pujol, Fundacio irsiCaixa, Lab Retrovirol, Barcelona 08916, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa	Menendez-Arias, L (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Franco, Sandra/E-6114-2016; Menendez Arias, Luis/G-2436-2016; Matamoros, Tania/F-2580-2016; Martinez, Miguel Angel/K-6435-2014; Franco, Sandra/S-6843-2019; Arias, Luis Menendez/N-7447-2016; Mas, Antonio/F-2505-2011	Franco, Sandra/0000-0003-4126-2202; Matamoros, Tania/0000-0001-9268-0696; Martinez, Miguel Angel/0000-0002-6681-4950; Franco, Sandra/0000-0003-4126-2202; Arias, Luis Menendez/0000-0002-1251-6640; Mas, Antonio/0000-0003-2563-570X				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Balotta C, 2000, J ACQ IMMUN DEF SYND, V24, P232; Boyer PL, 2002, J VIROL, V76, P9143, DOI 10.1128/JVI.76.18.9143-9151.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Briones C, 2000, VIRUS RES, V66, P13, DOI 10.1016/S0168-1702(99)00120-3; Cases-Gonzalez CE, 2000, J BIOL CHEM, V275, P19759, DOI 10.1074/jbc.M910361199; Chamberlain PP, 2002, J VIROL, V76, P10015, DOI 10.1128/JVI.76.19.10015-10019.2002; de Ronde A, 2001, J VIROL, V75, P595, DOI 10.1128/JVI.75.2.595-602.2001; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Garcia-Lerma JG, 2001, P NATL ACAD SCI USA, V98, P13907, DOI 10.1073/pnas.241300698; Goudsmit J, 1997, J VIROL, V71, P4479, DOI 10.1128/JVI.71.6.4479-4484.1997; Gutierrez-Rivas M, 1999, J MOL BIOL, V290, P615, DOI 10.1006/jmbi.1999.2880; Harrigan PR, 2002, ANTIMICROB AGENTS CH, V46, P1067, DOI 10.1128/AAC.46.4.1067-1072.2002; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996; Izopet J, 1999, J MED VIROL, V59, P507, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt;507::AID-JMV14&gt;3.0.CO;2-C; Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A; KELLAM P, 1994, ANTIMICROB AGENTS CH, V38, P23, DOI 10.1128/AAC.38.1.23; LARDER BA, 1994, J GEN VIROL, V75, P951, DOI 10.1099/0022-1317-75-5-951; Larder BA, 1999, ANTIMICROB AGENTS CH, V43, P1961, DOI 10.1128/AAC.43.8.1961; Lennerstrand J, 2001, ANTIMICROB AGENTS CH, V45, P2144, DOI 10.1128/AAC.45.7.2144-2146.2001; Lukashov VV, 2001, AIDS RES HUM RETROV, V17, P807, DOI 10.1089/088922201750252007; Marchand B, 2003, J BIOL CHEM, V278, P35362, DOI 10.1074/jbc.M304262200; Margot NA, 2002, AIDS, V16, P1227, DOI 10.1097/00002030-200206140-00004; MartinHernandez AM, 1996, EMBO J, V15, P4434, DOI 10.1002/j.1460-2075.1996.tb00816.x; MartinHernandez AM, 1997, NUCLEIC ACIDS RES, V25, P1383, DOI 10.1093/nar/25.7.1383; Mas A, 2002, J MOL BIOL, V323, P181, DOI 10.1016/S0022-2836(02)00911-7; Mas A, 2000, EMBO J, V19, P5752, DOI 10.1093/emboj/19.21.5752; Masquelier B, 2001, ANTIMICROB AGENTS CH, V45, P1836, DOI 10.1128/AAC.45.6.1836-1842.2001; Menendez-Arias L, 2002, TRENDS PHARMACOL SCI, V23, P381, DOI 10.1016/S0165-6147(02)02054-0; Meyer PR, 2003, J VIROL, V77, P3871, DOI 10.1128/JVI.77.6.3871-3877.2003; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2003, J VIROL, V77, P6127, DOI 10.1128/JVI.77.11.6127-6137.2003; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Naeger LK, 2001, ANTIVIR THER, V6, P115; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; Quinones-Mateu ME, 2002, J VIROL, V76, P10546, DOI 10.1128/JVI.76.20.10546-10552.2002; Ray AS, 2003, BIOCHEMISTRY-US, V42, P8831, DOI 10.1021/bi034435l; Ren JS, 1998, P NATL ACAD SCI USA, V95, P9518, DOI 10.1073/pnas.95.16.9518; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Schneider V, 2004, CLIN MICROBIOL INFEC, V10, P127, DOI 10.1111/j.1198-743x.2003.00864.x; Selmi B, 2003, ANTIVIR THER, V8, P143; Sharma B, 2002, BIOCHEMISTRY-US, V41, P15685, DOI 10.1021/bi026311z; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626; Tamalet C, 1998, AIDS, V12, pF161, DOI 10.1097/00002030-199814000-00003; Telesnitsky A., 1997, P121; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z; Van Vaerenbergh K, 2000, ANTIMICROB AGENTS CH, V44, P2109, DOI 10.1128/AAC.44.8.2109-2117.2000; Whitcomb JM, 2003, J INFECT DIS, V188, P992, DOI 10.1086/378281; White KL, 2004, ANTIMICROB AGENTS CH, V48, P992, DOI 10.1128/AAC.48.3.992-1003.2004; Winters MA, 2000, J VIROL, V74, P10707, DOI 10.1128/JVI.74.22.10707-10713.2000; Winters MA, 1997, ANTIMICROB AGENTS CH, V41, P757, DOI 10.1128/AAC.41.4.757; Winters MA, 1998, J CLIN INVEST, V102, P1769, DOI 10.1172/JCI4948; Yerly S, 1998, J VIROL, V72, P3520, DOI 10.1128/JVI.72.5.3520-3523.1998	61	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24569	24577		10.1074/jbc.M312658200	http://dx.doi.org/10.1074/jbc.M312658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047690				2022-12-25	WOS:000221702500086
J	Hasenjager, A; Gillissen, B; Muller, A; Normand, G; Hemmati, PG; Schuler, M; Dorken, B; Daniel, PT				Hasenjager, A; Gillissen, B; Muller, A; Normand, G; Hemmati, PG; Schuler, M; Dorken, B; Daniel, PT			Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-x(L) in a strictly caspase-3-dependent manner in human carcinoma cells	ONCOGENE			English	Article						Smac; apoptosis; Bax; Bcl-x(L); caspase-3; caspase-9	DRUG-INDUCED APOPTOSIS; IDENTIFIES PATIENTS; DNA FRAGMENTATION; SERINE-PROTEASE; BAX; CASPASE-3; OVEREXPRESSION; ACTIVATION; EXPRESSION; DEATH	The mitochondrial apoptosis pathway mediates cell death through the release of various pro-apoptotic factors including cytochrome c and Smac, the second mitochondrial activator of caspases, into the cytosol. Smac was shown previously to inhibit IAP proteins and to facilitate initiation of the caspase cascade upon cytochrome c release. To investigate Smac function during apoptosis and to explore Smac as an experimental cancer therapeutic, we constructed an expression system based on a single adenoviral vector containing Smac under control of the Tet-off system supplied in cis. Conditional expression of Smac induced apoptosis in human HCT116 and DU145 carcinoma cells regardless of the loss of Bax or overexpression of BCl-X-L. Nevertheless, apoptosis induced by Smac was associated with cytochrome c release and breakdown of the mitochondrial membrane potential. This indicates that Smac acts independently of Bax and BCl-X-L during initiation of apoptosis and triggers a positive feedback loop that results in Bax/BCl-X-L-independent activation of mitochondria. In caspase-proficient cells, Smac-induced apoptosis could be inhibited partially by cell-permeable LEHD (caspase-9 inhibitor) and DEVD (caspase-3 inhibitor) peptides. Furthermore, loss of caspase-3 expression in MCF-7 cells carrying a caspase-3 null mutation completely abrogated the sensitivity for Smac-induced apoptotic or nonapoptotic, necrosis-like cell death, while re-expression of caspase-3 conferred sensitivity. Altogether, caspase-3 but not caspase-9 activation was necessary for execution of Smac-induced cell death. Notably, Smac did not induce caspase-9 processing in the absence of caspase-3. Thus, caspase-9 processing occurs secondary to caspase-3 activation during Smac-induced apoptosis. Altogether, Smac is capable of circumventing defects in mitochondrial apoptosis signaling such as loss of Bax or overexpression of BCl-X-L that are frequently observed in tumor cells resistant to anticancer therapy. Consequently, Smac appears to be a promising therapeutic target in anticancer treatment.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Johannes Gutenberg Univ Mainz, Dept Med 3, Mainz, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Gillissen, Bernhard/0000-0002-1815-2091; Normand, Guillaume/0000-0003-1228-3813				Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Brand K, 1997, CANCER GENE THER, V4, P9; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MROZEK A, 2003, IN PRESS CELL DEATH; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; RAU B, 2003, IN PRESS J CLIN ONCO; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	37	68	77	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4523	4535		10.1038/sj.onc.1207594	http://dx.doi.org/10.1038/sj.onc.1207594			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064710	Bronze			2022-12-25	WOS:000221799000003
J	Kimura, A; Ohmichi, M; Kawagoe, J; Kyo, S; Mabuchi, S; Takahashi, T; Ohshima, C; Arimoto-Ishida, E; Nishio, Y; Inoue, M; Kurachi, H; Tasaka, K; Murata, Y				Kimura, A; Ohmichi, M; Kawagoe, J; Kyo, S; Mabuchi, S; Takahashi, T; Ohshima, C; Arimoto-Ishida, E; Nishio, Y; Inoue, M; Kurachi, H; Tasaka, K; Murata, Y			Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines	ONCOGENE			English	Article						estrogen; telomerase; Akt; ovarian cancer	TELOMERASE REVERSE-TRANSCRIPTASE; NF-KAPPA-B; REGULATED PROTEIN-KINASE; CATALYTIC SUBUNIT GENE; NITRIC-OXIDE SYNTHASE; CRITICAL DETERMINANT; MESSENGER-RNA; ACTIVATION; INHIBITION; RECEPTOR	We examined the mechanism by which estrogen regulates telomerase activity in Caov-3 human ovarian cancer cell lines, which express ER, to determine whether the regulation affects the expression and/or phosphorylation of the telomerase catalytic subunit (hTERT). 17beta-Estradiol (E-2) induced telomerase activity and hTERT expression. Transient expression assays using luciferase reporter plasmids containing various fragments of hTERT promoter showed that the estrogen-responsive element appeared to be partially responsible for the E-2-induced activation of the hTERT promoter. Either pretreatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, or transfection with a dominant-negative Akt attenuated the E-2-induced activation of the hTERT promoter. In addition, estrogen induced the phosphorylation Of IkappaB inhibitor protein via the Akt cascade, and cotransfection with a dominant-negative subunit of NFkappaB attenuated the response of the ERE-deleted hTERT promoter to E-2-Moreover, E2 induced the phosphorylation of hTERT, the association of 14-3-3 protein and NFkappaB with hTERT, and nuclear accumulation of hTERT in an Akt-dependent manner. These results indicate that E-2 induces telomerase activity not only by transcriptional regulation of hTERT via an ERE-dependent mechanism and a PI3K/Akt/NFkappaB cascade, but also by post-transcriptional regulation via Akt-dependent phosphorylation of hTERT. Thus, the phosphorylation of Akt is a key event in the induction of telomeras activity by E-2 in human ovarian cancer cells.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan; Yamagata Univ, Sch Med, Div Nursing, Yamagata 9909585, Japan	Osaka University; Yamagata University; Kanazawa University; Yamagata University	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	masa@gyne.med.osaka-u.ac.jp	Mabuchi, Seiji/AAX-1986-2020					Akalin A, 2001, CANCER RES, V61, P4791; Akiyama M, 2003, CANCER RES, V63, P18; Akiyama M, 2002, CANCER RES, V62, P3876; Alfonso-De Matte MY, 2002, CANCER RES, V62, P4575; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Boldrini L, 2002, INT J ONCOL, V21, P493; Bourgarel-Rey V, 2001, MOL PHARMACOL, V59, P1165, DOI 10.1124/mol.59.5.1165; Breitschopf K, 2001, FEBS LETT, V493, P21, DOI 10.1016/S0014-5793(01)02272-4; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chow SN, 1996, INT SURG, V81, P152; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Hayakawa J, 2000, CANCER RES, V60, P5988; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kraemer K, 2003, CLIN CANCER RES, V9, P3794; Kyo S, 1999, INT J CANCER, V80, P804; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Kyo S, 1999, CANCER RES, V59, P5917; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Murakami J, 1997, CANCER, V80, P1085; Nakano K, 1998, AM J PATHOL, V153, P857, DOI 10.1016/S0002-9440(10)65627-1; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Ozes ON, 1999, NATURE, V401, P82; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Takakura M, 1998, CANCER RES, V58, P1558; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Teng LS, 2003, J CLIN ENDOCR METAB, V88, P1362, DOI 10.1210/jc.2002-021222; Wang Z, 2000, CANCER RES, V60, P5376; Wang ZO, 2002, ONCOGENE, V21, P3517, DOI 10.1038/sj.onc.1205463; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	61	114	123	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4505	4515		10.1038/sj.onc.1207582	http://dx.doi.org/10.1038/sj.onc.1207582			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15048073				2022-12-25	WOS:000221799000001
J	Sugiura, H; Iwata, K; Matsuoka, M; Hayashi, H; Takemiya, T; Yasuda, S; Ichikawa, M; Yamauchi, T; Mehlen, P; Haga, T; Yamagata, K				Sugiura, H; Iwata, K; Matsuoka, M; Hayashi, H; Takemiya, T; Yasuda, S; Ichikawa, M; Yamauchi, T; Mehlen, P; Haga, T; Yamagata, K			Inhibitory role of endophilin 3 in receptor-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; CENTRAL-NERVOUS-SYSTEM; DOPAMINE D2 RECEPTORS; HOMOLOGY 3 DOMAIN; SH3 DOMAIN; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; CULTURED-CELLS; PROTEIN; SYNAPTOJANIN	Endophilin 1 (Endo1) participates in synaptic vesicle biogenesis through interactions of its Src homology 3 domain with the polyphosphoinositide phosphatase Synaptojanin and the GTPase Dynamin. Endo1 has also been reported to affect endocytosis by converting membrane curvature via its lysophosphatidic acid acyltransferase activity. Here we report that a closely related isoform of Endo1, Endo3, inhibits clathrin-mediated endocytosis. Mutational analyses showed that the variable region of Endo3 is important in regulating transferrin endocytosis. In the brain, Endo3 is co-localized with dopamine D2 receptor in olfactory nerve terminals and inhibits its clathrin-mediated endocytosis in COS-7 cells. Furthermore, overexpression of Endo3 in an olfactory epithelium-derived cell line suppressed dopamine D2 receptor-mediated endocytosis and therefore accelerated its dopamine-induced differentiation. These results indicate that Endo3 may act as a negative regulator of clathrin-mediated endocytosis in brain neurons.	Tokyo Metropolitan Inst Neurosci, Dept Neuropharmacol, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Basictech & Facil, Tokyo 1838526, Japan; Tokyo Metropolitan Hiroo Gen Hosp, Dept Neuropsychiat, Shibuya Ku, Tokyo 1500012, Japan; Niigata Univ, Sch Med, Dept Neurobiol & Anat, Niigata 9518510, Japan; Univ Tokushima, Fac Pharmaceut Sci, Dept Biochem, Tokushima 7708505, Japan; Univ Lyon 1, CNRS, UMR 5534,Mol & Cellular Genet Ctr, Apoptosis Differentiat Lab Label La Ligue, F-69622 Villeurbanne, France; Gakushuin Univ, Fac Sci, Inst Biomol Sci, Toshima Ku, Tokyo 1718588, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Niigata University; Tokushima University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Gakushuin University	Yamagata, K (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Neuropharmacol, Tokyo 1838526, Japan.	kyamagat@min.ac.jp						Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; Coronas V, 1997, J NEUROCHEM, V69, P1870; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Ennis M, 2001, J NEUROPHYSIOL, V86, P2986, DOI 10.1152/jn.2001.86.6.2986; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huttner WB, 2002, TRENDS CELL BIOL, V12, P155, DOI 10.1016/S0962-8924(02)02252-3; Irie Y, 2000, J BIOL CHEM, V275, P2647, DOI 10.1074/jbc.275.4.2647; Ito K, 1999, EUR J BIOCHEM, V260, P112, DOI 10.1046/j.1432-1327.1999.00125.x; Itokawa M, 1996, MOL PHARMACOL, V49, P560; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Koster NL, 1999, J COMP NEUROL, V411, P666, DOI 10.1002/(SICI)1096-9861(19990906)411:4<666::AID-CNE10>3.0.CO;2-S; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Modregger J, 2003, J BIOL CHEM, V278, P4160, DOI 10.1074/jbc.M208568200; Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378; PINCHING AJ, 1971, J CELL SCI, V9, P347; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Schuske KR, 2003, NEURON, V40, P749, DOI 10.1016/S0896-6273(03)00667-6; Shipley MT, 1996, J NEUROBIOL, V30, P123; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SUGIURA H, 1992, BRAIN RES, V593, P97, DOI 10.1016/0006-8993(92)91269-K; Torrey T, 1998, MAMM GENOME, V9, P74, DOI 10.1007/s003359900683; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Verstreken P, 2003, NEURON, V40, P733, DOI 10.1016/S0896-6273(03)00644-5; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001	38	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23343	23348		10.1074/jbc.M312607200	http://dx.doi.org/10.1074/jbc.M312607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15066995	hybrid			2022-12-25	WOS:000221570900069
J	Wong, CM; Siu, KL; Jin, DY				Wong, CM; Siu, KL; Jin, DY			Peroxiredoxin-null yeast cells are hypersensitive to oxidative stress and are genomically unstable	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN PEROXIDASE-I; CYSTEINE-SULFINIC ACID; SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; THIOL PEROXIDASE; GLUTATHIONE-PEROXIDASE; ANTIOXIDANT DEFENSE; DEPENDENT REDUCTION; GLOBAL ANALYSIS; NITRIC-OXIDE	Peroxiredoxins are a family of abundant peroxidases found in all organisms. Although these antioxidant enzymes are thought to be critically involved in cellular defense and redox signaling, their exact physiological roles are largely unknown. In this study, we took a genetic approach to address the functions of peroxiredoxins in budding yeast. We generated and characterized a yeast mutant lacking all five peroxiredoxins. The quintuple peroxiredoxin-null mutant was still viable, though the growth rate was lower under normal aerobic conditions. Although peroxiredoxins are not essential for cell viability, peroxiredoxin-null yeast cells were more susceptible to oxidative and nitrosative stress. In the complete absence of peroxiredoxins, the expression of other antioxidant proteins including glutathione peroxidase and glutathione reductase was induced. In addition, the quintuple mutant was hypersensitive to glutathione depletion. Thus, the glutathione system might cooperate with other antioxidant enzymes to compensate for peroxiredoxin deficiency. Interestingly, the peroxiredoxinnull yeast cells displayed an increased rate of spontaneous mutations that conferred resistance to canavanine. This mutator phenotype was rescued by yeast peroxiredoxin Tsa1p, but not by its active-site mutant defective for peroxidase activity. Our findings suggest that the antioxidant function of peroxiredoxins is important for maintaining genome stability in eukaryotic cells.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Jin, DY (corresponding author), Univ Hong Kong, Dept Biochem, 3-F Lab Block,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	dyjin@hkucc.hku.hk	Siu, Kam Leung/C-4508-2009; Wong, Chi-Ming/A-7627-2013	Wong, Chi-Ming/0000-0002-0025-7135				AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x; AWASTHI YC, 1981, BLOOD, V58, P733; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Cha MK, 2003, J BIOL CHEM, V278, P34952, DOI 10.1074/jbc.M301819200; Cha MK, 2003, J BIOL CHEM, V278, P24636, DOI 10.1074/jbc.M302628200; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Demasi APD, 2001, FEBS LETT, V509, P430, DOI 10.1016/S0014-5793(01)03215-X; Dietz KJ, 2003, ANNU REV PLANT BIOL, V54, P93, DOI 10.1146/annurev.arplant.54.031902.134934; EBERHARDT I, 1995, CURR GENET, V27, P306, DOI 10.1007/BF00352097; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Grant CM, 1998, BIOCHEM BIOPH RES CO, V253, P893, DOI 10.1006/bbrc.1998.9864; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Izawa S, 2004, APPL MICROBIOL BIOT, V64, P120, DOI 10.1007/s00253-003-1421-5; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; JIN DY, 2000, ANTIOXIDANT REDOX RE, P381; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Lee SM, 1998, ARCH BIOCHEM BIOPHYS, V359, P99, DOI 10.1006/abbi.1998.0896; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Leikert JF, 2001, FEBS LETT, V506, P131, DOI 10.1016/S0014-5793(01)02901-5; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Monteiro G, 2002, FREE RADICAL BIO MED, V32, P278, DOI 10.1016/S0891-5849(01)00801-2; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Nguyen-nhu NT, 2002, TOXICOL LETT, V135, P219, DOI 10.1016/S0378-4274(02)00280-1; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; Peshenko IV, 2001, FREE RADICAL BIO MED, V31, P292, DOI 10.1016/S0891-5849(01)00579-2; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; Silveira LR, 2003, FREE RADICAL BIO MED, V35, P455, DOI 10.1016/S0891-5849(03)00271-5; Singer MS, 1998, GENETICS, V150, P613; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wong CM, 2003, FREE RADICAL BIO MED, V34, P585, DOI 10.1016/S0891-5849(02)01354-0; Wong CM, 2002, J BIOL CHEM, V277, P5385, DOI 10.1074/jbc.M106846200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231; Zhou Y, 1997, BIOCHEM BIOPH RES CO, V233, P848, DOI 10.1006/bbrc.1997.6564	62	98	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23207	23213		10.1074/jbc.M402095200	http://dx.doi.org/10.1074/jbc.M402095200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15051715	hybrid			2022-12-25	WOS:000221570900052
J	Lanvin, O; Gouilleux, F; Mullie, C; Maziere, C; Fuentes, V; Bissac, E; Dantin, F; Maziere, JC; Regnier, A; Lassoued, K; Gouilleux-Gruart, V				Lanvin, O; Gouilleux, F; Mullie, C; Maziere, C; Fuentes, V; Bissac, E; Dantin, F; Maziere, JC; Regnier, A; Lassoued, K; Gouilleux-Gruart, V			Interleukin-7 induces apoptosis of 697 pre-B cells expressing dominant-negative forms of STAT5: evidence for caspase-dependent and -independent mechanisms	ONCOGENE			English	Article						transcription factors; apoptosis; cytokines; pre-B cells	RECEPTOR-GAMMA CHAIN; GENE-EXPRESSION; T-LYMPHOCYTES; TRANSACTIVATION DOMAIN; LYMPHOID DEVELOPMENT; HEMATOPOIETIC-CELLS; CYCLE PROGRESSION; DNA-BINDING; MICE; ACTIVATION	The transcription factors STAT5A and STAT5B (STAT: signal transducer and activator of transcription) play a major role in the signaling events elicited by a number of growth factor and cytokine receptors. In this work, we aimed to investigate the role of STAT5 in human precursor B cell survival by introducing dominant-negative (DN) forms of STAT5A or STAT5B in the 697 pre-B cell line. All clones expressing DN forms of either transcription factor exhibited a higher spontaneous apoptotic rate that was massively enhanced upon interleukin-7 (IL-7) stimulation. This was associated with caspase 8 cleavage, mitochondrial transmembrane potential disruption and caspase 3 activation. However, the DN forms of STAT5 did not alter the expression of Bcl-2, Bax, Bcl-x, Bim, Al and Mcl1 proteins in IL-7-stimulated cells. The pancaspase inhibitor Z-Val-Ala-Asp-fluoromylmethyl ketone partially suppressed IL-7-mediated mitochondrial transmembrane potential disruption and cell death, suggesting that IL-7 induced the death of DN STAT5 expressing 697 cells through caspase-dependent and -independent mechanisms that both require mitochondrial activation.	INSERM, Immunol Lab, F-80036 Amiens, France; CHU Amiens, Biochim Lab, F-80054 Amiens, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Gouilleux-Gruart, V (corresponding author), INSERM, Immunol Lab, EMI 0351,3 Rue Louvels, F-80036 Amiens, France.	valerie.gouilleux@sa.u-picardie.fr	Mullié, Catherine/AAW-2304-2020	Mullié, Catherine/0000-0001-8986-9666; Regnier, Jean-Claude/0000-0001-6992-9027; Gouilleux, Fabrice/0000-0001-6047-1718				Ahonen TJ, 2003, J BIOL CHEM, V278, P27287, DOI 10.1074/jbc.M304307200; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; BILLIPS LG, 1995, J EXP MED, V182, P973, DOI 10.1084/jem.182.4.973; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Deas O, 1998, J IMMUNOL, V161, P3375; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DITTEL BN, 1995, J IMMUNOL, V154, P58; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FINDLEY HW, 1982, BLOOD, V60, P1305; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Isaksen DE, 1999, J IMMUNOL, V163, P5971; Karras JG, 1996, J IMMUNOL, V157, P39; Kieslinger M, 2000, GENE DEV, V14, P232; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; LeBien TW, 2000, BLOOD, V96, P9, DOI 10.1182/blood.V96.1.9; Levy Y, 1997, CLIN EXP IMMUNOL, V110, P329; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Mahajan S, 2001, J BIOL CHEM, V276, P31216, DOI 10.1074/jbc.M104874200; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qin JZ, 2001, J INVEST DERMATOL, V117, P583, DOI 10.1046/j.0022-202x.2001.01436.x; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shelburne CP, 2002, MOL IMMUNOL, V38, P1187, DOI 10.1016/S0161-5890(02)00061-5; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; vanderPlas DC, 1996, LEUKEMIA, V10, P1317; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WOLF ML, 1993, J IMMUNOL, V151, P138; Zamorano J, 1998, J IMMUNOL, V160, P3502	44	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3040	3047		10.1038/sj.onc.1207450	http://dx.doi.org/10.1038/sj.onc.1207450			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048088	Green Published			2022-12-25	WOS:000220845200008
J	Wang, WG; Graeler, MH; Goetzl, EJ				Wang, WG; Graeler, MH; Goetzl, EJ			Physiological sphingosine 1-phosphate requirement for optimal activity of mouse CD4(+)25(+) regulatory T Cells	FASEB JOURNAL			English	Article						lysophospholipids; G proteins; cytokines; chemokines; proliferation	LYSOPHOSPHATIDIC ACID; CUTTING EDGE; RECEPTORS; GROWTH; SUPPRESSION; LYMPHOCYTES; EXPRESSION; CHEMOTAXIS	Sphingosine 1-phosphate (S1P) evokes T cell chemotaxis at 1-100 nM and inhibits chemotaxis to chemokines at 300 nM-1 uM through their predominant S1P(1) G protein-coupled receptor (R). Mouse CD4(+)25(+) regulatory T cells now are shown to express the same pattern of S1P(1) > S1P(4) >> other S1P Rs as other CD4 T cells. CD4(+)25(+) T cell suppression of H-3-thymidine uptake and IL-2 generation by CD4(+)25(-)T cells stimulated with anti-T cell receptor antibodies without S1P was enhanced significantly by S1P at normal blood and lymph concentrations. These levels of S1P also enhanced IL-10 generation by CD4(+)25(+) T cells by up to threefold compared with that without S1P but decreased IL-10 from CD4(+)25-T cells. That IL-10 from CD4+25+ T cells incubated with S1P mediates suppressive activity was demonstrated by prevention with neutralizing anti-IL-10 or anti-IL-10 receptor antibodies. Extracellular fluid S1P thus is required for optimal activity of CD4(+)25(+) T cells.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, UB8B,Box 0711 533 Parnassus & 4th, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; GRALER MH, 2004, FASEB J; Idzko M, 2002, FASEB J, V16, P625, DOI 10.1096/fj.01-0625fje; Kveberg L, 2002, EUR J IMMUNOL, V32, P1856, DOI 10.1002/1521-4141(200207)32:7<1856::AID-IMMU1856>3.0.CO;2-B; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shevach EM, 2001, ADV EXP MED BIOL, V490, P21; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Sundstedt A, 2003, J IMMUNOL, V170, P1240, DOI 10.4049/jimmunol.170.3.1240; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317; Zheng YH, 2000, FASEB J, V14, P2387	22	38	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1043	+		10.1096/fj.04-1555fje	http://dx.doi.org/10.1096/fj.04-1555fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084513				2022-12-25	WOS:000221108800002
J	Schwarzenbacher, R; Stenner-Liewen, F; Liewen, H; Robinson, H; Hua, YA; Bossy-Wetzel, E; Reed, JC; Liddington, RC				Schwarzenbacher, R; Stenner-Liewen, F; Liewen, H; Robinson, H; Hua, YA; Bossy-Wetzel, E; Reed, JC; Liddington, RC			Structure of the Chlamydia protein CADD reveals a redox enzyme that modulates host cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; CRYSTAL-STRUCTURE; PNEUMONIAE; DEATH	The Chlamydia protein CADD (Chlamydia protein associating with death domains) has been implicated in the modulation of host cell apoptosis via binding to the death domains of tumor necrosis factor family receptors. Transfection of CADD into mammalian cells induces apoptosis. Here we present the CADD crystal structure, which reveals a dimer of seven-helix bundles. Each bundle contains a di-iron center adjacent to an internal cavity, forming an active site similar to that of methane mono-oxygenase hydrolase. We further show that CADD mutants lacking critical metal-coordinating residues are substantially less effective in inducing apoptosis but retain their ability to bind to death domains. We conclude that CADD is a novel redox protein toxin unique to Chlamydia species and propose that both its redox activity and death domain binding ability are required for its biological activity.	Burnham Inst, La Jolla, CA 92037 USA; Univ Saarland, Dept Med 1, D-66421 Homburg, Germany; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Sanford Burnham Prebys Medical Discovery Institute; Saarland University; United States Department of Energy (DOE); Brookhaven National Laboratory	Liddington, RC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org		Stenner, Frank/0000-0003-4541-8817; Liewen, Heike/0000-0002-6161-4749	NCI NIH HHS [CA69381] Funding Source: Medline; NEI NIH HHS [R01 EY016164] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTILLA T, 2001, J AM MED ASS, V285; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belland RJ, 2001, P NATL ACAD SCI USA, V98, P13984, DOI 10.1073/pnas.241377698; CHRISTOPHER JA, 1998, SPOCK; Eriksson M, 1998, BIOCHEMISTRY-US, V37, P13359, DOI 10.1021/bi981380s; Fischer SF, 2001, INFECT IMMUN, V69, P7121, DOI 10.1128/IAI.69.11.7121-7129.2001; Geng YM, 2000, J IMMUNOL, V164, P5522, DOI 10.4049/jimmunol.164.10.5522; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jaroszewski L, 2002, PROTEIN SCI, V11, P1702, DOI 10.1110/ps.4820102; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Magnusson OT, 2004, P NATL ACAD SCI USA, V101, P7913, DOI 10.1073/pnas.0402640101; MEULENBERG JJM, 1990, FEMS MICROBIOL LETT, V71, P337, DOI 10.1016/0378-1097(90)90244-K; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PANG ASH, 1991, J BACTERIOL, V173, P46, DOI 10.1128/jb.173.1.46-54.1991; Perfettini JL, 2003, BIOCHIMIE, V85, P763, DOI 10.1016/j.biochi.2003.08.006; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; SCHACHTER J, 1988, CURR TOP MICROBIOL, V138, P109; Schoier J, 2001, MICROB PATHOGENESIS, V31, P173, DOI 10.1006/mpat.2001.0460; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Stenner-Liewen F, 2002, J BIOL CHEM, V277, P9633, DOI 10.1074/jbc.C100693200; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	26	37	39	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29320	29324		10.1074/jbc.M401268200	http://dx.doi.org/10.1074/jbc.M401268200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15087448	hybrid			2022-12-25	WOS:000222445300062
J	Wang, JC; Walker, A; Blackwell, TK; Yamamoto, KR				Wang, JC; Walker, A; Blackwell, TK; Yamamoto, KR			The Caenorhabditis elegans ortholog of TRAP240, CeTRAP240/let-19, selectively modulates gene expression and is essential for embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; C-ELEGANS; MEDIATOR COMPLEXES; DEPENDENT TRANSCRIPTION; EMBRYONIC-DEVELOPMENT; COACTIVATOR COMPLEX; NUCLEAR RECEPTORS; PROTEIN; YEAST	Mediator complexes are large multiprotein assemblies that function in the regulation of eukaryotic gene transcription. In yeast, certain mediator subunits appear to comprise a subcomplex that acts in the regulation of a specific subset of genes. We investigated in a metazoan, Caenorhabditis elegans, the roles and interactions of two of those subunits, CeTRAP240/let-19 and CeTRAP230/dpy-22. We found that CeTRAP240/let-19 contains four domains that are conserved in the human TRAP240 protein and that one of those domains displays intrinsic transcriptional repression activity. Using RNA interference, we found that reduced expression of CeTRAP240/let-19 displayed a high penetrance of embryonic lethality in F1 progeny; animals that escaped embryonic arrest showed mutant phenotypes such as burst vulva and molting defects. CeTRAP240/let-19 appeared to affect specific genes, as CeTRAP240/let-19(RNAi) led to selectively reduced expression of a subset of reporter genes examined. Genetic experiments supported the view that CeTRAP240/let-19 and CeTRAP230/dpy-22, like their Drosophila and yeast counterparts, can operate on common pathways. Thus, a male tail phenotype caused by the pal-1(e2091) mutation was suppressed not only by CeTRAP230/dpy-22 mutants, as reported previously, but also by reduced expression of CeTRAP240/let-19. Additionally, CeTRAP240/let-19(RNAi) in a CeTRAP230/dpy-22 mutant background produced a strong synthetic lethal phenotype. Overall, our results establish specific roles of CeTRAP240/let-19 in C. elegans embryonic development and a functional interaction between CeTRAP240/let-19 and CeTRAP230/dpy-22. Interestingly, whereas this interaction has been conserved from yeast to mammals, the subcomplex modulates metazoan-specific genetic pathways, likely in addition to those also controlled in yeast.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA; Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA	University of California System; University of California San Francisco; Harvard University; Joslin Diabetes Center, Inc.	Yamamoto, KR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, S572D,Genentech Hall,600 16th St, San Francisco, CA 94107 USA.	yamamoto@cmp.ucsf.edu	Wang, Jen-Chywan/AAX-4445-2020	Wang, Jen-Chywan/0000-0001-6030-6886	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062891] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; DELONG L, 1987, GENETICS, V117, P657; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Horner MA, 1998, GENE DEV, V12, P1947, DOI 10.1101/gad.12.13.1947; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2002, EMBO J, V21, P3464, DOI 10.1093/emboj/cdf348; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh K, 2001, DEVELOPMENT, V128, P2867; KRAUSE M, 1995, BIOESSAYS, V17, P219, DOI 10.1002/bies.950170308; Kwon JY, 1999, P NATL ACAD SCI USA, V96, P14990, DOI 10.1073/pnas.96.26.14990; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Maduro MF, 2001, MOL CELL, V7, P475, DOI 10.1016/S1097-2765(01)00195-2; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; Shim EY, 2002, J BIOL CHEM, V277, P30413, DOI 10.1074/jbc.C200305200; Sluder AE, 1997, DEV BIOL, V184, P303, DOI 10.1006/dbio.1997.8544; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Treisman JE, 2001, DEVELOPMENT, V128, P603; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; Zhang H, 2000, GENE DEV, V14, P2161, DOI 10.1101/gad.814700; Zhang H, 2001, DEVELOPMENT, V128, P767; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	52	27	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29270	29277		10.1074/jbc.M401242200	http://dx.doi.org/10.1074/jbc.M401242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15073178	hybrid			2022-12-25	WOS:000222445300056
J	Gaidamashvili, M; Ohizumi, Y; Iijima, S; Takayama, T; Ogawa, T; Muramoto, K				Gaidamashvili, M; Ohizumi, Y; Iijima, S; Takayama, T; Ogawa, T; Muramoto, K			Characterization of the yam tuber storage proteins from Dioscorea batatas exhibiting unique lectin activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-INHIBITOR ACTIVITIES; CARBONIC-ANHYDRASE; ANTIOXIDANT ACTIVITIES; PLANT-LECTINS; CHITINASE; LAM; GLYCOPROTEIN; SPECIFICITY; FAMILIES; MANNOSE	Four major proteins designated DB1, DB2, DB3, and DB4 were isolated and characterized from the yam tuber Dioscorea batatas. The ratios of their yields were 20: 50: 20: 10. DB1 was a mannose-binding lectin (20 kDa) consisting of 10-kDa subunits and was classified as the monocot mannose-binding lectin family. DB2, accounting for 50% of the total protein, was the storage protein, commonly called dioscorins consisting of a 31-kDa subunit. On the basis of amino acid sequence, DB2 was classified to be dioscorin A. DB3 was a maltose-binding lectin, having an apparent molecular mass of 120 kDa and composed of a 66-kDa subunit and two 31-kDa subunits (DB3S). The 66-kDa subunit was further composed of two 31-kDa subunits (DB3L) cross-linked by disulfide bonds. DB3L and DB3S (242 and 241 amino acid residues, respectively) were homologous with each other with 72% sequence identity. They showed a sequence homology to dioscorin B and dioscorin A from Dioscorea alata, with 90 and 93% identity, respectively, and to carbonic anhydrase from Arabidopsis thaliana with about 45% identity. DB3S had one intrachain disulfide bond located at Cys(28)-Cys(187), whereas DB3L had one interchain disulfide bond (Cys(40) - Cys(40')) in addition to the intrachain disulfide bond (Cys(28) - Cys(188)) to form a 66-kDa subunit. DB1 and DB3 agglutinated rabbit erythrocytes at 2.7 and 3.9 mug/ml, respectively. Despite the structural homology between DB2 and DB3, DB2 had no lectin activity. The 66-kDa subunit itself revealed the full hemagglutinating activity of DB3, indicating that DB3L but not DB3S was responsible for the activity. The hemagglutinating activity of DB3 required Ca2+ ions and was exclusively inhibited by maltose and oligomaltoses ( e. g. maltopentaose and maltohexaose) but not by D-glucose. DB3 could not be classified into any known plant lectin family. DB4 was a chitinase, homologous to an acidic chitinase from Dioscorea japonica. DB1, DB2, and DB3 did not show any activity of carbonic anhydrase, amylase, or trypsin inhibitor activity. These results show that two of the four major proteins isolated from the yam tubers D. batatas have unique lectin activities.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9818555, Japan	Tohoku University	Muramoto, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9818555, Japan.	muramoto@biochem.tohoku.ac.jp	Gaidamashvili, Mariam/AAQ-8009-2020	Ogawa, Tomohisa/0000-0001-8700-6330				ARAKI T, 1992, J BIOL CHEM, V267, P19944; ARAKI T, 1995, BIOSCI BIOTECH BIOCH, V59, P430, DOI 10.1271/bbb.59.430; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; Chen HL, 2003, NUTR RES, V23, P791, DOI 10.1016/S0271-5317(03)00036-8; CONLAN RS, 1995, PLANT MOL BIOL, V28, P369, DOI 10.1007/BF00020387; Conlan S, 1998, J PLANT PHYSIOL, V153, P25, DOI 10.1016/S0176-1617(98)80040-0; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEVINE PL, 1990, BIOTECHNIQUES, V8, P492; EINHOFF W, 1986, LECTINS BIOL BIOCH C, V5, P53; HARVEY PJ, 1983, PHYTOCHEMISTRY, V22, P1687, DOI 10.1016/S0031-9422(00)80252-6; HESTER G, 1995, NAT STRUCT BIOL, V2, P472, DOI 10.1038/nsb0695-472; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; HILDER VA, 1995, TRANSGENIC RES, V4, P18, DOI 10.1007/BF01976497; Hou WC, 1999, J AGR FOOD CHEM, V47, P2168, DOI 10.1021/jf980738o; Hou WC, 1999, PLANT SCI, V149, P151, DOI 10.1016/S0168-9452(99)00152-1; Hou WC, 2000, BOT BULL ACAD SINICA, V41, P191; Hou WC, 1998, BOT BULL ACAD SINICA, V39, P93; Hou WC, 2001, J AGR FOOD CHEM, V49, P4956, DOI 10.1021/jf010606m; Hsu CL, 2003, FOOD CHEM, V83, P85, DOI 10.1016/S0308-8146(03)00053-0; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1993, ANAL BIOCHEM, V212, P206, DOI 10.1006/abio.1993.1313; MAESHIMA M, 1985, PHYTOCHEMISTRY, V24, P1899, DOI 10.1016/S0031-9422(00)83088-5; MURAMOTO K, 1990, ANAL BIOCHEM, V189, P223, DOI 10.1016/0003-2697(90)90112-M; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; Peumans WJ, 1997, GLYCOCONJUGATE J, V14, P259, DOI 10.1023/A:1018502107707; Pusztai A, 1996, TRENDS GLYCOSCI GLYC, V8, P149, DOI 10.4052/tigg.8.149; RACUSEN D, 1980, J FOOD BIOCHEM, V4, P43, DOI 10.1111/j.1745-4514.1980.tb00876.x; RACUSEN D, 1984, CAN J BOT, V62, P1641; RAHBE Y, 1995, ENTOMOL EXP APPL, V76, P143, DOI 10.1007/BF02383212; Shewry PR, 2003, ANN BOT-LONDON, V91, P755, DOI 10.1093/aob/mcg084; Tateno H, 1998, J BIOL CHEM, V273, P19190, DOI 10.1074/jbc.273.30.19190; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; VANDAMME EJM, 1991, EUR J BIOCHEM, V202, P23, DOI 10.1111/j.1432-1033.1991.tb16339.x; VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1; VERPOORTE JA, 1967, J BIOL CHEM, V242, P4221; Yeh KW, 1997, PLANT MOL BIOL, V33, P565, DOI 10.1023/A:1005764702510	37	55	61	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26028	26035		10.1074/jbc.M402139200	http://dx.doi.org/10.1074/jbc.M402139200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15047697	hybrid			2022-12-25	WOS:000222003000014
J	Yeh, PY; Yeh, KH; Chuang, SE; Song, YC; Cheng, AL				Yeh, PY; Yeh, KH; Chuang, SE; Song, YC; Cheng, AL			Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappa B activation by protein phosphatase 4-mediated NF-kappa B p65 Thr dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELA TRANSCRIPTION FACTOR; NECROSIS-FACTOR-ALPHA; DNA-DAMAGE; KINASE; CANCER; PHOSPHORYLATION; CELLS; SPECIFICITY; APOPTOSIS; SUBUNIT	87We previously reported that suppression of the MEK/ERK pathway increases drug resistance of SiHa cells. In this study, we further characterized the underlying mechanism of this phenomenon. Pretreatment of SiHa cells with MEK/ERK inhibitor enhanced cisplatin-induced NF-kappaB activation. However, results of immunoblotting analysis showed that neither cisplatin nor MEK/ERK inhibitors induced marked IkappaBalpha degradation, suggesting that suppression of the MEK/ERK signaling pathway may enhance cisplatin-induced NF-kappaB activation via mechanisms other than the conventional pathway. Previous findings that protein phosphatase 4 (PP4), a nuclear serine/threonine phosphatase, directly interacts with and activates NF-kappaB led us to examine the phosphorylation status of NF-kappaB p65. Coincident with activation of NF-kappaB, cisplatin induced Ser phosphorylation but decreased Thr phosphorylation of NF-kappaB p65. Suppression of the MEK/ERK pathway further enhanced cisplatin-induced Thr dephosphorylation but did not affect cisplatin-induced Ser phosphorylation of NF-kappaB p65. Further, in parallel with Thr dephosphorylation, the protein level of nuclear PP4 was increased in cisplatin-treated cells and was further increased by suppression of the MEK/ERK pathway. SiHa cells were then transfected by a sense or an antisense PP4 gene. PP4-overexpressing cells showed a decrease in Thr phosphorylation of NF-kappaB p65 to nearly undetectable levels, and both basal and cisplatin-induced NF-kappaB activities were higher than those in parental cells. By contrast, cisplatin, either alone or with MEK/ERK inhibitors, induced little NF-kappaB activation in antisense PP4-transfected cells. Coprecipitated complex kinase assay revealed a fragment of NF-kappaB p65 (amino acids 279-444) to contain potential phosphorylation sites that directly interact with PP4. Further studies by site-directed mutagenesis suggested that Thr(435) was the major phosphorylation site.	Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10016, Taiwan; Natl Taiwan Univ, Ctr Canc Res, Taipei 10016, Taiwan; Natl Hlth Res Inst, Div Canc Res, Taipei 10016, Taiwan; Far Eastern Mem Hosp, Dept Med Res, Taipei 10016, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan; Far Eastern Memorial Hospital	Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 10016, Taiwan.	andrew@ha.mc.ntu.edu.tw	Chuang, Shuang-En/D-2080-2010; Yeh, Kun-Huei/HGD-3316-2022	Cheng, Ann-Lii/0000-0002-9152-6512; YEH, Kun-Huei/0000-0002-7306-174X; Song, Ying-Chyi/0000-0003-0279-4652				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; XIA Z, 1995, SCIENCE, V24, P1326; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou GS, 2002, J BIOL CHEM, V277, P6391, DOI 10.1074/jbc.M107014200; ZONG H, 1997, CELL, V89, P413	36	88	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26143	26148		10.1074/jbc.M402362200	http://dx.doi.org/10.1074/jbc.M402362200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15073167	hybrid			2022-12-25	WOS:000222003000028
J	Finzer, P; Krueger, A; Stohr, M; Brenner, D; Soto, U; Kuntzen, C; Krammer, PH; Rosl, F				Finzer, P; Krueger, A; Stohr, M; Brenner, D; Soto, U; Kuntzen, C; Krammer, PH; Rosl, F			HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway	ONCOGENE			English	Article						human papillomavirus; cervical carcinoma cells; HDAC inhibitors	CERVICAL-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; CD95 APO-1/FAS; GENE-EXPRESSION; E2F; INDUCTION; P53; DEGRADATION; CANCER	Histone deacetylase (HDAC) inhibitors induce an intrinsic type of apoptosis in human papillomavirus (HPV)-positive cells by disrupting the mitochondrial transmembrane potential (DeltaPsi(m)). Loss of DeltaPsi(m) was only detected in E7, but not in E6 oncogene-expressing cells. HDAC inhibition led to a time-dependent degradation of the pocket proteins pRb, p107 and p130, releasing 'free' E2F-1 following initial G1 arrest. Inhibition of proteasomal proteolysis, but not of caspase activity rescued pRb from degradation and functionally restored its inhibitory effect on the cyclin E gene, known to be suppressedby pRb-E2F-1 in conjunction with HDAC1. Using siRNA targeted against p53, E2F-1 still triggered apoptosis by inducing the E2F-responsive proapoptotic alpha- and beta-isoforms of p73. These data may determine future therapeutic strategies in which HDAC inhibitors can effectively eliminate HPV-positive cells by an apoptotic route that does not rely on the reactivation of the 'classical' p53 pathway through a preceding shut-off of viral gene expression.	Deutsch Krebsforschungszentrum, Forschungsschewerpunkt Angew Tumorvirol, Abt Virale Transformat Mech, D-69120 Heidelberg, Germany; Abt Immungenet, D-69120 Heidelberg, Germany; Forschungsschwerpunkt Zytometrie, D-69120 Heidelberg, Germany; Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; Dana Farber Canc Inst, Boston, MA 02115 USA	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Harvard University; Dana-Farber Cancer Institute	Finzer, P (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschewerpunkt Angew Tumorvirol, Abt Virale Transformat Mech, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	p.finzer@dkfz.de	Krueger, Andreas/B-9427-2009	Krueger, Andreas/0000-0001-7873-7334; Brenner, Dirk/0000-0001-8979-1045				Aguilar-Lemarroy A, 2001, INT J CANCER, V93, P823, DOI 10.1002/ijc.1405; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bernard HU, 2002, ANTIVIR THER, V7, P219; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Finzer P, 2003, J CANCER RES CLIN, V129, P107, DOI 10.1007/s00432-003-0416-z; Finzer P, 2002, VIROLOGY, V304, P265, DOI 10.1006/viro.2002.1667; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Re D, 2000, EXP HEMATOL, V28, P31, DOI 10.1016/S0301-472X(99)00125-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rosato RR, 2003, CANCER RES, V63, P3637; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; STOHR M, 1978, STAIN TECHNOL, V53, P205; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang QM, 2000, CLIN CANCER RES, V6, P2951; Wharton W, 2000, J BIOL CHEM, V275, P33981, DOI 10.1074/jbc.M005600200; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	73	38	38	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4807	4817		10.1038/sj.onc.1207620	http://dx.doi.org/10.1038/sj.onc.1207620			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077164				2022-12-25	WOS:000222104200001
J	Angata, K; Chan, D; Thibault, J; Fukuda, M				Angata, K; Chan, D; Thibault, J; Fukuda, M			Molecular dissection of the ST8Sia IV polysialyltransferase - Distinct domains are required for neural cell adhesion molecule recognition and polysialylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; POLYSIALIC ACID SYNTHESIS; NERVOUS-SYSTEM; COOPERATIVE POLYSIALYLATION; CATALYTIC DOMAIN; OLFACTORY-BULB; DISULFIDE BOND; AMINO-ACIDS; IN-VITRO; EXPRESSION	Polysialic acid, a homopolymer of alpha2,8-linked sialic acid expressed on the neural cell adhesion molecule ( NCAM), is thought to play critical roles in neural development. Two highly homologous polysialyltransferases, ST8Sia II and ST8Sia IV, which belong to the sialyltransferase gene family, synthesize polysialic acid on NCAM. By contrast, ST8Sia III, which is moderately homologous to ST8Sia II and ST8Sia IV, adds oligosialic acid to itself but very inefficiently to NCAM. Here, we report domains of polysialyltransferases required for NCAM recognition and polysialylation by generating chimeric enzymes between ST8Sia IV and ST8Sia III or ST8Sia II. We first determined the catalytic domain of ST8Sia IV by deletion mutants. To identify domains responsible for NCAM polysialylation, different segments of the ST8Sia IV catalytic domain, identified by the deletion experiments, were replaced with corresponding segments of ST8Sia II and ST8Sia III. We found that larger polysialic acid was formed on the enzymes themselves (autopolysialylation) when chimeric enzymes contained the carboxyl-terminal region of ST8Sia IV. However, chimeric enzymes that contain only the carboxyl-terminal segment of ST8Sia IV and the amino-terminal segment of ST8Sia III showed very weak activity toward NCAM, even though they had strong activity in polysialylating themselves. In fact, chimeric enzymes containing the amino-terminal portion of ST8Sia IV fused to downstream sequences of ST8Sia III inhibited NCAM polysialylation in vitro, although they did not polysialylate NCAM. These results suggest that in polysialyltransferases the NCAM recognition domain is distinct from the polysialylation domain and that some chimeric enzymes may act as a dominant negative enzyme for NCAM polysialylation.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham-inst.org	Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NCI NIH HHS [R01 CA33895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Angata K, 2002, J BIOL CHEM, V277, P36808, DOI 10.1074/jbc.M204632200; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; CHUNG WW, 1991, J COMP NEUROL, V314, P290, DOI 10.1002/cne.903140207; Close BE, 2003, J BIOL CHEM, V278, P30796, DOI 10.1074/jbc.M305390200; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Cremer H, 2000, INT J DEV NEUROSCI, V18, P213, DOI 10.1016/S0736-5748(99)00090-8; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; EDELMAN GM, 1984, ANNU REV NEUROSCI, V7, P339; FINNE J, 1982, J BIOL CHEM, V257, P1966; FUKUDA M, 2000, MOL CELLULAR GLYCOBI, P1; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gregoriadis G, 2000, CELL MOL LIFE SCI, V57, P1964, DOI 10.1007/PL00000676; Hildebrandt H, 1998, CANCER RES, V58, P779; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; Jimbo T, 2001, INT J CANCER, V94, P192, DOI 10.1002/ijc.1458; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Korczak B, 2000, GLYCOBIOLOGY, V10, P595, DOI 10.1093/glycob/10.6.595; Legaigneur P, 2001, J BIOL CHEM, V276, P21608, DOI 10.1074/jbc.M100860200; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Ma B, 2003, J BIOL CHEM, V278, P21893, DOI 10.1074/jbc.M301704200; Muhlenhoff M, 2001, J BIOL CHEM, V276, P34066, DOI 10.1074/jbc.M101022200; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Sarkar M, 1998, GLYCOCONJUGATE J, V15, P193, DOI 10.1023/A:1006928624913; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Seki T, 1998, J NEUROSCI, V18, P3757; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Tanaka F, 2000, CANCER RES, V60, P3072; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; Yabe U, 2003, J BIOL CHEM, V278, P13875, DOI 10.1074/jbc.M300458200; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257	56	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25883	25890		10.1074/jbc.M401562200	http://dx.doi.org/10.1074/jbc.M401562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15067013	hybrid			2022-12-25	WOS:000221827900120
J	Babich, V; Zeng, WZ; Yeh, BI; Ibraghimov-Beskrovanaya, O; Cai, YQ; Somlo, S; Huang, CL				Babich, V; Zeng, WZ; Yeh, BI; Ibraghimov-Beskrovanaya, O; Cai, YQ; Somlo, S; Huang, CL			The N-terminal extracellular domain is required for polycystin-1-dependent channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; GENE-PRODUCT; DIRECT ACTIVATION; PROTEIN PRODUCT; PRIMARY CILIUM; IN-VITRO; MEMBRANE; PKD2; EXPRESSION; LOCALIZATION	Autosomal dominant polycystic kidney disease (PKD) is caused by mutation of polycystin-1 or polycystin-2. Polycystin-2 is a Ca2+-permeable cation channel. Polycystin-1 is an integral membrane protein of less defined function. The N-terminal extracellular region of polycystin-1 contains potential motifs for protein and carbohydrate interaction. We now report that expression of polycystin-1 alone in Chinese hamster ovary (CHO) cells and in PKD2-null cells can confer Ca2+-permeable nonselective cation currents. Co-expression of a loss-of-function mutant of polycystin-2 in CHO cells does not reduce polycystin-1-dependent channel activity. A polycystin-1 mutant lacking similar to2900 amino acids of the extracellular region is targeted to the cell surface but does not produce current. Extracellular application of antibodies against the immunoglobulin-like PKD domains reduces polycystin-1-dependent current. These results support the hypothesis that polycystin-1 is a surface membrane receptor that transduces the signal via changes in ionic currents.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Nephrol, Dallas, TX 75390 USA; Genzyme Corp, Framingham, MA 01701 USA; Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06519 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanofi-Aventis; Genzyme Corporation; Yale University	Huang, CL (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	chou-long.huang@UTSouthwestern.edu						Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; Bukanov NO, 2002, HUM MOL GENET, V11, P923, DOI 10.1093/hmg/11.8.923; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Foggensteiner L, 2000, J AM SOC NEPHROL, V11, P814, DOI 10.1681/ASN.V115814; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GENG L, 2000, BIOCHIM BIOPHYS ACTA, V535, P21; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Grimm DH, 2003, J BIOL CHEM, V278, P36786, DOI 10.1074/jbc.M306536200; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Praetorius HA, 2003, CURR OPIN NEPHROL HY, V12, P517, DOI 10.1097/00041552-200309000-00006; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Reynolds DM, 1999, J AM SOC NEPHROL, V10, P2342; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; Scheffers MS, 2000, HUM MOL GENET, V9, P2743, DOI 10.1093/hmg/9.18.2743; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; van Adelsberg J, 1999, DEV GENET, V24, P299, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<299::AID-DVG13>3.0.CO;2-J; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; WARD CJ, 1994, CELL, V77, P881; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Xu GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/jbc.M107828200; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V283, pF630, DOI 10.1152/ajprenal.00378.2001	43	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25582	25589		10.1074/jbc.M402829200	http://dx.doi.org/10.1074/jbc.M402829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060061	hybrid			2022-12-25	WOS:000221827900085
J	Parmar, S; Katsoulidis, E; Verma, A; Li, Y; Sassano, A; Lal, L; Majchrzak, B; Ravandi, F; Tallman, MS; Fish, EN; Platanias, LC				Parmar, S; Katsoulidis, E; Verma, A; Li, Y; Sassano, A; Lal, L; Majchrzak, B; Ravandi, F; Tallman, MS; Fish, EN; Platanias, LC			Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; EARLY GENE INDUCTION; P38-ALPHA MAP KINASE; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; INTERFERON-ALPHA; STRUCTURAL BASIS; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION	Imatinib mesylate (STI571), a specific inhibitor of the BCR-ABL tyrosine kinase, exhibits potent antileukemic effects in vitro and in vivo. Despite the well established role of STI571 in the treatment of chronic myelogenous leukemia, the precise mechanisms by which inhibition of BCR-ABL tyrosine kinase activity results in generation of antileukemic responses remain unknown. In the present study we provide evidence that treatment of CML-derived BCR-ABL-expressing leukemia cells with STI571 results in activation of the p38 mitogen-activated protein (MAP) kinase signaling pathway. Our data indicate that STI571 induces phosphorylation of the p38 and activation of its kinase domain, in KT-1 cells and other BCR-ABL-expressing cell lines. We also identify the kinases MAP kinase-activated protein kinase-2 and Msk1 as two downstream effectors of p38, activated during inhibition of BCR-ABL activity by STI571. Importantly, pharmacological inhibition of p38 reverses the growth inhibitory effects of STI571 on primary leukemic colony-forming unit granulocyte/ macrophage progenitors from patients with CML. Altogether, our data establish that activation of the p38 MAP kinase signaling cascade plays an important role in the generation of the effects of STI571 on BCR-ABL-expressing cells. They also suggest that, in addition to activation of mitogenic pathways, BCR-ABL promotes leukemogenesis by suppressing the function of growth inhibitory signaling cascades.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; Univ Toronto, Div Cell & Mol Biol, Toronto Res Inst, Univ Network, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University of Toronto	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks St,Olson 8250, Chicago, IL 60611 USA.	l-platanias@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA077816, R01CA094079] Funding Source: NIH RePORTER; NCI NIH HHS [CA77816, CA94079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Andreakos ET, 2002, CYTOKINE GROWTH F R, V13, P299, DOI 10.1016/S1359-6101(02)00018-7; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Buchdunger E, 1996, CANCER RES, V56, P100; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Ebos JML, 2002, MOL CANCER RES, V1, P89; Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008; Fitzgerald CE, 2003, NAT STRUCT BIOL, V10, P764, DOI 10.1038/nsb949; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Grumbach IM, 2001, BRIT J HAEMATOL, V112, P327, DOI 10.1046/j.1365-2141.2001.02556.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; Kantarjian HM, 1996, BLOOD, V87, P3069, DOI 10.1182/blood.V87.8.3069.bloodjournal8783069; Kawauchi K, 2003, BLOOD CELL MOL DIS, V31, P11, DOI 10.1016/S1079-9796(03)00070-6; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kurzrock R, 2003, ANN INTERN MED, V138, P819, DOI 10.7326/0003-4819-138-10-200305200-00010; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2003, BLOOD, V101, P2368, DOI 10.1182/blood.V101.6.2368; Marley SB, 2002, BRIT J HAEMATOL, V116, P162, DOI 10.1046/j.1365-2141.2002.03237.x; Mauro MJ, 2002, J CLIN ONCOL, V20, P325, DOI 10.1200/JCO.20.1.325; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Newton R, 2003, BIODRUGS, V17, P113, DOI 10.2165/00063030-200317020-00004; Nishihara T, 2003, INT J HEMATOL, V78, P233, DOI 10.1007/BF02983800; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Pargellis Christopher, 2003, Curr Opin Investig Drugs, V4, P566; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; RASKIND WH, 1987, CANCER GENET CYTOGEN, V25, P271, DOI 10.1016/0165-4608(87)90188-9; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Traina F, 2003, FEBS LETT, V535, P17, DOI 10.1016/S0014-5793(02)03845-0; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200; Verma A, 2002, LEUKEMIA LYMPHOMA, V43, P703, DOI 10.1080/10428190290016782; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; von Bubnoff N, 2003, LEUKEMIA, V17, P829, DOI 10.1038/sj.leu.2402889; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Wong S, 2003, BLOOD, V101, P4088, DOI 10.1182/blood-2002-11-3376; Yen A, 1998, CANCER RES, V58, P3163; YU C, 2002, CANCER RES, V62, P18	72	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25345	25352		10.1074/jbc.M400590200	http://dx.doi.org/10.1074/jbc.M400590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15056660	hybrid			2022-12-25	WOS:000221827900056
J	Posewitz, MC; King, PW; Smolinski, SL; Zhang, LP; Seibert, M; Ghirardi, ML				Posewitz, MC; King, PW; Smolinski, SL; Zhang, LP; Seibert, M; Ghirardi, ML			Discovery of two novel radical S-adenosylmethionine proteins required for the assembly of an active [Fe] hydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALGA CHLAMYDOMONAS-REINHARDTII; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BIOTIN SYNTHASE; IRON-HYDROGENASE; DESULFOVIBRIO-DESULFURICANS; THERMOTOGA-MARITIMA; ONLY HYDROGENASE; 4FE-4S CLUSTERS; SITE	To identify genes necessary for the photoproduction of H-2 in Chlamydomonas reinhardtii, random insertional mutants were screened for clones unable to produce H-2. One of the identified mutants, denoted hydEF-1, is incapable of assembling an active [Fe] hydrogenase. Although the hydEF-1 mutant transcribes both hydrogenase genes and accumulates full-length hydrogenase protein, H-2 production activity is not observed. The HydEF protein contains two unique domains that are homologous to two distinct prokaryotic proteins, HydE and HydF, which are found exclusively in organisms containing [Fe] hydrogenase. In the C. reinhardtii genome, the HydEF gene is adjacent to another hydrogenase-related gene, HydG. All organisms with [Fe] hydrogenase and sequenced genomes contain homologues of HydE, HydF, and HydG, which, prior to this study, were of unknown function. Within several prokaryotic genomes HydE, HydF, and HydG are found in putative operons with [Fe] hydrogenase structural genes. Both HydE and HydG belong to the emerging radical S-adenosylmethionine (commonly designated "Radical SAM") superfamily of proteins. We demonstrate here that HydEF and HydG function in the assembly of [Fe] hydrogenase. Northern blot analysis indicates that mRNA transcripts for both the HydEF gene and the HydG gene are anaerobically induced concomitantly with the two C. reinhardtii [Fe] hydrogenase genes, HydA1 and HydA2. Complementation of the bx;1C. reinhardtii hydEF-1 mutant with genomic DNA corresponding to a functional copy of the HydEF gene restores hydrogenase activity. Moreover, co-expression of the C. reinhardtii HydEF, HydG, and HydA1 genes in Escherichia coli results in the formation of an active HydA1 enzyme. This represents the first report on the nature of the accessory genes required for the maturation of an active [Fe] hydrogenase.	Colorado Sch Mines, Natl Renewable Energy Lab, Golden, CO 80401 USA; Colorado Sch Mines, Dept Environm Sci & Engn, Golden, CO 80401 USA	Colorado School of Mines; United States Department of Energy (DOE); National Renewable Energy Laboratory - USA; Colorado School of Mines	Ghirardi, ML (corresponding author), Colorado Sch Mines, Natl Renewable Energy Lab, Golden, CO 80401 USA.	maria_ghirardi@nrel.gov	King, Paul W./D-9979-2011	King, Paul W./0000-0001-5039-654X				ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; Asada Y, 2000, BBA-GENE STRUCT EXPR, V1490, P269, DOI 10.1016/S0167-4781(00)00010-5; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; BOICHENKO VA, 2004, MOL GLOBAL PHOTOSYNT, P397; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Casalot L, 2001, TRENDS MICROBIOL, V9, P228, DOI 10.1016/S0966-842X(01)02009-1; Cosper NJ, 2000, BIOCHEMISTRY-US, V39, P15668, DOI 10.1021/bi0022184; Davies JP, 1999, PLANT CELL, V11, P1179, DOI 10.1105/tpc.11.6.1179; Flynn T, 2002, INT J HYDROGEN ENERG, V27, P1421, DOI 10.1016/S0360-3199(02)00117-9; Forestier M, 2003, EUR J BIOCHEM, V270, P2750, DOI 10.1046/j.1432-1033.2003.03656; Frey M, 2002, CHEMBIOCHEM, V3, P153, DOI 10.1002/1439-7633(20020301)3:2/3<153::AID-CBIC153>3.0.CO;2-B; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; Gaffron Hans, 1942, JOUR GEN PHYSIOL, V26, P219, DOI 10.1085/jgp.26.2.219; Garcin E, 1999, STRUCT FOLD DES, V7, P557, DOI 10.1016/S0969-2126(99)80072-0; GFELLER RP, 1984, PLANT PHYSIOL, V75, P212, DOI 10.1104/pp.75.1.212; Ghirardi ML, 1997, APPL BIOCHEM BIOTECH, V63-5, P141, DOI 10.1007/BF02920420; Ghirardi ML, 2000, TRENDS BIOTECHNOL, V18, P506, DOI 10.1016/S0167-7799(00)01511-0; HAPPE T, 1993, EUR J BIOCHEM, V214, P475, DOI 10.1111/j.1432-1033.1993.tb17944.x; Happe T, 2002, EUR J BIOCHEM, V269, P1022, DOI 10.1046/j.0014-2956.2001.02743.x; Higuchi Y, 1997, STRUCTURE, V5, P1671, DOI 10.1016/S0969-2126(97)00313-4; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; Krebs C, 2000, J AM CHEM SOC, V122, P12497, DOI 10.1021/ja003335p; Lumbreras V, 1998, PLANT J, V14, P441, DOI 10.1046/j.1365-313X.1998.00145.x; Lyon EJ, 2004, EUR J BIOCHEM, V271, P195, DOI 10.1046/j.1432-1033.2003.03920.x; Melis A, 2000, PLANT PHYSIOL, V122, P127, DOI 10.1104/pp.122.1.127; MENON NK, 1991, J BACTERIOL, V173, P4851, DOI 10.1128/jb.173.15.4851-4861.1991; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Nicolet Y, 2001, J AM CHEM SOC, V123, P1596, DOI 10.1021/ja0020963; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Ollagnier-de-Choudens S, 2002, BIOCHEMISTRY-US, V41, P9145, DOI 10.1021/bi0122011; Pan GL, 2003, J BIOL INORG CHEM, V8, P469, DOI 10.1007/s00775-002-0439-y; Paschos A, 2001, FEBS LETT, V488, P9, DOI 10.1016/S0014-5793(00)02408-X; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Pierik AJ, 1998, EUR J BIOCHEM, V258, P572, DOI 10.1046/j.1432-1327.1998.2580572.x; Reissmann S, 2003, SCIENCE, V299, P1067, DOI 10.1126/science.1080972; Siebert M., 2001, . U.S. patent, Patent No. [6,277,589, 6277589, 6,277,589 B1]; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tamagnini P, 2002, MICROBIOL MOL BIOL R, V66, P1, DOI 10.1128/MMBR.66.1.1-20.2002; Ugulava NB, 2000, BIOCHEMISTRY-US, V39, P5206, DOI 10.1021/bi9926227; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; VOORDOUW G, 1987, EUR J BIOCHEM, V162, P31, DOI 10.1111/j.1432-1033.1987.tb10537.x; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243; Wykoff DD, 1998, PLANT PHYSIOL, V117, P129, DOI 10.1104/pp.117.1.129	47	316	332	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25711	25720		10.1074/jbc.M403206200	http://dx.doi.org/10.1074/jbc.M403206200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15082711	hybrid			2022-12-25	WOS:000221827900101
J	Wang, H; Fang, RH; Cho, JY; Libermann, TA; Oettgen, P				Wang, H; Fang, RH; Cho, JY; Libermann, TA; Oettgen, P			Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; KERATINOCYTE TERMINAL DIFFERENTIATION; DNA-BINDING; KU AUTOANTIGEN; GENE-EXPRESSION; CELLS; COACTIVATOR; PROMOTER; EPITHELIUM; RECEPTOR	Epithelium-specific ETS (ESE)-1 is a prototypic member of a novel subset of the ETS transcription factor family that is predominantly expressed in cells of epithelial origin but can also be induced in other cell types including vascular endothelial and smooth muscle cells in response to inflammatory stimuli. To further define the molecular mechanisms by which the transcriptional activity of ESE-1 is regulated, we have focused our attention on identifying proteins that interact with ESE-1. We have determined that Ku70, Ku86, p300, and CREB-binding protein (CBP) are ESE-1 interacting proteins. The Ku proteins have previously been shown to bind to breaks in DNA where they function to recruit additional proteins that promote DNA repair. Interestingly, Ku70 and Ku 86 negatively regulate the transcriptional activity of ESE-1. Using a series of deletion constructs, we have determined that the Ku proteins bind to the DNA-binding domain of ESE-1. The Ku proteins inhibit the ability of ESE-1 to bind to oligonucleotide probes in gel mobility shift assays. The finding that Ku proteins can interact with other transcription factors and block their function has not been previously demonstrated. In contrast, co-transfection of p300 and CBP with ESE-1 enhances the transcriptional activity of ESE-1. Moreover, the induction of ESE-1 in response to inflammatory cytokine interleukin-1 is associated with a parallel increase of the expression of p300 in vascular endothelial cells, suggesting that in the setting of inflammation, the transcriptional activity of ESE-1 is positively modulated by interaction with the transcriptional co-activator p300. In summary, our results demonstrated that the activity of ESE-1 is positively and negatively modulated by other interacting proteins including Ku70, Ku86, p300, and CBP.	Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School	Oettgen, P (corresponding author), Harvard Univ, Inst Med, 4 Blackfan Circle, Boston, MA 02115 USA.	joettgen@bicmc.harvard.edu	Wang, Hong/H-6298-2012; Oettgen, Peter/AAF-5026-2021; Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067219, T32HL007374] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67219, T32 HL07374-24] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aird SD, 2002, TOXICON, V40, P335, DOI 10.1016/S0041-0101(01)00232-X; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; Bryntesson F, 2001, RADIAT RES, V156, P167, DOI 10.1667/0033-7587(2001)156[0167:AOGTIC]2.0.CO;2; Bush TS, 2003, BLOOD, V101, P311, DOI 10.1182/blood.V101.1.311; Camara-Clayette V, 1999, NUCLEIC ACIDS RES, V27, P1656, DOI 10.1093/nar/27.7.1656; Camara-Clayette V, 1999, BIOCHEM BIOPH RES CO, V265, P170, DOI 10.1006/bbrc.1999.1634; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Dube A, 2001, CIRC RES, V88, P237; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jeanson L, 2002, VIROLOGY, V300, P100, DOI 10.1006/viro.2002.1515; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; Lee JH, 1996, J BIOL CHEM, V271, P4561; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; OKUMURA K, 1994, FEBS LETT, V356, P94, DOI 10.1016/0014-5793(94)01243-1; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pedley J, 1998, MELANOMA RES, V8, P471, DOI 10.1097/00008390-199812000-00001; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Schaffer A, 2003, J BIOL CHEM, V278, P23141, DOI 10.1074/jbc.M212952200; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Silverman ES, 2002, AM J RESP CELL MOL, V27, P697, DOI 10.1165/rcmb.2002-0011OC; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; Warriar N, 1996, J BIOL CHEM, V271, P18662, DOI 10.1074/jbc.271.31.18662; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Woodard RL, 2001, J BIOL CHEM, V276, P15423, DOI 10.1074/jbc.M010752200; Yamamoto H, 2002, CELL GROWTH DIFFER, V13, P69; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	56	36	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25241	25250		10.1074/jbc.M401356200	http://dx.doi.org/10.1074/jbc.M401356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15075319	hybrid			2022-12-25	WOS:000221827900042
J	Castillejo-Lopez, C; Arias, WM; Baumgartner, S				Castillejo-Lopez, C; Arias, WM; Baumgartner, S			The fat-like gene of Drosophila is the true orthologue of vertebrate fat cadherins and is involved in the formation of tubular organs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-ADHESION; CAENORHABDITIS-ELEGANS; GENOME SEQUENCE; ENCODES; PROTEIN; SUPERFAMILY; MORPHOGENESIS; MELANOGASTER; EXPRESSION	Fat cadherins constitute a subclass of the large cadherin family characterized by the presence of 34 cadherin motifs. To date, three mammalian Fat cadherins have been described; however, only limited information is known about the function of these molecules. In this paper, we describe the second fat cadherin in Drosophila, fat-like (ftl). We show that ftl is the true orthologue of vertebrate fat-like genes, whereas the previously characterized tumor suppressor cadherin, fat, is more distantly related as compared with ftl. Ftl is a large molecule of 4705 amino acids. It is expressed apically in luminal tissues such as trachea, salivary glands, proventriculus, and hindgut. Silencing of ftl results in the collapse of tracheal epithelia giving rise to breaks, deletions, and sac-like structures. Other tubular organs such as proventriculus, salivary glands, and hindgut are also malformed or missing. These data suggest that Ftl is required for morphogenesis and maintenance of tubular structures of ectodermal origin and underline its similarity in function to a reported lethal mouse knock-out of fat1 where glomerular epithelial processes collapse. Based on our results, we propose a model where Ftl acts as a spacer to keep tubular epithelia apart rather than the previously described adhesive properties of the cadherin superfamily.	Lund Univ, Dept Cell & Mol Biol, S-22184 Lund, Sweden	Lund University	Castillejo-Lopez, C (corresponding author), Lund Univ, Dept Cell & Mol Biol, BMC B13, S-22184 Lund, Sweden.	Casimiro.Castillejo-Lopez@medkem.lu.se	Baumgartner, Stefan/A-5879-2011	Baumgartner, Stefan/0000-0001-5320-8321				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Arias A.M., 1993, DEV DROSOPHILA, P609; CamposOrtega J. A., 1985, EMBRYONIC DEV DROSOP, P9, DOI DOI 10.1007/978-3-662-22489-2_2; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; CLARK HF, 1995, GENE DEV, V9, P1530, DOI 10.1101/gad.9.12.1530; Cox B, 2000, DEV DYNAM, V217, P233, DOI 10.1002/(SICI)1097-0177(200003)217:3<233::AID-DVDY1>3.0.CO;2-O; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; Fortier E, 2000, GENESIS, V26, P240, DOI 10.1002/(SICI)1526-968X(200004)26:4<240::AID-GENE40>3.0.CO;2-P; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; Gaunt MW, 2002, MOL BIOL EVOL, V19, P748, DOI 10.1093/oxfordjournals.molbev.a004133; Hill E, 2001, J MOL BIOL, V305, P1011, DOI 10.1006/jmbi.2000.4361; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; Inoue T, 2001, KIDNEY INT, V59, P1003, DOI 10.1046/j.1523-1755.2001.00583.x; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Jazwinska A, 2003, NAT CELL BIOL, V5, P895, DOI 10.1038/ncb1049; Kalidas S, 2002, NEURON, V33, P177, DOI 10.1016/S0896-6273(02)00560-3; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Matsuyoshi N, 1997, J INVEST DERMATOL, V108, P908, DOI 10.1111/1523-1747.ep12292703; Mitsui K, 2002, BIOCHEM BIOPH RES CO, V290, P1260, DOI 10.1006/bbrc.2002.6338; Myat MM, 2002, CELL, V111, P879, DOI 10.1016/S0092-8674(02)01140-6; Nakayama M, 2002, MOL CELL NEUROSCI, V20, P563, DOI 10.1006/mcne.2002.1146; Noirot C., 1982, P351; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Pettitt J, 1996, DEVELOPMENT, V122, P4149; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; Ponassi M, 1999, MECH DEVELOP, V80, P207, DOI 10.1016/S0925-4773(98)00217-2; Prout M, 1997, GENETICS, V146, P275; Rawls AS, 2002, CURR BIOL, V12, P1021, DOI 10.1016/S0960-9822(02)00893-X; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Walsh EP, 1998, GENETICS, V150, P791; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wilk R, 2000, DEV BIOL, V219, P183, DOI 10.1006/dbio.2000.9619; Wilkin MB, 2000, CURR BIOL, V10, P559, DOI 10.1016/S0960-9822(00)00482-6; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X	44	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24034	24043		10.1074/jbc.M313878200	http://dx.doi.org/10.1074/jbc.M313878200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15047711	hybrid			2022-12-25	WOS:000221702500025
J	Hansen, SB; Talley, TT; Radic, Z; Taylor, P				Hansen, SB; Talley, TT; Radic, Z; Taylor, P			Structural and ligand recognition characteristics of an acetylcholine-binding protein from Aplysia californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; CHOLINERGIC RECEPTOR; NICOTINIC RECEPTORS; DOMAIN; PEPTIDES; REVEALS	We generated an acetylcholine-binding protein from Aplysia californica by synthesis of a cDNA found in existing data bases and its expression in mammalian cell culture. Its subunit assembly and ligand recognition behavior were compared with the binding protein previously derived from Lymnaea stagnalis. The secreted proteins were purified by elution from columns of attached antibodies directed to the FLAG epitope encoded in the expression construct. Although the sequences of the two proteins from marine and fresh water mollusks exhibit the characteristic features of the extracellular domain of the nicotinic receptor, they only possess 33% amino acid identity. Both assemble as stable pentamers with five binding sites per pentamer, yet they show distinguishing features of stability and sensitivity to epitope tag placement. Both proteins exhibit changes in tryptophan fluorescence upon ligand binding; however, the magnitude of the changes differs greatly. Moreover, certain ligands show marked differences in dissociation constants for the two proteins and can be regarded as distinguishing or signature ligands. Hence, the two soluble proteins from mollusks, which can be studied by a variety of physical methods, become discrete surrogate proteins for the extracellular domains of distinct sub-types of nicotinic acetylcholine receptors.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.		Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM NS043063, GM 07752, R37-GM18360, R37 GM018360, T32 GM007752] Funding Source: Medline; NINDS NIH HHS [F32 NS043063-01, F32 NS043063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; LEE C Y, 1963, Showa Igakkai Zasshi, V23, P221; LEE CY, 1972, ANNU REV PHARMACOLOG, V12, P265, DOI 10.1146/annurev.pa.12.040172.001405; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sixma TK, 2003, ANNU REV BIOPH BIOM, V32, P311, DOI 10.1146/annurev.biophys.32.110601.142536; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; SMIT AB, 2001, Patent No. 0158951; TAYLOR P, 2000, HANDB EXP PHARM, V144, P79; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; WEILAND G, 1977, J BIOL CHEM, V252, P7648; ZOLI M, 2000, HANDB EXP PHARM, V144, P213	22	132	137	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24197	24202		10.1074/jbc.M402452200	http://dx.doi.org/10.1074/jbc.M402452200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069068	hybrid, Green Accepted			2022-12-25	WOS:000221702500043
J	Krejci, L; Macris, M; Li, Y; Van Komen, S; Villemain, J; Ellenberger, T; Klein, H; Sung, P				Krejci, L; Macris, M; Li, Y; Van Komen, S; Villemain, J; Ellenberger, T; Klein, H; Sung, P			Role of ATP hydrolysis in the antirecombinase function of Saccharomyces cerevisiae Srs2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE ACTIVITIES; YEAST RAD51 PROTEIN; MITOTIC RECOMBINATION; STRAND EXCHANGE; GENETIC-CONTROL; REPAIR; MUTATIONS; TRANSCRIPTION; CATALYSIS; SUPPRESS	Mutants of the Saccharomyces cerevisiae SRS2 gene are hyperrecombinogenic and sensitive to genotoxic agents, and they exhibit a synthetic lethality with mutations that compromise DNA repair or other chromosomal processes. In addition, srs2 mutants fail to adapt or recover from DNA damage checkpoint-imposed G(2)/M arrest. These phenotypic consequences of ablating SRS2 function are effectively overcome by deleting genes of the RAD52 epistasis group that promote homologous recombination, implicating an untimely recombination as the underlying cause of the srs2 mutant phenotypes. The SRS2-encoded protein has a single-stranded( ss)DNA-dependent ATPase activity, a DNA helicase activity, and an ability to disassemble the Rad51-ssDNA nucleoprotein filament, which is the key catalytic intermediate in Rad51- mediated recombination reactions. To address the role of ATP hydrolysis in Srs2 protein function, we have constructed two mutant variants that are altered in the Walker type A sequence involved in the binding and hydrolysis of ATP. The srs2 K41A and srs2 K41R mutant proteins are both devoid of ATPase and helicase activities and the ability to displace Rad51 from ssDNA. Accordingly, yeast strains harboring these srs2 mutations are hyperrecombinogenic and sensitive to methyl-methane sulfonate, and they become inviable upon introducing either the sgs1Delta or rad54Delta mutation. These results highlight the importance of the ATP hydrolysis-fueled DNA motor activity in SRS2 functions.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA	Yale University; Harvard University; Harvard Medical School; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; New York University	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,SHM C130A, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu	Krejci, Lumir/B-7842-2009	Krejci, Lumir/0000-0002-4732-1405; Klein, Hannah/0000-0003-4228-8535	NIEHS NIH HHS [ES07061] Funding Source: Medline; NIGMS NIH HHS [F32GM065746, GM57814, GM53738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053738, F32GM065746] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1988, GENETICS, V119, P779; Aylon Y, 2003, MOL CELL BIOL, V23, P1403, DOI 10.1128/MCB.23.4.1403-1417.2003; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Chanet R, 1996, MOL CELL BIOL, V16, P4782; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Klein H, 2001, GENETICS, V157, P557; Klein HL, 2000, NAT GENET, V25, P132, DOI 10.1038/75957; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Krejci L, 2002, J BIOL CHEM, V277, P40132, DOI 10.1074/jbc.M206511200; LAWRENCE CW, 1979, J BACTERIOL, V139, P866, DOI 10.1128/JB.139.3.866-876.1979; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Liberi G, 2000, EMBO J, V19, P5027, DOI 10.1093/emboj/19.18.5027; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RONG L, 1991, GENETICS, V127, P75; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SHERMAN F, 1991, P3; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; THOMAS BJ, 1989, GENETICS, V123, P725; Van Komen S, 2003, J BIOL CHEM, V278, P44331, DOI 10.1074/jbc.M307256200; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	30	57	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23193	23199		10.1074/jbc.M402586200	http://dx.doi.org/10.1074/jbc.M402586200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047689	hybrid			2022-12-25	WOS:000221570900050
J	van Dolleweerd, CJ; Kelly, CG; Chargelegue, D; Ma, JKC				van Dolleweerd, CJ; Kelly, CG; Chargelegue, D; Ma, JKC			Peptide mapping of a novel discontinuous epitope of the major surface adhesin from Streptococcus mutans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN PANCREATIC-POLYPEPTIDE; LOCAL PASSIVE-IMMUNIZATION; PROTEIN ANTIGEN GENE; X-RAY-ANALYSIS; MONOCLONAL-ANTIBODIES; CELL-SURFACE; SEROTYPE-C; MOLECULAR CHARACTERIZATION; DENTAL-CARIES; BINDING-SITE	Guy's 13 is a mouse monoclonal antibody that specifically recognizes the major cell-surface adhesion protein SA I/II of Streptococcus mutans, one of the major causative agents of dental caries. Passive immunization with Guy's 13 prevents bacterial colonization in humans. To help elucidate the mechanism of prevention of colonization conferred by this antibody, the SA I/II epitope recognized by Guy's 13 was investigated. It was previously established that the epitope is conformational, being assembled from two non-contiguous regions of SA I/II. In the current study, using recombinant fragments of SA I/II and, ultimately, synthetic peptides, the discontinuous epitope was localized to residues 170-218 and 956-969. This work describes the mapping of a novel discontinuous epitope that requires an interaction between each determinant in order for epitope assembly and recognition by antibody to take place. Guy's 13 binds to the assembled epitope but not to these individual epitope fragments. The assembled epitope results from the interaction between the individual antigenic determinants and can be formed by mixing together determinants present on separate polypeptide chains. The data are consistent with one of the epitope fragments adopting a polyproline II-like helical conformation.	Guys Hosp, Guys Kings & St Thomas Hosp Med Sch, Dept Oral Med & Pathol, London SE1 9RT, England; St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; St Georges University London	van Dolleweerd, CJ (corresponding author), Guys Hosp, Guys Kings & St Thomas Hosp Med Sch, Dept Oral Med & Pathol, Floor 28 Guys Tower, London SE1 9RT, England.	craig.van_dolleweerd@kcl.ac.uk		Ma, Julian/0000-0003-0767-0042; van Dolleweerd, Craig/0000-0002-1380-6930				ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BLUNDELL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4175, DOI 10.1073/pnas.78.7.4175; BOLLET C, 1991, NUCLEIC ACIDS RES, V19, P1955, DOI 10.1093/nar/19.8.1955; DARBON H, 1992, EUR J BIOCHEM, V209, P765, DOI 10.1111/j.1432-1033.1992.tb17346.x; DEMUTH DR, 1990, J BIOL CHEM, V265, P7120; Demuth DR, 2002, INFECT IMMUN, V70, P6389, DOI 10.1128/IAI.70.11.6389-6398.2002; DORNER B, 2000, FMOC SOLID PHASE PEP; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GLOVER I, 1983, BIOPOLYMERS, V22, P293, DOI 10.1002/bip.360220138; GLOVER ID, 1984, EUR J BIOCHEM, V142, P379, DOI 10.1111/j.1432-1033.1984.tb08298.x; Jenkinson HF, 1997, MOL MICROBIOL, V23, P183, DOI 10.1046/j.1365-2958.1997.2021577.x; KELLY C, 1989, FEBS LETT, V258, P127, DOI 10.1016/0014-5793(89)81632-1; KELLY C, 1990, ARCH ORAL BIOL, V35, pS33, DOI 10.1016/0003-9969(90)90128-W; Kelly CG, 1999, NAT BIOTECHNOL, V17, P42, DOI 10.1038/5213; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Kruger C, 2002, NAT BIOTECHNOL, V20, P702, DOI 10.1038/nbt0702-702; LAPOLLA RJ, 1991, INFECT IMMUN, V59, P2677, DOI 10.1128/IAI.59.8.2677-2685.1991; LEHNER T, 1985, INFECT IMMUN, V50, P796, DOI 10.1128/IAI.50.3.796-799.1985; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; MA JK, 1989, CLIN EXP IMMUNOL, V77, P331; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; Ma JKC, 1998, NAT MED, V4, P601, DOI 10.1038/nm0598-601; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; OGIER JA, 1990, ARCH ORAL BIOL, V35, pS25, DOI 10.1016/0003-9969(90)90127-V; OKAHASHI N, 1989, MOL MICROBIOL, V3, P221, DOI 10.1111/j.1365-2958.1989.tb01811.x; OKAHASHI N, 1989, MOL MICROBIOL, V3, P673, DOI 10.1111/j.1365-2958.1989.tb00215.x; Prodinger WM, 1998, J IMMUNOL, V161, P4604; Reineke U, 1999, NAT BIOTECHNOL, V17, P271, DOI 10.1038/7018; RUSSELL MW, 1980, INFECT IMMUN, V28, P486; RUSSELL MW, 1978, ARCH ORAL BIOL, V23, P7, DOI 10.1016/0003-9969(78)90047-X; Schier R, 1996, GENE, V169, P147, DOI 10.1016/0378-1119(95)00821-7; SMITH R, 1989, ORAL MICROBIOL IMMUN, V4, P153, DOI 10.1111/j.1399-302X.1989.tb00243.x; Spendlove I, 2000, EUR J IMMUNOL, V30, P2944, DOI 10.1002/1521-4141(200010)30:10<2944::AID-IMMU2944>3.0.CO;2-U; TAYLOR TC, 1988, MOL IMMUNOL, V25, P961, DOI 10.1016/0161-5890(88)90002-8; Troffer-Charlier N, 2002, J MOL BIOL, V318, P179, DOI 10.1016/S0022-2836(02)00025-6; van Dolleweerd CJ, 2003, INFECT IMMUN, V71, P754, DOI 10.1128/IAI.71.2.754-765.2003; Wellings DA, 1997, METHOD ENZYMOL, V289, P44	39	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22198	22203		10.1074/jbc.M400820200	http://dx.doi.org/10.1074/jbc.M400820200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15060072	hybrid			2022-12-25	WOS:000221417100065
J	Kang, AD; Park, G; Kim, YH; Oh, IH				Kang, AD; Park, G; Kim, YH; Oh, IH			Differential modulation of Myb family genes by Ets-2	ONCOGENE			English	Article						myb family gene; ets-2; transcriptional cooperation	MURINE A-MYB; C-MYB; B-MYB; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; EXPRESSION; ONCOGENE; PHOSPHORYLATION; PROTEINS; DISTINCT	The myb family of genes encodes highly homologous nuclear transcription factors that play distinct roles in the development of breast, germ cells and hematoid organs. While the mechanisms associated with the regulation of these genes remain unknown, the transactivation of c-Myb was previously shown to be upregulated by transcriptional cooperation with Ets-2. The present study examines the transactivation potential of the myb gene family in cooperation with Ets-2. A-Myb and c-Myb showed similar transcriptional cooperation with Ets-2, but not with Ets-1. Interestingly, B-Myb showed no cooperative activity with Ets-2 or Ets-1. Additionally, deletion mutants of A-Myb or c-Myb, where the C-terminal negative regulatory domain was deleted, did not abrogate their ability to cooperate with Ets-2. However, the deletion mutant of B-Myb, where the C-terminal positive regulatory domain was deleted, restored its ability to cooperate with Ets-2. Furthermore, studies using a series of 'domain-swapped' mutants between c-Myb and B-Myb revealed that the C-terminus of B-Myb, which is responsible for the protein's transactivation potential, blocks transcriptional cooperation with Ets-2. These results suggest that the myb gene family can be differentially modulated by Ets-2, and that the C-terminus is the domain that regulates this activity.	Catholic Univ Korea, Cell & Gene Therapy Inst, Dept Cellular Med & Biol, Seoul 137701, South Korea; Catholic Univ Korea, Dept Clin Pathol, Seoul 137701, South Korea; Korea Univ, Seoul 136701, South Korea	Catholic University of Korea; Catholic University of Korea; Korea University	Oh, IH (corresponding author), Catholic Univ Korea, Cell & Gene Therapy Inst, Dept Cellular Med & Biol, 505 Banpo Dong, Seoul 137701, South Korea.	iho@catholic.ac.kr		Kim, Yeul Hong/0000-0002-2555-2333				BALUDA MA, 1994, ONCOGENE, V9, P2761; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; KALKBRENNER F, 1990, ONCOGENE, V5, P657; METTUS RV, 1994, ONCOGENE, V9, P3077; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Patel G, 1996, ONCOGENE, V13, P1197; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	25	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4177	4181		10.1038/sj.onc.1207537	http://dx.doi.org/10.1038/sj.onc.1207537			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064740				2022-12-25	WOS:000221520200017
J	Chumakov, AM; Kubota, T; Walter, S; Koeffler, HP				Chumakov, AM; Kubota, T; Walter, S; Koeffler, HP			Identification of murine and human XCP1 genes as C/EBP-epsilon-dependent members of FIZZ/Resistin gene family	ONCOGENE			English	Article						C/EBP; resistin; transcriptional regulation; myeloid; chemotaxis; defensin; innate immunity	BINDING-PROTEIN-EPSILON; MYELOID TRANSCRIPTION FACTOR; CELL-LINE; EXPRESSION; DEFENSINS; LEUKEMIA; RESISTIN; DIFFERENTIATION; MYB; CHEMOKINES	The CCAAT enhancer binding protein epsilon (C/EBP-epsilon) transcription factor is expressed predominantly in granulocytes. Mice with a disruption of the C/EBP-epsilon gene fail to produce mature granulocytes and eosinophils. Cells derived from the peritoneal exudates of C/EBP-epsilon -/- mice lack the expression of a number of chemokines and chemokine receptor genes. We have found a novel C/EBP-epsilon dependent promyelocyte-specific gene, mXCP1. mXCP1 belongs to a family of XCP/FIZZ/Resistin genes, which includes four murine genes and two human genes, hXCP1 and hXCP2. These genes have four exons and encode short secreted proteins sharing a ten-cysteine motif. Murine mXCP1, mXCP2 and mXCP3 genes map to murine chromosome 16 and mXCP4 is positioned on chromosome 8; the hXCP1 and hXCP2 genes are located at homologous regions of chromosomes 3 and 19. Introduction of an inducible C/EBP-epsilon gene into the NIH3T3 and myeloid cells from C/EBP-epsilon-null mice line revealed that the conditional expression of C/EBP-epsilon induced mXCP1. The HXCP1 gene was identified as a C/EBP-epsilon-dependent regulatory homologue of mXCP1. The expression data for other members of XCP/FIZZ gene family are presented. Further studies indicate that XCP1 is a secreted protein that is chemotactic to myeloid cells from C/EBP-epsilon-null mice and is able to interact directly with alpha-defensin.	Univ Calif Los Angeles, Sch Med,Burns & Allen Res Inst, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Kochi Med Sch, Dept Med, Kochi 783, Japan	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Kochi University	Chumakov, AM (corresponding author), Univ Calif Los Angeles, Sch Med,Burns & Allen Res Inst, Cedars Sinai Med Ctr, Div Hematol Oncol, Davis Bldg 5022,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	achumakov@hotmail.com	Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; Banerjee RR, 2001, J BIOL CHEM, V276, P25970, DOI 10.1074/jbc.M103109200; Broxmeyer HE, 1999, ANN NY ACAD SCI, V872, P142, DOI 10.1111/j.1749-6632.1999.tb08460.x; CHUMAKOV A, 1993, GENE, V131, P231, DOI 10.1016/0378-1119(93)90298-H; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gropp R, 1999, HUM GENE THER, V10, P957, DOI 10.1089/10430349950018355; Hartman HB, 2002, J BIOL CHEM, V277, P19754, DOI 10.1074/jbc.M201451200; Haugen F, 2001, FEBS LETT, V507, P105, DOI 10.1016/S0014-5793(01)02968-4; Herwig S, 1996, BLOOD, V87, P350, DOI 10.1182/blood.V87.1.350.bloodjournal871350; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; Ichinose M, 1996, IMMUNOPHARMACOLOGY, V35, P103, DOI 10.1016/S0162-3109(96)00118-X; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Kubota T, 2000, BLOOD, V96, P3953, DOI 10.1182/blood.V96.12.3953.h8003953_3953_3957; LANOTTE M, 1991, BLOOD, V77, P1080; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes J, 1999, BLOOD, V93, P3096; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Masera RG, 1996, REGUL PEPTIDES, V62, P13, DOI 10.1016/0167-0115(95)00150-6; Mink S, 1996, MOL CELL BIOL, V16, P1316; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; SCOTT LM, 1992, BLOOD, V80, P1725; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Verbeek W, 1999, BLOOD, V94, P3141, DOI 10.1182/blood.V94.9.3141.421k41_3141_3150; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; YOUNT NY, 1995, J IMMUNOL, V155, P4476; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	46	31	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3414	3425		10.1038/sj.onc.1207126	http://dx.doi.org/10.1038/sj.onc.1207126			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064728				2022-12-25	WOS:000220975000016
J	Weissenberger, J; Loeffler, S; Kappeler, A; Kopf, M; Lukes, A; Afanasieva, TA; Aguzzi, A; Weis, J				Weissenberger, J; Loeffler, S; Kappeler, A; Kopf, M; Lukes, A; Afanasieva, TA; Aguzzi, A; Weis, J			IL-6 is required for glioma development in a mouse model	ONCOGENE			English	Article						gliomas; mouse model; IL-6 knockout; STAT3 signalling	GROWTH-FACTOR; CELL-GROWTH; STAT3; ACTIVATION; GLIOBLASTOMA; ASTROCYTES; EXPRESSION; DIFFERENTIATION; OVEREXPRESSION; PROLIFERATION	The pleiotropic cytokine interleukin- 6 (IL-6) contributes to malignant progression and apoptosis resistance of various cancer types. Although IL-6 is elevated in malignant gliomas, and glioma cells respond to IL-6, its functional role in gliomagenesis is unclear. We have investigated this role of IL-6 in a mouse model of spontaneous astrocytoma by crossbreeding glial fibrillary acidic protein (GFAP)-viral src oncogene transgenic mice with IL-6-deficient mice. We show here that ablation of IL-6 prevents tumour formation in these predisposed animals, but did not affect preneoplastic astrogliosis. Moreover, we demonstrate phosphorylation and nuclear translocation of the transcription factor signal transducer and activator of transcription (STAT) 3, a prerequisite for IL-6 signalling, in 51 human gliomas WHO grade II-IV and all experimental mouse tumours investigated. Together with the observation that STAT3 activation increases with malignancy, these findings indicate an important role for IL-6 in the development and malignant progression of astrocytomas.	Univ Bern, Inst Pathol, Div Neuropathol, CH-3010 Bern, Switzerland; Swiss Fed Inst Technol, Dept Environm Sci, CH-8952 Zurich, Switzerland; Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland; Rhein Westfal TH Aachen, Univ Hosp, Inst Neuropathol, D-52074 Aachen, Germany	University of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bern; University Hospital of Bern; University of Zurich; RWTH Aachen University; RWTH Aachen University Hospital	Weissenberger, J (corresponding author), Univ Bern, Inst Pathol, Div Neuropathol, Murtenstr 31, CH-3010 Bern, Switzerland.	weissenb@patho.unibe.ch	Weis, Joachim/G-1984-2014; Kopf, Manfred/B-6907-2009; Aguzzi, Adriano/A-3351-2008	Weis, Joachim/0000-0003-3280-6773; Kopf, Manfred/0000-0002-0628-7140; Adams, Tatiana/0000-0002-8656-7096; Aguzzi, Adriano/0000-0002-0344-6708				Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brunello AG, 2000, AM J PATHOL, V157, P1485, DOI 10.1016/S0002-9440(10)64787-6; Buettner R, 2002, CLIN CANCER RES, V8, P945; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Candi E, 1997, J NEURO-ONCOL, V31, P115, DOI 10.1023/A:1005706019048; Cardenas H, 2003, BRAIN RES, V985, P89, DOI 10.1016/S0006-8993(03)03172-X; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; Goswami S, 1998, J NEUROCHEM, V71, P1837; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kleihues P, 2000, PATHOLOGY GENETICS T; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nagashima G, 2002, CLIN NEUROL NEUROSUR, V104, P125, DOI 10.1016/S0303-8467(01)00197-4; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SEHGAL PB, 2002, J BIOL CHEM, V28, P28; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Senger DL, 2002, CANCER RES, V62, P2131; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Takizawa T, 2001, CYTOKINE, V13, P272, DOI 10.1006/cyto.2000.0831; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; VAN MEIR E, 1990, CANCER RES, V50, P6683; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	43	144	159	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3308	3316		10.1038/sj.onc.1207455	http://dx.doi.org/10.1038/sj.onc.1207455			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064729				2022-12-25	WOS:000220975000005
J	Janz, JM; Farrens, DL				Janz, JM; Farrens, DL			Rhodopsin activation exposes a key hydrophobic binding site for the transducin alpha-subunit C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE SUBSTITUTION MUTANTS; PROTEIN-COUPLED RECEPTORS; COVALENT CROSS-LINKING; F LOOP REGION; CONFORMATIONAL-CHANGES; CYTOPLASMIC LOOPS; METARHODOPSIN-II; BOVINE RHODOPSIN; SULFHYDRYL REACTIVITY; TRANSMEMBRANE HELICES	Conformational changes enable the photoreceptor rhodopsin to couple with and activate the G-protein transducin. Here we demonstrate a key interaction between these proteins occurs between the C terminus of the transducin alpha-subunit (G(Talpha)) and a hydrophobic cleft in the rhodopsin cytoplasmic face exposed during receptor activation. We mapped this interaction by labeling rhodopsin mutants with the fluorescent probe bimane and then assessed how binding of a peptide analogue of the G(Talpha) C terminus ( containing a tryptophan quenching group) affected their fluorescence. From these and other assays, we conclude that the G(Talpha) C-terminal tail binds to the inner face of helix 6 in a retinal-linked manner. Further, we find that a "hydrophobic patch" comprising key residues in the exposed cleft is required for transducin binding/activation because it enhances the binding affinity for the G(Talpha) C-terminal tail, contributing up to 3 kcal/mol for this interaction. We speculate the hydrophobic interactions identified here may be important in other GPCR signaling systems, and our Trp/ bimane fluorescence methodology may be generally useful for mapping sites of protein-protein interaction.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Farrens, DL (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Mail Code L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	farrensd@ohsu.edu			NATIONAL EYE INSTITUTE [T32EY007123, R01EY012095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014896] Funding Source: NIH RePORTER; NEI NIH HHS [T32-EY07123-09, EY12095] Funding Source: Medline; NIDA NIH HHS [DA14896] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Alexiev U, 2003, J MOL BIOL, V328, P705, DOI 10.1016/S0022-2836(03)00326-7; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; Bourne HR, 2000, SCIENCE, V289, P733, DOI 10.1126/science.289.5480.733; Brabazon DM, 2003, BIOCHEMISTRY-US, V42, P302, DOI 10.1021/bi0268899; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fahmy K, 1996, BIOCHEMISTRY-US, V35, P15065, DOI 10.1021/bi961486s; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FONG TM, 1999, REC BIOCH M, P1; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; Janz JM, 2001, BIOCHEMISTRY-US, V40, P7219, DOI 10.1021/bi002937i; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Klein-Seetharaman J, 1999, BIOCHEMISTRY-US, V38, P7938, DOI 10.1021/bi990013t; Klein-Seetharaman J, 1999, P NATL ACAD SCI USA, V96, P13744, DOI 10.1073/pnas.96.24.13744; Koenig BW, 2002, J MOL BIOL, V322, P441, DOI 10.1016/S0022-2836(02)00745-3; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; MANSOOR SE, 2004, IN PRESS BIOCHEMISTR; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Mielke T, 2002, BIOCHEMISTRY-US, V41, P7875, DOI 10.1021/bi011862v; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RESEK JF, 1994, P NATL ACAD SCI USA, V91, P7643, DOI 10.1073/pnas.91.16.7643; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Struthers M, 2000, BIOCHEMISTRY-US, V39, P7938, DOI 10.1021/bi000771f; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Terakita A, 2002, J BIOL CHEM, V277, P40, DOI 10.1074/jbc.M104960200; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; Yamashita T, 2000, J BIOL CHEM, V275, P34272, DOI 10.1074/jbc.M002954200; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yeagle PL, 2003, BIOCHEMISTRY-US, V42, P1365, DOI 10.1021/bi0270539	59	95	95	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29767	29773		10.1074/jbc.M402567200	http://dx.doi.org/10.1074/jbc.M402567200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15070895	hybrid			2022-12-25	WOS:000222445300113
J	Stove, C; Vanrobaeys, F; Devreese, B; Van Beeumen, J; Mareel, M; Bracke, M				Stove, C; Vanrobaeys, F; Devreese, B; Van Beeumen, J; Mareel, M; Bracke, M			Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition	ONCOGENE			English	Article						follistatin; activin; Smad; melanoma; growth; apoptosis	MESSENGER-RIBONUCLEIC-ACID; FOLLICULAR-FLUID; BINDING PROTEIN; FACTOR SYSTEM; FACTOR-BETA; EXPRESSION; MORPHOGENESIS; LINE; FSH; PROLIFERATION	Using a proteomic approach to screen for new growth factors released by melanoma cells, we identified follistatin as a major heparin-binding factor in medium conditioned by the Bowes melanoma cell line. Since follistatin is primarily studied in relation to its neutralization of activin, a member of the transforming growth factor-beta family of ligands, the expression and function of this receptor system was investigated in a panel of melanoma cell lines and melanocytes. All cell lines expressed activin receptors and showed phosphorylation of Smad signal transduction molecules upon treatment with activin. Secretion of follistatin, either native or after retroviral transduction, efficiently prevented Smad activation or activation of an activin-responsive luciferase reporter construct. In melanocytes, activin treatment led to growth inhibition and induction of apoptosis. These effects were counteracted by cotreatment with follistatin. In summary, we characterized the activin-activin receptor system in melanocytes and melanoma cell lines and found that secretion of follistatin by melanoma cells may represent an effective way to circumvent activin's negative regulatory effects.	Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	Bracke, M (corresponding author), Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	brackemarc@hotmail.com	Devreese, Bart/B-2011-2009; Stove, Christophe/B-6057-2008; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Stove, Christophe/0000-0001-7126-348X; Devreese, Bart/0000-0002-9764-2581				Alanko T, 2000, J INVEST DERMATOL, V115, P286, DOI 10.1046/j.1523-1747.2000.00045.x; Ball EMA, 2001, DEV BIOL, V238, P1, DOI 10.1006/dbio.2001.0399; Bartkova J, 1996, CANCER RES, V56, P5475; Beer HD, 2000, J INVEST DERM SYMP P, V5, P34, DOI 10.1046/j.1087-0024.2000.00009.x; Berking C, 2001, CANCER RES, V61, P8306; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cho SH, 2003, J IMMUNOL, V170, P4045, DOI 10.4049/jimmunol.170.8.4045; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delbaere A, 1999, ENDOCRINOLOGY, V140, P2463, DOI 10.1210/en.140.6.2463; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Devreese B, 2002, J CHROMATOGR A, V976, P113, DOI 10.1016/S0021-9673(02)01153-6; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Gullick WJ, 2001, BREAST CANCER RES, V3, P390, DOI 10.1186/bcr328; Gumienny TL, 2002, TRENDS ENDOCRIN MET, V13, P295, DOI 10.1016/S1043-2760(02)00615-X; Hager JW, 2002, RAPID COMMUN MASS SP, V16, P512, DOI 10.1002/rcm.607; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Hempen PM, 2003, CANCER RES, V63, P994; Innis CA, 2003, J BIOL CHEM, V278, P39969, DOI 10.1074/jbc.M211284200; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; Knight PG, 1996, FRONT NEUROENDOCRIN, V17, P476, DOI 10.1006/frne.1996.0013; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Liu QY, 1996, CANCER RES, V56, P1155; Luisi S, 2001, EUR J ENDOCRINOL, V145, P225, DOI 10.1530/eje.0.1450225; Massague J, 2000, GENE DEV, V14, P627; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; MICHEL U, 1992, ENDOCRINOLOGY, V130, P3684, DOI 10.1210/en.130.6.3684; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Risbridger GP, 2001, ENDOCR REV, V22, P836, DOI 10.1210/er.22.6.836; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; Rodeck U, 1999, CANCER RES, V59, P547; RODECK U, 1994, CANCER RES, V54, P575; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sandra K, 2004, J AM SOC MASS SPECTR, V15, P413, DOI 10.1016/j.jasms.2003.11.003; Schneyer AL, 1996, ENDOCRINOLOGY, V137, P240, DOI 10.1210/en.137.1.240; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Shellman YG, 2000, J INVEST DERMATOL, V114, P1200, DOI 10.1046/j.1523-1747.2000.00988.x; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Sidis Y, 2002, ENDOCRINOLOGY, V143, P1613, DOI 10.1210/en.143.5.1613; Sidis Y, 2001, J BIOL CHEM, V276, P17718, DOI 10.1074/jbc.M100736200; Stove C, 2003, J INVEST DERMATOL, V121, P802, DOI 10.1046/j.1523-1747.2003.12522.x; Stove V, 2003, BLOOD, V102, P2925, DOI 10.1182/blood-2003-03-0833; TANO M, 1995, MOL CELL ENDOCRINOL, V109, P167, DOI 10.1016/0303-7207(95)03499-W; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Wang QF, 2000, ENDOCRINOLOGY, V141, P3183, DOI 10.1210/en.141.9.3183; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Welt C, 2002, EXP BIOL MED, V227, P724, DOI 10.1177/153537020222700905; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8	56	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5330	5339		10.1038/sj.onc.1207699	http://dx.doi.org/10.1038/sj.onc.1207699			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064726	Green Published			2022-12-25	WOS:000222491600008
J	Boucher, A; Lu, DH; Burgess, SC; Telemaque-Potts, S; Jensen, MV; Mulder, H; Wang, MY; Unger, RH; Sherry, AD; Newgard, CB				Boucher, A; Lu, DH; Burgess, SC; Telemaque-Potts, S; Jensen, MV; Mulder, H; Wang, MY; Unger, RH; Sherry, AD; Newgard, CB			Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; FATTY-ACID OXIDATION; LONG-TERM EXPOSURE; ACETYL-COA CARBOXYLASE-2; MALONYL-COA; PHOSPHOFRUCTOKINASE ACTIVITY; REGULATED ANAPLEROSIS; ISOTOPOMER ANALYSIS; GENE-EXPRESSION; ISLETS	Hyperlipidemia appears to play an integral role in loss of glucose-stimulated insulin secretion (GSIS) in type 2 diabetes. This impairment can be simulated in vitro by chronic culture of 832/13 insulinoma cells with high concentrations of free fatty acids, or by study of lipid-laden islets from Zucker diabetic fatty rats. Here we show that impaired GSIS is not a simple result of saturation of lipid storage pathways, as adenovirus-mediated overexpression of a cytosolically localized variant of malonyl-CoA decarboxylase in either cellular model results in dramatic lowering of cellular triglyceride stores but no improvement in GSIS. Instead, the glucose-induced increment in "pyruvate cycling" activity ( pyruvate exchange with tricarboxylic acid cycle intermediates measured by C-13 NMR), previously shown to play an important role in GSIS, is completely ablated in concert with profound suppression of GSIS in lipid-cultured 832/13 cells, whereas glucose oxidation is unaffected. Moreover, GSIS is partially restored in both lipid-cultured 832/13 cells and islets from Zucker diabetic fatty rats by addition of a membrane permeant ester of a pyruvate cycling intermediate ( dimethyl malate). We conclude that chronic exposure of islet beta-cells to fatty acids grossly alters a mitochondrial pathway of pyruvate metabolism that is important for normal GSIS.	Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Med Ctr, Durham, NC 27704 USA; Univ Texas, SW Med Ctr, Mary Nell & Ralph Rogers Magnet Resonance Ctr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabat Res, Dallas, TX 75390 USA; Wayne State Univ, Dept Internal Med, Detroit, MI 48201 USA; Lund Univ, Dept Cell & Mol Biol, Lund, Sweden; Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Durham, NC 27704 USA; Duke Univ, Dept Med, Med Ctr, Durham, NC 27704 USA; Duke Univ, Dept Biochem, Med Ctr, Durham, NC 27704 USA	Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Wayne State University; Lund University; Duke University; Duke University; Duke University	Newgard, CB (corresponding author), Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Med Ctr, Independence Pk Facil,4321 Med Pk Dr,Ste 200, Durham, NC 27704 USA.	Newga002@mc.duke.edu	Mulder, Hindrik/E-1045-2012; Sherry, Dean/P-2348-2018	Sherry, Dean/0000-0001-7150-8301; Mulder, Hindrik/0000-0002-6593-8417	NHLBI NIH HHS [HL-34557] Funding Source: Medline; NIDDK NIH HHS [P01-DK-58398, R01-DK-42582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034557, R01HL034557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Briaud I, 2002, DIABETES, V51, P662, DOI 10.2337/diabetes.51.3.662; Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Gao JM, 1999, J LIPID RES, V40, P178; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Iizuka K, 2002, BBA-MOL BASIS DIS, V1586, P23, DOI 10.1016/S0925-4439(01)00082-5; Jacqueminet S, 2000, METABOLISM, V49, P532, DOI 10.1016/S0026-0495(00)80021-9; Jeffrey FMH, 1996, AM J PHYSIOL-ENDOC M, V271, pE788, DOI 10.1152/ajpendo.1996.271.4.E788; Kelpe CL, 2003, J BIOL CHEM, V278, P30015, DOI 10.1074/jbc.M302548200; Kelpe CL, 2002, ENDOCRINOLOGY, V143, P3326, DOI 10.1210/en.2002-220402; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Liu YQ, 1999, DIABETES, V48, P1747, DOI 10.2337/diabetes.48.9.1747; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; Liu YQ, 1998, DIABETES, V47, P1889, DOI 10.2337/diabetes.47.12.1889; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; Malloy CR, 1996, MAGN RESON MATER PHY, V4, P35, DOI 10.1007/BF01759778; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Porterfield DM, 2000, DIABETES, V49, P1511, DOI 10.2337/diabetes.49.9.1511; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; SCHNEDL WJ, 1994, DIABETES, V43, P1326, DOI 10.2337/diabetes.43.11.1326; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sweet Ian R, 2002, Diabetes Technol Ther, V4, P661, DOI 10.1089/152091502320798303; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; Zhou YP, 1996, METABOLISM, V45, P981, DOI 10.1016/S0026-0495(96)90267-X; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898; [No title captured]	48	100	101	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27263	27271		10.1074/jbc.M401167200	http://dx.doi.org/10.1074/jbc.M401167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073188	hybrid			2022-12-25	WOS:000222120400055
J	Ferraroni, M; Solyanikova, IP; Kolomytseva, MP; Scozzafava, A; Golovleva, L; Briganti, F				Ferraroni, M; Solyanikova, IP; Kolomytseva, MP; Scozzafava, A; Golovleva, L; Briganti, F			Crystal structure of 4-chlorocatechol 1,2-dioxygenase from the chlorophenol-utilizing gram-positive Rhodococcus opacus 1CP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRELIMINARY CRYSTALLOGRAPHIC ANALYSIS; NONHEME IRON DIOXYGENASE; MODIFIED ORTHO-PATHWAY; PROTOCATECHUATE 3,4-DIOXYGENASE; CHLOROCATECHOL 1,2-DIOXYGENASE; CATECHOL 1,2-DIOXYGENASE; 2,4-D METABOLISM; 2,4-DICHLOROPHENOXYACETIC ACID; HYDROXYQUINOL 1,2-DIOXYGENASE; MICROBIAL-DEGRADATION	The crystal structure of the 4-chlorocatechol 1,2-dioxygenase from the Gram-positive bacterium Rhodococcus opacus (erythropolis) 1CP, a Fe(III) ion-containing enzyme involved in the aerobic biodegradation of chloroaromatic compounds, has been solved by multiple wavelength anomalous dispersion using the weak anomalous signal of the two catalytic irons (1 Fe/257 amino acids) and refined at a 2.5 Angstrom resolution (R-free 28.7%; R factor 21.4%). The analysis of the structure and its comparison with the structure of catechol 1,2-dioxygenase from Acinetobacter calcoaceticus ADP1 (Ac 1,2-CTD) highlight significant differences between these enzymes. The general topology of the present enzyme comprises two catalytic domains (one for each subunit) related by a noncrystallographic 2-fold axis and separated by a common alpha-helical zipper motif consisting of five N-terminal helices from each subunit; furthermore the C-terminal tail is shortened significantly with respect to the known Ac 1,2-CTD. The presence of two phospholipids binding in a hydrophobic tunnel along the dimer axis is shown here to be a common feature for this class of enzyme. The active site cavity presents several dissimilarities with respect to the known catechol-cleaving enzyme. The catalytic nonheme iron(III) ion is bound to the side chains of Tyr-134, Tyr-169, His-194, and His-196, and a cocrystallized benzoate ion, bound to the metal center, reveals details on a novel mode of binding of bidentate inhibitors and a distinctive hydrogen bond network with the surrounding ligands. Among the amino acid residues expected to interact with substrates, several are different from the corresponding analogs of Ac 1,2-CTD: Asp-52, Ala-53, Gly-76, Phe-78, and Cys-224; in addition, regions of largely conserved amino acid residues in the catalytic cleft show different shapes resulting from several substantial backbone and side chain shifts. The present structure is the first of intradiol dioxygenases that specifically catalyze the cleavage of chlorocatechols, key intermediates in the aerobic catabolism of toxic chloroaromatics.	Univ Florence, Dipartimento Chim, I-50019 Sesto Fiorentino, FI, Italy; Russian Acad Sci, Skryabin Inst Biochem & Physiol Microorganisms, Pushchino 142290, Moscow Region, Russia	University of Florence; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences	Briganti, F (corresponding author), Univ Florence, Dipartimento Chim, Via Lastruccia 3, I-50019 Sesto Fiorentino, FI, Italy.	fabrizio.briganti@unifi.it	Kolomytseva, Marina P/M-8264-2015; Solyanikova, Inna/X-4742-2019; Briganti, Fabrizio/C-6661-2012; Solyanikova, Inna/R-8059-2019; Ferraroni, Marta/P-6441-2016	Kolomytseva, Marina P/0000-0002-6287-4868; Solyanikova, Inna/0000-0001-7502-4849; Ferraroni, Marta/0000-0001-7258-738X; Scozzafava, Andrea/0000-0001-5020-3322; Ludmila, Golovleva/0000-0001-9773-8957				*ACC INC, 1997, QUANTA SOFTW; ALEXANDER M, 1981, SCIENCE, V211, P132, DOI 10.1126/science.7444456; APAJALAHTI JHA, 1987, J BACTERIOL, V169, P5125, DOI 10.1128/jb.169.11.5125-5130.1987; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bashford D, 1997, LECT NOTES COMPUTER, P233, DOI [10.1007/3-540-63827-X, DOI 10.1007/3-540-63827-X_66]; Benvenuti M, 1999, ACTA CRYSTALLOGR D, V55, P901, DOI 10.1107/S0907444998017715; BHAT MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P738, DOI 10.1006/abbi.1993.1102; BOLLAG JM, 1968, J AGR FOOD CHEM, V16, P829, DOI 10.1021/jf60159a034; Briganti F, 1997, FEBS LETT, V416, P61, DOI 10.1016/S0014-5793(97)01167-8; Briganti F, 2000, J PROTEIN CHEM, V19, P709, DOI 10.1023/A:1007116703991; Briganti F, 1998, FEBS LETT, V433, P58, DOI 10.1016/S0014-5793(98)00884-9; BRODERICK JB, 1991, BIOCHEMISTRY-US, V30, P7349, DOI 10.1021/bi00243a040; CHAUDHRY GR, 1991, MICROBIOL REV, V55, P59, DOI 10.1128/MMBR.55.1.59-79.1991; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DORN E, 1978, BIOCHEM J, V174, P85, DOI 10.1042/bj1740085; DORN E, 1978, BIOCHEM J, V174, P73, DOI 10.1042/bj1740073; DUXBURY JM, 1970, J AGR FOOD CHEM, V18, P199, DOI 10.1021/jf60168a029; EARHART CA, 1994, J MOL BIOL, V236, P377, DOI 10.1006/jmbi.1994.1144; EARHART CA, 1994, J MOL BIOL, V236, P374, DOI 10.1006/jmbi.1994.1143; Eley KL, 2001, J ORG CHEM, V66, P2091, DOI 10.1021/jo001669r; Elgren TE, 1997, BIOCHEMISTRY-US, V36, P11504, DOI 10.1021/bi970691k; Ferraroni M, 2003, ACTA CRYSTALLOGR D, V59, P188, DOI 10.1107/S0907444902020395; Ferraroni M, 2002, ACTA CRYSTALLOGR D, V58, P1074, DOI 10.1107/S0907444902007242; FRANTZ B, 1986, BACTERIA, V10; GHOSAL D, 1985, SCIENCE, V228, P135, DOI 10.1126/science.228.4696.135; GORLATOV SN, 1989, MICROBIOLOGY+, V58, P647; Haggblom MM, 1995, MICROBIAL TRANSFORMA, P389; Hammer A, 1996, ARCH MICROBIOL, V166, P92, DOI 10.1007/s002030050361; HINTEREGGER C, 1992, FEMS MICROBIOL LETT, V97, P261, DOI 10.1111/j.1574-6968.1992.tb05473.x; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; JANG HG, 1991, J AM CHEM SOC, V113, P9200, DOI 10.1021/ja00024a028; JOSHI DK, 1993, APPL ENVIRON MICROB, V59, P1779, DOI 10.1128/AEM.59.6.1779-1785.1993; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kaschabek SR, 1998, J BACTERIOL, V180, P296, DOI 10.1128/JB.180.2.296-302.1998; KOZYREVA LP, 1993, MICROBIOLOGY+, V62, P78; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI DY, 1991, APPL ENVIRON MICROB, V57, P1920, DOI 10.1128/AEM.57.7.1920-1928.1991; LUDWIG ML, 1984, J BIOL CHEM, V259, P4840; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MALTSEVA OV, 1994, EUR J BIOCHEM, V226, P1053, DOI 10.1111/j.1432-1033.1994.01053.x; MALTSEVA OV, 1991, BIOCHEMISTRY-MOSCOW+, V56, P1548; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; MIGUEZ CB, 1993, CAN J MICROBIOL, V39, P1, DOI 10.1139/m93-001; Moiseeva OV, 2001, BIOCHEMISTRY-MOSCOW+, V66, P548, DOI 10.1023/A:1010267104238; Moiseeva OV, 1999, MICROBIOLOGY+, V68, P400; NAKAI C, 1990, J BIOL CHEM, V265, P660; NGAI KL, 1988, J BACTERIOL, V170, P2412, DOI 10.1128/jb.170.5.2412-2413.1988; Nielsen JE, 1999, PROTEIN ENG, V12, P657, DOI 10.1093/protein/12.8.657; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; Orville AM, 1997, BIOCHEMISTRY-US, V36, P10039, DOI 10.1021/bi970468n; Orville AM, 1997, BIOCHEMISTRY-US, V36, P10052, DOI 10.1021/bi970469f; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIEPER DH, 1988, ARCH MICROBIOL, V150, P95, DOI 10.1007/BF00409724; Potrawfke T, 1998, APPL ENVIRON MICROB, V64, P3798; Potrawfke T, 2001, J BACTERIOL, V183, P997, DOI 10.1128/JB.183.3.997-1011.2001; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; REINEKE W, 1988, ANNU REV MICROBIOL, V42, P263, DOI 10.1146/annurev.mi.42.100188.001403; Ritchie DW, 1999, J COMPUT CHEM, V20, P383, DOI 10.1002/(SICI)1096-987X(199903)20:4<383::AID-JCC1>3.0.CO;2-M; SANGODKAR UMX, 1988, GENE, V71, P267, DOI 10.1016/0378-1119(88)90043-1; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SOLYANIKOVA IP, 1992, BIOCHEMISTRY-MOSCOW+, V57, P1310; SOLYANIKOVA IP, 1995, J BACTERIOL, V177, P2821, DOI 10.1128/jb.177.10.2821-2826.1995; SZE ISY, 1984, J BACTERIOL, V159, P353, DOI 10.1128/JB.159.1.353-359.1984; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TIEDJE JM, 1969, J AGR FOOD CHEM, V17, P1021, DOI 10.1021/jf60165a037; Travkin VM, 1997, FEBS LETT, V407, P69, DOI 10.1016/S0014-5793(97)00297-4; van der Meer J R, 1991, J Bacteriol, V173, P6; Vetting MW, 2000, BIOCHEMISTRY-US, V39, P7943, DOI 10.1021/bi000151e; Vetting MW, 2000, STRUCTURE, V8, P429, DOI 10.1016/S0969-2126(00)00122-2	71	44	46	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27646	27655		10.1074/jbc.M401692200	http://dx.doi.org/10.1074/jbc.M401692200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15060064	hybrid			2022-12-25	WOS:000222120400099
J	Li, XJ; Fan, HZ				Li, XJ; Fan, HZ			Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich/disintegrin domains of the tumor necrosis factor-alpha converting enzyme (TACE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Matrix Metalloproteinase Gordon Research Conference	AUG, 2003	Big Sky, MT	UMDNJ Fdn, Amer Heart Assoc, Natl Ctr, New Jersey Commiss Canc Res			GROWTH-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; TNF-ALPHA; TGF-ALPHA; L-SELECTIN; TISSUE INHIBITOR; FACTOR-RECEPTOR; CELL-ADHESION; CLEAVAGE; ACTIVATION	Tumor necrosis factor-alpha converting enzyme ( TACE), a multidomain protease essential for development and disease, releases the ectodomains from many transmembrane proteins in a regulated fashion. To understand the mechanism underlying the regulation of TACE activity, we sought to identify the cause of ectodomain shedding deficiencies in two mutated CHO sublines designated M1 and M2. Transfection of expression vectors for human and mouse TACE restored ectodomain shedding of TNF-alpha and TGF-alpha, suggesting that defects in the TACE gene contribute to the phenotype of M1 and M2 cells. The overall levels of endogenous TACE forms in M1 cells were significantly lower than those found in their parental cells, whereas only TACE zymogen, but not its mature form, was detectable in M2 cells. Molecular analyses suggested that M1 cells contained only one expressible TACE allele encoding an M435I point mutation in the catalytic center of the protease, and M2 cells produced two TACE variants with distinct point mutations in the catalytic domain (C225Y) and the cysteine-rich/ disintegrin domain (C600Y). Overexpression of the C225Y and C600Y TACE by transient transfection largely compensated for maturation defects in the variants but failed to restore TNF-alpha and TGF-alpha release in the shedding-defective CHO cell lines and fibroblasts derived from TACE-null mouse embryo. Further mutagenesis and functional analyses demonstrated that Cys(600) was absolutely essential for ectodomain shedding, suggesting that Cys(600), similar to Cys(225), participates in disulfide bonding, which is critical for both the processing and catalysis of TACE.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Fan, HZ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	fanhu@umdnj.edu	Fan, Huizhou/E-5835-2012	FAN, HUIZHOU/0000-0002-4903-926X				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Beer S, 1999, J CELL SCI, V112, P2667; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brynskov J, 2002, GUT, V51, P37, DOI 10.1136/gut.51.1.37; Butler GS, 2004, J BIOL CHEM, V279, P15615, DOI 10.1074/jbc.M312727200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Codony-Servat J, 1999, CANCER RES, V59, P1196; Conway JG, 2001, J PHARMACOL EXP THER, V298, P900; Cruz AC, 2004, J BIOL CHEM, V279, P5612, DOI 10.1074/jbc.M312323200; de la Torre TV, 2004, BIOCHEM BIOPH RES CO, V314, P1028, DOI 10.1016/j.bbrc.2003.12.186; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fan HZ, 2003, J BIOL CHEM, V278, P18617, DOI 10.1074/jbc.M300331200; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Fujisawa T, 2002, BIOORGAN MED CHEM, V10, P2569, DOI 10.1016/S0968-0896(02)00109-8; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gomez-Gaviro MV, 2002, J BIOL CHEM, V277, P38212, DOI 10.1074/jbc.M205142200; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hahn D, 2003, J BIOL CHEM, V278, P42829, DOI 10.1074/jbc.M211169200; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Itai T, 2001, EUR J BIOCHEM, V268, P2074, DOI 10.1046/j.1432-1327.2001.02085.x; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jasuja RR, 2000, INT J IMMUNOPATH PH, V13, P1; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Lee MH, 2003, BIOCHEM J, V371, P369, DOI 10.1042/BJ20021538; Lee MH, 2002, FEBS LETT, V520, P102, DOI 10.1016/S0014-5793(02)02776-X; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Marin V, 2002, EUR J IMMUNOL, V32, P2965, DOI 10.1002/1521-4141(2002010)32:10<2965::AID-IMMU2965>3.0.CO;2-V; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nelson KK, 1999, BIOCHEM J, V343, P673, DOI 10.1042/0264-6021:3430673; Ohta S, 2001, J RHEUMATOL, V28, P1756; Patel IR, 1998, J IMMUNOL, V160, P4570; PAXTON CJ, 1998, P NATL ACAD SCI USA, V95, P3408; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Shi W, 2003, DEV BIOL, V261, P371, DOI 10.1016/S0012-1606(03)00315-4; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; STOCKER W, 1995, PROTEIN SCI, V4, P823; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Vincent B, 2001, J BIOL CHEM, V276, P37743; Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176; Zhao JS, 2001, INT J DEV BIOL, V45, P623; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200	78	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27365	27375		10.1074/jbc.M401690200	http://dx.doi.org/10.1074/jbc.M401690200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	830KH	15075334	hybrid			2022-12-25	WOS:000222120400067
J	Vickers, TJ; Fairlamb, AH				Vickers, TJ; Fairlamb, AH			Trypanothione S-transferase activity in a trypanosomatid ribosomal elongation factor 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; RESISTANT LEISHMANIA-TARENTOLAE; HUMAN GLUTATHIONE TRANSFERASES; TRANSPORTER GENE PGPA; PROTEIN-SYNTHESIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BINDING PROTEINS; FACTOR 1-GAMMA; CRUZI	Trypanothione is a thiol unique to the Kinetoplastida and has been shown to be a vital component of their antioxidant defenses. However, little is known as to the role of trypanothione in xenobiotic metabolism. A trypanothione S- transferase activity was detected in extracts of Leishmania major, L. infantum, L. tarentolae, Trypanosoma brucei, and Crithidia fasciculata, but not Trypanosoma cruzi. No glutathione S- transferase activity was detected in any of these parasites. Trypanothione S- transferase was purified from C. fasciculata and shown to be a hexadecameric complex of three subunits with a relative molecular weight of 650,000. This enzyme complex was specific for the thiols trypanothione and glutathionylspermidine and only used 1-chloro-2,4-dinitrobenzene from a range of glutathione S- transferase substrates. Peptide sequencing revealed that the three components were the alpha, beta, and gamma subunits of ribosomal eukaryotic elongation factor 1B (eEF1B). Partial dissociation of the complex suggested that the S- transferase activity was associated with the gamma subunit. Moreover, Cibacron blue was found to be a tight binding inhibitor and reactive blue 4 an irreversible time-dependent inhibitor that covalently modified only the gamma subunit. The rate of inactivation by reactive blue 4 was increased more than 600-fold in the presence of trypanothione, and Cibacron blue protected the enzyme from inactivation by 1-chloro-2,4-dinitrobenzene, confirming that these dyes interact with the active site region. Two eEF1Bgamma genes were cloned from C. fasciculata, but recombinant C. fasciculata eEF1Bgamma had no S-transferase activity, suggesting that eEF1Bgamma is unstable in the absence of the other subunits.	Univ Dundee, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Fairlamb, AH (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland.	a.h.fairlamb@dundee.ac.uk	Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329	Wellcome Trust [079838] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADANG AEP, 1990, BIOCHEM J, V269, P47, DOI 10.1042/bj2690047; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; ASHTON AR, 1978, BIOCHEM J, V175, P501, DOI 10.1042/bj1750501; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; BEC G, 1989, J BIOL CHEM, V264, P21131; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BillautMulot O, 1997, GENE, V198, P259, DOI 10.1016/S0378-1119(97)00323-5; BILLAUTMULOT O, 1993, NUCLEIC ACIDS RES, V21, P3901, DOI 10.1093/nar/21.16.3901; BLACK S, 1993, BIOCHEM BIOPH RES CO, V191, P95, DOI 10.1006/bbrc.1993.1189; BLACK S, 1986, SCIENCE, V234, P1111, DOI 10.1126/science.3535073; BLACK S, 1983, J BIOL CHEM, V258, P2112; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; DATTA J, 1992, MOL CELL BIOCHEM, V118, P31, DOI 10.1007/BF00249692; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Fairlamb AH, 2003, TRENDS PARASITOL, V19, P488, DOI 10.1016/j.pt.2003.09.002; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Foley V, 1998, BIOCHEM J, V333, P839, DOI 10.1042/bj3330839; GABRIEL A, 1987, J BIOL CHEM, V262, P16192; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Habig W H, 1981, Methods Enzymol, V77, P398; Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0; HAYES JD, 1988, GLUTATHIONE CONJUGAT, P316; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; Jeppesen MG, 2003, J BIOL CHEM, V278, P47190, DOI 10.1074/jbc.M306630200; Kamiie K, 2002, BIOSCI BIOTECH BIOCH, V66, P558, DOI 10.1271/bbb.66.558; Kobayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P509, DOI 10.1006/bbrc.2001.5799; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; KOSOWER NS, 1971, BIOCHEM BIOPH RES CO, V45, P816, DOI 10.1016/0006-291X(71)90490-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legare D, 1997, EXP PARASITOL, V87, P275, DOI 10.1006/expr.1997.4222; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MASAI E, 1993, FEBS LETT, V323, P135, DOI 10.1016/0014-5793(93)81465-C; MOUTIEZ M, 1995, BBA-GEN SUBJECTS, V1245, P161, DOI 10.1016/0304-4165(95)00085-P; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; NAVAL J, 1982, COMP BIOCHEM PHYS B, V71, P403, DOI 10.1016/0305-0491(82)90401-1; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; PLUMASMARTY B, 1993, RES IMMUNOL, V144, P553, DOI 10.1016/S0923-2494(05)80002-1; PLUMASMARTY B, 1994, PARASITOL RES, V80, P626, DOI 10.1007/BF00933014; PLUMASMARTY B, 1992, PARASITOLOGY, V104, P87, DOI 10.1017/S0031182000060832; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANG LJ, 2002, BIOCHEM BIOPH RES CO, V291, P158; Sheu GT, 1997, J BIOL CHEM, V272, P33290, DOI 10.1074/jbc.272.52.33290; Sies H, 1988, GLUTATHIONE CONJUGAT; SMALL DAP, 1982, EUR J BIOCHEM, V128, P119; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; VICKERS TJ, 2003, THESIS U DUNDEE; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; WARHOLM M, 1986, BIOCHEMISTRY-US, V25, P4119, DOI 10.1021/bi00362a020; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5; YAWETZ A, 1981, COMP BIOCHEM PHYS B, V68, P237, DOI 10.1016/0305-0491(81)90093-6; Zilberstein D, 2002, WORLD CL PARASITES, V4, P115	65	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27246	27256		10.1074/jbc.M311039200	http://dx.doi.org/10.1074/jbc.M311039200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073172	hybrid, Green Accepted			2022-12-25	WOS:000222120400053
J	Chen, CB; Wallis, R				Chen, CB; Wallis, R			Two mechanisms for mannose-binding protein modulation of the activity of its associated serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE DOMAIN; SUBSTRATE SPECIFICITIES; LECTIN; ACTIVATION; COMPLEXES; SEQUENCE	Serum mannose-binding protein (MBP) neutralizes invading microorganisms by binding to cell surface carbohydrates and activating MBP-associated serine proteases-1, -2, and -3 (MASPs). MASP-2 subsequently cleaves complement components C2 and C4 to activate the complement cascade. To analyze the mechanisms of activation and substrate recognition by MASP-2, zymogen and activated forms have been produced, and MBP . MASP-2 complexes have been created. These preparations have been used to show that MBP modulates MASP-2 activity in two ways. First, MBP stimulates MASP-2 autoactivation by increasing the rate of autocatalysis when MBP . MASP-2 complexes bind to a glycan-coated surface. Second, MBP occludes accessory C4-binding sites on MASP-2 until activation occurs. Once these sites become exposed, MASP-2 binds to C4 while separate structural changes create a functional catalytic site able to cleave C4. Only activated MASP-2 binds to C2, suggesting that this substrate interacts only near the catalytic site and not at accessory sites. MASP-1 cleaves C2 almost as efficiently as MASP-2 does, but it does not cleave C4. Thus MASP-1 probably enhances complement activation triggered by MBP . MASP-2 complexes, but it cannot initiate activation itself.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Wallis, R (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.	rwallis@glycob.ox.ac.uk		Wallis, Russell/0000-0002-8705-5295				Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; BELT KT, 1984, CELL, V36, P907; BENTLEY DR, 1984, P NATL ACAD SCI-BIOL, V81, P1212, DOI 10.1073/pnas.81.4.1212; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Khan AR, 1998, PROTEIN SCI, V7, P815; Kolble K, 1993, Int Rev Immunol, V10, P17, DOI 10.3109/08830189309051169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Minton AP, 1997, PROG COLL POL SCI S, V107, P11; OGATA RT, 1995, J IMMUNOL, V154, P2351; PORTER RR, 1978, NATURE, V275, P699, DOI 10.1038/275699a0; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rossi V, 2001, J BIOL CHEM, V276, P40880, DOI 10.1074/jbc.M105934200; SIM RB, 1983, ANN NY ACAD SCI, V421, P259, DOI 10.1111/j.1749-6632.1983.tb18114.x; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 2004, J BIOL CHEM, V279, P14065, DOI 10.1074/jbc.M400171200; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wallis R, 2002, IMMUNOBIOLOGY, V205, P433, DOI 10.1078/0171-2985-00144; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	32	94	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26058	26065		10.1074/jbc.M401318200	http://dx.doi.org/10.1074/jbc.M401318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15060079	hybrid			2022-12-25	WOS:000222003000018
J	Freiberg, C; Brunner, NA; Schiffer, G; Lampe, T; Pohlmann, J; Brands, M; Raabe, M; Habich, D; Ziegelbauer, K				Freiberg, C; Brunner, NA; Schiffer, G; Lampe, T; Pohlmann, J; Brands, M; Raabe, M; Habich, D; Ziegelbauer, K			Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; ACYL CARRIER PROTEIN; COENZYME-A CARBOXYLASE; CARBOXYLTRANSFERASE COMPONENT; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TARGET; FABI; PURIFICATION; MUTATIONS	The multisubunit acetyl-CoA carboxylase, which catalyzes the first committed step in fatty acid biosynthesis, is broadly conserved among bacteria. Its rate-limiting role in formation of fatty acids makes this enzyme an attractive target for the design of novel broad-spectrum antibacterials. However, no potent inhibitors have been discovered so far. This report describes the identification and characterization of highly potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity for the first time. We demonstrate that pseudopeptide pyrrolidine dione antibiotics such as moiramide B inhibit the Escherichia coli enzyme at nanomolar concentrations. Moiramide B targets the carboxyltransferase reaction of this enzyme with a competitive inhibition pattern versus malonyl-CoA (K-i value = 5 nM). Inhibition at nanomolar concentrations of the pyrrolidine diones is also demonstrated using recombinantly expressed carboxyltransferases from other bacterial species ( Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa). We isolated pyrrolidine dione-resistant strains of E. coli, S. aureus, and Bacillus subtilis, which contain mutations within the carboxyltransferase subunits AccA or AccD. We demonstrate that such mutations confer resistance to pyrrolidine diones. Inhibition values (IC50) of > 100 muM regarding an eukaryotic acetyl-CoA carboxylase from rat liver indicate high selectivity of pyrrolidine diones for the bacterial multisubunit enzyme. The natural product moiramide B and synthetic analogues show broad-spectrum antibacterial activity. The knowledge of the target and the availability of facile assays using carboxyltransferases from different pathogens will enable evaluation of the antibacterial potential of the pyrrolidine diones as a promising antibacterial compound class acting via a novel mode of action.	Bayer HealthCare, Pharma Res, Inst Antiinfect Res, D-42096 Wuppertal, Germany; Bayer HealthCare, Pharma Res, Inst Chem Res, D-42096 Wuppertal, Germany; Bayer HealthCare, Pharma Res, Inst Cardiovasc Res, D-42096 Wuppertal, Germany	Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals	Freiberg, C (corresponding author), Bayer HealthCare, Pharma Res, Inst Antiinfect Res, D-42096 Wuppertal, Germany.	christoph.freiberg@bayerhealthcare.com						Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; Blanchard CZ, 1999, BIOCHEM BIOPH RES CO, V266, P466, DOI 10.1006/bbrc.1999.1844; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; Chirala SS, 1997, P NATL ACAD SCI USA, V94, P5588, DOI 10.1073/pnas.94.11.5588; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Daines RA, 2003, J MED CHEM, V46, P5, DOI 10.1021/jm025571b; DAVIES SG, 1998, J CHEM SOC P1, V17, P2635; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; Davis MS, 2001, J BACTERIOL, V183, P1499, DOI 10.1128/JB.183.4.1499-1503.2001; FALL RR, 1976, BIOCHIM BIOPHYS ACTA, V450, P475, DOI 10.1016/0005-2760(76)90022-9; FREDENHAGEN A, 1987, J AM CHEM SOC, V109, P4409, DOI 10.1021/ja00248a055; Guchhait R B, 1975, Methods Enzymol, V35, P32, DOI 10.1016/0076-6879(75)35135-5; Haas M, 2001, MICROBIOL-SGM, V147, P1783, DOI 10.1099/00221287-147-7-1783; HARWOOD JL, 1990, METHODS PLANT BIOCH, P96; He X, 2002, ANTIMICROB AGENTS CH, V46, P1310, DOI 10.1128/AAC.46.5.1310-1318.2002; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HOSOKAWA Y, 1986, ANAL BIOCHEM, V153, P45, DOI 10.1016/0003-2697(86)90058-8; Khandekar SS, 2001, J BIOL CHEM, V276, P30024, DOI 10.1074/jbc.M101769200; Levert KL, 2002, BIOCHEM BIOPH RES CO, V291, P1213, DOI 10.1006/bbrc.2002.6576; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; Marrakchi H, 2002, BIOCHEM SOC T, V30, P1050, DOI 10.1042/bst0301050; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MCWORTHER W, 1989, J CHEM SOC CHEM COMM, V5, P299; Miller WH, 2002, J MED CHEM, V45, P3246, DOI 10.1021/jm020050+; NEEDHAM J, 1994, J ORG CHEM, V59, P2058, DOI 10.1021/jo00087a020; OCLARIT JM, 1994, MICROBIOS, V78, P7; Payne DJ, 2002, ANTIMICROB AGENTS CH, V46, P3118, DOI 10.1128/AAC.46.10.3118-3124.2002; Payne DJ, 2001, DRUG DISCOV TODAY, V6, P537, DOI 10.1016/S1359-6446(01)01774-3; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RAO AVR, 1991, TETRAHEDRON LETT, V32, P4393, DOI 10.1016/S0040-4039(00)92179-8; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Sambrook J, 2001, MOL CLONING LAB MANU; Schujman GE, 2003, DEV CELL, V4, P663, DOI 10.1016/S1534-5807(03)00123-0; Schujman GE, 2001, J BACTERIOL, V183, P3032, DOI 10.1128/JB.183.10.3032-3040.2001; Schweizer HP, 1998, ANTIMICROB AGENTS CH, V42, P394; Seefeld MA, 2003, J MED CHEM, V46, P1627, DOI 10.1021/jm0204035; Singh MP, 1997, J ANTIBIOT, V50, P270, DOI 10.7164/antibiotics.50.270; THAMPY KG, 1988, J BIOL CHEM, V263, P6447; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3	47	158	194	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26066	26073		10.1074/jbc.M402989200	http://dx.doi.org/10.1074/jbc.M402989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15066985	hybrid			2022-12-25	WOS:000222003000019
J	Merot, Y; Metivier, R; Penot, G; Manu, D; Saligaut, C; Gannon, F; Pakdel, F; Kah, O; Flouriot, G				Merot, Y; Metivier, R; Penot, G; Manu, D; Saligaut, C; Gannon, F; Pakdel, F; Kah, O; Flouriot, G			The relative contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha transcriptional activity depends upon the differentiation stage of the cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION 1; BREAST-CANCER; ER-ALPHA; PROSTATE-CANCER; HISTONE ACETYLTRANSFERASE; STEROID-RECEPTORS; PROMOTER-CONTEXT; HER-ALPHA; COACTIVATOR; GENE	The activity of the transactivation functions (activation function (AF)-1 and AF-2) of the estrogen receptor alpha (ERalpha) is cell-specific. This study aimed to decipher the yet unclear mechanisms involved in this differential cell sensitivity, with particular attention to the specific influence that cell differentiation may have on these processes. Hence, we comparatively evaluated the permissiveness of cells to either ERalpha AFs in two different cases: (i) a series of cell lines originating from a common tissue, but with distinct differentiation phenotypes; and (ii) cell lines that undergo differentiation processes in culture. These experiments demonstrate that the respective contribution that AF-1 and AF-2 make toward ERalpha activity varies in a cell differentiation stage-dependent manner. Specifically, whereas AF-1 is the dominant AF involved in ERalpha transcriptional activity in differentiated cells, the more a cell is de-differentiated the more this cell mediates ERalpha signaling through AF-2. For instance, AF-2 is the only active AF in cells that have achieved their epithelial-mesenchymal transition. Moreover, the stable expression of a functional ERalpha in strictly AF-2 permissive cells restores an AF-1-sensitive cell context. These results, together with data obtained in different ERalpha-positive cell lines tested strongly suggest that the transcriptional activity of ERalpha relies on its AF-1 in most estrogen target cell types.	Univ Rennes 1, CNRS, UMR 6026, F-35042 Rennes, France; EMBL, D-69117 Heidelberg, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; European Molecular Biology Laboratory (EMBL)	Flouriot, G (corresponding author), Univ Rennes 1, CNRS, UMR 6026, F-35042 Rennes, France.	gilles.flouriot@univ-rennes1.fr	saligaut, christian/K-3360-2015; kah, olivier/K-7624-2012; Flouriot, Gilles/K-1833-2015; Gannon, Frank/G-1194-2015; Pakdel, Farzad/K-1700-2015	Flouriot, Gilles/0000-0001-6250-4173; Pakdel, Farzad/0000-0002-3067-3156				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Chlenski A, 2001, PROSTATE, V47, P66; Coradini D, 1997, TUMOR BIOL, V18, P22, DOI 10.1159/000218012; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Couse JF, 1995, BIOCHEM SOC T, V23, P929, DOI 10.1042/bst0230929; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Endoh H, 1999, MOL CELL BIOL, V19, P5363; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Fujita T, 2003, J BIOL CHEM, V278, P26704, DOI 10.1074/jbc.M301031200; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; Griffin C, 1999, MOL ENDOCRINOL, V13, P1571, DOI 10.1210/me.13.9.1571; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jarrard DF, 1998, CANCER RES, V58, P5310; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JORDAN VC, 1995, BREAST CANCER RES TR, V36, P267, DOI 10.1007/BF00713399; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; MCGUIRE WL, 1986, CANCER SURV, V5, P527; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Metivier R, 2002, EMBO J, V21, P3443, DOI 10.1093/emboj/cdf344; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Oda Y, 2003, MOL ENDOCRINOL, V17, P2329, DOI 10.1210/me.2003-0063; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pendaries C, 2002, P NATL ACAD SCI USA, V99, P2205, DOI 10.1073/pnas.042688499; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605	54	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26184	26191		10.1074/jbc.M402148200	http://dx.doi.org/10.1074/jbc.M402148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15078875	hybrid			2022-12-25	WOS:000222003000033
J	Torpey, N; Maher, SE; Bothwell, ALM; Pober, JS				Torpey, N; Maher, SE; Bothwell, ALM; Pober, JS			Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; TYROSINE PHOSPHORYLATION; IFN-GAMMA; MCP-1 DEFICIENCY; DENDRITIC CELLS; IL-12 RESPONSES; EXPRESSION; TRANSCRIPTION	STAT4 signaling, activated by either interleukin 12 (IL12) or interferon alpha (IFNalpha), promotes T(H)1 responses in CD4(+) T cells. Vascular endothelial cells (EC) may also become polarized in response to various cytokines, favoring recruitment and activation of T(H)1 or T(H)2 effector cells. Here we have investigated the role of the STAT4 pathway in EC. Cultured human umbilical vein EC ( HUVEC) express low levels of STAT4, which may be tyrosine-phosphorylated by treatment with IFNalpha but not IL12. This is because HUVEC lack both subunits of the IL12 receptor (IL12Rbeta1 and IL12Rbeta2), even following treatment with various cytokines. IL12 phosphorylation of STAT4 can be observed in HUVEC that have been transduced to express the IL12R. To identify STAT4-induced genes we pursued three approaches: analysis by DNA microarray and quantitative RT-PCR (Q-PCR) of the IL12 responses in IL12R-transduced EC; analysis by Q-PCR of IFNalpha responses in STAT4-overexpressing EC; and analysis of IFNalpha responses in U3A neuroblastoma cell lines that express either STAT1 or STAT4, but not both. In all three instances we observe STAT4-mediated induction of the chemokine monocyte chemoattractant protein 1 (MCP1) and suppressor of cytokine signaling 3 (SOCS3) mRNA, and we confirm the production of each protein in both IL12R-transduced EC and STAT4-transduced U3A cells. These observations reveal that there is a STAT4 response of EC, activated by IFNalpha but not IL12, and that it may modulate the proinflammatory behavior of EC.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England	Yale University; Yale University; Yale University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol, 333 Cedar St, New Haven, CT 06510 USA.	Jordan.pober@yale.edu			NHLBI NIH HHS [P01 HL70295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Bennett BL, 1997, J BIOL CHEM, V272, P10212; Briscoe DM, 1997, J IMMUNOL, V159, P3247; Chitnis T, 2001, J CLIN INVEST, V108, P739, DOI 10.1172/JCI200112563; Cho SS, 1996, J IMMUNOL, V157, P4781; Cuvelier SL, 2001, J EXP MED, V194, P1699, DOI 10.1084/jem.194.12.1699; da Silva AJ, 2002, J INTERF CYTOK RES, V22, P173, DOI 10.1089/107999002753536149; DOUKAS J, 1990, J IMMUNOL, V145, P1727; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Durali D, 2003, BLOOD, V102, P4084, DOI 10.1182/blood-2003-02-0518; Eyles JL, 2002, J BIOL CHEM, V277, P43735, DOI 10.1074/jbc.M208586200; Farrar JD, 2000, NAT IMMUNOL, V1, P65, DOI 10.1038/76932; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; Frucht DM, 2000, J IMMUNOL, V164, P4659, DOI 10.4049/jimmunol.164.9.4659; Fukao T, 2001, J IMMUNOL, V166, P4446, DOI 10.4049/jimmunol.166.7.4446; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Hoey T, 2003, EMBO J, V22, P4237, DOI 10.1093/emboj/cdg393; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Jaruga B, 2003, J IMMUNOL, V171, P3233, DOI 10.4049/jimmunol.171.6.3233; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kim WJH, 2003, BIOCHEM BIOPH RES CO, V310, P936, DOI 10.1016/j.bbrc.2003.09.088; Kluger MS, 1997, J IMMUNOL, V158, P887; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Luscinskas FW, 2002, SEMIN IMMUNOL, V14, P105, DOI 10.1006/smim.2001.0347; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; Mahboubi K, 2003, J BIOL CHEM, V278, P25014, DOI 10.1074/jbc.M211867200; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Monaco C, 2002, J LEUKOCYTE BIOL, V71, P659; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Niculescu F, 1999, IMMUNOPHARMACOLOGY, V42, P187, DOI 10.1016/S0162-3109(99)00014-4; Pober JS, 1999, IMMUNOL RES, V19, P225, DOI 10.1007/BF02786490; Raju R, 2003, TRANSPLANTATION, V75, P1072, DOI 10.1097/01.TP.0000058349.08707.E6; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Shinkai A, 1999, J IMMUNOL, V163, P1602; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stamm LM, 1999, EUR J IMMUNOL, V29, P2524, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2524::AID-IMMU2524&gt;3.0.CO;2-H; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; THORNHILL MH, 1991, J IMMUNOL, V146, P592; Waxman AB, 2003, AM J RESP CELL MOL, V29, P513, DOI 10.1165/rcmb.2002-0044OC; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V310, P1188, DOI 10.1016/j.bbrc.2003.09.140; Yamamoto K, 2002, BIOCHEM BIOPH RES CO, V297, P1245, DOI 10.1016/S0006-291X(02)02378-1; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	56	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26789	26796		10.1074/jbc.M401517200	http://dx.doi.org/10.1074/jbc.M401517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15087447	hybrid			2022-12-25	WOS:000222003000106
J	Moeschel, K; Beck, A; Weigert, C; Lammers, R; Kalbacher, H; Voelter, W; Schleicher, ED; Haring, HU; Lehmann, R				Moeschel, K; Beck, A; Weigert, C; Lammers, R; Kalbacher, H; Voelter, W; Schleicher, ED; Haring, HU; Lehmann, R			Protein kinase C-zeta-induced phosphorylation of Ser(318) in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SERINE/THREONINE PHOSPHORYLATION; RESISTANCE; SER(307); ALPHA; CELLS; IDENTIFICATION; MODULATION; MECHANISM; ABILITY	Insulin receptor substrate-1 (IRS-1) was recently identified as a novel upstream substrate for the insulin-activated protein kinase C (PKC)-zeta. This interaction down-regulates insulin signal transduction under hyper-insulinemic conditions. To clarify the molecular mechanism of this feedback loop, we sought to identify the PKC-zeta phosphorylation sites of IRS-1 and to investigate their biological significance. Upon incubation of recombinant IRS-1 fragments with PKC-zeta, we identified Ser(318) of rat IRS-1 (Ser(323) in human IRS-1) as the major in vitro phosphorylation site ( confirmed by mutation of Ser(318) to alanine). To monitor phosphorylation of Ser(318) in cellular extracts, we prepared a polyclonal phosphosite-specific antibody. The biological significance was studied in baby hamster kidney cells stably expressing the insulin receptor (BHKIR). Using the phospho-Ser(318)-specific antibody we observed that insulin stimulates phosphorylation of Ser(318) in IRS-1, which is mediated, at least partially, by PKC-zeta. Moreover, we found that the previously described insulin-stimulated, PKC-zeta-mediated inhibition of the interaction of IRS-1 with the insulin receptor and the reduced tyrosine phosphorylation of IRS-1 was abrogated by mutation of IRS-1 Ser(318) to alanine. These results, generated in BHKIR cells, suggest that phosphorylation of Ser(318) by PKC-zeta might contribute to the inhibitory effect of prolonged hyperinsulinemia on IRS-1 function.	Univ Tubingen Hosp, Dept Internal Med Endocrinol Metab Pathobiochem &, D-72076 Tubingen, Germany; Univ Tubingen, Inst Physiol Chem, Dept Phys Biochem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Lehmann, R (corresponding author), Univ Tubingen Hosp, Dept Internal Med Endocrinol Metab Pathobiochem &, Otfried Muller Str 10, D-72076 Tubingen, Germany.	rainer.lehmann@med.uni-tuebingen.de	Lehmann, Rainer/AAF-4281-2019	Lehmann, Rainer/0000-0003-1218-6810				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Johnston AM, 2003, FEBS LETT, V546, P32, DOI 10.1016/S0014-5793(03)00438-1; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANTI JF, 1994, J BIOL CHEM, V269, P6051; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	25	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25157	25163		10.1074/jbc.M402477200	http://dx.doi.org/10.1074/jbc.M402477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069075	hybrid			2022-12-25	WOS:000221827900031
J	Solski, PA; Wilder, RS; Rossman, KL; Sondek, J; Cox, AD; Campbell, SL; Der, CJ				Solski, PA; Wilder, RS; Rossman, KL; Sondek, J; Cox, AD; Campbell, SL; Der, CJ			Requirement for C-terminal sequences in regulation of Ect2 guanine nucleotide exchange specificity and transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CYSTEINE-RICH DOMAINS; RHO-GTPASES; DBL FAMILY; EXPRESSION CLONING; DISTINCT ROLES; CELL-CYCLE; PH DOMAINS; ACTIVATION; CDC42	Ect2 was identified originally as a transforming protein and a member of the Dbl family of Rho guanine nucleotide exchange factors (GEFs). Like all Dbl family proteins, Ect2 contains a tandem Dbl homology (DH) and pleckstrin homology (PH) domain structure. Previous studies demonstrated that N-terminal deletion of sequences upstream of the DH domain created a constitutively activated, transforming variant of Ect2 (designated DeltaN-Ect2DH/PH/C), indicating that the N terminus served as a negative regulator of DH domain function in vivo. The role of sequences C-terminal to the DH domain has not been established. Therefore, we assessed the consequences of mutation of C-terminal sequences on Ect2-transforming activity. Surprisingly, in contrast to observations with other Dbl family proteins, we found that mutation of the invariant tryptophan residue in the PH domain did not impair DeltaN-Ect2DH/PH/C transforming activity. Furthermore, although the sequences C-terminal to the PH domain lack any known functional domains or motifs, deletion of these sequences (DeltaN-Ect2 DH/PH) resulted in a dramatic reduction in transforming activity. Whereas DeltaN-Ect2 caused formation of lamellipodia, DeltaN-Ect2 DH/PH enhanced actin stress fiber formation, suggesting that C-terminal sequences influenced Ect2 Rho GTPase specificity. Consistent with this possibility, we determined that DeltaN-Ect2 DH/PH activated RhoA, but not Rac1 or Cdc42, whereas DeltaN-Ect2 DH/PH/C activated all three Rho GTPases in vivo. Taken together, these observations suggest that regions of Ect2 C-terminal to the DH domain alter the profile of Rho GTPases activated in vivo and consequently may contribute to the enhanced transforming activity of DeltaN-Ect2 DH/PH/C.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Sondek, John/0000-0002-1127-8310; Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747; campbell, sharon/0000-0003-0311-409X	NATIONAL CANCER INSTITUTE [R01CA092240, R01CA063071, S15CA062299, U19CA067771, R01CA089614] Funding Source: NIH RePORTER; NCI NIH HHS [CA62299, CA63071, CA67771, CA89614, CA92240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; COX AD, 1995, METHOD ENZYMOL, V255, P195; Cozier GE, 2004, CURR TOP MICROBIOL, V282, P49; De Toledo M, 2001, ONCOGENE, V20, P7307, DOI 10.1038/sj.onc.1204921; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; MICHIELS F, 1997, J CELL BIOL, V137, P1; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Solski PA, 2000, METHOD ENZYMOL, V325, P425; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	40	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25226	25233		10.1074/jbc.M313792200	http://dx.doi.org/10.1074/jbc.M313792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15073184	Green Published, hybrid			2022-12-25	WOS:000221827900040
J	Xu, Q; Brecht, WJ; Weisgraber, KH; Mahley, RW; Huang, YD				Xu, Q; Brecht, WJ; Weisgraber, KH; Mahley, RW; Huang, YD			Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PEPTIDE; PROTEIN CONFORMATIONAL-CHANGES; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; TRANSGENIC MICE; HUMAN BRAIN; INCREASED EXPRESSION; E IMMUNOREACTIVITY; TERMINAL DOMAIN; TYPE-4 ALLELE	Apolipoprotein (apo) E4 is a major risk factor for Alzheimer disease. Although the mechanisms remain to be determined, the detrimental effects of apoE4 in neurobiology must be based on its unique structural and biophysical properties. One such property is domain interaction mediated by a salt bridge between Arg-61 in the N-terminal domain and Glu-255 in the C-terminal domain of apoE4. This interaction, which does not occur in apoE3 or apoE2, causes apoE4 to bind preferentially to certain lipoprotein particles in vitro and in vivo. Here we used fluorescence resonance energy transfer (FRET) to determine whether apoE4 domain interaction occurs in living neuronal cells. Neuro-2a cells were transfected with constructs encoding apoE3 or apoE4 in which yellow fluorescent protein (YFP) was fused to the N terminus, and cyan fluorescent protein (CFP) was fused to the C terminus. To generate a FRET signal that can be detected by spectrum confocal microscopy, the labeled N and C termini must be in close proximity (<100 angstrom). FRET signals occurred in cells transfected with YFP-apoE4-CFP but not in those transfected with YFP-apoE3-CFP, suggesting that the N and C termini of apoE4 are in close proximity in living cells and that those of apoE3 are not. FRET signals did not occur in cells cotransfected with YFP-apoE4 and apoE4-CFP, suggesting that the FRET in YFP-apoE4-CFP-transfected cells was intramolecular. Mutation of Arg-61 to Thr or Glu-255 to Ala in apoE4, which disrupts domain interaction, abolished FRET in Neuro-2a cells, strongly suggesting that the FRET in YFP-apoE4-CFP cells was caused by domain interaction. ApoE4-producing cells secreted less phospholipid than apoE3-producing cells, but after disruption of domain interaction in apoE4, phospholipid secretion increased to the levels seen with apoE3, suggesting that domain interaction decreases the phospholipid-binding capacity of apoE4. Thus, apoE4 domain interaction occurs in living neuronal cells and may be a molecular basis for apoE4-related neurodegeneration.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Huang, YD (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, POB 419100, San Francisco, CA 94141 USA.	yhuang@gladstone.ucsf.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG022074, R01AG020235] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG022074, R01 AG20235] Funding Source: Medline; NINDS NIH HHS [R21 NS046465] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aoki K, 2003, STROKE, V34, P875, DOI 10.1161/01.STR.0000064320.73388.C6; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bao F, 1996, NEUROREPORT, V7, P1733, DOI 10.1097/00001756-199607290-00008; Bastiaens PIH, 2000, TRENDS BIOCHEM SCI, V25, P631, DOI 10.1016/S0968-0004(00)01714-X; Beffert U, 1996, ANN NY ACAD SCI, V777, P166, DOI 10.1111/j.1749-6632.1996.tb34415.x; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Boschert U, 1999, NEUROBIOL DIS, V6, P508, DOI 10.1006/nbdi.1999.0251; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Buttini M, 2002, J NEUROSCI, V22, P10539; Buttini M, 1999, J NEUROSCI, V19, P4867; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CROWTHER RA, 1993, CURR OPIN STRUC BIOL, V3, P202, DOI 10.1016/S0959-440X(05)80153-8; Dekroon RM, 2001, GLIA, V33, P298, DOI 10.1002/1098-1136(20010315)33:4<298::AID-GLIA1028>3.0.CO;2-N; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Dupont-Wallois L, 1997, NEUROBIOL DIS, V4, P356, DOI 10.1006/nbdi.1997.0155; Ferreira S, 2000, EXP NEUROL, V166, P415, DOI 10.1006/exnr.2000.7510; Fisher CA, 1999, J LIPID RES, V40, P93; Gadella TWJ, 1999, TRENDS PLANT SCI, V4, P287, DOI 10.1016/S1360-1385(99)01426-0; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; HAN SH, 1994, J NEUROPATH EXP NEUR, V53, P535, DOI 10.1097/00005072-199409000-00013; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Heyduk T, 2002, CURR OPIN BIOTECH, V13, P292, DOI 10.1016/S0958-1669(02)00332-4; Hink MA, 2002, PLANT MOL BIOL, V50, P871, DOI 10.1023/A:1021282619035; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1999, ADV VASC BIOL, V5, P257; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; Ivanovic A, 1998, J BIOL CHEM, V273, P19933, DOI 10.1074/jbc.273.32.19933; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Ljungberg MC, 2002, NEUROREPORT, V13, P867, DOI 10.1097/00001756-200205070-00026; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Metzger RE, 1996, J NEUROPATH EXP NEUR, V55, P372, DOI 10.1097/00005072-199603000-00013; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Neininger A, 2001, EMBO REP, V2, P703, DOI 10.1093/embo-reports/kve157; Onuki R, 2002, P NATL ACAD SCI USA, V99, P14716, DOI 10.1073/pnas.232177599; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raffai RL, 2003, J LIPID RES, V44, P1423, DOI 10.1194/jlr.R300007-JLR200; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Riven I, 2003, NEURON, V38, P225, DOI 10.1016/S0896-6273(03)00193-4; Romas SN, 2002, ARCH NEUROL-CHICAGO, V59, P87, DOI 10.1001/archneur.59.1.87; Roses AD, 1996, CURR OPIN NEUROBIOL, V6, P644, DOI 10.1016/S0959-4388(96)80098-5; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schonle A, 2000, APPL OPTICS, V39, P6306, DOI 10.1364/AO.39.006306; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WELTY FK, 1995, CIRCULATION, V92, P2036, DOI 10.1161/01.CIR.92.8.2036; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; Xu PT, 1999, NEUROBIOL DIS, V6, P63, DOI 10.1006/nbdi.1998.0213; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	82	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25511	25516		10.1074/jbc.M311256200	http://dx.doi.org/10.1074/jbc.M311256200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15054100	hybrid			2022-12-25	WOS:000221827900076
J	Houliston, RS; Hodges, RS; Sharom, FJ; Davis, JH				Houliston, RS; Hodges, RS; Sharom, FJ; Davis, JH			Characterization of the proto-oncogenic and mutant forms of the transmembrane region of neu in micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; MOLECULAR-DYNAMICS SIMULATIONS; ENCODED P185 PROTEIN; HYDROGEN-EXCHANGE; POINT MUTATION; COAT PROTEIN; NEU/ERBB-2 RECEPTOR; STRUCTURAL DYNAMICS; CIRCULAR-DICHROISM; SELF-ASSOCIATION	We have investigated peptides corresponding to the complete transmembrane region of both proto-oncogenic (Val(664)) and mutant (Glu(664)) forms of the receptor Neu in detergent micelles by NMR and CD spectroscopy. Both forms of the peptide appear to adopt similar levels of helicity and dimeric interactions based on the analysis of CD spectra and nuclear Overhauser effect connectivity profiles. There are considerable differences in the chemical shifts of amide and, to a lesser extent, CHalpha resonances between the two forms of the peptides, and these differences are most pronounced in residues upstream of the mutation site and close to the N terminus of the transmembrane domain. Similarly, there are substantial differences in the amide hydrogen-deuterium exchange rates for residues close to and upstream of the mutation site; amide protons in this region of the proto-oncogenic peptide are much more resistant to exchange than those in the mutant form. In both molecules, residues downstream of the mutation site exhibit slow exchange. We therefore demonstrate that, although transmembrane Neu peptides exhibit similar levels of secondary structure when dispersed in detergent, there are detectable differences in their adopted micellar states that may provide insight into the dimer-promoting ability of the polar transforming mutation.	Univ Guelph, Dept Phys, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Guelph; University of Guelph; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Davis, JH (corresponding author), Univ Guelph, Dept Phys, Guelph, ON N1G 2W1, Canada.	jhd@physics.uoguelph.ca	Sharom, Frances/A-1613-2010	Sharom, Frances/0000-0002-9521-5367				Almeida FCL, 1997, J MOL BIOL, V270, P481, DOI 10.1006/jmbi.1997.1114; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Bader R, 2002, BIOCHEMISTRY-US, V41, P8031, DOI 10.1021/bi0201419; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P749, DOI 10.1007/BF01024899; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; Chen LI, 1997, J CELL BIOL, V137, P619, DOI 10.1083/jcb.137.3.619; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Damberg P, 2001, METHOD ENZYMOL, V339, P271, DOI 10.1016/S0076-6879(01)39318-7; Duneau JP, 1997, J BIOMOL STRUCT DYN, V15, P555, DOI 10.1080/07391102.1997.10508966; ENGELMAN DM, 1993, SOC GEN PHY, V48, P11; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; Fleishman SJ, 2002, P NATL ACAD SCI USA, V99, P15937, DOI 10.1073/pnas.252640799; Goetz M, 2001, BIOCHEMISTRY-US, V40, P6534, DOI 10.1021/bi0027938; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; Houliston RS, 2003, FEBS LETT, V535, P39, DOI 10.1016/S0014-5793(02)03852-8; Jones DH, 2000, BIOCHEMISTRY-US, V39, P1870, DOI 10.1021/bi992495e; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; ONEIL JDJ, 1988, BIOCHEMISTRY-US, V27, P2753, DOI 10.1021/bi00408a015; Opella SJ, 2001, METHOD ENZYMOL, V339, P285, DOI 10.1016/S0076-6879(01)39319-9; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; Petti LM, 1998, ONCOGENE, V16, P843, DOI 10.1038/sj.onc.1201590; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Sajot N, 2000, EUR BIOPHYS J BIOPHY, V28, P648, DOI 10.1007/s002490050005; Sajot N, 2001, J BIOMOL STRUCT DYN, V19, P15, DOI 10.1080/07391102.2001.10506717; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1994, PRACTICAL GUIDE MEMB; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; Sharpe S, 2002, BIOCHEMISTRY-US, V41, P2341, DOI 10.1021/bi011340f; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Smith SO, 2002, BIOCHEMISTRY-US, V41, P9321, DOI 10.1021/bi012117l; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Therien AG, 2001, NAT STRUCT BIOL, V8, P597, DOI 10.1038/89631; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; Williams KA, 1996, BIOCHEMISTRY-US, V35, P5145, DOI 10.1021/bi952897w; WILLIAMSON M P, 1990, Biopolymers, V29, P1423, DOI 10.1002/bip.360291009; Yee A, 1999, BIOCHEMISTRY-US, V38, P6489, DOI 10.1021/bi982959t; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	53	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24073	24080		10.1074/jbc.M401919200	http://dx.doi.org/10.1074/jbc.M401919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051716	hybrid			2022-12-25	WOS:000221702500029
J	Kittur, FS; Manithody, C; Rezaie, AR				Kittur, FS; Manithody, C; Rezaie, AR			Role of the N-terminal epidermal growth factor-like domain of factor X/Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; FACTOR-FACTOR-VIIA; SOLUBLE TISSUE FACTOR; FACTOR-VA BINDING; FACTOR-X; FACTOR-IX; PROTHROMBINASE COMPLEX; PROTEIN-C; ACTIVE-SITE; SUBSTRATE RECOGNITION	The functional importance of the N-terminal epidermal growth factor-like domain (EGF-N) of factor X/Xa (FX/Xa) was investigated by constructing an FX mutant in which the exon coding for EGF-N was deleted from FX cDNA. Following expression and purification to homogeneity, the mutant was characterized with respect to its ability to function as a zymogen for either the factor VIIa-tissue factor complex or the factor IXa-factor VIIIa complex and then to function as an enzyme in the prothrombinase complex to catalyze the conversion of prothrombin to thrombin. It was discovered that EGF-N is essential for the recognition and efficient activation of FX by both activators in the presence of the cofactors. On the other hand, the FXa mutant interacted with factor Va with a normal apparent dissociation constant and activated prothrombin with similar to3-fold lower catalytic efficiency in the prothrombinase complex. Surprisingly, the mutant activated prothrombin with similar to12-fold better catalytic efficiency than wild-type FXa in the absence of factor Va. The mutant was inactive in both prothrombin time and activated partial thromboplastin time assays; however, it exhibited a similar specific activity in a one-stage FXa clotting assay. These results suggest that EGF-N of FX is required for the cofactor-dependent zymogen activation by both physiological activators, but it plays no apparent role in FXa recognition of the cofactor in the prothrombinase complex.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu	Kittur, Farooqahmed S/G-3832-2012	Kittur, Farooqahmed/0000-0002-2272-3387	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R01HL062565] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68571, HL62565] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Chen L, 2004, PROTEIN SCI, V13, P431, DOI 10.1110/ps.03406904; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P1; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Furie B.C., 1976, Methods Enzymol, V45, P191; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; Kirchhofer D, 2000, BIOCHEMISTRY-US, V39, P7380, DOI 10.1021/bi000182+; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; McCallum CD, 1997, J BIOL CHEM, V272, P30160, DOI 10.1074/jbc.272.48.30160; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; ROSING J, 1980, J BIOL CHEM, V255, P274; RUF W, 1992, J BIOL CHEM, V267, P6375; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; STENFLO J, 1991, BLOOD, V78, P1637; Thiec F, 2003, J BIOL CHEM, V278, P10393, DOI 10.1074/jbc.M212144200; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Yang LK, 2003, J BIOL CHEM, V278, P10484, DOI 10.1074/jbc.M211797200; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	42	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24189	24196		10.1074/jbc.M402302200	http://dx.doi.org/10.1074/jbc.M402302200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15069066	hybrid			2022-12-25	WOS:000221702500042
J	Wang, FD; Dufner-Beattie, J; Kim, BE; Petris, MJ; Andrews, G; Eide, DJ				Wang, FD; Dufner-Beattie, J; Kim, BE; Petris, MJ; Andrews, G; Eide, DJ			Zinc-stimulated endocytosis controls activity of the mouse ZIP1 and ZIP3 zinc uptake transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ENCODES; FUNCTIONAL EXPRESSION; UPTAKE SYSTEM; FAMILY; LOCALIZATION; ARABIDOPSIS; IDENTIFICATION; SUBFAMILY; PROTEINS; MEMBER	The mouse mZip1 and mZip3 zinc transporters have been implicated in zinc acquisition by the cells of many tissues. This hypothesis raised the question of whether activity of these proteins is regulated to maintain zinc homeostasis. Neither mZIP1 nor mZIP3 mRNA levels are highly regulated by zinc status. Therefore, we investigated whether zinc controls the activity of these proteins post-translationally by altering their subcellular distribution. When expressed in transfected cells grown in zinc-replete medium, both mZip1 and mZip3 were largely present in intracellular organelles. However, these proteins were found to rapidly transit between the plasma membrane and intracellular compartments in zinc-replete cells. Zinc deficiency increased plasma membrane levels of mZip1 and mZip3 by decreasing their rates of endocytosis. Greater zinc deficiency was required to alter mZip3 distribution than was needed to affect mZip1. Increased surface levels correlated with increased zinc uptake activity. Taken together, these results suggest that post-translational control of mZip1 and mZip3 localization plays a role in zinc homeostasis. Moreover, our results indicate that zinc-responsive endocytosis is a conserved mechanism controlling activity of many mammalian zinc uptake transporters.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Kansas; University of Kansas Medical Center	Eide, DJ (corresponding author), Univ Missouri, Dept Biochem, 217 Gwynn Hall, Columbia, MO 65211 USA.	eided@missouri.edu	Wang, Fudi/L-7888-2018	Wang, Fudi/0000-0001-8730-0003	NIDDK NIH HHS [R01 DK59369] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059369] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P50142, DOI 10.1074/jbc.M304163200; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EIDE DJ, 2003, PFLUGERS ARCH; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; Franklin RB, 2003, J INORG BIOCHEM, V96, P435, DOI 10.1016/S0162-0134(03)00249-6; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Grass G, 2002, J BACTERIOL, V184, P864, DOI 10.1128/JB.184.3.864-866.2002; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Kelleher SL, 2003, J NUTR, V133, P3378, DOI 10.1093/jn/133.11.3378; Kim BE, 2004, J BIOL CHEM, V279, P4523, DOI 10.1074/jbc.M310799200; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; Lioumi M, 1999, GENOMICS, V62, P272, DOI 10.1006/geno.1999.5993; Milon B, 2001, FEBS LETT, V507, P241, DOI 10.1016/S0014-5793(01)02950-7; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Taylor KM, 2003, BBA-BIOMEMBRANES, V1611, P16, DOI 10.1016/S0005-2736(03)00048-8; Vert G, 2001, PLANT J, V26, P181, DOI 10.1046/j.1365-313x.2001.01018.x; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; Wang FD, 2004, HUM MOL GENET, V13, P563, DOI 10.1093/hmg/ddh049; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	30	105	110	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24631	24639		10.1074/jbc.M400680200	http://dx.doi.org/10.1074/jbc.M400680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15054103	hybrid			2022-12-25	WOS:000221702500093
J	Xu, WL; Dunn, CA; Jones, CR; D'Souza, G; Bessman, MJ				Xu, WL; Dunn, CA; Jones, CR; D'Souza, G; Bessman, MJ			The 26 nudix hydrolases of Bacillus cereus, a close relative of Bacillus anthracis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME SEQUENCE; SUBFAMILY; GENE; INVASION; FAMILY; ACID	The genome of Bacillus cereus contains 26 Nudix hydrolase genes, second only to its closest relative, Bacillus anthracis which has 30. All 26 genes have been cloned, 25 have been expressed, and 21 produced soluble proteins suitable for analysis. Substrates for 16 of the enzymes were identified; these included ADP-ribose, diadenosine polyphosphates, sugar nucleotides, and deoxynucleoside triphosphates. One of the enzymes was a CDP-choline pyrophosphatase, the first Nudix hydrolase active on this substrate. Furthermore, as a result of this and previous work we have identified a new subfamily of the Nudix hydrolase superfamily recognizable by a specific amino acid motif outside of the Nudix box.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BULLIONS LC, 1993, THESIS J HOPKINS U B; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Gaywee J, 2002, MOL CELL PROTEOMICS, V1, P179, DOI 10.1074/mcp.M100030-MCP200; HELGASON E, 2000, APPL ENVIRON MICROB, V68, P1414; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; Xu WL, 2000, BIOCHEM BIOPH RES CO, V273, P753, DOI 10.1006/bbrc.2000.2999; Xu WL, 2003, J BIOL CHEM, V278, P37492, DOI 10.1074/jbc.M307639200; Xu WL, 2001, MOL MICROBIOL, V39, P286, DOI 10.1046/j.1365-2958.2001.02267.x	18	46	48	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24861	24865		10.1074/jbc.M403272200	http://dx.doi.org/10.1074/jbc.M403272200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15060060	hybrid			2022-12-25	WOS:000221702500117
J	Tchernitsa, OI; Sers, C; Zuber, J; Hinzmann, B; Grips, M; Schramme, A; Lund, P; Schwendel, A; Rosenthal, A; Schafer, R				Tchernitsa, OI; Sers, C; Zuber, J; Hinzmann, B; Grips, M; Schramme, A; Lund, P; Schwendel, A; Rosenthal, A; Schafer, R			Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells	ONCOGENE			English	Article						suppressive subtraction hybridization; signal transduction; ovarian cancer; gene regulation; mitogen-activated; protein kinase	JUNCTIONAL INTERCELLULAR COMMUNICATION; GENE-EXPRESSION PROFILES; K-RAS PROTOONCOGENE; GENOMIC INSTABILITY; DNA METHYLATION; PROTEIN-KINASES; DOWN-REGULATION; LUNG-CANCER; TUMOR-CELLS; E-CADHERIN	To understand the relationship between oncogenic signaling and the reprogramming of gene expression, we performed transcriptional profiling in rat ovarian surface epithelial cells (ROSE), in which neoplastic transformation is driven by a mutated KRAS oncogene. We identified >200 genes whose expression was elevated or reduced following permanent KRAS expression. Deregulated KRAS-responsive genes encode transcriptional regulators, signaling effectors, proteases, extracellular matrix and adhesion proteins, transformation-suppressing proteins and negative growth regulators. Many of them have not been previously identified in cells expressing oncogenic RAS genes or in other well-studied models of oncogenic signaling. The number of critical genes related to the execution of anchorage-independent proliferation and epithelial-mesenchymal transition was narrowed down to 79 by selectively inhibiting the mitogen-activated protein kinase (MAPK/ERK) and phosphatidylinositol 3-kinase (PI3K) pathways. Blocking MAPK/ERK-signaling caused reversion to the normal epithelial phenotype in conjunction with the reversal of deregulated target transcription to pretransformation levels. In addition, silencing of the overexpressed transcriptional regulator Fra-1 by RNA interference resulted in growth reduction, suggesting that this factor partially contributes to, but is not sufficient for the proliferative capacity of KRAS-transformed epithelial cells.	Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumor Pathol, D-10117 Berlin, Germany; MetaGen Pharmaceut GmbH, D-13347 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schafer, R (corresponding author), Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumor Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	reinhold.schaefer@charite.de	Sers, Christine/B-5438-2010; Lund, Per G/M-9019-2017; Schäfer, Reinhold/AAB-5110-2021; Zuber, Johannes/E-7517-2011; Lund, Per/Q-6737-2017	Zuber, Johannes/0000-0001-8810-6835; Lund, Per/0000-0002-7457-4360; Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Alvarez AA, 2001, GYNECOL ONCOL, V82, P273, DOI 10.1006/gyno.2001.6287; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Baruch RR, 2001, CELL BIOL INT, V25, P411, DOI 10.1006/cbir.2000.0647; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BISHOP JM, 1985, TRENDS GENET, V1, P245, DOI 10.1016/0168-9525(85)90094-0; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOS JL, 1989, CANCER RES, V49, P4682; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEVOUGE MW, 1992, ONCOGENE, V7, P109; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 2001, NATURE, V411, P759, DOI 10.1038/35081138; DOWNWARD J, 1998, MOL B INT U, V3, P171; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ENOMOTO T, 1991, AM J PATHOL, V139, P777; Evangelou A, 2000, CANCER RES, V60, P929; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Furuya M, 2000, GYNECOL ONCOL, V78, P106, DOI 10.1006/gyno.2000.5856; Giampuzzi M, 2001, J BIOL CHEM, V276, P29226, DOI 10.1074/jbc.M101695200; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; HOFMANN M, 1993, CANCER RES, V53, P1516; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; ICHIKAWA Y, 1994, CANCER RES, V54, P33; Imren S, 1996, CANCER RES, V56, P2891; IVER VR, 1999, SCIENCE, V283, P83; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kessler R, 1999, ONCOGENE, V18, P1733, DOI 10.1038/sj.onc.1202484; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LEWIS JE, 1994, J INVEST DERMATOL, V102, P870, DOI 10.1111/1523-1747.ep12382690; LUO XN, 1995, ONCOGENE, V11, P743; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; Majidi M, 2000, J BIOL CHEM, V275, P6560, DOI 10.1074/jbc.275.9.6560; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mok SC, 1996, ONCOGENE, V12, P1895; MOK SCH, 1993, CANCER RES, V53, P1489; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Olski TM, 2001, J CELL SCI, V114, P525; OZAKI T, 1994, CANCER RES, V54, P646; Paterson IC, 2001, J PATHOL, V193, P458, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V; Patton SE, 1998, CANCER RES, V58, P2253; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Schorge JO, 2000, GYNECOL ONCOL, V76, P369, DOI 10.1006/gyno.1999.5711; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sehgal A, 1997, J SURG ONCOL, V65, P249, DOI 10.1002/(SICI)1096-9098(199708)65:4<249::AID-JSO5>3.0.CO;2-5; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Sumitomo K, 2000, CANCER LETT, V155, P37, DOI 10.1016/S0304-3835(00)00407-9; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; Umhauer S, 2000, AM J OBSTET GYNECOL, V182, P999, DOI 10.1016/S0002-9378(00)70135-9; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	90	60	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4536	4555		10.1038/sj.onc.1207585	http://dx.doi.org/10.1038/sj.onc.1207585			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064704				2022-12-25	WOS:000221799000004
J	Liu, H; Chen, B; Xiong, H; Huang, QH; Zhang, QH; Wang, ZG; Li, BL; Chen, Z; Chen, SJ				Liu, H; Chen, B; Xiong, H; Huang, QH; Zhang, QH; Wang, ZG; Li, BL; Chen, Z; Chen, SJ			Functional contribution of EEN to leukemogenic transformation by MLL-EEN fusion protein	ONCOGENE			English	Article						MLL-EEN; transcriptional factor; HoxA7; leukemogenesis	LEUKEMIA-CELL LINE; SYNAPTIC VESICLE ENDOCYTOSIS; CENTRAL-NERVOUS-SYSTEM; HOMOLOGY 3 DOMAIN; MYELOID PROGENITORS; DOWN-REGULATION; ANTISENSE OLIGODEOXYRIBONUCLEOTIDE; CHROMOSOMAL TRANSLOCATION; ONCOGENIC ACTIVATION; BINDING PARTNERS	The EEN (extra eleven nineteen) gene was originally cloned from a case of acute myeloid leukemia M5 subtype with translocation t (11;19)(q23; p13), in which EEN was fused with MLL. To explore the involvement of EEN in leukemogenesis caused by MLL-EEN, we studied the transformation potential of the MLL-EEN fusion protein. MLL-EEN had oncogenic features, while, as a control, MLLDelta, the truncated form of MLL lacking the EEN moiety, did not show any oncogenic potential. MLL-EEN exerted a dominant-negative effect over wild-type EEN in terms of subcellular localization. Normally, EEN was found in the cytoplasm, but the MLL-EEN fusion protein was located in the nucleus, and EEN could be delocalized by MLL-EEN. This interaction is via a coiled-coil dimerization domain of EEN, which is reserved in the fusion protein. In addition, MLL-EEN might act as a potential transcriptional factor with the MLL part providing the DNA-binding domain and the EEN part providing the transcription activation domain, though EEN seems to have no direct role in transcriptional regulation. As an aberrant transcriptional factor, MLL-EEN could transactivate the promoter of HoxA7, a potential target gene of MLL.	Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Gen, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Chen, SJ (corresponding author), Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Gen, 197 Ruijin Rd 2, Shanghai 200025, Peoples R China.	sjchen@stn.sh.cn		Liu, Han/0000-0002-0022-1861				Akao Y, 1998, CANCER RES, V58, P3773; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Chan LC, 2002, BLOOD, V100, p199B; Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; COLLINS SJ, 1987, BLOOD, V70, P1233; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dorrie J, 1999, LEUKEMIA, V13, P1539, DOI 10.1038/sj.leu.2401479; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; Hayashi Y, 2000, CANCER RES, V60, P1139; Hsu K, 2003, CANCER CELL, V4, P81, DOI 10.1016/S1535-6108(03)00192-2; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Joh T, 1996, ONCOGENE, V13, P1945; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kawagoe H, 2001, LEUKEMIA, V15, P1743, DOI 10.1038/sj.leu.2402262; Kersey JH, 1998, LEUKEMIA, V12, P1561, DOI 10.1038/sj.leu.2401148; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Kwon KB, 2002, EXP MOL MED, V34, P32, DOI 10.1038/emm.2002.5; Lanza C, 1996, GENE CHROMOSOME CANC, V15, P48, DOI 10.1002/(SICI)1098-2264(199601)15:1<48::AID-GCC7>3.0.CO;2-4; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Mahgoub N, 1998, GENE CHROMOSOME CANC, V21, P270, DOI 10.1002/(SICI)1098-2264(199803)21:3<270::AID-GCC14>3.0.CO;2-T; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Mayer BJ, 2001, J CELL SCI, V114, P1253; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Mollinedo F, 1998, ANIMAL CELL CULTURE TECHNIQUES, P264; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NAOE T, 1993, BLOOD, V82, P2260, DOI 10.1182/blood.V82.7.2260.bloodjournal8272260; Niitsu N, 2001, ONCOGENE, V20, P375, DOI 10.1038/sj.onc.1204081; Ormerod MG, 1998, LEUKEMIA, V12, P1013, DOI 10.1038/sj.leu.2401061; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; POCOCK CFE, 1995, BRIT J HAEMATOL, V90, P855, DOI 10.1111/j.1365-2141.1995.tb05207.x; Polak PE, 2003, MOL BIOL CELL, V14, P1517, DOI 10.1091/mbc.E02-07-0394; Reutens AT, 2002, INT J BIOCHEM CELL B, V34, P1173, DOI 10.1016/S1357-2725(02)00063-8; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Rogaia D, 1997, CANCER RES, V57, P799; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubnitz JE, 1996, LEUKEMIA, V10, P74; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; YAM JW, 2003, BLOOD; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2003, LEUKEMIA, V17, P359, DOI 10.1038/sj.leu.2402804; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	65	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3385	3394		10.1038/sj.onc.1207402	http://dx.doi.org/10.1038/sj.onc.1207402			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077184				2022-12-25	WOS:000220975000013
J	Pickett, HA; Baird, DM; Hoff-Olsen, P; Meling, GI; Rognum, TO; Shaw, J; West, KP; Royle, NJ				Pickett, HA; Baird, DM; Hoff-Olsen, P; Meling, GI; Rognum, TO; Shaw, J; West, KP; Royle, NJ			Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene	ONCOGENE			English	Article						telomere; mutation; microsatellite instability; mismatch repair; colon cancer	HUMAN XP/YP TELOMERE; SMALL POOL PCR; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; REPEAT INSTABILITY; SOMATIC MOSAICISM; HUMAN-CELLS; DNA; MAINTENANCE; CARCINOMAS	Human telomeres are essential for genome stability and are composed of long simple tandem repeat arrays (STRs), comprising the consensus TTAGGG repeat interspersed, at the proximal end, with sequence-variant repeats. While the dynamics of telomere attrition through incomplete replication has been studied extensively, the effects on telomeres of error-prone DNA repair processes, known to affect other STRs, are poorly understood. We have compared the TTAGGG and sequence-variant interspersion patterns in the proximal 720 bp of telomeres in colon cancer and normal DNA samples. The frequency of telomere mutations was 5.8% per allele in a randomly collected panel of sporadic colon cancers, showing that telomere mutations occur in vivo. The mutation frequency rose to 18.6% per allele in sporadic tumours that exhibit instability at the polyA tract in the TGFbetaRII gene and to 35% per allele in tumours with somatic mutations in the hMSH2 gene. The majority of the characterized mutations resulted in the loss of one or a few repeats. If the mutation spectrum and frequency described here is reiterated in the rest of the array, there is the potential for extensive telomere destabilization especially in mismatch repair-defective cells. This may in turn lead to a greater requirement for telomere length maintenance earlier in tumourigenesis.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Oslo, Rikshosp, Univ Hosp, Inst Forens Med, N-0027 Oslo, Norway; Univ Leicester, Dept Pathol, Leicester LE2 7LX, Leics, England	University of Leicester; University of Oslo; National Hospital Norway; University of Leicester	Royle, NJ (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	njr@le.ac.uk	Baird, Duncan M/C-9671-2011	Baird, Duncan M/0000-0001-8408-5467; Royle, Nicola/0000-0003-1174-6329; Shaw, Jacqui/0000-0003-4227-503X				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BAIRD DM, 1995, EMBO J, V14, P5433, DOI 10.1002/j.1460-2075.1995.tb00227.x; Baird DM, 1997, HUM MOL GENET, V6, P2291, DOI 10.1093/hmg/6.13.2291; Baird DM, 2000, AM J HUM GENET, V66, P235, DOI 10.1086/302721; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cheng AJ, 1998, J NATL CANCER I, V90, P316, DOI 10.1093/jnci/90.4.316; Coleman J, 1999, HUM MOL GENET, V8, P1637, DOI 10.1093/hmg/8.9.1637; Coleman MG, 2001, BRIT J CANCER, V85, P1486, DOI 10.1054/bjoc.2001.2058; Crawford DC, 2000, HUM MOL GENET, V9, P2909, DOI 10.1093/hmg/9.19.2909; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ellegren H, 2000, NAT GENET, V24, P400, DOI 10.1038/74249; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fortune MT, 2000, HUM MOL GENET, V9, P439, DOI 10.1093/hmg/9.3.439; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; Jiricny J, 2003, CURR OPIN GENET DEV, V13, P61, DOI 10.1016/S0959-437X(03)00004-2; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOTHE RA, 1993, CANCER RES, V53, P5849; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Martorell L, 1998, HUM MOL GENET, V7, P307, DOI 10.1093/hmg/7.2.307; MONCKTON DG, 1995, HUM MOL GENET, V4, P1; PARSONS R, 1995, CANCER RES, V55, P5548; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Savouret C, 2003, EMBO J, V22, P2264, DOI 10.1093/emboj/cdg202; Sharma R, 2002, HUM MOL GENET, V11, P2175, DOI 10.1093/hmg/11.18.2175; Sinden RR, 2001, NATURE, V411, P757, DOI 10.1038/35081234; Takayanagi H, 2000, NTT REVIEW, V12, P17; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; van den Broek WJAA, 2002, HUM MOL GENET, V11, P191, DOI 10.1093/hmg/11.2.191; Varley H, 2002, NAT GENET, V30, P301, DOI 10.1038/ng834; Xu X, 2000, NAT GENET, V24, P396, DOI 10.1038/74238; Yamamoto H, 1999, GASTROENTEROLOGY, V116, P1348, DOI 10.1016/S0016-5085(99)70499-3	42	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3434	3443		10.1038/sj.onc.1207477	http://dx.doi.org/10.1038/sj.onc.1207477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15048084				2022-12-25	WOS:000220975000018
J	Horejsi, Z; Falck, J; Bakkenist, CJ; Kastan, MB; Lukas, J; Bartek, J				Horejsi, Z; Falck, J; Bakkenist, CJ; Kastan, MB; Lukas, J; Bartek, J			Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation	ONCOGENE			English	Article						Nbs1; ATM; DNA damage; ionizing radiation; cell cycle checkpoints	NIJMEGEN-BREAKAGE-SYNDROME; S-PHASE CHECKPOINT; TELANGIECTASIA-MUTATED ATM; DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; DEPENDENT PHOSPHORYLATION; FOCUS FORMATION; MRE11 COMPLEX; IN-VIVO	The ATM kinase is a tumour suppressor and a key activator of genome integrity checkpoints in mammalian cells exposed to ionizing radiation (IR) and other insults that elicit DNA double-strand breaks (DSBs). In response to IR, autophosphorylation on serine 1981 causes dissociation of ATM dimers and initiates cellular ATM kinase activity. Here, we show that the kinetics and magnitude of ATM Ser1981 phosphorylation after exposure of human fibroblasts to low doses (2 Gy) of IR are altered in cells deficient in Nbs1, a substrate of ATM and a component of the MRN (Mre11-Rad50-Nbs1) complex involved in processing/repair of DSBs and ATM-dependent cell cycle checkpoints. Timely phosphorylation of both ATM Ser1981 and the ATM substrate Smc1 after IR were rescued via retrovirally mediated reconstitution of Nbs1-deficient cells by wild-type Nbs1 or mutants of Nbs1 defective in the FHA domain or nonphosphorylatable by ATM, but not by Nbs1 lacking the Mre11-interaction domain. Our data indicate that apart from its role downstream of ATM in the DNA damage checkpoint network, the MRN complex serves also as a modulator/amplifier of ATM activity. Although not absolutely required for ATM activation, the MRN nuclease complex may help reach the threshold activity of ATM necessary for optimal genome maintenance and prevention of cancer.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; St Jude Childrens Res Hosp, Memphis, TN 38105 USA	Danish Cancer Society; St Jude Children's Research Hospital	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	bartek@biobase.dk	Bartek, Jiri/G-5870-2014	Licenikova Horejsi, Zuzana/0000-0002-9943-1649; Lukas, Jiri/0000-0001-9087-506X	NCI NIH HHS [CA 71387, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2000, CANCER RES, V60, P5934; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lee JH, 2003, MOL CANCER RES, V1, P674; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	41	99	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3122	3127		10.1038/sj.onc.1207447	http://dx.doi.org/10.1038/sj.onc.1207447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048089				2022-12-25	WOS:000220845200017
J	Becker, KP; Hannun, YA				Becker, KP; Hannun, YA			Isoenzyme-specific translocation of protein kinase C (PKC) beta II and not PKC beta I to a juxtanuclear subset of recycling endosomes - Involvement of phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE HYDROLYSIS; ALPHA-THROMBIN; GROWTH-FACTOR; ACTIVATION; ISOZYMES; DIACYLGLYCEROL; FIBROBLASTS; OVEREXPRESSION; PROLIFERATION; LOCALIZATION	Elucidation of isoenzyme-specific functions of individual protein kinase C (PKC) isoenzymes has emerged as an important goal in the study of this family of kinases, but this task has been complicated by modest substrate specificity and high homology among the individual members of each PKC subfamily. The classical PKCbetaI and PKCbetaII isoenzymes provide a unique opportunity because they are the alternatively spliced products of the beta gene and are 100% identical except for the last 50 of 52 amino acids. In this study, it is shown that green fluorescent protein-tagged PKCbetaII and not PKCbetaI translocates to a recently described juxtanuclear site of localization for PKCalpha and PKCbetaII isoenzymes that arises with sustained stimulation of PKC. Mechanistically, translocation of PKCbetaII to the juxtanuclear region required kinase activity. PKCbetaII, but not PKCbetaI, was found to activate phospholipase D within this time frame. Inhibitors of phospholipase D (1-butanol and a dominant negative construct) prevented the translocation of PKCbetaII to the juxtanuclear region but not to the plasma membrane, thus demonstrating a role for phospholipase D in the juxtanuclear translocation of PKCbetaII. Taken together, these results define specific biochemical and cellular actions of PKCbetaII when compared with PKCbetaI.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HA KS, 1993, J BIOL CHEM, V268, P10534; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hu TH, 2003, J BIOL CHEM, V278, P2348, DOI 10.1074/jbc.M210093200; Hurley JH, 1997, PROTEIN SCI, V6, P477; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; Yamamoto M, 1998, EXP CELL RES, V240, P349, DOI 10.1006/excr.1998.3999; Yamamoto M, 2000, AM J PHYSIOL-CELL PH, V279, pC587, DOI 10.1152/ajpcell.2000.279.3.C587; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	31	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28251	28256		10.1074/jbc.M400770200	http://dx.doi.org/10.1074/jbc.M400770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15067001	hybrid			2022-12-25	WOS:000222265400055
J	Xie, MT; Smith, JL; Ding, ZW; Zhang, DQ; Cornell, RB				Xie, MT; Smith, JL; Ding, ZW; Zhang, DQ; Cornell, RB			Membrane binding modulates the quaternary structure of CTP : phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; ENDOPLASMIC-RETICULUM; DOMAIN; PHOSPHATIDYLCHOLINE; IDENTIFICATION; PROTEINS; LOCALIZATION; ACTIVATION; ENZYME; ALPHA	CTP:phosphocholine cytidylyltransferase (CCT), a key enzyme that controls phosphatidylcholine synthesis, is regulated by reversible interactions with membranes containing anionic lipids. Previous work demonstrated that CCT is a homodimer. In this work we show that the structure of the dimer interface is altered upon encountering membranes that activate CCT. Chemical cross-linking reactions were established which captured intradimeric interactions but not random CCT dimer collisions. The efficiency of capturing covalent cross-links with four different reagents was diminished markedly upon presentation of activating anionic lipid vesicles but not zwitterionic vesicles. Experiments were conducted to show that the anionic vesicles did not interfere with the chemistry of the cross-linking reactions and did not sequester available cysteine sites on CCT for reaction with the cysteine-directed cross-linking reagent. Thus, the loss of cross-linking efficiency suggested that contact sites at the dimer interface had increased distance or reduced flexibility upon binding of CCT to membranes. The regions of the enzyme involved in dimerization were mapped using three approaches: 1) limited proteolysis followed by cross-linking of fragments, 2) yeast two-hybrid analysis of interactions between select domains, and 3) disulfide bonding potential of CCTs with individual cysteine to serine substitutions for the seven native cysteines. We found that the N-terminal domain (amino acids 1-72) is an important participant in forming the dimer interface, in addition to the catalytic domain (amino acids 73-236). We mapped the intersubunit disulfide bond to the cystine 37 pair in domain N and showed that this disulfide is sensitive to anionic vesicles, implicating this specific region in the membrane-sensitive dimer interface.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University; Simon Fraser University	Cornell, RB (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	cornell@sfu.ca		Xie, Mingtang/0000-0002-2797-0598				Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; Drobnies AE, 1999, BIOCHEMISTRY-US, V38, P15606, DOI 10.1021/bi991573v; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Friesen JA, 1999, J BIOL CHEM, V274, P13384, DOI 10.1074/jbc.274.19.13384; HABEEB AFS, 1968, ARCH BIOCHEM BIOPHYS, V126, P16, DOI 10.1016/0003-9861(68)90554-7; JAMIL H, 1990, J BIOL CHEM, V265, P4332; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; Johnson JE, 2003, J BIOL CHEM, V278, P514, DOI 10.1074/jbc.M206072200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; Randez-Gil F, 1998, FEBS LETT, V425, P475, DOI 10.1016/S0014-5793(98)00289-0; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; Taneva S, 2003, BIOCHEMISTRY-US, V42, P11768, DOI 10.1021/bi035234k; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9	28	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28817	28825		10.1074/jbc.M403311200	http://dx.doi.org/10.1074/jbc.M403311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15069071	hybrid			2022-12-25	WOS:000222265400120
J	Izard, T; Vonrhein, C				Izard, T; Vonrhein, C			Structural basis for amplifying vinculin activation by talin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITES; INTRAMOLECULAR ASSOCIATION; CYTOPLASMIC DOMAIN; FOCAL ADHESIONS; HEAD DOMAIN; KINASE; ACTIN; CONTAINS; DISRUPTION; REGION	Talin interactions with vinculin are essential for focal adhesions. Curiously, talin contains three noncontiguous vinculin binding sites (VBS) that can bind individually to the vinculin head (Vh) domain. Here we report the crystal structure of the human Vh . VBS1 complex, a validated model of the Vh . VBS2 structure, and biochemical studies that demonstrate that all of talin VBSs activate vinculin by provoking helical bundle conversion of the Vh domain, which displaces the vinculin tail (Vt) domain. Thus, helical bundle conversion is a structurally conserved response in talin-vinculin interactions. Furthermore, talin VBSs bind to Vh in a mutually exclusive manner but do differ in their affinity for Vh and in their ability to displace Vt, suggesting that the strengths of these interactions could lead to differences in signaling outcome. These findings support a model in which talin binds to and activates multiple vinculin molecules to provoke rapid reorganization of the actin cytoskeleton.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Global Phasing Ltd, Cambridge CB3 0AX, England	St Jude Children's Research Hospital; Global Phasing Limited	Izard, T (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	tina.izard@stjude.org			NCI NIH HHS [CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bailly M, 2003, TRENDS CELL BIOL, V13, P163, DOI 10.1016/S0962-8924(03)00030-8; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; Bricogne G, 1997, METHOD ENZYMOL, V276, P361, DOI 10.1016/S0076-6879(97)76069-5; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; EIMER W, 1993, J MOL BIOL, V229, P146, DOI 10.1006/jmbi.1993.1014; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; Hemmings L, 1996, J CELL SCI, V109, P2715; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Lesay A, 2001, NEUROREPORT, V12, P2111, DOI 10.1097/00001756-200107200-00014; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MCGREGOR A, 1994, BIOCHEM J, V301, P225, DOI 10.1042/bj3010225; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; MOLONY L, 1987, J BIOL CHEM, V262, P7790; NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Propato A, 2001, NAT MED, V7, P807, DOI 10.1038/89930; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rush CL, 2004, ACTA CRYSTALLOGR D, V60, P945, DOI 10.1107/S0907444904006547; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; STEENBERGEN C, 1987, CIRC RES, V60, P478, DOI 10.1161/01.RES.60.4.478; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Winkler J, 1997, EUR J BIOCHEM, V243, P430, DOI 10.1111/j.1432-1033.1997.0430a.x; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; Xu WM, 1998, DEVELOPMENT, V125, P327	51	80	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27667	27678		10.1074/jbc.M403076200	http://dx.doi.org/10.1074/jbc.M403076200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15070891	hybrid			2022-12-25	WOS:000222120400101
J	Jiang, C; Ito, M; Piening, V; Bruck, K; Roeder, RG; Xiao, H				Jiang, C; Ito, M; Piening, V; Bruck, K; Roeder, RG; Xiao, H			TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEAR RECEPTOR; IN-VITRO; COMPLEXES; TUMORIGENESIS; RECRUITMENT; EXPRESSION; MECHANISMS; ELONGATION; MOUSE	Deregulation of c-myc expression is implicated in the pathogenesis of many neoplasias. Estrogen receptor alpha (ERalpha) can increase the rate of c-myc transcription through the recruitment of a variety of cofactors to the promoter, yet the precise roles of these cofactors in transcription and tumorigenesis are largely unknown. We show here that a putative tumor suppressor TIP30, also called CC3 or Htatip2, interacts with an ERalpha-interacting coactivator CIA. Using chromatin immunoprecipitation assays, we demonstrate that TIP30 and CIA are distinct cofactors that are dynamically associated with the promoter and downstream regions of the c-myc gene in response to estrogen. Both TIP30 and CIA are recruited to the c-myc gene promoter by liganded ERalpha in the second transcription cycle. TIP30 overexpression represses ERalpha-mediated c-myc transcription, whereas TIP30 deficiency enhances c-myc transcription in both the absence and presence of estrogen. Ectopic CIA cooperates with TIP30 to repress ERalpha-mediated c-myc transcription. Moreover, virgin TIP30 knockout mice exhibit increased c-myc expression in mammary glands. Together, these results reveal an important role for TIP30 in the regulation of ERalpha-mediated c-myc transcription and suggest a mechanism for tumorigenesis promoted by TIP30 deficiency.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Kobe Univ, Sch Med, Dept Med, Div Hematol Oncol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Kobe University; Rockefeller University	Xiao, H (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	hxiao@unmc.edu						BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Couse JF, 1999, ANN ENDOCRINOL-PARIS, V60, P143; Cunha GR, 2000, ADV EXP MED BIOL, V480, P93; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBIK D, 1992, ONCOGENE, V7, P1587; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Freedman LP, 1999, TRENDS ENDOCRIN MET, V10, P403, DOI 10.1016/S1043-2760(99)00208-8; FREEDMAN LP, 1999, ANNU REV BIOCHEM, V70, P475; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ito M, 2003, CANCER RES, V63, P8763; Ito M, 2002, EMBO J, V21, P3464, DOI 10.1093/emboj/cdf348; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; NicAmhlaoibh R, 2001, ONCOGENE, V20, P270, DOI 10.1038/sj.onc.1204075; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Rudd MD, 1996, J BIOL CHEM, V271, P21549, DOI 10.1074/jbc.271.35.21549; Sauve FD, 2001, MOL CELL BIOL, V21, P343, DOI 10.1128/MCB.21.1.343-353.2001; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; SPENCER CA, 1990, ANN NY ACAD SCI, V599, P12; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Whitman S, 2000, MOL CELL BIOL, V20, P583, DOI 10.1128/MCB.20.2.583-593.2000; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1999, J BIOL CHEM, V274, P3937, DOI 10.1074/jbc.274.7.3937; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939	43	61	66	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27781	27789		10.1074/jbc.M401809200	http://dx.doi.org/10.1074/jbc.M401809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15073177	hybrid			2022-12-25	WOS:000222120400113
J	Alric, J; Tsukatani, Y; Yoshida, M; Matsuura, K; Shimada, K; Hienerwadel, R; Schoepp-Cothenet, B; Nitschke, W; Nagashima, KVP; Vermeglio, A				Alric, J; Tsukatani, Y; Yoshida, M; Matsuura, K; Shimada, K; Hienerwadel, R; Schoepp-Cothenet, B; Nitschke, W; Nagashima, KVP; Vermeglio, A			Structural and functional characterization of the unusual triheme cytochrome bound to the reaction center of Rhodovulum sulfidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; ELECTRON-PARAMAGNETIC-RESONANCE; IRON-SULFUR PROTEIN; BLODGETT MONOLAYER FILMS; REACTION-CENTER COMPLEX; TETRAHEME CYTOCHROME; RHODOPSEUDOMONAS-VIRIDIS; PURPLE BACTERIUM; INTERACTION SITE; SUBUNIT	The cytochrome bound to the photosynthetic reaction center of Rhodovulum sulfidophilum presents two unusual characteristics with respect to the well characterized tetraheme cytochromes. This cytochrome contains only three hemes because it lacks the peptide motif CXXCH, which binds the most distal fourth heme. In addition, we show that the sixth axial ligand of the third heme is a cysteine (Cys-148) instead of the usual methionine ligand. This ligand exchange results in a very low midpoint potential ( - 160 +/- 10 mV). The influence of the unusual cysteine ligand on the midpoint potential of this distal heme was further investigated by site-directed mutagenesis. The midpoint potential of this heme is upshifted to + 310 mV when cysteine 148 is replaced by methionine, in agreement with the typical redox properties of a His/Met coordinated heme. Because of the large increase in the midpoint potential of the distal heme in the mutant, both the native and modified high potential hemes are photooxidized at a redox poise where only the former is photooxidizable in the wild type. The relative orientation of the three hemes, determined by EPR measurements, is shown different from tetraheme cytochromes. The evolutionary basis of the concomitant loss of the fourth heme and the down-conversion of the third heme is discussed in light of phylogenetic relationships of the Rhodovulum species triheme cytochromes to other reaction center-associated tetraheme cytochromes.	CEA Cadarache, DSV DEVM Lab Bioenerget Cellulaire, UMR CNRS CEA CNRS Aix Marseille 2 6191, F-13108 St Paul Les Durance, France; Lab Genet & Biophys Plantes, UMR CNRS CEA CNRS Aix Marseille 2 6191, Marseille, France; Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan; Inst Biol Struct & Microbiol, Lab Bioenerget & Ingn Prot, CNRS, UPR 9036, F-13402 Marseille 20, France	CEA; CEA; UDICE-French Research Universities; Aix-Marseille Universite; Tokyo Metropolitan University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Vermeglio, A (corresponding author), CEA Cadarache, DSV DEVM Lab Bioenerget Cellulaire, UMR CNRS CEA CNRS Aix Marseille 2 6191, F-13108 St Paul Les Durance, France.	avermeglio@cea.fr	Schoepp-Cothenet, Barbara/AAH-8911-2021; Alric, Jean/E-3538-2013; Nitschke, Wolfgang/C-4812-2012; Nagashima, Kenji V. P./M-2208-2017; Tsukatani, Yusuke/A-6448-2014	Schoepp-Cothenet, Barbara/0000-0002-6820-4478; Alric, Jean/0000-0003-3574-2234; Nagashima, Kenji V. P./0000-0002-4526-6625; Tsukatani, Yusuke/0000-0003-2831-8996; Nitschke, Wolfgang/0000-0003-2084-3032				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P239, DOI 10.1016/S0005-2728(05)80107-0; Baymann F, 1998, BIOCHEMISTRY-US, V37, P15320, DOI 10.1021/bi980963z; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; Cheesman MR, 2001, BIOCHEMISTRY-US, V40, P10562, DOI 10.1021/bi0100081; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; MAILER C, 1972, CAN J BIOCHEM CELL B, V50, P1048, DOI 10.1139/o72-145; Masuda S, 1999, J BIOL CHEM, V274, P10795, DOI 10.1074/jbc.274.16.10795; Masuda S, 2002, BIOCHEMISTRY-US, V41, P11211, DOI 10.1021/bi0258492; McDevitt CA, 2002, MOL MICROBIOL, V44, P1575, DOI 10.1046/j.1365-2958.2002.02978.x; Montoya G, 1999, EUR J BIOCHEM, V259, P709, DOI 10.1046/j.1432-1327.1999.00094.x; NITSCHKE W, 1993, BIOCHEMISTRY-US, V32, P8871, DOI 10.1021/bi00085a019; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1100, P49; NITSCHKE W, 1989, BIOCHEMISTRY-US, V28, P3161, DOI 10.1021/bi00434a008; Nitschke W., 1995, ANOXYGENIC PHOTOSYNT, P775; Nogi T, 2000, P NATL ACAD SCI USA, V97, P13561, DOI 10.1073/pnas.240224997; ORTEGA JM, 1993, BIOCHEMISTRY-US, V32, P1141, DOI 10.1021/bi00055a020; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P15779, DOI 10.1021/bi990907d; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P2861, DOI 10.1021/bi982747w; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RAPHAEL AL, 1991, J AM CHEM SOC, V113, P1038, DOI 10.1021/ja00003a045; RUTHERFORD AW, 1990, BIOCHIM BIOPHYS ACTA, V1019, P128, DOI 10.1016/0005-2728(90)90133-O; SCHEIDT WR, 1986, J AM CHEM SOC, V108, P1163, DOI 10.1021/ja00266a008; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; TIEDE DM, 1978, BIOCHIM BIOPHYS ACTA, V503, P524, DOI 10.1016/0005-2728(78)90151-2; Tsukatani Y, 2004, PHOTOSYNTH RES, V79, P83, DOI 10.1023/B:PRES.0000011922.56394.92; VERMEGLIO A, 1989, FEBS LETT, V243, P259, DOI 10.1016/0014-5793(89)80140-1; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Yoshida MT, 2001, BBA-BIOENERGETICS, V1506, P23, DOI 10.1016/S0005-2728(01)00177-3	36	24	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26090	26097		10.1074/jbc.M400361200	http://dx.doi.org/10.1074/jbc.M400361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069076	hybrid			2022-12-25	WOS:000222003000022
J	Carter, WJ; Myles, T; Gibbs, CS; Leung, LL; Huntington, JA				Carter, WJ; Myles, T; Gibbs, CS; Leung, LL; Huntington, JA			Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ BINDING-SITE; POTENT ANTICOAGULANT; ACTIVE-SITE; SLOW; PROCOAGULANT; SPECIFICITY; ACTIVATION; MECHANISMS	Thrombin is the ultimate protease of the blood clotting cascade and plays a major role in its own regulation. The ability of thrombin to exhibit both pro- and anti-coagulant properties has spawned efforts to turn thrombin into an anticoagulant for therapeutic purposes. This quest culminated in the identification of the E217K variant through scanning and saturation mutagenesis. The antithrombotic properties of E217K thrombin are derived from its inability to convert fibrinogen to a fibrin clot while maintaining its thrombo-modul-independent ability to activate the anticoagulant protein C pathway. Here we describe the 2.5-Angstrom crystal structure of human E217K thrombin, which displays a dramatic restructuring of the geometry of the active site. Of particular interest is the repositioning of Glu-192, which hydrogen bonds to the catalytic Ser-195 and which results in the complete occlusion of the active site and the destruction of the oxyanion hole. Substrate binding pockets are further blocked by residues previously implicated in thrombin allostery. We have concluded that the E217K mutation causes the allosteric inactivation of thrombin by destabilizing the Na+ binding site and that the structure thus may represent the Na+-free, catalytically inert "slow" form.	Univ Cambridge, Dept Haematol, Div Struct Med, Thrombosis Res Unit,Cambridge Inst Med Res, Cambridge CB2 2XY, England; Stanford Univ, Sch Med, Dept Med, Div Hematol, Stanford, CA 94305 USA; Gilead Sci Inc, Foster City, CA 94404 USA	University of Cambridge; Stanford University; Gilead Sciences	Huntington, JA (corresponding author), Univ Cambridge, Dept Haematol, Div Struct Med, Thrombosis Res Unit,Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			Medical Research Council [G117/444] Funding Source: Medline; NHLBI NIH HHS [R01 HL68629, R01 HL57530] Funding Source: Medline; MRC [G117/444] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530, R01HL068629] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Edwards PD, 2000, BIOORG MED CHEM LETT, V10, P2291, DOI 10.1016/S0960-894X(00)00460-1; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; GUILLIN MC, 1995, THROMB HAEMOSTASIS, V74, P129; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; Hall SW, 1997, CELL MOL LIFE SCI, V53, P731, DOI 10.1007/s000180050092; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2003, TRENDS PHARMACOL SCI, V24, P589, DOI 10.1016/j.tips.2003.09.002; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PARRY MAA, 1993, BIOCHEM J, V290, P665, DOI 10.1042/bj2900665; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	37	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26387	26394		10.1074/jbc.M402364200	http://dx.doi.org/10.1074/jbc.M402364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15075325	hybrid			2022-12-25	WOS:000222003000059
J	Geddie, ML; Matsumura, I				Geddie, ML; Matsumura, I			Rapid evolution of beta-glucuronidase specificity by saturation mutagenesis of an active site loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PCR-MEDIATED RECOMBINATION; IN-VITRO RECOMBINATION; DIRECTED EVOLUTION; ESCHERICHIA-COLI; THERMOANAEROBACTERIUM-SACCHAROLYTICUM; GLYCOSIDE HYDROLASES; MOLECULAR EVOLUTION; METABOLIC PATHWAYS; INVERSE PCR; AMPLIFICATION	Protein engineers have widely adopted directed evolution as a design algorithm, but practitioners have not come to a consensus about the best method to evolve protein molecular recognition. We previously used DNA shuffling to direct the evolution of Escherichia coli beta-glucuronidase (GUS) variants with increased beta-galactosidase activity. Epistatic ( synergistic) mutations in amino acids 557, 566, and 568, which are part of an active site loop, were identified in that experiment (Matsumura, I., and Ellington, A. D. (2001) J. Mol. Biol. 305, 331-339). Here we show that site saturation mutagenesis of these residues, overexpression of the resulting library in E. coli, and high throughput screening led to the rapid evolution of clones exhibiting increased activity in reactions with p-nitrophenyl-beta-D-xylopyranoside (pNP-xyl). The xylosidase activities of the 14 fittest clones were 30-fold higher on average than that of the wild-type GUS. The 14 corresponding plasmids were pooled, amplified by long PCR, self-ligated with T4 DNA ligase, and transformed into E. coli. Thirteen clones exhibiting an average of 80-fold improvement in xylosidase activity were isolated in a second round of screening. One of the evolved proteins exhibited a similar to200-fold improvement over the wild type in reactivity (k(cat)/K-m) with pNP-xyl, with a 290,000-fold inversion of specificity. Sequence analysis of the 13 round 2 isolates suggested that all were products of intermolecular recombination events that occurred during whole plasmid PCR. Further rounds of evolution using DNA shuffling and staggered extension process (StEP) resulted in modest improvement. These results underscore the importance of epistatic interactions and demonstrate that they can be optimized through variations of the facile whole plasmid PCR technique.	Emory Univ, Sch Med, Rollins Res Ctr, Ctr Fundamental & Mol Evolut,Dept Biochem, Atlanta, GA 30322 USA	Emory University	Matsumura, I (corresponding author), Emory Univ, Sch Med, Rollins Res Ctr, Ctr Fundamental & Mol Evolut,Dept Biochem, 1510 Clifton Rd,Rm 4119, Atlanta, GA 30322 USA.	imatsum@emory.edu	Matsumura, Ichiro/E-1985-2011					Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; Coco WM, 2002, NAT BIOTECHNOL, V20, P1246, DOI 10.1038/nbt757; DeSantis G, 2003, J AM CHEM SOC, V125, P11476, DOI 10.1021/ja035742h; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Eisinger DP, 1997, BIOTECHNIQUES, V22, P250, DOI 10.2144/97222bm11; ElHawrani AS, 1996, J MOL BIOL, V264, P97, DOI 10.1006/jmbi.1996.0626; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; Geddie ML, 2004, METHOD ENZYMOL, V388, P134; GRAHAM LD, 1993, BIOCHEMISTRY-US, V32, P6250, DOI 10.1021/bi00075a019; Harris JL, 1998, CURR OPIN CHEM BIOL, V2, P127, DOI 10.1016/S1367-5931(98)80044-6; Hayes RJ, 2002, P NATL ACAD SCI USA, V99, P15926, DOI 10.1073/pnas.212627499; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, P NATL ACAD SCI USA, V93, P5674; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Judo MSB, 1998, NUCLEIC ACIDS RES, V26, P1819, DOI 10.1093/nar/26.7.1819; Juers DH, 2001, BIOCHEMISTRY-US, V40, P14781, DOI 10.1021/bi011727i; KACSER H, 1984, J MOL EVOL, V20, P38, DOI 10.1007/BF02101984; Lazcano A, 1995, Adv Space Res, V15, P345, DOI 10.1016/S0273-1177(99)80106-9; Lingen B, 2002, PROTEIN ENG, V15, P585, DOI 10.1093/protein/15.7.585; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; Matsumura I, 2001, J MOL BIOL, V305, P331, DOI 10.1006/jmbi.2000.4259; Matsumura I, 1999, NAT BIOTECHNOL, V17, P696, DOI 10.1038/10910; MATSUMURA I, 2001, IN VITRO MUTAGENESIS, V182, P259; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Ness JE, 2002, NAT BIOTECHNOL, V20, P1251, DOI 10.1038/nbt754; Northrop DB, 1998, J CHEM EDUC, V75, P1153, DOI 10.1021/ed075p1153; Parikh A, 1998, BIOTECHNIQUES, V24, P428, DOI 10.2144/98243st01; Powell KA, 2001, ANGEW CHEM INT EDIT, V40, P3948, DOI 10.1002/1521-3773(20011105)40:21<3948::AID-ANIE3948>3.0.CO;2-N; Rowe LA, 2003, J MOL BIOL, V332, P851, DOI 10.1016/S0022-2836(03)00972-0; Schmidt-Dannert C, 2001, BIOCHEMISTRY-US, V40, P13125, DOI 10.1021/bi011310c; Shafikhani S, 2002, ENVIRON MICROBIOL, V4, P482, DOI 10.1046/j.1462-2920.2002.00326.x; Sio CF, 2002, EUR J BIOCHEM, V269, P4495, DOI 10.1046/j.1432-1033.2002.03143.x; STEMMER WPC, 1993, GENE, V123, P1, DOI 10.1016/0378-1119(93)90531-7; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEWART ACM, 1995, GENOME RES, V5, P79, DOI 10.1101/gr.5.1.79; Temesgen B, 1996, BIOTECHNIQUES, V21, P828; THOMAS MR, 1994, BIOTECHNIQUES, V16, P988; Vocadlo DJ, 2002, BIOCHEMISTRY-US, V41, P9727, DOI 10.1021/bi020077v; Voigt CA, 2001, P NATL ACAD SCI USA, V98, P3778, DOI 10.1073/pnas.051614498; WALEY SG, 1969, COMP BIOCHEM PHYSIOL, V30, P1, DOI 10.1016/0010-406X(69)91293-6; Whitehead TR, 1997, CURR MICROBIOL, V35, P282, DOI 10.1007/s002849900255; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Yang JK, 2004, J MOL BIOL, V335, P155, DOI 10.1016/j.jmb.2003.10.026; YCAS M, 1974, J THEOR BIOL, V44, P145, DOI 10.1016/S0022-5193(74)80035-4; Zhao HM, 2002, CURR OPIN BIOTECH, V13, P104, DOI 10.1016/S0958-1669(02)00291-4; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	49	57	67	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26462	26468		10.1074/jbc.M401447200	http://dx.doi.org/10.1074/jbc.M401447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15069062	hybrid			2022-12-25	WOS:000222003000068
J	Rajakumar, A; Thamotharan, S; Raychaudhuri, N; Menon, RK; Devaskar, SU				Rajakumar, A; Thamotharan, S; Raychaudhuri, N; Menon, RK; Devaskar, SU			Trans-activators regulating neuronal glucose transporter isoform-3 gene expression in mammalian neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; SP1-MEDIATED TRANSCRIPTIONAL ACTIVATION; RECEPTOR GENE; IN-VIVO; MESSENGER-RNA; SP1; PROMOTER; BRAIN; GLUT3; FAMILY	The murine facilitative glucose transporter isoform 3 is developmentally regulated and is predominantly expressed in neurons. By employing the primer extension assay, the transcription start site of the murine Glut 3 gene in the brain was localized to - 305 bp 5' to the ATG translation start codon. Transient transfection assays in N2A neuroblasts using murine GLUT3-luciferase reporter constructs mapped enhancer activities to two regions located at - 203 to - 177 and - 104 to - 29 bp flanking a previously described repressor element (-137 to -130 bp). Dephosphorylated Sp1 and Sp3 proteins from the 1- and 21-day-old mouse brain nuclear extracts bound the repressor elements, whereas both dephosphorylated and phosphorylated cAMP-response element-binding protein ( CREB) in N2A, 1- and 21-day-old mouse brain nuclear extracts bound the 5'-enhancer cis-elements ( - 187 to - 180 bp) of the Glut 3 gene, and the Y box protein MSY-1 bound the sense strand of the - 83- to - 69-bp region. Sp3, CREB, and MSY-1 binding to the GLUT 3 DNA was confirmed by the chromatin immunoprecipitation assay, whereas CREB and MSY-1 interaction was detected by the co-immunoprecipitation assay. Furthermore, small interference RNA targeted at CREB in N2A cells decreased endogenous CREB concentrations, and CREB mediated GLUT 3 transcription. Thus, in the murine brain similar to the N2A cells, phosphorylated CREB and MSY-1 bound the Glut 3 gene trans-activating the expression in neurons, whereas Sp1/Sp3 bound the repressor elements. We speculate that phosphorylated CREB and Sp3 also interacted to bring about GLUT 3 expression in response to development/ cell differentiation and neurotransmission.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Neonatol & Dev Biol, Los Angeles, CA 90095 USA; Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh, PA 15213 USA; Univ Michigan, Dept Pediat, Div Endocrinol, Ann Arbor, MI 48109 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan	Devaskar, SU (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, 10833 Le Conte Ave,MDCC B2-375, Los Angeles, CA 90024 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD041230] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD025024, R01HD025024, R01HD033997] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25024, HD41230, HD33997] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Balschun D, 2003, J NEUROSCI, V23, P6304; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BELL GI, 1993, J BIOL CHEM, V268, P19161; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carayannopoulos MO, 2000, P NATL ACAD SCI USA, V97, P7313, DOI 10.1073/pnas.97.13.7313; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHEN GJC, 2003, MOL GENET METAB, V80, P121; Chen JP, 1997, J BIOL CHEM, V272, P23144, DOI 10.1074/jbc.272.37.23144; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DERMIETZEL R, 1992, DEV DYNAM, V193, P152, DOI 10.1002/aja.1001930207; DEVASKAR S, 1991, ENDOCRINOLOGY, V129, P1530, DOI 10.1210/endo-129-3-1530; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; Fandos C, 1999, J MOL BIOL, V294, P103, DOI 10.1006/jmbi.1999.3216; Fields HM, 1999, BRAIN RES, V846, P260, DOI 10.1016/S0006-8993(99)01979-4; Geiger A, 2001, BIOCHEM BIOPH RES CO, V285, P838, DOI 10.1006/bbrc.2001.5239; Greenlee MHW, 2003, J NEUROSCI RES, V73, P518, DOI 10.1002/jnr.10684; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; He QP, 2003, NEUROBIOL DIS, V12, P25, DOI 10.1016/S0969-9961(02)00006-2; Joost HG, 2002, AM J PHYSIOL-ENDOC M, V282, pE974, DOI 10.1152/ajpendo.00407.2001; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; KHAN JY, 1999, AM J PHYSIOL, V45, pR892; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Kurdistani SK, 2003, METHODS, V31, P90, DOI 10.1016/S1046-2023(03)00092-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee DH, 2000, DIABETES RES CLIN PR, V47, P15, DOI 10.1016/S0168-8227(99)00107-2; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; MAHER F, 1994, MOL CELL NEUROSCI, V5, P369, DOI 10.1006/mcne.1994.1044; Maher F, 1996, BIOCHEM J, V315, P827, DOI 10.1042/bj3150827; MAIELLO B, 1997, J BIOL CHEM, V272, P4021; McVie-Wylie AJ, 2001, GENOMICS, V72, P113, DOI 10.1006/geno.2000.6457; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Minelli A, 2003, NEUROSCIENCE, V117, P337, DOI 10.1016/S0306-4522(02)00864-3; Molenda HA, 2002, ENDOCRINOLOGY, V143, P436, DOI 10.1210/en.143.2.436; NAGAMATSU S, 1994, BIOCHEM J, V300, P125, DOI 10.1042/bj3000125; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Obrietan K, 2002, J NEUROPHYSIOL, V88, P1005, DOI 10.1152/jn.2002.88.2.1005; Pan XL, 2001, ENDOCRINOLOGY, V142, P1635, DOI 10.1210/en.142.4.1635; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; RICHTER JD, 1984, J MOL BIOL, V173, P227, DOI 10.1016/0022-2836(84)90191-8; Rogers S, 2002, AM J PHYSIOL-ENDOC M, V282, pE733, DOI 10.1152/ajpendo.2002.282.3.E733; SACHS GM, 1986, J COMP NEUROL, V246, P395, DOI 10.1002/cne.902460308; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Santalucia T, 1999, J BIOL CHEM, V274, P17626, DOI 10.1074/jbc.274.25.17626; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Schwartzbauer G, 1998, J BIOL CHEM, V273, P24760, DOI 10.1074/jbc.273.38.24760; SENGUPTA PK, 1994, AM J HEMATOL, V46, P169, DOI 10.1002/ajh.2830460302; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Stern EA, 2001, NEURON, V31, P305, DOI 10.1016/S0896-6273(01)00360-9; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; Vannucci SJ, 1998, DEV BRAIN RES, V107, P255, DOI 10.1016/S0165-3806(98)00021-2; Walton M, 1999, BRAIN RES REV, V29, P137, DOI 10.1016/S0165-0173(98)00053-8; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wessner Renee, 1997, Leukemia (Basingstoke), V11, P10; Whetstine JR, 2001, J BIOL CHEM, V276, P6350, DOI 10.1074/jbc.M008074200; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x; Wilkerson DC, 2002, J CELL BIOCHEM, V86, P716, DOI 10.1002/jcb.10265; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Wu XH, 2002, GENOMICS, V80, P553, DOI 10.1006/geno.2002.7010; Wu XH, 2002, MOL GENET METAB, V76, P37, DOI 10.1016/S1096-7192(02)00018-5; Yang EJ, 2004, J BIOL CHEM, V279, P1827, DOI 10.1074/jbc.M308722200; Yoo J, 2002, J BIOL CHEM, V277, P11904, DOI 10.1074/jbc.M111788200; Zovein A, 2004, AM J PHYSIOL-REG I, V286, pR273, DOI 10.1152/ajpregu.00160.2003	80	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26768	26779		10.1074/jbc.M402735200	http://dx.doi.org/10.1074/jbc.M402735200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15054091	hybrid			2022-12-25	WOS:000222003000104
J	Makatsori, D; Kourmouli, N; Polioudaki, H; Shultz, LD; Mclean, K; Theodoropoulos, PA; Singh, PB; Georgatos, SD				Makatsori, D; Kourmouli, N; Polioudaki, H; Shultz, LD; Mclean, K; Theodoropoulos, PA; Singh, PB; Georgatos, SD			The inner nuclear membrane protein lamin B receptor forms distinct microdomains and links epigenetically marked chromatin to the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3; HETEROCHROMATIN; KINASE; IDENTIFICATION; METHYLATION; DOCKING; SITES; LBR	Using heterochromatin-enriched fractions, we have detected specific binding of mononucleosomes to the N-terminal domain of the inner nuclear membrane protein lamin B receptor. Mass spectrometric analysis reveals that LBR-associated particles contain complex patterns of methylated/acetylated histones and are devoid of "euchromatic" epigenetic marks. LBR binds heterochromatin as a higher oligomer and forms distinct nuclear envelope microdomains in vivo. The organization of these membrane assemblies is affected significantly in heterozygous ic (ichthyosis) mutants, resulting in a variety of structural abnormalities and nuclear defects.	Univ Ioannina, Sch Med, Biol Lab, GR-45110 Ioannina, Greece; Roslin Inst, Dept Gene Express & Dev, Nucl Reprogramming Lab, Roslin EH25 9PS, Midlothian, Scotland; Univ Crete, Sch Med, Dept Basic Sci, Iraklion 95110, Crete, Greece; Jackson Lab, Bar Harbor, ME 04609 USA; Moredun Res Inst, Funct Genom Unit, Penicuik EH26 0PZ, Midlothian, Scotland	University of Ioannina; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Crete; Jackson Laboratory; Moredun Research Institute	Georgatos, SD (corresponding author), Univ Ioannina, Sch Med, Biol Lab, GR-45110 Ioannina, Greece.	sgeorgat@cc.uoi.gr	Polioudaki, Hara/AAT-8496-2020; Singh, Prim/G-1088-2014	Singh, Prim/0000-0002-9571-0974; Georgatos, Spyros/0000-0002-2078-7467	NCI NIH HHS [CA20408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020408] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; Bridger JM, 2000, CURR BIOL, V10, P149, DOI 10.1016/S0960-9822(00)00312-2; Bridger JM, 1998, TRENDS GENET, V14, P403, DOI 10.1016/S0168-9525(98)01572-8; Carvalho C, 2001, MOL BIOL CELL, V12, P3563, DOI 10.1091/mbc.12.11.3563; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Foisner R, 2001, J CELL SCI, V114, P3791; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; Georgatos SD, 2001, EMBO J, V20, P2989, DOI 10.1093/emboj/20.12.2989; HARRIS JR, 1971, J ULTRA MOL STRUCT R, V36, P8, DOI 10.1016/S0022-5320(71)80085-0; HARRIS JR, 1978, BIOCHIM BIOPHYS ACTA, V515, P55, DOI 10.1016/0304-4157(78)90008-4; Holmer L, 1998, GENOMICS, V54, P469, DOI 10.1006/geno.1998.5615; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Maison C, 1997, EMBO J, V16, P4839, DOI 10.1093/emboj/16.16.4839; MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491; Martins SB, 2000, J CELL SCI, V113, P3703; MEIER J, 1994, EMBO J, V13, P1888, DOI 10.1002/j.1460-2075.1994.tb06458.x; Nikolakaki E, 1997, J BIOL CHEM, V272, P6208, DOI 10.1074/jbc.272.10.6208; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012; Polioudaki H, 2001, EMBO REP, V2, P920, DOI 10.1093/embo-reports/kve199; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shultz LD, 2003, HUM MOL GENET, V12, P61, DOI 10.1093/hmg/ddg003; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; Simos G, 1996, J BIOL CHEM, V271, P12617, DOI 10.1074/jbc.271.21.12617; Spector DL, 2003, EMBO REP, V4, P18, DOI 10.1038/sj.embor.embor701; Tumbar T, 2001, NAT CELL BIOL, V3, P134, DOI 10.1038/35055033; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Zhang KL, 2003, J CHROMATOGR B, V783, P173, DOI 10.1016/S1570-0232(02)00631-1; Zhang KL, 2002, ANAL BIOCHEM, V306, P259, DOI 10.1006/abio.2002.5719; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	36	119	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25567	25573		10.1074/jbc.M313606200	http://dx.doi.org/10.1074/jbc.M313606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15056654	hybrid			2022-12-25	WOS:000221827900083
J	Nittis, T; Gitlin, JD				Nittis, T; Gitlin, JD			Role of copper in the proteosome-mediated degradation of the multicopper oxidase hephaestin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BIOCHEMICAL-CHARACTERIZATION; HUMAN CERULOPLASMIN; IRON-DEFICIENCY; DISEASE PROTEIN; EXPRESSION; YEAST; MECHANISMS; PATHWAY; ACERULOPLASMINEMIA	To elucidate the mechanisms of cuproprotein biosynthesis in the secretory pathway, a polyclonal antiserum was generated against hephaestin, a multicopper oxidase essential for enteric iron absorption. Immunoblot analysis and pulse-chase metabolic labeling revealed that hephaestin is synthesized as a single-chain polypeptide modified by N-linked glycosylation to a mature 161-kDa species. Cell surface biotinylation and immunofluorescent studies of polarized, differentiated colon carcinoma cells detected hephaestin on the basolateral surface under steady-state conditions. However, a decrease in the intracellular copper concentration resulted in a marked diminution in the abundance of this protein. Metabolic studies revealed no effect of decreased intracellular copper on the rate of hephaestin synthesis but a dramatic, specific, and reproducible increase in the turnover of the mature 161-kDa protein. Surprisingly, inhibitor studies revealed that this turnover occurs exclusively in the proteasome, and consistent with this finding, in vitro studies identified polyubiquitinated hephaestin under conditions abrogating copper incorporation into this protein. Taken together, these studies demonstrate the presence of a quality control system for posttranslational protein modification occurring beyond the endoplasmic reticulum that, in the case of hephaestin, directly links the rate of enteric iron uptake to nutritional copper status.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.	gitlin@kids.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061763] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07873] Funding Source: Medline; NIDDK NIH HHS [DK61763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Chen HJ, 2003, BLOOD, V102, P1893, DOI 10.1182/blood-2003-02-0347; Culotta VC, 2001, MOL METABOLIC BASIS, VII, P3105, DOI DOI 10.1036/OMMBID.155; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Frazer DM, 2001, AM J PHYSIOL-GASTR L, V281, pG931, DOI 10.1152/ajpgi.2001.281.4.G931; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; Hellman NE, 2002, J BIOL CHEM, V277, P1375, DOI 10.1074/jbc.M109123200; Hitchcock AL, 2003, P NATL ACAD SCI USA, V100, P12735, DOI 10.1073/pnas.2135500100; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; Lencer WI, 2003, TRENDS BIOCHEM SCI, V28, P639, DOI 10.1016/j.tibs.2003.10.002; Li LT, 2003, BIOCHEM J, V375, P793, DOI 10.1042/BJ20030866; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Nittis T, 2002, SEMIN HEMATOL, V39, P282, DOI 10.1053/shem.2002.35633; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; SATO M, 1991, J BIOL CHEM, V266, P5128; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; Syed BA, 2002, PROTEIN ENG, V15, P205, DOI 10.1093/protein/15.3.205; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Zoller H, 2003, GASTROENTEROLOGY, V125, P746, DOI 10.1016/S0016-5085(03)01063-1	37	57	57	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25696	25702		10.1074/jbc.M401151200	http://dx.doi.org/10.1074/jbc.M401151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15087449	hybrid			2022-12-25	WOS:000221827900099
J	Penzo, D; Petronilli, V; Angelin, A; Cusan, C; Colonna, R; Scorrano, L; Pagano, F; Prato, M; Di Lisa, F; Bernardi, P				Penzo, D; Petronilli, V; Angelin, A; Cusan, C; Colonna, R; Scorrano, L; Pagano, F; Prato, M; Di Lisa, F; Bernardi, P			Arachidonic acid released by phospholipase A(2) activation triggers Ca2+-dependent apoptosis through the mitochondrial pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PERMEABILITY TRANSITION PORE; CELL-DEATH; FACTOR-ALPHA; ARISTOLOCHIC ACID; GD3 GANGLIOSIDE; CYTOCHROME-C; CALCIUM IONOPHORE; HUMAN-NEUTROPHILS; CORTICAL-NEURONS	We studied the effects of the divalent cation ionophore A23187 on apoptotic signaling in MH1C1 cells. Addition of A23187 caused a fast rise of cytosolic Ca2+ ([Ca2+](c)), which returned close to the resting level within about 40 s. The [Ca2+](c) rise was immediately followed by phospholipid hydrolysis, which could be inhibited by aristolochic acid or by pretreatment with thapsigargin in Ca2+-free medium, indicating that the Ca2+-dependent cytosolic phospholipase A(2) (cPLA(2)) was involved. These early events were followed by opening of the mitochondrial permeability transition pore (PTP) and by apoptosis in about 30% of the cell population. In keeping with a cause-effect relationship between addition of A23187, activation of cPLA2, PTP opening, and cell death, all events but the [Ca2+](c) rise were prevented by aristolochic acid. The number of cells killed by A23187 was doubled by treatment with 0.5 muM MK886 and 5 muM indomethacin, which inhibit arachidonic acid metabolism through the 5-lipoxygenase and cyclooxygenase pathway, respectively. Consistent with the key role of free arachidonic acid, its levels increased within minutes of treatment with A23187; the increase being more pronounced in the presence of MK886 plus indomethacin. Cell death was preceded by cytochrome c release and cleavage of caspase 9 and 3, but not of caspase 8. All these events were prevented by aristolochic acid and by the PTP inhibitor cyclosporin A. Thus, A23187 triggers the apoptotic cascade through the release of arachidonic acid by cPLA2 in a process that is amplified when transformation of arachidonic acid into prostaglandins and leukotrienes is inhibited. These findings identify arachidonic acid as the causal link between A23187-dependent perturbation of Ca2+ homeostasis and the effector mechanisms of cell death.	Univ Padua, Inst Neurosci, Consiglio Nazl Ric, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Inst Neurosci, Consiglio Nazl Ric, Dept Biol Chem, I-35121 Padua, Italy; Univ Trieste, Dept Pharmaceut Sci, I-34127 Trieste, Italy; Venetian Inst Mol Med, Dulbecco Telethon Inst, I-35129 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Trieste; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine	Bernardi, P (corresponding author), Univ Padua, Inst Neurosci, Consiglio Nazl Ric, Dept Biomed Sci, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.	bernardi@bio.unipd.it	Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015; Scorrano, Luca/K-3967-2019; Prato, Maurizio/G-7067-2012; Scorrano, Luca/A-6652-2008	Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404; Scorrano, Luca/0000-0002-8515-8928; Prato, Maurizio/0000-0002-8869-8612; Scorrano, Luca/0000-0002-8515-8928; Di Lisa, Fabio/0000-0001-9757-8818	Telethon [TCP02016] Funding Source: Medline	Telethon(Fondazione Telethon)		Arora AS, 1997, HEPATOLOGY, V25, P958, DOI 10.1002/hep.510250428; BABCOCK DF, 1976, J BIOL CHEM, V251, P3881; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chandra V, 2002, BIOCHEMISTRY-US, V41, P10914, DOI 10.1021/bi0258593; DE MR, 1997, SCIENCE, V277, P1652; DORDICK RS, 1980, J BIOL CHEM, V255, P299; Fleckenstein A, 1974, Recent Adv Stud Cardiac Struct Metab, V4, P563; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Grewal S, 2003, J CELL SCI, V116, P2303, DOI 10.1242/jcs.00446; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; LUKAS W, 1994, NEUROSCIENCE, V61, P307, DOI 10.1016/0306-4522(94)90233-X; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MICHEL PP, 1994, EUR J NEUROSCI, V6, P577, DOI 10.1111/j.1460-9568.1994.tb00302.x; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Penzo D, 2002, BBA-BIOENERGETICS, V1555, P160, DOI 10.1016/S0005-2728(02)00272-4; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; PFEIFFER DR, 1976, BIOCHEMISTRY-US, V15, P935, DOI 10.1021/bi00650a001; PICKETT WC, 1976, BIOCHIM BIOPHYS ACTA, V486, P209; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; REED PW, 1972, J BIOL CHEM, V247, P6970; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SHEN AC, 1972, AM J PATHOL, V67, P417; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; Takadera T, 1997, EUR J BIOCHEM, V249, P8, DOI 10.1111/j.1432-1033.1997.00008.x; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317	52	138	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25219	25225		10.1074/jbc.M310381200	http://dx.doi.org/10.1074/jbc.M310381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15070903	hybrid			2022-12-25	WOS:000221827900039
J	Standaert, ML; Sajan, MP; Miura, A; Kanoh, Y; Chen, HC; Farese, RV; Farese, RV				Standaert, ML; Sajan, MP; Miura, A; Kanoh, Y; Chen, HC; Farese, RV; Farese, RV			Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver - Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high fat-induced insulin-resistant states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; TRANSCRIPTION FACTOR FKHR; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; PROMOTER ACTIVITY; SKELETAL-MUSCLE; POTENTIAL ROLE; KAKIZAKI RATS	Insulin resistance in type 2 diabetes is characterized by defects in muscle glucose uptake and hepatic overproduction of both glucose and lipids. These hepatic defects are perplexing because insulin normally suppresses glucose production and increases lipid synthesis in the liver. To understand the mechanisms for these seemingly paradoxical defects, we examined the activation of atypical protein kinase C (aPKC) and protein kinase B (PKB), two key signaling factors that operate downstream of phosphatidylinositol 3-kinase and regulate various insulin-sensitive metabolic processes. Livers and muscles of three insulin-resistant rodent models were studied. In livers of type 2 diabetic non-obese Goto-Kakazaki rats and ob/ob-diabetic mice, the activation of PKB was impaired, whereas activation of aPKC was surprisingly maintained. In livers of non-diabetic high fat-fed mice, the activation of both aPKC and PKB was maintained. In contrast to the maintenance of aPKC activation in the liver, insulin activation of aPKC was impaired in muscles of Goto-Kakazaki-diabetic rats and ob/ob-diabetic and non-diabetic high fat-fed mice. These findings suggest that, at least in these rodent models, (a) defects in aPKC activation contribute importantly to skeletal muscle insulin resistance observed in both high fat feeding and type 2 diabetes; (b) insulin signaling defects in muscle are not necessarily accompanied by similar defects in liver; (c) defects in hepatic PKB activation occur in association with, and probably contribute importantly to, the development of overt diabetes; and (d) maintenance of hepatic aPKC activation may explain the continued effectiveness of insulin for stimulating certain metabolic actions in the liver.	James A Haley Vet Adm Med Ctr, Res Serv, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Farese, RV (corresponding author), James A Haley Vet Hosp, ACOS 151,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rfarese@hsc.usf.edu	Farese, Robert/B-3605-2015	Chen, Hubert/0000-0002-7599-7218	NIDDK NIH HHS [R01 DK056084, R01 DK065969, 2R01-DK-38079, K08-DK-61363, R01-DK-56804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056084, R01DK056804, K08DK061363, R01DK065969, R01DK038079] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Beeson M, 2003, DIABETES, V52, P1926, DOI 10.2337/diabetes.52.8.1926; Begum N, 1998, METABOLISM, V47, P54, DOI 10.1016/S0026-0495(98)90193-7; Bergman RN, 2000, DIABETOLOGIA, V43, P946, DOI 10.1007/s001250051474; BISBIS S, 1993, AM J PHYSIOL, V265, P807; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; FARESE RV, 1994, P NATL ACAD SCI USA, V91, P11040, DOI 10.1073/pnas.91.23.11040; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Kanoh Y, 2000, J BIOL CHEM, V275, P16690, DOI 10.1074/jbc.M000287200; Kanoh Y, 2001, ENDOCRINOLOGY, V142, P1595, DOI 10.1210/en.142.4.1595; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; KROOK A, 1997, DIABETES, V46, P211; Matsumoto M, 2003, J CLIN INVEST, V112, P935, DOI 10.1172/JCI200318816; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Peak M, 1998, DIABETOLOGIA, V41, P16, DOI 10.1007/s001250050861; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Standaert ML, 2002, DIABETES, V51, P2936, DOI 10.2337/diabetes.51.10.2936; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 2000, J CLIN INVEST, V105, P1437, DOI 10.1172/JCI7656; Valverde AM, 2003, DIABETES, V52, P2239, DOI 10.2337/diabetes.52.9.2239; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; Wang QH, 1999, MOL CELL BIOL, V19, P4008; YAMOUCHI T, 1996, MOL CELL BIOL, V16, P3074	35	72	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					24929	24934		10.1074/jbc.M402440200	http://dx.doi.org/10.1074/jbc.M402440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15069067	hybrid			2022-12-25	WOS:000221827900006
J	Zhang, X; Turnell, AS; Gorbea, C; Mymryk, JS; Gallimore, PH; Grand, RJA				Zhang, X; Turnell, AS; Gorbea, C; Mymryk, JS; Gallimore, PH; Grand, RJA			The targeting of the proteasomal regulatory subunit S2 by adenovirus E1A causes inhibition of proteasomal activity and increased p53 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26S PROTEASOME; BINDING PROTEIN; REPRESSION DOMAIN; CELLULAR PROTEIN; TATA BOX; MDM2; REGION; TRANSFORMATION; DEGRADATION; UBIQUITINATION	Although adenovirus early region 1A (AdE1A) can modulate protein expression through its interaction with transcriptional regulators it can also influence the ability of the cell to degrade proteins by binding to components of the 26 S proteasome. We demonstrate here that AdE1A interacts with the S2 subunit of the 19 S regulatory complex in addition to the ATPase subunits S4 and S8 previously identified. S2 forms complexes with both the 13 and 12 S AdE1A proteins both in vivo and in vitro. Mutational analysis has shown direct binding through a short sequence toward the N terminus of conserved region 2 of AdE1A, which encompasses the LXCXE motif, involved in interaction with the pRb family of proteins. In vivo, additional contacts are made between AdE1A and proteasomal components, as well as within the proteasome, such that deletion of the N-terminal region of E1A as well as part of conserved region 2 is required to completely disrupt S2 binding. Mutation of AdE1A, which disrupts complex formation with S2, results in the loss of its ability to stabilize the p53 protein. Similarly down-regulation of S2 expression using small interfering RNAs leads to the inhibition of p53 degradation. These effects were observed in normally growing cells and those subjected to UV irradiation. Furthermore, AdE1A had no effect on the Mdm2-mediated ubiquitination of p53. We suggest therefore that interaction of AdE1A with S2, as well as with the ATPases S4 and S8, directly causes inhibition of proteasomal activity and consequent increase in the protein levels of p53.	Univ Birmingham, Sch Med, Canc Res United Kingdom Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Western Ontario, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada	University of Birmingham; Utah System of Higher Education; University of Utah; Western University (University of Western Ontario); Western University (University of Western Ontario)	Grand, RJA (corresponding author), Univ Birmingham, Sch Med, Canc Res United Kingdom Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	R.J.A.Grand@bham.ac.uk	Gorbea, Carlos/L-4406-2019					Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Camus S, 2003, FEBS LETT, V536, P220, DOI 10.1016/S0014-5793(03)00054-1; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Finley D, 2002, NAT CELL BIOL, V4, pE121, DOI 10.1038/ncb0502-e121; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glickman MH, 2002, CURR TOP MICROBIOL, V268, P43; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gorbea C, 2000, J BIOL CHEM, V275, P875, DOI 10.1074/jbc.275.2.875; Grand RJA, 1999, ONCOGENE, V18, P449, DOI 10.1038/sj.onc.1202304; GRAND RJA, 2001, VIRUSES CELL TRANSFO, P43; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Mymryk JS, 1998, NUCLEIC ACIDS RES, V26, P292, DOI 10.1093/nar/26.1.292; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Seeger M, 1997, MOL BIOL REP, V24, P83, DOI 10.1023/A:1006837600040; SHENK T, 1991, ADV CANCER RES, V57, P47; SHENK T, 1996, FIELDS VIROLOGY, P2111; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; Song CZ, 1997, MOL CELL BIOL, V17, P2186, DOI 10.1128/MCB.17.4.2186; Traidej M, 2000, ANTISENSE NUCLEIC A, V10, P17, DOI 10.1089/oli.1.2000.10.17; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	48	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25122	25133		10.1074/jbc.M403287200	http://dx.doi.org/10.1074/jbc.M403287200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15056666	hybrid			2022-12-25	WOS:000221827900027
J	Devroe, E; Erdjument-Bromage, H; Tempst, P; Silver, PA				Devroe, E; Erdjument-Bromage, H; Tempst, P; Silver, PA			Human mob proteins regulate the NDR1 and NDR2 serine-threonine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; TRANSCRIPTION FACTOR; PHOSPHORYLATION; LOCALIZATION; CYTOKINESIS; INTERACTS; INTEGRASE; COMPLEXES; YEAST	Human NDR1 (nuclear Dbf2-related) is a widely expressed nuclear serine-threonine kinase that has been implicated in cell proliferation and/or tumor progression. Here we present molecular characterization of the human NDR2 serine-threonine kinase, which shares similar to87% sequence identity with NDR1. NDR2 is expressed in most human tissues with the highest expression in the thymus. In contrast to NDR1, NDR2 is excluded from the nucleus and exhibits a punctate cytoplasmic distribution. The differential localization of NDR1 and NDR2 suggests that each kinase may serve distinct functions. Thus, to identify proteins that interact with NDR1 or NDR2, epitope-tagged kinases were immunoprecipitated from Jurkat T-cells. Two uncharacterized proteins that are homologous to the Saccharomyces cerevisiae kinase regulators Mob1 and Mob2 were identified. We demonstrate that NDR1 and NDR2 partially colocalize with human Mob2 in HeLa cells and confirm the NDR-Mob interactions in cell extracts. Interestingly, NDR1 and NDR2 form stable complexes with Mob2, and this association dramatically stimulates NDR1 and NDR2 catalytic activity. In summary, this work identifies a unique class of human kinase-activating subunits that may be functionally analagous to cyclins.	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Cell Biol, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Mol Biol Program, New York, NY 10021 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center	Silver, PA (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	pamela_silver@dfci.harvard.edu		Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594				Adeyinka A, 2002, CLIN CANCER RES, V8, P3788; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hauschild A, 1999, ONCOLOGY-BASEL, V56, P338, DOI 10.1159/000011989; Hou MC, 2000, CURR BIOL, V10, P619, DOI 10.1016/S0960-9822(00)00492-9; Hou MC, 2003, J CELL SCI, V116, P125, DOI 10.1242/jcs.00206; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Limon A, 2002, J VIROL, V76, P10598, DOI 10.1128/JVI.76.21.10598-10607.2002; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Luca FC, 2001, MOL CELL BIOL, V21, P6972, DOI 10.1128/MCB.21.20.6972-6983.2001; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Stavridi ES, 2003, STRUCTURE, V11, P1163, DOI 10.1016/S0969-2126(03)00182-5; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0	23	74	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24444	24451		10.1074/jbc.M401999200	http://dx.doi.org/10.1074/jbc.M401999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15067004	hybrid			2022-12-25	WOS:000221702500071
J	Filizola, M; Hassan, SA; Artoni, A; Coller, BS; Weinstein, H				Filizola, M; Hassan, SA; Artoni, A; Coller, BS; Weinstein, H			Mechanistic insights from a refined three-dimensional model of integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE MONOCLONAL-ANTIBODY; GLANZMANNS-THROMBASTHENIA; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; BINDING; SIMULATION; DOMAINS; IIB	The integrin alpha(IIb)beta(3) plays an important role in platelet function, and abnormalities of this protein result in a serious bleeding disorder, known as Glanzmann thrombasthenia. Although crystallographic data exist for the related integrin alpha(V)beta(3), to date, there are no high resolution structures of integrin alpha(IIb)beta(3) available in the literature. Therefore, it is still unclear how specific elements of the alpha(IIb) subunit contribute to integrin alpha(IIb)beta(3) function. Here we describe a refined model of the alpha(IIb) N-terminal portion of integrin alpha(IIb)beta(3) obtained by using the alpha(V)beta(3) template combined with a new method for predicting the conformations of the unique alpha(IIb) loop regions comprising residues 71-85, 114-125, and 148-164. The refined model was probed based on a structural prediction that differentiates it from standard homology models: specifically, that Lys-118 of alpha(IIb) contacts Glu-171 of beta(3). To test this hypothesis experimentally, the mutant integrin chains alpha(IIb) K118C and beta(3) E171C were cotransfected into HEK 293 cells. We show that the cells expressed the mutants alpha(IIb)beta(3) on their surface as a disulfide-linked dimer, supporting the close proximity between alpha(IIb) Lys-118 and beta(3) Glu-171 predicted from the refined model. This validated model provides a specific structural context for the analysis and interpretation of structure-function relations of integrin alpha(IIb)beta(3). In addition, it suggests mechanistic hypotheses pertaining to both naturally occurring mutations responsible for Glanzmann thrombasthenia and to point mutations that affect ligand binding.	Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Lab Blood & Vasc Biol, New York, NY 10021 USA; NIH, Ctr Mol Modeling, Div Computat Biosci, CIT, Bethesda, MD 20892 USA	Cornell University; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT)	Filizola, M (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, Box 75,1300 York Ave, New York, NY 10021 USA.	maf2037@med.cornell.edu	WEINSTEIN, HAREL/O-8245-2019; hassan, sherif hassan mohamed/ABG-1513-2020	WEINSTEIN, HAREL/0000-0003-3473-9818; hassan, sherif hassan mohamed/0000-0002-2190-096X; Artoni, Andrea/0000-0003-0625-8320; Filizola, Marta/0000-0002-4382-8276	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000265] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019278, R37HL019278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19278] Funding Source: Medline; NIDA NIH HHS [T32 DA074135, DA00060] Funding Source: Medline	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Artoni A, 2002, BLOOD, V100, p64B; Bellucci S, 2002, BLOOD REV, V16, P193, DOI 10.1016/S0268-960X(02)00030-9; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; COLLER BS, 2000, WILLIAMS HEMATOLOGY, P1551; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Hassan SA, 2000, J PHYS CHEM B, V104, P6478, DOI 10.1021/jp993895e; Hassan SA, 2000, J PHYS CHEM B, V104, P6490, DOI 10.1021/jp9938967; Hassan SA, 2002, LECT NOTES COMP SCI, V24, P197; Hassan SA, 2003, PROTEINS, V51, P109, DOI 10.1002/prot.10330; Hassan SA, 2002, PROTEINS, V47, P45, DOI 10.1002/prot.10059; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; Lazaridis T, 2000, CURR OPIN STRUC BIOL, V10, P139, DOI 10.1016/S0959-440X(00)00063-4; Mehler EL, 2002, J COMPUT AID MOL DES, V16, P841, DOI 10.1023/A:1023845015343; Mitchell WB, 2003, BLOOD, V101, P2268, DOI 10.1182/blood-2002-07-2266; Nair S, 2002, PLATELETS, V13, P387, DOI 10.1080/0953710021000024394; NOGUTI T, 1985, BIOPOLYMERS, V24, P527, DOI 10.1002/bip.360240308; Peretz H., 2000, Haemostasis, V30, P71; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	25	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24624	24630		10.1074/jbc.M400243200	http://dx.doi.org/10.1074/jbc.M400243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15056669	hybrid			2022-12-25	WOS:000221702500092
J	Vanin, AF; Svistunenko, DA; Mikoyan, VD; Serezhenkov, VA; Fryer, MJ; Baker, NR; Cooper, CE				Vanin, AF; Svistunenko, DA; Mikoyan, VD; Serezhenkov, VA; Fryer, MJ; Baker, NR; Cooper, CE			Endogenous superoxide production and the nitrite/nitrate ratio control the concentration of bioavailable free nitric oxide in leaves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; PLANT NITRATE REDUCTASE; CYTOCHROME-C-OXIDASE; REACTIVE OXYGEN; IRON-DITHIOCARBAMATE; ALTERNATIVE OXIDASE; CELL-DEATH; PEROXYNITRITE; SIGNAL; ACID	We have quantitatively measured nitric oxide production in the leaves of Arabidopsis thaliana and Vicia faba by adapting ferrous dithiocarbamate spin tapping methods previously used in animal systems. Hydrophobic diethyldithiocarbamate complexes were used to measure NO interacting with membranes, and hydrophilic N-methyl-D-glucamine dithiocarbamate was used to measure NO released into the external solution. Both complexes were able to trap levels of NO, readily detectable by EPR spectroscopy. Basal rates of NO production (in the order of 1 nmol g(-1) h(-1)) agreed with previous studies. However, use of methodologies that corrected for the removal of free NO by endogenously produced superoxide resulted in a significant increase in trapped NO (up to 18 nmol g(-1) h(-1)). Basal NO production in leaves is therefore much higher than previously thought, but this is masked by significant superoxide production. The effects of nitrite ( increased rate) and nitrate ( decreased rate) are consistent with a role for nitrate reductase as the source of this basal NO production. However, rates under physiologically achievable nitrite concentrations never approach that reported following pathogen induction of plant nitric-oxide synthase. In Hibiscus rosa sinensis, the addition of exogenous nitrite generated sufficient NO such that EPR could be used to detect its production using endogenous spin traps ( forming paramagnetic dinitrosyl iron complexes). Indeed the levels of this nitrosylated iron pool are sufficiently high that they may represent a method of maintaining bioavailable iron levels under conditions of iron starvation, thus explaining the previously observed role of NO in preventing chlorosis under these conditions.	Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England; Russian Acad Sci, Inst Chem Phys, Moscow 117977, Russia	University of Essex; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences	Cooper, CE (corresponding author), Univ Essex, Dept Biol Sci, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.	ccooper@essex.ac.uk	Cooper, Chris/AAK-9729-2020; Vanin, Anatoly F/I-1069-2016; Shumaev, Konstantin/AAI-2362-2020	Cooper, Chris/0000-0003-0381-3990; Vanin, Anatoly F/0000-0001-8392-4601; Svistunenko, Dimitri/0000-0001-8060-2738				Affourtit C, 1999, J BIOL CHEM, V274, P6212, DOI 10.1074/jbc.274.10.6212; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ALIEV DI, 1986, STUD BIOPHYS, V115, P173; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Barone MC, 2003, J BIOL CHEM, V278, P27520, DOI 10.1074/jbc.M304129200; Beligni MV, 1999, TRENDS PLANT SCI, V4, P299, DOI 10.1016/S1360-1385(99)01451-X; Beligni MV, 2000, PLANTA, V210, P215, DOI 10.1007/PL00008128; Beligni MV, 2001, PLANT CELL ENVIRON, V24, P267, DOI 10.1046/j.1365-3040.2001.00672.x; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Caro A, 1998, PHYSIOL PLANTARUM, V104, P357, DOI 10.1034/j.1399-3054.1998.1040310.x; Chandok MR, 2003, CELL, V113, P469, DOI 10.1016/S0092-8674(03)00350-7; Clarke A, 2000, PLANT J, V24, P667, DOI 10.1046/j.1365-313x.2000.00911.x; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Delledonne M, 2002, PLANT PHYSIOL BIOCH, V40, P605, DOI 10.1016/S0981-9428(02)01397-9; Delledonne M, 2001, P NATL ACAD SCI USA, V98, P13454, DOI 10.1073/pnas.231178298; Desikan R, 2002, P NATL ACAD SCI USA, V99, P16314, DOI 10.1073/pnas.252461999; Fryer MJ, 1998, PLANT PHYSIOL, V116, P571, DOI 10.1104/pp.116.2.571; Fryer MJ, 2003, PLANT J, V33, P691, DOI 10.1046/j.1365-313X.2003.01656.x; Fryer MJ, 2002, J EXP BOT, V53, P1249, DOI 10.1093/jexbot/53.372.1249; Graziano M, 2002, PLANT PHYSIOL, V130, P1852, DOI 10.1104/pp.009076; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; KLEPPER L, 1991, PESTIC BIOCHEM PHYS, V39, P43, DOI 10.1016/0048-3575(91)90212-5; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUBRINA LN, 1993, BIOCHIM BIOPHYS ACTA, V1176, P240, DOI 10.1016/0167-4889(93)90050-Y; Lamattina L, 2003, ANNU REV PLANT BIOL, V54, P109, DOI 10.1146/annurev.arplant.54.031902.134752; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Leshem YY, 1998, PLANT PHYSIOL BIOCH, V36, P825, DOI 10.1016/S0981-9428(99)80020-5; Millar AH, 1996, FEBS LETT, V398, P155, DOI 10.1016/S0014-5793(96)01230-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morot-Gaudry-Talarmain Y, 2002, PLANTA, V215, P708, DOI 10.1007/s00425-002-0816-3; Neill SJ, 2003, NEW PHYTOL, V159, P11, DOI 10.1046/j.1469-8137.2003.00804.x; Noritake T, 1996, PLANT CELL PHYSIOL, V37, P113, DOI 10.1093/oxfordjournals.pcp.a028908; Ort DR, 2002, CURR OPIN PLANT BIOL, V5, P193, DOI 10.1016/S1369-5266(02)00259-5; PACKER L, 1996, METHODS ENZYMOLOGY, V268; PACKER L, 1996, METHODS ENZYMOLOGY, V269; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pedroso MC, 2000, PLANT SCI, V157, P173, DOI 10.1016/S0168-9452(00)00278-8; Rockel P, 2002, J EXP BOT, V53, P103, DOI 10.1093/jexbot/53.366.103; Rose P, 2003, BIOCHEM BIOPH RES CO, V302, P397, DOI 10.1016/S0006-291X(03)00193-1; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Sherameti I, 2002, J BIOL CHEM, V277, P46594, DOI 10.1074/jbc.M202924200; Smirnoff N, 2001, ANNU REV PLANT PHYS, V52, P437, DOI 10.1146/annurev.arplant.52.1.437; STEVENS TH, 1979, P NATL ACAD SCI USA, V76, P3320, DOI 10.1073/pnas.76.7.3320; Tsuchiya K, 2000, J BIOL CHEM, V275, P1551, DOI 10.1074/jbc.275.3.1551; Vanin AF, 2000, BBA-GEN SUBJECTS, V1474, P365, DOI 10.1016/S0304-4165(00)00033-7; Vanin AF, 2002, METHOD ENZYMOL, V359, P27; Vanin AF, 2001, FREE RADICAL BIO MED, V30, P813, DOI 10.1016/S0891-5849(01)00466-X; Wendehenne D, 2001, TRENDS PLANT SCI, V6, P177, DOI 10.1016/S1360-1385(01)01893-3; Yamasaki H, 2000, FEBS LETT, V468, P89, DOI 10.1016/S0014-5793(00)01203-5; Yamasaki H, 1999, TRENDS PLANT SCI, V4, P128, DOI 10.1016/S1360-1385(99)01393-X; Yamasaki H, 2000, PHILOS T R SOC B, V355, P1477, DOI 10.1098/rstb.2000.0708; Yokozawa T, 2002, NEPHRON, V92, P133, DOI 10.1159/000064483; Zottini M, 2002, FEBS LETT, V515, P75, DOI 10.1016/S0014-5793(02)02438-9; Zou YN, 2002, J AGR FOOD CHEM, V50, P5884, DOI 10.1021/jf020496z	59	64	74	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24100	24107		10.1074/jbc.M312601200	http://dx.doi.org/10.1074/jbc.M312601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15056652	hybrid			2022-12-25	WOS:000221702500032
J	Lee, JH; Park, SJ; Abraham, SC; Seo, JS; Nam, JH; Choi, C; Juhng, SW; Rashid, A; Hamilton, SR; Wu, TT				Lee, JH; Park, SJ; Abraham, SC; Seo, JS; Nam, JH; Choi, C; Juhng, SW; Rashid, A; Hamilton, SR; Wu, TT			Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas	ONCOGENE			English	Article						gastric neoplasms; precursor lesions; CpG island methylation	HMLH1 GENE PROMOTER; DNA HYPERMETHYLATION; APC GENE; CLINICOPATHOLOGICAL FEATURES; MICROSATELLITE INSTABILITY; MALIGNANT TRANSFORMATION; ABERRANT METHYLATION; SOMATIC MUTATIONS; MULTIPLE GENES; E-CADHERIN	Gastric carcinogenesis involves multiple genetic and epigenetic alterations. Epigenetic silencing of tumor-related genes due to CpG island methylation (CIM) has been recently reported in gastric cancer, but the role in precursor lesions is not well understood. We analysed the methylation status of the tumor suppressor gene p16, the DNA mismatch repair gene hMLH1, and four CpG islands (MINT1, MINT2, MINT25, and MINT31) using methylation-specific polymerase chain reaction in 35 polypoid adenomas and 46 flat dysplasias unassociated with carcinoma, 34 early adenocarcinomas (T1N0M0) and associated adenomas/dysplasias, and corresponding adjacent non-neoplastic mucosa. The extent of CIM was defined by the fraction of methylated loci (methylation index), and compared with previously characterized genetic alterations (microsatellite instability (MSI) and APC gene mutation). We found that methylation of p16 was more frequent in adenocarcinoma-associated dysplasias/adenomas (29%) and adenocarcinomas (44%) as compared to flat dysplasias (4%) and adenomas (18%) unassociated with adenocarcinorna (P = 0.001). The mean methylation index increased from normal/chronic gastritis (CG) mucosa (0.09) to intestinal metaplasia (IM) (0.16), flat dysplasias (0.40) or polypoid adenomas (0.41) unassociated with carcinoma, dysplasias/adenomas associated with carcinoma (0.44), and adenocarcinomas (0.44). There was no difference in frequencies of high-level CpG island methylation (CIM-H, methylation index greater than or equal to0.5) among flat dysplasias (50%) and polypoid adenomas (51%) unassociated with carcinoma, dysplasias/adenomas associated with adenocarcinoma (47%), and adenocarcinoma (47%). CIM-H was present in 15% of IM, but not in normal/CG mucosa. There was a significant correlation between methylation of hMLH1 and high-level of microsatellite instability (MSI-H): methylation of hMLH1 was present in 71% of MSI-H tumors, but only 8% of MSI-low tumors and 13% of microsatellite-stable tumors (P=0.0001). There was no statistical difference between methylation index and APC mutation. Our results indicate that concurrent promoter methylation is an early and frequent event in gastric tumorigenesis, including both MSI-H and microsatellite-stable neoplasms. Methylation of the p16 gene may contribute to the malignant transformation of gastric precursor lesions.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Chonnam Natl Univ, Sch Med, Kwangju 501190, South Korea	University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Chonnam National University	Wu, TT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, G1-3595C,Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	twu@mdanderson.org	Seo, Jeong-Sun/J-2763-2012					Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BANKFALVI A, 1994, J PATHOL, V174, P223, DOI 10.1002/path.1711740312; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BECKER KF, 1994, CANCER RES, V54, P3845; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Endoh Y, 2000, AM J PATHOL, V157, P717, DOI 10.1016/S0002-9440(10)64584-1; Fleisher AS, 1999, CANCER RES, V59, P1090; Fleisher AS, 2001, ONCOGENE, V20, P329, DOI 10.1038/sj.onc.1204104; Fujimoto J, 2000, CANCER LETT, V149, P125, DOI 10.1016/S0304-3835(99)00349-3; Gunther T, 1998, PATHOL RES PRACT, V194, P809, DOI 10.1016/S0344-0338(98)80082-4; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IIDA S, 2002, INT J CANCER, V87, P654; Jang TJ, 2001, INT J CANCER, V93, P629, DOI 10.1002/ijc.1394; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KAMIYA T, 1982, CANCER, V50, P2496, DOI 10.1002/1097-0142(19821201)50:11<2496::AID-CNCR2820501140>3.0.CO;2-1; Kanai Y, 1998, CANCER LETT, V122, P135, DOI 10.1016/S0304-3835(97)00380-7; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Kang GH, 2001, CANCER RES, V61, P2847; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; KIHANA T, 1991, JPN J CANCER RES, V82, P308, DOI 10.1111/j.1349-7006.1991.tb01847.x; KOLODZIEJCZYK P, 1994, CANCER-AM CANCER SOC, V74, P2896, DOI 10.1002/1097-0142(19941201)74:11<2896::AID-CNCR2820741103>3.0.CO;2-P; Kwong J, 2002, CLIN CANCER RES, V8, P131; Lee JH, 2002, AM J PATHOL, V161, P611, DOI 10.1016/S0002-9440(10)64216-2; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MAESAWA C, 1995, J PATHOL, V176, P249, DOI 10.1002/path.1711760307; Maruyama R, 2001, CANCER RES, V61, P8659; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; ORLOWSKA J, 1995, AM J GASTROENTEROL, V90, P2152; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Park WS, 1999, CANCER RES, V59, P4257; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Stadtlander CTKH, 1999, CARCINOGENESIS, V20, P2195, DOI 10.1093/carcin/20.12.2195; TAMURA G, 1994, CANCER RES, V54, P1149; Toyota M, 2000, ELECTROPHORESIS, V21, P329, DOI 10.1002/(SICI)1522-2683(20000101)21:2<329::AID-ELPS329>3.0.CO;2-9; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Ueki T, 2001, CANCER RES, V61, P8540; Virmani AK, 2001, CLIN CANCER RES, V7, P584; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8	49	96	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4646	4654		10.1038/sj.onc.1207588	http://dx.doi.org/10.1038/sj.onc.1207588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064707				2022-12-25	WOS:000221799000015
J	Calonge, MJ; Seoane, J; Massague, J				Calonge, MJ; Seoane, J; Massague, J			Opposite smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; COUP-TF; EPIDERMOLYSIS-BULLOSA; HISTONE DEACETYLASE; RESPONSE ELEMENTS; THYROID-HORMONE; DIRECT BINDING; RECEPTOR; REPRESSION; CELLS	A critical component of the epidermal basement membrane, collagen type VII, is produced by keratinocytes and fibroblasts, and its production is stimulated by the cytokine transforming growth factor-beta (TGF-beta). The gene, COL7A1, is activated by TGF-beta via Smad transcription factors in cooperation with AP1. Here we report a previously unsuspected level of complexity in this regulatory process. We provide evidence that TGF-beta may activate the COL7A1 promoter by two distinct inputs operating through a common region of the promoter. One input is provided by TGF-beta-induced Smad complexes via two Smad binding elements that function redundantly depending on the cell type. The second input is provided by relieving the COL7A1 promoter from chicken ovalbumin upstream promoter transcription factor (COUP-TF)-mediated transcriptional repression. We identified COUP-TFI and - TFII as factors that bind to the TGF-beta-responsive region of the COL7A1 promoter in an expression library screening. COUP-TFs bind to a site between the two Smad binding elements independently of Smad or AP1 and repress the basal and TGF-beta-stimulated activities of this promoter. We provide evidence that endogenous COUP-TF activity represses the COL7A1 promoter. Furthermore, we show that TGF-beta addition causes a rapid and profound down-regulation of COUP-TF expression in keratinocytes and fibroblasts. The results suggest that TGF-beta signaling may exert tight control over COL7A1 by offsetting the balance between opposing Smad and COUP-TFs.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, Box 116,1275 York Ave, New York, NY 10021 USA.	j-massague@mskmail.mskcc.org	Seoane, Joan/AAG-9173-2019; Calonge, Margarita/K-2839-2014	Seoane, Joan/0000-0002-6541-5974; Calonge, Margarita/0000-0001-8178-4836; Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achatz G, 1997, MOL CELL BIOL, V17, P4914, DOI 10.1128/MCB.17.9.4914; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Cooney AJ, 2001, TRENDS ENDOCRIN MET, V12, P247, DOI 10.1016/S1043-2760(01)00424-6; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Germain S, 2000, GENE DEV, V14, P435; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Iavarone A, 1997, NATURE, V387, P417; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kobayashi S, 2002, ENDOCR RES, V28, P579, DOI 10.1081/ERC-120016844; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Naso M, 2003, J INVEST DERMATOL, V121, P1469, DOI 10.1111/j.1523-1747.2003.12640.x; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Robinson CE, 1999, ENDOCRINOLOGY, V140, P1586, DOI 10.1210/en.140.4.1586; RYYNANEN J, 1992, J CLIN INVEST, V89, P163, DOI 10.1172/JCI115557; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Smirnov DA, 2000, VIROLOGY, V268, P319, DOI 10.1006/viro.1999.0181; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; Uitto J, 1996, MOL BIOL REP, V23, P35, DOI 10.1007/BF00357071; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; WOODLEY DT, 1985, BIOCHEM BIOPH RES CO, V130, P1267, DOI 10.1016/0006-291X(85)91751-6; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	51	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23759	23765		10.1074/jbc.M402178200	http://dx.doi.org/10.1074/jbc.M402178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15047696	hybrid			2022-12-25	WOS:000221570900118
J	Schmitt, E; Paquet, C; Beauchemin, M; Bertrand, R				Schmitt, E; Paquet, C; Beauchemin, M; Bertrand, R			Bcl-xES, a BH4-and BH2-containing antiapoptotic protein, delays Bax oligomer formation and binds Apaf-1, blocking procaspase-9 activation	ONCOGENE			English	Review						Bcl-x; Bax; Apaf-1; caspase; apoptosis	INNER MITOCHONDRIAL-MEMBRANE; DEPENDENT ANION CHANNEL; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; FAMILY-MEMBERS; X-L; PROMOTES APOPTOSIS; BH4 DOMAIN; CASPASE ACTIVATION; CONSERVED DOMAINS	Bcl-2 family members either negatively or positively regulate the apoptotic threshold of cells. Bcl-xES ( extra short), a novel Bcl-x member, possesses a unique combination of BH4 and BH2 domains as well as a COOH-terminal hydrophobic transmembrane anchor domain. Bcl-xES contains sequences of hydrophobic alpha-6 helices but lacks sequences of alpha-5 helices, suggesting that it does not have pore channel-forming activity but functions uniquely as a trapping protein. mRNA expression analysis by reverse transcriptase-polymerase chain reaction and RNase protection assay reveal that Bcl-xES is expressed in a variety of human cancer cell lines and human tumors, including bone marrow from patients with acute lymphoblastic leukemia. Bcl-xES expression is much less pronounced in some specimens of normal human tissues, including the breast, ovary, testis and lung. Stable, transfected human B lymphoma Namalwa variant cells expressing Bcl-xES were derived to investigate its role in apoptosis. Bcl-xES had a preventive effect on cell death induced by tumor necrosis factor-alpha and various concentrations of anticancer drugs, including camptothecin, etoposide and cisplatin. Its protective action on cell death was correlated with the inhibition of mitochondrial cytochrome c release and caspase activation. In a yeast two-hybrid system, Bcl-xES interacted with most Bcl-2 family members, including those containing only a BH3 domain, and with the Ced-4 homolog Apaf-1. Co-immunoprecipitation and gel filtration chromatography experiments suggest that Bcl-xES delays drug-induced apoptosis by disturbing the formation of Bax oligomers and preventing cytochrome c release, but also by interacting with Apaf-1 and inhibiting procaspase-9 activation, thus averting the apoptogenic proteolytic caspase cascade and cell death.	Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Bertrand, R (corresponding author), Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Rech, 1560 Sherbrooke St E,Room Y-5634, Montreal, PQ H2L 4M1, Canada.	richard.bertrand@umontreal.ca						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERTRAND R, 1991, CANCER RES, V51, P6280; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Droin N, 2000, CANCER RES, V60, P7039; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; He HL, 1998, J IMMUNOL, V161, P1169; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schmitt E, 1998, CELL DEATH DIFFER, V5, P506, DOI 10.1038/sj.cdd.4400376; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shi B, 1999, BIOCHEM BIOPH RES CO, V254, P779, DOI 10.1006/bbrc.1998.0130; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 1999, FEBS LETT, V448, P23, DOI 10.1016/S0014-5793(99)00335-X; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	103	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3915	3931		10.1038/sj.onc.1207554	http://dx.doi.org/10.1038/sj.onc.1207554			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048082				2022-12-25	WOS:000221382000004
J	de Fraipont, F; Keramidas, M; El Atifi, M; Chambaz, EM; Berger, F; Feige, JJ				de Fraipont, F; Keramidas, M; El Atifi, M; Chambaz, EM; Berger, F; Feige, JJ			Expression of the thrombospondin 1 fragment 167-569 in C6 glioma cells stimulates tumorigenicity despite reduced neovascularization	ONCOGENE			English	Article						tumor angiogenesis; thrombospondin; glioma	INTEGRIN-ASSOCIATED PROTEIN; ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; BRAIN-TUMORS; FACTOR-BETA; TGF-BETA; INHIBITION; PROGRESSION; MECHANISMS; CARCINOMA	Gliomas are among the most malignant and most highly vascularized human tumors. We studied the therapeutic action of an angiostatic fragment of human thrombospondin 1 (named TSP1ang) on experimental glioma tumor growth. TSP1ang (enclosing amino acids 167-569) comprised the procollagen-homology domain and the three type I repeats of the original molecule. C6 glioma cells that stably express TSP1ang were generated, and their rate of in vitro growth did not appear to differ from that of C6 cells transfected with an empty plasmid. TSP1ang expressing C6 cells were then injected either subcutaneously or intracerebrally into nude mice. The resulting tumors appeared to be less vascularized, but unexpectedly started to grow earlier and had a much more invasive phenotype than tumors derived from control C6 cells. They were also much more aggressive, since the mice bearing intracerebral TSP1ang-expressing tumor cells died before day 19 post-implantation, whereas all mice bearing control C6 tumors were alive at this time point. These results indicate that careful attention should be paid at designing smaller fragments from the multimodular angiostatic molecule TSP1 since, as observed in this study, it may unmask protumorigenic properties that counteract its antiangiogenic activity.	CEA G, ANGIO, DRDC, Dept Cellular Response & Dynam,INSERM EMI 01 05, F-38054 Grenoble 09, France; Univ Hosp Grenoble, Dept Integrat Biol, F-38043 Grenoble, France; Univ Hosp Grenoble, INSERM, U318, F-38043 Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Feige, JJ (corresponding author), CEA G, ANGIO, DRDC, Dept Cellular Response & Dynam,INSERM EMI 01 05, 17 Rue Martyrs, F-38054 Grenoble 09, France.	jjfeige@cea.fr	Feige, Jean-Jacques/M-8905-2017; de Fraipont, Florence/P-4936-2014	Feige, Jean-Jacques/0000-0002-1354-7692; de Fraipont, Florence/0000-0001-9594-6584				ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BLACK PM, 1991, NEW ENGL J MED, V324, P1471, DOI 10.1056/NEJM199105233242105; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Claffey KP, 1996, CANCER RES, V56, P172; de Fraipont F, 2000, J CLIN ENDOCR METAB, V85, P4734, DOI 10.1210/jc.85.12.4734; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; FEIGE JJ, 2000, ENCY REFERENCE VASCU, P285; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Freyberg MA, 2000, BIOCHEM BIOPH RES CO, V271, P584, DOI 10.1006/bbrc.2000.2678; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Goldbrunner RH, 2000, J NEURO-ONCOL, V50, P53, DOI 10.1023/A:1006462504447; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Grainger DJ, 2000, BIOCHEM J, V350, P291, DOI 10.1042/0264-6021:3500291; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harpel JG, 2001, BIOCHEM BIOPH RES CO, V284, P11, DOI 10.1006/bbrc.2001.4922; Hsu SC, 1996, CANCER RES, V56, P5684; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Ohta Y, 1999, CANCER, V85, P2570, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2570::AID-CNCR12>3.3.CO;2-6; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; PLATE KH, 1995, GLIA, V15, P339, DOI 10.1002/glia.440150313; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Siemeister G, 1998, CANCER METAST REV, V17, P241, DOI 10.1023/A:1006027124696; Stratmann A, 1997, ADV STER F, V12, P105; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Taraboletti G, 2000, FASEB J, V14, P1674; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; Vailhe B, 2003, CURR PHARM DESIGN, V9, P583, DOI 10.2174/1381612033391342; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Wang TN, 1996, SURGERY, V120, P449, DOI 10.1016/S0039-6060(96)80322-9; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Yoshida Y, 1999, INT J ONCOL, V15, P1221; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	51	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3642	3649		10.1038/sj.onc.1207438	http://dx.doi.org/10.1038/sj.onc.1207438			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077189				2022-12-25	WOS:000221101700016
J	Sambamurti, K; Kinsey, R; Maloney, B; Ge, YW; Lahiri, DK				Sambamurti, K; Kinsey, R; Maloney, B; Ge, YW; Lahiri, DK			Gene structure and organization of the human beta-secretase (BACE) promoter	FASEB JOURNAL			English	Article						dementia; aging; genomic; Alzheimer's disease; amyloid	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; EXPRESSION; IDENTIFICATION; SITE; CYTOKINES; CLEAVAGE; CLONING	The first step in the generation of the amyloid-beta peptide (Abeta) deposited in the brains of patients with Alzheimer's disease ( AD) is the processing of the larger Abeta precursor protein (APP) by an integral membrane aspartyl protease named the beta-site APP-cleaving enzyme (BACE). We present the genomic organization of the BACE gene. BACE mRNAs are synthesized as nine exons and eight introns from a 30.6 kb region of chromosome 11q23.2-11q23.3. Regulation of BACE may play an important role in regulating the levels of Abeta produced and is therefore likely to play an important role in AD. Herein, we report the cloning and detailed analysis of 3765 nucleotides of the promoter region of BACE and 364 nucleotides of the 5' untranslated region of the BACE mRNA (5' UTR). Characteristic "CAAT" and "TATA" boxes are absent within 1.5 kb of the transcription start site (TSS). The promoter region and 5' UTR contain multiple transcription factor binding sites, such as activator protein (AP) 1, AP2, cAMP response element binding protein ( CREB), estrogen responsive element ( ERE), glucocorticoid responsive element (GRE), "GC" box, nuclear factor (NF)-kappaB, signal transducer and activator of transcription ( STAT) 1, stimulating protein (SP) 1, metal-regulatory elements, and possible Zeste binding sites. Limited interspecies similarity was observed between the human sequence and corresponding genomic DNA from the rat and mouse sequences, but several transcription factor-binding sites are conserved. Thus, the BACE gene contains basal regulatory elements, inducible features and sites for regulated activity by various transcription factors. These results identify the important regions for functional analysis of the binding domains and neuron-specific expression ( 1). Such a study will allow us to further examine the possible role of changes in the promoter of BACE in AD pathogenesis.	Med Univ S Carolina, Charleston, SC 29425 USA; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Medical University of South Carolina; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Lahiri, DK (corresponding author), 791 N Union Dr, Indianapolis, IN 46206 USA.	dlahiri@iupui.edu	Lahiri, Debomoy/AAZ-3322-2020; Sambamurti, Kumar/A-1620-2012; Maloney, Bryan J/C-4924-2011	Sambamurti, Kumar/0000-0001-9507-9214; Maloney, Bryan J/0000-0003-2364-9649	NATIONAL INSTITUTE ON AGING [R01AG018379, R01AG018884] Funding Source: NIH RePORTER; NIA NIH HHS [AG18379, AG18884] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; GE YW, 2004, FASEB J         0401, DOI DOI 10.1096/FJ.03-1739FJE; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Huang XQ, 1996, GENOMICS, V33, P21, DOI 10.1006/geno.1996.0155; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; Lahiri DK, 2003, CURR DRUG TARGETS, V4, P97, DOI 10.2174/1389450033346957; LAHIRI DK, 1995, MOL BRAIN RES, V32, P233, DOI 10.1016/0169-328X(95)00078-7; Lange-Dohna C, 2003, J NEUROSCI RES, V73, P73, DOI 10.1002/jnr.10639; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; Nishiyama K, 1999, J NEUROSCI, V19, P6538; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; Satoh J, 2000, NEUROPATHOLOGY, V20, P289, DOI 10.1046/j.1440-1789.2000.00349.x; SCHUG J, TESS TRANSCRIPTION E; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1998, GENE, V217, P165, DOI 10.1016/S0378-1119(98)00340-0; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tanahashi H, 2001, NEUROSCI LETT, V307, P9, DOI 10.1016/S0304-3940(01)01912-7; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vattemi G, 2003, EXP NEUROL, V179, P150, DOI 10.1016/S0014-4886(02)00025-0; Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407	41	150	157	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1034	+		10.1096/fj.03-1378fje	http://dx.doi.org/10.1096/fj.03-1378fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059975				2022-12-25	WOS:000221108800026
J	Reynolds, M; Peterson, E; Quievryn, G; Zhitkovich, A				Reynolds, M; Peterson, E; Quievryn, G; Zhitkovich, A			Human nucleotide excision repair efficiently removes chromium-DNA phosphate adducts and protects cells against chromate toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; GROUP-A PROTEIN; MAMMALIAN-CELLS; CROSS-LINKS; IN-VITRO; NUCLEAR-MATRIX; AMINO-ACIDS; TRANSCRIPTION; MUTAGENESIS; RECOGNITION	Intracellular reduction of carcinogenic Cr(VI) leads to the extensive formation of Cr(III)-DNA phosphate adducts. Repair mechanisms for chromium and other DNA phosphate-based adducts are currently unknown in human cells. We found that nucleotide excision repair (NER)-proficient human cells rapidly removed chromium-DNA adducts, with an average t(1/2) of 7.1 h, whereas NER-deficient XP-A, XP-C, and XP-F cells were severely compromised in their ability to repair chromium-DNA lesions. Activation of NER in Cr(VI)-treated human fibroblasts or lung epithelial H460 cells was manifested by XPC-dependent binding of the XPA protein to the nuclear matrix, which was also observed in UV light-treated (but not oxidant-stressed) cells. Intracellular replication of chromium-modified plasmids demonstrated increased mutagenicity of binary Cr(III)-DNA and ternary cysteine-Cr(III)-DNA adducts in cells with inactive NER. NER deficiency created by the loss of XPA in fibroblasts or by knockdown of this protein by stable expression of small interfering RNA in H460 cells increased apoptosis and clonogenic death by Cr(VI), providing genetic evidence for the role of monofunctional chromium-DNA adducts in the toxic effects of this metal. The rate of NER of chromium-DNA adducts under saturating conditions was calculated to be similar to50,000 lesions/min/cell. Because chromium-DNA adducts cause only small changes in the DNA helix, rapid repair of these modifications in human cells indicates that the presence of major structural distortions in DNA is not required for the efficient detection of the damaged sites by NER proteins in vivo.	Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA	Brown University	Zhitkovich, A (corresponding author), Brown Univ, Dept Pathol & Lab Med, 69 Brown St,POB G-B511, Providence, RI 02912 USA.	Anatoly_Zhitkovich@brown.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007272, R01ES008786] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20 RR015578] Funding Source: Medline; NIEHS NIH HHS [2R01 ES008786, 5T32 ES007272, R01 ES008786] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Araujo SJ, 2000, GENE DEV, V14, P349; Araujo SJ, 2001, MOL CELL BIOL, V21, P2281, DOI 10.1128/MCB.21.7.2281-2291.2001; Blankert SA, 2003, CHEM RES TOXICOL, V16, P847, DOI 10.1021/tx034007g; BODELL WJ, 1979, NUCLEIC ACIDS RES, V6, P2819, DOI 10.1093/nar/6.8.2819; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; BRIDGEWATER LC, 1994, CARCINOGENESIS, V15, P2421, DOI 10.1093/carcin/15.11.2421; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; MACCUBBIN AE, 1991, CANCER RES, V51, P886; MCCARTHY TV, 1985, NUCLEIC ACIDS RES, V13, P2683, DOI 10.1093/nar/13.8.2683; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Nakatsu Y, 2000, J BIOL CHEM, V275, P34931, DOI 10.1074/jbc.M004936200; O'Brien T, 2002, BIOCHEMISTRY-US, V41, P12529, DOI 10.1021/bi020452j; Otrin VR, 1997, J CELL SCI, V110, P1159; Perdiz D, 2000, J BIOL CHEM, V275, P26732; Quievryn G, 2002, BIOCHEMISTRY-US, V41, P3156, DOI 10.1021/bi011942z; Quievryn G, 2000, CARCINOGENESIS, V21, P1573, DOI 10.1093/carcin/21.8.1573; Quievryn G, 2003, BIOCHEMISTRY-US, V42, P1062, DOI 10.1021/bi0271547; Rademakers S, 2003, MOL CELL BIOL, V23, P5755, DOI 10.1128/MCB.23.16.5755-5767.2003; SINGER B, 1985, ENVIRON HEALTH PERSP, V62, P41, DOI 10.2307/3430091; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Tomky LA, 1998, NUCLEIC ACIDS RES, V26, P2298, DOI 10.1093/nar/26.10.2298; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; Voitkun V, 1998, NUCLEIC ACIDS RES, V26, P2024, DOI 10.1093/nar/26.8.2024; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; You JS, 2003, J BIOL CHEM, V278, P7476, DOI 10.1074/jbc.M210603200; Zhitkovich A, 1996, BIOCHEMISTRY-US, V35, P7275, DOI 10.1021/bi960147w; ZHITKOVICH A, 1995, CARCINOGENESIS, V16, P907, DOI 10.1093/carcin/16.4.907; Zhitkovich A, 2001, BIOCHEMISTRY-US, V40, P549, DOI 10.1021/bi0015459; Zhitkovich A., 2002, BIOMARKERS ENV ASS D, P267, DOI [10.1039/c3ja50198a, DOI 10.1039/C3JA50198A]	42	89	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30419	30424		10.1074/jbc.M402486200	http://dx.doi.org/10.1074/jbc.M402486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15087443	hybrid			2022-12-25	WOS:000222531900068
J	West, AB; Kapatos, G; O'Farrell, C; Gonzalez-de-Chavez, F; Chiu, K; Farrer, MJ; Maidment, NT				West, AB; Kapatos, G; O'Farrell, C; Gonzalez-de-Chavez, F; Chiu, K; Farrer, MJ; Maidment, NT			N-myc regulates parkin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-CONJUGATING ENZYME; NEUROBLASTOMA-CELLS; SENSORY NEUROPATHY; GENE; IDENTIFICATION; MUTATIONS; DISEASE; PROGRESSION; PGP9.5	Mutations in the parkin gene are common in early-onset and familial Parkinson's disease (PD), and the parkin protein interacts in the ubiquitin-proteasome system as an E3 ligase. However, the regulatory pathways that govern parkin expression are unknown. In this study, we showed that a phylogenetically conserved N-myc binding site in the bi-directional parkin promoter interacted with myc-family transcription factors in reporter assays, and N-myc bound to the parkin promoter in chromatin immunoprecipitation assays and repressed transcription activity. Parkin expression was inversely correlated with N-myc levels in the developing mouse and human brain, in human neuroblastoma cell lines with various levels of n-myc amplification, and in an inducible N-myc cell line. Although parkin and N-myc expression were dramatically altered upon retinoic acid-induced differentiation of a human neuroblastoma cell line, modulation of parkin expression did not significantly affect either rates of cellular proliferation or levels of cyclin E. Analysis of additional genes associated with familial PD revealed a shared basis of transcription regulation mediated by N-myc and the cell cycle. Our results, in combination with functional knowledge of the proteins encoded by these genes, suggest a common pathway linking together PD, the ubiquitin-proteasome system, and cell cycle control.	Univ Calif Los Angeles, Inst Neuropsychiat, Morris K Udall Ctr Parkinsons Dis Res, Los Angeles, CA 90024 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Mayo Clin Jacksonville, Labs Neurogenet, Morris K Udall Ctr Parkinsons Dis Res, Jacksonville, FL 32224 USA	University of California System; University of California Los Angeles; Wayne State University; Mayo Clinic	West, AB (corresponding author), 760 Westwood Plaza,Box 77, Los Angeles, CA 90024 USA.	abwest7@yahoo.com		Farrer, Matthew/0000-0003-1159-5321; West, Andrew/0000-0002-3034-4061	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026081] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26081] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Feany MB, 2003, NEURON, V38, P13, DOI 10.1016/S0896-6273(03)00201-0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Hardy J, 2003, LANCET NEUROL, V2, P221, DOI 10.1016/S1474-4422(03)00350-8; Harris RG, 2002, J BIOL CHEM, V277, P34815, DOI 10.1074/jbc.M109609200; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Khan NL, 2003, BRAIN, V126, P1279, DOI 10.1093/brain/awg142; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitada T, 2000, MAMM GENOME, V11, P417, DOI 10.1007/s003350010080; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Lee SS, 2003, NEUROBIOL AGING, V24, P687, DOI 10.1016/S0197-4580(02)00196-3; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Lutz W, 1996, ONCOGENE, V13, P803; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Okuma Y, 2003, PARKINSONISM RELAT D, V9, P313, DOI 10.1016/S1353-8020(02)00114-1; Peverali FA, 1996, ONCOGENE, V12, P457; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; Wang M, 2001, J NEUROCHEM, V77, P1561, DOI 10.1046/j.1471-4159.2001.00372.x; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; West AB, 2003, NEUROSCI LETT, V341, P139, DOI 10.1016/S0304-3940(03)00188-5; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28896	28902		10.1074/jbc.M400126200	http://dx.doi.org/10.1074/jbc.M400126200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15078880	hybrid			2022-12-25	WOS:000222445300010
J	Koeck, T; Fu, XM; Hazen, SL; Crabb, JW; Stuehr, DJ; Aulak, KS				Koeck, T; Fu, XM; Hazen, SL; Crabb, JW; Stuehr, DJ; Aulak, KS			Rapid and selective oxygen-regulated protein tyrosine denitration and nitration in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; OXIDATIVE STRESS; IN-VIVO; PEROXYNITRITE; GENERATION; HYPOXIA; DEGRADATION; SUPEROXIDE; ISCHEMIA; HEART	Growing evidence connects a cumulative formation of 3-nitrotyrosyl adducts in proteins as a marker for oxidative damage with the pathogenesis of various diseases and pathological conditions associated with oxidative stress. A physiological signaling role for protein nitration has also been suggested. Controlled "denitration" would be essential for such a contribution of protein nitration to cellular regulatory processes. Thus, we further characterized such a potentially controlled, reversible tyrosine nitration that occurs in respiring mitochondria during oxygen deprivation followed by reoxygenation, which we recently discovered. Mitochondria constitute cellular centers of protein nitration and are leading candidates for a "nitrative" regulation. Mitochondria are capable of completely eliminating 3-nitrotyrosyl adducts during 20 min of hypoxia-anoxia and undergoing a selective partial reduction after only 5 min. This denitration is independent of protein degradation but depends on the oxygen tension. Reoxygenation re-establishes protein tyrosine nitration patterns that are almost identical to the pattern that occurs before hypoxia- anoxia, with nitration levels that depend on the duration of hypoxia- anoxia. The identified mitochondrial targets of this process are critical for energy and antioxidant homeostasis and, therefore, cell and tissue viability. This cycle of protein nitration and denitration shows analogies to protein phosphorylation, and we demonstrate that the cycle meets most of the criteria for a cellular signaling mechanism. Taken together, our data reveal that protein tyrosine nitration in mitochondria can be controlled, is target-selective and rapid, and is dynamic enough to serve as a nitrative regulatory signaling process that likely affects cellular energy, redox homeostasis, and pathological conditions when these features become disturbed.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cole Eye Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Koeck, T (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NB-30,9500 Euclid Ave, Cleveland, OH 44195 USA.	koeckt@ccf.org	Hazen, Stanley L/ABD-5845-2021					Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Aulak KS, 2004, AM J PHYSIOL-HEART C, V286, pH30, DOI 10.1152/ajpheart.00743.2003; Balabanli B, 1999, P NATL ACAD SCI USA, V96, P13136, DOI 10.1073/pnas.96.23.13136; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; Cruthirds DL, 2003, ARCH BIOCHEM BIOPHYS, V412, P27, DOI 10.1016/S0003-9861(03)00039-0; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Dunlop RA, 2002, FREE RADICAL BIO MED, V33, P894, DOI 10.1016/S0891-5849(02)00958-9; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; Ferdinandy P, 2003, BRIT J PHARMACOL, V138, P532, DOI 10.1038/sj.bjp.0705080; Fleischer S, 1974, Methods Enzymol, V31, P6; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Ghafourifari P, 2003, ANTIOXID REDOX SIGN, V5, P349, DOI 10.1089/152308603322110913; Giulivi C, 2003, FREE RADICAL BIO MED, V34, P397, DOI 10.1016/S0891-5849(02)01298-4; Gonzalez-Hernandez JC, 2003, AMINO ACIDS, V24, P163, DOI 10.1007/s00726-002-0317-5; GU G, 1998, FREE RADIC BIOL MED, V25, P1066; Guerra F C, 1974, Methods Enzymol, V31, P299; HOLCOMBE RF, 1993, CLIN IMMUNOL IMMUNOP, V67, P31, DOI 10.1006/clin.1993.1042; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Kuo WN, 1999, MOL CELL BIOCHEM, V201, P11, DOI 10.1023/A:1007024126947; Kuo Wu-Nan, 2002, J Biochem Mol Biol Biophys, V6, P143, DOI 10.1080/10258140290027298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Manevich Y, 2001, AM J PHYSIOL-HEART C, V280, pH2126, DOI 10.1152/ajpheart.2001.280.5.H2126; Manzo-Avalos S, 2002, AMINO ACIDS, V22, P381, DOI 10.1007/s007260200022; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Paddenberg R, 2003, AM J PHYSIOL-LUNG C, V284, pL710, DOI 10.1152/ajplung.00149.2002; Parker A, 2000, BIOCHEM J, V345, P429, DOI 10.1042/0264-6021:3450429; Potoka DA, 2003, AM J PHYSIOL-GASTR L, V285, pG861, DOI 10.1152/ajpgi.00412.2002; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Schild L, 2003, FASEB J, V17, P2194, DOI 10.1096/fj.02-1170com; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Turko IV, 2003, J BIOL CHEM, V278, P33972, DOI 10.1074/jbc.M303734200; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; Turko IV, 2001, AM J PHYSIOL-HEART C, V281, pH2289, DOI 10.1152/ajpheart.2001.281.6.H2289; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Walker LM, 2001, TOXICOL SCI, V63, P143, DOI 10.1093/toxsci/63.1.143; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Warnholtz A, 2002, ARTERIOSCL THROM VAS, V22, P525, DOI 10.1161/01.ATV.0000014220.78856.97; ZLATANOVA JS, 1990, MOL CELL BIOCHEM, V92, P1; Zou MH, 1999, J EXP MED, V190, P135, DOI 10.1084/jem.190.1.135	51	149	150	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27257	27262		10.1074/jbc.M401586200	http://dx.doi.org/10.1074/jbc.M401586200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15084586	hybrid			2022-12-25	WOS:000222120400054
J	Larkin, D; Murphy, D; Reilly, DF; Cahill, M; Sattler, E; Harriott, P; Cahill, DJ; Moran, N				Larkin, D; Murphy, D; Reilly, DF; Cahill, M; Sattler, E; Harriott, P; Cahill, DJ; Moran, N			ICln, a novel integrin alpha(IIb)beta(3)-associated protein, functionally regulates platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNELS; CYTOPLASMIC TAIL; CELL-ADHESION; I-CLN; MEMBRANE; BINDING; EXPRESSION; DOMAIN; POTASSIUM; SEQUENCE	A critical role for the conserved alpha-integrin cytoplasmic motif, KVGFFKR, is recognized in the regulation of activation of the platelet integrin alpha(IIb)beta(3). To understand the molecular mechanisms of this regulation, we sought to determine the nature of the protein interactions with this cytoplasmic motif. We used a tagged synthetic peptide, biotin-KVGFFKR, to probe a high density protein expression array ( 37,200 recombinant human proteins) for high affinity interactions. A number of potential integrin-binding proteins were identified. One such protein, a chloride channel regulatory protein, ICln, was characterized further because its affinity for the integrin peptide was highest as was its expression in platelets. We verified the presence of ICln in human platelets by PCR, Western blots, immunohistochemistry, and its co-association with alpha(IIb)beta(3) by surface plasmon resonance. The affinity of this interaction was 82.2 +/- 24.4 nM in a cell free assay. ICln co-immunoprecipitates with alpha(IIb)beta(3) in platelet lysates demonstrating that this interaction is physiologically relevant. Furthermore, immobilized KVGFFKR peptides, but not control KAAAAAR peptides, specifically extract ICln from platelet lysates. Acyclovir ( 100 muM to 5 mM), a pharmacological inhibitor of the ICln chloride channel, specifically inhibits integrin activation (PAC-1 expression) and platelet aggregation without affecting CD62 P expression confirming a specific role for ICln in integrin activation. In parallel, a cell-permeable peptide corresponding to the potential integrin-recognition domain on ICln (AKFEEE, 10 - 100 muM) also inhibits platelet function. Thus, we have identified, verified, and characterized a novel functional interaction between the platelet integrin and ICln, in the platelet membrane.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland; Royal Coll Surgeons Ireland, Ctr Human Proteom, Dublin 2, Ireland; Queens Univ Belfast, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland; Queens University Belfast	Moran, N (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, St Stephens Green, Dublin 2, Ireland.	nmoran@rcsi.ie	Murphy, Derek/F-6138-2011; Moran, Niamh/F-4188-2012	Moran, Niamh/0000-0002-8614-3242; Murphy, Derek/0000-0002-6905-0167				Abdel-Ghany M, 2003, J BIOL CHEM, V278, P49406, DOI 10.1074/jbc.M309086200; Artym VV, 2002, J GEN PHYSIOL, V120, P29, DOI 10.1085/jgp.20028607; Browe DM, 2003, J GEN PHYSIOL, V122, P689, DOI 10.1085/jgp.200308899; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Cattelino A, 1999, MOL BIOL CELL, V10, P373, DOI 10.1091/mbc.10.2.373; Colden-Stanfield M, 2002, AM J PHYSIOL-CELL PH, V283, pC990, DOI 10.1152/ajpcell.00481.2001; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Davis MJ, 2002, CELL BIOCHEM BIOPHYS, V36, P41, DOI 10.1385/CBB:36:1:41; de Tassigny AD, 2003, FUND CLIN PHARMACOL, V17, P539, DOI 10.1046/j.1472-8206.2003.00197.x; Eigenthaler R, 1997, J BIOL CHEM, V272, P7693, DOI 10.1074/jbc.272.12.7693; Emma F, 1998, AM J PHYSIOL-CELL PH, V274, pC1545, DOI 10.1152/ajpcell.1998.274.6.C1545; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; Furst J, 2000, CELL PHYSIOL BIOCHEM, V10, P329, DOI 10.1159/000016374; Furst J, 2000, PFLUG ARCH EUR J PHY, V440, P100; Gschwentner M, 1996, J ALLERGY CLIN IMMUN, V98, pS98, DOI 10.1016/S0091-6749(96)80135-7; GSCHWENTNER M, 1995, MOL MED, V1, P407, DOI 10.1007/BF03401578; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Israels SJ, 2001, THROMB HAEMOSTASIS, V85, P134; Kato A, 2002, J BIOL CHEM, V277, P28934, DOI 10.1074/jbc.M204340200; Kawasaki J, 2004, J BIOL CHEM, V279, P12959, DOI 10.1074/jbc.M313791200; Kieffer JD, 1995, BIOCHEM BIOPH RES CO, V217, P466, DOI 10.1006/bbrc.1995.2799; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; Laich A, 1997, KIDNEY INT, V51, P477, DOI 10.1038/ki.1997.65; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; Lueking Angelika, 2003, Methods Mol Biol, V205, P31; McPhee JC, 1998, J BIOL CHEM, V273, P34696, DOI 10.1074/jbc.273.52.34696; McRedmond JP, 2004, MOL CELL PROTEOMICS, V3, P133, DOI 10.1074/mcp.M300063-MCP200; Menegazzi R, 1999, J IMMUNOL, V162, P423; Menegazzi R, 2000, J IMMUNOL, V165, P4606, DOI 10.4049/jimmunol.165.8.4606; MORAN N, 2004, IN PRESS J THROMBOSI; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; Peter K, 1996, BLOOD COAGUL FIBRIN, V7, P233, DOI 10.1097/00001721-199603000-00031; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Quinn M, 1999, CIRCULATION, V99, P2231, DOI 10.1161/01.CIR.99.17.2231; Ritter M, 2003, J BIOL CHEM, V278, P50163, DOI 10.1074/jbc.M300374200; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Shakibael M, 2003, HISTOL HISTOPATHOL, V18, P343, DOI 10.14670/HH-18.343; SheikhHamad D, 1997, AM J PHYSIOL-CELL PH, V273, pC902, DOI 10.1152/ajpcell.1997.273.3.C902; Stephens G, 1998, J BIOL CHEM, V273, P20317, DOI 10.1074/jbc.273.32.20317; Sullivan R, 1996, BLOOD, V87, P648, DOI 10.1182/blood.V87.2.648.bloodjournal872648; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Thiel M, 2001, J LEUKOCYTE BIOL, V70, P261; Vasilyev DV, 2003, J PHYSIOL-LONDON, V547, P859, DOI 10.1113/jphysiol.2002.036889; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; Wang ZY, 2003, BLOOD, V102, P1307, DOI 10.1182/blood-2002-09-2753; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Weljie AM, 2002, P NATL ACAD SCI USA, V99, P5878, DOI 10.1073/pnas.092515799	57	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27286	27293		10.1074/jbc.M402159200	http://dx.doi.org/10.1074/jbc.M402159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15075326	hybrid			2022-12-25	WOS:000222120400058
J	Brennan, K; Gonzalez-Sancho, JM; Castelo-Soccio, LA; Howe, LR; Brown, AMC				Brennan, K; Gonzalez-Sancho, JM; Castelo-Soccio, LA; Howe, LR; Brown, AMC			Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of Frizzled proteins	ONCOGENE			English	Article						wnt signaling; beta-catenin; receptors; Frizzled; LRP6; Arrow	SIGNALING PATHWAY; SPEMANN ORGANIZER; ILLEGITIMATE TRANSCRIPTION; DROSOPHILA; WINGLESS; GENE; FAMILY; DENSITY; MECHANISM; MEMBER	Secreted signaling proteins of the Wnt family are known to regulate a diverse range of developmental processes, and their signaling pathway through beta-catenin is frequently activated in cancer. The identification of both Frizzled and LRP5/6 (LRP: low-density lipoprotein receptor-related protein) proteins as components of cell-surface receptors for Wnt proteins has raised questions about their individual functions. We have investigated this issue through a structure-function analysis of Frizzled and LRP proteins that have been implicated in Wnt1 signaling. Consistent with other reports, we find that LRP6/Arrow proteins deleted for their extracellular domain are able to activate the Wnt/beta-catenin signaling pathway. Importantly, our results demonstrate that this signaling from LRP6/Arrow derivatives can occur in a Frizzled- and ligand-independent manner. Furthermore, we show that the PPSP motifs within the intracellular domain of LRP6 are required for signaling. In contrast to results with LRP6, overexpression of Frizzled proteins did not activate the pathway. Based on evidence of ligand binding to both Frizzled and LRP6, current models suggest that both proteins are components of a Wnt receptor complex that signals to beta-catenin. In light of these models, our data imply that LRP5/6/Arrow proteins constitute the distal signal-initiating component of these receptors. The results also support the notion that LRP5/6 are candidate oncogenes.	Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA; Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA	Cornell University; Rockefeller University	Brown, AMC (corresponding author), Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, 1300 York Ave, New York, NY 10021 USA.	amcbrown@med.cornell.edu	Gonzalez-Sancho, Jose/AAA-6010-2019	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Howe, Louise/0000-0002-1468-7136; Brennan, Keith/0000-0002-9384-125X	NCI NIH HHS [CA47207, R01 CA047207] Funding Source: Medline; NIGMS NIH HHS [R01 GM067739, GM67739] Funding Source: Medline; Wellcome Trust [065994] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047207, R29CA047207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Binari RC, 1997, DEVELOPMENT, V124, P2623; Boutros M, 2000, SCIENCE, V288, P1825, DOI 10.1126/science.288.5472.1825; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; Chen CM, 1999, DEVELOPMENT, V126, P5441; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; Deardorff MA, 2001, DEVELOPMENT, V128, P3655; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Holmen SL, 2002, J BIOL CHEM, V277, P34727, DOI 10.1074/jbc.M204989200; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kaplan Jean-Claude, 1992, Human Mutation, V1, P357, DOI 10.1002/humu.1380010502; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Nusse R, 1997, COLD SPRING HARB SYM, V62, P185; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Sato A, 1999, DEVELOPMENT, V126, P4421; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schweizer L, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-4; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Toyofuku T, 2000, J CELL BIOL, V150, P225, DOI 10.1083/jcb.150.1.225; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Uusitalo M, 1999, EXP CELL RES, V253, P336, DOI 10.1006/excr.1999.4710; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110	60	83	87	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4873	4884		10.1038/sj.onc.1207642	http://dx.doi.org/10.1038/sj.onc.1207642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064719	Green Accepted			2022-12-25	WOS:000222104200008
J	Lesley, J; Gal, I; Mahoney, DJ; Cordell, MR; Rugg, MS; Hyman, R; Day, AJ; Mikecz, K				Lesley, J; Gal, I; Mahoney, DJ; Cordell, MR; Rugg, MS; Hyman, R; Day, AJ; Mikecz, K			TSG-6 modulates the interaction between hyaluronan and cell surface CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTER-ALPHA-INHIBITOR; SMOOTH-MUSCLE-CELLS; LINK MODULE; PROTEIN TSG-6; PRIMARY ADHESION; UP-REGULATION; BINDING-SITE; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX	Interactions between CD44 and hyaluronan are implicated in the primary adhesion of lymphocytes to endothelium at inflammatory locations. Here we show that preincubation of hyaluronan with full-length recombinant TSG-6 or its Link module domain (Link_TSG6) enhances or induces the binding of hyaluronan to cell surface CD44 on constitutive and inducible cell backgrounds, respectively. These effects are blocked by CD44-specific antibodies and are absent in CD44-negative cells. Enhancement of CD44-mediated interactions of lymphoid cells with hyaluronan by TSG-6 proteins was seen under conditions of flow at shear forces that occur in post-capillary venules. Increases in the number of rolling cells were observed on substrates comprising TSG-6-hyaluronan complexes as compared with a substrate containing hyaluronan alone. In ligand competition experiments, cell surface-bound TSG-6-hyaluronan complexes were more potent than hyaluronan alone in inhibiting cell adhesion to immobilized hyaluronan. Link_TSG6 mutants with impaired hyaluronan binding function had a reduced ability to modulate ligand binding by cell surface CD44. However, some mutants that exhibited close to wild-type hyaluronan binding were found to have either reduced or increased activity, suggesting that some amino acid residues outside of the hyaluronan binding site might be involved in protein self-association, potentially leading to the formation of cross-linked hyaluronan fibers. In turn, cross-linked hyaluronan could increase the binding avidity of CD44 by inducing receptor clustering. The ability of TSG-6 to modulate the interaction of hyaluronan with CD44 has important implications for CD44-mediated cell activity at sites of inflammation, where TSG-6 is expressed.	Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Salk Inst, Mol & Cell Biol Lab, San Diego, CA 92186 USA; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	Rush University; Rush University; Salk Institute; University of Oxford	Day, AJ (corresponding author), Rush Univ, Med Ctr, Dept Orthoped Surg, 1735 W Harrison St,712 Cohn, Chicago, IL 60612 USA.	tony.day@bioch.ox.ac.uk; Katalin_Mikecz@rsh.net	Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134; Mikecz, Katalin/0000-0003-1506-4296	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045652] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31613] Funding Source: Medline; NIAMS NIH HHS [AR45652] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; Bandman O, 2002, ANN NY ACAD SCI, V975, P77, DOI 10.1111/j.1749-6632.2002.tb05943.x; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Camenisch TD, 2000, AM J RESP CELL MOL, V23, P431, DOI 10.1165/ajrcmb.23.4.f201; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; Gal I, 2003, J BIOL CHEM, V278, P11150, DOI 10.1074/jbc.M210661200; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; HATHCOCK KS, 1993, J IMMUNOL, V151, P6712; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HYMAN R, 1991, IMMUNOGENETICS, V33, P392, DOI 10.1007/BF00216699; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; Kahmann JD, 1997, PROTEIN EXPRES PURIF, V9, P315, DOI 10.1006/prep.1996.0694; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2000, J BIOL CHEM, V275, P26967; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 2002, HYALURONAN, V1, P341; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Oertli B, 1998, J IMMUNOL, V161, P3431; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; PITSILLIDES AA, 1994, BRIT J RHEUMATOL, V33, P5; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; Stoop R, 2002, EUR J IMMUNOL, V32, P2532, DOI 10.1002/1521-4141(200209)32:9<2532::AID-IMMU2532>3.0.CO;2-A; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; WISNIEWSKI HG, 1996, PFLUEGERS ARCH EUR J, V431, P225; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	55	133	144	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25745	25754		10.1074/jbc.M313319200	http://dx.doi.org/10.1074/jbc.M313319200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15060082	hybrid			2022-12-25	WOS:000221827900104
J	Roca, J				Roca, J			The path of the DNA along the dimer interface of topoisomerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; 2-GATE MECHANISM; DOUBLE HELIX; TRANSPORT; PROTEIN; GYRASE; PURIFICATION; FRAGMENTS; SUBUNIT	The eukaryotic DNA topoisomerase II is a dyadic enzyme that, upon ATP binding, transports one duplex DNA (T-segment) through a transient double-stranded break in another (G-segment). The path of the T-segment involves the sequential crossing of three gates along the dimer interface: the entrance or N-gate, the DNA gate, and the exit or C-gate. Coordination among these gates is critical for dimer stability and the prevention of chromosome damage. This study examines DNA transactions by yeast topoisomerase II derivatives defective in gate function. The results indicate that, although the N-gate is not required for G-segment cleavage, the DNA gate per se is not able to widen unless ATP binds to the N-gate. Next, a captured T-segment cannot be held in the inter-domainal region between the N-gate and the DNA gate. Finally, the G-segment can be religated while a T-segment is held in the central cavity of the enzyme between the DNA gate and the C-gate. These quaternary couplings for gate opening and closing suggest that topoisomerase II ensures a transient DNA gating state, during which dimer interface contacts are maximized and backtracking of the transported DNA is minimized.	CSIC, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Roca, J (corresponding author), CSIC, Inst Biol Mol Barcelona, Jordi Girona 18-26, ES-08034 Barcelona, Spain.	jrbbmc@cid.csic.es	Roca, Joaquim/AAP-1077-2020	Roca, Joaquim/0000-0003-1462-954X				BARZILAI R, 1973, J MOL BIOL, V74, P739, DOI 10.1016/0022-2836(73)90062-4; Benedetti P, 1997, J BIOL CHEM, V272, P12132, DOI 10.1074/jbc.272.18.12132; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Fass D, 1999, NAT STRUCT BIOL, V6, P322; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PENG H, 1993, J BIOL CHEM, V268, P24481; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; REECE RJ, 1989, J BIOL CHEM, V264, P19648; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; ROCA J, 1999, METHODS MOL BIOL DNA, P75; ROWE TC, 1984, J BIOL CHEM, V259, P9177; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; TSE YC, 1980, J BIOL CHEM, V255, P5560; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	32	36	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 11	2004	279	24					25783	25788		10.1074/jbc.M402555200	http://dx.doi.org/10.1074/jbc.M402555200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	826KL	15047688	hybrid			2022-12-25	WOS:000221827900108
J	Laudon, H; Karlstrom, H; Mathews, PM; Farmery, MR; Gandy, SE; Lundkvist, J; Lendahl, U; Naslund, J				Laudon, H; Karlstrom, H; Mathews, PM; Farmery, MR; Gandy, SE; Lundkvist, J; Lendahl, U; Naslund, J			Functional domains in presenilin 1 - The TYR-288 residue controls gamma-secretase activity and endoproteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE-ASSOCIATED PRESENILIN-1; ALZHEIMERS-DISEASE; BETA-APP; CAENORHABDITIS-ELEGANS; INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; NICASTRIN; NOTCH; CLEAVAGE	Processing of the Alzheimer amyloid precursor protein (APP) into the amyloid beta-protein and the APP intracellular domain is a proteolysis event mediated by the gamma-secretase complex where presenilin ( PS) proteins are key constituents. PS is subjected to an endoproteolytic cleavage, generating a stable heterodimer composed of an N-terminal and a C-terminal fragment. Here we aimed at further understanding the role of PS in endoproteolysis, in proteolytic processing of APP and Notch, and in assembly of the gamma-secretase complex. By using a truncation protocol and alanine scanning, we identified Tyr-288 in the PS1 N-terminal fragment as critical for PS-dependent intramembrane proteolysis. Further mutagenesis of the 288 site identified mutants differentially affecting endoproteolysis and gamma-secretase activity. The Y288F mutant was endoproteolyzed to the same extent as wild type PS but increased the amyloid beta-protein 42/40 ratio by similar to75%. In contrast, the Y288N mutant was also endoproteolytically processed but was inactive in reconstituting gamma-secretase in PS null cells. The Y288D mutant was deficient in both endoproteolysis and gamma-secretase activity. All three mutant PS1 molecules were incorporated into gamma-secretase complexes and stabilized Pen-2 in PS null cells. Thus, mutations at Tyr-288 do not affect gamma-secretase complex assembly but can differentially control endoproteolysis and gamma-secretase activity.	Karolinska Inst, Novum, Dept Neurotec, Div Expt Geriatr, SE-14186 Huddinge, Sweden; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; NYU, Sch Med, Nathan Kline Inst, Ctr Dementia Res, Orangeburg, NY 10962 USA; Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA	Karolinska Institutet; Karolinska Institutet; Nathan Kline Institute for Psychiatric Research; New York University; Jefferson University	Naslund, J (corresponding author), Karolinska Inst, Novum, Kaspac Pl 5, SE-14157 Huddinge, Sweden.	jan.naslund@neurotec.ki.se		Karlstrom, Helena/0000-0002-0498-2473; Lendahl, Urban/0000-0001-9543-8141				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Campbell WA, 2002, BIOCHEMISTRY-US, V41, P3372, DOI 10.1021/bi015810h; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Mathews PM, 2000, MOL MED, V6, P878, DOI 10.1007/BF03401825; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Taniguchi Y, 2002, P NATL ACAD SCI USA, V99, P4014, DOI 10.1073/pnas.052017699; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	43	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					23925	23932		10.1074/jbc.M401277200	http://dx.doi.org/10.1074/jbc.M401277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15051718	hybrid			2022-12-25	WOS:000221702500013
J	Ratineau, C; Bernard, C; Poncet, G; Blanc, M; Josso, C; Fontaniere, S; Calender, A; Chayvialle, JA; Zhang, CX; Roche, C				Ratineau, C; Bernard, C; Poncet, G; Blanc, M; Josso, C; Fontaniere, S; Calender, A; Chayvialle, JA; Zhang, CX; Roche, C			Reduction of menin expression enhances cell proliferation and is tumorigenic in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; CYCLIN D1 OVEREXPRESSION; TUMOR-SUPPRESSOR GENE; FACTOR TYPE-BETA; NEUROENDOCRINE TUMORS; RECEPTOR EXPRESSION; GROWTH-INHIBITION; ACTIVATED RAS; TYPE-1 GENE; II RECEPTOR	Menin, the product of the tumor suppressor gene MEN1, is widely expressed in mammalian endocrine and non-endocrine tissues, including intestine. Its known abundant expression in several types of cells with high proliferative capacity led us to investigate the physiological function of the protein menin in intestinal epithelium, one of the most rapidly growing epithelia. Here we showed that the Men1 gene is mainly expressed in the crypt compartment of the proximal small intestine and that its expression was increased during fasting in vivo, both suggesting a role of menin in the control of cell growth. Indeed, specific reduction of menin expression by transfected antisense cDNA in the rat duodenal crypt-like cell line, IEC-17, increased cell proliferation. The latter is correlated to a loss of cell-cycle arrest in G(1) phase by resting cells and an overexpression of cyclin D1 and cyclin-dependent kinase (Cdk)-4. Furthermore, these cells lost the inhibition of proliferation induced by transforming growth factor-beta1, associated with a decrease of transforming growth factor-beta type II receptor expression. As a result of deregulated proliferation, antisense menin transfected IEC-17 cells became tumorigenic as shown in vitro as well as in vivo in immunosuppressed animals. These results indicate that menin contributes to proliferation control in intestinal epithelial cells. The present study reveals an unknown physiological function for menin in intestine that may be important in the regulation of epithelial homeostasis.	INSERM, U45, F-69008 Lyon, France; Fac Laennec, Inst Federatif Rech 62, F-69008 Lyon, France; CNRS, FRE 2692, F-69008 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	Roche, C (corresponding author), Fac Med Laennec, INSERM, U45, 7 Rue Guillaume Paradin, F-69372 Lyon 8, France.	croche@lyon.inserm.fr	Roche, Colette/M-3549-2018; ZHANG, Chang Xian/G-2905-2013	Roche, Colette/0000-0003-1404-8040; Zhang, Chang Xian/0000-0002-5443-8951				BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Bertolino P, 2003, MECH DEVELOP, V120, P549, DOI 10.1016/S0925-4773(03)00039-X; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; Clavel CE, 2001, J PATHOL, V194, P20, DOI 10.1002/path.868; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Dumortier J, 2000, AM J PATHOL, V156, P671, DOI 10.1016/S0002-9440(10)64771-2; FILMUS J, 1994, ONCOGENE, V9, P3627; Forsberg L, 2001, INT J MOL MED, V8, P681; Fromaget M, 2003, J MOL BIOL, V333, P87, DOI 10.1016/j.jmb.2003.08.001; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Gevrey JC, 2001, FEBS LETT, V503, P19, DOI 10.1016/S0014-5793(01)02683-7; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Ikeo Y, 2000, LAB INVEST, V80, P797, DOI 10.1038/labinvest.3780084; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1995, ONCOGENE, V10, P177; Ko TC, 2002, WORLD J SURG, V26, P812, DOI 10.1007/s00268-002-4057-1; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Maruyama K, 1999, MOL CELL ENDOCRINOL, V156, P25, DOI 10.1016/S0303-7207(99)00150-1; Nian M, 2002, AM J PHYSIOL-REG I, V282, pR173, DOI 10.1152/ajpregu.00215.2001; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; QUARONI A, 1981, J NATL CANCER I, V67, P1353; Shih IM, 2000, CANCER RES, V60, P1671; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhang T, 1997, CANCER RES, V57, P1638; ZHAO J, 1995, CANCER RES, V55, P6181	38	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24477	24484		10.1074/jbc.M401835200	http://dx.doi.org/10.1074/jbc.M401835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15054094	hybrid			2022-12-25	WOS:000221702500075
J	Zhang, ZQ; Wu, CH; Gilmour, DS				Zhang, ZQ; Wu, CH; Gilmour, DS			Analysis of polymerase II elongation complexes by native gel electrophoresis - Evidence for a novel carboxyl-terminal domain-mediated termination mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRANSCRIPTION TERMINATION; STRUCTURAL BASIS; DROSOPHILA-MELANOGASTER; LARGEST SUBUNIT; POLY(A) SIGNAL; HEAT-SHOCK; IN-VIVO; INITIATION; SPT5	Genetic and proteomic approaches have identified numerous proteins that are potentially involved in regulating transcriptional elongation, but the mechanisms of action of these proteins remain largely unknown. We describe an experimental approach using native gel electrophoresis for studying interactions of elongation factors with isolated Pol II elongation complexes. The gel distinguishes Pol IIA and Pol IIB containing complexes. The interaction of DSIF (Spt4/Spt5) with the elongation complexes can be readily detected, and this association is not dependent on the carboxyl-terminal domain of the largest subunit of Pol II. We also report the surprising observation that a monoclonal antibody that binds the carboxyl-terminal domain of Pol II triggers the dissociation of the elongation complex. The action of the antibody could be mimicking the action of cellular factors involved in transcription termination.	Penn State Univ, Ctr Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Gilmour, DS (corresponding author), Penn State Univ, Ctr Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	dsg11@psu.edu			NIGMS NIH HHS [GM47477] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN S, 1983, NUCLEIC ACIDS RES, V11, P6041, DOI 10.1093/nar/11.17.6041; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Boehm AK, 2003, MOL CELL BIOL, V23, P7628, DOI 10.1128/MCB.23.21.7628-7637.2003; Bourgeois CF, 2002, MOL CELL BIOL, V22, P1079, DOI 10.1128/MCB.22.4.1079-1093.2002; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; Douziech M, 1999, J BIOL CHEM, V274, P19868, DOI 10.1074/jbc.274.28.19868; Fujinaga K, 2004, MOL CELL BIOL, V24, P787, DOI 10.1128/MCB.24.2.787-795.2004; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Kim SJ, 2003, J BIOL CHEM, V278, P41691, DOI 10.1074/jbc.M306304200; KIM WY, 1988, J BIOL CHEM, V263, P18880; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KRAMER A, 1980, MOL GEN GENET, V180, P193, DOI 10.1007/BF00267369; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; Sadowski M, 2003, EMBO J, V22, P2167, DOI 10.1093/emboj/cdg200; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; Tran DP, 2001, MOL CELL BIOL, V21, P7495, DOI 10.1128/MCB.21.21.7495-7508.2001; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	49	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23223	23228		10.1074/jbc.M402956200	http://dx.doi.org/10.1074/jbc.M402956200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	15056674	hybrid			2022-12-25	WOS:000221570900054
J	Jackson, MW; Agarwal, MK; Agarwal, ML; Agarwal, A; Stanhope-Baker, P; Williams, BRG; Stark, GR				Jackson, MW; Agarwal, MK; Agarwal, ML; Agarwal, A; Stanhope-Baker, P; Williams, BRG; Stark, GR			Limited role of N-terminal phosphoserine residues in the activation of transcription by p53	ONCOGENE			English	Article						p14ARF; adriamycin; p21; MDM2	ARF TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; PROLYL ISOMERASE PIN1; ACID-BINDING PROTEIN; RING-FINGER DOMAIN; DNA-DAMAGE; ONCOPROTEIN MDM2; STABILIZES P53; GROWTH ARREST; MAMMARY-GLAND	The p53 tumor suppressor is phosphorylated in response to various cellular stress signals, such as DNA damage, leading to its release from MDM2 and consequent stabilization and activation as a transcription factor. In human U2OS cells, treatment with adriamycin causes p53 to be phosphorylated on all six serine residues tested, leading to the dissociation of p53 from MDM2 and transcription of the p21 and mdm2 genes. In contrast, in these cells, IPTG-dependent induction of p14ARF, which sequesters MDM2 away from p53, does not lead to detectable phosphorylation of any of the five N-terminal serine residues tested (6, 9, 15, 20, 37). Only C-terminal serine 392 is phosphorylated. However, the increase of p21 and mdm2 mRNAs was indistinguishable following treatment with adriamycin or induction of p14ARF. By using cDNA arrays to examine global p53-dependent gene expression in response to adriamycin or p14ARF, we found that most genes were regulated similarly by the two treatments. However, a subset of p53-regulated genes whose products have proliferative roles or regulate VEGF activity, newly described here, are repressed by p14ARF much more than by adriamycin. We conclude that the phosphorylation of p53 on N-terminal serine residues is not required for increased transcription of the great majority of p53-responsive genes and that the induction of p53 by p14ARF, with little phosphorylation, leads to substantial repression of genes whose products have roles in proliferation.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, NC20,9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [R01CA089279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NCI NIH HHS [CA 89279] Funding Source: Medline; NIGMS NIH HHS [GM 049345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alarcon R, 1999, CANCER RES, V59, P6046; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chehab NH, 2000, GENE DEV, V14, P278; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Jing C, 2000, CANCER RES, V60, P2390; Jing C, 2001, CANCER RES, V61, P4357; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kar S, 2002, J BIOL CHEM, V277, P15579, DOI 10.1074/jbc.M106915200; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mayo LD, 1997, CANCER RES, V57, P5013; McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; Sherr CJ, 2000, CANCER RES, V60, P3689; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Xiao G, 2000, CANCER RES, V60, P1711; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	87	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4477	4487		10.1038/sj.onc.1207575	http://dx.doi.org/10.1038/sj.onc.1207575			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064747				2022-12-25	WOS:000221661300013
J	Obad, S; Brunnstrom, H; Vallon-Christersson, J; Borg, A; Drott, K; Gullberg, U				Obad, S; Brunnstrom, H; Vallon-Christersson, J; Borg, A; Drott, K; Gullberg, U			Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells	ONCOGENE			English	Article						p53; Staf50; transcriptional target	WILD-TYPE P53; INTERFERON-ALPHA/BETA; TUMOR SUPPRESSION; DIFFERENTIATION; EXPRESSION; INDUCTION; FAMILY; P73; APOPTOSIS; RECEPTOR	The tumor suppressor gene p53 is a transcription factor that mediates both cell cycle arrest and apoptosis. Interestingly, p53 also induces differentiation of a number of tissues, including leukemic cells. However, although p53-mediated differentiation of leukemic U-937 cells depends on the transcriptional activity of p53, a p53 target gene mediating differentiation has hitherto not been identified. To screen for novel p53 target genes in leukemic cells, a cDNA microarray analysis was performed with U-937-4/ptsp53 cells, expressing a temperature-sensitive p53 mutant. We report that transcription of the Staf50 ( stimulated transacting factor of 50 kDa) gene is upregulated in response to wild-type p53 in U-937-4, K562 and MCF-7 cells. Staf50 was directly activated by p53, as determined by the independence of de novo protein synthesis. Moreover, while the proximal promoter of Staf50 was found not to be p53 responsive, a functional enhancer-like p53-response element in intron 1 of the Staf50 gene was identified that was also transactivated by the p53-family member p73. Direct binding of p53 to the response element was shown by electrophoretic mobility shift analysis. Ectopic expression of Staf50 in U-937 cells resulted in reduced clonogenic growth. Moreover, levels of endogenous Staf50 mRNA correlated to all-trans retinoic acid-induced differentiation of promyelocytic NB-4 and HL60 cells, suggesting that Staf50 could be involved in proliferation and/or differentiation of leukemic cells.	Lund Univ, BMC, Dept Hematol, S-22184 Lund, Sweden; Lund Univ, Dept Oncol, S-22184 Lund, Sweden	Lund University; Lund University	Gullberg, U (corresponding author), Lund Univ, BMC, Dept Hematol, C14, S-22184 Lund, Sweden.	urban.gullberg@hematologi.lu.se	Brunnström, Hans/AAZ-6803-2020	Brunnström, Hans/0000-0001-7402-138X; Vallon-Christersson, Johan/0000-0002-2195-0385				ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P561; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; Ehinger M, 1997, CELL GROWTH DIFFER, V8, P1127; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Fei PW, 2002, CANCER RES, V62, P7316; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Gongora C, 2000, J INTERF CYTOK RES, V20, P955, DOI 10.1089/10799900050198390; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; JACKSON P, 1993, ONCOGENE, V8, P589; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Momand J, 1997, J CELL BIOCHEM, V64, P343; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLSSON I, 1983, CANCER RES, V43, P5862; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Pestka S, 2003, CANCER CELL, V4, P85, DOI 10.1016/S1535-6108(03)00193-4; Peters UR, 1999, CANCER RES, V59, P4233; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sharma K, 1998, INT J CANCER, V76, P259, DOI 10.1002/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Swiatecka J, 2000, NEOPLASMA, V47, P15; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tissot C, 1996, GENOMICS, V34, P151, DOI 10.1006/geno.1996.0258; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang ZG, 1998, SCIENCE, V279, P1547; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	61	57	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4050	4059		10.1038/sj.onc.1207524	http://dx.doi.org/10.1038/sj.onc.1207524			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064739				2022-12-25	WOS:000221520200002
J	Komarova, EA; Kondratov, RV; Wang, KH; Christov, K; Golovkina, TV; Goldblum, JR; Gudkov, AV				Komarova, EA; Kondratov, RV; Wang, KH; Christov, K; Golovkina, TV; Goldblum, JR; Gudkov, AV			Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice	ONCOGENE			English	Article						p53; radiation; hematopoietic syndrome; gastro-intestinal syndrome; apoptosis; growth arrest	SMALL-INTESTINE; INDUCED APOPTOSIS; P53-DEFICIENT MICE; IONIZING-RADIATION; CANCER-THERAPY; SUPPRESSION; IRRADIATION; INHIBITOR; NEURONS; CELLS	Ionizing radiation (IR) induces p53-dependent apoptosis in radiosensitive tissues, suggesting that p53 is a determinant of radiation syndromes. In fact, p53-deficient mice survive doses of IR that cause lethal hematopoietic syndrome in wild-type animals. Surprisingly, p53 deficiency results in sensitization of mice to higher doses of IR, causing lethal gastro-intestinal (GI) syndrome. While cells in the crypts of p53-wild-type epithelium undergo prolonged growth arrest after irradiation, continuous cell proliferation ongoing in p53-deficient epithelium correlates with accelerated death of damaged cells followed by rapid destruction of villi and accelerated lethality. p21-deficient mice are also characterized by increased sensitivity to GI syndrome-inducing doses of IR. We conclude that p53/p21-mediated growth arrest plays a protective role in the epithelium of small intestine after severe doses of IR. Pharmacological inhibition of p53 by a small molecule that can rescue from lethal hematopoietic syndrome has no effect on the lethality from gastro-intestinal syndrome, presumably because of a temporary and reversible nature of its action.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Quark Biotech Inc, Cleveland, OH 44195 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Jackson Laboratory; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gudkov@uic.edu		Kondratov, Roman/0000-0003-3449-745X; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Booth C, 2002, NAT MED, V8, P1360, DOI 10.1038/nm1202-1360; Botchkarev VA, 2000, CANCER RES, V60, P5002; Cai WB, 1997, INT J RADIAT BIOL, V71, P145, DOI 10.1080/095530097144265; Cui Y. F., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P159; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; Ohkusu-Tsukada K, 1999, J IMMUNOL, V163, P1966; Ookawa K, 2002, J BIOL CHEM, V277, P48270, DOI 10.1074/jbc.M207986200; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Somosy Z, 2002, MICRON, V33, P167, DOI 10.1016/S0968-4328(01)00013-0; Watson AJM, 2000, AM J PHYSIOL-GASTR L, V278, pG1, DOI 10.1152/ajpgi.2000.278.1.G1; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	27	181	197	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3265	3271		10.1038/sj.onc.1207494	http://dx.doi.org/10.1038/sj.onc.1207494			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064735				2022-12-25	WOS:000220975000001
J	Kageyama, Y; Koshiji, M; To, KKW; Tian, YM; Ratcliffe, PJ; Huang, LE				Kageyama, Y; Koshiji, M; To, KKW; Tian, YM; Ratcliffe, PJ; Huang, LE			Leu-574 of human HIF-1a is a molecular determinant of prolyl hydroxylation	FASEB JOURNAL			English	Article						hypoxia; prolyl-4-hydroxylases; transcription factor	HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; ARNT TRANSCRIPTION FACTOR; STRUCTURAL BASIS; FACTOR 1-ALPHA; GENE-EXPRESSION; ALPHA-SUBUNIT; HIF-1-ALPHA; VHL	Hypoxia-inducible factor (HIF)-1alpha, a master regulator of oxygen homeostasis, regulates genes crucial for cell growth and survival. In normoxia, HIF-1alpha is constantly degraded via the ubiquitin-proteasome pathway. The von Hippel-Lindau (VHL) E3 ubiquitin ligase binds HIF-1alpha through specific recognition of hydroxylated Pro-402 or Pro-564, both of which are modified by the oxygen-dependent HIF prolyl hydroxylases (PHDs/HPHs). Despite the identification of a conserved Leu-X-X-Leu-Ala-Pro motif, the molecular requirement of HIF-1alpha for PHDs/HPHs binding remains elusive. Recently, we demonstrated that Leu-574 of human HIF-1alpha-10 residues downstream of Pro-564-is essential for VHL recognition. We show here that the role of Leu-574 is to recruit PHD2/HPH2 for Pro-564 hydroxylation. An antibody specific for hydroxylated Pro-564 has been used to determine the hydroxylation status; mutation or deletion of Leu-574 results in a significant decrease in the ratio of the hydroxylated HIF-1alpha to the total amount. The nine-residue spacing between Pro-564 and Leu-574 is not obligatory for prolyl hydroxylation. Furthermore, mutation of Leu-574 disrupts the binding of PHD2/HPH2, a key prolyl hydroxylase for oxygen-dependent proteolysis of HIF-1alpha. Hence, our findings indicate that Leu-574 is essential for recruiting PHD2/HPH2, thereby providing a molecular basis for modulating HIF-1alpha activity.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Henry wellcome Bldg Genom Med, Oxford OX3 7BN, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oxford	Huang, LE (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA.	huange@mail.nih.gov	To, Kenneth K W/M-4500-2013	To, Kenneth K W/0000-0003-2755-0283; Huang, Eric/0000-0002-6444-1708; Ratcliffe, Peter/0000-0002-2853-806X	DIVISION OF BASIC SCIENCES - NCI [Z01BC010424] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Huang LE, 2002, J BIOL CHEM, V277, P41750, DOI 10.1074/jbc.M207280200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pereira T, 2003, J BIOL CHEM, V278, P6816, DOI 10.1074/jbc.M209297200; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Willam C, 2002, P NATL ACAD SCI USA, V99, P10423, DOI 10.1073/pnas.162119399; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	43	59	60	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1028	+		10.1096/fj.03-1233fje	http://dx.doi.org/10.1096/fj.03-1233fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15084514				2022-12-25	WOS:000221108800003
